<SEC-DOCUMENT>0001564590-21-013512.txt : 20210316
<SEC-HEADER>0001564590-21-013512.hdr.sgml : 20210316
<ACCEPTANCE-DATETIME>20210316150143
ACCESSION NUMBER:		0001564590-21-013512
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		105
CONFORMED PERIOD OF REPORT:	20201231
FILED AS OF DATE:		20210316
DATE AS OF CHANGE:		20210316

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BIODESIX INC
		CENTRAL INDEX KEY:			0001439725
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MEDICAL LABORATORIES [8071]
		IRS NUMBER:				203986492
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39659
		FILM NUMBER:		21745283

	BUSINESS ADDRESS:	
		STREET 1:		2970 WILDERNESS PLACE
		STREET 2:		SUITE 100
		CITY:			BOULDER
		STATE:			CO
		ZIP:			80301
		BUSINESS PHONE:		303-417-0500

	MAIL ADDRESS:	
		STREET 1:		2970 WILDERNESS PLACE
		STREET 2:		SUITE 100
		CITY:			BOULDER
		STATE:			CO
		ZIP:			80301
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>bdsx-10k_20201231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml  version="1.0" encoding="utf-8"?>
<!-- DFIN ActiveDisclosure(SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-03-16T14:31:09.9216157+00:00 -->
<!-- Version            : 5.0.1.571 -->
<!-- Package ID         : dca80741ea2145de953066364db43c8f -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:bdsx="http://biodesix.com/20201231" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2020-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2020-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:dei-std="http://xbrl.sec.gov/dei-std/2020-01-31" xmlns:dei-ent-std="http://xbrl.sec.gov/dei-ent-std/2020-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns="http://www.w3.org/1999/xhtml">
<head>
<meta http-equiv="Content-Type" content="text/html" />
<title>
bdsx-10k_20201231.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body><div style="display:none">
	<ix:header>
		<ix:hidden>
			<ix:nonNumeric id="F_000001" name="dei:AmendmentFlag" contextRef="C_0001439725_20200101_20201231">false</ix:nonNumeric>
			<ix:nonNumeric id="F_000005" name="dei:DocumentFiscalPeriodFocus" contextRef="C_0001439725_20200101_20201231">FY</ix:nonNumeric>
			<ix:nonNumeric id="F_000006" name="dei:EntityCentralIndexKey" contextRef="C_0001439725_20200101_20201231">0001439725</ix:nonNumeric>
			<ix:nonNumeric id="F_000007" name="dei:CurrentFiscalYearEndDate" contextRef="C_0001439725_20200101_20201231">--12-31</ix:nonNumeric>
			<ix:nonFraction unitRef="U_iso4217USD" id="F_000358" name="bdsx:IncreaseDecreaseInAccumulatedDeficit" contextRef="C_0001439725_srtRestatementAxis_srtRevisionOfPriorPeriodErrorCorrectionAdjustmentMember_20190101_20191231" decimals="-5" sign="-">3400000</ix:nonFraction>
			<ix:nonFraction unitRef="U_bdsxsegment" id="F_000360_2" name="us-gaap:NumberOfOperatingSegments" contextRef="C_0001439725_20200101_20201231" decimals="INF">1</ix:nonFraction>
			<ix:nonNumeric id="F_000390" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" contextRef="C_0001439725_srtRangeAxis_srtMinimumMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_bdsxProductLifeAndPatentLifeMember_20200101_20201231">P9Y</ix:nonNumeric>
			<ix:nonFraction unitRef="U_iso4217USD" id="F_000393" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" contextRef="C_0001439725_20190101_20191231" decimals="INF">0</ix:nonFraction>
			<ix:nonFraction unitRef="U_iso4217USD" id="F_000527" name="us-gaap:GoodwillAndIntangibleAssetImpairment" contextRef="C_0001439725_20190101_20191231" decimals="INF">0</ix:nonFraction>
			<ix:nonNumeric id="F_000562" name="us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" contextRef="C_0001439725_srtRangeAxis_srtMinimumMember_us-gaapLongtermDebtTypeAxis_bdsxNotesPayable2018NotesMember_20180201_20180228">P24M</ix:nonNumeric>
			<ix:nonNumeric id="F_000563" name="us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" contextRef="C_0001439725_srtRangeAxis_srtMaximumMember_us-gaapLongtermDebtTypeAxis_bdsxNotesPayable2018NotesMember_20180201_20180228">P36M</ix:nonNumeric>
			<ix:nonFraction unitRef="U_xbrlishares" id="F_000659" name="us-gaap:PreferredStockSharesOutstanding" contextRef="C_0001439725_20201231" decimals="INF">0</ix:nonFraction>
			<ix:nonFraction unitRef="U_iso4217USD" id="F_000821" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" contextRef="C_0001439725_20190101_20191231" decimals="INF">0</ix:nonFraction>
			<ix:nonNumeric id="F_000822" name="us-gaap:DefinedContributionPlanPlanNameExtensibleList" contextRef="C_0001439725_20200101_20201231">bdsx:FourZeroOneKPlanMember</ix:nonNumeric>
			<ix:nonNumeric id="F_000823" name="us-gaap:DefinedContributionPlanPlanNameExtensibleList" contextRef="C_0001439725_20190101_20191231">bdsx:FourZeroOneKPlanMember</ix:nonNumeric>
			<ix:nonFraction unitRef="U_bdsxsegment" id="F_000360" name="us-gaap:NumberOfOperatingSegments" contextRef="C_0001439725_20200101_20201231" decimals="INF">1</ix:nonFraction>
			<ix:nonNumeric id="F_000416" name="bdsx:BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod" contextRef="C_0001439725_us-gaapBusinessAcquisitionAxis_bdsxIntegratedDiagnosticsIncMember_20180630_20180630">P7Y</ix:nonNumeric>
			<ix:nonNumeric id="F_000572" name="us-gaap:DebtInstrumentMaturityDate" contextRef="C_0001439725_us-gaapShortTermDebtTypeAxis_bdsxMarchTwoThousandAndTwentyConvertibleNotesMember_20200301_20200331">2020-08-31</ix:nonNumeric>
			<ix:nonNumeric id="F_000585" name="us-gaap:DebtInstrumentMaturityDate" contextRef="C_0001439725_us-gaapShortTermDebtTypeAxis_bdsxDecemberTwoThousandAndNineteenConvertibleNotesMember_20191201_20191231">2020-08-31</ix:nonNumeric>
			<ix:nonNumeric id="F_000598" name="us-gaap:DebtInstrumentMaturityDate" contextRef="C_0001439725_us-gaapShortTermDebtTypeAxis_bdsxAugustTwoThousandAndNineteenConvertibleNotesMember_20190801_20190930">2020-08-31</ix:nonNumeric>
			<ix:nonNumeric id="F_000645" name="us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" contextRef="C_0001439725_20200101_20201231">2028-02-29</ix:nonNumeric>
			<ix:nonNumeric id="F_000697" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" contextRef="C_0001439725_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_bdsxBonusToOptionsProgramMember_20200101_20201231">P10Y</ix:nonNumeric>
			<ix:nonFraction unitRef="U_iso4217USD" id="F_000077" name="us-gaap:CommitmentsAndContingencies" contextRef="C_0001439725_20201231" xsi:nil="true"></ix:nonFraction>
			<ix:nonFraction unitRef="U_iso4217USD" id="F_000078" name="us-gaap:CommitmentsAndContingencies" contextRef="C_0001439725_20191231" xsi:nil="true"></ix:nonFraction>
			<ix:nonFraction unitRef="U_iso4217USD" id="F_000080" name="us-gaap:PreferredStockValue" contextRef="C_0001439725_20201231" xsi:nil="true"></ix:nonFraction>
			<ix:nonFraction unitRef="U_iso4217USD" id="F_000081" name="us-gaap:PreferredStockValue" contextRef="C_0001439725_20191231" xsi:nil="true"></ix:nonFraction>
			<ix:nonNumeric id="F_000723" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="C_0001439725_20190101_20191231">P7Y7M6D</ix:nonNumeric>
			<ix:nonNumeric id="F_000724" name="bdsx:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1" contextRef="C_0001439725_20200101_20201231">P0Y</ix:nonNumeric>
			<ix:nonNumeric id="F_000725" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="C_0001439725_20200101_20201231">P7Y4M24D</ix:nonNumeric>
			<ix:nonNumeric id="F_000726" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" contextRef="C_0001439725_20200101_20201231">P6Y3M18D</ix:nonNumeric>
			<ix:nonNumeric id="F_000730" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_0001439725_20200101_20201231">P5Y8M23D</ix:nonNumeric>
		</ix:hidden>
		<ix:references>
			<link:schemaRef xlink:type="simple" xlink:href="bdsx-20201231.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase"></link:schemaRef>
		</ix:references>
		<ix:resources>
			<xbrli:context id="C_0001439725_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_xbrlishares">
				<xbrli:measure>xbrli:shares</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001439725_20210312">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-12</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_iso4217USD">
				<xbrli:measure>iso4217:USD</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001439725_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_iso4217USD_xbrlishares">
				<xbrli:divide>
					<xbrli:unitNumerator>
						<xbrli:measure>iso4217:USD</xbrli:measure>
					</xbrli:unitNumerator>
					<xbrli:unitDenominator>
						<xbrli:measure>xbrli:shares</xbrli:measure>
					</xbrli:unitDenominator>
				</xbrli:divide>
			</xbrli:unit>
			<xbrli:context id="C_0001439725_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapStatementClassOfStockAxis_us-gaapSeriesHPreferredStockMember_20190201_20190228">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesHPreferredStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-02-01</xbrli:startDate>
					<xbrli:endDate>2019-02-28</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapStatementClassOfStockAxis_us-gaapSeriesHPreferredStockMember_20190301_20190331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesHPreferredStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-03-01</xbrli:startDate>
					<xbrli:endDate>2019-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapStatementClassOfStockAxis_us-gaapSeriesHPreferredStockMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesHPreferredStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_bdsxTest">
				<xbrli:measure>bdsx:Test</xbrli:measure>
			</xbrli:unit>
			<xbrli:unit id="U_xbrlipure">
				<xbrli:measure>xbrli:pure</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001439725_20201019_20201019">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-10-19</xbrli:startDate>
					<xbrli:endDate>2020-10-19</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_20201031">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-10-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20201027_20201027">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-10-27</xbrli:startDate>
					<xbrli:endDate>2020-10-27</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20201027">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-10-27</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_srtRestatementAxis_srtRevisionOfPriorPeriodErrorCorrectionAdjustmentMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_srtRestatementAxis_srtRevisionOfPriorPeriodErrorCorrectionAdjustmentMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_bdsxsegment">
				<xbrli:measure>bdsx:segment</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001439725_srtProductOrServiceAxis_bdsxTestingServicesMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bdsx:TestingServicesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_srtMajorCustomersAxis_bdsxTheBigTenConferenceMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bdsx:TheBigTenConferenceMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_srtMajorCustomersAxis_bdsxCenturaHealthcareMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bdsx:CenturaHealthcareMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_srtMajorCustomersAxis_bdsxCovanceCentralLaboratoryServicesMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bdsx:CovanceCentralLaboratoryServicesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_srtMajorCustomersAxis_bdsxMedicareMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bdsx:MedicareMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_srtMajorCustomersAxis_bdsxMedicareMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bdsx:MedicareMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_srtMajorCustomersAxis_bdsxTheBigTenConferenceMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bdsx:TheBigTenConferenceMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_srtMajorCustomersAxis_bdsxCenturaHealthcareMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bdsx:CenturaHealthcareMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_srtMajorCustomersAxis_bdsxMedicareMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bdsx:MedicareMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_srtMajorCustomersAxis_bdsxMedicareMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bdsx:MedicareMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_srtMajorCustomersAxis_bdsxCovanceCentralLaboratoryServicesMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bdsx:CovanceCentralLaboratoryServicesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_srtMajorCustomersAxis_bdsxCovanceCentralLaboratoryServicesMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bdsx:CovanceCentralLaboratoryServicesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_srtMajorCustomersAxis_bdsxJanssenResearchAndDevelopmentLLCMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bdsx:JanssenResearchAndDevelopmentLLCMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_srtMajorCustomersAxis_bdsxJanssenResearchAndDevelopmentLLCMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bdsx:JanssenResearchAndDevelopmentLLCMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_srtMajorCustomersAxis_bdsxPfizerIncMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bdsx:PfizerIncMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_srtMajorCustomersAxis_bdsxPfizerIncMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bdsx:PfizerIncMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapBalanceSheetLocationAxis_us-gaapOtherCurrentAssetsMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapBalanceSheetLocationAxis_us-gaapOtherCurrentAssetsMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_srtRangeAxis_srtMinimumMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_srtRangeAxis_srtMaximumMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_srtRangeAxis_srtMinimumMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_bdsxProductLifeAndPatentLifeMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bdsx:ProductLifeAndPatentLifeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_srtRangeAxis_srtMaximumMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_bdsxProductLifeAndPatentLifeMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bdsx:ProductLifeAndPatentLifeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapBusinessAcquisitionAxis_bdsxOncimmuneLimitedMember_20191031_20191031">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bdsx:OncimmuneLimitedMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-10-31</xbrli:startDate>
					<xbrli:endDate>2019-10-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapBusinessAcquisitionAxis_bdsxOncimmuneLimitedMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bdsx:OncimmuneLimitedMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_srtProductOrServiceAxis_us-gaapLicenseMember_srtStatementGeographicalAxis_countryUS_us-gaapBusinessAcquisitionAxis_bdsxOncimmuneLimitedMember_20191031_20191031">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bdsx:OncimmuneLimitedMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-10-31</xbrli:startDate>
					<xbrli:endDate>2019-10-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapBusinessAcquisitionAxis_bdsxOncimmuneLimitedMember_20191031">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bdsx:OncimmuneLimitedMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-10-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapBusinessAcquisitionAxis_bdsxIntegratedDiagnosticsIncMember_20180630_20180630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bdsx:IntegratedDiagnosticsIncMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-06-30</xbrli:startDate>
					<xbrli:endDate>2018-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapBusinessAcquisitionAxis_bdsxIntegratedDiagnosticsIncMember_20180630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bdsx:IntegratedDiagnosticsIncMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapBusinessAcquisitionAxis_bdsxIntegratedDiagnosticsIncMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bdsx:IntegratedDiagnosticsIncMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapBusinessAcquisitionAxis_bdsxIntegratedDiagnosticsIncMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20180630_20180630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bdsx:IntegratedDiagnosticsIncMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-06-30</xbrli:startDate>
					<xbrli:endDate>2018-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_bdsxInstallment">
				<xbrli:measure>bdsx:Installment</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001439725_us-gaapBusinessAcquisitionAxis_bdsxIntegratedDiagnosticsIncMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20180630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bdsx:IntegratedDiagnosticsIncMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapBusinessAcquisitionAxis_bdsxIntegratedDiagnosticsIncMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bdsx:IntegratedDiagnosticsIncMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapBusinessAcquisitionAxis_bdsxIntegratedDiagnosticsIncMember_us-gaapInvestmentTypeAxis_bdsxRepurchaseMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20180630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bdsx:IntegratedDiagnosticsIncMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">bdsx:RepurchaseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapBusinessAcquisitionAxis_bdsxIntegratedDiagnosticsIncMember_us-gaapInvestmentTypeAxis_bdsxRepurchaseMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20180630_20180630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bdsx:IntegratedDiagnosticsIncMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">bdsx:RepurchaseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-06-30</xbrli:startDate>
					<xbrli:endDate>2018-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementBasisAxis_us-gaapCarryingReportedAmountFairValueDisclosureMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementBasisAxis_us-gaapEstimateOfFairValueFairValueDisclosureMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementBasisAxis_us-gaapCarryingReportedAmountFairValueDisclosureMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementBasisAxis_us-gaapEstimateOfFairValueFairValueDisclosureMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByLiabilityClassAxis_bdsxContingentConsiderationMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:ContingentConsiderationMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByLiabilityClassAxis_bdsxContingentConsiderationMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:ContingentConsiderationMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByLiabilityClassAxis_bdsxPutOptionLiabilityMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:PutOptionLiabilityMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByLiabilityClassAxis_bdsxWarrantLiabilityMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:WarrantLiabilityMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByLiabilityClassAxis_bdsxContingentValueRightsMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:ContingentValueRightsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByLiabilityClassAxis_bdsxPutOptionLiabilityMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:PutOptionLiabilityMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByLiabilityClassAxis_bdsxContingentConsiderationMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:ContingentConsiderationMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByLiabilityClassAxis_bdsxWarrantLiabilityMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:WarrantLiabilityMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByLiabilityClassAxis_bdsxContingentValueRightsMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:ContingentValueRightsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapLongtermDebtTypeAxis_bdsxNotesPayable2018NotesMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesGPreferredStockMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:NotesPayable2018NotesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesGPreferredStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapStatementClassOfStockAxis_us-gaapSeriesFPreferredStockMember_20160131">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesFPreferredStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2016-01-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapStatementClassOfStockAxis_us-gaapSeriesFPreferredStockMember_20160101_20160131">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesFPreferredStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2016-01-01</xbrli:startDate>
					<xbrli:endDate>2016-01-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_srtCounterpartyNameAxis_bdsxAVEOOncologyMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesFPreferredStockMember_20200901_20200930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesFPreferredStockMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bdsx:AVEOOncologyMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-09-01</xbrli:startDate>
					<xbrli:endDate>2020-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapEquipmentMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapEquipmentMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapComputerEquipmentMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapComputerEquipmentMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapSoftwareAndSoftwareDevelopmentCostsMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapSoftwareAndSoftwareDevelopmentCostsMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapConstructionInProgressMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapConstructionInProgressMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapFairValueByAssetClassAxis_us-gaapPropertyPlantAndEquipmentMember_us-gaapIncomeStatementLocationAxis_bdsxDirectCostsAndExpensesMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">bdsx:DirectCostsAndExpensesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapFairValueByAssetClassAxis_us-gaapPropertyPlantAndEquipmentMember_us-gaapIncomeStatementLocationAxis_bdsxDirectCostsAndExpensesMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">bdsx:DirectCostsAndExpensesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapFairValueByAssetClassAxis_us-gaapPropertyPlantAndEquipmentMember_us-gaapIncomeStatementLocationAxis_us-gaapSellingGeneralAndAdministrativeExpensesMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapFairValueByAssetClassAxis_us-gaapPropertyPlantAndEquipmentMember_us-gaapIncomeStatementLocationAxis_us-gaapSellingGeneralAndAdministrativeExpensesMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapFairValueByAssetClassAxis_us-gaapPropertyPlantAndEquipmentMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapFairValueByAssetClassAxis_us-gaapPropertyPlantAndEquipmentMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapPatentsMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_bdsxPurchasedTechnologyMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bdsx:PurchasedTechnologyMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapPatentsMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_bdsxPurchasedTechnologyMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bdsx:PurchasedTechnologyMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_bdsxPurchaseOptionMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bdsx:PurchaseOptionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapTrademarksMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapTrademarksMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapIncomeStatementLocationAxis_bdsxDirectCostsAndExpensesMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">bdsx:DirectCostsAndExpensesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapIncomeStatementLocationAxis_bdsxDirectCostsAndExpensesMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">bdsx:DirectCostsAndExpensesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapIncomeStatementLocationAxis_us-gaapSellingGeneralAndAdministrativeExpensesMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapIncomeStatementLocationAxis_us-gaapSellingGeneralAndAdministrativeExpensesMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapLongtermDebtTypeAxis_bdsxNotesPayable2018NotesMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:NotesPayable2018NotesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapLongtermDebtTypeAxis_bdsxNotesPayable2018NotesMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:NotesPayable2018NotesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapDebtInstrumentAxis_bdsxCARESActMember_us-gaapLongtermDebtTypeAxis_bdsxPPPLoanMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:PPPLoanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bdsx:CARESActMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapLongtermDebtTypeAxis_bdsxNotesPayable2018NotesMember_20180228">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:NotesPayable2018NotesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-02-28</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapLongtermDebtTypeAxis_bdsxNotesPayable2018NotesMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesGPreferredStockMember_20180228">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:NotesPayable2018NotesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesGPreferredStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-02-28</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapLongtermDebtTypeAxis_bdsxNotesPayable2018NotesMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:NotesPayable2018NotesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapLongtermDebtTypeAxis_bdsxNotesPayable2018NotesMember_20180201_20180228">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:NotesPayable2018NotesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-02-01</xbrli:startDate>
					<xbrli:endDate>2018-02-28</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_srtRangeAxis_srtMinimumMember_us-gaapLongtermDebtTypeAxis_bdsxNotesPayable2018NotesMember_20180201_20180228">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:NotesPayable2018NotesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-02-01</xbrli:startDate>
					<xbrli:endDate>2018-02-28</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_srtRangeAxis_srtMaximumMember_us-gaapLongtermDebtTypeAxis_bdsxNotesPayable2018NotesMember_20180201_20180228">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:NotesPayable2018NotesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-02-01</xbrli:startDate>
					<xbrli:endDate>2018-02-28</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapDebtInstrumentAxis_bdsxCARESActMember_us-gaapLongtermDebtTypeAxis_bdsxPPPLoanMember_20200430">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:PPPLoanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bdsx:CARESActMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-04-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapLongtermDebtTypeAxis_bdsxPPPLoanMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:PPPLoanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapInvestmentTypeAxis_us-gaapInterestBearingDepositsMember_us-gaapLongtermDebtTypeAxis_bdsxPPPLoanMember_20200430">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:PPPLoanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:InterestBearingDepositsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-04-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_srtRangeAxis_srtMinimumMember_us-gaapDebtInstrumentAxis_bdsxCARESActMember_us-gaapLongtermDebtTypeAxis_bdsxPPPLoanMember_20200401_20200430">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:PPPLoanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bdsx:CARESActMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-04-01</xbrli:startDate>
					<xbrli:endDate>2020-04-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapDebtInstrumentAxis_bdsxCARESActMember_us-gaapLongtermDebtTypeAxis_bdsxPPPLoanMember_20200401_20200430">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:PPPLoanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bdsx:CARESActMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-04-01</xbrli:startDate>
					<xbrli:endDate>2020-04-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapShortTermDebtTypeAxis_bdsxMarchTwoThousandAndTwentyConvertibleNotesMember_20200301_20200331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">bdsx:MarchTwoThousandAndTwentyConvertibleNotesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-03-01</xbrli:startDate>
					<xbrli:endDate>2020-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapShortTermDebtTypeAxis_bdsxMarchTwoThousandAndTwentyConvertibleNotesMember_20200801_20200831">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">bdsx:MarchTwoThousandAndTwentyConvertibleNotesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-08-01</xbrli:startDate>
					<xbrli:endDate>2020-08-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapDebtInstrumentRedemptionPeriodAxis_us-gaapDebtInstrumentRedemptionPeriodOneMember_us-gaapShortTermDebtTypeAxis_bdsxMarchTwoThousandAndTwentyConvertibleNotesMember_20200301_20200331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">bdsx:MarchTwoThousandAndTwentyConvertibleNotesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-03-01</xbrli:startDate>
					<xbrli:endDate>2020-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapDebtInstrumentRedemptionPeriodAxis_us-gaapDebtInstrumentRedemptionPeriodTwoMember_us-gaapShortTermDebtTypeAxis_bdsxMarchTwoThousandAndTwentyConvertibleNotesMember_20200601_20200630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">bdsx:MarchTwoThousandAndTwentyConvertibleNotesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-06-01</xbrli:startDate>
					<xbrli:endDate>2020-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapShortTermDebtTypeAxis_bdsxMarchTwoThousandAndTwentyConvertibleNotesMember_20200331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">bdsx:MarchTwoThousandAndTwentyConvertibleNotesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapShortTermDebtTypeAxis_bdsxMarchTwoThousandAndTwentyConvertibleNotesMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesHPreferredStockMember_20200301_20200331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">bdsx:MarchTwoThousandAndTwentyConvertibleNotesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesHPreferredStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-03-01</xbrli:startDate>
					<xbrli:endDate>2020-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapShortTermDebtTypeAxis_bdsxMarchTwoThousandAndTwentyConvertibleNotesMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesHPreferredStockMember_20200331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">bdsx:MarchTwoThousandAndTwentyConvertibleNotesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesHPreferredStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapShortTermDebtTypeAxis_bdsxMarchTwoThousandAndTwentyConvertibleNotesMember_20201001_20201031">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">bdsx:MarchTwoThousandAndTwentyConvertibleNotesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-10-01</xbrli:startDate>
					<xbrli:endDate>2020-10-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapShortTermDebtTypeAxis_bdsxMarchTwoThousandAndTwentyConvertibleNotesMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201031">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">bdsx:MarchTwoThousandAndTwentyConvertibleNotesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-10-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapShortTermDebtTypeAxis_bdsxDecemberTwoThousandAndNineteenConvertibleNotesMember_20191201_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">bdsx:DecemberTwoThousandAndNineteenConvertibleNotesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-12-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapShortTermDebtTypeAxis_bdsxDecemberTwoThousandAndNineteenConvertibleNotesMember_20200801_20200831">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">bdsx:DecemberTwoThousandAndNineteenConvertibleNotesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-08-01</xbrli:startDate>
					<xbrli:endDate>2020-08-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapDebtInstrumentRedemptionPeriodAxis_us-gaapDebtInstrumentRedemptionPeriodOneMember_us-gaapShortTermDebtTypeAxis_bdsxDecemberTwoThousandAndNineteenConvertibleNotesMember_20191201_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">bdsx:DecemberTwoThousandAndNineteenConvertibleNotesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-12-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapDebtInstrumentRedemptionPeriodAxis_us-gaapDebtInstrumentRedemptionPeriodTwoMember_us-gaapShortTermDebtTypeAxis_bdsxDecemberTwoThousandAndNineteenConvertibleNotesMember_20200201_20200229">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">bdsx:DecemberTwoThousandAndNineteenConvertibleNotesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-02-01</xbrli:startDate>
					<xbrli:endDate>2020-02-29</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapShortTermDebtTypeAxis_bdsxDecemberTwoThousandAndNineteenConvertibleNotesMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">bdsx:DecemberTwoThousandAndNineteenConvertibleNotesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapShortTermDebtTypeAxis_bdsxDecemberTwoThousandAndNineteenConvertibleNotesMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesHPreferredStockMember_20191201_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">bdsx:DecemberTwoThousandAndNineteenConvertibleNotesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesHPreferredStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-12-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapShortTermDebtTypeAxis_bdsxDecemberTwoThousandAndNineteenConvertibleNotesMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesHPreferredStockMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">bdsx:DecemberTwoThousandAndNineteenConvertibleNotesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesHPreferredStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapShortTermDebtTypeAxis_bdsxDecemberTwoThousandAndNineteenConvertibleNotesMember_20201001_20201031">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">bdsx:DecemberTwoThousandAndNineteenConvertibleNotesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-10-01</xbrli:startDate>
					<xbrli:endDate>2020-10-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapShortTermDebtTypeAxis_bdsxDecemberTwoThousandAndNineteenConvertibleNotesMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201031">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">bdsx:DecemberTwoThousandAndNineteenConvertibleNotesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-10-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapShortTermDebtTypeAxis_bdsxAugustTwoThousandAndNineteenConvertibleNotesMember_20190801_20190930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">bdsx:AugustTwoThousandAndNineteenConvertibleNotesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-08-01</xbrli:startDate>
					<xbrli:endDate>2019-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapShortTermDebtTypeAxis_bdsxAugustTwoThousandAndNineteenConvertibleNotesMember_20200801_20200831">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">bdsx:AugustTwoThousandAndNineteenConvertibleNotesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-08-01</xbrli:startDate>
					<xbrli:endDate>2020-08-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapShortTermDebtTypeAxis_bdsxAugustTwoThousandAndNineteenConvertibleNotesMember_20190930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">bdsx:AugustTwoThousandAndNineteenConvertibleNotesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapShortTermDebtTypeAxis_bdsxAugustTwoThousandAndNineteenConvertibleNotesMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesHPreferredStockMember_20190801_20190930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">bdsx:AugustTwoThousandAndNineteenConvertibleNotesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesHPreferredStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-08-01</xbrli:startDate>
					<xbrli:endDate>2019-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapShortTermDebtTypeAxis_bdsxAugustTwoThousandAndNineteenConvertibleNotesMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesHPreferredStockMember_20190930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">bdsx:AugustTwoThousandAndNineteenConvertibleNotesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesHPreferredStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapShortTermDebtTypeAxis_bdsxAugustTwoThousandAndNineteenConvertibleNotesMember_20191201_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">bdsx:AugustTwoThousandAndNineteenConvertibleNotesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-12-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapShortTermDebtTypeAxis_bdsxAugustTwoThousandAndNineteenConvertibleNotesMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">bdsx:AugustTwoThousandAndNineteenConvertibleNotesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapShortTermDebtTypeAxis_bdsxAugustTwoThousandAndNineteenConvertibleNotesMember_20201001_20201031">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">bdsx:AugustTwoThousandAndNineteenConvertibleNotesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-10-01</xbrli:startDate>
					<xbrli:endDate>2020-10-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapShortTermDebtTypeAxis_bdsxAugustTwoThousandAndNineteenConvertibleNotesMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201031">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">bdsx:AugustTwoThousandAndNineteenConvertibleNotesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-10-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapStatementClassOfStockAxis_us-gaapSeriesHPreferredStockMember_20190228">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesHPreferredStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-02-28</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapStatementClassOfStockAxis_us-gaapSeriesHPreferredStockMember_20190331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesHPreferredStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapStatementClassOfStockAxis_bdsxSeriesA1PreferredStockMember_20201027_20201027">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bdsx:SeriesA1PreferredStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-10-27</xbrli:startDate>
					<xbrli:endDate>2020-10-27</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapStatementClassOfStockAxis_bdsxSeriesA2PreferredStockMember_20201027_20201027">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bdsx:SeriesA2PreferredStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-10-27</xbrli:startDate>
					<xbrli:endDate>2020-10-27</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapStatementClassOfStockAxis_bdsxSeriesA3PreferredStockMember_20201027_20201027">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bdsx:SeriesA3PreferredStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-10-27</xbrli:startDate>
					<xbrli:endDate>2020-10-27</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20201027_20201027">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-10-27</xbrli:startDate>
					<xbrli:endDate>2020-10-27</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapStatementClassOfStockAxis_us-gaapSeriesCPreferredStockMember_20201027_20201027">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-10-27</xbrli:startDate>
					<xbrli:endDate>2020-10-27</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapStatementClassOfStockAxis_us-gaapSeriesDPreferredStockMember_20201027_20201027">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-10-27</xbrli:startDate>
					<xbrli:endDate>2020-10-27</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapStatementClassOfStockAxis_us-gaapSeriesEPreferredStockMember_20201027_20201027">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesEPreferredStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-10-27</xbrli:startDate>
					<xbrli:endDate>2020-10-27</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapStatementClassOfStockAxis_us-gaapSeriesFPreferredStockMember_20201027_20201027">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesFPreferredStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-10-27</xbrli:startDate>
					<xbrli:endDate>2020-10-27</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapStatementClassOfStockAxis_us-gaapSeriesGPreferredStockMember_20201027_20201027">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesGPreferredStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-10-27</xbrli:startDate>
					<xbrli:endDate>2020-10-27</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapStatementClassOfStockAxis_us-gaapSeriesHPreferredStockMember_20201027_20201027">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesHPreferredStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-10-27</xbrli:startDate>
					<xbrli:endDate>2020-10-27</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapStatementClassOfStockAxis_bdsxSeriesB1ConvertiblePreferredStockMember_20201027_20201027">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bdsx:SeriesB1ConvertiblePreferredStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-10-27</xbrli:startDate>
					<xbrli:endDate>2020-10-27</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_20201027_20201027">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-10-27</xbrli:startDate>
					<xbrli:endDate>2020-10-27</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapClassOfWarrantOrRightAxis_bdsxSeriesEConvertiblePreferredStockWarrantsMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">bdsx:SeriesEConvertiblePreferredStockWarrantsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapClassOfWarrantOrRightAxis_bdsxSeriesGConvertiblePreferredStockWarrantsMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">bdsx:SeriesGConvertiblePreferredStockWarrantsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapClassOfWarrantOrRightAxis_bdsxSeriesEConvertiblePreferredStockWarrantsMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">bdsx:SeriesEConvertiblePreferredStockWarrantsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapClassOfWarrantOrRightAxis_bdsxSeriesGConvertiblePreferredStockWarrantsMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">bdsx:SeriesGConvertiblePreferredStockWarrantsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_srtProductOrServiceAxis_bdsxDiagnosticTestsMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bdsx:DiagnosticTestsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_srtProductOrServiceAxis_bdsxDiagnosticTestsMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bdsx:DiagnosticTestsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_srtProductOrServiceAxis_us-gaapServiceMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_srtProductOrServiceAxis_us-gaapServiceMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_srtProductOrServiceAxis_bdsxCOVID19DiagnosticTestRevenueMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bdsx:COVID19DiagnosticTestRevenueMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_srtProductOrServiceAxis_bdsxLungDiagnosticRevenueMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bdsx:LungDiagnosticRevenueMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapBalanceSheetLocationAxis_bdsxDeferredRevenueMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">bdsx:DeferredRevenueMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapBalanceSheetLocationAxis_bdsxDeferredRevenueMember_20200101">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">bdsx:DeferredRevenueMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-01-01</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20201031">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-10-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapPlanNameAxis_bdsxTwoThousandTwentyEquityIncentivePlanMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bdsx:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapPlanNameAxis_bdsxTwoThousandTwentyEquityIncentivePlanMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bdsx:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_srtRangeAxis_srtMaximumMember_us-gaapPlanNameAxis_bdsxTwoThousandTwentyEquityIncentivePlanMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bdsx:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_srtRangeAxis_srtMaximumMember_us-gaapPlanNameAxis_bdsxTwoThousandSixPlanMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bdsx:TwoThousandSixPlanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapPlanNameAxis_bdsxTwoThousandAndSixteenPlanMember_20160229">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bdsx:TwoThousandAndSixteenPlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2016-02-29</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_srtRangeAxis_srtMaximumMember_us-gaapPlanNameAxis_bdsxTwoThousandAndSixteenPlanMember_20160229">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bdsx:TwoThousandAndSixteenPlanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2016-02-29</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapPlanNameAxis_bdsxTwoThousandSixPlanTwoThousandSixteenPlanAndTwoThousandTwentyEquityIncentivePlanMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bdsx:TwoThousandSixPlanTwoThousandSixteenPlanAndTwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_srtRangeAxis_srtMaximumMember_us-gaapPlanNameAxis_bdsxTwoThousandTwentyEquityIncentivePlanMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bdsx:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapAwardTypeAxis_bdsxPerformanceConditionOptionsMember_us-gaapPlanNameAxis_bdsxTwoThousandTwentyEquityIncentivePlanMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bdsx:PerformanceConditionOptionsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bdsx:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapAwardTypeAxis_bdsxPerformanceConditionOptionsMember_us-gaapPlanNameAxis_bdsxTwoThousandTwentyEquityIncentivePlanMember_20190101_20190101">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bdsx:PerformanceConditionOptionsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bdsx:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-01-01</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapAwardTypeAxis_bdsxPerformanceConditionOptionsMember_us-gaapPlanNameAxis_bdsxTwoThousandTwentyEquityIncentivePlanMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bdsx:PerformanceConditionOptionsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bdsx:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapAwardTypeAxis_bdsxPerformanceConditionOptionsMember_us-gaapPlanNameAxis_bdsxTwoThousandTwentyEquityIncentivePlanMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bdsx:PerformanceConditionOptionsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bdsx:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_srtRangeAxis_srtMinimumMember_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_bdsxTwoThousandTwentyEquityIncentivePlanMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bdsx:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_bdsxBonusToOptionsProgramMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bdsx:BonusToOptionsProgramMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_bdsxBonusToOptionsProgramMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bdsx:BonusToOptionsProgramMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapAwardTypeAxis_bdsxBonusToOptionsProgramMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bdsx:BonusToOptionsProgramMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapAwardTypeAxis_bdsxBonusToOptionsProgramMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bdsx:BonusToOptionsProgramMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapAwardTypeAxis_bdsxOptionsAndRestrictedStockUnitsMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bdsx:OptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapAwardTypeAxis_bdsxOptionsAndRestrictedStockUnitsMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bdsx:OptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapAwardTypeAxis_bdsxServiceConditionRSUsMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bdsx:ServiceConditionRSUsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_srtRangeAxis_srtMinimumMember_us-gaapAwardTypeAxis_bdsxServiceConditionRSUsMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bdsx:ServiceConditionRSUsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapAwardTypeAxis_bdsxServiceConditionRSUsMember_us-gaapVestingAxis_us-gaapShareBasedCompensationAwardTrancheOneMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bdsx:ServiceConditionRSUsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapAwardTypeAxis_bdsxServiceConditionRSUsMember_us-gaapVestingAxis_us-gaapShareBasedCompensationAwardTrancheTwoMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bdsx:ServiceConditionRSUsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_bdsxOptionsToPurchaseCommonStockMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bdsx:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_bdsxOptionsToPurchaseCommonStockMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bdsx:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapWarrantMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapWarrantMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapRestrictedStockUnitsRSUMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapRestrictedStockUnitsRSUMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapConvertibleDebtSecuritiesMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_srtCounterpartyNameAxis_bdsxAVEOOncologyMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_bdsxNSCLCPOCTrialMember_20201031">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bdsx:AVEOOncologyMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bdsx:NSCLCPOCTrialMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-10-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_srtCounterpartyNameAxis_bdsxAVEOOncologyMember_srtProductOrServiceAxis_bdsxBDX004Member_us-gaapEquitySecuritiesByIndustryAxis_bdsxFiclatuzumabMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_bdsxPOCClinicalTrialsMember_20201031">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bdsx:BDX004Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:EquitySecuritiesByIndustryAxis">bdsx:FiclatuzumabMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bdsx:AVEOOncologyMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bdsx:POCClinicalTrialsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-10-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_srtCounterpartyNameAxis_bdsxAVEOOncologyMember_us-gaapEquitySecuritiesByIndustryAxis_bdsxFiclatuzumabMember_20200901_20200930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:EquitySecuritiesByIndustryAxis">bdsx:FiclatuzumabMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bdsx:AVEOOncologyMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-09-01</xbrli:startDate>
					<xbrli:endDate>2020-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_srtCounterpartyNameAxis_bdsxAVEOOncologyMember_20201202_20201202">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bdsx:AVEOOncologyMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-12-02</xbrli:startDate>
					<xbrli:endDate>2020-12-02</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_srtCounterpartyNameAxis_bdsxAVEOOncologyMember_us-gaapEquitySecuritiesByIndustryAxis_bdsxFiclatuzumabMember_20201202_20201202">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:EquitySecuritiesByIndustryAxis">bdsx:FiclatuzumabMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bdsx:AVEOOncologyMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-12-02</xbrli:startDate>
					<xbrli:endDate>2020-12-02</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_srtCounterpartyNameAxis_bdsxAVEOOncologyMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bdsx:AVEOOncologyMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_srtCounterpartyNameAxis_bdsxAVEOOncologyMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bdsx:AVEOOncologyMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_bdsxBioRadLicenseMember_20190801_20190831">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bdsx:BioRadLicenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-08-01</xbrli:startDate>
					<xbrli:endDate>2019-08-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_bdsxBioRadLicenseMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bdsx:BioRadLicenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_bdsxBioRadLicenseMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bdsx:BioRadLicenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001439725_us-gaapBusinessAcquisitionAxis_bdsxOncimmuneLimitedMember_us-gaapTypeOfArrangementAxis_bdsxRevenueShareAgreementMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bdsx:RevenueShareAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bdsx:OncimmuneLimitedMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
		</ix:resources>
	</ix:header>
</div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="border-top:Double 2.25pt;padding-top:1pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> <span style="margin-left:36pt;"> </span>&#160;</p>
<p style="border-top:Double 2.25pt;padding-top:1pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">UNITED STATES </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECURITIES AND EXCHANGE COMMISSION </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Washington, D.C. 20549 </p>
<p style="text-align:center;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;margin-right:46.15%;text-indent:0%;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FORM <ix:nonNumeric id="F_000000" name="dei:DocumentType" contextRef="C_0001439725_20200101_20201231">10-K</ix:nonNumeric><span style="font-weight:normal;"> </span></p>
<p style="text-align:center;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;margin-right:46.15%;text-indent:0%;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> (Mark&#160;One) </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Segoe UI Symbol;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000002" name="dei:DocumentAnnualReport" contextRef="C_0001439725_20200101_20201231" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric></p></td>
<td valign="top" style="width:96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ANNUAL REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF&#160;1934 </p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">For the fiscal year ended <ix:nonNumeric id="F_000003" name="dei:DocumentPeriodEndDate" contextRef="C_0001439725_20200101_20201231" format="ixt:datemonthdayyearen">December 31, <ix:nonNumeric id="F_000004" name="dei:DocumentFiscalYearFocus" contextRef="C_0001439725_20200101_20201231">2020</ix:nonNumeric></ix:nonNumeric></p>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">OR </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Segoe UI Symbol;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000008" name="dei:DocumentTransitionReport" contextRef="C_0001439725_20200101_20201231" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p></td>
<td valign="top" style="width:96%;">
<p style="margin-top:2pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF&#160;1934 FOR THE TRANSITION PERIOD FROM&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; TO &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Commission File Number&#160;<ix:nonNumeric id="F_000009" name="dei:EntityFileNumber" contextRef="C_0001439725_20200101_20201231">001-39659</ix:nonNumeric> </p>
<p style="text-align:center;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;margin-right:46.15%;text-indent:0%;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:22pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000010" name="dei:EntityRegistrantName" contextRef="C_0001439725_20200101_20201231">Biodesix, Inc.</ix:nonNumeric></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(Exact name of Registrant as specified in its Charter) </p>
<p style="text-align:center;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;margin-right:46.15%;text-indent:0%;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000011" name="dei:EntityIncorporationStateCountryCode" contextRef="C_0001439725_20200101_20201231" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></p></td>
<td valign="bottom" style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000012" name="dei:EntityTaxIdentificationNumber" contextRef="C_0001439725_20200101_20201231">20-3986492</ix:nonNumeric></p></td>
</tr>
<tr>
<td valign="bottom" style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(State or other jurisdiction of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">incorporation or organization)</p></td>
<td valign="bottom" style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(I.R.S. Employer</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Identification No.)</p></td>
</tr>
<tr>
<td valign="bottom" style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000013" name="dei:EntityAddressAddressLine1" contextRef="C_0001439725_20200101_20201231">2970 Wilderness Place</ix:nonNumeric>, <ix:nonNumeric id="F_000014" name="dei:EntityAddressAddressLine2" contextRef="C_0001439725_20200101_20201231">Suite 100</ix:nonNumeric></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000015" name="dei:EntityAddressCityOrTown" contextRef="C_0001439725_20200101_20201231">Boulder</ix:nonNumeric>, <ix:nonNumeric id="F_000016" name="dei:EntityAddressStateOrProvince" contextRef="C_0001439725_20200101_20201231">CO</ix:nonNumeric></p></td>
<td valign="bottom" style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000017" name="dei:EntityAddressPostalZipCode" contextRef="C_0001439725_20200101_20201231">80301</ix:nonNumeric></p></td>
</tr>
<tr>
<td valign="bottom" style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Address of principal executive offices)</p></td>
<td valign="bottom" style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Zip Code)</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Registrant&#8217;s telephone number, including area code: (<ix:nonNumeric id="F_000018" name="dei:CityAreaCode" contextRef="C_0001439725_20200101_20201231">303</ix:nonNumeric>)&#160;<ix:nonNumeric id="F_000019" name="dei:LocalPhoneNumber" contextRef="C_0001439725_20200101_20201231">417-0500</ix:nonNumeric> </p>
<p style="text-align:center;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;margin-right:46.15%;text-indent:0%;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Securities registered pursuant to Section&#160;12(b) of the Act: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr style="height:4pt;">
<td valign="bottom" style="width:39%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Title of each class</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="width:20%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Trading</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Symbol(s)</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="width:39%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Name of each exchange on which registered</p></td>
</tr>
<tr>
<td valign="top" style="width:39%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000020" name="dei:Security12bTitle" contextRef="C_0001439725_20200101_20201231">Common Stock, par value $0.001 per share</ix:nonNumeric></p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;">&#160;</p></td>
<td valign="bottom" style="width:20%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000022" name="dei:TradingSymbol" contextRef="C_0001439725_20200101_20201231">BDSX</ix:nonNumeric></p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;">&#160;</p></td>
<td valign="bottom" style="width:39%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000023" name="dei:SecurityExchangeName" contextRef="C_0001439725_20200101_20201231" format="ixt-sec:exchnameen">The NASDAQ Global Market</ix:nonNumeric></p></td>
</tr>
</table></div>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Securities registered pursuant to Section&#160;12(g) of the Act: <span style="font-weight:bold;">None </span></p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule&#160;405 of the Securities Act.&#160;<span style="text-transform:uppercase;">Yes</span>&#160;<span style="font-family:Segoe UI Symbol;">&#9744;</span> <span style="text-transform:uppercase;"><ix:nonNumeric id="F_000024" name="dei:EntityWellKnownSeasonedIssuer" contextRef="C_0001439725_20200101_20201231">No</ix:nonNumeric></span>&#160;<span style="font-family:Segoe UI Symbol;">&#9746;</span></p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark if the Registrant is not required to file reports pursuant to Section&#160;13 or 15(d) of the Act. &#160;<span style="text-transform:uppercase;"><ix:nonNumeric id="F_000025" name="dei:EntityVoluntaryFilers" contextRef="C_0001439725_20200101_20201231">Yes</ix:nonNumeric></span>&#160;<span style="font-family:Segoe UI Symbol;">&#9746;</span> <span style="text-transform:uppercase;">No</span>&#160;<span style="font-family:Segoe UI Symbol;">&#9744;</span></p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the Registrant: (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the Registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days. &#160;<span style="text-transform:uppercase;"><ix:nonNumeric id="F_000026" name="dei:EntityCurrentReportingStatus" contextRef="C_0001439725_20200101_20201231">Yes</ix:nonNumeric></span>&#160;<span style="font-family:Segoe UI Symbol;">&#9746;</span> <span style="text-transform:uppercase;">No</span>&#160;<span style="font-family:Segoe UI Symbol;">&#9744;</span></p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation&#160;S-T (&#167;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the Registrant was required to submit such files). &#160;<span style="text-transform:uppercase;"><ix:nonNumeric id="F_000027" name="dei:EntityInteractiveDataCurrent" contextRef="C_0001439725_20200101_20201231">Yes</ix:nonNumeric></span>&#160;<span style="font-family:Segoe UI Symbol;">&#9746;</span> <span style="text-transform:uppercase;">No</span>&#160;<span style="font-family:Segoe UI Symbol;">&#9744;</span></p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr style="height:10.8pt;">
<td valign="top" style="width:19.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Large&#160;accelerated&#160;filer</p></td>
<td valign="top" style="width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:55.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</p></td>
<td valign="top" style="width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:20.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accelerated&#160;filer</p></td>
<td valign="top" style="width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:2.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</p></td>
</tr>
<tr style="height:1.9pt;">
<td valign="top" style="width:19.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:56.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:21.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:2.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:19.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000028" name="dei:EntityFilerCategory" contextRef="C_0001439725_20200101_20201231" format="ixt-sec:entityfilercategoryen">Non-accelerated filer</ix:nonNumeric></p></td>
<td valign="top" style="width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:55.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</p></td>
<td valign="top" style="width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:20.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Smaller&#160;reporting&#160;company</p></td>
<td valign="top" style="width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:2.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000029" name="dei:EntitySmallBusiness" contextRef="C_0001439725_20200101_20201231" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric></p></td>
</tr>
<tr style="height:1.9pt;">
<td valign="top" style="width:19.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&#160;</p></td>
<td valign="top" style="width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&#160;</p></td>
<td valign="top" style="width:55.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&#160;</p></td>
<td valign="top" style="width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&#160;</p></td>
<td valign="top" style="width:20.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&#160;</p></td>
<td valign="top" style="width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&#160;</p></td>
<td valign="top" style="width:2.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:19.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Emerging growth company</p></td>
<td valign="top" style="width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="top" style="width:55.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000030" name="dei:EntityEmergingGrowthCompany" contextRef="C_0001439725_20200101_20201231" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric></p></td>
<td valign="top" style="width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="top" style="width:20.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="top" style="width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="top" style="width:2.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#160;<span style="font-family:Segoe UI Symbol;"><ix:nonNumeric id="F_000031" name="dei:EntityExTransitionPeriod" contextRef="C_0001439725_20200101_20201231" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span></p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.&#160;&#160;<span style="font-family:Segoe UI Symbol;"><ix:nonNumeric id="F_000021" name="dei:IcfrAuditorAttestationFlag" contextRef="C_0001439725_20200101_20201231" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span></p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the Registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act). &#160;<span style="text-transform:uppercase;">Yes</span>&#160;<span style="font-size:8.5pt;font-family:Segoe UI Symbol;"><ix:nonNumeric id="F_000032" name="dei:EntityShellCompany" contextRef="C_0001439725_20200101_20201231" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span> <span style="text-transform:uppercase;">No</span>&#160;<span style="font-family:Segoe UI Symbol;">&#9746;</span></p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The aggregate market value of the Registrant&#8217;s common stock, par value $.001 per share (the &#8220;Common Stock&#8221;) held by non-affiliates was approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000034" name="dei:EntityPublicFloat" contextRef="C_0001439725_20201231" decimals="0" format="ixt:numdotdecimal">344,635,079</ix:nonFraction> based upon the December 31, 2020, closing price of $20.16 as reported by the Nasdaq Global Select Market. The Registrant has elected to use December 31, 2020 as the calculation date, which was the last trading date of the registrant&#8217;s most recently completed fiscal year, because on June 30, 2020 (the last business day of the registrant&#8217;s second fiscal quarter), the Registrant was a privately held company. </p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The number of shares of Registrant&#8217;s Common Stock outstanding as of March 12, 2021 was <ix:nonFraction unitRef="U_xbrlishares" id="F_000033" name="dei:EntityCommonStockSharesOutstanding" contextRef="C_0001439725_20210312" decimals="INF" format="ixt:numdotdecimal">26,577,782</ix:nonFraction>. </p><ix:nonNumeric id="F_000273" name="dei:DocumentsIncorporatedByReferenceTextBlock" contextRef="C_0001439725_20200101_20201231" escape="true">
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DOCUMENTS INCORPORATED BY REFERENCE</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Portions of the Company&#8217;s definitive Proxy Statement for its 2021 Annual Meeting of Shareholders are to be incorporated by reference into Part</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">III, as specifically set forth in Part III.)</p></ix:nonNumeric>
<p style="border-bottom:Double 2.25pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-size:3pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;">&#160;</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Table of Contents</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:83%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Page</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PART I</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;1.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1_BUSINESS"><span style="text-decoration:underline;">Business</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;1A.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1A_RISK_FACTOR"><span style="text-decoration:underline;">Risk Factors</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;1B.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#N1B_UNRESOLVED_STAFF_COMMENTS"><span style="text-decoration:underline;">Unresolved Staff Comments</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;2.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_2_PROPERTIES"><span style="text-decoration:underline;">Properties</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;3.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_3_LEGAL_PROCEEDINGS"><span style="text-decoration:underline;">Legal Proceedings</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;4.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_4_MINE_SAFETY_DISCLOSURES"><span style="text-decoration:underline;">Mine Safety Disclosures</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PART&#160;II</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;5.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_5_MARKET_FOR_REGISTRANTS_COMMON_EQU"><span style="text-decoration:underline;">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;6.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_6_SELECTED_FINANCIAL_DATA"><span style="text-decoration:underline;">Selected Financial Data</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;7.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_7_MANAGEMENTS_DISCUSSION_ANALYSIS_F"><span style="text-decoration:underline;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">102</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;7A.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_7A_QUANTITATIVE_QUALITATIVE_DISCLOS"><span style="text-decoration:underline;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">115</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;8.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_8_FINANCIAL_STATEMENTS_SUPPLEMENTAR"><span style="text-decoration:underline;">Financial Statements and Supplementary Data</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">115</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;9.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_9_CHANGES_IN_DISAGREEMENTS_WITH_ACC"><span style="text-decoration:underline;">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">115</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;9A.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_9A_CONTROLS_PROCEDURES"><span style="text-decoration:underline;">Controls and Procedures</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">115</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;9B.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_9B_OR_INFORMATION"><span style="text-decoration:underline;">Other Information</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">115</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PART&#160;III</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;10.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_10_DIRECTORS_EXECUTIVE_FICERS_CORPO"><span style="text-decoration:underline;">Directors, Executive Officers and Corporate Governance</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">116</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;11.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_11_EXECUTIVE_COMPENSATION"><span style="text-decoration:underline;">Executive Compensation</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">116</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;12.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_12_SECURITY_OWNERSHIP_CERTAIN_BENEF"><span style="text-decoration:underline;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">116</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;13.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_13_CERTAIN_RELATIONSHIPS_RELATED_TR"><span style="text-decoration:underline;">Certain Relationships and Related Transactions, and Director Independence</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">116</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;14.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_14_PRINCIPAL_ACCOUNTING_FEES_SERVIC"><span style="text-decoration:underline;">Principal Accounting Fees and Services</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">116</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PART&#160;IV</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;15.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_15_EXHIBITS_FINANCIAL_STATEMENT_SCH"><span style="text-decoration:underline;">Exhibits, Financial Statement Schedules</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">117</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;16</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_16_FORM_10K_SUMMARY"><span style="text-decoration:underline;">Form 10-K Summary</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">117</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">i</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Annual Report on Form 10-K contains forward-looking statements about us and our industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this Annual Report on Form 10-K, including statements regarding our future financial condition, results of operations, business strategy and plans, and objectives of management for future operations, as well as statements regarding industry trends, are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potentially,&#8221; &#8220;predict,&#8221; &#8220;should,&#8221; &#8220;will&#8221; or the negative of these terms or other similar expressions.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have based these forward-looking statements largely on our current expectations and projections about future events and trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. These forward-looking statements are subject to a number of risks, uncertainties, factors, and assumptions described under the section titled &#8220;Risk Factors&#8221; and elsewhere in this annual Report on Form 10-K, regarding, among other things:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our inability to achieve or sustain profitability&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our ability to attain significant market acceptance among payers, providers, clinics, patients, and biopharmaceutical companies for our diagnostic tests&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">difficulties managing our growth, which could disrupt our operations&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">failure to retain sales and marketing personnel, and failure to increase our sales and marketing capabilities or develop broad awareness of our diagnostic tests to generate revenue growth&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">failure to maintain our current relationships, or enter into new relationships, with biopharmaceutical companies&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">significant fluctuation in our operating results, causing our operating results to fall below expectations or any guidance we provide&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the demand for our COVID-19 and antibody testing program and our ability to meet such demand&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">product performance and reliability to maintain and grow our business&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">third-party suppliers, including courier services, contract manufacturers and single source suppliers&#59; making us vulnerable to supply problems and price fluctuations&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the impact of a pandemic, epidemic, or outbreak of an infectious disease in the United States or worldwide, including the COVID-19 pandemic on our business&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">natural or man-made disasters and other similar events, including the COVID-19 pandemic, negatively impacting our business, financial condition, and results of operations&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">failure to offer high-quality support for our diagnostic tests, which may adversely affect our relationships with providers and negatively impact our reputation among patients and providers&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our inability to continue to innovate and improve our diagnostic tests and services we offer&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">security or data privacy breaches or other unauthorized or improper access&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">significant disruptions in our information technology systems&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the incurrence of substantial liabilities and limiting or halting the marketing and sale of our diagnostic tests due to product liability lawsuits&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our inability to compete successfully with competition from many sources, including larger companies&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">performance issues, service interruptions or price increases by our shipping carriers and warehousing providers&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">cost-containment efforts of our customers, purchasing groups and integrated delivery networks having a material adverse effect on our sales and profitability&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">potential effects of litigation and other proceedings&#59;</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">general economic and financial market conditions&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our ability to attract and retain key personnel&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">current and future debt financing placing restrictions on our operating and financial flexibility&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our need to raise additional capital to fund our existing operations, develop our platform, commercialize new diagnostic tests, or expand our operations&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the acquisition of other businesses, which could require significant management attention&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the uncertainty of the insurance coverage and reimbursement status of newly approved diagnostic tests&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">future healthcare reform measures that could hinder or prevent the commercial success of our diagnostic tests&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">compliance with anti-corruption, anti-bribery, anti-money laundering and similar laws&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">compliance with healthcare fraud and abuse laws&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our ability to develop, receive regulatory clearance or approval or certification for, and introduce new diagnostic tests or enhancements to existing diagnostic tests that will be accepted by the market in a timely manner&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">failure to comply with ongoing FDA or other domestic and foreign regulatory authority requirements, or unanticipated problems with our diagnostic tests, causing them to be subject to restrictions or withdrawal from the market&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">future product recalls&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">legal proceedings initiated by third parties alleging that we are infringing, misappropriating, or otherwise violating their intellectual property rights, the outcome of which would be uncertain&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the volatility of the trading price of our common stock&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">inaccurate estimates or judgments relating to our critical accounting policies, which could cause our operating results to fall below the expectations of securities analysts and investors&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">other risks, uncertainties and factors, including those set forth under Risk Factors.</span></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These risks are not exhaustive. Other sections of this Annual Report on Form 10-K may include additional factors that could harm our business and financial performance. New risk factors may emerge from time to time and it is not possible for our management to predict all risk factors, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in, or implied by, any forward-looking statements.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. Except as required by law, we undertake no obligation to update publicly any forward-looking statements for any reason after the date of this Annual Report on Form 10-K or to conform these statements to actual results or to changes in our expectations.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, statements that &#8220;we believe&#8221; and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this Annual Report on Form 10-K, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">You should read this Annual Report on Form 10-K and the documents that we reference and have filed as exhibits with the understanding that our actual future results, levels of activity, performance and achievements may be different from what we expect. We qualify all of our forward-looking statements by these cautionary statements.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PART I</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_1_BUSINESS">Item 1. Business. </p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our <span style="font-weight:bold;">mission</span> is to improve every patient&#8217;s lung disease care by empowering physicians with swift, comprehensive and actionable insights.</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our <span style="font-weight:bold;">vision</span> is to be a trusted business partner that the world relies on for data-driven diagnostics in lung disease and beyond.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Business Overview</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Biodesix, Inc. (&#8220;Biodesix&#8221;, &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our&#8221; or the &#8220;Company&#8221;) is a leading data-driven diagnostic solutions company leveraging state of the art technologies with our proprietary artificial intelligence (AI) platform to discover, develop, and commercialize solutions for clinical unmet needs, with a primary focus in lung disease. By combining a technology agnostic approach with a holistic view of the patient&#8217;s disease state, we believe our solutions provide physicians with greater insights to help personalize their patient&#8217;s care and meaningfully improve disease detection, evaluation, and treatment. Our unique approach to precision medicine provides timely and actionable clinical information, which we believe improves overall patient outcomes and lowers the overall healthcare cost by reducing the use of ineffective and unnecessary treatments and procedures. In addition to our diagnostic tests, we provide biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our core belief is that no single technology will answer all clinical questions that we encounter. Therefore, we employ multiple technologies, including genomics, transcriptomics, proteomics, and radiomics, and leverage our proprietary AI platform, the Diagnostic Cortex&#174;, to discover innovative diagnostic tests for clinical use. Because of this approach, we believe we are unique in the diagnostics market as this approach allows for a broader and more holistic understanding of each patient&#8217;s disease state. Our data-driven and technology agnostic approach is designed to enable us to discover diagnostic tests that answer critical clinical questions faced by physicians, researchers, and biopharmaceutical companies.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We operate in a single segment and derive our revenue from two sources: (i) providing diagnostic testing services associated with blood-based lung and Coronavirus Disease 2019 (COVID-19) tests (Diagnostic Tests)&#59; and (ii) providing biopharmaceutical companies with services that include diagnostic research, clinical research, development and testing services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics (Services). We derived 90% and 71% of our total revenues for fiscal 2020 and fiscal 2019, respectively, from our diagnostic testing business.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;letter-spacing:-0.4pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are dedicated to continuously publishing and presenting new data on the clinical validation and utility of our diagnostic tests. Since our inception, we have performed over 285,000 tests and continue to generate a large and growing body of clinical evidence. We have participated in 27 clinical studies, five of which are ongoing, and have published over 275 peer-reviewed publications and presentations. We have over 140,000 samples and data in our biobank, including tumor profiles and immune profiles, which are used for both internal and external research and development (R&#38;D)<span style="letter-spacing:-0.1pt;"> </span>initiatives.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have commercialized six diagnostic tests which are currently on market and we perform over 30 assays for research use as part of our laboratory services that have been used by over 50 biopharmaceutical customers and academic partners.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Blood-Based Lung Tests</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have four diagnostic blood-based tests across the lung cancer continuum of care, <span style="Background-color:#FFFFFF;">which generated $12.6 million and $17.3 million in revenue for fiscal 2020 and 2019</span>, respectively.</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;color:#000000;">Nodify XL2&#174; </span><span style="color:#000000;">and </span><span style="font-style:italic;color:#000000;">Nodify CDT&#8482; </span><span style="color:#000000;">tests, together marketed as part of our Nodify Lung</span><span style="font-style:italic;color:#000000;">&#8482; </span><span style="color:#000000;">Nodule Risk Assessment testing strategy, assess the risk of lung cancer to help identify the most appropriate treatment </span><span style="letter-spacing:-0.15pt;color:#000000;">pathway. </span><span style="letter-spacing:-0.4pt;color:#000000;">We </span><span style="color:#000000;">believe we are the only company to offer two commercial blood-based tests to help physicians reclassify risk of malignancy in patients with suspicious lung</span><span style="letter-spacing:-1.2pt;color:#000000;"> </span><span style="color:#000000;">nodules.</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="text-decoration:none;Background-color:#auto;font-family:'Times New Roman';"></span><span style="color:#000000;"></span><span style="font-style:italic;color:#000000;">GeneStrat</span><span style="font-style:italic;color:#000000;">&#174; </span><span style="color:#000000;">and </span><span style="font-style:italic;letter-spacing:-0.15pt;color:#000000;">VeriStrat</span><span style="font-style:italic;letter-spacing:-0.15pt;color:#000000;">&#174; </span><span style="color:#000000;">tests, </span><span style="color:#000000;">together </span><span style="color:#000000;">marketed as part of our Biodesix Lung Reflex</span><span style="font-style:italic;color:#000000;">&#174; </span><span style="color:#000000;">testing strategy, are used following diagnosis of lung cancer to measure the presence of mutations in the tumor and the</span><span style="letter-spacing:-0.75pt;color:#000000;"> </span><span style="color:#000000;">state</span><span style="color:#000000;"> of the patient&#8217;s immune system to establish the patient&#8217;s prognosis and help guide treatment decisions. The GeneStrat tumor profiling test and the VeriStrat immune profiling test have a three-day average turnaround time, providing physicians with timely results to facilitate treatment decisions.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">COVID-19 Tests</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In response to the COVID-19 pandemic, through our partnership with Bio-Rad, we commercialized the Biodesix <span style="letter-spacing:-0.15pt;">WorkSafe&#8482; </span>testing program. We generated $28.3 million in revenue from COVID-19 testing during fiscal 2020. Our scientific diagnostic expertise, technologies, and existing commercial infrastructure enabled us to rapidly commercialize two United States Food and<span style="letter-spacing:-0.25pt;"> </span>Drug<span style="letter-spacing:-0.2pt;"> </span>Administration<span style="letter-spacing:-0.25pt;"> </span>(FDA)<span style="letter-spacing:-0.2pt;"> </span>Emergency<span style="letter-spacing:-0.25pt;"> </span>Use<span style="letter-spacing:-0.2pt;"> </span>Authorization<span style="letter-spacing:-0.2pt;"> </span>(EUA)-authorized<span style="letter-spacing:-0.25pt;"> </span>tests,<span style="letter-spacing:-0.2pt;"> </span>a<span style="letter-spacing:-0.25pt;"> </span>part<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.25pt;"> </span>our<span style="letter-spacing:-0.2pt;"> </span>customizable<span style="letter-spacing:-0.15pt;"> WorkSafe&#8482;</span><span style="letter-spacing:-0.2pt;"> </span>program.<span style="letter-spacing:-0.25pt;"> </span>Both<span style="letter-spacing:-0.2pt;"> </span>diagnostic<span style="letter-spacing:-0.25pt;"> </span>tests<span style="letter-spacing:-0.2pt;"> </span>are owned<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>were<span style="letter-spacing:-0.1pt;"> </span>developed<span style="letter-spacing:-0.15pt;"> </span>by<span style="letter-spacing:-0.1pt;"> </span>Bio-Rad<span style="letter-spacing:-0.1pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>Bio-Rad<span style="letter-spacing:-0.1pt;"> </span>has<span style="letter-spacing:-0.1pt;"> </span>granted<span style="letter-spacing:-0.15pt;"> </span>us<span style="letter-spacing:-0.1pt;"> </span>permission<span style="letter-spacing:-0.1pt;"> </span>to<span style="letter-spacing:-0.15pt;"> </span>utilize<span style="letter-spacing:-0.1pt;"> </span>both<span style="letter-spacing:-0.1pt;"> </span>tests<span style="letter-spacing:-0.15pt;"> </span>for<span style="letter-spacing:-0.1pt;"> </span>commercial<span style="letter-spacing:-0.1pt;"> </span>diagnostic<span style="letter-spacing:-0.15pt;"> </span>services.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2020, the U.S. Department of Health and Human Services Secretary declared a public health emergency for COVID-19 which justified the authorization of emergency use of diagnostic tests for the detection and/or diagnosis of COVID-19. The Bio-Rad <span style="letter-spacing:-0.15pt;">SARS-CoV-2 </span>Droplet Digital&#8482; <span style="letter-spacing:-0.15pt;">polymerase chain reaction (</span>ddPCR) test and the Platelia <span style="letter-spacing:-0.15pt;">SARS-CoV-2 Total </span>Ab test have been granted FDA EUA pursuant to the current emergency declaration. The Bio-Rad SARS-<span style="letter-spacing:-0.2pt;">CoV-2 </span>ddPCR test was FDA EUA authorized on May 1, 2020, authorizing performance of the test in laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) to perform high complexity tests. The second test is the Platelia <span style="letter-spacing:-0.15pt;">SARS-CoV-2 Total </span>Ab test, which is an antibody test intended for detecting a B-cell immune response to <span style="letter-spacing:-0.15pt;">SARS-CoV-2, </span>indicating recent or prior infection. The Platelia <span style="letter-spacing:-0.15pt;">SARS-CoV-2 Total </span>Ab test was FDA EUA authorized on April 29, 2020. Medical products that are granted an EUA are only permitted to commercialize their products under the terms and conditions provided in the authorization. The FDA may revoke an EUA where it is determined that the underlying health emergency no longer exists or warrants such authorization, if the conditions for the issuance of the EUA are no longer met, or if other circumstances make revocation appropriate to protect the public health or safety, and we cannot predict how long the EUAs for the <span style="letter-spacing:-0.15pt;">SARS-CoV-2 </span>tests will remain in place. Using the Bio-Rad <span style="letter-spacing:-0.15pt;">SARS-CoV-2 </span>ddPCR test and the Platelia <span style="letter-spacing:-0.15pt;">SARS-CoV-2 Total </span>Ab tests, we operate and have commercialized the Biodesix <span style="letter-spacing:-0.15pt;">WorkSafe </span>testing<span style="letter-spacing:-1.6pt;"> </span>program.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to using the Bio-Rad tests as part of our WorkSafe testing program, we performed feasibility, verification, and validation studies, including developing software for process automation, sample accessioning, data management and reporting, all required to demonstrate the test operated as claimed by the manufacturer and as required by our certifying regulatory agencies for high complexity laboratory testing. We secured independent reference specimens run with EUA tests to validate these tests as fit for diagnostic use in our laboratories. Post-launch development support for these tests have included improvements in on-boarding new personnel, logistics of sample collection, sample receipt and data reporting, all required to support our testing program. Additional releases of the laboratory data management software are ongoing and planned for the foreseeable future.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These tests are utilized by healthcare providers, including hospitals and nursing homes, and are also offered to businesses and educational systems to assist in their back-to-work or back-to-school strategies, a crucial element of restarting economic activity. During 2020, we announced multiple partnerships for COVID-19 testing and have entered into an agreement with the State of Colorado to be one of the diagnostic companies to support wide-spread COVID-19 testing for the State. Additionally, we oversee and manage onsite testing and validating testing for the Big Ten Conference athletic competitions.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">COVID-19 Pandemic</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The COVID-19 pandemic has disrupted, and we expect will continue to disrupt, our non-COVID-19 testing operations. To protect the health and well-being of our workforce, partners, vendors and customers, we provide voluntary COVID-19 testing for employees working on-site, implemented social distance and building entry policies at work, restricted travel and facility visits, and followed the States of Colorado and Kansas&#8217; public health orders and the guidance from the Centers for Disease Control and Prevention. Employees who can perform their duties remotely are asked to work from home and those on site are asked to follow our social distance guidelines. Our sales, marketing and business development efforts have also been constrained by our operational response to the COVID-19 pandemic due to travel restrictions. We expect to continue to adjust our operational norms in an effort to help slow the spread of COVID-19 in the coming months, including complying with government directives and guidelines as they are modified and supplemented.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The COVID-19 pandemic also has started to negatively affect, and we expect will continue to negatively affect, our non-</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">COVID-19 </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">testing- related revenue and our clinical studies. For example, cancer patients may have more limited access to hospitals, healthcare providers and medical resources as they take steps to control the spread of COVID-19. Our biopharmaceutical customers are facing challenges in recruiting patients and in conducting clinical trials to advance their pipelines, for which our tests could be utilized. As a result of the COVID-19 pandemic, beginning in the latter half of March 2020, we have been receiving fewer samples for non-COVID-19 testing on a daily average basis from our clinical and biopharmaceutical customers than before the outbreak of the COVID-19 pandemic. Further, our clinical studies, such as our ongoing INSIGHT study and our recently launched ALTITUDE study, as well as our arrangements with our biopharmaceutical customers, are expected to take longer to complete than what we </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">originally </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">expected before the outbreak of the COVID-19 pandemic.</span></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Conversely, we are also experiencing an increase in revenues related to an increase in the demand for our Biodesix WorkSafe testing program which generated revenue of $28.3 million during fiscal 2020 of which $21.4 million is attributable to the fourth quarter 2020. As a result, our operating costs to expand capacity for COVID-19 testing also increased substantially during 2020 and we expect that trend to continue into the first quarter of 2021. There is no assurance that our COVID-19 testing program will continue to be accepted by the market or that other diagnostic tests will become more accepted, produce quicker results or are more accurate. Further, the longevity and extent of the COVID-19 pandemic is uncertain. If the pandemic were to dissipate, whether due to acquiring herd immunity based on previous natural infection, and the availability and rapid distribution of vaccines, the evolution of variant strains that impact diagnostic test performance, or otherwise, the need for a COVID-19 test could decrease significantly and this could have an adverse effect on our results of operations and profitability. As a result, the increase in revenue due to any increase in demand for these diagnostic tests may not be indicative of our future revenue. See &#8220;Risk Factors&#8221; for a description of how the COVID-19 pandemic may adversely affect our business, financial condition and results of operations.</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Full Year Results for 2020</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the year ended December 31, 2020, compared to the prior year:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;letter-spacing:-0.2pt;color:#000000;">Total </span><span style="font-style:italic;color:#000000;">Revenue </span><span style="color:#000000;">was $45.6 million, an increase of 86%&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;color:#000000;">Gross Margin </span><span style="color:#000000;">was $23.6 million,</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">an increase of 27%&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;color:#000000;">Operating Expenses, Excluding Cost of Revenue, </span><span style="color:#000000;">were $46.5 million, an increase of 3%&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;color:#000000;">Net Loss and Comprehensive Loss </span><span style="color:#000000;">was $31.4 million, an increase of</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">2%&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;color:#000000;">Basic and Diluted Net Loss Per Common Share </span><span style="color:#000000;">was $6.48&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;color:#000000;">Net Cash Used by Operating Activities </span><span style="color:#000000;">was $21.4 million, compared to $21.7 million used&#59;</span><span style="letter-spacing:-0.55pt;color:#000000;"> </span><span style="color:#000000;">and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;color:#000000;">Cash and Cash Equivalents </span><span style="color:#000000;">was $62.1 million at December 31,</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">2020, an increase of $56.8 million primarily resulting from our successful initial public offering in October 2020.</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Our Market Opportunity</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Diagnostic Testing Market Size and Opportunity</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Despite significant advances over the last decade, lung cancer is still the deadliest type of cancer in both men and women in the United States today. While diagnostic testing has become routinely used at certain points in the lung cancer continuum of care (diagnosis, treatment and monitoring), we believe there is a substantial need for novel, advanced testing to improve on the current standard of care. We estimate that in the United States, the lung cancer continuum of care currently represents over 10 million annual testing opportunities, and is over a $27 billion market annually for testing alone.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gegguy50oztz000001.jpg" title="" alt="" style="width:610px;height:178px;" /></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Over the last two decades, the use of biomarker testing in clinical trials has increased, with 55% of oncology trials involving the use of biomarker testing in 2018 versus 15% in 2000. We believe the field of biomarker discovery and companion diagnostic development for biopharmaceutical therapeutics is set to continue growing as biopharmaceutical companies seek to de-risk their research and development pipelines and increase chances of drug development success. We estimate that the biopharmaceutical partnering and research opportunities represent over a $2 billion market annually.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Lung Cancer Continuum of Care &#8211; Clinical Unmet Needs</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Standards of care in lung cancer have evolved rapidly over the past decade, along with our understanding of the disease. With the introduction of<span style="letter-spacing:0.05pt;"> </span>numerous<span style="letter-spacing:-0.25pt;"> </span>treatment<span style="letter-spacing:-0.2pt;"> </span>options,<span style="letter-spacing:-0.25pt;"> </span>physicians<span style="letter-spacing:-0.2pt;"> </span>need<span style="letter-spacing:-0.2pt;"> </span>an<span style="letter-spacing:-0.25pt;"> </span>ever-increasing<span style="letter-spacing:-0.2pt;"> </span>amount<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.25pt;"> </span>information<span style="letter-spacing:-0.2pt;"> </span>in<span style="letter-spacing:-0.25pt;"> </span>order<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.2pt;"> </span>select<span style="letter-spacing:-0.25pt;"> </span>the<span style="letter-spacing:-0.2pt;"> </span>best<span style="letter-spacing:-0.2pt;"> </span>treatment<span style="letter-spacing:-0.25pt;"> </span>plan<span style="letter-spacing:-0.2pt;"> </span>for<span style="letter-spacing:-0.2pt;"> </span>each<span style="letter-spacing:-0.25pt;"> </span>individual<span style="letter-spacing:-0.2pt;"> </span>patient.<span style="letter-spacing:0.05pt;"> </span>We believe that the lung cancer continuum of care has a variety of clinical unmet needs ranging from initial diagnosis of lung cancer after discovery of a<span style="letter-spacing:0.05pt;"> </span>lung<span style="letter-spacing:-0.1pt;"> </span>nodule<span style="letter-spacing:-0.1pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>treatment<span style="letter-spacing:-0.1pt;"> </span>guidance<span style="letter-spacing:-0.05pt;"> </span>for<span style="letter-spacing:-0.1pt;"> </span>early<span style="letter-spacing:-0.1pt;"> </span>and<span style="letter-spacing:-0.05pt;"> </span>advanced<span style="letter-spacing:-0.1pt;"> </span>stage<span style="letter-spacing:-0.05pt;"> </span>disease,<span style="letter-spacing:-0.1pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>monitoring<span style="letter-spacing:-0.05pt;"> </span>for<span style="letter-spacing:-0.1pt;"> </span>disease<span style="letter-spacing:-0.05pt;"> </span>progression.</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-weight:bold;color:#000000;">Diagnosis</span><span style="color:#000000;">: We estimate approximately 1.6 million new incidental lung nodules and potentially 4 million lung nodules from the adoption of screening could be identified annually in the United States. Following initial discovery of a nodule, patients are typically evaluated by a pulmonologist for risk of lung cancer before an invasive procedure is carried out to obtain a tissue sample to confirm diagnosis. This risk assessment is based on clinical factors such as the patient&#8217;s smoking history and age, and radiological features such as the size and location of the nodule, obtained from a computed tomography (CT) scan. On initial assessment, we estimate that approximately 80% of patients are identified as low to moderate risk (5-65%) where guideline recommendations for their care plan are unclear, often</span><span style="font-size:9pt;color:#000000;"> </span><span style="color:#000000;">resulting</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">in</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">either</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="font-style:italic;color:#000000;">overtreatment</span><span style="font-style:italic;letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">patients</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">with</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">benign</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">nodules</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="font-style:italic;color:#000000;">undertreatment</span><span style="font-style:italic;letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">in</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">patients</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">with</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">cancer.</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">An</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">estimated</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">17%</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">patients</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">with</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">malignant nodules are initially sent to watchful waiting, where a follow-up CT scan is scheduled in three to six months, potentially delaying</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">their diagnosis. Conversely, we estimate that 62% of biopsies and 35% of surgeries performed on lung nodules find benign disease,</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">representing a significant overtreatment that incurs both risk and cost to the patient and their providers. We therefore believe that there is a</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">clear clinical need for blood-based diagnostic testing to help improve the initial risk assessment of pulmonary nodules, helping direct patients</span><span style="letter-spacing:-2.1pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">relevant</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">treatment</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">pathway,</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">ultimately</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">improving</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">patient</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">outcomes</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">saving</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">costs</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">system.</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="text-decoration:none;Background-color:#auto;"></span><span style="color:#000000;"></span><span style="font-weight:bold;color:#000000;">Treatment Guidance &#8211; Early Stage</span><span style="color:#000000;">: We estimate that there are over 700,000 testing opportunities annually in the United States in early</span><span style="color:#000000;">-</span><span style="color:#000000;">stage lung cancer to assess a patient&#8217;s risk of recurrence following curative-intent surgery, and to detect potential target mutations for therapeutics. Depending on a patient&#8217;s risk of recurrence, they may also receive chemotherapy, radiotherapy or chemoradiation post-surgery. The assessment of risk of recurrence is primarily based on the stage of cancer at diagnosis, with stage I patients typically receiving no additional treatment beyond surgery. However, 20 to 40% of patients with stage I disease do still recur within five years following surgery, representing a sub-group of patients who may have benefitted from more intensive treatment protocol. We believe there is a clear clinical need for blood-based diagnostic testing prior to surgery to identify stage I patients who may benefit from a more </span><span style="color:#000000;">intensive treatment protocol and we also believe there is the need for identifying stage II and IIIA patients where low risk patients may benefit from a less intensive treatment protocol. There have also been recent advances in the use of targeted therapies in early</span><span style="color:#000000;">-</span><span style="color:#000000;">stage lung disease. These therapies typically target specific genomic mutations or alterations found in some tumors. We believe there is therefore an emerging need for testing designed specifically for mutation detection in </span><span style="color:#000000;">early</span><span style="color:#000000;">-stage</span><span style="color:#000000;"> disease.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-weight:bold;color:#000000;">Treatment Guidance &#8211; Advanced Stage: </span><span style="color:#000000;">We estimate that there are over 3 million diagnostic testing opportunities annually in the United States to guide advanced stage lung cancer treatment decisions. With nearly 50 FDA-approved systemic treatment regimens listed in national treatment guidelines for non-small cell lung cancer (NSCLC), there is an elevated need for personalized biomarkers to help physicians identify the right patient for the right treatment. Multiple tissue-based diagnostic tests have been approved to identify patients eligible for targeted therapies and immunotherapy&#59; however, about 50% of patients do not have sufficient tissue collected following diagnosis to facilitate testing. To compound the issue, different molecular tests take varying amounts of time (days versus weeks) to report results back to the ordering physician, which often leads to treatment decisions being made on incomplete information. Therefore, we believe there is an imminent need for a blood-based testing solution that measures tumor mutations and the patient&#8217;s immune profile, to provide physicians with more comprehensive and timely information to assess the overall prognosis of the patient and personalize treatment.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:9.08%;margin-right:1.71%;text-indent:-3.85%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-weight:bold;color:#000000;">Monitoring</span><span style="color:#000000;">: We estimate that there are over 800,000 testing opportunities in the United States for blood-based tumor and immune profiling to monitor for disease recurrence and progression in NSCLC patients. Unfortunately, advanced stage lung cancer is often terminal, so repeat tissue biopsy to assess the evolution of resistance mutations or to detect disease progression is not feasible from either a cost or risk perspective to the patient, which we believe demonstrates an important need for blood-based testing to help routinely monitor these patients. As a patient progresses through therapies, changes in their immune system occur and blood-based immune profiling could help physicians identify these changes prior to subsequent therapy selection.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Current Limitations in Biomarker Discovery and Companion Diagnostics</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.8%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We<span style="letter-spacing:-0.25pt;"> </span>estimate<span style="letter-spacing:-0.25pt;"> </span>the<span style="letter-spacing:-0.25pt;"> </span>biopharmaceutical<span style="letter-spacing:-0.25pt;"> </span>biomarker<span style="letter-spacing:-0.25pt;"> </span>testing<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.25pt;"> </span>companion<span style="letter-spacing:-0.25pt;"> </span>diagnostic<span style="letter-spacing:-0.25pt;"> </span>market<span style="letter-spacing:-0.25pt;"> </span>opportunity<span style="letter-spacing:-0.25pt;"> </span>is<span style="letter-spacing:-0.25pt;"> </span>$2<span style="letter-spacing:-0.25pt;"> </span>billion<span style="letter-spacing:-0.25pt;"> </span>annually<span style="font-style:italic;">.</span><span style="font-style:italic;letter-spacing:-0.25pt;"> </span>Over<span style="letter-spacing:-0.25pt;"> </span>the<span style="letter-spacing:-0.25pt;"> </span>last<span style="letter-spacing:-0.25pt;"> </span>two<span style="letter-spacing:-0.25pt;"> </span>decades,<span style="letter-spacing:0.05pt;"> </span>the use of biomarker testing in clinical trials has increased, with 55% of oncology trials involving the use of biomarker testing in 2018 versus 15% in 2000.<span style="letter-spacing:-2.1pt;"> </span>From<span style="letter-spacing:-0.1pt;"> </span>2005<span style="letter-spacing:-0.05pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>2015,<span style="letter-spacing:-0.05pt;"> </span>a study identified that incorporating biomarkers into clinical development programs increased their probability of therapeutic success rate from phase 1 to<span style="letter-spacing:0.05pt;"> </span>FDA-approval by 570%, representing an increase from 1.6% without biomarkers to 10.7% with biomarkers. We believe the field of biomarker discovery<span style="letter-spacing:0.05pt;"> </span>and<span style="letter-spacing:-0.25pt;"> </span>companion<span style="letter-spacing:-0.25pt;"> </span>diagnostic<span style="letter-spacing:-0.25pt;"> </span>development<span style="letter-spacing:-0.25pt;"> </span>for<span style="letter-spacing:-0.25pt;"> </span>biopharmaceutical<span style="letter-spacing:-0.25pt;"> </span>therapeutics<span style="letter-spacing:-0.25pt;"> </span>is<span style="letter-spacing:-0.25pt;"> </span>set<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.25pt;"> </span>continue<span style="letter-spacing:-0.25pt;"> </span>growing<span style="letter-spacing:-0.2pt;"> </span>as<span style="letter-spacing:-0.25pt;"> </span>biopharmaceutical<span style="letter-spacing:-0.25pt;"> </span>companies<span style="letter-spacing:-0.25pt;"> </span>seek<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.25pt;"> </span>de-risk<span style="letter-spacing:-0.25pt;"> </span>their<span style="letter-spacing:0.05pt;"> </span>product development efforts and increase chances of drug development success. However, we believe as the market continues to advance, inherent<span style="letter-spacing:0.05pt;"> </span>limitations<span style="letter-spacing:-0.1pt;"> </span>of<span style="letter-spacing:-0.1pt;"> </span>both<span style="letter-spacing:-0.05pt;"> </span>biomarker<span style="letter-spacing:-0.1pt;"> </span>discovery<span style="letter-spacing:-0.1pt;"> </span>and<span style="letter-spacing:-0.05pt;"> </span>companion<span style="letter-spacing:-0.1pt;"> </span>diagnostic<span style="letter-spacing:-0.1pt;"> </span>development<span style="letter-spacing:-0.05pt;"> </span>have<span style="letter-spacing:-0.1pt;"> </span>become<span style="letter-spacing:-0.1pt;"> </span>more<span style="letter-spacing:-0.05pt;"> </span>apparent.</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.8%;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Biomarker<span style="letter-spacing:-0.25pt;"> </span>Discovery<span style="font-style:italic;font-weight:normal;">:</span><span style="font-style:italic;letter-spacing:-0.25pt;font-weight:normal;"> </span><span style="font-weight:normal;">There</span><span style="letter-spacing:-0.25pt;font-weight:normal;"> </span><span style="font-weight:normal;">are</span><span style="letter-spacing:-0.25pt;font-weight:normal;"> </span><span style="font-weight:normal;">many</span><span style="letter-spacing:-0.25pt;font-weight:normal;"> </span><span style="font-weight:normal;">limitations</span><span style="letter-spacing:-0.25pt;font-weight:normal;"> </span><span style="font-weight:normal;">with</span><span style="letter-spacing:-0.25pt;font-weight:normal;"> </span><span style="font-weight:normal;">biomarker</span><span style="letter-spacing:-0.2pt;font-weight:normal;"> </span><span style="font-weight:normal;">discovery</span><span style="letter-spacing:-0.25pt;font-weight:normal;"> </span><span style="font-weight:normal;">in</span><span style="letter-spacing:-0.25pt;font-weight:normal;"> </span><span style="font-weight:normal;">biopharmaceutical</span><span style="letter-spacing:-0.25pt;font-weight:normal;"> </span><span style="font-weight:normal;">drug</span><span style="letter-spacing:-0.25pt;font-weight:normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;development, including:</span></p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Biomarkers</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">with</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">clinical</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">utility</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">are</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">difficult</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">discover</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">validate</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">in</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">independent</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">datasets. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Classical</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">statistical</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">approaches</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">biomarker</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">discovery</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">are</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">limited.</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">Single-omic</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">tests</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">fail</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">see</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">whole</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">biological</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">picture.</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="text-decoration:none;Background-color:#auto;"></span><span style="color:#000000;"></span><span style="color:#000000;">Tissue</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">biopsies</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">are</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">limited</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">by</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">amount</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">a</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">sample</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">that</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">can</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">be</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">collected:</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">longitudinal</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">testing</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">is</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">difficult</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">biology</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">is</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">only</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">from</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">profile</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">tumor</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">(host</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">response</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">is</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">not</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">accounted</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">for).</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Clinical</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">trials</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">are</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">expensive</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">take</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">a</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">long</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">period</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">time.</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">It</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">is</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">often</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">difficult</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">meet</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">enrollment</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">goals</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">for</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">clinical</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">trials</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">with</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">slow</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">diagnostic</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">testing</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">turnaround</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">times.</span></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Companion<span style="letter-spacing:-0.25pt;"> </span>Diagnostics<span style="letter-spacing:-0.25pt;"> </span>(CDx):<span style="letter-spacing:-0.25pt;"> </span><span style="font-weight:normal;">While</span><span style="letter-spacing:-0.25pt;font-weight:normal;"> </span><span style="font-weight:normal;">developing</span><span style="letter-spacing:-0.2pt;font-weight:normal;"> </span><span style="font-weight:normal;">companion</span><span style="letter-spacing:-0.25pt;font-weight:normal;"> </span><span style="font-weight:normal;">diagnostics</span><span style="letter-spacing:-0.25pt;font-weight:normal;"> </span><span style="font-weight:normal;">is</span><span style="letter-spacing:-0.25pt;font-weight:normal;"> </span><span style="font-weight:normal;">critical</span><span style="letter-spacing:-0.2pt;font-weight:normal;"> </span><span style="font-weight:normal;">to</span><span style="letter-spacing:-0.25pt;font-weight:normal;"> </span><span style="font-weight:normal;">precision</span><span style="letter-spacing:-0.25pt;font-weight:normal;"> </span><span style="font-weight:normal;">medicine,</span><span style="letter-spacing:-0.25pt;font-weight:normal;"> </span><span style="font-weight:normal;">the</span><span style="letter-spacing:-0.2pt;font-weight:normal;"> </span><span style="font-weight:normal;">promise</span><span style="letter-spacing:-0.25pt;font-weight:normal;"> </span><span style="font-weight:normal;">of</span><span style="letter-spacing:-0.25pt;font-weight:normal;"> </span><span style="font-weight:normal;">companion</span><span style="letter-spacing:0.05pt;font-weight:normal;"> </span><span style="font-weight:normal;">diagnostics has not been fully realized and there are multiple limitations that still need resolution. The path to co-develop a successful</span><span style="letter-spacing:0.05pt;font-weight:normal;"> </span><span style="font-weight:normal;">companion</span><span style="letter-spacing:-0.1pt;font-weight:normal;"> </span><span style="font-weight:normal;">diagnostic</span><span style="letter-spacing:-0.05pt;font-weight:normal;"> </span><span style="font-weight:normal;">with</span><span style="letter-spacing:-0.1pt;font-weight:normal;"> </span><span style="font-weight:normal;">a</span><span style="letter-spacing:-0.05pt;font-weight:normal;"> </span><span style="font-weight:normal;">corresponding</span><span style="letter-spacing:-0.1pt;font-weight:normal;"> </span><span style="font-weight:normal;">drug</span><span style="letter-spacing:-0.05pt;font-weight:normal;"> </span><span style="font-weight:normal;">has</span><span style="letter-spacing:-0.1pt;font-weight:normal;"> </span><span style="font-weight:normal;">several</span><span style="letter-spacing:-0.05pt;font-weight:normal;"> </span><span style="font-weight:normal;">challenges,</span><span style="letter-spacing:-0.05pt;font-weight:normal;"> </span><span style="font-weight:normal;">including:</span></p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Traditional</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">companion</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">diagnostic</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">agreements</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">fail</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">realize</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">full</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">value</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">a</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">testing</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">opportunity,</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">leading</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">difficulty</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">in</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">funding</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">appropriate</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">commercialization.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Drug</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">development</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">is</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">a</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">lengthy,</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">complex</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">costly</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">process.</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">There</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">can</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">be</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">a</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">financial</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">impact</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">a</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">pharmaceutical</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">company</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">have</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">a</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">drug</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">selected</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">by</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">a</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">test.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Current</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">diagnostic</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">reimbursement</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">policies</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">not</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">always</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">support</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">coverage</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">payment</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">new</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">companion</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">diagnostics.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Regulatory</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">agencies</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">continue</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">work</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">on</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">defining</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">co-development</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">process,</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">but</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">environment</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">is</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">continually</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">changing.</span></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">The Diagnostic Cortex - Our Proprietary Artificial Intelligence (AI) Platform</p>
<p style="margin-bottom:0pt;margin-top:5pt;text-indent:4.8%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our core belief is that no single technology will answer all clinical questions that we encounter. Therefore, we employ multiple technologies, including genomics, transcriptomics, proteomics, and radiomics, and leverage our proprietary AI platform, the Diagnostic Cortex, to discover innovative diagnostic tests for clinical use. We<span style="letter-spacing:-0.25pt;"> </span>focus<span style="letter-spacing:-0.25pt;"> </span>on<span style="letter-spacing:-0.25pt;"> </span>developing<span style="letter-spacing:0.05pt;"> </span>technologies<span style="letter-spacing:-0.1pt;"> </span>that<span style="letter-spacing:-0.05pt;"> </span>are<span style="letter-spacing:-0.05pt;"> </span>capable<span style="letter-spacing:-0.1pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>single<span style="letter-spacing:-0.05pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>multi-omic<span style="letter-spacing:-0.05pt;"> </span>research<span style="letter-spacing:-0.05pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>development.</p>
<p style="margin-bottom:0pt;margin-top:5pt;text-indent:4.8%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Diagnostic Cortex is an extensively validated deep learning platform optimized for the discovery of clinical diagnostic tests, which we believe<span style="letter-spacing:0.05pt;"> </span>overcomes standard machine learning challenges faced in life sciences research. Researchers commonly encounter issues with machine learning-based<span style="letter-spacing:0.05pt;"> </span>biological discoveries that cannot be repeated or validated when assessed in additional specimen cohorts. This challenge, commonly referred to as<span style="letter-spacing:0.05pt;"> </span>overfitting,<span style="letter-spacing:-0.2pt;"> </span>occurs<span style="letter-spacing:-0.15pt;"> </span>when<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>machine<span style="letter-spacing:-0.2pt;"> </span>identifies<span style="letter-spacing:-0.15pt;"> </span>a<span style="letter-spacing:-0.15pt;"> </span>perfect<span style="letter-spacing:-0.15pt;"> </span>pattern<span style="letter-spacing:-0.15pt;"> </span>in<span style="letter-spacing:-0.2pt;"> </span>an<span style="letter-spacing:-0.15pt;"> </span>initial<span style="letter-spacing:-0.15pt;"> </span>training<span style="letter-spacing:-0.15pt;"> </span>dataset<span style="letter-spacing:-0.15pt;"> </span>but<span style="letter-spacing:-0.2pt;"> </span>is<span style="letter-spacing:-0.15pt;"> </span>unable<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.15pt;"> </span>identify<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>same<span style="letter-spacing:-0.15pt;"> </span>pattern<span style="letter-spacing:-0.15pt;"> </span>in<span style="letter-spacing:-0.15pt;"> </span>a<span style="letter-spacing:-0.2pt;"> </span>new<span style="letter-spacing:-0.15pt;"> </span>dataset.<span style="letter-spacing:-0.15pt;"> </span>For<span style="letter-spacing:0.05pt;"> </span>over 15 years we have focused on developing our platform to overcome this challenge through proprietary computational techniques to ensure each<span style="letter-spacing:0.05pt;"> </span>diagnostic<span style="letter-spacing:-0.1pt;"> </span>test<span style="letter-spacing:-0.1pt;"> </span>that<span style="letter-spacing:-0.05pt;"> </span>is<span style="letter-spacing:-0.1pt;"> </span>discovered<span style="letter-spacing:-0.1pt;"> </span>can<span style="letter-spacing:-0.05pt;"> </span>be<span style="letter-spacing:-0.1pt;"> </span>further<span style="letter-spacing:-0.1pt;"> </span>developed<span style="letter-spacing:-0.05pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>perform<span style="letter-spacing:-0.05pt;"> </span>consistently<span style="letter-spacing:-0.1pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>clinical<span style="letter-spacing:-0.1pt;"> </span>testing<span style="letter-spacing:-0.1pt;"> </span>environment.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.8%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We<span style="letter-spacing:-0.25pt;"> </span>are<span style="letter-spacing:-0.25pt;"> </span>able<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.25pt;"> </span>combine<span style="letter-spacing:-0.2pt;"> </span>blood-based<span style="letter-spacing:-0.25pt;"> </span>biological<span style="letter-spacing:-0.25pt;"> </span>information<span style="letter-spacing:-0.25pt;"> </span>related<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.25pt;"> </span>the<span style="letter-spacing:-0.25pt;"> </span>tumor,<span style="letter-spacing:-0.25pt;"> </span>immune<span style="letter-spacing:-0.2pt;"> </span>system,<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.25pt;"> </span>host-status<span style="letter-spacing:-0.25pt;"> </span>with<span style="letter-spacing:-0.2pt;"> </span>clinical<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.25pt;"> </span>radiomic<span style="letter-spacing:-0.25pt;"> </span>data<span style="letter-spacing:0.05pt;"> </span>through<span style="letter-spacing:-0.15pt;"> </span>our<span style="letter-spacing:-0.15pt;"> </span>proprietary<span style="letter-spacing:-0.15pt;"> </span>AI<span style="letter-spacing:-0.1pt;"> </span>platform,<span style="letter-spacing:-0.15pt;"> </span>which<span style="letter-spacing:-0.15pt;"> </span>enables<span style="letter-spacing:-0.1pt;"> </span>us<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.15pt;"> </span>interpret<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>holistic<span style="letter-spacing:-0.15pt;"> </span>disease<span style="letter-spacing:-0.1pt;"> </span>state<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:-0.15pt;"> </span>each<span style="letter-spacing:-0.1pt;"> </span>patient<span style="letter-spacing:-0.15pt;"> </span>or<span style="letter-spacing:-0.15pt;"> </span>clinical<span style="letter-spacing:-0.1pt;"> </span>dataset<span style="letter-spacing:-0.15pt;"> </span>we<span style="letter-spacing:-0.15pt;"> </span>encounter.</p>
<p style="margin-bottom:0pt;margin-top:4pt;text-indent:4.8%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We continuously evolve and improve the Diagnostic Cortex platform. These improvements range from basic code optimization to complex<span style="letter-spacing:0.05pt;"> </span>improvements<span style="letter-spacing:-0.25pt;"> </span>such<span style="letter-spacing:-0.2pt;"> </span>as<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.2pt;"> </span>incorporation<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.2pt;"> </span>novel<span style="letter-spacing:-0.2pt;"> </span>computational<span style="letter-spacing:-0.2pt;"> </span>methods<span style="letter-spacing:-0.2pt;"> </span>for<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.2pt;"> </span>optimization<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:-0.2pt;"> </span>multi-omic<span style="letter-spacing:-0.2pt;"> </span>diagnostic<span style="letter-spacing:-0.2pt;"> </span>tests.<span style="letter-spacing:-0.2pt;"> </span>Any<span style="letter-spacing:-0.2pt;"> </span>AI<span style="letter-spacing:-0.2pt;"> </span>platform<span style="letter-spacing:-0.2pt;"> </span>is<span style="letter-spacing:-0.2pt;"> </span>inherently<span style="letter-spacing:0.05pt;"> </span>limited without the highest quality data inputs. Therefore, all of the technologies that we employ have been chosen and developed to provide high-quality<span style="letter-spacing:0.05pt;"> </span>data to enable our Diagnostic Cortex platform. We feel that this level of data integrity is crucial for the development of diagnostic tests that require the<span style="letter-spacing:0.05pt;"> </span>advanced<span style="letter-spacing:-0.1pt;"> </span>pattern<span style="letter-spacing:-0.05pt;"> </span>matching<span style="letter-spacing:-0.05pt;"> </span>abilities<span style="letter-spacing:-0.05pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>deep<span style="letter-spacing:-0.1pt;"> </span>learning<span style="letter-spacing:-0.05pt;"> </span>algorithms.  </p>
<p style="margin-bottom:0pt;margin-top:4pt;text-indent:4.8%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We continuously incorporate new market insights and patient data to enhance our platform through a data-driven learning loop. We regularly engage<span style="letter-spacing:-2.1pt;">  </span> our customers, key opinion leaders, and scientific experts to stay ahead of the rapidly evolving diagnostic and therapeutic landscape and learn about<span style="letter-spacing:0.05pt;"> </span>biological discoveries that are clinically meaningful. Additionally, we incorporate clinical and molecular profiling data aggregated through our commercial<span style="letter-spacing:-2.1pt;"> </span>clinical testing, research studies, clinical trials, and biopharmaceutical customers or academic partnerships, into our platform. We have over 140,000<span style="letter-spacing:0.05pt;"> </span>samples<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>data<span style="letter-spacing:-0.2pt;"> </span>in<span style="letter-spacing:-0.2pt;"> </span>our<span style="letter-spacing:-0.2pt;"> </span>biobank,<span style="letter-spacing:-0.25pt;"> </span>including<span style="letter-spacing:-0.2pt;"> </span>tumor<span style="letter-spacing:-0.2pt;"> </span>profiles<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>immune<span style="letter-spacing:-0.25pt;"> </span>profiles,<span style="letter-spacing:-0.2pt;"> </span>which<span style="letter-spacing:-0.2pt;"> </span>are<span style="letter-spacing:-0.2pt;"> </span>used<span style="letter-spacing:-0.2pt;"> </span>for<span style="letter-spacing:-0.25pt;"> </span>both<span style="letter-spacing:-0.2pt;"> </span>internal<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>external<span style="letter-spacing:-0.2pt;"> </span>development<span style="letter-spacing:-0.25pt;"> </span>initiatives.<span style="letter-spacing:-0.2pt;"> </span>With<span style="letter-spacing:0.05pt;"> </span>our data-driven and technology agnostic approach as data inputs into the Diagnostic Cortex, we are able to discover diagnostic tests that answer critical<span style="letter-spacing:0.05pt;"> </span>clinical<span style="letter-spacing:-0.1pt;"> </span>questions<span style="letter-spacing:-0.05pt;"> </span>faced<span style="letter-spacing:-0.1pt;"> </span>by<span style="letter-spacing:-0.05pt;"> </span>physicians,<span style="letter-spacing:-0.05pt;"> </span>researchers,<span style="letter-spacing:-0.1pt;"> </span>and<span style="letter-spacing:-0.05pt;"> </span>biopharmaceutical<span style="letter-spacing:-0.05pt;"> </span>companies.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:5pt;text-indent:4.8%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">following</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">is</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">diagram</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">outlining</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">innovative</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">diagnostic</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">test</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">discovery,</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">development</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">commercialization</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">infrastructure</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">as</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">outlined</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">text</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">above.</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.8%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gegguy50oztz000002.jpg" title="" alt="" style="width:542px;height:280px;" /></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:4.8%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We<span style="letter-spacing:-0.35pt;"> </span>employ<span style="letter-spacing:-0.3pt;"> </span>multiple<span style="letter-spacing:-0.3pt;"> </span>technologies,<span style="letter-spacing:-0.35pt;"> </span>as<span style="letter-spacing:-0.3pt;"> </span>illustrated<span style="letter-spacing:-0.3pt;"> </span>below,<span style="letter-spacing:-0.3pt;"> </span>including<span style="letter-spacing:-0.35pt;"> </span>genomics,<span style="letter-spacing:-0.3pt;"> </span>proteomics,<span style="letter-spacing:-0.3pt;"> </span>transcriptomics,<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.3pt;"> </span>radiomics,<span style="letter-spacing:-0.3pt;"> </span>generated<span style="letter-spacing:-0.3pt;"> </span>by<span style="letter-spacing:-0.35pt;"> </span>different<span style="letter-spacing:-0.3pt;"> </span>assay<span style="letter-spacing:0.05pt;"> </span>techniques,<span style="letter-spacing:-0.25pt;"> </span>including<span style="letter-spacing:-0.25pt;"> </span>ddPCR,<span style="letter-spacing:-0.25pt;"> </span>NGS,<span style="letter-spacing:-0.25pt;"> </span>LC-MS,<span style="letter-spacing:-0.25pt;"> </span>ELISA,<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.25pt;"> </span>our<span style="letter-spacing:-0.25pt;"> </span>proprietary<span style="letter-spacing:-0.25pt;"> </span>DeepMALDI<span style="letter-spacing:-0.25pt;"> </span>mass<span style="letter-spacing:-0.25pt;"> </span>spectrometry<span style="letter-spacing:-0.25pt;"> </span>platform<span style="letter-spacing:-0.25pt;"> </span>for<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.25pt;"> </span>blood-based<span style="letter-spacing:-0.25pt;"> </span>molecular<span style="letter-spacing:-0.25pt;"> </span>analysis<span style="letter-spacing:0.05pt;"> </span>of the tumor, immune system, and host-status of each patient and/or clinical dataset. Through our learning loop, we continuously revisit our technology<span style="letter-spacing:0.05pt;"> </span>strategy and roadmap to integrate new technologies into our evolving platform, which ultimately support the addition of new service and product revenue<span style="letter-spacing:0.05pt;"> </span>offerings.<span style="letter-spacing:-0.1pt;"> </span>We<span style="letter-spacing:-0.1pt;"> </span>focus<span style="letter-spacing:-0.1pt;"> </span>on<span style="letter-spacing:-0.1pt;"> </span>developing<span style="letter-spacing:-0.1pt;"> </span>technologies<span style="letter-spacing:-0.1pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>are<span style="letter-spacing:-0.1pt;"> </span>capable<span style="letter-spacing:-0.1pt;"> </span>of<span style="letter-spacing:-0.1pt;"> </span>single<span style="letter-spacing:-0.1pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>multi-omic<span style="letter-spacing:-0.1pt;"> </span>research<span style="letter-spacing:-0.05pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>development.</p>
<p style="margin-top:0pt;margin-bottom:6pt;margin-left:1.78%;text-indent:4.8%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gegguy50oztz000003.jpg" title="" alt="" style="width:546px;height:150px;" /></p>
<p style="margin-top:0pt;margin-bottom:6pt;margin-left:1.78%;text-indent:4.8%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:5pt;margin-bottom:6pt;text-indent:4.8%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Most diagnostic companies focus their strategy on using a single technology to discover biomarkers for a broad range of clinical questions. We believe that no single technology can interrogate the complexity of the human disease state to help solve all clinical questions. For that reason, we employ a technology agnostic approach to solving diagnostic challenges leveraging our proprietary AI platform. Because of this approach, we believe we are unique in the diagnostics market, allowing for a broader and more holistic understanding of each patient&#8217;s disease state.</p>
<p style="margin-top:5pt;margin-bottom:6pt;text-indent:4.81%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are experts in many technologies, but we are a true market leader with over 15 years of experience in the field of clinical proteomics. For over 10 years, we have been discovering and developing proteomic-based diagnostic tests and have a deep understanding of how to incorporate technologies that can be applied to blood samples in order to extract important protein-based biological information in the form of diagnostic tests, which can aid clinicians and scientists in understanding the dynamic biology of their system of interest, such as a patient with cancer.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:4.81%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">suite</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">technologies</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">that</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">assist</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">us</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">discovery,</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">development</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">commercialization</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">novel</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">diagnostic</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">tests</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">includes:</span></p>
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:4.81%;text-indent:0%;font-weight:bold;font-style:italic;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">DeepMALDI Mass Spectrometry</p>
<p style="margin-top:5pt;margin-bottom:6pt;text-indent:4.8%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have developed DeepMALDI, a proprietary high-density matrix-assisted laser desorption/ionization time-of-flight (MALDI-ToF) mass<span style="letter-spacing:0.05pt;"> </span>spectrometry (MS) technology, to produce blood-based proteomic data for disease diagnosis, personalized health care, precision medicine for direct<span style="letter-spacing:0.05pt;"> </span>treatment options, and disease screening in lung and other disease states. DeepMALDI overcomes the limitations of conventional MALDI and other mass<span style="letter-spacing:-2.1pt;"> </span>spectrometry<span style="letter-spacing:-0.25pt;"> </span>methods<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.25pt;"> </span>produce<span style="letter-spacing:-0.2pt;"> </span>highly<span style="letter-spacing:-0.25pt;"> </span>sensitive,<span style="letter-spacing:-0.2pt;"> </span>stable,<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>reproducible<span style="letter-spacing:-0.25pt;"> </span>data<span style="letter-spacing:-0.2pt;"> </span>by:<span style="letter-spacing:-0.2pt;"> </span>(1)<span style="letter-spacing:-0.25pt;"> </span>utilizing<span style="letter-spacing:-0.2pt;"> </span>optimized<span style="letter-spacing:-0.25pt;"> </span>signal-to-noise<span style="letter-spacing:-0.2pt;"> </span>reduction<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>signal<span style="letter-spacing:-0.25pt;"> </span>processing<span style="letter-spacing:0.05pt;"> </span>algorithms&#59; and (2) novel batch correction methods and spectral alignment methods. The combination of these improvements yields substantially higher<span style="letter-spacing:0.05pt;"> </span>quality<span style="letter-spacing:-0.1pt;"> </span>data<span style="letter-spacing:-0.1pt;"> </span>content<span style="letter-spacing:-0.05pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>is<span style="letter-spacing:-0.05pt;"> </span>thereby<span style="letter-spacing:-0.1pt;"> </span>much<span style="letter-spacing:-0.1pt;"> </span>better<span style="letter-spacing:-0.05pt;"> </span>suited<span style="letter-spacing:-0.1pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>discovery<span style="letter-spacing:-0.05pt;"> </span>of<span style="letter-spacing:-0.1pt;"> </span>biomarkers<span style="letter-spacing:-0.1pt;"> </span>with<span style="letter-spacing:-0.05pt;"> </span>clinical<span style="letter-spacing:-0.1pt;"> </span>utility.</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:4.8%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our current DeepMALDI methods allow us to achieve finer mass resolution, greater sensitivity, and 20-times faster imaging speeds than other<span style="letter-spacing:0.05pt;"> </span>instruments. Additionally, we believe enhancements to our DeepMALDI methods and MALDI-ToF technology evolution will allow us to measure<span style="letter-spacing:0.05pt;"> </span>approximately 1,500 proteins, an improvement from the estimated 900 proteins we can measure today. We intend to maintain our leadership role in the<span style="letter-spacing:0.05pt;"> </span>discovery<span style="letter-spacing:-0.3pt;"> </span>of<span style="letter-spacing:-0.3pt;"> </span>proteomics-based<span style="letter-spacing:-0.3pt;"> </span>diagnostic<span style="letter-spacing:-0.3pt;"> </span>tests.<span style="letter-spacing:-0.3pt;"> </span>We<span style="letter-spacing:-0.3pt;"> </span>utilize<span style="letter-spacing:-0.3pt;"> </span>our<span style="letter-spacing:-0.3pt;"> </span>DeepMALDI<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.3pt;"> </span>MALDI-ToF<span style="letter-spacing:-0.3pt;"> </span>technologies<span style="letter-spacing:-0.3pt;"> </span>in<span style="letter-spacing:-0.3pt;"> </span>our<span style="letter-spacing:-0.3pt;"> </span>discovery<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.3pt;"> </span>development<span style="letter-spacing:-0.3pt;"> </span>efforts<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.3pt;"> </span>as<span style="letter-spacing:0.05pt;"> </span>part<span style="letter-spacing:-0.1pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:-0.1pt;"> </span>collaborations<span style="letter-spacing:-0.05pt;"> </span>with<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:-0.1pt;"> </span>biopharmaceutical<span style="letter-spacing:-0.05pt;"> </span>customers<span style="letter-spacing:-0.05pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>academic<span style="letter-spacing:-0.05pt;"> </span>partners.</p>
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:4.81%;text-indent:0%;font-weight:bold;font-style:italic;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Liquid Chromatography Mass Spectrometry MS</p>
<p style="margin-top:5pt;margin-bottom:6pt;text-indent:4.8%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We use Multiple Reaction Monitoring (MRM) MS with triple quadrupole mass spectrometers and up-front liquid chromatography (LC) sample<span style="letter-spacing:0.05pt;"> </span>injection<span style="letter-spacing:-0.25pt;"> </span>in<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.25pt;"> </span>Nodify<span style="letter-spacing:-0.2pt;"> </span>XL2<span style="letter-spacing:-0.25pt;"> </span>test.<span style="letter-spacing:-0.2pt;"> </span>This<span style="letter-spacing:-0.25pt;"> </span>mass<span style="letter-spacing:-0.2pt;"> </span>spectrometry<span style="letter-spacing:-0.2pt;"> </span>method<span style="letter-spacing:-0.25pt;"> </span>offers<span style="letter-spacing:-0.2pt;"> </span>highly<span style="letter-spacing:-0.25pt;"> </span>sensitive,<span style="letter-spacing:-0.2pt;"> </span>specific,<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>cost-effective<span style="letter-spacing:-0.25pt;"> </span>analysis<span style="letter-spacing:-0.2pt;"> </span>for<span style="letter-spacing:-0.2pt;"> </span>simultaneous<span style="letter-spacing:-0.25pt;"> </span>quantitation<span style="letter-spacing:0.05pt;"> </span>of hundreds to several thousands of targeted peptides in a single experiment. We have since included the MRM technologies as part of our services for<span style="letter-spacing:0.05pt;"> </span>discovery<span style="letter-spacing:-0.1pt;"> </span>and<span style="letter-spacing:-0.05pt;"> </span>development<span style="letter-spacing:-0.1pt;"> </span>with<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:-0.1pt;"> </span>biopharmaceutical<span style="letter-spacing:-0.05pt;"> </span>customers<span style="letter-spacing:-0.05pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>academic<span style="letter-spacing:-0.05pt;"> </span>partners.</p>
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:4.81%;text-indent:0%;font-weight:bold;font-style:italic;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Enzyme-Linked Immunosorbent Assay</p>
<p style="margin-top:5pt;margin-bottom:6pt;text-indent:4.8%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ELISA is the most widely used ligand binding assay platform within and outside the pharmaceutical industry. Formats include direct, indirect and sandwich assays and are typically run in manually or semi-automated modes. We use a semi-automated implementation of ELISA in clinical testing for the Nodify CDT test and the Platelia SARS-CoV-2 Total Ab test for COVID-19. The acquisition of Oncimmune USA in 2019 expanded our ability to conduct very high throughput and cost-effective ELISAs in our clinical testing laboratory. We have now included the ELISA technologies for research and development both internally and externally with our biopharmaceutical customers and academic partners.</p>
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:4.81%;text-indent:0%;font-weight:bold;font-style:italic;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Droplet Digital PCR Platform</p>
<p style="margin-top:5pt;margin-bottom:6pt;text-indent:4.8%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We<span style="letter-spacing:-0.3pt;"> </span>use<span style="letter-spacing:-0.3pt;"> </span>the<span style="letter-spacing:-0.25pt;"> </span>ddPCR<span style="letter-spacing:-0.3pt;"> </span>technology<span style="letter-spacing:-0.25pt;"> </span>for<span style="letter-spacing:-0.3pt;"> </span>multiplexed,<span style="letter-spacing:-0.25pt;"> </span>semi-automated<span style="letter-spacing:-0.3pt;"> </span>nucleic<span style="letter-spacing:-0.25pt;"> </span>acid<span style="letter-spacing:-0.3pt;"> </span>detection.<span style="letter-spacing:-0.25pt;"> </span>This<span style="letter-spacing:-0.3pt;"> </span>allows<span style="letter-spacing:-0.25pt;"> </span>high<span style="letter-spacing:-0.3pt;"> </span>sensitivity,<span style="letter-spacing:-0.25pt;"> </span>fast<span style="letter-spacing:-0.3pt;"> </span>turn-around<span style="letter-spacing:-0.25pt;"> </span>times,<span style="letter-spacing:-0.3pt;"> </span>flexibility<span style="letter-spacing:0.05pt;"> </span>in our laboratory workflows, rapid scaling from low to moderate analyte complexity, and high-volume scalability. ddPCR is an absolute quantitation<span style="letter-spacing:0.05pt;"> </span>method<span style="letter-spacing:-0.15pt;"> </span>based<span style="letter-spacing:-0.15pt;"> </span>on<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>partitioning<span style="letter-spacing:-0.1pt;"> </span>of<span style="letter-spacing:-0.15pt;"> </span>circulating<span style="letter-spacing:-0.1pt;"> </span>nucleic<span style="letter-spacing:-0.15pt;"> </span>acids<span style="letter-spacing:-0.1pt;"> </span>into<span style="letter-spacing:-0.15pt;"> </span>up<span style="letter-spacing:-0.1pt;"> </span>to<span style="letter-spacing:-0.15pt;"> </span>20,000<span style="letter-spacing:-0.1pt;"> </span>droplets<span style="letter-spacing:-0.15pt;"> </span>per<span style="letter-spacing:-0.1pt;"> </span>reaction<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>is<span style="letter-spacing:-0.15pt;"> </span>used<span style="letter-spacing:-0.1pt;"> </span>for<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>GeneStrat<span style="letter-spacing:-0.15pt;"> </span>test<span style="letter-spacing:-0.1pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>Bio-Rad SARS-CoV-2<span style="letter-spacing:-0.3pt;"> </span>ddPCR<span style="letter-spacing:-0.3pt;"> </span>test<span style="letter-spacing:-0.25pt;"> </span>for<span style="letter-spacing:-0.3pt;"> </span>COVID-19.<span style="letter-spacing:-0.3pt;"> </span>We<span style="letter-spacing:-0.25pt;"> </span>have<span style="letter-spacing:-0.3pt;"> </span>included<span style="letter-spacing:-0.3pt;"> </span>the<span style="letter-spacing:-0.25pt;"> </span>ddPCR<span style="letter-spacing:-0.3pt;"> </span>technologies<span style="letter-spacing:-0.3pt;"> </span>for<span style="letter-spacing:-0.25pt;"> </span>research<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.3pt;"> </span>development<span style="letter-spacing:-0.25pt;"> </span>both<span style="letter-spacing:-0.3pt;"> </span>internally<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.25pt;"> </span>externally<span style="letter-spacing:-0.3pt;"> </span>with<span style="letter-spacing:-0.3pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>biopharmaceutical<span style="letter-spacing:-0.1pt;"> </span>customers<span style="letter-spacing:-0.05pt;"> </span>and<span style="letter-spacing:-0.05pt;"> </span>academic<span style="letter-spacing:-0.05pt;"> </span>partners.</p>
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:4.81%;text-indent:0%;font-weight:bold;font-style:italic;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Next Generation Sequencing Technology</p>
<p style="margin-top:5pt;margin-bottom:6pt;text-indent:4.8%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We<span style="letter-spacing:-0.25pt;"> </span>use<span style="letter-spacing:-0.2pt;"> </span>an<span style="letter-spacing:-0.2pt;"> </span>NGS<span style="letter-spacing:-0.25pt;"> </span>technology<span style="letter-spacing:-0.2pt;"> </span>for<span style="letter-spacing:-0.2pt;"> </span>broad<span style="letter-spacing:-0.2pt;"> </span>genomic<span style="letter-spacing:-0.25pt;"> </span>sequencing<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.2pt;"> </span>clinical<span style="letter-spacing:-0.25pt;"> </span>specimens.<span style="letter-spacing:-0.2pt;"> </span>Our<span style="letter-spacing:-0.2pt;"> </span>strategy<span style="letter-spacing:-0.2pt;"> </span>with<span style="letter-spacing:-0.25pt;"> </span>NGS<span style="letter-spacing:-0.2pt;"> </span>relies<span style="letter-spacing:-0.2pt;"> </span>on<span style="letter-spacing:-0.25pt;"> </span>a<span style="letter-spacing:-0.2pt;"> </span>menu<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.2pt;"> </span>off-the-shelf<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>custom<span style="letter-spacing:0.05pt;"> </span>research use assays, which we develop and make available as a part of our biopharmaceutical test services. The NGS technology integrates automated<span style="letter-spacing:0.05pt;"> </span>systems<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>yield<span style="letter-spacing:-0.1pt;"> </span>high<span style="letter-spacing:-0.1pt;"> </span>sensitivity<span style="letter-spacing:-0.1pt;"> </span>results<span style="letter-spacing:-0.1pt;"> </span>with<span style="letter-spacing:-0.1pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>rapid<span style="letter-spacing:-0.1pt;"> </span>turnaround<span style="letter-spacing:-0.1pt;"> </span>time.<span style="letter-spacing:-0.1pt;"> </span>Since<span style="letter-spacing:-0.1pt;"> </span>adoption<span style="letter-spacing:-0.1pt;"> </span>of<span style="letter-spacing:-0.1pt;"> </span>this<span style="letter-spacing:-0.1pt;"> </span>technology,<span style="letter-spacing:-0.1pt;"> </span>we<span style="letter-spacing:-0.1pt;"> </span>have<span style="letter-spacing:-0.1pt;"> </span>included<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>NGS technologies<span style="letter-spacing:-0.25pt;"> </span>for<span style="letter-spacing:-0.25pt;"> </span>research<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.25pt;"> </span>development<span style="letter-spacing:-0.25pt;"> </span>both<span style="letter-spacing:-0.2pt;"> </span>internally<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>externally<span style="letter-spacing:-0.25pt;"> </span>with<span style="letter-spacing:-0.25pt;"> </span>our<span style="letter-spacing:-0.2pt;"> </span>biopharmaceutical<span style="letter-spacing:-0.25pt;"> </span>customers<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.25pt;"> </span>academic<span style="letter-spacing:-0.25pt;"> </span>partners.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Our Solutions and Products</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.81%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To<span style="letter-spacing:-0.25pt;"> </span>help<span style="letter-spacing:-0.25pt;"> </span>address<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.25pt;"> </span>current<span style="letter-spacing:-0.25pt;"> </span>limitations<span style="letter-spacing:-0.2pt;"> </span>with<span style="letter-spacing:-0.25pt;"> </span>standard<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.25pt;"> </span>care<span style="letter-spacing:-0.25pt;"> </span>in<span style="letter-spacing:-0.2pt;"> </span>lung<span style="letter-spacing:-0.25pt;"> </span>cancer<span style="letter-spacing:-0.25pt;"> </span>diagnosis,<span style="letter-spacing:-0.2pt;"> </span>treatment,<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>monitoring,<span style="letter-spacing:-0.25pt;"> </span>we<span style="letter-spacing:-0.25pt;"> </span>use<span style="letter-spacing:-0.2pt;"> </span>combinations<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:-0.25pt;"> </span>tumor,<span style="letter-spacing:0.05pt;"> </span>immune and host profiling, radiological imaging, patient clinical profiling, and our proprietary AI platform to provide a holistic view of each patient&#8217;s<span style="letter-spacing:-2.1pt;"> </span>dynamic<span style="letter-spacing:-0.1pt;"> </span>disease<span style="letter-spacing:-0.05pt;"> </span>state.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.81%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We<span style="letter-spacing:-0.25pt;"> </span>have<span style="letter-spacing:-0.2pt;"> </span>four<span style="letter-spacing:-0.2pt;"> </span>blood-based<span style="letter-spacing:-0.2pt;"> </span>diagnostic<span style="letter-spacing:-0.25pt;"> </span>tests<span style="letter-spacing:-0.2pt;"> </span>across<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.2pt;"> </span>lung<span style="letter-spacing:-0.25pt;"> </span>cancer<span style="letter-spacing:-0.2pt;"> </span>continuum<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.2pt;"> </span>care<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.2pt;"> </span>help<span style="letter-spacing:-0.2pt;"> </span>address<span style="letter-spacing:-0.2pt;"> </span>clinical<span style="letter-spacing:-0.25pt;"> </span>unmet<span style="letter-spacing:-0.2pt;"> </span>needs<span style="letter-spacing:-0.2pt;"> </span>by<span style="letter-spacing:-0.2pt;"> </span>physicians.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.76%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-weight:bold;color:#000000;">Diagnosis</span><span style="color:#000000;">: We believe there is a clinical need to help physicians reclassify risk of malignancy in patients presenting with suspicious lung</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">nodules.</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">We</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">offer</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">blood-based</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">Nodify</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">Lung</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">Nodule</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">Risk</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">Assessment</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">testing</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">strategy</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">aid</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">physicians</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">in</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">stratifying</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">patients</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">into</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">distinct</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">nodule management treatment pathways: diagnostic procedure or imaging surveillance. Nodify Lung consists of two blood-based proteomic</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">tests: the Nodify CDT test helps identify patients with lung nodules that are likely malignant and the Nodify XL2 test conversely helps</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">identify</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">those</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">that</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">are</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">likely</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">benign.</span></p></td></tr></table></div>
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:9.08%;text-indent:-3.85%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-weight:bold;color:#000000;">Treatment Guidance</span><span style="color:#000000;">: We believe there is an imminent need for a blood-based testing solution that measures tumor-specific mutations and the patient&#8217;s immune profile to provide physicians with more comprehensive information to assess the overall prognosis of the patient and personalize treatment plans. We offer the blood-based Biodesix Lung Reflex testing strategy, which consists of the GeneStrat tumor profiling test and the VeriStrat immune profiling test for patients diagnosed with NSCLC. With a three-day turnaround time, we are able to quickly provide critical diagnostic information to physicians to facilitate personalized treatment decisions for their patients.</span></p></td></tr></table></div>
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:9.08%;text-indent:-3.85%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:4pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:4pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:4pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-weight:bold;color:#000000;">Monitoring</span><span style="color:#000000;">:</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">We</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">believe</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">longitudinally</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">monitoring</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">advanced</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">NSCLC</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">patients</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">for</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">dynamic</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">evolution</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">their</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">tumor</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">immune</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">profile</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">while on treatment can provide an earlier indication of treatment resistance and/or disease progression. We offer the Biodesix Lung Reflex</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">testing</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">strategy</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">as</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">a</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">blood-based</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">monitoring</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">tool</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">for</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">physicians</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">track</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">their</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">patients&#8217;</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">disease</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">evolution.</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:0pt;margin-bottom:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gegguy50oztz000004.jpg" title="" alt="" style="width:542px;height:222px;" /></p>
<p style="margin-top:0pt;margin-bottom:6pt;text-indent:0%;font-size:12.5pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.81%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Diagnosis &#8211; Nodule Management</p>
<p style="margin-top:5pt;margin-bottom:6pt;text-indent:4.8%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe we are the only company to offer two commercial blood-based tests to help physicians reclassify risk of malignancy in patients with<span style="letter-spacing:0.05pt;"> </span>suspicious lung nodules. Our blood-based nodule management offering, Nodify Lung Nodule Risk Assessment assists physicians in reclassifying a<span style="letter-spacing:0.05pt;"> </span>patient&#8217;s<span style="letter-spacing:-0.25pt;"> </span>risk<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:-0.2pt;"> </span>lung<span style="letter-spacing:-0.25pt;"> </span>cancer<span style="letter-spacing:-0.2pt;"> </span>by<span style="letter-spacing:-0.25pt;"> </span>incorporating<span style="letter-spacing:-0.2pt;"> </span>their<span style="letter-spacing:-0.25pt;"> </span>protein<span style="letter-spacing:-0.2pt;"> </span>biomarker<span style="letter-spacing:-0.25pt;"> </span>results<span style="letter-spacing:-0.2pt;"> </span>with<span style="letter-spacing:-0.25pt;"> </span>radiographic<span style="letter-spacing:-0.25pt;"> </span>imaging<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.25pt;"> </span>clinical<span style="letter-spacing:-0.2pt;"> </span>characteristics.<span style="letter-spacing:-0.25pt;"> </span>Nodify<span style="letter-spacing:-0.2pt;"> </span>Lung<span style="letter-spacing:-0.25pt;"> </span>consists<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>the Nodify CDT and Nodify XL2 proteomic tests, which can be ordered separately or together from a single blood draw to help reclassify risk of cancer to<span style="letter-spacing:0.05pt;"> </span>aid<span style="letter-spacing:-0.1pt;"> </span>physicians<span style="letter-spacing:-0.1pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>stratifying<span style="letter-spacing:-0.1pt;"> </span>patients<span style="letter-spacing:-0.05pt;"> </span>into<span style="letter-spacing:-0.1pt;"> </span>distinct<span style="letter-spacing:-0.05pt;"> </span>nodule<span style="letter-spacing:-0.1pt;"> </span>management<span style="letter-spacing:-0.1pt;"> </span>pathways:<span style="letter-spacing:-0.05pt;"> </span>intervention<span style="letter-spacing:-0.1pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>surveillance.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:4pt;margin-bottom:6pt;text-indent:4.8%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Nodify CDT test is used to help identify lung nodules that are likely malignant and the Nodify XL2 test helps identify lung nodules that are</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">likely benign. Nodify Lung is available for patients 40 years or older, with nodules between 8 and 30mm, and less than 65% pre-test risk of lung cancer.</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The testing strategy starts with the Nodify CDT test to determine if a nodule is likely malignant or at a higher risk of lung cancer. The Nodify CDT test</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">helps physicians identify cancer more quickly by prioritizing patients with a higher risk of malignancy for a diagnostic procedure, such as biopsy or</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">surgery. If the nodule is not identified as having a high risk of malignancy by Nodify CDT, then the Nodify XL2 test is performed to help determine if the</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">patient&#8217;s</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">nodule</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">is</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">likely</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">benign</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">has</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">reduced</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">risk</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">lung</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">cancer</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">be</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">candidate</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CT</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">imaging</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">surveillance.</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Nodify</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lung</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">testing</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">strategy</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">is represented graphically in the image below starting with the patient&#8217;s pre-test risk of malignancy and ending with the guideline-recommended diagnostic</span><span style="letter-spacing:-2.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">procedure</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">each</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">risk</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">category.</span></p>
<p style="margin-top:4pt;margin-bottom:6pt;margin-left:1.78%;text-indent:4.8%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gegguy50oztz000005.jpg" title="" alt="" style="width:542px;height:270px;" /></p>
<p style="margin-top:0pt;margin-bottom:6pt;text-indent:0%;font-size:8pt;">&#160;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:4.8%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe we are the only company to offer two commercial blood-based tests to help physicians reclassify risk of malignancy in patients with<span style="letter-spacing:0.05pt;"> </span>suspicious<span style="letter-spacing:-0.25pt;"> </span>lung<span style="letter-spacing:-0.25pt;"> </span>nodules.<span style="letter-spacing:-0.25pt;"> </span>We<span style="letter-spacing:-0.2pt;"> </span>launched<span style="letter-spacing:-0.25pt;"> </span>the<span style="letter-spacing:-0.25pt;"> </span>Nodify<span style="letter-spacing:-0.25pt;"> </span>Lung<span style="letter-spacing:-0.2pt;"> </span>combined<span style="letter-spacing:-0.25pt;"> </span>offering<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:-0.25pt;"> </span>Nodify<span style="letter-spacing:-0.2pt;"> </span>CDT<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.25pt;"> </span>Nodify<span style="letter-spacing:-0.25pt;"> </span>XL2<span style="letter-spacing:-0.2pt;"> </span>in<span style="letter-spacing:-0.25pt;"> </span>March<span style="letter-spacing:-0.25pt;"> </span>2020.<span style="letter-spacing:-0.25pt;"> </span>However,<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.25pt;"> </span>Nodify<span style="letter-spacing:-0.25pt;"> </span>XL2<span style="letter-spacing:-0.25pt;"> </span>test<span style="letter-spacing:0.05pt;"> </span>has been available to all physicians since September 2019 and has been available to a select group of physicians since October 2018. We acquired the<span style="letter-spacing:0.05pt;"> </span>Nodify<span style="letter-spacing:-0.1pt;"> </span>XL2<span style="letter-spacing:-0.1pt;"> </span>test<span style="letter-spacing:-0.1pt;"> </span>from<span style="letter-spacing:-0.1pt;"> </span>Integrated<span style="letter-spacing:-0.1pt;"> </span>Diagnostics<span style="letter-spacing:-0.1pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>July<span style="letter-spacing:-0.1pt;"> </span>2018,<span style="letter-spacing:-0.1pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>acquired<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>Nodify<span style="letter-spacing:-0.05pt;"> </span>CDT<span style="letter-spacing:-0.1pt;"> </span>from<span style="letter-spacing:-0.1pt;"> </span>Oncimmune<span style="letter-spacing:-0.1pt;"> </span>USA<span style="letter-spacing:-0.1pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>October<span style="letter-spacing:-0.1pt;"> </span>2019.</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.81%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Nodify<span style="letter-spacing:-0.1pt;"> </span>CDT</p>
<p style="margin-top:5pt;margin-bottom:6pt;text-indent:4.8%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Nodify<span style="letter-spacing:-0.2pt;"> </span>CDT<span style="letter-spacing:-0.15pt;"> </span>is<span style="letter-spacing:-0.15pt;"> </span>a<span style="letter-spacing:-0.2pt;"> </span>blood-based<span style="letter-spacing:-0.15pt;"> </span>proteomic<span style="letter-spacing:-0.15pt;"> </span>test<span style="letter-spacing:-0.2pt;"> </span>that<span style="letter-spacing:-0.15pt;"> </span>helps<span style="letter-spacing:-0.15pt;"> </span>identify<span style="letter-spacing:-0.15pt;"> </span>patients<span style="letter-spacing:-0.2pt;"> </span>who<span style="letter-spacing:-0.15pt;"> </span>have<span style="letter-spacing:-0.15pt;"> </span>a<span style="letter-spacing:-0.2pt;"> </span>suspicious<span style="letter-spacing:-0.15pt;"> </span>lung<span style="letter-spacing:-0.15pt;"> </span>nodule<span style="letter-spacing:-0.2pt;"> </span>that<span style="letter-spacing:-0.15pt;"> </span>is<span style="letter-spacing:-0.15pt;"> </span>likely<span style="letter-spacing:-0.15pt;"> </span>malignant<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:-0.15pt;"> </span>at<span style="letter-spacing:-0.15pt;"> </span>a<span style="letter-spacing:-0.2pt;"> </span>higher<span style="letter-spacing:-0.15pt;"> </span>risk<span style="letter-spacing:0.05pt;"> </span>of being cancerous. Results allow physicians to identify patients who may be better candidates for timely invasive diagnostic procedures such as<span style="letter-spacing:0.05pt;"> </span>bronchoscopy, transthoracic needle biopsy, or surgical resection, with the hope of catching cancer earlier. Nodify CDT enhances lung nodule risk<span style="letter-spacing:0.05pt;"> </span>assessment to facilitate compliance with clinical treatment guidelines such as those of the American College of Chest Physicians (ACCP). Nodify CDT is<span style="letter-spacing:0.05pt;"> </span>intended<span style="letter-spacing:-0.15pt;"> </span>for<span style="letter-spacing:-0.1pt;"> </span>use<span style="letter-spacing:-0.1pt;"> </span>in<span style="letter-spacing:-0.15pt;"> </span>patients<span style="letter-spacing:-0.1pt;"> </span>who<span style="letter-spacing:-0.1pt;"> </span>are<span style="letter-spacing:-0.15pt;"> </span>40<span style="letter-spacing:-0.1pt;"> </span>years<span style="letter-spacing:-0.1pt;"> </span>or<span style="letter-spacing:-0.1pt;"> </span>older,<span style="letter-spacing:-0.15pt;"> </span>have<span style="letter-spacing:-0.1pt;"> </span>nodules<span style="letter-spacing:-0.1pt;"> </span>between<span style="letter-spacing:-0.15pt;"> </span>8<span style="letter-spacing:-0.1pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>30mm,<span style="letter-spacing:-0.1pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>pre-test<span style="letter-spacing:-0.1pt;"> </span>risk<span style="letter-spacing:-0.1pt;"> </span>of<span style="letter-spacing:-0.15pt;"> </span>lung<span style="letter-spacing:-0.1pt;"> </span>cancer<span style="letter-spacing:-0.1pt;"> </span>of<span style="letter-spacing:-0.15pt;"> </span>less<span style="letter-spacing:-0.1pt;"> </span>than<span style="letter-spacing:-0.1pt;"> </span>65%.</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:4.8%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The test measures the levels of seven circulating autoantibodies (P53, NY-ESO-1, CAGE, GBU4-5, SOX2, HuD, and MAGE A4) associated with<span style="letter-spacing:0.05pt;"> </span>lung<span style="letter-spacing:-0.25pt;"> </span>cancer,<span style="letter-spacing:-0.2pt;"> </span>combined<span style="letter-spacing:-0.2pt;"> </span>by<span style="letter-spacing:-0.25pt;"> </span>an<span style="letter-spacing:-0.2pt;"> </span>algorithm<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.25pt;"> </span>report<span style="letter-spacing:-0.2pt;"> </span>out<span style="letter-spacing:-0.2pt;"> </span>three<span style="letter-spacing:-0.25pt;"> </span>potential<span style="letter-spacing:-0.2pt;"> </span>results:<span style="letter-spacing:-0.2pt;"> </span>High<span style="letter-spacing:-0.25pt;"> </span>Level,<span style="letter-spacing:-0.2pt;"> </span>Moderate<span style="letter-spacing:-0.2pt;"> </span>Level,<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:-0.2pt;"> </span>No<span style="letter-spacing:-0.2pt;"> </span>Significant<span style="letter-spacing:-0.2pt;"> </span>Levels<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:-0.2pt;"> </span>Antibodies<span style="letter-spacing:-0.2pt;"> </span>Detected<span style="letter-spacing:0.05pt;"> </span>(NSLAD).<span style="letter-spacing:-0.15pt;"> </span>The<span style="letter-spacing:-0.1pt;"> </span>seven<span style="letter-spacing:-0.1pt;"> </span>autoantibodies<span style="letter-spacing:-0.1pt;"> </span>have<span style="letter-spacing:-0.1pt;"> </span>shown<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.1pt;"> </span>elevated<span style="letter-spacing:-0.1pt;"> </span>for<span style="letter-spacing:-0.1pt;"> </span>all<span style="letter-spacing:-0.1pt;"> </span>types<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:-0.1pt;"> </span>lung<span style="letter-spacing:-0.1pt;"> </span>cancer,<span style="letter-spacing:-0.1pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>from<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>earliest<span style="letter-spacing:-0.1pt;"> </span>stage<span style="letter-spacing:-0.1pt;"> </span>of<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>disease.</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:4.8%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unlike the tumor antigens themselves, the autoantibody levels can be measured accurately through a blood sample, based upon the signal amplification generated by the immune response to cancer. This mechanism of action likely reflects very early events in a tumor&#8217;s evolution&#59; as the immune system initiates a response to the cancer, it can also trigger an expansion of self-reactive antibodies that can be measured in circulation.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:4.8%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to the test result of High Level, Moderate Level, or NSLAD, each test report includes the patient&#8217;s pre-test risk of malignancy as</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">calculated by the Solitary Pulmonary Nodule Risk Assessment calculator, and their post-test risk of cancer incorporating the result of the test. The Solitary</span><span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">Pulmonary </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Nodule Risk Assessment calculator was developed by Stephen Swensen, M.D., of the Mayo Clinic and is designed to provide a risk of</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">malignancy for a patient with a newly discovered incidental nodule. The model incorporates six clinical and radiologic factors into the equation: age,</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">nodule size, smoking status, nodule location, spiculation (nodule edge characteristic), and previous history of lung cancer. Incorporating the autoantibody</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">levels</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">with</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">risk</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">model</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">provides</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">physicians</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">with</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">more</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">accurate</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">assessment</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">risk.</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">test</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">has</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">been</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">studied</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">peer</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">reviewed</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">published</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">studies</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">presentations.</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.81%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Nodify<span style="letter-spacing:-0.1pt;"> </span>XL2</p>
<p style="margin-top:5pt;margin-bottom:6pt;text-indent:4.8%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Nodify<span style="letter-spacing:-0.2pt;"> </span>XL2<span style="letter-spacing:-0.15pt;"> </span>is<span style="letter-spacing:-0.15pt;"> </span>a<span style="letter-spacing:-0.15pt;"> </span>blood-based<span style="letter-spacing:-0.2pt;"> </span>proteomic<span style="letter-spacing:-0.15pt;"> </span>test<span style="letter-spacing:-0.15pt;"> </span>that<span style="letter-spacing:-0.15pt;"> </span>helps<span style="letter-spacing:-0.15pt;"> </span>identify<span style="letter-spacing:-0.2pt;"> </span>patients<span style="letter-spacing:-0.15pt;"> </span>who<span style="letter-spacing:-0.15pt;"> </span>have<span style="letter-spacing:-0.15pt;"> </span>a<span style="letter-spacing:-0.15pt;"> </span>suspicious<span style="letter-spacing:-0.2pt;"> </span>lung<span style="letter-spacing:-0.15pt;"> </span>nodule<span style="letter-spacing:-0.15pt;"> </span>that<span style="letter-spacing:-0.15pt;"> </span>is<span style="letter-spacing:-0.2pt;"> </span>likely<span style="letter-spacing:-0.15pt;"> </span>benign<span style="letter-spacing:-0.15pt;"> </span>or<span style="letter-spacing:-0.15pt;"> </span>at<span style="letter-spacing:-0.15pt;"> </span>a<span style="letter-spacing:-0.2pt;"> </span>reduced<span style="letter-spacing:-0.15pt;"> </span>risk<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>being cancerous. Results allow physicians to identify patients who may be better candidates for routine CT surveillance to monitor for growth or shrinkage<span style="letter-spacing:0.05pt;"> </span>of the nodule over time instead of an invasive diagnostic procedure. Nodify XL2 is used for patients who are 40 years or older, have nodules between 8 and<span style="letter-spacing:-2.1pt;"> </span>30mm,<span style="letter-spacing:-0.1pt;"> </span>and<span style="letter-spacing:-0.05pt;"> </span>have<span style="letter-spacing:-0.05pt;"> </span>a<span style="letter-spacing:-0.05pt;"> </span>pre-test<span style="letter-spacing:-0.1pt;"> </span>risk<span style="letter-spacing:-0.05pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>lung<span style="letter-spacing:-0.05pt;"> </span>cancer<span style="letter-spacing:-0.05pt;"> </span>of<span style="letter-spacing:-0.1pt;"> </span>less<span style="letter-spacing:-0.05pt;"> </span>than<span style="letter-spacing:-0.05pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>equal<span style="letter-spacing:-0.1pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>50%.</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:4.8%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Nodify XL2 integrates peptides measured by LC-MS with clinical and radiological characteristics that are combined by an algorithm to report out<span style="letter-spacing:0.05pt;"> </span>three<span style="letter-spacing:-0.25pt;"> </span>potential<span style="letter-spacing:-0.25pt;"> </span>results:<span style="letter-spacing:-0.25pt;"> </span>Likely<span style="letter-spacing:-0.25pt;"> </span>Benign,<span style="letter-spacing:-0.2pt;"> </span>Reduced<span style="letter-spacing:-0.25pt;"> </span>Risk,<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:-0.25pt;"> </span>Indeterminate.<span style="letter-spacing:-0.2pt;"> </span>Specifically,<span style="letter-spacing:-0.25pt;"> </span>the<span style="letter-spacing:-0.25pt;"> </span>Nodify<span style="letter-spacing:-0.25pt;"> </span>XL2<span style="letter-spacing:-0.2pt;"> </span>test<span style="letter-spacing:-0.25pt;"> </span>measures<span style="letter-spacing:-0.25pt;"> </span>the<span style="letter-spacing:-0.25pt;"> </span>relative<span style="letter-spacing:-0.2pt;"> </span>abundance<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:-0.25pt;"> </span>two<span style="letter-spacing:-0.25pt;"> </span>peptides<span style="letter-spacing:0.05pt;"> </span>(LG3BP<span style="letter-spacing:-0.1pt;"> </span>and<span style="letter-spacing:-0.05pt;"> </span>C163A)<span style="letter-spacing:-0.05pt;"> </span>in circulation<span style="letter-spacing:-0.25pt;"> </span>in<span style="letter-spacing:-0.25pt;"> </span>the<span style="letter-spacing:-0.2pt;"> </span>patient&#8217;s<span style="letter-spacing:-0.25pt;"> </span>blood.<span style="letter-spacing:-0.25pt;"> </span>The<span style="letter-spacing:-0.2pt;"> </span>native<span style="letter-spacing:-0.25pt;"> </span>proteins<span style="letter-spacing:-0.2pt;"> </span>from<span style="letter-spacing:-0.25pt;"> </span>which<span style="letter-spacing:-0.25pt;"> </span>the<span style="letter-spacing:-0.2pt;"> </span>peptides<span style="letter-spacing:-0.25pt;"> </span>are<span style="letter-spacing:-0.25pt;"> </span>derived,<span style="letter-spacing:-0.2pt;"> </span>have<span style="letter-spacing:-0.25pt;"> </span>been<span style="letter-spacing:-0.2pt;"> </span>associated<span style="letter-spacing:-0.25pt;"> </span>with<span style="letter-spacing:-0.25pt;"> </span>an<span style="letter-spacing:-0.2pt;"> </span>inflammatory<span style="letter-spacing:-0.25pt;"> </span>response<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.2pt;"> </span>cancer.<span style="letter-spacing:0.05pt;"> </span>The<span style="letter-spacing:-0.15pt;"> </span>clinical<span style="letter-spacing:-0.1pt;"> </span>factors<span style="letter-spacing:-0.1pt;"> </span>are<span style="letter-spacing:-0.1pt;"> </span>patient<span style="letter-spacing:-0.1pt;"> </span>age<span style="letter-spacing:-0.1pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>smoking<span style="letter-spacing:-0.1pt;"> </span>status,<span style="letter-spacing:-0.1pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>radiological<span style="letter-spacing:-0.1pt;"> </span>factors<span style="letter-spacing:-0.1pt;"> </span>are<span style="letter-spacing:-0.1pt;"> </span>nodule<span style="letter-spacing:-0.1pt;"> </span>size,<span style="letter-spacing:-0.1pt;"> </span>location,<span style="letter-spacing:-0.1pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>edge<span style="letter-spacing:-0.1pt;"> </span>characteristics.</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:4.8%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to the test result of Likely Benign, Reduced Risk, or Indeterminate, each test report includes the patient&#8217;s pre-test risk of lung cancer as<span style="letter-spacing:0.05pt;"> </span>calculated<span style="letter-spacing:-0.25pt;"> </span>by<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.2pt;"> </span>Solitary<span style="letter-spacing:-0.2pt;"> </span>Pulmonary<span style="letter-spacing:-0.2pt;"> </span>Nodule<span style="letter-spacing:-0.25pt;"> </span>Risk<span style="letter-spacing:-0.2pt;"> </span>Assessment<span style="letter-spacing:-0.2pt;"> </span>calculator,<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>their<span style="letter-spacing:-0.2pt;"> </span>post-Nodify<span style="letter-spacing:-0.25pt;"> </span>XL2<span style="letter-spacing:-0.2pt;"> </span>risk<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.2pt;"> </span>malignancy<span style="letter-spacing:-0.2pt;"> </span>incorporating<span style="letter-spacing:-0.25pt;"> </span>the<span style="letter-spacing:-0.2pt;"> </span>result<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.2pt;"> </span>test.<span style="letter-spacing:0.05pt;"> </span>Incorporating<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>peptide<span style="letter-spacing:-0.15pt;"> </span>levels<span style="letter-spacing:-0.15pt;"> </span>with<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>risk<span style="letter-spacing:-0.15pt;"> </span>model<span style="letter-spacing:-0.15pt;"> </span>provides<span style="letter-spacing:-0.15pt;"> </span>physicians<span style="letter-spacing:-0.15pt;"> </span>with<span style="letter-spacing:-0.1pt;"> </span>a<span style="letter-spacing:-0.15pt;"> </span>revised<span style="letter-spacing:-0.15pt;"> </span>assessment<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:-0.15pt;"> </span>risk<span style="letter-spacing:-0.1pt;"> </span>incorporating<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>patient&#8217;s<span style="letter-spacing:-0.15pt;"> </span>biology.</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:4.8%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In<span style="letter-spacing:-0.2pt;"> </span>summary,<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.2pt;"> </span>inclusion<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.2pt;"> </span>Nodify<span style="letter-spacing:-0.2pt;"> </span>Lung<span style="letter-spacing:-0.2pt;"> </span>testing<span style="letter-spacing:-0.2pt;"> </span>strategy<span style="letter-spacing:-0.2pt;"> </span>into<span style="letter-spacing:-0.2pt;"> </span>clinical<span style="letter-spacing:-0.2pt;"> </span>practice<span style="letter-spacing:-0.2pt;"> </span>helps<span style="letter-spacing:-0.2pt;"> </span>physicians<span style="letter-spacing:-0.2pt;"> </span>reclassify<span style="letter-spacing:-0.15pt;"> </span>risk<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.2pt;"> </span>malignancy<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.2pt;"> </span>low<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.2pt;"> </span>moderate<span style="letter-spacing:0.05pt;"> </span>risk lung nodules by incorporating the patient&#8217;s own biology into the assessment. The Nodify CDT test helps physicians identify patients with a high-risk<span style="letter-spacing:0.05pt;"> </span>lung nodule who may benefit from timely intervention, which can ultimately help identify lung cancer earlier. The Nodify XL2 test helps physicians<span style="letter-spacing:0.05pt;"> </span>identify<span style="letter-spacing:-0.15pt;"> </span>patients<span style="letter-spacing:-0.1pt;"> </span>with<span style="letter-spacing:-0.1pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>very<span style="letter-spacing:-0.15pt;"> </span>low<span style="letter-spacing:-0.1pt;"> </span>risk<span style="letter-spacing:-0.1pt;"> </span>lung<span style="letter-spacing:-0.1pt;"> </span>nodule<span style="letter-spacing:-0.15pt;"> </span>who<span style="letter-spacing:-0.1pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>benefit<span style="letter-spacing:-0.1pt;"> </span>from<span style="letter-spacing:-0.15pt;"> </span>CT<span style="letter-spacing:-0.1pt;"> </span>surveillance<span style="letter-spacing:-0.1pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>could<span style="letter-spacing:-0.1pt;"> </span>avoid<span style="letter-spacing:-0.15pt;"> </span>unnecessary<span style="letter-spacing:-0.1pt;"> </span>invasive<span style="letter-spacing:-0.1pt;"> </span>procedures.</p>
<p style="margin-top:0pt;margin-bottom:6pt;text-indent:4.8%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Blood<span style="letter-spacing:-0.3pt;"> </span>samples<span style="letter-spacing:-0.25pt;"> </span>for<span style="letter-spacing:-0.25pt;"> </span>Nodify<span style="letter-spacing:-0.25pt;"> </span>XL2<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.25pt;"> </span>Nodify<span style="letter-spacing:-0.25pt;"> </span>CDT<span style="letter-spacing:-0.25pt;"> </span>can<span style="letter-spacing:-0.25pt;"> </span>be<span style="letter-spacing:-0.25pt;"> </span>collected<span style="letter-spacing:-0.25pt;"> </span>in<span style="letter-spacing:-0.25pt;"> </span>the<span style="letter-spacing:-0.3pt;"> </span>physician&#8217;s<span style="letter-spacing:-0.25pt;"> </span>office,<span style="letter-spacing:-0.25pt;"> </span>laboratory,<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:-0.25pt;"> </span>at<span style="letter-spacing:-0.25pt;"> </span>home<span style="letter-spacing:-0.25pt;"> </span>through<span style="letter-spacing:-0.25pt;"> </span>use<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:-0.25pt;"> </span>mobile<span style="letter-spacing:-0.25pt;"> </span>phlebotomy.<span style="letter-spacing:0.05pt;"> </span>Mobile phlebotomy options facilitate testing for patients even if they are not seen in person by the physician and instead are seen through telehealth visits.<span style="letter-spacing:0.05pt;"> </span>This benefits the patient as scheduling can be conveniently fit to their needs and can keep them away from a physician&#8217;s office or hospital for safety<span style="letter-spacing:0.05pt;"> </span>concerns, especially with the evolving coronavirus pandemic. Additionally, mobile phlebotomy benefits the physician as the logistics around a blood draw<span style="letter-spacing:-2.1pt;"> </span>or tissue sampling are out of their hands. We have a national network of contracted Nurses and Phlebotomists to support at-home or mobile blood<span style="letter-spacing:0.05pt;"> </span>collection.</p>
<p style="margin-top:0pt;margin-bottom:6pt;text-indent:4.8%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Both tests require a single blood sample shipped at ambient temperature to our certified, high-complexity clinical laboratory in De Soto, Kansas.&#160;&#160;Nodify<span style="letter-spacing:-0.2pt;"> </span>CDT<span style="letter-spacing:-0.2pt;"> </span>requires<span style="letter-spacing:-0.2pt;"> </span>whole<span style="letter-spacing:-0.2pt;"> </span>blood<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>Nodify<span style="letter-spacing:-0.2pt;"> </span>XL2<span style="letter-spacing:-0.2pt;"> </span>requires<span style="letter-spacing:-0.2pt;"> </span>whole<span style="letter-spacing:-0.2pt;"> </span>blood<span style="letter-spacing:-0.2pt;"> </span>spotted<span style="letter-spacing:-0.2pt;"> </span>onto<span style="letter-spacing:-0.2pt;"> </span>our<span style="letter-spacing:-0.2pt;"> </span>proprietary<span style="letter-spacing:-0.2pt;"> </span>Blood<span style="letter-spacing:-0.2pt;"> </span>Collection<span style="letter-spacing:-0.2pt;"> </span>Device<span style="letter-spacing:-0.2pt;"> </span>(BCD).<span style="letter-spacing:-0.2pt;"> </span>The<span style="letter-spacing:-0.2pt;"> </span>introduction<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>BCD<span style="letter-spacing:-0.05pt;"> </span>as<span style="letter-spacing:-0.05pt;"> </span>a<span style="letter-spacing:-0.05pt;"> </span>qualified<span style="letter-spacing:-0.05pt;"> </span>specimen collection<span style="letter-spacing:-0.2pt;"> </span>method<span style="letter-spacing:-0.15pt;"> </span>for<span style="letter-spacing:-0.2pt;"> </span>use<span style="letter-spacing:-0.15pt;"> </span>with<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.2pt;"> </span>Nodify<span style="letter-spacing:-0.15pt;"> </span>XL2<span style="letter-spacing:-0.15pt;"> </span>test<span style="letter-spacing:-0.2pt;"> </span>alleviated<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>need<span style="letter-spacing:-0.2pt;"> </span>for<span style="letter-spacing:-0.15pt;"> </span>serum<span style="letter-spacing:-0.15pt;"> </span>separation<span style="letter-spacing:-0.2pt;"> </span>processing<span style="letter-spacing:-0.15pt;"> </span>steps<span style="letter-spacing:-0.15pt;"> </span>by<span style="letter-spacing:-0.2pt;"> </span>phlebotomists<span style="letter-spacing:-0.15pt;"> </span>at<span style="letter-spacing:-0.2pt;"> </span>blood<span style="letter-spacing:-0.15pt;"> </span>draw<span style="letter-spacing:-0.15pt;"> </span>sites<span style="letter-spacing:-0.2pt;"> </span>such<span style="letter-spacing:-0.15pt;"> </span>as<span style="letter-spacing:0.05pt;"> </span>centrifugation, and cold chain (dry ice) shipments, which has increased the market access to our proteomic-based tests. Results for Nodify CDT alone are<span style="letter-spacing:-2.1pt;"> &#160;&#160; </span>typically available within one day. If both tests are ordered for the patient and Nodify CDT returns a result of NSLAD, then both test results are typically<span style="letter-spacing:0.05pt;"> </span>available<span style="letter-spacing:-0.1pt;"> </span>within<span style="letter-spacing:-0.1pt;"> </span>4<span style="letter-spacing:-0.05pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>5<span style="letter-spacing:-0.05pt;"> </span>days.<span style="letter-spacing:-0.1pt;"> </span>All<span style="letter-spacing:-0.05pt;"> </span>results<span style="letter-spacing:-0.1pt;"> </span>are<span style="letter-spacing:-0.05pt;"> </span>available<span style="letter-spacing:-0.1pt;"> </span>through<span style="letter-spacing:-0.05pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>portal,<span style="letter-spacing:-0.05pt;"> </span>fax,<span style="letter-spacing:-0.1pt;"> </span>hard<span style="letter-spacing:-0.05pt;"> </span>copy,<span style="letter-spacing:-0.1pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>mobile<span style="letter-spacing:-0.1pt;"> </span>device.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Treatment Guidance and Monitoring</span></p>
<p style="margin-top:5pt;margin-bottom:6pt;text-indent:4.8%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Profiling the tumor through blood-based testing can help identify mutations in genes that may be driving growth of the tumor and may be targets for<span style="letter-spacing:-2.1pt;"> </span>therapeutics. However, tumors also suppress intrinsic mechanisms that prevent the patient&#8217;s immune system from identifying and eliminating the cancer<span style="letter-spacing:0.05pt;"> </span>cells. Profiling the immune system can show if the patient&#8217;s immune system may have been subverted and therefore, is less likely to be responsive to<span style="letter-spacing:0.05pt;"> </span>immunotherapies.<span style="letter-spacing:-0.3pt;"> </span>Our<span style="letter-spacing:-0.25pt;"> </span>blood-based<span style="letter-spacing:-0.25pt;"> </span>Biodesix<span style="letter-spacing:-0.25pt;"> </span>Lung<span style="letter-spacing:-0.25pt;"> </span>Reflex<span style="letter-spacing:-0.25pt;"> </span>testing<span style="letter-spacing:-0.25pt;"> </span>strategy<span style="letter-spacing:-0.25pt;"> </span>consists<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:-0.25pt;"> </span>the<span style="letter-spacing:-0.25pt;"> </span>GeneStrat<span style="letter-spacing:-0.25pt;"> </span>tumor<span style="letter-spacing:-0.25pt;"> </span>profiling<span style="letter-spacing:-0.25pt;"> </span>test<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.3pt;"> </span>the<span style="letter-spacing:-0.25pt;"> </span>VeriStrat<span style="letter-spacing:-0.25pt;"> </span>immune<span style="letter-spacing:-0.25pt;"> </span>profiling<span style="letter-spacing:0.05pt;"> </span>test,<span style="letter-spacing:-0.25pt;"> </span>which<span style="letter-spacing:-0.25pt;"> </span>can<span style="letter-spacing:-0.25pt;"> </span>be<span style="letter-spacing:-0.2pt;"> </span>ordered<span style="letter-spacing:-0.25pt;"> </span>together<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:-0.25pt;"> </span>separately<span style="letter-spacing:-0.2pt;"> </span>for<span style="letter-spacing:-0.25pt;"> </span>patients<span style="letter-spacing:-0.25pt;"> </span>with<span style="letter-spacing:-0.25pt;"> </span>NSCLC.<span style="letter-spacing:-0.2pt;"> </span>Together,<span style="letter-spacing:-0.25pt;"> </span>the<span style="letter-spacing:-0.25pt;"> </span>tests<span style="letter-spacing:-0.2pt;"> </span>typically<span style="letter-spacing:-0.25pt;"> </span>have<span style="letter-spacing:-0.25pt;"> </span>a<span style="letter-spacing:-0.25pt;"> </span>3-day<span style="letter-spacing:-0.2pt;"> </span>turnaround<span style="letter-spacing:-0.25pt;"> </span>time,<span style="letter-spacing:-0.25pt;"> </span>providing<span style="letter-spacing:-0.25pt;"> </span>physicians<span style="letter-spacing:0.05pt;"> </span>with<span style="letter-spacing:-0.1pt;"> </span>timely<span style="letter-spacing:-0.05pt;"> </span>results<span style="letter-spacing:-0.05pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>facilitate<span style="letter-spacing:-0.05pt;"> </span>treatment<span style="letter-spacing:-0.05pt;"> </span>decisions.</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.81%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">GeneStrat</p>
<p style="margin-top:5pt;margin-bottom:6pt;text-indent:4.8%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GeneStrat is a blood-based tumor profiling test that detects the guideline recommended, actionable mutations in lung cancer: <span style="font-style:italic;">EGFR, KRAS, BRAF,</span><span style="font-style:italic;letter-spacing:0.05pt;"> </span><span style="font-style:italic;">EML4-ALK, ROS-1, </span>and <span style="font-style:italic;">RET. </span>Physicians can order one or any combination of the gene tests, whichever they deem medically necessary for the individual<span style="letter-spacing:0.05pt;"> </span>patient.<span style="letter-spacing:-0.25pt;"> </span>The<span style="letter-spacing:-0.2pt;"> </span>presence<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:-0.2pt;"> </span>a<span style="letter-spacing:-0.25pt;"> </span>mutation<span style="letter-spacing:-0.2pt;"> </span>in<span style="letter-spacing:-0.25pt;"> </span>one<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.25pt;"> </span>the<span style="letter-spacing:-0.2pt;"> </span>genes<span style="letter-spacing:-0.25pt;"> </span>could<span style="letter-spacing:-0.2pt;"> </span>indicate<span style="letter-spacing:-0.25pt;"> </span>the<span style="letter-spacing:-0.2pt;"> </span>patient<span style="letter-spacing:-0.25pt;"> </span>is<span style="letter-spacing:-0.2pt;"> </span>a<span style="letter-spacing:-0.25pt;"> </span>candidate<span style="letter-spacing:-0.2pt;"> </span>for<span style="letter-spacing:-0.25pt;"> </span>the<span style="letter-spacing:-0.2pt;"> </span>associated<span style="letter-spacing:-0.25pt;"> </span>guideline-recommended<span style="letter-spacing:-0.2pt;"> </span>targeted<span style="letter-spacing:-0.25pt;"> </span>therapy.<span style="letter-spacing:0.05pt;"> </span>The<span style="letter-spacing:-0.1pt;"> </span>GeneStrat<span style="letter-spacing:-0.1pt;"> </span>test<span style="letter-spacing:-0.05pt;"> </span>performance<span style="letter-spacing:-0.1pt;"> </span>and<span style="letter-spacing:-0.05pt;"> </span>potential<span style="letter-spacing:-0.1pt;"> </span>clinical<span style="letter-spacing:-0.05pt;"> </span>utility<span style="letter-spacing:-0.1pt;"> </span>have<span style="letter-spacing:-0.05pt;"> </span>been<span style="letter-spacing:-0.1pt;"> </span>published<span style="letter-spacing:-0.05pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>3<span style="letter-spacing:-0.05pt;"> </span>peer<span style="letter-spacing:-0.1pt;"> </span>reviewed<span style="letter-spacing:-0.1pt;"> </span>studies.</p>
<p style="margin-top:4pt;margin-bottom:6pt;text-indent:4.8%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GeneStrat test results are typically available within 72 hours from our receipt of the sample in our Boulder, Colorado clinical laboratory. In a study at<span style="letter-spacing:-2.1pt;"> </span>Eastern<span style="letter-spacing:-0.25pt;"> </span>Carolina<span style="letter-spacing:-0.2pt;"> </span>University,<span style="letter-spacing:-0.2pt;"> </span>it<span style="letter-spacing:-0.2pt;"> </span>was<span style="letter-spacing:-0.2pt;"> </span>observed<span style="letter-spacing:-0.25pt;"> </span>that<span style="letter-spacing:-0.2pt;"> </span>blood-based<span style="letter-spacing:-0.2pt;"> </span>testing<span style="letter-spacing:-0.2pt;"> </span>was<span style="letter-spacing:-0.2pt;"> </span>up<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.2pt;"> </span>three<span style="letter-spacing:-0.2pt;"> </span>weeks<span style="letter-spacing:-0.2pt;"> </span>faster<span style="letter-spacing:-0.2pt;"> </span>than<span style="letter-spacing:-0.25pt;"> </span>tissue-based<span style="letter-spacing:-0.2pt;"> </span>testing,<span style="letter-spacing:-0.2pt;"> </span>with<span style="letter-spacing:-0.2pt;"> </span>tissue-based<span style="letter-spacing:-0.2pt;"> </span>testing<span style="letter-spacing:-0.2pt;"> </span>taking<span style="letter-spacing:0.05pt;"> </span>a median of 26 days from sample collection. With GeneStrat testing, results are typically available in time for the patients first oncology visit, allowing the<span style="letter-spacing:0.05pt;"> </span>patient<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.2pt;"> </span>start<span style="letter-spacing:-0.2pt;"> </span>front-line<span style="letter-spacing:-0.15pt;"> </span>treatment<span style="letter-spacing:-0.2pt;"> </span>as<span style="letter-spacing:-0.2pt;"> </span>quickly<span style="letter-spacing:-0.15pt;"> </span>as<span style="letter-spacing:-0.2pt;"> </span>possible.<span style="letter-spacing:-0.2pt;"> </span>In<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>same<span style="letter-spacing:-0.2pt;"> </span>study,<span style="letter-spacing:-0.2pt;"> </span>it<span style="letter-spacing:-0.15pt;"> </span>was<span style="letter-spacing:-0.2pt;"> </span>observed<span style="letter-spacing:-0.2pt;"> </span>that<span style="letter-spacing:-0.2pt;"> </span>only<span style="letter-spacing:-0.15pt;"> </span>4%<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.2pt;"> </span>patients<span style="letter-spacing:-0.15pt;"> </span>had<span style="letter-spacing:-0.2pt;"> </span>tissue-based<span style="letter-spacing:-0.2pt;"> </span>molecular<span style="letter-spacing:-0.15pt;"> </span>test<span style="letter-spacing:-0.2pt;"> </span>results<span style="letter-spacing:0.05pt;"> </span>prior to start of front-line treatment. Meanwhile, after integrating Biodesix Lung Reflex testing at the institution, 72% of patients had molecular test results<span style="letter-spacing:0.05pt;"> </span>available.<span style="letter-spacing:-0.15pt;"> </span>Testing<span style="letter-spacing:-0.1pt;"> </span>with<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>GeneStrat<span style="letter-spacing:-0.1pt;"> </span>test<span style="letter-spacing:-0.1pt;"> </span>can<span style="letter-spacing:-0.1pt;"> </span>help<span style="letter-spacing:-0.1pt;"> </span>physicians<span style="letter-spacing:-0.1pt;"> </span>identify<span style="letter-spacing:-0.1pt;"> </span>driver<span style="letter-spacing:-0.1pt;"> </span>mutations<span style="letter-spacing:-0.1pt;"> </span>quickly<span style="letter-spacing:-0.1pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>help<span style="letter-spacing:-0.15pt;"> </span>speed<span style="letter-spacing:-0.1pt;"> </span>up<span style="letter-spacing:-0.1pt;"> </span>time<span style="letter-spacing:-0.1pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>treatment.</p>
<p style="margin-top:4pt;margin-bottom:6pt;margin-left:1.78%;text-indent:4.8%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gegguy50oztz000006.jpg" title="" alt="" style="width:544px;height:298px;" /></p>
<p style="margin-top:0pt;margin-bottom:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:4.8%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We<span style="letter-spacing:-0.25pt;"> </span>believe<span style="letter-spacing:-0.25pt;"> </span>that<span style="letter-spacing:-0.25pt;"> </span>rapid,<span style="letter-spacing:-0.25pt;"> </span>blood-based<span style="letter-spacing:-0.25pt;"> </span>tumor<span style="letter-spacing:-0.2pt;"> </span>profiling<span style="letter-spacing:-0.25pt;"> </span>with<span style="letter-spacing:-0.25pt;"> </span>the<span style="letter-spacing:-0.25pt;"> </span>GeneStrat<span style="letter-spacing:-0.25pt;"> </span>test<span style="letter-spacing:-0.2pt;"> </span>is<span style="letter-spacing:-0.25pt;"> </span>complementary<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.25pt;"> </span>both<span style="letter-spacing:-0.25pt;"> </span>targeted<span style="letter-spacing:-0.25pt;"> </span>tissue-based<span style="letter-spacing:-0.2pt;"> </span>testing<span style="letter-spacing:-0.25pt;"> </span>(including<span style="letter-spacing:-0.25pt;"> </span>PD-L1)<span style="letter-spacing:0.05pt;"> </span>and<span style="letter-spacing:-0.3pt;"> </span>broad<span style="letter-spacing:-0.25pt;"> </span>genomic<span style="letter-spacing:-0.3pt;"> </span>sequencing.<span style="letter-spacing:-0.25pt;"> </span>Testing<span style="letter-spacing:-0.3pt;"> </span>with<span style="letter-spacing:-0.25pt;"> </span>GeneStrat<span style="letter-spacing:-0.3pt;"> </span>at<span style="letter-spacing:-0.25pt;"> </span>diagnosis<span style="letter-spacing:-0.3pt;"> </span>can<span style="letter-spacing:-0.25pt;"> </span>help<span style="letter-spacing:-0.3pt;"> </span>quickly<span style="letter-spacing:-0.25pt;"> </span>identify<span style="letter-spacing:-0.3pt;"> </span>patients<span style="letter-spacing:-0.25pt;"> </span>who<span style="letter-spacing:-0.3pt;"> </span>are<span style="letter-spacing:-0.25pt;"> </span>eligible<span style="letter-spacing:-0.3pt;"> </span>for<span style="letter-spacing:-0.25pt;"> </span>targeted<span style="letter-spacing:-0.3pt;"> </span>therapies.<span style="letter-spacing:-0.25pt;"> </span>Additionally,<span style="letter-spacing:0.05pt;"> </span>blood-based testing upfront can help save valuable tissue for diagnostic evaluation, PD-L1 testing and broad genomic profiling for rare mutations to enroll<span style="letter-spacing:-2.1pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>clinical<span style="letter-spacing:-0.05pt;"> </span>trials.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.81%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><span style="font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">VeriStrat</span></p>
<p style="margin-top:5pt;margin-bottom:6pt;text-indent:4.8%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">VeriStrat is a blood-based proteomic test that provides a personalized view of each patient&#8217;s immune response to their lung cancer. Results help<span style="letter-spacing:0.05pt;"> </span>inform<span style="letter-spacing:-0.3pt;"> </span>physicians<span style="letter-spacing:-0.25pt;"> </span>whether<span style="letter-spacing:-0.25pt;"> </span>their<span style="letter-spacing:-0.3pt;"> </span>patient<span style="letter-spacing:-0.25pt;"> </span>has<span style="letter-spacing:-0.25pt;"> </span>a<span style="letter-spacing:-0.25pt;"> </span>more<span style="letter-spacing:-0.3pt;"> </span>aggressive<span style="letter-spacing:-0.25pt;"> </span>cancer<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.25pt;"> </span>can<span style="letter-spacing:-0.3pt;"> </span>help<span style="letter-spacing:-0.25pt;"> </span>with<span style="letter-spacing:-0.25pt;"> </span>treatment<span style="letter-spacing:-0.25pt;"> </span>planning.<span style="letter-spacing:-0.3pt;"> </span>VeriStrat<span style="letter-spacing:-0.25pt;"> </span>profiles<span style="letter-spacing:-0.25pt;"> </span>the<span style="letter-spacing:-0.25pt;"> </span>patient&#8217;s<span style="letter-spacing:-0.3pt;"> </span>immune<span style="letter-spacing:-0.25pt;"> </span>system<span style="letter-spacing:0.05pt;"> </span>by<span style="letter-spacing:-0.25pt;"> </span>measuring<span style="letter-spacing:-0.2pt;"> </span>eight<span style="letter-spacing:-0.2pt;"> </span>protein<span style="letter-spacing:-0.2pt;"> </span>features<span style="letter-spacing:-0.2pt;"> </span>measured<span style="letter-spacing:-0.2pt;"> </span>by<span style="letter-spacing:-0.2pt;"> </span>mass<span style="letter-spacing:-0.2pt;"> </span>spectrometry<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>interpreted<span style="letter-spacing:-0.2pt;"> </span>by<span style="letter-spacing:-0.25pt;"> </span>a<span style="letter-spacing:-0.2pt;"> </span>proprietary<span style="letter-spacing:-0.2pt;"> </span>machine<span style="letter-spacing:-0.2pt;"> </span>learning-based<span style="letter-spacing:-0.2pt;"> </span>algorithm<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.2pt;"> </span>produce<span style="letter-spacing:-0.2pt;"> </span>either<span style="letter-spacing:-0.2pt;"> </span>a<span style="letter-spacing:0.05pt;"> </span>VeriStrat<span style="letter-spacing:-0.15pt;"> </span>Good<span style="letter-spacing:-0.1pt;"> </span>or<span style="letter-spacing:-0.1pt;"> </span>VeriStrat<span style="letter-spacing:-0.1pt;"> </span>Poor<span style="letter-spacing:-0.15pt;"> </span>test<span style="letter-spacing:-0.1pt;"> </span>result.<span style="letter-spacing:-0.1pt;"> </span></p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:4.8%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The presence of a VeriStrat Poor result indicates the presence of chronic inflammation and a chronic acute phase immune response. A chronic acute<span style="letter-spacing:-2.1pt;"> </span>phase immune response can trigger the immune system to provide growth factors to the tumor to increase blood flow and tumor growth. The test has been<span style="letter-spacing:-2.1pt;"> </span>studied<span style="letter-spacing:-0.3pt;"> </span>in<span style="letter-spacing:-0.25pt;"> </span>over<span style="letter-spacing:-0.3pt;"> </span>85<span style="letter-spacing:-0.25pt;"> </span>peer-reviewed<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.3pt;"> </span>published<span style="letter-spacing:-0.25pt;"> </span>clinical<span style="letter-spacing:-0.3pt;"> </span>studies<span style="letter-spacing:-0.25pt;"> </span>across<span style="letter-spacing:-0.25pt;"> </span>many<span style="letter-spacing:-0.3pt;"> </span>different<span style="letter-spacing:-0.25pt;"> </span>types<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:-0.3pt;"> </span>therapies<span style="letter-spacing:-0.25pt;"> </span>such<span style="letter-spacing:-0.3pt;"> </span>as<span style="letter-spacing:-0.25pt;"> </span>chemotherapy,<span style="letter-spacing:-0.25pt;"> </span>targeted<span style="letter-spacing:-0.3pt;"> </span>therapies,<span style="letter-spacing:-0.25pt;"> </span>immune<span style="letter-spacing:0.05pt;"> </span>therapies, and combinations. The results consistently show the test to be predictive of outcomes, independent of other prognostic factors including PD-L1<span style="letter-spacing:0.05pt;"> </span>expression and performance status. Patients who test as VeriStrat Poor, on average, have an overall survival that is less than half of those who test as<span style="letter-spacing:0.05pt;"> </span>VeriStrat Good, independent of treatment type, demonstrating that the test is strongly prognostic. Conversely, patients with a VeriStrat Good test result<span style="letter-spacing:0.05pt;"> </span>typically<span style="letter-spacing:-0.1pt;"> </span>respond<span style="letter-spacing:-0.05pt;"> </span>better<span style="letter-spacing:-0.05pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>standard<span style="letter-spacing:-0.05pt;"> </span>of<span style="letter-spacing:-0.1pt;"> </span>care<span style="letter-spacing:-0.05pt;"> </span>treatments<span style="letter-spacing:-0.05pt;"> </span>than<span style="letter-spacing:-0.05pt;"> </span>those patients<span style="letter-spacing:-0.3pt;"> </span>that<span style="letter-spacing:-0.25pt;"> </span>test<span style="letter-spacing:-0.25pt;"> </span>as<span style="letter-spacing:-0.3pt;"> </span>VeriStrat<span style="letter-spacing:-0.25pt;"> </span>Poor.<span style="letter-spacing:-0.25pt;"> </span>By<span style="letter-spacing:-0.3pt;"> </span>using<span style="letter-spacing:-0.25pt;"> </span>the<span style="letter-spacing:-0.25pt;"> </span>VeriStrat<span style="letter-spacing:-0.3pt;"> </span>test<span style="letter-spacing:-0.25pt;"> </span>for<span style="letter-spacing:-0.25pt;"> </span>immune<span style="letter-spacing:-0.3pt;"> </span>profiling,<span style="letter-spacing:-0.25pt;"> </span>physicians<span style="letter-spacing:-0.25pt;"> </span>can<span style="letter-spacing:-0.25pt;"> </span>help<span style="letter-spacing:-0.3pt;"> </span>identify<span style="letter-spacing:-0.25pt;"> </span>the<span style="letter-spacing:-0.25pt;"> </span>patients<span style="letter-spacing:-0.3pt;"> </span>with<span style="letter-spacing:-0.25pt;"> </span>an<span style="letter-spacing:-0.25pt;"> </span>immune<span style="letter-spacing:-0.3pt;"> </span>status<span style="letter-spacing:0.05pt;"> </span>associated<span style="letter-spacing:-0.1pt;"> </span>with<span style="letter-spacing:-0.1pt;"> </span>generally<span style="letter-spacing:-0.05pt;"> </span>poor<span style="letter-spacing:-0.1pt;"> </span>prognosis<span style="letter-spacing:-0.05pt;"> </span>who<span style="letter-spacing:-0.1pt;"> </span>should<span style="letter-spacing:-0.05pt;"> </span>be<span style="letter-spacing:-0.1pt;"> </span>treated<span style="letter-spacing:-0.05pt;"> </span>with<span style="letter-spacing:-0.1pt;"> </span>alternate<span style="letter-spacing:-0.05pt;"> </span>therapies<span style="letter-spacing:-0.1pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>clinical<span style="letter-spacing:-0.05pt;"> </span>trials.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.76%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GeneStrat<span style="letter-spacing:-0.25pt;"> </span>requires<span style="letter-spacing:-0.25pt;"> </span>whole<span style="letter-spacing:-0.25pt;"> </span>blood<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.25pt;"> </span>VeriStrat<span style="letter-spacing:-0.25pt;"> </span>requires<span style="letter-spacing:-0.25pt;"> </span>a<span style="letter-spacing:-0.2pt;"> </span>whole<span style="letter-spacing:-0.25pt;"> </span>blood<span style="letter-spacing:-0.25pt;"> </span>sample<span style="letter-spacing:-0.25pt;"> </span>spotted<span style="letter-spacing:-0.2pt;"> </span>onto<span style="letter-spacing:-0.25pt;"> </span>our<span style="letter-spacing:-0.25pt;"> </span>proprietary<span style="letter-spacing:-0.25pt;"> </span>BCD.<span style="letter-spacing:-0.2pt;"> </span>Both<span style="letter-spacing:-0.25pt;"> </span>samples<span style="letter-spacing:-0.25pt;"> </span>are<span style="letter-spacing:-0.25pt;"> </span>shipped<span style="letter-spacing:-0.2pt;"> </span>at<span style="letter-spacing:-0.25pt;"> </span>ambient<span style="letter-spacing:0.05pt;"> </span>temperature and testing is performed in our certified, high-complexity clinical laboratory in Boulder, Colorado. GeneStrat is performed using the ddPCR<span style="letter-spacing:0.05pt;"> </span>technology, and the protein features in VeriStrat are measured using matrix-assisted laser desorption/ionization time of flight (MALDI-ToF) mass<span style="letter-spacing:0.05pt;"> </span>spectrometry.<span style="letter-spacing:-0.1pt;"> </span>Results<span style="letter-spacing:-0.1pt;"> </span>are<span style="letter-spacing:-0.1pt;"> </span>typically<span style="letter-spacing:-0.1pt;"> </span>available<span style="letter-spacing:-0.1pt;"> </span>within<span style="letter-spacing:-0.05pt;"> </span>72<span style="letter-spacing:-0.1pt;"> </span>hours<span style="letter-spacing:-0.1pt;"> </span>through<span style="letter-spacing:-0.1pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>portal,<span style="letter-spacing:-0.05pt;"> </span>fax,<span style="letter-spacing:-0.1pt;"> </span>hard<span style="letter-spacing:-0.1pt;"> </span>copy,<span style="letter-spacing:-0.1pt;"> </span>or<span style="letter-spacing:-0.1pt;"> </span>mobile<span style="letter-spacing:-0.05pt;"> </span>device.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">COVID-19</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:4.76%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Biodesix<span style="letter-spacing:-0.45pt;"> </span>WorkSafe<span style="letter-spacing:-0.4pt;"> </span>COVID-19<span style="letter-spacing:-0.45pt;"> </span>Testing<span style="letter-spacing:-0.4pt;"> </span>Program</p>
<p style="margin-top:5pt;margin-bottom:6pt;text-indent:4.8%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In<span style="letter-spacing:-0.25pt;"> </span>response<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.25pt;"> </span>the<span style="letter-spacing:-0.25pt;"> </span>COVID-19<span style="letter-spacing:-0.25pt;"> </span>pandemic,<span style="letter-spacing:-0.25pt;"> </span>through<span style="letter-spacing:-0.25pt;"> </span>our<span style="letter-spacing:-0.25pt;"> </span>partnership<span style="letter-spacing:-0.2pt;"> </span>with<span style="letter-spacing:-0.25pt;"> </span>Bio-Rad,<span style="letter-spacing:-0.25pt;"> </span>we<span style="letter-spacing:-0.25pt;"> </span>commercialized<span style="letter-spacing:-0.25pt;"> </span>the<span style="letter-spacing:-0.25pt;"> </span>Biodesix<span style="letter-spacing:-0.25pt;"> </span>WorkSafe<span style="letter-spacing:-0.25pt;"> </span>testing<span style="letter-spacing:-0.2pt;"> </span>program.<span style="letter-spacing:-0.25pt;"> </span>Our<span style="letter-spacing:0.05pt;"> </span>scientific<span style="letter-spacing:-0.2pt;"> </span>diagnostic<span style="letter-spacing:-0.2pt;"> </span>expertise,<span style="letter-spacing:-0.15pt;"> </span>technologies,<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>existing<span style="letter-spacing:-0.15pt;"> </span>commercial<span style="letter-spacing:-0.2pt;"> </span>infrastructure<span style="letter-spacing:-0.2pt;"> </span>enabled<span style="letter-spacing:-0.15pt;"> </span>us<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.2pt;"> </span>rapidly<span style="letter-spacing:-0.15pt;"> </span>commercialize<span style="letter-spacing:-0.2pt;"> </span>two<span style="letter-spacing:-0.2pt;"> </span>diagnostic<span style="letter-spacing:-0.15pt;"> </span>tests<span style="letter-spacing:-0.2pt;"> </span>for<span style="letter-spacing:-0.15pt;"> </span>the SARS-CoV-2<span style="letter-spacing:-0.3pt;"> </span>virus<span style="letter-spacing:-0.25pt;"> </span>that<span style="letter-spacing:-0.25pt;"> </span>causes<span style="letter-spacing:-0.25pt;"> </span>COVID-19.<span style="letter-spacing:-0.25pt;"> </span>The<span style="letter-spacing:-0.25pt;"> </span>first<span style="letter-spacing:-0.25pt;"> </span>test<span style="letter-spacing:-0.25pt;"> </span>is<span style="letter-spacing:-0.25pt;"> </span>the<span style="letter-spacing:-0.25pt;"> </span>Bio-Rad<span style="letter-spacing:-0.25pt;"> </span>SARS-CoV-2<span style="letter-spacing:-0.3pt;"> </span>ddPCR<span style="letter-spacing:-0.25pt;"> </span>test,<span style="letter-spacing:-0.25pt;"> </span>which<span style="letter-spacing:-0.25pt;"> </span>is<span style="letter-spacing:-0.25pt;"> </span>a<span style="letter-spacing:-0.25pt;"> </span>molecular<span style="letter-spacing:-0.25pt;"> </span>test<span style="letter-spacing:-0.25pt;"> </span>intended<span style="letter-spacing:-0.25pt;"> </span>for<span style="letter-spacing:-0.25pt;"> </span>detecting<span style="letter-spacing:-0.25pt;"> </span>active<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">SARS-CoV-2 infection. The test was FDA EUA authorized on May 1, 2020, authorizing performance </span>of the test in laboratories certified under CLIA to<span style="letter-spacing:0.05pt;"> </span>perform high complexity tests. The second test is the Platelia SARS-CoV-2 Total Ab test, which is an antibody test intended for detecting a B-cell<span style="letter-spacing:0.05pt;"> </span>immune<span style="letter-spacing:-0.15pt;"> </span>response<span style="letter-spacing:-0.1pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>SARS-CoV-2,<span style="letter-spacing:-0.1pt;"> </span>indicating<span style="letter-spacing:-0.1pt;"> </span>recent<span style="letter-spacing:-0.1pt;"> </span>or<span style="letter-spacing:-0.1pt;"> </span>prior<span style="letter-spacing:-0.1pt;"> </span>infection.<span style="letter-spacing:-0.1pt;"> </span>The<span style="letter-spacing:-0.1pt;"> </span>test<span style="letter-spacing:-0.1pt;"> </span>was<span style="letter-spacing:-0.1pt;"> </span>FDA<span style="letter-spacing:-0.1pt;"> </span>EUA<span style="letter-spacing:-0.1pt;"> </span>authorized<span style="letter-spacing:-0.1pt;"> </span>on<span style="letter-spacing:-0.1pt;"> </span>April<span style="letter-spacing:-0.1pt;"> </span>29,<span style="letter-spacing:-0.15pt;"> </span>2020.</p>
<p style="margin-top:0pt;margin-bottom:6pt;text-indent:4.8%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Within a month of initiating our development collaboration with Bio-Rad, we were able to launch two tests for commercial use. We were able to<span style="letter-spacing:0.05pt;"> </span>bring<span style="letter-spacing:-0.2pt;"> </span>these<span style="letter-spacing:-0.2pt;"> </span>tests<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.2pt;"> </span>market<span style="letter-spacing:-0.15pt;"> </span>as<span style="letter-spacing:-0.2pt;"> </span>fast<span style="letter-spacing:-0.2pt;"> </span>as<span style="letter-spacing:-0.15pt;"> </span>possible<span style="letter-spacing:-0.2pt;"> </span>due<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.2pt;"> </span>our<span style="letter-spacing:-0.2pt;"> </span>scientific<span style="letter-spacing:-0.15pt;"> </span>diagnostic<span style="letter-spacing:-0.2pt;"> </span>expertise,<span style="letter-spacing:-0.15pt;"> </span>technologies<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>existing<span style="letter-spacing:-0.15pt;"> </span>commercial<span style="letter-spacing:-0.2pt;"> </span>infrastructure.<span style="letter-spacing:-0.15pt;"> </span>In<span style="letter-spacing:-0.2pt;"> </span>addition<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>our launch agility, we have been able to rapidly scale our laboratory operations for high-volume testing. We remain committed to delivering rapid test<span style="letter-spacing:0.05pt;"> </span>results<span style="letter-spacing:-0.1pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>24<span style="letter-spacing:-0.05pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>48<span style="letter-spacing:-0.05pt;"> </span>hours<span style="letter-spacing:-0.05pt;"> </span>on<span style="letter-spacing:-0.05pt;"> </span>average.</p>
<p style="margin-top:4pt;margin-bottom:6pt;text-indent:4.8%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Using<span style="letter-spacing:-0.35pt;"> </span>the<span style="letter-spacing:-0.3pt;"> </span>Bio-Rad<span style="letter-spacing:-0.3pt;"> </span>SARS-CoV-2<span style="letter-spacing:-0.3pt;"> </span>ddPCR<span style="letter-spacing:-0.3pt;"> </span>test<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.3pt;"> </span>the<span style="letter-spacing:-0.3pt;"> </span>Platelia<span style="letter-spacing:-0.3pt;"> </span>SARS-CoV-2<span style="letter-spacing:-0.3pt;"> </span>Total<span style="letter-spacing:-0.3pt;"> </span>Ab<span style="letter-spacing:-0.3pt;"> </span>tests,<span style="letter-spacing:-0.3pt;"> </span>we<span style="letter-spacing:-0.3pt;"> </span>operate<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.3pt;"> </span>have<span style="letter-spacing:-0.3pt;"> </span>commercialized<span style="letter-spacing:-0.3pt;"> </span>the<span style="letter-spacing:-0.3pt;"> </span>Biodesix<span style="letter-spacing:0.05pt;"> </span>WorkSafe<span style="letter-spacing:-0.1pt;"> </span>testing<span style="letter-spacing:-0.05pt;"> </span>program.</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:4.8%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to using the Bio-Rad tests as part of our testing program, we performed feasibility, verification, and validation studies, including developing<span style="letter-spacing:0.05pt;"> </span>software for process automation, sample accessioning, data management and reporting, all required to demonstrate the test operated as claimed by the<span style="letter-spacing:0.05pt;"> </span>manufacturer<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.25pt;"> </span>as<span style="letter-spacing:-0.25pt;"> </span>required<span style="letter-spacing:-0.3pt;"> </span>by<span style="letter-spacing:-0.25pt;"> </span>our<span style="letter-spacing:-0.25pt;"> </span>certifying<span style="letter-spacing:-0.25pt;"> </span>regulatory<span style="letter-spacing:-0.3pt;"> </span>agencies<span style="letter-spacing:-0.25pt;"> </span>for<span style="letter-spacing:-0.25pt;"> </span>high<span style="letter-spacing:-0.25pt;"> </span>complexity<span style="letter-spacing:-0.3pt;"> </span>laboratory<span style="letter-spacing:-0.25pt;"> </span>testing.<span style="letter-spacing:-0.25pt;"> </span>We<span style="letter-spacing:-0.25pt;"> </span>secured<span style="letter-spacing:-0.3pt;"> </span>independent<span style="letter-spacing:-0.25pt;"> </span>reference<span style="letter-spacing:-0.25pt;"> </span>specimens<span style="letter-spacing:-0.25pt;"> </span>run<span style="letter-spacing:0.05pt;"> </span>with EUA tests to validate these tests as fit for diagnostic use in our laboratories. Post-launch development support for these tests have included<span style="letter-spacing:0.05pt;"> </span>improvements in on-boarding new personnel, logistics of sample collection, sample receipt and data reporting, all required to support our testing program.<span style="letter-spacing:0.05pt;"> </span>Additional<span style="letter-spacing:-0.1pt;"> </span>releases<span style="letter-spacing:-0.1pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>laboratory<span style="letter-spacing:-0.1pt;"> </span>data<span style="letter-spacing:-0.05pt;"> </span>management<span style="letter-spacing:-0.1pt;"> </span>software<span style="letter-spacing:-0.1pt;"> </span>are<span style="letter-spacing:-0.05pt;"> </span>ongoing<span style="letter-spacing:-0.1pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>planned<span style="letter-spacing:-0.05pt;"> </span>for<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>foreseeable<span style="letter-spacing:-0.05pt;"> </span>future.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:4.8%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">tests</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">are</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">utilized</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">by</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">healthcare</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">providers,</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">including</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">hospitals</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">nursing</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">homes</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">are</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">also</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">offered</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">businesses</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">educational</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">systems</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">assist in their back-to-work or back to school strategies. Recently, we announced multiple partnerships for COVID-19 testing, and Colorado Governor</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Jared Polis announced at a press conference on July 23, 2020 that we will now be supporting wide-spread COVID-19 testing for the State of Colorado.</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, we announced a partnership as the official COVID-19 testing partner for the Major </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">League </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lacrosse as they competed in their 2020</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">tournament. We also announced </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">on September 30, 2020</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">that we will oversee and manage onsite testing and testing </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">validation </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for the Big Ten Conference athletic</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">competitions.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.76%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Bio-Rad<span style="letter-spacing:-0.25pt;"> </span>SARS-CoV-2<span style="letter-spacing:-0.25pt;"> </span>ddPCR<span style="letter-spacing:-0.2pt;"> </span>test</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.59%;text-indent:0%;font-size:9pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.76%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Bio-Rad SARS-CoV-2 ddPCR test, also known as a molecular or viral test, is intended for the qualitative detection of nucleic acid from SARS-CoV-2, the virus that causes COVID-19. The test targets detection of the nucleic acid from SARS-CoV-2 (not from any other viruses or pathogens) in respiratory specimens to identify and isolate infected individuals. Recent studies have shown that ddPCR-based testing is more sensitive than qPCR for detecting SARS-CoV-2, specifically in the reduction of false negative results. In one study, the ddPCR test demonstrated 95% accuracy vs. 47% for other &#8220;bulk&#8221; RT-PCR technologies used in other molecular tests Specimens are shipped at ambient temperature or dry ice depending on the viral transport media (VTM) used, and testing is performed using ddPCR in our certified, high-complexity clinical laboratory in Boulder, Colorado. Results are typically available through fax, hard copy, or encrypted email within 24 to 48 hours on average from receipt of the sample.</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.76%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Platelia<span style="letter-spacing:-0.45pt;"> </span>SARS-CoV-2<span style="letter-spacing:-0.4pt;"> </span>Total<span style="letter-spacing:-0.4pt;"> </span>Ab<span style="letter-spacing:-0.4pt;"> </span>Test</p>
<p style="margin-top:5pt;margin-bottom:6pt;text-indent:4.8%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Platelia SARS-CoV-2 Total Ab test (also known as a serology or antibody test) is intended for use as an aid in identifying individuals who<span style="letter-spacing:0.05pt;"> </span>have developed an adaptive immune response to the SARS-CoV-2 virus, indicating recent or prior infection. The test uses whole blood to detect<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">circulating antibodies </span>against the virus. The sensitivity is 98% and specificity is 99% eight days after the onset of symptoms. At this time, it is not known<span style="letter-spacing:0.05pt;"> </span>how long antibodies persist following infection and if the presence of antibodies confers protective immunity. The test is intended for the qualitative<span style="letter-spacing:0.05pt;"> </span>detection of total anti-SARS-CoV-2 nucleocapsid antibodies (IgG, IgM and IgA) in human serum or plasma specimens. The test requires a 3 mL blood<span style="letter-spacing:0.05pt;"> </span>draw, and samples are shipped at ambient temperature. Testing is conducted using semi-automated ELISA technology in our certified, high-complexity<span style="letter-spacing:0.05pt;"> </span>clinical<span style="letter-spacing:-0.2pt;"> </span>laboratory<span style="letter-spacing:-0.2pt;"> </span>in<span style="letter-spacing:-0.2pt;"> </span>De<span style="letter-spacing:-0.2pt;"> </span>Soto,<span style="letter-spacing:-0.2pt;"> </span>Kansas.<span style="letter-spacing:-0.2pt;"> </span>Results<span style="letter-spacing:-0.15pt;"> </span>are<span style="letter-spacing:-0.2pt;"> </span>typically<span style="letter-spacing:-0.2pt;"> </span>available<span style="letter-spacing:-0.2pt;"> </span>within<span style="letter-spacing:-0.2pt;"> </span>24<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.15pt;"> </span>48<span style="letter-spacing:-0.2pt;"> </span>hours<span style="letter-spacing:-0.2pt;"> </span>from<span style="letter-spacing:-0.2pt;"> </span>receipt<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.2pt;"> </span>sample<span style="letter-spacing:-0.15pt;"> </span>through<span style="letter-spacing:-0.2pt;"> </span>fax,<span style="letter-spacing:-0.2pt;"> </span>hard<span style="letter-spacing:-0.2pt;"> </span>copy,<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:-0.2pt;"> </span>encrypted<span style="letter-spacing:0.05pt;"> </span>email.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Biopharmaceutical Diagnostic Discovery, Development and Testing Services Business</p>
<p style="margin-top:5pt;margin-bottom:6pt;text-indent:4.8%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe our leadership in clinical proteomics and our technology agnostic approach to probe the cancer disease state provides our customers with<span style="letter-spacing:-2.1pt;"> </span>a clear and distinct advantage over other diagnostic service providers who solely focus on either genomics or proteomics. Similar to our commercial<span style="letter-spacing:0.05pt;"> </span>clinical<span style="letter-spacing:-0.3pt;"> </span>testing<span style="letter-spacing:-0.3pt;"> </span>business,<span style="letter-spacing:-0.25pt;"> </span>our<span style="letter-spacing:-0.3pt;"> </span>biopharmaceutical<span style="letter-spacing:-0.25pt;"> </span>diagnostic<span style="letter-spacing:-0.3pt;"> </span>discovery,<span style="letter-spacing:-0.25pt;"> </span>development<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.25pt;"> </span>testing<span style="letter-spacing:-0.3pt;"> </span>services<span style="letter-spacing:-0.25pt;"> </span>business<span style="letter-spacing:-0.3pt;"> </span>leverages<span style="letter-spacing:-0.25pt;"> </span>the<span style="letter-spacing:-0.3pt;"> </span>Diagnostic<span style="letter-spacing:-0.25pt;"> </span>Cortex<span style="letter-spacing:-0.3pt;"> </span>to<span style="letter-spacing:-0.25pt;"> </span>provide<span style="letter-spacing:0.05pt;"> </span>an<span style="letter-spacing:-0.25pt;"> </span>extensively<span style="letter-spacing:-0.25pt;"> </span>validated<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>deep<span style="letter-spacing:-0.25pt;"> </span>learning<span style="letter-spacing:-0.25pt;"> </span>approach<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.25pt;"> </span>discovering<span style="letter-spacing:-0.25pt;"> </span>new<span style="letter-spacing:-0.25pt;"> </span>biomarkers,<span style="letter-spacing:-0.2pt;"> </span>which<span style="letter-spacing:-0.25pt;"> </span>in<span style="letter-spacing:-0.25pt;"> </span>turn<span style="letter-spacing:-0.2pt;"> </span>helps<span style="letter-spacing:-0.25pt;"> </span>drive<span style="letter-spacing:-0.25pt;"> </span>the<span style="letter-spacing:-0.25pt;"> </span>clinical<span style="letter-spacing:-0.2pt;"> </span>development<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:-0.25pt;"> </span>therapeutics.<span style="letter-spacing:-0.2pt;"> </span>We<span style="letter-spacing:0.05pt;"> </span>recognize each clinical development program is complex, which is why we offer end-to-end diagnostic solutions, ranging from initial biomarker discovery<span style="letter-spacing:0.05pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>feasibility<span style="letter-spacing:-0.05pt;"> </span>projects<span style="letter-spacing:-0.05pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>commercialization<span style="letter-spacing:-0.1pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>companion<span style="letter-spacing:-0.05pt;"> </span>diagnostics.</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:4.8%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To address the increasing complexity of disease biology and new drug mechanisms of action, we employ a technology agnostic approach to uncover<span style="letter-spacing:-2.1pt;"> </span>insights about the tumor biology and patient&#8217;s immune response to cancer for therapeutics in clinical development. With our broad technology and service<span style="letter-spacing:0.05pt;"> </span>offering, including the performance of over 30 assays for research use as part of our laboratory services (see diagram below), we are able to provide the<span style="letter-spacing:0.05pt;"> </span>depth and breadth of biomarker tools for our partners for multi-omic analyses across their product development efforts. Although we recognize the<span style="letter-spacing:0.05pt;"> </span>importance of a multi-omic, technology agnostic approach in translational research, we are experts in discovering and developing proteomic-based<span style="letter-spacing:0.05pt;"> </span>diagnostic<span style="letter-spacing:-0.25pt;"> </span>tests<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.25pt;"> </span>help<span style="letter-spacing:-0.25pt;"> </span>interrogate<span style="letter-spacing:-0.25pt;"> </span>the<span style="letter-spacing:-0.25pt;"> </span>immune<span style="letter-spacing:-0.25pt;"> </span>profile<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.25pt;"> </span>host<span style="letter-spacing:-0.25pt;"> </span>disease<span style="letter-spacing:-0.25pt;"> </span>state<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:-0.25pt;"> </span>patients<span style="letter-spacing:-0.25pt;"> </span>on<span style="letter-spacing:-0.2pt;"> </span>particular<span style="letter-spacing:-0.25pt;"> </span>therapeutics.<span style="letter-spacing:-0.25pt;"> </span>Traditionally,<span style="letter-spacing:-0.25pt;"> </span>oncology<span style="letter-spacing:-0.25pt;"> </span>biomarkers<span style="letter-spacing:-0.25pt;"> </span>have<span style="letter-spacing:0.05pt;"> </span>been discovered from tumor tissue, but with the increased trend in the number of programs featuring immuno-oncology agents in therapeutic development,<span style="letter-spacing:-2.15pt;"> </span>we<span style="letter-spacing:-0.2pt;"> </span>believe<span style="letter-spacing:-0.15pt;"> </span>there<span style="letter-spacing:-0.2pt;"> </span>is<span style="letter-spacing:-0.15pt;"> </span>a<span style="letter-spacing:-0.2pt;"> </span>clinical<span style="letter-spacing:-0.15pt;"> </span>unmet<span style="letter-spacing:-0.2pt;"> </span>need<span style="letter-spacing:-0.15pt;"> </span>for<span style="letter-spacing:-0.2pt;"> </span>blood-based<span style="letter-spacing:-0.15pt;"> </span>tumor<span style="letter-spacing:-0.2pt;"> </span>markers<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>host/immune<span style="letter-spacing:-0.15pt;"> </span>biomarkers<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.2pt;"> </span>complement<span style="letter-spacing:-0.15pt;"> </span>information<span style="letter-spacing:-0.2pt;"> </span>obtained<span style="letter-spacing:-0.15pt;"> </span>from<span style="letter-spacing:-0.2pt;"> </span>tissue.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:1.78%;text-indent:4.8%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:6pt;text-indent:0%;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gegguy50oztz000007.jpg" title="" alt="" style="width:544px;height:254px;" /></p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:4.8%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe we provide benefit to our biopharmaceutical customers as they integrate strategies for increasing the probability of success for pivotal<span style="letter-spacing:0.05pt;"> </span>clinical trials. Specifically, our diagnostic testing services may help enable quicker enrollment rates for patients in prospective clinical trials, ranging from<span style="letter-spacing:0.05pt;"> </span>phase 1 to phase 3, and could help identify patient populations who may experience the greatest benefit from new therapeutics. Ultimately, our goal is to<span style="letter-spacing:0.05pt;"> </span>help<span style="letter-spacing:-0.3pt;"> </span>biopharmaceutical<span style="letter-spacing:-0.25pt;"> </span>customers<span style="letter-spacing:-0.25pt;"> </span>realize<span style="letter-spacing:-0.3pt;"> </span>greater<span style="letter-spacing:-0.25pt;"> </span>efficiency<span style="letter-spacing:-0.25pt;"> </span>in<span style="letter-spacing:-0.3pt;"> </span>their<span style="letter-spacing:-0.25pt;"> </span>clinical<span style="letter-spacing:-0.25pt;"> </span>development<span style="letter-spacing:-0.3pt;"> </span>programs.<span style="letter-spacing:-0.25pt;"> </span>Additionally,<span style="letter-spacing:-0.25pt;"> </span>we<span style="letter-spacing:-0.25pt;"> </span>have<span style="letter-spacing:-0.3pt;"> </span>the<span style="letter-spacing:-0.25pt;"> </span>ability<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.3pt;"> </span>access<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.25pt;"> </span>leverage<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.1pt;"> </span>large<span style="letter-spacing:-0.1pt;"> </span>sample<span style="letter-spacing:-0.05pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>data<span style="letter-spacing:-0.05pt;"> </span>biobank<span style="letter-spacing:-0.1pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:-0.1pt;"> </span>partners&#8217;<span style="letter-spacing:-0.1pt;"> </span>data<span style="letter-spacing:-0.05pt;"> </span>mining<span style="letter-spacing:-0.1pt;"> </span>needs,<span style="letter-spacing:-0.05pt;"> </span>including<span style="letter-spacing:-0.1pt;"> </span>new<span style="letter-spacing:-0.05pt;"> </span>test<span style="letter-spacing:-0.1pt;"> </span>discovery.</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:4.8%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">While<span style="letter-spacing:-0.3pt;"> </span>our<span style="letter-spacing:-0.25pt;"> </span>biopharmaceutical<span style="letter-spacing:-0.25pt;"> </span>discovery,<span style="letter-spacing:-0.25pt;"> </span>diagnostic<span style="letter-spacing:-0.3pt;"> </span>development<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.25pt;"> </span>testing<span style="letter-spacing:-0.25pt;"> </span>revenue<span style="letter-spacing:-0.25pt;"> </span>continues<span style="letter-spacing:-0.3pt;"> </span>to<span style="letter-spacing:-0.25pt;"> </span>grow,<span style="letter-spacing:-0.25pt;"> </span>it<span style="letter-spacing:-0.25pt;"> </span>is<span style="letter-spacing:-0.3pt;"> </span>important<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.25pt;"> </span>note<span style="letter-spacing:-0.25pt;"> </span>that<span style="letter-spacing:-0.25pt;"> </span>we<span style="letter-spacing:-0.3pt;"> </span>benefit<span style="letter-spacing:-0.25pt;"> </span>greatly<span style="letter-spacing:0.05pt;"> </span>from<span style="letter-spacing:-0.1pt;"> </span>these<span style="letter-spacing:-0.05pt;"> </span>partnerships<span style="letter-spacing:-0.05pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>many<span style="letter-spacing:-0.05pt;"> </span>ways<span style="letter-spacing:-0.05pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>expand<span style="letter-spacing:-0.05pt;"> </span>beyond<span style="letter-spacing:-0.05pt;"> </span>revenue.<span style="letter-spacing:-0.1pt;"> </span>We are continuously expanding our knowledge and biological understanding of multiple diseases and the rapidly evolving treatment landscape, while our<span style="letter-spacing:-2.1pt;"> </span>Diagnostic<span style="letter-spacing:-0.25pt;"> </span>Cortex<span style="letter-spacing:-0.25pt;"> </span>continues<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.25pt;"> </span>be<span style="letter-spacing:-0.2pt;"> </span>powered<span style="letter-spacing:-0.25pt;"> </span>through<span style="letter-spacing:-0.2pt;"> </span>these<span style="letter-spacing:-0.25pt;"> </span>biomarker<span style="letter-spacing:-0.2pt;"> </span>analyses.<span style="letter-spacing:-0.25pt;"> </span>Additionally,<span style="letter-spacing:-0.2pt;"> </span>our<span style="letter-spacing:-0.25pt;"> </span>sample<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.25pt;"> </span>data<span style="letter-spacing:-0.2pt;"> </span>biobank<span style="letter-spacing:-0.25pt;"> </span>continue<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.25pt;"> </span>grow<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.25pt;"> </span>can<span style="letter-spacing:-0.2pt;"> </span>be<span style="letter-spacing:0.05pt;"> </span>further leveraged for internal test development and external partnering. Importantly, we look to supplement our product development efforts with<span style="letter-spacing:0.05pt;"> </span>companion<span style="letter-spacing:-0.1pt;"> </span>diagnostics<span style="letter-spacing:-0.05pt;"> </span>as<span style="letter-spacing:-0.05pt;"> </span>they<span style="letter-spacing:-0.05pt;"> </span>are<span style="letter-spacing:-0.05pt;"> </span>developed.</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:4.8%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To date, we have over 50 biopharmaceutical customers and academic partners who have utilized our diagnostic tests and services. The following are a few case studies of early-stage biomarker discovery and development with our biopharmaceutical customers.</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:4pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:4pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:4pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-weight:bold;letter-spacing:-0.05pt;color:#000000;">AstraZeneca: </span><span style="letter-spacing:-0.05pt;color:#000000;">We provided services to AstraZeneca to </span><span style="color:#000000;">retrospectively analyze samples from the FLAURA clinical trial (NCT02296125).</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">The goal of this analysis was to interpret and establish the clinical utility of blood-based longitudinal monitoring of EGFR sensitizing and</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">resistance mutations by ddPCR in advanced NSCLC patients treated with osimertinib. The data demonstrated that these circulating DNA</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">mutations</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">could</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">be</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">tracked</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">in</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">blood</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">interpret</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">patient&#8217;s</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">prognosis,</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">could</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">help</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">AstraZeneca</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">identify</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">disease</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">progression</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">3</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">months</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">(median)</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">in</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">advance</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">standard</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">imaging.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-weight:bold;color:#000000;">Genentech: </span><span style="color:#000000;">We partnered with Genentech to discover a novel proteomic classifier for advanced NSCLC patients treated with atezolizumab.</span><span style="letter-spacing:-2.1pt;color:#000000;"> </span><span style="color:#000000;">The test was discovered on a small clinical cohort (n&#61;77) and was independently validated on blinded samples (n&#61;270) from the POPLAR</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">clinical</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">trial</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">(NCT01903993).</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">The</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">validation</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">revealed</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">that</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">proteomic</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">test</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">was</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">predictive</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">progression</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">free</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">survival</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">overall</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">survival</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">for atezolizumab versus the control arm docetaxel. Additionally, an analysis compared the correlation between our proteomic classifier with</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">standard of care biomarkers (PD-L1 expression status and tumor mutation burden), which revealed there was no significant correlation. This </span><span style="letter-spacing:-2.1pt;color:#000000;"> </span><span style="color:#000000;">implies that our classifier provides unique and valuable information in the treatment of patients with advanced NSCLC. It is our belief that</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">Genentech</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">could</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">use</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">this</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">strategy</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">identify</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">patients</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">that</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">could</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">derive</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">a</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">longer</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">progression</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">free</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">survival</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">from</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">atezolizumab.</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="text-decoration:none;Background-color:#auto;"></span><span style="color:#000000;"></span><span style="font-weight:bold;color:#000000;">Merck KGaA &#38; Pfizer: </span><span style="color:#000000;">We announced the initiation of a clinical phase development program for the anti-PD-L1 checkpoint inhibitor,</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">avelumab</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">with</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">Merck</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">KGaA</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">Pfizer</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">on</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">February</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">12,</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">2020.</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">The</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">new</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">proteomic</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">test</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">was</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">developed</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">through</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">retrospective</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">analysis</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">circulating proteome combined with our proprietary AI platform. We have completed initial discovery of the test that identifies likely</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">responders to avelumab and efforts are now focusing on transferring the test into our CLIA lab in Boulder, Colorado for clinical phase test</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">validation.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Our Competitive Advantages</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe the following are our key competitive advantages:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-weight:bold;color:#000000;">Our proprietary extensively validated deep learning platform, which is tailored to discover diagnostic tests that address clinical</span><span style="font-weight:bold;letter-spacing:0.05pt;color:#000000;"> </span><span style="font-weight:bold;color:#000000;">unmet needs. </span><span style="color:#000000;">Our platform is an extensively validated deep learning platform optimized for discovery of diagnostic tests. By combining our</span><span style="letter-spacing:-2.1pt;color:#000000;"> </span><span style="color:#000000;">data-driven</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">technology</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">agnostic</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">approach</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">with</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">deep</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">learning</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">techniques,</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">we</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">believe</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">we</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">have</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">overcome</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">many</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">standard</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">machine</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">learning</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">challenges. This has enabled us to develop commercial tests for clinical unmet needs and collaborate with our biopharmaceutical customers</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">academic</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">partners.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-weight:bold;color:#000000;">Our data-driven approach to precision medicine combined with our biobank, which enables us to accelerate development of new tests. </span><span style="color:#000000;">We have over 140,000 samples and data in our biobank, including tumor profiles and immune profiles, used for both internal and external research and development initiatives. Our biobank, clinical trials, commercial testing and other partnerships provide an ongoing source of new data that further enhances our proprietary AI platform. We are continuously identifying and incorporating new market insights and input from our customers, key opinion leaders, and scientific experts to leverage this data in developing our diagnostic tests.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-weight:bold;color:#000000;">Our leadership in clinical proteomics, demonstrated research, development, and scientific expertise, combined with our intellectual property portfolio. </span><span style="color:#000000;">Our leadership in clinical proteomics and our technology agnostic approach, we believe provides us with a distinct advantage over our competitors, who focus on any single technology, such as genomics or proteomics. Our certified, high-complexity laboratories offer significant advantages in development of commercial tests.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-weight:bold;color:#000000;">Our proprietary technologies and processes are protected by a portfolio of approximately 87 issued patents in the United States and internationally, and 22 uniquely registered United States trademarks. </span><span style="color:#000000;">We take efforts to protect our proprietary position using a variety of methods, such as a pursuit of United States and foreign patent applications related to our proprietary technology, use of trade secrets, trademarks, know-how, continuing technological innovation and potential in-licensing and acquisition opportunities.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-weight:bold;color:#000000;">Our demonstrated success commercializing diagnostic tests in lung disease. </span><span style="color:#000000;">With six diagnostic tests launched and three currently in</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">development, our commercial portfolio of blood-based solutions currently addresses clinical unmet needs within diagnosis, treatment and</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">monitoring</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">lung</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">cancer.</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">Our</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">diagnostic</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">tests</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">provide</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">rapid,</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">actionable,</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">holistic</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">diagnostic</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">information</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">help</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">inform</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">physicians</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">on</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">next steps in a patient&#8217;s care plan. We have displayed agility in our R&#38;D and commercial launch efforts and within a month of initiating a</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">development</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">collaboration,</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">launched</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">two</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">diagnostic</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">tests</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">for</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">COVID-19</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">for</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">commercial</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">use.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-weight:bold;color:#000000;">Our depth and breadth of point of care access to physicians allows us to drive adoption of our diagnostic tests while incorporating</span><span style="font-weight:bold;letter-spacing:-2.1pt;color:#000000;"> </span><span style="font-weight:bold;color:#000000;">real-life feedback to inform new product development. </span><span style="color:#000000;">Our commercial team&#8217;s primary focus is to articulate the scientific and clinical</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">evidence</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">behind</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">tests,</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">how</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">they</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">impact</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">clinical</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">care</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">can</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">ultimately</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">help</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">improve</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">patient</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">outcomes.</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">Our</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">demonstrated</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">scientific</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">expertise, leadership in clinical proteomics and breadth of data, including peer-reviewed publications, presentations and clinical studies,</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">forms</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">basis</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">relationships</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">with</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">major</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">hospitals</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">physician</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">networks</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">across</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">United</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">States.</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="text-decoration:none;Background-color:#auto;"></span><span style="color:#000000;"></span><span style="font-weight:bold;color:#000000;">Our commercial infrastructure, which includes our extensive knowledge and experience in sales, marketing, reimbursement and</span><span style="font-weight:bold;letter-spacing:0.05pt;color:#000000;"> </span><span style="font-weight:bold;color:#000000;">operations,</span><span style="font-weight:bold;letter-spacing:-0.3pt;color:#000000;"> </span><span style="font-weight:bold;color:#000000;">provides</span><span style="font-weight:bold;letter-spacing:-0.25pt;color:#000000;"> </span><span style="font-weight:bold;color:#000000;">us</span><span style="font-weight:bold;letter-spacing:-0.25pt;color:#000000;"> </span><span style="font-weight:bold;color:#000000;">with</span><span style="font-weight:bold;letter-spacing:-0.25pt;color:#000000;"> </span><span style="font-weight:bold;color:#000000;">the</span><span style="font-weight:bold;letter-spacing:-0.25pt;color:#000000;"> </span><span style="font-weight:bold;color:#000000;">ability</span><span style="font-weight:bold;letter-spacing:-0.3pt;color:#000000;"> </span><span style="font-weight:bold;color:#000000;">to</span><span style="font-weight:bold;letter-spacing:-0.25pt;color:#000000;"> </span><span style="font-weight:bold;color:#000000;">launch,</span><span style="font-weight:bold;letter-spacing:-0.25pt;color:#000000;"> </span><span style="font-weight:bold;color:#000000;">scale</span><span style="font-weight:bold;letter-spacing:-0.25pt;color:#000000;"> </span><span style="font-weight:bold;color:#000000;">and</span><span style="font-weight:bold;letter-spacing:-0.25pt;color:#000000;"> </span><span style="font-weight:bold;color:#000000;">drive</span><span style="font-weight:bold;letter-spacing:-0.3pt;color:#000000;"> </span><span style="font-weight:bold;color:#000000;">revenue.</span><span style="font-weight:bold;letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">We</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">believe</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">commitment</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">commercial</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">excellence</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">helps</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">us to leverage insights, operational </span><span style="color:#000000;">excellence and proven approaches to deliver revenue growth and enhance the brand of our company and</span><span style="letter-spacing:-2.1pt;color:#000000;"> </span><span style="color:#000000;">products.</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">We</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">are</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">able</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">deploy</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">rapid</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">clinical</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">testing</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">turnaround</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">times</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">develop</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">commercial</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">tests</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">at</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">scale.</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">Scaling</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">test</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">capacity</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">meet</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">volumes</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">is</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">then</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">achieved</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">by</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">adding</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">instrumentation</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">qualified</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">personnel</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">quality</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">systems.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Our Strategy</p>
<p style="margin-top:5pt;margin-bottom:6pt;text-indent:4.8%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We<span style="letter-spacing:-0.25pt;"> </span>strive<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.25pt;"> </span>provide<span style="letter-spacing:-0.2pt;"> </span>swift,<span style="letter-spacing:-0.2pt;"> </span>comprehensive<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>actionable<span style="letter-spacing:-0.25pt;"> </span>insights<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.2pt;"> </span>improve<span style="letter-spacing:-0.25pt;"> </span>patient<span style="letter-spacing:-0.2pt;"> </span>outcomes<span style="letter-spacing:-0.25pt;"> </span>across<span style="letter-spacing:-0.2pt;"> </span>lung<span style="letter-spacing:-0.25pt;"> </span>disease<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.25pt;"> </span>help<span style="letter-spacing:-0.2pt;"> </span>answer<span style="letter-spacing:-0.25pt;"> </span>critical<span style="letter-spacing:-0.2pt;"> </span>clinical<span style="letter-spacing:0.05pt;"> </span>questions<span style="letter-spacing:-0.1pt;"> </span>faced<span style="letter-spacing:-0.1pt;"> </span>by<span style="letter-spacing:-0.1pt;"> </span>physicians,<span style="letter-spacing:-0.05pt;"> </span>researchers,<span style="letter-spacing:-0.1pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>biopharmaceutical<span style="letter-spacing:-0.05pt;"> </span>companies.<span style="letter-spacing:-0.1pt;"> </span>To<span style="letter-spacing:-0.1pt;"> </span>achieve<span style="letter-spacing:-0.1pt;"> </span>this,<span style="letter-spacing:-0.05pt;"> </span>we<span style="letter-spacing:-0.1pt;"> </span>intend<span style="letter-spacing:-0.1pt;"> </span>to:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-weight:bold;color:#000000;">Drive increased awareness, adoption, and reimbursement coverage of our diagnostic tests by:</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">continuously</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">educating</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">physicians,</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">key</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">opinion</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">leaders,</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">hospital</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">systems,</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">advocacy</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">groups,</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">patients,</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">payers,</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">academic</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">research</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">organizations,</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">technology</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">assessment</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">guideline</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">organizations</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">on</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">clinical</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">data</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">benefits</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">tests&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">utilizing our pulmonology-focused sales force and commercial reach with targeted awareness campaigns to employ highly targeted sales and marketing tactics in pulmonology clinics specializing in the management of lung nodules and the diagnosis of lung cancer&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:4pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:4pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:4pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">continuing</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">invest</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">in</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">expansion</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">sales</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">force</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">commercial</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">support</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">team&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">incorporating</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">testing</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">services</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">into</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">diagnostic</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">pathways</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">protocols</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">via</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">a</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">top-down</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">strategy</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">that</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">introduces</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">diagnostic</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">tests</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">largest</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">United</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">States</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">health</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">systems&#59;</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">leveraging</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">clinical</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">data</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">gain</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">broad</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">coverage</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">from</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">public</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">private</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">payers</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">for</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">tests.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-weight:bold;color:#000000;">Deepen our relationships with current biopharmaceutical customers and establish new customer opportunities by:</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">selling</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">complete</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">offering</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">tests</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">services</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">biopharmaceutical</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">companies</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">in</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">United</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">States</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">internationally&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">leveraging</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">existing</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">projects</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">relationships</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">expand</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">sales</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">with</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">current</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">biopharmaceutical</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">customers&#59;</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">targeting</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">companies</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">developing</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">novel</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">companion</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">diagnostic</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">strategies</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">drug</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">development</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">projects</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">best</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">suited</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">platform</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">for</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">new</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">test</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">discovery,</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">development</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">commercialization.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-weight:bold;color:#000000;">Further demonstrate the clinical utility and economic benefits of our diagnostic tests by:</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">investing in commercial clinical testing, research studies and clinical trials to further demonstrate the clinical utility of our tests&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">providing</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">rapid,</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">actionable,</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">holistic</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">diagnostic</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">information</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">help</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">inform</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">physicians</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">on</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">next</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">steps</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">in</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">a</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">patient&#8217;s</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">care</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">plan&#59;</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">providing</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">timely</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">actionable</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">clinical</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">information</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">help</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">improve</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">overall</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">patient</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">outcomes</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">lower</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">overall</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">healthcare</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">cost.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-weight:bold;color:#000000;">Introduce new diagnostic tests in lung disease by:</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">engaging</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">with</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">customers,</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">key</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">opinion</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">leaders,</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">scientific</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">experts</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">stay</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">ahead</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">rapidly</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">evolving</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">diagnostic</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">therapeutic</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">landscape</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">identify</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">additional</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">clinical</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">unmet</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">needs&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">entering</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">strategic</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">partnerships</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">with</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">biopharmaceutical</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">companies,</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">academic</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">research</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">organizations,</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">technology</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">providers,</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">other</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">diagnostic</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">companies&#59;</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">and</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="text-decoration:none;Background-color:#auto;"></span><span style="color:#000000;"></span><span style="color:#000000;">developing</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">companion</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">diagnostic</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">tests</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">support</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">therapeutics&#8217;</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">regulatory</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">approval</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">adoption</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">process</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">for</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">biopharmaceutical</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">customers.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-weight:bold;color:#000000;">Enhance our proprietary AI platform and expand our technology portfolio by:</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">continuing</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">invest</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">in</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">R&#38;D</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">capabilities</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">foster</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">innovation</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">in</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">test</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">discovery</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">development&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">identifying,</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">acquiring</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">technologies</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">integrating</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">new</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">data</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">types</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">into</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">proprietary</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">AI</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">platform&#59;</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">entering</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">strategic</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">partnerships</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">across</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">commercial</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">product</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">portfolio</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">product</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">development</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">efforts</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">in</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">order</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">further</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">development</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">capabilities,</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">accelerate</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">launch</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">commercial</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">products,</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">expand</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">service</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">offering.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-weight:bold;color:#000000;">Continue to expand and leverage our biobank by:</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">expanding</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">enhancing</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">robustness</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">samples</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">data</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">set,</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">including</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">through</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">collaborations</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">partnerships&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">pursuing</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">commercial</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">opportunities</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">with</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">companies</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">researchers</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">who</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">are</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">interested</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">in</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">utilizing</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">biobank</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">for</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">their</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">own</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">discovery</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">development</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">efforts&#59;</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">monetizing</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">these</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">commercial</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">opportunities.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Our Diagnostic Tests in Development</p>
<p style="margin-top:5pt;margin-bottom:6pt;text-indent:4.8%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">With<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.2pt;"> </span>goal<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.2pt;"> </span>finding<span style="letter-spacing:-0.2pt;"> </span>solutions<span style="letter-spacing:-0.15pt;"> </span>for<span style="letter-spacing:-0.2pt;"> </span>clinical<span style="letter-spacing:-0.2pt;"> </span>unmet<span style="letter-spacing:-0.2pt;"> </span>needs<span style="letter-spacing:-0.2pt;"> </span>related<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.2pt;"> </span>diagnosis,<span style="letter-spacing:-0.2pt;"> </span>treatment<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>monitoring<span style="letter-spacing:-0.15pt;"> </span>in<span style="letter-spacing:-0.2pt;"> </span>lung<span style="letter-spacing:-0.2pt;"> </span>disease,<span style="letter-spacing:-0.2pt;"> </span>our<span style="letter-spacing:-0.2pt;"> </span>diagnostic<span style="letter-spacing:-0.15pt;"> </span>tests<span style="letter-spacing:-0.2pt;"> </span>in<span style="letter-spacing:0.05pt;"> </span>development<span style="letter-spacing:-0.1pt;"> </span>include<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>following:</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.81%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Early-Stage<span style="letter-spacing:-0.2pt;"> </span>NSCLC&#8212;Risk<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:-0.2pt;"> </span>Recurrence</p>
<p style="margin-top:5pt;margin-bottom:6pt;text-indent:4.8%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Currently,<span style="letter-spacing:-0.25pt;"> </span>surgical<span style="letter-spacing:-0.2pt;"> </span>resection<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.2pt;"> </span>tumor<span style="letter-spacing:-0.25pt;"> </span>without<span style="letter-spacing:-0.2pt;"> </span>systemic<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:-0.25pt;"> </span>radiation<span style="letter-spacing:-0.2pt;"> </span>therapy<span style="letter-spacing:-0.2pt;"> </span>is<span style="letter-spacing:-0.25pt;"> </span>standard<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.25pt;"> </span>care<span style="letter-spacing:-0.2pt;"> </span>for<span style="letter-spacing:-0.2pt;"> </span>stage<span style="letter-spacing:-0.25pt;"> </span>I<span style="letter-spacing:-0.2pt;"> </span>NSCLC<span style="letter-spacing:-0.2pt;"> </span>patients.<span style="letter-spacing:-0.25pt;"> </span>However,<span style="letter-spacing:-0.2pt;"> </span>20<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.25pt;"> </span>40%<span style="letter-spacing:0.05pt;"> </span>of surgically treated patients will suffer a recurrence within 5 years after surgery. From market research with pulmonologists, thoracic surgeons, and<span style="letter-spacing:0.05pt;"> </span>medical<span style="letter-spacing:-0.2pt;"> </span>oncologists,<span style="letter-spacing:-0.15pt;"> </span>we<span style="letter-spacing:-0.2pt;"> </span>identified<span style="letter-spacing:-0.15pt;"> </span>a<span style="letter-spacing:-0.15pt;"> </span>significant<span style="letter-spacing:-0.2pt;"> </span>clinical<span style="letter-spacing:-0.15pt;"> </span>unmet<span style="letter-spacing:-0.15pt;"> </span>need<span style="letter-spacing:-0.2pt;"> </span>for<span style="letter-spacing:-0.15pt;"> </span>a<span style="letter-spacing:-0.2pt;"> </span>blood-based<span style="letter-spacing:-0.15pt;"> </span>test<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.2pt;"> </span>help<span style="letter-spacing:-0.15pt;"> </span>identify<span style="letter-spacing:-0.15pt;"> </span>stage<span style="letter-spacing:-0.2pt;"> </span>I<span style="letter-spacing:-0.15pt;"> </span>NSCLC<span style="letter-spacing:-0.15pt;"> </span>patients<span style="letter-spacing:-0.2pt;"> </span>who<span style="letter-spacing:-0.15pt;"> </span>are<span style="letter-spacing:-0.2pt;"> </span>at<span style="letter-spacing:-0.15pt;"> </span>a<span style="letter-spacing:-0.15pt;"> </span>higher<span style="letter-spacing:-0.2pt;"> </span>risk<span style="letter-spacing:0.05pt;"> </span>of<span style="letter-spacing:-0.25pt;"> </span>recurrence<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>may<span style="letter-spacing:-0.25pt;"> </span>benefit<span style="letter-spacing:-0.2pt;"> </span>from<span style="letter-spacing:-0.2pt;"> </span>neoadjuvant<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:-0.25pt;"> </span>adjuvant<span style="letter-spacing:-0.2pt;"> </span>systemic<span style="letter-spacing:-0.2pt;"> </span>treatment.<span style="letter-spacing:-0.2pt;"> </span>With<span style="letter-spacing:-0.25pt;"> </span>this<span style="letter-spacing:-0.2pt;"> </span>information,<span style="letter-spacing:-0.2pt;"> </span>we<span style="letter-spacing:-0.25pt;"> </span>discovered<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.2pt;"> </span>Risk<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.25pt;"> </span>Recurrence<span style="letter-spacing:-0.2pt;"> </span>(ROR)<span style="letter-spacing:-0.2pt;"> </span>test,<span style="letter-spacing:0.05pt;"> </span>which is a pre-surgery blood-based proteomic test, designed with the Diagnostic Cortex to predict whether a stage I NSCLC patient has a higher risk of<span style="letter-spacing:0.05pt;"> </span>recurrence post-surgical resection. Knowing this information early and before surgery may support treatment decisions such as neoadjuvant or adjuvant<span style="letter-spacing:0.05pt;"> </span>therapy, which have the potential to reduce tumor volume and address micro-metastatic disease as early as possible. Our ROR test validated in an<span style="letter-spacing:0.05pt;"> </span>independent<span style="letter-spacing:-0.15pt;"> </span>sample<span style="letter-spacing:-0.1pt;"> </span>set,<span style="letter-spacing:-0.1pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>we<span style="letter-spacing:-0.15pt;"> </span>are currently<span style="letter-spacing:-0.1pt;"> </span>working<span style="letter-spacing:-0.1pt;"> </span>with<span style="letter-spacing:-0.15pt;"> </span>major<span style="letter-spacing:-0.1pt;"> </span>academic<span style="letter-spacing:-0.1pt;"> </span>institutions<span style="letter-spacing:-0.1pt;"> </span>across<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>United<span style="letter-spacing:-0.1pt;"> </span>States<span style="letter-spacing:-0.1pt;"> </span>to<span style="letter-spacing:-0.15pt;"> </span>further<span style="letter-spacing:-0.1pt;"> </span>validate<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>test.</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.81%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Late-Stage NSCLC&#8212;Immunotherapy Treatment Guidance</p>
<p style="margin-top:5pt;margin-bottom:6pt;text-indent:4.8%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2015, the first immunotherapy-based treatment regimen was approved by the FDA for use in lung cancer. Currently, there are 9 immune<span style="letter-spacing:0.05pt;"> </span>checkpoint<span style="letter-spacing:-0.25pt;"> </span>inhibitor<span style="letter-spacing:-0.2pt;"> </span>(ICI)<span style="letter-spacing:-0.2pt;"> </span>regimens<span style="letter-spacing:-0.2pt;"> </span>(single<span style="letter-spacing:-0.25pt;"> </span>agent<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:-0.2pt;"> </span>combinations)<span style="letter-spacing:-0.2pt;"> </span>recommended<span style="letter-spacing:-0.2pt;"> </span>by<span style="letter-spacing:-0.25pt;"> </span>the<span style="letter-spacing:-0.2pt;"> </span>NCCN<span style="letter-spacing:-0.2pt;"> </span>guidelines<span style="letter-spacing:-0.2pt;"> </span>for<span style="letter-spacing:-0.25pt;"> </span>treatment<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.2pt;"> </span>advanced<span style="letter-spacing:-0.2pt;"> </span>NSCLC<span style="letter-spacing:-0.2pt;"> </span>patients.<span style="letter-spacing:-0.25pt;"> </span>For<span style="letter-spacing:0.05pt;"> </span>a<span style="letter-spacing:-0.2pt;"> </span>portion<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.2pt;"> </span>patients<span style="letter-spacing:-0.15pt;"> </span>treated,<span style="letter-spacing:-0.2pt;"> </span>these<span style="letter-spacing:-0.2pt;"> </span>drugs<span style="letter-spacing:-0.15pt;"> </span>can<span style="letter-spacing:-0.2pt;"> </span>result<span style="letter-spacing:-0.2pt;"> </span>in<span style="letter-spacing:-0.15pt;"> </span>significant<span style="letter-spacing:-0.2pt;"> </span>improvement<span style="letter-spacing:-0.2pt;"> </span>in<span style="letter-spacing:-0.15pt;"> </span>overall<span style="letter-spacing:-0.2pt;"> </span>survival<span style="letter-spacing:-0.2pt;"> </span>compared<span style="letter-spacing:-0.15pt;"> </span>with<span style="letter-spacing:-0.2pt;"> </span>platinum-based<span style="letter-spacing:-0.2pt;"> </span>chemotherapy<span style="letter-spacing:-0.15pt;"> </span>options.</p>
<p style="margin-top:0pt;margin-bottom:6pt;text-indent:4.8%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<span style="letter-spacing:-0.2pt;"> </span>combination<span style="letter-spacing:-0.2pt;"> </span>ICI<span style="letter-spacing:-0.2pt;"> </span>regimens<span style="letter-spacing:-0.2pt;"> </span>see<span style="letter-spacing:-0.15pt;"> </span>some<span style="letter-spacing:-0.2pt;"> </span>improvement<span style="letter-spacing:-0.2pt;"> </span>in<span style="letter-spacing:-0.2pt;"> </span>performance<span style="letter-spacing:-0.15pt;"> </span>over<span style="letter-spacing:-0.2pt;"> </span>single<span style="letter-spacing:-0.2pt;"> </span>agent<span style="letter-spacing:-0.2pt;"> </span>ICI,<span style="letter-spacing:-0.15pt;"> </span>but<span style="letter-spacing:-0.2pt;"> </span>side<span style="letter-spacing:-0.2pt;"> </span>effect<span style="letter-spacing:-0.2pt;"> </span>profiles<span style="letter-spacing:-0.15pt;"> </span>are<span style="letter-spacing:-0.2pt;"> </span>worse,<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>costs<span style="letter-spacing:-0.15pt;"> </span>are<span style="letter-spacing:-0.2pt;"> </span>higher<span style="letter-spacing:-0.2pt;"> </span>than<span style="letter-spacing:-0.2pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>single agent ICI. In addition, recent data have shown that a subset of patients experience more rapid disease progression on ICI compared with<span style="letter-spacing:0.05pt;"> </span>chemotherapy. We utilized the Diagnostic Cortex platform to discover our Primary Immune Response (PIR) test. PIR is a blood-based proteomic test<span style="letter-spacing:0.05pt;"> </span>designed to profile a patient&#8217;s immune response to their cancer and stratify by who is likely to respond to ICI treatment. Our PIR test has been validated in<span style="letter-spacing:0.05pt;"> </span>multiple independent sample sets for advanced stage NSCLC patients treated with single agent ICI, and we are currently working with major academic<span style="letter-spacing:0.05pt;"> </span>institutions<span style="letter-spacing:-0.1pt;"> </span>across<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>United<span style="letter-spacing:-0.05pt;"> </span>States<span style="letter-spacing:-0.1pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>further<span style="letter-spacing:-0.1pt;"> </span>validate<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>test<span style="letter-spacing:-0.05pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>a<span style="letter-spacing:-0.05pt;"> </span>prospective<span style="letter-spacing:-0.1pt;"> </span>study<span style="letter-spacing:-0.05pt;"> </span>called<span style="letter-spacing:-0.1pt;"> </span>BEACON-Lung.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.81%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><span style="font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Monitoring &#8211; Progression &#38; Resistance</span></p>
<p style="margin-top:5pt;margin-bottom:6pt;text-indent:4.8%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Blood-based monitoring with our ddPCR technology may offer a feasible method to non-invasively evaluate therapeutic mechanism of action,<span style="letter-spacing:0.05pt;"> </span>disease progression, and the emergence of resistance mutations in patients treated with targeted therapies. Our internal validation studies have shown the<span style="letter-spacing:0.05pt;"> </span>utility<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>GeneStrat<span style="letter-spacing:-0.15pt;"> </span><span style="font-style:italic;">EGFR</span><span style="font-style:italic;letter-spacing:-0.2pt;"> </span>ddPCR<span style="letter-spacing:-0.15pt;"> </span>test<span style="letter-spacing:-0.15pt;"> </span>in<span style="letter-spacing:-0.15pt;"> </span>all<span style="letter-spacing:-0.15pt;"> </span>three<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.15pt;"> </span>these<span style="letter-spacing:-0.15pt;"> </span>indications.<span style="letter-spacing:-0.15pt;"> </span>The<span style="letter-spacing:-0.15pt;"> </span>test<span style="letter-spacing:-0.2pt;"> </span>can<span style="letter-spacing:-0.15pt;"> </span>identify<span style="letter-spacing:-0.15pt;"> </span>disease<span style="letter-spacing:-0.15pt;"> </span>progression<span style="letter-spacing:-0.2pt;"> </span>up<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.15pt;"> </span>3<span style="letter-spacing:-0.15pt;"> </span>months<span style="letter-spacing:-0.15pt;"> </span>(median)<span style="letter-spacing:-0.2pt;"> </span>in<span style="letter-spacing:-0.15pt;"> </span>advance<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>standard imaging. Using ddPCR for longitudinal blood-based monitoring of EGFR cell-free DNA mutations is a cost-effective testing method while<span style="letter-spacing:0.05pt;"> </span>patients<span style="letter-spacing:-0.1pt;"> </span>are<span style="letter-spacing:-0.05pt;"> </span>being<span style="letter-spacing:-0.05pt;"> </span>treated<span style="letter-spacing:-0.05pt;"> </span>with<span style="letter-spacing:-0.05pt;"> </span>targeted<span style="letter-spacing:-0.05pt;"> </span>therapies.</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.81%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">COVID-19 Viral Infection &#8211; Risk of Severe Outcomes</p>
<p style="margin-top:5pt;margin-bottom:6pt;text-indent:4.8%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Despite significant medical advances in the prevention and treatment of COVID-19, the virus continues to place health systems under pressure, with COVID-19 hospitalization rates in the United States exceeding 417 hospitalizations per 100,000 population the week ending January 31, 2021. Better understanding of how to identify which patients are at greatest risk of developing severe lung disease, requiring intubation, or dying from COVID-19 would help inform physicians of the risks and benefits of treatments, target higher risk patients for clinical trials, compare outcomes between patients with similar risk, and prioritize resources in a time of shortage. In partnership with an academic institution, we have developed an artificial intelligence (AI)-based algorithm for clinical decision support to help stratify patients hospitalized with COVID-19 who are likely to require intervention, such as treatment with ventilators, admission to intensive care units, or those patients who may develop acute respiratory distress syndrome (ARDS), versus those who will likely not require intervention. Our COVID-19 AI-based algorithm validated in a blinded, independent study, and uses 26 easily obtainable variables from the emergency department at time of initial evaluation to classify patients, including patient characteristics, vital signs, and readily available laboratory test values. We are working with a United States and International COVID-19 consortia consisting of major academic institutions to perform additional large, blinded, independent validation testing of the classifier and we are currently exploring options for making the algorithm widely available to hospitals for future patient use.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Clinical Trials</p>
<p style="margin-top:5pt;margin-bottom:6pt;text-indent:4.8%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are dedicated to continuously publishing and presenting new data on the clinical validation and utility of our diagnostic tests. We have<span style="letter-spacing:0.05pt;"> </span>participated<span style="letter-spacing:-0.25pt;"> </span>in<span style="letter-spacing:-0.2pt;"> </span>27<span style="letter-spacing:-0.2pt;"> </span>clinical<span style="letter-spacing:-0.2pt;"> </span>studies,<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.2pt;">5 </span>of<span style="letter-spacing:-0.2pt;"> </span>which<span style="letter-spacing:-0.2pt;"> </span>are<span style="letter-spacing:-0.25pt;"> </span>ongoing,<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>have<span style="letter-spacing:-0.2pt;"> </span>published<span style="letter-spacing:-0.25pt;"> </span>over<span style="letter-spacing:-0.2pt;"> </span>275<span style="letter-spacing:-0.2pt;"> </span>peer-reviewed<span style="letter-spacing:-0.2pt;"> </span>publications<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>presentations.<span style="letter-spacing:-0.2pt;"> </span>The<span style="letter-spacing:-0.2pt;"> </span>following<span style="letter-spacing:-0.25pt;"> </span>are<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.1pt;"> </span>ongoing<span style="letter-spacing:-0.05pt;"> </span>clinical<span style="letter-spacing:-0.05pt;"> </span>studies<span style="letter-spacing:-0.05pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:-0.1pt;"> </span>diagnostic<span style="letter-spacing:-0.05pt;"> </span>testing<span style="letter-spacing:-0.05pt;"> </span>solutions.</p>
<p style="margin-top:4pt;margin-bottom:0pt;margin-left:4.81%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">ORACLE<span style="letter-spacing:-0.25pt;"> </span>Registry<span style="letter-spacing:-0.2pt;"> </span>Study<span style="letter-spacing:-0.2pt;"> </span>(NCT03766958)</p>
<p style="margin-top:5pt;margin-bottom:6pt;text-indent:4.8%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The ORACLE registry study was designed to develop real-world clinical utility data for Nodify XL2 and is titled &#8220;An Observational Registry Study<span style="letter-spacing:0.05pt;"> </span>to<span style="letter-spacing:-0.25pt;"> </span>Evaluate<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.2pt;"> </span>Performance<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.2pt;"> </span>Nodify<span style="letter-spacing:-0.2pt;"> </span>XL2<span style="letter-spacing:-0.2pt;"> </span>Test&#8221;.<span style="letter-spacing:-0.2pt;"> </span>The<span style="letter-spacing:-0.2pt;"> </span>study<span style="letter-spacing:-0.2pt;"> </span>objectives<span style="letter-spacing:-0.2pt;"> </span>are<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.2pt;"> </span>show<span style="letter-spacing:-0.2pt;"> </span>a<span style="letter-spacing:-0.2pt;"> </span>reduction<span style="letter-spacing:-0.2pt;"> </span>in<span style="letter-spacing:-0.2pt;"> </span>invasive<span style="letter-spacing:-0.2pt;"> </span>procedures<span style="letter-spacing:-0.2pt;"> </span>on<span style="letter-spacing:-0.2pt;"> </span>patients<span style="letter-spacing:-0.2pt;"> </span>with<span style="letter-spacing:-0.2pt;"> </span>benign<span style="letter-spacing:-0.2pt;"> </span>nodules<span style="letter-spacing:0.05pt;"> </span>compared to a historical control obtained from chart review. The first patient enrolled on October 16, 2018. As of May 1, 2020, 423 patients have been<span style="letter-spacing:0.05pt;"> </span>enrolled<span style="letter-spacing:-0.1pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>are<span style="letter-spacing:-0.1pt;"> </span>undergoing<span style="letter-spacing:-0.1pt;"> </span>primary<span style="letter-spacing:-0.1pt;"> </span>endpoint<span style="letter-spacing:-0.1pt;"> </span>analysis,<span style="letter-spacing:-0.1pt;"> </span>with<span style="letter-spacing:-0.1pt;"> </span>2-year<span style="letter-spacing:-0.1pt;"> </span>follow-up<span style="letter-spacing:-0.1pt;"> </span>estimated<span style="letter-spacing:-0.1pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.1pt;"> </span>completed<span style="letter-spacing:-0.1pt;"> </span>by<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>first<span style="letter-spacing:-0.1pt;"> </span>half<span style="letter-spacing:-0.1pt;"> </span>of<span style="letter-spacing:-0.1pt;"> </span>2022.</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.81%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">ALTITUDE<span style="letter-spacing:-0.25pt;"> </span>Clinical<span style="letter-spacing:-0.2pt;"> </span>Utility<span style="letter-spacing:-0.25pt;"> </span>Study<span style="letter-spacing:-0.2pt;"> </span>(NCT04171492)</p>
<p style="margin-top:5pt;margin-bottom:6pt;text-indent:4.8%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The ALTITUDE clinical utility study is designed to evaluate the performance of Nodify Lung (Nodify XL2 and Nodify CDT) in a randomized<span style="letter-spacing:0.05pt;"> </span>controlled study (RCT). The study is titled &#8220;A Multicenter, Randomized Controlled Trial, Prospectively Evaluating the Clinical Utility of the Nodify XL2<span style="letter-spacing:0.05pt;"> </span>Proteomic Test in Incidentally Discovered Low to Moderate Risk Lung Nodules&#8221;. We received central investigational review board (IRB) approval in<span style="letter-spacing:0.05pt;"> </span>December<span style="letter-spacing:-0.2pt;"> </span>2019<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>have<span style="letter-spacing:-0.2pt;"> </span>an<span style="letter-spacing:-0.2pt;"> </span>enrollment<span style="letter-spacing:-0.15pt;"> </span>goal<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.15pt;"> </span>2,000<span style="letter-spacing:-0.2pt;"> </span>patients.<span style="letter-spacing:-0.2pt;"> </span>The<span style="letter-spacing:-0.15pt;"> </span>study<span style="letter-spacing:-0.2pt;"> </span>objectives<span style="letter-spacing:-0.15pt;"> </span>are<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.2pt;"> </span>evaluate<span style="letter-spacing:-0.15pt;"> </span>how<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>addition<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>Nodify<span style="letter-spacing:-0.2pt;"> </span>Lung<span style="letter-spacing:-0.2pt;"> </span>test<span style="letter-spacing:-0.15pt;"> </span>result<span style="letter-spacing:-0.2pt;"> </span>impacts<span style="letter-spacing:0.05pt;"> </span>the clinical decision making for patients with new, incidentally identified solid lung nodules assessed as low to moderate risk of lung cancer. The trial has<span style="letter-spacing:0.05pt;"> </span>an adaptive study design with a blinded standard of care arm and 2:1 randomization for open-label results for Nodify XL2. The study launched in December of 2020. Phase 1 of the study with only Nodify XL2 is expected to enroll 500 patients. Phase 2 of the adaptive study design will<span style="letter-spacing:0.05pt;"> </span>include<span style="letter-spacing:-0.1pt;"> </span>an<span style="letter-spacing:-0.1pt;"> </span>open-label<span style="letter-spacing:-0.05pt;"> </span>arm<span style="letter-spacing:-0.1pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>Nodify<span style="letter-spacing:-0.1pt;"> </span>CDT,<span style="letter-spacing:-0.05pt;"> </span>which<span style="letter-spacing:-0.1pt;"> </span>is<span style="letter-spacing:-0.05pt;"> </span>aligned<span style="letter-spacing:-0.1pt;"> </span>with<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:-0.1pt;"> </span>commercial<span style="letter-spacing:-0.05pt;"> </span>testing<span style="letter-spacing:-0.1pt;"> </span>algorithm.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.81%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><span style="font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">INSIGHT</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Observational</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Study</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(NCT03289780)</span></p>
<p style="margin-top:5pt;margin-bottom:6pt;text-indent:4.8%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<span style="letter-spacing:-0.2pt;"> </span>INSIGHT<span style="letter-spacing:-0.2pt;"> </span>observational<span style="letter-spacing:-0.2pt;"> </span>study<span style="letter-spacing:-0.2pt;"> </span>is<span style="letter-spacing:-0.2pt;"> </span>designed<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.2pt;"> </span>evaluate<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.2pt;"> </span>real-world<span style="letter-spacing:-0.2pt;"> </span>clinical<span style="letter-spacing:-0.2pt;"> </span>utility<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>performance<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.2pt;"> </span>Biodesix<span style="letter-spacing:-0.2pt;"> </span>Lung<span style="letter-spacing:-0.2pt;"> </span>Reflex<span style="letter-spacing:-0.2pt;"> </span>(GeneStrat<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>VeriStrat) testing strategy. The title is &#8220;Observational Study Assessing the Clinical Effectiveness of VeriStrat and Validating Immunotherapy Tests in<span style="letter-spacing:0.05pt;"> </span>Subjects with Non-Small Cell Lung Cancer (INSIGHT)&#8221; and the first patient enrolled was on May 11, 2016. To date, we have over 3,500 patients enrolled<span style="letter-spacing:0.05pt;"> </span>with a target 5,000 enrollment goal. Final analysis with 3-year follow-up is estimated to be completed by 2024. Results of an interim analysis were<span style="letter-spacing:0.05pt;"> </span>presented at ASCO 2020. The study rationale is to guide the adoption of VeriStrat and inform medical decision making, including treatment choice, and<span style="letter-spacing:0.05pt;"> </span>enable the validation of additional mass spectrometry-based proteomic tests. The primary study objective is to describe the impact of the VeriStrat test<span style="letter-spacing:0.05pt;"> </span>results on treatment decisions, including but not limited to the percentage change in treatment decision, differences in chosen treatments between patients<span style="letter-spacing:0.05pt;"> </span>classified<span style="letter-spacing:-0.3pt;"> </span>as<span style="letter-spacing:-0.3pt;"> </span>VeriStrat<span style="letter-spacing:-0.25pt;"> </span>Good<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.25pt;"> </span>those<span style="letter-spacing:-0.3pt;"> </span>classified<span style="letter-spacing:-0.25pt;"> </span>as<span style="letter-spacing:-0.3pt;"> </span>VeriStrat<span style="letter-spacing:-0.25pt;"> </span>Poor,<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.25pt;"> </span>the<span style="letter-spacing:-0.3pt;"> </span>percentage<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:-0.3pt;"> </span>patients<span style="letter-spacing:-0.3pt;"> </span>receiving<span style="letter-spacing:-0.25pt;"> </span>systemic<span style="letter-spacing:-0.3pt;"> </span>therapy<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:-0.3pt;"> </span>supportive<span style="letter-spacing:-0.25pt;"> </span>therapies<span style="letter-spacing:-0.3pt;"> </span>only.</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.81%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">BEACON-Lung<span style="letter-spacing:-0.25pt;"> </span>Clinical<span style="letter-spacing:-0.2pt;"> </span>Study<span style="letter-spacing:-0.2pt;"> </span>(Trial in Progress)</p>
<p style="margin-top:5pt;margin-bottom:6pt;text-indent:4.8%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In<span style="letter-spacing:-0.25pt;"> </span>partnership<span style="letter-spacing:-0.2pt;"> </span>with<span style="letter-spacing:-0.2pt;"> </span>ALCMI<span style="letter-spacing:-0.2pt;"> </span>(Addario<span style="letter-spacing:-0.2pt;"> </span>Lung<span style="letter-spacing:-0.2pt;"> </span>Cancer<span style="letter-spacing:-0.25pt;"> </span>Medical<span style="letter-spacing:-0.2pt;"> </span>Institute),<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.2pt;"> </span>BEACON-Lung<span style="letter-spacing:-0.2pt;"> </span>clinical<span style="letter-spacing:-0.2pt;"> </span>study<span style="letter-spacing:-0.2pt;"> </span>is<span style="letter-spacing:-0.25pt;"> </span>intended<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.2pt;"> </span>evaluate<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.2pt;"> </span>performance<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>utility of our proteomic product currently in development, PIR, in advanced stage NSCLC patients who express high PD-L1. The study title is &#8220;A<span style="letter-spacing:0.05pt;"> </span>Biomarker Analysis in High PD-L1 Expressing NSCLC Patients Treated With An Immune Checkpoint Inhibitor (ICI) With or Without Platinum-Based<span style="letter-spacing:0.05pt;"> </span>Chemotherapy.&#8221; The study design is an observational, multicenter, open-label study to assess<span style="letter-spacing:0.05pt;"> </span>biomarkers (serum, microbiome, radiomics and tissue) as predictive of early progression in 390 treatment-naive patients with advanced stage NSCLC and<span style="letter-spacing:0.05pt;"> </span>PD-L1 greater than or equal to 50% treated with two standard of care regimens, triplet therapy (platinum-based chemotherapy plus ICI regimen) and ICI<span style="letter-spacing:0.05pt;"> </span>monotherapy (single agent ICI). The objectives are to collect biospecimens and evaluate candidate biomarkers, with a focus on PIR, to detect early<span style="letter-spacing:0.05pt;"> </span>progression<span style="letter-spacing:-0.1pt;"> </span>on<span style="letter-spacing:-0.05pt;"> </span>ICI<span style="letter-spacing:-0.05pt;"> </span>monotherapy<span style="letter-spacing:-0.05pt;"> </span>versus<span style="letter-spacing:-0.1pt;"> </span>triplet<span style="letter-spacing:-0.05pt;"> </span>therapy.</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.59%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">DROPLET (Pending IRB Submission)</p>
<p style="margin-top:5pt;margin-bottom:6pt;text-indent:4.8%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Droplet is an exploratory direct to patient study to assess the utility a novel gene linkage phenomenon as measured by the Bio-Rad SARS-CoV-2 ddPCR test, on the correlative immune response in individuals previously infected with the COVID-19 virus.&#160;&#160;The primary objective of this study (titled &#8220;ddPCR Linkage, Viral Load and Immune Response in Individuals Infected with COVID-19&#8221;) is to evaluate the correlation between linkage, viral load and the immune responses in individuals who have had a natural infection with SARS-CoV-2.&#160;&#160;Fifty patients will be enrolled and serially tested for viral load and immune responses for up to 12 months.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Commercialization</p>
<p style="margin-top:5pt;margin-bottom:6pt;text-indent:4.8%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For our lung cancer and nodule management tests, commercial efforts are focused on the promotion of our testing strategies to healthcare<span style="letter-spacing:0.05pt;"> </span>professionals actively involved in the diagnosis and treatment of lung cancer. Primarily focusing on pulmonology, the commercial team, consisting of<span style="letter-spacing:0.05pt;"> </span>specialty sales representatives, medical affairs, marketing and customer care representatives, works to educate and inform the entire patient care group<span style="letter-spacing:0.05pt;"> </span>consisting of physicians, nurses, office staff, laboratory personnel, and administration as to the appropriate use and value provided by our testing. The<span style="letter-spacing:0.05pt;"> </span>team&#8217;s<span style="letter-spacing:-0.2pt;"> </span>goal<span style="letter-spacing:-0.2pt;"> </span>is<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.2pt;"> </span>drive<span style="letter-spacing:-0.2pt;"> </span>test<span style="letter-spacing:-0.15pt;"> </span>adoption<span style="letter-spacing:-0.2pt;"> </span>through<span style="letter-spacing:-0.2pt;"> </span>articulating<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.2pt;"> </span>scientific<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>clinical<span style="letter-spacing:-0.2pt;"> </span>evidence<span style="letter-spacing:-0.2pt;"> </span>behind<span style="letter-spacing:-0.2pt;"> </span>our<span style="letter-spacing:-0.15pt;"> </span>tests,<span style="letter-spacing:-0.2pt;"> </span>how<span style="letter-spacing:-0.2pt;"> </span>they<span style="letter-spacing:-0.2pt;"> </span>impact<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>clinical<span style="letter-spacing:-0.2pt;"> </span>care<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.2pt;"> </span>a<span style="letter-spacing:-0.2pt;"> </span>patient,<span style="letter-spacing:0.05pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>how<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>tests<span style="letter-spacing:-0.05pt;"> </span>can<span style="letter-spacing:-0.05pt;"> </span>ultimately<span style="letter-spacing:-0.1pt;"> </span>help<span style="letter-spacing:-0.05pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>improve<span style="letter-spacing:-0.05pt;"> </span>patient<span style="letter-spacing:-0.05pt;"> </span>outcomes.</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:4.8%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Patients with pulmonary nodules are concentrated in this sub-specialty, where additional resources such as lung cancer screening and nodule<span style="letter-spacing:0.05pt;"> </span>management<span style="letter-spacing:-0.25pt;"> </span>clinics<span style="letter-spacing:-0.2pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>exist<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.25pt;"> </span>provide<span style="letter-spacing:-0.2pt;"> </span>an<span style="letter-spacing:-0.2pt;"> </span>increased<span style="letter-spacing:-0.2pt;"> </span>level<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:-0.2pt;"> </span>care.<span style="letter-spacing:-0.2pt;"> </span>We<span style="letter-spacing:-0.2pt;"> </span>are<span style="letter-spacing:-0.25pt;"> </span>also<span style="letter-spacing:-0.2pt;"> </span>engaging<span style="letter-spacing:-0.2pt;"> </span>large<span style="letter-spacing:-0.2pt;"> </span>hospital<span style="letter-spacing:-0.25pt;"> </span>systems<span style="letter-spacing:-0.2pt;"> </span>in<span style="letter-spacing:-0.2pt;"> </span>a<span style="letter-spacing:-0.2pt;"> </span>&#8220;top-down&#8221;<span style="letter-spacing:-0.25pt;"> </span>approach,<span style="letter-spacing:-0.2pt;"> </span>with<span style="letter-spacing:-0.2pt;"> </span>a<span style="letter-spacing:-0.2pt;"> </span>goal<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>incorporating<span style="letter-spacing:-0.1pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>tests<span style="letter-spacing:-0.05pt;"> </span>into<span style="letter-spacing:-0.05pt;"> </span>system<span style="letter-spacing:-0.05pt;"> </span>wide<span style="letter-spacing:-0.1pt;"> </span>pathways<span style="letter-spacing:-0.05pt;"> </span>and<span style="letter-spacing:-0.05pt;"> </span>protocols.</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:4.8%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">After<span style="letter-spacing:-0.2pt;"> </span>a<span style="letter-spacing:-0.2pt;"> </span>physician<span style="letter-spacing:-0.2pt;"> </span>orders<span style="letter-spacing:-0.2pt;"> </span>our<span style="letter-spacing:-0.2pt;"> </span>tests,<span style="letter-spacing:-0.15pt;"> </span>blood<span style="letter-spacing:-0.2pt;"> </span>is<span style="letter-spacing:-0.2pt;"> </span>collected<span style="letter-spacing:-0.2pt;"> </span>either<span style="letter-spacing:-0.2pt;"> </span>in<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>physician<span style="letter-spacing:-0.2pt;"> </span>office<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:-0.2pt;"> </span>laboratory,<span style="letter-spacing:-0.2pt;"> </span>third-party<span style="letter-spacing:-0.2pt;"> </span>&#8220;store<span style="letter-spacing:-0.2pt;"> </span>front&#8221;<span style="letter-spacing:-0.2pt;"> </span>patient<span style="letter-spacing:-0.2pt;"> </span>service<span style="letter-spacing:-0.2pt;"> </span>centers,<span style="letter-spacing:-0.15pt;"> </span>or<span style="letter-spacing:-0.2pt;"> </span>it<span style="letter-spacing:0.05pt;"> </span>can be collected in the patient&#8217;s home or workplace. We have contracted with a network of patient service centers and mobile phlebotomy services to be<span style="letter-spacing:0.05pt;"> </span>enable<span style="letter-spacing:-0.1pt;"> </span>collection<span style="letter-spacing:-0.1pt;"> </span>of<span style="letter-spacing:-0.1pt;"> </span>blood<span style="letter-spacing:-0.05pt;"> </span>samples<span style="letter-spacing:-0.1pt;"> </span>outside<span style="letter-spacing:-0.1pt;"> </span>of<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>physician<span style="letter-spacing:-0.1pt;"> </span>office,<span style="letter-spacing:-0.1pt;"> </span>at<span style="letter-spacing:-0.1pt;"> </span>home<span style="letter-spacing:-0.05pt;"> </span>or<span style="letter-spacing:-0.1pt;"> </span>work<span style="letter-spacing:-0.1pt;"> </span>for<span style="letter-spacing:-0.1pt;"> </span>patients<span style="letter-spacing:-0.05pt;"> </span>across<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>United<span style="letter-spacing:-0.1pt;"> </span>States.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:4.8%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Biodesix</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WorkSafe</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">COVID-19</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">testing</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">program,</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">have</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">dedicated</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">outreach</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">team</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">that</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">works</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">with</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.2pt;">the State of Colorado </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">healthcare</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">providers</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">hospitals,</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">employers looking to safely return to work across many industries, including food services, oil and gas, biotechnology and pharmaceuticals, sports teams,</span><span style="letter-spacing:-2.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">universities, and many small businesses. We recognize everyone&#8217;s COVID-19 situation is unique, which is why we provide end-to-end customized</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">solutions to support testing for our different customers, such as risk assessment tools, physician ordering services, on-site testing, phlebotomy services,</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">shipping</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">logistics,</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ongoing</span><span style="letter-spacing:-0.05pt;"> </span><span style="letter-spacing:-0.05pt;">client </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">support.</span></p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:4.8%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our business development team is focused on selling our complete offering of tests and services to biopharmaceutical companies in the United States and internationally. Our team consists of customer facing business development associates that work with our biopharmaceutical customers to identify projects, draw up statements of work and negotiate service agreements. Alliance managers help to manage the contractual obligations and scope of the project, whereas our operations team assures the project is managed with adequate resources and delivers on time. We take a two-pronged approach generating business in this segment. Primarily, we leverage existing projects and relationships to expand sales in current accounts. We also actively map ongoing drug development projects in biopharmaceutical companies and target programs best suited to our platform for new test development.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Coverage and Reimbursement</p>
<p style="margin-top:5pt;margin-bottom:6pt;text-indent:4.8%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The primary source of reimbursement for our tests in the United States is from third-party payers including government payers, such as Medicare,<span style="letter-spacing:0.05pt;"> </span>and<span style="letter-spacing:-0.25pt;"> </span>commercial<span style="letter-spacing:-0.2pt;"> </span>payers,<span style="letter-spacing:-0.2pt;"> </span>such<span style="letter-spacing:-0.2pt;"> </span>as<span style="letter-spacing:-0.2pt;"> </span>insurance<span style="letter-spacing:-0.25pt;"> </span>companies.<span style="letter-spacing:-0.2pt;"> </span>For<span style="letter-spacing:-0.2pt;"> </span>our<span style="letter-spacing:-0.2pt;"> </span>COVID-19<span style="letter-spacing:-0.2pt;"> </span>testing<span style="letter-spacing:-0.2pt;"> </span>program,<span style="letter-spacing:-0.25pt;"> </span>the<span style="letter-spacing:-0.2pt;"> </span>primary<span style="letter-spacing:-0.2pt;"> </span>source<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.2pt;"> </span>reimbursement<span style="letter-spacing:-0.2pt;"> </span>is<span style="letter-spacing:-0.25pt;"> </span>through<span style="letter-spacing:-0.2pt;"> </span>contracts<span style="letter-spacing:-0.2pt;"> </span>with<span style="letter-spacing:0.05pt;"> </span>hospitals, companies providing wellness testing for their employees, or direct pay from patients. We believe that our lung cancer tests can both improve<span style="letter-spacing:0.05pt;"> </span>patient outcomes and help guide cost-effective treatment choices for patients with and at-risk of lung cancer. Achieving broad coverage and adequate<span style="letter-spacing:0.05pt;"> </span>reimbursement<span style="letter-spacing:-0.1pt;"> </span>for<span style="letter-spacing:-0.1pt;"> </span>each<span style="letter-spacing:-0.1pt;"> </span>of<span style="letter-spacing:-0.1pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>tests<span style="letter-spacing:-0.1pt;"> </span>is<span style="letter-spacing:-0.1pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>key<span style="letter-spacing:-0.1pt;"> </span>component<span style="letter-spacing:-0.05pt;"> </span>of<span style="letter-spacing:-0.1pt;"> </span>our<span style="letter-spacing:-0.1pt;"> </span>financial<span style="letter-spacing:-0.1pt;"> </span>success<span style="letter-spacing:-0.1pt;"> </span>and<span style="letter-spacing:-0.05pt;"> </span>will<span style="letter-spacing:-0.1pt;"> </span>continue<span style="letter-spacing:-0.1pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.1pt;"> </span>important<span style="letter-spacing:-0.05pt;"> </span>over<span style="letter-spacing:-0.1pt;"> </span>time.</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:4.81%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Families First Coronavirus Response Act (FFCRA) and Coronavirus Aid, Relief, and Economic Security Act (CARES), Congress has<span style="letter-spacing:-2.1pt;"> </span>imposed<span style="letter-spacing:-0.3pt;"> </span>a<span style="letter-spacing:-0.3pt;"> </span>broad<span style="letter-spacing:-0.25pt;"> </span>requirement<span style="letter-spacing:-0.3pt;"> </span>that<span style="letter-spacing:-0.25pt;"> </span>Medicare<span style="letter-spacing:-0.3pt;"> </span>fee-for-service,<span style="letter-spacing:-0.25pt;"> </span>Medicare<span style="letter-spacing:-0.3pt;"> </span>Advantage,<span style="letter-spacing:-0.25pt;"> </span>Medicaid,<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.25pt;"> </span>commercial<span style="letter-spacing:-0.3pt;"> </span>payers<span style="letter-spacing:-0.25pt;"> </span>generally<span style="letter-spacing:-0.3pt;"> </span>cover<span style="letter-spacing:-0.25pt;"> </span>clinical<span style="letter-spacing:-0.3pt;"> </span>diagnostic<span style="letter-spacing:0.05pt;"> </span>laboratory<span style="letter-spacing:-0.2pt;"> </span>tests<span style="letter-spacing:-0.15pt;"> </span>administered<span style="letter-spacing:-0.15pt;"> </span>during<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>Public<span style="letter-spacing:-0.15pt;"> </span>Health<span style="letter-spacing:-0.15pt;"> </span>Emergency<span style="letter-spacing:-0.15pt;"> </span>for<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>detection<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:-0.15pt;"> </span>SARS-CoV-2<span style="letter-spacing:-0.15pt;"> </span>or<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>diagnosis<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>virus<span style="letter-spacing:-0.15pt;"> </span>that<span style="letter-spacing:-0.15pt;"> </span>causes COVID-19.<span style="letter-spacing:-0.25pt;"> </span>Where<span style="letter-spacing:-0.25pt;"> </span>applicable,<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.25pt;"> </span>FFCRA<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.25pt;"> </span>CARES<span style="letter-spacing:-0.2pt;"> </span>require<span style="letter-spacing:-0.25pt;"> </span>payers<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.25pt;"> </span>cover<span style="letter-spacing:-0.25pt;"> </span>COVID-19<span style="letter-spacing:-0.2pt;"> </span>tests<span style="letter-spacing:-0.25pt;"> </span>without<span style="letter-spacing:-0.2pt;"> </span>cost<span style="letter-spacing:-0.25pt;"> </span>sharing<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:-0.25pt;"> </span>medical<span style="letter-spacing:-0.2pt;"> </span>management<span style="letter-spacing:-0.25pt;"> </span>techniques<span style="letter-spacing:0.05pt;"> </span>like<span style="letter-spacing:-0.15pt;"> </span>prior<span style="letter-spacing:-0.15pt;"> </span>authorization.<span style="letter-spacing:-0.15pt;"> </span>Medicare<span style="letter-spacing:-0.15pt;"> </span>fee-for-service<span style="letter-spacing:-0.15pt;"> </span>does<span style="letter-spacing:-0.15pt;"> </span>not<span style="letter-spacing:-0.15pt;"> </span>require<span style="letter-spacing:-0.15pt;"> </span>cost<span style="letter-spacing:-0.1pt;"> </span>sharing<span style="letter-spacing:-0.15pt;"> </span>or<span style="letter-spacing:-0.15pt;"> </span>prior<span style="letter-spacing:-0.15pt;"> </span>authorization<span style="letter-spacing:-0.15pt;"> </span>for<span style="letter-spacing:-0.15pt;"> </span>any<span style="letter-spacing:-0.15pt;"> </span>clinical<span style="letter-spacing:-0.15pt;"> </span>diagnostic<span style="letter-spacing:-0.15pt;"> </span>laboratory<span style="letter-spacing:-0.1pt;"> </span>tests.</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:4.81%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<span style="letter-spacing:-0.2pt;"> </span>Department<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.2pt;"> </span>Health<span style="letter-spacing:-0.2pt;"> </span>&#38;<span style="letter-spacing:-0.2pt;"> </span>Human<span style="letter-spacing:-0.2pt;"> </span>Services<span style="letter-spacing:-0.2pt;"> </span>(HHS)<span style="letter-spacing:-0.2pt;"> </span>has<span style="letter-spacing:-0.2pt;"> </span>indicated<span style="letter-spacing:-0.2pt;"> </span>in<span style="letter-spacing:-0.2pt;"> </span>guidance<span style="letter-spacing:-0.2pt;"> </span>that<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.2pt;"> </span>coverage<span style="letter-spacing:-0.2pt;"> </span>requirements<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>FFCRA<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>CARES<span style="letter-spacing:-0.2pt;"> </span>can<span style="letter-spacing:-0.2pt;"> </span>apply<span style="letter-spacing:0.05pt;"> </span>both to infection and serological testing, but that they are only applicable to testing that is &#8220;diagnostic,&#8221; which &#8220;may include testing of individuals with<span style="letter-spacing:0.05pt;"> </span>signs or symptoms compatible with COVID-19, as well as asymptomatic individuals with known or suspected recent exposure to SARS-CoV-2.&#8221; Testing<span style="letter-spacing:0.05pt;"> </span>that is &#8220;not primarily intended for individualized diagnosis or treatment of COVID-19 or another health condition,&#8221; including &#8220;testing conducted to screen<span style="letter-spacing:-2.1pt;"> </span>for general workplace health and safety,&#8221; is beyond the scope of the statutory coverage requirements. We believe these coverage requirements apply to the<span style="letter-spacing:-2.1pt;">   </span>Bio-Rad SARS-CoV-2 ddPCR test and the Platelia SARS-CoV-2 Total Ab test when performed for diagnostic purposes. In some cases, we<span style="letter-spacing:0.05pt;"> </span>submit claims to insurance payers for the Bio-Rad SARS-CoV-2 ddPCR test and/or the Platelia SARS-CoV-2 Total Ab test. In these cases,<span style="letter-spacing:0.05pt;"> </span>insurance payers may have a different position on the scope of mandatory coverage of our tests under the FFCRA and CARES. More commonly, we enter into <span style="letter-spacing:-2.1pt;">  a</span>rrangements<span style="letter-spacing:-0.05pt;"> </span>with<span style="letter-spacing:-0.05pt;"> </span>clients<span style="letter-spacing:-0.1pt;"> </span>under<span style="letter-spacing:-0.05pt;"> </span>which<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>client<span style="letter-spacing:-0.1pt;"> </span>pays<span style="letter-spacing:-0.05pt;"> </span>us<span style="letter-spacing:-0.05pt;"> </span>directly<span style="letter-spacing:-0.05pt;"> </span>for<span style="letter-spacing:-0.1pt;"> </span>testing.</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:4.81%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Compliance<span style="letter-spacing:-0.25pt;"> </span>with<span style="letter-spacing:-0.2pt;"> </span>applicable<span style="letter-spacing:-0.2pt;"> </span>laws<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>regulations,<span style="letter-spacing:-0.25pt;"> </span>as<span style="letter-spacing:-0.2pt;"> </span>well<span style="letter-spacing:-0.2pt;"> </span>as<span style="letter-spacing:-0.2pt;"> </span>internal<span style="letter-spacing:-0.2pt;"> </span>compliance<span style="letter-spacing:-0.2pt;"> </span>policies<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>procedures<span style="letter-spacing:-0.2pt;"> </span>adds<span style="letter-spacing:-0.2pt;"> </span>complexity<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.25pt;"> </span>billing<span style="letter-spacing:-0.2pt;"> </span>process.<span style="letter-spacing:-0.2pt;"> </span>The<span style="letter-spacing:0.05pt;"> Centers for Medicare &#38; Medicaid Services (</span>CMS) is responsible for overseeing the establishment of new Healthcare Common Procedure Coding System (HCPCS) codes for billing the Medicare<span style="letter-spacing:0.05pt;"> </span>program<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.25pt;"> </span>other<span style="letter-spacing:-0.25pt;"> </span>payers.<span style="letter-spacing:-0.25pt;"> </span>CMS<span style="letter-spacing:-0.25pt;"> </span>continuously<span style="letter-spacing:-0.25pt;"> </span>evaluates<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.3pt;"> </span>implements<span style="letter-spacing:-0.25pt;"> </span>changes<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.25pt;"> </span>the<span style="letter-spacing:-0.25pt;"> </span>Medicare<span style="letter-spacing:-0.25pt;"> </span>billing,<span style="letter-spacing:-0.25pt;"> </span>coding,<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.3pt;"> </span>reimbursement<span style="letter-spacing:-0.25pt;"> </span>processes.<span style="letter-spacing:-0.25pt;"> </span>To<span style="letter-spacing:-0.25pt;"> </span>receive<span style="letter-spacing:0.05pt;"> </span>reimbursement from third-party payers, we bill our tests using a variety of HCPCS codes or Current Procedural Terminology (CPT) codes, as defined by the American Medical Association.<span style="letter-spacing:0.05pt;"> </span>For some of the tests we conduct, there may not be a specific CPT or HCPCS code, in which case the test may be billed under a miscellaneous code for an<span style="letter-spacing:-2.1pt;"> </span>unlisted molecular pathology procedure or unlisted multiple analyte test with algorithmic analysis (MAAA) procedure. Because these miscellaneous<span style="letter-spacing:0.05pt;"> </span>codes do not describe a specific service, the third-party payer claim may be examined to determine the service provided, whether the service was<span style="letter-spacing:0.05pt;"> </span>appropriate and medically necessary and whether payment should be rendered. This process can result in a delay in processing the claim, a lower<span style="letter-spacing:0.05pt;"> </span>reimbursement<span style="letter-spacing:-0.1pt;"> </span>amount,<span style="letter-spacing:-0.05pt;"> </span>and/or<span style="letter-spacing:-0.05pt;"> </span>denial<span style="letter-spacing:-0.05pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>claim.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#auto;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;color:#auto;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Competitors</span></p>
<p style="margin-top:5pt;margin-bottom:6pt;text-indent:4.8%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We primarily face competition from lung cancer diagnostic solutions companies in the United States, Europe and Asia seeking to answer clinical<span style="letter-spacing:0.05pt;"> </span>questions<span style="letter-spacing:-0.25pt;"> </span>in<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.25pt;"> </span>space,<span style="letter-spacing:-0.2pt;"> </span>all<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:-0.2pt;"> </span>whom<span style="letter-spacing:-0.25pt;"> </span>provide<span style="letter-spacing:-0.2pt;"> </span>cancer-focused<span style="letter-spacing:-0.2pt;"> </span>diagnostic<span style="letter-spacing:-0.25pt;"> </span>tests<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.25pt;"> </span>hospitals,<span style="letter-spacing:-0.2pt;"> </span>researchers,<span style="letter-spacing:-0.25pt;"> </span>clinicians,<span style="letter-spacing:-0.2pt;"> </span>laboratories<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.25pt;"> </span>other<span style="letter-spacing:-0.2pt;"> </span>medical<span style="letter-spacing:-0.25pt;"> </span>facilities.</p>
<p style="margin-top:2pt;margin-bottom:0pt;margin-left:4.81%;text-indent:0%;font-weight:bold;font-style:italic;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Diagnosis&#8212;Nodule<span style="letter-spacing:-0.25pt;"> </span>Management</p>
<p style="margin-top:5pt;margin-bottom:6pt;text-indent:4.8%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We<span style="letter-spacing:-0.25pt;"> </span>are<span style="letter-spacing:-0.2pt;"> </span>not<span style="letter-spacing:-0.2pt;"> </span>aware<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.25pt;"> </span>any<span style="letter-spacing:-0.2pt;"> </span>other<span style="letter-spacing:-0.2pt;"> </span>company<span style="letter-spacing:-0.2pt;"> </span>that<span style="letter-spacing:-0.25pt;"> </span>offers<span style="letter-spacing:-0.2pt;"> </span>two<span style="letter-spacing:-0.2pt;"> </span>commercial<span style="letter-spacing:-0.2pt;"> </span>blood-based<span style="letter-spacing:-0.25pt;"> </span>tests<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.2pt;"> </span>help<span style="letter-spacing:-0.2pt;"> </span>physicians<span style="letter-spacing:-0.25pt;"> </span>reclassify<span style="letter-spacing:-0.2pt;"> </span>risk<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.2pt;"> </span>malignancy<span style="letter-spacing:-0.25pt;"> </span>in<span style="letter-spacing:-0.2pt;"> </span>patients<span style="letter-spacing:-0.2pt;"> </span>with<span style="letter-spacing:0.05pt;"> </span>suspicious lung nodules. We are aware of efforts by Veracyte, Inc. to develop and validate a test that may be competitive to the Nodify XL2 and/or Nodify<span style="letter-spacing:0.05pt;"> </span>CDT tests in the future. Additionally, Veracyte currently markets a test that is used post-bronchoscopy that is not competitive with our pre-bronchoscopy<span style="letter-spacing:0.05pt;"> </span>nodule<span style="letter-spacing:-0.1pt;"> </span>risk<span style="letter-spacing:-0.05pt;"> </span>assessment<span style="letter-spacing:-0.05pt;"> </span>tests.</p>
<p style="margin-top:2pt;margin-bottom:0pt;margin-left:4.81%;text-indent:0%;font-weight:bold;font-style:italic;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Prognosis,<span style="letter-spacing:-0.3pt;"> </span>Treatment<span style="letter-spacing:-0.25pt;"> </span>Guidance<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.25pt;"> </span>Monitoring&#8212;NSCLC</p>
<p style="margin-top:5pt;margin-bottom:6pt;text-indent:4.8%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We<span style="letter-spacing:-0.3pt;"> </span>are<span style="letter-spacing:-0.25pt;"> </span>unaware<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:-0.3pt;"> </span>any<span style="letter-spacing:-0.25pt;"> </span>other<span style="letter-spacing:-0.25pt;"> </span>diagnostic<span style="letter-spacing:-0.25pt;"> </span>test<span style="letter-spacing:-0.3pt;"> </span>available,<span style="letter-spacing:-0.25pt;"> </span>commercially<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:-0.3pt;"> </span>in<span style="letter-spacing:-0.25pt;"> </span>development,<span style="letter-spacing:-0.25pt;"> </span>that<span style="letter-spacing:-0.25pt;"> </span>will<span style="letter-spacing:-0.3pt;"> </span>compete<span style="letter-spacing:-0.25pt;"> </span>with<span style="letter-spacing:-0.25pt;"> </span>our<span style="letter-spacing:-0.3pt;"> </span>VeriStrat<span style="letter-spacing:-0.25pt;"> </span>immune<span style="letter-spacing:-0.25pt;"> </span>profiling<span style="letter-spacing:-0.25pt;"> </span>test.<span style="letter-spacing:0.05pt;"> </span>There is substantial interest and activity in tumor profiling through liquid biopsy. Our genomic test offering, GeneStrat, faces competition from academic<span style="letter-spacing:-2.1pt;"> </span>hospital laboratories, and companies such as Guardant Health and Foundation Medicine. We believe that there are several companies and academic<span style="letter-spacing:0.05pt;"> </span>research<span style="letter-spacing:-0.2pt;"> </span>institutions<span style="letter-spacing:-0.15pt;"> </span>in<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>process<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.15pt;"> </span>developing<span style="letter-spacing:-0.2pt;"> </span>tests<span style="letter-spacing:-0.15pt;"> </span>for<span style="letter-spacing:-0.15pt;"> </span>monitoring<span style="letter-spacing:-0.2pt;"> </span>patients<span style="letter-spacing:-0.15pt;"> </span>on<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:-0.15pt;"> </span>following<span style="letter-spacing:-0.2pt;"> </span>treatment<span style="letter-spacing:-0.15pt;"> </span>for<span style="letter-spacing:-0.2pt;"> </span>recurrence<span style="letter-spacing:-0.15pt;"> </span>or<span style="letter-spacing:-0.15pt;"> </span>progression<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.15pt;"> </span>lung<span style="letter-spacing:-0.2pt;"> </span>cancer.</p>
<p style="margin-top:2pt;margin-bottom:0pt;margin-left:4.81%;text-indent:0%;font-weight:bold;font-style:italic;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">COVID-19<span style="letter-spacing:-0.3pt;"> </span>Testing</p>
<p style="margin-top:5pt;margin-bottom:6pt;text-indent:4.8%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe that our competitors include university and state laboratories, national reference laboratories such as Lab Corporation and Quest Diagnostics, in-hospital laboratories, and a number of other diagnostic providers. We are aware that a number of other companies have announced development efforts to develop COVID-19 tests.</p>
<p style="margin-top:4pt;margin-bottom:0pt;margin-left:4.81%;text-indent:0%;font-weight:bold;font-style:italic;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Biopharmaceutical<span style="letter-spacing:-0.4pt;"> </span>Diagnostic<span style="letter-spacing:-0.35pt;"> </span>Discovery,<span style="letter-spacing:-0.35pt;"> </span>Development<span style="letter-spacing:-0.35pt;"> </span>&#38;<span style="letter-spacing:-0.35pt;"> </span>Testing<span style="letter-spacing:-0.35pt;"> </span>Services</p>
<p style="margin-top:5pt;margin-bottom:6pt;text-indent:4.8%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We<span style="letter-spacing:-0.25pt;"> </span>are<span style="letter-spacing:-0.2pt;"> </span>aware<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.25pt;"> </span>a<span style="letter-spacing:-0.2pt;"> </span>number<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.25pt;"> </span>companies<span style="letter-spacing:-0.2pt;"> </span>who<span style="letter-spacing:-0.2pt;"> </span>compete<span style="letter-spacing:-0.25pt;"> </span>with<span style="letter-spacing:-0.2pt;"> </span>our<span style="letter-spacing:-0.25pt;"> </span>diagnostic<span style="letter-spacing:-0.2pt;"> </span>tests<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.25pt;"> </span>services,<span style="letter-spacing:-0.2pt;"> </span>including<span style="letter-spacing:-0.2pt;"> </span>diagnostic<span style="letter-spacing:-0.25pt;"> </span>research,<span style="letter-spacing:-0.2pt;"> </span>clinical<span style="letter-spacing:-0.2pt;"> </span>trial<span style="letter-spacing:-0.25pt;"> </span>testing,<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>the discovery, development, and commercialization of companion diagnostics. From the perspective of tumor profiling, we believe Guardant Health and<span style="letter-spacing:0.05pt;"> </span>Foundation Medicine are our most significant competitors. Conversely, in the immune profiling market, we believe Adaptive Biotechnologies and<span style="letter-spacing:0.05pt;"> </span>Personalis<span style="letter-spacing:-0.1pt;"> </span>are<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>most<span style="letter-spacing:-0.05pt;"> </span>significant<span style="letter-spacing:-0.05pt;"> </span>competitors.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#auto;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Clinical<span style="letter-spacing:-0.25pt;"> </span>Laboratory<span style="letter-spacing:-0.2pt;"> </span>Operations</p>
<p style="margin-top:5pt;margin-bottom:6pt;text-indent:4.8%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We perform the VeriStrat, GeneStrat, and COVID-19 ddPCR tests in our Boulder, Colorado clinical laboratory. The laboratory is CAP-accredited,<span style="letter-spacing:0.05pt;"> </span>CLIA-certified,<span style="letter-spacing:-0.35pt;"> </span>New<span style="letter-spacing:-0.3pt;"> </span>York<span style="letter-spacing:-0.35pt;"> </span>Department<span style="letter-spacing:-0.3pt;"> </span>of<span style="letter-spacing:-0.35pt;"> </span>Health<span style="letter-spacing:-0.3pt;"> </span>(NYSDOH)&#8212;<span style="letter-spacing:-0.3pt;"> </span>permitted<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.3pt;"> </span>licensed,<span style="letter-spacing:-0.35pt;"> </span>ISO<span style="letter-spacing:-0.3pt;"> </span>13485:2016<span style="letter-spacing:-0.3pt;"> </span>Quality<span style="letter-spacing:-0.35pt;"> </span>Management<span style="letter-spacing:-0.3pt;"> </span>Systems&#8212;Requirements<span style="letter-spacing:-0.35pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>Regulatory Purposes for Medical Devices certified, along with all other states that require licensing: California, Maryland, Pennsylvania, and Rhode Island.<span style="letter-spacing:-2.1pt;"> </span>All aspects of the testing process from receipt of the test requisition form through to delivery of test results are performed in the Boulder, Colorado facility.<span style="letter-spacing:-2.1pt;"> &#160;&#160;</span>The proprietary testing methods use semi-automated workflows that facilitate the successful delivery of greater than 90% of our tests within 3 days, and we <span style="letter-spacing:-2.1pt;">  </span>believe<span style="letter-spacing:-0.1pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>existing<span style="letter-spacing:-0.1pt;"> </span>workflows<span style="letter-spacing:-0.05pt;"> </span>will<span style="letter-spacing:-0.05pt;"> </span>continue<span style="letter-spacing:-0.1pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>successfully<span style="letter-spacing:-0.05pt;"> </span>deliver<span style="letter-spacing:-0.1pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>tests<span style="letter-spacing:-0.1pt;"> </span>within<span style="letter-spacing:-0.05pt;"> </span>this<span style="letter-spacing:-0.05pt;"> </span>timeframe.</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:4.8%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Nodify XL2, Nodify CDT, and COVID-19 total antibody tests are performed in our De Soto, Kansas clinical laboratory. This clinical<span style="letter-spacing:0.05pt;"> </span>laboratory is CLIA-certified, COLA-accredited, New York Department of Health&#8212;permitted and licensed, and licensed by California, Maryland,<span style="letter-spacing:0.05pt;"> </span>Pennsylvania, and Rhode Island. Efforts are underway with the NYSDOH to become permitted and licensed to perform Nodify XL2 and Nodify CDT<span style="letter-spacing:0.05pt;"> </span>testing for samples from the state of New York. Receipt of requisitions and testing is performed in our De Soto, Kansas clinical laboratory. Delivery of the<span style="letter-spacing:-2.1pt;"> &#160;&#160;&#160;&#160;</span>test results is performed by personnel from our Boulder, Colorado headquarters. The proprietary testing methods use semi-automated workflows that<span style="letter-spacing:0.05pt;"> </span>facilitate<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>successful<span style="letter-spacing:-0.2pt;"> </span>delivery<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:-0.2pt;"> </span>greater<span style="letter-spacing:-0.15pt;"> </span>than<span style="letter-spacing:-0.15pt;"> </span>90%<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.15pt;"> </span>our<span style="letter-spacing:-0.2pt;"> </span>tests<span style="letter-spacing:-0.15pt;"> </span>within<span style="letter-spacing:-0.2pt;"> </span>5<span style="letter-spacing:-0.15pt;"> </span>days,<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>we<span style="letter-spacing:-0.15pt;"> </span>believe<span style="letter-spacing:-0.2pt;"> </span>our<span style="letter-spacing:-0.15pt;"> </span>existing<span style="letter-spacing:-0.2pt;"> </span>workflows<span style="letter-spacing:-0.15pt;"> </span>will<span style="letter-spacing:-0.15pt;"> </span>continue<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.15pt;"> </span>successfully<span style="letter-spacing:-0.2pt;"> </span>deliver<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.1pt;"> </span>tests<span style="letter-spacing:-0.05pt;"> </span>within<span style="letter-spacing:-0.05pt;"> </span>this<span style="letter-spacing:-0.05pt;"> </span>timeframe.</p>
<p style="margin-top:0pt;margin-bottom:6pt;text-indent:4.8%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Personnel<span style="letter-spacing:-0.25pt;"> </span>in<span style="letter-spacing:-0.2pt;"> </span>both<span style="letter-spacing:-0.2pt;"> </span>facilities<span style="letter-spacing:-0.25pt;"> </span>are<span style="letter-spacing:-0.2pt;"> </span>responsible<span style="letter-spacing:-0.2pt;"> </span>for<span style="letter-spacing:-0.2pt;"> </span>quality<span style="letter-spacing:-0.25pt;"> </span>assurance<span style="letter-spacing:-0.2pt;"> </span>oversight,<span style="letter-spacing:-0.2pt;"> </span>licensing,<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.25pt;"> </span>regulation<span style="letter-spacing:-0.2pt;"> </span>compliance<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>maintenance<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.2pt;"> </span>ensure<span style="letter-spacing:-0.2pt;"> </span>data<span style="letter-spacing:0.05pt;"> </span>integrity<span style="letter-spacing:-0.1pt;"> </span>and<span style="letter-spacing:-0.05pt;"> </span>consistent,<span style="letter-spacing:-0.05pt;"> </span>validated<span style="letter-spacing:-0.05pt;"> </span>processes.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#auto;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;color:#auto;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Supply</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-weight:bold;color:#auto;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Chain</span></p>
<p style="margin-top:6pt;margin-bottom:6pt;text-indent:4.76%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We rely on third-party suppliers, including in some instances single source suppliers, to provide us with certain components of our diagnostic tests. The number of suppliers feeding into the production of our diagnostic tests is in excess of 65 worldwide. We consider a select few of these suppliers,<span style="letter-spacing:0.05pt;"> </span>located<span style="letter-spacing:-0.25pt;"> </span>in<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.2pt;"> </span>United<span style="letter-spacing:-0.2pt;"> </span>States,<span style="letter-spacing:-0.2pt;"> </span>Europe<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.25pt;"> </span>China,<span style="letter-spacing:-0.2pt;"> </span>as<span style="letter-spacing:-0.2pt;"> </span>critical<span style="letter-spacing:-0.2pt;"> </span>single<span style="letter-spacing:-0.2pt;"> </span>source<span style="letter-spacing:-0.2pt;"> </span>providers<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:-0.2pt;"> </span>components.<span style="letter-spacing:-0.2pt;"> </span>Bio-Rad,<span style="letter-spacing:-0.2pt;"> </span>as<span style="letter-spacing:-0.2pt;"> </span>described<span style="letter-spacing:-0.2pt;"> </span>below,<span style="letter-spacing:-0.2pt;"> </span>is<span style="letter-spacing:-0.25pt;"> </span>the<span style="letter-spacing:-0.2pt;"> </span>sole<span style="letter-spacing:-0.2pt;"> </span>source<span style="letter-spacing:-0.2pt;"> </span>supplier<span style="letter-spacing:0.05pt;"> </span>for our GeneStrat test and COVID-19 and antibody testing program. Oncimmune is also the sole source supplier for our Nodify CDT tests but<span style="letter-spacing:0.05pt;"> </span>there are known secondary suppliers for these materials. We have initiated the second source qualification process for the majority of these critical<span style="letter-spacing:0.05pt;"> </span>components.</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:4.8%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In<span style="letter-spacing:-0.25pt;"> </span>addition,<span style="letter-spacing:-0.2pt;"> </span>we<span style="letter-spacing:-0.2pt;"> </span>purchase<span style="letter-spacing:-0.25pt;"> </span>supplies<span style="letter-spacing:-0.2pt;"> </span>through<span style="letter-spacing:-0.2pt;"> </span>purchase<span style="letter-spacing:-0.25pt;"> </span>orders<span style="letter-spacing:-0.2pt;"> </span>without<span style="letter-spacing:-0.2pt;"> </span>long-term<span style="letter-spacing:-0.25pt;"> </span>supply<span style="letter-spacing:-0.2pt;"> </span>agreements<span style="letter-spacing:-0.2pt;"> </span>with,<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:-0.2pt;"> </span>guaranteed<span style="letter-spacing:-0.2pt;"> </span>commitments<span style="letter-spacing:-0.25pt;"> </span>from,<span style="letter-spacing:-0.2pt;"> </span>many<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.25pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">suppliers,</span><span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">including</span><span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">single</span><span style="letter-spacing:0.1pt;"> </span><span style="letter-spacing:-0.05pt;">source</span><span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">suppliers.</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.05pt;">Additionally,</span><span style="letter-spacing:0.1pt;"> </span><span style="letter-spacing:-0.05pt;">at</span><span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">present,</span><span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">we</span><span style="letter-spacing:0.1pt;"> </span><span style="letter-spacing:-0.05pt;">rely</span><span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">on</span><span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">contract</span><span style="letter-spacing:0.1pt;"> </span>manufacturers<span style="letter-spacing:0.05pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.1pt;"> </span>production<span style="letter-spacing:0.05pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:0.1pt;"> </span>diagnostic<span style="letter-spacing:0.05pt;"> </span>tests.<span style="letter-spacing:-0.05pt;"> </span>We<span style="letter-spacing:0.05pt;"> </span>depend on our suppliers and contract manufacturers to provide us and our customers with materials in a timely manner that meet our and their quality,<span style="letter-spacing:0.05pt;"> </span>quantity<span style="letter-spacing:-0.1pt;"> </span>and<span style="letter-spacing:-0.05pt;"> </span>cost<span style="letter-spacing:-0.05pt;"> </span>requirements.</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:4.8%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We entered into a nonexclusive license and supply agreement with Bio-Rad in August 2019. We rely on Bio-Rad to supply equipment and reagents<span style="letter-spacing:0.05pt;"> </span>used to perform ddPCR testing, a service offered by us under a variety of fee for service agreements and the core technology powering the GeneStrat test,<span style="letter-spacing:0.05pt;"> </span>but<span style="letter-spacing:-0.2pt;"> </span>these<span style="letter-spacing:-0.15pt;"> </span>supplies<span style="letter-spacing:-0.15pt;"> </span>are<span style="letter-spacing:-0.2pt;"> </span>able<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.2pt;"> </span>supplied<span style="letter-spacing:-0.15pt;"> </span>by<span style="letter-spacing:-0.15pt;"> </span>known<span style="letter-spacing:-0.15pt;"> </span>suppliers.<span style="letter-spacing:-0.2pt;"> </span>A<span style="letter-spacing:-0.15pt;"> </span>disruption<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.2pt;"> </span>this<span style="letter-spacing:-0.15pt;"> </span>supply<span style="letter-spacing:-0.15pt;"> </span>would<span style="letter-spacing:-0.2pt;"> </span>negatively<span style="letter-spacing:-0.15pt;"> </span>impact<span style="letter-spacing:-0.15pt;"> </span>our<span style="letter-spacing:-0.15pt;"> </span>ability<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.15pt;"> </span>perform<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.2pt;"> </span>GeneStrat<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>SARS<span style="letter-spacing:-0.1pt;">-</span>CoV-2<span style="letter-spacing:-0.05pt;"> </span>tests<span style="letter-spacing:-0.05pt;"> </span>until<span style="letter-spacing:-0.05pt;"> </span>alternatives<span style="letter-spacing:-0.1pt;"> </span>could<span style="letter-spacing:-0.05pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>validated.</p>
<p style="margin-top:4pt;margin-bottom:6pt;text-indent:4.8%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">While<span style="letter-spacing:-0.2pt;"> </span>we<span style="letter-spacing:-0.2pt;"> </span>have<span style="letter-spacing:-0.15pt;"> </span>initiated<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>second<span style="letter-spacing:-0.2pt;"> </span>source<span style="letter-spacing:-0.15pt;"> </span>qualification<span style="letter-spacing:-0.2pt;"> </span>process<span style="letter-spacing:-0.15pt;"> </span>for<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.2pt;"> </span>majority<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:-0.2pt;"> </span>these<span style="letter-spacing:-0.15pt;"> </span>critical<span style="letter-spacing:-0.2pt;"> </span>components,<span style="letter-spacing:-0.15pt;"> </span>we<span style="letter-spacing:-0.2pt;"> </span>may<span style="letter-spacing:-0.15pt;"> </span>not<span style="letter-spacing:-0.2pt;"> </span>be<span style="letter-spacing:-0.2pt;"> </span>successful<span style="letter-spacing:-0.15pt;"> </span>in<span style="letter-spacing:-0.2pt;"> </span>securing<span style="letter-spacing:0.05pt;"> </span>second sourcing for all of them at all or on a timely basis. A disruption to this supply would negatively impact our ability to perform these tests until an<span style="letter-spacing:0.05pt;"> </span>alternative<span style="letter-spacing:-0.1pt;"> </span>supplier<span style="letter-spacing:-0.05pt;"> </span>could<span style="letter-spacing:-0.05pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>validated.</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:4.8%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All<span style="letter-spacing:-0.25pt;"> </span>materials<span style="letter-spacing:-0.2pt;"> </span>for<span style="letter-spacing:-0.2pt;"> </span>our<span style="letter-spacing:-0.2pt;"> </span>VeriStrat<span style="letter-spacing:-0.25pt;"> </span>test<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>Nodify<span style="letter-spacing:-0.2pt;"> </span>XL2<span style="letter-spacing:-0.2pt;"> </span>tests<span style="letter-spacing:-0.25pt;"> </span>have<span style="letter-spacing:-0.2pt;"> </span>alternative<span style="letter-spacing:-0.2pt;"> </span>suppliers<span style="letter-spacing:-0.2pt;"> </span>readily<span style="letter-spacing:-0.2pt;"> </span>available,<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>a<span style="letter-spacing:-0.2pt;"> </span>disruption<span style="letter-spacing:-0.2pt;"> </span>in<span style="letter-spacing:-0.25pt;"> </span>any<span style="letter-spacing:-0.2pt;"> </span>single<span style="letter-spacing:-0.2pt;"> </span>supplier<span style="letter-spacing:-0.2pt;"> </span>would<span style="letter-spacing:-0.2pt;"> </span>not<span style="letter-spacing:0.05pt;"> </span>materially<span style="letter-spacing:-0.1pt;"> </span>impact<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>ability<span style="letter-spacing:-0.05pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>deliver<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>test.</p>
<p style="margin-top:0pt;margin-bottom:6pt;text-indent:4.8%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<span style="letter-spacing:-0.25pt;"> </span>COVID-19<span style="letter-spacing:-0.2pt;"> </span>pandemic<span style="letter-spacing:-0.2pt;"> </span>has<span style="letter-spacing:-0.25pt;"> </span>allowed<span style="letter-spacing:-0.2pt;"> </span>us<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.25pt;"> </span>pressure-test<span style="letter-spacing:-0.2pt;"> </span>our<span style="letter-spacing:-0.2pt;"> </span>supply<span style="letter-spacing:-0.25pt;"> </span>chain<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>logistics<span style="letter-spacing:-0.25pt;"> </span>processes<span style="letter-spacing:-0.2pt;"> </span>as<span style="letter-spacing:-0.2pt;"> </span>we<span style="letter-spacing:-0.25pt;"> </span>purchased<span style="letter-spacing:-0.2pt;"> </span>additional<span style="letter-spacing:-0.2pt;"> </span>manufacturing<span style="letter-spacing:-0.25pt;"> </span>capacity<span style="letter-spacing:0.05pt;"> </span>above our normal run rates to ensure that supply to execute on tests for the foreseeable future was available in-stock and in-house. Our suppliers have been<span style="letter-spacing:0.05pt;"> </span>able to allocate sufficient capacity to meet this increased demand with reasonable lead times and therefore we believe sufficient capacity exists for all tests<span style="letter-spacing:0.05pt;"> </span>for<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>next<span style="letter-spacing:-0.05pt;"> </span>24<span style="letter-spacing:-0.05pt;"> </span>months.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#auto;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intellectual<span style="letter-spacing:-0.2pt;"> </span>Property</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.76%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our success depends, in part, on our ability to obtain and maintain intellectual property and proprietary protection for our products and other know-how, to operate our business without infringing, misappropriating or otherwise violating the intellectual property and proprietary rights of others, and to defend and enforce our intellectual property and proprietary rights. We take efforts to protect our proprietary position using a variety of methods, which include pursuit of United States and foreign patent applications related to our proprietary technology, inventions and improvements that we determine are important to our business. We also may rely on trade secrets, trademarks, know-how, continuing technological innovation and potential in-licensing and acquisition opportunities to develop and maintain our proprietary position. For more information regarding risks relating to intellectual property, please see &#8220;Risk Factors&#8212;Risks Related to Our Intellectual Property.&#8221;</p>
<p style="margin-top:6pt;margin-bottom:6pt;text-indent:4.76%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have invested heavily in the protection of our key assets, namely the VeriStrat&#174; and GeneStrat&#174; tests, and we acquired a patent portfolio relating to the Nodify XL2&#174; and Nodify CDT&#8482; tests in our acquisitions of Integrated Diagnostics in June 2018, and of Oncimmune USA in October 2019 from<span style="letter-spacing:0.05pt;"> </span>Oncimmune Limited (Oncimmune). We own patents and patent applications as well as trade secrets relating to our products currently in development,<span style="letter-spacing:0.05pt;"> </span>collection device for whole blood, business strategy, client lists and business methods. Further, we have expanded our access to key intellectual property<span style="letter-spacing:0.05pt;"> </span>through<span style="letter-spacing:-0.25pt;"> </span>license<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.25pt;"> </span>co-development<span style="letter-spacing:-0.2pt;"> </span>agreements,<span style="letter-spacing:-0.25pt;"> </span>including<span style="letter-spacing:-0.25pt;"> </span>our<span style="letter-spacing:-0.25pt;"> </span>Non-Exclusive<span style="letter-spacing:-0.2pt;"> </span>License<span style="letter-spacing:-0.25pt;"> </span>Agreement<span style="letter-spacing:-0.25pt;"> </span>with<span style="letter-spacing:-0.25pt;"> </span>Bio-Rad<span style="letter-spacing:-0.2pt;"> </span>(the<span style="letter-spacing:-0.25pt;"> </span>Bio-Rad<span style="letter-spacing:-0.25pt;"> </span>License),<span style="letter-spacing:-0.2pt;"> </span>which<span style="letter-spacing:-0.25pt;"> </span>allows<span style="letter-spacing:-0.25pt;"> </span>us<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>use<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>Droplet<span style="letter-spacing:-0.05pt;"> </span>Digital<span style="letter-spacing:-0.1pt;"> </span>PCR&#8482;<span style="letter-spacing:0.35pt;"> </span>technology<span style="letter-spacing:-0.1pt;"> </span>developed<span style="letter-spacing:-0.05pt;"> </span>by<span style="letter-spacing:-0.1pt;"> </span>Bio-Rad<span style="letter-spacing:-0.05pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>which<span style="letter-spacing:-0.05pt;"> </span>we<span style="letter-spacing:-0.1pt;"> </span>employ<span style="letter-spacing:-0.05pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>GeneStrat<span style="letter-spacing:-0.1pt;"> </span>test.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:0pt;margin-bottom:6pt;text-indent:4.8%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our patent strategy has focused on creating and acquiring protection for our VeriStrat and Nodify XL2 proteomic tests, while utilizing trade secret</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and some methods patent protection for our genomic test (the GeneStrat test) and ELISA test (the Nodify CDT test). We have entered into a non-exclusive</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">license agreement with Bio-Rad, without the right to grant sublicenses, to utilize certain of Bio-Rad&#8217;s intellectual property, machinery, materials, reagents,</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">supplies and know-how necessary for the performance of ddPCR in cancer detection testing for third parties in the United States. For more information</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">regarding this license and supply agreement, please see &#8220;&#8212;</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Material Agreements&#8212;Agreements with Bio-Rad.&#8221; Bio-Rad owns patents relating to ddPCR</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and to which we have a non-exclusive license to utilize for the performance of ddPCR in cancer detection testing for third parties as set forth in the Bio-</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Rad License Agreement. In addition, we have separately been granted permission by Bio-Rad to use the Bio-Rad SARS-CoV-2 ddPCR </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">test</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and Platelia</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SARS-CoV-2 Total Ab </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">test</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for commercial diagnostic services. For more information regarding the permission granted to us by Bio-Rad with respect to</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">such</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">tests,</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">please</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">see</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;Business&#8212;Material</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Agreements&#8212;Agreements</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">with</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Bio-Rad.&#8221;</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">are</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">unaware</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">patents</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">owned</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">by</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Bio-Rad</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">relating</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">its</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">COVID-</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19 antibody test but acknowledge that Bio-Rad has know-how and trade secrets relating to this </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">test</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. We have patent protection in the United States and</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">other countries around the world for the primary use of the VeriStrat test for profiling of patients with NSCLC, and various other uses of the VeriStrat test,</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">such as breast cancer, prostate cancer, head and neck cancer have received patent protection. We have also received patent protection relating to our core</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">classifier development program, our Diagnostic Cortex</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#174; </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">technologies and our approaches to using mass shot matrix-assisted laser desorption time of flight</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="letter-spacing:-2.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(MALDI-T</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">oF</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">) technology (DeepMALDI</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#174; </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">techniques). Additionally, our first device patent was issued in 2019 for our internally designed blood</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">co</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">llection</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">device.</span></p>
<p style="margin-top:4pt;margin-bottom:6pt;text-indent:4.8%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of October 21, 2020, our patent portfolio includes approximately 49 issued United States patents, 38 issued foreign patents, which includes 3<span style="letter-spacing:0.05pt;"> </span>European<span style="letter-spacing:-0.25pt;"> </span>patents<span style="letter-spacing:-0.2pt;"> </span>that<span style="letter-spacing:-0.25pt;"> </span>were<span style="letter-spacing:-0.2pt;"> </span>nationalized<span style="letter-spacing:-0.2pt;"> </span>in<span style="letter-spacing:-0.25pt;"> </span>multiple<span style="letter-spacing:-0.2pt;"> </span>European<span style="letter-spacing:-0.2pt;"> </span>countries,<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>40<span style="letter-spacing:-0.2pt;"> </span>pending<span style="letter-spacing:-0.25pt;"> </span>applications<span style="letter-spacing:-0.2pt;"> </span>(including<span style="letter-spacing:-0.2pt;"> </span>23<span style="letter-spacing:-0.2pt;"> </span>foreign<span style="letter-spacing:-0.2pt;"> </span>patent<span style="letter-spacing:0.05pt;"> </span>applications). With regard to our product development efforts, provisional applications have been filed around new developments relating to ARDS and COVID diagnostics, and national stage applications are now in active prosecution to protect our ROR and PIR<span style="letter-spacing:-0.1pt;"> </span>tests.</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:4.8%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<span style="letter-spacing:-0.15pt;"> </span>patent<span style="letter-spacing:-0.15pt;"> </span>portfolio<span style="letter-spacing:-0.15pt;"> </span>can<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>broken<span style="letter-spacing:-0.15pt;"> </span>down<span style="letter-spacing:-0.15pt;"> </span>into<span style="letter-spacing:-0.15pt;"> </span>5<span style="letter-spacing:-0.15pt;"> </span>categories:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:-0.05pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:-0.05pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:-0.05pt;">1)</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:-0.05pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Issued</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">patents</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">patent</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">applications</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">relating</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">VeriStrat</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">Nodify</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">tests</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">uses</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">these</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">tests&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:-0.05pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:-0.05pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:-0.05pt;">2)</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:-0.05pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Issued</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">patents</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">patent</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">applications</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">relating</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">methods</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">for</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">developing</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">classifiers</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">using</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">Diagnostic</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">Cortex</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">DeepMALDI</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">technologies&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:-0.05pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:-0.05pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:-0.05pt;">3)</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:-0.05pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Issued</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">patents</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">patent</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">applications</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">relating</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">tests</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">currently</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">in</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">development&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:-0.05pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:-0.05pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:-0.05pt;">4)</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:-0.05pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Issued</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">patents</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">patent</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">applications</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">relating</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">novel</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">blood</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">collection</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">device&#59;</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:-0.05pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:-0.05pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:-0.05pt;">5)</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:-0.05pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Issued</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">patents</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">patent</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">applications</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">relating</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">tests</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">developed</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">for</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">third-party</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">partners.</span></p></td></tr></table></div>
<p style="margin-top:0pt;margin-bottom:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:4.8%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<span style="letter-spacing:-0.2pt;"> </span>patents<span style="letter-spacing:-0.2pt;"> </span>relating<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.2pt;"> </span>VeriStrat<span style="letter-spacing:-0.2pt;"> </span>test<span style="letter-spacing:-0.2pt;"> </span>are<span style="letter-spacing:-0.2pt;"> </span>scheduled<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.2pt;"> </span>expire<span style="letter-spacing:-0.2pt;"> </span>between<span style="letter-spacing:-0.2pt;"> </span>2026<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>2032.<span style="letter-spacing:-0.2pt;"> </span>The<span style="letter-spacing:-0.2pt;"> </span>patents<span style="letter-spacing:-0.2pt;"> </span>relating<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.2pt;"> </span>Nodify<span style="letter-spacing:-0.2pt;"> </span>XL2<span style="letter-spacing:-0.2pt;"> </span>test<span style="letter-spacing:-0.2pt;"> </span>are<span style="letter-spacing:-0.2pt;"> </span>scheduled<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>expire beginning in 2031 (excluding any patent term extension granted by the USPTO), and the patents relating to the Nodify CDT test are scheduled to<span style="letter-spacing:0.05pt;"> </span>expire in 2027. The patent related to the blood collection device is scheduled to expire in 2039. Should our current patent applications in prosecution in the<span style="letter-spacing:-2.1pt;"> </span>United States issue, the resulting patents would be scheduled to have expiration dates between 2036 and 2040 (excluding any patent term extension(s)<span style="letter-spacing:0.05pt;"> </span>granted<span style="letter-spacing:-0.1pt;"> </span>by<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>USPTO).</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:4.8%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">While we do not currently have any pending PCT applications, we often convert provisional patent applications to PCT applications. PCT patent applications are not eligible to become issued patents until, among other things, we file such PCT applications as national stage<span style="letter-spacing:0.05pt;"> </span>patent application(s) within 30 months in the countries in which we seek patent protection. If we do not timely file any national stage patent applications,<span style="letter-spacing:0.05pt;"> </span>we may lose our priority date with respect to any such PCT patent applications and any patent protection on the inventions disclosed in such PCT patent<span style="letter-spacing:0.05pt;"> </span>applications. Provisional patent applications are not eligible to become issued patents but can become the basis of PCT foreign stage and United States non-provisional<span style="letter-spacing:0.05pt;"> </span>patent<span style="letter-spacing:-0.25pt;"> </span>applications,<span style="letter-spacing:-0.2pt;"> </span>if<span style="letter-spacing:-0.2pt;"> </span>such<span style="letter-spacing:-0.2pt;"> </span>applications<span style="letter-spacing:-0.2pt;"> </span>are<span style="letter-spacing:-0.2pt;"> </span>filed<span style="letter-spacing:-0.2pt;"> </span>within<span style="letter-spacing:-0.2pt;"> </span>12<span style="letter-spacing:-0.2pt;"> </span>months<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.2pt;"> </span>filing<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.2pt;"> </span>related<span style="letter-spacing:-0.2pt;"> </span>provisional<span style="letter-spacing:-0.2pt;"> </span>patent<span style="letter-spacing:-0.2pt;"> </span>application.<span style="letter-spacing:0.05pt;"> </span>If we do not timely file any non-provisional patent applications, we will lose our priority date and any patent protection on the inventions disclosed in any<span style="letter-spacing:0.05pt;"> </span>such<span style="letter-spacing:-0.1pt;"> </span>provisional<span style="letter-spacing:-0.05pt;"> </span>patent<span style="letter-spacing:-0.05pt;"> </span>application.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:4.8%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, the term of individual issued patents depends upon the legal term for patents in the countries in which they are obtained. In most</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">countries in which we have filed, including the United States, the patent term is generally 20 years from the earliest filing date of a non-provisional patent</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">application, assuming</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">patent has</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">not</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">been terminally</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">disclaimed</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">over a</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">commonly-owned</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">patent</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or a</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">patent</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">naming a</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">common</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">inventor, or</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">over</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">patent not commonly owned but that was disqualified as prior art as the result of activities undertaken within the scope of a joint research agreement. The</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">life of a patent, and the protection it affords, is therefore limited and once the patent </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">lives of our issued patents have expired, we may face competition,</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">including</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">from</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">other</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">competing</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">technologies.</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">United</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">States,</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">term</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">patent</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">also</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">be</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">eligible</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">patent</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">term</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">adjustment</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">delays</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">within</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">USPTO. The term of a patent that covers a biological product may also be eligible for patent term extension when FDA approval is granted for a portion of</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the term effectively lost as a result of the FDA regulatory review period, subject to certain limitations and provided statutory and regulatory requirements</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">are met. Any such patent term extension can be for no more than five years, only one patent per approved product can be extended, the extension cannot</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">extend the total patent term beyond 14 years from approval, and only those claims covering the approved biological product, a method for using it or a</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">method for manufacturing it may be extended. We may not receive an extension if we fail to exercise due diligence during the testing phase or regulatory</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">review process, fail to apply within applicable deadlines, fail to apply prior to expiration of relevant patents or otherwise fail to satisfy applicable</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">requirements. Moreover, the length of the extension could be less than we request. There can be no assurance that we will benefit from any patent term</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">extension</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">favorable</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">adjustment</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">term</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">any</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">patents.</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">result,</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">owned</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">licensed</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">patent</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">portfolio</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">not</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">provide</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">us</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">with</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">sufficient</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">rights</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">exclude</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">others</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">from</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">commercializing</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">products</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">similar</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">identical</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ours.</span></p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:4.8%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our<span style="letter-spacing:-0.2pt;"> </span>ability<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.2pt;"> </span>maintain<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>solidify<span style="letter-spacing:-0.2pt;"> </span>our<span style="letter-spacing:-0.2pt;"> </span>proprietary<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>intellectual<span style="letter-spacing:-0.2pt;"> </span>property<span style="letter-spacing:-0.2pt;"> </span>position<span style="letter-spacing:-0.2pt;"> </span>will<span style="letter-spacing:-0.15pt;"> </span>depend<span style="letter-spacing:-0.2pt;"> </span>on<span style="letter-spacing:-0.2pt;"> </span>our<span style="letter-spacing:-0.2pt;"> </span>success<span style="letter-spacing:-0.2pt;"> </span>in<span style="letter-spacing:-0.2pt;"> </span>obtaining<span style="letter-spacing:-0.2pt;"> </span>effective<span style="letter-spacing:-0.2pt;"> </span>patent<span style="letter-spacing:-0.2pt;"> </span>claims<span style="letter-spacing:0.05pt;"> </span>and maintaining and enforcing claims that are granted. However, our owned and licensed patents could be invalidated or narrowed or otherwise fail to<span style="letter-spacing:0.05pt;"> </span>adequately protect our proprietary and intellectual property position and our pending owned and licensed patent applications, and any patent applications<span style="letter-spacing:0.05pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>may<span style="letter-spacing:-0.05pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>future<span style="letter-spacing:-0.05pt;"> </span>file<span style="letter-spacing:-0.1pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>license<span style="letter-spacing:-0.05pt;"> </span>from<span style="letter-spacing:-0.05pt;"> </span>third<span style="letter-spacing:-0.1pt;"> </span>parties,<span style="letter-spacing:-0.05pt;"> </span>may<span style="letter-spacing:-0.05pt;"> </span>not<span style="letter-spacing:-0.1pt;"> </span>result<span style="letter-spacing:-0.05pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>issuance<span style="letter-spacing:-0.05pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>patents.</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:4.81%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because branding is as much a part of any intellectual property strategy as patent or trade secret protection we have a number of registered and<span style="letter-spacing:0.05pt;"> </span>pending trademarks relating to our company and products. We have received or filed for trademark protection in the United States for our tradename<span style="letter-spacing:0.05pt;"> </span>(Biodesix),<span style="letter-spacing:-0.25pt;"> </span>the<span style="letter-spacing:-0.2pt;"> </span>names<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.2pt;"> </span>four<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.2pt;"> </span>our<span style="letter-spacing:-0.2pt;"> </span>commercial<span style="letter-spacing:-0.2pt;"> </span>tests<span style="letter-spacing:-0.2pt;"> </span>(namely<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.2pt;"> </span>VeriStrat,<span style="letter-spacing:-0.25pt;"> </span>GeneStrat,<span style="letter-spacing:-0.2pt;"> </span>Nodify<span style="letter-spacing:-0.2pt;"> </span>XL2<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>Nodify<span style="letter-spacing:-0.2pt;"> </span>CDT<span style="letter-spacing:-0.2pt;"> </span>tests),<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>a<span style="letter-spacing:-0.2pt;"> </span>suite<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.25pt;"> </span>research<span style="letter-spacing:-0.2pt;"> </span>tests<span style="letter-spacing:0.05pt;"> </span>(ImmunoStrat), as well as having trademark protection for our core development and methodological platforms, such as our Diagnostic Cortex and<span style="letter-spacing:0.05pt;"> </span>DeepMALDI technologies. In all, as of September 21, 2020, we have 22 uniquely registered United States trademarks 10 of which (including Biodesix,<span style="letter-spacing:0.05pt;"> </span>VeriStrat,<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.25pt;"> </span>GeneStrat)<span style="letter-spacing:-0.25pt;"> </span>have<span style="letter-spacing:-0.25pt;"> </span>received<span style="letter-spacing:-0.25pt;"> </span>foreign<span style="letter-spacing:-0.25pt;"> </span>issuances<span style="letter-spacing:-0.25pt;"> </span>as<span style="letter-spacing:-0.25pt;"> </span>well.<span style="letter-spacing:-0.25pt;"> </span>We<span style="letter-spacing:-0.25pt;"> </span>will<span style="letter-spacing:-0.25pt;"> </span>continue<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.25pt;"> </span>pursue<span style="letter-spacing:-0.2pt;"> </span>protection<span style="letter-spacing:-0.25pt;"> </span>in<span style="letter-spacing:-0.25pt;"> </span>the<span style="letter-spacing:-0.25pt;"> </span>United<span style="letter-spacing:-0.25pt;"> </span>States<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.25pt;"> </span>abroad<span style="letter-spacing:-0.25pt;"> </span>for<span style="letter-spacing:-0.25pt;"> </span>our<span style="letter-spacing:-0.25pt;"> </span>branded<span style="letter-spacing:0.05pt;"> </span>assets<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>will<span style="letter-spacing:-0.2pt;"> </span>continue<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.2pt;"> </span>use<span style="letter-spacing:-0.2pt;"> </span>branding<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.2pt;"> </span>protect<span style="letter-spacing:-0.2pt;"> </span>products<span style="letter-spacing:-0.2pt;"> </span>currently<span style="letter-spacing:-0.2pt;"> </span>in<span style="letter-spacing:-0.2pt;"> </span>development,<span style="letter-spacing:-0.2pt;"> </span>key<span style="letter-spacing:-0.2pt;"> </span>Biodesix<span style="letter-spacing:-0.2pt;"> </span>developments<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>non-trade<span style="letter-spacing:-0.2pt;"> </span>secret<span style="letter-spacing:-0.2pt;"> </span>methodologies.</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:4.81%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We also rely on trade secrets, including know how, confidential information, unpatented technologies and other proprietary information, to strengthen or enhance our competitive position, protect and maintain aspects of our business that are not amenable to, or that we do not presently consider appropriate for, patent protection, and prevent competitors from reverse engineering or copying our technologies. We have decided that some technologies, such as our laboratory methodologies (including sample preparation and assay development), and some information (such as client and billing information) are best kept as trade secrets. However, trade secrets and confidential know-how are difficult to protect. To avoid inadvertent and improper disclosure of trade secrets, and to avoid the risks of former employees using these trade secrets to future employment, it is our policy to require employees, consultants and independent contractors to assign all rights to intellectual property they develop in connection with their employment with or services for the Company to the Company. We also protect our existing and developing intellectual property expressly through confidentiality provisions in agreements with third parties. There can be no assurance, however, that these agreements will be self-executing or otherwise provide meaningful protection for our trade secrets or other intellectual property or proprietary information, or adequate remedies in the event of unauthorized use or disclosure of such trade secrets or other intellectual property or proprietary information.</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:4.81%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We also seek to preserve the integrity and confidentiality of our trade secrets and other confidential information by maintaining physical security of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.2pt;"> </span>premises<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>physical<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>electronic<span style="letter-spacing:-0.2pt;"> </span>security<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.15pt;"> </span>our<span style="letter-spacing:-0.2pt;"> </span>information<span style="letter-spacing:-0.2pt;"> </span>technology<span style="letter-spacing:-0.2pt;"> </span>systems.<span style="letter-spacing:-0.15pt;"> </span>While<span style="letter-spacing:-0.2pt;"> </span>we<span style="letter-spacing:-0.2pt;"> </span>have<span style="letter-spacing:-0.2pt;"> </span>confidence<span style="letter-spacing:-0.2pt;"> </span>in<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.2pt;"> </span>measures<span style="letter-spacing:-0.2pt;"> </span>we<span style="letter-spacing:-0.2pt;"> </span>take<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.2pt;"> </span>protect<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>preserve our trade secrets, such measures can be breached, and we may not have adequate remedies for any such breach. In addition, our trade secrets may<span style="letter-spacing:0.05pt;"> </span>otherwise<span style="letter-spacing:-0.1pt;"> </span>become<span style="letter-spacing:-0.05pt;"> </span>known<span style="letter-spacing:-0.05pt;"> </span>or<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>independently<span style="letter-spacing:-0.05pt;"> </span>discovered<span style="letter-spacing:-0.05pt;"> </span>by<span style="letter-spacing:-0.1pt;"> </span>competitors.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:4.8%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">intend</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">pursue</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">additional</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">intellectual</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">property</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">protection</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">extent</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">believe</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">it</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">would</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">advance</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">business</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">objectives,</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">which</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">include</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">objectives within and outside the United States. Despite our efforts to protect our intellectual property rights, and despite the breadth of protection that has</span><span style="letter-spacing:-2.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">issued around our key assets, these rights may not be respected in the future or may be circumvented or challenged (and potentially invalidated) in a legal</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">proceeding in any jurisdiction where we have intellectual property rights. In addition, the laws of various </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">foreign countries where we have received</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">intellectual property protection and where we may eventually distribute our products may not afford the same protections or assurances to the same extent</span><span style="letter-spacing:-2.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">as the laws in the United States. See &#8220;Risk Factors&#8212;Risks Related to Our Intellectual Property&#8221; for additional information regarding these and other risks</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">related</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">intellectual</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">property</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">portfolio</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">their</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">potential</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">effect</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">on</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">us.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#auto;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Government<span style="letter-spacing:-0.25pt;"> </span>Regulations</p>
<p style="margin-top:5pt;margin-bottom:6pt;text-indent:4.8%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical laboratory tests like our diagnostic tests are regulated under CLIA and State law. The FDA regulates medical devices pursuant to the<span style="letter-spacing:0.05pt;"> </span>FDCA, including many diagnostic test kits, such as IVDs. However, most LDTs are not currently subject to the FDA&#8217;s regulation (although reagents,<span style="letter-spacing:0.05pt;"> </span>instruments, software or components provided by third parties and used to perform LDTs may be subject to such regulation) because the FDA has<span style="letter-spacing:0.05pt;"> </span>historically exercised enforcement discretion over LDTs. LDTs are a subset of in vitro diagnostic (IVD) tests that are intended for clinical use and<span style="letter-spacing:0.05pt;"> </span>developed,<span style="letter-spacing:-0.3pt;"> </span>validated,<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.3pt;"> </span>offered<span style="letter-spacing:-0.25pt;"> </span>within<span style="letter-spacing:-0.3pt;"> </span>a<span style="letter-spacing:-0.3pt;"> </span>single<span style="letter-spacing:-0.3pt;"> </span>laboratory<span style="letter-spacing:-0.3pt;"> </span>for<span style="letter-spacing:-0.25pt;"> </span>use<span style="letter-spacing:-0.3pt;"> </span>only<span style="letter-spacing:-0.3pt;"> </span>in<span style="letter-spacing:-0.3pt;"> </span>that<span style="letter-spacing:-0.25pt;"> </span>laboratory.<span style="letter-spacing:-0.3pt;"> </span>FDA&#8217;s<span style="letter-spacing:-0.3pt;"> </span>authority<span style="letter-spacing:-0.3pt;"> </span>to<span style="letter-spacing:-0.25pt;"> </span>regulate<span style="letter-spacing:-0.3pt;"> </span>LDTs<span style="letter-spacing:-0.3pt;"> </span>has<span style="letter-spacing:-0.3pt;"> </span>been<span style="letter-spacing:-0.25pt;"> </span>contested<span style="letter-spacing:-0.3pt;"> </span>for<span style="letter-spacing:-0.3pt;"> </span>many<span style="letter-spacing:0.05pt;"> </span>years,<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>there<span style="letter-spacing:-0.2pt;"> </span>have<span style="letter-spacing:-0.2pt;"> </span>been<span style="letter-spacing:-0.2pt;"> </span>several<span style="letter-spacing:-0.2pt;"> </span>legislative<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>administrative<span style="letter-spacing:-0.2pt;"> </span>proposals<span style="letter-spacing:-0.2pt;"> </span>regarding<span style="letter-spacing:-0.2pt;"> </span>LDT<span style="letter-spacing:-0.2pt;"> </span>regulation<span style="letter-spacing:-0.2pt;"> </span>seeking<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.2pt;"> </span>end<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:-0.2pt;"> </span>limit<span style="letter-spacing:-0.2pt;"> </span>enforcement<span style="letter-spacing:-0.2pt;"> </span>discretion<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>bring<span style="letter-spacing:-0.1pt;"> </span>LDTs<span style="letter-spacing:-0.05pt;"> </span>under<span style="letter-spacing:-0.05pt;"> </span>new<span style="letter-spacing:-0.1pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>existing<span style="letter-spacing:-0.05pt;"> </span>FDA<span style="letter-spacing:-0.05pt;"> </span>regulatory<span style="letter-spacing:-0.1pt;"> </span>frameworks:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">On</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">July</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">9,</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">2012,</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">Congress</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">passed</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">legislation</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">in</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.2pt;color:#000000;"> Food and Drug Administration Safety and Innovation Act of 2012 (</span><span style="color:#000000;">FDASIA</span><span style="letter-spacing:-0.2pt;color:#000000;">) </span><span style="color:#000000;">requiring</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">agency</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">notify</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">Committee</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">on</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">Health,</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">Education,</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">Labor,</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">Pensions and the House Committee on Energy and Commerce of its intent to regulate LDTs. This law, though enacted, had a 5-year sunset</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">provision,</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">meaning</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">that</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">FDA</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">is</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">no</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">longer</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">subject</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">this</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">notification</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">requirement.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">In</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">October</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">2014,</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">FDA</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">issued</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">two</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">draft</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">guidance</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">documents:</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="font-style:italic;color:#000000;">Framework</span><span style="font-style:italic;letter-spacing:-0.25pt;color:#000000;"> </span><span style="font-style:italic;color:#000000;">for</span><span style="font-style:italic;letter-spacing:-0.25pt;color:#000000;"> </span><span style="font-style:italic;color:#000000;">Regulatory</span><span style="font-style:italic;letter-spacing:-0.25pt;color:#000000;"> </span><span style="font-style:italic;color:#000000;">Oversight</span><span style="font-style:italic;letter-spacing:-0.3pt;color:#000000;"> </span><span style="font-style:italic;color:#000000;">of</span><span style="font-style:italic;letter-spacing:-0.25pt;color:#000000;"> </span><span style="font-style:italic;color:#000000;">Laboratory</span><span style="font-style:italic;letter-spacing:-0.25pt;color:#000000;"> </span><span style="font-style:italic;color:#000000;">Developed</span><span style="font-style:italic;letter-spacing:-0.25pt;color:#000000;"> </span><span style="font-style:italic;color:#000000;">Tests</span><span style="color:#000000;">,</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">which</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">provided an overview of how the FDA would regulate LDTs through a risk-based approach, and </span><span style="font-style:italic;color:#000000;">FDA Notification and Medical Device</span><span style="font-style:italic;letter-spacing:0.05pt;color:#000000;"> </span><span style="font-style:italic;letter-spacing:-0.05pt;color:#000000;">Reporting for Laboratory Developed Tests</span><span style="letter-spacing:-0.05pt;color:#000000;">, which provided </span><span style="color:#000000;">guidance on how the FDA intended to collect information on existing LDTs,</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">including adverse event reports. In the Framework for Regulatory Oversight draft guidance, the FDA asserted that LDT manufacturers would</span><span style="letter-spacing:-2.1pt;color:#000000;"> </span><span style="color:#000000;">be subject to medical device premarket submission, registration, listing, and adverse event reporting requirements phased in over several</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">years</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">based</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">on</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">which</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">tests</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">posed</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">highest</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">risk</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">public</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">health.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">On</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">November</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">18,</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">2016,</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">however,</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">FDA</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">announced</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">that</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">it</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">would</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">not</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">release</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">final</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">guidance</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">would</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">instead</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">continue</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">work</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">with</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">stakeholders,</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">new</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">administration,</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">Congress</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">determine</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">right</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">approach.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">On</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">January</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">13,</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">2017,</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">FDA</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">released</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">a</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">discussion</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">paper</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">on</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">possible</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">approaches</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">regulate</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">LDTs</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">in</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">which</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">it</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">described</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">a</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">policy</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">wherein</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">previously marketed LDTs would not be expected to comply with most or all FDA oversight requirements, except for adverse event and</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">malfunction reporting. In addition, certain new and significantly modified LDTs would not be expected to comply with pre-market review</span><span style="letter-spacing:-2.1pt;color:#000000;"> </span><span style="color:#000000;">unless</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">agency</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">determines</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">certain</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">tests</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">could</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">lead</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">patient</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">harm.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">In</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">March</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">2017,</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">draft</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">Diagnostic</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">Accuracy</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">Innovation</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">Act</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">(DAIA)</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">was</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">introduced</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">outlined</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">a</span><span style="letter-spacing:-0.2pt;color:#000000;"> risk-based </span><span style="color:#000000;">regulatory</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">approach</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">for</span><span style="letter-spacing:-0.2pt;color:#000000;"> in vitro clinical tests (</span><span style="color:#000000;">IVCT),</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">i.e.,</span><span style="letter-spacing:-0.1pt;color:#000000;"> all </span><span style="color:#000000;">IVDs</span><span style="letter-spacing:-0.05pt;color:#000000;"> regardless of whether they are commercially distributed diagnostic kits </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">LDTs.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">In</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">April</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">2017,</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">FDA</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">issued</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">a</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">document</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">describing</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">20</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">case</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">studies</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">LDTs</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">that</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">raised</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">concerns</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">about</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">safety</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">efficacy</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">this</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">category</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">tests.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">In August 2018, the FDA responded to the DAIA draft with its own proposal for IVCTs, including PMA, provisional approval, and</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">precertification,</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">in</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">addition</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">authority</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">revoke</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">approval,</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">request</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">raw</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">data,</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">take</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">corrective</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">action</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">against</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">test</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">developers</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">protect</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">public</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">health.</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="text-decoration:none;Background-color:#auto;"></span><span style="color:#000000;"></span><span style="color:#000000;">On October 31, 2018, the FDA issued its Safety Communication entitled &#8220;The FDA Warns Against the Use of Many Genetic Tests with</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">Unapproved Claims to Predict Patient Response to Specific Medications&#8221; alleging that the agency was &#8220;aware&#8221; of healthcare providers</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">making &#8220;inappropriate changes to a patient&#8217;s antidepressant medication based on the results from genetic tests.&#8221; Following this Safety Alert,</span><span style="letter-spacing:-2.1pt;color:#000000;"> </span><span style="color:#000000;">the FDA contacted several laboratories that offered tests that made claims regarding drug responses for specific medications. While most</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">laboratories</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">addressed</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">FDA&#8217;s</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">concerns</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">by</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">removing</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">specific</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">medication</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">names</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">from</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">their</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">labeling,</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">FDA</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">issued</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">an</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">enforcement</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">letter</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">against</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">a</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">laboratory</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">for</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">making</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">such</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">claims</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">without</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">first</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">undergoing</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">FDA</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">premarket</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">review.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">In</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">December</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">2018,</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">a</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">new</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">draft</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">bill</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">which</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">revised</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">DAIA</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">incorporated</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">feedback</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">from</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">FDA</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">was</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">released.</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">The</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">Verifying</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">Accurate,</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">Leading-edge,</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">IVCT</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">Development</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">(VALID)</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">Act</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">creates</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">a</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">risk-based</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">regulatory</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">framework</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">for</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">IVCT</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">regulation. Under the VALID Act framework, premarket review would be required for certain higher risk tests, while lower risk tests would be subject to a precertification pathway.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:4pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:4pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:4pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">On April 4, 2019, the FDA issued a warning letter to Inova Genomics Laboratory for its pharmacogenomics tests, i.e., tests that predict</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">medication</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">response,</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">among</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">other</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">things.</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">In</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">this</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">letter,</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">FDA</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">rebutted</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">Inova&#8217;s</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">argument</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">that</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">it</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">believed</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">it</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">was</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">operating</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">within</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">scope</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">of FDA&#8217;s LDT exemption and not subject to the FDA&#8217;s premarket review or labeling requirements by noting that the FDA has not created a</span><span style="letter-spacing:-2.1pt;color:#000000;"> </span><span style="color:#000000;">legal</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">&#8220;carve-out&#8221;</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">exemption</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">for</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">LDTs</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">that</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">it</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">ultimately</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">retains</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">discretion</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">take</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">action</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">when</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">appropriate.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">On</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">March</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">5,</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">2020,</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">identical</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">versions</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">VALID</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">Act</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">were</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">introduced</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">in</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">both</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">chambers</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">Congress.&#160;&#160;The same day, the House bill was referred to the House Committee on Energy and Commerce.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">On</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">August</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">19,</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">2020,</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">HHS</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">announced</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">a</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">new</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">policy</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">determining</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">that</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">FDA</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">must</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">engage</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">in</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">notice-and-comment</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">rulemaking</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">before</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">requiring</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">premarket</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">review</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">LDTs.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">On Nov. 16, 2020, HHS directed FDA to review voluntarily submitted EUAs for LDTs&#59; if FDA&#8217;s review time exceeds 14 days, the submission would be referred to the National Institute of Health National Cancer Institute and also to other scientific government agencies, or to outside technical contractors if FDA remains unable to conduct the reviews. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.81%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We currently market our GeneStrat, VeriStrat, Nodify XL2 and Nodify CDT tests as LDTs in the United States. As a result, we believe our diagnostic services are not currently subject to the FDA&#8217;s enforcement of its medical device regulations and the applicable FDCA provisions. If the FDA disagrees with the LDT status of any of our tests, the FDA may consider the test to be an unapproved medical device and may subject us to FDA enforcement action, including, without limitation, requiring us to seek clearance, authorization or approval for the laboratory test. If the FDA were to begin enforcement with respect to our LDTs, we could incur substantial costs and delays associated with trying to obtain pre-market clearance or approval and costs associated with complying with post-market requirements.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.81%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To<span style="letter-spacing:-0.25pt;"> </span>date,<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.2pt;"> </span>FDA<span style="letter-spacing:-0.2pt;"> </span>has<span style="letter-spacing:-0.25pt;"> </span>not<span style="letter-spacing:-0.2pt;"> </span>engaged<span style="letter-spacing:-0.2pt;"> </span>in<span style="letter-spacing:-0.2pt;"> </span>notice-and-comment<span style="letter-spacing:-0.25pt;"> </span>rulemaking<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:-0.2pt;"> </span>released<span style="letter-spacing:-0.2pt;"> </span>broad-sweeping<span style="letter-spacing:-0.25pt;"> </span>guidance,<span style="letter-spacing:-0.2pt;"> </span>but<span style="letter-spacing:-0.2pt;"> </span>it<span style="letter-spacing:-0.2pt;"> </span>could<span style="letter-spacing:-0.25pt;"> </span>choose<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.2pt;"> </span>do<span style="letter-spacing:-0.2pt;"> </span>so<span style="letter-spacing:-0.25pt;"> </span>in<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.2pt;"> </span>future<span style="letter-spacing:0.05pt;"> </span>and if pre-market review is required, our business could be negatively impacted as a result of commercial delay that may be caused by the new<span style="letter-spacing:0.05pt;"> </span>requirements.<span style="letter-spacing:-0.25pt;"> </span>The<span style="letter-spacing:-0.2pt;"> </span>cost<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.2pt;"> </span>conducting<span style="letter-spacing:-0.25pt;"> </span>clinical<span style="letter-spacing:-0.2pt;"> </span>trials<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>otherwise<span style="letter-spacing:-0.2pt;"> </span>developing<span style="letter-spacing:-0.25pt;"> </span>data<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>information<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.25pt;"> </span>support<span style="letter-spacing:-0.2pt;"> </span>pre-market<span style="letter-spacing:-0.2pt;"> </span>applications<span style="letter-spacing:-0.2pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>be<span style="letter-spacing:-0.25pt;"> </span>significant.<span style="letter-spacing:-0.2pt;"> </span>If<span style="letter-spacing:0.05pt;"> </span>we are required to submit applications for our currently marketed tests, we may be required to conduct additional studies, which may be time-consuming,<span style="letter-spacing:0.05pt;"> </span>costly and could result in our currently-marketed tests being withdrawn from the market. Continued compliance with the FDA&#8217;s<span style="letter-spacing:0.05pt;"> </span>regulations would increase the cost of conducting our business, and subject us to heightened regulation by the FDA including penalties for failure to<span style="letter-spacing:0.05pt;"> </span>comply with these requirements. Failure to comply with applicable regulatory requirements could result in an enforcement action by the FDA, such as<span style="letter-spacing:0.05pt;"> </span>fines, product suspensions, warning letters, recalls, injunctions and other civil and criminal sanctions. There are other regulatory and legislative proposals<span style="letter-spacing:0.05pt;"> </span>that<span style="letter-spacing:-0.3pt;"> </span>would<span style="letter-spacing:-0.3pt;"> </span>increase<span style="letter-spacing:-0.3pt;"> </span>general<span style="letter-spacing:-0.25pt;"> </span>FDA<span style="letter-spacing:-0.3pt;"> </span>oversight<span style="letter-spacing:-0.3pt;"> </span>of<span style="letter-spacing:-0.3pt;"> </span>clinical<span style="letter-spacing:-0.25pt;"> </span>laboratories<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.3pt;"> </span>LDTs.<span style="letter-spacing:-0.25pt;"> </span>Until<span style="letter-spacing:-0.3pt;"> </span>the<span style="letter-spacing:-0.3pt;"> </span>FDA<span style="letter-spacing:-0.3pt;"> </span>finalizes<span style="letter-spacing:-0.25pt;"> </span>its<span style="letter-spacing:-0.3pt;"> </span>regulatory<span style="letter-spacing:-0.3pt;"> </span>position<span style="letter-spacing:-0.25pt;"> </span>regarding<span style="letter-spacing:-0.3pt;"> </span>LDTs,<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:-0.3pt;"> </span>the<span style="letter-spacing:-0.25pt;"> </span>VALID<span style="letter-spacing:0.05pt;"> </span>Act or other legislation is passed reforming the federal government&#8217;s regulation of LDTs, it is unknown how the FDA may regulate our tests in the future<span style="letter-spacing:0.05pt;"> </span>and what testing and data may be required to support any required clearance or approval. The outcome and ultimate impact of such proposals on the<span style="letter-spacing:0.05pt;"> </span>business is difficult to predict at this time and we are monitoring developments and anticipate that our products will be able to comply with requirements that<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>imposed<span style="letter-spacing:-0.1pt;"> </span>by<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>FDA.<span style="letter-spacing:-0.15pt;"> </span>In<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>meantime,<span style="letter-spacing:-0.1pt;"> </span>we<span style="letter-spacing:-0.15pt;"> </span>maintain<span style="letter-spacing:-0.1pt;"> </span>our<span style="letter-spacing:-0.15pt;"> </span>CLIA<span style="letter-spacing:-0.1pt;"> </span>accreditation,<span style="letter-spacing:-0.15pt;"> </span>which<span style="letter-spacing:-0.1pt;"> </span>permits<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>use<span style="letter-spacing:-0.1pt;"> </span>of<span style="letter-spacing:-0.15pt;"> </span>LDTs<span style="letter-spacing:-0.1pt;"> </span>for<span style="letter-spacing:-0.15pt;"> </span>diagnostics<span style="letter-spacing:-0.1pt;"> </span>purposes.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#auto;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;color:#auto;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FDA</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-weight:bold;color:#auto;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Emergency</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-weight:bold;color:#auto;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Use</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-weight:bold;color:#auto;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Authorization</span></p>
<p style="margin-top:5pt;margin-bottom:6pt;text-indent:4.8%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Section 564 of the FDCA allows the FDA to authorize the shipment of drugs, biological products, or medical devices that either lack required<span style="letter-spacing:0.05pt;"> </span>approval,<span style="letter-spacing:-0.25pt;"> </span>licensure,<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:-0.2pt;"> </span>clearance<span style="letter-spacing:-0.2pt;"> </span>(unapproved<span style="letter-spacing:-0.2pt;"> </span>products),<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:-0.2pt;"> </span>are<span style="letter-spacing:-0.2pt;"> </span>approved<span style="letter-spacing:-0.2pt;"> </span>but<span style="letter-spacing:-0.2pt;"> </span>are<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.2pt;"> </span>be<span style="letter-spacing:-0.2pt;"> </span>used<span style="letter-spacing:-0.2pt;"> </span>for<span style="letter-spacing:-0.2pt;"> </span>unapproved<span style="letter-spacing:-0.2pt;"> </span>ways<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.2pt;"> </span>diagnose,<span style="letter-spacing:-0.2pt;"> </span>treat,<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:-0.2pt;"> </span>prevent<span style="letter-spacing:-0.2pt;"> </span>serious<span style="letter-spacing:0.05pt;"> </span>diseases<span style="letter-spacing:-0.15pt;"> </span>or<span style="letter-spacing:-0.1pt;"> </span>conditions<span style="letter-spacing:-0.1pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>event<span style="letter-spacing:-0.1pt;"> </span>of<span style="letter-spacing:-0.1pt;"> </span>an<span style="letter-spacing:-0.1pt;"> </span>emergency<span style="letter-spacing:-0.1pt;"> </span>declaration<span style="letter-spacing:-0.1pt;"> </span>by<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>HHS<span style="letter-spacing:-0.1pt;"> </span>Secretary.<span style="letter-spacing:-0.1pt;"> </span>21<span style="letter-spacing:-0.1pt;"> </span>U.S.C.<span style="letter-spacing:-0.1pt;"> </span>&#167;<span style="letter-spacing:-0.1pt;"> </span>360bbb-3(a)(1)-(2).</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:4.8%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On February 4, 2020, HHS Secretary Alex M. Azar II declared a public health emergency for COVID-19, under 21 U.S.C. &#167; 360bbb-3(b)(1),<span style="letter-spacing:0.05pt;"> </span>justifying<span style="letter-spacing:-0.25pt;"> </span>the<span style="letter-spacing:-0.2pt;"> </span>authorization<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.2pt;"> </span>emergency<span style="letter-spacing:-0.25pt;"> </span>use<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.2pt;"> </span>IVDs<span style="letter-spacing:-0.2pt;"> </span>for<span style="letter-spacing:-0.25pt;"> </span>detection<span style="letter-spacing:-0.2pt;"> </span>and/or<span style="letter-spacing:-0.2pt;"> </span>diagnosis<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.2pt;"> </span>COVID-19.<span style="letter-spacing:-0.25pt;"> </span>This<span style="letter-spacing:-0.2pt;"> </span>determination<span style="letter-spacing:-0.2pt;"> </span>was<span style="letter-spacing:-0.2pt;"> </span>published<span style="letter-spacing:-0.25pt;"> </span>in<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.2pt;"> </span>Federal<span style="letter-spacing:0.05pt;"> </span>Register<span style="letter-spacing:-0.1pt;"> </span>on<span style="letter-spacing:-0.05pt;"> </span>February<span style="letter-spacing:-0.05pt;"> </span>7,<span style="letter-spacing:-0.05pt;"> </span>2020.<span style="letter-spacing:-0.1pt;"> </span>85<span style="letter-spacing:-0.05pt;"> </span>Fed.<span style="letter-spacing:-0.05pt;"> </span>Reg.<span style="letter-spacing:-0.05pt;"> </span>7316<span style="letter-spacing:-0.05pt;"> </span>(Feb.<span style="letter-spacing:-0.1pt;"> </span>7,<span style="letter-spacing:-0.05pt;"> </span>2020).</p>
<p style="margin-top:4pt;margin-bottom:6pt;text-indent:4.8%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">While<span style="letter-spacing:-0.25pt;"> </span>this<span style="letter-spacing:-0.2pt;"> </span>emergency<span style="letter-spacing:-0.2pt;"> </span>declaration<span style="letter-spacing:-0.2pt;"> </span>is<span style="letter-spacing:-0.2pt;"> </span>effective,<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.2pt;"> </span>FDA<span style="letter-spacing:-0.2pt;"> </span>may<span style="letter-spacing:-0.25pt;"> </span>authorize<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.2pt;"> </span>use<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.2pt;"> </span>an<span style="letter-spacing:-0.2pt;"> </span>unapproved<span style="letter-spacing:-0.2pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:-0.2pt;"> </span>an<span style="letter-spacing:-0.25pt;"> </span>unapproved<span style="letter-spacing:-0.2pt;"> </span>use<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.2pt;"> </span>an<span style="letter-spacing:-0.2pt;"> </span>approved<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:-0.1pt;"> </span>if<span style="letter-spacing:-0.05pt;"> </span>it<span style="letter-spacing:-0.05pt;"> </span>concludes<span style="letter-spacing:-0.05pt;"> </span>that:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">an</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">agent</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">referred</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">in</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">emergency</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">declaration</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">could</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">cause</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">a</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">serious</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">life-threatening</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">disease</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">condition&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">it</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">is</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">reasonable</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">believe</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">that</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">authorized</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">product</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">be</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">effective</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">in</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">diagnosing,</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">treating,</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">preventing</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">that</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">disease</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">condition</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">a</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">serious</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">life-threatening</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">disease</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">condition</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">caused</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">by</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">an</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">approved</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">product</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">a</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">product</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">marketed</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">under</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">an</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">EUA&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">known</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">potential</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">benefits</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">authorized</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">product,</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">when</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">used</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">for</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">that</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">disease</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">condition,</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">outweigh</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">known</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">potential</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">risks,</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">taking</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">into</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">consideration</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">material</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">threat</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">agents</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">identified</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">in</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">emergency</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">declaration&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">there</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">is</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">no</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">adequate,</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">approved,</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">available</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">alternative</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">authorized</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">product</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">for</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">diagnosing,</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">preventing,</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">treating</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">relevant</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">disease</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">condition&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">any</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">other</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">criteria</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">prescribed</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">by</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">FDA</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">is</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">satisfied.</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="font-style:italic;color:#000000;">Id.</span><span style="font-style:italic;letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">&#167;</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">360bbb-3(c).</span></p></td></tr></table></div>
<p style="margin-top:0pt;margin-bottom:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:4.8%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Medical products that are granted an EUA are only permitted to commercialize their products under the terms and conditions provided in the<span style="letter-spacing:0.05pt;"> </span>authorization.<span style="letter-spacing:-0.2pt;"> </span>The<span style="letter-spacing:-0.2pt;"> </span>FDA<span style="letter-spacing:-0.2pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>revoke<span style="letter-spacing:-0.2pt;"> </span>an<span style="letter-spacing:-0.2pt;"> </span>EUA<span style="letter-spacing:-0.2pt;"> </span>where<span style="letter-spacing:-0.2pt;"> </span>it<span style="letter-spacing:-0.2pt;"> </span>is<span style="letter-spacing:-0.2pt;"> </span>determined<span style="letter-spacing:-0.2pt;"> </span>that<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.2pt;"> </span>underlying<span style="letter-spacing:-0.2pt;"> </span>health<span style="letter-spacing:-0.2pt;"> </span>emergency<span style="letter-spacing:-0.2pt;"> </span>no<span style="letter-spacing:-0.2pt;"> </span>longer<span style="letter-spacing:-0.2pt;"> </span>exists<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:-0.2pt;"> </span>warrants<span style="letter-spacing:-0.2pt;"> </span>such<span style="letter-spacing:-0.2pt;"> </span>authorization,<span style="letter-spacing:-0.2pt;"> </span>if<span style="letter-spacing:0.05pt;"> </span>the conditions for the issuance of the EUA are no longer met, or if other circumstances make revocation appropriate to protect the public health or safety,<span style="letter-spacing:0.05pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>cannot<span style="letter-spacing:-0.1pt;"> </span>predict<span style="letter-spacing:-0.05pt;"> </span>how<span style="letter-spacing:-0.1pt;"> </span>long<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>EUAs<span style="letter-spacing:-0.05pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>SARS-CoV-2<span style="letter-spacing:-0.05pt;"> </span>tests<span style="letter-spacing:-0.1pt;"> </span>will<span style="letter-spacing:-0.05pt;"> </span>remain<span style="letter-spacing:-0.1pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>place.</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:4.8%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Bio-Rad SARS-CoV-2 ddPCR test and the Platelia SARS-CoV-2 Total Ab test have been granted FDA EUA pursuant to the current emergency<span style="letter-spacing:0.05pt;"> </span>declaration. We have completed all required performance verification studies to validate the use of the tests in our laboratories in accordance with the FDA<span style="letter-spacing:0.05pt;"> </span>Policy<span style="letter-spacing:-0.35pt;"> </span>for<span style="letter-spacing:-0.3pt;"> </span>Coronavirus<span style="letter-spacing:-0.3pt;"> </span>Disease-2019<span style="letter-spacing:-0.3pt;"> </span>Tests<span style="letter-spacing:-0.3pt;"> </span>During<span style="letter-spacing:-0.35pt;"> </span>the<span style="letter-spacing:-0.3pt;"> </span>Public<span style="letter-spacing:-0.3pt;"> </span>Health<span style="letter-spacing:-0.3pt;"> </span>Emergency,<span style="letter-spacing:-0.3pt;"> </span>CAP<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.3pt;"> </span>New<span style="letter-spacing:-0.3pt;"> </span>York<span style="letter-spacing:-0.3pt;"> </span>State<span style="letter-spacing:-0.3pt;"> </span>Clinical<span style="letter-spacing:-0.3pt;"> </span>Laboratory<span style="letter-spacing:-0.35pt;"> </span>Standards<span style="letter-spacing:-0.3pt;"> </span>of<span style="letter-spacing:-0.3pt;"> </span>Practice<span style="letter-spacing:-0.3pt;"> </span>(NYS<span style="letter-spacing:0.05pt;"> </span>CLEP) requirements. The FDA Policy for COVID-19 tests is a guidance document that explains the FDA&#8217;s current thinking on the topic, is subject to<span style="letter-spacing:0.05pt;"> </span>change, and does not establish any legally enforceable responsibilities. As stated in the FDA&#8217;s Policy for COVID-19, the FDA does not expect a separate<span style="letter-spacing:0.05pt;"> </span>notification<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:-0.2pt;"> </span>EUA<span style="letter-spacing:-0.2pt;"> </span>request<span style="letter-spacing:-0.2pt;"> </span>from<span style="letter-spacing:-0.2pt;"> </span>laboratories<span style="letter-spacing:-0.25pt;"> </span>that<span style="letter-spacing:-0.2pt;"> </span>are<span style="letter-spacing:-0.2pt;"> </span>performing<span style="letter-spacing:-0.2pt;"> </span>testing<span style="letter-spacing:-0.2pt;"> </span>using<span style="letter-spacing:-0.25pt;"> </span>EUA-authorized<span style="letter-spacing:-0.2pt;"> </span>test<span style="letter-spacing:-0.2pt;"> </span>kits<span style="letter-spacing:-0.2pt;"> </span>purchased<span style="letter-spacing:-0.2pt;"> </span>from<span style="letter-spacing:-0.25pt;"> </span>commercial<span style="letter-spacing:-0.2pt;"> </span>manufacturers<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:-0.2pt;"> </span>their<span style="letter-spacing:0.05pt;"> </span>distributors. According to the FDA Policy for COVID-19 tests, a laboratory may make certain modifications to an EUA-authorized test if the modified test<span style="letter-spacing:-2.1pt;"> </span>is validated using a bridging study without submitting an EUA amendment or formal notification. A laboratory may modify an EUA authorized test for use<span style="letter-spacing:-2.1pt;"> </span>of a new specimen through a bridging study when the new specimen type has been previously authorized for another test of the same technology without<span style="letter-spacing:0.05pt;"> </span>submitting<span style="letter-spacing:-0.1pt;"> </span>an<span style="letter-spacing:-0.05pt;"> </span>EUA<span style="letter-spacing:-0.05pt;"> </span>amendment<span style="letter-spacing:-0.05pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>formal<span style="letter-spacing:-0.05pt;"> </span>notification.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#auto;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Federal<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.25pt;"> </span>State<span style="letter-spacing:-0.25pt;"> </span>Laboratory<span style="letter-spacing:-0.25pt;"> </span>Licensing<span style="letter-spacing:-0.25pt;"> </span>Requirements</p>
<p style="margin-top:5pt;margin-bottom:6pt;text-indent:4.8%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<span style="letter-spacing:-0.25pt;"> </span>Biodesix<span style="letter-spacing:-0.25pt;"> </span>Boulder,<span style="letter-spacing:-0.2pt;"> </span>Colorado<span style="letter-spacing:-0.25pt;"> </span>clinical<span style="letter-spacing:-0.2pt;"> </span>laboratory<span style="letter-spacing:-0.25pt;"> </span>is<span style="letter-spacing:-0.25pt;"> </span>a<span style="letter-spacing:-0.2pt;"> College of American Pathology (</span>CAP)-accredited<span style="letter-spacing:-0.25pt;"> </span>clinical<span style="letter-spacing:-0.2pt;"> </span>laboratory<span style="letter-spacing:-0.25pt;"> </span>regulated<span style="letter-spacing:-0.2pt;"> </span>by<span style="letter-spacing:-0.25pt;"> </span>CMS<span style="letter-spacing:-0.25pt;"> </span>pursuant<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.25pt;"> </span>CLIA.<span style="letter-spacing:-0.2pt;"> </span>CMS<span style="letter-spacing:-0.25pt;"> </span>has<span style="letter-spacing:-0.25pt;"> </span>granted<span style="letter-spacing:0.05pt;"> </span>CAP<span style="letter-spacing:-0.2pt;"> </span>deeming<span style="letter-spacing:-0.2pt;"> </span>authority<span style="letter-spacing:-0.2pt;"> </span>under<span style="letter-spacing:-0.2pt;"> </span>CLIA,<span style="letter-spacing:-0.2pt;"> </span>which<span style="letter-spacing:-0.15pt;"> </span>allows<span style="letter-spacing:-0.2pt;"> </span>CAP<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.2pt;"> </span>inspect<span style="letter-spacing:-0.2pt;"> </span>laboratories<span style="letter-spacing:-0.2pt;"> </span>in<span style="letter-spacing:-0.15pt;"> </span>lieu<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.2pt;"> </span>CMS.<span style="letter-spacing:-0.2pt;"> </span>In<span style="letter-spacing:-0.25pt;"> </span>addition<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.2pt;"> </span>holding<span style="letter-spacing:-0.25pt;"> </span>a<span style="letter-spacing:-0.25pt;"> </span>CLIA<span style="letter-spacing:-0.2pt;"> </span>Certificate<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.25pt;"> </span>CAP<span style="letter-spacing:-0.25pt;"> </span>laboratory<span style="letter-spacing:-0.2pt;"> </span>accreditation,<span style="letter-spacing:-0.25pt;"> </span>Biodesix&#8217;s<span style="letter-spacing:-0.25pt;"> </span>Quality<span style="letter-spacing:-0.2pt;"> </span>Management<span style="letter-spacing:-0.25pt;"> </span>System<span style="letter-spacing:0.05pt;"> </span>(QMS) holds an ISO 13485:2016 certificate. The Biodesix Boulder, Colorado clinical laboratory has received approval from The New York State Department of Health (NYSDOH), New York State Clinical Laboratory Evaluation Program (NYS CLEP) in<span style="letter-spacing:0.05pt;"> </span>Soluble Tumor Markers and Molecular, Cellular Tumor Markers as well as holding state permits and licenses in California, Maryland, New York,<span style="letter-spacing:0.05pt;"> </span>Pennsylvania,<span style="letter-spacing:-0.1pt;"> </span>and<span style="letter-spacing:-0.05pt;"> </span>Rhode<span style="letter-spacing:-0.05pt;"> </span>Island.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:4.8%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CLIA</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">regulations</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">establish</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">standards</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">proficiency</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">testing&#59;</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">facility</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">administration&#59;</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">general</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">laboratory</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">systems&#59;</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">pre-analytic,</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">analytic</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">systems,</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">post-</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">analytic systems&#59; personnel qualifications and responsibilities&#59; quality control, quality assessment&#59; and specific provisions for laboratories performing</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">moderate</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">high</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">complexity</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">tests.</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Boulder,</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Colorado</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">clinical</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">laboratory</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">is</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">inspected</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">biennially</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">as</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">part</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">its</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ongoing</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">certification</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">under</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CLIA</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">certificate</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">accreditation</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">by</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CAP.</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Boulder,</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Colorado</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">clinical</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">laboratory</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">most</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">recently</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">passed</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">its</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CAP</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">inspection</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">February</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2019.</span></p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:4.8%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under<span style="letter-spacing:-0.2pt;"> </span>CLIA,<span style="letter-spacing:-0.2pt;"> </span>a<span style="letter-spacing:-0.2pt;"> </span>laboratory<span style="letter-spacing:-0.15pt;"> </span>is<span style="letter-spacing:-0.2pt;"> </span>any<span style="letter-spacing:-0.2pt;"> </span>facility<span style="letter-spacing:-0.2pt;"> </span>that<span style="letter-spacing:-0.15pt;"> </span>performs<span style="letter-spacing:-0.2pt;"> </span>laboratory<span style="letter-spacing:-0.2pt;"> </span>testing<span style="letter-spacing:-0.2pt;"> </span>on<span style="letter-spacing:-0.15pt;"> </span>specimens<span style="letter-spacing:-0.2pt;"> </span>derived<span style="letter-spacing:-0.2pt;"> </span>from<span style="letter-spacing:-0.2pt;"> </span>humans<span style="letter-spacing:-0.15pt;"> </span>for<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.2pt;"> </span>purpose<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.15pt;"> </span>providing<span style="letter-spacing:-0.2pt;"> </span>information<span style="letter-spacing:0.05pt;"> </span>for the diagnosis, prevention or treatment of disease, or the impairment of or assessment of health. CLIA requires that a laboratory hold a certificate<span style="letter-spacing:0.05pt;"> </span>applicable to the type of laboratory examinations it performs and that it complies with, among other things, standards covering operations, personnel,<span style="letter-spacing:0.05pt;"> </span>facilities administration, quality systems and proficiency testing, which are intended to ensure, among other things, that clinical laboratory testing services<span style="letter-spacing:0.05pt;"> </span>are<span style="letter-spacing:-0.1pt;"> </span>accurate,<span style="letter-spacing:-0.05pt;"> </span>reliable<span style="letter-spacing:-0.05pt;"> </span>and<span style="letter-spacing:-0.05pt;"> </span>timely.</p>
<p style="margin-top:0pt;margin-bottom:6pt;text-indent:4.8%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<span style="letter-spacing:-0.25pt;"> </span>Biodesix<span style="letter-spacing:-0.2pt;"> </span>De<span style="letter-spacing:-0.2pt;"> </span>Soto,<span style="letter-spacing:-0.2pt;"> </span>Kansas<span style="letter-spacing:-0.2pt;"> </span>clinical<span style="letter-spacing:-0.2pt;"> </span>laboratory<span style="letter-spacing:-0.2pt;"> </span>is<span style="letter-spacing:-0.2pt;"> </span>a<span style="letter-spacing:-0.2pt;"> </span>COLA-accredited<span style="letter-spacing:-0.2pt;"> </span>clinical<span style="letter-spacing:-0.2pt;"> </span>laboratory<span style="letter-spacing:-0.2pt;"> </span>regulated<span style="letter-spacing:-0.2pt;"> </span>by<span style="letter-spacing:-0.2pt;"> </span>CMS<span style="letter-spacing:-0.2pt;"> </span>pursuant<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.2pt;"> </span>CLIA.<span style="letter-spacing:-0.2pt;"> </span>COLA<span style="letter-spacing:-0.2pt;"> </span>Inc.<span style="letter-spacing:-0.2pt;"> </span>(COLA)<span style="letter-spacing:0.05pt;"> </span>was founded in 1988 as a private alternative to help laboratories stay in compliance with CLIA. In 1993, the Health Care Financing Administration (now<span style="letter-spacing:0.05pt;"> </span>CMS) granted COLA deeming authority under CLIA, and in 1997 The Joint Commission also recognized COLA Inc.&#8217;s laboratory accreditation program.<span style="letter-spacing:0.05pt;"> </span>The De Soto, Kansas clinical laboratory is inspected biennially by COLA. The De Soto, Kansas clinical laboratory most recently passed inspection in<span style="letter-spacing:0.05pt;"> </span>August 2019. The De Soto, Kansas clinical laboratory also holds state permits and licenses in California, Maryland, New York, Pennsylvania, and Rhode<span style="letter-spacing:0.05pt;"> </span>Island.</p>
<p style="margin-top:0pt;margin-bottom:6pt;text-indent:4.8%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<span style="letter-spacing:-0.25pt;"> International Organization for Standardization (</span>ISO)<span style="letter-spacing:-0.25pt;"> </span>is<span style="letter-spacing:-0.25pt;"> </span>an<span style="letter-spacing:-0.25pt;"> </span>independent,<span style="letter-spacing:-0.25pt;"> </span>non-governmental<span style="letter-spacing:-0.25pt;"> </span>international<span style="letter-spacing:-0.25pt;"> </span>organization<span style="letter-spacing:-0.25pt;"> </span>that<span style="letter-spacing:-0.25pt;"> </span>defines<span style="letter-spacing:-0.25pt;"> </span>world-class<span style="letter-spacing:-0.25pt;"> </span>specifications<span style="letter-spacing:-0.25pt;"> </span>for<span style="letter-spacing:-0.25pt;"> </span>products,<span style="letter-spacing:-0.25pt;"> </span>services<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.25pt;"> </span>systems,<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>ensure quality, safety and efficiency. ISO 13485:2016 is a harmonized, international regulatory benchmark for quality management systems that addresses<span style="letter-spacing:0.05pt;"> </span>most or<span style="letter-spacing:0.05pt;"> </span>all of<span style="letter-spacing:0.05pt;"> </span>the QMS<span style="letter-spacing:0.05pt;"> </span>requirements in<span style="letter-spacing:0.05pt;"> </span>markets including<span style="letter-spacing:0.05pt;"> </span>the United<span style="letter-spacing:0.05pt;"> </span>States, European<span style="letter-spacing:0.05pt;"> </span>Union, Australia,<span style="letter-spacing:0.05pt;"> </span>Japan and<span style="letter-spacing:0.05pt;"> </span>Canada. The<span style="letter-spacing:0.05pt;"> </span>ISO 13485:2016<span style="letter-spacing:0.05pt;"> </span>certificate confirms that an organization operates a QMS that conforms to the standards established by ISO.<span style="letter-spacing:0.05pt;"> </span>The FDA has proposed a rule to<span style="letter-spacing:0.05pt;"> </span>harmonize and modernize its QSR, which would supplant the existing requirements with ISO 13485:2016 although this rule has been delayed several times spring 2018. In February 2021, we passed an ISO 13485:2016<span style="letter-spacing:0.05pt;"> </span>inspection.</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:4.8%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To<span style="letter-spacing:-0.25pt;"> </span>renew<span style="letter-spacing:-0.2pt;"> </span>our<span style="letter-spacing:-0.2pt;"> </span>CLIA<span style="letter-spacing:-0.2pt;"> </span>certificate,<span style="letter-spacing:-0.25pt;"> </span>we<span style="letter-spacing:-0.2pt;"> </span>are<span style="letter-spacing:-0.2pt;"> </span>subject<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.25pt;"> </span>survey<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>inspection<span style="letter-spacing:-0.2pt;"> </span>every<span style="letter-spacing:-0.25pt;"> </span>two<span style="letter-spacing:-0.2pt;"> </span>years<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.2pt;"> </span>assess<span style="letter-spacing:-0.2pt;"> </span>compliance<span style="letter-spacing:-0.25pt;"> </span>with<span style="letter-spacing:-0.2pt;"> </span>program<span style="letter-spacing:-0.2pt;"> </span>standards.<span style="letter-spacing:-0.2pt;"> </span>Laboratories<span style="letter-spacing:0.05pt;"> </span>such as ours, which are performing high complexity testing, are required to meet more stringent CLIA requirements than laboratories performing less<span style="letter-spacing:0.05pt;"> </span>complex tests, and therefore our laboratories are also subject to random, unannounced survey and inspection at any time. In addition, a laboratory that is<span style="letter-spacing:0.05pt;"> </span>certified as &#8220;high complexity&#8221; under CLIA may develop, manufacture, validate and use proprietary LDTs. CLIA requires analytical validation including<span style="letter-spacing:0.05pt;"> </span>accuracy, precision, specificity, sensitivity and establishment of a reference range for any LDT used in clinical testing. The regulatory and compliance<span style="letter-spacing:0.05pt;"> </span>standards<span style="letter-spacing:-0.15pt;"> </span>applicable<span style="letter-spacing:-0.1pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>testing<span style="letter-spacing:-0.1pt;"> </span>we<span style="letter-spacing:-0.1pt;"> </span>perform<span style="letter-spacing:-0.1pt;"> </span>may<span style="letter-spacing:-0.15pt;"> </span>change<span style="letter-spacing:-0.1pt;"> </span>over<span style="letter-spacing:-0.1pt;"> </span>time<span style="letter-spacing:-0.1pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>any<span style="letter-spacing:-0.1pt;"> </span>such<span style="letter-spacing:-0.1pt;"> </span>changes<span style="letter-spacing:-0.1pt;"> </span>could<span style="letter-spacing:-0.15pt;"> </span>have<span style="letter-spacing:-0.1pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>material<span style="letter-spacing:-0.15pt;"> </span>effect<span style="letter-spacing:-0.1pt;"> </span>on<span style="letter-spacing:-0.1pt;"> </span>our<span style="letter-spacing:-0.1pt;"> </span>business.</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:4.8%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CLIA provides that a state may adopt laboratory regulations that are more stringent than those under federal law, and a number of states have<span style="letter-spacing:0.05pt;"> </span>implemented their own more stringent laboratory regulatory requirements. State laws may require that out-of-state laboratories maintain an in-state<span style="letter-spacing:0.05pt;"> </span>laboratory<span style="letter-spacing:-0.2pt;"> </span>license<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.15pt;"> </span>perform<span style="letter-spacing:-0.2pt;"> </span>tests<span style="letter-spacing:-0.15pt;"> </span>on<span style="letter-spacing:-0.15pt;"> </span>samples<span style="letter-spacing:-0.15pt;"> </span>from<span style="letter-spacing:-0.2pt;"> </span>patients<span style="letter-spacing:-0.15pt;"> </span>who<span style="letter-spacing:-0.15pt;"> </span>reside<span style="letter-spacing:-0.2pt;"> </span>in<span style="letter-spacing:-0.15pt;"> </span>that<span style="letter-spacing:-0.15pt;"> </span>state.<span style="letter-spacing:-0.15pt;"> </span>As<span style="letter-spacing:-0.2pt;"> </span>a<span style="letter-spacing:-0.15pt;"> </span>condition<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:-0.2pt;"> </span>licensure,<span style="letter-spacing:-0.15pt;"> </span>certain<span style="letter-spacing:-0.15pt;"> </span>states<span style="letter-spacing:-0.15pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>require<span style="letter-spacing:-0.15pt;"> </span>that<span style="letter-spacing:-0.15pt;"> </span>laboratory<span style="letter-spacing:0.05pt;"> </span>personnel<span style="letter-spacing:-0.25pt;"> </span>meet<span style="letter-spacing:-0.2pt;"> </span>qualifications,<span style="letter-spacing:-0.2pt;"> </span>quality<span style="letter-spacing:-0.25pt;"> </span>control<span style="letter-spacing:-0.2pt;"> </span>procedures,<span style="letter-spacing:-0.2pt;"> </span>facility<span style="letter-spacing:-0.25pt;"> </span>requirements,<span style="letter-spacing:-0.2pt;"> </span>record<span style="letter-spacing:-0.2pt;"> </span>maintenance<span style="letter-spacing:-0.2pt;"> </span>requirements<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:-0.2pt;"> </span>other<span style="letter-spacing:-0.2pt;"> </span>state-specific<span style="letter-spacing:-0.25pt;"> </span>requirements.</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:4.8%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because our Boulder, Colorado clinical laboratory is located in the State of Colorado, we do not need a specific State of Colorado laboratory license, however, we maintain licenses to conduct testing in other states where nonresident laboratories are required to obtain state laboratory licenses. We maintain licenses for our Boulder, Colorado and De Soto, Kansas laboratories with the New York State Dept. of Health (NYSDOH). We also hold licenses in other states in which we operate, including California, Maryland, Pennsylvania and Rhode Island, that require licensing of out-of-state laboratories under certain circumstances. Other states may currently have or adopt similar licensure requirements in the future, which may require us to modify, delay or stop its operations in those states until such requirements are met.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:4pt;margin-bottom:6pt;text-indent:4.8%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Failure</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">comply</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">with</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CLIA</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">certification</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">state</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">clinical</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">laboratory</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">licensure</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">requirements</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">result</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">range</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">enforcement</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">actions,</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">including</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">certificate or license suspension, limitation, or revocation, directed plan of action, onsite monitoring, civil monetary penalties, criminal sanctions, and</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">revocation</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">laboratory&#8217;s</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">approval</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">receive</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Medicare</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Medicaid</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">payment</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">its</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">services,</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">as</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">well</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">as</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">significant</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">adverse</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">publicity.</span></p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:4.8%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CLIA<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.25pt;"> </span>state<span style="letter-spacing:-0.2pt;"> </span>laws<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>regulations,<span style="letter-spacing:-0.25pt;"> </span>operating<span style="letter-spacing:-0.2pt;"> </span>together,<span style="letter-spacing:-0.25pt;"> </span>sometimes<span style="letter-spacing:-0.2pt;"> </span>limit<span style="letter-spacing:-0.25pt;"> </span>the<span style="letter-spacing:-0.2pt;"> </span>ability<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:-0.2pt;"> </span>laboratories<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.2pt;"> </span>offer<span style="letter-spacing:-0.25pt;"> </span>consumer-initiated<span style="letter-spacing:-0.2pt;"> </span>testing,<span style="letter-spacing:-0.25pt;"> </span>also<span style="letter-spacing:-0.2pt;"> </span>known<span style="letter-spacing:-0.25pt;"> </span>as<span style="letter-spacing:0.05pt;"> </span>direct<span style="letter-spacing:-0.15pt;"> </span>access<span style="letter-spacing:-0.15pt;"> </span>testing.<span style="letter-spacing:-0.1pt;"> </span>We<span style="letter-spacing:-0.15pt;"> </span>do<span style="letter-spacing:-0.1pt;"> </span>not<span style="letter-spacing:-0.15pt;"> </span>offer<span style="letter-spacing:-0.1pt;"> </span>direct<span style="letter-spacing:-0.15pt;"> </span>access<span style="letter-spacing:-0.1pt;"> </span>testing<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>instead<span style="letter-spacing:-0.15pt;"> </span>require<span style="letter-spacing:-0.1pt;"> </span>that<span style="letter-spacing:-0.15pt;"> </span>our<span style="letter-spacing:-0.1pt;"> </span>tests<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.1pt;"> </span>ordered<span style="letter-spacing:-0.15pt;"> </span>by<span style="letter-spacing:-0.1pt;"> </span>licensed<span style="letter-spacing:-0.15pt;"> </span>healthcare<span style="letter-spacing:-0.15pt;"> </span>providers.</p>
<p style="margin-top:0pt;margin-bottom:6pt;text-indent:4.8%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our Boulder, Colorado and De Soto, Kansas laboratories are certified and adhere to the New York State Clinical Laboratory Evaluation Program (NYS CLEP), based on New York State Public Health Law,<span style="letter-spacing:0.05pt;"> </span>Article 5 Title 5. New York State Clinical Laboratory Evaluation Program is exempt from CLIA and establishes their own method of laboratory certification and test validation approval. To process<span style="letter-spacing:0.05pt;"> </span>New York State patient specimens a laboratory must submit a robust analytical and clinical validation package to demonstrate clinical utility of the test and receive<span style="letter-spacing:0.05pt;"> </span>approval<span style="letter-spacing:-0.25pt;"> </span>prior<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.25pt;"> </span>offering<span style="letter-spacing:-0.25pt;"> </span>the<span style="letter-spacing:-0.2pt;"> </span>test<span style="letter-spacing:-0.25pt;"> </span>in<span style="letter-spacing:-0.25pt;"> </span>the<span style="letter-spacing:-0.25pt;"> </span>state<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:-0.2pt;"> </span>New<span style="letter-spacing:-0.25pt;"> </span>York.<span style="letter-spacing:-0.25pt;"> </span>Our<span style="letter-spacing:-0.25pt;"> </span>GeneStrat<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>VeriStrat<span style="letter-spacing:-0.25pt;"> </span>tests<span style="letter-spacing:-0.25pt;"> </span>have<span style="letter-spacing:-0.25pt;"> </span>received<span style="letter-spacing:-0.25pt;"> </span>New York State Clinical Laboratory Evaluation Program<span style="letter-spacing:-0.25pt;"> </span>approval.<span style="letter-spacing:-0.25pt;"> </span>New York State Clinical Laboratory Evaluation Program<span style="letter-spacing:-0.25pt;"> </span>requires<span style="letter-spacing:-0.2pt;"> </span>semi-<span style="letter-spacing:0.05pt;"> </span>annual inspections to ensure the laboratory meets all general and specialty standards. Biodesix passed New York State Clinical Laboratory Evaluation Program inspection in May 2019 and is currently<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">scheduled for a routine re-inspection in May 2021.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#auto;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Regulatory<span style="letter-spacing:-0.2pt;"> </span>framework<span style="letter-spacing:-0.2pt;"> </span>for<span style="letter-spacing:-0.15pt;"> </span>medical<span style="letter-spacing:-0.2pt;"> </span>devices<span style="letter-spacing:-0.2pt;"> </span>in<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.2pt;"> </span>United<span style="letter-spacing:-0.2pt;"> </span>States</p>
<p style="margin-top:5pt;margin-bottom:6pt;text-indent:4.8%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to its authority under the FDCA, the FDA has jurisdiction over medical devices, which are defined to include, among other things, IVDs.<span style="letter-spacing:-2.1pt;"> </span>The<span style="letter-spacing:-0.35pt;"> </span>FDA<span style="letter-spacing:-0.3pt;"> </span>regulates<span style="letter-spacing:-0.3pt;"> </span>the<span style="letter-spacing:-0.3pt;"> </span>research,<span style="letter-spacing:-0.3pt;"> </span>design,<span style="letter-spacing:-0.35pt;"> </span>development,<span style="letter-spacing:-0.3pt;"> </span>pre-clinical<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.3pt;"> </span>clinical<span style="letter-spacing:-0.3pt;"> </span>testing,<span style="letter-spacing:-0.3pt;"> </span>manufacturing,<span style="letter-spacing:-0.35pt;"> </span>safety,<span style="letter-spacing:-0.3pt;"> </span>effectiveness,<span style="letter-spacing:-0.3pt;"> </span>packaging,<span style="letter-spacing:-0.3pt;"> </span>labeling,<span style="letter-spacing:-0.3pt;"> </span>storage,<span style="letter-spacing:0.05pt;"> </span>recordkeeping, pre-market clearance or approval, adverse event reporting, marketing, promotion, sales, distribution and import and export of medical<span style="letter-spacing:0.05pt;"> </span>devices. It is possible that one of our current, or future, tests will be subject to FDA authority and oversight as either an IVD or a CDx pursuant to the<span style="letter-spacing:0.05pt;"> </span>FDA&#8217;s<span style="letter-spacing:-0.1pt;"> </span>authority<span style="letter-spacing:-0.05pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>regulate<span style="letter-spacing:-0.05pt;"> </span>medical<span style="letter-spacing:-0.05pt;"> </span>devices<span style="letter-spacing:-0.1pt;"> </span>under<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>FDCA.</p>
<p style="margin-top:5pt;margin-bottom:6pt;text-indent:4.8%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Medical devices are subject to extensive regulation in the United States and elsewhere, including by the FDA and its foreign counterparts.&#160;&#160;Government<span style="letter-spacing:-0.2pt;"> </span>regulations<span style="letter-spacing:-0.2pt;"> </span>specific<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.2pt;"> </span>medical<span style="letter-spacing:-0.2pt;"> </span>devices<span style="letter-spacing:-0.2pt;"> </span>are<span style="letter-spacing:-0.2pt;"> </span>wide<span style="letter-spacing:-0.2pt;"> </span>ranging<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>govern,<span style="letter-spacing:-0.2pt;"> </span>among<span style="letter-spacing:-0.2pt;"> </span>other<span style="letter-spacing:-0.2pt;"> </span>things:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">product</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">design,</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">development,</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">manufacture,</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">release&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">laboratory</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">clinical</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">testing,</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">labeling,</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">packaging,</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">storage</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">distribution&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">product</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">safety</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">efficacy&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">premarketing</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">clearance</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">approval&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">service</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">operations&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">record</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">keeping&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">product</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">marketing,</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">promotion</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">advertising,</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">sales</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">distribution&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">post-marketing</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">surveillance,</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">including</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">reporting</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">deaths</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">serious</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">injuries</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">recalls</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">correction</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">removals&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">post-market</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">approval</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">studies&#59;</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">product</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">import</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">export</span></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.81%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Market access, sales and marketing of medical devices in non-U.S. countries are subject to foreign regulatory requirements that vary widely from country to country. For example, in the European Economic </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Area (EEA), a medical device must meet the Medical Devices Directive&#8217;s (MDD)/In Vitro Medical Devices Directive&#8217;s (IVDD) Essential Requirements or, applicable on May 26, 2021, the Medical Devices Regulation&#8217;s (MDR) / applicable on May 26, 2022, In Vitro Medical Devices Regulation&#8217;s (IVDR) General Safety and Performance Requirements which apply to it, taking into account its intended purpose as defined by the data supplied by the manufacturer on the label, in the instructions for use or in promotional or sales materials or </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">statements and as specified by the manufacturer in the clinical evaluation. Before placing a medical device on the EEA market, the manufacturer must draw up a declaration of conformity, certifying that the device complies with the MDD/IVDD/MDR/IVDR, and must then affix the CE mark. For medium and high</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">risk devices as well as low risk devices that are placed on the market in sterile condition, have a measuring function, or are reusable surgical instruments, the manufacturer must obtain a CE Certificate from a notified body. The notified body typically audits </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and examines the device&#8217;s technical documentation, including the clinical evaluation, and the quality system for the manufacture, design and final inspection of the relevant device before issuing a CE Certificate. Following the issuance of this CE Certificate, manufacturers may draw up the declaration of conformity and affix the CE mark to the devices covered by this CE Certificate. </span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.81%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Manufacturers of medical devices must document in a clinical evaluation report (CER) the evaluation of the clinical data related to the device. The CER is part of the device&#8217;s technical file. The evaluation shall document that the applicable Essential Requirements/General Safety and Performance Requirements are met and document the evaluation of the undesirable side-effects and the acceptability of the benefit-risk- ratio. The CER must be updated based on information from the post-market surveillance and vigilance activities related to the device. The CER shall consist, inter alia, of analyzed clinical data collected from a clinical investigation of the device, or the results of other studies on substantially equivalent devices. Reliance on &#8220;substantially equivalent&#8221; devices is very restrictive and requires, inter alia, that the manufacturer has full access to the technical documentation of the equivalent device on an ongoing basis and, if the &#8220;equivalent device&#8221; is not its own, that the manufacture has in place a contract with the manufacturer of the &#8220;equivalent device.&#8221;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.81%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Similar requirements apply in the UK. For access to the UK market, manufacturers must obtain a UKCA Certificate and affix a UKCA mark to their medical devices. However, the CE mark will be accepted in the UK until July 1, 2023.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Device classification</p>
<p style="margin-bottom:6pt;margin-top:5pt;text-indent:4.8%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the FDCA, medical devices are classified into one of three classes: Class I, Class II or Class III, depending on the degree of risk to patients that is associated with each medical device and the amount of oversight needed to provide reasonable assurances with respect to safety and effectiveness of the medical device.</p>
<p style="margin-bottom:6pt;margin-top:5pt;text-indent:4.76%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Class I includes devices with the lowest risk to the patient and are those for which safety and effectiveness can be reasonably assured by adherence to a set of FDA regulations, referred to as the General Controls for Medical Devices, which require compliance with the applicable portions of the FDA&#8217;s QSR, facility registration and product listing, reporting of adverse events and malfunctions, and appropriate, truthful and non-misleading labeling and promotional materials. Some Class I devices also require premarket clearance by the FDA through the 510(k) premarket notification process described below. Most Class I products are exempt from the premarket notification requirements.</p>
<p style="margin-bottom:6pt;margin-top:5pt;text-indent:4.8%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Class II devices are subject to the General Controls as well as any special controls as deemed necessary by the FDA to ensure the safety and effectiveness of the device. These special controls can include performance standards, patient registries, FDA guidance documents and post-market surveillance. Most Class II devices are subject to premarket review and clearance by the FDA. Premarket review and clearance by the FDA for Class II devices is accomplished through the 510(k) premarket notification process, although some Class II devices are exempt from the 510(k) requirements.</p>
<p style="margin-bottom:6pt;margin-top:5pt;text-indent:4.8%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Class III devices include devices deemed by the FDA to pose the greatest risk: such as life-supporting or life-sustaining devices, implantable devices, or those deemed novel and not substantially equivalent to a predicate device following the 510(k) process. CDx tests are regularly considered Class III devices.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Premarket submission process</p>
<p style="margin-bottom:6pt;margin-top:5pt;text-indent:4.8%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unless a statutory or regulatory exemption or enforcement discretion policy applies, before a new medical device, or a new intended use of, claim for, or significant modification to an existing device, can be marketed in the United States, the manufacturer must obtain the FDA&#8217;s: (1) permission for commercial distribution under section 510(k) of the FDCA (510(k) clearance)&#59; or (2) approval of a PMA&#59; or (3) de novo classification and authorization. These processes can be resource intensive, expensive, and lengthy, and require payment of significant user fees.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:6pt;margin-top:5pt;text-indent:4.8%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the 510(k) clearance process, the manufacturer must submit to the FDA a premarket notification, demonstrating that the device is &#8220;substantially equivalent&#8221; to a legally marketed predicate device. A predicate device is a legally marketed device that is not subject to a PMA, i.e., a device that was legally marketed prior to May 28, 1976 (pre-amendments device) and therefore a PMA is not required, a device that has been reclassified from Class III to Class II or I, or a device that was previously found substantially equivalent through the 510(k) process. To be </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;substantially equivalent,&#8221; the proposed device must have the same intended use as the predicate device, and either have the same technological characteristics as the predicate device or have different technological characteristics and not raise different questions of safety or effectiveness than the predicate device. Premarket notifications typically include bench, analytical, and preclinical data. Clinical data is sometimes required to support substantial equivalence. If a manufacturer obtains a 510(k) clearance for its device and then makes a modification that could significantly affect the device&#8217;s safety or effectiveness or constitutes a major change or modification in the intended use of the device, a new clearance, authorization or approval may be required.</span></p>
<p style="margin-bottom:6pt;margin-top:5pt;text-indent:4.8%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By statute, the FDA is required to complete its review of a 510(k) notification within 90 days of receiving the 510(k) notification. As a practical matter, clearance often takes longer, and clearance is never assured. Although many 510(k) premarket notifications are cleared without clinical data, the FDA may require further information, including clinical data, to make a determination regarding substantial equivalence, which may significantly prolong the review process. If the FDA agrees that the device is substantially equivalent, it will grant clearance to commercially market the device. If the FDA determines that the device is not &#8220;substantially equivalent&#8221; to a predicate device, or if the device is automatically classified into Class III, the device sponsor must then fulfill the much more rigorous, costly, and time-consuming PMA approval process or seek reclassification of the device through the de novo process.</p>
<p style="margin-bottom:6pt;margin-top:5pt;text-indent:4.8%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To obtain a PMA, the applicant must submit data and information demonstrating reasonable assurance of the safety and effectiveness of the device for its intended use to the FDA&#8217;s satisfaction. Accordingly, a PMA typically includes, but is not limited to, extensive technical information regarding device design and development, pre-clinical and clinical trial data, manufacturing information, labeling, and financial disclosure information for the clinical investigators in device studies. The PMA application must provide valid scientific evidence that demonstrates to the FDA&#8217;s satisfaction a reasonable assurance of the safety and effectiveness of the device for its intended use.</p>
<p style="margin-bottom:6pt;margin-top:5pt;text-indent:4.8%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Once filed as a PMA, the FDA has 180 days to review the filed PMA application, although the review of an application more often occurs over a significantly longer period of time. During this review period, the FDA may request additional information or clarification of information already provided, and the FDA may issue a major deficiency letter to the applicant, requesting the applicant&#8217;s response to deficiencies communicated by the FDA.</p>
<p style="margin-bottom:6pt;margin-top:5pt;text-indent:4.8%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to approval of a PMA, the FDA may conduct inspections of any clinical trial data and clinical trial sites, as well as inspections of any manufacturing facility and processes. The FDA can delay, limit or deny approval of a PMA application for many reasons, including (1) the device may not be shown safe or effective to the FDA&#8217;s satisfaction&#59; (2) the data from pre-clinical studies and/or clinical trials may be found unreliable or insufficient to support approval&#59; (3) the manufacturing process or facilities may not meet applicable requirements&#59; and (4) changes in FDA approval policies or adoption of new regulations may require additional data.</p>
<p style="margin-bottom:6pt;margin-top:5pt;text-indent:4.8%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If the FDA evaluation of a PMA is favorable, the FDA will issue either an approval letter, or an approvable letter, the latter of which usually contains a number of conditions that must be met in order to secure final approval of the PMA. When and if those conditions have been fulfilled to the satisfaction of the FDA, the agency will issue a PMA approval letter authorizing commercial marketing of the device, subject to the conditions of approval and the limitations established in the approval letter. The FDA also may determine that additional tests or clinical trials are necessary, in which case the PMA approval may be delayed for several months or years while the trials are conducted and data is submitted in an amendment to the PMA, or the PMA is withdrawn and resubmitted when data is available. The PMA process can be expensive, uncertain and lengthy. A number of devices for which the FDA approval has been sought by other companies have never been approved by the FDA for marketing. New PMA applications or PMA supplements are required for any modifications to the manufacturing process, equipment or facility, quality control procedures, sterilization, packaging, expiration date, labeling, device specifications, ingredients, materials or design of a device that has been approved through the PMA process.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.76%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a condition of PMA application approval, the FDA may also require some form of post-approval study or post-market surveillance, whereby the applicant conducts a follow-up study or follows certain patient groups for a number of years and makes periodic reports to the FDA on the clinical status of those patients when necessary to protect the public health or to provide additional or longer</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">term safety and effectiveness data for the device. The FDA may also approve a PMA application with other post-approval conditions intended to ensure the safety and effectiveness of the device, such as, among other things, restrictions on labeling, promotion, sale, distribution and use.</span></p>
<p style="margin-bottom:6pt;margin-top:5pt;text-indent:4.8%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Alternatively, the FDA also allows the submission of a direct de novo petition. This procedure allows a manufacturer whose novel device is automatically classified into Class III to request down-classification of its medical device into Class I or Class II on the basis that the device presents low or moderate risk, rather than requiring the submission and approval of a PMA application. Prior to the enactment of FDASIA, a medical device could only be eligible for de novo classification if the manufacturer first submitted a 510(k) premarket notification and received a determination from the FDA that the device was not substantially equivalent. FDASIA streamlined the de novo classification pathway by permitting manufacturers to request de novo classification directly without first submitting a 510(k) premarket notification to the FDA and receiving a not substantially equivalent determination.</p>
<p style="margin-bottom:6pt;margin-top:5pt;text-indent:4.8%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The 510(k), de-novo or PMA processes can be expensive, lengthy and unpredictable. The FDA&#8217;s 510(k) clearance process usually takes from three to 12 months, but can last longer. The process of obtaining a PMA is much more costly and uncertain than the 510(k) clearance process and generally takes from one to three years, or even longer, from the time the application is filed with the FDA. In addition, a PMA generally requires the performance of one or more clinical trials. Despite the time, effort and cost, a device may not be approved or cleared by the FDA. Any delay or failure to obtain necessary regulatory clearances or approvals could harm our business. Furthermore, even if we are granted regulatory clearances or approvals, they may include significant limitations on the indicated uses for the device, which may limit the market for the device.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Companion Diagnostics and the Premarket Process</p>
<p style="margin-bottom:6pt;margin-top:5pt;text-indent:4.8%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe that one of our future product candidates may include a companion diagnostic or complementary diagnostic (collectively CDx). CDx&#8217;s can identify patients who are most likely to benefit from a particular therapeutic product&#59; identify patients likely to be at increased risk for serious side effects as a result of treatment with a particular therapeutic product&#59; or monitor response to treatment with a particular therapeutic product for the purpose of adjusting treatment to achieve improved safety or effectiveness. The use of the CDx will be stipulated in the labeling of both the CDx and the therapeutic product. The FDA may require an application for the CDx separate from the drug approval process, and this could potentially delay the approval of any new drug application or the CDx, or complicate the review process. CDx&#8217;s are generally regulated as Class III medical devices by the FDA and are therefore most often subject to the PMA approval process.</p>
<p style="margin-bottom:6pt;margin-top:5pt;text-indent:4.8%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA issued guidance in July 2016 for the co-development of CDx tests with a therapeutic product and issued another draft guidance in December 2018 specific to oncology CDx tests. The FDA finalized this draft guidance in April 2020 in &#8220;Developing and Labeling In vitro Companion Diagnostic Devices for a Specific Group of Oncology Therapeutic Products.&#8221; The guidance is meant to guide the development of CDx products, which are defined as IVDs that provide information that is essential for the safe and effective use of the therapeutic product. A CDx is often developed and approved or cleared contemporaneously with the therapeutic, and the use of the CDx is stipulated in the labeling of both the CDx and the corresponding therapeutic product. While it supports contemporaneous marketing authorizations, if there are any deficiencies in the submissions, the FDA may place a PMA review of a CDx on hold or request additional testing, which could potentially delay the approval of the corresponding new drug application or the marketing authorization of the CDx, or otherwise complicate the review process. Some oncology CDx tests can be developed in a way that results in labeling for a specific group of oncology therapeutic products, rather than a single therapeutic product.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Post-Market FDA Regulation</span></p>
<p style="margin-bottom:6pt;margin-top:5pt;text-indent:4.8%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if regulatory clearance, authorization or approval of a device is granted, the FDA may impose limitations on the uses and indications for which the device may be labeled and promoted, and the device remains subject to significant regulatory requirements. Medical devices may be marketed only for the uses and indications for which they are cleared, authorized or approved. After a device, including a device exempt from FDA premarket review, is placed on the market, numerous post-market regulatory requirements apply, and the FDA has broad authority to enforce these requirements. Medical device manufacturers are subject to unannounced inspections by the FDA and other state, local and foreign regulatory authorities to assess compliance with the QSR and other applicable regulations, and these inspections may include the manufacturing facilities of any suppliers. Failure to comply with applicable regulatory requirements can result in enforcement action by the FDA, which may include sanctions such as: warning letters, fines, injunctions, consent decrees and civil penalties&#59; unanticipated expenditures, including requirements to repair, replace, and/or refund the cost of the devices, recall or seizure of our products&#59; operating restrictions, partial suspension or total shutdown of production&#59; the FDA&#8217;s refusal of our requests for 510(k) clearance, de novo classification, or PMA of new products, new intended uses or modifications to existing products&#59; the FDA&#8217;s refusal to issue certificates to foreign governments needed to export products for sale in other countries&#59; and withdrawing 510(k) clearance or PMAs that have already been granted and criminal prosecution. In the event that a supplier fails to maintain compliance with the FDA&#8217;s or our quality requirements, we may have to qualify a new supplier and could experience manufacturing delays as a result.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Federal and State Fraud and Abuse Laws</p>
<p style="margin-bottom:6pt;margin-top:5pt;text-indent:4.8%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are subject to federal fraud and abuse laws such as the federal Anti-Kickback Statute (AKS), the federal prohibition against physician self- referral (Stark Law), the Eliminating Kickbacks in Recovery Act (EKRA), and the federal False Claims Act (FCA). We are also subject to similar state and foreign fraud and abuse laws.</p>
<p style="margin-bottom:6pt;margin-top:5pt;text-indent:4.8%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The AKS prohibits knowingly and willfully offering, paying, soliciting, or receiving remuneration, directly or indirectly, overtly or covertly, in cash or in kind, in return for or to induce such person to refer an individual, or to purchase, lease, order, arrange for, or recommend purchasing, leasing or ordering, any item or service that may be reimbursable, in whole or in part, under a federal healthcare program, such as Medicare or Medicaid. There are a number of statutory exceptions and regulatory safe harbors to the AKS that provide protection from AKS liability to arrangements that fully satisfy the applicable requirements.</p>
<p style="margin-bottom:6pt;margin-top:5pt;text-indent:4.8%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EKRA prohibits knowingly and willfully soliciting, receiving, offering or paying remuneration, directly or indirectly, in return for the referral of a patient to, or in exchange for an individual using the services of certain entities, including laboratories, if the services are covered by a health care benefit program. The term &#8220;health care benefit program&#8221; is broadly defined such that EKRA extends to referrals reimbursed by both governmental and commercial third-party payers. EKRA includes a number of statutory exceptions that provide protection from EKRA liability if the applicable requirements are met.</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:4.8%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Stark Law generally prohibits, among other things, clinical laboratories and other so-called &#8220;designated health services&#8221; entities from billing Medicare for any services when the physician ordering the service, or any member of such physician&#8217;s immediate family, has a financial relationship, such as a direct or indirect investment interest in or compensation arrangement with the billing entity, unless the arrangement meets an exception to the prohibition. The Stark Law also prohibits physicians from making such referrals to a designated health services entity. There are also similar state laws that apply where Medicaid and/or commercial payers are billed.</p>
<p style="margin-bottom:6pt;margin-top:5pt;text-indent:4.8%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FCA imposes civil penalties against individuals or entities for, among other things, knowingly presenting, or causing to be presented, claims for payment to the government that are false or fraudulent, or knowingly making, using or causing to be made or used a false record or statement material to such a false or fraudulent claim, or knowingly concealing or knowingly and improperly avoiding, decreasing, or concealing an obligation to pay money to the federal government. This statute also permits a private individual acting as a &#8220;qui tam&#8221; whistleblower to bring actions on behalf of the federal government alleging violations of the FCA and to share in any monetary recovery. FCA liability is potentially significant in the healthcare industry because the statute provides for treble damages and mandatory penalties of $11,665 to $23,331 per false claim or statement for penalties assessed after June 19, 2020, with respect to violations occurring after November 2, 2015.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:6pt;margin-top:5pt;text-indent:4.8%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other federal statutes pertaining to healthcare fraud and abuse include the civil monetary penalties statute, which prohibits, among other things, the offer or payment of remuneration to a Medicaid or Medicare beneficiary that the offeror or payer knows or should know is likely to influence the beneficiary to order or receive a reimbursable item or service from a particular provider, practitioner, or supplier, and contracting with an individual or entity that the person knows or should know is excluded from participation in a federal health care program. In addition, federal criminal statutes created by HIPAA prohibit, among other things, knowingly and willfully executing or attempting to execute a scheme to defraud any healthcare benefit program or obtain by means of false or fraudulent pretenses, representations or promises any money or property owned by or under the control of any healthcare benefit program in connection with the delivery of or payment for healthcare benefits, items or services.</span></p>
<p style="margin-bottom:6pt;margin-top:5pt;text-indent:4.8%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to these federal laws, there are often similar state anti-kickback and false claims laws that typically apply to arrangements involving reimbursement by a state-funded Medicaid or other health care program. Often, these laws closely follow the language of their federal law counterparts, although they do not always have the same exceptions or safe harbors. In some states, these anti-kickback laws apply with respect to all payers, including commercial payers.</p>
<p style="margin-bottom:6pt;margin-top:5pt;text-indent:4.8%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A number of states have enacted laws that require pharmaceutical and medical device companies to monitor and report payments, gifts and other remuneration made to physicians and other healthcare providers, and, in some states, marketing expenditures. In addition, some state statutes impose outright bans on certain manufacturer gifts to physicians or other health care professionals. Some of these laws, referred to as &#8220;aggregate spend&#8221; or &#8220;gift&#8221; laws, carry substantial fines if they are violated.</p>
<p style="margin-bottom:6pt;margin-top:5pt;text-indent:4.8%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs and extensive annual trainings for all of our employees and contractors. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, imprisonment, exclusion from participation in government-funded healthcare programs, such as Medicare and Medicaid, disgorgement, contractual damages, reputational harm, diminished profits and future earnings, additional reporting or oversight obligations if we become subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance with the law, and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations. If any of the physicians or other healthcare providers or entities with whom we do business is found to be not in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government-funded healthcare programs.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Anti-Corruption</p>
<p style="margin-bottom:6pt;margin-top:5pt;text-indent:4.8%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FCPA and similar international bribery laws make it unlawful for entities to make payments to foreign government officials to assist in obtaining and maintaining business. Specifically, the anti-bribery provisions of the FCPA prohibit any offer, payment, promise to pay, or authorizing the payment of money or anything of value to any person, while knowing that all or a portion of such money or thing of value will be offered, given or promised, directly or indirectly, to a foreign official to do or omit to do an act in violation of his or her duty, or to secure any improper advantage in order to assist in obtaining or retaining business for or with, or directing business, to any person. In addition to the anti-bribery provisions of the FCPA, the statute also contains accounting requirements designed to operate in tandem with the anti-bribery provisions. Covered companies are required to make and keep books and records that accurately and fairly reflect the transactions of the company and devise and maintain an adequate system of internal accounting controls. With our international operations through our third-party partnerships, we could incur significant fines and penalties, as well as criminal liability, if we fail to comply with either the anti-bribery or accounting requirements of the FCPA, or similar international bribery laws. Even an unsuccessful challenge of our compliance with these laws could cause us to incur adverse publicity and significant legal and related costs.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Privacy and Data Protection Laws</span></p>
<p style="margin-bottom:6pt;margin-top:5pt;text-indent:4.8%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Numerous federal and state laws and regulations, including HIPAA, as amended by the HITECH, govern the collection, dissemination, security, use and confidentiality of protected health information (PHI) and personal information. In the course of performing our business we obtain personal information, including PHI. Laws and regulations relating to privacy, data protection, and consumer protection are evolving and subject to potentially differing interpretations. Under HIPAA and HITECH, the HHS, issues regulations that establish uniform standards governing the conduct of certain electronic healthcare transactions and requirements for protecting the privacy and security of PHI, used or disclosed by covered entities (CEs) and their authorized business associates (BAs). Because we are a health care provider that electronically transmits health care information, we are at times either a CE or a BA, as defined by HIPAA. Our subcontractors that create, receive, maintain, transmit or otherwise process PHI on our behalf are HIPAA BAs and must also comply with HIPAA, as applicable.</p>
<p style="margin-bottom:6pt;margin-top:5pt;text-indent:4.8%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HIPAA and HITECH include the privacy and security rules, breach notification requirements and electronic transaction standards. The privacy rule governs the use and disclosure of PHI by CEs and BAs. The privacy rule generally prohibits the use or disclosure of PHI except as permitted under the rule. The rule also sets forth individual patient rights, such as the right to access or amend certain records containing such individual&#8217;s PHI, or to request restrictions on the use or disclosure of such individual&#8217;s PHI. The security rule requires CEs and BAs to safeguard the confidentiality, integrity, and availability of electronically transmitted or stored PHI (also referred to as ePHI) by implementing administrative, physical and technical safeguards. Under HITECH&#8217;s breach notification rule, a CE must notify individuals, the Secretary of HHS, and in some circumstances, the media of certain breaches of unsecured PHI or ePHI.</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.81%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Penalties for failure to comply with a requirement of HIPAA and HITECH vary depending on the number and nature of the violations and any history of prior violations, but can be significant and include civil monetary or criminal penalties. HIPAA is enforced by the Department of Health and Human Services, Office for Civil Rights, and HIPAA also authorizes state attorneys general to file suit on behalf of their residents for violations. Courts are able to award damages, costs and attorneys&#8217; fees related to violations of HIPAA in such cases. While HIPAA does not create a private right of action allowing individuals to file suit in civil court for violations of HIPAA, its standards have been used as the basis for duty of care cases in state civil suits such as those for negligence or recklessness in the misuse or breach resulting in improper access to PHI. In addition, HIPAA mandates that the Secretary of HHS conduct periodic compliance audits of HIPAA CEs, such as us, and their BAs for compliance with the HIPAA privacy and security standards. It also tasks HHS with establishing a methodology whereby harmed individuals who were the victims of breaches of unsecured PHI may receive a percentage of the civil monetary penalty paid by the violator.</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.81%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, we may be subject to state privacy, cybersecurity, and data breach notification laws, which may govern the collection, use, disclosure and protection of health-related and other personal information. California, for example, has enacted the Confidentiality of Medical Information Act, which, in addition to HIPAA and HITECH, sets forth standards with which all California health care providers must abide. State laws may be more stringent, broader in scope or offer greater individual rights with respect to PHI than HIPAA, and state laws may differ from each other, which may complicate compliance efforts. For instance, the CCPA became effective on January 1, 2020. The CCPA, among other things, gives California residents expanded rights to access and delete their personal information, opt out of certain personal information sharing and receive detailed information about how their personal information is used by requiring covered companies to provide new disclosures to California consumers (as that term is broadly defined) and provide such consumers new ways to opt-out of certain sales of personal information. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. The CCPA has been amended from time to time, and it remains unclear what, if any, further modifications will be made to this legislation or how it will be interpreted. Although there are certain exemptions for PHI and clinical trial data, the CCPA&#8217;s implementation standards and enforcement practices are likely to remain uncertain for the foreseeable future and the CCPA may increase our compliance costs and potential liability. Additionally, a California ballot initiative, the California Privacy Rights Act (CPRA) was adopted by California voters. The CPRA will impose additional data protection obligations on companies doing business in California, including additional consumer rights processes and opt outs for certain uses of sensitive data. It would also create a new California data protection agency specifically tasked to enforce the law, which would likely result in increased regulatory scrutiny of California businesses in the areas of data protection and security. Similar laws have been proposed in other states and at the federal level, and if passed, such laws may have potentially conflicting requirements that could continue to make compliance challenging and costly.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:6pt;margin-top:5pt;text-indent:4.8%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, the Federal Trade Commission (FTC) and state attorneys general enforce consumer protection laws that prohibit unfair and deceptive acts and practices, including Section 5 of the FTC Act, which creates standards for the collection, use, dissemination and security of health-related and other personal information. Claims of unfair or deceptive trade practices regarding privacy and security can lead to significant liabilities and consequences, including regulatory investigations, penalties, fines and orders as well as civil claims, which could impact our data practices and operations or cause reputational damage.</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may also be subject to laws and regulations in foreign countries covering data privacy and other protection of health and employee information that may add additional compliance burden and complexity. For example, in the EEA, the collection and use of personal data is governed by the GDPR. In the United Kingdom, the GDPR will be adopted in substantially the same form. The GDPR, together with national legislation, regulations and guidelines of the EU member states and the United Kingdom governing the processing of personal data, impose strict obligations and restrictions on the ability to collect, analyze, store, transfer and otherwise process personal data. European and United Kingdom data protection authorities may interpret the GDPR and national laws differently and impose additional requirements, which adds to the complexity of processing personal data in or from the EEA or United Kingdom. Guidance on implementation and compliance practices are often updated or otherwise revised. GDPR applies extra-territorially under certain circumstances and imposes stringent requirements on controllers and processors of personal data, including, for example, requirements to ensure a legal bases to process personal information, provide robust disclosures to individuals, facilitate data subject rights, provide data security breach notifications within 72 hours after discovering a breach in certain circumstances, limit retention of personal information and apply enhanced protections to health data and other categories of sensitive personal information. The GDPR also has requirements around international transfers of personal data. Requirements around transfers to the United States and other jurisdictions have increased since a July 2020 decision by the Court of Justice of the European Union invalidated the Privacy Shield as a basis to transfer personal data from Europe to the United States, and added requirements for reliance on Standard Contractual Clauses. Regulatory guidance on requirements for international transfers, and other GDPR compliance matters, continues to evolve. Failure to comply with the requirements of the GDPR may result in fines of up to &#8364;20 million or up to 4% of the total worldwide annual turnover of our preceding fiscal year, whichever is higher, and other administrative penalties. To comply with the GDPR and other applicable international data protection laws and regulations, we may be required to put in place additional mechanisms ensuring compliance, which may result in other substantial expenditures.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Cybersecurity</p>
<p style="margin-bottom:6pt;margin-top:5pt;text-indent:4.8%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our business relies on secure and continuous processing of information and the availability of our IT networks and IT resources, as well as critical IT vendors that support our technology, research and other data processing operations. While we take steps to protect our systems and data, security incidents, data breaches, computer malware and computer hacking attacks have become more prevalent across industries, including the life sciences sector, and may occur on our systems or those of our third-party service providers. Unauthorized persons may in the future be able to exploit weaknesses in the security systems of our (or our third-party service providers) IT networks and gain access to PHI and other personal information, or sensitive trade secrets or other proprietary information. Any wrongful use or disclosure of PHI, other personal information, trade secrets or other proprietary information by us or our third-party service providers could subject us to regulatory fines or penalties, third-party claims or otherwise could adversely affect our business and results of operations. Although HIPAA and the regulations promulgated thereunder do not provide for a private right of action, failures to adequately protect PHI or our IT systems could be viewed as violations of the HIPAA security rule or violations of other applicable information security laws, regulations, contractual obligations or industry standards, and could further result in costly data breach notification obligations that negatively impact our reputation.</p>
<p style="margin-bottom:6pt;margin-top:5pt;text-indent:4.8%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, data security incidents or data breaches, as well as attacks on our IT systems, could result in operational disruptions or data loss or corruption that could adversely impact our business and operations, result in substantial investment of resources to investigate, recover and remediate and subject us to heightened regulatory scrutiny.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">International Regulations</span></p>
<p style="margin-bottom:6pt;margin-top:5pt;text-indent:4.8%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Many countries in which we may offer any of our diagnostic tests in the future have anti-kickback regulations prohibiting providers from offering, paying, soliciting or receiving remuneration, directly or indirectly, in order to induce business that is reimbursable under any national health care program. In situations involving physicians employed by state-funded institutions or national health care agencies, violation of the local anti-kickback law may also constitute a violation of the FCPA.</p>
<p style="margin-bottom:6pt;margin-top:5pt;text-indent:4.8%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FCPA prohibits any United States individual, business entity or employee of a United States business entity to offer or provide, directly or through a third party, including any potential distributors we may rely on in certain markets, anything of value to a foreign government official with corrupt intent to influence an award or continuation of business or to gain an unfair advantage, whether or not such conduct violates local laws. In addition, it is illegal for a company that reports to the SEC to have false or inaccurate books or records or to fail to maintain a system of internal accounting controls. We will also be required to maintain accurate information and control over sales and distributors&#8217; activities that may fall within the purview of the FCPA, its books and records provisions and its anti-bribery provisions.</p>
<p style="margin-bottom:6pt;margin-top:5pt;text-indent:4.8%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The standard of intent and knowledge in anti-bribery cases is minimal. Intent and knowledge are usually inferred from that fact that bribery took place. The accounting provisions do not require intent. Violations of the FCPA&#8217;s anti-bribery provisions for corporations and other business entities are subject to a fine of up to $2 million and officers, directors, stockholders, employees, and agents are subject to a fine of up to $100,000 and imprisonment for up to five years. Other countries, including the United Kingdom and other OECD Anti-Bribery Convention members, have similar anti-corruption regulations, such as the United Kingdom Anti-Bribery Act.</p>
<p style="margin-bottom:6pt;margin-top:5pt;text-indent:4.8%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">When marketing our diagnostic tests outside of the United States, we may be subject to foreign regulatory requirements governing human clinical testing, prohibitions on the import of tissue necessary for us to perform our diagnostic tests or restrictions on the export of tissue imposed by countries outside of the United States or the import of tissue into the United States, and marketing approval. These requirements vary by jurisdiction, differ from those in the United States and may in some cases require us to perform additional pre-clinical or clinical testing. In many countries outside of the United States, coverage, pricing and reimbursement approvals are also required.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.8%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Market access, sales and marketing of medical devices in non-U.S. countries are subject to foreign regulatory requirements that vary widely from country to country. For example, in the European Economic Area (EEA), a medical device must meet MDDs/ IVDD Essential Requirements or, applicable on May 26, 2021, the MDR applicable on May 26, 2022, IVDR General Safety and Performance Requirements which apply to it, taking into account its intended purpose as defined by the data supplied by the manufacturer on the label, in the instructions for use or in promotional or sales materials or statements and as specified by the manufacturer in the clinical evaluation. Before placing a medical device on the EEA market, the manufacturer must draw up a declaration of conformity, certifying that the device complies with the MDD/IVDD/MDR/IVDR, and must then affix the CE mark. For medium and high-risk devices as well as low risk devices that are placed on the market in sterile condition, have a measuring function, or are reusable surgical instruments, the manufacturer must obtain a CE Certificate from a notified body. The notified body typically audits and examines the device&#8217;s technical documentation, including the clinical evaluation, and the quality system for the manufacture, design and final inspection of the relevant device before issuing a CE Certificate. Following the issuance of this CE Certificate, manufacturers may draw up the declaration of conformity and affix the CE mark to the devices covered by this CE Certificate.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.81%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Manufacturers of medical devices must document in a CER the evaluation of the clinical data related to the device. The CER is part of the device&#8217;s technical file. The evaluation shall document that the applicable Essential Requirements/General Safety and Performance Requirements are met and document the evaluation of the undesirable side-effects and the acceptability of the benefit-risk- ratio. The CER must be updated based on information from the post-market surveillance and vigilance activities related to the device. The CER shall consist, <span style="font-style:italic;">inter alia</span>, of analyzed clinical data collected from a clinical investigation of the device, or the results of other studies on substantially equivalent devices. Reliance on &#8220;substantially equivalent&#8221; devices is very restrictive and requires, <span style="font-style:italic;">inter alia</span>, that the manufacturer has full access to the technical documentation of the equivalent device on an ongoing basis and, if the &#8220;equivalent device&#8221; is not its own, that the manufacture has in place a contract with the manufacturer of the &#8220;equivalent device.&#8221;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.81%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Similar requirements apply in the UK. For access to the UK market, manufacturers must obtain a UKCA Certificate and affix a UKCA mark to their medical devices. However, the CE mark will be accepted in the UK until July 1, 2023.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Healthcare Reform</p>
<p style="margin-bottom:6pt;margin-top:5pt;text-indent:4.8%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2010, the Patient Protection and Affordable Care Act (ACA) was enacted in the United States. The ACA made a number of substantial changes to the way healthcare is financed both by governmental and private insurers. For example, the ACA requires each medical device manufacturer to pay a sales tax equal to 2.3% of the price for which such manufacturer sells its medical devices. The medical device tax was permanently repealed at the end of 2019. The ACA also contains a number of other provisions, including provisions governing enrollment in federal and state healthcare programs, reimbursement matters, and fraud and abuse, which we expect will impact our industry and our operations in ways that we cannot currently predict.</p>
<p style="margin-bottom:6pt;margin-top:5pt;text-indent:4.8%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">While the Biden administration has recently signaled its intent to pursue policies strengthening the ACA, the Trump administration and Congress sought to modify, repeal, or otherwise invalidate all, or certain provisions of, the ACA. The Trump administration issued three executive orders and other directives designed to delay the implementation of certain provisions of the ACA or otherwise circumvent some of the requirements for health insurance mandated by the ACA. For example, on December 20, 2019, President Trump signed appropriations legislation for fiscal year 2020 that repealed certain ACA-mandated fees, including the so-called &#8220;Cadillac&#8221; tax on certain high-cost employer-sponsored insurance plans, for tax years beginning after December 31, 2019&#59; the annual fee imposed on certain health insurance providers based on market share, for calendar years beginning December 31, 2020&#59; and the medical device excise tax on non-exempt medical devices, for sales after December 31, 2019. While Congress has not passed comprehensive legislation that would repeal all or part of the ACA, two bills affecting the implementation of certain taxes under the ACA have been signed into law. The Tax Cuts and Jobs Act of 2017 (TCJA) among other things, included a provision repealing, effective January 1, 2019, the tax-based shared responsibility payment, or penalty, imposed by the ACA on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the &#8220;individual mandate.&#8221; In December 2018, a federal district court in Texas ruled that the ACA&#8217;s individual mandate, without the penalty that was repealed effective January 1, 2019, was unconstitutional and could not be severed from the ACA. As a result, the court ruled the remaining provisions of the ACA were also invalid. The Fifth Circuit Court of Appeals affirmed the district court&#8217;s ruling that the individual mandate was unconstitutional, but it remanded the case back to the district court for further analysis of whether the mandate could be severed from the ACA&#59; that is, whether the entire ACA was therefore also unconstitutional. The United States Supreme Court granted certiorari on March 2, 2020 and heard oral argument on November 10, 2020&#59; the case is expected to be decided in 2021.</p>
<p style="margin-bottom:6pt;margin-top:5pt;text-indent:4.8%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other legislative changes have been proposed and adopted in the United States since the ACA was enacted to reduce healthcare expenditures. These changes include the Budget Control Act of 2011, which, among other things, led to aggregate reductions of Medicare payments to providers of up to 2% per fiscal year that started in 2013 and, due to subsequent statutory amendments, will remain in effect through 2030 unless additional Congressional action is taken. In 2020, the CARES Act temporarily suspended the 2% cut in Medicare payments from May 1, 2020 through December 31, 2020, and it extended the sequestrian reductions through FY 2030 to offset the cost of such temporary suspension. The Consolidated Appropriations Act, 2021 further extended the temporary suspension through March 31, 2021. The American Taxpayer Relief Act of 2012 made other changes, including reduced Medicare payments to several types of providers and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. If federal spending is further reduced, anticipated budgetary shortfalls may also impact the ability of relevant agencies, such as the FDA or the National Institutes of Health to continue to function at current levels. Amounts allocated to federal grants and contracts may be reduced or eliminated. These reductions may also impact the ability of relevant agencies to timely review and approve R&#38;D, manufacturing, and marketing activities, which may delay our ability to develop, market and sell any products we may develop. Additionally, the Biden administration has already indicated a shift in direction from Trump administration policies by issuing orders and other documents rolling back regulations and Executive Orders from the Trump administration, and as noted, indicating that it will pursue policies strengthening the ACA. The recent change in presidential administration could materially impact our business in ways that are difficult to predict.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:6pt;margin-top:5pt;text-indent:4.8%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2020, in its enactment of the Consolidated Appropriations Act, Congress enacted the No Surprises Act. This law, which takes effect January 1, 2022, bars </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">an out-of-network provi</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ders</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> from billing patient</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> in excess of the in-network cost sharing for services furnished with respect to a visit at </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">certain in-network health care facilities. The law establishes an independent dispute resolution process between the provider and the payer to determine the appropriate payment rate to the provider. As written, the No Surprises Act may apply to laboratory tests</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> furnished </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">by an independent laboratory </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">with respect to a hospital visit</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. The law establishes a notice and consent exception that generally does not apply to laboratory tests, although it allows HHS to apply this exception to certain advanced tests. Additional information on the applicability of the No Surprises Act, any applicability of the notice and consent exception to advanced tests, and the rules governing the independent dispute resolution process may be determined in rulemaking and subregulatory guidance from HHS, the Department of Labor, and the Department of the Treasury in 2021.&#160;&#160;</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Coverage and Reimbursement</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.81%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Reimbursement for laboratory tests in the United States is determined by various payers, including private third-party payers, managed care organizations, and state and federal health care programs, such as Medicare and Medicaid.&#160;In Medicare, coverage of an item or service depends on whether it is &#8220;reasonable and necessary&#8221; under the section 1862(a)(1)(A) of the Social Security Act (SSA). &#160;For single-source laboratory tests, this determination is typically made by the Medicare Administrative Contractor (MAC) with jurisdiction over the laboratory where the test is performed. Our Boulder, Colorado laboratory is currently under the jurisdiction of Novitas Solutions, Inc. Our De Soto, Kansas laboratory is under the jurisdiction of </span><span style="text-decoration:none;Background-color:#FFFFFF;color:#auto;">Wisconsin Physicians Service Insurance Corporation</span><span style="Background-color:#FFFFFF;">, which participates in the MolDX program (administered by another MAC, Palmetto GBA) to set coverage policy for molecular diagnostic tests. </span></p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:4.81%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Medicare pays for clinical diagnostic laboratory tests (CDLTs), on the Clinical Laboratory Fee Schedule (CLFS). Section 216(a) of the Protecting Access to Medicare Act of 2014 (PAMA), added section 1834A to the SSA, which established the current CLFS rate setting processes and coding provisions for CDLTs, and created a new subcategory of CDLTs called Advanced Diagnostic Laboratory Tests (ADLTs), with separate reporting and payment requirements.</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:3.85%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:4.81%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under section 1834A and its implementing regulations, clinical laboratories that receive the majority of their Medicare revenues from payments made under the CLFS and the Physician Fee Schedule report on a triennial basis (or annually for ADLTs), private payer rates and volumes for their tests with specific billing codes based on final payments made during a set data collection period. The payment rate for a test for the ensuing three-year period (or one year for ADLTs) is set at the weighted median of the rates reported under the specific billing code for that test. Newly established codes for CDLTs are priced until the next private payer rate reporting cycle either based on the payment rate of a comparable code on the CLFS (as determined by CMS) or at the median of rates submitted by the individual MACs based on statutory and regulatory factors. New ADLTs are initially priced at &#8220;actual list charge&#8221; for a nine-month period, after which they are priced based on private payer rates, with a recoupment provision if actual list charge is more than 130% of the weighted median of private payer rates reported. </p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:3.85%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:4.81%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The various payers in the United States also determine their own billing rules. In December 2020, Medicare revised its billing rules for clinical laboratory tests to require cancer-related protein-based Multianalyte Assays with Algorithmic Analyses to be billed directly to Medicare by the performing laboratory in most cases when performed on a specimen collected from a hospital outpatient. Molecular pathology tests and most ADLTs are also generally required to be billed directly to Medicare by the laboratory under these circumstances.&#160;&#160;</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Environmental, Health and Safety Regulations</p>
<p style="margin-bottom:6pt;margin-top:5pt;text-indent:4.8%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are subject to various federal, state, local, and foreign environmental, health and safety laws and regulations and permitting and licensing requirements. Such laws include those governing laboratory practices, the generation, storage, use, manufacture, handling, transportation, treatment, remediation, release and disposal of, and exposure to, hazardous materials and wastes and worker health and safety. Our operations involve the generation, use, storage and disposal of hazardous materials, and the risk of injury, contamination or non-compliance with environmental, health and safety laws and regulations or permitting or licensing requirements cannot be eliminated. In particular, the introduction of our Bio-Rad SARS-CoV-2 ddPCR and Platelia SARS-CoV-2 Total Ab tests requires that we maintain compliance with applicable and evolving federal and state laws and regulations relating to COVID-19, including the generation, use, storage, and disposal of testing materials and agents. Compliance with environmental laws and regulations has not had a material effect on our capital expenditures, earning or competitive position.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Corporate Information</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We were incorporated in Delaware in 2005 as Elston Technologies, Inc. Our principal executive offices are located at 2970 Wilderness Place, Suite 100, Boulder, Colorado 80301, and our telephone number is (303) 417-0500. On June 20, 2006, we changed our name to Biodesix, Inc.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Implications of Being an Emerging Growth Company and Smaller Reporting Company</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are an &#8220;emerging growth company&#8221; within the meaning of the Jumpstart Our Business Startups Act (JOBS Act). As an emerging growth company, we may take advantage of certain exemptions from various public company reporting requirements, including the requirement that our internal control over financial reporting be audited by our independent registered public accounting firm pursuant to Section 404 of the Sarbanes-Oxley Act of 2002, certain requirements related to the disclosure of executive compensation in our periodic reports and proxy statements, the requirement that we hold a nonbinding advisory vote on executive compensation and any golden parachute payments. We may take advantage of these exemptions until we are no longer an emerging growth company. Section 107 of the JOBS Act provides that an &#8220;emerging growth company&#8221; can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act of 1933, as amended (the Securities Act), for complying with new or revised accounting standards. In other words, an &#8220;emerging growth company&#8221; can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have elected to take advantage of the extended transition period to comply with new or revised accounting standards and to adopt certain of the reduced disclosure requirements available to emerging growth companies. As a result of the accounting standards election, we will not be subject to the same implementation timing for new or revised accounting standards as other public companies that are not emerging growth companies, which may make comparison of our financials to those of other public companies more difficult. Additionally, because we have taken advantage of certain reduced reporting requirements, the information contained herein may be different from the information you receive from other public companies in which you hold stock.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We will remain an emerging growth company until the earliest to occur of (i) the last day of the fiscal year in which we have more than $1.07 billion in annual revenue&#59; (ii) the date we qualify as a &#8220;large accelerated filer,&#8221; with at least $700 million of equity securities held by non-affiliates&#59; (iii) the date on which we have issued, in any three-year period, more than $1.0 billion in non-convertible debt securities&#59; and (iv) the last day of the fiscal year ending after the fifth anniversary of the completion of our initial public offering.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, we are a &#8220;smaller reporting company<span style="font-style:italic;">&#8221; </span>as defined in Item 10(f)(1) of Regulation S-K. Smaller reporting companies may take advantage of certain reduced disclosure obligations, including, among other things, providing only two years of audited financial statements. We will remain a smaller reporting company until the last day of the fiscal year in which (i) the market value of our common stock held by non-affiliates exceeds $250 million as of the end of that year&#8217;s second fiscal quarter, or (ii) our annual revenues exceeded $100 million during such completed fiscal year and the market value of our common stock held by non-affiliates exceeds $700 million as of the end of that year&#8217;s second fiscal quarter. To the extent we take advantage of such reduced disclosure obligations, it may also make comparison of our financial statements with other public companies difficult or impossible.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For certain risks related to our status as an emerging growth company, see &#8220;Risk Factors&#8212;Risks Related to our Common Stock&#8212;We are an &#8220;emerging growth company&#8221; and a &#8220;smaller reporting company,&#8221; and the reduced disclosure requirements applicable to emerging growth companies and smaller reporting companies may make our common stock less attractive to investors.&#8221;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Human Capital Resources</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our culture is underpinned by our cultural beliefs including an unwavering commitment to inclusion and diversity. We are committed to fostering a diverse and inclusive workplace that attracts and retains exceptional talent offering opportunities for our team members to grow and develop in their careers, supported by strong compensation, benefits and health and wellness programs. We regularly engage our team members in monthly all-hands meetings to align and focus on the current state of affairs of our business, our partnerships, new products, clinical trials, and other pertinent information about our business. We engage our team members in programs such as peer recognition, recruitment and our newly introduced Diversity, Equity and Inclusion Council that focus on recognizing outstanding individual contributions to company performance, cultural fit of new team members and acknowledging the diversity or our team to ensure our team members feel valued and can do their best work. We have a national annual community service initiative, &#8220;Biodesix Gives Back&#8221; that allows each team member to invest ten hours of paid community service to organizations of their choosing.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020, we had approximately 200 full-time and part-time employees </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">with more than 95% located in the United States. Of our 200 full-time and part-time team members, the majority of our team member base is located in proximity to our </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">corporate office</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">testing facilities located in Boulder, Colorado and </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our laboratory in </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">De</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Soto, Kansas</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Diversity, Equity and Inclusion</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.81%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe that a diverse employee population, including across background, gender, ethnicity, sexual orientation and lived experiences, is critical to our success. Our employees are encouraged to leverage their personal strengths and experiences to continually innovate and contribute to the development of new ideas and process improvements that drive better experiences for our partners. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Employee Engagement</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.81%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our company culture emphasizes the satisfaction and well-being of our team members and a diverse, engaged workforce. We solicit the opinion and views of our team members through surveys and peer focus groups. We have an established and valued Peer Recognition Culture. Teammates recognize other teammates publicly for their support and contributions fostering engagement and retention. We are reviewing feedback we received on our current cultural beliefs to determine if any modifications are needed. Additionally, the Company celebrates our top sales performers through the President&#8217;s Club and other top company performers as nominated by fellow team members through our four (4) Performance Excellence Awards that recognize creativity and innovation, an entrepreneurial spirit, a strategic impact on the success of the Company and lastly, embodying the Biodesix cultural beliefs and goes &#8220;above and beyond&#8221; daily.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Training and Development</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.81%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We invest in our team members career growth and provide team members with a wide range of development opportunities, including face-to-face, virtual, and self-directed learning, mentoring, coaching, and external development.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Health, Safety and Wellness</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.81%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The physical health, financial stability, life balance and mental health of each of our team members is vital to our success. We sponsor several cancer awareness activities in our local communities to bring engagement and awareness of health, safety and wellness to positively impact lives. We provide an Employee Assistance Program through our professional employer organization (PEO) to enhance physical, financial, and mental well-being for all our team members.&#160;&#160;Since the onset of the COVID-19 pandemic, we have successfully transitioned a significant portion of our workforce to a remote working environment and implemented several safety and social distancing measures in our sites to protect the health and safety of our team members. We also have provided extraordinary safety protocols and standards for all of &#8220;essential&#8221; team members who work in our Laboratories and our field sales organization including regularly scheduled serial testing for COVID-19. We also have an active &#8220;Friends and Family&#8221; COVID-19 testing program for our team members, their families and close friends.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Pay Equity</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.81%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The main objective of our compensation program is to provide a compensation package that will attract, retain, motivate, and reward superior team members who operate in a highly competitive and technologically challenging environment. We emphasize overall Company performance and provide equity incentives for all team members to align their financial interests with the interests of shareholders.&#160;&#160;In addition, we offer an employee stock purchase plan to all employees in which participants are eligible to purchase shares at a discount to market.&#160;&#160;We think like customers and act like owners.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.76%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Biodesix seeks fairness in total compensation. We benchmark with external comparisons, internal comparisons and look at the relationship between team member roles within the organization. We also review our compensation practices, both in terms of our overall workforce and individual team members, to ensure our pay is fair and equitable. We have no pay disparities based on gender, race, or ethnicity.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Available Information</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.76%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We file with, or furnish to, the SEC reports including our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and amendments to those reports pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended. These reports are available free of charge on our corporate website (www.biodesix.com) as soon as reasonably practicable after they are electronically filed with or furnished to the SEC. Copies of any materials we file with the SEC can be obtained at www.sec.gov. The foregoing website addresses are provided as inactive textual references only. The information provided on our website (or any other website referred to in this report) is not part of this report and is not incorporated by reference as part of this Annual Report on Form 10-K.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:6pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_1A_RISK_FACTOR">Item 1A. Risk Factors</p>
<p style="text-align:justify;margin-top:5pt;margin-bottom:6pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risk Factors Summary</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following<span style="letter-spacing:-0.4pt;"> </span>is<span style="letter-spacing:-0.35pt;"> </span>a<span style="letter-spacing:-0.35pt;"> </span>summary<span style="letter-spacing:-0.35pt;"> </span>of<span style="letter-spacing:-0.35pt;"> </span>the<span style="letter-spacing:-0.35pt;"> </span>principal<span style="letter-spacing:-0.35pt;"> </span>risks<span style="letter-spacing:-0.4pt;"> </span>that<span style="letter-spacing:-0.35pt;"> </span>could adversely affect<span style="letter-spacing:-0.35pt;"> </span>our<span style="letter-spacing:-0.35pt;"> </span>business, operations and financial results. <span style="letter-spacing:-0.35pt;"> </span>This<span style="letter-spacing:-0.35pt;"> </span>summary<span style="letter-spacing:-0.35pt;"> </span>does<span style="letter-spacing:-0.35pt;"> </span>not<span style="letter-spacing:-0.35pt;"> </span>address<span style="letter-spacing:-0.35pt;"> </span>all<span style="letter-spacing:-0.4pt;"> </span>of<span style="letter-spacing:-0.35pt;"> </span>the risk<span style="letter-spacing:-0.4pt;"> </span>that<span style="letter-spacing:-0.35pt;"> </span>we<span style="letter-spacing:-0.4pt;"> </span>face<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.35pt;"> </span>should<span style="letter-spacing:-0.3pt;"> </span>be<span style="letter-spacing:-0.3pt;"> </span>read in conjunction<span style="letter-spacing:-0.35pt;"> </span>with<span style="letter-spacing:-0.3pt;"> </span>the entire Risk Factors section below beginning at &#8220;Risks Related to Our Business<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.35pt;"> </span>Industry&#8221; within this Item 1A. Risk Factors.</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">We have a history of net losses, and we expect to continue to incur losses for the foreseeable future. If we achieve profitability, we may not be able to sustain it.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">The commercial success of our current and future diagnostic tests and services depends upon attaining significant market acceptance among payers, providers, clinics, patients, and biopharmaceutical companies.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">We may encounter difficulties in managing our growth, which could disrupt our operations.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">If we fail to retain sales and marketing personnel and, as we grow, fail to increase our sales and marketing capabilities or develop broad awareness of our diagnostic tests in a cost-effective manner, we may not be able to generate revenue growth.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">If we cannot maintain our current relationships, or enter into new relationships, with biopharmaceutical companies, our revenue prospects could be reduced.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Our commercial success and revenue growth are highly dependent on the demand for, and increased adoption of, our diagnostic tests, including our COVID-19 testing program, which are subject to a number of risks and uncertainty.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">We need to ensure strong product performance and reliability to maintain and grow our business.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">We depend upon third-party suppliers, including contract manufacturers and single source suppliers, making us vulnerable to supply problems and price fluctuations.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Natural or man-made disasters, pandemics, outbreaks, or other similar events, including a sustained outbreak or second wave of the novel strain of coronavirus disease, COVID-19, could significantly disrupt our business, and negatively impact our business, financial condition and results of operations.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Our industry is highly competitive and subject to rapid change, which could make our diagnostic tests and services obsolete. If we are unable to continue to innovate and expand and enhance our diagnostic tests and service offerings, we could lose customers or market share.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Any failure to offer high-quality support for our diagnostic tests and services may adversely affect our relationships with providers and negatively impact our reputation among patients and providers, which may adversely affect our business, financial condition and results of operations.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">We may face additional costs, loss of revenue, significant liabilities, harm to our brand, decreased use of our products or services and business disruption if there are disruptions in our information technology systems, including any security or data privacy breaches or other unauthorized or improper</span><span style="letter-spacing:0.3pt;color:#000000;"> </span><span style="color:#000000;">access.</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risk Factors</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Our operations and financial results are subject to various risks and uncertainties that could adversely affect our business, financial condition, and results of operations and cash flows.&#160;&#160;All of the risks described below should be carefully considered together with the other information contained and incorporated by reference in this report.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to our Business and Industry</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We have a history of net losses, and we expect to continue to incur losses for the foreseeable future. If we achieve profitability, we may not be able to sustain it.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have incurred losses since our inception, and expect to continue to incur losses for the foreseeable future. We have reported net losses of $31.4 million and $30.7 million the years ended December 31, 2020 and 2019, respectively. As a result of these losses, as of December 31, 2020, we had an accumulated deficit of approximately $258.8 million. Our cash and cash equivalents were $62.1<span style="font-weight:bold;"> </span>million as of December 31, 2020 and we expect our cash and cash equivalents will enable us to fund our operating expenses for at least the next twelve months. We have based this estimate on assumptions that in the future may prove to be wrong, and we could use our capital resources sooner than we currently expect. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect that our sales and marketing, research and development, regulatory and other expenses will continue to increase as we expand our marketing efforts for our diagnostic tests and services, expand existing relationships with our customers, obtain regulatory clearances or approvals or certifications for future enhancements to our existing diagnostic tests and services and conduct further clinical trials. In addition, we expect our general and administrative expenses to increase due to the additional costs associated with scaling our business operations and testing capacity, particularly with respect to our COVID-19 testing capacity, as well as being a public company, including due to legal, accounting, insurance, exchange listing and compliance, investor relations and other expenses. As a result, we expect to continue to incur operating losses and may never achieve profitability. We will need to generate significant additional revenue in order to achieve and sustain profitability. Even if we achieve profitability, we cannot be sure that we will remain profitable for any substantial period of time. If we do not achieve or sustain profitability, it will be more difficult for us to finance our business and accomplish our strategic objectives, either of which would have a material adverse effect on our business, financial condition and results of operations.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The commercial success of our current and future diagnostic tests and services and our revenue growth depends upon attaining significant market acceptance among payers, providers, clinics, patients, and biopharmaceutical companies.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our commercial success depends, in part, on the acceptance of our diagnostic tests and services as being safe and relatively simple for medical personnel to learn and use, clinically flexible, operationally versatile and, with respect to providers and payers, cost effective. We cannot predict how quickly, if at all, payers, providers, clinics and patients will accept future diagnostic tests and services or, if accepted, how frequently they will be used. These constituents must believe that our diagnostic tests offer benefits over other available alternatives.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The degree of market acceptance of our current and future diagnostic tests and services depends on a number of factors, including:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">whether</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">there</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">is</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">adequate</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">utilization</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">tests</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">by</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">clinicians,</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">biopharmaceutical</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">companies</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">other</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">target</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">groups</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">based</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">on</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">potential and perceived advantages of our diagnostic tests over those of our</span><span style="letter-spacing:-0.75pt;color:#000000;"> </span><span style="color:#000000;">competitors&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the convenience and ease of use of our diagnostic tests relative to those currently on the</span><span style="letter-spacing:-1.15pt;color:#000000;"> </span><span style="color:#000000;">market&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the effectiveness of our sales and marketing</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">efforts&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">ability</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">provide</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">incremental</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">data</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">that</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">show</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">clinical</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">benefits</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">cost</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">effectiveness,</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">operational</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">benefits,</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">diagnostic</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">tests&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the coverage and reimbursement acceptance of our products and</span><span style="letter-spacing:-0.6pt;color:#000000;"> </span><span style="color:#000000;">services&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">pricing</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">pressure,</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">including</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">from</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">group</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">purchasing</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">organizations</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">(GPOs),</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">seeking</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">obtain</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">discounts</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">on</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">diagnostic</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">tests</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">based</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">on</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">the collective bargaining power of the GPO</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">members&#59;</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="text-decoration:none;Background-color:#auto;"></span><span style="color:#000000;"></span><span style="color:#000000;">negative publicity regarding our or our competitors&#8217; diagnostic tests resulting from defects or</span><span style="letter-spacing:-1pt;color:#000000;"> </span><span style="color:#000000;">errors&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the accuracy of our tests relative to those of our</span><span style="letter-spacing:-0.6pt;color:#000000;"> </span><span style="color:#000000;">competitors&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">product labeling or product insert requirements by the FDA or other regulatory authorities or conformity assessment bodies&#59;</span><span style="letter-spacing:-1pt;color:#000000;"> </span><span style="color:#000000;">and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">limitations or warnings contained in the labeling cleared or approved by the FDA or other</span><span style="letter-spacing:-1.15pt;color:#000000;"> regulatory </span><span style="color:#000000;">authorities or conformity assessment bodies.</span></p></td></tr></table></div>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, even if our diagnostic tests achieve widespread market acceptance, they may not maintain that market acceptance over time if competing diagnostic tests or technologies, which are more cost effective or are received more favorably, are introduced. Failure to achieve or maintain market acceptance and/or market share would limit our ability to generate revenue and would have a material adverse effect on our business, financial condition and results of operations.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There is no assurance that our COVID-19 and antibody testing program will continue to be accepted by the market or that other diagnostic tests will become more accepted, produce quicker results or are more accurate. Further, the longevity and extent of the COVID-19 pandemic is uncertain. If the pandemic were to dissipate, whether due to a significant decrease in new infections, due to the availability of vaccines, or otherwise, the need for a COVID-19 test could decrease significantly and this could have an adverse effect on our results of operation and profitability.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may encounter difficulties in managing our growth, which could disrupt our operations.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020, we had approximately 200 full and part-time employees. Over the next several years, we expect to increase significantly the number of our employees and the scope of our operations, particularly in the areas of sales, marketing and reimbursement, product development, regulatory affairs and other functional areas, including finance, accounting, quality and legal. Additionally, we expect to expand our testing capacity as we commercialize additional diagnostic tests. To manage our anticipated future growth, we must continue to implement and improve our managerial, operational quality and financial systems, expand our facilities and continue to recruit and train additional qualified personnel. Due to our limited financial resources, we may not be able to manage the expansion of our operations or recruit and train additional qualified personnel in an effective manner. Any inability to manage growth could delay the execution of our business plans or disrupt our operations and have a material and adverse effect on our prospects.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since our inception, we have experienced multiple cycles of growth and anticipate further growth in our business operations. This future growth could create strain on our organizational, administrative and operational infrastructure, including laboratory operations, quality control, customer service and sales organization management. We expect to continue to increase headcount and to hire more specialized personnel in the future as we grow our business. We will need to continue to hire, train and manage additional qualified scientists, laboratory personnel, client and account services personnel, and sales and marketing staff and improve and maintain our technology to properly manage our growth. If our new hires perform poorly, if we are unsuccessful in hiring, training, managing and integrating these new employees or if we are not successful in retaining our existing employees, our business may be harmed.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may not be able to maintain the quality or expected turnaround times of our diagnostic tests and services, or satisfy customer demand as it grows. We may not be able to expand our COVID-19 testing capacity rapidly enough to meet the current and anticipated demand. Our ability to manage our growth properly will require us to continue to improve our operational, financial and management controls, as well as our reporting systems and procedures. The time and resources required to implement these new systems and procedures is uncertain, and failure to complete this in a timely and efficient manner could materially adversely affect our operations.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If we fail to retain sales and marketing personnel and, as we grow, fail to increase our sales and marketing capabilities or develop broad awareness of our diagnostic tests in a cost-effective manner, we may not be able to generate revenue growth.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have limited experience marketing and selling our diagnostic tests. We currently rely on our direct sales force to sell our diagnostic tests in the United States, and any failure to maintain and grow our direct sales force will negatively affect our business, financial condition and results of operations. The members of our direct sales force are highly trained and possess substantial technical expertise, which we believe is critical in increasing adoption of our diagnostic tests. The members of our United States sales force are at-will employees. The loss of these personnel to competitors, or otherwise, will negatively affect our business, financial condition and results of operations. If we are unable to retain our direct sales force personnel or replace them with individuals of equivalent technical expertise and qualifications, or if we are unable to successfully instill such technical expertise in replacement personnel, it may negatively affect our business, financial condition and results of operations.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In order to generate future growth, we plan to continue to expand and leverage our sales and marketing infrastructure. Identifying and recruiting qualified sales and marketing personnel and training them on how to promote our diagnostic tests, on applicable federal and state laws and regulations and on our internal policies and procedures requires significant time, expense and attention. It often takes several months or more before a sales representative is fully trained and productive. Our sales force may subject us to higher fixed costs than those of companies with competing techniques or diagnostic tests that utilize independent third parties, which could place us at a competitive disadvantage. It will negatively affect our business, financial condition and results of operations if our efforts to expand and train our sales force do not generate a corresponding increase in revenue, and our higher fixed costs may slow our ability to reduce costs in the face of a sudden decline in demand for our diagnostic tests. Any failure to hire, develop and retain talented sales personnel, to achieve desired productivity levels in a reasonable period of time, or timely reduce fixed costs, could negatively affect our business, financial condition and results of operations. Our ability to increase our customer base and achieve broader market acceptance of our diagnostic tests will depend to a significant extent on our ability to expand our marketing efforts. <span style="letter-spacing:-0.4pt;">We </span>plan to dedicate significant resources to our marketing programs. It will negatively affect our business, financial condition and results of operations if our marketing efforts and expenditures do not generate a corresponding increase in revenue. In addition, we believe that developing and maintaining broad awareness of our diagnostic tests in a cost-effective manner is critical to achieving broad<span style="letter-spacing:-0.2pt;"> </span>acceptance<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:-0.2pt;"> </span>our<span style="letter-spacing:-0.2pt;"> </span>diagnostic<span style="letter-spacing:-0.2pt;"> </span>tests.<span style="letter-spacing:-0.2pt;"> </span>Promotion<span style="letter-spacing:-0.2pt;"> </span>activities<span style="letter-spacing:-0.2pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>not<span style="letter-spacing:-0.2pt;"> </span>generate<span style="letter-spacing:-0.2pt;"> </span>patient<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:-0.2pt;"> </span>physician<span style="letter-spacing:-0.2pt;"> </span>awareness<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:-0.2pt;"> </span>increase<span style="letter-spacing:-0.2pt;"> </span>revenue,<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>even<span style="letter-spacing:-0.2pt;"> </span>if<span style="letter-spacing:-0.2pt;"> </span>they<span style="letter-spacing:-0.2pt;"> </span>do,<span style="letter-spacing:-0.2pt;"> </span>any increase in revenue may not offset the costs and expenses we incur in building our brand. If we fail to successfully promote, maintain and protect our brand, we may fail to attract or retain the physician acceptance necessary to realize a sufficient return on our brand building efforts, or to achieve the level of brand awareness that is critical for broad use of our diagnostic tests, which in turn could have a material adverse effect on our business, financial condition and results of<span style="letter-spacing:-0.25pt;"> </span>operations.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If we cannot maintain our current relationships, or enter into new relationships, with biopharmaceutical companies, our revenue prospects could be reduced.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We collaborate with biopharmaceutical companies to analyze patient samples for multiple applications primarily to support clinical trials, including patient identification, companion or complementary diagnostics and retrospective testing. For fiscal years 2020 and 2019, revenue from our top biopharmaceutical customer accounted for 3% and 21% of our total revenue, respectively. The revenue attributable to our biopharmaceutical customers may also fluctuate in the future, which could have a material adverse effect on our financial condition and results of operations. In addition, the termination of these relationships could result in a temporary or permanent loss of revenue.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our future success depends in part on our ability to maintain these relationships and to establish new relationships. Many factors have the potential to impact such collaborations, including the type of biomarker support required and our ability to deliver it and our biopharmaceutical customers&#8217; satisfaction with our tests or services and other factors that may be beyond our control. Furthermore, our biopharmaceutical customers may decide to decrease or discontinue their use of our tests due to changes in research and product development plans, failures in their clinical trials, financial constraints, or utilization of internal testing resources or tests performed by other parties, or other circumstances outside of our control. In addition to reducing our revenue, the loss of one or more of these relationships may reduce our exposure to research and clinical trials that facilitate the collection and incorporation of new information into our biobank and proprietary AI platform.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We engage in conversations with biopharmaceutical companies regarding potential commercial opportunities on an ongoing basis. There is no assurance that any of these conversations will result in a commercial agreement, or if an agreement is reached, that the resulting relationship will be successful or that clinical or research studies conducted as part of the engagement will produce successful outcomes. Speculation in the industry about our </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">existing or potential relationships with biopharmaceutical companies can also be a catalyst for adverse speculation about us, our tests and our technology, which can adversely affect our reputation and our business.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our operating results may fluctuate significantly, which makes our future operating results difficult to predict and could cause our operating results to fall below expectations or any guidance we may provide.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our quarterly and annual revenue and operating results may fluctuate significantly, which makes it difficult for us to predict our future operating results. Our quarterly and annual operating results may fluctuate as a result of a variety of factors, many of which are outside our control and, as a result, may not fully reflect the underlying performance of our business. These fluctuations may occur due to a variety of factors, including, but not limited to:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the level of demand for our diagnostic tests, which may vary</span><span style="letter-spacing:-0.7pt;color:#000000;"> </span><span style="color:#000000;">significantly&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">timing</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">cost</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">manufacturing</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">diagnostic</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">tests,</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">which</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">vary</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">depending</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">on</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">quantity</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">production</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">terms</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">our agreements with third-party suppliers and</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">manufacturers&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">expenditures that we may incur to acquire, develop, or commercialize additional tests and</span><span style="letter-spacing:-1.1pt;color:#000000;"> </span><span style="color:#000000;">technologies&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">unanticipated pricing</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">pressures&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">rate</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">at</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">which</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">we</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">grow</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">sales</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">force</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">speed</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">at</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">which</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">newly</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">hired</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">salespeople</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">become</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">effective,</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">cost</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">level</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">of investment</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">therein&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">degree</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">competition</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">in</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">industry</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">any</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">change</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">in</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">competitive</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">landscape</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">industry,</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">including</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">consolidation</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">among</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">our competitors or future</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">partners&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">coverage</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">reimbursement</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">policies</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">with</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">respect</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">lung</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">cancer</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">treatment</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">equipment,</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">potential</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">future</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">diagnostic</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">tests</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">that</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">compete</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">with our diagnostic</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">tests&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">timing</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">success</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">failure</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">clinical</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">trials</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">for</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">diagnostic</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">tests</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">any</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">enhancements</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">such</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">tests</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">we</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">develop</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">competing diagnostic</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">tests&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">positive</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">negative</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">coverage,</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">public</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">perception,</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">diagnostic</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">tests</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">those</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">competitors</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">broader</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">industry</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">trends&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the impact, if </span><span style="letter-spacing:-0.2pt;color:#000000;">any, </span><span style="color:#000000;">of the spread of COVID-19 and any newly discovered variants, and the resulting effects on the number of patients treated or the demand for our non-COVID-19</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">tests&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the timing and cost of, and level of investment in, research, development, licenses, regulatory approval, conformity certification, commercialization activities, acquisitions</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">other</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">strategic</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">transactions,</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">other</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">significant</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">events</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">relating</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">diagnostic</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">tests,</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">which</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">change</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">from</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">time</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">time&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">timing</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">cost</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">obtaining</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">regulatory</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">approvals,</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">conformity certifications or</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">clearances</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">for</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">planned</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">future</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">improvements</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">enhancements</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">diagnostic tests&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">changes in regulatory requirements or in the status of regulatory approvals or</span><span style="letter-spacing:-0.9pt;color:#000000;"> </span><span style="color:#000000;">applications or conformity certifications&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">pricing, discounts, and incentives for our diagnostic</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">tests&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">future accounting pronouncements or changes in our accounting policies&#59;</span><span style="letter-spacing:-0.65pt;color:#000000;"> </span><span style="color:#000000;">and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">general market</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">conditions.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, we can provide no assurances that the demand for our COVID-19 and antibody testing program will be sustained, and even if it is, the period of time for which it would be sustained. As vaccines for COVID-19 become more available and widespread in the future, we expect the demand for our COVID-19 diagnostic and antibody tests will decrease. As a result, the increase in revenue due to any increase in demand for our COVID-19 and antibody testing program is not indicative of results expected for any future period.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The cumulative effects of these factors could result in large fluctuations and unpredictability in our quarterly and annual financial results. As a result, comparing our operating results on a period-to-period basis may not be meaningful. Further, our historical results are not necessarily indicative of results expected for any future period, and </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">quarterly results are not necessarily indicative of the results to be expected for the full year or any other period, and accordingly should not be relied upon as indicative of future performance.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This variability and unpredictability could also result in our failing to meet the expectations of industry or financial analysts or investors for any period. If our revenue or operating results fall below the expectations of analysts or investors or below any guidance we may provide, or if the guidance we provide is below the expectations of analysts or investors, the price of our common stock could decline substantially. Such a stock price decline could occur even when we have met any publicly stated guidance we may provide, and could in turn negatively impact our business, financial condition and results of operations.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We need to ensure strong product performance and reliability to maintain and grow our business<span style="font-weight:normal;">.</span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We need to maintain and continuously improve the performance and reliability of our diagnostic tests, including our Biodesix WorkSafe testing program, the Nodify XL2 and Nodify CDT tests, and the GeneStrat and VeriStrat tests, to achieve our profitability objectives. Poor product performance and reliability could lead to customer dissatisfaction, adversely affect our reputation and revenues, and increase our service and distribution costs and working capital requirements. Our diagnostic tests may contain errors or defects, and while we have made efforts to test them extensively, we cannot assure that our current diagnostic tests, or those developed in the future, will not have performance problems. Performance issues with our diagnostic tests will increase our costs in the near-term and accordingly adversely affect our business, financial condition and results of operations.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We depend upon third-party suppliers, including contract manufacturers and single source suppliers, making us vulnerable to supply problems and price fluctuations.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We rely on third-party suppliers, including in some instances single source suppliers, to provide us with certain components of our diagnostic tests. The number of suppliers feeding into the production of our diagnostic tests is in excess of 65 worldwide. We consider a select few of these suppliers, located in the United States, Europe and China, as critical single source providers of components. Bio-Rad Laboratories, as described below, is the sole source supplier for our GeneStrat tests and COVID-19 diagnostic and antibody testing program. Oncimmune is also the sole source supplier for our Nodify CDT tests. While we have initiated the second source qualification process for the majority of these critical components, we may not be successful in securing second sourcing for all of them at all or on a timely basis.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, we may purchase supplies through purchase orders and may not have long-term supply agreements with, or guaranteed commitments from, many of our suppliers, including single source suppliers. Additionally, at present, we rely on contract manufacturers for the production of our supplies for our diagnostic test. Many of our suppliers and contract manufacturers are not obligated to perform services or supply diagnostic testing materials for any specific period, in any specific quantity or at any specific price, except as may be provided in a particular purchase order. We depend on our suppliers and contract manufacturers to provide us and our customers with materials in a timely manner that meet our and their quality, quantity and cost requirements. These suppliers and contract manufacturers may encounter problems during manufacturing for a variety of reasons, any of which could delay or impede their ability to meet our demand. These suppliers and contract manufacturers may cease producing the components we purchase from them or otherwise decide to cease doing business with us. Further, we maintain limited volumes of inventory from most of our suppliers and contract manufacturers. If we inaccurately forecast demand for finished goods, we may be unable to meet customer demand which could harm our competitive position and reputation. In addition, if we fail to effectively manage our relationships with our suppliers and contract manufacturers, we may be required to change suppliers or contract manufacturers. While we believe replacement suppliers exist for all materials, components and services necessary to manufacture our diagnostic tests, establishing additional or replacement suppliers for any of these materials, components or services, if required, could be time-consuming and expensive, may result in interruptions in our operations and product delivery, may affect the performance of our diagnostic tests or could require that we modify their processes. Even if we are able to find replacement suppliers, we will be required to verify that the new supplier maintains facilities, procedures and operations that comply with our quality expectations and applicable regulatory requirements. Any of these events could require that we obtain a new regulatory authority approval before we implement the change, which we may not obtain on a timely basis or at all.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If our third-party suppliers fail to deliver the required commercial quantities of materials on a timely basis and at commercially reasonable prices, and we are unable to find one or more replacement suppliers capable of </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">production at a substantially equivalent cost in substantially equivalent volumes and quality on a timely basis, the continued commercialization of our diagnostic tests, the supply of our diagnostic tests to customers and the development of any future diagnostic tests will be delayed, limited or prevented, which could have material adverse effect on our business, financial condition and results of operations.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We entered into a nonexclusive license and supply agreement with Bio-Rad in August 2019. We rely on Bio-Rad to supply equipment and reagents used to perform ddPCR testing, a service offered by us under a variety of fee for service agreements and the core technology powering the GeneStrat test. Under the terms of this arrangement, we were granted non-exclusive rights to utilize the intellectual property, machinery, materials, reagents, supplies and know-how necessary for the performance of ddPCR in cancer detection testing for third parties in the United States. We agreed to purchase all of the necessary supplies and reagents for such testing exclusively from Bio-Rad. As further consideration for the non-exclusive license, we agreed to pay a royalty of two and one half percent (2.5%) on net service fees (such fees are defined in the Non-Exclusive License Agreement with Bio-Rad) collected from contracted third parties who receive ddPCR services from us. In addition, we have separately been granted permission by Bio-Rad to use the Bio-Rad SARS-CoV-2 ddPCR test and Platelia SARS-CoV-2 Total Ab test for commercial diagnostic services. For more information regarding this license and supply agreement and the permission granted to us by Bio-Rad with respect to such tests, please see &#8220;Business&#8212;Material Agreements&#8212;Agreements with Bio-Rad.&#8221;</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This relationship may require us to incur non-recurring and other charges, increase our near and long-term expenditures, issue securities that dilute our existing stockholders or disrupt our management and business. We cannot be certain that, following the realization of this relationship, we will achieve the revenue or specific net income that justifies our entry into it. Any termination of this relationship, or delays in entering into new strategic partnership agreements with Bio-Rad, could delay our sales and marketing efforts, which would harm our business prospects, financial condition and results of operations.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may not be able to sufficiently reduce costs in the performance, manufacturing and production of our diagnostic tests to achieve sustainable gross margins.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We partner with contract manufacturers in the development and production of supplies for our diagnostic tests. While we are undertaking a number of initiatives designed to reduce the cost of performing our diagnostic tests, including reducing the costs of supplies, there is no guarantee that we will be able to achieve planned cost reductions from our various cost savings initiatives. There may also be unforeseen occurrences that increase our costs, such as increased prices of the components of our diagnostic tests, changes to labor costs or less favorable terms with third-party suppliers or contract manufacturing partners. If we are unable to reduce our costs, or if cost reductions are less significant or less timely than projected, we will not be able to achieve sustainable gross margins, which would adversely affect our ability to invest in and grow our business and adversely impact our business, financial condition and results of operations.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">A pandemic, epidemic or outbreak of an infectious disease in the United States or worldwide, including the outbreak of the novel strain of coronavirus disease, COVID-19, and its variants could adversely affect our business.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If a pandemic, epidemic or outbreak of an infectious disease occurs in the United States or worldwide, our business may be adversely affected. COVID-19 has spread throughout the United States and to most countries globally. Numerous U.S. state and local jurisdictions have imposed, and others in the future may impose, &#8220;shelter-in-place&#8221; orders, quarantines, executive orders and similar government orders and restrictions for their residents to control the spread of<span style="letter-spacing:-0.25pt;"> </span>COVID-19.<span style="letter-spacing:-0.2pt;"> </span>In<span style="letter-spacing:-0.2pt;"> </span>March<span style="letter-spacing:-0.2pt;"> </span>2020,<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.2pt;"> </span>Governor<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.2pt;"> </span>Colorado,<span style="letter-spacing:-0.25pt;"> </span>where<span style="letter-spacing:-0.2pt;"> </span>our<span style="letter-spacing:-0.2pt;"> </span>headquarters<span style="letter-spacing:-0.2pt;"> </span>are<span style="letter-spacing:-0.2pt;"> </span>located,<span style="letter-spacing:-0.2pt;"> </span>issued<span style="letter-spacing:-0.2pt;"> </span>&#8220;stay<span style="letter-spacing:-0.2pt;"> </span>at<span style="letter-spacing:-0.2pt;"> </span>home&#8221;<span style="letter-spacing:-0.25pt;"> </span>orders<span style="letter-spacing:-0.2pt;"> </span>limiting<span style="letter-spacing:-0.2pt;"> </span>non-essential<span style="letter-spacing:-0.2pt;"> </span>activities, travel and business operations. Such orders or restrictions have resulted in reduced operations at our headquarters, work stoppages, slowdowns and delays, travel restrictions and cancellation of events. Other disruptions or potential disruptions include the inability of our suppliers to manufacture components and parts and to deliver these to us on a timely basis, or at all&#59; disruptions in our production schedule and ability to assemble diagnostic tests&#59; inventory shortages or obsolescence&#59; delays in actions of regulatory bodies&#59; diversion of or limitations on employee resources that would otherwise be focused on the operations of our business&#59; delays in growing or reductions in our sales organization, including through delays in hiring, lay-offs, furloughs or other losses of sales representatives&#59; business adjustments or disruptions of certain third parties, including suppliers, medical institutions and clinical investigators with whom we conduct business&#59; and additional government requirements or other incremental mitigation efforts that may further impact our or our suppliers&#8217; capacity to manufacture our diagnostic<span style="letter-spacing:-0.3pt;"> </span>tests.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The COVID-19 pandemic also has negatively </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">affect</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ed</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> our non-COVID-19 testing-related revenue and our clinical studies.</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> For example, cancer patients may have more limited access to hospitals, healthcare providers and medical resources as they take steps to control the spread of COVID-19. Our biopharmaceutical customers are facing challenges in recruiting patients and in conducting clinical trials to advance their pipelines, for which our tests could be utilized. As a result of the COVID-19 pandemic, beginning in the latter half of March 2020, we have been receiving fewer samples for non-COVID-19 testing on a daily average basis from our clinical and biopharmaceutical customers than before the outbreak of the COVID-19 pandemic. Further, our clinical studies, such as our ongoing INSIGHT study and our recently launched ALTITUDE study, as well as our arrangements with our biopharmaceutical customers, are expected to take longer to complete than what we expected before the outbreak of the COVID-19 pandemic.</span></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The COVID-19 pandemic has also created an opportunity for our diagnostic tests and we have commercialized two diagnostic tests to test for the presence of COVID-19 and antibodies. We are expecting to increase our testing capacity for our COVID-19 diagnostic and antibody testing program in the near term to meet the rising demand for rapid and accurate testing. We expect that the revenue we generate from this expansion will comprise a significant portion of our revenue for the first quarter of 2021. However, there is no assurance that our COVID-19 diagnostic and antibody testing program will continue to be accepted by the market or that other diagnostic tests will become more accepted, produce quicker results or be accurate. Further, the longevity and extent of the COVID-19 pandemic is uncertain. If the pandemic were to dissipate, whether due to a significant decrease in new infections, due to the availability of vaccines, or otherwise, the need for a COVID-19 test could decrease significantly and this could have an adverse effect on our results of operations and profitability. As a result, the increase in revenue due to any increase in demand for these diagnostic tests may not be indicative of our future revenue.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The extent to which the COVID-19 pandemic impacts our business will depend on future developments, which are highly uncertain and cannot be predicted, including new information which may emerge concerning the severity and spread of COVID-19 and the actions to contain COVID-19 or treat its impact, among others. Furthermore, there is no assurance that our diagnostic tests will continue to be effective against the virus in the future.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">While the potential economic impact brought by, and the duration of, any pandemic, epidemic or outbreak of an infectious disease, including COVID-19, may be difficult to assess or predict, the widespread COVID-19 pandemic has resulted in, and may continue to result in, significant disruption of global financial markets and a reduction in our ability to access capital, which could adversely affect our liquidity. In addition, a recession or market correction resulting from the spread of an infectious disease, including COVID-19, could materially affect our business. Such economic recession could have a material adverse effect on our long-term business. To the extent the COVID-19 pandemic adversely affects our business and financial results, it may also have the effect of heightening many of the other risks described in this &#8220;Risk Factors&#8221; section.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Natural or man-made disasters and other similar events, including the COVID-19 pandemic, may significantly disrupt our business, and negatively impact our business, financial condition and results of operations.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A significant portion of our employee base, operating facilities and infrastructure are centralized in Boulder, Colorado and we operate a laboratory facility in De Soto, Kansas. Any of our facilities may be harmed or rendered inoperable by natural or man-made disasters, including earthquakes, wildfires, floods, nuclear disasters, riots, acts of terrorism or other criminal activities, infectious disease outbreaks or pandemic events, including the COVID-19 pandemic, power outages and other infrastructure failures, which may render it difficult or impossible for us to operate our business for some period of time. Our facilities would likely be costly to repair or replace, and any such efforts would likely require substantial time. Any disruptions in our operations could adversely affect our business, financial condition and results of operations and harm our reputation. Moreover, although we have disaster recovery plans, they may prove inadequate. We may not carry sufficient business insurance to compensate for losses that may occur. Any such losses or damages could have a material adverse effect on our business, financial condition and results of operations. In addition, the facilities of our suppliers and manufacturers may be harmed or rendered inoperable by such natural or man-made disasters, which may cause disruptions, difficulties or otherwise materially and adversely affect our business.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Any failure to offer high-quality support for our diagnostic tests and services may adversely affect our relationships with providers and negatively impact our reputation among patients and providers, which may adversely affect our business, financial condition and results of operations.</span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In implementing and using our diagnostic tests and services, providers depend on our support to resolve issues in a timely manner. We may be unable to respond quickly enough to accommodate short-term increases in demand for customer support. Increased customer demand for support could increase costs and adversely affect our business, financial condition and results of operations. Our sales are highly dependent on our reputation and on positive recommendations from our existing patients, care partners, providers and clinics. Any failure to maintain high-quality customer support, or a market perception that we do not maintain high-quality customer support, could adversely affect our reputation, our ability to sell our diagnostic tests and services, and in turn our business, financial condition and results of operations.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The sizes of the markets for our diagnostic tests and services and any future diagnostic tests and services may be smaller than we estimate and may decline.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our estimates of the annual total addressable market for our diagnostic tests and services are based on a number of internal and third-party estimates and assumptions, including, without limitation, the assumed prices at which we can sell our diagnostic tests and services in the market. While we believe our assumptions and the data underlying our estimates are reasonable, these assumptions and estimates may not be correct and the conditions supporting our assumptions or estimates may change at any time, thereby reducing the predictive accuracy of these underlying factors.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a result, our estimates of the annual total addressable market for our diagnostic tests and services in different market segments may prove to be incorrect. If the actual number of patients who would benefit from our diagnostic tests, the price at which we can sell them or the annual total addressable market for them is smaller than we have estimated, it may impair our sales growth and negatively affect our business, financial condition and results of operations.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our industry is subject to rapid change, which could make our solutions and the diagnostic tests we develop and services we offer, obsolete. If we are unable to continue to innovate and improve our diagnostic tests and services we offer, we could lose customers or market share.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our industry is characterized by rapid changes, including technological and scientific breakthroughs, frequent new product introductions and enhancements and evolving industry standards, all of which could make our current diagnostic tests and others we are developing obsolete. Our future success will depend on our ability to keep pace with the evolving needs of our customers on a timely and cost-effective basis and to pursue new market opportunities that develop as a result of scientific and technological advances. In recent years, there have been numerous advances in technologies relating to the diagnosis and treatment of cancer. There have also been advances in methods used to analyze very large amounts of molecular information. We must continuously enhance our offerings and develop new and improved diagnostic tests to keep pace with evolving standards of care. If we do not leverage or scale our sample and data biobank to discover new diagnostic tests or applications or update our diagnostic tests to reflect new scientific knowledge, including about lung cancer biology, information about new cancer therapies or relevant clinical trials, our diagnostic tests could become obsolete and sales of our current diagnostic tests and any new tests we develop could decline or fail to grow as expected. This failure to make continuous improvements to our diagnostic tests to keep ahead of those of our competitors could result in the loss of customers or market share that would adversely affect our business, financial condition and results of operations.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may face additional costs, loss of revenue, significant liabilities, harm to our brand, decreased use of our products or services and business disruption if there are any security or data privacy breaches or other unauthorized or improper access.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with various facets of our business, we collect and use a variety of personal data, such as names, mailing addresses, email addresses, mobile phone numbers, location information, prescription information and other medical information. Any failure to prevent or mitigate security breaches or improper access to, use, disclosure or other misappropriation of our data or consumers&#8217; personal data could result in significant liability under state (e.g., state breach notification and privacy laws such as the California Consumer Privacy Act (CCPA) federal (e.g., the Health Insurance Portability and Accountability Act of 1996 (HIPAA) and the Health Information Technology for Economic and Clinical Health Act (HITECH Act) and laws in other jurisdictions (e.g., the EU General Data Protection Regulation (GDPR). Such an incident may also cause a material loss of revenue from the potential adverse impact to our reputation and brand, affect our ability to retain or attract new users of our diagnostic tests and services and potentially disrupt our business.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unauthorized disclosure of sensitive or confidential patient or employee data, including personally identifiable information, whether through a breach of computer systems, systems failure, employee negligence, fraud or misappropriation, or otherwise, or unauthorized access to or through our information systems and networks, whether by our employees or third parties, could result in negative publicity, legal liability and damage to our reputation. Unauthorized disclosure of personally identifiable information could also expose us to sanctions for violations of data privacy laws and regulations around the world. </span><span style="letter-spacing:-0.35pt;">To </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the extent that any disruption or security breach resulted in a loss of or damage to our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability and the further development of our product candidates could be delayed.</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">example,</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">loss</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">damage</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">clinical</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">trial</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">data,</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">such</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">as</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">from</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">completed</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ongoing</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">clinical</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">trials,</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">any</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">product</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">candidates</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">would likely</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">result</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">delays</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">marketing</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">approval</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">efforts</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">significantly</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">increased</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">costs</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">an</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">effort</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">recover</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">reproduce</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">data.</span></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As we become more dependent on information technologies to conduct our operations, cyber incidents, including deliberate attacks and attempts to gain unauthorized access to computer systems and networks, may increase in frequency and sophistication. These threats pose a risk to the security of our systems and networks, the confidentiality and the availability and integrity of our data and these risks apply both to us, and to third parties on whose systems we rely for the conduct of our business. Because the techniques used to obtain unauthorized access, disable or degrade service or sabotage systems change frequently and often are not recognized until launched against a target, we and our partners may be unable to anticipate these techniques or to implement adequate preventative measures. We have in the past experienced, and may in the future, experience security incidents. While no security incidents in the past have had a material adverse effect on our business, financial condition and results of operations, we cannot predict the impact of any such future events. Further, we do not have any control over the operations of the facilities or technology of our cloud and service providers, including any third-party vendors that collect, process and store personal data on our behalf. Our systems, servers and platforms and those of our service providers may be vulnerable to computer viruses or physical or electronic break-ins that our or their security measures may not detect. Individuals able to circumvent such security measures may misappropriate our confidential or proprietary information, disrupt our operations, damage our computers or otherwise impair our reputation and business. We may need to expend significant resources and make significant capital investments to protect against security breaches or to mitigate the impact of any such breaches. In addition, to the extent that our cloud and other service providers, experience security breaches that result in the unauthorized or improper use of confidential data, employee data or personal data, we may not be indemnified for any losses resulting from such breaches. There can be no assurance that we or our third-party providers will be successful in preventing cyber-attacks or successfully mitigating their effects. If we are unable to prevent or mitigate the impact of such security breaches, our ability to attract and retain new customers, patients and other partners could be harmed as they may be reluctant to entrust their data to us, and we could be exposed to litigation and governmental investigations, which could lead to a potential disruption to our business or other adverse consequences.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We have significant payer concentration, with a limited number of customers accounting for a substantial portion of our revenues.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For year ended December 31, 2020, Medicare reimbursed to us 18% of our diagnostic test revenue and two<span style="font-weight:bold;"> </span>healthcare providers accounted for 47% of our total revenue. For the year ended December 31, 2019, Medicare reimbursed to us 60% of our diagnostic test revenue and one biopharmaceutical customer accounted for 21% of our total revenue and 71% of our service revenue. There are risks whenever a large percentage of total revenues are concentrated with a limited number of payers and customers. It is not possible for us to predict the level of demand for our diagnostic tests and services that will be generated by any of these customers in the future. In addition, revenues from these larger customers may fluctuate from time to time based on these customers&#8217; business needs, the timing of which may be affected by market conditions or other factors outside of our control. These payers and customers could also potentially pressure us to reduce the prices we charge for our diagnostic tests and services, which could have an adverse effect on our margins and financial position and could negatively affect our revenues and results of operations. If any of our largest payers terminates its relationship with us or our tests are no longer reimbursable by such payer, such termination could negatively affect our revenues and results of operations.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our results of operations will be materially harmed if we are unable to accurately forecast customer demand for, and utilization of, our diagnostic tests and manage our inventory.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;letter-spacing:-0.35pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To ensure adequate inventory <span style="letter-spacing:-0.15pt;">supply, </span>we must forecast inventory needs and manufacture our diagnostic tests based on our estimates of future demand for our diagnostic tests. Our ability to accurately forecast demand for them could be negatively affected by many factors, including our failure to accurately manage our expansion strategy, product introductions by competitors, an increase or decrease in customer demand for our diagnostic tests or for those of our competitors, our failure to accurately forecast customer acceptance of new diagnostic tests, unanticipated changes in general market conditions or regulatory matters and weakening of economic conditions or consumer confidence in future economic conditions. Inventory levels in excess of customer demand may result in inventory write-downs or write-offs, which would cause our gross margin to be adversely affected and could impair the strength of our brand. Conversely, if we underestimate customer demand for our diagnostic tests, our supply chain, manufacturing partners and/or internal manufacturing team may not be able to deliver components and diagnostic tests to meet our requirements, and this could result in damage to our reputation, sales growth and customer relationships. In addition, if we experience a significant increase in demand, such as we are currently experiencing with respect to our COVID-19 and antibody testing program, additional supplies of raw materials or additional manufacturing capacity may not be available when required on terms that are acceptable to us, or at all, or suppliers may not be able to allocate sufficient capacity in order to meet our increased requirements, which will adversely affect our business, financial condition and results of operations.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If we experience significant disruptions in our information technology systems, our business may be adversely affected.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We depend on our information technology systems for the efficient functioning of our business, including the performance, distribution and maintenance of our diagnostic tests and services, as well as for accounting, data storage, compliance, purchasing and inventory management. We do not have redundant information technology in all aspects of our systems at this time. Our information technology systems may be subject to computer viruses, ransomware or other malware, attacks by computer hackers, failures during the process of upgrading or replacing software, databases or components thereof, power outages, damage or interruption from fires or other natural disasters, hardware failures, telecommunication failures and user errors, among other malfunctions. We could be subject to an unintentional event that involves a third party gaining unauthorized access to our systems, which could disrupt our operations, corrupt our data or result in release of our confidential information. Technological interruptions would disrupt our operations, including our ability to timely ship and track diagnostic test orders and results, project inventory requirements, manage our supply chain and otherwise adequately service our customers or disrupt our customers&#8217; ability to use our diagnostic tests. In the event we experience significant disruptions, we may be unable to repair our systems in an efficient and timely manner. Accordingly, such events may disrupt or reduce the efficiency of our entire operation and have a material adverse effect on our business, financial condition and results of operations.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Currently, we carry business interruption coverage to mitigate certain potential losses but this insurance is limited in amount, and we cannot be certain that such potential losses will not exceed our policy limits. The successful assertion of one or more large claims against us that exceed or are not covered by our insurance coverage or changes in our insurance policies, including premium increases or the imposition of large deductible or co-insurance requirements, could have a material adverse effect on our business, financial condition and results of operations. <span style="letter-spacing:-0.4pt;">We </span>are increasingly dependent on complex information technology to manage our infrastructure. Our information systems require an ongoing commitment of significant resources to maintain, protect and enhance our existing systems. Failure to maintain or protect our information systems and data integrity effectively could have a material adverse effect on our business, financial condition and results of operations.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit or halt the marketing and sale of our diagnostic tests and services. The expense and potential unavailability of insurance coverage for liabilities resulting from issues with our diagnostic tests and services could harm us and negatively impact sales.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We face an inherent risk of product liability as a result of the marketing and sale of our diagnostic tests and services. For example, we may be sued if our diagnostic tests or services cause or are perceived to cause injury or are found to be otherwise unsuitable during manufacturing, marketing or sale. Any such product liability claim may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability or a breach of warranties. In addition, we may be subject to claims against us even if the apparent injury is due to the actions of others or the pre-existing health of the patient. For example, medical personnel, care partners and patients collect samples for our diagnostic tests. If these medical personnel, care partners or patients are not properly trained, are negligent or use our diagnostic tests incorrectly, the capabilities of such tests may be diminished or the patient may suffer critical injury. We may also be subject to claims that are caused by the activities of our suppliers, such as those who provide us with components and sub-assemblies for our diagnostic tests.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit or halt the marketing and sale of our diagnostic tests and services. Even successful defense would require significant financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">decreased demand for our diagnostic tests and</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">services&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">harm to our</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">reputation&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">initiation of investigations by</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">regulators&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">costs to defend the related</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">litigation&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">a diversion of management&#8217;s time and our</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">resources&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">substantial monetary awards to trial participants or</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">patients&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">product recalls, withdrawals, or labeling, marketing, or promotional</span><span style="letter-spacing:-0.55pt;color:#000000;"> </span><span style="color:#000000;">restrictions&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">loss of</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">revenue&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">adverse impact on the market price of our common stock&#59;</span><span style="letter-spacing:-0.6pt;color:#000000;"> </span><span style="color:#000000;">and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">exhaustion of any available insurance and our capital</span><span style="letter-spacing:-0.5pt;color:#000000;"> </span><span style="color:#000000;">resources.</span></p></td></tr></table></div>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe we have adequate product liability insurance, but it may not prove to be adequate to cover all liabilities that we may incur. Insurance coverage is increasingly expensive. We may not be able to maintain or obtain insurance at a reasonable cost or in an amount adequate to satisfy any liability that may arise. Our insurance policy contains various exclusions, and we may be subject to a product liability claim for which we have no coverage. The potential inability to obtain sufficient product liability insurance at an acceptable cost to protect against product liability claims could prevent or inhibit the marketing and sale of our diagnostic tests and services. We may have to pay any amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient capital to pay such amounts, which would have a material adverse effect on our business, financial condition and results of operations. In addition, any product liability claims brought against us, with or without merit, could increase our product liability insurance rates or prevent us from securing continuing coverage, harm our reputation in the industry, significantly increase our expenses and reduce product sales.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We face competition from many sources, including larger companies, and we may be unable to compete successfully.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There are a number of lung cancer diagnostic solutions companies in the United States, Europe and Asia. Notable competitors in the United States include Veracyte, Inc., Guardant Health, Inc., and Foundation Medicine, Inc. These competitors all provide cancer-focused diagnostic tests to hospitals, researchers, clinicians, laboratories and other medical facilities. Many of these organizations are significantly larger with greater financial and personnel resources than us, and enjoy significantly greater market share and have greater resources than we do. As a consequence, they may be able to spend more on product development, marketing, sales and other product initiatives than we can. Some of our competitors have:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">substantially greater name</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">recognition&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">broader, deeper, or longer-term relations with healthcare professionals, customers, and third-party</span><span style="letter-spacing:-1pt;color:#000000;"> </span><span style="color:#000000;">payers&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">more established distribution</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">networks&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">additional</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">lines</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">diagnostic</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">tests</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">ability</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">offer</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">rebates</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">bundle</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">them</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">offer</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">greater</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">discounts</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">other</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">incentives</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">gain</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">a competitive</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">advantage&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">greater</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">experience</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">in</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">conducting</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">research</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">development,</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">manufacturing,</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">clinical</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">trials,</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">marketing</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">obtaining</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">regulatory</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">clearance</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">or approval or certification for diagnostic tests&#59;</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">greater financial and human resources for product development, sales and marketing and patent</span><span style="letter-spacing:-1.15pt;color:#000000;"> </span><span style="color:#000000;">litigation.</span></p></td></tr></table></div>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our continued success depends on our ability to:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">further penetrate the lung disease diagnostic solutions market and increase utilization of our diagnostic</span><span style="letter-spacing:-1.15pt;color:#000000;"> </span><span style="color:#000000;">tests&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">maintain</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">widen</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">technology</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">lead</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">over</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">competitors</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">by</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">continuing</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">innovate</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">deliver</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">new</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">product</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">enhancements</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">on</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">a</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">continuous basis&#59;</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">cost-effectively</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">manufacture</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">diagnostic</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">tests</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">their</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">component</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">parts</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">as</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">well</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">as</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">drive</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">down</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">cost</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">service.</span></p></td></tr></table></div>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, competitors with greater financial resources than ours could acquire other companies to gain enhanced name recognition and market share,<span style="letter-spacing:-0.2pt;"> </span>as<span style="letter-spacing:-0.2pt;"> </span>well<span style="letter-spacing:-0.2pt;"> </span>as<span style="letter-spacing:-0.2pt;"> </span>new<span style="letter-spacing:-0.15pt;"> </span>technologies<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:-0.2pt;"> </span>diagnostic<span style="letter-spacing:-0.2pt;"> </span>tests<span style="letter-spacing:-0.2pt;"> </span>that<span style="letter-spacing:-0.15pt;"> </span>could<span style="letter-spacing:-0.2pt;"> </span>effectively<span style="letter-spacing:-0.2pt;"> </span>compete<span style="letter-spacing:-0.2pt;"> </span>with<span style="letter-spacing:-0.2pt;"> </span>our<span style="letter-spacing:-0.15pt;"> </span>existing<span style="letter-spacing:-0.2pt;"> </span>diagnostic<span style="letter-spacing:-0.2pt;"> </span>tests,<span style="letter-spacing:-0.2pt;"> </span>which<span style="letter-spacing:-0.2pt;"> </span>may<span style="letter-spacing:-0.15pt;"> </span>cause<span style="letter-spacing:-0.2pt;"> </span>our<span style="letter-spacing:-0.2pt;"> </span>revenue<span style="letter-spacing:-0.2pt;"> </span>to decline and would harm our<span style="letter-spacing:-0.3pt;"> </span>business.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our competitors also compete with us in recruiting and retaining qualified scientific, management and commercial personnel, as well as in acquiring technologies complementary to, or necessary for, development of our diagnostic tests. Because of the complex and technical nature of diagnostic testing and the dynamic market in which we compete, any failure to attract and retain a sufficient number of qualified employees could materially harm our ability to develop and commercialize our diagnostic tests, which would have a material adverse effect on our business, financial condition and results of operations.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As we attain greater commercial success, our competitors are likely to develop diagnostic tests that offer features and functionality similar to our diagnostic tests that are currently on the market. Improvements in existing competitive diagnostic tests or the introduction of new competitive diagnostic tests may make it more difficult for us to compete for sales, particularly if those competitive diagnostic tests demonstrate better reliability, convenience or effectiveness or are offered at lower prices.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Performance issues, service interruptions or price increases by our shipping carriers and warehousing providers could adversely affect our business and harm our reputation and ability to provide our services on a timely basis.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expedited, reliable shipping and delivery services and secure warehousing are essential to our operations. We rely heavily on providers of transport services for reliable and secure point-to-point transport of our diagnostic tests to our customers and for tracking of these shipments, and from time to time require warehousing for our diagnostic tests, sample collection kits and supplies. Should a carrier encounter delivery performance issues such as loss, damage or destruction of any systems, it would be costly to replace such systems in a timely manner and such occurrences may damage our reputation and lead to decreased demand for our diagnostic tests and increased cost and expense to our business. In addition, any significant increase in shipping or warehousing rates could adversely affect our operating margins and results of operations. Similarly, strikes, severe weather, natural disasters, civil unrest and disturbances or other service interruptions affecting delivery or warehousing services we use would adversely affect our ability to process orders for our diagnostic tests on a timely basis.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We rely on commercial courier delivery services to transport samples to our laboratory facility in a timely and cost-efficient manner and if these delivery services are disrupted, our business will be harmed. Our business depends on our ability to quickly and reliably deliver test results to our customers. Blood samples are typically received within days from the United States and outside the United States for analysis at our Boulder, Colorado and De Soto, Kansas facilities. Disruptions in delivery service, whether due to labor disruptions, bad weather, natural disaster, civil unrest or disturbances, terrorist acts or threats or for other reasons could adversely affect specimen integrity and our ability to process samples in a timely manner and to service our customers, and ultimately our reputation and our business. In addition, if we are unable to continue to obtain expedited delivery services on commercially reasonable terms, our operating results may be adversely affected.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Cost-containment efforts of our customers, purchasing groups and governmental purchasing organizations could have a material adverse effect on our sales and profitability.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In an effort to reduce costs, many hospitals in the United States have become members of GPOs and Integrated Delivery Networks (IDNs). GPOs and IDNs negotiate pricing arrangements with medical device companies and distributors on behalf of their members, which may include hospitals and other providers. GPOs and IDNs typically award contracts on a category-by-category basis through a competitive bidding process. Bids are generally solicited from multiple providers with the intention of driving down pricing or reducing the number of vendors. Due to the highly competitive nature of the GPO and IDN contracting processes, we may not be able to obtain new, or maintain existing, contract positions with major GPOs and IDNs. Furthermore, the increasing leverage of organized buying groups may reduce market prices for our diagnostic tests, thereby reducing our revenue and margins.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">While having a contract with a GPO or IDN for a given product category can facilitate sales to members of that GPO or IDN, such contract positions can offer no assurance that any level of sales will be achieved, as sales are typically made pursuant to individual purchase orders. Even when a provider is the sole contracted supplier of a GPO or IDN for a certain product category, members of the GPO or IDN are generally free to purchase from other suppliers. Furthermore, GPO and IDN contracts typically are terminable without cause by the GPO or IDN upon 60 to 90 days&#8217; notice. Accordingly, the members of such groups may choose to purchase alternative diagnostic tests due to the price or quality offered by other companies, which could result in a decline in our revenue.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pricing and reimbursement of medical devices is not harmonized at European level, but is the exclusive competence of the EU Member States.&#160;&#160;In Europe, pricing and reimbursement decisions are generally made by regional or centralized bodies based on an assessment of the efficacy and clinical effectiveness of the devices or broad device types or procedures.&#160;&#160;There is a general trend for EU Member States to adopt cost containment measures to control public spend on medical devices.&#160;&#160;Due to the competitive nature of product offers and prices, we may not be able to obtain new, or maintain existing, contract positions with the EU Member States.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Litigation and other legal proceedings may adversely affect our business.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From time to time we may become involved in legal proceedings relating to patent and other intellectual property matters, product liability claims, employee claims, tort or contract claims, federal regulatory investigations, securities class action and other legal proceedings or investigations, which could have an adverse impact on our reputation, business and financial condition and divert the attention of our management from the operation of our business. Litigation is inherently unpredictable and can result in excessive or unanticipated verdicts and/or injunctive relief that affect how we operate our business. We could incur judgments or enter into settlements of claims for monetary damages or for agreements to change the way we operate our business, or both. There may be an increase in the scope of these matters or there may be additional lawsuits, claims, proceedings or investigations in the future, which could have a material adverse effect on our business, financial condition and results of operations. Adverse publicity about regulatory or legal action against us could damage our reputation and brand image, undermine our customers&#8217; confidence and reduce long-term demand for our diagnostic tests and services, even if the regulatory or legal action is unfounded or not material to our operations.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;letter-spacing:-0.4pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We maintain product and professional liability insurance, but this insurance may not fully protect us from the financial impact of defending against product liability or professional liability claims. Any product liability or professional liability claim brought against us, with or without merit, could increase our insurance rates or prevent us from securing insurance coverage in the<span style="letter-spacing:-0.9pt;"> </span>future.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">58</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">General</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">economic</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">financial</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">market</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">conditions</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">may</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">exacerbate</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">business</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">risks.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Global macroeconomic conditions and the world&#8217;s financial markets remain susceptible to significant stresses, resulting in reductions in available credit and government spending, economic downturn or stagnation, foreign currency fluctuations and volatility in the valuations of securities generally. As a result of uncertainties with respect to financial institutions and the global credit markets and other macroeconomic challenges currently or potentially affecting the economy of the United States and other parts of the world, customers and distributors may experience serious cash flow problems and other financial difficulties, decreasing demand for our products. Our customers and distributors may respond to such economic pressures by reducing or deferring their capital spending or reducing staff.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, events in the United States or foreign markets, such as the United Kingdom&#8217;s exit from the European Union, the worldwide effects from the spread of COVID-19 and political and social unrest in various countries around the world, can impact the global economy and capital markets. Additionally, if our customers and distributors are not successful in generating sufficient revenue or are precluded from securing financing, their businesses will suffer, which may materially and adversely affect our business, financial condition and results of operations.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">We may not realize the benefits or costs of our Co-Development and Collaboration Agreement with AVEO Oncology.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2014, we entered into a Co-Development and Collaboration Agreement with AVEO Oncology (formerly known as AVEO Pharmaceuticals, Inc.) (AVEO) whereby the two parties agreed to various terms and conditions necessary for the co-development of AVEO&#8217;s compound ficlatuzumab (the Collaboration Agreement).</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;letter-spacing:-0.4pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We were granted a limited legal interest in ficlatuzumab and may not have the right to control the development and exploitation of ficlatuzumab. As consideration for the grant, we agreed to cover the first $15.0 million of ficlatuzumab&#8217;s clinical development costs, with both parties then sharing all costs equally after the cap was reached.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In October of 2016, the Collaboration Agreement was amended to eliminate the requirement that we cover all of the initial costs. Under the amended terms, we agreed to allow AVEO to recapture its cost that it otherwise would not have been responsible for said recapture to occur out of any royalties or revenues eventually derived from the Collaboration Agreement. As part of the Collaboration Agreement, unless we or AVEO exercise our right to opt-out of co-development, we equally share in any income received from licensing rights to ficlatuzumab to any third parties. In September 2020, we exercised our opt-out right for the payment of half of the development and regulatory costs for ficlatuzumab. This opt-out was effective as of December 2, 2020 with remaining obligations estimated to be $0.3 million. Following the effective date, we will be entitled to a 10% royalty of net sales of ficlatuzumab and 25% of license income generated from the licensing of ficlatuzumab. Ficlatuzumab is currently being evaluated in squamous cell carcinoma of the head and neck (SCCHN), metastatic pancreatic ductal cancer (PDAC), and acute myeloid leukemia (AML). For more information regarding this Collaboration Agreement, please see &#8220;Business &#8212;Drug Co-Development.&#8221;</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our relationship with AVEO may require us to incur non-recurring and other charges, increase our near and long-term expenditures, or disrupt our management and business. We cannot be certain that, following the realization of this relationship, we will achieve the revenue or specific net income that justifies our entry into it. Any termination of this relationship, or delays in entering into new strategic partnership agreements with AVEO, could delay our sales and marketing efforts, which would harm our business prospects, financial condition and results of operations.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We are exposed to significant future payments and other obligations associated with our acquisitions of Integrated Diagnostics and Oncimmune, U.S.A., and may not realize the advantages we expect from these acquisitions.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We purchased select assets and liabilities from Integrated Diagnostics, Inc. and IND Funding, LLC (collectively, the Seller) which included the Clinical Laboratory Improvement Amendments (CLIA) lab in Seattle, Washington, and all rights to the Nodify XL2 test and intellectual property rights related to that test. The purchase was made for total consideration of $27.6 million, consisting of $8.0 million (10,649,604 shares) of our Series G Preferred Stock and contingent consideration with an initial fair market value of $19.6 million.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The acquisition of </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Integrated Diagnostics</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> included a contingent consideration arrangement that requires additional consideration to be paid by us to the Seller based on the milestone of the attainment of a three consecutive month gross margin target of $2 million within a seven-year period. </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If the gross margin target is met, the Company is required to issue 2,520,108 shares of common stock.&#160;&#160;</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the 6 months following the achievement of the milestone, the Seller has the option to require us to </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">redeem the common shares for $37 million</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> in cash over 8 equal installments due each calendar quarter. If the Seller elects not to exercise this option, we have 12 months to </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">repurchase the common stock</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> in two equal quarterly cash installments</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> totaling $37 million.</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December 31</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, 2020, we have not made any payments in connection with the contingent consideration</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, on October 31, 2019 we completed an acquisition of United Kingdom-based Oncimmune, Ltd.&#8217;s (Oncimmune) United States operations including its CLIA lab in De Soto, Kansas and its incidental pulmonary nodule (IPN) malignancy test, then marketed in the United States as the EarlyCDT&#174;-Lung. We renamed the test and relaunched the test on February 28, 2020 as the Nodify CDT test and the De Soto, Kansas lab will be the sole United States provider of the Nodify CDT test.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As part of the acquisition, we and Oncimmune entered into several agreements to govern the relationship between the parties and to allow us to provide the Nodify CDT test. The overarching umbrella Purchase and Commercialization Agreement (PCA) defines the general relationship between the parties. Included under the PCA was (a) an APA whereby we acquired all of the United States assets associated with the De Soto, Kansas clinical laboratory, as well as the trademarks and patent application associated with the test&#59; (b) an intellectual property license granting us the rights necessary under Oncimmune&#8217;s background intellectual property rights to perform the Nodify CDT test&#59; (c) a supply agreement for supplying us with the necessary materials and reagents needed to run the Nodify CDT test&#59; and (d) a development agreement where Oncimmune agrees to assist us in further developing the Nodify CDT test. We were also granted an option through December 31, 2020 to acquire the rights to expand the field of use of the Nodify CDT test to include lung cancer screening, which we elected to not exercise.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As consideration for the rights granted to us, we agreed to payments of $1.2 million and further agreed to an option fee for the screening option of $9.0 million due within 30 days of exercising the option. As of December 31, 2020, we have paid $1.2 million of the agreed upon payments. We also agreed to a revenue share payment of 8% of recognized revenue for non-screening tests up to an annual minimum volume and 5% thereafter, with an escalating minimum through the first four years of sales. An insignificant amount of royalty payments was paid for the year ended December 31, 2020. In September 2020, we notified Oncimmune that we would not exercise this option for expansion of the field of use.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our acquisitions may require us to incur non-recurring and other charges, increase our near and long-term expenditures, issue securities that dilute our existing stockholders or disrupt our management and business. We cannot be certain that, following the realization of these acquisitions, we will achieve the revenue or specific net income that justifies our entry into them. This could delay our sales and marketing efforts, which would harm our business prospects, financial condition and results of operations.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We are highly dependent on our senior management team and key personnel, and our business could be harmed if we are unable to attract and retain personnel necessary for our success.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are highly dependent on our senior management and other key personnel. Our success will depend on our ability to retain senior management and to attract and retain qualified personnel in the future, including sales and marketing professionals, scientists, clinical specialists, and other highly skilled personnel and to integrate current and additional personnel in all departments. The loss of members of our senior management, sales and marketing professionals, scientists, clinical and regulatory specialists could result in delays in product development and harm our business. If we are not successful in attracting and retaining highly qualified personnel, it would have a material adverse effect on our business, financial condition and results of operations.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our research and development programs and laboratory operations depend on our ability to attract and retain highly skilled scientists and technicians.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may not be able to attract or retain qualified scientists and technicians in the future due to the competition for qualified personnel among life science businesses, particularly near our headquarters in Boulder, Colorado and our laboratory facility in De Soto, Kansas. We also face competition from universities and public and private research institutions in recruiting and retaining highly qualified scientific personnel. We may have difficulties locating, recruiting, or retaining qualified salespeople. Recruiting and retention difficulties can limit our ability to support our research and development and sales programs. To induce valuable employees to remain at our company, in addition to salary and cash incentives, we have issued and may continue to issue equity awards that vest over time. The value to employees of equity awards that vest over time may be significantly affected by movements in our stock price that are beyond our control and may at any time be insufficient to counteract more lucrative offers from other companies. Despite our efforts to retain valuable employees, members of our management, scientific and development teams may terminate their employment with us on short notice. Our employment arrangements with our employees provide for at-will employment, which means that any of our employees could leave our employment at any time, with or without notice. We also do not maintain &#8220;key man&#8221; insurance policies on the lives of these individuals or the lives of any of our other employees.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our corporate culture has contributed to our success, and if we cannot maintain this culture as we grow, we could lose the innovation, creativity and teamwork fostered by our culture and our business may be harmed.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe that our culture has been and will continue to be a critical contributor to our success. We expect to continue to hire aggressively as we expand, and we believe our corporate culture has been crucial in our success and our ability to attract highly skilled personnel. If we do not continue to develop our corporate culture or maintain and preserve our core values as we grow and evolve, we may be unable to foster the innovation, curiosity, creativity, focus on execution, teamwork and the facilitation of critical knowledge transfer and knowledge sharing we believe we need to support our growth. Moreover, liquidity available to our employee securityholders could lead to disparities of wealth among our employees, which could adversely impact relations among employees and our culture in general. Our anticipated headcount growth and our transition from a private company to a public company may result in a change to our corporate culture, which could harm our business.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our ability to utilize our net operating loss carryforwards and research and development credit may be limited.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In general, under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended (the Code) a corporation that undergoes an ownership change, generally defined as a greater than 50% change by value in its equity ownership by certain shareholders over a three-year period, is subject to limitations on its ability to utilize its pre-change net operating losses (NOLs) and its research and development credit carryforwards to offset future taxable income. The applicable rules generally operate by focusing on changes in ownership among stockholders considered by the rules as owning, directly or indirectly, 5% or more of the stock of a company, as well as changes in ownership arising from new issuances of stock by the company. We believe that our NOLs are currently not subject to limitation under these rules. However, if we undergo an ownership change now or in the future, our ability to utilize NOLs and research and development credit carryforwards could be limited by Sections 382 and 383 of the Code. Future changes in stock ownership may be beyond our control. In addition, our ability to deduct net interest expense may be limited if we have insufficient taxable income for the year during which the interest is incurred, and any carryovers of such disallowed interest would be subject to the limitation rules similar to those applicable to NOLs and other attributes. For these reasons, in the event we experience a change of control, we may not be able to utilize a material portion of the NOLs, research and development credit carryforwards or disallowed interest expense carryovers, even if we attain profitability.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The terms of our secured credit agreement require us to meet certain operating and financial covenants and place restrictions on our operating and financial flexibility. If we raise additional capital through debt financing, the terms of any new debt could further restrict our ability to operate our business.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2018, we entered into an agreement with Innovatus Life Sciences Lending Fund to refinance long-term debt carried over from earlier loan agreements (the 2018 Notes). The initial amount borrowed under the 2018 Notes was $23 million and the maturity date is February 2023. We are required to make quarterly interest payments that began in June 2018 and outstanding principal is due in 24 equal installments commencing in March 2021. The agreement has been amended multiple times to adjust terms to account for our acquisitions and growth. Further, we granted the lender a security interest in all of our assets through a pledge and security agreement, patent security agreement and trademark security agreement, each between us and the lender.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The loan may be prepaid by us at any time, subject to a prepayment penalty of up to 3% of the principal amount, depending on the date of prepayment. Upon payment of the 2018 Notes at maturity or prepayment on any </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">earlier date, unless waived, a 2% back-end facility fee will apply to the amounts paid or prepaid. The 2% fee is being recorded as additional interest expense over the term of the 2018 Notes.</span></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The 2018 Notes contain customary affirmative and negative covenants for a loan, requires us to comply with a minimum daily liquidity covenant, and<span style="letter-spacing:-0.2pt;"> </span>has<span style="letter-spacing:-0.15pt;"> </span>a<span style="letter-spacing:-0.15pt;"> </span>rolling<span style="letter-spacing:-0.2pt;"> </span>monthly<span style="letter-spacing:-0.15pt;"> </span>revenue<span style="letter-spacing:-0.15pt;"> </span>requirement.<span style="letter-spacing:-0.2pt;"> </span>Failure<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.15pt;"> </span>comply<span style="letter-spacing:-0.2pt;"> </span>with<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>covenants<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>loan<span style="letter-spacing:-0.15pt;"> </span>requirements<span style="letter-spacing:-0.2pt;"> </span>may<span style="letter-spacing:-0.15pt;"> </span>result<span style="letter-spacing:-0.15pt;"> </span>in<span style="letter-spacing:-0.2pt;"> </span>early<span style="letter-spacing:-0.15pt;"> </span>amortization<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>loan<span style="letter-spacing:-0.15pt;"> </span>in a 24- or 36-month payment<span style="letter-spacing:-0.3pt;"> </span>schedule.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The 2018 Notes also contain certain covenants that prevent us from making acquisitions, incurring additional indebtedness, or making or terminating any agreement valued above a certain dollar threshold without the prior written consent of the lender. These covenants may restrict our ability to pursue new business opportunities and access additional capital.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the event of a default, including, among other things, our failure to make any payment when due or our failure to comply with any covenant under the 2018 Notes, the lender could elect to declare all amounts outstanding to be immediately due and payable, and could proceed against the collateral granted to them to secure such indebtedness, including all of our intellectual property, which could have a material adverse effect on our business, financial condition, and results of operations.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We will need to raise additional capital to fund our existing operations, develop our platform, commercialize new diagnostic tests or expand our operations.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We will need to raise additional capital in the future to expand our business, to pursue strategic investments, to take advantage of financing opportunities or for other reasons, including to:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">increase our sales and marketing efforts to drive market adoption of and address competitive</span><span style="letter-spacing:-1.25pt;color:#000000;"> </span><span style="color:#000000;">developments&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">fund development and marketing efforts of our diagnostic tests or any other future diagnostic</span><span style="letter-spacing:-1.1pt;color:#000000;"> </span><span style="color:#000000;">tests&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">expand our technologies into other types of cancer management and lung disease detection diagnostic</span><span style="letter-spacing:-1.25pt;color:#000000;"> </span><span style="color:#000000;">tests&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">acquire, license, or invest in</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">technologies&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">acquire or invest in complementary businesses or assets&#59;</span><span style="letter-spacing:-0.5pt;color:#000000;"> </span><span style="color:#000000;">and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">finance capital expenditures and general and administrative</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">expenses.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our present and future funding requirements will depend on many factors, including:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our ability to achieve revenue</span><span style="letter-spacing:-1.15pt;color:#000000;"> </span><span style="color:#000000;">growth&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">rate</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">progress</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">in</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">establishing</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">payer</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">coverage</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">reimbursement</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">arrangements</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">with</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">domestic</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">international</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">commercial</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">third-party payers and government</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">payers&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the cost of expanding our laboratory operations and offerings, including our sales and marketing</span><span style="letter-spacing:-1.2pt;color:#000000;"> </span><span style="color:#000000;">efforts&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">rate</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">progress</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">in,</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">cost</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">sales</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">marketing</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">activities</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">associated</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">with,</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">establishing</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">adoption</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">reimbursement</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">for</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">our diagnostic</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">tests&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">rate</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">progress</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">in,</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">cost</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">research</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">development</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">activities</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">associated</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">with,</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">diagnostic</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">tests</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">in</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">research</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">early</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">development&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the effect of competing technological and market</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">developments&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">costs related to international expansion&#59;</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">potential</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">cost</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">delays</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">in</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">product</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">development</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">as</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">a</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">result</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">any</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">regulatory</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">oversight</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">applicable</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">diagnostic</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">tests.</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The various ways we could raise additional capital carry potential risks. If we raise funds by issuing equity securities, our stockholders could experience dilution. Any preferred equity securities issued also could provide for</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> rights, preferences or privileges senior to those of holders of our common stock. If we raise funds by issuing debt securities, those debt securities would have rights, preferences and privileges senior to those of holders of our common stock. The terms of debt securities issued or borrowings pursuant to a credit agreement could impose </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">significant restrictions on our operations. If we raise funds through collaborations and licensing arrangements, we might be required to relinquish significant rights to our platform technologies or diagnostic tests, pay a portion of our royalties, or grant licenses on terms that are not favorable to us.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may acquire other businesses, which could require significant management attention, disrupt our business, dilute stockholder value and adversely affect our results of operations.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As part of our business strategy, we may in the future make additional acquisitions or investments in complementary companies, diagnostic tests or technologies that we believe fit within our business model and can address the needs of our customers and potential customers. In the future, we may not be able to acquire and integrate other companies, diagnostic tests or technologies in a successful manner. We may not be able to find suitable acquisition candidates, and we may not be able to complete such acquisitions on favorable terms, if at all. In addition, the pursuit of potential acquisitions may divert the attention of management and cause us to incur additional expenses in identifying, investigating, and pursuing suitable acquisitions, whether or not they are consummated. If we do complete acquisitions, we may not ultimately strengthen our competitive position or achieve our goals, including increases in revenue, and any acquisitions we complete could be viewed negatively by our customers, investors and industry analysts.</p>
<p style="margin-top:10pt;margin-bottom:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Future acquisitions may reduce our cash available for operations and other uses and could result in amortization expense related to identifiable assets acquired. We may have to pay cash, incur debt or issue equity securities to pay for any such acquisition, each of which could adversely affect our financial condition or the value of our common stock. The sale or issuance of equity to finance any such acquisitions would result in dilution to our stockholders. The incurrence of indebtedness to finance any such acquisition would result in fixed obligations and could also include covenants or other restrictions that could impede our ability to manage our operations. In addition, our future results of operations may be adversely affected by the dilutive effect of an acquisition, performance earn-outs or contingent bonuses associated with an acquisition. Furthermore, acquisitions may require large, onetime charges and can result in increased debt or contingent liabilities, adverse tax consequences, additional stock-based compensation expenses and the recording and subsequent amortization of amounts related to certain purchased intangible assets, any of which items could negatively affect our future results of operations. We may also incur goodwill impairment charges in the future if we do not realize the expected value of any such acquisitions.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Also, the anticipated benefit of any strategic alliance, joint venture or acquisition may not materialize, or such strategic alliance, joint venture or acquisition may be prohibited. For example, our 2018 Notes restrict our ability to pursue certain mergers, acquisitions, amalgamations or consolidations that we may believe to be in our best interest. Additionally, future acquisitions or dispositions could result in potentially dilutive issuances of our equity securities, the incurrence of debt, contingent liabilities or amortization expenses or write-offs of goodwill, any of which could harm our financial condition. We cannot predict the number, timing or size of future joint ventures or acquisitions, or the effect that any such transactions might have on our operating results.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to our Governmental Regulation</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The insurance coverage and reimbursement status of newly approved diagnostic tests, particularly in a new category of diagnostics and therapeutics, is uncertain.<span style="letter-spacing:-0.25pt;"> </span>Failure<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.2pt;"> </span>obtain<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:-0.2pt;"> </span>maintain<span style="letter-spacing:-0.2pt;"> </span>adequate<span style="letter-spacing:-0.2pt;"> </span>coverage<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>reimbursement<span style="letter-spacing:-0.2pt;"> </span>for<span style="letter-spacing:-0.2pt;"> </span>current<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:-0.2pt;"> </span>future<span style="letter-spacing:-0.2pt;"> </span>diagnostic<span style="letter-spacing:-0.2pt;"> </span>tests<span style="letter-spacing:-0.2pt;"> </span>could<span style="letter-spacing:-0.2pt;"> </span>limit<span style="letter-spacing:-0.2pt;"> </span>our<span style="letter-spacing:-0.2pt;"> </span>ability,<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>that<span style="letter-spacing:-0.2pt;"> </span>of our collaborators, to fully commercialize our diagnostic tests and decrease our ability to generate<span style="letter-spacing:-1.1pt;"> </span>revenue.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The availability and extent of reimbursement by governmental and private payers is essential for most patients to be able to afford the clinical diagnostic tests and cellular therapeutics that we and our collaborators currently or in the future plan to develop and sell. In addition, because our clinical diagnostics and diagnostic tests represent new approaches to the research, diagnosis, detection and treatment of diseases, we cannot accurately estimate how our diagnostic tests, and those jointly created with our collaborators, would be priced, whether reimbursement could be obtained or any potential revenue generated. Sales of our diagnostic tests will depend substantially, both domestically and internationally, on the extent to which the costs of our diagnostic tests are paid by health </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">maintenance, managed care, pharmacy benefit and similar healthcare management organizations, or reimbursed by government</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">health</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">administration</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">authorities,</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">private</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">health</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">coverage</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">insurers</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">other</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">third-party</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">payers.</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">reimbursement</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">is</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">not</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">available,</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">is</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">available only to limited levels, we may not be able to successfully commercialize some of our diagnostic tests or services. Even if coverage is provided, the available reimbursement amount may not be high enough to allow us to establish or maintain pricing sufficient to realize an adequate return </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">on our investment in any of our diagnostic tests or services. Changes in the reimbursement landscape may </span><span style="letter-spacing:-0.1pt;">occur, </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">which are outside of our control, and may impact the commercial viability of our diagnostic</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">tests.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There is significant uncertainty related to the insurance coverage and reimbursement of newly launched, cleared, authorized or approved diagnostic tests. In the United States, many significant decisions about reimbursement for new diagnostics and medicines are typically made by the Centers for Medicare and Medicaid Services (CMS), an agency within the Department of Health and Human Services (HHS). CMS decides whether and to what extent a new diagnostic or medicine will be covered and reimbursed under Medicare, although it frequently delegates this authority to local Medicare Administrative Contractors (MACs). Private payers tend to follow Medicare to a substantial degree. It is difficult to predict what CMS will decide with respect to reimbursement for novel diagnostic tests such as ours. Additionally, reimbursement authorities or bodies in Europe may be more conservative than CMS. For example, a number of cancer drugs have been approved for reimbursement in the United States and have not been approved for reimbursement, or have been approved under restricted conditions, in certain European countries.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.29%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outside the United States, the reimbursement process and timelines vary significantly. In Europe, pricing and reimbursement of medical devices is the exclusive competence of the EU Member States.&#160;&#160;However, the European Commission is facilitating a voluntary corporation between the EU Member States on health technology assessments (HTA) which consists of a network of the EU Member States&#8217; national authorities and bodies responsible for HTA and a joint action to support cooperation at scientific and technical level between the HTA bodies. We cannot be sure that such prices and reimbursement decisions will be acceptable to us or our collaborators. If the regulatory authorities in these foreign jurisdictions set prices or make reimbursement criteria that are not commercially attractive for us or our collaborators, our revenues and the potential profitability of our products in those countries would be negatively affected. An increasing number of countries are taking initiatives to control the healthcare budget by focusing cost-cutting efforts on medicinal products, and to a lesser extent, medical devices, provided under their state-run healthcare systems. These price control efforts have impacted all regions of the world, but have been most prominent in the EU. Additionally, some countries require approval of the sale price of a product before it can be marketed or mandatory discounts or profit caps may be applied. Further, after the sale price is approved, it remains subject to review during the product lifecycle. In many countries, the pricing review period begins after marketing or product licensing approval is granted or the CE mark is obtained. As a result, we or our collaborators might obtain marketing approval for a product or service in a particular country, but then may experience delays in the reimbursement approval or be subject to price regulations that would delay the commercial launch of our product or service, possibly for lengthy time periods, which could negatively impact the revenues we are able to generate from the sale of that product or service in that particular country.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.29%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, increasing efforts by governmental and third-party payers, in the United States and abroad, to cap or reduce healthcare costs may cause such organizations to limit both coverage and level of reimbursement for newly cleared, authorized, certified or approved devices and medicines and, as a result, they may not cover or provide adequate payment for our clinical diagnostics to be sold by us or our collaborators. For example, in May 2018 the United States government released a &#8220;blueprint,&#8221; or plan, to reduce the cost of drugs. This blueprint contains certain measures that HHS has been working to implement, although it is possible that HHS&#8217;s regulatory priorities may change under the new Biden administration. At the state level, legislatures are increasingly passing legislation and implementing regulations designed to control pharmaceutical and biological pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, which are, in some cases, designed to encourage importation from other countries and bulk purchasing.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect to experience pricing pressures on our clinical diagnostics sold by us and our collaborators due to the trend toward value-based pricing and coverage, the increasing influence of health maintenance organizations and additional legislative changes. The downward pressure on healthcare costs in general, particularly prescription drugs, surgical procedures and other treatments, has become very intense. As a result, increasingly high barriers are being erected to the entry of new diagnostic tests.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Measures to reduce healthcare costs may hurt our business.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The majority of our customers are healthcare providers who depend upon reimbursement by government and commercial insurance payers for lung cancer diagnostic solutions services. With a majority of United States patients with lung cancer covered by Medicare, the Medicare reimbursement rate is an important factor in a customer&#8217;s decision to use our diagnostic tests and limits the prices we may charge for them. Commercial insurance payers may also exert downward pressure on payment rates for lung cancer treatment services. A reduction in reimbursement rates for lung cancer treatments may adversely affect our customers&#8217; businesses and cause them to enact cost reduction measures that may include reducing the scope of their programs, thereby potentially reducing demand for our diagnostic tests.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Healthcare reform measures could hinder or prevent the commercial success of our diagnostic tests.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.29%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the United States, there have been, and we expect there will continue to be, a number of legislative and regulatory changes to the healthcare system in ways that may harm our future revenues and profitability and the demand for our diagnostic tests. Federal and state lawmakers regularly propose and, at times, enact legislation that would result in significant changes to the healthcare system, some of which are intended to contain or reduce the costs of medical products and services. Current and future legislative proposals to further reform healthcare or reduce healthcare costs may limit coverage of or lower reimbursement for the procedures associated with the use of our diagnostic tests. The effect of any healthcare reform initiative implemented in the future could impact our revenue from the sale of our diagnostic tests. For example, the Patient Protection and Affordable Care Act of 2010, as amended by the Health Care and Education Reconciliation Act of 2010 (collectively, the ACA), contains a number of provisions, including those governing enrollment in federal healthcare programs, reimbursement changes and fraud and abuse measures, all of which will impact existing government healthcare programs and will result in the development of new programs.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.29%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There have been judicial challenges to certain aspects of the ACA, as well as efforts by the Trump administration and Congress to repeal, replace or alter the implementation of certain aspects of the ACA. For example, as part of the <span style="letter-spacing:-0.25pt;">Tax </span>Cuts and Jobs Act of 2017 (TCJA), Congress eliminated the tax penalty, starting January 1, 2019, for not complying with the <span style="letter-spacing:-0.35pt;">ACA&#8217;s </span>individual mandate to carry health insurance. The Further Consolidated Appropriations Act of 2020, Pub. L. No. 116-94, signed into law December 20, 2019, fully repealed the <span style="letter-spacing:-0.35pt;">ACA&#8217;s </span>&#8220;Cadillac <span style="letter-spacing:-0.2pt;">Tax&#8221; </span>on certain high-cost employer-sponsored insurance plans, the annual fee imposed on certain health insurance providers based on market share (repeal effective in 2021), and the medical device excise tax on non-exempt medical devices. On December 14, 2018, a <span style="letter-spacing:-0.2pt;">Texas </span>District Court Judge invalidated the ACA in its entirety because he concluded that the individual mandate, which was repealed by Congress as noted above, is unconstitutional and cannot be severed from the remainder of the ACA. The Fifth Circuit Court of Appeals affirmed the district court&#8217;s ruling that the individual mandate was unconstitutional, but it remanded the case back to the district court for further analysis of whether the mandate could be severed from the ACA&#59; that is, whether the entire ACA was therefore also invalid. The Supreme Court of the United States granted certiorari on March 2, 2020 and heard oral argument on November 10, 2020&#59; the case is expected to be decided by mid-2021. It is unclear how this decision, subsequent appeals, and other efforts to challenge, repeal, or replace, or alter the implementation of the ACA will affect our business, financial condition and results of operations.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.29%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, other legislative changes have been proposed and adopted since the ACA was enacted. For example, the Budget Control Act of 2011, among other things, included reductions to CMS payments to providers of 2% per fiscal year, which went into effect on April 1, 2013 and, due to subsequent legislative amendments to the statute, will remain in effect through 2030 unless additional Congressional action is taken, with the exception of a temporary suspension of the 2% cut in Medicare payments from May 1, 2020 through March 31, 2021. Additionally, the American Taxpayer Relief Act of 2012, among other things, reduced CMS payments to several providers, including hospitals, and increased the statute of limitations period for the government to recover Medicare overpayments to providers from three to five years.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.29%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Biden administration and Congress may continue to pursue significant changes to the current healthcare laws, and the Biden administration has indicated its intent to strengthen the ACA and focus on reducing the cost of healthcare. We face uncertainties that might result from modifications or repeal of any of the provisions of the ACA, including as a result of current and future executive orders and legislative actions. The impact of those changes on us and potential effect on the medical device industry as a whole is currently unknown. Any changes to the ACA are likely to have an impact on our results of operations, and may negatively affect our business, financial condition and results of operations. We cannot predict what other healthcare programs and regulations will ultimately be implemented at the federal or state level or the effect of any future legislation or regulation in the United States on our business, financial condition and results of operations.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The continuing efforts of the government, insurance companies, managed care organizations and other payers </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of healthcare services to contain or reduce costs of healthcare may harm:</span></p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our ability to set a price that we believe is fair for our diagnostic</span><span style="letter-spacing:-0.85pt;color:#000000;"> </span><span style="color:#000000;">tests&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our ability to generate revenue and achieve or maintain profitability&#59;</span><span style="letter-spacing:-0.65pt;color:#000000;"> </span><span style="color:#000000;">and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the availability of</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">capital.</span></p></td></tr></table></div>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The ACA substantially changed the way healthcare is financed by both governmental and private insurers, and significantly impacts our industry. Future changes in healthcare policy could increase our costs and subject us to additional regulatory requirements that may interrupt commercialization of our current and future solutions. Future changes in healthcare policy could also decrease our revenue and impact sales of and reimbursement for our current and future diagnostic tests.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We must comply with anti-corruption, anti-bribery, anti-money laundering and similar laws.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are subject to the Foreign Corrupt Practices Act of 1977 (FCPA), which generally prohibits companies in the United States from engaging in bribery or other prohibited payments to foreign officials for the purpose of obtaining or retaining business and requires companies to maintain accurate books and records and internal controls. We are also subject to requirements under the United States Treasury Department&#8217;s Office of Foreign Assets Control, United States domestic bribery laws and other anti-corruption, anti-bribery and anti-money laundering laws. While we have policies and procedures in place designed to promote compliance with such laws, our employees or other agents may nonetheless engage in prohibited conduct under these laws for which we or our executives might be held responsible. If our employees or other agents are found to have engaged in such practices, we could suffer severe penalties and other consequences that may have an adverse effect on our business, financial condition and results of operations.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furthermore, international customers may currently order our diagnostic tests, either directly from us or through a potential joint venture, and we are subject to the <span style="letter-spacing:-0.2pt;">FCPA, </span>which prohibits companies and their intermediaries from making payments in violation of law to non-United States government officials for the purpose of obtaining or retaining business or securing any other improper advantage. Our reliance on independent distributors to sell our diagnostic tests internationally demands a high degree of vigilance in maintaining our policy against participation in corrupt activity, because these distributors could be deemed to be our agents and we could be held responsible for their actions. Other United States companies in the medical device and biopharmaceutical field have faced criminal penalties under the <span style="letter-spacing:-0.25pt;">FCPA </span>for allowing their agents to deviate from appropriate practices in doing business with these individuals. <span style="letter-spacing:-0.4pt;">We </span>are also subject to similar anti-bribery laws in the jurisdictions in which we operate, including laws promulgated by OECD countries in which we operate, such as Israel. These laws are complex and far-reaching in nature, and, as a result, we cannot assure you that we would not be required<span style="letter-spacing:-0.15pt;"> </span>in<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>future<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.15pt;"> </span>alter<span style="letter-spacing:-0.1pt;"> </span>one<span style="letter-spacing:-0.15pt;"> </span>or<span style="letter-spacing:-0.15pt;"> </span>more<span style="letter-spacing:-0.1pt;"> </span>of<span style="letter-spacing:-0.15pt;"> </span>our<span style="letter-spacing:-0.15pt;"> </span>practices<span style="letter-spacing:-0.1pt;"> </span>to<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>compliance<span style="letter-spacing:-0.15pt;"> </span>with<span style="letter-spacing:-0.15pt;"> </span>these<span style="letter-spacing:-0.1pt;"> </span>laws<span style="letter-spacing:-0.15pt;"> </span>or<span style="letter-spacing:-0.15pt;"> </span>any<span style="letter-spacing:-0.1pt;"> </span>changes<span style="letter-spacing:-0.15pt;"> </span>in<span style="letter-spacing:-0.15pt;"> </span>these<span style="letter-spacing:-0.1pt;"> </span>laws<span style="letter-spacing:-0.15pt;"> </span>or<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>interpretation<span style="letter-spacing:-0.15pt;"> </span>thereof. Any violations of these laws, or allegations of such violations, could disrupt our operations, involve significant management distraction, involve significant costs and expenses, including legal fees and could result in a material adverse effect on our business, prospects, financial condition and results of operations. We could also suffer severe penalties, including criminal and civil penalties, disgorgement and other remedial measures.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We must comply with healthcare fraud and abuse laws.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Various federal and state laws, as well as the laws of foreign countries, prohibit payments to induce the referral, purchase, order or use of healthcare products or services and require medical device companies to limit prevent, and/or monitor, and report certain payments to third-party payers, health care professionals, and other individuals. These healthcare fraud and abuse, anti-kickback, public reporting and aggregate spend laws affect our sales, marketing and other promotional activities by limiting the kinds of financial arrangements, including sales programs, we may have with lung cancer treatment providers, hospitals, physicians or other potential purchasers or users, including patients, of medical devices and services. They also impose additional administrative and compliance burdens on us. In particular, these laws influence, among other things, how we structure our sales offerings, including discount practices, customer support, education and training programs and physician consulting and other service arrangements. These laws prohibit certain marketing initiatives that are commonplace in other industries. If we were to offer or pay inappropriate inducements for the purchase, order or use of our diagnostic tests or our services, or our arrangements are perceived as inappropriate inducements, we could be subject to claims under various healthcare fraud and abuse laws.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restrictions under applicable United States federal and state healthcare laws and regulations include the following:</span></p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the federal Anti-Kickback Statute, a criminal </span><span style="letter-spacing:-0.2pt;color:#000000;">law, </span><span style="color:#000000;">prohibits, among other things, persons and entities from knowingly and willfully offering, paying,</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">soliciting</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">receiving</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">any</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">remuneration,</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">directly</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">indirectly,</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">in</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">cash</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">in</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">kind,</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">induce</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">reward</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">purchasing,</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">leasing,</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">ordering,</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">or arranging </span><span style="letter-spacing:-0.15pt;color:#000000;">for, </span><span style="color:#000000;">referring, or recommending the purchase, lease, order of any good or service for which payment may be made, in whole or in part, under federal healthcare programs such as Medicare and</span><span style="letter-spacing:-0.6pt;color:#000000;"> </span><span style="color:#000000;">Medicaid&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the Eliminating Kickbacks in Recovery Act, which prohibits knowingly and willfully soliciting, receiving, offering or paying remuneration, directly</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">indirectly,</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">in</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">return</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">for</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">referral</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">a</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">patient</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">to,</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">in</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">exchange</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">for</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">an</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">individual</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">using</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">services</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">certain</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">entities,</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">including laboratories, if the services are covered by a health care benefit</span><span style="letter-spacing:-0.7pt;color:#000000;"> </span><span style="color:#000000;">program&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">Beneficiary</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">Inducement</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">Statute,</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">which</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">prohibits</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">any</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">person,</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">organization,</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">entity</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">from</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">giving</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">anything</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">value</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">a</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">federal</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">health</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">care program</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">beneficiary</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">that</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">is</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">likely</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">induce</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">influence</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">beneficiary&#8217;s</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">choice</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">provider,</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">practitioner,</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">supplier</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">for</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">covered</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">services&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the federal civil False Claims Act, which may be enforced through civil whistleblower or </span><span style="font-style:italic;color:#000000;">qui tam </span><span style="color:#000000;">actions and is often used to enforce the federal Anti-Kickback Statute and other healthcare laws and regulations, imposes civil penalties and potential exclusion from federal healthcare programs, against individuals or entities </span><span style="letter-spacing:-0.15pt;color:#000000;">for, </span><span style="color:#000000;">among other things, knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent or for making a false record or statement material to an obligation to pay the federal government or for knowingly and improperly avoiding, decreasing or concealing an obligation to pay money to the federal government&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">federal criminal statutes created by </span><span style="letter-spacing:-0.2pt;color:#000000;">HIPAA </span><span style="color:#000000;">impose criminal liability </span><span style="letter-spacing:-0.15pt;color:#000000;">for, </span><span style="color:#000000;">among other things, knowingly and willfully executing or attempting to execute a scheme to defraud any healthcare benefit program, including private insurance plans, </span><span style="letter-spacing:-0.15pt;color:#000000;">or, </span><span style="color:#000000;">in any matter involving a healthcare benefit program, for knowingly and willfully making materially false, fictitious, or fraudulent statements in connection with the delivery of or payment for health care benefits&#59;</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws, may apply to sales or marketing arrangements</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">claims</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">involving</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">healthcare</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">items</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">services</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">reimbursed</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">by</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">non-governmental</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">third-party</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">payers,</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">including</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">private insurers.</span></p></td></tr></table></div>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.29%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other federal and state laws, as well as the laws of foreign countries, generally prohibit individuals or entities from knowingly presenting, or causing to be presented, claims for payments to government or commercial payers that are false or fraudulent, or for items or services that were not provided as claimed. Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, imprisonment, exclusion of product candidates and medical devices from government-funded healthcare programs, such as Medicare and Medicaid, disgorgement, contractual damages, reputational harm, diminished profits and future earnings, and the curtailment or restructuring of our operations. Moreover, any investigation into our practices could cause adverse publicity and require a costly and time-consuming response. If any physicians or other healthcare providers or entities with whom we expect to do business are found not to be in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government-funded healthcare programs.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.29%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Manufacturers can also be held liable under these laws if they are deemed to &#8220;cause&#8221; the submission of false or fraudulent claims by providing inaccurate billing or coding information to customers, by providing improper financial inducements, or through certain other activities. We attempt to ensure that any billing and coding information we provide for our diagnostic tests emphasizes the need for physicians and other providers to make independent judgments, use accurate and appropriate billing and coding that complies with all applicable payer policies, and document the medical need for their patients as appropriate. Nevertheless, the government may not regard any billing errors that may be made by our customers as inadvertent and may examine our role in providing information to our customers, physicians and patients concerning the benefits and potential coverage of more frequent therapy.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">FDA regulation of our industry generally or our tests specifically could be disruptive to our business.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our operations are subject to extensive federal, state, local and foreign laws and regulations, including FDA laws and regulations, all of which are subject to change. These laws and regulations are complex and are subject to interpretation by the courts and by government agencies. We believe that we are in material compliance with all statutory and regulatory requirements applicable to us, but there is a risk that one or more government agencies could take a contrary position, or that a private party could file suit under the qui tam provisions of the federal False Claims Act or a similar state law. Such occurrences, regardless of their outcome, could damage our reputation and adversely affect important business relationships with third parties, including managed care organizations, and other private third-party payers.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA has recently increased its attention to marketing of pharmacogenetic tests. For example, in late 2018, the FDA issued a safety communication regarding genetic laboratory tests with claims to predict a patient&#8217;s response to specific medications that have not been reviewed by the FDA and may not be supported by clinical evidence. Among other tests, the FDA notice cited genetic tests that claim results can be used to help physicians identify which antidepressant medication would have increased effectiveness or side effects compared to other antidepressant medications. As explained by the FDA in its update to this safety communication, the FDA sent notices to several firms marketing such pharmacogenetic tests where the FDA believes the relationship between genetic variations and the medication&#8217;s effects has not been established, including a warning letter sent to a laboratory, in part, for failing to obtain premarket review of its test. HHS recently issued an announcement stating that the FDA cannot require premarket review of any LDT without engaging in formal notice-and-comment rulemaking, as opposed to through guidance documents, compliance manuals, website statements, or other informal issuances.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The HHS announcement was made on the Department&#8217;s website and we can provide no assurances that the HHS statement will not be rescinded or revised or that it would preclude the FDA from renewing its attention on diagnostic tests, including those that we provide. If this were to happen, it may impact our marketing practices relating to the relevant tests, which in turn may have an adverse impact on our business, financial condition and results of operations.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The SARS-CoV-2 tests we perform are currently the subject of EUAs, which permit the use of unapproved medical products or unapproved uses of medical products to be used in an emergency to diagnose, treat, or prevent serious or life-threatening diseases or conditions when there are no adequate, approved, and available alternatives, as provided under section 564 for the Federal Food, Drug, and Cosmetic Act (FDCA). EUAs are temporary authorizations that are revoked at the end of the public health emergency, when there is an adequate, approved, or available alternative, or when there are performance or safety concerns. These EUAs also set out conditions for laboratories who are authorized to perform the particular test. The HHS statement mentioned above did not affect EUAs for COVID-19 laboratory-developed tests that were already in effect at the time the statement was released. The HHS statement did not affect EUAs issued for commercially developed COVID-19 IVD tests, which apply to test developers and authorized laboratories.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The EUA for Bio-Rad&#8217;s SARS-CoV-2 Droplet Digital PCR&#8482; test provides several conditions for authorized laboratories, including that the test result reports will include Fact Sheets that are authorized as part of the EUA, deviations from the authorized procedures, including specimen types, are not permitted, notification of public health authorities of intent to run the test prior to initiating testing, collection and reporting of performance data to the FDA, including false positives, false negatives, and significant deviations from the established performance characteristics, and appropriate training and protective equipment for laboratory staff. This EUA also states that authorized laboratories must maintain records associated with the EUA and be made available to the FDA for inspection upon request. Printed materials, advertising, and promotion related to use of the test must be consistent with the authorized labeling and Fact Sheets, as well as other terms set forth in the EUA and any applicable requirements under the FDCA and its implementing regulations, and conspicuously bear the following statements:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">This test has not been FDA cleared or</span><span style="letter-spacing:-0.5pt;color:#000000;"> </span><span style="color:#000000;">approved&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">This test has been authorized by the FDA under an EUA for use by authorized</span><span style="letter-spacing:-1.05pt;color:#000000;"> </span><span style="color:#000000;">laboratories&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">This</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">test</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">has</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">been</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">authorized</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">only</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">for</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">detection</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">nucleic</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">acid</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">from</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">SARS-</span><span style="letter-spacing:-0.2pt;color:#000000;">CoV-2,</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">not</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">for</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">any</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">other</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">viruses</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">pathogens&#59;</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">and</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">68</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="text-decoration:none;Background-color:#auto;"></span><span style="color:#000000;"></span><span style="color:#000000;">This</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">test</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">is</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">only</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">authorized</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">for</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">duration</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">declaration</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">that</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">circumstances</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">exist</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">justifying</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">authorization</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">emergency</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">use</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">in vitro</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">diagnostics</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">for</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">detection</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">and/or</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">diagnosis</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">COVID-19</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">under</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">Section</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">564(b)(1)</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">Act,</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">21</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">U.S.C.</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">&#167;</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">360bbb-3(b)(1),</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">unless</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">the authorization is terminated or revoked</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">sooner.</span></p></td></tr></table></div>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other statements that appear in advertising and promotional materials must not represent or suggest that this test is safe or effective for the detection of SARS-CoV-2.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The EUA for Bio-Rad&#8217;s serological test for the antibodies associated with SARS-CoV-2, also sets out several conditions for authorized laboratories that mirror the conditions for the PCR test described above, except that the printed materials, advertising, and promotion of the test must conspicuously bear the following statements:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">This test has not been FDA cleared or</span><span style="letter-spacing:-0.5pt;color:#000000;"> </span><span style="color:#000000;">approved&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">This test has been authorized by the FDA under an EUA for use by authorized</span><span style="letter-spacing:-1.05pt;color:#000000;"> </span><span style="color:#000000;">laboratories&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">This test has been authorized only for the detection of total antibodies, including IgM/IgG/IgA, against </span><span style="letter-spacing:-0.15pt;color:#000000;">SARS-CoV-2, </span><span style="color:#000000;">not for any other viruses or pathogens&#59;</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">This</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">test</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">is</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">only</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">authorized</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">for</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">duration</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">declaration</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">that</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">circumstances</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">exist</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">justifying</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">authorization</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">emergency</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">use</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">in vitro</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">diagnostics</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">for</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">detection</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">and/or</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">diagnosis</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">COVID-19</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">under</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">Section</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">564(b)(1)</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">Act,</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">21</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">U.S.C.</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">&#167;</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">360bbb-3(b)(1),</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">unless</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">the authorization is terminated or revoked</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">sooner.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Failure to comply with federal, state and foreign laboratory licensing requirements and the applicable requirements of the FDA or any other regulatory authority, could cause us to lose the ability to perform our tests, experience disruptions to our business, or become subject to administrative or judicial sanctions.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.29%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The diagnostic testing industry is subject to extensive laws and regulations, many of which have not been interpreted by the courts, including the application of the FDA&#8217;s EUA authority. As noted above, the EUAs for the COVID-19 tests that are part of our Biodesix WorkSafe testing program set out certain conditions for authorized laboratories using the tests, which have not received premarket clearance, approval, or a de novo from the FDA. If we fail to meet these conditions, the FDA may take enforcement action, such as issuing a warning letter, seeking an injunction, seizure, fines, or criminal penalties. Pursuant to the August 19, 2020 statement by HHS, the FDA cannot require any LDT to undergo premarket approval until it has engaged in notice-and-comment rulemaking. Laboratory tests that have already received an EUA to detect the COVID-19 virus were &#8220;unaffected&#8221; by the announcement. Tests without FDA clearance, approval, or authorization would not be considered covered countermeasures under the Public Readiness and Emergency Preparedness Act (PREP Act). The HHS statement also did not affect EUAs issued for commercially developed COVID-19 IVD tests, which apply to test developers and authorized laboratories.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.29%;letter-spacing:-0.4pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are also subject to CLIA, a federal law that regulates clinical laboratories that perform testing on specimens derived from humans for the purpose of providing information for the diagnosis, prevention or treatment of disease. CLIA requires virtually all laboratories to be certified by the federal government and mandates compliance with various operational, personnel, facilities administration, quality and proficiency testing requirements intended to ensure that testing services are accurate, reliable and timely. CLIA certification is also a prerequisite to be eligible to bill state and federal health care programs, as well as many private third-party payers, for laboratory testing services. As a condition of CLIA certification, each of our laboratories is subject to survey and inspection every other <span style="letter-spacing:-0.15pt;">year, </span>in addition to being subject to additional random inspections. The biennial survey is conducted by CMS, a CMS agent (typically a state agency), <span style="letter-spacing:-0.15pt;">or, </span>if the laboratory holds a CLIA certificate of accreditation, a CMS-approved accreditation organization.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.29%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sanctions for failure to comply with CLIA requirements, including proficiency testing violations, may include suspension, revocation, or limitation of a laboratory&#8217;s CLIA certificate, which is necessary to conduct our business, as well as the imposition of significant fines or criminal penalties.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.29%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any sanction imposed under CLIA, its implementing regulations, or state or foreign laws or regulations governing licensure, or our failure to renew a CLIA certificate, a state or foreign license, or accreditation, could have a material adverse effect on our business. If the CLIA certificate of any one of our laboratories is revoked, CMS could seek revocation of the CLIA certificates of our other laboratories based on their common ownership or operation, even though they are separately certified.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, we are subject to state laws and regulations governing laboratory licensure. Some states have enacted state licensure laws that are more stringent than CLIA. Although we have obtained licenses from states where we believe we are required to be licensed, we may become aware of other states that require out-of-state laboratories to obtain licensure in order to accept specimens from the state, and it is possible that other states currently have such requirements or will have such requirements in the future.</span></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may also be subject to regulation in foreign jurisdictions as we seek to expand international utilization of our tests or such jurisdictions adopt new licensure requirements, which may require review of our tests in order to offer them or may have other limitations that may limit our ability to make our tests available outside of the United States. Complying with licensure requirements in new jurisdictions may be expensive, time-consuming and subject us to significant and unanticipated delays. Changes in state or foreign licensure laws that affect our ability to offer and provide diagnostic services across state or foreign country lines could materially and adversely affect our business. In addition, state and foreign requirements for laboratory certification may be costly or difficult to meet and could affect our ability to receive specimens from certain states or foreign countries.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Failure to comply with applicable clinical laboratory licensure requirements may result in a range of enforcement actions, including suspension, limitation or revocation of our CLIA certificate and/or state licenses, imposition of a directed plan of action, onsite monitoring, civil monetary penalties, criminal sanctions and revocation of the laboratory&#8217;s approval to receive Medicare and Medicaid payment for its services, as well as significant adverse publicity.<span style="letter-spacing:-0.25pt;"> </span>Any<span style="letter-spacing:-0.25pt;"> </span>sanction<span style="letter-spacing:-0.25pt;"> </span>imposed<span style="letter-spacing:-0.2pt;"> </span>under<span style="letter-spacing:-0.25pt;"> </span>CLIA,<span style="letter-spacing:-0.25pt;"> </span>its<span style="letter-spacing:-0.2pt;"> </span>implementing<span style="letter-spacing:-0.25pt;"> </span>regulations,<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:-0.2pt;"> </span>state<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:-0.25pt;"> </span>foreign<span style="letter-spacing:-0.2pt;"> </span>laws<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:-0.25pt;"> </span>regulations<span style="letter-spacing:-0.2pt;"> </span>governing<span style="letter-spacing:-0.25pt;"> </span>clinical<span style="letter-spacing:-0.25pt;"> </span>laboratory<span style="letter-spacing:-0.2pt;"> </span>licensure<span style="letter-spacing:-0.25pt;"> </span>or our failure to renew our CLIA certificate, a state or foreign license or accreditation, could have a material adverse effect on our business, financial condition and results of operations. Even if we were able to bring our laboratory back into compliance, we could incur significant expenses and potentially lose revenue in doing<span style="letter-spacing:-0.25pt;"> </span>so.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our Boulder, Colorado and De Soto, Kansas laboratories are College of American Pathologists (CAP)-accredited (Boulder) or COLA-accredited (De Soto) clinical laboratories regulated by CMS pursuant to CLIA. We also have a current CLIA certificate for each facility. To maintain these certificates, we are subject to survey and inspection every two years. Moreover, CLIA inspectors may make random inspections of our laboratory from time to time. Furthermore, our diagnostic tests are categorized as Laboratory Developed Tests (LDTs) and are not currently subject to FDA regulation, although certain components provided by third parties and used to create and/or administer the test may be. LDTs are a subset of in vitro diagnostics (IVDs) that are intended for clinical use and developed, validated, and offered within a single laboratory for use only in that laboratory. The FDA&#8217;s authority to regulate LDTs has been frequently contested, and HHS recently issued a public statement purporting to rescind the FDA&#8217;s policies regarding the premarket review of LDTs. According to the HHS statement, the FDA will not require premarket review of LDTs unless it engages in notice-and-comment rulemaking. There is no guarantee, however, that the HHS statement will not be revised or rescinded, that legislation reforming the federal government&#8217;s regulation of LDTs will not be passed, or that LDTs will otherwise continue to be able to operate without first receiving FDA premarket review. Failure to adhere to any new FDA regulation would result in fines, product suspensions, warning letters, recalls, injunctions and other civil and criminal penalties.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Changes in the way that the FDA regulates tests performed by laboratories like ours could result in delay or additional expense in offering our tests and tests that we may develop in the future.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Historically, the FDA has exercised enforcement discretion with respect to most <span style="letter-spacing:-0.2pt;">LDTs </span>and has not required laboratories that furnish <span style="letter-spacing:-0.2pt;">LDTs </span>to comply with the agency&#8217;s requirements for medical devices (e.g., establishment registration, device listing, quality systems regulations, premarket clearance or premarket approval, and post-market controls). In recent years, however, the FDA publicly announced its intention to regulate certain <span style="letter-spacing:-0.2pt;">LDTs </span>and issued two draft guidance documents that set forth a proposed phased-in risk-based regulatory framework that would apply varying levels of FDA oversight to <span style="letter-spacing:-0.15pt;">LDTs. </span>However, these guidance documents were withdrawn at the end of the Obama administration and replaced by an informal discussion paper reflecting some of the feedback that the FDA had received on LDT regulation. The FDA acknowledged that the discussion paper in January 2017 does not represent the formal position of the FDA and is not enforceable. Nevertheless, the FDA wanted to share its synthesis of the feedback that it had received in the hope that it might advance public discussion on future LDT oversight. HHS has since issued a statement purporting to rescind <span style="letter-spacing:-0.35pt;">FDA&#8217;s </span>policies regarding the premarket review of <span style="letter-spacing:-0.15pt;">LDTs, </span>stating that FDA must engage in notice and comment rulemaking (as opposed to through guidance documents, compliance manuals, website statements, or other informal issuances) prior to requiring premarket review of <span style="letter-spacing:-0.15pt;">LDTs. </span>HHS issued this statement on its website and it may be subject to change. Also, it is possible that Congress will pass legislation to reform the federal government&#8217;s regulation of <span style="letter-spacing:-0.2pt;">LDTs </span>or that FDA will engage in notice-and-comment rulemaking to require premarket review of <span style="letter-spacing:-0.15pt;">LDTs, </span>which could result in delay or additional expense in offering our tests and tests that we may develop in the<span style="letter-spacing:-0.35pt;"> </span>future.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our current line of diagnostic tests </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">is</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"> covered under CLIA and CMS, although our COVID testing program and select partnerships we may enter may cause us to be subject to additional FDA requirements.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The laws and regulations governing the marketing of diagnostic products are evolving, extremely complex and in many instances, there are no significant regulatory or judicial interpretations of these laws and regulations. Pursuant to its authority under the FDCA, the FDA has jurisdiction over medical devices, including in vitro diagnostics and, therefore, potentially our clinical laboratory tests.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the FDCA and its implementing regulations, the FDA regulates the research, testing, manufacturing, safety, labeling, storage, recordkeeping, premarket clearance or approval, marketing and promotion, and sales and distribution of medical devices in the United States to ensure that medical products distributed domestically are safe and effective for their intended uses. Although the FDA has asserted that it has authority to regulate the development and use of LDTs, such as our and many other laboratories&#8217; tests, as medical devices, it has generally exercised enforcement discretion and is not otherwise regulating most tests developed and performed within a single high complexity CLIA-certified laboratory. On August 19, 2020, HHS issued a statement purporting to rescind the FDA&#8217;s policies regarding the premarket review of LDTs, absent notice-and-comment rulemaking. the FDA&#8217;s policies to date have been articulated through guidance documents, compliance manuals, website statements, and other informal issuances. The FDA could, at any time, engage in notice-and-comment rulemaking, or Congress could take action to amend the law to change the current regulatory framework for in vitro diagnostics and LDTs. Further, the HHS statement was issued on its website and may be subject to change, particularly given the reasoning that additional flexibility is needed due to the COVID-19 pandemic.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;letter-spacing:-0.4pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe that our tests, as utilized in our clinical laboratory, are and would be considered <span style="letter-spacing:-0.2pt;">LDTs </span>and that as a result, the FDA does not require that we obtain regulatory clearances or approvals for our <span style="letter-spacing:-0.2pt;">LDTs </span>or their components pursuant to the <span style="letter-spacing:-0.35pt;">FDA&#8217;s </span>current policies and guidance. Although we believe that our tests and test components are either exempt from FDA medical device regulations or are subject to an enforcement discretion <span style="letter-spacing:-0.15pt;">policy, </span>it is possible that<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.2pt;"> </span>FDA<span style="letter-spacing:-0.15pt;"> </span>would<span style="letter-spacing:-0.2pt;"> </span>not<span style="letter-spacing:-0.15pt;"> </span>agree<span style="letter-spacing:-0.2pt;"> </span>with<span style="letter-spacing:-0.2pt;"> </span>our<span style="letter-spacing:-0.15pt;"> </span>determinations<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:-0.15pt;"> </span>that<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>FDA<span style="letter-spacing:-0.2pt;"> </span>will<span style="letter-spacing:-0.2pt;"> </span>change<span style="letter-spacing:-0.15pt;"> </span>its<span style="letter-spacing:-0.2pt;"> </span>regulations<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>policies<span style="letter-spacing:-0.15pt;"> </span>such<span style="letter-spacing:-0.2pt;"> </span>that<span style="letter-spacing:-0.2pt;"> </span>our<span style="letter-spacing:-0.15pt;"> </span>products<span style="letter-spacing:-0.2pt;"> </span>become<span style="letter-spacing:-0.15pt;"> </span>regulated<span style="letter-spacing:-0.2pt;"> </span>as medical<span style="letter-spacing:-0.1pt;"> </span>devices.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In contrast with our <span style="letter-spacing:-0.15pt;">LDTs, </span>the FDA has regulatory jurisdiction over the two FDA EUA-authorized COVID-19 tests that were developed by Bio-Rad, which we offer as part of our Biodesix <span style="letter-spacing:-0.15pt;">WorkSafe </span>testing programs.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our operations, therefore, are or may become subject to extensive regulation by the FDA in the United States. Government regulations specific to medical devices are wide ranging and govern, among other things:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">test design, development, manufacture, and</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">release&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">laboratory and clinical testing, labeling, packaging, storage, and</span><span style="letter-spacing:-0.55pt;color:#000000;"> </span><span style="color:#000000;">distribution&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">product safety and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">efficacy&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">premarketing clearance or</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">approval&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">service</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">operations&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">record</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">keeping&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">product marketing, promotion and advertising, sales, and</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">distribution&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">post-marketing surveillance, including reporting of deaths or serious injuries and recalls and correction and</span><span style="letter-spacing:-1.35pt;color:#000000;"> </span><span style="color:#000000;">removals&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">post-market approval studies&#59;</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">product import and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">export.</span></p></td></tr></table></div>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA classifies medical devices into one of three classes on the basis of the intended use of the device, the risk associated with the use of the device for that indication, as determined by the FDA, and on the controls deemed by the FDA to be necessary to reasonably ensure their safety and effectiveness. Class I devices, which have the lowest level of risk associated with them, are subject to general controls. Class II devices are subject to general controls and special controls, including performance standards. Class III devices, which have the highest level of risk associated with them, are subject to general controls and premarket approval.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Before a new medical device or service, or a new intended use for an existing product or service, can be marketed in the United States, a company must first submit and receive either 510(k) clearance, de-novo authorization, or premarket approval (PMA) from the FDA, unless an exemption applies. Most Class I devices and some Class II devices are exempt from these requirements. In the 510(k) clearance process, before a device may be marketed, the FDA must determine that a proposed device is substantially equivalent to a legally-marketed predicate device, which includes a device that has been previously cleared through the 510(k) process, a device that was legally marketed prior to May 28, 1976 (preamendments device), a device that was originally on the United States market pursuant to an approved PMA and later down-classified, or a 510(k)-exempt device. To be substantially equivalent, the proposed device must have the same intended use as the predicate device, and either have the same technological characteristics as the predicate device or have different technological characteristics and not raise different questions of safety or effectiveness than the predicate device. Clinical data are sometimes required to support substantial equivalence.</span></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the process of obtaining PMA approval, the FDA must determine that a proposed device is safe and effective for its intended use based, in part, on extensive data, including, but not limited to, technical, clinical trial, manufacturing and labeling data. The PMA process is typically required for devices that are deemed to pose the greatest risk, such as life-sustaining, life-supporting or implantable devices.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA also allows the submission of a direct de-novo petition. This procedure allows a manufacturer whose novel device is automatically classified into Class III to request down-classification of its medical device into Class I or Class II on the basis that the device presents low or moderate risk, rather than requiring the submission and approval of a PMA application. Prior to the enactment of the Food and Drug Administration Safety and Innovation Act of 2012 (FDASIA), a medical device could only be eligible for de novo classification if the manufacturer first submitted a 510(k) premarket notification and received a determination from the FDA that the device was not substantially equivalent. FDASIA streamlined the de novo classification pathway by permitting manufacturers to request de novo classification directly without first submitting a 510(k) premarket notification to the FDA and receiving a not substantially equivalent determination.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The 510(k), de-novo or PMA process can be expensive, lengthy and unpredictable. The FDA can delay, limit, or deny clearance or approval of a device for many reasons, including:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">inability</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">demonstrate</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">satisfaction</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">FDA</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">applicable</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">regulatory</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">entity</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">conformity assessment body</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">that</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">diagnostic</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">tests</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">are</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">safe or effective for their proposed intended</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">uses&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">disagreement</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">FDA</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">with</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">design</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">implementation</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">clinical</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">trials</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">interpretation</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">data</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">from</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">clinical</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">trials&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">serious and unexpected adverse device effects experienced by participants in our clinical</span><span style="letter-spacing:-0.95pt;color:#000000;"> </span><span style="color:#000000;">trials&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the data from our clinical trials may be insufficient to support clearance or approval, where</span><span style="letter-spacing:-1.2pt;color:#000000;"> </span><span style="color:#000000;">required&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our inability to demonstrate that the clinical and other benefits of the device outweigh the</span><span style="letter-spacing:-1.1pt;color:#000000;"> </span><span style="color:#000000;">risks&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the manufacturing process or facilities we use may not meet applicable requirements&#59;</span><span style="letter-spacing:-0.85pt;color:#000000;"> </span><span style="color:#000000;">and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">potential</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">for</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">approval</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">policies</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">regulations</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">FDA</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">applicable</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">foreign</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">regulatory</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">bodies</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">change</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">significantly</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">in</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">a</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">manner rendering our clinical data or regulatory filings insufficient for clearance or</span><span style="letter-spacing:-0.85pt;color:#000000;"> </span><span style="color:#000000;">approval.</span></p></td></tr></table></div>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA and state authorities have broad enforcement powers. Our failure to comply with applicable regulatory requirements could result in enforcement action by any such agency, which may include any of the following sanctions:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">adverse</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">publicity,</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">warning</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">letters,</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">untitled</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">letters,</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">it</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">has</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">come</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">attention</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">letters,</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">fines,</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">injunctions,</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">consent</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">decrees</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">civil</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">penalties&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">repair, replacement, refunds, recall or seizure of our diagnostic</span><span style="letter-spacing:-0.6pt;color:#000000;"> </span><span style="color:#000000;">tests&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">operating restrictions, partial suspension, or total shutdown of</span><span style="letter-spacing:-0.55pt;color:#000000;"> </span><span style="color:#000000;">production&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">denial</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">requests</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">for</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">regulatory</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">clearance</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">premarket</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">approval</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">new</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">diagnostic</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">tests</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">services,</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">new</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">intended</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">uses,</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">modifications to existing diagnostic tests or</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">services&#59;</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="text-decoration:none;Background-color:#auto;"></span><span style="color:#000000;"></span><span style="color:#000000;">withdrawal of regulatory clearance or premarket approvals that have already been granted&#59;</span><span style="letter-spacing:-0.95pt;color:#000000;"> </span><span style="color:#000000;">or</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">criminal</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">prosecution.</span></p></td></tr></table></div>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As discussed above, we believe that our current line of diagnostic tests and their components are LDTs, subject to state licensing requirements and federal regulation by CMS under CLIA, although our COVID-19 testing program and select partnerships we may enter may cause us to be subject to additional FDA regulations discussed above.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">While we believe that we are currently in material compliance with applicable laws and regulations, it is possible that the FDA, or other regulatory agencies, would not agree with our determinations. If our products became become subject to 510(k) or other similar FDA regulations, we would need to comply with the applicable regulations or face significant civil and criminal penalties. In addition, IVDs and CDx tests are widely considered to be Class III devices, and it is possible that in the future, we may develop tests that fall into this category. CDx tests in particular may require further administrative procedures in the PMA process. Exposure to these additional regulatory requirements would also affect our business, financial condition and results of operations.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our future success depends on our ability to develop, receive regulatory clearance or approval or certification for, and introduce new diagnostic tests or enhancements to existing diagnostic tests that will be accepted by the market in a timely manner. There is no guarantee that the FDA will grant 510(k) clearance or PMA approval of our future diagnostic tests and failure to obtain necessary clearances or approvals for our future diagnostic tests would adversely affect our ability to grow our business.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">It is important to our business that we build a pipeline of diagnostic test offerings that address limitations of current lung disease diagnostic tests. As such, our success will depend in part on our ability to develop and introduce new diagnostic tests. However, we may not be able to successfully develop and obtain regulatory clearance or approval or certification for enhancements to our existing diagnostic tests, or new diagnostic tests for any number of reasons, including due to the cost associated with certain regulatory approval requirements, or these diagnostic tests may not be accepted by physicians or users.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The success of any new diagnostic test or enhancement to an existing diagnostic test will depend on a number of factors, including our ability to, among others:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">identify and anticipate physician and patient needs</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">properly&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">develop and introduce new diagnostic tests or enhancements to our existing diagnostic tests in a timely</span><span style="letter-spacing:-1.4pt;color:#000000;"> </span><span style="color:#000000;">manner&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">avoid infringing upon, misappropriating, or violating the intellectual property rights of third</span><span style="letter-spacing:-0.9pt;color:#000000;"> </span><span style="color:#000000;">parties&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">demonstrate, if required, the safety and efficacy of new diagnostic tests with data from clinical</span><span style="letter-spacing:-1.15pt;color:#000000;"> </span><span style="color:#000000;">studies&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">obtain</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">necessary</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">regulatory</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">clearances</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">approvals or certifications</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">for</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">new</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">diagnostic</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">tests</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">enhancements</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">existing</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">diagnostic</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">tests&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">comply fully with FDA and foreign regulations on marketing of new diagnostic tests or modified diagnostic tests&#59;</span><span style="letter-spacing:-1.5pt;color:#000000;"> </span><span style="color:#000000;">and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">provide adequate training to potential users of our diagnostic</span><span style="letter-spacing:-0.55pt;color:#000000;"> </span><span style="color:#000000;">tests.</span></p></td></tr></table></div>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If<span style="letter-spacing:-0.2pt;"> </span>we<span style="letter-spacing:-0.15pt;"> </span>do<span style="letter-spacing:-0.2pt;"> </span>not<span style="letter-spacing:-0.15pt;"> </span>develop<span style="letter-spacing:-0.15pt;"> </span>new<span style="letter-spacing:-0.2pt;"> </span>diagnostic<span style="letter-spacing:-0.15pt;"> </span>tests<span style="letter-spacing:-0.15pt;"> </span>or<span style="letter-spacing:-0.2pt;"> </span>enhancements<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.2pt;"> </span>our<span style="letter-spacing:-0.15pt;"> </span>existing<span style="letter-spacing:-0.15pt;"> </span>diagnostic<span style="letter-spacing:-0.2pt;"> </span>tests<span style="letter-spacing:-0.15pt;"> </span>in<span style="letter-spacing:-0.15pt;"> </span>time<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.15pt;"> </span>meet<span style="letter-spacing:-0.2pt;"> </span>market<span style="letter-spacing:-0.15pt;"> </span>demand<span style="letter-spacing:-0.15pt;"> </span>or<span style="letter-spacing:-0.2pt;"> </span>if<span style="letter-spacing:-0.15pt;"> </span>there<span style="letter-spacing:-0.15pt;"> </span>is<span style="letter-spacing:-0.2pt;"> </span>insufficient demand for these diagnostic tests or enhancements, or if our competitors introduce new diagnostic tests with functionalities that are superior to ours, our results of operations will<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.15pt;">suffer.</span></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Some of our future diagnostic tests may require FDA clearance of a 510(k) submission. Other diagnostic tests may require the approval of a PMA. In addition, some of our future diagnostic tests may require clinical trials to support regulatory approval and we may not successfully complete these clinical trials. The FDA may not approve or clear these diagnostic tests for the indications that are necessary or desirable for successful commercialization. Indeed, the FDA may refuse our requests for 510(k) clearance or premarket approval of new diagnostic tests. Failure to receive clearance or approval for our new diagnostic tests would have an adverse effect on our ability to expand our business.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">73</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Modifications to our marketed tests may require new 510(k) clearances or PMA approvals, or may require us to cease marketing or recall the modified tests until clearances or approvals are obtained.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Modifications to our diagnostic tests may require new regulatory approvals or clearances, including 510(k) clearances or premarket approvals, or require us to recall or cease marketing the modified systems until these clearances or approvals are obtained. The FDA requires device manufacturers to initially make and document a determination of whether or not a modification requires a new approval, supplement or clearance. A manufacturer may determine that a modification could not significantly affect safety or efficacy and does not represent a major change in its intended use, so that no new 510(k) clearance is necessary. However, the FDA can review a manufacturer&#8217;s decision and may disagree. The FDA may also on its own initiative determine that a new clearance or approval is required. We have made modifications to our diagnostic tests in the past and may make additional modifications in the future that we believe do not or will not require additional clearances or approvals. If the FDA disagrees and requires new clearances or approvals for the modifications, we may be required to recall and to stop marketing our diagnostic tests as modified, which could require us to redesign our diagnostic tests and harm our operating results. In these circumstances, we may be subject to significant enforcement actions.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If a manufacturer determines that a modification to an FDA-cleared device could significantly affect its safety or efficacy, or would constitute a major change in its intended use, then the manufacturer must file for a new 510(k) clearance or possibly a premarket approval application. Where we determine that modifications to our diagnostic tests require a new 510(k) clearance or premarket approval application, we may not be able to obtain those additional clearances or approvals for the modifications or additional indications in a timely manner, or at all. Obtaining clearances and approvals can be a time-consuming process, and delays in obtaining required future clearances or approvals would adversely affect our ability to introduce new or enhanced diagnostic tests in a timely manner, which in turn would harm our future growth.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If we or our suppliers fail to comply with ongoing FDA or other domestic and foreign regulatory authority or conformity assessment body requirements, or if we experience unanticipated problems with our diagnostic tests, they could be subject to restrictions or withdrawal from the market.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any medical device that we manufacture, including those for which we obtain regulatory clearance or approval or certification, and the manufacturing processes, reporting requirements, post-approval clinical data and promotional activities for such diagnostic test, will be subject to continued regulatory review, oversight, and periodic inspections by the FDA and other domestic and foreign regulatory bodies or conformity assessment bodies. In particular, we and our suppliers may be required to comply with FDA&#8217;s Quality System Regulations (QSR codified at 21 C.F.R. &#167; 820) for medical devices and International Standards Organization (ISO) regulations for the manufacture of our diagnostic tests and other regulations which cover the methods and documentation of the design, testing, production, control, quality assurance, labeling, packaging, storage and shipping of any diagnostic test for which we obtain clearance or approval. Regulatory bodies, such as the FDA, and conformity assessment bodies enforce the QSR and other regulations through periodic inspections and audits. The failure by us or one of our suppliers to comply with applicable statutes and regulations administered by the FDA and other regulatory bodies or conformity assessment bodies, or the failure to timely and adequately respond to any adverse inspectional observations or product safety issues, could result in, among other things, one or more of the following enforcement actions:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">untitled letters, warning letters, fines, injunctions, consent decrees and civil</span><span style="letter-spacing:-0.7pt;color:#000000;"> </span><span style="color:#000000;">penalties&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">unanticipated expenditures to address or defend such</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">actions&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">customer notifications for repair, replacement, or</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">refunds&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">recall, detention, or seizure of our diagnostic</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">tests&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">operating restrictions or partial suspension or total shutdown of</span><span style="letter-spacing:-0.6pt;color:#000000;"> </span><span style="color:#000000;">production&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">refusing</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">delaying</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">requests</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">for</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">510(k)</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">clearance</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">premarket</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">approval</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">new</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">diagnostic</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">tests</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">modified</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">versions</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">current diagnostic</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">tests&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">operating</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">restrictions&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">withdrawing 510(k) clearances on PMA approvals that have already been</span><span style="letter-spacing:-0.7pt;color:#000000;"> </span><span style="color:#000000;">granted&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">revocation of EUAs that have been authorized previously&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">refusal to grant export approval for our diagnostic tests&#59;</span><span style="letter-spacing:-0.55pt;color:#000000;"> </span><span style="color:#000000;">and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">criminal</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">prosecution.</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If any of these actions were to occur it would harm our reputation and cause our diagnostic test sales and profitability to suffer and may prevent us from generating revenue. Furthermore, our key component suppliers may not currently be or may not continue to be in compliance with all applicable regulatory requirements which could result in our failure to produce our diagnostic tests on a timely basis and in the required quantities, if at all.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, we are required to conduct surveillance to monitor the safety or effectiveness of our diagnostic tests, and we must comply with medical device reporting requirements, including the reporting of adverse events and malfunctions related to our diagnostic tests. Later discovery of previously unknown problems with our diagnostic tests, including unanticipated adverse events or adverse events of unanticipated severity or frequency, manufacturing problems, or failure to comply with regulatory requirements such as QSR, may result in changes to labeling, restrictions on such diagnostic tests or manufacturing processes, withdrawal of the diagnostic tests from the market, voluntary or mandatory recalls, a requirement to repair, replace or refund the cost of any medical device we manufacture or distribute, fines, suspension of regulatory approvals, product seizures, injunctions or the imposition of civil or criminal penalties which would adversely affect our business, operating results and prospects.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our diagnostic tests and services may in the future be subject to product recalls that could harm our reputation, business and financial results.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Medical devices can experience performance problems in the field that require review and possible corrective action. The occurrence of component failures, manufacturing errors, software errors, design defects or labeling inadequacies affecting a medical device could lead to a government-mandated or voluntary recall by the device manufacturer, in particular when such deficiencies may endanger health. The FDA requires that certain classifications of recalls be reported to the FDA within 10 working days after the recall is initiated. Companies are required to maintain certain records of recalls, even if they are not reportable to the FDA. We may initiate voluntary recalls involving our diagnostic tests and services in the future that we determine do not require notification of the FDA. If the FDA disagrees with our determinations, they could require us to report those actions as recalls. Product recalls may divert management attention and financial resources, expose us to product liability or other claims, harm our reputation with customers and adversely impact our business, financial condition and results of operations. Other jurisdictions have similar recall requirements.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Legislative or regulatory reforms may make it more difficult and costly for us to obtain regulatory clearance or approval or certification of any future diagnostic tests and to manufacture, market and distribute our diagnostic tests after clearance or approval is obtained.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From time to time, legislation is drafted and introduced in Congress that could significantly change the statutory provisions governing the regulatory approval, manufacture and marketing of regulated products or the reimbursement thereof. For example, the Verifying Accurate, Leading-edge IVCT Development (VALID) Act recently introduced in Congress would codify into law the term &#8220;in vitro clinical test&#8221; in order to create a new medical product category separate from medical devices that would include products currently regulated as in vitro diagnostics as well as LDTs.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, FDA regulations and guidance are often revised or reinterpreted by the FDA in ways that may significantly affect our business and our diagnostic tests. Any new regulations or revisions or reinterpretations of existing regulations may impose additional costs or lengthen review times of planned or future diagnostic tests. It is impossible to predict whether legislative changes will be enacted or FDA regulations, guidance or interpretations changed, and what the impact of such changes, if any, may be.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any change in the laws or regulations that govern the clearance and approval processes relating to our current, planned and future diagnostic tests could make it more difficult and costly to obtain clearance or approval for new diagnostic tests or to produce, market and distribute existing diagnostic tests. Significant delays in receiving clearance or approval or the failure to receive clearance or approval for any new diagnostic tests would have an adverse effect on our ability to expand our business.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Clinical trials may be necessary to support future product submissions to FDA. These clinical trials are expensive and will require the enrollment of large numbers of patients, and suitable patients may be difficult to identify and recruit. Delays or failures in our clinical trials will prevent us from commercializing any modified or new diagnostic tests and will adversely affect our business, operating results and prospects.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Initiating and completing clinical trials necessary to support any future PMA applications, and additional safety and efficacy data beyond that typically required for a 510(k) clearance, for our possible future product candidates, will be time consuming and expensive and the outcome uncertain. Moreover, the results of early clinical trials are not necessarily predictive of future results, and any product we advance into clinical trials may not have favorable results in later clinical trials.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Conducting successful clinical studies will require the enrollment of large numbers of patients, and suitable patients may be difficult to identify and recruit. Patient enrollment in clinical trials and completion of patient participation and follow-up depends on many factors, including the size of the patient population, the nature of the trial protocol, the attractiveness of, or the discomforts and risks associated with, the treatments received by enrolled subjects, the availability of appropriate clinical trial investigators, support staff, and proximity of patients to clinical sites and ability to comply with the eligibility and exclusion criteria for participation in the clinical trial and patient compliance. For example, patients may be discouraged from enrolling in our clinical trials if the trial protocol requires them to undergo extensive post-treatment procedures or follow-up to assess the safety and effectiveness of our diagnostic tests or if they determine that the treatments received under the trial protocols are not attractive or involve unacceptable risks or discomforts.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Development of sufficient and appropriate clinical protocols to demonstrate safety and efficacy are required and we may not adequately develop such protocols to support clearance and approval. Further, the FDA may require us to submit data on a greater number of patients than we originally anticipated and/or for a longer follow-up period or change the data collection requirements or data analysis applicable to our clinical trials. Delays in patient enrollment or failure of patients to continue to participate in a clinical trial may cause an increase in costs and delays in the approval and attempted commercialization of our diagnostic tests or result in the failure of the clinical trial. In addition, despite considerable time and expense invested in our clinical trials, the FDA may not consider our data adequate to demonstrate safety and efficacy. Such increased costs and delays or failures could adversely affect our business, operating results and prospects.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If the third parties on which we rely to conduct our clinical trials and to assist us with pre-clinical development do not perform as contractually required or expected, we may not be able to obtain regulatory clearance or approval or certification for or commercialize our diagnostic tests and services.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;letter-spacing:-0.4pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may not have the ability to independently conduct our pre-clinical and clinical trials for our future diagnostic tests and services and we must rely on third parties, such as contract research organizations, medical institutions, clinical investigators and contract laboratories to conduct such trials. If these third parties do not successfully carry out their contractual duties or regulatory obligations or meet expected deadlines, if these third parties need to be replaced, or if the quality or accuracy of the data they obtain is compromised due to the failure to adhere to our clinical protocols or regulatory requirements or for other reasons, our pre-clinical development activities or clinical trials may be extended, delayed, suspended or terminated, and we may not be able to obtain regulatory approval <span style="letter-spacing:-0.15pt;">for, </span>or successfully commercialize, our diagnostic tests and services on a timely basis, if at all, and our business, operating<span style="letter-spacing:-0.25pt;"> </span>results<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.25pt;"> </span>prospects<span style="letter-spacing:-0.2pt;"> </span>may<span style="letter-spacing:-0.25pt;"> </span>be<span style="letter-spacing:-0.2pt;"> </span>adversely<span style="letter-spacing:-0.25pt;"> </span>affected.<span style="letter-spacing:-0.2pt;"> </span>Furthermore,<span style="letter-spacing:-0.2pt;"> </span>our<span style="letter-spacing:-0.25pt;"> </span>third-party<span style="letter-spacing:-0.2pt;"> </span>clinical<span style="letter-spacing:-0.25pt;"> </span>trial<span style="letter-spacing:-0.2pt;"> </span>investigators<span style="letter-spacing:-0.25pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>be<span style="letter-spacing:-0.2pt;"> </span>delayed<span style="letter-spacing:-0.25pt;"> </span>in<span style="letter-spacing:-0.2pt;"> </span>conducting<span style="letter-spacing:-0.25pt;"> </span>our<span style="letter-spacing:-0.2pt;"> </span>clinical trials for reasons outside of their<span style="letter-spacing:-0.35pt;"> </span>control.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our use, disclosure, and other processing of personally identifiable information, including health information, is subject to HIPAA and other federal, state, and foreign privacy and security regulations, and our failure to comply with those regulations or to adequately secure the information we hold could result in significant liability or reputational harm and, in turn, a material adverse effect on our business, operating results and prospects.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We maintain and process, and our third-party vendors, collaborators, contractors and consultants maintain and process on our behalf, a large quantity of sensitive information, including confidential business, personal and patient health information in connection with our clinical studies and our employees, and are subject to data privacy and protection laws and regulations that apply to the collection, transmission, storage and use of personally identifying information, which among other things, impose certain requirements relating to the privacy, security and </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">76</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">transmission of personal information. Failure by us or our third-party vendors, collaborators, contractors and consultants to comply with any of these laws and regulations could result in notification obligations or enforcement actions against us, which could result in fines, imprisonment of company officials and public censure, claims for damages by affected individuals, damage to our reputation and loss of goodwill, any of which could have a material adverse effect on our business, financial condition, results of operations or prospects. These laws, rules and regulations evolve frequently and their scope may continually change, through new legislation, amendments to existing legislation and changes in enforcement, and may be inconsistent from one jurisdiction to another. The interpretation and application of consumer, health-related and data protection laws, especially with respect to genetic samples and data, in the United States, the European Union (EU) and elsewhere, are often uncertain, contradictory and in flux. As a result, implementation standards and enforcement practices are likely to remain uncertain for the foreseeable future.</span></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the United States, numerous federal and state laws and regulations, including federal health information privacy laws, state data breach notification laws, state health information privacy laws and federal and state consumer protection laws (e.g., Section 5 of the Federal Trade Commission Act), that govern the collection, use, disclosure and protection of health-related and other personal information could apply to our operations or the operations of our collaborators.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Domestic laws in this area are complex and developing rapidly. Many state legislatures have adopted legislation relating to privacy, data security and data breaches. Laws in all 50 states require businesses to provide notice to customers whose personally identifiable information has been disclosed as a result of a data breach. The laws are not consistent, and compliance in the event of a widespread data breach is costly. States are also frequently amending existing laws, requiring attention to frequently changing regulatory requirements. For example, California recently enacted the CCPA, which became effective on January 1, 2020. The CCPA, among other things, requires new disclosures to California consumers and affords such consumers new abilities to access and delete their personal information, opt-out of certain sales of personal information and receive detailed information about how their personal information is used. The CCPA provides for fines of up to $7,500 per violation, as well as a private right of action for data breaches that is expected to increase the frequency of data breach litigation. While the CCPA has already been amended multiple times, it is unclear how this legislation will be further modified or how it will be interpreted. Interpretations of the CCPA may continue to evolve with regulatory guidance and the CCPA continue to be amended, including through a ballot initiative, the California Privacy Rights Act (the CPRA). That passed in November 2020. The CPRA will impose additional data protection obligations on companies doing business in California, including additional consumer rights, including regarding certain uses of sensitive data. It also creates a new California data protection agency specifically tasked to enforce the law, which may likely result in increased regulatory scrutiny of California businesses in the areas of data protection and security. The effects of this legislation potentially are far-reaching, however, and may require us to modify our data processing practices and policies and incur substantial compliance-related costs and expenses. The CCPA and other changes in state and federal laws or regulations relating to privacy, data protection and information security, particularly any new or modified laws or regulations that require enhanced protection of certain types of data or new obligations with regard to data retention, transfer or disclosure, could increase the cost of providing our offerings, require significant changes to our operations or even prevent us from providing certain offerings in jurisdictions in which we currently operate and in which we may operate in the future.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because of the breadth of these data protection laws and the narrowness of their exceptions and safe harbors, it is possible that our business or data protection policies could be subject to challenge under one or more of such laws. The scope and enforcement of each of these laws is uncertain and subject to rapid change in the current environment of heightened regulatory focus on data privacy and security issues. Although we endeavor to comply with our published policies and documentation and ensure their compliance with current laws, rules and regulations, we may at times fail to do so or be alleged to have failed to do so. The publication of our privacy policy and other documentation that provide promises and assurances about privacy and security can subject us to potential state and federal action in the United States if they are found to be deceptive, unfair, or misrepresentative of our actual practices. Any failure by us or other parties with whom we do business to comply with this documentation or with federal, state, local or international regulations could result in proceedings against us by governmental entities, private parties or others. In many jurisdictions, enforcement actions and consequences for noncompliance are rising.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">77</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If our operations are found to be in violation of any of the data protection laws described above or any other laws that apply to us, we may be subject to penalties, including, but not limited to, criminal, civil and administrative penalties, damages, fines, disgorgement, individual imprisonment, possible exclusion from participation in government healthcare programs, injunctions, private qui tam actions brought by individual whistleblowers in the name of the government, class action litigation and the curtailment or restructuring of our operations, as well as additional reporting obligations and oversight if we become subject to a corrective action plan or other agreement to resolve allegations of non-compliance with these laws, any of which could adversely affect our ability to operate our business and our results of operations.</span></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, numerous state and federal laws and regulations govern the collection, dissemination, use, privacy, confidentiality, security, availability, integrity, and other processing of PHI and PII. These laws and regulations include HIPAA. HIPAA establishes a set of national privacy and security standards for the protection of protected health information (as defined in HIPAA, PHI) by health plans, healthcare clearinghouses and certain healthcare providers, referred to as covered entities, and the business associates with whom such covered entities contract for services. We are a covered entity under HIPAA when we are conducting our clinical trials. We are a covered entity with regard to our observational studies and clinical trials, and also a business associate under HIPAA for certain other business activities, and we execute business associate agreements with our clients.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HIPAA requires covered entities and business associates, such as us, to develop and maintain policies with respect to the protection of, use and disclosure of electronic PHI, including the adoption of administrative, physical and technical safeguards to protect such information, and certain notification requirements in the event of a data breach.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;letter-spacing:-0.2pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HIPAA imposes mandatory penalties for certain violations. Penalties for violations of HIPAA and its implementing regulations start at <span style="letter-spacing:-0.15pt;">$119 </span>per violation and are subject to a cap of $1,785,651 for violations of the same standard in a single calendar<span style="letter-spacing:-0.15pt;"> year. </span>However, a single breach incident can result in violations of multiple standards. HIPAA also authorizes state attorneys general to file suit on behalf of their residents. Courts may award damages, costs and attorneys&#8217; fees related to violations of HIPAA in such cases. While HIPAA does not create a private right of action allowing individuals to sue us in civil court for violations of HIPAA, its standards have been used as the basis for duty of care in state civil suits such as those for negligence or recklessness in the misuse or breach of PHI.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, HIPAA mandates that the Secretary of HHS conduct periodic compliance audits of HIPAA covered entities and business associates. With regard to business associates, those audits assess the business associate&#8217;s compliance with the HIPAA Privacy and Security Standards. Such audits are conducted randomly and after an entity experiences a breach affecting more than 500 individuals&#8217; data. Undergoing an audit can be costly, can result in fines or onerous obligations, and can damage a business associate&#8217;s reputation.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to HIPAA, numerous other federal, state, and foreign laws and regulations protect the confidentiality, privacy, availability, integrity and security of PHI and other types of PII. Some of these laws and regulations may be preempted by HIPAA with respect to PHI, or may exclude PHI from their scope but impose obligations with regard to PII that is not PHI, and in some cases, can impose additional obligations with regard to PHI. These laws and regulations are often uncertain, contradictory, and subject to changing or differing interpretations, and we expect new laws, rules and regulations regarding privacy, data protection, and information security to be proposed and enacted in the future. HHS is also proposing amendments to the HIPPA Privacy Rule to modernize certain data sharing provisions and enhance patient access to their information. This complex, dynamic legal landscape regarding privacy, data protection, and information security creates significant compliance issues for us and our clients and potentially exposes us to additional expense, adverse publicity and liability. While we have implemented data privacy and security measures in an effort to comply with applicable laws and regulations relating to privacy and data protection, some PHI and other PII or confidential information is transmitted to us by third parties, who may not implement adequate security and privacy measures, but it is possible that laws, rules and regulations relating to privacy, data protection, or information security may be interpreted and applied in a manner that is inconsistent with our practices or those of third parties who transmit PHI and other PII or confidential information to us. If we or these third parties are found to have violated such laws, rules or regulations, it could result in government-imposed fines, orders requiring that we or these third parties change our or their practices, or criminal charges, which could adversely affect our business.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">78</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Complying with these various laws and regulations could cause us to incur substantial costs or require us to change our business practices, systems and compliance procedures in a manner adverse to our business.</span></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may eventually operate in a number of countries outside of the United States whose laws, including data privacy laws, may in some cases be more stringent than the requirements in the United States. For example, EU and UK data privacy laws have specific requirements relating to cross-border transfers of personal data to certain jurisdictions, including to the United States, have strict requirements relating to personal data collection, use or sharing, and have more stringent requirements relating to organizations&#8217; privacy programs and provide stronger individual rights. Moreover, we may also be subject to evolving international privacy and data security regulations which could result in greater compliance costs and in turn lead to penalties, where such compliance programs are not implemented correctly. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain of our processing activities are subject to the EU General Data Protection Regulation and the UK General Data Protection Regulation (collectively, the &#8220;GDPR&#8221;) &#8211; including, those involving pseudonymised / key-coded data - as the GDPR applies extra-territorially. The GDPR imposes strict requirements on controllers and processors processing personal data, including, for example, requirements to: (i) identify a legal basis for the processing of personal data, (ii) provide robust disclosures to individuals, (iii) respond to requests from individuals to exercise their data subject rights, (iv) provide personal data breach notifications within 72 hours after discovering the breach, (v) limit the collection and retention of personal data, (vi) impose specific contractual obligations on processors engaged to process personal data on the instructions of the controller, and (vii) apply enhanced protections to health data and other special categories of personal data. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The EU GDPR also provides that EU Member States may make their own further laws and regulations limiting the processing of personal data, including genetic, biometric or health data, which could limit our ability to use and share such personal data and cause our costs to increase and harm our financial condition. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Failure to comply with the requirements of the GDPR may result in fines of up to &#8364;20 million (&#163;17.5 million in the case of the UK GDPR) or up to 4% of the total worldwide annual turnover of our preceding fiscal year, whichever is higher, and other administrative penalties. GDPR compliance may require us to put in place additional mechanisms, which may result in compliance costs and other substantial expenditures. This may be onerous and adversely affect our business, financial condition, results of operations and the profitability of our platform of diagnostic tests. Failure to comply with the GDPR and other countries&#8217; privacy or data security-related laws, rules or regulations could result in material penalties imposed by regulators, affect our compliance with contracts entered into with our collaborators and other third-party payers, and have an adverse effect on our business and financial condition. Currently, the GDPR is only applicable to us as a processor, but as we continue to expand into the European market, the GDPR will have direct applicability to us as a controller.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The GDPR also prohibits the transfer of personal data from the EEA/UK to a country outside of the EEA/UK (e.g., the United States) unless made to a country deemed to have adequate data privacy laws by the European Commission (or UK Government in case of the UK GDPR) or a data transfer mechanism has been put in place. Until recently, one such data transfer mechanism was the EU-US Privacy Shield. However, in July 2020 the Court of Justice of the European Union (CJEU) declared the Privacy Shield to be invalid. The CJEU upheld the validity of standard contractual clauses (SCCs) as a legal mechanism to transfer personal data but companies relying on SCCs will need to carry out a transfer privacy impact assessment, which among other things, assesses laws governing access to personal data in the recipient country and considers whether supplementary measures that provide privacy protections additional to those provided under SCCs will need to be implemented to ensure an essentially equivalent level of data protection to that afforded in the EEA.&#160; In turn, the findings of the CJEU will have significant implications for cross-border data flows and may lead to increased transaction, compliance, and technological costs to support international data transfers.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Organizations operating in Canada and covered by the Personal Information Protection and Electronic Documents Act (PIPEDA), or equivalent Canadian provincial laws, must obtain an individual&#8217;s consent when they collect, use or disclose that individual&#8217;s personal information. Individuals have the right to access and challenge the accuracy of their personal information held by an organization, and personal information may only be used for the purposes for which it was collected. If an organization intends to use personal information for another purpose, it must again obtain that individual&#8217;s consent.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">79</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We regularly monitor, defend against and respond to attacks to our networks and other information security incidents. Despite our information security efforts, our facilities, systems, and data, as well as those of our third-party service providers, may be vulnerable to privacy and information security incidents such as data breaches, viruses or other malicious code, coordinated attacks, data loss, phishing attacks, ransomware, denial of service attacks, or other security or IT incidents caused by threat actors, technological vulnerabilities or human error. If we, or any of our vendors that support our IT or have access to our data, including any third</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">party vendors that collect, process and store personal data on our behalf, fail to comply with laws requiring the protection of personal information, or fail to safeguard and defend personal information or other critical data assets or IT systems, we may be subject to regulatory enforcement and fines as well as private civil actions. We may be required to expend significant resources in the response, containment, mitigation of cybersecurity incidents as well as in defense against claims that our information security was unreasonable or otherwise violated applicable laws or contractual obligations.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our employees, collaborators, independent contractors and consultants may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are exposed to the risk that our employees, collaborators, independent contractors and consultants may engage in fraudulent or other illegal activity with respect to our business. Misconduct by these employees could include intentional, reckless and/or negligent conduct or unauthorized activity that violates:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">FDA</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">regulations,</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">including</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">those</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">laws</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">requiring</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">reporting</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">true,</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">complete,</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">accurate</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">information</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">FDA</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">authorities&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">federal and state healthcare fraud and abuse laws and regulations&#59;</span><span style="letter-spacing:-0.65pt;color:#000000;"> </span><span style="color:#000000;">or</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">laws that require the true, complete and accurate reporting of financial information or</span><span style="letter-spacing:-0.95pt;color:#000000;"> </span><span style="color:#000000;">data.</span></p></td></tr></table></div>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Misconduct by these parties could also involve individually identifiable information, including, without limitation, the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. Any incidents or any other conduct that leads to an employee, contractor, or other agent, or our company, receiving an FDA debarment or exclusion by the HHS Office of Inspector General (OIG) could result in penalties, a loss of business from third parties, and severe reputational harm.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have adopted a Code of Business Conduct and Ethics and compliance policies to govern and deter such behaviors, but it is not always possible to identify and deter misconduct by our employees and other agents, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of civil, criminal and administrative penalties, treble damages, monetary fines, disgorgement, imprisonment, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational harm, diminished profits and future earnings, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, and curtailment of our operations.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Clinical development involves a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our ongoing research and development and clinical trial activities are subject to extensive regulation and review by numerous governmental authorities both in the United States and abroad. We are currently conducting pre-and post-market clinical studies of some of our tests. In the future we may conduct clinical trials to support approval of new diagnostic tests and services, or new indications. Clinical studies may need to be conducted in compliance with FDA regulations or the FDA may take enforcement action. The data collected from these clinical studies may ultimately be used to support marketing authorization for these diagnostic tests and services. Even if our clinical trials are completed as planned, we cannot be certain that their results will support our product candidate claims or that the FDA or foreign authorities and conformity assessment bodies will agree with our conclusions </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">regarding them.</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Success in</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">pre-clinical studies and early clinical trials does not ensure that later clinical trials will be successful, and we cannot be sure that the later trials will replicate the results of prior trials and pre-clinical studies. The clinical trial process may fail to demonstrate that our tests are safe and effective for the proposed indicated uses, which could cause us to abandon development of our tests and may delay development of others. Any delay or termination of our clinical trials will delay the filing of our product submissions and, ultimately, may impact our ability to commercialize our tests and generate revenues.</span></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Many<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>factors<span style="letter-spacing:-0.15pt;"> </span>that<span style="letter-spacing:-0.15pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>cause<span style="letter-spacing:-0.15pt;"> </span>or<span style="letter-spacing:-0.15pt;"> </span>lead<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.15pt;"> </span>a<span style="letter-spacing:-0.15pt;"> </span>delay<span style="letter-spacing:-0.2pt;"> </span>in<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>commencement<span style="letter-spacing:-0.15pt;"> </span>or<span style="letter-spacing:-0.15pt;"> </span>completion<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:-0.2pt;"> </span>clinical<span style="letter-spacing:-0.15pt;"> </span>trials<span style="letter-spacing:-0.15pt;"> </span>may<span style="letter-spacing:-0.15pt;"> </span>also<span style="letter-spacing:-0.15pt;"> </span>ultimately<span style="letter-spacing:-0.15pt;"> </span>lead<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.15pt;"> </span>delay<span style="letter-spacing:-0.15pt;"> </span>or<span style="letter-spacing:-0.15pt;"> </span>denial of regulatory clearance or approval or certification. The commencement of clinical trials may be delayed due to insufficient patient enrollment, which is a function of many factors, including the size of the patient population, the nature of the protocol, the proximity of patients to clinical sites and the eligibility criteria for the clinical<span style="letter-spacing:-0.15pt;"> </span>trial.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may find it necessary to engage contract research organizations to perform data collection and analysis and other aspects of our clinical trials, which might increase the cost and complexity of our trials. We may also depend on clinical investigators, medical institutions, and contract research organizations to perform the trials, and would control only certain aspects of their activities. Nevertheless, we would be responsible for ensuring that each of our trials is conducted in accordance with the applicable protocol, legal, regulatory and scientific standards, and our reliance on these third parties would not relieve us of our regulatory responsibilities. We and our third-party contractors are required to comply with good clinical practices (GCPs) which are regulations and guidelines enforced by the FDA, and comparable regulations enforced by foreign regulatory authorities for products in clinical development. Regulatory authorities enforce these GCPs through periodic inspections of trial sponsors, principal investigators and trial sites. If we or any third-party contractor fails to comply with applicable GCPs, the clinical data generated in clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities or conformity assessment bodies may require us to perform additional clinical trials before clearing or approving our marketing applications. A failure to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory clearance or approval or certification process. In addition, if these parties do not successfully carry out their contractual duties or obligations or meet expected deadlines, or if the quality, completeness or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols or for other reasons, our clinical trials may have to be extended, delayed or terminated. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Many of these factors could be beyond our control. We may not be able to undertake additional trials, repeat trials or enter into new arrangements with third parties without undue delays or considerable expenditures. If there are delays in testing or clearances or approvals as a result of the failure to perform by third parties, our research and development costs would increase and we may not be able to obtain regulatory clearance or approval or certification for our tests. In addition, we may not be able to establish or maintain relationships with these parties on favorable terms, if at all. Each of these outcomes would harm our ability to market our tests, or to achieve sustained profitability.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The results of our clinical trials may not support our product candidate claims or may result in the discovery of adverse side effects.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;letter-spacing:-0.4pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We cannot be certain that the results of our future clinical trials will support our future product claims or that the FDA or comparable foreign regulatory authorities or conformity assessment bodies will agree with our conclusions<span style="letter-spacing:-0.2pt;"> </span>regarding<span style="letter-spacing:-0.2pt;"> </span>them.<span style="letter-spacing:-0.2pt;"> </span>Success<span style="letter-spacing:-0.2pt;"> </span>in<span style="letter-spacing:-0.15pt;"> </span>pre-clinical<span style="letter-spacing:-0.2pt;"> </span>studies<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>early<span style="letter-spacing:-0.2pt;"> </span>clinical<span style="letter-spacing:-0.15pt;"> </span>trials<span style="letter-spacing:-0.2pt;"> </span>does<span style="letter-spacing:-0.2pt;"> </span>not<span style="letter-spacing:-0.2pt;"> </span>ensure<span style="letter-spacing:-0.2pt;"> </span>that<span style="letter-spacing:-0.15pt;"> </span>later<span style="letter-spacing:-0.2pt;"> </span>clinical<span style="letter-spacing:-0.2pt;"> </span>trials<span style="letter-spacing:-0.2pt;"> </span>will<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.2pt;"> </span>successful,<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>we<span style="letter-spacing:-0.2pt;"> </span>cannot be sure that the later trials will replicate the results of prior trials and pre-clinical studies. The clinical trial process may fail to demonstrate that our product candidates are safe and effective for the proposed indicated uses, which could cause us to abandon a product candidate and may delay development of others. Any delay or termination of our clinical trials will delay the filing of our product submissions and, ultimately, our ability to commercialize our product candidates and generate revenues. It is also possible that patients enrolled in clinical trials will experience adverse side effects that are not currently part of the future product&#8217;s<span style="letter-spacing:-0.3pt;"> </span>profile. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">81</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our billing, collections and claims processing activities are complex and time-consuming, and any delay in transmitting and collecting claims or failure to comply with applicable billing requirements, could have an adverse effect on our future revenue.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Billing for our tests is complex, time-consuming and expensive. Depending on the billing arrangement and applicable law, we bill various payers, such as government payers, insurance companies and patients, all of which may have different billing requirements. We may face increased risk in our collection efforts, including long collection cycles and the risk that we may never collect at all, either of which could adversely affect our business, financial condition and results of operations. Several factors make the billing process complex, including:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">differences between the list price for our tests and the reimbursement rates of</span><span style="letter-spacing:-0.9pt;color:#000000;"> </span><span style="color:#000000;">payers&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">compliance</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">with</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">complex</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">federal</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">state</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">regulations</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">related</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">billing</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">government</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">healthcare</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">programs,</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">including</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">Medicare</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">Medicaid, to the extent our tests are covered by such</span><span style="letter-spacing:-0.55pt;color:#000000;"> </span><span style="color:#000000;">programs&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">differences in coverage among payers and the effect of patient co-payments or</span><span style="letter-spacing:-0.95pt;color:#000000;"> </span><span style="color:#000000;">co-insurance&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">differences in information and billing requirements among</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">payers&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">changes to codes and coding instructions governing our</span><span style="letter-spacing:-0.5pt;color:#000000;"> </span><span style="color:#000000;">tests&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">incorrect or missing billing information&#59;</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the resources required to manage the billing and claims appeals</span><span style="letter-spacing:-0.65pt;color:#000000;"> </span><span style="color:#000000;">process.</span></p></td></tr></table></div>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These billing complexities and the related uncertainty in obtaining payment for our tests could negatively affect our revenue and cash flow, our ability to achieve profitability and the consistency and comparability of our results of operations. In addition, if claims for our tests are not submitted to payers on a timely basis, or if we fail to comply with applicable billing requirements, it could have an adverse effect on our revenue and our business.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Third-party payers require us to identify the test for which we are seeking reimbursement using a Current Procedural Terminology (CPT) code. The CPT code set is maintained by the American Medical Association (AMA). In cases where there is not a specific CPT code to describe a test, such as with Nodify CDT and GeneStrat, the test may be billed under an unlisted molecular pathology procedure code or through the use of a combination of single gene CPT codes, depending on the payer. The Protecting Access to Medicare Act of 2014 (PAMA) authorized the adoption of new, temporary billing codes and unique test identifiers for FDA-cleared or approved tests as well as advanced diagnostic laboratory tests. The AMA has created a new section of CPT codes, Proprietary Laboratory Analyses codes to facilitate implementation of this section of PAMA. In addition, CMS may assign unique level II Healthcare Common Procedure Coding System codes to tests that are not already described by a unique CPT code. VeriStrat and Nodify XL2 both have test specific CPT codes, but GeneStrat and Nodify CDT do not at this time.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the instance where a code used does not describe a specific test, the insurance claim must be examined to determine what test was provided, whether the test was appropriate and medically necessary, and whether payment should be rendered, which may require a letter of medical necessity from the ordering physician. This process can result in a delay in processing the claim, a lower reimbursement amount or denial of the claim. As a result, obtaining approvals from third-party payers to cover our tests and establishing adequate reimbursement levels is an unpredictable, challenging, time-consuming and costly process and we may never be successful.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We and our third-party manufacturers and suppliers must comply with environmental, health and safety laws and regulations, which can be expensive and restrict how we do, or interrupt our, business.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our research and development activities and our third-party manufacturers&#8217; and suppliers&#8217; activities involve the generation, use, storage and disposal of hazardous materials. We work with materials, including chemicals, biological agents and compounds and samples that could be hazardous to human health and safety or the environment. Our operations also produce hazardous and biological waste products. Accordingly, we and our third-party manufacturers and suppliers are subject to federal, state, local and foreign environmental, health and safety laws and regulations, and permitting and licensing requirements, including those governing the generation, use, manufacture, storage, handling, transportation, release and disposal of, and exposure to, these materials, and worker health and safety.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">82</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We cannot eliminate the risk of contamination or injury resulting from such hazardous materials. We also cannot guarantee that the procedures utilized by our third-party manufacturers for handling and disposing of hazardous materials and wastes comply with all applicable environmental, health and safety laws and regulations. As a result, we may be held liable for any resulting damages, costs or liabilities, including cleanup costs and liabilities, which could be significant, or our commercialization, research and development efforts and business operations may be restricted or interrupted.</span></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Environmental, health and safety laws and regulations are complex, change frequently and have tended to become more stringent. Compliance with such laws and regulations is expensive, and current or future environmental, health and safety laws and regulations may restrict our operations. If we do not comply with applicable environmental health and safety laws and regulations, and permitting and licensing requirements, we may be subject to fines, penalties, a suspension of our business or other sanctions.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to our Intellectual Property</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our success may be impaired if we are unable to obtain, maintain and protect our intellectual property rights.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our commercial success will depend in part on our ability to obtain and maintain patent and other intellectual property protection in the United States and other countries with respect to our diagnostic tests, products and services and technology. We rely on patent protection, as well as a combination of copyright, trade secret and trademark laws, to protect our proprietary technology and prevent others from duplicating our suite of diagnostic tests and products. However, these means may afford only limited protection and may not:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">prevent</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">competitors</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">from</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">duplicating</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">diagnostic</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">tests</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">products,</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">including</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">COVID-19</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">testing</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">program</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">Nodify</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">XL2, Nodify </span><span style="letter-spacing:-0.2pt;color:#000000;">CDT, </span><span style="color:#000000;">GeneStrat and </span><span style="letter-spacing:-0.15pt;color:#000000;">VeriStrat</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">tests&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">prevent</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">competitors</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">from</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">gaining</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">access</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">proprietary</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">information</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">technology,</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">including</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">Diagnostic</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">Cortex</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">platform,</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">tech platforms</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">such</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">as</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">DeepMALDI</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">analysis</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">intellectual</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">property</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">covering</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">technologies</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">that</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">allow</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">us</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">develop</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">&#8220;test</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">algorithms&#8221;&#59;</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">or</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">allow us to gain or maintain a competitive</span><span style="letter-spacing:-0.5pt;color:#000000;"> </span><span style="color:#000000;">advantage.</span></p></td></tr></table></div>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.29%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any of our patents, including those we may license, may be challenged, invalidated, rendered unenforceable or circumvented. Consequently, we do not know whether any of our diagnostic tests, products and services will be protectable or remain protected by valid and enforceable patents. We may not prevail if our patents are challenged by competitors or other third parties. The United States federal courts or equivalent national courts or patent offices elsewhere may invalidate our patents, find them unenforceable, or narrow their scope. Furthermore, competitors may be able to design around our patents by developing similar or alternative technologies or products in a non-infringing manner, or obtain patent protection for more effective technologies, designs or methods, including for treating lung cancer. If these developments were to occur, our diagnostic tests and products may become less competitive and sales may decline.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.29%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have filed numerous patent applications seeking protection of diagnostic tests and other inventions originating from our research and development. Our patent applications may not result in issued patents, and any patents that are issued may not provide meaningful protection against competitors or competitive technologies. Further, the examination process may require us to narrow the claims for our pending patent applications, which may limit the scope of patent protection that may be obtained if these applications issue. The scope of a patent may also be reinterpreted and significantly reduced after issuance. Even if patent applications we license or own currently or in the future issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors or other third parties from competing with us, or otherwise provide us with the protection or competitive advantages we are seeking.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.29%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, some of our owned and in-licensed patents and patent applications are, and may in the future be, co-owned with third parties. If we are unable to obtain or maintain an exclusive license to any such third-party co-owners&#8217; interest in such patents or patent applications, such co-owners may be able to license their rights to other third parties, including our competitors, and our competitors could market competing products and technology. In addition, we may need the cooperation of any such co-owners of our patents in order to enforce such patents against third parties, and such cooperation may not be provided to us. Any of the foregoing could have a material adverse effect on our competitive position, business, financial condition, results of operations, and prospects.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">83</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The patent position of biotechnology companies generally is highly uncertain, involves complex legal and factual questions, and has been the subject of much litigation in recent years. No consistent policy regarding the breadth of claims allowed in biotechnology and pharmaceutical patents has emerged to date in the United States or in many foreign jurisdictions. In addition, the determination of patent rights with respect to pharmaceutical compounds and technologies commonly involves complex legal and factual questions, which has in recent years been the subject of much litigation. Various courts, including the United States Supreme Court have rendered</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">decisions that affect the scope of patentability of certain inventions or discoveries relating to biotechnology. These decisions state, among other things, that a patent claim that recites an abstract idea, natural </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">phenomenon,</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> or law of nature (for example, the relationship between particular genetic variants and cancer) are not themselves patentable. Precisely what constitutes a law of nature or abstract idea is uncertain, and it is possible that certain aspects of our technology could be considered unpatentable under applicable law. As a result, the issuance, scope, validity, enforceability, and commercial value of our patent rights are highly uncertain. Depending on decisions by the United States Congress, the federal courts and the United States Patent and Trademark Office (USPTO), the laws and regulations governing patents could change in unpredictable ways that would weaken our and our licensors&#8217; ability to obtain new patents or to enforce our existing owned or in-licensed patents and patents that we might obtain or in-license in the future. Additionally, our pending and future patent applications may not result in patents being issued which protect our technology or products or which effectively prevent others from commercializing competitive technologies and products. The scope of patent protection outside of the United States is also uncertain. Changes in either the patent laws or their interpretation in the United States and other countries may diminish our ability to protect our inventions, obtain, maintain, and enforce our intellectual property rights and, more generally, could affect the value of our intellectual property rights or narrow the scope of our owned and licensed patents.</span></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we are unable to obtain and maintain patent protection for our technology, or if the scope of the patent protection obtained is not sufficient, our competitors could develop and commercialize diagnostic tests, products and services similar or superior to ours, and our competitive position may be adversely affected. It is also possible that we will fail to identify patentable aspects of inventions made in the course of our development and commercialization activities before it is too late to obtain patent protection on them. Therefore, we may miss potential opportunities to strengthen our patent position. In addition, the patent prosecution process is expensive, time-consuming and complex, and we may not be able to file, prosecute, maintain, enforce or license all necessary or desirable patent applications at a reasonable cost or in a timely manner. Although we enter into non-disclosure and confidentiality agreements with parties who have access to confidential or patentable aspects of our research and development output, such as our employees, consultants, advisors and other third parties, any of these parties may breach the agreements and disclose such output before a patent application is filed, thereby jeopardizing our ability to seek patent protection.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, while software and other of our proprietary works may be protected under copyright law, we have chosen not to register any copyrights in these works, and instead, primarily rely on protecting our software as a trade secret. In order to bring a copyright infringement lawsuit in the United States, the copyright must be registered. Accordingly, the remedies and damages available to us for unauthorized use of our copyrights may be limited.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position may be harmed.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to seeking patent protection for the patents underlying our diagnostic tests, products and services, we also rely upon unpatented trade secrets, know-how and continuing technological innovation to develop and maintain a competitive position. Trade secrets and know-how can be difficult to protect. We seek to protect such proprietary information, in part, through confidentiality agreements with our employees, collaborators, contractors, advisors, consultants and other third parties and invention assignment agreements with our employees. We also have agreements with some of our consultants that require them to assign to us any inventions created as a result of their working with us. The confidentiality agreements are designed to protect our proprietary information and, in the case of agreements or clauses containing invention assignment, to grant us ownership of technologies that are developed through a relationship with employees or third parties.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">84</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We cannot guarantee that we have entered into such agreements with each party that has or may have had access to our trade secrets or proprietary information. Additionally, despite these efforts, any of these parties may</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the United States are less willing or unwilling to protect trade secrets. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor or other third party, we would have no right to prevent them from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to, or independently developed by, a competitor or other third party, our competitive position would be materially and adversely harmed. Furthermore, we expect these trade secrets, know-how and proprietary information to over time be disseminated within the industry through independent development, the publication of journal articles describing the methodology and the movement of personnel from academic to industry scientific positions. Consequently, we may be unable to prevent our proprietary technology from being exploited in the United States and abroad, which could affect our ability to expand in domestic and international markets or require costly efforts to protect our technology.</span></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We also seek to preserve the integrity and confidentiality of our data and trade secrets by maintaining physical security of our premises and physical and electronic security of our information technology systems. While we have confidence in these individuals, organizations and systems, agreements or security measures may be breached, and we may not have adequate remedies for any breach. In addition, our trade secrets may otherwise become known, or be independently discovered by, competitors. To the extent that our employees, consultants, contractors or collaborators use intellectual property rights owned by others in their work for us, disputes may arise as to the rights in related or resulting know-how and inventions, which could have a material adverse effect on our business, financial condition and results of operations.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may be subject to claims that we or our employees have misappropriated the intellectual property rights of a third party, including trade secrets or know-how, or are in breach of non-competition or non-solicitation agreements with our competitors, and third parties may claim an ownership interest in intellectual property we regard as our own.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Many of our employees and consultants were previously employed at or engaged by universities or other medical device, diagnostic, biotechnology or pharmaceutical companies, including our competitors or potential competitors. Some of these employees, consultants and contractors, may have executed proprietary rights, non-disclosure and non-competition agreements in connection with such previous employment. Although we try to ensure that our employees, consultants and independent contractors do not use the intellectual property rights, proprietary information, know-how or trade secrets of others in their work for us, we may be subject to claims that we or these individuals have, inadvertently or otherwise, used, infringed, misappropriated or otherwise violated the intellectual property rights or disclosed the alleged trade secrets or other proprietary information, of these former employers, competitors or other third parties, or to claims that we have improperly used or obtained such trade secrets. Litigation may be necessary to defend against these claims. If we fail in defending such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel, which could adversely impact our business. Any litigation or the threat of litigation may adversely affect our ability to hire employees or contract with independent sales representatives. A loss of key personnel or their work product could hamper or prevent our ability to commercialize potential diagnostic tests, products and services, which could harm our business. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to management and other employees.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, we may be subject to claims from third parties challenging our ownership interest in intellectual property rights we regard as our own, based on claims that our employees or consultants have breached an obligation to assign inventions to another employer, to a former employer, or to another person or entity. Litigation may be necessary to defend against any other claims, and it may be necessary or we may desire to enter into a license to settle any such claim&#59; however, there can be no assurance that we would be able to obtain a license on commercially reasonable terms, if at all. If our defense to those claims fails, in addition to paying monetary damages, a court could prohibit us from using technologies or features that are essential to our diagnostic tests or products, if such technologies or features are found to incorporate or be derived from the trade secrets or other proprietary information of the former employers.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">An inability to incorporate technologies or features that are important or essential to our diagnostic tests or products could have a material adverse effect on our business, financial condition and results of operations, and may prevent us from selling our rights to our COVID-19 testing program, either of the Nodify XL2 and Nodify CDT tests, or the VeriStrat and GeneStrat tests.</span></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, while it is our policy to require our employees and contractors who may be involved in the conception or development of intellectual property rights to execute agreements assigning such intellectual property rights to us, we may be unsuccessful in executing such an agreement with each party who, in fact, conceives or develops intellectual property rights that we regard as our own. The assignment of intellectual property rights may not be self-executing, or the assignment agreements may be breached, and we may be forced to bring claims against third parties, or defend claims that they may bring against us, to determine the ownership of what we regard as our intellectual property rights. Such claims could have a material adverse effect on our business, financial condition, results of operations, and prospects.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Changes in patent law could diminish the value of patents in general, thereby impairing our ability to protect our existing and future diagnostic tests, products and services.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Recent patent reform legislation could increase the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of issued patents. In 2011, the Leahy-Smith America Invents Act (Leahy-Smith Act) was signed into <span style="letter-spacing:-0.2pt;">law. </span>The Leahy-Smith Act includes a number of<span style="letter-spacing:-0.25pt;"> </span>significant<span style="letter-spacing:-0.2pt;"> </span>changes<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.2pt;"> </span>United<span style="letter-spacing:-0.2pt;"> </span>States<span style="letter-spacing:-0.2pt;"> </span>patent<span style="letter-spacing:-0.2pt;"> law.</span><span style="letter-spacing:-0.35pt;"> </span>These<span style="letter-spacing:-0.2pt;"> </span>include<span style="letter-spacing:-0.2pt;"> </span>provisions<span style="letter-spacing:-0.2pt;"> </span>that<span style="letter-spacing:-0.2pt;"> </span>affect<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.2pt;"> </span>way<span style="letter-spacing:-0.2pt;"> </span>patent<span style="letter-spacing:-0.2pt;"> </span>applications<span style="letter-spacing:-0.2pt;"> </span>are<span style="letter-spacing:-0.2pt;"> </span>prosecuted<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>also<span style="letter-spacing:-0.25pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>affect<span style="letter-spacing:-0.2pt;"> </span>patent litigation. These also include provisions that switched the United States from a first-to-invent system to a first-inventor-to-file system, allow third-party submission of prior art to the USPTO during patent prosecution and set forth additional procedures to attack the validity of a patent by the USPTO administered post grant proceedings, including post-grant <span style="letter-spacing:-0.15pt;">review, </span><span style="font-style:italic;">inter partes </span>review and derivation proceedings. Under a first-inventor-to-file system, assuming the other requirements for patentability are met, the first inventor to file a patent application generally will be entitled to the patent on an invention regardless of whether another inventor was the first to invent the claimed invention. The USPTO recently developed new regulations and procedures to govern administration of the Leahy-Smith Act, and many of the substantive changes to patent law associated with the Leahy-Smith Act, and in particular, the first to file provisions, only became effective in 2013. Accordingly, it is not clear what, if <span style="letter-spacing:-0.2pt;">any, </span>impact the Leahy-Smith Act will have on the operation of our business. The Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business, financial condition and results of<span style="letter-spacing:-0.25pt;"> </span>operations.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, patent reform legislation may pass in the future that could lead to additional uncertainties and increased costs surrounding the prosecution, enforcement and defense of our patents and applications. Furthermore, the United States Supreme Court and the United States Court of Appeals for the Federal Circuit have made, and will likely continue to make, changes in how the patent laws of the United States are interpreted. Recent United States Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. This combination of events has created uncertainty with respect to the validity and enforceability of patents, once obtained. Similarly, foreign courts have made, and will likely continue to make, changes in how the patent laws in their respective jurisdictions are interpreted. We cannot predict future changes in the interpretation of patent laws or changes to patent laws that might be enacted into law by United States and foreign legislative bodies. Those changes may materially affect our patents or patent applications and our ability to obtain additional patent protection in the future.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If our trademarks and tradenames are not adequately protected, then we may not be able to build name recognition in our markets and our business may be adversely affected.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our trademarks or trade names may be challenged, infringed, circumvented, declared generic or determined to be violating or infringing on other marks. We may not be able to protect our rights to these trademarks and trade names or may be forced to stop using these trademarks or trade names, which we need to build name recognition among potential partners and customers in our markets of interest. At times, competitors or other third parties may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement or dilution claims brought by owners of other trademarks. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively and our business may be adversely affected.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">86</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have not yet registered certain of our trademarks in all of our potential markets, although we have registered several connected to our diagnostic tests, products and services in the United States. If we apply to register these and trademarks in the United States and other countries, our applications may not be allowed for registration in a timely fashion or at all, and our registered trademarks may not be maintained or enforced. During trademark registration proceedings, we may receive rejections. Although we would be given an opportunity to respond to those rejections, we may be unable to overcome such rejections. In addition, in the USPTO and in comparable agencies in many foreign jurisdictions, third parties are given an opportunity to oppose pending trademark applications and to seek to cancel registered trademarks. Opposition or cancellation proceedings may be filed against our trademark applications and registrations, and our trademarks may not survive such proceedings. If we do not secure registrations for our trademarks, we may encounter more difficulty in enforcing them against third parties than we otherwise would.</span></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our efforts to enforce or protect our rights related to trademarks, trade secrets, domain names or other intellectual property rights may be ineffective, could result in substantial costs and diversion of resources and could adversely affect our business, financial condition and results of operations.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may become involved in lawsuits to protect or enforce our patents, the patents of our licensors or other intellectual property rights, which could be expensive, time consuming and unsuccessful.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Competitors or other third parties may infringe, misappropriate or otherwise violate our patents, the patents of our licensors or other intellectual property rights, or we may be required to defend against claims of infringement, misappropriation or other violations. In addition, our patents also may become involved in inventorship, priority or validity disputes. To counter or defend against such claims can be expensive and time-consuming. Any claims we assert against perceived infringers could provoke those parties to assert counterclaims against us alleging that we infringe their patents or other intellectual property. In any such proceeding, a court or other administrative body may decide that a patent or other intellectual property right owned by us is invalid or unenforceable, or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover such technology. Grounds for a validity challenge could include an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, written description, non-enablement or failure to claim patent-eligible subject matter. Grounds for an unenforceability assertion could include an allegation that someone connected with prosecution of the patent withheld information material to patentability from the USPTO, or made a misleading statement, during prosecution. Third parties also may raise similar claims before administrative bodies in the United States or abroad, even outside the context of litigation. Such mechanisms include reexamination, post-grant review, <span style="font-style:italic;">inter partes </span>review, interference proceedings, derivation proceedings and equivalent proceedings in foreign jurisdictions, including opposition proceedings. Such proceedings could result in the revocation or cancellation of or amendment to our patents in such a way that they no longer cover our diagnostic tests, products and services or prevent third parties from competing with our diagnostic tests, products and services. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which the patent examiner and we or our licensing partners were unaware during prosecution. If a third party were to prevail on a legal assertion of invalidity or unenforceability, we could lose at least part, and perhaps all, of the patent protection on our diagnostic tests, products and services. An adverse result in any litigation or other proceeding could put one or more of our patents at risk of being invalidated or interpreted narrowly. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during litigation.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, some of our owned and in-licensed patents and patent applications are, and may in the future be, co-owned with third parties. If we are unable to obtain an exclusive license to any such third-party co-owners&#8217; interest in such patents or patent applications, such co-owners may be able to license their rights to other third parties, including our competitors, and our competitors could market competing diagnostic tests, products, services or technology. In addition, we may need the cooperation of any such co-owners of our patents in order to enforce such patents against third parties, and such cooperation may not be provided to us. Any of the foregoing could have a material adverse effect on our business, financial condition or results of operations.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">87</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if resolved in our favor, litigation or other proceedings relating to intellectual property claims may cause us to incur significant expenses and could distract our management and other personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments, and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on our common stock price. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources and more mature and developed intellectual property portfolios. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace. Any of the foregoing could have a material adverse effect on our business, financial condition or results of operations.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Third parties may initiate legal proceedings alleging that we are infringing, misappropriating, or otherwise violating their intellectual property rights, the outcome of which would be uncertain and could have a material adverse effect on the success of our business.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The intellectual property landscape in the field of precision oncology is in flux, and it may remain uncertain for the coming years. There may be significant intellectual property related litigation and proceedings relating to our owned and in-licensed, and other third party, intellectual property and proprietary rights in the future. As we move into new markets and applications for our diagnostic tests, products or services, incumbent participants in such markets may assert their patents and other intellectual property rights against us as a means of slowing our entry into such markets or as a means to extract substantial license and royalty payments from us. Our competitors and others may now and, in the future, have significantly larger and more mature patent portfolios than we currently have. In addition, future litigation may involve patent holding companies or other adverse patent owners who have no relevant product or service revenue and against whom our own patents may provide little or no deterrence or protection. Therefore, our commercial success depends in part on our non-infringement of the patents or other intellectual property rights of third parties.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">However, we may in the future be subject to claims that we, or other parties we have agreed to indemnify, infringe, misappropriate or otherwise violate patents or other intellectual property rights owned or controlled by third parties. Because patent applications are published sometime after filing, and because applications can take several years to issue, there may be additional currently pending third-party patent applications that are unknown to us, which may later result in issued patents. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. We may not have sufficient resources to bring these actions to a successful conclusion.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There is a substantial amount of litigation and other patent challenges, both within and outside the United States, involving patent and other intellectual property rights in the biotechnology industry, including patent infringement lawsuits, interferences, oppositions and <span style="font-style:italic;">inter partes </span>review proceedings before the USPTO, and corresponding foreign patent offices. Numerous United States and foreign issued patents and pending patent applications, which are owned by third parties, including our competitors, exist in the fields in which we are developing diagnostic tests and in which we may develop future diagnostic tests, products and services. As the precision oncology industry expands and more patents are issued, the risk increases that our diagnostic tests may be subject to claims of infringement of the patent rights of third parties. Numerous significant intellectual property issues have been litigated, are being litigated and will likely continue to be litigated, between existing and new participants in our existing and targeted markets, and competitors have and may assert that our diagnostic tests or services infringe their intellectual property rights as part of a business strategy to impede our successful entry into or growth in those markets.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We could incur substantial costs and divert the attention of our management and technical personnel in defending against any of these claims. Parties making claims against us may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">88</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because of the inevitable uncertainty in intellectual property litigation, we could lose a patent infringement or other action asserted against us regardless of our perception of the merits of the case. There is no assurance that a court would find in our favor on questions of infringement, validity, enforceability, or priority. A court of competent jurisdiction could hold that these third</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">party patents are valid, enforceable, and infringed, which could materially and adversely affect our ability to commercialize any product candidates we may develop and any other product candidates or technologies covered</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">by</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">asserted</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">third</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-party</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">patents.</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">order</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">successfully</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">challenge</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">validity</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">any</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">such</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">United</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">States</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">patent</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">federal</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">court,</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">would</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">need to overcome a presumption of validity. As this burden is a high one requiring us to present clear and convincing evidence as to the invalidity of any such United</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">States</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">patent</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">claim,</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">there</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">is</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">no</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">assurance</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">that</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">court</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">competent</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">jurisdiction</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">would</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">invalidate</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">claims</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">any</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">such</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">United</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">States</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">patent.</span></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Parties making claims against us may be able to obtain injunctive or other relief, which could block our ability to develop, commercialize and sell diagnostic tests, products or services, and could result in the award of substantial damages against us, including treble damages, attorney&#8217;s fees, costs, and expenses<span style="letter-spacing:-0.2pt;"> </span>if<span style="letter-spacing:-0.15pt;"> </span>we<span style="letter-spacing:-0.15pt;"> </span>are<span style="letter-spacing:-0.15pt;"> </span>found<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.15pt;"> </span>have<span style="letter-spacing:-0.15pt;"> </span>willfully<span style="letter-spacing:-0.15pt;"> </span>infringed.<span style="letter-spacing:-0.2pt;"> </span>In<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>event<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:-0.2pt;"> </span>a<span style="letter-spacing:-0.15pt;"> </span>successful<span style="letter-spacing:-0.15pt;"> </span>claim<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:-0.15pt;"> </span>infringement<span style="letter-spacing:-0.2pt;"> </span>against<span style="letter-spacing:-0.15pt;"> </span>us,<span style="letter-spacing:-0.15pt;"> </span>we<span style="letter-spacing:-0.15pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>required<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.15pt;"> </span>pay<span style="letter-spacing:-0.2pt;"> </span>damages<span style="letter-spacing:-0.15pt;"> </span>and ongoing royalties, which could be significant, and obtain one or more licenses from third parties, or be prohibited from selling certain diagnostic tests, products<span style="letter-spacing:-0.15pt;"> </span>or<span style="letter-spacing:-0.15pt;"> </span>services.<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.4pt;">We</span><span style="letter-spacing:-0.15pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>not<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>able<span style="letter-spacing:-0.1pt;"> </span>to<span style="letter-spacing:-0.15pt;"> </span>obtain<span style="letter-spacing:-0.1pt;"> </span>these<span style="letter-spacing:-0.15pt;"> </span>licenses<span style="letter-spacing:-0.1pt;"> </span>on<span style="letter-spacing:-0.15pt;"> </span>acceptable<span style="letter-spacing:-0.15pt;"> </span>or<span style="letter-spacing:-0.1pt;"> </span>commercially<span style="letter-spacing:-0.15pt;"> </span>reasonable<span style="letter-spacing:-0.1pt;"> </span>terms,<span style="letter-spacing:-0.15pt;"> </span>if<span style="letter-spacing:-0.15pt;"> </span>at<span style="letter-spacing:-0.1pt;"> </span>all,<span style="letter-spacing:-0.15pt;"> </span>or<span style="letter-spacing:-0.1pt;"> </span>these<span style="letter-spacing:-0.15pt;"> </span>licenses<span style="letter-spacing:-0.1pt;"> </span>may<span style="letter-spacing:-0.15pt;"> </span>be non-exclusive, which could result in our competitors gaining access to the same intellectual property. In addition, we could encounter delays in diagnostic test introductions while we attempt to develop alternative diagnostic tests, products or services to avoid infringing third-party patents or intellectual property rights. Defense of any lawsuit or failure to obtain any of these licenses could prevent us from commercializing diagnostic tests, products or services, and the prohibition of sale of any of our diagnostic tests, products or services could materially affect our business and our ability to gain market acceptance for our diagnostic tests, products and services.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. In addition, during the course of this kind of litigation, there could be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, our agreements with some of our customers, suppliers or other entities with whom we do business require us to defend or indemnify these parties to the extent they become involved in infringement claims, including the types of claims described above. We could also voluntarily agree to defend or indemnify third parties in instances where we are not obligated to do so if we determine it would be important to our business relationships. If we are required or agree to defend or indemnify third parties in connection with any infringement claims, we could incur significant costs and expenses that could adversely affect our business, operating results or financial condition.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may be subject to claims challenging the priority or inventorship of our patents and other intellectual property rights.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We or our licensors may be subject to claims that former employees, collaborators or other third parties have an interest in our owned or in-licensed patents, trade secrets or other intellectual property rights as an inventor or co-inventor. For example, we or our licensors may have inventorship disputes arise from conflicting obligations of employees, consultants or others who are involved in developing our product candidates. Litigation may be necessary to defend against these and other claims challenging inventorship or our or our licensors&#8217; ownership of our owned or in-licensed patents, trade secrets or other intellectual property rights. If we or our licensors fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, intellectual property rights that are important to our product candidates.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we or our licensors are unsuccessful in any interference proceeding or other priority or inventorship dispute, we may be required to obtain and maintain licenses from third parties, including parties involved in any such interference proceedings or other priority or inventorship disputes. Such licenses may not be available on commercially reasonable terms or at all, or may be non-exclusive. If we are unable to obtain and maintain such licenses, we may need to cease the development, manufacture, and commercialization of one or more of our diagnostic tests, products or services. The loss of exclusivity or the narrowing of our owned and licensed patent </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">89</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:10pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">claims could limit our ability to stop others from using or commercializing similar or identical technology and products. Any of the foregoing could result in a material adverse effect on our business, financial condition, results of operations, or prospects. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Obtaining and maintaining our patent protection depends on compliance with various required procedures, document submissions, fee payments and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on patents and/or applications will be due to be paid to the USPTO and various governmental patent agencies outside of the United States at several stages over the lifetime of the patents and/or applications. We have systems in place to remind us to pay these fees, and we employ an outside firm and rely on our outside counsel to pay these fees due to non-United States patent agencies. We are also dependent on our licensors to take the necessary action to comply with these requirements with respect to our licensed intellectual property rights. The USPTO and various non-US governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. We employ reputable law firms and other professionals to help us comply, and in some cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules. However, there are situations in which non-compliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, our competitors may be able to enter the market without infringing our patents and this circumstance would have a material adverse effect on our business.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Issued patents covering our diagnostic tests and any other or future diagnostic tests, products or services could be found invalid or unenforceable if challenged.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability and some of our patents or patent applications, including licensed patents, may be challenged, in courts or patent offices in the United States and abroad, in opposition, derivation, reexamination, <span style="font-style:italic;">inter partes </span>review, post-grant review or interference. Additionally, if we and our licensing partners initiate or become involved in legal proceedings against a third party to enforce a patent covering one of our diagnostic tests, products, services or technologies, the defendant could counterclaim that the patent covering our diagnostic tests, products or services is invalid or unenforceable. In patent litigation in the United States, counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including patent eligible subject matter, lack of novelty, obviousness or non-enablement. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO, or made a misleading statement during prosecution. In addition, the United States now awards patent priority to the first party to file a patent application, and others may submit patent claims covering our inventions prior to us. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art of which we and the patent examiner were unaware during prosecution. If a third party were to prevail on a legal assertion of invalidity or unenforceability, we would lose at least part, and perhaps all, of the patent protection on our diagnostic tests or any diagnostic tests, products and services that we may develop.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A successful third-party challenge to our patents could result in the unenforceability or invalidity of such patents, allow third parties to commercialize our technology or products and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize products<span style="letter-spacing:-0.2pt;"> </span>without<span style="letter-spacing:-0.2pt;"> </span>infringing<span style="letter-spacing:-0.2pt;"> </span>third-party<span style="letter-spacing:-0.2pt;"> </span>patent<span style="letter-spacing:-0.2pt;"> </span>rights,<span style="letter-spacing:-0.15pt;"> </span>which<span style="letter-spacing:-0.2pt;"> </span>could<span style="letter-spacing:-0.2pt;"> </span>have<span style="letter-spacing:-0.2pt;"> </span>a<span style="letter-spacing:-0.2pt;"> </span>material<span style="letter-spacing:-0.2pt;"> </span>adverse<span style="letter-spacing:-0.15pt;"> </span>impact<span style="letter-spacing:-0.2pt;"> </span>on<span style="letter-spacing:-0.2pt;"> </span>our<span style="letter-spacing:-0.2pt;"> </span>business.<span style="letter-spacing:-0.2pt;"> </span>Furthermore,<span style="letter-spacing:-0.2pt;"> </span>if<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.2pt;"> </span>breadth<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:-0.2pt;"> </span>strength<span style="letter-spacing:-0.2pt;"> </span>of protection provided by our patents and patent applications is threatened, regardless of the outcome, it could dissuade companies from collaborating with us to license, develop or commercialize current or future diagnostic tests, products or<span style="letter-spacing:-0.85pt;"> </span>services.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may not be aware of all third-party intellectual property rights potentially relating to our current or future diagnostic tests, products or services.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">90</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until approximately 18 months after filing </span><span style="letter-spacing:-0.15pt;">or, </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in some cases, not until such patent applications issue as patents. </span><span style="letter-spacing:-0.3pt;">We, </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or our current or future license partners or collaborators, might not have been the first to make the inventions covered by each of our pending patent applications and we might not have been the first to file patent applications for these inventions. </span><span style="letter-spacing:-0.35pt;">To </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">determine the priority of these inventions, we may have to participate in interference proceedings, derivation proceedings or other post-grant proceedings declared by the USPTO. The outcome of such proceedings is uncertain, and other patent applications may have priority over our patent applications. Such proceedings could also result in substantial costs to us and divert our management&#8217;s attention and resources.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We rely on licenses from third parties in relation to certain diagnostic tests, products and services and if we lose these licenses then we may be subjected to future litigation.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are a party to license agreements that grant us rights to use certain intellectual property rights, including patents and patent applications, typically in certain specified fields of use, in connection with our diagnostic tests, products and services. Some of those licensed rights could provide us with freedom to operate for aspects of our diagnostic tests, products and services. We may need to obtain additional licenses from others to advance our research, development and commercialization activities.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The in-licensing and acquisition of third-party intellectual property rights is a competitive area, and a number of more established companies are also pursuing<span style="letter-spacing:-0.25pt;"> </span>strategies<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.25pt;"> </span>in-license<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:-0.25pt;"> </span>acquire<span style="letter-spacing:-0.2pt;"> </span>third-party<span style="letter-spacing:-0.25pt;"> </span>intellectual<span style="letter-spacing:-0.25pt;"> </span>property<span style="letter-spacing:-0.25pt;"> </span>rights<span style="letter-spacing:-0.25pt;"> </span>that<span style="letter-spacing:-0.2pt;"> </span>we<span style="letter-spacing:-0.25pt;"> </span>may<span style="letter-spacing:-0.25pt;"> </span>consider<span style="letter-spacing:-0.25pt;"> </span>attractive<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:-0.25pt;"> </span>necessary.<span style="letter-spacing:-0.2pt;"> </span>These<span style="letter-spacing:-0.25pt;"> </span>established<span style="letter-spacing:-0.25pt;"> </span>companies may<span style="letter-spacing:-0.15pt;"> </span>have<span style="letter-spacing:-0.15pt;"> </span>a<span style="letter-spacing:-0.15pt;"> </span>competitive<span style="letter-spacing:-0.15pt;"> </span>advantage<span style="letter-spacing:-0.1pt;"> </span>over<span style="letter-spacing:-0.15pt;"> </span>us<span style="letter-spacing:-0.15pt;"> </span>due<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.15pt;"> </span>their<span style="letter-spacing:-0.1pt;"> </span>size,<span style="letter-spacing:-0.15pt;"> </span>cash<span style="letter-spacing:-0.15pt;"> </span>resources<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>greater<span style="letter-spacing:-0.1pt;"> </span>clinical<span style="letter-spacing:-0.15pt;"> </span>development<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>commercialization<span style="letter-spacing:-0.1pt;"> </span>capabilities.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furthermore,<span style="letter-spacing:-0.2pt;"> </span>companies<span style="letter-spacing:-0.15pt;"> </span>that<span style="letter-spacing:-0.2pt;"> </span>perceive<span style="letter-spacing:-0.15pt;"> </span>us<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>a<span style="letter-spacing:-0.2pt;"> </span>competitor<span style="letter-spacing:-0.15pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>unwilling<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.2pt;"> </span>assign<span style="letter-spacing:-0.15pt;"> </span>or<span style="letter-spacing:-0.2pt;"> </span>license<span style="letter-spacing:-0.15pt;"> </span>rights<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.2pt;"> </span>us.<span style="letter-spacing:-0.15pt;"> </span>In<span style="letter-spacing:-0.2pt;"> </span>addition,<span style="letter-spacing:-0.15pt;"> </span>we<span style="letter-spacing:-0.15pt;"> </span>expect<span style="letter-spacing:-0.2pt;"> </span>that<span style="letter-spacing:-0.15pt;"> </span>competition<span style="letter-spacing:-0.2pt;"> </span>for the in-licensing or acquisition of<span style="letter-spacing:-0.3pt;"> </span>third-party intellectual property rights for product candidates that are attractive to us may increase in the future, which may mean fewer suitable opportunities for us as well as higher acquisition or licensing costs. We may be unable to in-license or acquire the third-party intellectual property rights for product candidates on terms that would allow us to make an appropriate return on our investment. If we are unable to successfully obtain rights to suitable product candidates, our business, financial condition, results of operations and prospects for growth could suffer.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our existing license agreements impose, and we expect that our future license agreements will impose, various diligence, royalty payment, milestone payment, insurance and other obligations on us. If we fail to comply with these obligations or other obligations in our license agreements, our licensors may have the right to terminate these agreements, in which event we may not be able to develop and market any product or use any technology that is covered by these agreements. If our license agreements terminate, or we experience a reduction or elimination of licensed rights under these agreements, we may have to negotiate new or reinstated licenses with less favorable terms or we may not have sufficient intellectual property rights to operate our business. The occurrence of such events could materially harm our business.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our success may depend in part on the ability of our licensors to obtain, maintain and enforce patent protection for our licensed intellectual property rights. Our licensors may not successfully prosecute the patent applications we license. Even if patents issue in respect of these patent applications, our licensors may fail to maintain these patents, may determine not to pursue litigation against other companies that are infringing these patents or may pursue such litigation less aggressively than we would. Without protection for the intellectual property rights we license, other companies might be able to offer substantially identical diagnostic tests for sale, which could adversely affect our competitive business position and harm our business prospects.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any of the foregoing could have a material adverse effect on our competitive position, business, financial conditions, results of operations and prospects.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">91</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, disputes may also arise between us and our current or future licensors regarding intellectual property rights subject to a license agreement, including those relating to:</span></p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the scope of rights granted under the license agreement and other interpretation-related</span><span style="letter-spacing:-0.9pt;color:#000000;"> </span><span style="color:#000000;">issues&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">whether,</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">extent</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">which,</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">diagnostic</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">tests,</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">products,</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">services,</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">technology,</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">processes</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">infringe</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">on</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">intellectual</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">property</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">rights</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">of the licensor that is not subject to the licensing</span><span style="letter-spacing:-0.55pt;color:#000000;"> </span><span style="color:#000000;">agreement&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">whether our licensor or its licensor had the right to grant the license</span><span style="letter-spacing:-0.85pt;color:#000000;"> </span><span style="color:#000000;">agreement&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">whether</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">third</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">parties</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">are</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">entitled</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">compensation</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">equitable</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">relief,</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">such</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">as</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">an</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">injunction,</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">for</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">use</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">intellectual</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">property</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">rights without their</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">authorization&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our involvement in the prosecution of licensed patents and our licensors&#8217; overall patent enforcement</span><span style="letter-spacing:-1.25pt;color:#000000;"> </span><span style="color:#000000;">strategy&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the amounts of royalties, milestones, or other payments due under the license</span><span style="letter-spacing:-0.85pt;color:#000000;"> </span><span style="color:#000000;">agreement&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">right</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">sublicense</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">patent</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">other</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">rights</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">third</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">parties</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">under</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">collaborative</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">development</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">relationships&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">diligence</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">obligations</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">under</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">license</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">agreement</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">what</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">activities</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">satisfy</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">those</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">diligence</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">obligations&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">inventorship</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">ownership</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">inventions</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">know-how</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">resulting</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">from</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">joint</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">creation</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">use</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">intellectual</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">property</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">rights</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">by</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">our licensors and us and our collaborators&#59;</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the priority of invention of patented</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">technology.</span></p></td></tr></table></div>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we do not prevail in such disputes, we may lose any or all of our rights under such license agreements.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, the agreements under which we currently license intellectual property rights or technology from third parties are complex and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property rights or technology, or increase what we believe to be our financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our business, financial condition, results of operations and prospects. Moreover, if disputes over intellectual property rights that we have licensed prevent or impair our ability to maintain our current licensing arrangements on commercially acceptable terms, or are insufficient to provide us the necessary rights to use the intellectual property rights, we may be unable to successfully develop and commercialize any affected diagnostic tests, products or services, which could have a material adverse effect on our business, financial conditions, results of operations and prospects.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Absent the license agreements, we may infringe patents subject to those agreements, and if the license agreements are terminated, we may be subject to litigation by the licensor. Litigation could result in substantial costs to us and distract our management. If we do not prevail, we may be required to pay damages, including treble damages, attorneys&#8217; fees, costs and expenses and royalties or be enjoined from selling our diagnostic tests, products or services, which could adversely affect our ability to offer diagnostic tests, products or services, our ability to continue operations and our financial condition.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Some intellectual property that we in-license may have been developed through government funded programs and thus may be subject to federal regulations such as &#8220;march-in&#8221; rights, certain reporting requirements and a preference for companies based in the United States. Compliance with such regulations may limit our exclusive rights, and limit our ability to contract with manufacturers that are not based in the United States.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain of the intellectual property that we license may have been developed through the use of United States government funding and therefore may be subject to certain federal regulations. As a result, the United States government may have certain rights to intellectual property embodied in our diagnostic tests, products and services pursuant to the Bayh-Dole Act of 1980 (Bayh-Dole Act). These United States government rights in certain inventions developed under a government-funded program include a non-exclusive, non-transferable, irrevocable worldwide license to use inventions for any governmental purpose. In addition, the United States government has </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">92</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the right to require us to grant exclusive, partially exclusive, or non-exclusive licenses to any of these inventions to a third party if it determines that: (i) adequate steps have not been taken to commercialize the invention&#59;</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">government action is necessary to meet public health or safety needs&#59; or (iii) government action is necessary to meet requirements for public use under federal regulations (also referred to as &#8220;march-in rights&#8221;). </span><span style="letter-spacing:-0.35pt;">To </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">date, none of our commercialized products are subject to march-in rights. The United States government</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">also</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">has</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">right</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">take</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">title</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">these</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">inventions</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">if</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we,</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">applicable</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">licensor,</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">fail</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">disclose</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">invention</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">government</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">fail</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">file an application to register the intellectual property within specified time limits. Intellectual property generated under a government funded program is also subject to certain reporting requirements, compliance with which may require us or the applicable licensor to expend substantial resources. In addition, the United States government requires that any products of the subject invention or produced through the use of the subject invention be manufactured substantially in the United States. The manufacturing preference requirement can be waived if the owner of the intellectual property can show that reasonable but unsuccessful efforts have been made to grant licenses on similar terms to potential licensees that would be likely to manufacture substantially in the United States or that under the circumstances domestic manufacture is not commercially feasible. This preference for United States manufacturers may limit our ability to contract with product manufacturers outside of the United States for products covered by such intellectual property. </span><span style="letter-spacing:-0.35pt;">To </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the extent any of our current or future owned or licensed intellectual property is generated through the use of United States government funding, the provisions of the Bayh-Dole Act may similarly </span><span style="letter-spacing:-0.15pt;">apply. </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any failure by us to comply with federal regulations regarding intellectual property rights that were developed through the use of United States government funding could have a material adverse effect on our business, financial condition, results of operations, and</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">prospects.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Patent terms may be inadequate to protect our competitive position on our diagnostic tests, products and services for an adequate amount of time.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Patents have a limited lifespan. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest United States non-provisional filing date. Various extensions may be available, but the life of a patent, and the protection it affords, is limited.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if patents covering our diagnostic tests, products and services are obtained, once the patent life has expired, we may be open to competition from competitive diagnostic tests, products and services. Given the amount of time required for the development, testing and regulatory review of potential new diagnostic tests, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing diagnostic tests, products or services similar or identical to ours.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may not be able to protect our intellectual property rights throughout the world.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Third parties may attempt to commercialize competitive diagnostic tests, products or services in foreign countries where we do not have any patents or patent applications and/or where legal recourse may be limited. This may have a significant commercial impact on our foreign business operations.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Filing, prosecuting and defending patents on our diagnostic tests, products and services in all countries throughout the world would be prohibitively expensive, and the laws of foreign countries may not protect our rights to the same extent as the laws of the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing diagnostic tests or products made using our inventions in and into the United States or other jurisdictions. Competitors may use our diagnostic tests, products, services and technologies in jurisdictions where we have not obtained patent protection to develop their own diagnostic tests and, further, may export otherwise infringing diagnostic tests or products to territories where we have patent protection but enforcement is not as strong as that in the United States. These diagnostic tests and products may compete with our diagnostic tests, products or services and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">93</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property protection, which could make it difficult for us to stop the infringement of our patents or marketing of competing diagnostic tests, products and services in violation of our intellectual property rights generally. Proceedings to enforce our intellectual property </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly, could put our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</span></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Many countries, including India, China, and certain countries in Europe, have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patent. If we or any of our current or future licensors are forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired, and our business, financial condition and results of operations may be adversely affected.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Intellectual property rights do not necessarily address all potential threats.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations and may not adequately protect our business or permit us to maintain our competitive advantage. For example:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">others may be able to make diagnostic tests or products that are similar to our Nodify XL2, Nodify </span><span style="letter-spacing:-0.2pt;color:#000000;">CDT, </span><span style="color:#000000;">GeneStrat or </span><span style="letter-spacing:-0.15pt;color:#000000;">VeriStrat </span><span style="color:#000000;">tests or the COVID-19</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">tests</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">that</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">we</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">use</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">in</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">COVID-19</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">testing</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">program</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">utilize</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">similar</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">technology</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">that</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">is</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">not</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">covered</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">by</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">claims</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">patents</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">or that incorporates certain technology in our Nodify XL2, Nodify </span><span style="letter-spacing:-0.2pt;color:#000000;">CDT, </span><span style="color:#000000;">GeneStrat or </span><span style="letter-spacing:-0.15pt;color:#000000;">VeriStrat </span><span style="color:#000000;">tests or such COVID-19 tests that is in the public</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">domain&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">we,</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">current</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">future</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">licensors</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">collaborators,</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">might</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">not</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">have</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">been</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">first</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">make</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">inventions</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">covered</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">by</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">applicable</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">issued patent or pending patent application that we own or license now or may own or license in the</span><span style="letter-spacing:-1.4pt;color:#000000;"> </span><span style="color:#000000;">future&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">we,</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">current</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">future</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">licensors</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">collaborators,</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">might</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">not</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">have</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">been</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">first</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">file</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">patent</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">applications</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">covering</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">certain</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">their inventions&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">others</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">independently</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">develop</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">similar</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">alternative</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">technologies</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">duplicate</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">any</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">technologies</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">without</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">infringing</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">intellectual property</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">rights&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">it is possible that our current or future pending patent applications will not lead to issued</span><span style="letter-spacing:-1.15pt;color:#000000;"> </span><span style="color:#000000;">patents&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">issued</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">patents</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">that</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">we</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">hold</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">rights</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">be</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">held</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">invalid</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">unenforceable,</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">including</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">as</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">a</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">result</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">legal</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">challenges</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">by</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">competitors</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">or other third</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">parties&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">competitors</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">other</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">third</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">parties</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">might</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">conduct</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">research</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">development</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">activities</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">in</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">countries</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">where</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">we</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">do</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">not</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">have</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">patent</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">rights</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">and then use the information learned from such activities to develop competitive diagnostic tests, products and services for sale in our major commercial</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">markets&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">we may not develop additional proprietary technologies that are</span><span style="letter-spacing:-0.6pt;color:#000000;"> </span><span style="color:#000000;">patentable&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the patents of others may harm our business&#59;</span><span style="letter-spacing:-0.5pt;color:#000000;"> </span><span style="color:#000000;">and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">we</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">choose</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">not</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">file</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">a</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">patent</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">in</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">order</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">maintain</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">certain</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">trade</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">secrets</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">know-how,</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">a</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">third</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">party</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">subsequently</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">file</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">a</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">patent covering such intellectual property</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">rights.</span></p></td></tr></table></div>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any of the foregoing could have a material adverse effect on our business, financial condition and results of operations.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">94</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">General Risk Factors</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">There has been no prior public market for our common stock and an active trading market may not develop.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We completed our initial public offering in October 2020. Prior to that time, there had not been a public market for our common stock. An active trading market may not develop <span style="letter-spacing:-0.15pt;">or </span>may<span style="letter-spacing:-0.15pt;"> </span>not<span style="letter-spacing:-0.2pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>sustained.<span style="letter-spacing:-0.15pt;"> </span>The<span style="letter-spacing:-0.2pt;"> </span>lack<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:-0.15pt;"> </span>an<span style="letter-spacing:-0.2pt;"> </span>active<span style="letter-spacing:-0.15pt;"> </span>trading<span style="letter-spacing:-0.15pt;"> </span>market<span style="letter-spacing:-0.2pt;"> </span>may<span style="letter-spacing:-0.15pt;"> </span>impair<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.2pt;"> </span>value<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:-0.15pt;"> </span>your<span style="letter-spacing:-0.2pt;"> </span>shares<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>your<span style="letter-spacing:-0.15pt;"> </span>ability<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.2pt;"> </span>sell<span style="letter-spacing:-0.15pt;"> </span>your<span style="letter-spacing:-0.15pt;"> </span>shares at the time you wish to sell them. An inactive trading market may also impair our ability to both raise capital by selling shares of common stock and acquire other complementary diagnostic tests, technologies or businesses by using our shares of common stock as<span style="letter-spacing:-1.6pt;"> </span>consideration.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we fail to satisfy the continued listing standards of the Nasdaq Global Market, we could be de-listed, which would negatively impact the price of our common stock.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We expect that the price of our common stock will fluctuate substantially and you may not be able to sell your shares at or above the price you paid for them.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The market price of our common stock is likely to be highly volatile and may fluctuate substantially due to many factors, including:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">volume and customer mix for our COVID-19, Nodify XL2, Nodify </span><span style="letter-spacing:-0.2pt;color:#000000;">CDT, </span><span style="color:#000000;">GeneStrat and </span><span style="letter-spacing:-0.15pt;color:#000000;">VeriStrat</span><span style="letter-spacing:-0.85pt;color:#000000;"> </span><span style="color:#000000;">testing&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the introduction of new diagnostic tests or enhancements to such tests by us or others in our</span><span style="letter-spacing:-1.3pt;color:#000000;"> </span><span style="color:#000000;">industry&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">disputes or other developments with respect to our or others&#8217; intellectual property</span><span style="letter-spacing:-0.85pt;color:#000000;"> </span><span style="color:#000000;">rights&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">ability</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">develop,</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">obtain</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">regulatory</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">clearance</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">approval or certification</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="letter-spacing:-0.15pt;color:#000000;">for,</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">market</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">new</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">enhanced</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">diagnostic</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">tests</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">on</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">a</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">timely</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">basis&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">product liability claims or other</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">litigation&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">quarterly variations in our results of operations or those of others in our</span><span style="letter-spacing:-0.85pt;color:#000000;"> </span><span style="color:#000000;">industry&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">media exposure of our diagnostic tests or of those of others in our</span><span style="letter-spacing:-0.85pt;color:#000000;"> </span><span style="color:#000000;">industry&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">changes in governmental regulations or in the status of our regulatory approvals or</span><span style="letter-spacing:-1pt;color:#000000;"> </span><span style="color:#000000;">applications&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">changes in earnings estimates or recommendations by securities analysts&#59;</span><span style="letter-spacing:-0.6pt;color:#000000;"> </span><span style="color:#000000;">and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">general</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">market</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">conditions</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">other</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">factors,</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">including</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">factors</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">unrelated</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">operating</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">performance</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">operating</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">performance</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">our competitors.</span></p></td></tr></table></div>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In recent years, the stock markets generally have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of those companies. Broad market and industry factors may significantly affect the market price of our common stock, regardless of our actual operating performance, and you may not realize any return on your investment in us and may lose some or all of your investment.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, in the past, class action litigation has often been instituted against companies whose securities have experienced periods of volatility in market price. Securities litigation brought against us following volatility in our stock price, regardless of the merit or ultimate results of such litigation, could result in substantial costs, which would hurt our financial condition and operating results and divert management&#8217;s attention and resources from our business.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Securities analysts may not publish favorable research or reports about our business or may publish no information at all, which could cause our stock price or trading volume to decline.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If a trading market for our common stock develops, the trading market will be influenced to some extent by the research and reports that industry or financial analysts publish about us and our business. We do not control these analysts. As a newly public company, we may be slow to attract research coverage and the analysts who publish information about our common stock will have had relatively little experience with us, which could affect their ability to accurately forecast our results and could make it more likely that we fail to meet their estimates. In the event we obtain securities or industry analyst coverage, if any of the analysts who cover us provide inaccurate or unfavorable research or issue an adverse opinion regarding our stock price, our stock price could decline. If one or more of these analysts cease coverage of us or fail to publish reports covering us regularly, we could lose visibility in the market, which in turn could cause our stock price or trading volume to decline.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">95</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We are an &#8220;emerging growth company&#8221; and a &#8220;smaller reporting company,&#8221; and the reduced disclosure requirements applicable to emerging growth companies and smaller reporting companies may make our common stock less attractive to investors.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are an &#8220;emerging growth company,&#8221; as defined in the JOBS Act. We may take advantage of certain exemptions and relief from various public reporting requirements, including the requirement that our internal control over financial reporting be audited by our independent registered public accounting firm pursuant to Section 404 of the Sarbanes-Oxley Act of 2002 (the Sarbanes-Oxley Act). We will be exempt from any rules that could be adopted by the Public Company Accounting Oversight Board requiring mandatory audit firm rotations or a supplement to the auditor&#8217;s report on financial statements&#59; we will be subject to reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements&#59; and we will not be required to hold nonbinding advisory votes on executive compensation or stockholder approval of any golden parachute payments not previously approved.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Section 7(a)(2)(B) of the Securities Act, for complying with new or revised accounting standards. In other words, an &#8220;emerging growth company&#8221; can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have elected to take advantage of the extended transition period to comply with new or revised accounting standards and to adopt certain of the reduced disclosure requirements available to emerging growth companies. As a result of the accounting standards election, we will not be subject to the same implementation timing for new or revised accounting standards as other public companies that are not emerging growth companies, which may make comparison of our financials to those of other public companies more difficult. Additionally, because we have taken advantage of certain reduced reporting requirements, the information contained herein may be different from the information you receive from other public companies in which you hold stock.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We will remain an &#8220;emerging growth company&#8221; until the earliest to occur of (i) the last day of the fiscal year in which we have more than $1.07 billion in annual revenue&#59; (ii) the date we qualify as a &#8220;large accelerated filer,&#8221; with at least $700 million of equity securities held by non-affiliates&#59; the<span style="letter-spacing:-0.2pt;"> </span>date<span style="letter-spacing:-0.15pt;"> </span>on<span style="letter-spacing:-0.15pt;"> </span>which<span style="letter-spacing:-0.15pt;"> </span>we<span style="letter-spacing:-0.15pt;"> </span>have<span style="letter-spacing:-0.2pt;"> </span>issued,<span style="letter-spacing:-0.15pt;"> </span>in<span style="letter-spacing:-0.15pt;"> </span>any<span style="letter-spacing:-0.15pt;"> </span>three-year<span style="letter-spacing:-0.15pt;"> </span>period,<span style="letter-spacing:-0.15pt;"> </span>more<span style="letter-spacing:-0.2pt;"> </span>than<span style="letter-spacing:-0.15pt;"> </span>$1.0<span style="letter-spacing:-0.15pt;"> </span>billion<span style="letter-spacing:-0.15pt;"> </span>in<span style="letter-spacing:-0.15pt;"> </span>non-convertible<span style="letter-spacing:-0.2pt;"> </span>debt<span style="letter-spacing:-0.15pt;"> </span>securities&#59;<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>(iv)<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>last<span style="letter-spacing:-0.2pt;"> </span>day<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>fiscal year ending after the fifth anniversary of the completion of our initial public<span style="letter-spacing:-0.9pt;"> </span>offering.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are also a &#8220;smaller reporting company&#8221; as defined in Item 10(f)(1) of Regulation S-K. Smaller reporting companies may take advantage of certain reduced disclosure obligations, including, among other things, providing only two years of audited financial statements. We will remain a smaller reporting company until the last day of the fiscal year in which (1) the market value of our common shares held by non-affiliates exceeds $250 million as of the end of that year&#8217;s second fiscal quarter, or (2) our annual revenues exceeded $100 million during such completed fiscal year and the market value of our common shares held by nonaffiliates exceeds $700 million as of the end of that year&#8217;s second fiscal quarter. To the extent we take advantage of such reduced disclosure obligations, it may also make comparison of our financial statements with other public companies difficult or impossible.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Investors may find our common stock less attractive to the extent we rely on the exemptions and relief granted by the JOBS Act. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may decline or become more volatile.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If our estimates or judgments relating to our critical accounting policies are based on assumptions that change or prove to be incorrect, our operating results could fall below the expectations of securities analysts and investors, resulting in a decline in the market price of our common stock.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in our financial statements and accompanying notes. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets, liabilities, <span style="letter-spacing:-0.15pt;">equity, </span>revenue and expenses that are not readily apparent from other sources. It is possible that interpretation, industry practice and guidance may evolve over time. If our assumptions change or if actual circumstances differ from our assumptions, our operating results may be adversely affected and could fall below the expectations of securities analysts and investors, resulting in a decline in the market price of our common<span style="letter-spacing:-0.45pt;"> </span>stock.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">96</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">A significant portion of our total outstanding shares are restricted from immediate resale but may be sold into the market in the near future. This could cause the market price of our common stock to drop significantly, even if our business is doing well.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales of a substantial number of shares of our common stock in the public market could occur at any time. These sales, or the perception in the market that the holders of a large number of shares intend to sell their shares, could result in a decrease in the market price of our common stock. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have 26,561,504 outstanding shares of common stock based on the number of shares outstanding as of December 31, 2020. This includes the 4,000,000 shares that we sold in our initial public offering in October 2020, which may be resold in the public market immediately without restriction, unless purchased by our affiliates. Of the remaining shares, 22,561,504 shares are currently restricted as a result of securities laws or Section 107 of the JOBS Act provides that an &#8220;emerging growth company&#8221; can take advantage of the extended transition period provided in 180-day lock-up agreements but will be able to be sold after the offering. Moreover, holders of an aggregate of 20,090,745 shares of our common stock that were issued upon conversion of our convertible preferred stock have rights, subject to some conditions, to require us to file registration statements covering their shares or to include their shares in registration statements that we may file for ourselves or other stockholders. <span style="letter-spacing:-0.4pt;">We </span>also intend to register all shares of common stock<span style="letter-spacing:-0.2pt;"> </span>that<span style="letter-spacing:-0.15pt;"> </span>we<span style="letter-spacing:-0.15pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>issue<span style="letter-spacing:-0.15pt;"> </span>under<span style="letter-spacing:-0.15pt;"> </span>our<span style="letter-spacing:-0.15pt;"> </span>equity<span style="letter-spacing:-0.2pt;"> </span>compensation<span style="letter-spacing:-0.15pt;"> </span>plans.<span style="letter-spacing:-0.15pt;"> </span>Once<span style="letter-spacing:-0.2pt;"> </span>we<span style="letter-spacing:-0.15pt;"> </span>register<span style="letter-spacing:-0.15pt;"> </span>these<span style="letter-spacing:-0.15pt;"> </span>shares,<span style="letter-spacing:-0.2pt;"> </span>they<span style="letter-spacing:-0.15pt;"> </span>can<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.2pt;"> </span>freely<span style="letter-spacing:-0.15pt;"> </span>sold<span style="letter-spacing:-0.15pt;"> </span>in<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.2pt;"> </span>public<span style="letter-spacing:-0.15pt;"> </span>market,<span style="letter-spacing:-0.15pt;"> </span>subject<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.15pt;"> </span>volume limitations applicable to affiliates lock-up agreements.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our directors, officers and principal stockholders have significant voting power and may take actions that may not be in the best interests of our other stockholders.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our officers, directors and principal stockholders each holding more than 5% of our common stock collectively control approximately 60.7% of our outstanding common stock. As a result, these<span style="letter-spacing:-0.25pt;"> </span>stockholders,<span style="letter-spacing:-0.2pt;"> </span>if<span style="letter-spacing:-0.25pt;"> </span>they<span style="letter-spacing:-0.2pt;"> </span>act<span style="letter-spacing:-0.2pt;"> </span>together,<span style="letter-spacing:-0.25pt;"> </span>will<span style="letter-spacing:-0.2pt;"> </span>be<span style="letter-spacing:-0.2pt;"> </span>able<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.2pt;"> </span>control<span style="letter-spacing:-0.25pt;"> </span>the<span style="letter-spacing:-0.2pt;"> </span>management<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.25pt;"> </span>affairs<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.2pt;"> </span>our<span style="letter-spacing:-0.25pt;"> </span>company<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.25pt;"> </span>most<span style="letter-spacing:-0.2pt;"> </span>matters<span style="letter-spacing:-0.2pt;"> </span>requiring<span style="letter-spacing:-0.25pt;"> </span>stockholder<span style="letter-spacing:-0.2pt;"> </span>approval, including the election of directors and approval of significant corporate transactions. This concentration of ownership may have the effect of delaying or preventing a change of control and might adversely affect the market price of our common stock. This concentration of ownership may not be in the best interests of our other stockholders. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We expect to incur significant additional costs as a result of being a public company, which may adversely affect our business, financial condition and results of operations.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a result of our initial public offering completed in October 2020, we expect to incur costs associated with corporate governance requirements that are applicable to us as a public company, including rules and regulations of the SEC, under the Sarbanes-Oxley Act, the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010, and the Securities Exchange Act of 1934, as amended (the Exchange Act), as well as the rules of Nasdaq. These rules and regulations are expected to significantly increase our accounting, legal and financial compliance costs and make some activities more time-consuming. We also expect these rules and regulations to make it more expensive for us to maintain directors&#8217; and officers&#8217; liability insurance. As a result, it may be more difficult for us to attract and retain qualified persons to serve on our Board of Directors or as executive officers. Accordingly, increases in costs incurred as a result of becoming a publicly traded company may adversely affect our business, financial condition and results of operations.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If we experience material weaknesses in the future or otherwise fail to maintain an effective system of internal controls in the future, we may not be able to accurately report our financial condition or results of operations, which may adversely affect investor confidence in us and, as a result, the value of our common stock.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a result of becoming a public company, we will be required, under Section 404 of the Sarbanes-Oxley Act to furnish a report by management on, among other things, the effectiveness of our internal control over financial reporting beginning with our Annual Report on Form 10-K for the year ended December 31, 2021. This assessment will need to include disclosure of any material weaknesses identified by our management in our internal control over financial reporting. A material weakness is a deficiency or combination of deficiencies in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of a company&#8217;s annual and interim financial statements will not be detected or prevented on a timely basis.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">97</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are further enhancing internal controls, processes and related documentation necessary to perform the evaluation needed to comply with Section 404. We may not be able to complete our evaluation, testing and any required remediation in a timely fashion. During the evaluation and testing process, if we identify one or more material weaknesses in our internal control over financial reporting, we will be unable to assert that our internal controls are effective. The effectiveness of our controls and procedures may be limited by a variety of factors, including:</span></p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">faulty human judgment and simple errors, omissions, or</span><span style="letter-spacing:-0.5pt;color:#000000;"> </span><span style="color:#000000;">mistakes&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">fraudulent action of an individual or collusion of two or more</span><span style="letter-spacing:-0.7pt;color:#000000;"> </span><span style="color:#000000;">people&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">inappropriate management override of procedures&#59;</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">possibility</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">that</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">any</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">enhancements</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">controls</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">procedures</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">still</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">not</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">be</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">adequate</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">assure</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">timely</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">accurate</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">financial</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">control.</span></p></td></tr></table></div>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">When we cease to be an &#8220;emerging growth company&#8221; under the federal securities laws, our auditors will be required to express an opinion on the effectiveness of our internal controls. If we are unable to confirm that our internal control over financial reporting is effective, or if our independent registered public accounting firm is unable to express an opinion on the effectiveness of our internal controls, we could lose investor confidence in the accuracy and completeness of our financial reports, which could cause the price of our common stock to decline.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are subject to the periodic reporting requirements of the Exchange Act. We have designed our disclosure controls and procedures to provide reasonable assurance that information we must disclose in reports we file or submit under the Exchange Act is accumulated and communicated to management, and recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC. We believe that any disclosure controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in our control system, misstatements due to error or fraud may occur and not be detected.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Provisions in our corporate charter documents and under Delaware law could make an acquisition of us more difficult and may prevent attempts by our stockholders to replace or remove our current management.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Provisions in our amended and restated certificate of incorporation and our amended and restated bylaws may discourage, delay or prevent a merger, acquisition or other change in control of us that stockholders may consider favorable, including transactions in which stockholders might otherwise receive a premium for their shares. These provisions could also limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock. In addition, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our Board of Directors. Because our Board of Directors is responsible for appointing the members of our management team, these provisions could in turn affect any attempt by our stockholders to replace current members of our management team.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law, which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">98</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware will be the exclusive forum for substantially all disputes between us and our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our amended and restated certificate of incorporation specifies that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware will be the sole and exclusive forum for most legal actions involving actions brought against us by stockholders. Notwithstanding the foregoing, the exclusive forum provision will not apply to any claim to enforce any liability or duty created by the Exchange Act or the Securities Act and for which the federal courts have exclusive jurisdiction. We believe this exclusive forum provision benefits us by providing increased consistency in the application of Delaware law by chancellors particularly experienced in resolving corporate disputes, efficient administration of cases on a more expedited schedule relative to other forums and protection against the burdens of multi-forum litigation. However, the provision may have the effect of discouraging lawsuits against our directors and officers. The enforceability of similar choice of forum provisions in other companies&#8217; certificates of incorporation has been challenged in legal proceedings, and it is possible that, in connection with any applicable action brought against us, a court could find the choice of forum provisions contained in our amended and restated certificate of incorporation to be inapplicable or unenforceable in such action.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Claims for indemnification by our directors and officers may reduce our available funds to satisfy successful third-party claims against us and may reduce the amount of money available to us.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our amended and restated articles of incorporation provide that we will indemnify our directors and officers to the fullest extent permitted by Section 145 of the Delaware General Corporate Law.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, as permitted by the Delaware General Corporate Law, our amended and restated articles of incorporation and our indemnification agreements that we have entered into with our directors and officers provide that:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">we will indemnify our directors and officers for serving us in those capacities or for serving other business enterprises at our request, to the fullest extent permitted by applicable </span><span style="letter-spacing:-0.2pt;color:#000000;">law. </span><span style="color:#000000;">Such law provides that a corporation may indemnify such person if such person acted in good faith and in a manner such person reasonably believed to be in or not opposed to our best interests and, with respect to any criminal proceeding, had no reasonable cause to believe such person&#8217;s conduct was</span><span style="letter-spacing:-0.7pt;color:#000000;"> </span><span style="color:#000000;">unlawful&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">we</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="letter-spacing:-0.2pt;color:#000000;">may,</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">in</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">discretion,</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">indemnify</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">employees</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">agents</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">in</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">those</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">circumstances</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">where</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">indemnification</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">is</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">permitted</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">by</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">applicable</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">law&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">we are required to advance expenses, as incurred, to our directors and officers in connection with defending a proceeding, except that such directors</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">officers</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">shall</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">undertake</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">repay</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">such</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">advances</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">if</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">it</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">is</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">ultimately</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">determined</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">that</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">such</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">person</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">is</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">not</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">entitled</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">indemnification&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the rights conferred in our amended and restated articles of incorporation are not exclusive, and we are authorized to enter into indemnification</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">agreements</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">with</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">directors,</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">officers,</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">employees</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">agents</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">obtain</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">insurance</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">indemnify</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">such</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">persons&#59;</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">we</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">not</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">retroactively</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">amend</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">amended</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">restated</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">articles</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">incorporation</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">provisions</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">reduce</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">indemnification</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">obligations</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">to directors, officers, employees and</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">agents.</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap"></td>
<td valign="top">
</td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="N1B_UNRESOLVED_STAFF_COMMENTS">1B. Unresolved Staff Comments. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_2_PROPERTIES">Item 2. Properties. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our headquarters is located in Boulder, Colorado, where we office and laboratory space, under a lease that expires in January 2023. We also lease laboratory space located in De Soto, Kansas, under a lease that expires in October 2023. A portion of our employees are located outside of Colorado and Kansas, and others work from home. We believe our existing facilities meet our current needs. We will need additional office space in the future as we continue to build our development, commercial and support teams. We believe we can find suitable additional space in the future on commercially reasonable terms.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.34%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Location</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.34%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Use</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.02%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Square Feet</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.02%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Expiration</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.34%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Boulder, Colorado</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.34%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Office and laboratory</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.02%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,722</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.02%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">January 14, 2023</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">De Soto, Kansas</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Laboratory</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.02%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,066</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.02%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">October 31, 2023</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_3_LEGAL_PROCEEDINGS">Item 3. Legal Proceedings. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From time to time we may become involved in legal proceedings or investigations which could have an adverse impact on our reputation, business and financial condition and divert the attention of our management from the operation of our business. We are not presently a party to any legal proceedings that, if determined adversely to us, would individually or taken together have a material adverse effect on our business, results of operations, financial condition, or cash flows. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_4_MINE_SAFETY_DISCLOSURES">Item 4. Mine Safety Disclosures.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PART II</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_5_MARKET_FOR_REGISTRANTS_COMMON_EQU">Item 5. Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Market Information</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our common stock is traded on The NASDAQ Global Market under the symbol "BDSX." The high and low closing prices for our common stock on The NASDAQ Global Market for the period from October 28, 2020 (the date our common stock began trading following our initial public offering) to December 31, 2020 were $20.16 and $10.89, respectively.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Holders of our Common Stock</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.81%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of March 12, 2021, there were approximately 172 holders of our common stock.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Dividend Policy</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have never declared or paid dividends on our common stock and do not expect to pay dividends on our common stock for the foreseeable future. Instead, we anticipate that all of our earnings in the foreseeable future will be used for the operation and growth of our business. Any future determination to declare dividends will be subject to the discretion of our Board of Directors and will depend on various factors, including applicable laws, our results of operations, financial condition, future prospects, and any other factors deemed relevant by our Board of Directors. In addition, the terms of our credit agreement restrict our ability to pay dividends on our common stock, and we may also enter into credit agreements or other borrowing arrangements in the future that will further restrict our ability to declare or pay dividends on our common stock.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Use of Proceeds</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On October 28, 2020 we completed an initial public offering of our common stock. In connection with our initial public offering, we issued and sold 4,000,000 shares of common stock at a price to the public of $18.00 per share. As a result of the initial public offering, we received approximately $63.8 million in net proceeds, after deducting underwriting discounts and commissions of $5.0 million and offering expenses of approximately $3.2 million paid by us. The offering was completed in October 2020.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We registered the shares under the Securities Act on a Registration Statement on Form S-1 (Registration No.<span style="font-weight:bold;Background-color:#FFFFFF;color:#000000;font-size:8pt;">&#160;</span><span style="Background-color:#FFFFFF;color:#000000;">333-249260</span>), which was filed on October 29, 2020 and declared effective on October 27, 2020. From the date of the initial closing of the initial public offering through December 31, 2020, we have used a portion of the net proceeds from the sale of these securities to fund our operations, to make capital expenditures, for working capital and for other general corporate purposes.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Recent Sales of Unregistered Securities</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From January 1, 2019 through December 31, 2020, we granted stock options under our 2016 and 2006 Stock Plans to purchase 1.7 million shares of our common stock at exercise prices ranging from $0.77 to $6.83 per share, and issued an aggregate of 0.4 million shares of common stock pursuant to the exercise of stock options with aggregate proceeds of approximately $1.4 million. These issuances were undertaken in reliance upon an exemption from registration under Rule 701 of the Securities Act of 1933.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_6_SELECTED_FINANCIAL_DATA">Item 6. Selected Financial Data. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_7_MANAGEMENTS_DISCUSSION_ANALYSIS_F">Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">The following discussion of our financial condition and results of operations should be read together with our audited financial statements and related notes and other financial information included elsewhere in this Annual Report on Form 10-K and our audited financial statements and notes thereto and the related Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations included in our final prospectus dated October 29, 2020 that forms a part of our Registration Statement on Form S-1 (File No. 333-249260), as filed with the Securities and Exchange Commission (SEC) pursuant to Rule 424(b) under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), on October 29, 2020 (Prospectus).</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">In addition to historical financial information, this discussion and other parts of this report contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, based upon current expectations that involve risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors, including those set forth in the section titled &#8220;Risk Factors&#8221; under Part II, Item 1A below. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results and events to differ from those anticipated.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">These statements are based upon information available to us as of the date of this Annual Report on Form 10-K, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements, like all statements in this report, speak only as of their date, and we undertake no obligation to update or revise these statements in light of future developments. These statements are inherently uncertain, and investors are cautioned not to unduly rely upon these statements.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations (MD&#38;A), is provided to supplement the financial statements and the related notes in Part II - Item 8 of this Annual Report on Form10-K. We intend for this discussion to provide you with information that will assist you in understanding our financial statements, the changes in key items in those financial statements from year to year and the primary factors that accounted for those changes.&#160;&#160;Data for the years ended December 31, 2020 and 2019 has been derived from our audited financial statements included in this Annual Report on Form 10-K.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Overview</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are a leading data-driven diagnostic solutions company leveraging state of the art technologies with our proprietary AI platform to discover, develop, and commercialize solutions for clinical unmet needs, with a primary focus in lung disease. By combining a technology agnostic approach with a holistic view of the patient&#8217;s disease state, we believe our solutions provide physicians with greater insights to help personalize their patient&#8217;s care and meaningfully improve disease detection, evaluation, and treatment. Our unique approach to precision medicine provides timely and actionable clinical information, which we believe helps improve overall patient outcomes and lowers the overall healthcare cost by reducing the use of ineffective and unnecessary treatments and procedures. In addition to our diagnostic tests, we provide biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our core belief is that no single technology will answer all clinical questions that we encounter. Therefore, we employ multiple technologies, including genomics, transcriptomics, proteomics, and radiomics, and leverage our proprietary AI platform, the Diagnostic Cortex, to discover innovative diagnostic tests for clinical use. The Diagnostic Cortex is an extensively validated deep learning platform optimized for the discovery of diagnostic tests, which we believe overcomes standard machine learning challenges faced in life sciences research. Our data-driven and technology agnostic approach is designed to enable us to discover diagnostic tests that answer critical clinical questions faced by physicians, researchers, and biopharmaceutical companies.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">102</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We continuously incorporate new market insights and patient data to enhance our platform through a data-driven learning loop. We regularly engage with our customers, key opinion leaders, and scientific experts to stay ahead of the rapidly evolving diagnostic and therapeutic landscape to identify additional clinical unmet needs where </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a diagnostic test could help improve patient care. Additionally, we incorporate clinical and molecular profiling data from our commercial clinical testing, research studies, clinical trials, and biopharmaceutical customers or academic partnerships, to continue to advance our platform. We have over </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">140,000</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> samples and data in our biobank, including tumor profiles and immune profiles, which are used for both internal and external </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">research and development</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> initiatives.</span></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have commercialized six diagnostic tests which are currently available for use by physicians. Our Nodify XL2 and Nodify CDT tests, marketed as part of our Nodify Lung Nodule Risk Assessment testing strategy, assess the risk of lung cancer to help identify the most appropriate treatment pathway. We believe we are the only company to offer two commercial blood-based tests to help physicians reclassify risk of malignancy in patients with suspicious lung nodules. Our GeneStrat and VeriStrat tests, marketed as part of our Biodesix Lung Reflex testing strategy, are used following diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient&#8217;s immune system to establish the patient&#8217;s prognosis and help guide treatment decisions. The GeneStrat tumor profiling test and the VeriStrat immune profiling test have a three-day average turnaround time, providing physicians with timely results to facilitate treatment decisions. In response to the COVID-19 pandemic, through our partnership with Bio-Rad, we commercialized the Biodesix WorkSafe testing program. Our scientific diagnostic expertise, technologies, and existing commercial infrastructure enabled us to rapidly commercialize two FDA EUA authorized tests, a part of our customizable program. Both diagnostic tests are owned and were developed by Bio-Rad and Bio-Rad has granted us permission to utilize both tests for commercial diagnostic services. HHS Secretary Azar declared a public health emergency for COVID-19 in February 2020 which justified the authorization of emergency use of diagnostic tests for the detection and/or diagnosis of COVID-19. The Bio-Rad SARS-CoV-2 ddPCR test and the Platelia SARS-CoV-2 Total Ab test have been granted FDA EUA pursuant to the current emergency declaration. The Bio-Rad SARS-CoV- 2 ddPCR test was FDA EUA authorized on May 1, 2020, authorizing performance of the test in laboratories certified under Clinical Laboratory Improvement Amendments (CLIA) to perform high complexity tests. The second test is the Platelia SARS-CoV-2 Total Ab test, which is an antibody test intended for detecting a B-cell immune response to SARS-CoV-2, indicating recent or prior infection. The Platelia SARS-CoV-2 Total Ab test was FDA EUA authorized on April 29, 2020. Medical products that are granted an EUA are only permitted to commercialize their products under the terms and conditions provided in the authorization. The FDA may revoke an EUA where it is determined that the underlying health emergency no longer exists or warrants such authorization, if the conditions for the issuance of the EUA are no longer met, or if other circumstances make revocation appropriate to protect the public health or safety, and we cannot predict how long the EUAs for the SARS-CoV-2 tests will remain in place. Using the Bio-Rad SARS-CoV-2 ddPCR test and the Platelia SARS-CoV-2 Total Ab test, we operate and have commercialized the Biodesix WorkSafe testing program. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to using the Bio-Rad tests as part of our testing program, we performed feasibility, verification, and validation studies, including developing software for process automation, sample accessioning, data management and reporting, all required to demonstrate the test operated as claimed by the manufacturer and as required by our certifying regulatory agencies for high complexity laboratory testing. We secured independent reference specimens run with EUA tests to validate these tests as fit for diagnostic use in our laboratories. Post-launch development support for these tests have included improvements in on-boarding new personnel, logistics of sample collection, sample receipt and data reporting, all required to support our testing program. Additional releases of the laboratory data management software are ongoing and planned for the foreseeable future.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These tests are utilized by healthcare providers, including hospitals and nursing homes, and are also offered to businesses and educational systems to assist in their back-to-work or back-to-school strategies. Recently we announced multiple partnerships for COVID-19 testing, and have entered into an agreement with the State of Colorado to be one of the diagnostic companies to support widespread COVID-19 testing for the State. Additionally, we recently announced that we will oversee and manage onsite testing and validating testing for the Big Ten Conference athletic competitions.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">103</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to the six diagnostic tests currently on the market, we perform over</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> 30</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> assays for research use as part of our laboratory services that have been used by </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">over 50</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> biopharmaceutical customers and academic partners. All of our diagnostic testing is performed at one of our two certified, high</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">complexity clinical laboratories in Boulder, Colorado and De Soto, Kansas.</span></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since our inception, we have performed over 285,000 tests and continue to generate a large and growing body of clinical evidence consisting of over 275 clinical and scientific peer-reviewed publications and presentations. Through ongoing study of each of our tests, we continue to grow our depth of understanding of disease biology and the broad utility of each of our tests. We believe we are poised for rapid growth by leveraging our scientific development and laboratory operations expertise along with our commercial infrastructure which includes sales, marketing, reimbursement, and regulatory affairs. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the United States, we market our tests to clinical customers through our targeted sales organization, which includes sales representatives that are engaged in sales efforts and promotional activities primarily to pulmonologists, oncologists, cancer centers and nodule clinics. We market our tests and services to biopharmaceutical customers globally through our targeted business development team, which promotes the broad utility of our tests and testing capabilities throughout drug development and commercialization which is of value to pharmaceutical companies and their drug-development process.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have funded our operations to date principally from net proceeds from an initial public offering of our common stock, the sale of convertible preferred stock, revenue from diagnostic testing and services, and the incurrence of indebtedness. We had cash and cash equivalents of $62.1 million and $5.3 million as of December 31, 2020 and 2019, respectively.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Factors Affecting Our Performance</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe there are several important factors that have impacted our operating performance and results of operations, including:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-weight:bold;letter-spacing:-0.15pt;color:#000000;">Testing</span><span style="font-weight:bold;letter-spacing:-0.1pt;color:#000000;"> </span><span style="font-weight:bold;color:#000000;">volume</span><span style="font-weight:bold;letter-spacing:-0.05pt;color:#000000;"> </span><span style="font-weight:bold;color:#000000;">and</span><span style="font-weight:bold;letter-spacing:-0.05pt;color:#000000;"> </span><span style="font-weight:bold;color:#000000;">customer</span><span style="font-weight:bold;letter-spacing:-0.05pt;color:#000000;"> </span><span style="font-weight:bold;color:#000000;">mix.</span><span style="font-weight:bold;letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">Our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">revenues</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">costs</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">are</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">affected</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">by</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">volume</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">testing</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">mix</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">customers</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">from</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">period</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">to period.</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="letter-spacing:-0.4pt;color:#000000;">We</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">evaluate</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">both</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">volume</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">commercial</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">tests,</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">number</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">tests</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">that</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">we</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">perform</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">for</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">patients</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">on</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">behalf</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">clinicians,</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">as well</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">as</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">tests</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">for</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">biopharmaceutical</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">companies.</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">Our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">performance</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">depends</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">on</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">ability</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">retain</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">broaden</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">adoption</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">with</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">existing customers,</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">as</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">well</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">as</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">attract</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">new</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">customers.</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="letter-spacing:-0.4pt;color:#000000;">We</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">believe</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">that</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">test</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">volume</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">we</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">receive</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">from</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">clinicians</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">biopharmaceutical</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">companies</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">are indicators</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">growth</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">in</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">each</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">these</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">customer</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">verticals.</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">Customer</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">mix</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">for</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">tests</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">has</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">potential</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">significantly</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">impact</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">results</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">of operations,</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">as</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">average</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">selling</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">price</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">for</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">biopharmaceutical</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">sample</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">testing</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">is</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">currently</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">significantly</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">greater</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">than</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">average</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">selling</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">price&#160;&#160;for</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">clinical</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">tests</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">since</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">we</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">are</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">not</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">a</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">contracted</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">provider</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="letter-spacing:-0.15pt;color:#000000;">for,</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">tests</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">are</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">not</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">covered</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">by</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">all</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">clinical</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">patients&#8217;</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">insurance.</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="letter-spacing:-0.4pt;color:#000000;">We</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">evaluate</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">our average</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">selling</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">price</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">for</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">tests</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">that</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">are</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">covered</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">by</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">Medicare,</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">Medicare</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">Advantage</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">commercial</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">payers</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">understand</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">trends</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">in reimbursement</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">apply</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">those</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">trends</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">revenue</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">recognition</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">policies.</span><span style="letter-spacing:-0.05pt;color:#000000;"> O</span><span style="color:#000000;">ur</span><span style="letter-spacing:-0.05pt;color:#000000;"> operating revenues and </span><span style="color:#000000;">costs</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">significantly</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">increased</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">during</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">2020</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">due</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">the expected</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">increase</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">in</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">demand</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">for</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">COVID-19</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">testing.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-weight:bold;color:#000000;">Reimbursement</span><span style="font-weight:bold;letter-spacing:-0.05pt;color:#000000;"> </span><span style="font-weight:bold;color:#000000;">for</span><span style="font-weight:bold;letter-spacing:-0.1pt;color:#000000;"> </span><span style="font-weight:bold;color:#000000;">clinical</span><span style="font-weight:bold;letter-spacing:-0.05pt;color:#000000;"> </span><span style="font-weight:bold;color:#000000;">diagnostic</span><span style="font-weight:bold;letter-spacing:-0.05pt;color:#000000;"> </span><span style="font-weight:bold;color:#000000;">testing.</span><span style="font-weight:bold;letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">Our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">revenue</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">depends</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">on</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">achieving</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">broad</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">coverage</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">reimbursement</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">for</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">tests</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">from third-party</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">payers,</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">including</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">both</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">commercial</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">government</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">payers.</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">Payment</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">from</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">third-party</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">payers</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">differs</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">depending</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">on</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">whether</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">we have</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">entered</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">into</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">a</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">contract</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">with</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">payers</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">as</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">a</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">&#8220;participating</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">provider&#8221;</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">do</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">not</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">have</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">a</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">contract</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">are</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">considered</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">a</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">&#8220;non-participating provider.&#8221;</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">Payers</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">will</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">often</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">reimburse</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">non-participating</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">providers,</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">if</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">at</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">all,</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">at</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">a</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">lower</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">rate</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">than</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">participating</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">providers.</span></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:9.08%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Historically, we have experienced situations where commercial payers proactively reduced the amounts they were willing to reimburse for our tests, and in other situations, commercial payers have determined that the amounts they previously paid were too high and have sought to recover those perceived excess payments by deducting such amounts from payments otherwise being made. When we contract to serve as a participating provider, reimbursements are made pursuant to a negotiated fee schedule and are limited to only covered indications. Becoming a participating provider generally results in higher reimbursement for covered indications and lack of reimbursement for non-covered indications. As a result, the impact of becoming a participating provider with a specific payer will vary. If we are not able to obtain or maintain coverage and adequate reimbursement from third-party payers, we may not be able to effectively increase our testing volume and revenue as expected. Additionally, retrospective reimbursement adjustments can negatively impact our revenue and cause our financial results to fluctuate.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="text-decoration:none;Background-color:#auto;font-family:'Times New Roman';"></span><span style="color:#000000;"></span><span style="font-weight:bold;color:#000000;">Investment</span><span style="font-weight:bold;letter-spacing:-0.1pt;color:#000000;"> </span><span style="font-weight:bold;color:#000000;">in</span><span style="font-weight:bold;letter-spacing:-0.05pt;color:#000000;"> </span><span style="font-weight:bold;color:#000000;">clinical</span><span style="font-weight:bold;letter-spacing:-0.05pt;color:#000000;"> </span><span style="font-weight:bold;color:#000000;">studies</span><span style="font-weight:bold;letter-spacing:-0.05pt;color:#000000;"> </span><span style="font-weight:bold;color:#000000;">and</span><span style="font-weight:bold;letter-spacing:-0.05pt;color:#000000;"> </span><span style="font-weight:bold;color:#000000;">product</span><span style="font-weight:bold;letter-spacing:-0.05pt;color:#000000;"> </span><span style="font-weight:bold;color:#000000;">innovation</span><span style="font-weight:bold;letter-spacing:-0.05pt;color:#000000;"> </span><span style="font-weight:bold;color:#000000;">to</span><span style="font-weight:bold;letter-spacing:-0.05pt;color:#000000;"> </span><span style="font-weight:bold;color:#000000;">support</span><span style="font-weight:bold;letter-spacing:-0.05pt;color:#000000;"> </span><span style="font-weight:bold;color:#000000;">growth.</span><span style="font-weight:bold;letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">A</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">significant</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">aspect</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">business</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">is</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">investment</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">in research</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">development,</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">including</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">development</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">new</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">products</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">investments</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">in</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">clinical</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">utility</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">studies.</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="letter-spacing:-0.4pt;color:#000000;">We</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">have</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">invested heavily</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">in</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">clinical</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">studies</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">for</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">on</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">market</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">pipeline</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">products.</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">Our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">studies</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">focus</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">primarily</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">on</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">clinical</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">utility</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">tests</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">including</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">the ongoing</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">INSIGHT</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">study</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">which</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">seeks</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">enroll</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">up</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">5,000</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">patients</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">continue</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">clinical</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">understanding</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">predictive</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">prognostic value</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="letter-spacing:-0.15pt;color:#000000;">VeriStrat</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">test.</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">Our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">recently</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">launched</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="letter-spacing:-0.15pt;color:#000000;">ALTITUDE</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">study</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">seeks</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">further</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">demonstrate</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">efficacy</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">Nodify</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">XL2</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">Nodify CDT</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">test.</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">A</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">secondary</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">focus</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">studies</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">is</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">understanding</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">economic</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">impact</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">tests</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">in</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">guiding</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">treatment</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">choices</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">potential impact</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">tests</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">in</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">reducing</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">overall</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">healthcare</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">costs.</span></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:9.08%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our clinical research has resulted in over 80 peer-reviewed publications for our tests. In addition to clinical studies, we are collaborating with investigators from multiple academic cancer centers. We believe these studies are critical to gaining physician adoption and driving favorable coverage decisions by payers and expect our investments in research and development to increase. Further we also expect to increase our research and development expenses to fund further innovation and develop new clinically relevant tests.</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.81%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-weight:bold;color:#000000;">Ability</span><span style="font-weight:bold;letter-spacing:-0.1pt;color:#000000;"> </span><span style="font-weight:bold;color:#000000;">to</span><span style="font-weight:bold;letter-spacing:-0.05pt;color:#000000;"> </span><span style="font-weight:bold;color:#000000;">attract</span><span style="font-weight:bold;letter-spacing:-0.05pt;color:#000000;"> </span><span style="font-weight:bold;color:#000000;">new</span><span style="font-weight:bold;letter-spacing:-0.05pt;color:#000000;"> </span><span style="font-weight:bold;color:#000000;">biopharmaceutical</span><span style="font-weight:bold;letter-spacing:-0.05pt;color:#000000;"> </span><span style="font-weight:bold;color:#000000;">customers</span><span style="font-weight:bold;letter-spacing:-0.05pt;color:#000000;"> </span><span style="font-weight:bold;color:#000000;">and</span><span style="font-weight:bold;letter-spacing:-0.05pt;color:#000000;"> </span><span style="font-weight:bold;color:#000000;">maintain</span><span style="font-weight:bold;letter-spacing:-0.05pt;color:#000000;"> </span><span style="font-weight:bold;color:#000000;">and</span><span style="font-weight:bold;letter-spacing:-0.05pt;color:#000000;"> </span><span style="font-weight:bold;color:#000000;">expand</span><span style="font-weight:bold;letter-spacing:-0.05pt;color:#000000;"> </span><span style="font-weight:bold;color:#000000;">relationships</span><span style="font-weight:bold;letter-spacing:-0.05pt;color:#000000;"> </span><span style="font-weight:bold;color:#000000;">with</span><span style="font-weight:bold;letter-spacing:-0.05pt;color:#000000;"> </span><span style="font-weight:bold;color:#000000;">existing</span><span style="font-weight:bold;letter-spacing:-0.05pt;color:#000000;"> </span><span style="font-weight:bold;color:#000000;">customers</span><span style="color:#000000;">.</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">Our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">business development</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">team</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">promotes</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">broad</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">utility</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">products</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">for</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">biopharmaceutical</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">companies</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">in</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">United</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">States</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">internationally.</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">Our revenue,</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">business</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">opportunities</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">growth</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">depend</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">in</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">part</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">on</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">ability</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">attract</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">new</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">biopharmaceutical</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">customers</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">maintain</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">and expand</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">relationships</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">with</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">existing</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">biopharmaceutical</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">customers.</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="letter-spacing:-0.4pt;color:#000000;">We</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">expect</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">increase</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">sales</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">marketing</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">expenses</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">in</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">furtherance</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">of this as we continue to develop these relationships, we expect to support a growing number of investigations and clinical trials. If our relationships expand, we believe we may have opportunities to offer our platform for companion diagnostic development, novel target discovery and validation efforts, and to grow into other commercial opportunities. For example, we believe our multi-omic data including genomic and proteomic data, in combination with clinical outcomes or claims data, has revenue-generating potential, including for novel target identification and companion diagnostic discovery and development.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.81%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-weight:bold;color:#000000;">Motivating and expanding our field sales force and customer support team</span><span style="color:#000000;">. Our field sales force is the primary point of contact in the clinical setting. These representatives of the company must cover expansive geographic regions which limits their time for interaction and education of our products in the clinical setting. As a result of the successful capital raise associated with our initial public offering, we plan to invest heavily in the field sales force to increase the total number of sales representatives and thereby reduce the geographic footprint each representative must cover. This investment will allow the larger sales force to maximize their education and selling efforts and achieve greater returns. Additionally, we plan to invest in the Boulder-based marketing and customer support teams to continue to provide the field team with the resources to be successful in the field. Furthermore, as we increase testing volume for our COVID-19 testing program, we plan to hire additional project support members to assist us in managing testing capacity.</span></p></td></tr></table></div>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">While each of these areas present significant opportunities for us, they also pose significant risks and challenges that we must address. See Part II, Item 1A. &#8220;Risk Factors&#8221; for more information.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">COVID-19 Pandemic</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The COVID-19 pandemic has disrupted, and we expect will continue to disrupt, our lung diagnostic testing operations. To protect the health and well-being of our workforce, partners, vendors and customers, we provide voluntary COVID-19 testing for employees working on-site, implemented social distance and building entry policies at work, restricted travel and facility visits, and followed the States of Colorado and Kansas&#8217; public health orders and the guidance from the Centers for Disease Control and Prevention. Employees who can perform their duties remotely are asked to work from home and those on site are asked to follow our social distance guidelines. Our sales, marketing and business development efforts have also been constrained by our operational response to the COVID-19 pandemic due to travel restrictions. We expect to continue to adjust our operational norms to help slow the spread of COVID-19 in the coming months, including complying with government directives and guidelines as they are modified and supplemented.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">105</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The COVID-19 pandemic negatively affect</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ed</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, and we expect will continue to negatively affect, our </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">lung diagnostic</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> testing-related</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">revenue and our clinical studies. For example, cancer patients may have more limited access to hospitals, healthcare providers and medical resources as</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">they take steps to control the spread of COVID-</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19. Our</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> b</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">iopharmaceutical customers are facing challenges in recruiting patients and in conducting clinical</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">trials to advance their pipelines, for which our tests could be utilized. As a result of the COVID-19 pandemic, beginning in the latter half of March 2020,</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we have received fewer samples for non-COVID-19 testing on a daily average basis from our clinical and</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">biopharmaceutical customers than before the</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">outbreak of the COVID-19 pandemic. Further, our clinical studies, such as our ongoing INSIGHT study and our recently launched ALTITUDE study, as</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">well as our arrangements with our </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">b</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">iopharmaceutical customers, are expected to take longer to complete than what we expected before the outbreak of the</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">COVID-19 pandemic.</span></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Conversely, we are also experiencing a substantial increase in revenues related to an increase in the demand for our Biodesix WorkSafe testing program, our COVID-19 testing program. We expect that our costs to expand capacity for COVID-19 testing will increase for the first quarter of 2021 and we expect that the revenue that we generate from this expansion will comprise a significant portion of our revenue for these periods. However, there is no assurance that our COVID-19 testing program will continue to be accepted by the market or that other diagnostic tests will become more accepted, produce quicker results or are more accurate. Further, the longevity and extent of the COVID-19 pandemic is uncertain. If the pandemic were to dissipate, whether due to a significant decrease in new infections, due to acquiring herd immunity based on previous natural infection, and the availability and rapid distribution of vaccines, the evolution of variant strains that impact diagnostic test performance, or otherwise, the need for a COVID-19 test could decrease significantly and this could have an adverse effect on our results of operations and profitability. As a result, the increase in revenue due to any increase in demand for these diagnostic tests may not be indicative of our future revenue. See Part II., Item 1A. &#8220;Risk Factors&#8221; for a description of how the COVID-19 pandemic may adversely affect our business, financial condition and results of operations.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020 Financial and Operational Highlights</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our fiscal year corresponds to a calendar year. The Company generated record revenue in fiscal 2020 of $45.6 million, representing an increase of 86%, of which $27.0 million was associated with the three-month period ended December 31, 2020.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following were significant developments affecting our business, capital structure and liquidity during the year ended December 31, 2020:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">In October 2020 we completed our initial public offering, in which we sold 4.0 million shares of common stock for an offering price of $18.00 per common share. The successful offering enabled the Company to raise approximately $63.8 million in net proceeds, after deducting offering costs, underwriting discounts and commissions, providing significant cash resources to fund the Company&#8217;s growth strategy and working capital and general corporate purposes&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">As of December 31, 2020, we held cash and cash equivalents of $62.1 million, an increase of $56.8 million as compared to December 31, 2019.&#160;&#160;Our December 31, 2020 cash and cash equivalent balance includes a reduction for a prepayment of approximately $7 million for three years of premiums for the Company&#8217;s directors and officer (D&#38;O) liability insurance coverage&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Initiated biomarker study to affirm Nodify XL2&#174; test&#8217;s importance in clinical decision making (ALTITUDE).&#160;&#160;The first-in-class biomarker study is aligned with the recommendations from the official 2018 American Thoracic Society (ATS) policy statement of the early detection of lung cancer.&#160;&#160;Dr. Gerard A.&#160;&#160;Silvestri of Medical University of South Carolina named Principal Investigator&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Announced results of study showing the Company&#8217;s proprietary blood collection device (BCD) collects, separates, and transports blood at ambient temperature to simplify specimen collection and transport while maintaining accuracy of diagnostic test results&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Partnered with major public and private institutions, including the BIG 10 athletic conference, Purdue University, Colorado State University and the State of Colorado to support COVID-19 testing.</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">106</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Components of Operating Results</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Revenues</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We derive our revenue from two primary sources: (i) providing diagnostic testing in the clinical setting (Diagnostic Tests)&#59; and (ii) providing biopharmaceutical companies with services that include diagnostic research, clinical research, clinical trial testing, development and testing services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics (Services).</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Diagnostic Tests</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Diagnostic test revenue is generated from delivery of results from our diagnostic tests. In the United States, we performed tests as both an in- network and out-of-network service provider depending on the test performed and the contracted status of the insurer. We provide diagnostic tests in two primary categories (i) lung diagnostics testing and (ii) COVID-19 testing.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We consider diagnostic testing to be completed upon the delivery of test results to our customer, either the prescribing physician or third-party to which we contracted for services to be performed, which is considered the performance obligation. The fees for such services are billed either to a third party such as Medicare, medical facilities, commercial insurance payers, or to the patient. We determine the transaction price related to our contracts by considering the nature of the payer, the historical amount of time until payment by a payer and historical price concessions granted to groups of customers.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Services</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Services revenue is generated from the delivery of our on-market tests, pipeline tests, custom diagnostic testing, and other scientific services for a purpose as defined by any individual customer. At times we collaborate with large biopharmaceutical companies in an attempt to discover biomarkers that would be helpful in their drug development or marketing. The performance obligations and related revenue for these sales is defined by a written agreement between us and our customer. These services are generally completed upon the delivery of testing results, or other contractually defined milestone(s), to the customer, which is considered the performance obligation. Customers for these services are typically large pharmaceutical companies where collectability is reasonably assured and therefore revenue is accrued upon completion of the performance obligations. Revenue derived from services is often unpredictable and can cause dramatic swings in our overall net revenue line from quarter to quarter.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Operating Expenses</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Direct costs and expenses</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of diagnostic testing generally consists of cost of materials, direct labor, including bonus, employee benefits, equipment and infrastructure expenses associated with acquiring and processing test samples, including sample accessioning, test performance, quality control analyses, charges to collect and transport samples&#59; curation of test results for physicians&#59; and in some cases, license or royalty fees due to third parties.&#160;&#160;Costs associated with performing our tests are recorded as the tests are processed regardless of whether revenue was recognized with respect to the tests. Infrastructure expenses include depreciation of laboratory equipment, rent costs, amortization of leasehold improvements and information technology costs. Royalties for licensed technology are calculated as a percentage of revenues generated using the associated technology and recorded as expense at the time the related revenue is recognized. One-time royalty payments related to signing of license agreements or other milestones, such as issuance of new patents, are amortized to expense over the expected useful life of the patents. While we do not believe the technologies underlying these licenses are necessary to permit us to provide our tests, we do believe these technologies are potentially valuable and of possible strategic importance to us or our competitors. Under these license agreements, we are obligated to pay aggregate royalties ranging from 1% to 8% of sales in which the patents or know-how are used in the product or service sold, sometimes subject to minimum annual royalties or fees in certain agreements.&#160;&#160;</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect the aggregate cost of diagnostic testing to increase in line with the increase in the number of tests we perform, but the cost per test to decrease modestly over time due to the efficiencies we may gain as test volume increases, and from automation and other cost reductions.&#160;&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">107</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of services includes costs incurred for the performance o</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">f</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> development services requested by our customers. Cost</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> of</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> d</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">evelopment services will</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">vary depending on the nature, timing and scope of customer projects.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Research and development</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses consist of costs incurred to develop technology and include salaries and benefits, reagents and supplies used in research and development laboratory work, infrastructure expenses, including allocated facility occupancy and information technology costs, contract services, clinical studies, other outside costs and costs to develop our technology capabilities. Research and development expenses account for a significant portion of our operating expenses and consist primarily of external and internal costs incurred in connection with the discovery and development of our product candidates. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">External expenses include: (i) payments to third parties in connection with the clinical development of our product candidates, including contract research organizations and consultants&#59; (ii) the cost of manufacturing products for use in our preclinical studies and clinical trials, including payments to contract manufacturing organizations (CMOs) and consultants&#59; (iii) scientific development services, consulting research fees and for sponsored research arrangements with third parties&#59; (iv) laboratory supplies&#59; and (v) allocated facilities, depreciation and other expenses, which include direct or allocated expenses for IT, rent and maintenance of facilities. External expenses are recognized based on an evaluation of the progress to completion of specific tasks using information provided to us by our service providers or our estimate of the level of service that has been performed at each reporting date. We track external costs by the stage of program, clinical or preclinical.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Internal expenses include employee-related costs, including salaries and related benefits for employees engaged in research and development functions. We do not track internal costs by product candidate because these costs are deployed across multiple programs and, as such, are not separately classified.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development costs are expensed as incurred. Payments made prior to the receipt of goods or services to be used in research and development are deferred and recognized as expense in the period in which the related goods are received or services are rendered. Costs to develop our technology capabilities are recorded as research and development.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect our research and development expenses to increase as we continue to innovate and develop additional products and expand our data management resources. As our services revenue grows, an increasing portion of research and development dollars are expected to be allocated to cost of goods for biopharma service contracts. This expense, though expected to increase in dollars, is expected to decrease as a percentage of revenue in the long term, though it may fluctuate as a percentage of our revenues from period to period due to the timing and extent of these expenses.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Sales, marketing, general and administrative</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our sales and marketing expenses are expensed as incurred and include costs associated with our sales organization, including our direct sales force and sales management, client services, marketing and reimbursement, as well as business development personnel who are focused on our biopharmaceutical customers. These expenses consist primarily of salaries, commissions, bonuses, employee benefits, and travel, as well as marketing and educational activities and allocated overhead expenses. We expect our sales and marketing expenses to increase in dollars as we expand our sales force, increase our presence within the United States, and increase our marketing activities to drive further awareness and adoption of our tests and our future products. These expenses, though expected to increase in dollars, are expected to decrease as a percentage of revenue in the long term, though they may fluctuate as a percentage of our revenues from period to period due to the timing and extent of these expenses.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our general and administrative expenses include costs for our executive, accounting, finance, legal and human resources functions. These expenses consist principally of salaries, bonuses, employee benefits, and travel, as well as professional services fees such as consulting, audit, tax and legal fees, and general corporate costs and allocated overhead expenses. We expect that our general and administrative expenses will continue to increase in dollars, primarily due to increased headcount and costs associated with operating as a public company, including expenses related to legal, accounting, regulatory, maintaining compliance with exchange listing and requirements of the SEC, director and officer insurance premiums and investor relations. These expenses, though expected to increase in dollars, are expected to decrease as a percentage of revenue in the long term, though they may fluctuate as a percentage from period to period due to the timing and extent of these expenses.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">108</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><span style="font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Change in Fair Value of Contingent Consideration</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the purchase transaction of Integrated Diagnostics, Inc. (Indi), we recorded contingent consideration pertaining to the amounts potentially payable to Indi shareholder pursuant to the terms of the asset purchase agreement. The fair value of contingent consideration is assessed at each balance sheet date and changes, if any, to the fair value are recognized as operating expenses within the statement of operations. The estimated fair value of the contingent consideration is based upon significant assumptions including probability of successful achievement of a product gross margin target, the estimated timing in which the gross margin target is achieved, and discount rates. The estimated fair value could materially differ from actual values or fair values determined using different assumptions.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Interest Expense and Interest Income</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest expense consists of cash and non-cash interest from our term loan, payroll protection program loan, and convertible debt. Our convertible debt, along with the related accrued interest, was automatically converted to 1,848,280 shares of our common stock upon completion of our initial public offering in October 2020. Principal payments for our term loan are scheduled to begin in March 2021. Interest income consists of income earned on our cash and cash equivalents. Our interest income has increased primarily as a result of investment of the net proceeds from our recent offering.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Results of Operations</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table sets forth the significant components of our results of operations for the periods presented (in thousands, except percentages):</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Change</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenues</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45,557</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,552</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,005</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">86</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating expenses</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Direct costs and expenses</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,998</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,074</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,924</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">262</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,818</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,468</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">350</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales, marketing, general and administrative</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34,857</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,637</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,220</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in fair value of contingent consideration</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">818</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,114</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,296</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(80</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating expenses</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">68,491</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51,293</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,198</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss from operations</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(22,934</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(26,741</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,807</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other income (expense)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest income</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(37</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(67</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest expense</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7,604</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,008</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,596</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">153</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in fair value of warrant liability</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,252</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(104</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,148</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,104</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in fair value of put option liability</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,000</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,000</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(100</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other income, net</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">422</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,072</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(650</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(61</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total other expense</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(8,416</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,985</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,431</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">111</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(31,350</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(30,726</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(624</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Revenues</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We generate revenue from our diagnostic tests and services that we provide. Our revenues for the periods indicated were as follows (in thousands, except percentages):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Change</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Diagnostic revenue</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40,919</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,315</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,604</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">136</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Services revenue</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,638</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,237</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,599</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(36</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total revenue</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45,557</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,552</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,005</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">86</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">109</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total revenue was $45.6 million for the year ended December 31, 2020 as compared to $24.6 million for the year ended December 31, 2019, an increase of $21.0 million, or 86%.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Diagnostic test revenue increased to $40.9 million for the year ended December 31, 2020, as compared to $17.3 million for year ended December 31, 2019, an increase of $23.6 million or 136%. This increase was primarily attributable to the deployment of COVID-19 testing which generated $28.3 million of revenue and was partially offset by a decline in our lung diagnostic test volumes, which declined by $4.7 million or 27% as health care practitioners, including pulmonologists, were increasingly diverted to pandemic-related care. In addition, the Company sales efforts continued to be impacted by the reduction in travel and other COVID-19 pandemic related restrictions.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Services revenue decreased to $4.6 million for the year ended December 31, 2020 compared to $7.2 million for the prior year ended December 31, 2019, a decrease of $2.6 million or 36%, due primarily to a reduction in business development activities which was negatively impacted by the COVID-19 pandemic similar to the reduction we experienced in our lung diagnostic testing revenue.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Direct Costs and Expenses</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Direct costs and expenses related to revenue were $22.0 million for the year ended December 31, 2020 compared to $6.1 million for the prior year ended December 31, 2019, an increase of $16.0 million or 262%. The increase in direct costs and expenses were primarily driven by costs associated with the delivery of our COVID-19 tests as well as the release of our Nodify CDT test, offset in part by decreases costs related to our remaining lung diagnostic test costs.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Research and Development</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses were relatively consistent year over year with $10.8 million for the year ended December 31, 2020 as compared to $10.5 million for the prior year ended December 31, 2019, an increase of $0.3 million, or 3%. The overall increase in cost was attributable to an increase in internal costs primarily associated with variable compensation tied to fiscal 2020 performance measures slightly offset by a decrease in external costs.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes our external and internal costs for the years ended December 31, 2020 and 2019 (in thousands, except percentages):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Change</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">External expenses:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical trials and associated costs</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,487</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,141</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">346</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other external costs</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,823</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,784</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(961</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(25</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total external costs</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,310</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,925</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(615</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(10</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Internal expenses</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,508</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,543</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">965</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total research and development expenses</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,818</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,468</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">350</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Sales, Marketing, General and Administrative</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales, marketing, general and administrative expenses were $34.9 million for the year ended December 31, 2020 compared to $30.6 million for the prior year ended December 31, 2019, an increase of $4.2 million, or 14%, as a result of variable compensation tied to fiscal 2020 performance measures, including the Company&#8217;s bonus to equity program for senior executives offset by reductions in employee related costs associated with COVID-19 pandemic restrictions.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Change in Fair Value of Contingent Consideration</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in fair value of contingent consideration was $0.8 million for the year ended December 31, 2020 compared to $4.1 million for the year ended December 31, 2019, a net decrease of $3.3 million or 80%. The amounts recorded for change in fair value reflect the passage of time, as well as estimates regarding the period in which targets that trigger the payment of contingent consideration will be achieved and subsequently paid.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">110</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Interest Expense</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest expense was $7.6 million for the year ended December 31, 2020 compared to $3.0 million for the year ended December 31, 2019, an increase of $4.6 million, or 153%. This increase was due to the addition of interest expense related to convertible notes issued to certain shareholders from August 2019 through March 2020, including the non-cash interest expense of $4.4 million associated with the full amortization of debt discount resulting from the conversion discounts included in the convertible note terms, interest on our existing term loan, and interest on our payroll protection plan loan. Cash and non-cash interest expense for the twelve-month period ended December 31, 2020 was $1.8 million and $5.8 million, respectively.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Change in Fair Value of Warrant Liability</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the twelve-month period ended December 31, 2020, we recognized a charge for the change in estimated fair value of our warrant liability related to warrants issued in connection with our Series G preferred stock of $1.3 million, compared to a charge of $0.1 million during fiscal year 2019, a change of $1.2 million. Effective with the closing of our initial public offering in October 2020, the warrants to purchase Series G preferred stock were automatically converted to warrants to acquire common stock and the carrying value of the warrants of $1.6 million were reclassified to additional paid-in capital.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Change in Fair Value of Put Option Liability</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">During 2019, we issued $13.0&#160;million in convertible debt with terms that provided conversion rate discounts to the note holders in certain situations, including upon the completion of an initial public offering. The conversion discounts created a put option liability that was accounted for separately from the convertible debt instrument and reflected as a liability in our balance sheet. Subsequent to the initial measurement of the put option liability, changes in the estimated fair value will be reflected as other income or expense in the statement of operations. During 2019, we recorded a $2&#160;million increase in the fair value of the put option liability as other expense due to the increase in the conversion discount rate provided to note holders resulting from an amendment to terms of the convertible debt issued in August and September 2019.&#160;&#160;There were no changes to the fair value of the put option liability that was recorded during 2020. </span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Other Income and Expense, net</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other income, net, during fiscal 2020 and fiscal 2019 was income of $0.4 million and $1.1 million, respectively, a decrease of $0.7 million or 61%. The decrease was due primarily to proceeds from a non-recurring legal settlement received in fiscal 2019.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Liquidity and Capital Resources</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are an emerging growth company and, as such, have yet to generate positive cash flow from operations. We have funded our operating activities primarily through financing activities, such as debt and equity offerings.&#160;&#160;In October 2020, we completed an initial public offering, resulting in net proceeds of approximately $63.8 million after deducting offering costs, underwriting discounts and commissions. As of December 31, 2020 we held cash and cash equivalents of $62.1 million. We believe that our existing cash, cash equivalents, and cash generated from sales of our products and services will be sufficient to meet our anticipated needs for at least the next 12 months from the date of our most recent audited financial statements, including amounts due under our PPP loan. The Company currently intends to repay the PPP loan in accordance with the underlying terms and conditions.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect to continue to incur significant expenses for the foreseeable future and to incur operating losses in the near term while we make investments to support our anticipated growth. We may raise additional capital through the issuance of additional equity financing, debt financings or other sources. If this financing is not available to us at adequate levels, we may need to reevaluate our operating plans. If we do raise additional capital through public or private equity offerings, the ownership interest of our existing stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect our existing stockholders&#8217; rights. If we raise additional capital through debt financing, we may be subject to covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">111</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Cash Flows</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following summarizes our cash flows for the periods indicated (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash flows (used in) provided by:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating activities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(21,366</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(21,726</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Investing activities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,927</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,872</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financing activities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">81,131</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,972</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net increase in cash and cash equivalents and restricted cash</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56,838</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(626</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">2020 compared to 2019</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our cash flows resulted in a net increase in cash of $56.8 million during the year ended December 31, 2020. The net cash used in operating activities decreased by approximately $0.4 million, primarily due to a year-over-year increase in non-cash charges of: (i) $4.1 million associated with the increased amortization of convertible notes debt discount resulting from our initial public offering&#59; (ii) $3.5 million associated with the increased share-based compensation expense from achieving performance thresholds for our 2020 bonus to equity program&#59; (iii) $1.1 million associated with an increase in the expense recorded as a change in estimated fair value of warrant liability partially offset by&#59; (iv) a $3.3 million reduction in the year-over-year change in the estimated fair value of contingent consideration&#59; and (v) a $3.2 million net reduction&#160;&#160;in operating assets and liabilities</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in investing activities during the year ended December 31, 2020 totaled $2.9 million, an increase of $1.1 million compared to the same period in 2019. The increase in net cash used in investing activities was primarily due to an increase of $0.8 million in the purchases of research equipment and patent costs, and payments made for Oncimmune assets acquired of $0.3 million.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by financing activities during the year ended December 31, 2020 totaled $81.1 million, an increase of $58.2 million compared to the same period in 2019. The net cash provided by financing activities for the year ended December 31, 2020 primarily resulted from $72.0 million gross proceeds from our initial public offering, $13.0 million in proceeds from the issuance of convertible notes payable, $1.3 million proceeds from stock option exercises, and $3.1 from proceeds from our paycheck protection program note payable, offset in part by equity issuance costs associated with our initial public offering of $8.2 million. The net cash provided by financing activities for the year ended December 31, 2019 primarily resulted from $10.0 million in proceeds from the issuance of our Series H Preferred Stock and $13.0 million in proceeds from the issuance of convertible notes payable.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Contractual Obligations and Commitments</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes our non-cancelable contractual obligations and commitments as of December 31, 2020 (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="18" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Payments due by period<sup style="font-size:85%;line-height:120%;vertical-align:top"> (1)</sup></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Less&#160;than</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1 year</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1 to 3</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">years</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">4 to 5</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">years</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">More&#160;than</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">5 years</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease obligations <sup style="font-size:85%;line-height:120%;vertical-align:top">(2)</sup></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,539</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">703</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">836</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Borrowings and interest <sup style="font-size:85%;line-height:120%;vertical-align:top">(3)</sup></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31,517</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,921</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,596</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33,056</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,624</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,432</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(1)</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:9pt;color:#000000;">Royalty payments that we may owe are not included as the timing of such payments is uncertain.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(2)</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:9pt;color:#000000;">We are obligated under non-cancellable operating leases for all of our facilities. Lease terms for our facilities range from less than one to three years and generally require us to pay real estate taxes, certain insurance and operating costs.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(3)</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:9pt;color:#000000;">Includes a 2% back-end term loan facility fee of $0.5 million due at maturity. The term loan is also subject to a 3% prepayment penalty which is not included above. In addition, includes principal and accrued interest payable under the Company&#8217;s payroll protection plan loan.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.85%;text-indent:0%;font-size:9pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">112</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the purchase transaction of Integrated Diagnostics, Inc., we recorded contingent consideration pertaining to the amounts potentially payable to Integrated Diagnostics&#8217; shareholder pursuant to the terms of the asset purchase agreement. The estimated fair value of contingent consideration is assessed at each balance sheet date and changes, if any, to the fair value are recognized as operating expenses within the statement of operations. The estimated fair value of the contingent consideration is based upon significant assumptions including probability of successful achievement of the Milestone, the estimated timing in which the Milestone is achieved, and discount rates. The estimated fair value could materially differ from actual values or fair values determined using different assumptions. At December 31, 2020, the amount that would be due in cash at the option of the seller at the time the Milestone is met would be approximately $37 million.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Off-Balance Sheet Arrangements</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Critical Accounting Policies and Significant Judgments and Estimates</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In accordance with accounting principles generally accepted in the United States, we are required to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Certain of these estimates significantly influence the portrayal of our financial condition and results of operations and require us to make difficult, subjective or complex judgments. Our critical accounting policies primarily relate to our fair value estimates, and are described in greater detail in Note 1 to our financial statements in Part 8 of this Annual Report on Form 10-K.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Revenue Recognition</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We recognize revenue when our customers obtain control of promised goods or services, in an amount that reflects the consideration which we expect to receive in exchange for our goods or services. To determine revenue recognition for our arrangements with our customers, we perform a five-step process, which includes: (i) identifying the contract(s) with a customer&#59; (ii) identifying the performance obligations in the contract&#59; (iii) determining the transaction price&#59; (iv) allocating the transaction price to the performance obligations in the contract&#59; and (v) recognizing revenue when (or as) we satisfy our performance obligations. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Diagnostic service revenues are recognized upon completion of our performance obligation to the deliver test results to our customer, either the prescribing physician or third-party to which we contracted for services to be performed. Testing services revenues are recognized upon completion of our performance obligation to deliver testing results for assay development and testing services.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Change in Fair Value of Contingent Consideration</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the purchase transaction with Integrated Diagnostics, Inc. (Indi), we recorded contingent consideration pertaining to the amounts potentially payable to Indi&#8217;s shareholder pursuant to the terms of the asset purchase agreement. The fair value of contingent consideration is assessed at each balance sheet date and changes, if any, to the fair value are recognized as operating expenses within the statements of operations.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The estimated fair value of the contingent consideration is based upon significant assumptions including probabilities of successful achievement of product gross margin targets, the estimated timing in which achievement of the product gross margin target is expected, and discount rates. The estimated fair value could materially differ from actual values or fair values determined using different assumptions.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Share-based Compensation and Grant Date Fair Value</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Share-based compensation related to stock options granted to our employees, directors and non-employees is measured at the grant date based on the fair value of the award. For our service-based awards, the fair value of each award is recognized as expense on a straight-line basis over the requisite service period, which is generally the vesting period of the respective awards. Compensation expense for share-based awards with performance conditions is recognized based upon the probability the performance conditions will be met as defined in the grant. Restricted stock unit option awards are measured at their grant date fair value using the closing price of our common stock on the date of grant and recognized to expense on a straight-line basis over the vesting period of each award. We estimate forfeitures and adjust these estimates to actual forfeitures as they occur.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">113</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We use the Black-Scholes option-pricing model to estimate the fair value of our </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">share-based option awards</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, which requires</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> assumptions to be made related to expected term of an award, expected volatility, </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">risk-free rate and</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">expected dividend yield.</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Following the completion of our </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">initial public offering</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, our Board of Directors has determined the fair value of our common stock is based on our closing price as</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">reported on the date of grant on the primary stock exchange on which our common stock is traded</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to our initial public offering in October 2020, the fair value of our common stock was determined by our Board of Directors in accordance with the methodologies outlined in the American Institute of Certified Public Accountants Practice Aid, Valuation of Privately-Held-Company Equity Securities Issued as Compensation Practice Aid (Practice Aid). In doing so, our Board of Directors determined the best estimate of fair value of our common stock, exercising reasonable judgment and considering numerous objective and subjective factors, by first determining the enterprise value of our business, and then allocating the value among the various classes of our equity securities to derive a per share value of our common stock. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Recently Issued Accounting Pronouncements</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2016, the FASB issued Accounting Standards Update (ASU) No. 2016-2, <span style="font-style:italic;">Leases (Topic 842), </span>which requires lessees to recognize a right-of-use asset and corresponding lease liability on the balance sheet for substantially all leases. The ASU is effective for us for beginning January 1, 2022. We expect to recognize right-of-use assets and lease obligations in our balance sheets upon adoption using the modified retrospective method as permitted by ASU No. 2018-11, <span style="font-style:italic;">Leases (Topic 842): Targeted Improvements.</span> We do not currently expect adoption of this standard will have a significant effect on our results of operations or cash flows.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2016, the FASB issued ASU No. 2016-13, <span style="font-style:italic;">Financial Instruments-Credit Losses: Measurement of Credit Losses on Financial Instruments</span>. This ASU requires measurement and recognition of expected credit losses for financial assets. This guidance will become effective for us beginning January 1, 2022 with early adoption permitted. We have not yet begun evaluating the potential effect of this standard on our financial statements. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Implications of Being an Emerging Growth Company and Smaller Reporting Company</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are an &#8220;emerging growth company&#8221; within the meaning of the Jumpstart Our Business Startups Act (JOBS Act). As an emerging growth company, we may take advantage of certain exemptions from various public company reporting requirements, including the requirement that our internal control over financial reporting be audited by our independent registered public accounting firm pursuant to Section 404 of the Sarbanes-Oxley Act of 2002 (the &#8220;Sarbanes-Oxley Act&#8221;), certain requirements related to the disclosure of executive compensation in our periodic reports and proxy statements, the requirement that we hold a nonbinding advisory vote on executive compensation and any golden parachute payments. We may take advantage of these exemptions until we are no longer an emerging growth company. Section 107 of the JOBS Act provides that an emerging growth company can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act, for complying with new or revised accounting standards. In other words, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have elected to take advantage of the extended transition period to comply with new or revised accounting standards and to adopt certain of the reduced disclosure requirements available to emerging growth companies. As a result of the accounting standards election, we will not be subject to the same implementation timing for new or revised accounting standards as other public companies that are not emerging growth companies, which may make comparison of our financials to those of other public companies more difficult.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We will remain an emerging growth company until the earliest to occur of (i) the last day of the fiscal year in which we have more than $1.07 billion in annual revenue&#59; (ii) the date we qualify as a &#8220;large accelerated filer,&#8221; with at least $700 million of equity securities held by non-affiliates&#59; (iii) the date on which we have issued, in any three-year period, more than $1.0 billion in non-convertible debt securities&#59; and (iv) until December 31, 2025 (the year ended December 31st following the fifth anniversary of our initial public offering. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, we are a &#8220;smaller reporting company&#8221; as defined in Item 10(f)(1) of Regulation S-K. Smaller reporting companies may take advantage of certain reduced disclosure obligations, including, among other things, providing only two years of audited financial statements. We will remain a smaller reporting company until the last day of the fiscal year in which: (i) the market value of our common shares held by non-affiliates exceeds $250 million as of the end of that year&#8217;s second fiscal quarter, or (ii) our annual revenues exceeded $100 million during such completed fiscal year and the market value of our common shares held by non-affiliates exceeds $700 million as of the end of that year&#8217;s second fiscal quarter.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">114</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>

<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_7A_QUANTITATIVE_QUALITATIVE_DISCLOS">Item 7A. Quantitative and Qualitative Disclosures About Market Risk. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are exposed to market risk in the ordinary course of our business. Market risk represents the risk of loss that may impact our financial position due to adverse changes in financial market prices and rates.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Interest Rate Risk</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are exposed to market risk for changes in interest rates related primarily to our cash and cash equivalents, marketable securities and our indebtedness. We consider all highly liquid instruments purchased with an original maturity of three months or less to be cash equivalents. We continually monitor our positions with, and the credit quality of, the financial institutions with which we invest. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Periodically throughout the year, we have maintained balances in various operating accounts in excess of federally insured limits. Included in cash and cash equivalents are funds held in a bank savings account of $58.8 million and $4.7 million at December 31, 2020 and 2019, respectively. As of December 31, 2020, a hypothetical 100 basis point increase in interest rates would not have a material impact on our investment portfolio, financial position or results of operations. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_8_FINANCIAL_STATEMENTS_SUPPLEMENTAR">Item 8. Financial Statements and Supplementary Data. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The financial statements and supplementary data are as set forth in the index to the financial statements on page&#160;F-1.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_9_CHANGES_IN_DISAGREEMENTS_WITH_ACC">Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_9A_CONTROLS_PROCEDURES">Item 9A. Controls and Procedures. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Evaluation of Disclosure Controls and Procedures</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We maintain "disclosure controls and procedures," as such term is defined in Rule 13a-15(e) under the Securities Exchange Act of 1934, or Exchange Act, that are designed to ensure that information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in Securities and Exchange Commission rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating our disclosure controls and procedures, management recognized that disclosure controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the disclosure controls and procedures are met. Our disclosure controls and procedures have been designed to meet reasonable assurance standards. Additionally, in designing disclosure controls and procedures, our management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible disclosure controls and procedures. The design of any disclosure controls and procedures also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:3.85%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Based on their evaluation as of the end of the period covered by this Annual Report on Form 10-K, our Chief Executive Officer and Chief Financial Officer have concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:3.85%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This annual report does not include a report of management's assessment regarding internal control over financial reporting or an attestation report of our registered public accounting firm due to a transition period established by rules of the Securities and Exchange Commission for newly public companies.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_9B_OR_INFORMATION">Item 9B. Other Information. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">115</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>

<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PART III </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_10_DIRECTORS_EXECUTIVE_FICERS_CORPO">Item 10. Directors, Executive Officers and Corporate Governance. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.81%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information required by this item with respect to directors is incorporated by reference from the information under the caption "Election of Directors" contained in our Proxy Statement to be filed with the Securities and Exchange Commission in connection with the solicitation of proxies for our 2020 Annual Meeting of Stockholders to be held on May 26, 2021. Certain information required by this item concerning executive officers is set forth in Part I of this Report under the caption "Executive Officers of the Registrant" and is incorporated herein by reference.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 405 of Regulation S-K calls for disclosure of any known late filing or failure by an insider to file a report required by Section 16(a) of the Exchange Act. This disclosure is contained in the section entitled "Section 16(a) Beneficial Ownership Reporting Compliance" in the Proxy Statement and is incorporated herein by reference.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have adopted a Code of Business Conduct and Ethics that applies to all of our officers and employees, including our President and Chief Executive Officer, our Chief Financial Officer and other employees who perform financial or accounting functions. The Code of Business Conduct and Ethics sets forth the basic principles that guide the business conduct of our employees. Stockholders may request a free copy of our Code of Business Conduct and Ethics by contacting Biodesix, Inc., Attention: Chief Financial Officer, 2970 Wilderness Place, Suite 100, Boulder, Colorado 80301.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To date, there have been no waivers under our Code of Business Conduct and Ethics. We intend to disclose future amendments to certain provisions of our Code of Business Conduct and Ethics or waivers of such Codes granted to executive officers and directors on our website at http://www.biodesix.com within four business days following the date of such amendment or waiver.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our Board of Directors has appointed an Audit Committee, comprised of Ms. Jean Franchi, as Chairwoman, Mr. Hany Massarany and Dr. Matthew Strobeck. The Board of Directors has determined that Ms. Franchi qualifies as an Audit Committee Financial Expert under the definition outlined by the Securities and Exchange Commission. In addition, each of the members of the Audit Committee qualifies as an "independent director" under the current rules of The NASDAQ Stock Market and Securities and Exchange Commission rules and regulations.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_11_EXECUTIVE_COMPENSATION">Item 11. Executive Compensation. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.84%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information required by this item is incorporated by reference from the information under the captions "Election of Directors&#8212;Director Compensation" and "Executive Compensation" contained in the Company&#8217;s definitive<span style="color:#0000FF;"> </span>Proxy Statement for the 2021 Annual Meeting of Stockholders and is incorporated herein by reference.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_12_SECURITY_OWNERSHIP_CERTAIN_BENEF">Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.84%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information required by this item is incorporated by reference from the information under the captions "Security Ownership of Certain Beneficial Owners and Management" and "Executive Compensation&#8212;Equity Compensation Plan Information" contained in the Company&#8217;s definitive Proxy Statement for the 2021 Annual Meeting of Stockholders and is incorporated herein by reference. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_13_CERTAIN_RELATIONSHIPS_RELATED_TR">Item 13. Certain Relationships and Related Transactions, and Director Independence. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.84%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information required by this item is incorporated by reference from the information under the caption "Election of Directors&#8212;Certain Relationships and Related Transactions" and "&#8212;Director Independence" contained in the Company&#8217;s definitive Proxy Statement for the 2021 Annual Meeting of Stockholders and is incorporated herein by reference. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_14_PRINCIPAL_ACCOUNTING_FEES_SERVIC">Item 14. Principal Accounting Fees and Services. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.84%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information required by this item is incorporated by reference from the information under the caption "Ratification of the Appointment of Independent Registered Public Accounting Firm&#8212;Principal Accountant Fees and Services" contained in the Company&#8217;s definitive Proxy Statement for the 2021 Annual Meeting of Stockholders and is incorporated herein by reference. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">116</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>

<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PART IV </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_15_EXHIBITS_FINANCIAL_STATEMENT_SCH">Item 15. Exhibits, Financial Statement Schedules. </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</span></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Documents filed as a part of the report. </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Financial Statements</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:11.54%;text-indent:-3.85%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reference is made to the Index to Financial Statements of Biodesix, Inc. included in Item 8 of Part II hereof</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Financial Statement Schedules </p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:11.54%;text-indent:-3.85%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All schedules have been omitted because they are not required, not applicable, or the required information is included in the financial statements or notes thereto.</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">See Item 15(b) below. Each management contract or compensating plan or arrangement required to be filed has been identified. </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Exhibits. </p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_16_FORM_10K_SUMMARY">Item 16. Form 10-K Summary</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not applicable.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">117</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="EXHIBIT_INDEX"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Exhibit</span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> Index</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.34%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Description</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.18%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.34%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td colspan="3" valign="top" style="width:13.68%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;letter-spacing:-0.15pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.1**</p></td>
<td valign="top" style="width:86.32%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1439725/000119312520273369/d937421dex11.htm"><span style="text-decoration:underline;">Form of Underwriting</span><span style="letter-spacing:-0.4pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Agreement (incorporated by reference to Exhibit 1.1 to the Company&#8217;s Registration Statement on Form S-1/A filed with the SEC on October 21, 2020).</span></a></p></td>
</tr>
<tr>
<td colspan="3" valign="top" style="width:13.68%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.1**</p></td>
<td valign="top" style="width:86.32%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1439725/000156459020056735/bdsx-ex31_716.htm"><span style="text-decoration:underline;">Amended</span><span style="letter-spacing:-0.4pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">and</span><span style="letter-spacing:-0.4pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Restated</span><span style="letter-spacing:-0.4pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Certificate</span><span style="letter-spacing:-0.4pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">of</span><span style="letter-spacing:-0.45pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Incorporation</span><span style="letter-spacing:-0.4pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">of</span><span style="letter-spacing:-0.4pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Biodesix,</span><span style="letter-spacing:-0.4pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Inc.,</span><span style="letter-spacing:-0.4pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">dated October 30, 2020 (incorporated by reference to Exhibit 3.2 to the Company&#8217;s Quarterly Report on Form 10-Q filed with the SEC on October 12, 2020).</span></a></p></td>
</tr>
<tr>
<td colspan="3" valign="top" style="width:13.68%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;letter-spacing:-0.15pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.2**</p></td>
<td valign="top" style="width:86.32%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1439725/000156459020056735/bdsx-ex32_717.htm"><span style="text-decoration:underline;">Amended</span><span style="letter-spacing:-0.35pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">and</span><span style="letter-spacing:-0.4pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Restated</span><span style="letter-spacing:-0.4pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Bylaws</span><span style="letter-spacing:-0.35pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">of</span><span style="letter-spacing:-0.4pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Biodesix,</span><span style="letter-spacing:-0.35pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Inc. (incorporated by reference to Exhibit 3.2 to the Company&#8217;s Quarterly Report on Form 10-Q filed with the SEC on October 12, 2020).</span></a></p></td>
</tr>
<tr>
<td colspan="3" valign="top" style="width:13.68%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;letter-spacing:-0.15pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.1**</p></td>
<td valign="top" style="width:86.32%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1439725/000119312520273369/d937421dex41.htm"><span style="text-decoration:underline;">Specimen stock certificate evidencing shares of Common</span><span style="letter-spacing:-0.5pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Stock (incorporated by reference to Exhibit 4.1 to the Company&#8217;s Registration Statement on Form S-1/A filed with the SEC on October 21, 2020).</span></a></p></td>
</tr>
<tr>
<td colspan="3" valign="top" style="width:13.68%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.2**</p></td>
<td valign="top" style="width:86.32%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1439725/000119312520262422/d937421dex42.htm"><span style="text-decoration:underline;">Eleventh</span><span style="letter-spacing:-0.25pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Amended</span><span style="letter-spacing:-0.2pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">and</span><span style="letter-spacing:-0.2pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Restated</span><span style="letter-spacing:-0.2pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Investor</span><span style="letter-spacing:-0.2pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Rights</span><span style="letter-spacing:-0.2pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Agreement,</span><span style="letter-spacing:-0.2pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">by</span><span style="letter-spacing:-0.2pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">and</span><span style="letter-spacing:-0.2pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">among</span><span style="letter-spacing:-0.25pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Biodesix,</span><span style="letter-spacing:-0.2pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Inc.</span><span style="letter-spacing:-0.2pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">and</span><span style="letter-spacing:-0.2pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">the</span><span style="letter-spacing:-0.2pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">investors</span><span style="letter-spacing:-0.2pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">listed</span><span style="letter-spacing:-0.2pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">on</span><span style="letter-spacing:-0.2pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Exhibit</span><span style="letter-spacing:-0.2pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">A thereto, dated October 10,</span><span style="letter-spacing:0.15pt;text-decoration:underline;"> </span><span style="letter-spacing:-0.4pt;text-decoration:underline;">2018 </span><span style="text-decoration:underline;">(incorporated by reference to Exhibit 4.2 to the Company&#8217;s Registration Statement on Form S-1 filed with the SEC on October 2, 2020).</span></a></p></td>
</tr>
<tr>
<td colspan="3" valign="top" style="width:13.68%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.3**</p></td>
<td valign="top" style="width:86.32%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1439725/000119312520262422/d937421dex43.htm"><span style="text-decoration:underline;">Warrant</span><span style="letter-spacing:-0.7pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">held</span><span style="letter-spacing:-0.6pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">by</span><span style="letter-spacing:-0.65pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Innovatus</span><span style="letter-spacing:-0.65pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Life</span><span style="letter-spacing:-0.65pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Sciences</span><span style="letter-spacing:-0.6pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Lending</span><span style="letter-spacing:-0.7pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Fund</span><span style="letter-spacing:-0.6pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">I,</span><span style="letter-spacing:-0.65pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">LP,</span><span style="letter-spacing:-0.65pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">to</span><span style="letter-spacing:-0.7pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Purchase</span><span style="letter-spacing:-0.6pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Series</span><span style="letter-spacing:-0.65pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">G</span><span style="letter-spacing:-0.6pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Preferred</span><span style="letter-spacing:-0.65pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Stock,</span><span style="letter-spacing:-0.65pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">dated</span><span style="letter-spacing:-0.6pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">February</span><span style="letter-spacing:-0.65pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">23,</span><span style="letter-spacing:-0.6pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">3018 (incorporated by reference to Exhibit 4.3 to the Company&#8217;s Registration Statement on Form S-1 filed with the SEC on October 2, 2020).</span></a></p></td>
</tr>
<tr>
<td colspan="3" valign="top" style="width:13.68%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;letter-spacing:-0.15pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.4**</p></td>
<td valign="top" style="width:86.32%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1439725/000119312520262422/d937421dex44.htm"><span style="text-decoration:underline;">Secured</span><span style="letter-spacing:-0.6pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Promissory</span><span style="letter-spacing:-0.6pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Note</span><span style="letter-spacing:-0.6pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">held</span><span style="letter-spacing:-0.6pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">by</span><span style="letter-spacing:-0.6pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Innovatus</span><span style="letter-spacing:-0.6pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Life</span><span style="letter-spacing:-0.6pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Sciences</span><span style="letter-spacing:-0.6pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Lending</span><span style="letter-spacing:-0.6pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Fund</span><span style="letter-spacing:-0.6pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">I,</span><span style="letter-spacing:-0.6pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">LP,</span><span style="letter-spacing:-0.6pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">in</span><span style="letter-spacing:-0.6pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Biodesix,</span><span style="letter-spacing:-0.6pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Inc.,</span><span style="letter-spacing:-0.6pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">dated</span><span style="letter-spacing:-0.6pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">February</span><span style="letter-spacing:-0.6pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">23,</span><span style="letter-spacing:-0.6pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">2018 (incorporated by reference to Exhibit 4.3 to the Company&#8217;s Registration Statement on Form S-1 filed with the SEC on October 2, 2020).</span></a></p></td>
</tr>
<tr>
<td colspan="3" valign="top" style="width:13.68%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.5*</p></td>
<td valign="top" style="width:86.32%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="bdsx-ex45_270.htm"><span style="text-decoration:underline;">Description of Securities Registered Under Section 12 of the Securities Exchange Act of 1934.</span></a></p></td>
</tr>
<tr>
<td colspan="3" valign="top" style="width:13.68%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1+**</p></td>
<td valign="top" style="width:86.32%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1439725/000119312520266992/d937421dex101.htm"><span style="text-decoration:underline;">Biodesix, Inc. Amended and Restated 2006 Employee, Director and Consultant Stock Plan, as amended to date (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Registration Statement on Form S-1/A filed with the SEC on October 9, 2020).</span></a></p></td>
</tr>
<tr>
<td colspan="3" valign="top" style="width:13.68%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.2.1+**</p></td>
<td valign="top" style="width:86.32%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1439725/000119312520266992/d937421dex1021.htm"><span style="text-decoration:underline;">Form of Stock Option Grant Notice under the Amended and Restated 2006 Employee, Director and Consultant Stock Plan (incorporated by reference to Exhibit 10.2.1 to the Company&#8217;s Registration Statement on Form S-1/A filed with the SEC on October 9, 2020).</span></a></p></td>
</tr>
<tr>
<td colspan="3" valign="top" style="width:13.68%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.2.2+**</p></td>
<td valign="top" style="width:86.32%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1439725/000119312520266992/d937421dex1022.htm"><span style="text-decoration:underline;">Form of Option Agreement under the Amended and Restated 2006 Employee, Director and Consultant Stock Plan (incorporated by reference to Exhibit 10.2.2 to the Company&#8217;s Registration Statement on Form S-1/A filed with the SEC on October 9, 2020).</span></a></p></td>
</tr>
<tr>
<td colspan="3" valign="top" style="width:13.68%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.2.3+**</p></td>
<td valign="top" style="width:86.32%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1439725/000119312520266992/d937421dex1023.htm"><span style="text-decoration:underline;">Form of Notice of Exercise under the Amended and Restated 2006 Employee, Director and Consultant Stock Plan (incorporated by reference to Exhibit 10.2.3 to the Company&#8217;s Registration Statement on Form S-1/A filed with the SEC on October 9, 2020).</span></a></p></td>
</tr>
<tr>
<td colspan="3" valign="top" style="width:13.68%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.3+**</p></td>
<td valign="top" style="width:86.32%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1439725/000119312520262422/d937421dex103.htm"><span style="text-decoration:underline;">Biodesix, Inc. 2016 Equity Incentive Plan, as amended to date (incorporated by reference to Exhibit 10.3 to the Company&#8217;s Registration Statement on Form S-1 filed with the SEC on October 2, 2020).</span></a></p></td>
</tr>
<tr>
<td colspan="3" valign="top" style="width:13.68%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.4.1+**</p></td>
<td valign="top" style="width:86.32%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1439725/000119312520266992/d937421dex1041.htm"><span style="text-decoration:underline;">Form of Stock Option Grant Notice under the 2016 Equity Incentive Plan (incorporated by reference to Exhibit 10.4.1 to the Company&#8217;s Registration Statement on Form S-1/A filed with the SEC on October 9, 2020).</span></a></p></td>
</tr>
<tr>
<td colspan="3" valign="top" style="width:13.68%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.4.2+**</p></td>
<td valign="top" style="width:86.32%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1439725/000119312520266992/d937421dex1042.htm"><span style="text-decoration:underline;">Form of Option Agreement under the 2016 Equity Incentive Plan (incorporated by reference to Exhibit 10.4.2 to the Company&#8217;s Registration Statement on Form S-1/A filed with the SEC on October 9, 2020).</span></a></p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">118</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td colspan="3" valign="top" style="width:13.68%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.4.3+**</span></p></td>
<td valign="top" style="width:86.32%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1439725/000119312520266992/d937421dex1043.htm"><span style="text-decoration:underline;">Form of Notice of Exercise under the 2016 Equity Incentive Plan (incorporated by reference to Exhibit 10.4.3 to the Company&#8217;s Registration Statement on Form S-1/A filed with the SEC on October 9, 2020).</span></a></p></td>
</tr>
<tr>
<td colspan="3" valign="top" style="width:13.68%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.5+**</p></td>
<td valign="top" style="width:86.32%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1439725/000119312520275630/d937421dex105.htm"><span style="text-decoration:underline;">Biodesix, Inc. 2020 Equity Incentive Plan (incorporated by reference to Exhibit 10.5 to the Company&#8217;s Registration Statement on Form S-1/A filed with the SEC on October 26, 2020).</span></a></p></td>
</tr>
<tr>
<td colspan="3" valign="top" style="width:13.68%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.5.1+*</p></td>
<td valign="top" style="width:86.32%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="bdsx-ex1051_388.htm"><span style="text-decoration:underline;">Forms of Stock Option Grant Notice, Option Agreement and Notice of Exercise under the 2020 Equity Incentive Plan.</span></a></p></td>
</tr>
<tr>
<td colspan="3" valign="top" style="width:13.68%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.6+**</p></td>
<td valign="top" style="width:86.32%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1439725/000119312520275630/d937421dex106.htm"><span style="text-decoration:underline;">Biodesix, Inc. 2020 Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.6 to the Company&#8217;s Registration Statement on Form S-1/A filed with the SEC on October 26, 2020).</span></a></p></td>
</tr>
<tr>
<td colspan="3" valign="top" style="width:13.68%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.7.1+**</p></td>
<td valign="top" style="width:86.32%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1439725/000119312520262422/d937421dex1051.htm"><span style="text-decoration:underline;">Biodesix, Inc., First Amended Bonus-to-Options Program, adopted by the Board of Directors on October 15, 2010 (incorporated by reference to Exhibit 10.5.1 to the Company&#8217;s Registration Statement on Form S-1 filed with the SEC on October 2, 2020).</span></a></p></td>
</tr>
<tr>
<td colspan="3" valign="top" style="width:13.68%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.7.2+**</p></td>
<td valign="top" style="width:86.32%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1439725/000119312520262422/d937421dex1052.htm"><span style="text-decoration:underline;">Biodesix, Inc., Second Amended Bonus-to-Options Program, adopted by the Board of Directors on June 21, 2011 (incorporated by reference to Exhibit 10.5.2 to the Company&#8217;s Registration Statement on Form S-1 filed with the SEC on October 2, 2020).</span></a></p></td>
</tr>
<tr>
<td colspan="3" valign="top" style="width:13.68%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.7.3+**</p></td>
<td valign="top" style="width:86.32%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1439725/000119312520262422/d937421dex1053.htm"><span style="text-decoration:underline;">Biodesix, Inc., Third Amended Bonus-to-Options Program, adopted by the Board of Directors on December 31, 2015 (incorporated by reference to Exhibit 10.5.3 to the Company&#8217;s Registration Statement on Form S-1 filed with the SEC on October 2, 2020).</span></a></p></td>
</tr>
<tr>
<td colspan="3" valign="top" style="width:13.68%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.8.1+**</p></td>
<td valign="top" style="width:86.32%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1439725/000119312520266992/d937421dex1061.htm"><span style="text-decoration:underline;">Form of Stock Option Grant Notice under the Biodesix, Inc. Bonus-To-Options Program (incorporated by reference to Exhibit 10.6.1 to the Company&#8217;s Registration Statement on Form S-1/A filed with the SEC on October 9, 2020).</span></a></p></td>
</tr>
<tr>
<td colspan="3" valign="top" style="width:13.68%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.8.2+**</p></td>
<td valign="top" style="width:86.32%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1439725/000119312520266992/d937421dex1062.htm"><span style="text-decoration:underline;">Form of Option Agreement under the Biodesix, Inc. Bonus-To-Options Program (incorporated by reference to Exhibit 10.6.2 to the Company&#8217;s Registration Statement on Form S-1/A filed with the SEC on October 9, 2020).</span></a></p></td>
</tr>
<tr>
<td colspan="3" valign="top" style="width:13.68%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.9+**</p></td>
<td valign="top" style="width:86.32%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1439725/000119312520268763/d937421dex107.htm"><span style="text-decoration:underline;">Form of Indemnification Agreement, by and between Biodesix, Inc. and each of its directors and executive officers (incorporated by reference to Exhibit 10.7 to the Company&#8217;s Registration Statement on Form S-1/A filed with the SEC on October 14, 2020).</span></a></p></td>
</tr>
<tr>
<td colspan="3" valign="top" style="width:13.68%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.10.1&#8224;+**</p></td>
<td valign="top" style="width:86.32%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1439725/000119312520262422/d937421dex1091.htm"><span style="text-decoration:underline;">Executive Employment Letter, by and between Biodesix, Inc. and Scott Hutton, dated February 16, 2018 (incorporated by reference to Exhibit 10.9.1 to the Company&#8217;s Registration Statement on Form S-1 filed with the SEC on October 2, 2020).</span></a></p></td>
</tr>
<tr>
<td colspan="3" valign="top" style="width:13.68%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.10.2&#8224;+**</p></td>
<td valign="top" style="width:86.32%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1439725/000119312520262422/d937421dex1092.htm"><span style="text-decoration:underline;">Executive Employment Letter, by and between Biodesix, Inc. and Scott Hutton, dated February 23, 2020 (incorporated by reference to Exhibit 10.9.2 to the Company&#8217;s Registration Statement on Form S-1 filed with the SEC on October 2, 2020).</span></a></p></td>
</tr>
<tr>
<td colspan="3" valign="top" style="width:13.68%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.11.1&#8224;+**</p></td>
<td valign="top" style="width:86.32%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1439725/000119312520262422/d937421dex10101.htm"><span style="text-decoration:underline;">Employment Letter, by and between Biodesix, Inc. and Robin Harper Cowie, dated March 11, 2011 (incorporated by reference to Exhibit 10.10.1 to the Company&#8217;s Registration Statement on Form S-1 filed with the SEC on October 2, 2020).</span></a></p></td>
</tr>
<tr>
<td colspan="3" valign="top" style="width:13.68%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.11.2&#8224;+**</p></td>
<td valign="top" style="width:86.32%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1439725/000119312520262422/d937421dex10102.htm"><span style="text-decoration:underline;">Executive Employment Letter, by and between Biodesix, Inc. and Robin Harper Cowie, dated February 23, 2020 (incorporated by reference to Exhibit 10.10.2 to the Company&#8217;s Registration Statement on Form S-1 filed with the SEC on October 2, 2020).</span></a></p></td>
</tr>
<tr>
<td colspan="3" valign="top" style="width:13.68%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.12+**</p></td>
<td valign="top" style="width:86.32%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1439725/000119312520262422/d937421dex1011.htm"><span style="text-decoration:underline;">Consulting Agreement, by and between David Brunel and Biodesix, Inc., dated September 19, 2020 (incorporated by reference to Exhibit 10.11 to the Company&#8217;s Registration Statement on Form S-1 filed with the SEC on October 2, 2020).</span></a></p></td>
</tr>
<tr>
<td colspan="3" valign="top" style="width:13.68%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.13&#8224;**</p></td>
<td valign="top" style="width:86.32%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1439725/000119312520266992/d937421dex1011.htm"><span style="text-decoration:underline;">Office Lease between Aero-Tech Investments, LLC and Biodesix, Inc., dated October 5, 2011 (incorporated by reference to Exhibit 10.11 to the Company&#8217;s Registration Statement on Form S-1/A filed with the SEC on October 9, 2020).</span></a></p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">119</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td colspan="3" valign="top" style="width:13.68%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.14&#8224;**</span></p></td>
<td valign="top" style="width:86.32%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1439725/000119312520262422/d937421dex1013.htm"><span style="text-decoration:underline;">Lease Assignment of De Soto Facility, dated November 1, 2019 (incorporated by reference to Exhibit 10.13 to the Company&#8217;s Registration Statement on Form S-1 filed with the SEC on October 2, 2020).</span></a></p></td>
</tr>
<tr>
<td colspan="3" valign="top" style="width:13.68%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.15.1&#8224;**</p></td>
<td valign="top" style="width:86.32%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1439725/000119312520266992/d937421dex10131.htm"><span style="text-decoration:underline;">Loan</span><span style="letter-spacing:-0.5pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">and</span><span style="letter-spacing:-0.45pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Security</span><span style="letter-spacing:-0.45pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Agreement,</span><span style="letter-spacing:-0.45pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">by</span><span style="letter-spacing:-0.45pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">and</span><span style="letter-spacing:-0.5pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">among</span><span style="letter-spacing:-0.45pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Innovatus</span><span style="letter-spacing:-0.45pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Life</span><span style="letter-spacing:-0.45pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Sciences</span><span style="letter-spacing:-0.45pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Lending</span><span style="letter-spacing:-0.5pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Fund</span><span style="letter-spacing:-0.45pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">I,</span><span style="letter-spacing:-0.45pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">LP,</span><span style="letter-spacing:-0.45pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">the</span><span style="letter-spacing:-0.45pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Lenders</span><span style="letter-spacing:-0.5pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">listed</span><span style="letter-spacing:-0.45pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">therein,</span><span style="letter-spacing:-0.45pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">and</span><span style="letter-spacing:-0.45pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Biodesix, Inc., dated </span><span style="letter-spacing:-0.15pt;text-decoration:underline;">February </span><span style="text-decoration:underline;">23,</span><span style="letter-spacing:-0.45pt;text-decoration:underline;"> </span><span style="letter-spacing:-0.15pt;text-decoration:underline;">2018 </span><span style="text-decoration:underline;">(incorporated by reference to Exhibit 10.13.1 to the Company&#8217;s Registration Statement on Form S-1/A filed with the SEC on October 9, 2020).</span></a></p></td>
</tr>
<tr>
<td colspan="3" valign="top" style="width:13.68%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.15.2&#8224;**</p></td>
<td valign="top" style="width:86.32%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001439725/000119312520262422/d937421dex10142.htm"><span style="text-decoration:underline;">Limited Consent Agreement and Second Amendment to Loan and Security Agreement, by and among Innovatus Life Sciences Lending Fund I, LP, the Lenders listed therein, and Biodesix, Inc., dated June 30, 2018, as amended to date (incorporated by reference to Exhibit 10.14.2 to the Company&#8217;s Registration Statement on Form S-1 filed with the SEC on October 2, 2020).</span></a></p></td>
</tr>
<tr>
<td colspan="3" valign="top" style="width:13.68%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.16**</p></td>
<td valign="top" style="width:86.32%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1439725/000119312520262422/d937421dex1015.htm"><span style="text-decoration:underline;">Patent Assignment between Biodesix, Inc., and Integrated Diagnostics, Inc., dated June 30, 2018 (incorporated by reference to Exhibit 10.15 to the Company&#8217;s Registration Statement on Form S-1 filed with the SEC on October 2, 2020).</span></a></p></td>
</tr>
<tr>
<td colspan="3" valign="top" style="width:13.68%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;letter-spacing:-0.25pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.17&#8224;**</p></td>
<td valign="top" style="width:86.32%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1439725/000119312520266992/d937421dex1015.htm"><span style="text-decoration:underline;">IP</span><span style="letter-spacing:-0.95pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Assignment</span><span style="letter-spacing:-0.95pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Agreement</span><span style="letter-spacing:-0.9pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">between</span><span style="letter-spacing:-0.95pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Oncimmune</span><span style="letter-spacing:-0.9pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Limited,</span><span style="letter-spacing:-1pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">and</span><span style="letter-spacing:-0.95pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Biodesix,</span><span style="letter-spacing:-0.95pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Inc.,</span><span style="letter-spacing:-0.9pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">dated</span><span style="letter-spacing:-0.95pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">October</span><span style="letter-spacing:-0.95pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">31,</span><span style="letter-spacing:-0.9pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">2019 (incorporated by reference to Exhibit 10.15 to the Company&#8217;s Registration Statement on Form S-1/A filed with the SEC on October 9, 2020).</span></a></p></td>
</tr>
<tr>
<td colspan="3" valign="top" style="width:13.68%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;letter-spacing:-0.25pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.18&#8224;**</p></td>
<td valign="top" style="width:86.32%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1439725/000119312520266992/d937421dex1016.htm"><span style="text-decoration:underline;">IP</span><span style="letter-spacing:-0.7pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">License</span><span style="letter-spacing:-0.65pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Agreement</span><span style="letter-spacing:-0.7pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">between</span><span style="letter-spacing:-0.65pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Oncimmune</span><span style="letter-spacing:-0.7pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Limited,</span><span style="letter-spacing:-0.65pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">and</span><span style="letter-spacing:-0.7pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Biodesix,</span><span style="letter-spacing:-0.65pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Inc.,</span><span style="letter-spacing:-0.7pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">dated</span><span style="letter-spacing:-0.65pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">October</span><span style="letter-spacing:-0.7pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">31,</span><span style="letter-spacing:-0.65pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">2019 (incorporated by reference to Exhibit 10.16 to the Company&#8217;s Registration Statement on Form S-1/A filed with the SEC on October 9, 2020).</span></a></p></td>
</tr>
<tr>
<td colspan="3" valign="top" style="width:13.68%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;letter-spacing:-0.25pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.19&#8224;**</p></td>
<td valign="top" style="width:86.32%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1439725/000119312520266992/d937421dex1017.htm"><span style="text-decoration:underline;">Non-Exclusive</span><span style="letter-spacing:-0.65pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">License</span><span style="letter-spacing:-0.6pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Agreement</span><span style="letter-spacing:-0.55pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">between</span><span style="letter-spacing:-0.6pt;text-decoration:underline;"> </span><span style="letter-spacing:-0.15pt;text-decoration:underline;">Bio-Rad</span><span style="letter-spacing:-0.65pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Laboratories,</span><span style="letter-spacing:-0.55pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Inc.,</span><span style="letter-spacing:-0.6pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">and</span><span style="letter-spacing:-0.7pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Biodesix,</span><span style="letter-spacing:-0.65pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Inc.,</span><span style="letter-spacing:-0.65pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">dated</span><span style="letter-spacing:-0.65pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">August</span><span style="letter-spacing:-0.65pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">1,</span><span style="letter-spacing:-0.65pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">2019 (incorporated by reference to Exhibit 10.17 to the Company&#8217;s Registration Statement on Form S-1/A filed with the SEC on October 9, 2020).</span></a></p></td>
</tr>
<tr>
<td colspan="3" valign="top" style="width:13.68%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;letter-spacing:-0.25pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.20&#8224;**</p></td>
<td valign="top" style="width:86.32%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1439725/000119312520266992/d937421dex1018.htm"><span style="text-decoration:underline;">Supply</span><span style="letter-spacing:-0.3pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Agreement</span><span style="letter-spacing:-0.25pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">between</span><span style="letter-spacing:-0.25pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Biodesix,</span><span style="letter-spacing:-0.25pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Inc.,</span><span style="letter-spacing:-0.25pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">and</span><span style="letter-spacing:-0.25pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Oncimmune,</span><span style="letter-spacing:-0.25pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">dated</span><span style="letter-spacing:-0.25pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">October</span><span style="letter-spacing:-0.25pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">31,</span><span style="letter-spacing:-0.25pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">2019 (incorporated by reference to Exhibit 10.18 to the Company&#8217;s Registration Statement on Form S-1/A filed with the SEC on October 9, 2020).</span></a></p></td>
</tr>
<tr>
<td colspan="3" valign="top" style="width:13.68%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;letter-spacing:-0.15pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.21&#8224;**</p></td>
<td valign="top" style="width:86.32%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1439725/000119312520266992/d937421dex1019.htm"><span style="text-decoration:underline;">Supply Agreement between </span><span style="letter-spacing:-0.15pt;text-decoration:underline;">Bio-Rad </span><span style="text-decoration:underline;">Laboratories, Inc., and Biodesix, Inc., dated August </span><span style="letter-spacing:-0.15pt;text-decoration:underline;">1,</span><span style="letter-spacing:-1.05pt;text-decoration:underline;"> </span><span style="letter-spacing:-0.3pt;text-decoration:underline;">2019 </span><span style="text-decoration:underline;">(incorporated by reference to Exhibit 10.19 to the Company&#8217;s Registration Statement on Form S-1/A filed with the SEC on October 9, 2020).</span></a></p></td>
</tr>
<tr>
<td colspan="3" valign="top" style="width:13.68%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;letter-spacing:-0.15pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.22&#8224;**</p></td>
<td valign="top" style="width:86.32%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1439725/000119312520266992/d937421dex1020.htm"><span style="text-decoration:underline;">Co-Development</span><span style="letter-spacing:-0.75pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">and</span><span style="letter-spacing:-0.8pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Collaboration</span><span style="letter-spacing:-0.85pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Agreement</span><span style="letter-spacing:-0.8pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">between</span><span style="letter-spacing:-0.75pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">AVEO</span><span style="letter-spacing:-0.8pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Pharmaceuticals,</span><span style="letter-spacing:-0.8pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Inc.,</span><span style="letter-spacing:-0.8pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">and</span><span style="letter-spacing:-0.8pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Biodesix,</span><span style="letter-spacing:-0.8pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Inc.,</span><span style="letter-spacing:-0.8pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">dated</span><span style="letter-spacing:-0.65pt;text-decoration:underline;"> </span><span style="letter-spacing:-0.15pt;text-decoration:underline;">April</span><span style="letter-spacing:-0.9pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">9,</span><span style="letter-spacing:-0.95pt;text-decoration:underline;"> </span><span style="letter-spacing:-0.15pt;text-decoration:underline;">2014,</span><span style="letter-spacing:-0.95pt;text-decoration:underline;"> </span><span style="letter-spacing:-0.15pt;text-decoration:underline;">as </span><span style="text-decoration:underline;">amended October 14,</span><span style="letter-spacing:-0.7pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">2016 (incorporated by reference to Exhibit 10.20 to the Company&#8217;s Registration Statement on Form S-1/A filed with the SEC on October 9, 2020).</span></a></p></td>
</tr>
<tr>
<td colspan="3" valign="top" style="width:13.68%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;letter-spacing:-0.15pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.23&#8224;**</p></td>
<td valign="top" style="width:86.32%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1439725/000119312520262422/d937421dex1022.htm"><span style="text-decoration:underline;">Contingent</span><span style="letter-spacing:-0.6pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Value</span><span style="letter-spacing:-0.6pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Rights</span><span style="letter-spacing:-0.6pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Agreement</span><span style="letter-spacing:-0.6pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">between</span><span style="letter-spacing:-0.55pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Biodesix,</span><span style="letter-spacing:-0.6pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Inc.</span><span style="letter-spacing:-0.6pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">and</span><span style="letter-spacing:-0.6pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Holders</span><span style="letter-spacing:-0.6pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">on</span><span style="letter-spacing:-0.55pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Schedule</span><span style="letter-spacing:-0.6pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">A</span><span style="letter-spacing:-0.6pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">mentioned</span><span style="letter-spacing:-0.6pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">within,</span><span style="letter-spacing:-0.55pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">dated</span><span style="letter-spacing:-0.6pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">February</span><span style="letter-spacing:-0.6pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">22,</span><span style="letter-spacing:-0.6pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">2016 (incorporated by reference to Exhibit 10.22 to the Company&#8217;s Registration Statement on Form S-1 filed with the SEC on October 2, 2020).</span></a></p></td>
</tr>
<tr>
<td colspan="3" valign="top" style="width:13.68%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;letter-spacing:-0.25pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.24&#8224;**</p></td>
<td valign="top" style="width:86.32%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1439725/000119312520262422/d937421dex1023.htm"><span style="text-decoration:underline;">Asset</span><span style="letter-spacing:-0.2pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Purchase</span><span style="letter-spacing:-0.15pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Agreement</span><span style="letter-spacing:-0.2pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">among</span><span style="letter-spacing:-0.15pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Biodesix,</span><span style="letter-spacing:-0.15pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Inc.,</span><span style="letter-spacing:-0.2pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Integrated</span><span style="letter-spacing:-0.15pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Diagnostics,</span><span style="letter-spacing:-0.15pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Inc.,</span><span style="letter-spacing:-0.2pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">and</span><span style="letter-spacing:-0.15pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">the</span><span style="letter-spacing:-0.2pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">stockholders</span><span style="letter-spacing:-0.15pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">of</span><span style="letter-spacing:-0.15pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Integrated</span><span style="letter-spacing:-0.2pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Diagnostics,</span><span style="letter-spacing:-0.15pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Inc., listed therein, dated June 30, 2018 (incorporated by reference to Exhibit 10.23 to the Company&#8217;s Registration Statement on Form S-1 filed with the SEC on October 2, 2020).</span></a></p></td>
</tr>
<tr>
<td colspan="3" valign="top" style="width:13.68%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;letter-spacing:-0.15pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.25&#8224;**</p></td>
<td valign="top" style="width:86.32%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1439725/000119312520262422/d937421dex1024.htm"><span style="text-decoration:underline;">Asset</span><span style="letter-spacing:-0.2pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Purchase</span><span style="letter-spacing:-0.2pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Agreement</span><span style="letter-spacing:-0.2pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">between</span><span style="letter-spacing:-0.15pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Oncimmune</span><span style="letter-spacing:-0.2pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Limited</span><span style="letter-spacing:-0.25pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">and</span><span style="letter-spacing:-0.25pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Biodesix,</span><span style="letter-spacing:-0.2pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Inc.,</span><span style="letter-spacing:-0.2pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">dated</span><span style="letter-spacing:-0.2pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">June</span><span style="letter-spacing:-0.15pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">27,</span><span style="letter-spacing:-0.2pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">2019,</span><span style="letter-spacing:-0.2pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">as</span><span style="letter-spacing:-0.25pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">amended</span><span style="letter-spacing:-0.2pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">to</span><span style="letter-spacing:-0.25pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">date (incorporated by reference to Exhibit 10.24 to the Company&#8217;s Registration Statement on Form S-1 filed with the SEC on October 2, 2020).</span></a></p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">120</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td colspan="3" valign="top" style="width:13.68%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;letter-spacing:-0.15pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="letter-spacing:-0.15pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.26&#8224;</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">**</span></p></td>
<td valign="top" style="width:86.32%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;letter-spacing:-0.4pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1439725/000119312520262422/d937421dex1025.htm"><span style="text-decoration:underline;">COVID-19</span><span style="letter-spacing:-0.55pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Testing</span><span style="letter-spacing:-0.5pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Laboratory</span><span style="letter-spacing:-0.55pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Services</span><span style="letter-spacing:-0.5pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Agreement</span><span style="letter-spacing:-0.55pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">by</span><span style="letter-spacing:-0.5pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">and</span><span style="letter-spacing:-0.55pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">between</span><span style="letter-spacing:-0.5pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Biodesix,</span><span style="letter-spacing:-0.55pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Inc.,</span><span style="letter-spacing:-0.5pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">and</span><span style="letter-spacing:-0.55pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Centura</span><span style="letter-spacing:-0.5pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Health</span><span style="letter-spacing:-0.25pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Corporation,</span><span style="letter-spacing:-0.6pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">dated</span><span style="letter-spacing:-0.55pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">April</span><span style="letter-spacing:-0.55pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">3, </span><span style="text-decoration:underline;">2020 </span><span style="text-decoration:underline;">(incorporated by reference to Exhibit 10.25 to the Company&#8217;s Registration Statement on Form S-1 filed with the SEC on October 2, 2020).</span></a></p></td>
</tr>
<tr>
<td colspan="3" valign="top" style="width:13.68%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;letter-spacing:-0.15pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.27&#8224;**</p></td>
<td valign="top" style="width:86.32%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1439725/000119312520262422/d937421dex1026.htm"><span style="text-decoration:underline;">First</span><span style="letter-spacing:-0.65pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Amendment</span><span style="letter-spacing:-0.6pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">to</span><span style="letter-spacing:-0.6pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">COVID-19</span><span style="letter-spacing:-0.6pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Testing</span><span style="letter-spacing:-0.65pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Laboratory</span><span style="letter-spacing:-0.6pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Services</span><span style="letter-spacing:-0.6pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Agreement</span><span style="letter-spacing:-0.6pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">by</span><span style="letter-spacing:-0.65pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">and</span><span style="letter-spacing:-0.6pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">between</span><span style="letter-spacing:-0.6pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Biodesix,</span><span style="letter-spacing:-0.6pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Inc.</span><span style="letter-spacing:-0.65pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">and</span><span style="letter-spacing:-0.6pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Centura</span><span style="letter-spacing:-0.6pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Health Corporation, dated April 23,</span><span style="letter-spacing:-0.2pt;text-decoration:underline;"> </span><span style="letter-spacing:-0.4pt;text-decoration:underline;">2020 </span><span style="text-decoration:underline;">(incorporated by reference to Exhibit 10.26 to the Company&#8217;s Registration Statement on Form S-1 filed with the SEC on October 2, 2020).</span></a></p></td>
</tr>
<tr>
<td colspan="3" valign="top" style="width:13.68%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;letter-spacing:-0.15pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.28&#8224;**</p></td>
<td valign="top" style="width:86.32%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1439725/000119312520262422/d937421dex1027.htm"><span style="text-decoration:underline;">Second</span><span style="letter-spacing:-0.6pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Amendment</span><span style="letter-spacing:-0.55pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">to</span><span style="letter-spacing:-0.65pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">COVID-19</span><span style="letter-spacing:-0.6pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Testing</span><span style="letter-spacing:-0.6pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Laboratory</span><span style="letter-spacing:-0.6pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Services</span><span style="letter-spacing:-0.55pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Agreement</span><span style="letter-spacing:-0.6pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">by</span><span style="letter-spacing:-0.55pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">and</span><span style="letter-spacing:-0.6pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">between</span><span style="letter-spacing:-0.6pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Biodesix,</span><span style="letter-spacing:-0.6pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Inc.</span><span style="letter-spacing:-0.6pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">and</span><span style="letter-spacing:-0.6pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Centura</span><span style="letter-spacing:-0.6pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Health Corporation, dated May 27,</span><span style="letter-spacing:-0.5pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">2020 (incorporated by reference to Exhibit 10.27 to the Company&#8217;s Registration Statement on Form S-1 filed with the SEC on October 2, 2020).</span></a></p></td>
</tr>
<tr>
<td colspan="3" valign="top" style="width:13.68%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;letter-spacing:-0.15pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.29&#8224;**</p></td>
<td valign="top" style="width:86.32%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1439725/000119312520262422/d937421dex1028.htm"><span style="text-decoration:underline;">Third</span><span style="letter-spacing:-0.65pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Amendment</span><span style="letter-spacing:-0.6pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">to</span><span style="letter-spacing:-0.65pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">COVID-19</span><span style="letter-spacing:-0.6pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Testing</span><span style="letter-spacing:-0.6pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Laboratory</span><span style="letter-spacing:-0.65pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Services</span><span style="letter-spacing:-0.6pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Agreement</span><span style="letter-spacing:-0.6pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">by</span><span style="letter-spacing:-0.65pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">and</span><span style="letter-spacing:-0.6pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">between</span><span style="letter-spacing:-0.6pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Biodesix,</span><span style="letter-spacing:-0.65pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Inc.</span><span style="letter-spacing:-0.6pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">and</span><span style="letter-spacing:-0.6pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Centura</span><span style="letter-spacing:-0.65pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Health Corporation, dated August 7,</span><span style="letter-spacing:0.55pt;text-decoration:underline;"> </span><span style="letter-spacing:-0.4pt;text-decoration:underline;">2020 </span><span style="text-decoration:underline;">(incorporated by reference to Exhibit 10.28 to the Company&#8217;s Registration Statement on Form S-1 filed with the SEC on October 2, 2020).</span></a></p></td>
</tr>
<tr>
<td colspan="3" valign="top" style="width:13.68%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;letter-spacing:-0.15pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.30&#8224;**</p></td>
<td valign="top" style="width:86.32%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1439725/000119312520262422/d937421dex1029.htm"><span style="text-decoration:underline;">Contract</span><span style="letter-spacing:-0.55pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Agreement</span><span style="letter-spacing:-0.55pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">between</span><span style="letter-spacing:-0.5pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Biodesix,</span><span style="letter-spacing:-0.55pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Inc.</span><span style="letter-spacing:-0.55pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">and</span><span style="letter-spacing:-0.5pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">the</span><span style="letter-spacing:-0.55pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Colorado</span><span style="letter-spacing:-0.55pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Department</span><span style="letter-spacing:-0.5pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">of</span><span style="letter-spacing:-0.55pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Public</span><span style="letter-spacing:-0.55pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Health</span><span style="letter-spacing:-0.5pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">and</span><span style="letter-spacing:-0.55pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Environment,</span><span style="letter-spacing:-0.55pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">dated</span><span style="letter-spacing:-0.5pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">September</span><span style="letter-spacing:-0.25pt;text-decoration:underline;"> </span><span style="letter-spacing:-0.75pt;text-decoration:underline;">11, </span><span style="letter-spacing:-0.4pt;text-decoration:underline;">2020 </span><span style="text-decoration:underline;">(incorporated by reference to Exhibit 10.29 to the Company&#8217;s Registration Statement on Form S-1 filed with the SEC on October 2, 2020).</span></a></p></td>
</tr>
<tr>
<td colspan="3" valign="top" style="width:13.68%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;letter-spacing:-0.15pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.31&#8224;**</p></td>
<td valign="top" style="width:86.32%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1439725/000119312520262422/d937421dex1030.htm"><span style="text-decoration:underline;">Material</span><span style="letter-spacing:-0.3pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Transfer</span><span style="letter-spacing:-0.25pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Agreement</span><span style="letter-spacing:-0.25pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">by</span><span style="letter-spacing:-0.25pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">and</span><span style="letter-spacing:-0.25pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">between</span><span style="letter-spacing:-0.25pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Biodesix,</span><span style="letter-spacing:-0.25pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Inc.</span><span style="letter-spacing:-0.25pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">and</span><span style="letter-spacing:-0.25pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Bio-Rad</span><span style="letter-spacing:-0.3pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Laboratories,</span><span style="letter-spacing:-0.25pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Inc.,</span><span style="letter-spacing:-0.25pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">dated</span><span style="letter-spacing:-0.25pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">March</span><span style="letter-spacing:-0.25pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">23,</span><span style="letter-spacing:-0.25pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">2020 (incorporated by reference to Exhibit 10.30 to the Company&#8217;s Registration Statement on Form S-1 filed with the SEC on October 2, 2020).</span></a></p></td>
</tr>
<tr>
<td colspan="3" valign="top" style="width:13.68%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;letter-spacing:-0.15pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.32&#8224;**</p></td>
<td valign="top" style="width:86.32%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1439725/000119312520262422/d937421dex1031.htm"><span style="text-decoration:underline;">First</span><span style="letter-spacing:-0.65pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Amendment</span><span style="letter-spacing:-0.65pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">to</span><span style="letter-spacing:-0.65pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Material</span><span style="letter-spacing:-0.65pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Transfer</span><span style="letter-spacing:-0.65pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Agreement</span><span style="letter-spacing:-0.65pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">by</span><span style="letter-spacing:-0.65pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">and</span><span style="letter-spacing:-0.65pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">between</span><span style="letter-spacing:-0.65pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Biodesix,</span><span style="letter-spacing:-0.65pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Inc.</span><span style="letter-spacing:-0.65pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">and</span><span style="letter-spacing:-0.65pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Bio-Rad</span><span style="letter-spacing:-0.7pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Laboratories,</span><span style="letter-spacing:-0.65pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Inc.</span><span style="letter-spacing:-0.6pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">dated</span><span style="letter-spacing:-0.65pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">April</span><span style="letter-spacing:-0.65pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">3,</span><span style="letter-spacing:-0.65pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">2020 (incorporated by reference to Exhibit 10.31 to the Company&#8217;s Registration Statement on Form S-1 filed with the SEC on October 2, 2020).</span></a></p></td>
</tr>
<tr>
<td colspan="3" valign="top" style="width:13.68%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;letter-spacing:-0.25pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.33&#8224;**</p></td>
<td valign="top" style="width:86.32%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1439725/000119312520262422/d937421dex1032.htm"><span style="text-decoration:underline;">Material</span><span style="letter-spacing:-0.4pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Transfer</span><span style="letter-spacing:-0.35pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Agreement</span><span style="letter-spacing:-0.35pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">by</span><span style="letter-spacing:-0.35pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">and</span><span style="letter-spacing:-0.35pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">between</span><span style="letter-spacing:-0.35pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Biodesix,</span><span style="letter-spacing:-0.35pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Inc.</span><span style="letter-spacing:-0.35pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">and</span><span style="letter-spacing:-0.35pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Bio-Rad</span><span style="letter-spacing:-0.35pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Laboratories,</span><span style="letter-spacing:-0.35pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Inc.,</span><span style="letter-spacing:-0.35pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">dated</span><span style="letter-spacing:-0.35pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">April</span><span style="letter-spacing:-0.35pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">17,</span><span style="letter-spacing:-0.35pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">2020 (incorporated by reference to Exhibit 10.32 to the Company&#8217;s Registration Statement on Form S-1 filed with the SEC on October 2, 2020).</span></a></p></td>
</tr>
<tr>
<td colspan="3" valign="top" style="width:13.68%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;letter-spacing:-0.25pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.34&#8224;**</p></td>
<td valign="top" style="width:86.32%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1439725/000119312520262422/d937421dex1033.htm"><span style="text-decoration:underline;">Price</span><span style="letter-spacing:-0.65pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Agreement</span><span style="letter-spacing:-0.65pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">by</span><span style="letter-spacing:-0.65pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">and</span><span style="letter-spacing:-0.65pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">between</span><span style="letter-spacing:-0.65pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Biodesix,</span><span style="letter-spacing:-0.65pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Inc.</span><span style="letter-spacing:-0.65pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">and</span><span style="letter-spacing:-0.7pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Bio-Rad</span><span style="letter-spacing:-0.65pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Laboratories,</span><span style="letter-spacing:-0.7pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Inc.,</span><span style="letter-spacing:-0.6pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">dated</span><span style="letter-spacing:-0.65pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">May</span><span style="letter-spacing:-0.65pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">12,</span><span style="letter-spacing:-0.65pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">2020 (incorporated by reference to Exhibit 10.33 to the Company&#8217;s Registration Statement on Form S-1 filed with the SEC on October 2, 2020).</span></a></p></td>
</tr>
<tr>
<td colspan="3" valign="top" style="width:13.68%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;letter-spacing:-0.25pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.35**</p></td>
<td valign="top" style="width:86.32%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1439725/000119312520273369/d937421dex1033.htm"><span style="text-decoration:underline;">Letter from Bio-Rad Laboratories, Inc. dated August 7,</span><span style="letter-spacing:-1.55pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">2020 (incorporated by reference to Exhibit 10.33 to the Company&#8217;s Registration Statement on Form S-1/A filed with the SEC on October 21, 2020).</span></a></p></td>
</tr>
<tr>
<td colspan="3" valign="top" style="width:13.68%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;letter-spacing:-0.25pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.36**</p></td>
<td valign="top" style="width:86.32%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1439725/000119312520273369/d937421dex1034.htm"><span style="text-decoration:underline;">Letter from Bio-Rad Laboratories, Inc. dated August 14,</span><span style="letter-spacing:-1.25pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">2020 (incorporated by reference to Exhibit 10.34 to the Company&#8217;s Registration Statement on Form S-1/A filed with the SEC on October 21, 2020).</span></a></p></td>
</tr>
<tr>
<td colspan="3" valign="top" style="width:13.68%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;letter-spacing:-0.3pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23.1</p></td>
<td valign="top" style="width:86.32%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="bdsx-ex231_271.htm"><span style="text-decoration:underline;">Consent of independent registered public accounting</span><span style="letter-spacing:-1.2pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">firm.</span></a></p></td>
</tr>
<tr>
<td colspan="3" valign="top" style="width:13.68%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;letter-spacing:-0.2pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24.1</p></td>
<td valign="top" style="width:86.32%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#POWER_ATTORNEY"><span style="text-decoration:underline;">Power of</span><span style="letter-spacing:-0.05pt;text-decoration:underline;"> </span><span style="text-decoration:underline;">Attorney (included on the signature page of this Form 10-K).</span></a><span style="text-decoration:underline;"> </span></p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">121</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td colspan="3" valign="top" style="width:13.68%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">31.1*</span></p></td>
<td valign="top" style="width:86.32%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="bdsx-ex311_269.htm"><span style="text-decoration:underline;">Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
</tr>
<tr>
<td colspan="3" valign="top" style="width:13.68%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">31.2* </span></p></td>
<td valign="top" style="width:86.32%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="bdsx-ex312_268.htm"><span style="text-decoration:underline;">Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
</tr>
<tr>
<td colspan="3" valign="top" style="width:13.68%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">32.1* </span></p></td>
<td valign="top" style="width:86.32%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="bdsx-ex321_267.htm"><span style="text-decoration:underline;">Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
</tr>
<tr>
<td colspan="3" valign="top" style="width:13.68%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">32.2*</span></p></td>
<td valign="top" style="width:86.32%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="bdsx-ex322_266.htm"><span style="text-decoration:underline;">Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
</tr>
<tr>
<td colspan="3" valign="top" style="width:13.68%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">101.INS*</span></p></td>
<td valign="top" style="width:86.32%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Instance Document &#8211; the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document.</p></td>
</tr>
<tr>
<td colspan="3" valign="top" style="width:13.68%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">101.SCH*</span></p></td>
<td valign="top" style="width:86.32%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Taxonomy Extension Schema Document</p></td>
</tr>
<tr>
<td colspan="3" valign="top" style="width:13.68%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">101.CAL*</span></p></td>
<td valign="top" style="width:86.32%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Taxonomy Extension Calculation Linkbase Document</p></td>
</tr>
<tr>
<td colspan="3" valign="top" style="width:13.68%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">101.DEF*</span></p></td>
<td valign="top" style="width:86.32%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Taxonomy Extension Definition Linkbase Document</p></td>
</tr>
<tr>
<td colspan="3" valign="top" style="width:13.68%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">101.LAB*</span></p></td>
<td valign="top" style="width:86.32%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Taxonomy Extension Label Linkbase Document</p></td>
</tr>
<tr>
<td colspan="3" valign="top" style="width:13.68%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">101.PRE*</span></p></td>
<td valign="top" style="width:86.32%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Taxonomy Extension Presentation Linkbase Document</p></td>
</tr>
<tr>
<td colspan="3" valign="top" style="width:13.68%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">104</span></p></td>
<td valign="top" style="width:86.32%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cover Page Interactive Data File (embedded within the Inline XBRL document)</p></td>
</tr>
</table></div>
<p style="border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-right:84.62%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8224;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Portions of this exhibit have been omitted as the Registrant has determined that the omitted information (i) is not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed.</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">+</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Indicates management contract or compensatory<span style="letter-spacing:0.4pt;"> </span>plan.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*&#160;&#160;&#160;&#160; Filed herewith.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">**&#160;&#160; Previously filed. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">122</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="SIGNATURES">SIGNATURES</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of Section&#160;13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized<span style="font-weight:bold;">.</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Biodesix, Inc.</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date:&#160;&#160;March 16, 2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;ROBIN HARPER COWIE</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Robin Harper Cowie</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Chief Financial Officer, Secretary and Treasurer</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="POWER_ATTORNEY">POWER OF ATTORNEY</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Each person whose signature appears below constitutes and appoints Scott Hutton and Robin Harper Cowie, and each of them, his or her true and lawful agent, proxy and attorney-in-fact, with full power of substitution and resubstitution,for him or her and in his or her name, place and stead, in any and all capacities, to file with the Securities and Exchange Commission this Form 10-K and any and all amendments and exhibits thereto, and all documents in connection therewith, granting unto each such attorney-in-fact and agent full power and authority to do and perform each and every act and thing necessary or appropriate to be done, as fully for all intents and purposes as he or she might or could do in person, hereby approving, ratifying and confirming all that such agent, proxy and attorney-in-fact or any of his or her substitutes may lawfully do or cause to be done by virtue hereof.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.98%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Name</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.3%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Title</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.64%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Date</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.98%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:4pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:4pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.3%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:4pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:4pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.64%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:4pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.98%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;SCOTT HUTTON</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">President, Chief Executive Officer (Principal Executive Officer</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:21.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> March 16, 2021</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.98%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Scott Hutton</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:4pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.98%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;ROBIN HARPER COWIE</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Chief Financial Officer, Secretary and Treasurer</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:21.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> March 16, 2021</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.98%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Robin Harper Cowie</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:4pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.98%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;JOHN PATIENCE</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Chairman and Director</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:21.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> March 16, 2021</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.98%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">John Patience</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:4pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.98%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;JEAN FRANCHI</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Director</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:21.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> March 16, 2021</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.98%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Jean Franchi</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:4pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.98%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;HANY MASSARANY</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Director</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:21.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> March 16, 2021</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.98%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Hany Massarany</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:4pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.98%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;JACK SCHULER</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Director</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:21.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> March 16, 2021</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.98%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Jack Schuler</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:4pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.98%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;MATTHEW STROBECK</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Director</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:21.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> March 16, 2021</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.98%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Matthew Strobeck, Ph.D.</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:4pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.98%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;CHARLES WATTS</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Director</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:21.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> March 16, 2021</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.98%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Charles Watts M.D.</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:4pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">123</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Item 8. Financial Statements and Supplementary Data</p>
<p style="text-align:center;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">BIODESIX, Inc.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">INDEX TO FINANCIAL STATEMENTS</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:93%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#REPORT_INDEPENDENT_REGISTERED_PUBLIC_ACC"><span style="text-decoration:underline;">Report of Independent Registered Public Accounting Firm</span></a></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-2</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:93%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:93%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#BALANCE_SHEETS"><span style="text-decoration:underline;">Balance Sheets as of December 31, 2020 and 2019</span></a></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-3</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:93%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:93%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#STATEMENTS_OPERATIONS"><span style="text-decoration:underline;">Statements of Operations for the Years ended December 31, 2020 and 2019</span></a></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-4</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:93%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:93%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#STATEMENTS_CONVERTIBLE_PREFERRED_STOCK_S"><span style="text-decoration:underline;">Statements of Convertible Preferred Stock and Stockholders&#8217; Equity (Deficit) for the Years ended December 31, 2020 and 2019</span></a></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-5</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:93%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:93%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#STATEMENTS_CASH_FLOWS"><span style="text-decoration:underline;">Statements of Cash Flows for the Years ended December 31, 2020 and 2019</span></a></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-6</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:93%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:93%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#NOTES_TO_FINANCIAL_STATEMENTS"><span style="text-decoration:underline;">Notes to Financial Statements</span></a></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-8</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-1</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="REPORT_INDEPENDENT_REGISTERED_PUBLIC_ACC">Report of Independent Registered Public Accounting Firm</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To the Board of Directors and Stockholders of </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Biodesix, Inc.:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:5pt;margin-top:0pt;text-indent:0%;;font-family:Times New Roman;font-style:italic;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Opinion on the Financial Statements</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have audited the accompanying balance sheets of Biodesix, Inc. (the Company) as of December&#160;31, 2020 and 2019, the related statements of operations, convertible preferred stock and stockholders&#8217; equity (deficit), and cash flows for each of the years in the two&#8209;year period ended December&#160;31, 2020, and the related notes (collectively, the financial statements). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December&#160;31, 2020 and 2019, and the results of its operations and its cash flows for each of the years in the two&#8209;year period ended December&#160;31, 2020, in conformity with U.S. generally accepted accounting principles.</p>
<p style="margin-bottom:5pt;margin-top:0pt;text-indent:0%;;font-family:Times New Roman;font-style:italic;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Basis for Opinion</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on these financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ KPMG LLP</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have served as the Company&#8217;s auditor since 2016</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Denver, Colorado</p>
<p style="margin-top:0pt;margin-bottom:10pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 16, 2021</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-2</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">BIODESIX, INC.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="BALANCE_SHEETS">Balance Sheets</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(in thousands, except share data)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">As of December 31,</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td colspan="8" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:99%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Assets</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000035" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_0001439725_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">62,126</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000036" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_0001439725_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,286</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts receivable, net</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000037" name="us-gaap:AccountsReceivableNetCurrent" contextRef="C_0001439725_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">15,304</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000038" name="us-gaap:AccountsReceivableNetCurrent" contextRef="C_0001439725_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,292</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other current assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000039" name="us-gaap:OtherAssetsCurrent" contextRef="C_0001439725_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">8,710</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000040" name="us-gaap:OtherAssetsCurrent" contextRef="C_0001439725_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,122</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000041" name="us-gaap:AssetsCurrent" contextRef="C_0001439725_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">86,140</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000042" name="us-gaap:AssetsCurrent" contextRef="C_0001439725_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">12,700</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non&#8209;current assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000043" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_0001439725_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,178</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000044" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_0001439725_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,120</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible assets, net</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000045" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="C_0001439725_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">13,260</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000046" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="C_0001439725_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">15,092</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other long-term assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000047" name="us-gaap:OtherAssetsNoncurrent" contextRef="C_0001439725_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,461</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000048" name="us-gaap:OtherAssetsNoncurrent" contextRef="C_0001439725_20191231" decimals="-3" scale="3">90</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Goodwill</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000049" name="us-gaap:Goodwill" contextRef="C_0001439725_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">15,031</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000050" name="us-gaap:Goodwill" contextRef="C_0001439725_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">15,031</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total non&#8209;current assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000051" name="us-gaap:AssetsNoncurrent" contextRef="C_0001439725_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">34,930</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000052" name="us-gaap:AssetsNoncurrent" contextRef="C_0001439725_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">32,333</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000053" name="us-gaap:Assets" contextRef="C_0001439725_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">121,070</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000054" name="us-gaap:Assets" contextRef="C_0001439725_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">45,033</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td colspan="8" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:99%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Liabilities, Convertible Preferred Stock and Stockholders' Equity (Deficit)</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current liabilities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts payable</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000055" name="us-gaap:AccountsPayableCurrent" contextRef="C_0001439725_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">8,964</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000056" name="us-gaap:AccountsPayableCurrent" contextRef="C_0001439725_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,717</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued liabilities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000057" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="C_0001439725_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">7,789</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000058" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="C_0001439725_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,180</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000059" name="us-gaap:ContractWithCustomerLiabilityCurrent" contextRef="C_0001439725_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,532</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000060" name="us-gaap:ContractWithCustomerLiabilityCurrent" contextRef="C_0001439725_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,283</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current portion of notes payable</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000061" name="us-gaap:NotesPayableToBankCurrent" contextRef="C_0001439725_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">11,840</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000062" name="us-gaap:NotesPayableToBankCurrent" contextRef="C_0001439725_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">12,159</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Put option liability</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000063" name="bdsx:PutOptionLiabilityCurrent" contextRef="C_0001439725_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,261</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current liabilities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000064" name="us-gaap:LiabilitiesCurrent" contextRef="C_0001439725_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">32,125</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000065" name="us-gaap:LiabilitiesCurrent" contextRef="C_0001439725_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">22,600</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non&#8209;current liabilities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrant liability</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000066" name="us-gaap:WarrantsAndRightsOutstanding" contextRef="C_0001439725_20191231" decimals="-3" scale="3">329</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Long&#8209;term notes payable</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000067" name="us-gaap:LongTermNotesPayable" contextRef="C_0001439725_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">15,926</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000068" name="us-gaap:LongTermNotesPayable" contextRef="C_0001439725_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">23,812</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contingent consideration</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000069" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" contextRef="C_0001439725_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">29,932</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000070" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" contextRef="C_0001439725_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">29,114</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other long-term liabilities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000071" name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="C_0001439725_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,921</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000072" name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="C_0001439725_20191231" decimals="-3" scale="3">358</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total non&#8209;current liabilities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000073" name="us-gaap:LiabilitiesNoncurrent" contextRef="C_0001439725_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">47,779</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000074" name="us-gaap:LiabilitiesNoncurrent" contextRef="C_0001439725_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">53,613</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000075" name="us-gaap:Liabilities" contextRef="C_0001439725_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">79,904</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000076" name="us-gaap:Liabilities" contextRef="C_0001439725_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">76,213</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commitments and contingencies</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000077">&#160;</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000078">&#160;</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Convertible preferred stock</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Convertible preferred stock, $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000092" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" contextRef="C_0001439725_20201231" decimals="INF"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000093" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" contextRef="C_0001439725_20191231" decimals="INF">0.001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="U_xbrlishares" id="F_000094" name="us-gaap:TemporaryEquitySharesAuthorized" contextRef="C_0001439725_20201231" decimals="INF">0</ix:nonFraction> (2020) and <ix:nonFraction unitRef="U_xbrlishares" id="F_000095" name="us-gaap:TemporaryEquitySharesAuthorized" contextRef="C_0001439725_20191231" decimals="INF" format="ixt:numdotdecimal">174,237,067</ix:nonFraction></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2019) authorized&#59; <ix:nonFraction unitRef="U_xbrlishares" id="F_000096" name="us-gaap:TemporaryEquitySharesIssued" contextRef="C_0001439725_20201231" decimals="INF"><ix:nonFraction unitRef="U_xbrlishares" id="F_000098" name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="C_0001439725_20201231" decimals="INF">0</ix:nonFraction></ix:nonFraction> (2020) and <ix:nonFraction unitRef="U_xbrlishares" id="F_000097" name="us-gaap:TemporaryEquitySharesIssued" contextRef="C_0001439725_20191231" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction unitRef="U_xbrlishares" id="F_000099" name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="C_0001439725_20191231" decimals="INF" format="ixt:numdotdecimal">118,766,273</ix:nonFraction></ix:nonFraction> (2019) issued and outstanding&#59; liquidation preference of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000100" name="us-gaap:TemporaryEquityLiquidationPreference" contextRef="C_0001439725_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">202,582</ix:nonFraction> (2019)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000079" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="C_0001439725_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">193,959</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stockholders' equity (deficit)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Preferred stock, $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000101" name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="C_0001439725_20201231" decimals="INF"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000102" name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="C_0001439725_20191231" decimals="INF">0.001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="U_xbrlishares" id="F_000103" name="us-gaap:PreferredStockSharesAuthorized" contextRef="C_0001439725_20201231" decimals="INF" format="ixt:numdotdecimal">5,000,000</ix:nonFraction> (2020) and <ix:nonFraction unitRef="U_xbrlishares" id="F_000104" name="us-gaap:PreferredStockSharesAuthorized" contextRef="C_0001439725_20191231" decimals="INF">0</ix:nonFraction> (2019) authorized&#59; <ix:nonFraction unitRef="U_xbrlishares" id="F_000105" name="us-gaap:PreferredStockSharesIssued" contextRef="C_0001439725_20201231" decimals="INF"><ix:nonFraction unitRef="U_xbrlishares" id="F_000106" name="us-gaap:PreferredStockSharesIssued" contextRef="C_0001439725_20191231" decimals="INF"><ix:nonFraction unitRef="U_xbrlishares" id="F_000107" name="us-gaap:PreferredStockSharesOutstanding" contextRef="C_0001439725_20201231" decimals="INF"><ix:nonFraction unitRef="U_xbrlishares" id="F_000108" name="us-gaap:PreferredStockSharesOutstanding" contextRef="C_0001439725_20191231" decimals="INF">0</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> (2020 and 2019) issued and outstanding</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000080">&#8212;</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000081">&#8212;</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock, $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000109" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_0001439725_20201231" decimals="INF"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000110" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_0001439725_20191231" decimals="INF">0.001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="U_xbrlishares" id="F_000111" name="us-gaap:CommonStockSharesAuthorized" contextRef="C_0001439725_20201231" decimals="INF" format="ixt:numdotdecimal">200,000,000</ix:nonFraction> (2020) and <ix:nonFraction unitRef="U_xbrlishares" id="F_000112" name="us-gaap:CommonStockSharesAuthorized" contextRef="C_0001439725_20191231" decimals="INF" format="ixt:numdotdecimal">190,000,000</ix:nonFraction> (2019) authorized&#59; <ix:nonFraction unitRef="U_xbrlishares" id="F_000113" name="us-gaap:CommonStockSharesIssued" contextRef="C_0001439725_20201231" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction unitRef="U_xbrlishares" id="F_000115" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_0001439725_20201231" decimals="INF" format="ixt:numdotdecimal">26,561,504</ix:nonFraction></ix:nonFraction> (2020) and <ix:nonFraction unitRef="U_xbrlishares" id="F_000114" name="us-gaap:CommonStockSharesIssued" contextRef="C_0001439725_20191231" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction unitRef="U_xbrlishares" id="F_000116" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_0001439725_20191231" decimals="INF" format="ixt:numdotdecimal">254,918</ix:nonFraction></ix:nonFraction> (2019) issued and outstanding</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000082" name="us-gaap:CommonStockValue" contextRef="C_0001439725_20201231" decimals="-3" scale="3">27</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000083" name="us-gaap:CommonStockValue" contextRef="C_0001439725_20191231" decimals="-3" scale="3">1</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additional paid&#8209;in capital</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000084" name="us-gaap:AdditionalPaidInCapital" contextRef="C_0001439725_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">299,953</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000085" name="us-gaap:AdditionalPaidInCapital" contextRef="C_0001439725_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,324</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated deficit</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000086" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="C_0001439725_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">258,814</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000087" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="C_0001439725_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">227,464</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stockholders' equity (deficit)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000088" name="us-gaap:StockholdersEquity" contextRef="C_0001439725_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">41,166</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000089" name="us-gaap:StockholdersEquity" contextRef="C_0001439725_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">225,139</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities, convertible preferred stock and stockholders' equity (deficit)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000090" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="C_0001439725_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">121,070</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000091" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="C_0001439725_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">45,033</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying Notes are an integral part of these financial statements.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-3</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">BIODESIX, INC.</p>
<p style="text-align:center;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="STATEMENTS_OPERATIONS">Statements of Operations </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(in thousands, except per share data)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenues</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000117" name="us-gaap:Revenues" contextRef="C_0001439725_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">45,557</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000118" name="us-gaap:Revenues" contextRef="C_0001439725_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">24,552</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating expenses:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;Direct costs and expenses</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000119" name="bdsx:DirectCostsAndExpenses" contextRef="C_0001439725_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">21,998</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000120" name="bdsx:DirectCostsAndExpenses" contextRef="C_0001439725_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">6,074</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;Research and development</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000121" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_0001439725_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">10,818</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000122" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_0001439725_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">10,468</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;Sales, marketing, general and administrative</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000123" name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="C_0001439725_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">34,857</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000124" name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="C_0001439725_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">30,637</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;Change in fair value of contingent consideration</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000125" name="bdsx:ChangeInFairValueOfContingentConsiderationExcludingAccretionExpense" contextRef="C_0001439725_20200101_20201231" decimals="-3" scale="3">818</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000126" name="bdsx:ChangeInFairValueOfContingentConsiderationExcludingAccretionExpense" contextRef="C_0001439725_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,114</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating expenses</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000127" name="us-gaap:OperatingExpenses" contextRef="C_0001439725_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">68,491</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000128" name="us-gaap:OperatingExpenses" contextRef="C_0001439725_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">51,293</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss from operations</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000129" name="us-gaap:OperatingIncomeLoss" contextRef="C_0001439725_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">22,934</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000130" name="us-gaap:OperatingIncomeLoss" contextRef="C_0001439725_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">26,741</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other income (expense):</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;Interest income</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000131" name="us-gaap:InterestIncomeOther" contextRef="C_0001439725_20200101_20201231" decimals="-3" scale="3">18</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000132" name="us-gaap:InterestIncomeOther" contextRef="C_0001439725_20190101_20191231" decimals="-3" scale="3">55</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;Interest expense</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000133" name="us-gaap:InterestExpense" contextRef="C_0001439725_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">7,604</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000134" name="us-gaap:InterestExpense" contextRef="C_0001439725_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,008</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;Change in fair value of warrant liability</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000135" name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="C_0001439725_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,252</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000136" name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="C_0001439725_20190101_20191231" decimals="-3" scale="3">104</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;Change in fair value of put option liability</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000137" name="bdsx:ChangeInFairValueOfPutOptionLiability" contextRef="C_0001439725_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,000</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;Other income, net</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000138" name="us-gaap:OtherNonoperatingIncome" contextRef="C_0001439725_20200101_20201231" decimals="-3" scale="3">422</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000139" name="us-gaap:OtherNonoperatingIncome" contextRef="C_0001439725_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,072</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total other expense</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000140" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="C_0001439725_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">8,416</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000141" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="C_0001439725_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">3,985</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000142" name="us-gaap:NetIncomeLoss" contextRef="C_0001439725_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">31,350</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000143" name="us-gaap:NetIncomeLoss" contextRef="C_0001439725_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">30,726</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share, basic and diluted</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000144" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="C_0001439725_20200101_20201231" decimals="2" sign="-">6.48</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000145" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="C_0001439725_20190101_20191231" decimals="2" sign="-">126.97</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average shares outstanding, basic and diluted</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000146" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="C_0001439725_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,838</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000147" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="C_0001439725_20190101_20191231" decimals="-3" scale="3">242</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying Notes are an integral part of these financial statements.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-4</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">BIODESIX, INC.</p>
<p style="text-align:center;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="STATEMENTS_CONVERTIBLE_PREFERRED_STOCK_S">Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:37.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Convertible Preferred Stock</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Common Stock</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.86%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Additional</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Paid&#8209;In</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.86%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accumulated</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.86%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stockholders'</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:37.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.86%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Capital</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.86%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Deficit</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.86%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Deficit</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance &#8209; January 1, 2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000148" name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="C_0001439725_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20181231" decimals="INF" format="ixt:numdotdecimal">110,071</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000149" name="us-gaap:StockholdersEquity" contextRef="C_0001439725_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">183,962</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000150" name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="C_0001439725_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181231" decimals="INF">215</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000151" name="us-gaap:StockholdersEquity" contextRef="C_0001439725_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181231" decimals="-3" scale="3">1</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000152" name="us-gaap:StockholdersEquity" contextRef="C_0001439725_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,107</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000153" name="us-gaap:StockholdersEquity" contextRef="C_0001439725_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">196,738</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000154" name="us-gaap:StockholdersEquity" contextRef="C_0001439725_20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">194,630</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock issued upon exercise of stock options</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000155" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="C_0001439725_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231" decimals="INF">40</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000156" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_0001439725_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231" decimals="-3" scale="3">47</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000157" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_0001439725_20190101_20191231" decimals="-3" scale="3">47</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of Series H convertible preferred stock, in February and March 2019 at $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000199" name="bdsx:SaleOfStockTemporaryEquityPricePerShare" contextRef="C_0001439725_us-gaapStatementClassOfStockAxis_us-gaapSeriesHPreferredStockMember_20190201_20190228" decimals="INF"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000200" name="bdsx:SaleOfStockTemporaryEquityPricePerShare" contextRef="C_0001439725_us-gaapStatementClassOfStockAxis_us-gaapSeriesHPreferredStockMember_20190301_20190331" decimals="INF">1.15</ix:nonFraction></ix:nonFraction> per share, net of issuance costs of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000201" name="bdsx:TemporaryEquityIssuanceCosts" contextRef="C_0001439725_us-gaapStatementClassOfStockAxis_us-gaapSeriesHPreferredStockMember_20190101_20191231" decimals="-3" scale="3">3</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000158" name="bdsx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001439725_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20190101_20191231" decimals="INF" format="ixt:numdotdecimal">8,695</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000159" name="us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues" contextRef="C_0001439725_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">9,997</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock&#8209;based compensation expense</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000160" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0001439725_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231" decimals="-3" scale="3">170</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000161" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0001439725_20190101_20191231" decimals="-3" scale="3">170</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:37.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss and comprehensive loss</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000162" name="us-gaap:NetIncomeLoss" contextRef="C_0001439725_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">30,726</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000163" name="us-gaap:NetIncomeLoss" contextRef="C_0001439725_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">30,726</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance &#8209; December 31, 2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000164" name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="C_0001439725_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20191231" decimals="INF" format="ixt:numdotdecimal">118,766</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000165" name="us-gaap:StockholdersEquity" contextRef="C_0001439725_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">193,959</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000166" name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="C_0001439725_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231" decimals="INF">255</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000167" name="us-gaap:StockholdersEquity" contextRef="C_0001439725_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231" decimals="-3" scale="3">1</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000168" name="us-gaap:StockholdersEquity" contextRef="C_0001439725_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,324</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000169" name="us-gaap:StockholdersEquity" contextRef="C_0001439725_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">227,464</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000170" name="us-gaap:StockholdersEquity" contextRef="C_0001439725_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">225,139</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock issued upon exercise of stock options</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000171" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="C_0001439725_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231" decimals="INF">368</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000172" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_0001439725_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,340</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000173" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_0001439725_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,340</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock&#8209;based compensation expense</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000174" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0001439725_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,709</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000175" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0001439725_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,709</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common stock in initial public offering, net of discounts and commission of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000202" name="us-gaap:CapitalUnitsDeductionsFromTotalCostToInvestors" contextRef="C_0001439725_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,040</ix:nonFraction> and direct offering costs of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000203" name="us-gaap:CapitalUnitsTotalCostToInvestors" contextRef="C_0001439725_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,203</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000176" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001439725_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">4,000</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000177" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0001439725_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231" decimals="-3" scale="3">4</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000178" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0001439725_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">63,753</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000179" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0001439725_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">63,757</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Conversion of preferred stock into common stock upon initial public offering</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlishares" id="F_000180" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="C_0001439725_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20200101_20201231" decimals="INF" sign="-" format="ixt:numdotdecimal">118,766</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000181" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="C_0001439725_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">193,959</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000182" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="C_0001439725_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">20,091</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000183" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="C_0001439725_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231" decimals="-3" scale="3">20</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000184" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="C_0001439725_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">193,939</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000185" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="C_0001439725_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">193,959</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Conversion of convertible debt into common stock upon initial public offering</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000186" name="bdsx:StockIssuedDuringPeriodSharesConversionOfConvertibleSecuritiesCommonStock" contextRef="C_0001439725_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">1,848</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000187" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" contextRef="C_0001439725_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231" decimals="-3" scale="3">2</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000188" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" contextRef="C_0001439725_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">26,614</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000189" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" contextRef="C_0001439725_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">26,616</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reclassification of preferred stock warrant liability and put option into additional paid-in capital upon initial public offering</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000190" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="C_0001439725_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">8,274</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000191" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="C_0001439725_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">8,274</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:37.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss and comprehensive loss</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000192" name="us-gaap:NetIncomeLoss" contextRef="C_0001439725_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">31,350</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000193" name="us-gaap:NetIncomeLoss" contextRef="C_0001439725_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">31,350</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:37.54%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance &#8209; December 31, 2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000194" name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="C_0001439725_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231" decimals="INF" format="ixt:numdotdecimal">26,562</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000195" name="us-gaap:StockholdersEquity" contextRef="C_0001439725_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231" decimals="-3" scale="3">27</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000196" name="us-gaap:StockholdersEquity" contextRef="C_0001439725_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">299,953</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000197" name="us-gaap:StockholdersEquity" contextRef="C_0001439725_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">258,814</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000198" name="us-gaap:StockholdersEquity" contextRef="C_0001439725_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">41,166</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying Notes are an integral part of these financial statements.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-5</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">BIODESIX, INC.</p>
<p style="text-align:center;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="STATEMENTS_CASH_FLOWS">Statements of Cash Flows </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash flows from operating activities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000204" name="us-gaap:ProfitLoss" contextRef="C_0001439725_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">31,350</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000205" name="us-gaap:ProfitLoss" contextRef="C_0001439725_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">30,726</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Adjustments to reconcile net loss to net cash, cash equivalents, and</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; restricted cash used in operating activities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation and amortization</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000206" name="us-gaap:DepreciationAndAmortization" contextRef="C_0001439725_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,903</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000207" name="us-gaap:DepreciationAndAmortization" contextRef="C_0001439725_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,793</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amortization of convertible notes debt discount</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000208" name="us-gaap:AmortizationOfDebtDiscountPremium" contextRef="C_0001439725_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,389</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000209" name="us-gaap:AmortizationOfDebtDiscountPremium" contextRef="C_0001439725_20190101_20191231" decimals="-3" scale="3">262</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock&#8209;based compensation expense</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000210" name="us-gaap:ShareBasedCompensation" contextRef="C_0001439725_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,709</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000211" name="us-gaap:ShareBasedCompensation" contextRef="C_0001439725_20190101_20191231" decimals="-3" scale="3">170</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in fair value of warrant liability</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000212" name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="C_0001439725_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,252</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000213" name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="C_0001439725_20190101_20191231" decimals="-3" scale="3">104</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in contingent consideration</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000214" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" contextRef="C_0001439725_20200101_20201231" decimals="-3" scale="3">818</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000215" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" contextRef="C_0001439725_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,114</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in fair value of put option</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000216" name="bdsx:ChangeInFairValueOfPutOptionLiability" contextRef="C_0001439725_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,000</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued interest on notes payable and convertible notes payable</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000217" name="bdsx:AccruedInterestOnNotesPayableAndConvertibleNotesPayable" contextRef="C_0001439725_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,226</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000218" name="bdsx:AccruedInterestOnNotesPayableAndConvertibleNotesPayable" contextRef="C_0001439725_20190101_20191231" decimals="-3" scale="3">799</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amortization of debt issuance costs</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000219" name="us-gaap:AmortizationOfFinancingCosts" contextRef="C_0001439725_20200101_20201231" decimals="-3" scale="3">144</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000220" name="us-gaap:AmortizationOfFinancingCosts" contextRef="C_0001439725_20190101_20191231" decimals="-3" scale="3">144</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Provision for doubtful accounts</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000221" name="us-gaap:ProvisionForDoubtfulAccounts" contextRef="C_0001439725_20200101_20201231" decimals="-3" scale="3">296</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000222" name="us-gaap:ProvisionForDoubtfulAccounts" contextRef="C_0001439725_20190101_20191231" decimals="-3" scale="3">246</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss on disposals of assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000223" name="us-gaap:GainLossOnDispositionOfAssets1" contextRef="C_0001439725_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">48</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000224" name="us-gaap:GainLossOnDispositionOfAssets1" contextRef="C_0001439725_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">13</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Changes in operating assets and liabilities, net of assets acquired and</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; liabilities assumed in acquisitions:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts receivable</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000225" name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="C_0001439725_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">10,308</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000226" name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="C_0001439725_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,646</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other current assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000227" name="us-gaap:IncreaseDecreaseInOtherCurrentAssets" contextRef="C_0001439725_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">6,588</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000228" name="us-gaap:IncreaseDecreaseInOtherCurrentAssets" contextRef="C_0001439725_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">1</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other long-term assets and liabilities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000229" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet" contextRef="C_0001439725_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,808</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000230" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet" contextRef="C_0001439725_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">16</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts payable and other accrued liabilities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000231" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="C_0001439725_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">11,654</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000232" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="C_0001439725_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,193</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000233" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" contextRef="C_0001439725_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,249</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000234" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" contextRef="C_0001439725_20190101_20191231" decimals="-3" scale="3">791</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash and cash equivalents and restricted cash used in operating activities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000235" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="C_0001439725_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">21,366</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000236" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="C_0001439725_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">21,726</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash flows from investing activities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchase of property and equipment</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000237" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="C_0001439725_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,945</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000238" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="C_0001439725_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,310</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Patent costs and intangible asset acquisition, net</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000239" name="bdsx:PaymentsForProceedsFromPatentCostsAndIntangibleAssetAcquisitionNet" contextRef="C_0001439725_20200101_20201231" decimals="-3" scale="3">232</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000240" name="bdsx:PaymentsForProceedsFromPatentCostsAndIntangibleAssetAcquisitionNet" contextRef="C_0001439725_20190101_20191231" decimals="-3" scale="3">106</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Payments to acquire Oncimmune assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000241" name="bdsx:PaymentsToAcquireOncimmune" contextRef="C_0001439725_20200101_20201231" decimals="-3" scale="3">750</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000242" name="bdsx:PaymentsToAcquireOncimmune" contextRef="C_0001439725_20190101_20191231" decimals="-3" scale="3">456</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash and cash equivalents and restricted cash used in investing activities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000243" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="C_0001439725_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">2,927</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000244" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="C_0001439725_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">1,872</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash flows from financing activities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from initial public offering</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000245" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="C_0001439725_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">72,000</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from exercise of common stock options</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000246" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="C_0001439725_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,340</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000247" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="C_0001439725_20190101_20191231" decimals="-3" scale="3">47</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from issuance of series H preferred stock</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000248" name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" contextRef="C_0001439725_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">10,000</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from issuances of convertible notes payable</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000249" name="us-gaap:ProceedsFromConvertibleDebt" contextRef="C_0001439725_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">12,955</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000250" name="us-gaap:ProceedsFromConvertibleDebt" contextRef="C_0001439725_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">13,044</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from paycheck protection program note payable</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000251" name="us-gaap:ProceedsFromNotesPayable" contextRef="C_0001439725_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,085</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Equity financing costs</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000252" name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="C_0001439725_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">8,243</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000253" name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="C_0001439725_20190101_20191231" decimals="-3" scale="3">3</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000254" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" contextRef="C_0001439725_20200101_20201231" decimals="-3" sign="-" scale="3">6</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000255" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" contextRef="C_0001439725_20190101_20191231" decimals="-3" sign="-" scale="3">116</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash and cash equivalents and restricted cash provided by financing activities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000256" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="C_0001439725_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">81,131</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000257" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="C_0001439725_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">22,972</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net increase (decrease) in cash and cash equivalents and restricted cash</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000258" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="C_0001439725_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">56,838</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000259" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="C_0001439725_20190101_20191231" decimals="-3" sign="-" scale="3">626</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash, cash equivalents, and restricted cash &#8209; beginning of period</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000260" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_0001439725_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,468</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000261" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_0001439725_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">6,094</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash, cash equivalents, and restricted cash &#8209; end of period</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000262" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_0001439725_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">62,306</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000263" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_0001439725_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,468</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying Notes are an integral part of these financial statements.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-6</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">BIODESIX, INC.</p>
<p style="text-align:center;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Statements of Cash Flows </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Continued from the previous page)</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Supplemental cash flow information<span style="font-weight:normal;">:</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Conversion of preferred stock into common stock</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000264" name="bdsx:ConversionOfPreferredStockIntoCommonStock" contextRef="C_0001439725_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">193,959</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Conversion of convertible notes and accrued interest into common stock</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000265" name="us-gaap:ConversionOfStockAmountConverted1" contextRef="C_0001439725_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">26,616</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reclassification of put option liability to additional paid-in capital</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000266" name="bdsx:ReclassificationOfPutOptionLiabilityToAdditionalPaidInCapital" contextRef="C_0001439725_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">6,650</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Value of put option recorded at issuance of convertible debt payable</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000267" name="bdsx:ValueOfPutOptionRecordedAtIssuanceOfConvertibleNotesPayable" contextRef="C_0001439725_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,389</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000268" name="bdsx:ValueOfPutOptionRecordedAtIssuanceOfConvertibleNotesPayable" contextRef="C_0001439725_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,261</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash paid for interest</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000269" name="us-gaap:InterestPaidNet" contextRef="C_0001439725_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,844</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000270" name="us-gaap:InterestPaidNet" contextRef="C_0001439725_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,800</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reclassification of warrant liability to additional paid-in capital</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000271" name="bdsx:ReclassificationOfWarrantLiabilityToAdditionalPaidInCapital" contextRef="C_0001439725_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,624</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued business combination payments</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000272" name="us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" contextRef="C_0001439725_20190101_20191231" decimals="-3" scale="3">750</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash paid for income taxes</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying Notes are an integral part of these financial statements.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-7</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">BIODESIX, INC.</span></p>
<p style="text-align:center;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="NOTES_TO_FINANCIAL_STATEMENTS">Notes to Financial Statements</p><ix:nonNumeric id="F_000274" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" contextRef="C_0001439725_20200101_20201231" escape="true" continuedAt="F_000274_dcnt_f7c04d3c-459e-4d74-b338-97412554c533">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note 1 &#8211; Organization and Description of Business </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Biodesix, Inc. (the &#8220;Company&#8221;, &#8220;Biodesix&#8221;, &#8220;we&#8221; and &#8220;our&#8221;), formerly Elston Technologies, Inc., was incorporated in Delaware in 2005. The Company&#8217;s headquarters are in Colorado, with laboratories in Colorado and Kansas. The Company conducts all of its operations within a single legal entity. Biodesix is a data-driven diagnostic solutions company leveraging state of the art technologies with its proprietary artificial intelligence platform to discover, develop, and commercialize solutions for clinical unmet needs, with a primary focus in lung disease. In addition to diagnostic tests, the Company provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company performs its blood-based diagnostic tests for lung cancer in its laboratory facilities, which are located in Boulder, Colorado and De Soto, Kansas. In May 2020, the Federal Drug Administration (FDA) authorized performance of Bio-Rad SARS-CoV-2 Droplet Digital&#8482; <span style="letter-spacing:-0.15pt;">polymerase chain reaction </span>(ddPCR) test to detect Coronavirus Disease 2019 (COVID-19) infection. In April 2020, the FDA authorized our Platelia SARS-CoV-2 Total Ab test to detect COVID-19 antibodies. Medical products that are granted an Emergency Use Authorization (EUA) are only permitted to commercialize their products under the terms and conditions provided in the authorization. The FDA may revoke an EUA where it is determined that the underlying health emergency no longer exists or warrants such authorization, if the conditions for the issuance of the EUA are no longer met, or if other circumstances make revocation appropriate to protect the public health or safety.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Blood-Based Lung Tests</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company offers <ix:nonFraction unitRef="U_bdsxTest" id="F_000343" name="bdsx:NumberOfCancerTest" contextRef="C_0001439725_20200101_20201231" decimals="INF" format="ixt-sec:numwordsen">four</ix:nonFraction> blood-based lung cancer tests across the lung cancer continuum of care:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;color:#000000;">Nodify XL2&#174; </span><span style="color:#000000;">and </span><span style="font-style:italic;color:#000000;">Nodify CDT&#8482; </span><span style="color:#000000;">tests, marketed as part of our Nodify Lung</span><span style="font-style:italic;color:#000000;">&#8482; </span><span style="color:#000000;">Nodule Risk Assessment testing strategy, assess the risk of lung cancer to help identify the most appropriate treatment </span><span style="letter-spacing:-0.15pt;color:#000000;">pathway. </span><span style="letter-spacing:-0.4pt;color:#000000;">We </span><span style="color:#000000;">believe we are the only company to offer <ix:nonFraction unitRef="U_bdsxTest" id="F_000344" name="bdsx:NumberOfCommercialBloodBasedTest" contextRef="C_0001439725_20200101_20201231" decimals="INF" format="ixt-sec:numwordsen">two</ix:nonFraction> commercial blood-based tests to help physicians reclassify risk of malignancy in patients with suspicious lung</span><span style="letter-spacing:-1.2pt;color:#000000;"> </span><span style="color:#000000;">nodules</span>.</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;color:#000000;">GeneStrat&#174; </span><span style="color:#000000;">and </span><span style="font-style:italic;letter-spacing:-0.15pt;color:#000000;">VeriStrat&#174; </span><span style="color:#000000;">tests, marketed as part of our Biodesix Lung Reflex</span><span style="font-style:italic;color:#000000;">&#174; </span><span style="color:#000000;">testing strategy, are used following diagnosis of lung cancer to measure the presence of mutations in the tumor and the</span><span style="letter-spacing:-0.75pt;color:#000000;"> </span><span style="color:#000000;">state of the patient&#8217;s immune system to establish the patient&#8217;s prognosis and help guide treatment decisions. The GeneStrat tumor profiling test and the VeriStrat immune profiling test have a three-day average turnaround time, providing physicians with timely results to facilitate treatment decisions.</span></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">COVID-19 Tests<span style="font-weight:normal;">&#160;&#160;</span></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Using the Bio-Rad <span style="letter-spacing:-0.15pt;">SARS-CoV-2 </span>ddPCR test and the Platelia <span style="letter-spacing:-0.15pt;">SARS-CoV-2 Total </span>Ab tests, we operate and have commercialized the Biodesix <span style="letter-spacing:-0.15pt;">WorkSafe </span>testing<span style="letter-spacing:-1.6pt;"> </span>program. The Company offers <ix:nonFraction unitRef="U_bdsxTest" id="F_000345" name="bdsx:NumberOfSARSCoV2Test" contextRef="C_0001439725_20200101_20201231" decimals="INF" format="ixt-sec:numwordsen">two</ix:nonFraction> SARS-CoV-2 tests:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;color:#000000;">Bio-Rad SARS-CoV-2 ddPCR </span><span style="color:#000000;">test, which is authorized by the FDA to be performed by Clinical Laboratory Institute Amendments (CLIA) authorized laboratories that perform high complexity tests. The ddPCR test is designed to detect the presence of infection by the SARS-CoV-2 virus.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;color:#000000;">Platelia SARS-CoV-2 Total Ab </span><span style="color:#000000;">test, which is an antibody test, authorized by the FDA, intended for detecting a B-cell immune response to </span><span style="letter-spacing:-0.15pt;color:#000000;">SARS-CoV-2, </span><span style="color:#000000;">indicating recent or prior infection.</span></p></td></tr></table></div>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These tests are utilized by healthcare providers, including hospitals and nursing homes, and are also offered to businesses and educational systems to assist in their back-to-work or back-to-school strategies, a crucial element of restarting economic activity.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In developing the Company's products, the Company has built or gained access to unique biorepositories, proprietary technology, and bioinformatics that it believes are important to the development of new targeted therapies, determining clinical trial eligibility and guiding treatment selection.</p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-8</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000274_dcnt_f7c04d3c-459e-4d74-b338-97412554c533">
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All of the Company&#8217;s testing services are made available through its clinical laboratories.</span></p><ix:nonNumeric id="F_000292" name="bdsx:ReverseStockSplitPolicyTextBlock" contextRef="C_0001439725_20200101_20201231" escape="true">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Reverse Stock Split</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">O<span style="color:#000000;">n October 19, 2020, the Company obtained approval of an amended and restated certificate of incorporation effecting a <ix:nonNumeric id="F_000346" name="us-gaap:StockholdersEquityReverseStockSplit" contextRef="C_0001439725_20200101_20201231"><ix:nonFraction unitRef="U_xbrlipure" id="F_000347" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" contextRef="C_0001439725_20201019_20201019" decimals="7">0.1684664</ix:nonFraction>-for-1</ix:nonNumeric> reverse stock split of its issued and outstanding common stock as converted. All common shares, stock options, and per share information presented in these financial statements and notes thereto have been adjusted, where applicable, to reflect the reverse stock split on a retroactive basis for all periods</span> presented. </p></ix:nonNumeric><ix:nonNumeric id="F_000293" name="bdsx:ApprovalOfAmendedAndRestatedCertificateOfIncorporationPolicyTextBlock" contextRef="C_0001439725_20200101_20201231" escape="true">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Approval of Amended and Restated Certificate of Incorporation</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In October 2020, the Company&#8217;s Board of Directors and stockholders approved an amended and restated certificate of incorporation, which authorized <ix:nonFraction unitRef="U_xbrlishares" id="F_000348" name="us-gaap:CommonStockSharesAuthorized" contextRef="C_0001439725_20201031" decimals="INF" format="ixt:numdotdecimal">200,000,000</ix:nonFraction> shares of common stock, par value $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000349" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_0001439725_20201031" decimals="INF">0.001</ix:nonFraction> per share, and <ix:nonFraction unitRef="U_xbrlishares" id="F_000350" name="us-gaap:PreferredStockSharesAuthorized" contextRef="C_0001439725_20201031" decimals="INF" format="ixt:numdotdecimal">5,000,000</ix:nonFraction> shares of preferred stock, par value $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000351" name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="C_0001439725_20201031" decimals="INF">0.001</ix:nonFraction> per share. The amended and restated certificate of incorporation became effective on October 30, 2020.</p></ix:nonNumeric><ix:nonNumeric id="F_000294" name="bdsx:InitialPublicOfferingIPOPolicyTextBlock" contextRef="C_0001439725_20200101_20201231" escape="true">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Initial Public Offering</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On October 27, 2020, the Company completed its initial public offering, in which it issued and sold <ix:nonFraction unitRef="U_xbrlishares" id="F_000352" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001439725_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20201027_20201027" decimals="INF" format="ixt:numdotdecimal">4,000,000</ix:nonFraction> shares of its common stock at a public offering price of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000353" name="us-gaap:SharesIssuedPricePerShare" contextRef="C_0001439725_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20201027" decimals="INF">18.00</ix:nonFraction> per share. The Company received net proceeds of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000354" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="C_0001439725_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20201027_20201027" decimals="-5" scale="6">63.8</ix:nonFraction> million after deducting underwriting discounts and commissions and offering expenses payable by the Company. In addition, in connection with the initial public offering, all shares of the Company&#8217;s then-outstanding convertible preferred stock and convertible notes payable were automatically converted into <ix:nonFraction unitRef="U_xbrlishares" id="F_000355" name="bdsx:ConvertiblePreferredStockAndConvertibleNotesPayableConvertedToCommonStock" contextRef="C_0001439725_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20201027_20201027" decimals="INF" format="ixt:numdotdecimal">21,939,025</ix:nonFraction> shares of common stock, and all then outstanding warrants to purchase the Company&#8217;s Series G convertible preferred stock were automatically converted into warrants to purchase <ix:nonFraction unitRef="U_xbrlishares" id="F_000356" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="C_0001439725_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20201027" decimals="INF" format="ixt:numdotdecimal">103,326</ix:nonFraction> shares of the Company&#8217;s common stock.</p></ix:nonNumeric></ix:continuation><ix:nonNumeric id="F_000275" name="us-gaap:SignificantAccountingPoliciesTextBlock" contextRef="C_0001439725_20200101_20201231" escape="true" continuedAt="F_000275_dcnt_0e212b1f-9427-4691-89a7-51683fb60a53">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note 2 &#8211; Summary of Significant Accounting Policies</p><ix:nonNumeric id="F_000295" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" contextRef="C_0001439725_20200101_20201231" escape="true">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Basis of Presentation</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#212529;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s financial statements have been prepared in accordance with accounting principles generally accepted in the United States (U.S. GAAP). <span style="color:#000000;"><ix:nonNumeric id="F_000359" name="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsDescription" contextRef="C_0001439725_srtRestatementAxis_srtRevisionOfPriorPeriodErrorCorrectionAdjustmentMember_20200101_20201231">The 2019 balance sheet has been updated to reflect an increase in goodwill and a reduction in accumulated deficit of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000357" name="us-gaap:GoodwillPeriodIncreaseDecrease" contextRef="C_0001439725_srtRestatementAxis_srtRevisionOfPriorPeriodErrorCorrectionAdjustmentMember_20190101_20191231" decimals="-5" scale="6">3.4</ix:nonFraction> million related to the correction of an immaterial error recorded as part of the acquisition of Integrated Diagnostics, Inc. in 2018.</ix:nonNumeric></span>&#160;&#160;The Company determined that the reduction in the preexisting valuation allowance resulting from the acquisition should have been reflected as an income benefit within the tax provision rather than as a reduction in goodwill.&#160;&#160;The correction of the immaterial error had no impact on our 2020 or 2019 results of operations.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain prior period amounts have been reclassified to conform to the current period presentation.</p></ix:nonNumeric><ix:nonNumeric id="F_000296" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" contextRef="C_0001439725_20200101_20201231" escape="true">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Segment Reporting</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The chief operating decision maker for the Company is the Chief Executive Officer, who reviews financial information for purposes of allocating resources and assessing financial performance.&#160;&#160;The Company has a <span style="-sec-ix-hidden:F_000360">single</span> operating segment focused on providing diagnostic testing services to customers. Substantially all of the Company&#8217;s revenue and all long-lived assets were derived or located in the United States for the years ended December 31, 2020 and 2019.</p></ix:nonNumeric><ix:nonNumeric id="F_000297" name="us-gaap:UseOfEstimates" contextRef="C_0001439725_20200101_20201231" escape="true" continuedAt="F_000297_dcnt_e0aa883d-58cf-4765-9a6e-d20b5b7c6ef7">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Significant items subject to such estimates include: revenue recognition&#59; the useful lives of property and equipment&#59; the recoverability of long-lived assets&#59; the estimation of the fair value of intangible assets&#59; the valuation of contingent consideration related to a business combination&#59; stock options&#59; income tax uncertainties, including a valuation allowance for deferred tax assets&#59; and contingencies. The Company bases these estimates on historical and anticipated results, trends, and various other assumptions that the Company believes are reasonable under the circumstances, including assumptions as to future events. These estimates form the basis for making judgments about the carrying values of assets and liabilities and recognized revenue and expenses that are not readily apparent from other sources. Actual results could differ from those estimates and assumptions.</p></ix:nonNumeric></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-9</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000275_dcnt_0e212b1f-9427-4691-89a7-51683fb60a53" continuedAt="F_000275_dcnt_6f33d6ed-8a99-4309-a7cc-761f9d7d7ed0"><ix:continuation id="F_000297_dcnt_e0aa883d-58cf-4765-9a6e-d20b5b7c6ef7">
</ix:continuation><ix:nonNumeric id="F_000298" name="us-gaap:RevenueRecognitionPolicyTextBlock" contextRef="C_0001439725_20200101_20201231" escape="true">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Revenue Recognition</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company generates revenues from (i) diagnostic tests and (ii) assay development and testing services (services revenue).</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Diagnostic test revenues consist of blood-based lung tests and COVID-19 tests, which are recognized in the amount expected to be received in exchange for diagnostic tests when the diagnostic tests are delivered. The Company determines the transaction price related to its blood-based lung diagnostic test contracts using a portfolio approach by considering the nature of the payer and historical price concessions granted to groups of customers. The transaction price associated with COVID-19 testing arrangements are determined on the basis of the individual contract with each customer.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Services revenue consists of various types of tests or other scientific services for a purpose as defined by any individual customer, which are often larger biopharmaceutical companies, as defined by a written agreement between the Company and the customer. These services are generally completed upon the delivery of testing results, or achievement of contractual milestone(s) as defined in the customer agreements. Revenue for these services is recognized upon delivery of the completed test results, or upon completion of the contractual milestone(s). </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes revenues related to blood-based lung diagnostic billings based on estimates of the amounts ultimately expected to be collected from customers on a portfolio approach as discussed above. In determining the amount to accrue for a delivered test, the Company considers factors such as payment history, payer coverage, whether there is a reimbursement contract between the payer and the Company, payment as a percentage of agreed upon rate (if applicable), amount paid per test and any current developments or changes that could impact reimbursement. Variable consideration, if any, is estimated based on an analysis of historical experience and adjusted as better estimates become available. These estimates require significant judgment by management.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company also provides services to patients with whom the Company does not have contracts as defined in Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC 606). The Company recognizes revenue for these patients when contracts as defined in ASC 606 are established at the amount of consideration to which it expects to be entitled, or when the Company receives substantially all of the consideration subsequent to satisfaction and delivery of the performance obligations.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">See Note 13 &#8212; <span style="font-style:italic;">Revenue</span> for additional information.</p></ix:nonNumeric><ix:nonNumeric id="F_000299" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" contextRef="C_0001439725_20200101_20201231" escape="true">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Deferred Revenue</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue consists of payments received for research, development, and testing services fees received prior to the completion of performance of these tests and services. As of December 31, 2020, deferred revenue also includes $<ix:nonFraction unitRef="U_iso4217USD" id="F_000361" name="us-gaap:ContractWithCustomerLiabilityCurrent" contextRef="C_0001439725_srtProductOrServiceAxis_bdsxTestingServicesMember_20201231" decimals="-5" scale="6">2.8</ix:nonFraction> million in a Medicare advance payment on testing services which can either be paid back or earned back starting 1 year from receipt.</p></ix:nonNumeric><ix:nonNumeric id="F_000300" name="bdsx:DirectCostsAndExpensesPolicyTextBlock" contextRef="C_0001439725_20200101_20201231" escape="true" continuedAt="F_000300_dcnt_f0d67125-f05c-4551-a120-6a695c3bec55">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Direct Costs and Expenses</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The components of our cost of diagnostic tests and testing services consist of cost of materials, direct labor, including bonus, benefit and stock-based compensation, depreciation of laboratory equipment, rent costs, amortization of leasehold improvements and information technology costs associated with acquiring and processing test samples, including sample accessioning, test performance, quality control analyses, charges to collect and transport samples&#59; curation of test results for physicians&#59; and in some cases, license or royalty fees due to third parties.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Royalties for licensed technology are calculated as a percentage of revenues generated using the associated technology and recorded as expense at the time the related revenue is recognized. One-time royalty payments related to signing of license agreements or other milestones, such as issuance of new patents, are amortized to expense over the expected useful life of the patents. Costs associated with performing tests are expensed as the test is processed regardless of whether and when revenue is recognized with respect to that test.</p></ix:nonNumeric></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-10</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000275_dcnt_6f33d6ed-8a99-4309-a7cc-761f9d7d7ed0" continuedAt="F_000275_dcnt_30654c0f-5a6c-4189-bd5a-18d18f1158dd"><ix:continuation id="F_000300_dcnt_f0d67125-f05c-4551-a120-6a695c3bec55">
</ix:continuation><ix:nonNumeric id="F_000301" name="us-gaap:ResearchAndDevelopmentExpensePolicy" contextRef="C_0001439725_20200101_20201231" escape="true">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Research and Development <span style="color:#212529;">Expenses</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses include external and internal costs incurred to develop our technology, collect clinical samples, and conduct clinical studies to develop and support our products. External costs consist primarily of payments to clinical trial sites, sample acquisition costs and laboratory supplies purchased in connection with the Company&#8217;s discovery and preclinical activities, process development and clinical development activities.&#160; Internal costs consist primarily of salaries and benefits, reagents and supplies used in research and development laboratory work, infrastructure expenses, including allocated facility occupancy and information technology costs<span style="Background-color:#FFFFFF;">.</span> </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;color:#212529;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company estimates and accrues its expenses resulting from its obligations under contracts with vendors and consultants in connection with conducting research and development activities. The financial terms of these contracts vary from contract to contract and may result in payments that do not match the periods over which materials or services are provided under such contracts.<span style="color:#000000;">&#160;&#160;The Company&#8217;s estimates depend on the timeliness and accuracy of the data provided by consultants and vendors regarding the status of each activity.&#160;&#160;The Company periodically evaluates the estimates to determine if adjustments are necessary or appropriate based on information received. Research and development costs are expensed as incurred. </span></p></ix:nonNumeric><ix:nonNumeric id="F_000302" name="us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock" contextRef="C_0001439725_20200101_20201231" escape="true">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Sales, Marketing, General and Administrative Expenses</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Selling expenses consist primarily of costs associated with our sales organization, including our direct sales force and sales management, client services, marketing, and reimbursement, as well as business development personnel who are focused on our biopharmaceutical customers. These expenses consist primarily of salaries, commissions, bonuses, employee benefits, travel, and stock-based compensation, as well as marketing and educational activities and allocated overhead expenses. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales, marketing, general and administrative expenses also include costs for our marketing and sales organizations, and other functions including finance, legal, human resources, and information technology. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These expenses consist principally of salaries, bonuses, employee benefits, travel, and stock-based compensation, as well as professional services fees such as consulting, audit, tax and legal fees, and general corporate costs and allocated overhead expenses.</p></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:nonNumeric id="F_000303" name="us-gaap:ConcentrationRiskCreditRisk" contextRef="C_0001439725_20200101_20201231" escape="true" continuedAt="F_000303_dcnt_4d414783-eecc-4b3d-920d-29dc79d7806c">
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Concentrations of Credit Risk and Other Uncertainties</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Substantially all of the Company&#8217;s cash and cash equivalents are deposited with one major financial institution in the United States. The Company continually monitors its positions with, and the credit quality of, the financial institution with which it holds cash. Periodically throughout the year, the Company has maintained balances in various operating accounts in excess of federally insured limits. The Company has not experienced any losses on its deposits of cash and cash equivalents.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Several of the components of the Company's sample collection kit and test reagents, and certain test systems and related test kits are obtained from single-source suppliers. If these single-source suppliers fail to satisfy the Company's requirements on a timely basis, it could suffer delays in being able to deliver its diagnostic solutions, a possible loss of revenue, or incur higher costs, any of which could adversely affect its operating results.</p><ix:nonNumeric id="F_000318" name="us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" contextRef="C_0001439725_20200101_20201231" escape="true" continuedAt="F_000318_dcnt_ede301e7-37b7-4dd9-84c5-be4a466df679">
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s customers in excess of 10% of total revenue, and their related revenue as a percentage of total revenue were as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:79.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.86%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:79.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.86%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:79.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Big Ten Conference</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000362" name="us-gaap:ConcentrationRiskPercentage1" contextRef="C_0001439725_srtMajorCustomersAxis_bdsxTheBigTenConferenceMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20200101_20201231" decimals="2" scale="-2">30</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:79.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Centura Healthcare</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000363" name="us-gaap:ConcentrationRiskPercentage1" contextRef="C_0001439725_srtMajorCustomersAxis_bdsxCenturaHealthcareMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20200101_20201231" decimals="2" scale="-2">17</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:79.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Percent of total revenue</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000364" name="us-gaap:ConcentrationRiskPercentage1" contextRef="C_0001439725_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20200101_20201231" decimals="2" scale="-2">47</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:nonNumeric></ix:nonNumeric></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-11</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000275_dcnt_30654c0f-5a6c-4189-bd5a-18d18f1158dd" continuedAt="F_000275_dcnt_690bd0e6-ae22-4e60-8a1a-201729fa4ad0"><ix:continuation id="F_000303_dcnt_4d414783-eecc-4b3d-920d-29dc79d7806c"><ix:continuation id="F_000318_dcnt_ede301e7-37b7-4dd9-84c5-be4a466df679" continuedAt="F_000318_cnt_1">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:continuation>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">One customer, Covance, exceeded 10% of total revenue during 2019, representing <ix:nonFraction unitRef="U_xbrlipure" id="F_000365" name="us-gaap:ConcentrationRiskPercentage1" contextRef="C_0001439725_srtMajorCustomersAxis_bdsxCovanceCentralLaboratoryServicesMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20190101_20191231" decimals="2" scale="-2">21</ix:nonFraction>% of total revenue. In addition to the above table, we collect reimbursement on behalf of customers covered by Medicare, which accounted for <ix:nonFraction unitRef="U_xbrlipure" id="F_000366" name="us-gaap:ConcentrationRiskPercentage1" contextRef="C_0001439725_srtMajorCustomersAxis_bdsxMedicareMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20200101_20201231" decimals="2" scale="-2">17</ix:nonFraction>% and <ix:nonFraction unitRef="U_xbrlipure" id="F_000367" name="us-gaap:ConcentrationRiskPercentage1" contextRef="C_0001439725_srtMajorCustomersAxis_bdsxMedicareMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20190101_20191231" decimals="2" scale="-2">36</ix:nonFraction>% of the Company&#8217;s total revenue for the years ended December 31, 2020 and 2019, respectively.&#160;&#160;The Company is subject to credit risk from its accounts receivable related to services provided to its customers. The Company does not perform evaluations of customers' financial condition and does not require collateral. <ix:continuation id="F_000318_cnt_1" continuedAt="F_000318_cnt_2">The Company&#8217;s third-party payors and other customers in excess of 10% of accounts receivable, and their related accounts receivable as a percentage of total accounts receivable were as follows:</ix:continuation></p><ix:continuation id="F_000318_cnt_2">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.12%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">As of December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Big Ten Conference</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000368" name="us-gaap:ConcentrationRiskPercentage1" contextRef="C_0001439725_srtMajorCustomersAxis_bdsxTheBigTenConferenceMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20200101_20201231" decimals="2" scale="-2">35</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Centura Healthcare</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000369" name="us-gaap:ConcentrationRiskPercentage1" contextRef="C_0001439725_srtMajorCustomersAxis_bdsxCenturaHealthcareMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20200101_20201231" decimals="2" scale="-2">24</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Medicare</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000370" name="us-gaap:ConcentrationRiskPercentage1" contextRef="C_0001439725_srtMajorCustomersAxis_bdsxMedicareMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20200101_20201231" decimals="2" scale="-2">6</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000371" name="us-gaap:ConcentrationRiskPercentage1" contextRef="C_0001439725_srtMajorCustomersAxis_bdsxMedicareMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20190101_20191231" decimals="2" scale="-2">18</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Covance Central Laboratory Services</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000372" name="us-gaap:ConcentrationRiskPercentage1" contextRef="C_0001439725_srtMajorCustomersAxis_bdsxCovanceCentralLaboratoryServicesMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20200101_20201231" decimals="2" scale="-2">2</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000373" name="us-gaap:ConcentrationRiskPercentage1" contextRef="C_0001439725_srtMajorCustomersAxis_bdsxCovanceCentralLaboratoryServicesMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20190101_20191231" decimals="2" scale="-2">43</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Janssen Research and Development, LLC</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000374" name="us-gaap:ConcentrationRiskPercentage1" contextRef="C_0001439725_srtMajorCustomersAxis_bdsxJanssenResearchAndDevelopmentLLCMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20200101_20201231" decimals="2" scale="-2">5</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000375" name="us-gaap:ConcentrationRiskPercentage1" contextRef="C_0001439725_srtMajorCustomersAxis_bdsxJanssenResearchAndDevelopmentLLCMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20190101_20191231" decimals="2" scale="-2">12</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pfizer, Inc</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000376" name="us-gaap:ConcentrationRiskPercentage1" contextRef="C_0001439725_srtMajorCustomersAxis_bdsxPfizerIncMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20200101_20201231" decimals="2" scale="-2">4</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000377" name="us-gaap:ConcentrationRiskPercentage1" contextRef="C_0001439725_srtMajorCustomersAxis_bdsxPfizerIncMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20190101_20191231" decimals="2" scale="-2">10</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.26%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Percent of total accounts receivable</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000378" name="us-gaap:ConcentrationRiskPercentage1" contextRef="C_0001439725_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20200101_20201231" decimals="2" scale="-2">76</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000379" name="us-gaap:ConcentrationRiskPercentage1" contextRef="C_0001439725_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20190101_20191231" decimals="2" scale="-2">83</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:continuation></ix:continuation><ix:nonNumeric id="F_000304" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" contextRef="C_0001439725_20200101_20201231" escape="true">
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Cash and Cash Equivalents </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents consist of short-term, highly-liquid instruments with an original maturity of three months or less from the date of purchase. </p></ix:nonNumeric><ix:nonNumeric id="F_000305" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" contextRef="C_0001439725_20200101_20201231" escape="true">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Restricted Cash</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash consists of deposits related to the Company&#8217;s corporate credit card and a letter of credit related to an operating lease agreement. As of December 31, 2020 and 2019, the Company had $<ix:nonFraction unitRef="U_iso4217USD" id="F_000380" name="us-gaap:RestrictedCash" contextRef="C_0001439725_us-gaapBalanceSheetLocationAxis_us-gaapOtherCurrentAssetsMember_20201231" decimals="-5" scale="6"><ix:nonFraction unitRef="U_iso4217USD" id="F_000381" name="us-gaap:RestrictedCash" contextRef="C_0001439725_us-gaapBalanceSheetLocationAxis_us-gaapOtherCurrentAssetsMember_20191231" decimals="-5" scale="6">0.2</ix:nonFraction></ix:nonFraction> million restricted cash, respectively, which was included in &#8216;Other current assets&#8217; in the accompanying balance sheets.&#160;&#160; </p></ix:nonNumeric><ix:nonNumeric id="F_000306" name="us-gaap:ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" contextRef="C_0001439725_20200101_20201231" escape="true">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Accounts Receivable and Allowance for Doubtful Accounts</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts receivable are stated at the amount management expects to collect from customers based on their outstanding invoices. Management reviews accounts receivable <span style="color:#000000;">quarterly</span> to determine if any receivable will potentially be uncollectible and to estimate the amount of allowance for doubtful accounts necessary to reduce accounts receivable to its estimated net realizable value based on <span style="color:#000000;">historical experience, customer creditworthiness, facts, and circumstances specific to outstanding balances, and payment terms. The Company&#8217;s allowance for doubtful accounts was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000383" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" contextRef="C_0001439725_20191231" decimals="-5" scale="6"><ix:nonFraction unitRef="U_iso4217USD" id="F_000382" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" contextRef="C_0001439725_20201231" decimals="-5" scale="6">0.2</ix:nonFraction></ix:nonFraction> million as of December 31, 2020 and 2019.</span></p></ix:nonNumeric><ix:nonNumeric id="F_000307" name="us-gaap:InventorySuppliesPolicy" contextRef="C_0001439725_20200101_20201231" escape="true">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Inventory</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inventory consists primarily of material supplies, which are consumed in the performance of testing services and charged to cost of sales. Inventory is stated at cost and reported within &#8216;Other current assets&#8217; in the balance sheet and were $<ix:nonFraction unitRef="U_iso4217USD" id="F_000384" name="us-gaap:OtherInventorySupplies" contextRef="C_0001439725_us-gaapBalanceSheetLocationAxis_us-gaapOtherCurrentAssetsMember_20201231" decimals="-5" scale="6">3.2</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000385" name="us-gaap:OtherInventorySupplies" contextRef="C_0001439725_us-gaapBalanceSheetLocationAxis_us-gaapOtherCurrentAssetsMember_20191231" decimals="-5" scale="6">0.8</ix:nonFraction> million as of December 31, 2020 and 2019, respectively.</p></ix:nonNumeric><ix:nonNumeric id="F_000308" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" contextRef="C_0001439725_20200101_20201231" escape="true" continuedAt="F_000308_dcnt_51bb7872-d88c-495b-90df-8173c9bbafc8">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Property and Equipment</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment are stated at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally between <ix:nonNumeric id="F_000386" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="C_0001439725_srtRangeAxis_srtMinimumMember_20200101_20201231" format="ixt-sec:durwordsen" continuedAt="C_42b56556-a0e3-49b8-baa0-576ffd7ce7c1">three</ix:nonNumeric> and <ix:nonNumeric id="F_000387" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="C_0001439725_srtRangeAxis_srtMaximumMember_20200101_20201231" format="ixt-sec:durwordsen">five<ix:continuation id="C_42b56556-a0e3-49b8-baa0-576ffd7ce7c1"> years</ix:continuation></ix:nonNumeric>. Leasehold improvements are amortized using the straight-line method over the shorter of the estimated useful life of the asset or the term of the lease. Maintenance and repairs are charged to expense as incurred, and improvements and betterments are capitalized. When assets are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the balance sheet and any resulting gain or loss is reflected in the statements of operations and comprehensive loss in the period realized.</p></ix:nonNumeric></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-12</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000275_dcnt_690bd0e6-ae22-4e60-8a1a-201729fa4ad0" continuedAt="F_000275_dcnt_e1f5bc5d-bfac-484d-a4ba-bfa39005e2dc"><ix:continuation id="F_000308_dcnt_51bb7872-d88c-495b-90df-8173c9bbafc8">
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Long-lived assets to be held and used are evaluated for impairment when events or circumstances indicate the carrying value of a long-lived asset or asset group is less </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">than </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the undiscounted cash flows from the use and eventual disposition over its remaining useful life. The Company assesses recoverability by comparing the sum or projected undiscounted cash flows from the use and eventual disposition of the asset or asset group to it carrying value, and records an impairment loss if the carrying value is greater </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">than </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the undiscounted future cash flows.</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> There were </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000388" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" contextRef="C_0001439725_20200101_20201231" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_iso4217USD" id="F_000389" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" contextRef="C_0001439725_20190101_20191231" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> impairments for the years ended December 31, 2020 or 2019.</span></p></ix:continuation><ix:nonNumeric id="F_000309" name="us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" contextRef="C_0001439725_20200101_20201231" escape="true">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Intangible Assets</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible assets primarily consist of intangible assets acquired as part of business combinations, external costs associated with patent applications that are expected to be successful, and trademark costs. Finite-lived intangibles are stated at cost, net of accumulated amortization. The Company amortizes finite-lived intangible assets using the straight-line method over their estimated useful lives of 9 to <ix:nonNumeric id="F_000391" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" contextRef="C_0001439725_srtRangeAxis_srtMaximumMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_bdsxProductLifeAndPatentLifeMember_20200101_20201231" format="ixt-sec:duryear">10</ix:nonNumeric> years, based on management's estimate of the period over which their economic benefits will be realized, product life and patent life. Trademarks are considered indefinite lived and are not amortized.  </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible assets are reviewed for impairment whenever events or changes in circumstances indicate a reduction to fair value below their carrying amounts. There were <ix:nonFraction unitRef="U_iso4217USD" id="F_000392" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" contextRef="C_0001439725_20200101_20201231" decimals="INF" format="ixt-sec:numwordsen" scale="6">no</ix:nonFraction> impairments for the years ended December 31, 2020 or 2019.</p></ix:nonNumeric><ix:nonNumeric id="F_000310" name="us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy" contextRef="C_0001439725_20200101_20201231" escape="true">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Goodwill</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Goodwill represents the excess of purchase price over amounts allocated to acquired assets and liabilities assumed in business combinations. The carrying value of goodwill is evaluated for impairment at least annually or more frequently when events or circumstances occur indicate a potential for impairment. The annual impairment test is performed on the last day of our fourth quarter. Prior to performing a quantitative evaluation, an assessment of qualitative factors may be performed to determine whether it is more likely than not that the fair value of the reporting unit exceeds its carrying value. In the event the Company determines that it is more likely than not the carrying value of our single reporting unit is higher than its estimated fair value, quantitative testing is performed comparing recorded values to estimated fair values. If impairment is present, the impairment loss is measured as the excess of the recorded goodwill over its implied fair value. <span style="color:#000000;">There were <ix:nonFraction unitRef="U_iso4217USD" id="F_000394" name="us-gaap:GoodwillImpairmentLoss" contextRef="C_0001439725_20200101_20201231" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_iso4217USD" id="F_000395" name="us-gaap:GoodwillImpairmentLoss" contextRef="C_0001439725_20190101_20191231" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction> impairments for the years ended December 31, 2020 or 2019.</span></p></ix:nonNumeric><ix:nonNumeric id="F_000311" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" contextRef="C_0001439725_20200101_20201231" escape="true" continuedAt="F_000311_dcnt_3cd9ebfc-8a13-4b27-8a16-961e1a1af6f5">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Fair Value of Financial Instruments</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. GAAP for fair value establishes a hierarchy that prioritizes fair value measurements based on the types of inputs used for the various valuation techniques (market approach, income approach, and cost approach). We utilize a combination of market and income approaches to value our financial instruments. Our financial assets and liabilities are measured using inputs from the three levels of the fair value hierarchy. Fair value measurements are categorized within the fair value hierarchy based upon the lowest level of the most significant inputs used to determine fair value. The three levels of the hierarchy and the related inputs are as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:86.08%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inputs</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:86.08%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unadjusted quoted prices in active markets for identical assets and liabilities.</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:86.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unadjusted quoted prices in active markets for similar assets and liabilities&#59;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:86.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active&#59; or</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:86.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inputs other than quoted prices that are observable for the asset or liability.</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:86.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unobservable inputs for the asset or liability.</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The carrying amounts of certain financial instruments including cash and cash equivalents, accounts receivable, prepaid expenses and other current assets, accounts payable and accrued liabilities approximate fair value due to their relatively short maturities.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">See Note 5 <span style="color:#000000;">&#8212; </span><span style="font-style:italic;color:#000000;">Fair Value </span><span style="color:#000000;">for further discussion related to estimated fair value measurements.</span></p></ix:nonNumeric></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-13</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000275_dcnt_e1f5bc5d-bfac-484d-a4ba-bfa39005e2dc" continuedAt="F_000275_dcnt_fb56715e-c43e-4e84-8229-43ae89e0696d"><ix:continuation id="F_000311_dcnt_3cd9ebfc-8a13-4b27-8a16-961e1a1af6f5">
</ix:continuation><ix:nonNumeric id="F_000312" name="bdsx:ContingentConsiderationPolicyTextBlock" contextRef="C_0001439725_20200101_20201231" escape="true">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Contingent Consideration</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the purchase transaction with Integrated Diagnostics, Inc. (Indi), the Company recorded contingent consideration for amounts potentially payable to Indi&#8217;s shareholder pursuant to the terms of the asset purchase agreement. The fair value of contingent consideration is assessed at each balance sheet date and changes, if any, to the fair value are recognized as operating expenses within the statements of operations. The estimated fair value of the contingent consideration is based upon significant assumptions including the probability of successful achievement of product gross margin targets included in the acquisition agreement, the estimated timing of achievement of the product gross margin targets, and discount rates. The estimated fair value could materially differ from actual values or fair values determined using different assumptions.</p></ix:nonNumeric><ix:nonNumeric id="F_000313" name="bdsx:WarrantLiabilityPolicyTextBlock" contextRef="C_0001439725_20200101_20201231" escape="true">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Warrant Liability</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to the completion of the Company&#8217;s initial public offering in October 2020, certain warrants issued to purchase convertible preferred stock were classified as liabilities with changes in the estimated fair value of these liabilities recognized in our results of operations. Upon completion of the Company&#8217;s initial public offering in October 2020, the warrants were automatically converted to warrants to purchase common stock. Accordingly, the warrants were remeasured to an estimate of fair value and recognized in our results of operations and then reclassified to additional paid-in capital.</p></ix:nonNumeric><ix:nonNumeric id="F_000314" name="bdsx:PutOptionLiabilityPolicyTextBlock" contextRef="C_0001439725_20200101_20201231" escape="true">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Put Option Liability</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During 2020 and 2019, the Company issued convertible debt<span style="color:#000000;">&#160;</span>with terms that provided for a conversion rate to the convertible debtholders that was more favorable than the price that other investors would pay for common stock in certain situations, including the completion of an initial public offering. As a result, the convertible debt is a financial instrument that was bifurcated into two instruments, a debt obligation and a put option liability, which represented the estimated fair value of the favorable conversion rate.&#160;&#160;The estimated fair value of the put option liability was separated from the convertible debt at inception and reported as a liability and debt discount, and amortized to interest expense. As a result of our initial public offering, the convertible debt was automatically converted to common stock and the put option liability was remeasured to an estimate of fair value and recognized in our results of operations and then reclassified to additional paid-in capital.</p></ix:nonNumeric><ix:nonNumeric id="F_000315" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" contextRef="C_0001439725_20200101_20201231" escape="true" continuedAt="F_000315_dcnt_302d89d7-b947-4292-8dfd-5e0aea1ddb7c">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Share&#8209;Based Compensation</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Stock Options<span style="font-style:normal;"> </span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company grants service condition and performance condition stock options. Stock options are granted with exercise prices equal to the fair market value of our common stock on the date of grant. The grant date fair value of each employee stock option is estimated on the date of grant using the Black-Scholes option-pricing model, which requires the use of assumptions, including the expected term of the option, expected volatility of our stock price, expected dividend yield, and the risk-free interest rate, among others. These assumptions involve inherent uncertainties including market conditions and employee behavior that are generally outside of the Company&#8217;s control. Service condition stock options are expensed based on the grant date fair value of the awards using the straight-line method over the requisite service period, adjusted for forfeitures as they occur. Performance-condition stock options vest based on achievement of multiple weighted performance goals, certification of performance achievement by the Compensation Committee of the Board of Directors, and continued service. For performance-condition stock options, compensation expense is updated for our expected performance level against performance goals at the end of each reporting period, which involves judgment as to achievement of certain performance metrics.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to our initial public offering in October 2020, the fair value of our common stock was determined by the Board of Directors in accordance with the methodologies outlined in the American Institute of Certified Public Accountants Practice Aid, Valuation of Privately-Held-Company Equity Securities Issued as Compensation Practice Aid (Practice Aid). In doing so, the Board of Directors determined the best estimate of fair value of our common stock, exercising reasonable judgment and considering numerous objective and subjective factors<span style="color:#000000;">, by first determining the enterprise value of our business, and then allocating the value among the various classes of our equity securities to derive a per share value of our common stock. </span>Subsequent&#160;to the Company&#8217;s initial public offering, the fair value of the Company&#8217;s common stock is determined based on its traded market price.</p></ix:nonNumeric></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-14</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000275_dcnt_fb56715e-c43e-4e84-8229-43ae89e0696d"><ix:continuation id="F_000315_dcnt_302d89d7-b947-4292-8dfd-5e0aea1ddb7c">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><span style="font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Restricted Stock Units (RSUs)</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company grants service-condition RSUs. As a result of our initial public offering, the grant date fair values of these RSUs are based on the closing market price of our common stock on the grant date. The service-condition RSUs vest based on continued service with compensation expense, net of forfeitures, recognized on a straight-line basis over the requisite service period. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">See Note 14 &#8212; <span style="font-style:italic;">Share-Based Compensation</span> for additional information related to share-based compensation.</p></ix:continuation><ix:nonNumeric id="F_000316" name="us-gaap:EarningsPerSharePolicyTextBlock" contextRef="C_0001439725_20200101_20201231" escape="true">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Net Loss per Common Share </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic net loss per common share is calculated by dividing net loss by the weighted-average number of common shares outstanding during the period, without consideration of common stock equivalents. Diluted net loss per common share is computed by dividing net loss by the weighted-average number of common share equivalents outstanding for the period, if dilutive, using the treasury stock method. Potentially dilutive securities consisting of options to purchase common stock, warrants to purchase common stock, restricted stock units and shares subject to purchase under our employee stock purchase plan were excluded from the calculation of diluted net loss per common share because their effect would be anti-dilutive for all periods presented. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Until the Company&#8217;s initial public offering in October 2020, basic and diluted net loss attributable to common stockholders per share was calculated using the two-class method. The net loss was attributable entirely to common stockholders because the participating securities did not have a contractual obligation to share in the Company&#8217;s losses.&#160;&#160;As the Company has reported a net loss for all periods presented, diluted net loss per common share is the same as basic net loss per common share for all periods presented.</p></ix:nonNumeric></ix:continuation><ix:nonNumeric id="F_000276" name="us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" contextRef="C_0001439725_20200101_20201231" escape="true">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note 3 &#8211; Recent Accounting Pronouncements</p><ix:nonNumeric id="F_000317" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" contextRef="C_0001439725_20200101_20201231" escape="true">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Recently Issued Accounting Standards Not Yet Adopted</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2016, the FASB issued Accounting Standards Update (ASU) No. 2016-2, <span style="font-style:italic;">Leases (Topic 842), </span>which requires lessees to recognize a right-of-use asset and corresponding lease liability, including leases currently accounted for as operating leases. The ASU is effective for the Company for interim and annual periods beginning January 1, 2022. The Company expects to recognize right-of-use assets and lease obligations in its balance sheet upon adoption using the modified retrospective method as permitted by ASU No. 2018-11, <span style="font-style:italic;">Leases (Topic 842): Targeted Improvements.</span> The Company does not currently expect adoption of this standard will have a significant effect on its statements of operations or cash flows.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2016, the FASB issued ASU No. 2016-13, <span style="font-style:italic;">Financial Instruments-Credit Losses: Measurement of Credit Losses</span> on Financial Instruments. This ASU requires measurement and recognition of expected credit losses for financial assets. This guidance will become effective for the Company beginning January 1, 2022 with early adoption permitted. The Company has not yet begun evaluating the potential effect of this standard on its financial statements. </p></ix:nonNumeric></ix:nonNumeric><ix:nonNumeric id="F_000277" name="us-gaap:BusinessCombinationDisclosureTextBlock" contextRef="C_0001439725_20200101_20201231" escape="true" continuedAt="F_000277_dcnt_38ef80dd-cb58-456f-8e06-179cd2cfdc1a">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note 4 &#8211; Business Combinations </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Oncimmune Limited</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On October 31, 2019, the Company purchased select assets and liabilities from Oncimmune Limited (Oncimmune) for total consideration of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000396" name="us-gaap:BusinessCombinationConsiderationTransferred1" contextRef="C_0001439725_us-gaapBusinessAcquisitionAxis_bdsxOncimmuneLimitedMember_20191031_20191031" decimals="-5" scale="6">1.2</ix:nonFraction> million payable in <ix:nonNumeric id="F_000397" name="us-gaap:BusinessAcquisitionDescriptionOfAcquiredEntity" contextRef="C_0001439725_us-gaapBusinessAcquisitionAxis_bdsxOncimmuneLimitedMember_20200101_20201231">quarterly installments commencing 30 days following the closing of the transaction.</ix:nonNumeric> Concurrent with the Oncimmune purchase, the Company acquired an exclusive option to license rights within the United States to an additional indication for their product for $<ix:nonFraction unitRef="U_iso4217USD" id="F_000398" name="us-gaap:OtherPaymentsToAcquireBusinesses" contextRef="C_0001439725_srtProductOrServiceAxis_us-gaapLicenseMember_srtStatementGeographicalAxis_countryUS_us-gaapBusinessAcquisitionAxis_bdsxOncimmuneLimitedMember_20191031_20191031" decimals="-5" scale="6">9.0</ix:nonFraction> million.&#160;&#160;In September 2020, we notified Oncimmune that we would not exercise this option for the expansion of the field of use. As of December 31, 2020, the Company had paid the full $<ix:nonFraction unitRef="U_iso4217USD" id="F_000399" name="us-gaap:PaymentsToAcquireBusinessesGross" contextRef="C_0001439725_us-gaapBusinessAcquisitionAxis_bdsxOncimmuneLimitedMember_20200101_20201231" decimals="-5" scale="6">1.2</ix:nonFraction> million consideration. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The acquisition was accounted for as business combination and resulted in the recognition of goodwill of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000400" name="us-gaap:Goodwill" contextRef="C_0001439725_us-gaapBusinessAcquisitionAxis_bdsxOncimmuneLimitedMember_20191031" decimals="-5" scale="6">0.8</ix:nonFraction> million representing expected synergies, including expected increases in future revenues as a result of expansion of the acquired technology into additional markets, and lower expected operating expenses. The Company finalized its purchase price allocation of the transaction as of December 31, 2019.</p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-15</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000277_dcnt_38ef80dd-cb58-456f-8e06-179cd2cfdc1a">
<ix:nonNumeric id="F_000319" name="us-gaap:BusinessCombinationSegmentAllocationTableTextBlock" contextRef="C_0001439725_20200101_20201231" escape="true">
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the aggregate consideration paid by the Company and the allocation of the purchase price to assets acquired and liabilities assumed (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000401" name="us-gaap:PaymentsToAcquireBusinessesGross" contextRef="C_0001439725_us-gaapBusinessAcquisitionAxis_bdsxOncimmuneLimitedMember_20191031_20191031" decimals="-3" format="ixt:numdotdecimal" scale="3">1,206</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total fair value of consideration transferred</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000402" name="us-gaap:BusinessCombinationConsiderationTransferred1" contextRef="C_0001439725_us-gaapBusinessAcquisitionAxis_bdsxOncimmuneLimitedMember_20191031_20191031" decimals="-3" format="ixt:numdotdecimal" scale="3">1,206</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deposit</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000403" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" contextRef="C_0001439725_us-gaapBusinessAcquisitionAxis_bdsxOncimmuneLimitedMember_20191031" decimals="-3" scale="3">6</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inventory</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000404" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" contextRef="C_0001439725_us-gaapBusinessAcquisitionAxis_bdsxOncimmuneLimitedMember_20191031" decimals="-3" scale="3">14</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000405" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" contextRef="C_0001439725_us-gaapBusinessAcquisitionAxis_bdsxOncimmuneLimitedMember_20191031" decimals="-3" scale="3">241</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchase option</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000406" name="bdsx:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPurchaseOption" contextRef="C_0001439725_us-gaapBusinessAcquisitionAxis_bdsxOncimmuneLimitedMember_20191031" decimals="-3" scale="3">121</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Goodwill</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000407" name="us-gaap:Goodwill" contextRef="C_0001439725_us-gaapBusinessAcquisitionAxis_bdsxOncimmuneLimitedMember_20191031" decimals="-3" scale="3">827</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued liabilities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000408" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" contextRef="C_0001439725_us-gaapBusinessAcquisitionAxis_bdsxOncimmuneLimitedMember_20191031" decimals="-3" scale="3">3</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000409" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" contextRef="C_0001439725_us-gaapBusinessAcquisitionAxis_bdsxOncimmuneLimitedMember_20191031" decimals="-3" format="ixt:numdotdecimal" scale="3">1,206</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Integrated Diagnostics, Inc.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On June 30, 2018, the Company purchased select assets and liabilities from Integrated Diagnostics, Inc. (Indi) <span style="Background-color:#FFFFFF;">for total consideration of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000410" name="us-gaap:BusinessCombinationConsiderationTransferred1" contextRef="C_0001439725_us-gaapBusinessAcquisitionAxis_bdsxIntegratedDiagnosticsIncMember_20180630_20180630" decimals="-5" scale="6">27.6</ix:nonFraction> million, consisting of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000411" name="us-gaap:PaymentsToAcquireBusinessesGross" contextRef="C_0001439725_us-gaapBusinessAcquisitionAxis_bdsxIntegratedDiagnosticsIncMember_20180630_20180630" decimals="-5" scale="6">8.0</ix:nonFraction> million in the Company&#8217;s Series G Preferred Stock and contingent consideration with an initial estimated fair value of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000412" name="us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure" contextRef="C_0001439725_us-gaapBusinessAcquisitionAxis_bdsxIntegratedDiagnosticsIncMember_20180630" decimals="-5" scale="6">19.6</ix:nonFraction> million.&#160;&#160;The acquisition was </span>accounted for as a business combination and resulted in goodwill of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000413" name="us-gaap:Goodwill" contextRef="C_0001439725_us-gaapBusinessAcquisitionAxis_bdsxIntegratedDiagnosticsIncMember_20180630" decimals="-5" scale="6">14.2</ix:nonFraction> million representing expected synergies, including increases in future revenues as a result of expansion of the acquired technology into additional markets, and lower operating expenses.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The contingent consideration arrangement <ix:nonNumeric id="F_000414" name="us-gaap:BusinessAcquisitionDescriptionOfAcquiredEntity" contextRef="C_0001439725_us-gaapBusinessAcquisitionAxis_bdsxIntegratedDiagnosticsIncMember_20200101_20201231">requires additional consideration to be paid by the Company to Indi upon attainment of a three-consecutive month</ix:nonNumeric> gross margin target of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000415" name="us-gaap:CashAcquiredFromAcquisition" contextRef="C_0001439725_us-gaapBusinessAcquisitionAxis_bdsxIntegratedDiagnosticsIncMember_20180630_20180630" decimals="-5" scale="6">2.0</ix:nonFraction> million within the <span style="-sec-ix-hidden:F_000416">seven-year</span> period after the acquisition date.&#160;If the gross margin target is met, the Company is required to issue <ix:nonFraction unitRef="U_xbrlishares" id="F_000417" name="bdsx:BusinessCombinationContingentConsiderationShares" contextRef="C_0001439725_us-gaapBusinessAcquisitionAxis_bdsxIntegratedDiagnosticsIncMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20180630_20180630" decimals="INF" format="ixt:numdotdecimal">2,520,108</ix:nonFraction> shares of common stock. For the six months following the achievement of the gross margin target, Indi has the option to require the Company to redeem these common shares for $<ix:nonFraction unitRef="U_iso4217USD" id="F_000419" name="bdsx:BusinessCombinationContingentConsiderationArrangementsCommonSharesRedemptionAmount" contextRef="C_0001439725_us-gaapBusinessAcquisitionAxis_bdsxIntegratedDiagnosticsIncMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20180630_20180630" decimals="-5" scale="6">37.0</ix:nonFraction> million in cash over <ix:nonFraction unitRef="U_bdsxInstallment" id="F_000418" name="bdsx:BusinessAcquisitionContingentConsiderationNumberOfInstallments" contextRef="C_0001439725_us-gaapBusinessAcquisitionAxis_bdsxIntegratedDiagnosticsIncMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20180630" decimals="INF" format="ixt-sec:numwordsen">eight</ix:nonFraction> equal quarterly installments.&#160;&#160;<ix:nonNumeric id="F_000420" name="us-gaap:BusinessAcquisitionDescriptionOfAcquiredEntity" contextRef="C_0001439725_us-gaapBusinessAcquisitionAxis_bdsxIntegratedDiagnosticsIncMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231">If Indi elects to not exercise its option, the Company has 12 months to repurchase the common stock in <ix:nonFraction unitRef="U_bdsxInstallment" id="F_000421" name="bdsx:BusinessAcquisitionContingentConsiderationNumberOfInstallments" contextRef="C_0001439725_us-gaapBusinessAcquisitionAxis_bdsxIntegratedDiagnosticsIncMember_us-gaapInvestmentTypeAxis_bdsxRepurchaseMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20180630" decimals="INF" format="ixt-sec:numwordsen">two</ix:nonFraction> equal and consecutive quarterly cash installments totaling $<ix:nonFraction unitRef="U_iso4217USD" id="F_000422" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" contextRef="C_0001439725_us-gaapBusinessAcquisitionAxis_bdsxIntegratedDiagnosticsIncMember_us-gaapInvestmentTypeAxis_bdsxRepurchaseMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20180630_20180630" decimals="-5" scale="6">37.0</ix:nonFraction> million.</ix:nonNumeric> </p></ix:continuation><ix:nonNumeric id="F_000278" name="us-gaap:FairValueDisclosuresTextBlock" contextRef="C_0001439725_20200101_20201231" escape="true" continuedAt="F_000278_dcnt_2fd90989-5197-47da-9632-ca05c348bc0b">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note 5 - Fair Value</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Recurring Fair Value Measurements</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our borrowing instruments are recorded at their carrying values in the balance sheets, which may differ from their respective fair values. <ix:nonNumeric id="F_000320" name="us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" contextRef="C_0001439725_20200101_20201231" escape="true" continuedAt="F_000320_cnt_1">The fair values of outstanding borrowings, which are classified as Level 2, approximate their carrying values at December&#160;31, 2020 and 2019, based on interest rates currently available for similar borrowings and were:</ix:nonNumeric></p><ix:continuation id="F_000320_cnt_1" continuedAt="F_000320_dcnt_4fc84c0e-111f-4dc3-a0ae-9b73dfd79608">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.85%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">As of December 31,</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Carrying&#160;Value</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fair&#160;Value</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Carrying&#160;Value</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fair&#160;Value</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Borrowings</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000423" name="us-gaap:LongTermDebtFairValue" contextRef="C_0001439725_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementBasisAxis_us-gaapCarryingReportedAmountFairValueDisclosureMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">27,766</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000424" name="us-gaap:LongTermDebtFairValue" contextRef="C_0001439725_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementBasisAxis_us-gaapEstimateOfFairValueFairValueDisclosureMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">27,766</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000425" name="us-gaap:LongTermDebtFairValue" contextRef="C_0001439725_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementBasisAxis_us-gaapCarryingReportedAmountFairValueDisclosureMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">35,971</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000426" name="us-gaap:LongTermDebtFairValue" contextRef="C_0001439725_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementBasisAxis_us-gaapEstimateOfFairValueFairValueDisclosureMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">35,971</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.85%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:continuation></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-16</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000278_dcnt_2fd90989-5197-47da-9632-ca05c348bc0b" continuedAt="F_000278_dcnt_4a775138-af51-45c8-9607-0b82053886eb"><ix:continuation id="F_000320_dcnt_4fc84c0e-111f-4dc3-a0ae-9b73dfd79608">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:continuation>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The financial liabilities that are measured and recorded at estimated fair value on a recurring basis consist of our contingent consideration associated with our acquisition of Indi, and prior to the completion of our initial public offering in October 2020, the warrant liability and put option liability granted to certain holders of our convertible preferred stock and debt instruments, which were accounted for as liabilities and remeasured through our statements of operations. <ix:nonNumeric id="F_000321" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" contextRef="C_0001439725_20200101_20201231" escape="true" continuedAt="F_000321_cnt_1">The table below presents the reported fair values of these liabilities, all of which are classified as Level 3 in the fair value hierarchy, as of the dates indicated (in thousands):</ix:nonNumeric></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000321_cnt_1">
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">As of December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> Description</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contingent consideration</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000427" name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="C_0001439725_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByLiabilityClassAxis_bdsxContingentConsiderationMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">29,932</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000428" name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="C_0001439725_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByLiabilityClassAxis_bdsxContingentConsiderationMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">29,114</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Put option liability</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000429" name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="C_0001439725_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByLiabilityClassAxis_bdsxPutOptionLiabilityMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,261</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrant liability</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000430" name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="C_0001439725_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByLiabilityClassAxis_bdsxWarrantLiabilityMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231" decimals="-3" scale="3">372</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contingent value rights</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000431" name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="C_0001439725_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByLiabilityClassAxis_bdsxContingentValueRightsMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231" decimals="-3" scale="3">60</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.85%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:continuation><ix:nonNumeric id="F_000322" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" contextRef="C_0001439725_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table presents the changes in these financial liabilities for the year ended December 31, 2020 (in thousands):</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Level 3 Rollforward</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Contingent</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Consideration</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Put</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Option</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Liability</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Warrant</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Liability</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Contingent</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Value&#160;Rights</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Beginning balances</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000432" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="C_0001439725_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByLiabilityClassAxis_bdsxContingentConsiderationMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">29,114</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000433" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="C_0001439725_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByLiabilityClassAxis_bdsxPutOptionLiabilityMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,261</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000434" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="C_0001439725_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByLiabilityClassAxis_bdsxWarrantLiabilityMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231" decimals="-3" scale="3">372</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000435" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="C_0001439725_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByLiabilityClassAxis_bdsxContingentValueRightsMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231" decimals="-3" scale="3">60</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additions</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000436" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" contextRef="C_0001439725_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByLiabilityClassAxis_bdsxPutOptionLiabilityMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,389</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Changes in fair value</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000437" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="C_0001439725_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByLiabilityClassAxis_bdsxContingentConsiderationMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20200101_20201231" decimals="-3" scale="3">818</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000438" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="C_0001439725_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByLiabilityClassAxis_bdsxWarrantLiabilityMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,252</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000439" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="C_0001439725_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByLiabilityClassAxis_bdsxContingentValueRightsMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20200101_20201231" decimals="-3" sign="-" scale="3">60</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reclassified to additional paid-in capital</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000440" name="bdsx:FairValueMeasurementWithUnobservableInputsReconciliationReclassifiedToAdditionalPaidInCapital" contextRef="C_0001439725_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByLiabilityClassAxis_bdsxPutOptionLiabilityMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">6,650</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000441" name="bdsx:FairValueMeasurementWithUnobservableInputsReconciliationReclassifiedToAdditionalPaidInCapital" contextRef="C_0001439725_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByLiabilityClassAxis_bdsxWarrantLiabilityMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">1,624</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ending balances</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000442" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="C_0001439725_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByLiabilityClassAxis_bdsxContingentConsiderationMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">29,932</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Contingent Consideration</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the acquisition of Indi, the Company recorded contingent consideration for amounts contingently payable to Indi's selling shareholders pursuant to the Asset Purchase Agreement (See Note 4 &#8211; <span style="font-style:italic;">Business Combinations</span>). The significant unobservable inputs used in the measurement of fair value include the probability of successful achievement of the specified product gross margin targets, the period in which the targets are expected to be achieved, and discount rates which ranged from <ix:nonFraction unitRef="U_xbrlipure" id="F_000443" name="bdsx:PercentageOfProbabilitiesOfContingentConsiderationSuccessfulAchievementMilestoneDiscountRatesRange" contextRef="C_0001439725_srtRangeAxis_srtMinimumMember_20200101_20201231" decimals="INF" scale="-2">12.2</ix:nonFraction>% to <ix:nonFraction unitRef="U_xbrlipure" id="F_000444" name="bdsx:PercentageOfProbabilitiesOfContingentConsiderationSuccessfulAchievementMilestoneDiscountRatesRange" contextRef="C_0001439725_srtRangeAxis_srtMaximumMember_20200101_20201231" decimals="INF" scale="-2">13.5</ix:nonFraction>%. Significant increases or decreases in any of these inputs would result in a significantly higher or lower fair value measurement. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contingent consideration is recorded in the balance sheets as long-term liabilities. The net change to contingent consideration during the years ended December 31, 2020 and 2019 was an increase of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000445" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" contextRef="C_0001439725_20200101_20201231" decimals="-5" scale="6">0.8</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000446" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" contextRef="C_0001439725_20190101_20191231" decimals="-5" scale="6">4.1</ix:nonFraction> million, respectively, and are recorded as operating expenses in the statements of operations.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Put Option Liability</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The put option liability was valued based on the calculated returns as a result of the various discounts included in the Company&#8217;s convertible notes payable and the related probability assessments of the various settlement scenarios. During 2020, the Company recognized an addition to the put option liability of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000447" name="bdsx:PutOptionLiabilityCurrent" contextRef="C_0001439725_20201231" decimals="-5" scale="6">3.4</ix:nonFraction> million in connection with a favorable conversion rate granted to holders of issued convertible debt. The put option liability was settled upon the closing of the Company&#8217;s initial public offering in October 2020 and reclassified to additional paid-in capital. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Warrant Liability </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">In connection with entering into the 2018 Notes, the Company issued to the lender a warrant to purchase <ix:nonFraction unitRef="U_xbrlishares" id="F_000448" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" contextRef="C_0001439725_us-gaapLongtermDebtTypeAxis_bdsxNotesPayable2018NotesMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesGPreferredStockMember_20201231" decimals="INF" format="ixt:numdotdecimal">613,333</ix:nonFraction> shares of Series G convertible preferred stock, at an exercise price of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000449" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="C_0001439725_us-gaapLongtermDebtTypeAxis_bdsxNotesPayable2018NotesMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesGPreferredStockMember_20201231" decimals="INF">0.75</ix:nonFraction> per share, subject to adjustment upon specified dilutive issuances. The warrant was immediately exercisable upon issuance and expires on <ix:nonNumeric id="F_000450" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate" contextRef="C_0001439725_20201231" format="ixt:datemonthdayyearen">February 23, 2028</ix:nonNumeric>. The estimated fair value of the warrant on the issuance date of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000451" name="us-gaap:WarrantsNotSettleableInCashFairValueDisclosure" contextRef="C_0001439725_20201231" decimals="-5" scale="6">0.3</ix:nonFraction>&#160;million was recorded as a debt discount and as a preferred stock warrant liability. Through the effective date of the Company&#8217;s initial public offering, the Series G warrants were remeasured to an estimate of fair value using a Black Scholes pricing model. As a result of the Company&#8217;s initial public offering, the preferred stock warrants were automatically converted to warrants to purchase <ix:nonFraction unitRef="U_xbrlishares" id="F_000452" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="C_0001439725_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20201231" decimals="INF" format="ixt:numdotdecimal">103,326</ix:nonFraction> shares of common stock with a weighted average exercise price of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000453" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="C_0001439725_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20201231" decimals="2">4.46</ix:nonFraction> and were also transferred to additional paid-in capital.&#160;&#160;During 2020, the Company recorded an increase in the value of the warrant liability of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000454" name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="C_0001439725_20200101_20201231" decimals="-5" scale="6">1.3</ix:nonFraction> million.</span> </p></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-17</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000278_dcnt_4a775138-af51-45c8-9607-0b82053886eb">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><span style="font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Contingent Value Rights</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to the shares of Series F Preferred Stock that were issued in January 2016, investors who purchased more than their pro&#8209;rata amount in the financing described above received a calculated number of contingent value rights (CVRs). In connection with the Series F financing, the Company issued <ix:nonFraction unitRef="U_xbrlishares" id="F_000455" name="bdsx:ContingentValueRightsShares" contextRef="C_0001439725_us-gaapStatementClassOfStockAxis_us-gaapSeriesFPreferredStockMember_20160131" decimals="INF" format="ixt:numdotdecimal">3,999</ix:nonFraction> CVRs originally valued at $<ix:nonFraction unitRef="U_iso4217USD" id="F_000456" name="bdsx:ContingentValueRights" contextRef="C_0001439725_us-gaapStatementClassOfStockAxis_us-gaapSeriesFPreferredStockMember_20160131" decimals="-5" scale="6">0.5</ix:nonFraction> million. One CVR represents <ix:nonFraction unitRef="U_xbrlipure" id="F_000457" name="bdsx:ContingentValueRightsPercentage" contextRef="C_0001439725_us-gaapStatementClassOfStockAxis_us-gaapSeriesFPreferredStockMember_20160101_20160131" decimals="INF" scale="-2">0.00375</ix:nonFraction>% of the Company&#8217;s interest in the drug ficlatuzumab. The initial estimated value of the CVRs were recorded as a liability and as a reduction to the Series F proceeds. Upon receipt by the Company or a milestone, royalty, or any other type of payment from the Company&#8217;s ownership rights in the drug, the Company was required to make a cash payment to the CVR holders equal to <ix:nonFraction unitRef="U_xbrlipure" id="F_000458" name="bdsx:NetProceedsPercentageOfCashPaymentToCVRHolders" contextRef="C_0001439725_us-gaapStatementClassOfStockAxis_us-gaapSeriesFPreferredStockMember_20160101_20160131" decimals="2" scale="-2">15</ix:nonFraction>% of net proceeds, as defined. In September 2020, the Company exercised its opt-out right with AVEO Oncology (AVEO) for the payment of <ix:nonFraction unitRef="U_xbrlipure" id="F_000459" name="bdsx:PercentageOfDevelopmentAndRegulatoryCostsExercisedUsingOptOutRight" contextRef="C_0001439725_srtCounterpartyNameAxis_bdsxAVEOOncologyMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesFPreferredStockMember_20200901_20200930" decimals="2" scale="-2">50</ix:nonFraction>% of development and regulatory costs for ficlatuzumab. As a result, the CVRs were settled effective December 2, 2020. See Note 17 &#8211; <span style="font-style:italic;">Commitments and Contingencies</span> for a discussion of the Co-Development Agreement with AVEO. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Non-Financial Assets and Liabilities</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our non-financial assets, which primarily consist of property and equipment, goodwill, and other intangible assets, are not required to be carried at fair value on a recurring basis and are reported at carrying value. There were no changes to the valuation methods during the periods presented.</p></ix:continuation><ix:nonNumeric id="F_000279" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" contextRef="C_0001439725_20200101_20201231" escape="true">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note 6 &#8211; Property and Equipment </p><ix:nonNumeric id="F_000323" name="us-gaap:PropertyPlantAndEquipmentTextBlock" contextRef="C_0001439725_20200101_20201231" escape="true">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment consist of the following (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">As of December 31,</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lab equipment</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000460" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001439725_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapEquipmentMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,730</ix:nonFraction></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000461" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001439725_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapEquipmentMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,221</ix:nonFraction></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000462" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001439725_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,845</ix:nonFraction></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000463" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001439725_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,894</ix:nonFraction></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer equipment</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000464" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001439725_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapComputerEquipmentMember_20201231" decimals="-3" scale="3">871</ix:nonFraction></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000465" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001439725_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapComputerEquipmentMember_20191231" decimals="-3" scale="3">869</ix:nonFraction></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture and fixtures</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000466" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001439725_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20201231" decimals="-3" scale="3">424</ix:nonFraction></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000467" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001439725_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20191231" decimals="-3" scale="3">427</ix:nonFraction></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Software</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000468" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001439725_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapSoftwareAndSoftwareDevelopmentCostsMember_20201231" decimals="-3" scale="3">651</ix:nonFraction></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000469" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001439725_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapSoftwareAndSoftwareDevelopmentCostsMember_20191231" decimals="-3" scale="3">503</ix:nonFraction></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Construction in process</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000470" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001439725_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapConstructionInProgressMember_20201231" decimals="-3" scale="3">381</ix:nonFraction></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000471" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001439725_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapConstructionInProgressMember_20191231" decimals="-3" scale="3">592</ix:nonFraction></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000472" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001439725_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">9,902</ix:nonFraction></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000473" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001439725_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">8,506</ix:nonFraction></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less accumulated depreciation</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000474" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="C_0001439725_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">6,724</ix:nonFraction></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000475" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="C_0001439725_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">6,386</ix:nonFraction></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total property and equipment, net</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000476" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_0001439725_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,178</ix:nonFraction></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000477" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_0001439725_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,120</ix:nonFraction></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:nonNumeric id="F_000324" name="bdsx:ScheduleOfDepreciationAndAmortizationExpenseRelatedToPropertyAndEquipmentTableTextBlock" contextRef="C_0001439725_20200101_20201231" escape="true">
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation expense related to property and equipment, reported in &#8216;Direct costs and expenses&#8217; and &#8216;Sales, marketing, general and administrative&#8217; was: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.85%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year ended December 31,</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Direct costs and expenses</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000478" name="us-gaap:Depreciation" contextRef="C_0001439725_us-gaapFairValueByAssetClassAxis_us-gaapPropertyPlantAndEquipmentMember_us-gaapIncomeStatementLocationAxis_bdsxDirectCostsAndExpensesMember_20200101_20201231" decimals="-3" scale="3">361</ix:nonFraction></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000479" name="us-gaap:Depreciation" contextRef="C_0001439725_us-gaapFairValueByAssetClassAxis_us-gaapPropertyPlantAndEquipmentMember_us-gaapIncomeStatementLocationAxis_bdsxDirectCostsAndExpensesMember_20190101_20191231" decimals="-3" scale="3">183</ix:nonFraction></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales, marketing, general and administrative</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000480" name="us-gaap:Depreciation" contextRef="C_0001439725_us-gaapFairValueByAssetClassAxis_us-gaapPropertyPlantAndEquipmentMember_us-gaapIncomeStatementLocationAxis_us-gaapSellingGeneralAndAdministrativeExpensesMember_20200101_20201231" decimals="-3" scale="3">478</ix:nonFraction></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000481" name="us-gaap:Depreciation" contextRef="C_0001439725_us-gaapFairValueByAssetClassAxis_us-gaapPropertyPlantAndEquipmentMember_us-gaapIncomeStatementLocationAxis_us-gaapSellingGeneralAndAdministrativeExpensesMember_20190101_20191231" decimals="-3" scale="3">636</ix:nonFraction></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; Total</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000482" name="us-gaap:Depreciation" contextRef="C_0001439725_us-gaapFairValueByAssetClassAxis_us-gaapPropertyPlantAndEquipmentMember_20200101_20201231" decimals="-3" scale="3">839</ix:nonFraction></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000483" name="us-gaap:Depreciation" contextRef="C_0001439725_us-gaapFairValueByAssetClassAxis_us-gaapPropertyPlantAndEquipmentMember_20190101_20191231" decimals="-3" scale="3">819</ix:nonFraction></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Disposals of Property and Equipment</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gains on disposal of property and equipment were not significant for the years ended December&#160;31, 2020 and 2019, and are included in &#8216;Sales, marketing, general and administrative&#8217; in the statements of operations.</p></ix:nonNumeric>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-18</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:nonNumeric id="F_000280" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" contextRef="C_0001439725_20200101_20201231" escape="true">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note 7 &#8211; Goodwill and Intangible Assets</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Goodwill</p><ix:nonNumeric id="F_000325" name="us-gaap:ScheduleOfGoodwillTextBlock" contextRef="C_0001439725_20200101_20201231" escape="true">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Changes in goodwill for the years ended December 31, 2020 and 2019 were (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at January 1, 2019</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000484" name="us-gaap:Goodwill" contextRef="C_0001439725_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">14,204</ix:nonFraction></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:85.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;Attributable to acquisition of Oncimmune, Ltd.</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000485" name="us-gaap:GoodwillAcquiredDuringPeriod" contextRef="C_0001439725_20190101_20191231" decimals="-3" scale="3">827</ix:nonFraction></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:85.12%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31 2019</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000486" name="us-gaap:Goodwill" contextRef="C_0001439725_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">15,031</ix:nonFraction></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:85.12%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2020</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000487" name="us-gaap:Goodwill" contextRef="C_0001439725_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">15,031</ix:nonFraction></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Intangible Assets, Net</p><ix:nonNumeric id="F_000326" name="us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" contextRef="C_0001439725_20200101_20201231" escape="true">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible assets consist of the following (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.85%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.64%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2020</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2019</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Accumulated</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Amortization</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Net Carrying Value</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Accumulated</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Amortization</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Net Carrying Value</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible assets subject to amortization</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.2%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.44%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.2%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.2%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.24%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.2%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Patents</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000488" name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="C_0001439725_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapPatentsMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,474</ix:nonFraction></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000490" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="C_0001439725_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapPatentsMember_20201231" decimals="-3" scale="3">494</ix:nonFraction></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000492" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="C_0001439725_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapPatentsMember_20201231" decimals="-3" scale="3">980</ix:nonFraction></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000494" name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="C_0001439725_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapPatentsMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,245</ix:nonFraction></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000497" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="C_0001439725_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapPatentsMember_20191231" decimals="-3" scale="3">411</ix:nonFraction></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000500" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="C_0001439725_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapPatentsMember_20191231" decimals="-3" scale="3">834</ix:nonFraction></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchased technology</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000489" name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="C_0001439725_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_bdsxPurchasedTechnologyMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">16,900</ix:nonFraction></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000491" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="C_0001439725_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_bdsxPurchasedTechnologyMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,694</ix:nonFraction></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000493" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="C_0001439725_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_bdsxPurchasedTechnologyMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">12,206</ix:nonFraction></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000495" name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="C_0001439725_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_bdsxPurchasedTechnologyMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">16,900</ix:nonFraction></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000498" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="C_0001439725_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_bdsxPurchasedTechnologyMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,817</ix:nonFraction></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000501" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="C_0001439725_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_bdsxPurchasedTechnologyMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">14,083</ix:nonFraction></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchase option</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000496" name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="C_0001439725_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_bdsxPurchaseOptionMember_20191231" decimals="-3" scale="3">121</ix:nonFraction></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000499" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="C_0001439725_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_bdsxPurchaseOptionMember_20191231" decimals="-3" scale="3">17</ix:nonFraction></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000502" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="C_0001439725_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_bdsxPurchaseOptionMember_20191231" decimals="-3" scale="3">104</ix:nonFraction></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible assets not subject to amortization</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.2%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.44%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.2%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.2%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.24%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.2%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Trademarks</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000503" name="bdsx:IndefiniteLivedIntangibleAssetsExcludingGoodwillGross" contextRef="C_0001439725_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapTrademarksMember_20201231" decimals="-3" scale="3">74</ix:nonFraction></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.44%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000504" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" contextRef="C_0001439725_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapTrademarksMember_20201231" decimals="-3" scale="3">74</ix:nonFraction></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000505" name="bdsx:IndefiniteLivedIntangibleAssetsExcludingGoodwillGross" contextRef="C_0001439725_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapTrademarksMember_20191231" decimals="-3" scale="3">71</ix:nonFraction></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000506" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" contextRef="C_0001439725_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapTrademarksMember_20191231" decimals="-3" scale="3">71</ix:nonFraction></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.92%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; Total</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.2%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000507" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" contextRef="C_0001439725_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">18,448</ix:nonFraction></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.44%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000508" name="bdsx:IntangibleAssetsAccumulatedAmortizationExcludingGoodwill" contextRef="C_0001439725_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,188</ix:nonFraction></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.2%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000509" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="C_0001439725_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">13,260</ix:nonFraction></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.2%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000510" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" contextRef="C_0001439725_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">18,337</ix:nonFraction></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.24%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000511" name="bdsx:IntangibleAssetsAccumulatedAmortizationExcludingGoodwill" contextRef="C_0001439725_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,245</ix:nonFraction></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.2%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000512" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="C_0001439725_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">15,092</ix:nonFraction></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:nonNumeric id="F_000327" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" contextRef="C_0001439725_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amortization expense related to definite-lived intangible assets was (in thousands): </p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:73.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.16%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year ended December 31,</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:73.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:73.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Direct costs and expenses</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.98%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000513" name="us-gaap:AmortizationOfIntangibleAssets" contextRef="C_0001439725_us-gaapIncomeStatementLocationAxis_bdsxDirectCostsAndExpensesMember_20200101_20201231" decimals="-3" scale="3">13</ix:nonFraction></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000514" name="us-gaap:AmortizationOfIntangibleAssets" contextRef="C_0001439725_us-gaapIncomeStatementLocationAxis_bdsxDirectCostsAndExpensesMember_20190101_20191231" decimals="-3" scale="3">15</ix:nonFraction></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:73.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales, marketing, general and administrative</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000515" name="us-gaap:AmortizationOfIntangibleAssets" contextRef="C_0001439725_us-gaapIncomeStatementLocationAxis_us-gaapSellingGeneralAndAdministrativeExpensesMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,051</ix:nonFraction></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000516" name="us-gaap:AmortizationOfIntangibleAssets" contextRef="C_0001439725_us-gaapIncomeStatementLocationAxis_us-gaapSellingGeneralAndAdministrativeExpensesMember_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,959</ix:nonFraction></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:73.04%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; Total</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.98%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000517" name="us-gaap:AmortizationOfIntangibleAssets" contextRef="C_0001439725_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,064</ix:nonFraction></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000518" name="us-gaap:AmortizationOfIntangibleAssets" contextRef="C_0001439725_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,974</ix:nonFraction></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:nonNumeric><ix:nonNumeric id="F_000328" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" contextRef="C_0001439725_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Future estimated amortization expense of intangible assets is (in thousands):</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">As of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000519" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" contextRef="C_0001439725_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,946</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000520" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" contextRef="C_0001439725_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,940</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000521" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" contextRef="C_0001439725_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,936</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000522" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" contextRef="C_0001439725_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,928</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2025</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000523" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" contextRef="C_0001439725_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,924</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thereafter</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000524" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" contextRef="C_0001439725_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,512</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000525" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="C_0001439725_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">13,186</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There have been <ix:nonFraction unitRef="U_iso4217USD" id="F_000526" name="us-gaap:GoodwillAndIntangibleAssetImpairment" contextRef="C_0001439725_20200101_20201231" decimals="INF" format="ixt-sec:numwordsen" scale="3">no</ix:nonFraction> impairments of intangible assets for the twelve-month periods ended December 31, 2020 and December 31, 2019.</p></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-19</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:nonNumeric id="F_000281" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" contextRef="C_0001439725_20200101_20201231" escape="true">
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note 8 &#8211; Accrued Liabilities </p><ix:nonNumeric id="F_000329" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" contextRef="C_0001439725_20200101_20201231" escape="true">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amounts reported in &#8216;Accrued liabilities&#8217; in the balance sheets were (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Compensation related accruals</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000528" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="C_0001439725_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,975</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000529" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="C_0001439725_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,165</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued clinical trial expense</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000530" name="bdsx:AccruedClinicalTrialExpenseCurrent" contextRef="C_0001439725_20201231" decimals="-3" scale="3">715</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000531" name="bdsx:AccruedClinicalTrialExpenseCurrent" contextRef="C_0001439725_20191231" decimals="-3" scale="3">620</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other expenses</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000532" name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="C_0001439725_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,099</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000533" name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="C_0001439725_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,352</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrant liability, current</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000534" name="us-gaap:ProductWarrantyAccrualClassifiedCurrent" contextRef="C_0001439725_20191231" decimals="-3" scale="3">43</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total accrued liabilities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000535" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="C_0001439725_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">7,789</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000536" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="C_0001439725_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,180</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:nonNumeric><ix:nonNumeric id="F_000282" name="us-gaap:DebtDisclosureTextBlock" contextRef="C_0001439725_20200101_20201231" escape="true" continuedAt="F_000282_dcnt_a01d79e4-5ad5-4159-8f7b-b3ad360a2160">
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note 9 &#8211; Debt</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Notes Payable</p><ix:nonNumeric id="F_000330" name="us-gaap:ScheduleOfDebtInstrumentsTextBlock" contextRef="C_0001439725_20200101_20201231" escape="true">
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Long-term notes payable were as follows (in thousands): </p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">As of December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2018 Notes</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000537" name="us-gaap:DebtInstrumentCarryingAmount" contextRef="C_0001439725_us-gaapLongtermDebtTypeAxis_bdsxNotesPayable2018NotesMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">24,972</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000538" name="us-gaap:DebtInstrumentCarryingAmount" contextRef="C_0001439725_us-gaapLongtermDebtTypeAxis_bdsxNotesPayable2018NotesMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">24,270</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Payroll protection plan</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000539" name="us-gaap:DebtInstrumentCarryingAmount" contextRef="C_0001439725_us-gaapDebtInstrumentAxis_bdsxCARESActMember_us-gaapLongtermDebtTypeAxis_bdsxPPPLoanMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,107</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Convertible notes payable</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000540" name="us-gaap:ConvertibleNotesPayableCurrent" contextRef="C_0001439725_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">13,159</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unamortized debt discount and debt issuance costs</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000541" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" contextRef="C_0001439725_20201231" decimals="-3" scale="3">313</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000542" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" contextRef="C_0001439725_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,458</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000543" name="us-gaap:NotesPayable" contextRef="C_0001439725_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">27,766</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000544" name="us-gaap:NotesPayable" contextRef="C_0001439725_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">35,971</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: current maturities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000545" name="us-gaap:NotesPayableCurrent" contextRef="C_0001439725_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">11,840</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000546" name="us-gaap:NotesPayableCurrent" contextRef="C_0001439725_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">12,159</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Long-term notes payable</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000547" name="us-gaap:LongTermNotesPayable" contextRef="C_0001439725_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">15,926</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000548" name="us-gaap:LongTermNotesPayable" contextRef="C_0001439725_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">23,812</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2018, the Company issued long-term debt of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000549" name="us-gaap:DebtInstrumentCarryingAmount" contextRef="C_0001439725_us-gaapLongtermDebtTypeAxis_bdsxNotesPayable2018NotesMember_20180228" decimals="-5" scale="6">23.0</ix:nonFraction> million to Innovatus Life Sciences Lending Fund (Innovatus or Lender) (the 2018 Notes).&#160;&#160;Innovatus is also a holder of the Company&#8217;s common stock.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At the time of issuance, the Company paid a facility fee of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000550" name="us-gaap:DebtInstrumentFeeAmount" contextRef="C_0001439725_us-gaapLongtermDebtTypeAxis_bdsxNotesPayable2018NotesMember_20180228" decimals="-5" scale="6">0.2</ix:nonFraction> million and issued a warrant to Innovatus, with an initial estimated fair value of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000552" name="us-gaap:WarrantsNotSettleableInCashFairValueDisclosure" contextRef="C_0001439725_us-gaapLongtermDebtTypeAxis_bdsxNotesPayable2018NotesMember_20180228" decimals="-5" scale="6">0.3</ix:nonFraction> million, for the purchase of <ix:nonFraction unitRef="U_xbrlishares" id="F_000551" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" contextRef="C_0001439725_us-gaapLongtermDebtTypeAxis_bdsxNotesPayable2018NotesMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesGPreferredStockMember_20180228" decimals="INF" format="ixt:numdotdecimal">613,333</ix:nonFraction> shares of Series G preferred stock. The facility fee and the estimated warrant fair value were recorded as debt discount and is amortized to interest expense over the term of the 2018 Notes.&#160;&#160;The 2018 Notes bear annual interest at <ix:nonFraction unitRef="U_xbrlipure" id="F_000553" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="C_0001439725_us-gaapLongtermDebtTypeAxis_bdsxNotesPayable2018NotesMember_20180228" decimals="INF" scale="-2">10</ix:nonFraction>%, of which <ix:nonFraction unitRef="U_xbrlipure" id="F_000554" name="bdsx:DebtInstrumentPercentageOfStatedInterestRatePaidInCash" contextRef="C_0001439725_us-gaapLongtermDebtTypeAxis_bdsxNotesPayable2018NotesMember_20180228" decimals="INF" scale="-2">7.5</ix:nonFraction>% is payable in cash, with the remaining <ix:nonFraction unitRef="U_xbrlipure" id="F_000555" name="bdsx:DebtInstrumentPercentageOfStatedInterestRateAddedToPrincipalValueOfNotesPayable" contextRef="C_0001439725_us-gaapLongtermDebtTypeAxis_bdsxNotesPayable2018NotesMember_20180228" decimals="INF" scale="-2">2.5</ix:nonFraction>% added to principal through December 31, 2020.&#160;&#160;Total interest added to principal was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000556" name="bdsx:DebtInstrumentInterestAddedToPrincipalValue" contextRef="C_0001439725_us-gaapLongtermDebtTypeAxis_bdsxNotesPayable2018NotesMember_20201231" decimals="-5" scale="6">1.7</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000557" name="bdsx:DebtInstrumentInterestAddedToPrincipalValue" contextRef="C_0001439725_us-gaapLongtermDebtTypeAxis_bdsxNotesPayable2018NotesMember_20191231" decimals="-5" scale="6">1.1</ix:nonFraction> million as of December 31, 2020 and 2019, respectively. <ix:nonNumeric id="F_000558" name="us-gaap:DebtInstrumentFrequencyOfPeriodicPayment" contextRef="C_0001439725_us-gaapLongtermDebtTypeAxis_bdsxNotesPayable2018NotesMember_20200101_20201231">Commencing March 2021 and continuing through the maturity date February 2023, the outstanding principal is repayable in 24 equal monthly installments.</ix:nonNumeric>&#160;&#160;</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The loan may be prepaid by the Company at any time, subject to a prepayment penalty of up to <ix:nonFraction unitRef="U_xbrlipure" id="F_000559" name="bdsx:DebtInstrumentPrepaymentPenaltyPercentage" contextRef="C_0001439725_us-gaapLongtermDebtTypeAxis_bdsxNotesPayable2018NotesMember_20180201_20180228" decimals="INF" scale="-2">3</ix:nonFraction>% of the principal amount, depending on the date of prepayment. Upon payment of the 2018 Notes at maturity or prepayment on any earlier date, unless waived, a <ix:nonFraction unitRef="U_xbrlipure" id="F_000560" name="bdsx:DebtInstrumentBackEndFacilityFeePercentage" contextRef="C_0001439725_us-gaapLongtermDebtTypeAxis_bdsxNotesPayable2018NotesMember_20180201_20180228" decimals="2" scale="-2">2</ix:nonFraction>% back-end facility fee will apply to the amounts paid or prepaid. The <ix:nonFraction unitRef="U_xbrlipure" id="F_000561" name="bdsx:DebtInstrumentAdditionalInterestExpenseFeePercentage" contextRef="C_0001439725_us-gaapLongtermDebtTypeAxis_bdsxNotesPayable2018NotesMember_20180201_20180228" decimals="2" scale="-2">2</ix:nonFraction>% fee is recognized as additional interest expense over the loan term. The 2018 Notes are senior to all of the Company&#8217;s other indebtedness including any contingent consideration payable to Indi.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The 2018 Notes contain customary affirmative covenants, and contain negative covenants limiting the ability of the Company to, among other things, incur future debt, transfer assets except for the ordinary course of business, make acquisitions, make certain restricted payments, or to sell assets, subject to certain exceptions.&#160; In addition, the 2018 Notes require the Company to comply with a minimum daily liquidity covenant and a rolling monthly revenue requirement. Failure to comply with the covenants and loan requirements may result in early amortization of the loan in a 24- or 36-month payment schedule. As of December 31, 2020, the Company was in compliance with all terms and covenants.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company granted the Lender a security interest in all of the Company&#8217;s assets through a pledge and security agreement, patent security agreement and trademark security agreement, each between the Company and the Lender. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-20</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000282_dcnt_a01d79e4-5ad5-4159-8f7b-b3ad360a2160" continuedAt="F_000282_dcnt_809c7768-7943-4528-a8bd-490ad69ff5e9">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Paycheck Protection Program Note Payable</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In April 2020, the Company entered into a loan pursuant to the Paycheck Protection Program under the CARES Act, as administered by the U.S. Small Business Administration (the SBA). The loan, in the principal amount of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000564" name="us-gaap:DebtInstrumentCarryingAmount" contextRef="C_0001439725_us-gaapDebtInstrumentAxis_bdsxCARESActMember_us-gaapLongtermDebtTypeAxis_bdsxPPPLoanMember_20200430" decimals="-5" scale="6">3.1</ix:nonFraction> million (the PPP Loan), was disbursed by JPMorgan Chase Bank (JPM) pursuant to a Paycheck Protection Program Promissory Note and Agreement (the Note and Agreement).</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000565" name="us-gaap:DebtInstrumentDescription" contextRef="C_0001439725_us-gaapLongtermDebtTypeAxis_bdsxPPPLoanMember_20200101_20201231">The PPP Loan matures on the two-year anniversary of the funding date, April 2022, and bears interest at a fixed rate of <ix:nonFraction unitRef="U_xbrlipure" id="F_000566" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="C_0001439725_us-gaapInvestmentTypeAxis_us-gaapInterestBearingDepositsMember_us-gaapLongtermDebtTypeAxis_bdsxPPPLoanMember_20200430" decimals="INF" scale="-2">1.00</ix:nonFraction>% per annum. Monthly principal and interest payments, less the amount of any potential forgiveness (as discussed below), will commence in September 2021. The Company did not provide any collateral or guarantees in connection with the PPP Loan, nor did the Company pay any facility charge to obtain the PPP Loan.</ix:nonNumeric> The Note and Agreement provides for customary events of default, including those relating to failure to make payment, bankruptcy, breaches of representations and material adverse effects. The Company may prepay the principal of the PPP Loan at any time without incurring any prepayment charges.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All or a portion of the PPP Loan may be forgiven by the SBA and JPM upon application by the Company.&#160; Under the CARES Act, loan forgiveness is available for the sum of documented payroll costs, covered rent payments, and covered utilities during the eight-week period beginning on the approval date of the PPP Loan. For purposes of the CARES Act, payroll costs exclude compensation of an individual employee earning more than $<ix:nonFraction unitRef="U_iso4217USD" id="F_000567" name="bdsx:PayrollCostsExcludesCompensationOfEmployee" contextRef="C_0001439725_srtRangeAxis_srtMinimumMember_us-gaapDebtInstrumentAxis_bdsxCARESActMember_us-gaapLongtermDebtTypeAxis_bdsxPPPLoanMember_20200401_20200430" decimals="INF" format="ixt:numdotdecimal">100,000</ix:nonFraction>, prorated annually. Not more than <ix:nonFraction unitRef="U_xbrlipure" id="F_000568" name="bdsx:PercentageForNonPayrollCosts" contextRef="C_0001439725_us-gaapDebtInstrumentAxis_bdsxCARESActMember_us-gaapLongtermDebtTypeAxis_bdsxPPPLoanMember_20200401_20200430" decimals="INF" scale="-2">40</ix:nonFraction>% of the forgiven amount may be for non-payroll costs. Forgiveness is reduced if full-time headcount declines, or if salaries and wages for employees with salaries of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000569" name="bdsx:UpperLimitOfEmployeeSalaryToReduceForgiveness" contextRef="C_0001439725_us-gaapDebtInstrumentAxis_bdsxCARESActMember_us-gaapLongtermDebtTypeAxis_bdsxPPPLoanMember_20200401_20200430" decimals="INF" format="ixt:numdotdecimal">100,000</ix:nonFraction> or less annually are reduced by more than <ix:nonFraction unitRef="U_xbrlipure" id="F_000570" name="bdsx:PercentageOfUpperLimitOfEmployeeSalaryToReduceForgiveness" contextRef="C_0001439725_us-gaapDebtInstrumentAxis_bdsxCARESActMember_us-gaapLongtermDebtTypeAxis_bdsxPPPLoanMember_20200401_20200430" decimals="INF" scale="-2">25</ix:nonFraction>%.&#160;The Company currently intends to repay the PPP loan in accordance with the underlying terms and conditions.&#160;&#160;To the extent we elect to seek forgiveness, the Company cannot assure that the PPP Loan will be forgiven, in whole or in part. If the loan is forgiven in part or in whole, and legal release is received, the Company will&#160;reduce the liability by the amount forgiven and record a gain on extinguishment in the statements of operations.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Convertible Notes Payable</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">March 2020 Notes</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2020, the Company issued $<ix:nonFraction unitRef="U_iso4217USD" id="F_000571" name="us-gaap:NotesIssued1" contextRef="C_0001439725_us-gaapShortTermDebtTypeAxis_bdsxMarchTwoThousandAndTwentyConvertibleNotesMember_20200301_20200331" decimals="-5" scale="6">10.0</ix:nonFraction> million of convertible notes primarily to existing stockholders that were originally scheduled to mature in <span style="-sec-ix-hidden:F_000572">August 2020</span> (the March 2020 Notes). In August 2020, the Company and its lenders agreed to extend the maturity date to <ix:nonNumeric id="F_000573" name="bdsx:DebtInstrumentMaturityDateExtended" contextRef="C_0001439725_us-gaapShortTermDebtTypeAxis_bdsxMarchTwoThousandAndTwentyConvertibleNotesMember_20200801_20200831" format="ixt:datemonthdayyearen">June 30, 2021</ix:nonNumeric>. The March 2020 Notes were issued in two tranches of $<span><ix:nonFraction unitRef="U_iso4217USD" id="F_000574" name="us-gaap:NotesIssued1" contextRef="C_0001439725_us-gaapDebtInstrumentRedemptionPeriodAxis_us-gaapDebtInstrumentRedemptionPeriodOneMember_us-gaapShortTermDebtTypeAxis_bdsxMarchTwoThousandAndTwentyConvertibleNotesMember_20200301_20200331" decimals="-5" scale="6"><ix:nonFraction unitRef="U_iso4217USD" id="F_000575" name="us-gaap:NotesIssued1" contextRef="C_0001439725_us-gaapDebtInstrumentRedemptionPeriodAxis_us-gaapDebtInstrumentRedemptionPeriodTwoMember_us-gaapShortTermDebtTypeAxis_bdsxMarchTwoThousandAndTwentyConvertibleNotesMember_20200601_20200630" decimals="-5" scale="6">5.0</ix:nonFraction></ix:nonFraction> million</span>, with the first in March 2020 and the second in June 2020.&#160;&#160;Interest on the March 2020 Notes was <ix:nonFraction unitRef="U_xbrlipure" id="F_000576" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="C_0001439725_us-gaapShortTermDebtTypeAxis_bdsxMarchTwoThousandAndTwentyConvertibleNotesMember_20200331" decimals="INF" scale="-2">3</ix:nonFraction>% per annum, payable in full upon maturity through conversion to Series H Preferred Stock at <ix:nonFraction unitRef="U_xbrlipure" id="F_000577" name="us-gaap:DebtConversionConvertedInstrumentRate" contextRef="C_0001439725_us-gaapShortTermDebtTypeAxis_bdsxMarchTwoThousandAndTwentyConvertibleNotesMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesHPreferredStockMember_20200301_20200331" decimals="INF" scale="-2">80</ix:nonFraction>% of the original issuance price of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000578" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextRef="C_0001439725_us-gaapShortTermDebtTypeAxis_bdsxMarchTwoThousandAndTwentyConvertibleNotesMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesHPreferredStockMember_20200331" decimals="INF">1.15</ix:nonFraction> per share.&#160;&#160;Under the terms of the March 2020 Notes, on or before the maturity date and if the March 2020 Notes are unpaid, the outstanding principal and unpaid accrued interest under the March 2020 Notes shall be automatically converted into common stock in an initial public offering at a conversion price of <ix:nonFraction unitRef="U_xbrlipure" id="F_000579" name="bdsx:PercentageOfConversionPricePerShareOfCommonStock" contextRef="C_0001439725_us-gaapShortTermDebtTypeAxis_bdsxMarchTwoThousandAndTwentyConvertibleNotesMember_20200301_20200331" decimals="INF" scale="-2">80</ix:nonFraction>% of the per share price of common stock sold in the initial public offering. The discount on the automatic conversion was separated from the March 2020 Notes and reported as a debt discount and put option liability of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000580" name="bdsx:PutOptionLiabilityCurrent" contextRef="C_0001439725_us-gaapShortTermDebtTypeAxis_bdsxMarchTwoThousandAndTwentyConvertibleNotesMember_20200331" decimals="-5" scale="6">2.5</ix:nonFraction> million and was amortized over the term of the March 2020 Notes.&#160;&#160;Following the closing of the initial public offering in October 2020, the March 2020 Notes were automatically converted into <ix:nonFraction unitRef="U_xbrlishares" id="F_000581" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="C_0001439725_us-gaapShortTermDebtTypeAxis_bdsxMarchTwoThousandAndTwentyConvertibleNotesMember_20201001_20201031" decimals="INF" format="ixt:numdotdecimal">703,503</ix:nonFraction> shares of common stock at a conversion price of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000582" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextRef="C_0001439725_us-gaapShortTermDebtTypeAxis_bdsxMarchTwoThousandAndTwentyConvertibleNotesMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201031" decimals="INF">14.40</ix:nonFraction>, or <ix:nonFraction unitRef="U_xbrlipure" id="F_000583" name="bdsx:PercentageOfConversionPricePerShareOfCommonStock" contextRef="C_0001439725_us-gaapShortTermDebtTypeAxis_bdsxMarchTwoThousandAndTwentyConvertibleNotesMember_20201001_20201031" decimals="INF" scale="-2">80</ix:nonFraction>% of the initial public offering price per common share.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">December 2019 Notes</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2019, the Company issued $<ix:nonFraction unitRef="U_iso4217USD" id="F_000584" name="us-gaap:NotesIssued1" contextRef="C_0001439725_us-gaapShortTermDebtTypeAxis_bdsxDecemberTwoThousandAndNineteenConvertibleNotesMember_20191201_20191231" decimals="-5" scale="6">6.0</ix:nonFraction> million of convertible notes primarily to existing preferred shareholders that were originally scheduled to mature in <span style="-sec-ix-hidden:F_000585">August 2020</span> (the December 2019 Notes). In August 2020, the Company and its lenders agreed to extend the maturity date to <ix:nonNumeric id="F_000586" name="bdsx:DebtInstrumentMaturityDateExtended" contextRef="C_0001439725_us-gaapShortTermDebtTypeAxis_bdsxDecemberTwoThousandAndNineteenConvertibleNotesMember_20200801_20200831" format="ixt:datemonthdayyearen">June 30, 2021</ix:nonNumeric>. The December 2019 Notes were issued in two tranches of <span>$<ix:nonFraction unitRef="U_iso4217USD" id="F_000587" name="us-gaap:NotesIssued1" contextRef="C_0001439725_us-gaapDebtInstrumentRedemptionPeriodAxis_us-gaapDebtInstrumentRedemptionPeriodOneMember_us-gaapShortTermDebtTypeAxis_bdsxDecemberTwoThousandAndNineteenConvertibleNotesMember_20191201_20191231" decimals="-5" scale="6"><ix:nonFraction unitRef="U_iso4217USD" id="F_000588" name="us-gaap:NotesIssued1" contextRef="C_0001439725_us-gaapDebtInstrumentRedemptionPeriodAxis_us-gaapDebtInstrumentRedemptionPeriodTwoMember_us-gaapShortTermDebtTypeAxis_bdsxDecemberTwoThousandAndNineteenConvertibleNotesMember_20200201_20200229" decimals="-5" scale="6">3.0</ix:nonFraction></ix:nonFraction> million</span>, the first in December 2019 and the second in February 2020.&#160;&#160;Interest on the December 2019 Notes was <ix:nonFraction unitRef="U_xbrlipure" id="F_000589" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="C_0001439725_us-gaapShortTermDebtTypeAxis_bdsxDecemberTwoThousandAndNineteenConvertibleNotesMember_20191231" decimals="INF" scale="-2">3</ix:nonFraction>% per annum and payable in full upon maturity through the conversion to Series H Preferred Stock at <ix:nonFraction unitRef="U_xbrlipure" id="F_000590" name="us-gaap:DebtConversionConvertedInstrumentRate" contextRef="C_0001439725_us-gaapShortTermDebtTypeAxis_bdsxDecemberTwoThousandAndNineteenConvertibleNotesMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesHPreferredStockMember_20191201_20191231" decimals="INF" scale="-2">80</ix:nonFraction>% of the original issuance price of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000591" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextRef="C_0001439725_us-gaapShortTermDebtTypeAxis_bdsxDecemberTwoThousandAndNineteenConvertibleNotesMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesHPreferredStockMember_20191231" decimals="INF">1.15</ix:nonFraction> per share. Under the terms of the December 2019 Notes, on or before the maturity date and if the December 2019 Notes are unpaid, the outstanding principal and unpaid accrued interest under the December 2019 Notes shall be automatically converted into common stock in an initial public offering at a conversion price of <ix:nonFraction unitRef="U_xbrlipure" id="F_000592" name="bdsx:PercentageOfConversionPricePerShareOfCommonStock" contextRef="C_0001439725_us-gaapShortTermDebtTypeAxis_bdsxDecemberTwoThousandAndNineteenConvertibleNotesMember_20191201_20191231" decimals="INF" scale="-2">80</ix:nonFraction>% of the per share price of common stock sold in the initial public offering. The discount on the automatic conversion was separated from the December 2019 Notes and reported as a debt discount and put option liability of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000593" name="bdsx:PutOptionLiabilityCurrent" contextRef="C_0001439725_us-gaapShortTermDebtTypeAxis_bdsxDecemberTwoThousandAndNineteenConvertibleNotesMember_20191231" decimals="-5" scale="6">1.5</ix:nonFraction> million and was amortized over the term of the December 2019 Notes. Following the closing of the initial public offering in October 2020, the December 2019 Notes were automatically converted into <ix:nonFraction unitRef="U_xbrlishares" id="F_000594" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="C_0001439725_us-gaapShortTermDebtTypeAxis_bdsxDecemberTwoThousandAndNineteenConvertibleNotesMember_20201001_20201031" decimals="INF" format="ixt:numdotdecimal">426,386</ix:nonFraction> shares of common stock at a conversion price of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000595" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextRef="C_0001439725_us-gaapShortTermDebtTypeAxis_bdsxDecemberTwoThousandAndNineteenConvertibleNotesMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201031" decimals="INF">14.40</ix:nonFraction>, or <ix:nonFraction unitRef="U_xbrlipure" id="F_000596" name="bdsx:PercentageOfConversionPricePerShareOfCommonStock" contextRef="C_0001439725_us-gaapShortTermDebtTypeAxis_bdsxDecemberTwoThousandAndNineteenConvertibleNotesMember_20201001_20201031" decimals="INF" scale="-2">80</ix:nonFraction>% of the initial public offering price per common share.</p></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-21</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000282_dcnt_809c7768-7943-4528-a8bd-490ad69ff5e9">

<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">August 2019 Notes</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August and September 2019 (the August 2019 Notes), the Company issued $<ix:nonFraction unitRef="U_iso4217USD" id="F_000597" name="us-gaap:NotesIssued1" contextRef="C_0001439725_us-gaapShortTermDebtTypeAxis_bdsxAugustTwoThousandAndNineteenConvertibleNotesMember_20190801_20190930" decimals="-5" scale="6">10.0</ix:nonFraction> million of convertible notes primarily to existing preferred shareholders that were originally scheduled to mature in <span style="-sec-ix-hidden:F_000598">August 2020</span>. In August 2020, the Company and its lenders agreed to extend the maturity date to <ix:nonNumeric id="F_000599" name="bdsx:DebtInstrumentMaturityDateExtended" contextRef="C_0001439725_us-gaapShortTermDebtTypeAxis_bdsxAugustTwoThousandAndNineteenConvertibleNotesMember_20200801_20200831" format="ixt:datemonthdayyearen">June 30, 2021</ix:nonNumeric>. Interest on the August 2019 Notes was <ix:nonFraction unitRef="U_xbrlipure" id="F_000600" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="C_0001439725_us-gaapShortTermDebtTypeAxis_bdsxAugustTwoThousandAndNineteenConvertibleNotesMember_20190930" decimals="INF" scale="-2">3</ix:nonFraction>% per annum and payable in full upon maturity through the conversion to Series H Preferred Stock at <ix:nonFraction unitRef="U_xbrlipure" id="F_000601" name="bdsx:PercentageOfConversionPricePerShareOfConvertiblePreferredStock" contextRef="C_0001439725_us-gaapShortTermDebtTypeAxis_bdsxAugustTwoThousandAndNineteenConvertibleNotesMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesHPreferredStockMember_20190801_20190930" decimals="INF" scale="-2">95</ix:nonFraction>% of the original issuance price of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000602" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextRef="C_0001439725_us-gaapShortTermDebtTypeAxis_bdsxAugustTwoThousandAndNineteenConvertibleNotesMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesHPreferredStockMember_20190930" decimals="INF">1.15</ix:nonFraction> per share. Under the terms of the August 2019 Notes, on or before the maturity date and if the August 2019 Notes are unpaid, the outstanding principal and unpaid accrued interest under the August 2019 Notes shall be automatically converted into common stock in an initial public offering at a conversion price of <ix:nonFraction unitRef="U_xbrlipure" id="F_000604" name="bdsx:PercentageOfConversionPricePerShareOfCommonStock" contextRef="C_0001439725_us-gaapShortTermDebtTypeAxis_bdsxAugustTwoThousandAndNineteenConvertibleNotesMember_20190801_20190930" decimals="INF" scale="-2">95</ix:nonFraction>% of the per share price of common stock sold in the initial public offering.<span style="color:#000000;">&#160;</span>In connection with the issuance of the December 2019 Notes, the conversion price on the August 2019 Notes was amended to <ix:nonFraction unitRef="U_xbrlipure" id="F_000603" name="bdsx:PercentageOfConversionPricePerShareOfConvertiblePreferredStock" contextRef="C_0001439725_us-gaapShortTermDebtTypeAxis_bdsxAugustTwoThousandAndNineteenConvertibleNotesMember_20191201_20191231" decimals="INF" scale="-2">80</ix:nonFraction>%<span style="color:#000000;">.</span> The initial discount on the automatic conversion created an initial put option liability of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000605" name="bdsx:PutOptionLiabilityCurrent" contextRef="C_0001439725_us-gaapShortTermDebtTypeAxis_bdsxAugustTwoThousandAndNineteenConvertibleNotesMember_20190930" decimals="-5" scale="6">0.5</ix:nonFraction> million that was separated from the August 2019 Notes. The amendment to the conversion price of the August 2019 Notes in December 2019 resulted in an increase to the put option liability of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000606" name="bdsx:IncreaseToPutOptionLiability" contextRef="C_0001439725_us-gaapShortTermDebtTypeAxis_bdsxAugustTwoThousandAndNineteenConvertibleNotesMember_20191231" decimals="-5" scale="6">2.0</ix:nonFraction> million to a total estimated value of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000607" name="bdsx:PutOptionLiabilityCurrent" contextRef="C_0001439725_us-gaapShortTermDebtTypeAxis_bdsxAugustTwoThousandAndNineteenConvertibleNotesMember_20191231" decimals="-5" scale="6">2.5</ix:nonFraction> million as of December 31, 2019.&#160;&#160;The increase in the value of the put option liability was reflected as a change in put option in the 2019 statement of operations. Following the closing of the initial public offering in October 2020, the August 2019 Notes were automatically converted into <ix:nonFraction unitRef="U_xbrlishares" id="F_000608" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="C_0001439725_us-gaapShortTermDebtTypeAxis_bdsxAugustTwoThousandAndNineteenConvertibleNotesMember_20201001_20201031" decimals="INF" format="ixt:numdotdecimal">718,391</ix:nonFraction> shares of common stock at a conversion price of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000609" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextRef="C_0001439725_us-gaapShortTermDebtTypeAxis_bdsxAugustTwoThousandAndNineteenConvertibleNotesMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201031" decimals="INF">14.40</ix:nonFraction>, or <ix:nonFraction unitRef="U_xbrlipure" id="F_000610" name="bdsx:PercentageOfConversionPricePerShareOfCommonStock" contextRef="C_0001439725_us-gaapShortTermDebtTypeAxis_bdsxAugustTwoThousandAndNineteenConvertibleNotesMember_20201001_20201031" decimals="INF" scale="-2">80</ix:nonFraction>% of the initial public offering price per common share.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:nonNumeric id="F_000331" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" contextRef="C_0001439725_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Scheduled principal repayments (maturities) of long-term obligations as of December 31, 2020 were as follows (in thousands): </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:79.7%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year Ending December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.34%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">As of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:79.7%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.34%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000611" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" contextRef="C_0001439725_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">11,840</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:79.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.34%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000612" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" contextRef="C_0001439725_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">13,919</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:79.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.34%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000613" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" contextRef="C_0001439725_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,320</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:79.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.34%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:79.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2025</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.34%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:79.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thereafter</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.34%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:79.7%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.34%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000614" name="us-gaap:LongTermDebt" contextRef="C_0001439725_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">28,079</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:nonNumeric></ix:continuation><ix:nonNumeric id="F_000283" name="us-gaap:PreferredStockTextBlock" contextRef="C_0001439725_20200101_20201231" escape="true" continuedAt="F_000283_dcnt_c832c985-a75e-42b4-bafe-e7a8740b3b7c">
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note 10 &#8211; Convertible Preferred Stock</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company had issued convertible preferred stock from time to time to fund its operations and to make acquisitions. In February and March 2019, the Company issued <ix:nonFraction unitRef="U_xbrlishares" id="F_000615" name="us-gaap:TemporaryEquitySharesIssued" contextRef="C_0001439725_us-gaapStatementClassOfStockAxis_us-gaapSeriesHPreferredStockMember_20190228" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction unitRef="U_xbrlishares" id="F_000616" name="us-gaap:TemporaryEquitySharesIssued" contextRef="C_0001439725_us-gaapStatementClassOfStockAxis_us-gaapSeriesHPreferredStockMember_20190331" decimals="INF" format="ixt:numdotdecimal">8,695,621</ix:nonFraction></ix:nonFraction> shares of Series H Preferred Stock at $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000618" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" contextRef="C_0001439725_us-gaapStatementClassOfStockAxis_us-gaapSeriesHPreferredStockMember_20190331" decimals="2"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000617" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" contextRef="C_0001439725_us-gaapStatementClassOfStockAxis_us-gaapSeriesHPreferredStockMember_20190228" decimals="2">1.15</ix:nonFraction></ix:nonFraction> per share for total cash proceeds of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000620" name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" contextRef="C_0001439725_us-gaapStatementClassOfStockAxis_us-gaapSeriesHPreferredStockMember_20190301_20190331" decimals="-5" scale="6"><ix:nonFraction unitRef="U_iso4217USD" id="F_000619" name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" contextRef="C_0001439725_us-gaapStatementClassOfStockAxis_us-gaapSeriesHPreferredStockMember_20190201_20190228" decimals="-5" scale="6">10.0</ix:nonFraction></ix:nonFraction> million.<span style="color:#000000;">&#160;</span></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The Company&#8217;s convertible preferred stock was reported as temporary equity in the Company&#8217;s balance sheet because the preferred shareholders held a majority of the Company&#8217;s Board of Directors seats and as a result could have caused certain events to occur outside of the Company&#8217;s control, with the result the Company could have been obligated to redeem the convertible preferred stock.</span></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Immediately prior to the Company&#8217;s initial public offering and as of December 31, 2019, the Company had issued <ix:nonFraction unitRef="U_xbrlishares" id="F_000621" name="us-gaap:TemporaryEquitySharesIssued" contextRef="C_0001439725_20191231" decimals="INF" format="ixt:numdotdecimal">118,766,273</ix:nonFraction> convertible preferred shares. On October 27, 2020, upon closing of the Company&#8217;s initial public offering, each outstanding share of Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock, Series G Preferred Stock and Series H Preferred Stock automatically converted into <ix:nonFraction unitRef="U_xbrlipure" id="F_000622" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" contextRef="C_0001439725_us-gaapStatementClassOfStockAxis_bdsxSeriesA1PreferredStockMember_20201027_20201027" decimals="7"><ix:nonFraction unitRef="U_xbrlipure" id="F_000623" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" contextRef="C_0001439725_us-gaapStatementClassOfStockAxis_bdsxSeriesA2PreferredStockMember_20201027_20201027" decimals="7"><ix:nonFraction unitRef="U_xbrlipure" id="F_000628" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" contextRef="C_0001439725_us-gaapStatementClassOfStockAxis_us-gaapSeriesEPreferredStockMember_20201027_20201027" decimals="7"><ix:nonFraction unitRef="U_xbrlipure" id="F_000624" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" contextRef="C_0001439725_us-gaapStatementClassOfStockAxis_bdsxSeriesA3PreferredStockMember_20201027_20201027" decimals="7"><ix:nonFraction unitRef="U_xbrlipure" id="F_000629" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" contextRef="C_0001439725_us-gaapStatementClassOfStockAxis_us-gaapSeriesFPreferredStockMember_20201027_20201027" decimals="7"><ix:nonFraction unitRef="U_xbrlipure" id="F_000630" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" contextRef="C_0001439725_us-gaapStatementClassOfStockAxis_us-gaapSeriesGPreferredStockMember_20201027_20201027" decimals="7"><ix:nonFraction unitRef="U_xbrlipure" id="F_000631" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" contextRef="C_0001439725_us-gaapStatementClassOfStockAxis_us-gaapSeriesHPreferredStockMember_20201027_20201027" decimals="7"><ix:nonFraction unitRef="U_xbrlipure" id="F_000625" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" contextRef="C_0001439725_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20201027_20201027" decimals="7"><ix:nonFraction unitRef="U_xbrlipure" id="F_000626" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" contextRef="C_0001439725_us-gaapStatementClassOfStockAxis_us-gaapSeriesCPreferredStockMember_20201027_20201027" decimals="7"><ix:nonFraction unitRef="U_xbrlipure" id="F_000627" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" contextRef="C_0001439725_us-gaapStatementClassOfStockAxis_us-gaapSeriesDPreferredStockMember_20201027_20201027" decimals="7">0.1684664</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> share of common stock&#59; and each share of Series B-1 Preferred Stock automatically converted into <ix:nonFraction unitRef="U_xbrlipure" id="F_000632" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" contextRef="C_0001439725_us-gaapStatementClassOfStockAxis_bdsxSeriesB1ConvertiblePreferredStockMember_20201027_20201027" decimals="3">0.196</ix:nonFraction> shares of common stock. In the aggregate, all Series of preferred stock were converted into <ix:nonFraction unitRef="U_xbrlishares" id="F_000633" name="bdsx:NumberOfPreferredStockConvertedIntoCommonStock" contextRef="C_0001439725_20201027_20201027" decimals="INF" format="ixt:numdotdecimal">20,090,745</ix:nonFraction> shares of common stock. As a result, as of December 31, 2020 there are <ix:nonFraction unitRef="U_xbrlishares" id="F_000634" name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="C_0001439725_20201231" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction> longer any series of convertible preferred stock outstanding.</p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-22</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000283_dcnt_c832c985-a75e-42b4-bafe-e7a8740b3b7c">
</ix:continuation><ix:nonNumeric id="F_000284" name="bdsx:WarrantsForConvertiblePreferredStockTextBlock" contextRef="C_0001439725_20200101_20201231" escape="true">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note 11 &#8211; Warrants to Purchase Convertible Preferred Stock</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company issued warrants to purchase shares of convertible preferred stock in conjunction with the sale of certain of the convertible preferred shares and issuance of debt. The estimated grant date fair value as well as the estimated fair value at each reporting date of the warrants was determined using the Black&#8209;Scholes option pricing model with weighted average assumptions substantially consistent with those disclosed for stock options (see Note 14 &#8211; <span style="font-style:italic;">Shared Based Compensation</span>), other than term, which is the contractual term of the warrant and the use of the exercise price and estimated fair value of the underlying series of convertible preferred stock. At December 31, 2019 and through the closing of the Company&#8217;s initial public offering, the preferred warrants were classified as liabilities with estimated fair value remeasured at each reporting date reported within in the accompanying statements of operations.</p><ix:nonNumeric id="F_000332" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" contextRef="C_0001439725_20200101_20201231" escape="true">
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table presents the activity for convertible preferred stock warrants (in thousands, except weighted average exercise price):</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Series E</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Series G</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Warrants</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Exercise</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">price</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Warrants</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Exercise</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">price</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding &#8209; December 31, 2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000635" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="C_0001439725_us-gaapClassOfWarrantOrRightAxis_bdsxSeriesEConvertiblePreferredStockWarrantsMember_20191231" decimals="-3" scale="3">925</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000639" name="bdsx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" contextRef="C_0001439725_us-gaapClassOfWarrantOrRightAxis_bdsxSeriesEConvertiblePreferredStockWarrantsMember_20191231" decimals="2">5.00</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000636" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="C_0001439725_us-gaapClassOfWarrantOrRightAxis_bdsxSeriesGConvertiblePreferredStockWarrantsMember_20191231" decimals="-3" scale="3">613</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000640" name="bdsx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" contextRef="C_0001439725_us-gaapClassOfWarrantOrRightAxis_bdsxSeriesGConvertiblePreferredStockWarrantsMember_20191231" decimals="2">0.75</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited/canceled</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlishares" id="F_000637" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" contextRef="C_0001439725_us-gaapClassOfWarrantOrRightAxis_bdsxSeriesEConvertiblePreferredStockWarrantsMember_20200101_20201231" decimals="-3" scale="3">925</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000641" name="bdsx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" contextRef="C_0001439725_us-gaapClassOfWarrantOrRightAxis_bdsxSeriesEConvertiblePreferredStockWarrantsMember_20200101_20201231" decimals="2">5.00</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reclassification of warrant liability to additional paid-in capital</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlishares" id="F_000638" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsPeriodIncreaseDecrease" contextRef="C_0001439725_us-gaapClassOfWarrantOrRightAxis_bdsxSeriesGConvertiblePreferredStockWarrantsMember_20200101_20201231" decimals="-3" scale="3">613</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000642" name="bdsx:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsReclassificationOfWarrantLiabilityToAdditionalPaidInCapitalWeightedAverageExercisePrice" contextRef="C_0001439725_us-gaapClassOfWarrantOrRightAxis_bdsxSeriesGConvertiblePreferredStockWarrantsMember_20200101_20201231" decimals="2" sign="-">0.75</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding &#8209; December 31, 2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon closing of the Company&#8217;s initial public offering, the then outstanding Series G convertible preferred stock was automatically converted to common stock and the outstanding warrants to purchase Series G convertible preferred stock were automatically converted to warrants to purchase <ix:nonFraction unitRef="U_xbrlishares" id="F_000643" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="C_0001439725_20201231" decimals="INF" format="ixt:numdotdecimal">103,326</ix:nonFraction> shares of common stock at $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000644" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="C_0001439725_20201231" decimals="2">4.46</ix:nonFraction> per share and expire in <span style="-sec-ix-hidden:F_000645">February 2028</span>. The warrants were remeasured to an estimate of fair value as of the initial public offering with the change in fair value of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000646" name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="C_0001439725_20200101_20201231" decimals="-5" scale="6">1.3</ix:nonFraction> million recognized in our statements of operations. The carrying value of the warrants was reclassified to additional paid-in capital as a result of the initial public offering.</p></ix:nonNumeric><ix:nonNumeric id="F_000285" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" contextRef="C_0001439725_20200101_20201231" escape="true" continuedAt="F_000285_dcnt_56f888f8-5171-4cee-9e0f-e04ff146a4fd">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note 12 &#8211; Equity</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Common Stock</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s Restated Certificate of Incorporation authorizes the Company to issue up to <ix:nonFraction unitRef="U_xbrlishares" id="F_000647" name="us-gaap:CommonStockSharesAuthorized" contextRef="C_0001439725_20201231" decimals="INF" format="ixt:numdotdecimal">200,000,000</ix:nonFraction> shares of common stock with a par value of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000648" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_0001439725_20201231" decimals="INF">0.001</ix:nonFraction> per share. <ix:nonNumeric id="F_000649" name="us-gaap:CommonStockVotingRights" contextRef="C_0001439725_20200101_20201231">The holder of each share of common stock is entitled to one vote per share.</ix:nonNumeric> The common shareholders are entitled to dividends whenever funds and assets are legally available and when and if declared by the Board of Directors. The Company is currently subject to restrictions on the payment of dividends (see Note 9 - <span style="font-style:italic;">Debt</span>) and <ix:nonFraction unitRef="U_iso4217USD" id="F_000650" name="us-gaap:DividendsCommonStock" contextRef="C_0001439725_20200101_20201231" decimals="INF" format="ixt-sec:numwordsen" scale="3">no</ix:nonFraction> dividends have been declared as of December 31, 2020.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On October 27, 2020, the Company issued and sold <ix:nonFraction unitRef="U_xbrlishares" id="F_000651" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001439725_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20201027_20201027" decimals="INF" format="ixt:numdotdecimal">4,000,000</ix:nonFraction> shares of common stock in a registered initial public offering at a price to the public of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000652" name="us-gaap:SaleOfStockPricePerShare" contextRef="C_0001439725_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20201027" decimals="INF">18.00</ix:nonFraction> per share. The net proceeds to the Company were <span style="Background-color:#FFFFFF;">approximately </span>$<ix:nonFraction unitRef="U_iso4217USD" id="F_000653" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="C_0001439725_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20201027_20201027" decimals="-5" scale="6">63.8</ix:nonFraction> million, after deducting underwriting discounts and commissions of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000654" name="us-gaap:ExpenseRelatedToDistributionOrServicingAndUnderwritingFees" contextRef="C_0001439725_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20201027_20201027" decimals="-5" scale="6">5.0</ix:nonFraction> million and direct offering expenses of approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000655" name="bdsx:DirectOfferingExpenses" contextRef="C_0001439725_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20201027_20201027" decimals="-5" scale="6">3.2</ix:nonFraction> million. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Preferred Stock</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s Restated Certificate of Incorporation authorizes the Company to issue up to <ix:nonFraction unitRef="U_xbrlishares" id="F_000656" name="us-gaap:PreferredStockSharesAuthorized" contextRef="C_0001439725_20201231" decimals="INF" format="ixt:numdotdecimal">5,000,000</ix:nonFraction> shares of preferred stock with a par value of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000657" name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="C_0001439725_20201231" decimals="INF">0.001</ix:nonFraction> per share. As of December 31, 2020, <ix:nonFraction unitRef="U_xbrlishares" id="F_000658" name="us-gaap:PreferredStockSharesIssued" contextRef="C_0001439725_20201231" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction> shares of preferred stock were issued or outstanding.</p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-23</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000285_dcnt_56f888f8-5171-4cee-9e0f-e04ff146a4fd">
</ix:continuation><ix:nonNumeric id="F_000286" name="us-gaap:RevenueFromContractWithCustomerTextBlock" contextRef="C_0001439725_20200101_20201231" escape="true">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note 13 - Revenue</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s revenue is generated from (i) diagnostic tests and (ii) assay development and testing services. Diagnostic test revenues consist of blood-based lung tests and COVID-19 tests, which are recognized in the amount expected to be received in exchange for diagnostic tests when the diagnostic tests are delivered. The Company conducts diagnostic tests and delivers the completed test results to the prescribing physician or patient, as applicable. The fees for diagnostic tests are billed either to a third party such as Medicare, medical facilities, commercial insurance payers, or to the patient. The Company determines the transaction price related to its diagnostic test contracts by considering the nature of the payer and historical price concessions granted to groups of customers. For diagnostic test revenue, the Company estimates the transaction price, which is the amount of consideration it expects to be entitled to receive in exchange for providing services based on its historical collection experience, using a portfolio approach. The Company recognizes revenues for diagnostic tests upon delivery of the tests to the physicians requesting the tests or patient, as applicable.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Services revenue consists of on-market tests, pipeline tests, custom diagnostic testing, and other scientific services for a purpose as defined by any individual customer, which is often with large biopharmaceutical companies. The performance obligations and related revenue for these sales is defined by a written agreement between the Company and the customer. These services are generally completed upon the delivery of testing results, or other contractually defined milestone(s), to the customer. Revenue for these services is recognized upon delivery of the completed test results, or upon completion of the contractual milestone(s). </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:nonNumeric id="F_000333" name="us-gaap:DisaggregationOfRevenueTableTextBlock" contextRef="C_0001439725_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenues consisted of the following (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.12%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Diagnostic tests</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000660" name="us-gaap:Revenues" contextRef="C_0001439725_srtProductOrServiceAxis_bdsxDiagnosticTestsMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">40,919</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000661" name="us-gaap:Revenues" contextRef="C_0001439725_srtProductOrServiceAxis_bdsxDiagnosticTestsMember_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">17,315</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Services</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000662" name="us-gaap:Revenues" contextRef="C_0001439725_srtProductOrServiceAxis_us-gaapServiceMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,638</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000663" name="us-gaap:Revenues" contextRef="C_0001439725_srtProductOrServiceAxis_us-gaapServiceMember_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">7,237</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.26%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total revenue</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000664" name="us-gaap:Revenues" contextRef="C_0001439725_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">45,557</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000665" name="us-gaap:Revenues" contextRef="C_0001439725_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">24,552</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s fiscal 2020 diagnostic test revenue consists of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000666" name="us-gaap:Revenues" contextRef="C_0001439725_srtProductOrServiceAxis_bdsxCOVID19DiagnosticTestRevenueMember_20200101_20201231" decimals="-5" scale="6">28.3</ix:nonFraction> million in COVID-19 test revenue, which began in late fiscal 2020, and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000667" name="us-gaap:Revenues" contextRef="C_0001439725_srtProductOrServiceAxis_bdsxLungDiagnosticRevenueMember_20200101_20201231" decimals="-5" scale="6">12.6</ix:nonFraction> million in lung diagnostic revenue.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Contract Liabilities</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contract liabilities consist of cash payments from customers received in advance of delivery (advance deposits). As products are shipped and control transfers, the Company recognizes the deferred revenue in &#8216;Revenues&#8217; in the statements of operations. At January 1 and December&#160;31, 2020, $<ix:nonFraction unitRef="U_iso4217USD" id="F_000669" name="bdsx:AdvanceDeposits" contextRef="C_0001439725_us-gaapBalanceSheetLocationAxis_bdsxDeferredRevenueMember_20200101" decimals="-5" scale="6">1.3</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000668" name="bdsx:AdvanceDeposits" contextRef="C_0001439725_us-gaapBalanceSheetLocationAxis_bdsxDeferredRevenueMember_20201231" decimals="-5" scale="6">3.5</ix:nonFraction> million, respectively, of advance deposits were reported in &#8216;Deferred revenue&#8217; in the accompanying balance sheets. Of the $<ix:nonFraction unitRef="U_iso4217USD" id="F_000670" name="bdsx:AdvanceDeposits" contextRef="C_0001439725_us-gaapBalanceSheetLocationAxis_bdsxDeferredRevenueMember_20200101" decimals="-5" scale="6">1.3</ix:nonFraction> million in deferred revenue recorded at January 1, 2020, $<ix:nonFraction unitRef="U_iso4217USD" id="F_000671" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" contextRef="C_0001439725_20200101_20201231" decimals="-5" scale="6">0.7</ix:nonFraction> million was recognized in revenues during the year ended December&#160;31, 2020. The deferred revenue of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000672" name="us-gaap:ContractWithCustomerLiabilityCurrent" contextRef="C_0001439725_20201231" decimals="-5" scale="6">3.5</ix:nonFraction> million at December&#160;31, 2020 is expected to be recognized in revenues during 2021 as test results are delivered.</p></ix:nonNumeric><ix:nonNumeric id="F_000287" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" contextRef="C_0001439725_20200101_20201231" escape="true" continuedAt="F_000287_dcnt_db57e7a4-a6b7-4d2f-83f2-1b16524f75b7">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note 14 &#8211; Share Based Compensation</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">2016 Equity Incentive Plan and Predecessor 2006 Equity Incentive Plan</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2016, the Company adopted the 2016 Equity Incentive Plan (2016 Plan) as a successor to and continuation of the prior 2006 Equity Incentive Plan (2006 Plan). The 2016 Plan provides for the grant of incentive stock options, non-statutory stock options, stock appreciation rights, restricted stock awards, restricted stock units, and other stock awards to directors, employees, and consultants. Awards granted under the 2016 Plan or the 2006 Plan that expired or otherwise terminated, or were forfeited, cancelled, or repurchased by the Company, became available for future issuance under the 2016 Plan. In addition, shares subject to an award were withheld to satisfy a participant&#8217;s tax withholding obligations, or were reacquired by the Company as consideration for the exercise or purchase price of a stock award also became available for future issuance under the 2016 Incentive Plan.</p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-24</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000287_dcnt_db57e7a4-a6b7-4d2f-83f2-1b16524f75b7" continuedAt="F_000287_dcnt_29534202-2312-4087-b905-7194a682a751">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><span style="font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">2020 Equity Incentive Plan</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effective upon the closing of our initial public offering, the Company&#8217;s Board of Directors approved the 2020 Equity Incentive Plan (2020 Plan), which replaced the 2016 Plan. <span style="Background-color:#FFFFFF;">&#160;The 2020 Plan provides for the grant of incentive stock options, non-statutory stock options, stock appreciation rights, restricted stock awards, restricted stock units, performance awards and other stock awards. Officers, directors, employees, consultants, agents, and independent contractors who provide services to the Company may receive awards. The terms of all awards are governed by an agreement between the Company and the recipients, as administered and approved by the Compensation Committee of the Board of Directors.</span></p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Employee Stock Purchase Plan</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effective with our initial public offering in October 2020, the Company&#8217;s Board of Directors and its stockholders approved the Company&#8217;s Employee Stock Purchase Plan (ESPP). A total of <ix:nonFraction unitRef="U_xbrlishares" id="F_000673" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="C_0001439725_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20201031" decimals="INF" format="ixt:numdotdecimal">338,106</ix:nonFraction> shares of our common stock have been reserved for issuance under the ESPP. The maximum number of shares of our common stock available under the ESPP will automatically increase on the first trading day of each calendar year, commencing January 2021, by an amount equal to the lesser of (i) <ix:nonFraction unitRef="U_xbrlipure" id="F_000674" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" contextRef="C_0001439725_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20200101_20201231" decimals="INF" scale="-2">1</ix:nonFraction>% of the shares of our common stock issued and outstanding on December 31 of the immediately preceding calendar year, and (ii) an amount determined by our Board of Directors.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.77%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Subject to any plan limitations, the ESPP allows eligible employees to contribute, normally through payroll deductions, up to <ix:nonFraction unitRef="U_xbrlipure" id="F_000675" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" contextRef="C_0001439725_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20201231" decimals="INF" scale="-2">15</ix:nonFraction>% of their earnings for the purchase of the Company&#8217;s common stock at a discounted price per share. The price at which common stock is purchased under the ESPP is equal to <ix:nonFraction unitRef="U_xbrlipure" id="F_000676" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate" contextRef="C_0001439725_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20200101_20201231" decimals="INF" scale="-2">85</ix:nonFraction>% of the fair market value of the Company&#8217;s common stock on the first or last day of the offering period, whichever is lower. <ix:nonNumeric id="F_000677" name="bdsx:DescriptionOfVotingPowerOrValueOfStockForEmployeeParticipationInOfferingPeriod" contextRef="C_0001439725_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20200101_20201231">No employee may participate in an offering period if the employee owns 5% or more of the total combined voting power or value of the Company&#8217;s stock.</ix:nonNumeric> <ix:nonNumeric id="F_000678" name="bdsx:DescriptionOfOfferingPeriodUnderPlan" contextRef="C_0001439725_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20200101_20201231">The initial offering period will commence from January 1, 2021 through August 31, 2021.  On a going forward basis, the ESPP provides for successive six-month offering periods beginning on September 1st and March 1st of each year.</ix:nonNumeric></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Shares Reserved Subject to All Plans</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The number of shares reserved for issuance under the 2020 Plan is <ix:nonFraction unitRef="U_xbrlishares" id="F_000679" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="C_0001439725_us-gaapPlanNameAxis_bdsxTwoThousandTwentyEquityIncentivePlanMember_20201231" decimals="INF" format="ixt:numdotdecimal">1,893,395</ix:nonFraction>, plus an annual increase added on the first day of each calendar year, beginning with the calendar year ending December&#160;31, 2022, and continuing until, and including, the calendar year ending December&#160;31, 2030. The annual increase will be equal to the lesser of (i)&#160;<ix:nonFraction unitRef="U_xbrlipure" id="F_000680" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" contextRef="C_0001439725_us-gaapPlanNameAxis_bdsxTwoThousandTwentyEquityIncentivePlanMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231" decimals="INF" scale="-2">4</ix:nonFraction>% of the number of shares of our common stock issued and outstanding as of December&#160;31st of the immediately preceding calendar year and (ii)&#160;such lesser amount determined by the Board of Directors. Up to<ix:nonFraction unitRef="U_xbrlishares" id="F_000681" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" contextRef="C_0001439725_srtRangeAxis_srtMaximumMember_us-gaapPlanNameAxis_bdsxTwoThousandTwentyEquityIncentivePlanMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231" decimals="INF" format="ixt:numdotdecimal"> 1,893,395</ix:nonFraction> shares of our common stock that may be issued under the 2020 Plan may be issued in satisfaction of incentive stock option awards.</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the 2006 Plan, the Company is authorized to grant <span style="Background-color:#FFFFFF;">incentive stock options, non-statutory stock options, stock appreciation rights, restricted stock awards and restricted stock units</span> up to <ix:nonFraction unitRef="U_xbrlishares" id="F_000682" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="C_0001439725_srtRangeAxis_srtMaximumMember_us-gaapPlanNameAxis_bdsxTwoThousandSixPlanMember_20201231" decimals="INF" format="ixt:numdotdecimal">831,389</ix:nonFraction> total award shares.<span style="Background-color:#FFFFFF;"> <ix:nonFraction unitRef="U_xbrlishares" id="F_000683" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="C_0001439725_us-gaapPlanNameAxis_bdsxTwoThousandAndSixteenPlanMember_20160229" decimals="INF" format="ixt-sec:numwordsen">No</ix:nonFraction> additional awards may be granted under the 2006 Plan. Unallocated shares under the 2006 Plan were added to the shares available for issuance under the 2016 Plan.</span></p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Under the 2016 Plan, which is a successor to and continuation of the 2006 Plan, the Company is authorized to grant incentive stock options, non-statutory stock options, stock appreciation rights, restricted stock awards, restricted stock units and stock appreciation rights up to <ix:nonFraction unitRef="U_xbrlishares" id="F_000684" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="C_0001439725_srtRangeAxis_srtMaximumMember_us-gaapPlanNameAxis_bdsxTwoThousandAndSixteenPlanMember_20160229" decimals="INF" format="ixt:numdotdecimal">1,431,964</ix:nonFraction> total shares, plus any shares subject to stock awards made under the 2006 Plan</span>.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Our Compensation Committee may grant other stock awards that are based on or related to shares of our common stock, such as awards of shares of common stock granted as bonus and not subject to any vesting conditions, deferred stock units, stock purchase rights, and shares of our common stock issued in lieu of our obligations to pay cash under any compensatory plan or arrangement. To date, t</span><span style="color:#000000;">he Company has granted service-condition RSUs.</span></p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To the extent an equity award granted under the 2020 Plan (other than any substitute award) or granted under any other equity plan maintained by us under which awards are outstanding as of the effective date of the 2020 Plan (the Prior Plans) expires or otherwise terminates without having been exercised or paid in full, or is settled in cash, the shares subject to such award will become available for future grant under the 2020 Plan. In addition, to the extent shares subject to an award are withheld to satisfy a participant&#8217;s tax withholding obligation upon the exercise or settlement of such award (other than any substitute award) or to pay the exercise price of a stock option granted under the 2020 Plan or a Prior Plan, such shares will become available for future grant under the 2020 Plan. The total number of shares available for grant under all Plans was <ix:nonFraction unitRef="U_xbrlishares" id="F_000685" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="C_0001439725_us-gaapPlanNameAxis_bdsxTwoThousandSixPlanTwoThousandSixteenPlanAndTwoThousandTwentyEquityIncentivePlanMember_20201231" decimals="INF" format="ixt:numdotdecimal">4,647,380</ix:nonFraction> at December 31, 2020.</p></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-25</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000287_dcnt_29534202-2312-4087-b905-7194a682a751" continuedAt="F_000287_dcnt_43ef517c-6a58-459f-8a4d-2894a6758ec6">

<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Description of Awards Granted</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has granted incentive stock options, non-statutory stock options, performance-based stock options, and restricted stock units. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Incentive stock options, which may only be issued to employees, are granted at an exercise price per share equal to the fair market value per share of the underlying common stock on the grant date, and vest over time as determined by the Compensation Committee, provided that the term of the options may not exceed <ix:nonNumeric id="F_000686" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" contextRef="C_0001439725_srtRangeAxis_srtMaximumMember_us-gaapPlanNameAxis_bdsxTwoThousandTwentyEquityIncentivePlanMember_20200101_20201231" format="ixt-sec:durwordsen">ten years</ix:nonNumeric> from the date of grant. Accelerated vesting may occur in the event of an optionee's death, disability, or other events.<span style="Background-color:#FFFFFF;"> </span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Non-statutory stock options may be issued to non-employees and directors, with exercise prices, vesting conditions, option term and other conditions as determined by the Compensation Committee.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Performance-based stock options are typically granted on an annual basis and consist of a performance-based and service-based component. The performance targets and vesting conditions for performance-condition options are based on achievement of recognized revenue targets. <ix:nonNumeric id="F_000687" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" contextRef="C_0001439725_us-gaapAwardTypeAxis_bdsxPerformanceConditionOptionsMember_us-gaapPlanNameAxis_bdsxTwoThousandTwentyEquityIncentivePlanMember_20200101_20201231">Performance-based options vest in <ix:nonFraction unitRef="U_bdsxInstallment" id="F_000688" name="bdsx:NumberOfEqualAnnualInstallmentsForAwardVesting" contextRef="C_0001439725_us-gaapAwardTypeAxis_bdsxPerformanceConditionOptionsMember_us-gaapPlanNameAxis_bdsxTwoThousandTwentyEquityIncentivePlanMember_20200101_20201231" decimals="INF" format="ixt-sec:numwordsen">three</ix:nonFraction> equal annual installments beginning one year after the grant date</ix:nonNumeric>, pending certification of performance achievement by the Compensation Committee and continued service. The fair value of performance-condition awards is based on the closing market price of the Company&#8217;s common stock on the grant date. Compensation expense, net of forfeitures, is updated for the Company&#8217;s expected performance level against performance goals at the end of each reporting period. On January 1, 2019, the Company granted <ix:nonFraction unitRef="U_xbrlishares" id="F_000689" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="C_0001439725_us-gaapAwardTypeAxis_bdsxPerformanceConditionOptionsMember_us-gaapPlanNameAxis_bdsxTwoThousandTwentyEquityIncentivePlanMember_20190101_20190101" decimals="INF" format="ixt:numdotdecimal">168,466</ix:nonFraction> performance-condition options, with an exercise price of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000690" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="C_0001439725_us-gaapAwardTypeAxis_bdsxPerformanceConditionOptionsMember_us-gaapPlanNameAxis_bdsxTwoThousandTwentyEquityIncentivePlanMember_20190101_20190101" decimals="2">0.77</ix:nonFraction> per share and a term of <ix:nonNumeric id="F_000691" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" contextRef="C_0001439725_us-gaapAwardTypeAxis_bdsxPerformanceConditionOptionsMember_us-gaapPlanNameAxis_bdsxTwoThousandTwentyEquityIncentivePlanMember_20190101_20190101" format="ixt-sec:durwordsen">ten years</ix:nonNumeric>. During the year ended December 31, 2020, the performance conditions were met and <ix:nonFraction unitRef="U_xbrlishares" id="F_000692" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" contextRef="C_0001439725_us-gaapAwardTypeAxis_bdsxPerformanceConditionOptionsMember_us-gaapPlanNameAxis_bdsxTwoThousandTwentyEquityIncentivePlanMember_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">56,155</ix:nonFraction> options vested. During the year ended December 31, 2019, the performance conditions were not met and <ix:nonFraction unitRef="U_xbrlishares" id="F_000693" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="C_0001439725_us-gaapAwardTypeAxis_bdsxPerformanceConditionOptionsMember_us-gaapPlanNameAxis_bdsxTwoThousandTwentyEquityIncentivePlanMember_20190101_20191231" decimals="INF" format="ixt:numdotdecimal">56,155</ix:nonFraction> options were forfeited. As of December 31, 2020, there were <ix:nonFraction unitRef="U_xbrlishares" id="F_000694" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_0001439725_us-gaapAwardTypeAxis_bdsxPerformanceConditionOptionsMember_us-gaapPlanNameAxis_bdsxTwoThousandTwentyEquityIncentivePlanMember_20201231" decimals="INF" format="ixt:numdotdecimal">56,156</ix:nonFraction> performance condition options outstanding with a remaining life of approximately <ix:nonNumeric id="F_000695" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="C_0001439725_us-gaapAwardTypeAxis_bdsxPerformanceConditionOptionsMember_us-gaapPlanNameAxis_bdsxTwoThousandTwentyEquityIncentivePlanMember_20200101_20201231" format="ixt-sec:durwordsen">eight years</ix:nonNumeric>. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted stock units and the related terms and conditions are awarded at the discretion of the Compensation Committee. RSU<span style="Background-color:#FFFFFF;color:#000000;"> holders </span>have a contractual right to receive a share of common stock when vested. RSUs generally vest over <ix:nonNumeric id="F_000696" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" contextRef="C_0001439725_srtRangeAxis_srtMinimumMember_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_bdsxTwoThousandTwentyEquityIncentivePlanMember_20200101_20201231" format="ixt-sec:durwordsen">three years</ix:nonNumeric>. RSU agreements may provide for accelerated vesting in the event of a stock unit holder's death, disability, or retirement or other events.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Bonus-To-Options Program</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company also has a Bonus-to-Options Program (the &#8220;Bonus Option Program&#8221;), which is separate from predecessor Plans and was initially adopted by the Board of Directors in 2008, and subsequently amended and restated in 2010, 2011 and 2015. For fiscal year 2021, the Bonus Option Program is subject to the shares reserved under the 2020 Plan. The Bonus Option Program, which is limited to participation of the Chief Executive Officer, direct reports to the Chief Executive Officer and Vice Presidents of the Company, allows participants who so elect to convert all or a portion of their annual cash bonus into fully vested, non-qualified stock options to purchase shares of common stock (Bonus Options).<span style="font-size:12pt;"> </span>The exercise price for the options under the Bonus Option Program equals the then current price for the shares of the common stock as of the grant date, as disclosed below under &#8220;<span style="font-style:italic;">Fair Value of Common Stock</span>&#8221;. Bonus Options issued must be exercised within a <span style="-sec-ix-hidden:F_000697">ten-year</span> term. A maximum of <ix:nonFraction unitRef="U_xbrlipure" id="F_000698" name="bdsx:PercentageOfFullyDilutedEquityForBonusAwarded" contextRef="C_0001439725_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_bdsxBonusToOptionsProgramMember_20200101_20201231" decimals="INF" scale="-2">1</ix:nonFraction>% of the fully diluted equity, as of December 31 of the year for which the bonus was awarded, may be issued in any one year to the participants. As of December 31, 2020, there were <ix:nonFraction unitRef="U_xbrlishares" id="F_000699" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_0001439725_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_bdsxBonusToOptionsProgramMember_20201231" decimals="INF" format="ixt:numdotdecimal">173,229</ix:nonFraction> options outstanding under the Bonus Option Program. <span style="color:#000000;">These options are fully vested and have a weighted average exercise price of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000700" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" contextRef="C_0001439725_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_bdsxBonusToOptionsProgramMember_20201231" decimals="2">11.11</ix:nonFraction> per share and have an intrinsic value of approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000701" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="C_0001439725_us-gaapAwardTypeAxis_bdsxBonusToOptionsProgramMember_20201231" decimals="-5" scale="6">1.6</ix:nonFraction> million as of December 31, 2020</span>.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> <span style="color:#000000;">During the twelve-month period ended December 31, 2020, the Company accrued $<ix:nonFraction unitRef="U_iso4217USD" id="F_000702" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001439725_us-gaapAwardTypeAxis_bdsxBonusToOptionsProgramMember_20200101_20201231" decimals="-5" scale="6">3.4</ix:nonFraction> million as stock compensation expense associated with the estimate of options to be delivered to eligible participants under the Bonus Option Program and which were granted in February 2021 by the Compensation Committee of the Board of Directors.&#160;&#160;In determining the amount of stock compensation to recognize under the Bonus Option Program, the Company estimates the bonus attainment for the year and determines the expected number of options to be delivered to eligible participants.&#160;&#160;A Black-Scholes option pricing model is used to determine the estimated fair value of the expected number of options to be delivered to eligible participants.&#160;&#160;The key elements in determining the estimated fair value include assumptions for volatility, the risk free interest rate, expected dividends and strike price, utilizing the measurement date closing stock price until the grants are authorized.</span></p></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-26</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000287_dcnt_43ef517c-6a58-459f-8a4d-2894a6758ec6" continuedAt="F_000287_dcnt_7e47ee23-240b-45a3-bf0d-d20b01d3bdbe">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><span style="font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Share-Based Compensation Expense</span></p><ix:nonNumeric id="F_000334" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" contextRef="C_0001439725_20200101_20201231" escape="true">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pre-tax share-based compensation expense reported in the Company&#8217;s statements of operations was (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.52%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.78%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.5%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000703" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001439725_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20200101_20201231" decimals="-3" scale="3">589</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000704" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001439725_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20190101_20191231" decimals="-3" scale="3">33</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales, marketing, general and administrative</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000705" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001439725_us-gaapIncomeStatementLocationAxis_us-gaapSellingGeneralAndAdministrativeExpensesMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,120</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000706" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001439725_us-gaapIncomeStatementLocationAxis_us-gaapSellingGeneralAndAdministrativeExpensesMember_20190101_20191231" decimals="-3" scale="3">137</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.78%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000707" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001439725_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,709</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.5%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000708" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001439725_20190101_20191231" decimals="-3" scale="3">170</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The unrecognized remaining share-based compensation expense for options and RSUs was approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000709" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="C_0001439725_us-gaapAwardTypeAxis_bdsxOptionsAndRestrictedStockUnitsMember_20201231" decimals="-5" scale="6">0.6</ix:nonFraction> million as of December 31, 2020, and is expected to be amortized to expense over the next <ix:nonNumeric id="F_000710" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" contextRef="C_0001439725_us-gaapAwardTypeAxis_bdsxOptionsAndRestrictedStockUnitsMember_20200101_20201231" format="ixt-sec:duryear">3.7</ix:nonNumeric> years.</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Stock Options</p><ix:nonNumeric id="F_000335" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" contextRef="C_0001439725_20200101_20201231" escape="true">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock option activity during the year ended December 31, 2020, excluding the Bonus Option Program described above, was (in thousands, except weighted average exercise price and weighted average contractual life):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:27.7%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.28%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Options</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.28%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Exercise</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Price</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.28%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Contractual</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Life (Years)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.28%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding - December 31, 2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.28%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000711" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_0001439725_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,916</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.28%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000717" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="C_0001439725_20191231" decimals="2">1.72</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.28%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000723">7.6</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.28%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000712" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="C_0001439725_20200101_20201231" decimals="-3" scale="3">828</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000718" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="C_0001439725_20200101_20201231" decimals="2">2.81</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000724">&#8212;</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited/canceled</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlishares" id="F_000713" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" contextRef="C_0001439725_20200101_20201231" decimals="-3" scale="3">55</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000719" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" contextRef="C_0001439725_20200101_20201231" decimals="2">0.60</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:27.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.28%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlishares" id="F_000714" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="C_0001439725_20200101_20201231" decimals="-3" scale="3">368</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:14.28%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000720" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="C_0001439725_20200101_20201231" decimals="2">3.65</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:14.28%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:14.28%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:27.7%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding &#8209; December 31, 2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.28%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000715" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_0001439725_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,321</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.28%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000721" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="C_0001439725_20201231" decimals="2">1.82</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.28%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000725">7.4</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.28%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000727" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="C_0001439725_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">42,580</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:27.7%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercisable &#8209; December 31, 2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.28%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000716" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="C_0001439725_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,190</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.28%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000722" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="C_0001439725_20201231" decimals="2">2.35</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.28%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000726">6.3</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.28%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000728" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="C_0001439725_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">21,194</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Fair Value of Common Stock</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to the Company&#8217;s initial public offering, the fair value of the Company&#8217;s common stock underlying the stock options was determined by the Board of Directors with assistance from management and, in part, on input from an independent third-party valuation firm. The Board of Directors determined the fair value of common stock by considering a number of objective and subjective factors, including valuations of comparable companies, sales of convertible preferred stock, operating and financial performance, the lack of liquidity of the Company&#8217;s common stock and the general and industry-specific economic outlook. Subsequent&#160;to the Company&#8217;s initial public offering, the fair value of the Company&#8217;s common stock is determined based on its closing market price.</p><ix:nonNumeric id="F_000336" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" contextRef="C_0001439725_20200101_20201231" escape="true">
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair value of each option grant prior was estimated on the grant date using the Black&#8209;Scholes option pricing model with the following weighted average assumptions for the year ended December 31, 2020:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk&#8209;free rate</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000729" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="C_0001439725_20200101_20201231" decimals="4" scale="-2">0.34</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term (in years)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000730">5.73</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000731" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="C_0001439725_20200101_20201231" decimals="2" scale="-2">77</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company estimated volatility based on the historical volatility of its peer group and average expected life based on the review of historical exercise behavior of option grants with similar vesting periods. <span style="color:#000000;">&#160;</span> </p></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-27</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000287_dcnt_7e47ee23-240b-45a3-bf0d-d20b01d3bdbe">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><span style="font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Restricted Stock Units and Restricted Stock Unit Activity</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Service-condition RSUs were granted to Board members and <ix:nonNumeric id="F_000732" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" contextRef="C_0001439725_us-gaapAwardTypeAxis_bdsxServiceConditionRSUsMember_20200101_20201231">vest over <ix:nonNumeric id="F_000733" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" contextRef="C_0001439725_srtRangeAxis_srtMinimumMember_us-gaapAwardTypeAxis_bdsxServiceConditionRSUsMember_20200101_20201231" format="ixt-sec:durwordsen">three years</ix:nonNumeric>, <ix:nonFraction unitRef="U_xbrlipure" id="F_000734" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" contextRef="C_0001439725_us-gaapAwardTypeAxis_bdsxServiceConditionRSUsMember_us-gaapVestingAxis_us-gaapShareBasedCompensationAwardTrancheOneMember_20200101_20201231" decimals="2" scale="-2">40</ix:nonFraction>% over the first two years and the remaining <ix:nonFraction unitRef="U_xbrlipure" id="F_000735" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" contextRef="C_0001439725_us-gaapAwardTypeAxis_bdsxServiceConditionRSUsMember_us-gaapVestingAxis_us-gaapShareBasedCompensationAwardTrancheTwoMember_20200101_20201231" decimals="2" scale="-2">60</ix:nonFraction>% over the third year from the grant date.</ix:nonNumeric> During the year ended December&#160;31, 2020, the Company granted <ix:nonFraction unitRef="U_xbrlishares" id="F_000736" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="C_0001439725_us-gaapAwardTypeAxis_bdsxServiceConditionRSUsMember_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">52,736</ix:nonFraction> service-condition RSUs. As of December 31, 2020, there were <ix:nonFraction unitRef="U_xbrlishares" id="F_000737" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="C_0001439725_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20201231" decimals="INF" format="ixt:numdotdecimal">79,104</ix:nonFraction> RSUs outstanding, with a weighted average grant date fair value of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000738" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="C_0001439725_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20201231" decimals="2">6.83</ix:nonFraction> per share.</p></ix:continuation><ix:nonNumeric id="F_000288" name="us-gaap:EarningsPerShareTextBlock" contextRef="C_0001439725_20200101_20201231" escape="true" continuedAt="F_000288_dcnt_5d1f333f-61ac-4896-b7da-a78daf0660a5">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note 15 &#8211; Earnings per Share</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Excluded from determination of diluted net loss attributable to common stockholders for the periods presented because inclusion would be anti-dilutive are the instruments below, the terms of which are described in further detail in Note 14 &#8211; <span style="font-style:italic;">Share Based Compensation.&#160;&#160;</span>The potentially dilutive securities as of December 31, 2020 and 2019 primarily represent the shares subject to future issuance under stock options awards, warrants and RSUs and would be subject to the treasury stock method when dilutive. The number of common shares that convertible debt was assumed to convert to was based on the Company&#8217;s estimated common stock price as of December 31, 2019, as determined by the Company&#8217;s Board of Directors with assistance from a valuation firm. </p><ix:nonNumeric id="F_000337" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" contextRef="C_0001439725_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.08%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Numerator</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.76%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.76%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss attributable to common stockholders</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000739" name="us-gaap:NetIncomeLoss" contextRef="C_0001439725_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">31,350</ix:nonFraction></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000740" name="us-gaap:NetIncomeLoss" contextRef="C_0001439725_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">30,726</ix:nonFraction></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.76%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.76%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Denominator</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.76%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.76%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average shares outstanding used</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; in computing net loss per share, basic and diluted</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000741" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="C_0001439725_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,838</ix:nonFraction></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000742" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="C_0001439725_20190101_20191231" decimals="-3" scale="3">242</ix:nonFraction></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share, basic and diluted</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000743" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="C_0001439725_20200101_20201231" decimals="2" sign="-">6.48</ix:nonFraction></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000744" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="C_0001439725_20190101_20191231" decimals="2" sign="-">126.97</ix:nonFraction></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:nonNumeric id="F_000338" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" contextRef="C_0001439725_20200101_20201231" escape="true" continuedAt="F_000338_dcnt_d423906a-f41c-4e65-8944-29a5b7ae7e21">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following outstanding common stock equivalents were excluded from diluted net loss attributable to common stockholders for the periods presented because inclusion would be anti-dilutive (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.08%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options to purchase common stock</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000745" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001439725_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_bdsxOptionsToPurchaseCommonStockMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,495</ix:nonFraction></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000746" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001439725_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_bdsxOptionsToPurchaseCommonStockMember_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,104</ix:nonFraction></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Convertible preferred stock</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000747" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001439725_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">119,257</ix:nonFraction></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrants</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000748" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001439725_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapWarrantMember_20200101_20201231" decimals="-3" scale="3">103</ix:nonFraction></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000749" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001439725_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapWarrantMember_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,538</ix:nonFraction></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted stock units</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000750" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001439725_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapRestrictedStockUnitsRSUMember_20200101_20201231" decimals="-3" scale="3">79</ix:nonFraction></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000751" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001439725_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapRestrictedStockUnitsRSUMember_20190101_20191231" decimals="-3" scale="3">26</ix:nonFraction></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Convertible debt </p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000752" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001439725_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapConvertibleDebtSecuritiesMember_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">21,131</ix:nonFraction></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000753" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001439725_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,677</ix:nonFraction></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000754" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001439725_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">144,056</ix:nonFraction></p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.85%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:nonNumeric></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-28</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000288_dcnt_5d1f333f-61ac-4896-b7da-a78daf0660a5"><ix:continuation id="F_000338_dcnt_d423906a-f41c-4e65-8944-29a5b7ae7e21">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:continuation></ix:continuation><ix:nonNumeric id="F_000289" name="us-gaap:IncomeTaxDisclosureTextBlock" contextRef="C_0001439725_20200101_20201231" escape="true" continuedAt="F_000289_dcnt_b0d85215-20db-4b2d-acba-1e07dff5310a">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note 16 - Income Taxes</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since inception, the Company has incurred net taxable losses, and accordingly, <ix:nonFraction unitRef="U_iso4217USD" id="F_000755" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_0001439725_20200101_20201231" decimals="INF" format="ixt-sec:numwordsen" scale="3">no</ix:nonFraction> current provision for income taxes has been recorded.<span style="font-size:12pt;"> </span><ix:nonNumeric id="F_000339" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" contextRef="C_0001439725_20200101_20201231" escape="true" continuedAt="F_000339_cnt_1">The effective income tax rate of the provision for income taxes differs from the federal statutory rate as follows:</ix:nonNumeric></p><ix:continuation id="F_000339_cnt_1">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December 31,</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal statutory income tax rate</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000756" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="C_0001439725_20200101_20201231" decimals="INF" scale="-2">21</ix:nonFraction></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000757" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="C_0001439725_20190101_20191231" decimals="INF" scale="-2">21</ix:nonFraction></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State income taxes, net of federal benefit</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000758" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="C_0001439725_20200101_20201231" decimals="2" scale="-2">2</ix:nonFraction></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000759" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="C_0001439725_20190101_20191231" decimals="2" scale="-2">4</ix:nonFraction></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and developments credits</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlipure" id="F_000760" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" contextRef="C_0001439725_20200101_20201231" decimals="2" sign="-" scale="-2">1</ix:nonFraction></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000761" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" contextRef="C_0001439725_20190101_20191231" decimals="2" scale="-2">2</ix:nonFraction></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Permanent items</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlipure" id="F_000762" name="bdsx:EffectiveIncomeTaxRateReconciliationPermanentItems" contextRef="C_0001439725_20200101_20201231" decimals="2" scale="-2">6</ix:nonFraction></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlipure" id="F_000763" name="bdsx:EffectiveIncomeTaxRateReconciliationPermanentItems" contextRef="C_0001439725_20190101_20191231" decimals="2" scale="-2">4</ix:nonFraction></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in valuation allowance</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlipure" id="F_000764" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="C_0001439725_20200101_20201231" decimals="2" sign="-" scale="-2">16</ix:nonFraction></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlipure" id="F_000765" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="C_0001439725_20190101_20191231" decimals="2" sign="-" scale="-2">23</ix:nonFraction></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effective income tax rate</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div></ix:continuation>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:nonNumeric id="F_000340" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" contextRef="C_0001439725_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The tax effects of temporary differences that give rise to significant portions of the deferred income tax assets and liabilities are as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December 31,</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred Tax Assets:</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net operating loss carryforwards</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000766" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="C_0001439725_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">53,128</ix:nonFraction></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000767" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="C_0001439725_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">50,360</ix:nonFraction></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development tax credits</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000768" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" contextRef="C_0001439725_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,860</ix:nonFraction></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000769" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" contextRef="C_0001439725_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,040</ix:nonFraction></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000770" name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" contextRef="C_0001439725_20201231" decimals="-3" scale="3">279</ix:nonFraction></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000771" name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" contextRef="C_0001439725_20191231" decimals="-3" scale="3">370</ix:nonFraction></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000772" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="C_0001439725_20201231" decimals="-3" scale="3">865</ix:nonFraction></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accruals and reserves</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000773" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" contextRef="C_0001439725_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,406</ix:nonFraction></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000774" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" contextRef="C_0001439725_20191231" decimals="-3" scale="3">286</ix:nonFraction></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000775" name="us-gaap:DeferredTaxAssetsGross" contextRef="C_0001439725_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">58,538</ix:nonFraction></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000776" name="us-gaap:DeferredTaxAssetsGross" contextRef="C_0001439725_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">54,056</ix:nonFraction></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Valuation allowance</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000777" name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="C_0001439725_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">56,083</ix:nonFraction></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000778" name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="C_0001439725_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">51,135</ix:nonFraction></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax assets after valuation allowance</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000779" name="us-gaap:DeferredTaxAssetsNet" contextRef="C_0001439725_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,455</ix:nonFraction></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000780" name="us-gaap:DeferredTaxAssetsNet" contextRef="C_0001439725_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,921</ix:nonFraction></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred Tax Liabilities:</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible assets</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000781" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" contextRef="C_0001439725_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,455</ix:nonFraction></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000782" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" contextRef="C_0001439725_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,921</ix:nonFraction></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax liabilities</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000783" name="us-gaap:DeferredIncomeTaxLiabilities" contextRef="C_0001439725_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,455</ix:nonFraction></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000784" name="us-gaap:DeferredIncomeTaxLiabilities" contextRef="C_0001439725_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,921</ix:nonFraction></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net deferred tax assets and liabilities</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At December 31, 2020, the Company had $<ix:nonFraction unitRef="U_iso4217USD" id="F_000785" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" contextRef="C_0001439725_20201231" decimals="-5" scale="6">233.6</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000786" name="bdsx:DeferredTaxAssetsResearchAndExperimentationTaxCarryforwardsSubjectToExpiration" contextRef="C_0001439725_20201231" decimals="-5" scale="6">3.6</ix:nonFraction> million of net operating loss and research and experimentation tax carryforwards, respectively, which are set to <ix:nonNumeric id="F_000787" name="us-gaap:TaxCreditCarryforwardDescription" contextRef="C_0001439725_20200101_20201231">expire beginning in 2026</ix:nonNumeric>. The Internal Revenue Code contains provisions that may limit the net operating loss carryovers available to be used in any year if certain events occur, including significant changes in ownership interest. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In assessing the realizability of its deferred tax assets, the Company considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. The Company considers the scheduled reversal of deferred tax liabilities, projected future taxable income, and tax planning strategies in making this assessment. As the Company does not have any historical taxable income, projections of future taxable income over the periods in which the deferred tax assets are deductible, and after consideration of the history of operating losses, the <ix:nonNumeric id="F_000788" name="us-gaap:ValuationAllowanceDeferredTaxAssetExplanationOfChange" contextRef="C_0001439725_20200101_20201231">Company does not believe it is more likely than not that it will realize the benefits of net deferred tax assets and, accordingly, has established a valuation allowance equal to <ix:nonFraction unitRef="U_xbrlipure" id="F_000789" name="bdsx:PercentageOfValuationAllowanceEqualToNetDeferredTaxAssets" contextRef="C_0001439725_20200101_20201231" decimals="INF" scale="-2">100</ix:nonFraction>% of net deferred tax assets.</ix:nonNumeric> The valuation allowance increased by $<ix:nonFraction unitRef="U_iso4217USD" id="F_000790" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" contextRef="C_0001439725_20200101_20201231" decimals="-5" scale="6">4.9</ix:nonFraction> million during 2020 and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000791" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" contextRef="C_0001439725_20190101_20191231" decimals="-5" scale="6">7.0</ix:nonFraction> million during 2019.</p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-29</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000289_dcnt_b0d85215-20db-4b2d-acba-1e07dff5310a">

<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During 2020, the Company determined that it now has uncertain<span style="color:#000000;"> tax positions related to its U.S. research and development credits. As of December 31, 2020 and 2019, there was <ix:nonFraction unitRef="U_iso4217USD" id="F_000793" name="us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" contextRef="C_0001439725_20191231" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_iso4217USD" id="F_000792" name="us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" contextRef="C_0001439725_20201231" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction> accrued interest related to uncertain tax positions. The Company does not believe it is reasonably possible that its unrecognized tax benefits will significantly change in the next twelve months</span>. <ix:nonNumeric id="F_000341" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" contextRef="C_0001439725_20200101_20201231" escape="true" continuedAt="F_000341_cnt_1">A reconciliation of beginning and ending balances for unrecognized tax benefits is as follows (in thousands):</ix:nonNumeric></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000341_cnt_1">
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at January 1</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additions for tax positions related to the current year</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000794" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" contextRef="C_0001439725_20200101_20201231" decimals="-3" scale="3">106</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additions for tax positions related to prior years</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000795" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" contextRef="C_0001439725_20200101_20201231" decimals="-3" scale="3">609</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reductions for tax positions related to prior years</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reductions related to settlements</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reductions related to a lapse of statute</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000796" name="us-gaap:UnrecognizedTaxBenefits" contextRef="C_0001439725_20201231" decimals="-3" scale="3">715</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:continuation>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company monitors proposed and issued tax law, regulations, and cases to determine the potential impact of uncertain income tax positions. At December 31, 2020, the Company had not identified any potential subsequent events that would have a material impact on unrecognized income tax benefits within the next twelve months.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000797" name="us-gaap:IncomeTaxExaminationDescription" contextRef="C_0001439725_20200101_20201231">All years will remain open for examining by federal and state authorities for three and four years, respectively, from the date of utilization of any net operating loss carryforwards.</ix:nonNumeric> </p></ix:continuation><ix:nonNumeric id="F_000290" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" contextRef="C_0001439725_20200101_20201231" escape="true" continuedAt="F_000290_dcnt_ce04a83c-61fc-44ee-888d-30be9da4ae14">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note 17 &#8211; Commitments and Contingencies </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Leases</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company leases facilities under non&#8209;cancelable operating leases. Rent expense <span style="Background-color:#FFFFFF;">was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000798" name="us-gaap:OperatingLeasesRentExpenseNet" contextRef="C_0001439725_20200101_20201231" decimals="-5" scale="6">1.7</ix:nonFraction> million</span> and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000799" name="us-gaap:OperatingLeasesRentExpenseNet" contextRef="C_0001439725_20190101_20191231" decimals="-5" scale="6">2.1</ix:nonFraction> million for the years ended December 31, 2020 and 2019, respectively.</p><ix:nonNumeric id="F_000342" name="us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" contextRef="C_0001439725_20200101_20201231" escape="true" continuedAt="F_000342_dcnt_3637a528-8a53-4bbf-9861-b6cdd8535bae">
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Future minimum lease payments for operating lease obligations are as follows as of December 31, 2020 (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year Ending December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000800" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent" contextRef="C_0001439725_20201231" decimals="-3" scale="3">703</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000801" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears" contextRef="C_0001439725_20201231" decimals="-3" scale="3">724</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000802" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears" contextRef="C_0001439725_20201231" decimals="-3" scale="3">112</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2025</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thereafter</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000803" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDue" contextRef="C_0001439725_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,539</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:nonNumeric></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-30</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000290_dcnt_ce04a83c-61fc-44ee-888d-30be9da4ae14"><ix:continuation id="F_000342_dcnt_3637a528-8a53-4bbf-9861-b6cdd8535bae">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:continuation>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Co&#8209;Development Agreement</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In April 2014 and amended in October 2016, the Company entered into a worldwide agreement with AVEO to develop and commercialize AVEO's hepatocyte growth factor inhibitory antibody ficlatuzumab with the Company's proprietary companion diagnostic test, BDX004, a version of the Company&#8217;s serum protein test that is commercially available to help physicians guide treatment decisions for patients with advanced non&#8209;small cell lung cancer (NSCLC). Under the terms of the agreement, AVEO will conduct a proof&#8209;of&#8209;concept (POC) clinical study of ficlatuzumab for NSCLC in which BDX004 will be used to select clinical trial subjects (the NSCLC POC Trial). The Company and AVEO will share equally in the costs of the NSCLC POC Trial, and each will be responsible for <ix:nonFraction unitRef="U_xbrlipure" id="F_000804" name="bdsx:PercentageOfDevelopmentAndRegulatoryCosts" contextRef="C_0001439725_srtCounterpartyNameAxis_bdsxAVEOOncologyMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_bdsxNSCLCPOCTrialMember_20201031" decimals="2" scale="-2">50</ix:nonFraction>% of development and regulatory costs associated with all future clinical trials agreed upon by the Company and AVEO. The Company and AVEO continue to conduct POC clinical trials of ficlatuzumab in combination with BDX004 with each responsible for <ix:nonFraction unitRef="U_xbrlipure" id="F_000805" name="bdsx:PercentageOfDevelopmentAndRegulatoryCosts" contextRef="C_0001439725_srtCounterpartyNameAxis_bdsxAVEOOncologyMember_srtProductOrServiceAxis_bdsxBDX004Member_us-gaapEquitySecuritiesByIndustryAxis_bdsxFiclatuzumabMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_bdsxPOCClinicalTrialsMember_20201031" decimals="2" scale="-2">50</ix:nonFraction>% of development and regulatory costs. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In September 2020, the Company exercised its opt-out right with AVEO for the payment of <ix:nonFraction unitRef="U_xbrlipure" id="F_000806" name="bdsx:PercentageOfDevelopmentAndRegulatoryCostsExercisedUsingOptOutRight" contextRef="C_0001439725_srtCounterpartyNameAxis_bdsxAVEOOncologyMember_us-gaapEquitySecuritiesByIndustryAxis_bdsxFiclatuzumabMember_20200901_20200930" decimals="2" scale="-2">50</ix:nonFraction>% of development and regulatory costs for ficlatuzumab effective December 2, 2020. The Company had $<ix:nonFraction unitRef="U_iso4217USD" id="F_000807" name="bdsx:RemainingEstimatedObligation" contextRef="C_0001439725_srtCounterpartyNameAxis_bdsxAVEOOncologyMember_20201202_20201202" decimals="-5" scale="6">0.3</ix:nonFraction> million in remaining obligations related to the AVEO agreement as of the opt-out date. Following the effective date, the Company is entitled to a <ix:nonFraction unitRef="U_xbrlipure" id="F_000808" name="bdsx:PercentageOfRoyaltyPaymentsOnNetSales" contextRef="C_0001439725_srtCounterpartyNameAxis_bdsxAVEOOncologyMember_us-gaapEquitySecuritiesByIndustryAxis_bdsxFiclatuzumabMember_20201202_20201202" decimals="2" scale="-2">10</ix:nonFraction>% royalty of net sales of ficlatuzumab and <ix:nonFraction unitRef="U_xbrlipure" id="F_000809" name="bdsx:PercentageOfLicenseIncomeGeneratedFromLicensing" contextRef="C_0001439725_srtCounterpartyNameAxis_bdsxAVEOOncologyMember_us-gaapEquitySecuritiesByIndustryAxis_bdsxFiclatuzumabMember_20201202_20201202" decimals="2" scale="-2">25</ix:nonFraction>% of license income generated from the licensing of ficlatuzumab from AVEO.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expenses related to this agreement for the <span style="color:#000000;">years ended December 31, 2020 and 2019 </span>were approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000810" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_0001439725_srtCounterpartyNameAxis_bdsxAVEOOncologyMember_20200101_20201231" decimals="-5" scale="6">0.9</ix:nonFraction><span style="Background-color:#FFFF00;"> </span>million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000811" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_0001439725_srtCounterpartyNameAxis_bdsxAVEOOncologyMember_20190101_20191231" decimals="-5" scale="6">0.9</ix:nonFraction> million, respectively. </p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">License Agreement</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2019, we entered into a non-exclusive license agreement with Bio-Rad Laboratories, Inc. (Bio-Rad) (the Bio-Rad License). Under the terms of the Bio-Rad License, the Company received a non-exclusive license, without the right to grant sublicenses, to utilize certain of Bio-Rad&#8217;s intellectual property, machinery, materials, reagents, supplies and know-how necessary for the performance of Droplet Digital PCR&#8482; (ddPCR) in cancer detection testing for third parties in the United States. The Company also agreed to purchase all of the necessary supplies and reagents for such testing exclusively from Bio-Rad, pursuant to a separately executed supply agreement (the Supply Agreement) with Bio-Rad. As further consideration for the non-exclusive license, the Company agreed to pay a royalty of <ix:nonFraction unitRef="U_xbrlipure" id="F_000812" name="bdsx:PercentageOfRoyaltyPaymentsOnNetRevenue" contextRef="C_0001439725_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_bdsxBioRadLicenseMember_20190801_20190831" decimals="3" scale="-2">2.5</ix:nonFraction>% on the net revenue received for the performance of such ddPCR testing collected from third parties.&#160;&#160;The Bio-Rad License expires in <ix:nonNumeric id="F_000813" name="bdsx:LicenseAgreementExpiryDate" contextRef="C_0001439725_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_bdsxBioRadLicenseMember_20190801_20190831" format="ixt:datemonthyearen">August 2024</ix:nonNumeric>. Either party may terminate for the other&#8217;s uncured material breach or bankruptcy events. Bio-Rad may terminate the Bio-Rad License if the Company does not purchase licensed products under the Supply Agreement for a consecutive twelve-month period or for any material breach by us of the Supply Agreement.&#160;&#160;The Company incurred royalty expense of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000814" name="us-gaap:RoyaltyExpense" contextRef="C_0001439725_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_bdsxBioRadLicenseMember_20200101_20201231" decimals="-5" scale="6">0.1</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000815" name="us-gaap:RoyaltyExpense" contextRef="C_0001439725_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_bdsxBioRadLicenseMember_20190101_20191231" decimals="-5" scale="6">0.1</ix:nonFraction> million for the years ended December 31, 2020 and 2019, respectively, under the Bio-Rad License.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Revenue Share Agreement</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As part of the acquisition of Oncimmune, the Company entered into several agreements to govern the relationship between the parties. The Company agreed to a revenue share payment related to an acquired diagnostic test of <ix:nonFraction unitRef="U_xbrlipure" id="F_000816" name="bdsx:PercentageOfRevenueSharePaymentRelatedToAcquiredDiagnosticTestRecognizedRevenueForNonScreeningTests" contextRef="C_0001439725_us-gaapBusinessAcquisitionAxis_bdsxOncimmuneLimitedMember_us-gaapTypeOfArrangementAxis_bdsxRevenueShareAgreementMember_20200101_20201231" decimals="2" scale="-2">8</ix:nonFraction>% of recognized revenue for non-screen tests up to an annual minimum volume and <ix:nonFraction unitRef="U_xbrlipure" id="F_000817" name="bdsx:MinimumAnnualVolumePercentageThereafter" contextRef="C_0001439725_us-gaapBusinessAcquisitionAxis_bdsxOncimmuneLimitedMember_us-gaapTypeOfArrangementAxis_bdsxRevenueShareAgreementMember_20200101_20201231" decimals="INF" scale="-2">5</ix:nonFraction>% thereafter, with an escalating minimum <ix:nonNumeric id="F_000818" name="bdsx:PeriodOfEscalationsOfSales" contextRef="C_0001439725_us-gaapBusinessAcquisitionAxis_bdsxOncimmuneLimitedMember_us-gaapTypeOfArrangementAxis_bdsxRevenueShareAgreementMember_20200101_20201231">through the first four years of sales</ix:nonNumeric>. Revenue share expenses of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000819" name="bdsx:RevenueShareExpenses" contextRef="C_0001439725_us-gaapBusinessAcquisitionAxis_bdsxOncimmuneLimitedMember_us-gaapTypeOfArrangementAxis_bdsxRevenueShareAgreementMember_20200101_20201231" decimals="-5" scale="6">0.3</ix:nonFraction> million were recognized for the year ended December 31, 2020.</p></ix:continuation><ix:nonNumeric id="F_000291" name="us-gaap:DefinedContributionPlanTextBlock" contextRef="C_0001439725_20200101_20201231" escape="true">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note 18 &#8211; Defined Contribution 401(k) Plan</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company sponsors a 401(k) defined contribution plan covering all eligible employees. The Company did <ix:nonFraction unitRef="U_iso4217USD" id="F_000820" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" contextRef="C_0001439725_20200101_20201231" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction>t make any discretionary or employer matching contributions under the plan during the years ended December 31, 2020 or 2019.</p></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-31</p></body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.5
<SEQUENCE>2
<FILENAME>bdsx-ex45_270.htm
<DESCRIPTION>EX-4.5
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
bdsx-ex45_270.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 4.5</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:3.51%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">DESCRIPTION OF THE REGISTRANT&#8217;S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">The following summary describes the capital stock of Biodesix, Inc., (the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221;) and the material provisions of our amended and restated certificate of incorporation and our amended and restated bylaws, the amended and restated registration rights agreement to which we and certain stockholders are parties and of the General Corporation Law of the State of Delaware. Because the following is only a summary, it does not contain all of the information that may be important to you. For a complete description, you should refer to our amended and restated certificate of incorporation, amended and restated bylaws, and amended and restated registration rights agreement, copies of which are incorporated by reference as exhibits to our Annual Report on Form 10-K.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020, Biodesix Inc. (the &#8220;Company&#8221;) had common stock, $0.001 par value per share, registered under Section 12 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), and listed on the Nasdaq Global Select Market under the trading symbol &#8220;BDSX.&#8221;</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">General</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our amended and restated certificate of incorporation authorizes the issuance of 205,000,000 shares of capital stock, consisting of (i) 200,000,000 shares of common stock, $0.001 par value per share (the &#8220;Common Stock&#8221;) and (ii) 5,000,000 shares of preferred stock, par value $0.001 per share, <font style="color:#000000;">the rights, preferences and privileges of which may be designated from time to time by our board of directors. </font></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Common Stock</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Dividend Rights</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Subject to preferences that may apply to shares of preferred stock outstanding at the time, the holders of outstanding shares of our common stock are entitled to receive dividends out of funds legally available if our board of directors, in its discretion, determines to issue dividends and only then at the times and in the amounts that our board of directors may determine. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Voting Rights</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The holders of our common stock are entitled to one vote per share. Stockholders do not have the ability to cumulate votes for the election of directors. Our amended and restated certificate of incorporation and bylaws provide for a classified board of directors consisting of three classes of approximately equal size, each serving staggered three-year terms. Only one class of directors will be elected at each annual meeting of our stockholders, with the other classes continuing for the remainder of their respective three-year terms.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Preemptive or Other Rights</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our common stock is not entitled to preemptive rights and is not subject to redemption or sinking fund provisions.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Right to Receive Liquidation Distributions</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Upon our liquidation, dissolution or&#160;winding-up,&#160;the assets legally available for distribution to our stockholders would be distributable ratably among the holders of our common stock and any participating preferred stock outstanding at that time, subject to prior satisfaction of all outstanding debt and liabilities and the preferential rights of and the payment of liquidation preferences, if any, on any outstanding shares of preferred stock.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Preferred Stock</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our amended and restated certificate of incorporation provides that shares of preferred stock may be issued from time to time in one or more series. Our Board is authorized to fix the voting rights, if any, designations, powers, preferences and relative, participating, optional, special and other rights, if any, and any qualifications, limitations and restrictions thereof, applicable to the shares of each series. Our Board is able, without stockholder approval, to issue preferred stock with voting and other rights that could adversely affect the voting power and other rights of the holders of the Common Stock and could have anti-takeover effects. The ability of the our Board to issue preferred stock without stockholder approval could have the effect of delaying, deferring or preventing a change of control of us or the removal of existing management. We have no preferred stock outstanding at the date hereof. Although we do not currently intend to issue any shares of preferred stock, we cannot assure you that we will not do so in the future.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Certain Anti-Takeover Provisions of Delaware Law, the Company&#8217;s Certificate of Incorporation and Bylaws</font></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The provisions of the DGCL, our amended and restated certificate of incorporation and our bylaws could have the effect of delaying, deferring or discouraging another person from acquiring control of our company. These provisions, which are summarized below, are expected to discourage certain types of coercive takeover practices and inadequate takeover bids and encourage persons seeking to acquire control of our company to first negotiate with our board of directors. We believe that the benefits of increased protection of our potential ability to negotiate with an unfriendly or unsolicited acquirer outweigh the disadvantages of discouraging a proposal to acquire us because negotiation of these proposals could result in an improvement of their terms.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Section&#160;203 of the DGCL</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are subject to the provisions of Section&#160;203 of the DGCL regulating corporate takeovers. In general, Section&#160;203 prohibits a publicly held Delaware corporation from engaging in a &#8220;business combination&#8221; with an &#8220;interested stockholder&#8221; for a three-year period following the date that this stockholder becomes an interested stockholder, unless the business combination is approved in a prescribed manner. Under Section&#160;203, a business combination between a corporation and an interested stockholder is prohibited unless it satisfies one of the following conditions:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.55%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.51%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">before the stockholder became interested, our board of directors approved either the business combination or the transaction, which resulted in the stockholder becoming an interested stockholder;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.55%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.51%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">upon consummation of the transaction, which resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the voting stock outstanding, shares owned by persons who are directors and also officers, and employee stock plans in some instances, but not the outstanding voting stock owned by the interested stockholder; or</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.55%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.51%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">at or after the time the stockholder became interested, the business combination was approved by our board and authorized at an annual or special meeting of the stockholders by the affirmative vote of at least&#160;two-thirds&#160;of the outstanding voting stock, which is not owned by the interested stockholder.</font></p></td></tr></table></div>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Section&#160;203 defines a business combination to include:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.55%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.51%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">any merger or consolidation involving the corporation and the interested stockholder;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.55%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.51%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">any sale, transfer, lease, pledge or other disposition involving the interested stockholder of 10% or more of the assets of the corporation;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.55%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.51%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">subject to exceptions, any transaction that results in the issuance of transfer by the corporation of any stock of the corporation to the interested stockholder;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.55%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.51%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">subject to exceptions, any transaction involving the corporation that has the effect of increasing the proportionate share of the stock of any class or series of the corporation beneficially owned by the interested stockholder; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.55%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.51%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other financial benefits provided by or through the corporation.</font></p></td></tr></table></div>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In general, Section&#160;203 defines an interested stockholder as any entity or person beneficially owning 15% or more of the outstanding voting stock of the corporation and any entity or person affiliated with or controlling or controlled by the entity or person.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Amended and Restated Certificate of Incorporation and Bylaw Provisions</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our amended and restated certificate of incorporation and our bylaws include a number of provisions that may have the effect of deterring hostile takeovers, or delaying or preventing changes in control of our management team or changes in our board of directors or our governance or policy, including the following:</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Board Vacancies</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our amended and restated certificate of incorporation and bylaws authorize generally only our board of directors to fill vacant directorships resulting from any cause or created by the expansion of our board of directors. In addition, the number of directors </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-top:10pt;margin-bottom:0pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">constituting our board of directors may be set only by resolution adopted by a majority vote of our entire board of directors. These provisions prevent a stockholder from increasing the size of our board of directors and gaining control of our board of directors by filling the resulting vacancies with its own nominees.</font></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Classified Board</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our amended and restated certificate of incorporation and bylaws provide that our board of directors is classified into three classes of directors. The existence of a classified board of directors could delay a successful tender offeror from obtaining majority control of our board of directors, and the prospect of that delay might deter a potential offeror. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Directors Removed Only for Cause</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our amended and restated certificate of incorporation provides that stockholders may remove directors only for cause.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Supermajority Requirements for Amendments of Our Amended and Restated Certificate of Incorporation and Bylaws</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our amended and restated certificate of incorporation further provide that the affirmative vote of holders of at least&#160;two-thirds&#160;of the voting power of our outstanding common stock is required to amend certain provisions of our amended and restated certificate of incorporation, including provisions relating to the classified board, the size of the board of directors, removal of directors, special meetings, actions by written consent and designation of our preferred stock. The affirmative vote of holders of at least&#160;two-thirds&#160;of the voting power of our outstanding common stock is required to amend or repeal our bylaws, although our bylaws may be amended by a simple majority vote of our board of directors.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Stockholder Action; Special Meetings of Stockholders</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our amended and restated certificate of incorporation provides that our stockholders may not take action by written consent, but may only take action at annual or special meetings of our stockholders. As a result, holders of our capital stock are not be able to amend our bylaws or remove directors without holding a meeting of our stockholders called in accordance with our bylaws. Our amended and restated certificate of incorporation and our bylaws provide that special meetings of our stockholders may be called only by a majority of our board of directors, the chairperson of our board of directors, our chief executive officer, our president or the lead independent director, thus prohibiting a stockholder from calling a special meeting. These provisions might delay the ability of our stockholders to force consideration of a proposal or for stockholders to take any action, including the removal of directors.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Advance Notice Requirements for Stockholder Proposals and Director Nominations</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our bylaws provide advance notice procedures for stockholders seeking to bring business before our annual meeting of stockholders or to nominate candidates for election as directors at our annual meeting of stockholders. To be timely, a stockholder&#8217;s notice generally must be delivered to us not later than the close of business on the 90th day nor earlier than the close of business on the 120th day prior to the first anniversary of the preceding year&#8217;s annual meeting of stockholders. Our bylaws also specify certain requirements regarding the form and content of a stockholder&#8217;s notice. With respect to nominations of persons for election to our board of directors, the notice shall provide information about the nominee, including, among other things, name, age, address, principal occupation, ownership of our capital stock and whether they meet applicable independence requirements. With respect to the proposal of other business to be considered by our stockholders at an annual meeting, the notice shall provide a brief description of the business desired to be brought before the meeting, the text of the proposal or business, the reasons for conducting such business at the meeting and any material interest in such business by such stockholder and any beneficial owners and associated persons on whose behalf the notice is made, or the proposing persons. In addition, a stockholder&#8217;s notice must set forth certain information related to the proposing persons, including, among other things:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.55%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.51%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the name and address of the proposing persons;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.55%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.51%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">information as to the ownership by the proposing persons of our capital stock and any derivative interest or short interest in any of our securities held by the proposing persons;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.55%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.51%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">information as to any material relationships and interest between the proposing persons and us, any of our affiliates and any of our principal competitors;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.55%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.51%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">a representation that the stockholder is a holder of record of our stock entitled to vote at that meeting and that the stockholder intends to appear in person or by proxy at the meeting to propose such nomination or business; and</font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.55%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.51%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="text-decoration:none;Background-color:#auto;font-size:10pt;font-family:'Times New Roman';"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">a representation whether the proposing persons intend or are part of a group which intends to deliver a proxy statement or form of proxy to holders of at least the percentage of our outstanding capital stock required to elect the nominee or carry the proposal.</font></p></td></tr></table></div>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These provisions may preclude our stockholders from bringing matters before our annual meeting of stockholders or from making nominations for directors at our annual meeting of stockholders. We expect that these provisions might also discourage or deter a potential acquirer from conducting a solicitation of proxies to elect the acquirer&#8217;s own slate of directors or otherwise attempting to obtain control of our company.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">No Cumulative Voting</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The DGCL provides that stockholders are not entitled to the right to cumulate votes in the election of directors unless a corporation&#8217;s certificate of incorporation provides otherwise. Our amended and restated certificate of incorporation and bylaws will not provide for cumulative voting.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Issuance of Undesignated Preferred Stock</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our board has the authority, without further action by the stockholders, to issue up to 5,000,000 shares of undesignated preferred stock with rights and preferences, including voting rights, designated from time to time by our board of directors. The existence of authorized but unissued shares of preferred stock enables our board of directors to render more difficult or to discourage an attempt to obtain control of us by means of a merger, tender offer, proxy contest or otherwise.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Exclusive Forum</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our amended and restated certificate of incorporation provides that, unless we consent in writing to the selection of an alternative forum, to the fullest extent permitted by law, the sole and exclusive forum for (1)&#160;any derivative action or proceeding brought on our behalf under Delaware law, (2)&#160;any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers or other employees to us or our stockholders, (3)&#160;any action arising pursuant to any provision of the DGCL or our amended and restated certificate of incorporation or bylaws, (4)&#160;any other action asserting a claim that is governed by the internal affairs doctrine or (5)&#160;any other action asserting an &#8220;internal corporate claim,&#8221; as defined in Section&#160;115 of the DGCL, shall be the Court of Chancery of the State of Delaware (or, if the Court of Chancery does not have jurisdiction, the federal district court for the District of Delaware) in all cases subject to the court having jurisdiction over indispensable parties named as defendants. These exclusive-forum provisions do not apply to claims under the Securities Act or the Exchange Act. Any person or entity purchasing or otherwise acquiring any interest in our securities shall be deemed to have notice of and consented to this provision. Although we believe these provisions benefit us by providing increased consistency in the application of Delaware law for the specified types of actions and proceedings, the provisions may have the effect of discouraging lawsuits against us or our directors and officers.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To the extent that any such claims may be based upon federal law claims, Section&#160;27 of the Exchange Act creates exclusive federal jurisdiction over all suits brought to enforce any duty or liability created by the Exchange Act or the rules and regulations thereunder.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Section&#160;22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all suits brought to enforce any duty or liability created by the Securities Act or the rules and regulations thereunder. However, our amended and restated certificate of incorporation, which will become effective immediately prior to the completion of this offering, contains a federal forum provision which provides that unless the Company consents in writing to the selection of an alternative forum, the federal district courts of the United States of America will be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Transfer Agent and Registrar</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The transfer agent and registrar for our common stock is Computershare Trust Company, N.A.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</a></p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.5.1
<SEQUENCE>3
<FILENAME>bdsx-ex1051_388.htm
<DESCRIPTION>EX-10.5.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
bdsx-ex1051_388.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.5.1</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:12pt;text-align:center;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;text-transform:none;font-weight:bold;font-family:Times New Roman;font-style:normal;font-variant: normal;">BIODESIX, INC. </p>
<p style="text-align:center;margin-bottom:24pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;text-transform:none;font-weight:bold;font-family:Times New Roman;font-style:normal;font-variant: normal;">STOCK OPTION GRANT NOTICE<br />(2020 EQUITY INCENTIVE PLAN)</p>
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Biodesix, Inc.<font style="font-weight:normal;"> (the &#8220;</font><font style="font-style:italic;">Company</font><font style="font-weight:normal;">&#8221;), pursuant to its 2020 Equity Incentive Plan (as amended and/or restated as of the Date of Grant set forth below, the &#8220;</font><font style="font-style:italic;">Plan</font><font style="font-weight:normal;">&#8221;), has granted to Optionholder an option to purchase the number of shares of the Common Stock set forth below (the &#8220;</font><font style="font-style:italic;">Option</font><font style="font-weight:normal;">&#8221;).&nbsp;&nbsp;The Option is subject to all of the terms and conditions as set forth in this Stock Option Grant Notice (the &#8220;</font><font style="font-style:italic;">Grant Notice</font><font style="font-weight:normal;">&#8221;) and in the Plan, the Option Agreement, and the Notice of Exercise, all of which are attached to this Grant Notice and incorporated into this Grant Notice in their entirety.&nbsp;&nbsp;Capitalized terms not explicitly defined in this Grant Notice but defined in the Plan or the Option Agreement shall have the meanings set forth in the Plan or the Option Agreement, as applicable.  If the Company uses an electronic capitalization table system (such as Carta or Shareworks) and the fields below are blank or the information is otherwise provided in a different format electronically, the blank fields and other information (such as exercise schedule and type of grant) shall be deemed to come from the electronic capitalization system and is considered part of this Grant Notice.</font></p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:94.12%;">
<tr>
<td valign="top"  style="width:39.72%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Optionholder:</p></td>
<td valign="top"  style="width:60.28%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:39.72%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date of Grant:</p></td>
<td valign="top"  style="width:60.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:39.72%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vesting Commencement Date:</p></td>
<td valign="top"  style="width:60.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:39.72%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Number of Shares Subject to Option:</p></td>
<td valign="top"  style="width:60.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:39.72%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercise Price (Per Share)<sup style="font-size:85%;line-height:120%;vertical-align:top">1</sup><sup style="font-size:85%;line-height:120%;vertical-align:top"></sup>:</p></td>
<td valign="top"  style="width:60.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:39.72%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total Exercise Price:</p></td>
<td valign="top"  style="width:60.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:39.72%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expiration Date:</p></td>
<td valign="top"  style="width:60.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:39.72%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercise Schedule:</p></td>
<td valign="top"  style="width:60.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Same as Vesting Schedule</p></td>
</tr>
<tr>
<td valign="top"  style="width:39.72%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Type of Grant<sup style="font-size:85%;line-height:120%;vertical-align:top">2</sup><sup style="font-size:85%;line-height:120%;vertical-align:top"></sup>:</p></td>
<td valign="top"  style="width:60.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[Incentive Stock Option] [Nonstatutory Stock Option]</p></td>
</tr>
</table></div>
<div align="left"><table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:20%;"><tr><td style="width:20%;"></td></tr><tr><td valign="top"  style="border-bottom:Solid 1pt #000000;"><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;text-indent:0pt;font-size:8pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:0%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">1</sup>&nbsp;</font></p></td>
<td valign="top" style="width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> <font style="font-size:9pt;">The exercise price may be paid by one or a combination of the methods permitted in the Option Agreement.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:0%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">2</sup>&nbsp;</font></p></td>
<td valign="top" style="width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> If this is an Incentive Stock Option, it (plus other outstanding Incentive Stock Options) cannot be first <font style="font-style:italic;">exercisable</font> for more than $100,000 in value (measured by exercise price) in any calendar year.&nbsp;&nbsp;Any excess over $100,000 is a Nonstatutory Stock Option.</p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</a></p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ACTIVE 263957590</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Vesting Schedule:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Optionholder Acknowledgements:<font style="font-weight:normal;">&nbsp;&nbsp;By Optionholder&#8217;s signature below or by electronic acceptance or authentication in a form authorized by the Company, Optionholder understands and agrees that the Option is governed by this Grant Notice, and the provisions of the Plan and the Option Agreement and the Notice of Exercise, all of which are made a part of this document.</font></p>
<p style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By accepting this Option, Optionholder consents to receive this Grant Notice, the Option Agreement, the Plan, and any other Plan-related documents by electronic delivery and to participate in the Plan through an on-line or electronic system established and maintained by the Company or another third party designated by the Company.&nbsp;&nbsp;Optionholder represents that he or she has read and is familiar with the provisions of the Plan and the Option Agreement.&nbsp;&nbsp;Optionholder acknowledges and agrees that this Grant Notice and the Option Agreement may not be modified, amended or revised in a manner that materially impairs the rights of the Optionholder except in a writing signed by Optionholder and a duly authorized officer of the Company.</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Optionholder further acknowledges that in the event of any conflict between the provisions in this Grant Notice, the Option Agreement, the Notice of Exercise and the terms of the Plan, the terms of the Plan shall control.&nbsp;&nbsp;Optionholder further acknowledges that the Option Agreement sets forth the entire understanding between Optionholder and the Company regarding the acquisition of Common Stock and supersedes all prior oral and written agreements, promises and/or representations on that subject with the exception of other equity awards previously granted to Optionholder and any written employment agreement, offer letter, severance agreement, written severance plan or policy, or other written agreement between the Company and Optionholder, in each case that specifies the terms that should govern this Option.</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Grant Notice may be executed in one or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Counterparts may be delivered via facsimile, electronic mail (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act or other applicable law) or other transmission method and any counterpart so delivered will be deemed to have been duly and validly delivered and be valid and effective for all purposes.</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td colspan="2" valign="top"  style="width:49.5%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Biodesix, Inc. </p></td>
<td valign="top"  style="width:2.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:47.6%;">
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Optionholder:</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:7.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:3pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top"  style="width:41.7%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:2.9%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.82%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:3pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top"  style="width:39.78%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:7.8%;">
<p style="margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:41.7%;">
<p style="text-align:center;margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Signature)</p></td>
<td valign="top"  style="width:2.9%;">
<p style="margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.82%;">
<p style="margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:39.78%;">
<p style="text-align:center;margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Signature)</p></td>
</tr>
<tr>
<td valign="top"  style="width:7.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:3pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:</p></td>
<td valign="top"  style="width:41.7%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:2.9%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.82%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:3pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Email:</p></td>
<td valign="top"  style="width:39.78%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:7.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:3pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date:</p></td>
<td valign="top"  style="width:41.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:2.9%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.82%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:3pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date:</p></td>
<td valign="top"  style="width:39.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:3pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18.27%;text-indent:-18.27%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:18.27%;text-indent:-18.27%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Attachments<font style="font-weight:normal;">:&nbsp;&nbsp;Option Agreement, </font><font style="color:#000000;font-weight:normal;">2020 Equity Incentive Plan</font><font style="font-weight:normal;"> and Notice of Exercise</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;text-align:center;margin-top:0pt;text-indent:0%;font-size:10pt;font-weight:bold;text-transform:uppercase;font-family:Times New Roman;font-style:normal;font-variant: normal;">Biodesix, Inc.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-align:center;text-indent:0%;font-size:10pt;font-weight:bold;text-transform:uppercase;font-family:Times New Roman;font-style:normal;font-variant: normal;">2020 Equity Incentive Plan</p>
<p style="text-align:center;margin-bottom:24pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-weight:bold;text-transform:uppercase;font-family:Times New Roman;font-style:normal;font-variant: normal;"><br />OPTION AGREEMENT<br />(INCENTIVE STOCK OPTION OR NONSTATUTORY STOCK OPTION)</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to your Stock Option Grant Notice (&#8220;<font style="font-weight:bold;font-style:italic;">Grant Notice</font>&#8221;) and this Option Agreement, <font style="font-weight:bold;color:#000000;">Biodesix, Inc.</font><font style="color:#000000;"> </font>(the &#8220;<font style="font-weight:bold;font-style:italic;">Company</font>&#8221;) has grante<font style="color:#000000;">d you an option under its 2020 Equity Incentive Plan</font> (the &#8220;<font style="font-weight:bold;font-style:italic;">Plan</font>&#8221;) to purchase the number of shares of the Company&#8217;s Common Stock indicated in your Grant Notice at the exercise price indicated in your Grant Notice.&nbsp;&nbsp;The option is granted to you effective as of the date of grant set forth in the Grant Notice (the &#8220;<font style="font-weight:bold;font-style:italic;">Date of Grant</font>&#8221;).&nbsp;&nbsp;If there is any conflict between the terms in this Option Agreement and the Plan, the terms of the Plan will control. Capitalized terms not explicitly defined in this Option Agreement or in the Grant Notice but defined in the Plan will have the same definitions as in the Plan.</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The details of your option, in addition to those set forth in the Grant Notice and the Plan, are as follows:</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1.<font style="margin-left:36pt;"></font><font style="color:#000000;">Vesting</font><font style="font-variant: small-caps;font-weight:normal;color:#000000;">.</font><font style="font-weight:normal;color:#000000;">&nbsp;&nbsp;Your option will vest as provided in your Grant Notice.&nbsp;&nbsp;Vesting will cease upon the termination of your Continuous Service (as defined herein). </font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2.<font style="margin-left:36pt;"></font><font style="color:#000000;">Number of Shares and Exercise Price</font><font style="font-variant: small-caps;font-weight:normal;color:#000000;">.</font><font style="font-weight:normal;color:#000000;">&nbsp;&nbsp;The number of shares of Common Stock subject to your option and your exercise price per share in your Grant Notice will be adjusted in accordance with Section 5.7 of the Plan for changes in the capitalization of the Company.</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">3.<font style="margin-left:36pt;"></font><font style="color:#000000;">Definitions</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;For purposes of this Option Agreement, the following terms shall have the meanings set forth below.&nbsp;&nbsp;</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:15.38%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="font-style:italic;color:#000000;">Cause</font><font style="font-weight:normal;color:#000000;">&#8221; shall have the meaning ascribed to such term in any written agreement between you and the Company defining such term and which is in effect as of the Date of Grant and, in the absence of such agreement, such term means the occurrence of any of the following events: (i) your commission of any felony or any crime involving fraud, dishonesty or moral turpitude under the laws of the United States or any state thereof; (ii) your attempted commission of, or participation in, a fraud or act of dishonesty against the Company, or any of its employees or directors; (iii) your intentional, material violation of any contract or agreement between you and the Company, the Company&#8217;s employment policies, or of any statutory or other duty owed to the Company, (iv) your unauthorized use or disclosure of the Company&#8217;s confidential information or trade secrets; or (v) your gross misconduct.  The determination that a termination of your Continuous Service is either for Cause or without Cause will be made by the Company (or, if you are subject to Section 16 of the Exchange Act, the Committee), in its sole discretion.  Any determination by the Company that your Continuous Service was terminated with or without Cause for the purposes of this Option Agreement will have no effect upon any determination of the rights or obligations of the Company or you for any other purpose. Notwithstanding anything in the Plan or any award agreement to the contrary, the Company (or Committee, as applicable) may deem a termination or separation from service to be for Cause if, after such termination or separation (regardless of how originally designated), it discovers facts, circumstances or omissions that would constitute Cause if you were still employed.</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:15.38%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:36pt;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="font-style:italic;color:#000000;">Continuous Service</font><font style="font-weight:normal;color:#000000;">&#8221; means that your service with the Company or a Subsidiary, whether as an employee, director or consultant, is not interrupted or terminated.  A change in the capacity in which you render service to the Company or a Subsidiary as an employee, director or consultant or a change in the entity for which you render such service, provided that there is no interruption or termination of your service with the Company or a Subsidiary, will not terminate your Continuous Service; </font><font style="font-style:italic;font-weight:normal;color:#000000;">provided</font><font style="font-weight:normal;color:#000000;">, </font><font style="font-style:italic;font-weight:normal;color:#000000;">however</font><font style="font-weight:normal;color:#000000;">, that if the entity for which you are rendering services ceases to qualify as a Subsidiary, as determined by the Board in its sole discretion, your Continuous Service will be considered to have terminated on the date such entity ceases to qualify as a Subsidiary. </font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:15.38%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(c)<font style="margin-left:36pt;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="font-style:italic;color:#000000;">Disability</font><font style="font-weight:normal;color:#000000;">&#8221;</font><font style="letter-spacing:-0.55pt;font-weight:normal;color:#000000;"> </font><font style="font-weight:normal;color:#000000;">means your</font><font style="letter-spacing:-0.7pt;font-weight:normal;color:#000000;"> </font><font style="font-weight:normal;color:#000000;">inability</font><font style="letter-spacing:-0.6pt;font-weight:normal;color:#000000;"> </font><font style="font-weight:normal;color:#000000;">to</font><font style="letter-spacing:-0.4pt;font-weight:normal;color:#000000;"> </font><font style="font-weight:normal;color:#000000;">engage in any substantial gainful activity by reason of any medically determinable physical or mental impairment that can be expected to result in death or that has lasted or </font></p>
<p style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;color:#000000;">can be expected to last for a continuous period of not less than twelve (12) months as provided in Sections 22(e)(3) and 409A(a)(2)(c)(</font><font style="font-weight:normal;color:#000000;">i</font><font style="font-weight:normal;color:#000000;">) of the Code, and will</font><font style="letter-spacing:-0.35pt;font-weight:normal;color:#000000;"> </font><font style="font-weight:normal;color:#000000;">be</font><font style="letter-spacing:-0.3pt;font-weight:normal;color:#000000;"> </font><font style="font-weight:normal;color:#000000;">determined</font><font style="letter-spacing:-0.45pt;font-weight:normal;color:#000000;"> </font><font style="font-weight:normal;color:#000000;">by</font><font style="letter-spacing:-0.65pt;font-weight:normal;color:#000000;"> </font><font style="font-weight:normal;color:#000000;">the</font><font style="letter-spacing:-0.5pt;font-weight:normal;color:#000000;"> </font><font style="font-weight:normal;color:#000000;">Board</font><font style="letter-spacing:-0.15pt;font-weight:normal;color:#000000;"> </font><font style="font-weight:normal;color:#000000;">on</font><font style="letter-spacing:-0.65pt;font-weight:normal;color:#000000;"> </font><font style="font-weight:normal;color:#000000;">the</font><font style="letter-spacing:-0.3pt;font-weight:normal;color:#000000;"> </font><font style="font-weight:normal;color:#000000;">basis</font><font style="letter-spacing:-0.4pt;font-weight:normal;color:#000000;"> </font><font style="font-weight:normal;color:#000000;">of</font><font style="letter-spacing:-0.5pt;font-weight:normal;color:#000000;"> </font><font style="font-weight:normal;color:#000000;">such</font><font style="letter-spacing:-0.35pt;font-weight:normal;color:#000000;"> </font><font style="font-weight:normal;color:#000000;">medical</font><font style="letter-spacing:-0.15pt;font-weight:normal;color:#000000;"> </font><font style="font-weight:normal;color:#000000;">evidence</font><font style="letter-spacing:-0.3pt;font-weight:normal;color:#000000;"> </font><font style="font-weight:normal;color:#000000;">as</font><font style="letter-spacing:-0.4pt;font-weight:normal;color:#000000;"> </font><font style="font-weight:normal;color:#000000;">the</font><font style="letter-spacing:-0.55pt;font-weight:normal;color:#000000;"> </font><font style="font-weight:normal;color:#000000;">Board</font><font style="letter-spacing:-0.45pt;font-weight:normal;color:#000000;"> </font><font style="font-weight:normal;color:#000000;">deems</font><font style="letter-spacing:-0.35pt;font-weight:normal;color:#000000;"> </font><font style="font-weight:normal;color:#000000;">warranted</font><font style="letter-spacing:-0.2pt;font-weight:normal;color:#000000;"> </font><font style="font-weight:normal;color:#000000;">under the</font><font style="letter-spacing:-0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-weight:normal;color:#000000;">circumstances.</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">4.<font style="margin-left:36pt;"></font><font style="color:#000000;">Exercise and Method of Payment</font><font style="font-variant: small-caps;font-weight:normal;color:#000000;">.</font><font style="font-weight:normal;color:#000000;">&nbsp;&nbsp;Subject to the limitations set forth in this Option Agreement, you may exercise your option, to the extent vested, (a)&#160;by delivering to the Company an Exercise Notice in the form prescribed by the Company specifying the number of whole shares of Common Stock to be purchased and by accompanying such notice with payment therefor in full (or by arranging for such payment to the Company&#8217;s satisfaction) either (i)&#160;in cash, (ii)&#160;to the extent permitted by the Company (or, if you are subject to Section&#160;16 of the Exchange Act, the Committee), by delivery to the Company (either actual delivery or by attestation procedures established by the Company) of shares of Common Stock having an aggregate Fair Market Value, determined as of the date of exercise, equal to the aggregate purchase price payable pursuant to the option by reason of such exercise, (iii)&#160;to the extent permitted by the Company (or, if you are subject to Section&#160;16 of the Exchange Act, the Committee), by authorizing the Company to withhold whole shares of Common Stock which would otherwise be delivered having an aggregate Fair Market Value, determined as of the date of exercise, equal to the amount necessary to satisfy such obligation, (iv)&#160;except as may be prohibited by applicable law, in cash by a broker-dealer acceptable to the Company to whom you have submitted an irrevocable notice of exercise or (v)&#160;by a combination of (i), (ii)&#160;and (iii), and (b)&#160;by executing such documents as the Company may reasonably request.&nbsp;&nbsp;No share of Common Stock or certificate representing a share of Common Stock shall be issued or delivered until the full purchase price therefor and any withholding taxes thereon, as described in&#160;Section&#160;11, have been paid.&nbsp;&nbsp;If your option is an Incentive Stock Option, by exercising your option you agree that you will notify the Company in writing within 15 days after the date of any disposition of any of the shares of the Common Stock issued upon exercise of your option that occurs within two years after the Date of Grant or within one year after such shares of Common Stock are transferred upon exercise of your option.</font><font style="font-weight:normal;"> </font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">5.<font style="margin-left:36pt;"></font><font style="color:#000000;">Securities Law Compliance</font><font style="font-variant: small-caps;font-weight:normal;color:#000000;">.</font><font style="font-weight:normal;color:#000000;">&nbsp;&nbsp;In no event may you exercise your option unless the shares of Common Stock issuable upon exercise are then registered under the Securities Act of 1933, as amended (the &#8220;</font><font style="font-style:italic;color:#000000;">Securities Act</font><font style="font-weight:normal;color:#000000;">&#8221;) or, if not registered, the Company has determined that your exercise and the issuance of the shares would be exempt from the registration requirements of the Securities Act.&nbsp;&nbsp;The exercise of your option also must comply with all other applicable laws and regulations governing your option, and you may not exercise your option if the Company determines that such exercise would not be in material compliance with such laws and regulations (including any restrictions on exercise required for compliance with Treas. Reg. 1.401(k)-1(d)(3), if applicable).</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">6.<font style="margin-left:36pt;"></font><font style="color:#000000;">Term</font><font style="font-variant: small-caps;font-weight:normal;color:#000000;">.</font><font style="font-weight:normal;color:#000000;">&nbsp;&nbsp;You may not exercise your option before the Date of Grant or after the expiration of the option&#8217;s term.&nbsp;&nbsp;Except as set forth in your Grant Notice, the term of your option expires upon the earliest of the following:</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:15.38%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_C43"></a><font style="text-decoration:none;">(a)</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;color:#auto;font-weight:normal;">immediately upon the termination of your Continuous Service for Cause;</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:15.38%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:36pt;"></font><font style="font-weight:normal;color:#000000;">three months after the termination of your Continuous Service for any reason other than Cause,</font><font style="color:#0070C0;"> </font><font style="font-weight:normal;color:#000000;">your Disability or your death (except as otherwise provided in Section 6(d) below); </font><font style="font-style:italic;font-weight:normal;color:#000000;">provided</font><font style="font-weight:normal;color:#000000;">,</font><font style="font-style:italic;font-weight:normal;color:#000000;"> however</font><font style="font-weight:normal;color:#000000;">,</font><font style="font-style:italic;font-weight:normal;color:#000000;"> </font><font style="font-weight:normal;color:#000000;">that if during any part of such three month period your option is not exercisable solely because of the condition set forth in the section above relating to &#8220;Securities Law Compliance,&#8221; your option will not expire until the earlier of the Expiration Date or until it has been exercisable for an aggregate period of three months after the termination of your Continuous Service; </font><font style="font-style:italic;font-weight:normal;color:#000000;">provided further</font><font style="font-weight:normal;color:#000000;">, that if (i) your Continuous Service terminates within six months after the Date of Grant, and (ii) you have vested in a portion of your option at the time of your termination of Continuous Service, your option will not expire until the earlier of (x) the later of (A) the date that is seven months after the Date of Grant, and (B) the date that is three months after the termination of your Continuous Service, and (y) the Expiration Date;</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:15.38%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(c)<font style="margin-left:36pt;"></font><font style="font-weight:normal;color:#000000;">12 months after the termination of your Continuous Service due to your Disability (except as otherwise provided in Section 6(d) below);</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:15.38%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(d)<font style="margin-left:36pt;"></font><font style="font-weight:normal;color:#000000;">18 months after your death if you die either during your Continuous Service or within three (3) months after your Continuous Service terminates for any reason other than Cause; or</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:15.38%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(e)<font style="margin-left:36pt;"></font><font style="font-weight:normal;color:#000000;">the Expiration Date indicated in your Grant Notice.</font></p>
<p style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If your option is an Incentive Stock Option, note that to obtain the federal income tax advantages associated with an Incentive Stock Option, the Code requires that at all times beginning on the Date of Grant and ending on the day three months before the date of your option&#8217;s exercise, you must be an employee of the Company or a Subsidiary, except in the event of your death or Disability.&nbsp;&nbsp;The Company has provided for extended exercisability of your option under certain circumstances for your benefit but cannot guarantee that your option will necessarily be treated as an Incentive Stock Option if you continue to provide services to the Company or a Subsidiary as a consultant or director after your employment terminates or if you otherwise exercise your option more than three months after the date your employment with the Company or a Subsidiary terminates.</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_C61"></a><a name="_DV_X64"></a><a name="_DV_C62"></a>7.<font style="margin-left:36pt;"></font><font style="text-decoration:none;color:#auto;">Non-Transferability</font><font style="text-decoration:none;color:#auto;font-variant: small-caps;font-weight:normal;">.</font><font style="text-decoration:none;color:#auto;font-weight:normal;"><a name="_DV_X64"></a><a name="_DV_C62"></a>&nbsp;&nbsp;Except as otherwise provided in this Section 7, your option is not transferable, except by will or by the laws of descent and distribution, and is exercisable during your life only by you.&nbsp;&nbsp;</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:15.38%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_C71"></a><a name="_DV_M73"></a><a name="_DV_M74"></a>(a)<font style="margin-left:36pt;"></font><font style="text-decoration:none;color:#auto;">Certain Trusts</font><font style="text-decoration:none;color:#auto;font-weight:normal;">.<a name="_DV_M73"></a>&nbsp;&nbsp;Upon receiving written permission from the Board or its duly authorized designee,</font><font style="font-weight:normal;color:#000000;"><a name="_DV_M74"></a> you may transfer your option to a trust if you are considered to be the sole beneficial owner (determined under Section 671 of the Code and applicable state law) while the option is held in the trust.&nbsp;&nbsp;You and the trustee must enter into transfer and other agreements required by the Company.&nbsp;&nbsp;</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:15.38%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_C75"></a><a name="_DV_C76"></a>(b)<font style="margin-left:36pt;"></font><font style="text-decoration:none;color:#auto;">Domestic Relations Orders</font><font style="text-decoration:none;color:#auto;font-weight:normal;">.&nbsp;&nbsp;Upon receiving written permission from the Board or its duly authorized designee, and provided that you and the designated transferee enter into transfer and other agreements required by the Company, you may transfer your option pursuant to the terms of a domestic relations order, official marital settlement agreement or </font><font style="font-weight:normal;color:#000000;">other divorce or separation instrument as permitted by Treasury Regulation 1.421-1(b)(2)</font><font style="text-decoration:none;color:#auto;font-weight:normal;"> that contains the information required by the Company to effectuate the transfer.&nbsp;&nbsp;You are encouraged to discuss the proposed terms of any division of this option with the Company prior to finalizing the domestic relations order or marital settlement agreement to help ensure the required information is contained within the domestic relations order or marital settlement agreement.&nbsp;&nbsp;If this option is an Incentive Stock Option, this option may be deemed to be a Nonstatutory Stock Option as a result of<a name="_DV_C76"></a> such transfer.</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:15.38%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_C77"></a><a name="_DV_X66"></a><a name="_DV_C78"></a><a name="_DV_C79"></a><a name="_DV_X67"></a><a name="_DV_C80"></a><a name="_DV_C81"></a><a name="_DV_X69"></a><a name="_DV_C82"></a><a name="_DV_C83"></a>(c)<font style="margin-left:36pt;"></font><font style="text-decoration:none;color:#auto;">Beneficiary Designation</font><font style="text-decoration:none;color:#auto;font-weight:normal;">.<a name="_DV_X66"></a><a name="_DV_C78"></a>&nbsp;&nbsp;Upon receiving written permission from the Board or its duly authorized designee, you may, <a name="_DV_C79"></a>by delivering written notice to the Company, in a form<a name="_DV_X67"></a><a name="_DV_C80"></a> approved by <a name="_DV_C81"></a>the Company<a name="_DV_X69"></a><a name="_DV_C82"></a> and any broker designated by the Company to handle option exercises,<a name="_DV_C83"></a> designate a third party who, on your death, will thereafter be entitled to exercise this option and receive the Common Stock or other consideration resulting from such exercise.&nbsp;&nbsp;In the absence of such a designation, your executor or administrator of your estate will be entitled to exercise this option and receive, on behalf of your estate, the Common Stock or other consideration resulting from such exercise.&nbsp;&nbsp;</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">8.</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="color:#000000;">Issuance or Delivery of Shares</font><font style="font-weight:normal;color:#000000;">.</font><font style="color:#000000;">  </font><font style="text-decoration:none;color:#auto;font-weight:normal;">Upon the exercise of the option, in whole or in part, the Company shall issue or deliver, subject to the conditions of this Option Agreement, the number of shares of Common Stock purchased against full payment therefor.  Such issuance shall be evidenced by the appropriate entry on the books of the Company or of a duly authorized transfer agent of the Company.  The Company shall pay all original issue or transfer taxes and all fees and expenses incident to such issuance, except as otherwise provided in&#160;Section&#160;11.</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">9.<font style="margin-left:36pt;"></font><font style="color:#000000;">Option Confers No Rights as Stockholder</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;You</font><font style="font-weight:normal;"> shall not be entitled to any privileges of ownership with respect to shares of Common Stock subject to the option unless and until such shares are purchased and issued upon the exercise of the option, in whole or in part, and you become a stockholder of record with respect to such issued shares.  You shall not be considered a stockholder of the Company with respect to any such shares not so purchased and issued.</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">10.<font style="margin-left:36pt;"></font><font style="color:#000000;">Option not a Service Contract</font><font style="font-variant: small-caps;font-weight:normal;color:#000000;">.</font><font style="font-weight:normal;color:#000000;">&nbsp;&nbsp;Your option is not an employment or service contract, and nothing in your option will be deemed to create in any way whatsoever any obligation on your part to continue in the employ or service of the Company or an affiliate, or of the Company or an affiliate to continue your employment or service.&nbsp;&nbsp;In addition, nothing in your option will obligate the Company or an affiliate, their respective stockholders, boards of directors, officers or employees to continue any relationship that you might have as a director or consultant for the Company or an affiliate.</font></p>
<p style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">11.</font><font style="margin-left:36pt;"></font><font style="color:#000000;">Withholding Obligations</font><font style="font-weight:normal;color:#000000;">.</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:15.38%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;"></font><font style="font-weight:normal;color:#000000;">As a condition precedent to the issuance of Common Stock following the exercise of the option, you shall, upon request by the Company, pay to the Company in addition to the purchase price of the shares, such amount as the Company determines is required, under all applicable federal, state, local or other laws or regulations, to be withheld and paid over as income or other withholding taxes (the &#8220;</font><font style="font-style:italic;color:#000000;">Required Tax Payments</font><font style="font-weight:normal;color:#000000;">&#8221;) with respect to such exercise of the option.  If you shall fail to advance the Required Tax Payments after request by the Company, the Company may, in its discretion, deduct any Required Tax Payments from any amount then or thereafter payable by the Company to you.&nbsp;&nbsp;</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:15.38%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:36pt;"></font><font style="font-weight:normal;color:#000000;">You may elect to satisfy your obligation to advance the Required Tax Payments by any of the following means: (i)&#160;a cash payment to the Company; (ii)&#160;to the extent permitted by the Company (or, if you are subject to Section&#160;16 of the Exchange Act, the Committee), delivery to the Company (either actual delivery or by attestation procedures established by the Company) of previously owned whole shares of Common Stock having an aggregate Fair Market Value, determined as of the date on which such withholding obligation arises (the &#8220;</font><font style="font-style:italic;color:#000000;">Tax Date</font><font style="font-weight:normal;color:#000000;">&#8221;), equal to the Required Tax Payments; (iii)&#160;to the extent permitted by the Company (or, if you are subject to Section&#160;16 of the Exchange Act, the Committee), authorizing the Company to withhold whole shares of Common Stock which would otherwise be delivered to you upon exercise of the option having an aggregate Fair Market Value, determined as of the Tax Date, equal to the Required Tax Payments; (iv)&#160;except as may be prohibited by applicable law, a cash payment by a broker-dealer acceptable to the Company to whom you have submitted an irrevocable notice of exercise or (v)&#160;any combination of (i), (ii)&#160;and (iii).  Shares of Common Stock to be delivered or withheld may not have a Fair Market Value in excess of the amount determined by applying the maximum individual statutory tax rate in your jurisdiction; provided that the Company shall be permitted to limit the number of shares so withheld to a lesser number if necessary, as determined by the Company, to avoid adverse accounting consequences or for administrative convenience.  No share of Common Stock or certificate representing a share of Common Stock shall be issued or delivered until the Required Tax Payments have been satisfied in full.</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">12.<font style="margin-left:36pt;"></font><font style="color:#000000;">Tax Consequences</font><font style="font-weight:normal;color:#000000;">.  You hereby agree that the Company does not have a duty to design or administer the Plan or its other compensation programs in a manner that minimizes your tax liabilities. You will not make any claim against the Company, or any of its officers, directors, employees, affiliates or representatives related to tax liabilities arising from your option or your other compensation. </font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">13.<font style="margin-left:36pt;"></font><font style="color:#000000;">Notices</font><font style="font-variant: small-caps;font-weight:normal;color:#000000;">.</font><font style="font-weight:normal;color:#000000;">&nbsp;&nbsp;Any notices provided for in your option or the Plan will be given in writing (including electronically) and will be deemed effectively given upon receipt or, in the case of notices delivered by mail by the Company to you, five days after deposit in the United States mail, postage prepaid, addressed to you at the last address you provided to the Company.&nbsp;&nbsp;The Company may, in its sole discretion, decide to deliver any documents related to participation in the Plan and this option by electronic means or to request your consent to participate in the Plan by electronic means.&nbsp;&nbsp;By accepting this option, you consent to receive such documents by electronic delivery and to participate in the Plan through an on-line or electronic system established and maintained by the Company or another third party designated by the Company.</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">14.<font style="margin-left:36pt;"></font><font style="color:#000000;">Decisions of Board or Committee</font><font style="font-weight:normal;color:#000000;">.  The Board or the Committee shall have the right to resolve all questions which may arise in connection with the option or its exercise. Any interpretation, determination or other action made or taken by the Board or the Committee regarding the Plan or this Option Agreement shall be final, binding and conclusive.</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">15.<font style="margin-left:36pt;"></font><font style="color:#000000;">Successors</font><font style="font-weight:normal;color:#000000;">.  This Option Agreement shall be binding upon and inure to the benefit of any successor or successors of the Company and any person or persons who shall, upon your death, acquire any rights hereunder in accordance with this Option Agreement or the Plan.</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">16.<font style="margin-left:36pt;"></font><font style="color:#000000;">Protected Rights</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;Pursuant to 18 U.S.C. &#167; 1833(b), &#8220;an individual shall not be held criminally or civilly liable under any federal or state trade secret law for the disclosure of a trade secret that-(A) is made-(i) in confidence to a federal, state, or local government official, either directly or indirectly, or to an attorney; and (ii) solely for the purpose of reporting or investigating a suspected violation of law; or (B) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal.&#8221;  Accordingly, you have the right to disclose in confidence trade secrets to federal, state, and local government officials, or to an attorney, for the sole </font></p>
<p style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;color:#000000;">purpose of reporting or investigating a suspected violation of law. </font><font style="font-weight:normal;color:#000000;"> </font><font style="font-weight:normal;color:#000000;">You also have the right to disclose trade secrets in a document filed in a lawsuit or other proceeding, but only if the filing is made under seal and protected from public disclosure. </font><font style="font-weight:normal;color:#000000;"> </font><font style="font-weight:normal;color:#000000;">Nothing in this Option Agreement is intended to conflict with 18 U.S.C. &#167; 1833(b) or create liability for disclosures of trade secrets that are expressly allowed by 18 U.S.C. &#167; 1833(b).&nbsp;&nbsp;You understand that nothing contained in this Option Agreement limits your ability to file a charge or complaint with the Equal Employment Opportunity Commission, the National Labor Relations Board, the Occupational Safety and Health Administration, the Securities and Exchange Commission or any other federal, state or local governmental agency or commission (&#8220;</font><font style="font-style:italic;color:#000000;">Government Agencies</font><font style="font-weight:normal;color:#000000;">&#8221;).&nbsp;&nbsp;You further understand that this Option Agreement does not limit your ability to communicate with any Government Agencies or otherwise participate in any investigation or proceeding that may be conducted by any Government Agency, including providing documents or other information, without notice to the Company.&nbsp;&nbsp;This Option Agreement does not limit your right to receive an award for information provided to any Government Agencies.&nbsp;&nbsp; </font></p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">17.<font style="margin-left:36pt;"></font><font style="color:#000000;">Governing Plan Document</font><font style="font-variant: small-caps;font-weight:normal;color:#000000;">.</font><font style="font-weight:normal;color:#000000;">&nbsp;&nbsp;Your option is subject to all the provisions of the Plan, the provisions of which are hereby made a part of your option, and is further subject to all interpretations, amendments, rules and regulations, which may from time to time be promulgated and adopted pursuant to the Plan.&nbsp;&nbsp;If there is any conflict between the provisions of your option and those of the Plan, the provisions of the Plan will control.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;text-align:center;margin-top:0pt;text-indent:0%;font-size:10pt;font-weight:bold;text-transform:uppercase;font-family:Times New Roman;font-style:normal;font-variant: normal;">BIODESIX, INC.</p>
<p style="text-align:center;margin-bottom:24pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-weight:bold;text-transform:uppercase;font-family:Times New Roman;font-style:normal;font-variant: normal;">NOTICE OF EXERCISE</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This constitutes notice to <font style="font-weight:bold;color:#000000;">Biodesix, Inc.</font><font style="color:#000000;"> </font>(the &#8220;<font style="font-weight:bold;font-style:italic;">Company</font>&#8221;) under my stock option that I elect to purchase the below number of shares of Common Stock of the Company (the&#160;&#8220;<font style="font-weight:bold;font-style:italic;">Shares</font>&#8221;) for the price set forth below.&nbsp;&nbsp;Use of certain payment methods is subject to Company and/or Committee consent and certain additional requirements set forth in the Option Agreement and the Plan.&nbsp;&nbsp;<font style="color:#000000;">If the Company uses an electronic capitalization table system (such as Carta or Shareworks) and the fields below are blank, the blank fields shall be deemed to come from the electronic capitalization system and is considered part of this Notice of Exercise.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:57.84%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Option Information</font></p></td>
<td valign="top"  style="width:42.16%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:36pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:57.84%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:42.16%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:36pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:57.84%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Type of option (check one):</p></td>
<td valign="top"  style="width:42.16%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:36pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Incentive<font style="font-weight:bold;"> </font><font style="font-weight:bold;font-family:Segoe UI Symbol;">&#9744;</font><font style="font-weight:bold;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font>Nonstatutory <font style="font-weight:bold;font-family:Segoe UI Symbol;">&#9744;</font></p></td>
</tr>
<tr>
<td valign="bottom"  style="width:57.84%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock option dated:</p></td>
<td valign="top"  style="width:42.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:36pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:57.84%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Number of Shares as to which option is exercised:</p></td>
<td valign="top"  style="width:42.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:36pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:57.84%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares to be issued in name of:<sup style="font-size:85%;line-height:120%;vertical-align:top">3</sup><sup style="font-size:85%;line-height:120%;vertical-align:top"></sup></p></td>
<td valign="top"  style="width:42.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:36pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:57.84%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:36pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:42.16%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:36pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:57.84%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:36pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Exercise Information</font></p></td>
<td valign="top"  style="width:42.16%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:36pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:57.84%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:42.16%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:36pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:57.84%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date of Exercise:</p></td>
<td valign="top"  style="width:42.16%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:36pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:57.84%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total exercise price:</p></td>
<td valign="top"  style="width:42.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:36pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:57.84%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:27pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash:<sup style="font-size:85%;line-height:120%;vertical-align:top">4</sup><sup style="font-size:85%;line-height:120%;vertical-align:top"></sup></p></td>
<td valign="top"  style="width:42.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:36pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:57.84%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:27pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Value of _________ Shares delivered with this notice:<sup style="font-size:85%;line-height:120%;vertical-align:top">5</sup><sup style="font-size:85%;line-height:120%;vertical-align:top"></sup></p></td>
<td valign="top"  style="width:42.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:36pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:57.84%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:27pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Value of _________ Shares withheld pursuant to net exercise:</p></td>
<td valign="top"  style="width:42.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:36pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By this exercise, I agree (i)&#160;to provide such additional documents as you may require pursuant to the terms of the Plan, (ii)&#160;to provide for the payment by me to you (in the manner designated by you) of your withholding obligation, if any, relating to the exercise of this option, and (iii)&#160;if this exercise relates to an incentive stock option, to notify you in writing within 15 days after the date of any disposition of any of the Shares issued upon exercise of this option that occurs within two years after the date of grant of this option or within one year after such Shares are issued upon exercise of this option.&nbsp;&nbsp;I further agree that this Notice of Exercise may be delivered via facsimile, electronic mail (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act or other applicable law) or other transmission method and will be deemed to have been duly and validly delivered and be valid and effective for all purposes.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:53.85%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Very truly yours,</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:62.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-top:0pt;text-align:left;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:37.62%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:justify;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:62.38%;">
<p style="margin-top:0pt;text-align:left;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:37.62%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Signature)</p></td>
</tr>
<tr>
<td valign="top"  style="width:62.38%;">
<p style="margin-top:0pt;text-align:left;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:37.62%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:62.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-top:0pt;text-align:left;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:37.62%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:62.38%;">
<p style="margin-top:0pt;text-align:left;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:37.62%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name (Please Print)</p></td>
</tr>
<tr>
<td valign="top"  style="width:62.38%;">
<p style="margin-top:0pt;text-align:left;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:37.62%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr style="height:11.5pt;">
<td valign="top"  style="width:62.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="text-align:right;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Address of Record:</p></td>
<td valign="top"  style="width:37.62%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr style="height:11.5pt;">
<td valign="top"  style="width:62.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-top:0pt;margin-bottom:0pt;margin-left:252pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:37.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr style="height:12.55pt;">
<td valign="top"  style="width:62.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-top:0pt;margin-bottom:0pt;margin-left:252pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:37.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:62.38%;">
<p style="text-align:right;margin-top:0pt;margin-bottom:0pt;margin-left:252pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:37.62%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:62.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-top:0pt;margin-bottom:0pt;margin-left:252pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Email:</p></td>
<td valign="top"  style="width:37.62%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div align="left"><table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:20%;"><tr><td style="width:20%;"></td></tr><tr><td valign="top"  style="border-bottom:Solid 1pt #000000;"><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;text-indent:0pt;font-size:8pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:0%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">3</sup>&nbsp;</font></p></td>
<td valign="top" style="width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> If left blank, will be issued in the name of the option holder.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:0%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">4</sup>&nbsp;</font></p></td>
<td valign="top" style="width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Cash may be in the form of cash, check, bank draft, electronic funds transfer or money order payment.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:0%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">5</sup>&nbsp;</font></p></td>
<td valign="top" style="width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Shares must be valued in accordance with the terms of the option being exercised, and must be owned free and clear of any liens, claims, encumbrances or security interests.</p></td></tr></table></div>
<p style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>4
<FILENAME>bdsx-ex231_271.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
bdsx-ex231_271.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 23.1</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:20pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Consent of Independent Registered Public Accounting Firm</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Board of Directors<br />Biodesix, Inc.:</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We consent to the incorporation by reference in the registration statement (No. 333-249805) on Form S-8 of Biodesix, Inc. of our report dated March&#160;16, 2021, with respect to the balance sheets of Biodesix, Inc. as of December&#160;31, 2020 and 2019, the related statements of operations, convertible preferred stock and stockholders&#8217; equity (deficit), and cash flows for each of the years in the two-year period ended December&#160;31, 2020, and the related notes, which report appears in the December&#160;31, 2020 annual report on Form 10-K of Biodesix, Inc.</p>
<p style="text-align:center;margin-bottom:10pt;line-height:12pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ KPMG LLP</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Denver, Colorado<br />March 16, 2021</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>bdsx-ex311_269.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
bdsx-ex311_269.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 31.1</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">PRINCIPAL EXECUTIVE OFFICER CERTIFICATION</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I, Scott Hutton, certify that:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;border-left:none 0pt;padding-left:31pt;font-weight:normal;font-style:normal;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">1.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;border-left:none 0pt;padding-left:31pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;">I have reviewed this Annual Report on Form 10-K of Biodesix, Inc.;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;border-left:none 0pt;padding-left:31pt;font-weight:normal;font-style:normal;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">2.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;border-left:none 0pt;padding-left:31pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;border-left:none 0pt;padding-left:31pt;font-weight:normal;font-style:normal;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">3.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;border-left:none 0pt;padding-left:31pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;border-left:none 0pt;padding-left:31pt;font-weight:normal;font-style:normal;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">4.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;border-left:none 0pt;padding-left:31pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;border-left:none 0pt;padding-left:31pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;border-left:none 0pt;padding-left:31pt;font-weight:normal;font-style:normal;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(a)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;border-left:none 0pt;padding-left:31pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;border-left:none 0pt;padding-left:31pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;border-left:none 0pt;padding-left:31pt;font-weight:normal;font-style:normal;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(b)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;border-left:none 0pt;padding-left:31pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;">[Paragraph omitted in accordance with Exchange Act Rule 13a-14(a)];</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;border-left:none 0pt;padding-left:31pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;border-left:none 0pt;padding-left:31pt;font-weight:normal;font-style:normal;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(c)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;border-left:none 0pt;padding-left:31pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;">evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and </font><font style="font-size:10pt;color:#000000;">procedures</font><font style="font-size:10pt;">, as of the end of the period covered by this report based on such evaluation; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;border-left:none 0pt;padding-left:31pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;border-left:none 0pt;padding-left:31pt;font-weight:normal;font-style:normal;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(d)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;border-left:none 0pt;padding-left:31pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;">disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;border-left:none 0pt;padding-left:31pt;font-weight:normal;font-style:normal;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">5.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;border-left:none 0pt;padding-left:31pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;border-left:none 0pt;padding-left:31pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;border-left:none 0pt;padding-left:31pt;font-weight:normal;font-style:normal;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(a)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;border-left:none 0pt;padding-left:31pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;">all </font><font style="font-size:10pt;color:#000000;">significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;border-left:none 0pt;padding-left:31pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;border-left:none 0pt;padding-left:31pt;font-weight:normal;font-style:normal;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(b)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;border-left:none 0pt;padding-left:31pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></p></td></tr></table></div>
<p style="text-align:justify;border-left:none 0pt;padding-left:31pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:46.15%;"></td>
<td style="width:1.28%;"></td>
<td style="width:3.09%;"></td>
<td style="width:49.48%;"></td>
</tr>
<tr>
<td valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: March 16, 2021</p></td>
<td valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top"  style=" border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ SCOTT HUTTON</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Scott Hutton</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Executive Officer</p></td>
</tr>
</table></div>
<p style="text-align:justify;border-left:none 0pt;padding-left:31pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>bdsx-ex312_268.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
bdsx-ex312_268.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 31.2</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATION PURSUANT TO</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I, Robin Harper Cowie, certify that:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;border-left:none 0pt;padding-left:31pt;font-weight:normal;font-style:normal;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">1.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;border-left:none 0pt;padding-left:31pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;">I have reviewed this Annual Report on Form 10-K of Biodesix, Inc.;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;border-left:none 0pt;padding-left:31pt;font-weight:normal;font-style:normal;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">2.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;border-left:none 0pt;padding-left:31pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;border-left:none 0pt;padding-left:31pt;font-weight:normal;font-style:normal;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">3.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;border-left:none 0pt;padding-left:31pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;border-left:none 0pt;padding-left:31pt;font-weight:normal;font-style:normal;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">4.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;border-left:none 0pt;padding-left:31pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;border-left:none 0pt;padding-left:31pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;border-left:none 0pt;padding-left:31pt;font-weight:normal;font-style:normal;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(a)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;border-left:none 0pt;padding-left:31pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;border-left:none 0pt;padding-left:31pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;border-left:none 0pt;padding-left:31pt;font-weight:normal;font-style:normal;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(b)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;border-left:none 0pt;padding-left:31pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;">[Paragraph omitted in accordance with Exchange Act Rule 13a-14(a)];</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;border-left:none 0pt;padding-left:31pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;border-left:none 0pt;padding-left:31pt;font-weight:normal;font-style:normal;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(c)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;border-left:none 0pt;padding-left:31pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;">evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and </font><font style="font-size:10pt;color:#000000;">procedures</font><font style="font-size:10pt;">, as of the end of the period covered by this report based on such evaluation; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;border-left:none 0pt;padding-left:31pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;border-left:none 0pt;padding-left:31pt;font-weight:normal;font-style:normal;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(d)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;border-left:none 0pt;padding-left:31pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;">disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;border-left:none 0pt;padding-left:31pt;font-weight:normal;font-style:normal;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">5.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;border-left:none 0pt;padding-left:31pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;border-left:none 0pt;padding-left:31pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;border-left:none 0pt;padding-left:31pt;font-weight:normal;font-style:normal;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(a)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;border-left:none 0pt;padding-left:31pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;">all </font><font style="font-size:10pt;color:#000000;">significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;border-left:none 0pt;padding-left:31pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;border-left:none 0pt;padding-left:31pt;font-weight:normal;font-style:normal;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(b)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;border-left:none 0pt;padding-left:31pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></p></td></tr></table></div>
<p style="text-align:justify;border-left:none 0pt;padding-left:31pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:46.15%;"></td>
<td style="width:1.28%;"></td>
<td style="width:3.09%;"></td>
<td style="width:49.48%;"></td>
</tr>
<tr>
<td valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: March 16, 2021</p></td>
<td valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top"  style=" border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ ROBIN HARPER COWIE</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Robin Harper Cowie</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Financial Officer</p></td>
</tr>
</table></div>
<p style="text-align:justify;border-left:none 0pt;padding-left:31pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>7
<FILENAME>bdsx-ex321_267.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
bdsx-ex321_267.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Exhibit 32.1</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">CERTIFICATION PURSUANT TO</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the Annual Report of Biodesix, Inc. (the &#8220;Company&#8221;) on Form 10-K for the year ending December 31, 2020 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;border-left:none 0pt;padding-left:31pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;border-left:none 0pt;padding-left:31pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(1)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;border-left:none 0pt;padding-left:31pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;border-left:none 0pt;padding-left:31pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;border-left:none 0pt;padding-left:31pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(2)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;border-left:none 0pt;padding-left:31pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></p></td></tr></table></div>
<p style="text-align:justify;border-left:none 0pt;padding-left:31pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:50%;"></td>
<td style="width:1.28%;"></td>
<td style="width:3.85%;"></td>
<td style="width:44.87%;"></td>
</tr>
<tr>
<td valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: March 16, 2021</p></td>
<td valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top"  style=" border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ SCOTT HUTTON</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Scott Hutton</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Executive Officer</p></td>
</tr>
</table></div>
<p style="text-align:justify;border-left:none 0pt;padding-left:31pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>8
<FILENAME>bdsx-ex322_266.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
bdsx-ex322_266.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Exhibit 32.2</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">CERTIFICATION PURSUANT TO</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the Annual Report of Biodesix, Inc. (the &#8220;Company&#8221;) on Form 10-K for the year ending December 31, 2020 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;border-left:none 0pt;padding-left:31pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;border-left:none 0pt;padding-left:31pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(1)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;border-left:none 0pt;padding-left:31pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;border-left:none 0pt;padding-left:31pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;border-left:none 0pt;padding-left:31pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(2)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;border-left:none 0pt;padding-left:31pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></p></td></tr></table></div>
<p style="text-align:justify;border-left:none 0pt;padding-left:31pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:50%;"></td>
<td style="width:1.28%;"></td>
<td style="width:3.85%;"></td>
<td style="width:44.87%;"></td>
</tr>
<tr>
<td valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: March 16, 2021</p></td>
<td valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top"  style=" border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ ROBIN HARPER COWIE</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Robin Harper Cowie</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Financial Officer</p></td>
</tr>
</table></div>
<p style="text-align:justify;border-left:none 0pt;padding-left:31pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>gegguy50oztz000005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gegguy50oztz000005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" -,!J # 2(  A$! Q$!_\0
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M\Z,M_>/YT<H<QW7V^W_OK^='V^W_ .>B_G7"Y;^\?SHRWJ?SHY0YCNOM]O\
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M5SO4NHI'"*P)/H:GKCM#9O[3C!)QBNQSZ5,D6A:*2EI %%%% !1110 4444
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MZ+^=']JVW_/5?SKS3+?WC^=&6_O'\Z/[2D']G(]+_M6W_P">J_G2_P!JV_\
MSU7\Z\SRW]X_G1EO[Q_.G_:4@_LY'I?]JVW_ #U7\Z/[5MO^>J_G7FF6_O'\
MZ,M_>/YTO[2D']G'I?\ :MM_SU7\Z/[5MO\ GJOYUYIEO[Q_.C+?WC^=']I2
M#^SD>E_VK;?\]5_.E_M6V_YZK^=>9Y;^\?SHRW]X_G1_:4@_LX]+_M6V_P">
MB_G1_:EM_P ]5_.O-,M_>/YT9;^\?SH_M.0?V:>E_P!JVW_/5?SH_M6V_P">
MB_G7FF6_O'\Z-S?WC^=']IR#^S4>E_VK;?\ /1?SH_M6V_YZ+^=>:9;^\?SH
MRW]X_G1_:<@_LU'I?]JVW_/1?SH_M6V_YZ+^=>:9;^\?SHRW]X_G1_:<@_LU
M'I?]JVW_ #U7\Z/[5M_^>J_G7FF6_O'\Z,M_>/YT_P"TF']G(],_M6W_ .>J
M_G1_:MM_ST7\Z\SRW]X_G1EO[Q_.E_:;#^SCTS^U;;_GJOYTG]JVW_/5?SKS
M3+?WC^=&6_O'\Z?]I,/[.1Z9_:MM_P ]%_.C^U;;_GHOYUYGEO[Q_.C+?WC^
M=+^TY!_9IZ9_:MM_ST7\Z/[5M_\ GJOYUYGEO[Q_.C+?WC^=']I2#^SCTO\
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M117BGL!1113 **** "BBB@ H[44=\4+5V!Z*X# &6_"CISUS6U?V<2:? X4
ME<UC*"V !D^E:2@XZ,SA44E="45,;6X SY+;?6F"*1EW*A(I>SD4IH913A'(
M1N"$KZT&.3;NV':.II<C%SJXW-%36\1FF6,=ZMZAICVD:-R=W7VJO92M<'4B
MI6,ZBI8[::492-B/:F,CHQ5U*D>M+V;2NQJHF[(;[4#'0GGM5JPA6XN0AK2U
MK2A;JLT2\!1G%:0HN2NC.==1ERLPP2G!YS16YH6EB\)>49 /0UFWT/E7TL:C
M #8%$Z,E&X1Q$7+E*M%3?9;C;N$3;?6HMC%MJC+>E9>SDBU53$X!SU-!'/S#
M!K0T^QE:<>;"=OO3M:@6.]147'RC@5?LY6N1[=<UC-ZG/I14S6LX7=Y+;?6H
MQ'(WW4)QUJ7!W+4TU<;14AMYE )C(!IPM;@C(A;;ZT>SD+VD2'-'-3+;2F15
M,9&3BKU_I,EG"'Y;(JE1FTVA.K%-)]3+ZG%'&<5+';3ORD;,/:HV1HVPZD'W
MJ/9M:LMU%L(2JGU-!/' Y-6M.B62]1)%R&;O6_,EBEQ]G\I-V<9KHA1O&YA.
MORNQRP  Y/S49R/>MNXL4M;YF*!T/050O8]UWB&/!Q]T5$J+0XUU(ICDY/%'
M\JD>WFCQOC8#WK8NK-!INY(_G*TO92*]LD8?3\:*<T;Q@;U(STS3:RDFC6,K
MA1114E-A1113$%%%% !1111H%V'>I8&VU%WS2K79@%:J<F,?[LOQS'/6M6SD
M)(K"BY-;-EU%?3=#YU[G36C<"M)>E9=GT%:B=*8#J.]%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 E<]XP_Y -U_US-=#7/>,/^0#=?\ 7,U,MC;#
M_P 1'SK1117 ]S["*]T****!W844446 ****+ %%%%%@"BBBBP!11118 HHH
MHL 44446 ***446 0D#D=:,X.>OM7;VFC6TGA&*Z\I3*2<MW[5!X.TF&]U&1
M+B(,H1B :M0N<LL0K-]CC^1TY%'5AVKL;2&T@OY8GM%D4.V/SKFY;66YOY5M
MH"?F.%7M2Y2J5=,I8);BG8.>%SBK;Z3J$>=]K(OU%=9X8TJ&YTN^\V -*L61
MGKFCE"IB(QU.&_BS2C+=N*N7&EWL*;VM7"?WL53&?E ]>:7*:>TYE="9/9?Q
MH( [UZ3HMCID'AIKVZMHWPV,FH]1T?3M3T::^LDCC\O@JM7R'+]:5SSO/'2D
M]^]=;J<=M%I2A+,*X3EQ7/1Z5?31B5+:1D/.0*GD-U635RH QY"Y]:1LYR!7
M6>#M/CGN[V.ZB!*1YPW:LK6--G^VN;>W;RAW'2APL*->+=C(SFBE(P<>E)2L
M=""BBBE8 HHHHL 44446 ****+ %%%%%@"BBBBP!11118 HHHHL 4#K10.M-
M+4F6QWWA20KIC#_:KI893ZUROA?_ )!S?[U='#]X5V0/E,7_ !#H;%R:Z"T/
M KF['J*Z*T[5J<J.8U?_ )",GUJEWJ[J_P#R$9/K5+O5D,****"0HHHI@%%%
M%(84444 %%%% !1110 4444 !Z5J:2P8-"3]^LNI;:4V\ZRC^$T ;NHXLX4B
M_O\ %.BMQ%91M&X4GO6/?7[7Q4D_=Z5-!J48A6*<%@O3%("WJ$<0AB8D-*7&
M2*EU"=;5%$:E7VCYJR+FYC=U:,$ $&EO;TW)'L,4P+>G.MP&@?EG.<U//"EA
M:3(1\S\BL[2E/V]&6I]8N?-F5?[O!I#*-OS<H?>M/5U?[/#MSR:R(F\N4/[U
MJG58714=6.* N,TF!&ED,B[F5<U;M;@74[Q21-M .,UGKJ"P7+20@@,,&K#:
MK"B%H5(D/!- 7+$$,<D#VPQN+9J>>SA:W^SJ!O(K#M;UX+GSF-3C5"MVLISQ
M3$6-5"0P0Q#J%P:H:;_Q^1\8^:F75PUW(6)[\9IL$K02HY/"GM2L.YU$\%K+
M>.SH&=>:S+BX,]]L((48X-4Y=38W9ECR,GFB2\1[CSL'-%@N:+"&/4URF?DI
M;^)VL9&W;^>,=JS3?JUV)L' &*FEU)/L[0P @MR<T :]E&C6B[\<#I6#J3.9
MRN"$4\5(-394P#R.M17=XMRB#!W+WIB*?7VQ11CNW6CGO0 4444 %%%% !11
M10 4444 %%%% !1113$%%%%"&R&X_P!4:JQ]:M7'^J-58^M1(J)J6?WA72V7
M05S5G]X5TMET%24;$?W:DJ./[M24 %%%% !1110 4444 %%%% !1110 4444
M %%%% "=J6DI: *E_P#\><O^[7FMS_Q\-7I5_P#\><O^[7FMS_Q\-7C9EL>K
MEV[(:***\0]@**** "BBB@ HHHIH&%')/%%)D@9%73:YM2:E^70Z74E)TNUP
MI/R=JH:-:AII'D7IR :L1ZW#]ECBD5CM&*KOJB)*K0@@9YKNE.#=SAIPFDT:
M<=R9+Z2W,9\O&,>E$,,4>H26B@;=F157^V[<%W1&$K#K68FH2I=?:&;+FKE5
MIVT,U2J7.CM+&**)K:3!9F+"JFIPQV5C)%QN;D51EUAI+M9E)&%Q5?4M1-\R
M]>!BHJ5(*&A<*4^;49I\GE7D9'K6]JLOF&U0]'.#7,P2^5,K'M5V\U$W!AVY
M'EFLZ-9<C3-JM*7.FC8GD%E'%'%$>3@D=ZK:S"GV1;@)M=C@TR/6HO+5;A68
MKTQ5+4=1>\?:#^['05I4J4_9V1E2A-5+LDT(!M0QCM703SI>#['D!CWKF-/N
MULKDRG/3'%(;YQ=>>APW8U-+$1A%(JK1E.;9TT4BZ;=PVZ'(?KBJL]I&^IJ[
MX(9NE88U"4W:32MG;5B;5"\T<BY!4YJWB(RT9$</*.IJF\V:@UKY+&/.*([&
MW75[A@@PJY"U5&MV^TOL;SC_ !>]4DU69;UK@MRW!JG5ID*E4;-FUOVDOC&8
MFV@=*DGM8KG6X]X&-E4/[<ME?S$1A)T)JK-K#&^6>/(P,5?MJ25B?8U&[HWO
M+47 C=PT?=:IZ;# )+LD J&X]JI-JML5RJ-YA[U5M=2%NLZX/[TU#K4^8T5&
MI8O_ &@7&HI /]6&QBK5Y=&VOQ;)$WEAL<=*YV.Y:.Y\X'H<UL?VU;R /(C&
M0<YJ:=6&MPJTIW5BQJN(6B:(;,N*FUB=VMXUW<'&:Q;[5/MA7KA2#3;O4_M(
M51GC%$:\8W7<'0G*S['026ZPQ1B%@FY0367K<,($;*R[\<^],CUB,PA;H,V!
M@8K.O;A+EPR@X'2HJU(\A5.C.ZN2Z62=1@!_O5U$EO:27<KE 9$Y-<A;7 M[
MB.7GY3FK9U=OMSS)D!SS54:T8TK#K49RE=&@UP;K4F0@A1_":EQ%'K)&S^#K
M66VH0F[,ZJ0QZTAU/??^>V?+VXQWINK&Q$:$C5OX':S9_,#_ #<$=JTK6&-K
M1?,P>.E<]-J\/V4Q6ZLH)R<TC:PX1=AP0*OVL"/9396U-W-TRD$*#\N:I5>O
M;V.\5/E.]1R:HUP56F]#OHII:A1116"-V%%%% @HHHH **** #M2KUI.U*O6
MN[ _Q#CQG\,GAZUL6/45CP]:V+'J*^F6Q\^]SI+/H*U4Z5E6?05JITH$.[T4
M=Z* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KGO&/_ " ;K_KF:Z&N
M>\8_\@&Z_P"N9I2V-J'\1'SI1117GL^PAL%%%%#&%%%% !1110 4444 %%%%
M !1110 4444 %%%% !2CK2#I1WH ]6\-W-K;^#H6NH?,CR>/P%6O#>IZ/=7<
MR65GY,NQOFS7!0^(O)T%+#GY2:B\/ZZFCWSW#!B&4C ]ZWC-(\F>%E+F9U.B
M01SZK.)5S^\;K]:L:7:V]E8ZG>I#OFBD^7'45RUAXF6TNY)F#89B>/>M?PWJ
M5PXNI"VZU=\O&!R:%)&;I3BKFUH=[_;-I?&YMWS']TL/I2>'G2V;5FV\+'D5
M>L+F)+"^DC0PIC)#C&:XH>)([22^C4-^^7;Q571"C.K*R.ATO4(=;L;FW>,_
MNXBPS]*\U8".Y9?]O^M;.AZ\NE_: P;][&4&*PW?,Y<]SFL^9'H4Z4XMIGK&
M@Q6DO@YDO5!C,@ZU!XD>VT+0)+:Q@(69=VY>@KC_ /A(Q_8#:>-VXL&J67Q0
MMWH[65YN=B,*1V%5S(Y/JM1-G0ZA##_PCT,S1[BT>36G81I<:-:I;R+#E?F4
M_P 5<5=>*%ETY+.,,-J[1FK>G^)[&VMHA/'(TT0^4CIFES(?L:MC?\.6@A\3
MZA%(N!MP2:?XRC6QTH?85Y+8++W%<Q%XP*ZI=W3[L3+@8%+%XN62%[:Y#/!@
M[1[TG((4:BDF<BQRQ/?/-)4L[1O*S1@A2>AJ*LV>K&]M0HHHI%!1110 4444
M %%%% !1110 4444 %%%% !1110 4#K10.M-;DRV.Y\+_P#(-;_>KI(.HKF_
M"_\ R#6_WJZ2'J*[(;'RF+_B&Y8]171VG:N<L>HKH[3M6IR=3E]7_P"0C)]:
MI=ZNZO\ \A&3ZU2[U9+"BBB@D****8!1112&%%%% !1110 4444 %%%% !0.
M*** "BBB@ H'%%% $UO<R6K[X\;O>HY)&DD,C=2<TT\BI;:+SYUB?A3W% $3
M*>&QQ0#G[O>K=W*H_<H!MCXSBJR1F3[@- #=OS$#KWH'7%6;:WW3LC]0,FIY
M4LES\[9^E &?[T9!8<5H6MLKV[..1FF-$D43G^+M0!2()YP<"@<CBKUNZRCR
MW !;IBJL\?DRLOI0!&..O>@CF@\@44 %%%% "8XI>P'I110 $9HHHH ****
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MO^N9I2V-J'\1'SI12=Z6O/9]A#8****&,**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ H.1S1BC&#3L'F+M)8$ D^@K2TW6+O2)-T('7.&%:.A6,
M45@^K2C*1-M.>G^>*HZC#-=,UPL8$8Z;:?*SF=2,VTRU?^+=2OX6BFV*I&!L
M&*P,GOR:-KKU!_&N@T'1H+E);B]9EC494BBS&I4Z*NCGB#UQ2@?+QUKI;^WT
M0VVZWFD,GH14NF:18'15U"]=U4MM^44<HGB$U<Y0*V,=Z7:5'(-=!>6^D.P2
MVE<GW%:USH$,FE;T_P!9M&*?*'UEM7L<3M;&-IR>G%!#*/F!'U%;M_)#8/;M
M& SH/F!'>KMU:PZKIHN80!(B[G & *7*5[5]4<K@D4@/&#29.['I2D9I,W7*
MPHHSFBD/J%%%% /<****!!1110 4444 %%%% !1110 4444 %%%% !0.M% Z
MTUN3+8[GPO\ \@UO]ZNDAZBN;\+_ /(-;_>KI(>HKLAL?*8O^(;=CU%=':=J
MYRQZBNCM.U:G)U.8U?\ Y",GUJEWJ[J__(2D^M4N]60%%%% @HHHI@%%%%(8
M4444 %%%% !1110 4444 %%%% !1110 4444 ';%6K'B48ZYJJ1D8[U-:2A+
MA21P.M %JV2%KN4S-@YX'K5J?S5&8K9=G9JS[I!YAD5NIS3([N51AI"5]* )
M;:XDCN9)/+!)'(JQ;7:7,C(T2@X-4DN0LF[;G-6?[1B5?DMU5B.HH @"OYYB
M1B 3G JQ-']H "'H,'%4TGV2[NI-3P7PA))3.30,9:(4OD4^M+??\?4F?6I+
M?:9FN&.,'(%5;B7S;AF'<T"(_I1VH_BHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH ****:$0W'^J-58^M6KC_5&JL?6HD7$U+/[PKI;
M+H*YNSZBNDLN@J2C8C^[4E1Q_=J2@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHI* #M2TE+0!4O_\ CSE_W:\UN?\ CX:O2K__ (\Y?]VO-;G_ (^&KQ<R
M>AZN7;LAHHHKQ4>P%%%%, HHHH ****0PHHHI]!!1110KVL-I!1112>HDD%%
M%%%AA1110_(2\PHHHI^@K+J:&C\7C$?W34-M*T6HLZC<P8\4EE<?9I]^,Y&*
MEG5;:X$R'<#R:Z$]%8YVO>=UN6X]0$]TL;P)DFJT]M$ERQD?:&/%2)JD"@-]
MF4,.]9\LIGD9R>_ ]*N<U;4FG!WT+$MO:QHS)-N8C@5IVDJ0Z/&S %N^:P!\
MP(S5JUO?LXV2)O7L#4TZD8LJI"31?1TOHBJQJF,G(J"&^>UMGC\E6CW<DTV?
M45\C;#"$;/:F6MZD4)66$/DYYK535[HSY':S19>1+K3I+A8U1DX&VH[ RO&S
M!B6'1:BN=062$QQ1!%/4"F+>>7Y90;<=<=ZESM*Y2@^6Q)<VC.6D.=W5AZ5-
MI7*3Y.1LXJ-]1\Y?+"8+\$T_?'9VH"L"S#!J6US715GR\K,P\L3[T'K0W+Y
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M+'/M33D\^E'!Y IW)T#/844N0*0C/-3:Y2844446 ****=A!11118 HHHHL
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MI0!E[31M/I6I]C/I1]C/I0!E[#1L-:GV,^E'V,^E &7L-&PUJ?8SZ4?8SZ4
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MSM5_YX)^=:U% &3YVJ_\\$_.CSM5_P">"?G6M10!D>=JO_/!/S_^M1YVJ_\
M/!/S_P#K5KT4 9'GZK_SP3\ZIZEJ6K6<<;+ A+,!R?\ ZU='6+XBXMH#_P!-
M1_,4 .6XU4QJWD)R/6G>?JO_ #P3\ZTXO]2G^Z*=0!E>?JO_ #P3\Z//U7_G
M@GYUK44 9'GZK_SP3\Z//U7_ )X)^=:]% &1Y^J_\\$_.E\[5?\ G@GYUK44
M 9/G:K_SP3\Z/.U7_G@GYUK44 9/GZK_ ,\$_.CS]5_YX)^=:U% &3Y^J_\
M/!/SI/.U;_G@GY__ %JUZ* ,CSM6_P">"?G_ /6H\[5O^>"?G_\ 6K7HH R/
M.U;_ )X)^?\ ]:CSM6_YX)^?_P!:M>B@#)\[5?\ G@GYT>=JO_/!/SK6HH R
M?.U7_G@GYT>?JO\ SP3\ZUJ* ,GS]5_YX)^='GZK_P \$_.M:B@#)\[5?^>"
M?G1YVJ_\\$_.M:B@#)\[5?\ G@GYT>?JO_/!/SK6HH R?/U7_G@GYT>?JO\
MSP3\ZUJ* ,GS]5_YX)^='GZK_P \$_.M:B@#)\[5?^>"?G1YVJ_\\$_.M:B@
M#)\[5?\ G@GYT>?JO_/!/SK6HH R?/U7_G@GYTUY-4=&4P+@C'6MBB@"AI<+
MV]ILD&#G-7@<T@&1TQ2Y["@!:*2EH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***3\:
M %HI/QHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BD
MHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDI: "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "DI:* $[<4#@=:6B@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ K$\1<VL'_74?S%;=8OB+_CV@_ZZC^8H UHO]6G^
MZ*DID7^J3_=%/H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 3O1Q2TF *
M  4M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% ";@*3<OK4#;C/MSQBI/*H ?N7UHW+
MZTSRJ/*H ?N7U%&Y?44SRJ/*H ?N7U%&Y?44SRJ/*H ?N7U%&Y?44SRJ/*H
M?N7U%&Y?44SRJ/*H ?N7U%&Y?44SRJ/*H ?N7U%&Y?44SRJ/*H ?N7U%&Y?4
M4SRJ/*H ?N7U%&Y?44SRJ/*H ?N7U%&Y?44SRJ/*H ?N7U%&Y?44SRJ/*H ?
MN7U%&Y?44SRJ/*H ?N7U%&Y?44SRJ/*H ?N7U%&Y?44SRJ/*H ?N7U%&Y?44
MSRJ/*H ?N7U%&Y?44SRJ/*H ?N7U%&Y?45'Y5'E4 2;E]12@@]#4?E5&,I*>
M>* +-%)GBC- "T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %8OB+_ (]X/^NH_F*V:QO$1_T:#_KJ
M/YBF!KQ?ZI/]T4^F1?ZE/]T4^D 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% $'_ "\?A4]5Q_Q\_A5B@ HH
MHH **** "BBB@ HHHH **** "BDW#.,C/IFEH **:70-M+*&],\TZ@ HHHH
M**** "BD#J3@,,_6FF6,-M,BACVSS0 ^BFAT;[K*?H:=0 4444 %%%% !111
M0 4444 %%%% !24M)WH 6JDS[),U;K*U67R@#[T 6Q<#UI_G US@ON>M6XKO
M<1S0!NAP13JI02;AUJXIR* %HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M&FZB-6\0-<W$SJL+E0%; (S5^U22XU1H#(VP*>]9?A70X[VXO0TK+MF(X^M
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% $'_+U^%3U!_P O7X5/0 4444 %%%% !1378*,DXI@D1AN5QMH
MEI,BHY)8U7+.![TX$,N1SZ&@!U% Z4G3K2 Y]_#_ )GB">_,AQ(FW;^=95YX
M4N(=0-S973QJ1CRTZ5V:S1M(45@6':GU5Q6.#L?!=ROB&'4KF]DE9%(PWX58
MU;P@[7BW5K,R$<E%'WJ[3OFF\YQUHY@L<MH?AN>SG:>>Y=RQR%;M5G1_#QT[
MQ!?ZB9"WVG^$]JZ'US2CI1<+'.MX>)\03:AYAQ(/N^E+#H!B\0R:CYI(>/9M
MKH._6E)Q1<+&!::$;:_:?S"<@\?6FZ!H']D37#^:6\V0OSVK>:1(QEV ^M+O
M1AD,*+A8YK3/"JVLFH^9)O6[?<01TK'F\'7$%Q((+AQ'(<#'\-=_UI/QHN%C
MF;/PU-:Z<8A>/YA7&[O6(?!-Q>/%'<73GRY ^\]\'.*]!Y'O2_6BX6&PH(X4
MC_NJ!^5/I*2D,=132#D'/%+Q0 M%-[TH.:+ +1110 4E+10 5S?BK_CW7ZUT
ME<WXJ_X]U^M ''Q]:U;+J*RD^]6K9=10!TEGT%;$?W:Q[+H*V$^Z* 'T444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M 'T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M<-RBG!ZT])D?@5'):JYSDTL< 0YR:0R>BD[4M !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4F.<TM(>M !SWHINX$\'
MD4[&: %[44=J*0$'_+S^%3U!_P O/X5/3 **** "BBB@#)\06,VH:<880"Q]
M:Y(^#;P>$I--"CSFF\S&>V:]"/2DQVIW%8X#5/!]Y>:(+15&[:!UJ ^!KJPD
MLI].'[V)?G!/&:]&Y_&EHN%CR[4?!&II<B^LXT:ZE.Z0-TS6WX<T/4+=YI=2
MAB#R+@;1WKM@*.*+A8XG2?#%U9>,+K5)0!#)'M'/U_QKD?&FGPZIXT2"'/F
M*2!TKV*11(A7)&1BN>MO"%I#KAU4R.\NW&&Z4[BL:>DV:66GPQ*,?(,_E6+X
MK\/W&L;?( .!CDUU QMX[4H'%*X['':QX;N+W2+*U0#?"FT\_6FZAX8NKC0+
M.S0#?"/FYKL_K1VQFBX6. OO!,UUX>MK;://A;<,'OQ6,_@[Q%?0+;W6WRE;
M(^:O5P"..U+CG%%PL>?77@V\E\-&P"CS-X;K4^J^$[N\M+>-0,QQA3S7=\#B
MC )S3Y@L>8>)]!CB73Q$2MY&F$YP,URNK0:C]ILH[]U9BV$V-FO6O$7AJ'Q
MJ[YI(F08!3K6%IOPWM;2\CN);N>9HVR!(<_UHYA6*]]X:N]6T32DA4;H)-S9
MK3\3>&[K5=$M;2( O'*&//IC_"NN5!&@50 /:G 8X[47'8X'5O!,UWI"I&/]
M)7&.?2L.X\&^(]1L#;W(7 ("@-V%>M9'K1QBBX6.#N?"-Y+HT=KM&Y4"]:T-
M1\/7%SX:BT^,#S%CVGFNLI:+A8X>3PM=MX7L]/VCS(A@\UT/AG3I=+T2&TF
M#IUQ6MTX-( 1QVI7 ?1112&%%%% !7-^*O\ CW7ZUTE<WXJ_X]U^M ''I]ZM
M6RZBLI/O5JV744 =)9?=%;$?W:Q[+[HK8C^[0 ^BBB@ HHHH **** "BBB@
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MEHH 3\*/PI:* $_"C\*6B@!/PH_"EHH 3\*/PI:* $_"C\*6B@!/PH_"EHH
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MI+7=PLSJ1$IP<UZ#&@CC5%Z 8J&VMDMX@B*  ,<"K KZ+#4%2C8^>Q%9U97
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MFNKGSH)7:8MAE8G&,T[!<]5)7=C(SZ9H)&<9&?3-<DU_./&]M:@_NVA!//?
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH 0T8I:2@!,4$ CFEHH$E8SKO2+6[4[X4)/?%<[=^!;69BR
M.5]@*[/\*3BLITE(VA7G'9GGW_""!6P)'(JY;>"8E(+2-7:=^E+@5C]5C>YL
M\9-JQDV>@VUL!\H;'J*U4C5%PH 'M3J!TK>-.,=CFE4E)ZBT4E%:$ABEHHH
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M (]U^M ''Q]:U;/J*RH^M:MGU% '26?05L1_=K'L^@K8C^[0 ^BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH *2EHH **** $Y]:*6B@!,44M% K"44M% Q*6BB@!*6BB@ I*6B@!
M**6B@ HHHH 0U1U.]^Q11MC.YPM7ZQ?$7_'O!_UU'\Q0!KC+QJ>F0#3J;%_J
MD_W13Z "DI:* $H/2EHH 3M2T44 %%%% !1110 4444 %%%% !1110 4444
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M^/=?K0!Q\?6M6SZBLI/O5JV744 =)9]!6Q']VL>R^Z*V(_NT /HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ K%\1?\>\'_ %U'\Q6U6+XB_P"/:#_KJ/YB@#7B_P!4G^Z*?3(O]4G^Z*?0
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%(:6@"#_EZ_"IZ@_Y>OPJ>@ HHHH **** "BBB@ HHHH **** *]T
MADA=1W4BN2A:?3&>)E)R3T&:[,TPPH>J*?J*YZU'GU-J=7E5CF-.L)FW7$@[
MG%/T:VD5[DNO5^.*Z8(H&  /PI!&H/  _"I^K*Q7UALY*PLI6EU%"N-[?+Q]
M*I"T^QRO',CL3P-HKNPBCHH&>O%-,*$Y**3[BI^JH<<2T9.BV:Q0B8*0S#G-
M&NV#WMJ GWE;=6Q@+T %+C(YK;V"Y;&7MGS<QQC7=Q):FVV-N'&=O%.M]-EG
MTF>$C$C'CBNN\F/^XOY4JH .% _"N9X2\[W-OK/NV2..6XN8[8V90[@-H.WB
MKNBVLFR=)A]X8Z5T?DQYSL7/TID\9\AQ$ '(XJEAK.]P=>\>5(XE[-CK1@3[
MB,*[B",1PJH[5BZ9ID\5Y)<7 &YA6\.E70@XMW(K34K6#/-+24O>NHP8=J6D
MI: "BBB@ HHHH **** "N;\5?\>Z_6NCKG/%/_'NOUH X]/O5JV745E)]ZM6
MSZB@#I++[HK8C^[6/9_=%;$?W: 'T444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 5B^(O^/:#_KJ/YBMJL7Q
M'_Q[0?\ 74?S% &O%_J4_P!T4^F1?ZE/]T4^@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M2?>K5L^HH Z2S^Z*V(_NUCV?W16Q']V@!]%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ I*">:* "BBBEJ 4M)1FF M%%% !1110
M4444 )0*!1WYH #4,L$<P'F+G!J:CK0"&*%0;5''M3Z3&*!Q0&XM%':B@&@H
MS29!.*.]+4%9"TM-YS3J=PL%%%% !1110 4444 %%%)0 M%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M]JW?)'I2>2/2@#$6R&>E68K7!Z5I>2M/$0% $,46*L=!1BEH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1124 +1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 0W7_'K+_NFL_P_P#\@[_@1K0NO^/67_=-9_A__D'?\"- &M1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M!KBM$@:XU@N>1N/\ZV]=NPNEJ5/)Q47A.VW0M,1SN-%5^UJ*Q=.U.G)LZA%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ANO\ CTE_W36?
MX>_Y!O\ P(UH77_'I+_NFL_P]_R#?^!&@#6HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M8M5M/['\OS/FVGC\*XH_ZQB.Y-:8QQ<3S,'%QD[HUO#0QK47TK:\7?\ +/\
MW:P= F2#5HY)#A1WK:\17,-Z\:0MN;%&':^KM"Q"?UA-#-/LV;29FQU7BH-
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** (;K_CTE_W36?X>_P"0;_P(UH77_'I+_NFL_P /?\@W_@1H UJ*** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "DH-% !011FBAJX7,35_#MGJB'SH@S]B:X*_\!7,$C/$XV9X4
M"O6,4A4'M6$Z*D=5+%SIZ)GBP\.WJL08G./:ITT&\ YB;\J]A\M/[H_*D\M?
M[H_*L)8*$C=9C-'E5KH%W(^-C+]173Z9X3VL'N"K+Z5UWEH.0!3P.*4,#"+N
MR*F.J35D5[:RAM(O+B7:OI4^*6BNV,$E9'$VWN%!&1@T4M,0Q8PO04AB4MN(
MYJ2BF!#]GCV%0O!I$MHD<,JX8=ZGI*+@-:)6<,1R.E1RVL4Q!=<XJ:EH B^S
MQ;-FWY:;':Q0L2BXSQ4])GG%%P(C;Q&/85^7.<4&WB*[2O%2]Z*38$;0(Z;6
M&1216\4.?+7&>M2T4]P&21+(,,,BH5LHD.47%6:*EQCU&FUL(!@8I&C60889
MIU+5"(VB5X_+<97TIBV<*#Y4Q4]% %?['!N#;.14KQJ^,CITI]% "8I:** "
MC%%% "4M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% $-U_QZ2_[IK/\/?\ (-_X$:T+K_CTE_W3
M6?X>_P"0;_P(T :U%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% $-U_QZ2_
M[IK/\/?\@W_@1K0NO^/27_=-9_A[_D&_\"- &M1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %8OB+_CV@_ZZ
MC^8K:K%\1?\ 'O!_UU'\Q0A&O%_J4_W13Z9'_J4_W13Z!A1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 0W7_ !Z2_P"Z:S_#
MW_(-_P"!&M"Z_P"/27_=-9_A[_D&_P# C0!K4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 (*6DZ4=:  FL7Q'Q;P'
M_IJ/YBMHYK%\1'_1X!_TU'\Q32$V;$1_=)_NBGU%%@Q)_NBI!2&+1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%(:  FC( Y.*
M*S]1:4%%C<#- %[S$_O"CS$_O"LN.SNF0$R"G?8;G_GH* -+S$_O"CS$_O"L
MW[#<_P#/04?8;G_GH* -+S$_O"CS$_O"LW[#<_\ /04?8;G_ )Z"@#2\Q/[P
MH\Q/[PK-^PW/_/04?8;G_GH* -+S$_O"CS$_O"LW[#<_\]!1]AN?^>@H TO,
M3^\*/,3^\*S?L-S_ ,]!1]AN?^>@H TO,3^\*/,3^\*S?L-S_P ]!1]AN?\
MGH* -+S$_O"CS$_O"LW[#<_\]!1]AN?^>@H TO,3^\*/,3^\*S?L-S_ST%'V
M&Y_YZ"@#2\Q/[PH\Q/[PK-^PW/\ ST%'V&Y_YZ"@"[=.GV67YA]TUG^'W0:=
M]X?>-)<65S]EE^<?=-4-!LKG^SO]8/O&@#I?,3^\*/,3^\*S?L-S_P ]!1]A
MN?\ GH* -+S$_O"CS$_O"LW[#<_\]!1]AN?^>@H TO,3^\*/,3^\*S?L-S_S
MT%'V&Y_YZ"@#2\Q/[PH\Q/[PK-^PW/\ ST%'V&Y_YZ"@#2\Q/[PH\Q/[PK-^
MPW/_ #T%'V&Y_P">@H TO,3^\*/,3^\*S?L-S_ST%'V&Y_YZ"@#2\Q/[PH\Q
M/[PK-^PW/_/04?8;G_GH* -+S$_O"CS$_O"LW[#<_P#/04?8;G_GH* -+S$_
MO"CS%_O"LW[#<_\ /04?8KOM(* -+S5]10&##Y36:UE=[#^\7I4>FO,L_ER-
MF@#8%+110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% "<"CMQ12T <WXFUJ?1;99E4D$\[1FO/=1^):742(=P97
MR<K7KUY:17EN\4J*P88Y&:\4\:> YK*Y^T6D9,3L /SJD2S;A^*B.$B0.S\#
MA<UZ-HEW+>V(FE&"V".*\Z\#> C R7E['\WH>17JD4:Q($0  #' H8(?1114
ME!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4AI:* $K-
MU+_7P>YK3K-U+_70_6@"_%_JQ3Z9#_JA3Z "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** (;K_CUE_W36?X?_Y!W_ C6A=?\>DO^Z:S_#W_
M "#?^!&@#6HHHH **** "BDI: "BBB@ HI#2T %%%% !1110 4444 %%%% #
M6^Z?I65;?\A''M6LWW3]*R;;_D(?A0(UZ*04M PHHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M +1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M* %P.@I%VK\H&,4O?%.QG.3D.Q1@4M%,@**** "BBB@ HHHH **** "BBB@
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M5$-V5AU%%%( HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MH@0S9-5O J>7J>L+C"^;\H_*DQH[FBBBD4%%%% !1110 4'I10>E '#^)_\
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MLA'*GJ*9K6BKJ:18P&1PW/L:Q-$_<^*[Z)#F,#C'2NS'3-"">FPD2[(E7^Z
M*?115&04444""BBB@8>U'TI#TI,XXHN*^MA=P[US>O:\+?%M:Y:9^ 5YVFC7
MM=:W_P!%M#FX<?*1R!4>A:"48WEX-TKG=2.B,5%<TANAZ$0YO;P!Y9.<^]-\
M2ZA-O2SMF(+-M;Z5U04 >@KB/$CBPU6&=2&\R0 @<D5(1ES2-_0M&CTV $@>
M81R16R,CK4-JPDA5@" 1WJ;Z521E.[>HX4M(*6F2%%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M1RQB2,JW0UF:=A))8Y.[< UK5C7:M;ZE"X^YU-,1/<Z=N;S(B0PY SQ4275W
M;G$ZC:/2M(3HP4@]:&>$_> - %1=7MVXYS]*E^W6YY_I36BM7Z8'T%1?9+?^
M^: (M2NXI+0JGWL^E:-LH^SQ\#[M5/L=NPP7-6UDB50H;IQ0!+@>@_*C@=A3
M//C'5J8]S&BEF/RCO0!7U.0)$J\?,<5-80^1:A/QK-8_VE=#8<Q(<@^M;:C
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M+,>#(QVX/O69X>M[5A]MN)"\A.<-SUJ6;P@K<S+V@Z%Y;_:[K)E8[N3FNFX
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M;M\X/%6+=)!I4]S@[]_'ZUSPQDFMCHGA8Q>YT<FL0++L!'USTJVMW&\6\.,
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** $HY]:*,XZFA %%-\Q"<!US]:-X7[S ?C3$.HQ3!
M(A.U6'YTOF1C^-?SI#'=**0,K="#^-#,%^\P'U- "T8IJLK=&!^AIW2@ I:2
MEH **** "BBB@ HHHH **** "BBB@ HHHH *3J>#03@4SS(P<!AGZT 24E)N
M4#)(HW< CO0 ZBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHI* %S2?C
M37=5'S$ >YI596'RL#]#0 M+2?6C/.* %HHHI %%%%, HHHH 2BEHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH ***0]* #.*Q_$-U+;6#O"<.%XS6Q6#XJ!.E
MR*.I4TT(YNSGU=M-CO\ S8N>6&ZB^U^]O+&)XF57+@'=Q3-!\,S7FF6[RRRJ
M@YP&-1^+-,MTCCMC(\:!QRG!ZBF(Z32K:^\Q7EEC8%?X6S6)K']KV=T0K+M;
MD<UI^'-/LK.6/R+R>5]O1V)_K4GB4$W2#MMI#-#0HKM;4/=D;F&1BL77]4O&
MU*"U@(5&;:Q/%=58D&SA [+7-^(&TR[NHK>[E>*0G"%!S3 ETC^T8;V2.9XV
MMU^[@YK3N]=M;67RF)9L_P /-<=:O)IUS=VUE(\P"XRYR:N:!]B:X=KN1C=;
M?F5N0* .JDUBVCM/M#$[<].]0VOB&RNVVH2#Z-Q7)WSPG6]KR.+' P1ZU#J[
M6J^(K<6\C!O*X4< \"D!V<_B"S@!+$G'7%7+*_AOH]\+9'<5QGAVP2^GD>=F
MRKX /2I/!&]=8UB/<Q19< $].E '<T444AA1110 4444 %%%% !2=Z#10!4U
M*9H+)Y$^\*\^CU/5&AN[KS8_W3< M7>ZOSIT@KS2PTK3+B.]-U>3I\_(4G_&
MJ0CLK/4)[O3HY)&&X+SBM3^TH;*QCDF;.1VKA;"ZF:VN($!^SPC$;=R*FW9-
ME]L=UC+?)CO]:+".WLM;M;U6:,D8&2&XJ"?Q'9P#<26&<?+S7)ZIY"ZC<_8I
M'\W;\RC@ 4GAEK%X)//E9IMK9!Y HL%SN(]4MY+8SAQL'O5>WU^TN-VS=\IQ
MR*X1!$]G-%!/*;<R$ELG.<]*N:9+*=9MK.X4(KCY2O<46"YW?VZ(0-,6&U>O
M-2V]PES&'C.5/2O,7U"9+V\T>5F#7+[8N:]#T6U:RTJ"W?)9%P2:30TS0HHH
MI#"BBB@ HHHH **** $SSBCM0,]Q2 ^M ''ZYJ%VVM06$1"PR#YB>*GTF34K
M6=Q<R1M"#P5.>*9KXTV[OX[2[E>*5Q\I0<_G6"CMI[R6EC(\Z2'#-(<D4T(]
M#%Y$T9D!^4#)J-M3MQ )=WRMT.:Y2'4H8=&O8I)&\U8ZRXG:Y\,V!#O\[8)S
M]*=@.X@URUFF:($Y49)[5"/$MD9MF6'.,D<5@:C9/8Z#"UMEG,@W,>N.,U4U
M@Z8/#@99G!WC+#KFBP';2ZI;PVQG9OE'8=:BLM;M;YBL9((/1N,UY[>37B3V
MWD9>'RQU/6K-I]OFU^P>5!&J] G0_6BP'<2:]9QS-$22ZG! J>UU."Z=E0X*
M]<UQ_AVP%WXDU629F^23(';M1XDF?0)VN8B?WYP!2L!VB7T,ETUNIRZC)JQG
M YKE?"5N]Q;C5)&;S)1@@GBNHY)]J!CZ***0!1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !5>ZLX;N/;*BGZBK%% &"GAN)9PYD)0'A>U:
MYMXQ;F%4 0C&!4]% %6TM([.$1Q* OM4DUO%<1F.50ZGL14U% & OABV\_>S
MEDS_ *LCBKEYH]O=HB[0I085@.E:=% &/;Z!;02*^=S+W(JY!I\-O<R3HH#R
M=2!5RB@"G>:=!?(JSJ'53D BE.GV_P!E\CRE*=ACI5NB@#$M_#T,$_F&0L,_
M=/2KDNF02RJY4948'%7Z*+@9W]EVY)^4'\*CNM$M[F-5VA"O1@*U,"EHN!C6
MV@6UN#P&<C!<CDU=@L(K=2J*,$8Z5<HHN!GQZ5:I$T)C5E8YP156#P_%#=><
MLK8!^[VK:Q13N*QC7?AZ"Y.4;RO7:.M7[2SCM(51 .!RWK5JBD,3M2CI110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0!0^R>U'V3VJ_@48% %#[)[4X6N.U7L"C H K)!BIU7 I^** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
1HHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>gegguy50oztz000006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gegguy50oztz000006.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" .D!J0# 2(  A$! Q$!_\0
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M/3\_\>\GYT?\+3T__GWD_.O'L=Q1S3^J0N)5IGL'_"T]/_Y]Y/SI?^%IZ?\
M\^\GYUX]SZT<^M/ZI ?MI'L'_"T]/_Y]Y/SH_P"%IZ?_ ,^\GYUX_P ^M'-'
MU2 >VF>P?\+3T_\ Y]Y/SH_X6GI__/O)^=>/\^M'-'U2 >WF>P?\+3T__GWD
M_.C_ (6GI_\ S[R?G7C_ #ZT<^M'U2 O;S/8/^%IZ?\ \^\GYT?\+3T__GWD
M_.O'^?6CGUH^J0#V\SV#_A:>G_\ /O)^='_"T]/_ .?>3\Z\?Y]:.?6CZI /
M;S/8/^%IZ?\ \^\GYT?\+3T__GWD_.O'^?6CGUH^J0#V\SV#_A:>G_\ /O)^
M='_"T]/_ .?>3\Z\?Y]:.?6CZI /;S/8/^%IZ?\ \^\GYT?\+3T__GWD_.O'
M^?6CGUH^J0#V\SV#_A:>G_\ /O)^='_"T]/_ .?>3\Z\?Y]:.?6CZI /;S/8
M/^%IZ?\ \^\GYT?\+3T__GWD_.O'^?6CGUH^J0#V\SV#_A:>G_\ /O)^=+_P
MM/3_ /GWD_.O'N?6CGUH^J0#V\CV'_A:>G_\^\GYT?\ "T]/_P"?>3\Z\>YH
MYI?58 J\CV'_ (6GI_\ S[R?G1_PM/3_ /GWD_.O'N?6CFG]4AU#VTSV'_A:
M>G_\^\GYT?\ "T]/_P"?>3\Z\>YHYI/"TP]M,]A_X6GI_P#S[R?G2?\ "T]/
M_P"?>3\Z\?Y]:.:KZI3L'MI'L/\ PM/3_P#GWD_.C_A:>G_\^\GYUX]S1SZT
MEA*;#V\CV'_A:>G_ //O)^='_"T]/_Y]Y/SKQ[GUHYH^J4P]O(]A_P"%IZ?_
M ,^\GYT?\+3T_P#Y]Y/SKQ[GUHY]:7U6 >VD>P_\+3T__GWD_.D_X6GI_P#S
M[R?G7C_-'-/ZK3#VTCV'_A:>G_\ /O)^=)_PM/3_ /GWD_.O'^?6CFE]5@'M
MIGL'_"T]/_Y]Y/SH_P"%IZ?_ ,^\GYUX_P T<T_JD ]O,]@_X6GI_P#S[R?G
M2_\ "T]/_P"?>3\Z\>YHYH^J0#VTSV'_ (6GI_\ S[R?G1_PM/3_ /GWD_.O
M'N:.:7U2 _;2/8?^%IZ?_P ^\GYT?\+3T_\ Y]Y/SKQ[FCFCZK /;2/8?^%I
MZ?\ \^\GYT?\+3T__GWD_.O'N?6CFG]5@'MI'L/_  M/3_\ GWD_.D_X6GI_
M_/O)^=>/\T<T?5:8*O(]A_X6GI__ #[R?G1_PM/3_P#GWD_.O'N:.:/JD!>V
MG<]@_P"%I:?_ ,^\GYTO_"T]/_Y]Y/SKQ[FCGUH^JTQNO(]A_P"%IZ?_ ,^\
MGYT?\+3T_P#Y]Y/SKQ[FCGUH^JTP]M(]A_X6GI__ #[R?G1_PM/3_P#GWD_.
MO'N:.:/JM.X>VD>P_P#"T]/_ .?>3\Z/^%IZ?_S[R?G7CW-'-3]4@+VTD>P?
M\+3T_P#Y]Y/SI?\ A:>G_P#/O)^=>/<T<U;P=.P>WD>P?\+2T_\ Y]Y/SH_X
M6GI__/O)^=>/\T<U+PL ]M(]@_X6GI__ #[R?G2_\+3T_P#Y]Y/SKQ[FCFJ>
M$@'MY'L'_"T]/_Y]Y/SI?^%IZ?\ \^\GYUX]S1SZTGA(#]M(]@_X6G8?\^\G
MYT?\+3L/^?>3\Z\?YHYIK"0L+V\T>P?\+3T__GWD_.E_X6GI_P#S[R?G7CW-
M'/K26$@P]M-GL/\ PM/3_P#GWD_.D_X6GI__ #[R?G7C_-'--X."'[:1[#_P
MM/3_ /GWD_.D_P"%IZ?_ ,^\GYUX_P T<^M3]4@'MY'L'_"T]/\ ^?>3\Z7_
M (6GI_\ S[R?G7CW-'--82F'MY'L/_"T]/\ ^?>3\Z/^%IZ?_P ^\GYUX]S1
MS0\) /;L]A_X6GI__/O)^='_  M/3_\ GWD_.O'N:.?6DL)3#V\CV'_A:>G_
M //O)^='_"T]/_Y]Y/SKQ[FCFG]5@'MI'L/_  M/3_\ GWD_.C_A:>G_ //O
M)^=>/<T<T?5(7#VS/8?^%IZ?_P ^\GYTG_"T]/\ ^?>3\Z\?Y]:.:/JM,7MI
M'L'_  M/3_\ GWD_.E_X6GI__/O)^=>/<^M'-'U6F'MY'L/_  M/3_\ GWD_
M.C_A:>G_ //O)^=>/<^M'/K1]4@'MI'L/_"T]/\ ^?>3\Z/^%IZ?_P ^\GYU
MX]S1SZT_J=,/;2/8?^%IZ?\ \^\GYTG_  M/3_\ GWD_.O'^:.:3PD ]M(]@
M_P"%IZ?_ ,^\GYTO_"T]/_Y]Y/SKQ[GUHYH^J0'[>1[#_P +3T__ )]Y/SH_
MX6GI_P#S[R?G7CW/K1SZTW@X"]M(]A_X6GI__/O)^=)_PM/3_P#GWD_.O'^?
M6CGUI?5((?MI'L/_  M/3_\ GWD_.D_X6GI__/O)^=>/\^M'-+ZI 7MIGL'_
M  M/3_\ GWD_.C_A:>G_ //O)^=>/\T<T_JD ^L3/8?^%IZ?_P ^\GYTG_"T
M]/\ ^?>3\Z\?YHYI?58 JTSV#_A:>G_\^\GYT?\ "T]/_P"?>3\Z\?Y]:.?6
MCZI ?MI'L/\ PM/3_P#GWD_.C_A:>G_\^\GYUX]S1S3^J0%[:5CV'_A:>G_\
M^\GYTG_"TM/_ .?>3\Z\?YHY]:7U6 *O.Q[!_P +3T__ )]Y/SH_X6EI_P#S
M[R?G7C_-'-'U6 EB)'L'_"T]/_Y]Y/SI?^%IZ?\ \^\GYUX]SZT<T_JL!K$2
M/8?^%IZ?_P ^\GYTG_"T]/\ ^?>3\Z\?YHYH6%IA[:1[#_PM/3_^?>3\Z/\
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M!^VD>P_\+3T__GWD_.C_ (6GI_\ S[R?G7CW/K1SZT?58![:1[#_ ,+3T_\
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M#V\SV#_A:>G_ //O)^=+_P +3T__ )]Y/SKQ[GUHY]:/JE,/;S/8?^%IZ?\
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M19ZC-;!L^4VW/K4*22Q-F-BI]15_Q#_R'[WC_EI6;SCKGVKT*;YH',[W.W\
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MN%@HHHHN%@HHHHN%@HHHHN%@HHHHN%@HHHHN/4*]E^&__'A_P&O&J]E^&_\
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MR_G_ /7H_P"%5Z?_ ,]9?S_^O1]:B'LI'D=%>N?\*KT__GK+_G\:/^%5Z?\
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M?_SUE_/_ .O1_P *KL/^>LOY_P#UZ%BH)![.1Y&.**]<_P"%5V'_ #UE_/\
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M+_G\:/\ A5=A_P ]9?S_ /KTOK40]BSR.C/->N?\*KT__GK+_G\:/^%5Z?\
M\]9?\_C1]:@'L6>1T5ZY_P *KT__ )ZR_P"?QH_X57I__/67_/XT?68A[)GD
M?I[45ZY_PJO3_P#GK+^='_"J]/\ ^>LOYT_K40]DSR0'&:3MBO7/^%6:?_SU
MF_S^-'_"J]/_ .>LOYTOK,0]FSR.CO7KG_"J]/\ ^>LO^?QH_P"%5Z?_ ,]9
M?\_C1]:B'LF>1T5ZY_PJO3_^>LOY_P#UZ/\ A5>G_P#/67\__KTOK,1^S9Y'
M17KG_"J]/_YZR_Y_&C_A5>G_ //67_/XU7UJ(O9,\C/)H/)S7KG_  JO3_\
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M!**6B@!**6BAAH-Q2]J6BA["2$'2BEHH0PHHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 3
M.>E HI/?- "Y%&:0>N*0=<F@!V?2@4F>:4"@!:*** "BBB@ I*6B@ HHHH 3
M.,DT!L\TF.?7-'0]* %YS2TG>EH *.E%% "9HS0>O2D..G2@!=U&:.!UH]Z
M$)..*7-'THH 6D)Q]:.M(0"?I0 ZBDHH ,T9YQ1TZ4=\T &:,^M)D,.M*!0
MM)2TE "T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% "4444 %+24=J!7"BC(HH'N+
M124M !2&BB@5PHHHH&Q:*** $HHI: $HI:* "BBB@ HHHH *2EI* %HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH *2EI* "BEI#0 4M)10 M%)2T %%%% !1110 4444
M%)2TTYQQ0 N:"32"E/I0 9]*,TW'&*=T% !2T44@"BBBF 4444 )D#K1FDQG
MBESSBD M)FFY&>M._K3 ,TM)C H% "T444 %%(3BB@!:*0]:6@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MEVDKD8KI_#NI#4-,A;JP4;CZT["N;'84M)TI:0PHHHH **** "BBB@ HHHH
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MNAG1]+-JX&6Y;ZUSEUX<UC2[]I]&9%C=BSACWIW"QE^,- L-/U*TEME$9/+
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M0 4444 %%%% !1110 4444 %%%% !3:=32<#/IUH 6C-5X[J&64HCY;TJQ0
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MKP[G;G&0*AGOX!_N['4^$_%EQH=XB[R8'.&W'.!7O&D:Q;ZM:)/ X(89KY>
M(&[UZ5Z5\-?[6-SN"L;<@8YX%-&>-P\>7FZGM=%(O09I:H\4**** "BBB@ H
MHHH **** "BBB@!I/I1]:6HIYX[=-\K;5H06),8' H. *R_^$BTP-@W STK0
MAGCGCW1G(-,"6C ]*;FG=J0!BC%%+0 W&#P!BER <4&B@ ^E,.?P[U4EU2S@
MO8[227$TGW5]:N]LCH:  8QQ0,9X'-'TI1UH ,48I:* #%%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MS'%8.B_#.;3K^.<W8(5@<8KTYX5>W,;#((VFGT,L36C[12B?-6AZK+H&J><
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MP_\ 99!C).?QK/M?!$%MKXO@%\O!ROO78;1C&*7%.X6.6\9Z7)>Z+)' /F
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% #"$)Y49^E.P!11TZT +12=Z6@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***2@!:*2DS0 ZBDI"?
M>@!U%(#Q10 M%(,T4 +1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44AI,\XH =13"ZK]
MY@/J:;YT?]]?SH'9DM%0^?'G[Z_G2^?'_?7\Z LR6BH?/C_OK^=+Y\?=U_.@
M.5DM%,$J$X# _C3Z!!1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M HHHH ****8T':O1?!G_ ""T^M>==J]%\&?\@M/K6538N.YU%%%%<QJ%%%%
M!11128!36^Z?I3J:_P!T_2FA,\EUK_D(2_[QK.]*T=:_Y"$O^\:SO2NN&QA)
M!1115B"BBBD 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M*KL:1.KHHHKG-0HHHH ****0"4U_N&G4U_NFGU$]CR?7O^0S<?[U9M:6O?\
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M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444P"BBBD =J]$\'?\
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M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%  ?O5Z%X&_Y!DO\
MO_XUY[WKT+P-_P @R7_?_P :RJ;&D3JA2T@I:YV:A1110 4444@$IK_=-.IK
M_=-/J)['D^O?\AFX_P!ZLVM+7O\ D,W'^]6;79'8P84444Q!1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !7H?@G_D%'_>->>5Z'X)_Y!1_WC6=7X2X;G4]Z*.]%<R-F%%%%" 6
MBBB@ I#2TAH0F>2:Y_R%;C_?K.]*T=<_Y"MQ_OUG5UPV,6%%%%42%%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110""BBBF 5Z+X,_Y!:5YUVKT7P9_R"TK&IL:0.HHHHKG-0HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MA1115$A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M**,$#V%'7GM0,**.,\58M[.:=3M&30(KT4XHZ.<XX.*:3S[T!<**#CCUH^M
MKA10 2<#I3E1G.U03]!0.XVBG,A7[RD-[BFXPI+=:!V"B@9QF@ADP6'!Z4A6
M"B@AO48HIV$'\5>A>!O^09+_ +]>>]Z]"\#?\@R7_?K&KL:0.J%+245SLV%H
MI** %HI*.@H *:_W33J:_P!TT=1/8\GU[_D,W'^]6;6EKW_(9N/]ZLVNR.Q@
MPHHHIB"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MPHHHIB"BBB@ HHHH **** "BBCO0 44=Z.^* "B@\#-% !1110 448XS1B@
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M2%%%%%@"M;PXRQ:Y S-A<UDTZ.1XG$B'!'2IY0-OQ/(LEVIC;//:L_2FV:E
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M[=CORV:>VHZ"\K2F%]^<_P">*RM9UN.]C2& $1IV-0D.YJ1@?\(K;CW/]*?
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M)"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M&*S_ 'H&<=*+ *>Q]:2@\XHIB"BBBF 4444F#"O1/!__ !Z_\!KSNO1/!_\
MQZ_\!K.KL7 ZFBBBN8V/)O$/_(:GK+'6M3Q#_P AJ>LL=:[(G.PHH[T53$@H
M[444@#MBBBB@ H[8HHI@%%%% !VHHHI ';%%%% !1113 ,T444@#&!BBBBF
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M444 %(:6D-"$SR37/^0K<?[]9WI6CKG_ "%;C_?K.]*ZX;&+"BBBJ)"BBB@
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M_P!PT[O37^X:.H/8\GU[_D,W'^]6;6EKW_(9N/\ >K-KLCL82"BBBF2%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %>A^"?^04?]XUYY7H?@G_ )!1_P!XUG5^$N&YU/>BCO17
M,C9A1110@%HHHH *0TM(:$)GDFN?\A6X_P!^L[TK1UO_ )"MQ_OUG=JZX;&+
M"BBBJ)"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M9Y-K/_(0?ZFLZM'6?^0@_P!36=79#8QD%%%%4B0HHHI %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110P8
M5Z)X/_X]?^ UYW7HG@__ (]?^ UG5V+@=31117,;'DWB'_D-3UECK6IXA_Y#
M4]98ZUV1.=A11WHJF)!1112 **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ /6O0O W_(,E_W_P#&O/3]
MZO0O W_(,E_W_P#&LJFQI$ZH4M(*6N=FH4E+24 ':EI.U+2 3O37^X:=WIK_
M '#3Z@]CR?7O^0S<?[U9M:6O?\AFX_WJS:[([&$@HHHIDA1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !7H?@G_ )!1_P!XUYY7H?@G_D%'_>-9U?A+AN=3WHH[T5S(V84444(!
M:*** "D-+2&A"9Y)K?\ R%;C_?K.[5HZW_R%;C_?K.[5UPV,6%%%%42%%%%
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M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHI@%%%% ,.U>B>#?\
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MW&H]H@Y6<Y171_\ ")W?]QJ/^$3N_P"XU'M$'*SG**Z/_A$[O^XU'_")W?\
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M_<:E[1!RG.45T?\ PB=W_<:C_A$[O^XU'.@Y6<YVKT3P=_QX)]*YW_A$[O\
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MW?\ <:C_ (1.[_N-1[1!RLYRBNC_ .$3N_[C4?\ ")W?]QJ/:(.5G.45T?\
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MBBB@ HHHH **** "BBB@ HHHH 3H*,4IZT9YQ0*P"EI*6E884E%%,!:*2@4
M%'2BB@!,<YQUI:.?6B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH #2#CC%*:* "EI*!
M0 4&BB@!:*2B@!:3\:*3IS0 'KTI0*.V:.U K!1110,**** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBEH 2D
M]J6B@+"=.,4H&*,^U+0 4444 %%%% !1110 E%+10 E%%% @HHHH&%%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 )T[4O:CM1P:! *6D'%+0,**** "BBB@!**.]+0 A^E%%%%P
M"BEI*+@%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M>E%(*4#%27<6BBB@ HHHH **** "BBB@ HHHH **** #%%%% !1110 4444
M%)BEHH 3%+110 4444 %%%% !1110 4444 %%%% !24M)0 ?2BDYS2DXHL ?
M2HVGCC.)'53[FJ^H7\-A;-+(X  />O'/$7C:YO[X_9W(B4X_*M84G/8S=1+<
M]M!W#(/XTN>*X?P=XPCU2%;:=\2#Y1GBNW#!E^7FHG3<79E1FI;"^]*.::#N
MX_.G*,<5-R@HHI: $I:** "BBB@ HHHH **** "C%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $I.]+28HT&)CFLW6-&M
M]6M6BE49QP0.:TZ*:E9Z$2BF?/WB;PS<:-?,"A\D\YKGSZ5]':SH\&JVK1R(
M,D?>QS7BGB#PM=Z;?E(XB58DBO1P]>ZU9RSHZF D33.L<0)=N@KU/P3X+$*+
M>7B'<1N4'FCP5X+$"B[O$^8_,H85Z.B+&H50 .P%98BNV[)E4Z0JHJ+M50!V
M %.'2EI,5Q7N=2BD IU)2T@"BBBF 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4T]:=3<@TFK
M@*:IW^H0V%LTLK   FDU'4(-.M6EF<* ,C->+^+/%LNK7+10N1"#D%3UK:E3
MYV9SE9">+O%L^KW+0P/BW!Z@XKDSG.!T/6C(]:,CUKU*<8P5CCG>1/:W4MG.
MLD3D,/0XKV'P;XRCU*%;:Y<"5?E7WKQ?CUJ>TNYK.=9HV*E3D8/6HKPC-%4V
MXGTT"#R*4=:X;P?XQAU"W6VN9 LH&![FNX4Y'%>5*-F=D7=#J***104444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% "4M%)0 444G.<=J5@%H-)THIBN,EXC:O(K$*
MWCNZW -^]XSS7KDN!$V3UKR2P_Y'RYQS^]KHH=3*>C.L\>Q(-(4^6H()[4OP
MZ.[P[&0?XC3_ !_C^R%S[TSX<<>'H\?WC3:_=7$G[]CLNW%**3O2BN9FP444
M4#N%%%% 7"BBBD 4444P"DP<YI:3M3$SR;QQ\WB= >1O7C\:[^\AC&A+^Z3_
M %0_A]JX#QOC_A)T)X^=/YUZ#?'&@J?^F0_E6SV1D]SA_A\ NI7 R1^^/'XU
MZC7EW@#_ )"=P?\ IL?YUZC17^)#I[!112<YKGZFHZB@44P"BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 2B
MEI* "C'-%%*R 0CG.:KSV=K<,#-"KD=":GP6.>WI2[1WIW8K#5C5$"J %'0"
ME-.[4=L47"P"B@# Q12LAA2T44P"BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ IA'.>E/
MI#0!6N[**\39*H9?0UEGPII).?L47Y5N8-'.::FX[$N*9A?\(GI/_/E%^5+_
M ,(GI/\ SY1?E6[2U7M9/J3[-& ?">D_\^<7Y4G_  BFE=[.+\JWZ3OTI^UE
MW'[-,R+;P]I]I)YD5M&C#T%:Z].F*,'KUI14MW*Y;!2TE+4C"BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH 2BBBEJ 'I3"X522?E R33^U<-XY\0O8V_V.U<K,S
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M_KUW_P#8.G?\^ZT?V#IW_/NM3[2GV*Y9]S@/^%BZI_T"C^?_ ->C_A8NJ?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MQ7J.FV$6GVB0QK@*,&HF[*PXJ[+G4UA^*K-;K1IRW\"$BMSWK,U__D"W>/\
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M20K X8#BM6D 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M1IG2K$U%)G R:IS:M9P/L>7#4*+Z"=B]14$%U#<+OB;(-2C/>AWZC0^BBB@
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MN\8S7!)X*UBVF<VVL/$K=@/_ *U); SI_%NHPVNE20NPWRJ54'N:XZWLW@\
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M* "BBB@ HHHH **** "BBB@ I*6DH 9-_J'_ -TUY,G_ "4)O]RO69O]2_\
MNUY,/^2A-_NUO2^%F<]T>K@[;8$=D_I7DVI>*-5EUA[2SC9VW$  UZQ_RZ?\
M _I7DOA\ ^/,$9_>G^=.CU9,QWV[Q;_SY2_G1]N\6_\ /E+^=>M^4G]T4TK$
M#C H]M?H'L_,\F^W>+?^?*7\Z/MWBW_GRE_.O6<0^@HQ#[4_;>0.!Y-]N\6_
M\^4OYTGV[Q;_ ,^4WYUZUB'VI1'&?X12]OY"]GYGDOV[Q;_SY3?G1]N\6_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M>4%\H%.?EK?B18HPJ]!28#Z***0PHHHH **** "BBB@ HHHH **** "BBB@
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M0:?8_;+<8);&T"NQ\"?\BK:\8_R*K?$7CP]_P.K567M;"Y/<///AW.T?B>)
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MO'(9%08!-:1]JY3P3JLFH:5&DA+,B\N>]=7VKSYIIG7!W044#I14E!12TAH
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M/;@_;(5SQU8^]=-H'VS^RXA>H4FQ\P-:]%%QV&@8/6@>].HI#"BBB@ HHHH
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MC_A(])_Y_8_SJ_:5.Q#C$\Z?P/J\J[)+B=E]S7:^#- ?0=/DA<MEGW<UH?\
M"1Z4>EY'^=7K6\M[R,O;RAU!ZBIG4FXV8TE<R/%&BG6+!XESDC'%<%'X$U6(
M;(KB=%'H:]6N+F&UC,DT@51U)J@/$>D_\_D?YT0G)+0<DKGG1\%ZV.!=W)_X
M%2_\(5K14?Z7<_\ ?5>A_P#"2:3_ ,_L?YTG_"1Z2/\ E\CJO:5.Q/+&YYU_
MP@6I2S(TTLS@,#\QKU'3K7[+9QQ'^%0*K#Q%I18 7D>3P.:TE<. RG*D9!J)
MSE+XBX12V.+\9>%I=;N8Y82P9%Q\M<VG@G6E 5;JX '09KUDT4*JTK"<;L\G
M_P"$)UH\_;+D?\"I#X+UH*!]KN3_ ,"KUAW5%+,< =:XKQ/XTAL-UO:E99B=
MN >15QJ3D]"9121S-MH*Z'??:]2N'7'=JTK_ .(GEX@L$28@8!K(L="U?Q-<
M>9>S31PGD!NE=[I?A#3M/B >".5Q_$16LW%?%JR%%]#@VE\4ZRV^."2-3_=:
MG1^%?$<P)EGN5_X%7JZQV]JGRHJ >E5Y-:TZ$XDN44^]8\[VBC2W=GFO_"&Z
MV%_X^KG/^]4#>'?$]H=T4EQ(!ZM7I@\1:23C[9'GZU:BU"SN!B*96SZ4<\NJ
M"R[GED/B;7]$(6ZM"0."6-=3I'C^PO-J7,J12'M73W&FV-TI\Z!'SZBN0USP
M%!<AIK,B!QR @H<HRTL)IQ.XAFCGB#QME3SFI:\<M-5UGPO= 7BRR0*<?,>*
M]+T;7K75[=7BD7=CE1VJ9TFM2HR[FS24F23]**R-!:***2N 4F:4TG3WIW 6
MBF,X49)P!50ZM9(^QKA0WI3L3=%ZBF1RK*@=#E3W%/I%)W"EI** %I*,T4@#
M%%%%%P$Q2TF>YHI@V+124M ,**,BBBP"TE%% !1110 444M) %%)13 6BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ IG\5/IN.U "'D5P?Q!N;V6T:SMK61\X.Y17>X&,4C1JW4547RNY
M,E<\0\(^&;R;6HI+NV=8\\[A7MD$0AA2-> HP*<J*O04[M5U*KF3&-ALGRQD
MCK7B7C&VU>]UZX'V::2$'Y,#BO;C[TTQ*WWAFE"?([CG"Y\Y1Z/JT9W"QFS_
M +M6/LNO[<?99\_2OH4PI_=H\E,_=KH^M.QDJ&IYS\/HM11_]+BD3YOXA7I&
M:145/NBG 5S3E=W-E&PAZ=<5XCXOTF_F\1W$D5I(ZE^& ZU[?@$\BF-$I/(I
MPGRNXI1N8'@J&6#PU;131E&'4&JWCZWFNM"V0QM(V[.%KJU4 8I&4,,$4E+W
MN8=M+'BG@?3+^'Q7'+-9RQQ@'EAQ7JNMZ/%K.FO;.!N88R>U:JQ@-G%.VGM5
M2J-NY*A8\!U?PMJ.E7I\B&210?E*CI5=Y/$$T7DL)BHXV8KZ">))1AEJLNE6
MB2>8(OFK7ZQIJ0Z-]CQ_PQX-N[^Z26YC:)5()##K7L5M816MC]FB4*FW&!5I
M5"K@# I<5E5K.9<*21XSXT\)W-O?M/:0M(AYPHKGK7^W;=?*MXYESV KZ%9%
M88(JJFEVL<OFK'AO6M8XC2S(=*TKGA=]X9U1$69H9)7D&X@"NU^&EE=V9N1/
M;O%NQ]X?2O2/*4]NE*L83/'6B>)YHV*5/6YY7\1=/O+F=3#:R2C=_"*U?AS9
M75M;CSX7B^7HPKT!HPW44!=O2LW6?)RCY-;BX[5P'CWPO)J*F^@^:11@*!S7
M?]Z0C)SVK*$^5EO4\#L[GQ!HZ-%;QSQ#/.!UJ,:;K.N7BBYBE.X_>(Z5[M-I
MUM.<NF34D%I#!Q&F*ZOK"MHC'V>ID>%M%&D:;&AQO*X-;]'2BN64KLV2L+12
M44ABTA]*6D- '(^-M/EU""&")2688R.U)X4\)0Z3:I)*H:8CDUUI0$@D<BEJ
ME-I6%RI@HQQ2GBCFBI':P>]+110 4444 %%%% !1110 445&\\4?WY%7ZF@"
M2BH/MEM_SWC_ .^JD2:.3[CJWT- #Z*** "F'KP:=28 - "Y]J3G=GM2\T$A
M1DG I %+4!O+;_GO'_WU4B2)(,HP8>QI@/HHHI( HHHI@%%%% !14;SQ1MM>
M15)[$T\$$9!XH 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!.]!H[T&@".?_ %#_ $->
M3K_R4%O]VO6)_P#4/]#7DZ_\E!;_ ':WH[,QJ?$CU?\ Y=/^ ?TKR30/^1]'
M_74_SKUO_ET_X!_2O)- Y\>C/_/4_P Z=+:05-T>I:HQCTZ5@<''6O'[+1[G
MQ%KE[&MQY>QNI[UZ_JP_XEDV>FVO.O! _P"*CU#TW4Z3LG8)Q1*/AC>;<?;U
M_*@_#&\[:@OY5Z=16?MYLKV::/(-9\"WFE6#3F]#8/85T?PQ>1](N!))N*RX
M_G6SXV./#\GUK$^%P']E79[^=_C6CDY4KLA02F6_'\\D6CRA6*_+7'Z'X*N]
M7LDN%O FX9P176?$;_D#R>NRKG@7_D!P_P"X*(R:IW02BN8YS_A6-X?^7]?R
MH/PRO"N!?J/PKT[M1VYK/VTR_9H\.U[P[<^'YXB]V'^=>GUKU_0I&DTR$L<G
M8O\ *N$^) 'FQ_\ 71?YBNZT'(TN'_<7^5:U7>";(@K2-2FLV!D\#UI:YCQ?
MKZZ7I[HC?O77Y<&N>$;NQLY)*YC>,/%9B/V&R):9CM.TU4\*^#6N2NHZF-[O
MSM8<@U!X,\.MJ5Z^J7Z[BWSID=#7I5Q/#96[.[!549Y-;R:A[L3%)R?,Q!]G
ML;<# 2-?6N1UWQY;V<AM[1//?'5#6!K_ (CO];O38::7"$XSC(K:\.> +>T1
M9]0199R=VX5*C%*\@YV]$<RVH^)]9E_=>?#&?45=B\!ZQ>KYDVH8)Z@BO4(;
M>.! D8 4#I4G/:CVK7PE*E?<\Q_X5G? 9&H+GZ53N/#?B#2.8+QY,?W17K76
MC H]O+J'LNQY+:>+M8TEPNH6\\B@XR:[O1?%-EJT2GS$CD/\!/-:&H:-::E$
M4N8PU>;Z[X.NM$N#?Z9A5!^Z!DT[QGH%G'<]&U31[35K<QS1JVX<$UYC>6-_
MX-U,3PEFM<[B%' KI_"7C#[9BSO6(F!P"W'2NJU338-6L'@D4,KBDFX.SV$U
MSJZ*OA[7(=8LED1AN ^89Z5L\&O'K5[KPCXA\E24MI9.1CM7K-E=1WELDT9!
M##-34A;5%4Y7T+-%%%9&@4WOGM3C5.\OH+5/WDR(W8,<4TKLENR/./&WC&:*
MY^S6<IC*Y#$&N-L[C6KR]CD"RRJ6R6 JIJ[?:M?NCN!4R'!KV+PE'IEOH]NJ
M21B9E^8;ADUVR@J<-CG@^9V-GP^)1H\/F@A\<@UJ]J8-J1]0%%4Y]9L8.&N(
M\^FX5QV;>AT:1+PZ4M9UOK-C<#Y+B/Z;A4SZE9IPUS$#[L*7+),%),MT4R.1
M)%W(P8'N#44][;VXS+,B?4XI:W'HBP33>IK+'B#3R^W[3%_WT*T(+B"X7=%(
MKCV.:JS2!2'2MY<;.>0HS7(/\0+1;DP^7R&V]:Z74+VW@MYEEF16V'@M[5\]
MW#*=7D8'CS2<_C6U"ESWN93DTSZ,MYA<01RCHZYJ:LC1;ZU?3K6-9XR_ECY0
MW-:I954EB !WK&2:=C2+NKCL"BL^?6;& X:XCS_O"FP:W83MA;F+/^\*7+(.
M9&E134D21<HP(]13)KB*W7=+(J#U8XHU*3N2T55CU"UEX2>-OHU5Y=<L87VM
M<1Y'7YA3LQ<R-*EJ&">.YC#QL&4]"#4HJ-1W%HHHI@%%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !24M%
M "4M%)0 444M(!,4M)13 6DHHHL 44447 6DHHI,!:*2EI@)110:2 ***2GN
M+86BBBC884444"Z!10:2BP^@M% HH#H%%%%%K@%%%%%@"EHHI %%%%, I*6B
M@!*6BDH 6BBB@ HHHH **** "BBB@ HHI!0 'I7.>(-'O-0:/[*X7:><FNDI
M#0@9XY:P:M/XEN],,H_<].:]#T+3[G35W7<B@8ZEJY33B3\1]3'N*E\<>(7B
MN1IZL54,-Q7KBJ)/0!=V[' GB/L'%2;U"[BP"^I->.7*Z990)<V%W=O<9!*N
MQQ_.N@U#7KR^\$33P@AHR%X&#WHL%ST 7-NS;5FC+>@<5A^(]:;36A$4J#=U
MYKB-$BM)+B":UN;AKK&661SMS^=7?&.B)*+1Y)9!(XRP#''>BP7.]TN[%[81
MREU9F&3@TW696BTNX9#@B,D?E69X2TF/3],CD21V+KR&;-:&O<Z/<X_YYM_*
MEU'<\\\/:=JVMZ:UWYHP7('-:&C:EJ>D>*(]'OW#*Z[_ ):QO#7BPZ)H)C(^
M7S6P<9YS6II$-_KGB>/6Y47R4C*Y'^?:KL3<]',\:@%Y$7/]Y@*1;B&3B.:-
MC[,#7E6K:S%JVL_9KR66.W0E&,1(/Z576^M=$U6V_LR>XEC<YD\TDU-BKGKS
M2)$,O(J_4XI$GAD^Y*C>N&!KSCQ;J,LZ:<]PTB6\K?,8\@XYJ?P[#%%=3/IU
MQ+)"5X\UCFBPKGH8D0MM#J6] >:0RQJ?F8 ^YKB=!N)G\9W$3N2HCZ9^M-\9
MW<T-VBQL1R.AHL%Q?%=RZ>(+=$8@%,\'Z5;U7Q#)IHLXHY4&].<FL?Q"Q;5;
M#/> 9/X"L[Q1H4#3V1\V7YTR?F-.P7/3+&[2>RCF:1267).:F6Z@9MJSQD^@
M<5P]U9R:3X6+6SR,K1?,23D?2N?T:&UG-G-;75P;G<#(KN<?SI6 ]>^E!-10
MEO+ ?K[5)W]JDH=1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 )WH-'>@T ,F_P!0_P!#7DR_\E!;_=KU
MF;_4/]#7DR_\E!;_ ':WH[,QJ?$CU?\ Y=/^ ?TKR3P__P CZ/\ KJ?YUZW_
M ,NG_ /Z5Y)H'_(^C_KJ?YTZ6T@J;H]2U;_D&3?[M><^"?\ D9-0'^T*]&U7
M)TR;']VO*?#FL6ND>(;]KIBNYO2E2O9V"9[%@4$9%<N/'NB?\]6_*C_A/]$_
MYZO^59\DNQ:DDB7QK_R )/K6-\+P!I5T1_SV_P :A\3^,-*O]'>*&1BQ/I4O
MPN(.DW1&<&;/\ZVLU2U,U\=R?XBX.CR'_9JYX%S_ &)#G^Y53XB@G1Y,=-E9
MOA3Q9IFG:3%%/(P8)CI0KNG9#E\1Z1VHSQ7+#Q[HO_/5ORH_X3[1!UE;\JQ=
M.?8OG1S?Q(SYD8/_ #T7^8KN= _Y!,/^XO\ *O,O&FO66KS1BU8M\Z]1[UZ;
MH&3I4.?[B_RK6I?D29$-V:,LJPQEVX KR/4)9/$OBN. 9:&*3:U>@>,+[[#X
M>N) <,!Q7,_#G3][75Y*N6D;<I/X4J;Y8W":OH=S96D>G62Q( JH*\\\8:])
MJ&H#2K,L6#X8CI@UV?BC4TT[29LMAG0A:XSP%I3WETVIW2Y$B\$\U5-*SG(;
M>G*CI_"GAB+2+19)5!N".3UKIP<CBE50JX%13RB*)F/  )K!OF9>D44=7UNU
MTBW:6=ON]@>:\_O_ (G'S"+0D >HKEO%^O3ZEJCY<[(R5P#Q2>'O"5UK8:6-
M,H#\QKLC1@H7D<\ZLGI$WX?B9>"3]Z_R^PKK]"\<V.JLL3,1)[\5Q&I?#J[M
M;5IH4)VC+9-<:AN+"Z!R5>,YP#BJ5*G->Z3&I..Y]+J0PR#D4V5%E0JP!!&.
M:YKP1K#ZGHD33$>;WKJ".]<$TXNQTI\Z/+/&/AM]+N/[4L 0B_> ZYKJ_!VO
MKJU@%=OGC 4@UO7EI%>6KPR#*GU%>5::\GASQ<(&)6&60FNB+52%GN1\#L=C
MXXT1;_3'N%7]Y"N1BL[X=ZPTT+6,K?-"N.:[8JE[:8ZI(.:\H<MH/C5ECXCF
ME"TH/FBXL'[KN>PTG6DC8.@8=#3JYS9;"&O.?'6@ZGJ.HQ2V[XC"X/->C]:@
MN55HCD _A5TW:1+6A\U30R17K0-]\-@UVGASPSJWVNTN]_[G=G&>U<UJ'_(S
M7(QQYIKW/PXB_P!@VIVC[GI7H8B=HI')"/O'/^-/$KZ39""!\2'AJ\G#7^L7
M1V&0L>I&<5N>/YG;Q%<QL3M5N!7:_#?2[<Z1'=LBL[9'(!J5:G3YBM6['G<F
MG:KHP$P\S]:HW>IW=S(K/*P(XZFOH34+"VGM)%DB3&T_PCTKY[U>V6#5)4CZ
M;S_.G2J*HGH$HN)[=X:N"F@QR/DX05Y9XHUV\U+69;82$(KX7G%>I>&$^T:%
M$C\#8!Q7EWBKP_>Z=JT]UY?R.^Y"*SIJ/M'<)-V1 ?".K)8B^\W=&1D!6R:V
M_ ^MW]I??9IDE\G&!E365IOC;4["%8'A0Q#CYES_ $KN_#/BG3=1<1-'$LW?
M" 555.PD]2CXVT+4=2O&GMFPFS)YKRYXI$N#$3\X;%?2-X%-E*2HYC/;VKYY
MNA_Q.WV]/-/\Z,-4T:'46IV7A/PWJ\&KVEV[_N<9QFMOQOXLDTV-;6V?#L,-
M7::2H&D6QVC/ECG%>%^*YWFURY#GA)#BHI)5:MV7+W8#;6PU/7YF:-GW'J><
M4^]T35=!VRR,Y.>H)JWH_C&\TF!8X+>-AC&2F?Z59U+QSJ&H6[0RVL>UAC/E
M_P#UJZ/>Y[=#%-6.B\"^+WN)!973$L!UK4^(\I7P\S(Q#$C!!KR[0&N(]6C*
M(PRXR<>]>E?$7GPNI/7"_P JQJ4U&JC5/W=#S73-<NK/[KLTF>.IJQ_8FK:@
MS7#%\.<]Z?X)TT7^OP!QE.]>ZQ6D,421B), 8^Z**U11TL*";*'AFU:TT2VC
M?.X)@YK9IJJ%&   *=VKA<KLZ(H*6DI:104444 %%%% !1110 4444 %%%%
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MD/\ PK.PQC[3)1_PK2P_Y^9*F_X6'IW_ #UC_.E_X6%IW_/6/\Z=JHKQ(/\
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MK2XQTI:+!<;[XI>@I:,4D)#<YI:7%%-C;$(/7.*.W%+CUHQCI0A .E+28I:
M"DI:* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!***2@-Q:
M3K1WHJ;7=P12O-+M;Y=L\8(-9+>"='9LF \^]='S2UISR6Q/*CF_^$&T7_G@
M?SH_X0;1?^>!_.NDHI^TEW#DB<W_ ,(-HO\ SP/YT?\ "#:+_P \#^==)11[
M27<.2)S?_"#:+_SP/YT?\(-HO_/ _G7244>TEW#DB<W_ ,(/HO\ SP/YT?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MR- HHHH **** $I:** "BBB@ HHHH *2EHH 3%+110 4444 %%%% "8I:**
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "C%%% !1110 4444 %
M%%% "%0>HJ%[2&3[R T452;$T1C3K8'/EU,D$:?=4444VV*R)-H]*,"BBH&@
MQ1BBB@8M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
C!1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>gegguy50oztz000007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gegguy50oztz000007.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ,<!J0# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBD- !GBBDI&(523T'- -V!R%&:Y?Q+XPM-%C,8<&<C('45F>,?&D>G
M0M;VK!ICQ@UY%<W<]Y<-),[,6.>3G%=='#.6K.>I5-36_$U[JLQ\R0JAZ;3B
ML1LN>23BG1122/@#-:MOIJCELY/45Z$>6".;63,R*"27A!5M-+?&7'Y5?N7^
MQQ JBX'4U5BU83<* 34>UOL:^R0\:;"HRQ-.2UM=W5J<)BYR_"U!<:C#:R D
MC%95IOEL*45:QII86SIQFD?28\?+G-.@=[J-9HQT' %)'=7NY@(5(!KPI1U.
M-T$V4WTJ49*BJ<D+QL58=*W?ML:$><=K'M4VR*Y7( P>^*BQC4PO\IS2.Z_,
MK%<>AQ73Z!XNN=-=5=\Q]]QS67=:6<DQ9/M68Z[),?Q#M5*31A"4Z+/?-&U^
MUU>W#POST.?6MC(QFOGG3-7NM*N%EC8[0>1GBO8O#?B.WU:V4!P9 ,$5O&5S
MU\+BU4T9TE)12BM#N:"BBB@8M%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%(30 M%)FC- "T4F: <T +
M129YHS0 M%(31GB@!:*3-&: %HI,\4FZ@!U%(3@4@;(H =129HS0 M%)F@G
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M M%)2T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !33U]J=330)AW]J;)(D:,[D*HZDTZJ.K6LE]IL]O$0'=
M< FFK7!L:=:TX?\ +W%_WU2?VWIP/_'W%_WU7DVL^#-4TN$SRSH1C/!_^O6=
MH/A^_P!=8B*8 @9Y-=4:$7'FN8NH[GN']I6?E>=]HC\OIG/%26][;W0W02K(
M/]DUYGK>CW6A^#A#/("X?J#5OX82,]@Y8DGS#_,UFZ2Y;IE<[;L>@7%];6I
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M(XERAS([^">.X0/$X93T(-13W]I!)LEF1&]":YWP&[/X>MRQR=M<?XYE<>)
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M!+$I/EKFFEHRXQ<4T7_ 1 \/6X_V:XSQT0?$X]-Z_P ZBT;Q5=:)&;1T V#
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M]QP<5<GC74+F$IQZUE^3'&2RX//:M#2I=ETHQU-#6@[:7-BY7[/8^6.NW%8
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH Y[QA \^@7*("6*<8KD/AGILUM/=
MFXB(R!C<OTKTPA7!# $>A%(L<<?W(T7/]U<5HJC4;$.*;%$:CHH'T%<A\1;2
M6ZT)(XE+,'[#Z5V(Z4UU208958>XS4QDT[C<58\V\):"T_AN2WN(\,6)&1BL
M33+;4?#NOY"-Y.XGA2>]>QI$B#"HJ^P&*0P0GEHD)]U%:NN]B/9IF)JNE1^(
M-'"R*=[IQGBO,)=,UOPM=.;7E&/RX!->W  #@ ?2HFMXGY>-&)]5!J857$<H
M71XG)+XB\1.L-QD#/]TBO1/"/A1=$M_-E ^T%<,173K:PQG*PQ@^RBI?I53K
M-JR%"G;<\B\;Z9=7/BA9%C8KE>0/>O4-*C9-/A5QR$7^56G@B<Y>-&/J5%/
MQP!@5,ZK<4AQII.YC>*(FGT"XCC!+$<5P_@73KBTOYS,C#<_'%>HLH(P0"/>
MFK#$O*QJ/H,4H5+1L.4+GDOC>PNI-3\V)&.'R,"J5GKOB:VA6"($(O3*&O9F
M@B?EHT;ZJ#2"U@[P1?\ ? J_:^[8E4]3SW5#J&J>"HFNE)N"_( ^E3> +&YM
M=/D692,ENWUKOO*C(V^6FSTVC%"1QH,(BCZ"I]H^7E'[/6YX[+I5R?%@E$;;
M=QYVGUKLO%'A_P#M/04=4_?)'A:[#R(<Y\I-WKM%/*@K@@8],4_;MM,2I6/(
M_ NE7-CJ4@E0CYN3BNI\7^$5U:$SVX F'))KL%AB7E8T!]E%.(!'-#K2<N8%
M2LK'B,%[XB\.K]FC!91P/E)J1-.UWQ/=J;@*!D$Y7'%>S-;0/R88S]4%"011
M\I&B_10*KVSO<7)8H:'I4>D62P1C&0"WUK5I!TYI:PDW+4UB@K/_ +.1KMIF
M'.<UH=J*2N-B].E%%% "44M% "5@>+; 7FBW!QED0XKH*BGB$T31L/E88-5"
M7*[DS5U8^9)8FAE9)!AA5[39OGVGTK7\;Z4;'7)Y N(V;Y:YN*0HX9?7FO8I
MRYHG$URLN:O"7C.TX-<H9624J,]:[66/[7;;DY/2L"ZTHQL<CKS7/)69K"1-
MI$OF*0^<YXK7P<@U1LH%2$@?>JXJ,,9IHICFY(IPX^7TIA<;OI1YF"6/2A A
MPY>I$)5\BH1*C_=/-/3=OYJ*GPDR-N*5649]*E!Y_E6<A^7BE%T(CAL\UXTE
MJ<[1:N(%E7!Z]JS&MIHVP>E71J%NIP[$$]*LHR2+N7!%2(S(%D5\'I4.KS01
M6W[W=C/:MAHDDCP_'IBLR_TYKJW*R?=S5)E)F;:6L$L!D0'%/L(R+X, =JFK
M.E6PBB9(\E<\YJU<;+.!\ ;FY%*3,YU.5,S]0F\V<CT-2Z+;-<:K;J!E2XS5
M EG+.U>@?#W1S-,US*ORXRIH@KLX*,'4J'IEE;I;6RQ(, "K.*0  4'BNI:'
MT4596'4444%!3'02*5(ZT\]*3M0!0M=/6WNGE QD5?HZ"B@!*Y#QU;2W6ER1
MQJ22.PKKR!361)!AE!^HH>QG.',K,X;X>6#V]K<+/'CGC*UW(C4= !0D:1C"
M(J_08I3UJ8K0(4HQ5D<#\0[*:[@B6)"=K=A2Z3X?%[X,C@N(_G3)'&#G KNW
MB27[Z*WU%*(T5=JJ /0"AQNS)X=<[D>5>&OM^BZJ8948P9.,*:[+Q#H":W8\
M+^]*@@FN@^SPYR8DSZ[14@QVH4- 6'7+9GC(37/#<YC@R5SV!- M]:\1W"K/
MD#/<$5[$UM"Y^>)"?=10EO"A^6-!]%%')H9?5+/?0P]!\/QZ18[<?O"N&Q7
M:UI=Q)XS,JQL4\P'.WWKU_%,,$1;=Y2$^I49HY=#66'C9(9;)B!/]T5@^-[=
MY_#\B1@DD] *Z3@4C(LBX901Z$4[:&DJ:<.4X/X?64]I:3+*I&7SR*Y[Q/87
MG]K^= AR&/.VO7(XDC'R(J_08IK6\3'+1H?JHI-:&'U9<J1Y+#KWB.!$A4'
MX'R&M3Q+%?ZEX9LWF4M.3\V!7H@M8,_ZF/\ [Y%2>1&5VM&I [$4[(:H=#D/
M"%K+#X5,;J0VQN"/:N3T/3+F/Q*SLC!<GG'O7KHC15PJ@#T I@MX@VX1H#ZA
M14\N@YX=27*</XT\/&\L/M<:9E10!@54^'UA-;"42H0=W<5Z,ZJR;2H(]"*:
MD,:?<15^@Q3Y=0^K)2YCBO%?A(WX^T6P D')KD8[_P 0Z0HMHQE5XY4FO9B
M1R*B:U@<Y,,9/^Z*7+J$L,GJCR*WTG5O$>H*\X  (9LC%>IZ58)IUFL"#&.M
M6T@CC/RQJOT&*?C%-(='#JF[CO:C%-SW-.JCI%HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MQQ@%S@54EF:Z?RXN5]:RKF*]N90RJVW/2MBRS!!NE3:12>A,I*.Y,/+M(<G
M7N:P;N<SR$Y^7M4U]?><Y"GY?2J:(\CA%&2W2HW//JU74E:):TVR>_OHH%SA
MFQ7NF@Z8NFZ;%#MPRC!XKEO!/AL6L(N9TRS#*Y'2N^ P*Z:<;'HX+#\JYF*!
M2=Z=25H>DM!:*** $HQ2T4 )1CBEHH 2BEHH ;BEQ2T4"L)2$4ZB@8A%)CBG
M44 ,VTN*=10 E&.]+10 WFCFG44 M!*3%.HH ;BC'.:=10 A%)CFG44"L,QS
M3L&EHH&)BC%+10 E%+10 W&1S2BEHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M9HH[TG?K0 N:*!UI: $HI:* $HI:* $HI:* $HI:* $HI:* $HI:* $HI:*
M$HI:* $HI:* $HI:* $HI:* $HI:* $HI:* $HI:* $HI:* $HI:* $HI:*
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M'_"S;[^\/RH^JU ]M$]AHKQ[_A9M]_>'Y4?\+-OO[P_*CZK4#VT3V&BO'O\
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MZU^-'XUY+_PL:\_O#\J/^%C7G]X?E1[1!]?I'K7XT?C7DO\ PL:\_O#\J/\
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M"BBBG= %%%%%D 444460!11119 %%%%%D 444460!1111R]@"M?PW_R%X?\
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M7'_<7\J/+C_N+^5'UV78/JZ/G;_A&M2_Y]Y/^^:/^$:U+_GWD_[YKZ)\N/\
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MRD_N+^5/ZY+L'L$?.X\-Z@5R+:0?\!H_X1K41P+>3'^[7T0(DQ]Q?RH\J/\
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MW_"-:E_S[R?]\T?\(UJ7_/O)_P!\U]$^5'_<7\J/*C_N+^5'UR78/JZ/G?\
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M_P \)/\ OFC_ (1Z_P#^>$G_ 'S7OODQ_P!Q?RI?)C_N+^5'LD']FQ[G@/\
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M_P#^>$G_ 'S1_P ([?\ _/"3_OFO??*C_N+^5'DQ_P!Q?RH]DA_V;'N>!?\
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MKW[R8_[B_E1Y,?\ <7\J/9(/[-CW/ ?^$>U#_GA)_P!\T?\ "/:A_P \)/\
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M<V*:!S2Y]*0L.,F@+BG/:E'2J4.J6D]Y):QR9FC^\/2KHZ4AW%HHHH ****
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M\]]IR>E6-*M)!XTO-TS'"#C\ZN1^$I?/@EN;XR^4V5!'_P!:MJ'2UAU::^#
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M%G<R>,[$/.Y\R+=C/TK=@\"3)(&GU RX.1D=!^5;B: JZM;WWF M"FT#\O\
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MPS6[J#6K?#RY^S[2X0>9CUQ726?A.WBE>6Y*SR,Q(8CH#4'_  B"_8+JT6X
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M&JK>6S3O&80IQ\U<I=VMWJ=^EU9W$<6R,*5<\\"D_M=H-#N(KT^:P?&4Z=Z
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MM1&>)'VEUW'MFEN)1!;R3'D(N3B@!X]:.2..*HZ5J4>J6@G12H)Q@U>W+ZT
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M5MP!8XS^=,\3:6VI11V4:_=*G<.O% 6-#PV\\MG-)/\ Q.2OTYJCX=@2>XU
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M#:F1@XYK3T_4;QM.D,A!(;"_2MB_\(6-_="=W=6  ^7BK<6@VT-OY*,Q7U-
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M, UJ1V;KKDEP02I7%6-0L$U&#RW.!G-%QV."L);K5-2MK>ZM5M_DP&7KBH]
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MZ#PG>SW4C!F)B"_**T9_#-A/$J-"-JU>T_3+;3H@D"!0*5PL7:***0PHHHH
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M:=INA6FE>8;=>78L<CO1<+&/_;UR-1\A(W";L?=-8?B;4[8,MC"N)KOY7)'
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M,_6B:[BBX9QGZT#+'UI.O7I6-HNJ2:A<72-C;$V!BJ6L:MJ,-VD%FJ$EL<T
M=, !S@4HZ5R\>LZC8R[=45%5N$V^M7K/5WGU"2%L;%3=18#8SGGM3OI7)Q^*
MGD\1"T7'V7'+8[UTY8"+S%/;-*P7)>:;]X_2L?0]7DU*>Z23'[I]HQ5.XUJ]
MN[V6VTM59HCB3<*+!<Z;M28[FL?2Y=6,S"_1 N.-M:[OL1F]!18+BY_*E'%<
MQ;>)O-\1'3WQMVYSBGZ]XD&ESK"A!9AD46%<Z,Y!XHS7+:CK]VLMI!:!?,G3
M/S=*T=%O;VY\U;P(&3@;:+!<V12TW)P*=0,**** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "J&K:@FFV+7#@E0<
M<5?K,UT6QTUQ=[O*SSM'-"$S%M=;O6NT>1@UNW.%'.*VK"XGE>5Y77R\_+ST
M%<K&K:9,DMMA[<\G=R:6RO9IM.U:0Y&.1C\*H1VQN(<\31_]]"E,\0^]*@^K
M"O.Y+6.*SL;H3R^9*<D;S4\%JVK:C/%-)(JH,C:Q%(#O%: C<ICQZ@B@7$/3
MSH\_[PKSZ\N;C3%6RB9BA8 DDDX-2:EI\%C;)/!/,TC$$C>3UIVN,[&75H$U
M&*S+#?(,CFKV]".'4@=>:X<Z<K>)=.D9WYBSU/M2V=^ZV6L9<_NGPN3181VK
M2HH&9$4'U(H,T84'S4 ]=PKA-2>:\CT= SA93AR"?>H]=MKF&2*S@=_+5L E
MCFCE&>@I*DGW'5C[&G<XKCO#$-_;ZM)%,<P!.#G/-=ESGVJ1@#D4A)''>EH^
MM !VYHX%&/6DQSD=Z  TO;BD"\YIU "?6D.>U+BCF@ H[448H #TI/O4=Z4B
M@ Q1BC%)@Y]J %HHHYS0 '@'%-7U[T[C-&.<T )GO2GUHQSFCOB@ Z\TG%+0
M!B@ QQB@# HH% "T449H **0G I: "BBB@ HHHH **3-+0 4444 %%%% '%>
M/-$U/5K6%=.,@=7R=K$<5J>$;"\TW0HX+W=YP/.XY-=![4GM3N*QY]XD6!O&
M"+/.\*>5]Y>O:H[1X8-12*PF:XB;[TC]5-=O>:5:W<WFR1J9,8R11;:3:6P(
M2),DYSBBX6.,-G-'I>HW,<\C2 Y4$]*Q[2ZOGFM-S,),],]:]36TA5&3RU*M
MU&.M4TT2V2X\X(O!R!CI3N%CC5D$NI72ZC<20@#@ ]*99R1?:94ANY7C"G:2
M>IKN+K2+:[8.T:AL\G'6E72;2)"$@0$C&0*+A8XK1W>>[DMYY75MI.,UM>#[
M;R+:Y(9B/-/7ZFMJUTBWMV+A07/\6.:M0V\< (C4*"<D"E<+'&:DZ-KT(O+A
MXN?E53P15C4K2VNK%_)N'8*O-=%>Z5;WC!F1=XZ-CD4^&P@BA,>T'(P?>G<5
MC@;\Q:?;Z0SN2H?DFM'Q'J=KJXM8;%_,D24%AZ"NIN='M;J-$DC4A.F1THM]
M(M+<[EA0MZXI7"QP4^EB]\4O%DADAW9'7@4RPOVA\1A[L[61"@KT<64 NC<"
M-?,(P6QVJ)](LWE\PP)O]<4[A8\Y^S:W=V%\4LU?=(2CGKBNXT'44DTI8W;$
MD"[9!Z&MA8(HX]BJ OH*ABL8(A((T4;SEL=Z5QV//KB/5M1O]06WMEFC/W"W
M:K5C=S1:3_9EQF.Y@7E1ZUW<%M%#DH@!/7%0/IML\LDAC7>XP6Q3N*QPNCW<
MA::&:5A($.!FHM)O+A+N2)G;S>3M)[5W5OHUM;@D(K.1@MCFBWT:VMY3($5G
M/?%%QV//[Y[+^Q;F07\PF$GKTZ^]:=S/)IT-AJ/G.;>.,%R374-X>LG<DQ(5
M)R5QUJOK6G&\M181P#R67!([47%8B\+B29[B^+LT5P=R9/&*S-;NI-'OIF:1
MO]+.U 3WKJ]-M%L=/AME_@7%.N;"WNRAGB5RAR"1TI#L<Q%>P:-X>CEU-OWC
M9"[N>:3PO+!?7IOF?$Y!&T=,5TMWI=M>PK'+&K*IR 126>F6]F^8D4?047"Q
MB7N3XT@W?ZOR^?TI^LQI_:4&R-?N]<5I:KIGVU=Z,4E'1AUJ>&R7RT\SYF48
MR: L<AK6NV:K'81[0L@VRL!R*Z73U6+04%L=X"?*3WITN@6<TF]HDW>N*OQ6
MZP0>4@^4# %%PL<#+):-->&ZO98[C8<H#P*HS7<\?@NV:UF>3,^-Y/)Y%;&L
MV=Z^H3)#IH='X,E;>BZ+%#H:6EQ$.#G!'2G<+'(Z1->RZL S,#Y1^7/'2BRL
M'FT:_G>ZF\Q9B!STZUWEII,%JQ=5#-TSBIH["WCB=!&NUSEABBXK'GFMWE]%
M/IT<98ILY.>M.TF6[>TU,.[X*]<].E=[<:9;W*!6B7(& V.E$.E6\$#Q!%^<
M8)QUHN%CAO#EX8HYXKB1F39@%CG-=%X>W&X9D'[HCBK,OAV#8RQX7<,9 Z5>
MTG3ETVR6 -O*_P 1I,:1?ZBCOB@\"BD,6BBB@ HHHH **** "BBB@ HHHH *
M2EHH 0>]'L:AFNX8&"R.%)[5*K!U##D'I0 M%<=)XEU.6_N8+2Q\P0M@D&K]
MSKTMG8PM/"$N)>%C/<^E.PKG1=Z*Y:VU;6G=#)II4,<'GI3]8UV[M;H6]M;>
M;)@$BBP7.F'O1D]#7)W6OZC::2;N>RV," %)J*'Q/J:-')=:?Y=NPR9">E%@
MN=@<YZ<=Z7/2H;>42VZS \.,UG:CKD%K&XC8/(HY'I2&:I !SGK2]JS+'5(Y
M=-BNIR$WCI4.J:R+>SAN( ) \@7^5,1M=\4'..*PKKQ#';2I&P&2H-177B.0
M2(MG")LC)Q18+G1<[:!G&:HZ=?I>PE@1O7[R^AJ::\@@_P!9(%I#)^3UI><5
M4_M&U7:6F'S]*L>:G4-UH <,4I]ZI7MY]FBRH!?TK,M-8N+FZP(?W8ZFBP7-
M_'<4H.:S+/6;6Z9U60;D."*L?VA:F58_-&\]!18+EOV- X%9,NJ%+U80H(+8
MS5Q[^V6?R6E <=J+!<LY/I2<]:9YZ%BH;D#-9.KZZFG6_G+AAG%%@N;?:@53
MTZ^%_;B4 #(JX* %HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ IIR>*4]*0^E 'E^H>%-:D\6B\22;[.9=W#'&*]$G
MB<:5+'U;8>M7,>M#<C!'%.X'&:5JMI8:7+9W$FR;:WR_A6+ LC>%I CLA:XZ
MJ<<9KNI]"M)YO-**#WXJT-/M?($2PH$!SC%.XCD(+-K+Q!8[9Y&#0Y()X[5D
M:1]@>]U+[5=R1'S3C;7I!LX3,DI0;E& :I2Z#9R%R(D4L<D@=:+A8XF&YN!K
M$"12NT(?Y"3U%6)Y()=2U(7-U(A5> #TKM8],M8Q&!&NY.AQ45SHMK<2F0QJ
M&8_-QUHN*QPD$BMH<7E7<K*"<,3R:BFU"\33 D3,9]W*Y[5Z(-'M%@\I8451
MT %-AT>UB0@Q*Y/<BBX6/.].N+^6Y4 MG'/-7[22WE\T:C=R12!L* :[.#1;
M>"?S% SZ8I;C1;6>4-Y2CUXHN.QS_@@Q^?J B<N@?@G\*;K%]#9:O$\[;5W]
M:ZJTL(+(,(8U7=UP.M1WFEVUZ098U8CU%*X6.6UW4;76F@BL7WO&^YOI5=KT
M:?J$I8_,\>P#W(Q78V^E6EKRD*!CWQ1+I=K,X=XE+#U%.X6/.#9ZW!IC.]FJ
M[I=PD[XS7H5A=1W.E)M;)5 &^M7C!$\6QE!7TIL=M'"I5% 4]<4KBL<5X;U:
MR@O=1ADEVLTO%2Z-J-MIVL7K7+;5F;]V?7I71?V%9+,TJ1(&)R<#K4EQH]K/
M&N8E#+WQ1<=B(:W;W1EBLF$DZ#[M4([S77CG^UV:)&$)!!_^M6Q9:;!9C<B+
MO/5L<FK;J&0JW0C!%%PL>;V]E/>::UY:KNG$A&>_6F:E9W%SH,E[<*1-&P4#
MVKT6WLH;:,I&BA2<X HELX)8#$T:["<D8IW X^[%A(FGQW4[0RF(;2O6K/A6
MZ+75W#$?,1&P&/4]*W[G2;6XB"M&NY1A6QR*EL]/@L5Q%&H)ZD#K1<"U]:=2
M4M2,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "H9H4N8C'( 0>QJ:F]Z ,2#PY##=><9789SL/2II],2WLKD
M6Z!GE'W<5K#FCZTQ6/-CH>IRWT&8SL#?,,\**[BSTJ&S=I <LPP<U?"*&)VB
MEH"Q0FT>WGD:1P,D8Z51B\,01G+3._.<-6X1[TIZ4KL=BK_9\/GQS?Q1C XK
M,G\,6L\[.)77<<LHZ&M[H.E&/:B[%8SQI4(6W7&1#]TXHU'2(=04!R5([CK6
M@*3VSTHNQV*&G:6FGIM5V?\ VFZUH# XI.<4 @C- "GUHS1VHZT  ')H[T'T
MI!CH#R* '4444 %%%% !1124 (<YX%+BEI#B@!:*** "DYI:3W- !SBCF@<\
MYXI,G- "GIQ11WI!ZYH 4<]:6DI: "D)Q2TAH .E'/I1UI,DT +CFBDQQUI<
MX^M !S11GU[T8H ,\XHQS2>W4T9('O0 O>CG--/IGFG#/2@ I:3O2T %%%%
M"4E07-[;VB@SS)&"<#<<5)#/%<)YD,BNA[J:+!<?2]^E<GK>JW":XMA#/Y.4
MW;CTJ;2-7E6Z6UN)?/+'[XZ"BP7.FHJI_:%IOV^>A;Z]*<-0M"X07$>X]LT6
M LTG>J\M];1'#SHI]S0E];.O$Z-CN#0!9Z&BJ9U&UVLPG0X'0&H-)U:+58I'
MCXV.5H TZ3%0RWEO 0LLJJ3V)JAJNJQ0:?(\4ZA]ORD&G8#5QQ2CKCM7"7.K
MZ@MM8F.[RUPV.*OR:G>Z))&;Z0S)(P48[&BP7.L/%'?-<9+XL,'B<VC[O**
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M--\O(8R<X_"BP&RGB)(-7:WN3M4+GBMV*_@FA,JO\@[UP8>TA\3S->2!<PX
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M=N !ZFM6"]92)Y9T\HC.,UAZE?#Q)BQMXI%*X?+J1TJM- $LREPDA5>/E!H
MZ^TU:WNP[?<"G&6/6HEUV![K[.J$\XW=JX7S;V2-H(U8*?N\'I6O8WEDL:VX
MAF^U8P6*G&:+!<Z2;7;:&?R<;N<$@]*M)?V[A<.NT]#FN#CF@@EU".2*8S2#
M .TXS4[VES'X9M)8@WF(<D'.:+!<[*34;9)VB=U!49ZU!!K=O<2^605QW)KB
M[JUNK_1H]10.+@OAL@]!5:SENKNX$3(X('7:118+GH$NLV\;[%^9O8U)%J=O
M+$SA@ OWN>E<WH6GA[GS)5?<IQS69KD4FF7OV"W+9O3FD!Z##,LJ;E.0>AJ6
ML_1[=[?2X$?[X7FKXSCFD,6BBBD 4444P"BBB@ HHHH Y;Q;X7'B&WC3>Z[6
MS\K$5?\ #6C#0]*2TW,=I_B.:V><4E.X6./O['[3XT3<I,?E?K5:Q\/7O]K[
MIP3;[CU.>*[?RD+^84&_^]CFG8 [47%8\\@LY1;:HR J8WPG:HM,L;R]TK4/
M.+;PG[OD]>*[C4K!;G3YH(E"-(.2HYIVFV"V5A' 1SMPQ/>G<+'FMA+(BVME
M.K><C88XY_.MQ[&X77+@INVB/).>W-=J+&UW[O(CW#OMYJ7RH]Q;8N2,$XZT
M7"QYW=7EM=Z8+.U#_:!)DG;COZU/J-G=S3P+$6W",=S[5W"V-HK;A;Q@^H6I
M!#$3G8N1[47"QYWJ.H6DFA7%DB,;G&#E>_UKK+%Y+7PG"^/G2+I6E]@M&)S;
M1Y/4[:G\I!'Y>T;<8QCBE<+'GT.GZO*MW>11(1.O\7:HKAA'X=MK6]+B>%MV
M%]>*]&6-538% 7T%1M9VSCYH4;ZBBX6.&2?[;H"O<!D0-QM&.E5!+=W^G-%
MF$#=0,'BO11:6_E[!"FSTQQ0MI;H-J1( ?04[@<'?ZE:76F?9;=6^T*NT_+C
MFDUM+BTL['R20S)\W-=VMA: DBWCSZ[:S=4T?[=?6TG(2+J!THN _P /6X33
MHYFSYDB_-FM<'GWJ.*)8HU1> O2I*D8M%%% !1110 449HH **** "BC-&:
M"BBB@ HHHH 2BBB@!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M1U%<MIVN)$&ENY-L8)&:OVWBK2;NY%O#<AI#VHL!M8Y!H!!K*?Q%IL=P(6G
M<]JSF\56PU2*U5P?,;%%F,Z>FLRIC)ZUC3^*](MIGBEN0K)U%9NN>([5;2SN
MX9LPR2?>]J+,5SK*3>OJ*QK3Q'IFH[X(+C=($)(';BLJYNEBT1V@G9SYN,D^
M]%AG6\$<G]:<.E<N=0AL;1;EYV+!1D$U8TOQ197JONE (/:D!T-%4I=4M(7A
M5Y,&8X3WJ[0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M(0<@]J+;3V@N]618"L;C"_I18#8N-1@U6W?[)=8:,;OE[U8\.W;W.GKYQ/F
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MPP\9B)D\W^M=M!86ML28HE4D8XJ001;=@0;<YHN%CCS92O @DBRNT9!J1M(
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M_:4?\)-I?_/VE>#_ &F7^^:/M,W]\T.L']I>1[Q_PDVE_P#/TE'_  DVE_\
M/TE>#_:9O[YH^TS?WS3543S%WL>\?\)-I?\ S]I2_P#"3:7_ ,_:5X-]IF_O
MFC[3+_?-)U2_[0/=O^$ETO/_ !]I2CQ-I?\ S])7A'VF7^^:/M$O]\T_:D_V
M@TSW@^)M+[724?\ "3:7_P _25X/]IF_OFC[3-_?-'M0_M%W/>/^$FTO_GZ2
MC_A)M+_Y^TKP?[3-_?-'VF;^^:7M0_M$]X_X2;2_^?M*/^$FTO\ Y^TKP?[3
M-_?-'VF;^^:/:A_:)[Q_PDVE_P#/VE'_  DVE_\ /VE>#_:9O[YH^TS?WS1[
M4/[1/>/^$FTO_G[2C_A)M+_Y^TKP?[3-_?-'VF;^^:/:A_:)[Q_PDVE_\_:4
M?\)-I?\ S]I7@_VF;^^:/M,W]\T>U#^T3WC_ (2;2_\ G[2C_A)M+_Y^TKP?
M[3-_?-'VF;^^:/:A_:)[Q_PDVE_\_:4?\)-I?_/VE>#_ &F;^^:/M,W]\T>U
M#^T3WC_A)M+_ .?M*/\ A)M+_P"?M*\'^TS?WS1]IF_OFCVH?VB>\?\ "3:7
M_P _:4?\)-I?_/TE>#_:9O[YH^TS?WS1[4/[2/>#XFTO_GZ2D_X2;2_^?I*\
M(^TS?WS1]IF_OFFJPO[1;9[Q_P )-I?_ #])5NRU2UORPMY0^.N*^?/M$O\
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M!ZTR"T@MRWE)C=UJ4MZ$#ZT*Z'.U@Q'7!H B%I"LA<)ACU-3C@8%)]ZCOQ0
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M_2NTHHY4'U:GV.+_ .%?V?\ ST_2C_A7]G_ST_2NTHI\L0^K4^QQ?_"O[/\
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MV-6,=ZRO#WG_ -CP^?\ ?QSD5J]_:D M&,BBB@84444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MIUI?I2&+124G3DT .HI,XI#US0 ZBFY[&C% #J*:?>CZ]* '44S(/ IQY'-
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MI7>%0W!7-.V@# HN%CC]3_Y!8T\C%P2"$KI[!&6RA5A@A ,4/90R3B9D!<#
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M K7\4023:-)'$A=O[HK;)XI,#.::$T<!X>\)QRH[7D/!/W6%4];T6Y%TL5K
MP0'"E1TKTO@&DQ@_6GS"L>.F"6*.YMGT6268K@2XZGUJY/HEP_A;1HQ:/YJS
M R#'('%>JF)-V<<FEP.F*?,%CRCQ/HE[!>"XMX'>,J!L4=*+32+R31_,%NZM
MN^YBO5F4-\K#-"1J@VJ,"ES!8\L_LN^7Q%9R"VD,83DXX'2LV*SN+!]12?29
M+EIWRC8Z5[.%Q3#$C-N(Y%',%CD_!%O-#;RF2W:'(X5NU8WB8E]0NDET=[G_
M )YOCO7H^WGC\:;)&C$;AG%%PL>0QPZTFB011VTRJ[[2F/N@XYJQ?^#=4TZP
MBN(;EI274F-1R*]8P /:E/2BX['ENK:1?:MXEL (715MP&DQP#@5-H%C<6$=
MY'+8.9-_R28KTO: >!S2X'>GS!8\@NXI)M0 @T62.?=_KP._K78KHFL76EVX
M34F@D ^;CK76>2@.X#FGXI-A8XG7/#5[<:- DMR9YK=O,SCEL5G6GBW58+5+
M8Z1<,X;;N]OSKT:HQ%'OW[?FHN%CS36X;M]?BU.:QDGA$0!BQWP*F\/Z5+?F
M0FS:UA+\QL.M>D,BNN&&10JA>!P*+A8\M\+:#>MXDN9;N)UC@E_=%AQCVKJ[
MG0-7DU%IX]59(2V1'CM73D#.:=VHN%CRGQ5>:P;U;%+*>:&%^7 X<5W/A9\Z
M-'BS:U'_ #S/:MHHIZC)IV,# I7"QQ'C*RN+JX3R8&<;AR!6?XBLKB+5;&\-
MH]S#' %:,#O@5Z.0"*:0&0KBBX6/)K/2KB_CN)4T][9-W,9'WJM'0IH].G9;
M5AA>4Q]ZO4%4*,#BE901BG<5CQ9[6>\GTF.'1I(##*"[XKL=-LKB/X@WT[PL
M(FC #GH>M=L(E7D"E &=V.31S!8X3QE8WNMW0TZ)'6,$,),<9K)/AC5-&U>'
M4&G>Y9(MHP.G KU+'.:0C=UZ47"QXZ(YX+F22YT66X+MNSCI77^!+"YMA=RS
M(T:2ME$/\(XKLC&C#!'%."A0 .E%PL<;XVL[FZNM.,$3.%DRV.W6L3QAI=]+
MI]H8HG<K)DJ!TKTW'K2% PP>E%PL>6Z!IER;J:>:S<9A(R1[&LS1]/O[?6I"
M;*01'=QBO94C5%VJ.*01('W <^M%PL<%X3T=[?46FEM2I+D@D5Z .G%(% /
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ML+%KC-'>D/)I1R*0Q:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %)2TE "T4E+0 4444 %%%% !1112 **** "BBBF 4444
M %%%% !1110 4E+10 4444 %%%%( HHHH ****8!1110 4444 %%%% !1110
M 4444 %%%)0 M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%(:
M7- !129HSS0 M%)FC- "T4F:,T +129HS0 M%)D49H 6BDS1F@!:*3-!- "T
M4@-&: %HI,TM !1129XH 6BDS1F@!:*3-&: %HI,T9H 6BDS1F@!:*3-&: %
MHHS10 444F0>E "T4@.:6@ HHI,T +129%&: %HI,T9XH 6BDW49]: %HI,T
M9&<=Z %HI,T9% "T4@.:* %HI,\]*,T +129]*,T +129HS0 M%)FC- "T4F
M>*,T +129HS0 M%)FC- "T4F:,T +129HS0 M%)FEH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M N5?KDYK5HHN%B*&!((DC3[JC J.\LHKV/9*./:K-% 6,%?#%G;QRM%O+LI
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D4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>gegguy50oztz000001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gegguy50oztz000001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" (N!W,# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHS0 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !111F@ HI,BEH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@!*#TI:*3 2J,^JVMO(4D< CWJ]WKR_Q89!K#X<@8JXQNR6['?'7+'_
M )ZK^=']N6)_Y:K^=>1[Y%Y\QJDMDEN9/+61MQK7V2)YCUC^V['_ )[+^=(=
M=L<_ZU?SKRJZBFM)O)>1MPJ$-)U\QJ/9H.8]>M]8M;F7RT<$_6M&O*O#!<ZJ
MN7)YKU1?NCZ5G.-BHNXM%%%04%%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4WJ:
M=3.!2O8+ :44QW2)"[D!1W-$4T<R[HV##V-4#>I)WH[T44A(6BBB@84444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 E%%&: "C%%%  **** "BBBAAL+
M124M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M:0ON:-&:S3K5G_SU7\ZL6MW#=#,; _2AI@JB;LF6J*3O2BD:BT444""BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBDH 6BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M1"FK@$<YKT\?='TKSC0.-<0^HKT<=!651ZFD!:***S+"BBB@ HI** %HI**
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M!#]TUZ3\./\ CT;ZUYLWW37I/PX_X]&^M95OA/0R[^*CT&BBD-<)]0+2444
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M+#F/5=R^HI=R^HKRG_A+[_U-'_"7W_O1[%CYCU;<OJ*-R^HKRG_A+[_WI/\
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M\/SKPW_A/M6]31_PG^K>]+ZK(/K43W+>O]X?G1O7^\/SKPW_ (3_ %;WI?\
MA/M6]33^JR#ZU$]QWKZC\Z-Z_P!X?G7AW_"?:MZFC_A/]5]31]6D'UN)[CYB
M^H_.C>O]X?G7AW_"?:K[T?\ "?:K[T?5I"^MQ/<=Z_WA1O7^\*\._P"$^U7W
MI?\ A/M5]Z/JT@^MQ/<-Z_WA1O7^\*\/'C[5?>E_X3[5?>CZM(/K<3V_>O\
M>%&]?[PKQ#_A/=5]Z/\ A/-5]Z7U:0?7(GM^]?[PHWK_ 'A7B'_">ZM[TO\
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M9FEFES3$='&58&G5-C=:BTM-I:!BT4E+0 4444 %%%% !1110 4444 %%%%
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MRKEQ%6RLC:G$FAM8+< 11JOT%3TAI-P'\0KS[NYOH<[XX_Y%NX_W36/\,O\
MD%/_ +QK7\;$'PW<_,,[#6/\,R!I,A) ^8UT17[IF3^-&H_/C)/H/YUU/>N:
M50WBD29' _K71]3Q64U9FD'<CG'^CR8Z[:^;M9#C6[HMUWFOI5QF-A[5\]^,
MK;[-XAE&,;B375@I6F8U]C!-)@D44HKU-;G!%:G:>#)C-I][;*>1'G%<8X9)
MY01\P8UU'P_F6+76C<_+(-IJWXT\(W-E?M=VL9:%^3@5R\ZA4LS>UX71Q?49
M-+$I>=$0<L<4ICD#;/+.378^#/"%U>ZC'<W$96%3D9%;3J1C'<FE3NSU;PI"
MUOX=MT<8;%;+'Y2?2FQ1K#$L:# 48J*]E$-G,[' "DUXC=Y'H:)'A7CME?Q,
M[9KG/ZU?UV[^V:Q/(03AB!^=9^?8U[%+2)YM35BTM-R?0T[-7>YEKL%%&3Z4
M9/I2N%A:,4F3Z4N3Z&BX6#%+29/H: 3Z47 6BC/L:,_6BXA:6F_G2Y]J+BL+
M249]J,^U+FUL2U86BC@C'>D]L53=AI:7'44F3CI3N^:1(449YXH/M3 *6D^7
MN>: :3$+129I<\4KB"EI,T47%86BC\*.?2E<5A12TVG47"P4"D[T9HN)H=12
M9HSCM1<3NA:"?09K5TCP_>:O(/*0^7W.*]!TSX=P0HK3-N/<9K&==1.BEAY5
M#RM5DD.%C-7K?0]0N1^[A;GVKVRV\,Z; H'D*2/85?BTZUB'R1*,>U8/%'3'
M /N>)1^#M9?_ )8M_P!\U+_PA&L_\\6_[YKV\1QCHH_*G;5]!6;Q#-5@D>&M
MX*UI>?);_OFJ<_AS4[49DA;CVKWTJOH/RJ&2SMYAAXU/X4UB6MQ2P2?4^=WC
MEB;#1'--^;O&:]^D\/Z;)UMTR?857/A33"V?)7\JM8HP>7ON>%QQ2RMA8FJX
MNBWSKN6)L?2O<(_#^G1CY;=?R%61IUHJ[1"N/I2>*78<<O?5GD'A*SGM]>0/
M&1S7M"_<'TJHFFVD<WF)$H;UQ5RN>I/F=SMP]'V::,;Q1_R!I?I7B,G^M?\
MWJ]M\4$?V-*,]J\2EXD?']ZM\/L>/FC?M58T]2_Y!UK]/ZUEUJ:E_P @VU^G
M]:RZW6QY<_B-"R_X]Y?I5 =3]:OV7_'O+]*H="3[T+03#O24 ]Z7(IW($/W3
M7I7PY_X]&^M>:D\&O2?AS_QZM]:RK?">AE_\5'H->??$?_CV6O0*\_\ B/\
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MXD:20DL36M.%R)2%N)I+F4R2L2S=:BY[4HX'S<FCG-="C8Q; 'UH/KZ4?>.
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M\*UM_45Z#13^L5.X>PAV//O^%:P?WA^='_"M8/[WZUZ#11]8J=Q>PAV//O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M#3(8%&-JU?QD4(,(H]J6O+;NSU8JR$YI:6BI+$I:**8@HHHH **** "BBB@
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MYJ?NFO2?AS_QZL/>LJWPG?E_\5'H!H%%+7"?47"BBB@ HHHH **** "BBB@
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M@"NJE\)C/<Z($_\ "),<\[A_6N<R=HR<Y%='G'A(X]1_6N<7[F3Z4X[DG<>
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M,J^!CZ***P/6"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_2GR,7,CO**X/_A.I?\ GF/RI/\ A.I?^>8_*CV<@YD=[2UP/_"=2_\ //\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0U#P^FA?.=U%HMPVNV]S?2KM1LGC%;C>+M._MS[*<<#8#D5Y4VK:@_W[A_\
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MD%%%% PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHI* #O1BBEI
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M>3FE/K3<^Q_*C/L?RI +[T#U[TF?8_E1GV/Y4 +]Y?0T =C29]C^5&?8_E0
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M>C?E1N'HWY470QU%-WCT;\J-X]&_*C0!W>BF[_9ORHW_ .RWY4:"'=J*;O\
M9ORHW>S?E1H ZDI-P]&_*C>/1ORHN@%I>U-WCT;\J-X]&_*BZ =VQ1UYIN\>
MC?E1O'HWY4: +CG-'WN.F*3</1ORHW#T;\J U%S0>1@<4F[_ &6_*C=_LM^5
M #O:@8!YIN[_ &6_*C</1ORI!8=WS0?44W</1ORI-_LWY4!J.VGKFES@]*9O
M]F_*EWCT;\J8#N._-'T--WCT;\J-P]&_*DQBTN,"F[QZ-^5&\>C?E1<0ZBF[
MO9ORHW>S?E3N@'44W</1ORHW#T;\J- '44S=[-^5+N]F_*BZ =24F[V;\J-P
M]&_*C0!U%-W#T;\J-P]&_*BZ =13=X]&_*C>/1ORHT&.HINX?W6_*C?_ ++?
ME1H OUK4T/0[G6KM8HD.S/+8I^@^'[K7+M(T0B,GEL=*]3+Z?X,TORXU!N=O
M85S5JW+I$I127-((8-.\&:7CY6N=O7OFN U;5KC5KEI96.W/"TS4]6FU2X:6
M8N<G@$52W>Q_*N>,;ZL\G%XEU'RQV%]Z7M3=WL?RI=P]#^5:'!:0N,T=.*3>
M/0_E1N'HWY46068M%-W#T;\J7=[-^5%D%F+24F\>C?E2[QZ-^5/0=GV"EIN\
M>A_*EWCT;\J- L^PM)2;AZ'\J-P]#^5 6?8=24FX>A_*C</0_E0%GV%HI-P]
M#^5&[V/Y4"LQ:6F[O]D_E1N']T_E18$F.XQBCHM-W#^Z?RHW#T/Y4%-#N#1S
MFF[O]D_E1N]F_*C07*Q3STXI>,4W=[-^5&[V;\J- LQ>V!2XIN[V;\J-P]#^
M5&@K-"]&Z\4N 33=WLWY4;O8_E1H/6XX\C%'..M-W>Q_*C=[-^5&@<KN.R .
MG6CKUIN[V;\J-W^R?RHT#E:8[-'6F[AZ'\J-P]#^5&@GS-;"^U+[4W=[-^5&
M[V;\J- <6.[8HIN[V;\J-WLWY4P2:'44W=['\J-WL?RJ0UN.I*3=['\J-WLW
MY4QV?8=24F[V;\J-WLWY4!9]A:6F[O\ 9/Y4;O\ 9;\J-!+F[#J.V::&Y^Z?
MRI=W.W#%?I2T&DWT%SQFKVE:7/JET$C0X)Y.*=I.D7&J7*QQH?+SRV*] :6P
M\):;@+FXQV%9SE961VX>AS:RV!$L/">F;FVFX(XKS[6-8N-5N6=V.S/ IFIZ
MG=ZQ=-+('*D_*,=*B33+Z4#RX2<^U3!):LTJU)2]R"T*Q]129YZ$UT6G^$+Z
M]8!T*5U^F> (;<JUP=^.Q IRJI!#!5)NZ1Y_8Z'?7\B^5&=I[XKT30?!,-KM
MFN!N;J0:ZJSTZWLDVQ(%^E6P*YY56SU:&!C!WD,BB2) B* HZ 5)11FL7J>@
MDEL I:04M PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M0"4M%%, I*6B@!#1VHQQ1B@!.&ZBJ\MC!/\ ?0&K.*,4[BL94GAZPE^]$M0K
MX7L$D5UC'!K;I:.9ARHK2VB/;^0!A",5D'PG8EBVP9-;]%%V%CG_ /A$['N@
M_*E_X1.P_P">8_*M^BGSL7*CG_\ A$[#^X*/^$2L/[@KH*6CGD'*CGO^$2L/
M^>8I?^$2L/[@_*M_-'-'.Q\J,#_A$[#_ )YC\J/^$3L/[@_*M_FEHYV'*CG_
M /A$[#^X/RH_X1.P_N#\JZ"BCG8N5'/?\(G8_P#/,?E1_P (G8_\\Q^5=#11
MSL?*CGO^$2L/[@_*C_A$K#^X/RKH:*.=ARHY[_A$K#_GF/RH_P"$2L/^>8_*
MNAI.:.9BY4<__P (E8?\\Q^5'_")6'_/,?E7044<S#E1@?\ ")6']P?E2?\
M")6'_/,?E7044<S#E1S_ /PB5A_SS'Y4?\(E8?\ /,?E70<T4<S#E1S_ /PB
M=A_<%'_")V']P5T-%',PY4<]_P (G8?W!^5'_")V'_/,?E70TG-'.PY4<_\
M\(G8?\\Q^5'_  B=A_SS'Y5T'-'-'.Q\J.?_ .$3L/\ GF/RH_X1.P_YYC\J
MZ"BCG8N5'/\ _")V'_/,?E1_PB5A_P \Q^5=!1S1SL.5'/\ _")6'_/,?E1_
MPB5A_P \Q^5=!S2T<S'RHY[_ (1*P_N#\J/^$2L/[@_*NAHHYV'*CGO^$2L/
M[@_*C_A$K#^X/RKH:*.=ARHY[_A$K#^X/RH_X1*P_N#\JZ&BCG8<J.>_X1*P
M_N#\J/\ A$K#^X/RKH:*.=ARHY[_ (1*P_N#\J/^$2L/^>8_*NAHHYV+E1SW
M_")V'_/,?E1_PB=A_P \Q^5=#11SL.5'/?\ ")V'_/,?E1_PB=A_<'Y5T'-'
M-'.Q\J.?;PG8$8\L9^E:EG80V$(CA4"KE(!4W;UN"2.8OO!=CJ%RT]PH9CZU
M7'P\TE1Q$OY5V%%7[::T3$X)G'#X=Z1U\I?RI?\ A7FD_P#/)?RKKZ6G[6?<
M2IQ70X__ (5YI/\ SR7\J/\ A7FD_P#/)?RKL**%5GW#DCV./_X5YI/_ #R7
M\J/^%>:3_P \E_*NPHS1[:?</9Q[''_\*\TG_GDOY4?\*\TG_GDOY5V&>:,T
M>VGW#V<>QQ__  KS2?\ GDOY4?\ "O-)_P">2_E78T4>VGW#V<>QQW_"O-)_
MYY+^5'_"O-*_YY+^5=C11[:?</9Q[''?\*\TG_GDOY4?\*\TG_GDOY5V-%'M
MI]P]G'L<=_PKS2?^>2_E1_PKO2?^>2_E78TE'M9]PY(]CC_^%=Z3_P \E_*C
M_A7>D_\ /)?RKL:*/:S[CY(]CCO^%=Z3_P \E_*C_A7FD_\ /)?RKL:2CVT^
MXO9Q[''_ /"O-)_YY+^5'_"O-)_YY+^5=AS2T_;3[AR1[''?\*\TK_GDOY4?
M\*\TK_GDOY5V%%'MI]PY(]CC_P#A7FE?\\E_*C_A7FD_\\E_*NQI*/;3[AR1
M[''_ /"O-)_YY+^5'_"N])_YY+^5=C24>VGW#DCV./\ ^%=Z3_SR7\J/^%=Z
M3_SR7\J["EH]M/N')'L<=_PKO2?^>2_E1_PKO2?^>2_E78T4>VGW#DCV.._X
M5WI/_/)?RH_X5WI/_/)?RKL:*/;3[AR1[''?\*\TG_GDOY4?\*\TG_GDOY5V
M-%+VL^X>SCV.._X5YI/_ #R7\J/^%>:3_P \E_*NQHH]K/N'LX]CCO\ A7>D
M_P#/)?RH_P"%>:3_ ,\E_*NQHH]M/N'LX]CCO^%>:3_SR7\J/^%>:3_SR7\J
M[&BCVT^X>SCV.._X5YI/_/)?RH_X5YI/_/)?RKL:*/;3[A[./8X[_A7FD_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1112 2DYS2XHS30!0329&.M+P: "DZ<4F]<XW#/I2T +T
MI:9N7."PSZ4^@ HHHH ****0!1113 **** "BBB@ HHHH **** "DI:2@ %+
M24M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% "4M%% !1
M110 4444 )1111L 444M "4G-+2&BX=1:3FC@=Z0MCDG H2L@%)YQ1VIJLI&
M58&G9QR>* N'UHZTT.C?=8'\:49S188[M2TE% A:***0!1113 ****0!1113
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH *2EHH 2BBB@ HHHH ,TE%' /)H0"]J*2EZ#FCJ
M4WO2]1Q0!S18EMW"CZ4<9ZT$XH*T$Z4I]J8'4MPP-!E0-RXS3L3SH?FES2 Y
MI<4BD%%%% "T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1112 ****8!1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M^++Q8;=H4R7.#Q1RL+G> DGI2XYS7#ZIXEO;6XM88T!,@!8@4S4_%MU#(MO
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MY''M3L!VE-P,XKA;SQ#JOE-?0(#;#D'':NOTRY-[IT,[=6'-*P$L]G!<X,B
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M9!Q3$=N.!1WK@8?$6JWTLTML@,,;'/'8&I[OQ5<RV-L]HH+R,%/'>BP7.WH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M!HMV8[,R$EDSFNP'6BBX6.)OM!N9WF(7[TFX5I:EI+W5M'&WW50 _E729I"
MRE3R#1<+'ENJ7ES:Z;+ID2YA' />O0/#RE=$MPW7;WJM+X=BEO/,;_5D\KCB
MMJ*-(8UC084# %#8#J*6BD,***3- "T4F:,T +129HS0 M%)FC- "T4F:,T
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M* &[CZ4;CZ4ZB@!NX^E&X^E.HH ;N/I1N/I3J* &[CZ4;CZ4ZB@!H;VIU%%
M!1124 !.*3<:7K1B@0FZDW>U.(I.U Q-_M2[CZ4#I2T A-Q]*3<?2G44 -R3
M1N.<4ZEHN SG/2C)IU%(!A)STI23BG4M,"/)/.*7)I]% #,YYQTHR33Z* &9
M)[=*-Q/:GT4 ,S[49/I3Z* &9.:,\]*?10 W)]*3)]*?10 S..@HZ<XI]% $
M8/M2YXSBGT4 ,)/!HYQ3Z*8#,\=*!FGT4@&9)-&2>U/HH 82?2@'VI]% #-Q
M%!)ZXI]% #-Q!Z4NX^E.HH ;N/I1N/I3J* &[CZ4;CZ4ZB@!NX^E&X^E.HH
M;N-&33J* $!I:0T4 +244M #<FDW'TIQI#0 FZC=[44O6F&PF[VHW'TIU%(!
M-Q]*-U+10@$W>U&X^E&*6F)7&[O:@$TXT4#&ECBDR>]/HI ,R0:7-.- H#4;
MN/I1N/7%/HH BR1S3LFGT4 1Y]J.<5)10 S)':@,?2GT4 ,S[4%CV%/HH 9D
MXY%+N]J=10 W<?2C<?2G44 -W'THW'TIU% #=Q]*-Q]*=10 W<?2C<?2G44
M-W'THW'TIU% #=Q]*-Q]*=10 W<?2C<?2G44 -W'THW'TIU% #=Q]*-Q]*=1
M0 W<?2C<?2G44 -W'THR:=10 E+110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 )2TE+0 449IK.JKN8X ]: %HQWK!'B",ZP;7>NWUK<#J5W!ACUIM!<=1
M6?+K-G#+Y;2#=]:NQ31S)OC8$&BP#Z*AFNX8!EW ]LU'=:A#:6HGD/R&E8+E
MJEK _P"$MT[/WJU+*_@OH]\+ BG85RW2=Z.E&:0Q:*** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M)9:4Y8!MPQ6*7O'HU)?NOD>=:?9'4[.XO+BY*R(20"173>!;VYE2:*4LT:<
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% "4A&13J2@&<EK?A^[U6_!64K".HJ]IWABRL@N8PSCJ36_Q2$U7,S#ZO
M#FN8^OZ>]UI3Q6_RL!QBO-?M6KV^_375F8G'X5[#C/6LV32(9-0%T47(]JJ,
M[&6)P_/\)A^"]"DTV%IY1AI.HK*\;6=Q/K=HT<990PR?Q%>AA0HPO J.2VBF
M8,Z@D>HHYM;E/#?NN1'*^)KJ^LM M_LBGS,#.*KRV5UK7A53.#YP&<5V4EO%
M,@2100/:E2%(UVJH"^F*282H-RUV/)[+4]4TJVDLO)8YX%:_@S1;G[;+?7"E
M2^<9KNY--MI'WF)=WTJ=(DC&U5 'L*ISN8QPCYTWLCR/58K^V\52W,,+$ ]1
M^-)?RZOKDL<+PL(\X->L/90.Q8QJ2>O%"6D*'B-1^%'/=">$=WV92\/Z>=/T
MN*$]0,UK9IH&!3JS;.^$5&-A*4444BKBT444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 444AH 6DH) &34!NXP<$T 3]
M!1U%0?:XO6C[7%ZT 3>U'UJ'[7%ZT?:XO6@">CO4'VN+UH^U1>M $]%0?:X_
M6C[7'ZT 3\YHJ#[7'ZT?:X_6@">EJO\ :XO6C[7%ZT6 L457^UQ^M'VN/UH
ML457^UQ^M'VN/UH L457^UQ^M'VN/UH L457^UQ^M'VN/UH L457^UQ^M'VN
M/UH L457^UQ^M'VN/UH L457^UQ^M'VN/UH L457^UQ^M'VN/UH L457^UQ^
MM'VN/UH L457^UQ^M'VN/UH L457^UQ^M'VN/UH L457^UQ^M'VN/UH L457
M^UQ^M'VN/UH L457^UQ^M'VN/UH L457^UQ^M'VN/UH L457^UQ^M'VN/UH
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MUH^UQ^M %BBJ_P!KC]:/M<?K0!8HJO\ :X_6C[7'ZT 6**K_ &N/UH^UQ^M
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M^UQ^M'VN/UH L457^UQ^M'VN/UH L457^UQ^M'VN/UH L457^UQ^M'VN/UH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MS:^*DN-4FLPO,8S5-O&J"&:0+_JR1UH]G+8.>)V6:4]*X?3_ !J]V/M$D+)
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MQL)1C!W?2M;7/'2Z9.MM A<J.<$4Y46K6!5$=T3QQ2<XKCSXXM_[$^VJ,N"
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M/4Z<4M86@^((]60J1MD'4&MVI:L:0FIJZ"BBBD6%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !2&EI#0 U_N-]*XN
MQT[[3XBG\^,[,'!KMNW-,$4:MN"@,>^*:=A-'#)ITO\ :%[!$A53G:?QJKY\
MD=HU@;9C)N'SXKT)8HPQ8(,GOBF&TMS)O,*9]<5?.+D.'U#2I[73X7C4EWX.
M*J+I5S%=P1A&*2'+5Z0T<;@!E! Z9I##%D'8,CIQ2YV'*4;BT/\ 9!@3@A,5
MRFEWYL'^RR6I9MWWMM=YVJ V=NS[S"N[UQ24@Y3BKYI;/5Q=M 7C<<#'2J-O
M'+)>7,P@90ZG'%>B26T$N \:G'3(H%M OW8E_*GSBY3B8[1QX;DS#^\WG''/
M6NDT6(OX?BCD7!*8(-:GD1!-NP;3VQ3D547:HP!V%)RN-(\Z&EW!U&XM]C>6
M,L.*FT329YEO/-5@V"%S7?>5&"6V#<>^*%BC0Y50,]<4^<7*>9A7A9K62W9F
MW_>Q[UW-O;F'0F0 Y*=*OO:6Y?S&A4MZXJ;"E<8X]*3E<:B>=BWF$$F8FY?T
M]ZMWEFQ^P;8>PW8%=M]GA'_+->?:@PQG'R# Z<4^<.4XN[MY%U)RL>U/*Y('
MM6597OV:WN(A;[S)P#BO0[RV62UD"*-[*0#63H6D"VC<7,:L2>,BGSBY3EQI
M\XBBWQL0S@XQTYK<U^Q<6-K)#'Q'R0![5U!@B.!L7 Z<4YHT==K*"OH:7.Q\
MIP,9?5M2MU2W,8088XJ/4=,N8]7CMHT;RV;)(Z5WT=K!"Q9(E!]0*>T,;/O*
M MZXHYV'*<#K>G26%W%,L9=,<@"M+PU )[EKCRFCKJI(8IAMD0-]12Q01PKB
M-%4>PHY@Y3F?%4+O+;E(]WSC) ]ZK75N[:K:_NLIM&>..E=@T22?ZQ0<=,T>
M3$6!*#(Z'%)2T#E.*FLI6U>98T*J?05DQJ\,SVTMNQW.<''O7I7E1[]P0;O7
M%,:SMF?>T*[O7%5SARF=%:^1H1B4'E>E9?ABT*0WGFQ?,<XR/K75%01MQQ2"
M.-.%4#/7%3<+'"0V[A+D30MMSQQ533S<>>T<4!6/GJ*]%\B(Y!C7GVIJ6D$9
M^6)1GVJE,7*>>6]I<6NH/?")BJM]TBNXD+7ND-M!5F7I^%7?L\.TCRUP>HQ3
MD157:HP/2I<[CY3SCSI+>SGL3;,SGHV*?Y!32OWD#%L\#%>@&SMV;<84)]<4
MK6L#+M,2X],57M!<IP>FB:2TE$T+! O Q4%@MS)=>5%"40@\XKT06T*KM$:X
M],4B6L,9RL:@^PI^U#E/-MDEM=2V\MNS;V/.*O:A9K;V,8$+,>HKNFL[=WW-
M$I/KBG/;0R !HU./:CVH<IPEKYTND3?:(3M'W0!573S=,\J) 5CV'M7HGV:$
M)L\M=OIBD2T@3.V)1GVH]J'*</':/_8,A\G]YN/;FGW=I)_9MGLB(;'.![UV
M_P!GBV[=B[?3%!@C*@%%P.G%+V@<IYQ<P365XKO"SJRCMFK3V1:P6:.)ANZK
M7=R6L,H&Z-3CU%.%O"$V^6NWTQ1[0.4X[4+4^79,D/(QG ]A4L<#GQ'&?)^0
M+UQ[UUOD1D#* XZ<4"&,-NV#/KBES#L. Q2XHHJ"K"&E[TAI>] ''_$2"6XT
M()$A<EQP/K7*:AX=2/PC!,D+&?;R*]8DBCE&V1 P]"*8;:!D\LQJ4';%:PJ\
MJL9RI\SN>4ZMI]TFE:;>>2S+#]Y,>XI=.27Q%KR2QVS01*@!^7%>JM:P21>4
MT2E/3%-ALK:U'[B%$)]!5JN[$^R1XW=^';I]9FM%C?RDRP../6MSP+I-R=5D
M>[C($!^3<*]*^SP>87\I=YZG%*D$43$QHJD]<"G+$.2L-4D<7X_TVXN+>&XA
M4LL3 E1WYK/TW6O[5L9+".Q,3[-N[:!7HSHDJ%9%#+W!J"#3[.!B\5NBD]P*
MB-2RLP=)-GC8N9M-L[S3'L6DE<\/M![5.EC='PM;QFW;=YQ)&/I7KC:99/+Y
MKV\9;U*U)]DM]H7R4VCH,5?UG2PO8H\WUC3I$U'1W@@P1C<57WKN=6L1?:(T
M3+D[,CZUH-;0LP+1J2O3CI4N.,'I6<JM[,M4TD>#KH.H3?:9VC?="?DK>M/#
MMW+X6FN2C"9^HQSP:]5%K;X8>4N#UXZTY88DC\L(H3TQ6CQ+(]BCQ/2HC=S6
MUC+9NKQD9?&*]2UNR>;PTT$6=PC  _"M1--LTD,B6\8?U JQMXP1QZ5%2MS-
M,I4U8\+TV)R4TV>S?<&QNQ723:9(/%MD&A+1+'U(SV%>CC3;(3>:+>/?Z[:E
M:VA+B0QKN'0XK1XFY*HH\QEL'C\3W^(&$#(?NC@\UC::;F'7DBM;1E0DY)6O
M9_LT!8N8EW'J<5&FG6B2>8D"!O7%"Q'D+V)Y3=376B>(9I?LSOYJXR![U5CM
MKN?2KA_L[AG;.,?6O89;"UF;?) C-ZD4HLK91M6% /3%+VX_8G$QZ1)/X 6&
M.+9-LYXYKB=.5S)'8W%D^Y9!\VWWKW%8D5-BJ OI4 TVR$OF"WCW>NVIC6:3
M*]FB"TM1#I*Q8S\G0UY]I-E*LFL;K<@DG:<>U>HX &.U1"U@7.(E&[KQUJ8U
M6K@Z:;/+K'37/A*[#VY\[>Q'R\]169J&FWJ:)97#1.P0C*X]Z]D6V@"%!$NT
M]1BD:TMWB\IHE*>A%6L0[$^Q5SS7P?;K?:NEU]G>)D&.F!6S\1;>6XL[5(HR
M_P"\&<"NQ@L[:V'[F)$^@I\D,4N/,0-CID5#JWES%JFE&QQ.NV!3P3''#!^]
M*KD <]JY*XM)[#^S;YX6<1IS'CWKV-H8W3:R KZ$5RWBO2[JXC0V,:';_"1Q
M6M&LD]3.I3NM#SV*[_M'Q/YZ0>4=H&W&.U;NAZ?(\^KM/;DYSMROL*N^&_"U
MV-6^V7T:K@=%KOUMH$!VQJ,]<#K55*ZV0HTNYY7965P/"UXA@;=YIP"/]JNX
M\%PM#H,2O'L; SQ6X+6!4*B)=IZC%/C1(UVHH5?05SRFY&L86V/&-2N_L7C2
M>X\CS0O!7&:MZ?IUUK,MY?)$T*,"0N,5T]KX9E_X2>:[GC5X7/0UV45K! A2
M*)44]0!70ZZ25C)4KL\2EO)UT273!8,90_WM@]:VYK&;_A"[5#;DR8Z8Y'%>
MF_V99;RWV:/)ZG;4IMH-@C\I=HZ#%9RQ#*C1/,M1LIC<Z<$@/09('TK(UFWN
M-+UZ266V>9'7 XSWKV0VL!P3$IQTXZ4R:PM;GF6!'(]136(8O9:GE=QI;_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MR6'M7J<2>7"B>@Q2JJ*M8J#;W']Z***P2- HHQ10 M%%%, HHHH 2D-+0>E
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "D-+10 QUWQLI[
MC%<1=:??:?=2I;(6CEZ\5W--(7N 3]*:=A,Y,Z+,FA,@&97ZBM_2H6ATR.%Q
MA@N*NC!["EXIMW!(X75=,N7U']U$3D_>J6_TJ\@%O-$"TBCG%=KA3SM!]\4$
M#T!I\XN4XFQTV\-X\TJ'YA5:'3+MM0+B(HJG)/K7?[1Z#\J:R*RL HY'I1SL
M.4\YMS=KJER;92Q/!_.M!-"N!9;V4F1V#$5T.F:.+*\GF;!\P^GO6O\ +Z"C
MG#E.*O-(N;=8KJ!"9 .15F2*^OM)D$J'>3P*ZPA3Q@?E1A>F!^5','*<1-HM
MU;I%>0J?,4 %<5)9Z/<W[3SW*E6<5VF%(Q@8I, = ,>PHYV'*>?2:=J/E-:K
M&WEAOZU<O],G338U$1=@.E=KM7^Z/RI"!C!4'\*.<.4YWPS93VT+&;*[AP#4
M+:7,^N/(5.QN]=3@ <#\J3IS@4N8.4X$Z=J$1FMDC;RV;.:LPZ1<K-9,4.$(
MS7;87KM'Y48&.@_*FYL.4Y+4-+EGU?S2G[L(03^%8D\DUI;7%O'_ *HDUZ,Z
MAE88'(Q7-3^&9);DGS!Y;')&*J,Q<I/X64_V/TZBJ]II\T6JW$I3Y6'!KH;.
MU2TMEA3[HJ? ]!4.6I5CBO[ GG69B"&!RM10Z??W\T<$Z%8X^^*[KCT%&%'(
M4#\*?.+E.'N=,O-,NR;52RL,4FFZ-=/'=><A!<9%=P%'\0!_"E 'H!^%'.PY
M3SLV&HRPI;&)MB-P:U%T><WZ%E.TQA2?PKL-JY^ZOY48&>@HYV'*>?\ ]CSV
MMVT/D%XV/6M#5M*<6L7E0[B!R*[#:IYVC\J"!W4'\*.=ARG(Z;97<&D2%E.X
MCA:WM'\P6(61-K FM !<8P,?2C [#\J3=QI6 >].I*6I&%%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 AH'2BB@#D/'NGI=:6LA;#(P(_.O.+N[N
M[N[T^.?HC  8KV36],&JV1@S@]C7,Z9X(:"_6:Z<.J'*@ UT4ZO*C"=.[.?U
MKPS<V]Q%>P0F7>HR!6_HFD,- NR;;RYY%.!7:[%"A2H( P,BGA5 P% 'TI2K
M-HI4TC@M(T6Y@\,W$$D9WEB<8Z]:QO#>AZ@OB".8PM#$C<^]>JX&. ,?2D"J
M.551]!4^U=AJ!B>*;.6\T9X8EW.17,S:%=MX8MK8(?,5\D8^E>A<'J,T87IM
M&/I4QFUL4XW. U?1+J=-/"1_ZM<-Q[UC:QX:NK._2XAMS*&4 CTKUC:/0?E2
M,J'JJGZBK5:2(]F<]X3TY;/3P[0^7*W45DKH]R?&ZWICS".^/K7<;0.@ 'M1
M@9X49]:CG>Y:B<3XDT6>^UN&5$)C!Y(KE+[S]'U*Y2R^973#^U>PE5(Y -<9
MK'@V:]O'FMY@@?KD$UI"K969G.%SC= T^?4="O$C!+F3/Z5T>I:'=7&@65NL
M?SQL">/I76:#H<.C68B4 L?O'UK6VC.-HQ]*)5FPC3//M0T.[FU/2Y5C.V'&
MZNYGC+Z<\8'S&,C]*L$#/W1Q[4O:LY3;+4+'GFE:%=VVFZE$\9W2@[>*T_"F
MC2VVBSVTZ;6?=U'KFNO(&. .?:A< = /H*/:.U@Y$>/R>&[RPU.2 6IDBD?.
M[VK<USPO*NGVL]E&1)$0=H^N:]$*(>2BD^N*"!T*@^U7[>1/LT>3VNDZO?:[
M;7EU$P"8[=*W$T6Z'BMKHH?+,9&<>U=YL4'A5'X487/ &?I1[9C]F>?Z=HEU
M'<:H6CP)5(7CWJNF@W@\/RVWE'>9 >GUKTG:/[H_*DPN/NC\J7M6'LSR_6O"
MMR;*UNHXR\D:@%?PJQH^AR3Z==-+:F.4CY?RKTC:I&"HQ[B@(@X"@#V%/VTK
M"]D>>VNAW:>&+BV,7SLQP,>]1W>@W;^'K.V$9WHX)X^M>C;0/X1CZ4NU>A4?
ME2]J[W&J:*%E:D:0ENXP?+P?RKS.]TC5='NKY+6,F";))Q7K1Z\=*BN8%N+>
M2,J,LN,XI1JM,;A='DV@:4^I>'[F)!^\5V/XYIB:/K%XEO;RPL$@.!7H?AWP
M_P#V+YPR&#N6_,YK>")V1?RK25=D*D><V7AZY.M!GC(C,>TG\*J6VGZOH&J2
M06L;-"[YSBO4=JCD*/RH*(3DHI/J14.JQ^S/,=>\-7FLZA;L\9P!DGWJ?[!J
MAT:;39(V*J<(?:O1]JY^Z/RHVI_=7\J;JMC5.QYWJ6FK:^"#'<C;*I^7-6_A
M]IK6FA/<%?GE&<^M;WB+1&UJ&.(-M13DCUK2T^S2QLH[=!P@Q2]I[MA<FIB>
M&H[F.XN/.CV@MD$UT]- 4= !]!3JS;NS1*P4444AA1110 4444 %%%% "&@]
M*6D- +<:.*'^XWTI:&&5/N*8CS2XDN;?Q%+):IO;/05HV.BW4MK=7,RD2RC@
M5OV^C+!J;71P=W8BMD*.P'Y5;D<=.@GN<[8Z0S^'5M)5PVW%<]]FU/\ Y!_E
M'RMWWL=LUZ( *:47.=HS]*%)FD\/&UD<#J>FMI/V>6'F13G%9]I-/?>(@TH^
M8QD8_"NXUO2'U%%\I@K+TS5;1?#@LI#/.0\O8@4^<YOJ\N:RV&>'M.DMDN4E
M3&]B0:YV_P!&N+759&2 R(YKT<* .@I"BL<E0?J*GF.AX9.*1R-SI9CT/$4'
MS$<I6?HNEWBB:5HRB%2-E=]M4\$#'IB@(J]%'Y4^<3PL6TSSVPTN\;5@ZPF)
M%)S[U9B\/331WBR*1N?<OY5W.U0>%'X"C:/0?E1SL:PT4>>BTU*]:*RDB*QQ
M'[V*UK329K;4R=N4QUKK-B Y"C/TI2H]!FES@L,CF-%TR:VU6:5UPK$XJOXL
MT:2X=+J)"[*<XKKP .PI" PY /UI*6II*BG'E.(TC2#=P2--;F-\8%4&LM3@
M@N+".,E'Z'%>C!5' 4#Z"DV+G.T?E5<[,EA8W."BT.Y6PM(F0Y1\G\ZW/$>G
MRWFAB")<M[5T6U3Q@?E2X'0@4N8M8=)LXM=&G>ZARIVB/:?RK)N-&N+.^D1;
M8R(YZUZ2 /0?E043J5!_"G[1F?U.-[G%7FBOBU,,.,8+"NBO(Y%TG8BY;;C%
M:>%ST'Y4[ QTJ7(VC143-T42+8*)$VL#TK3I ,#H!2U-S5*P4444#"BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MEHH 3!S2T44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
)10 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>gegguy50oztz000003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gegguy50oztz000003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" '5!JL# 2(  A$! Q$!_\0
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MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W*]U"WT]
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MWYT?5$'UAGT=_P )/IO_ #\1_P#?0H_X2?3?^?B/_OH5\Y>8_P#?;\Z/,?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4E%%
M!03Z4"D/6@%J*>E)VHZ_2F.X5<D@*.N30V)NPK2(B[F( '4UGR:Y91L5,Z9'
M^U7(>*?%84/;6K$$<,:\_DEDD<REVW'KS6,JIQU,59V/:QX@LB<><@_X%1_P
MD%E_SV3_ +ZKQ$NQ&=S9^M&YO[S?G4>U,?KA[=_PD-E_SV3_ +ZI/^$ALA_R
MV3_OJO$]S?WF_.C>W]YOSI^U!XQGMG_"167_ #U3_OJD_P"$CL?^>J?]]5XI
MO?\ O-^=&Y_[S?G2]LQ?7&>U_P#"26/_ #U7_OJD_P"$DL?^>J_]]5XIN;^\
MWYT;F_O-^='MF'UQGM?_  DEC_SU7_OJC_A);+_GHO\ WU7BFYO[S?G2[F_O
M-^='MF'UQGM7_"367_/1?^^J/^$FLO\ GHO_ 'U7BNX_WF_.DWG^\WYTO;,/
MKDCVG_A)[+_GHO\ WU2_\)-9?\]%_P"^J\6W-C[Q_.C>W]X_G1[9A]<D>T?\
M)/9?\]%_[ZI/^$HLO[Z_]]5XON?^\?SI=S?WC^='MF'UR1[-_P )39?WU_[Z
MI#XJLA_$/^^J\:W-_>/YT;CG[Q_.CVS#ZY(]C_X2RR_O#\Z/^$MLO[P_.O'-
MS?WC^=)N;^\?SH]LP^N2/8SXNLAW'YTG_"867K^M>.Y;^\?SI=S?WC^='MF'
MUR1[#_PF%EZ_K2'QC9#_ /77C^YO[Q_.DW-_>/YT>V8OKDCV#_A,K+_)H_X3
M.R_R:\@W'^\?SHR?4_G1[9A]<D>NGQI8YZ'\Z3_A-+'^Z?SKR+<?4_G1N;U/
MYT>V8OKDSUW_ (36Q_NG\Z3_ (3>Q_NG\Z\CR?4_G1N/J:/;,/KDSUS_ (3>
MQ_NG\Z3_ (3BQ_NG\Z\DW'U-&3ZFCVS#ZY,]:_X3JR_N-^=)_P )U8_W&_.O
M)MY]31N/J:/;,/KDSUG_ (3JQ_N-^='_  G=C_<;\Z\EW'U-.R?4T>V8?79G
MK'_"=V/]QOSI#X[L?^>;?G7E&3ZFDR?4TO;,/KDSUC_A.['_ )YM^=(?'EB/
M^6;?G7E&?<T9SW-'MI!]<F>J_P#"?6/_ #R;\Z/^$_LO^>3?G7E63V-&3ZT>
MVD'UR9ZH?']E_P \G_.D_P"%@67_ #R?\Z\L)/K1SZT>VD+ZY,]4_P"%@67_
M #R?\Z3_ (6!9?\ /)_SKRS\:3)]:/;2#ZY,]3_X6#9?\\7_ #H_X6%9?\\7
M_.O+,_6BCVT@^N3/4O\ A8=E_P \7_.D_P"%AV7_ #Q?\Z\NI>?6CVT@^N3/
M4/\ A8EE_P \7H_X6)9?\\9*\NYHYH]M(/KDSU#_ (6)9_\ /&2C_A8EG_SP
MDKS"BCVTA?7)GI__  L6S_YX24G_  L6S_YX25YC11[:0?7)GIW_  L6S_YX
M24?\+&L_^>$E>8T4>VD'UR9Z;_PL:S_YX24'XC6?_/"2O,<T9H]M(/KDSTS_
M (6)9]X)*Z'0=;BUN!Y(U*[3CFO$LC=S7IWP[XT^?']ZM*=2[.C#UW*9U\]R
M(" >]-2[5SUK&\07#0R1<]:J6-VS,.:W/0W.M4AJ?56U;<@JU2"UCS;XLC_B
M4V_KYE>/'CI7L/Q9_P"05;_]=*\=/6O3PU^4X,1;F%  HHHKKZ& 4444AL**
M**+B"BBBBX!1111< HHHHN M)111< HHHHN&@44447 ****+@%%%%%P"BDI:
M+@%%%%%P$I:**+@)2T447 ****+@%%%%%P$I:**+@%%%%%P"BBBBX!124M%P
M"BBBBX!11247 *6BBBX :2EHHN 44447 ****+@%%%%%P"BBDHN M%%%%QZ!
MG/7MTJ2*>2&59$)# YX-1T4636HG=/0]:\$>-Q(J65X_084^]>C21K*@="#G
MTKYCAF>"59(V(8'/!KU;P1XX5U2RO7 (Z$G)KSJ]#6Z.RC5TLST&.4Q/M>KJ
ML&&:K21K,@D3G(R*CBF:,['XKDVT.K?4OT4U2&&13J "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *3-!I,<4 &
M1G%+31TIK.$4L3P.30V#T%=E122<"N \5>*P%:TM6X/#&CQ7XM"QO;V;!AT)
M[@UY_)(TK%V)+-R<USSF>?B,3;1"32-,Y9B233.U%%<[/.E*X?2BBBE8E!11
M118&%+244P"BBBBX!Q1110 4444!J%'%%% :AQ1111H 4444:#"CBBBC0 HX
MHHHT$'%%%% "TE%% !1Q111H,****- "DYI:*- "BBBC0 HHHHT ****+@%%
M%%%Q!12TE%P"BBBBX!1112N N:,TE%%P"BBBBXPHHHHN O%)2T47 3%&*6BB
MX!@49HI*+@&:,T447 7O7IWP[YL)_P#>KS#O7I_PZ_X\)_\ >K:BM3KPEN<L
M^*?]=#5+3OOBKOBG_70U2T[[XKL1[%M#L++_ %8JY5*R_P!6*NU/41YM\6?^
M05;_ /72O':]B^+/_(*M_P#KI7CQKU<-\!Y^(7O!11170V[&*2"BBE569@JC
M+'H*+Z UJ)15]-$U.1-ZV4I4]#BG?V#JV,_8)?RJ'-(I0;,ZBKG]E7_G^3]E
MD\S&=N.:@GMI[:39/$T;>AJE),3BT145;33+V2+S$MW9!U85 EO-)-Y21L7S
MC:*7,@Y61T58N+&YM/\ CXA:/TW574%B !UZ4[JUP<;.P45:?3;V.'SGMW6/
M^\>E50"> ,GTH4DPY6%%7X=&U&X ,-I(X/<"HY]+O;4$W%L\?^\*7.A\C*E%
M.C1I9-BC+'H*OC0M4896RE(]<4^9"Y69U%6Y]+OK==TULZ?6J8SZ4*28.+0M
M%2PVT]T^R")I'/0"KG]@ZKMS]AE_*DYI.P^5F;2U/<6-S:X\^%HR>FZI8-)O
M[B,/#:R.IZ$"DYI!R,IT5?;1-409:RE '7BJ3HT;[&&&'8TU-,3BT-HJ6"UG
MN6VP1,Y]!5PZ#JJKN:QE ]<4<R!1;U,ZBGO$\;%9%*L.QJQ;Z9>W:DP6[N!Z
M4<R#E*E%:/\ 8.JXS]AE_*J_]G7OV@VXMG,HY*8YI<Z'R,K45/<V=S:RB*6%
ME<]C4DNF7T,/G26SK'C.X]*?,A<K*E%'?%6SI=\(//\ LS^5C.[M3<DA6*E%
M6+:QNKPL+>!Y,#)VU');S0R^5+&R2?W3UI<R'8CHJVVF7J0^:ULXC_O55",S
M;0/F]*?,@Y=1M+6A'H6J3)NCLI6'J!4$^GW5K_Q\0/&?1J7,@<6BO24G.>E+
M5"L%%%% !1110 4444 %%%% !1110 4=Z2EH *2BEH ***2@!<4F*6BD%P&.
MYJ2&5X90Z,5P<Y%1T'D8HDKH:=F>M>"?&XD"6=XX!_O,:]%=$G02H<Y'%?,D
M4SPR*\;%6'<5ZMX(\;B7997K8)X#L>E<%:A;5'72J]&>@QRM&^&Z5=5@PS59
MT2X0/&1@C@BHXI6C?817&=2U+]%-5LC-+F@!:*2EH **** "BBB@ HHHH **
M** "BJLVHVENVV6=$/O3$U?3W;:MU&3]: +M%-5U==RG(]:@DO[:%_+EF5']
M#0!9HI P(!!Z]*KSZA:6S!9IT0GUH LT4U)%D0.A!4\@CO2E@JDDX ZT +15
M!]9TZ-]KW<:MZ$U8@NX+E=T,JN/:@">BH);N&W7=/(L8]33HKB*=-T3AU]10
M!+15;^T+7S?*\]/,/&WO5C<-N: %HJC-J]A VR6ZC1O0FIK>^MKK_4RJ_P!*
M +%%(3@9JE)K&GQ/LDNHU;T)H O45#%=0S)OCD#+ZBH'U>PC<J]U&&'4$T 7
M:*H?VUIW_/W'^=3'4+40K,9E\MNC4[!<LT5%#/%.F^)PR^HI)[J"V7=-(J+Z
MFD!-15%-9TZ5]J7<;-Z U<#!E!7D&@!U%)FH9[RWM1F:54'O0!/15"/6=/E.
MV.ZC9O0&KP8,,@Y% "T57GOK:V_UTRI]:BAU>PN'V174;MZ T 7:*0-FJDNJ
MV,,ACEN45AU!- %RBJ<>JV,K;8[E&/H#4LUW!;IOFE5%]30!/15#^VM._P"?
MN/\ .GPZI8W$@CBN4=ST - %RBJ<NJ64+;9+A%;T--76-/8X%U'D]LT6 O45
M6DO[6% \DRJIZ$U)%<13Q^9$X=/44 2T55;4;1)?*:= _P#=J1[J"/&^11D9
M&: )J*165URIR#2T %%%% !1110 4444 %%%)0 M%)2T %%)FC=SQ0 &D//?
MI2YIDCK&I9C@#J:&)NPDCA5))PH&2:X'Q5XK5-UO:N#ZD&D\6^+-FZTM&Y!Y
M937G\CF5RSG)/-<\YG!B,1T0/(SREV);<<\TS!5\_I1WS2]:YW=GFMW=V&>:
M3-!HH%8**559WVJ,D]*GELKFW7=-"R+ZFFDQJ.ERO14L5M/.<0Q,Y]!2302P
M-ME0JWH:5F-P>Y'14T5K//Q%$S_2IWTC4$7<UK(%]<4<HU&12HIS*R-AA@^E
M206L]R<0QL[>@HL*SO8AHJX^EW\0W26LBCU-10V=S<'$4+.0<<4^4?+(@HJ]
M_8^H_P#/I)^5,DTR^B4M);.JCN:'"P<DK7*E%!J>"SN+C_51,_TI)7)5V[(@
MHJU-IMY;KNFMW1?4U6Q\V,TW$;30E%&"3A>:LOI]VD0E:!Q&1G=24;B5V5J*
MEAMI[DD0Q,^/2DEAD@D*2J48=0:+:7&U)*Y'13HT>4X123Z"I9K*Y@7=-"R#
MWHY=+A9L@HJ6&VGN&"PQ,Y]J26"2!MLB%3Z&GRZ7#E=KD=%.CC:1]BC+'H/6
MI9[*YMU#30L@/<T<HDG:Y#258BL;J:/S(X&9/45#L;.W!W9QBERCY6-I:GEL
M+J"+S)('5?4TL5C=3H7B@9E'4BA1N'(RM13_ "Y#+Y6P[\XQ4LUE<VZ!I860
M'H33Y0Y=;%>BK46G7D\8>.W=E/0BI/['U#;G[))^5'(/V;*-%.:-XSMD4JWH
M:=##)/((XT+,>@%*PE&Y'15W^Q]1S_QZ28]<5%-9SV_^MC9/K3Y6ANFT5Z*L
MPZ?>7"[H;=W4]"*D.DWZC+6L@'THLP]FRE13G1T;:RD'TIT<$DS;8E+L>PHL
MR>76Q'15TZ/J(7)M) /I55XI(CMD4J1V-%F4Z;6XRBI[>RN;G/DPL^/2IAI&
MHD_\>DGY4<K!4VRE15@V%TLOE&!Q)_=ILUK/;L%FB9">QHLPY&0T59:PNTA\
MUH'"==U5J35B7&P459&GW;0^:L#F/&=U,AM9[ABL,;.1U I\K#E9#14LL$L,
MGER(5?T-/^PW1B\P0/L_O468^1E>BEP<[0.?2K<>EWTRY2V=A["BP*#>Q3HJ
MS/875OS+ ZCWJMWI-"<6@HHH'- K!WKT_P"'7_'A/_O5YAWKT_X=?\>$_P#O
M5K1?O'7A%^\+/BG_ %T-4=.^^*O>*?\ 70U2T[[XKK5SV;V.OLO]6*NU2LO]
M6*NTD(\V^+/_ ""[?_KI7CQKV#XL_P#(+M_^NE>/FO4PWP'!7^(****Z7L8!
M4MM((;F.4]%.:BHXQS2:NAIV9ZMX<\9V<WD636S%B0N<UTGB?7K3P_;+(]N7
M!..*\B\)@'6(-O'SCK7=_%')TZ/_ 'A_2N&47[1(ZJ;T&>'-4@U_Q?\ :(XB
MD?ED;37.?$B)4\0Q",;1L_PJS\,3_P 3WC^X:B^):G_A((FP?N?X4]8SM<5N
M8ZO0+>-O"<Q8<[1S7'^&[43>+L$959J[70%8>#YMW&5&,USW@> S>(KIQ_!+
M_04)_$5R['2^/?#D=UIWG1* 8@6->6^'-+DU35HX54[8V#'CM7LDVL1W6H7F
MF3'AOD -4-+\/0^&[BZO"% \LXYJ(5&H683@G*Y:\3Z1 GAP1118VC/Z5YUX
M,\-#4]2:64 PJS @^QKTNSU!M=\,RSDY/S#\A6%\/C&MC=QI_K/-?^9I1FU$
M<H)R)-0\5:3X;86T-ON8#DJ:ELM2TCQA \36X63H-QKR[Q)!-'K$PE!Y<D9%
M:O@.*Y_MV Q!O+#_ #<5;CI>Y+T=A;K0O[)\7VL>W$338 KTWQ!J]GX<TZ&9
MX"ZN< "N;\9/&WB72E3&X3?-^1KKM;TK3M4L+>&_ *AOE^;'-1.;=BH15F96
MGW.F>*],D<VF#L8@M]*\>UJR-AJ$D2L,9.,5['>_V9X,TEO)A<!@5&/<5XOJ
M-ZU]>/,W<G%:X=.[;9G6T1U'P[B5_$, ;D<UW?B3Q79>'[F.&2V9]P[5Q'PW
M'_%108]Z]#\0:%HE_<I)J.W<.F7 J:C]^R*@O=39GZWIUCKGA=M12 *XBWKG
MM4GA-(K3PJMQ(FXQQ[C5'Q#XATW2]!DTZS/#)L7!SBM/P:J7/A-%N/N-'AOI
M6<G)+4T23>A0T[QEIVJWAM#9MD\$DUS?CCPY!;ZDDEJ@4.5&T>]=K:>&=$T]
M&U&WA)(&<AL]*X[5/$<&J>)E 5A""  WJ#51D^;0EQ2W.BL-(TWPKHJWEU&K
MRD!ACKR,U6B^(.F7-P+9[8A#QDGBE^(<<SZ-&\8)C\M>!]*\D6-V?Y0=W855
M./-&[8IRMHD>I>,/#-G=:8NIV**JA-S8[U9^'T4:Z=/*Z;MJ9Q5Z!6B\!2_:
M.AA'!J/P))"+*X.T^7LYJ.9\K15D5[_QU:V=R\!TZ5MO<5E>&=0AUSQU/<)$
M4C:+[I_&M36=1\-J9U>!C,5/.?\ ZU<]\/VC;Q=+Y Q'L. ?QJE?E;)37-8D
M\?0I'XJA51@;5_I72^*K>)/ I=5PWEKS^%<[\0P&\5P_[J_TKJ/%N#X!(_Z9
MK_*FF[1!VU/%5_UE>T26\0^'RML^8P=?QKQ=<;\ <U[;+G_A7">HM_ZUK7=K
M6,J6MSG?A=#'+<W*NN?DIWCOPR8-1COXERKR 8 Z<T?"QBLMVPZB.NM_M&VU
M;49-,N.9(QN&3_GTK"4VIF\$G$R-4MXQX-4A?FS_ $KGO!'A:"\9]0O%#1(Y
M!4_6NQ\26;67AGRB1]_/X55\.8?PI<BW/S;S_6I4W8.5<Q1OO'>F:3*UO!:,
M0AQ\IK*\0>)-%U32RXM?W[+\IST-8.F6%K=Z_*FH#$9D.[<<5W=IX'\.W@8Q
M0Y4=?F%:?#JR&KGC;$L<@XI*V?$VGV^FZQ/;6PPB-@#-8U=L7=7.:6X44451
M(4444 %%%% !1110 4444 %%%% !1110 4E+24 +1110 4444 %/BE>&021G
M##O3*..])JXT['K7@CQN)=EG>.=W168]*]%=$GC#Q,#GN*^8HI7MY!(APPZ5
MZOX(\;^:%L[UR2,*I/%<%?#VU1UTJIZ#%*T;;&[5>5@PR*K.B3)YD9!SW!J*
M*5HVVM7&O,ZMR_2TQ6##(I] !1110 4444 %%%)0 M(3CFEI#0!XYXUGNI?$
M%O:PR[/-DVU//X,UNULS>0WZY4;L 5!XJS_PF5CZ";^AKU$.@TEB^-NWG-43
M<XGP'XGNI[MM,OY&:6-<DG_/M69XXO[B+Q;&D;D*=O'XU4TD*_Q!N6M?N;1T
MY[FE\=<^,(<^B?TIV%<];MG TZ&1C_RR!S^%>)^*]8O]0U*62WD;RX&*D"O3
MO$.JC2O"B3 X81J/TKRS0]6T^&"\%_;2R--)N!4?_6H2"YZAX'U@ZGI21EOF
MA4!JQ_''BN:TD2PLBRS2-L)%<]X"UI+76YX(\I'/)\JGTXJ+Q #%XZB>;_5F
M?@FBVH7+5EX(UK4K874]Z!(PSAAS70>%-$UK3=1*W%YO@"\+BM?Q'>WEOID4
MFDN Q;D@9XK@+CQOX@L[V.&689+ $;?4T6"YUOQ)N)+;P^\D;8<$<UB?#?Q4
MTG^@W;DR.WRDGM5KQU/)<^$1)+]]BI-<9%ILVFV\>N6H*B%1GZ_Y%-(+FZM_
M<?\ "P(8C(3&TIXKK/''B=]&M8X;;/FS A2O8UYSH&H?VCXOL9#G<7RV:W?'
MX=-=TYI/]5YO^-*P7(M.\)ZWXAMUOI[T*SC/S"H99-;\&:@GG7#/ 6"Y XZU
MZGH4D+Z1#Y1&W'&#7*?$^6W.C0H2ID\WH#SVH&:.L>)#_P (K]OMB0Q^4X^E
M>?:-I6H>)XYKQM11'5R K=:[#PIIT-[X,,-_@*6.-QQ7.R>$M<TF22YTF\@\
MD,3A3G^1HL@-OPE'K-O<R6ET[M'OP&QQBJ?B7PCJ=O%>ZD+Y?+7YPN*G\&^+
M[R?4/[.U%M\V_:"!BNO\7#=X6O\ M^[H8'E7A;1-2\1*QCNPFT9Y[UU/BFWN
M]#\(VD#3;I5?EAWZ4SX5?ZJ4>BUH_$__ ) T./[_ /A0!9\$7S?\(F9IVRR[
MCD_2N+N]6U;Q=K#6=G*\< )4Y'&0<5N^'HYI/ )$1^8%B?IBJ7PRGMUEFC;
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MX!A2749PXSA*Z2Q/_%#D]_)KGOA^?].N#WV5<5JC=QCS1+7C'0@'6\A7JP!
M^M6%A0>%F.WG-:S7\-[J+Z?-U"Y&:9J5D++09(^,%LT^579I*,;.QR'AC04U
M"]:XE4&)7((-;]]XCT[1F\B.'<1Q\IZ4[P8=VFW00@-YA_K7'?98Y?$SI>*?
M+,ASGBI44C+2,5H;U_XBTW4+!]UO\VWC)KA961G)1<*>E>EVWA;1+G<(H\CO
MAA7&^)--M]/O7AMQA5/ S431C6C:/,8?3I1THSCK1U;FLK''NM [UZ?\.O\
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MC)]U%*X6/,/!WAF^?61JMXH#!]W'%=YXH@>Y\-WL,8R[QX%:RHB#"J%^@I6
M*D, 1[T7 \_^&VE7.G12"=<$K5_XAV$VH:3#' N6#YKL$1$'R(J_04,BN/G4
M'ZBBX'*^"M.DM_"_V6X7YB2"/K7':OX4U30=4:_TD#9DD@GN:];550?* !Z
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M<'XBU-=3U+S!T7(%9GVF9AM:5S]6-,)R.>M*<[K0J=;FC9'H'AF]@ATJ9)&
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MIU "T4@I: "D.<]*6B@!,<T$4M% "=Z3Z4ZB@!N.<YI<<4M% #<9HYSS3J*
M$[TG4Y%.HH 3WI.W%.HH 3\*3'O3J* $XHZ4M% "8HZTM% "=:3I3J* $[4
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M10 44E+2 *.]%'>F 4444 %%%% !1110 4444 %%%% !1124 %%+10 4444
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M0 4444 %%%% !1110 4444 +24M)0 O:DI:2@ HHHH **** %I*6DH ****
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MR>7*N'J#J.>*:9-A:***8!1124@%HHI:8"4444 %%%% !1110 4444 %%%%
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MOS1QVJ#-MA1113$E8**** "BBB@ HHHH **** "BBB@ HHHH ***6@!****
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M<YJVVLWS2QR&=M\8PI]*S\>E+3L@4F.DD:61I'.]F.2:T=/U.5)X1(Y\N(\
MUF#CIQFBIL.YJZ[J/]H7DC*,)GBJ5E?3V#-)!(59AM)'I5<YZ#I1@4[$D\-[
M<6\YGBD*R'N*>NHW,=P)UD991T:JISG-*?F(S3BD/F9)Y\GG&?>?,)SGUJT^
MLWS[,S/\GW?:J'>BDXH.9CYI9)YFEE8LS=S6EI][(56&28^0ASY9Z5E=L'\*
M09'(ZGK1RH?,;.M:LMY^XMX_+A'\(Z9K&X["EY XHP*:0FQ*,4M%,0E%+10
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M8XJEG"X'%;WC):&+BXL]7\$>. Q2QO'ZG =CTKTIECN(Q)&001P17S!%(8I
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M64<N?F(R:0XR-'/-'>EHZB@U%HHHH **** "D-+2&@ &!28XXHX'%1NX49)
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MEI*I7)L%%%%#0]0I:**!!1110,****+BL%%%% PHHHH **** "BBB@ HHHH
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M/VUI>M=1.P8C&.U:ZCY>:KV%TE[:K-&<@^E6<<TBHI6(C;1$[C$A;UQ3]H
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M%%% "44M% !1110 44E+0 4444 %%%% !24M% !1110 4444 %%%% !1110
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M.:!!11UHH&@HHHH$PHHHI@%%%&* "BBB@ HHHH **** "BBB@ HHHH ****
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MV>H:ZETCDHI4YQZ&K6J>+X)-8BO;-MP6,(<BN&[8Q^-)@*N!4^RBAJ;/4O\
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MQBC^&CCH:#P>*:86L /&#1C'%'6DI687%HI**8"T444 %%%% !1110 444E
M"T4F:6@ HHHH **** $I:** "BBB@ HHHH ****2W#H(:]@^%]PIM%ASR 37
MD%>A_"J[VZP\3'@1\?K7/B5[IO0>IZK?C#9JM#G=QUJ_>+NAW50CSV%>;>QW
MV(]:G6VTB9W Z="*QM"\,I/_ *=-)+MD^95W''Y59\3!A9&7.8U7YJW-&=9-
M(M2G395<Q+/(/B$XBOC F0%;C%<,1CD_>->M?$;P[+<)]K@0M@[F->2D?-@]
M17H4)+E.&M%MCX2$FC?G<K U[WX.\00ZCIJ(6Q(H"C(QTKR/P;I":OK*P'D
M;J]ENO"EO<0(D,C6V% S'Q6.):;-J$;(M:YJAL=/D:$J9L?**R])\-I<XO[I
MG,DGS8)R!63J.AOI,JSRW4LL*#G>:[G3G5]/@9/NE>*Y=EH=!EZCX;MKVW=
M64XXV\5SVEZO%X:NVTV[&(TX5L9)/UKOJX^ZBAU#Q#/;M$I9#DG'--.^XK'1
M0ZC;WMFTL3Y7:>OTK$T/-Q?M/'_JP2#BL;7+"?1[I9H9'\J0B/;GCGC^M==H
M6G#3[)4!)W_/D^]#LD!J?6D(RP-.I,<UEU+1D>)Y1'X?O"?^>=?-MT_F3EQW
M->]?$"]%MHLD><&1"*^?QD]:[L.CEK,D4@\&G#Y>E,'(IX7FNV_0Y&[BX(.3
M1AB<+T[T'[VVNN\)^$;C6;A9'1A #\S"E.:@KCA!R8GA+PE-K-VKR(1"A^8^
MU>U6MI;:-IXCB50(UZXY-)9V=KHVGA$55"+R<=:YK5M7:[D,<3?(#U!KS*M5
MS9WPCR(=J>L-<OA&XSVKHM";=IRMUYKA5&6QUKN=!7;IBCWK!FJ-3FF3KNC(
MJ2D/-4(\U\-$6WB:ZC)P7FX%>E#)->97Z_V7XQMG/"R.2:](B<31+(IX(R*T
MJ*]C.&]B7J<4A]ZI7VJVNGQ[[B0)7-7'CVQ5\12*PJ5%O8IS2.SQD8(XIB11
MQ [%5<GL,5R-OX]LF8"615%;,FH1ZIIS-8R;V[8I.FT]0]HF:Q=.FX?G5._U
M2VT^!I)9  !GBN*EL/$32MB*3;GCYJKW'A?5YX&>1I2V/ND\4[(EMVT'^9-X
MIUA6CR;>)]P/M7H=M"EO"(D& *X/P[JZZ7,MA=Q)%(/ESCDUWZ,'&X=#WHD*
MG?J<-XXQOB_ZZK_,5VECC[%#C^XO\JXOQNV)8N/^6B_S%=E9-BSASQ\B_P J
M.@)JY9^M)N!S@]*@GNX;="TC8 KE-9\4B3_1-/(=WX)'45"+<HI$'B>_%_J-
MO91$DA]K8KK-*M/L-A'!C[HK \.Z"\;F[NP3(W/S=JZSZ4R()R=R.:W2X0+*
MH(!STHVK#"P4  "I!G.36;KMZ+'3VE)QGBD:3T5SE;(?;O%D<XY5"5/YUV&H
MR_9[!Y <;17.>#K(E)KN3.XR$CZ5>\67GDZ9)$OWF7B@Q7PW.8M+&ZUN\N&6
M20*I[.16I'X+#_ZV>?Z;S_C6MX6M#!IZ2E>9%R:W^!0$*2DKF3I.@P:7S&6+
M8QDUK=Z.O2C-!NDHJPM(>*6D89% TRI?V,-_;-%*H(88SCFO)_$7AV;2[AF5
M#Y+'Y37K#N8Y!G[M,O;*'4;5D=0=PX..E9SC='/7HJ:/"?N'GK28&,UT?B+P
M[+I4S.%)A)^5CWKG/Y^E<DH:GD3IN#"BBBH9&PAZ8KV7PC*'T>%0?NI7C=>E
M?#Z[\Z*:,G[@X_2NFDSKP<K2.HO1^\^AK&U>:6.U4J."<<5NWR8P?4U4"+(
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MW@PZ4CB+4K2&8QJCELD**.4/9(YCRWQ]TG\*#&X7[K?E75W5U!IL:".-'<D
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M!Y+GYF/:I9M.LI[.6?3KB1]@RZ]!0T"@E$YH#>VW^+M6[!I]I;V"3W982/\
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M+24M !1110 E+110 4444 )12T4 )2$4ZDH>H;#.5.1Q5RWU:_M2/*N9% [
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MLH&MX9%=2<[JH'4Q':R*I^8G(K%SM."*3'JU*YFZCOH=.T]AJ5NC7$BP21C
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M &#2YI.^:5D%V(0?6G$G;\M)118+L.HZ\T@X);KFEH[YI@!Y''%''3%%)BD
M=5/:ESD4'GK1VQ0P#WH'J:/:CMBA  ]:*!Q13$%%%% PHHHH **** "BBB@
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MMUIT46HI"LBNK '([5I7MMIMCY:R0JS%<YJO+8&SU)&R"A (Q6OK#Z.'A%S
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M4M)0 M%)2T %%%% !1110 444E "T444 %%%% !1110 4444 %%%% !1110
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M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %)2T4 !H!HI*
M%HHHH 2BEHH 2BEHH **** "BBB@ I*6B@!*6BB@!*6BB@ HHHH **** "BB
MB@ HHHH **** %I*6DH ***2@!:*** "BBB@04444#"BBCC/2A %%'?-&*38
M@/;BEY/ [TASD <YKLO"'@^;5YTEF7$0P?F%1.2BKLTA%R8G@_P?-JMPDLRD
M1]<D<5[-;P6FC60CC"HH'(]32V]O:Z/8B*(!$4=,]ZY75=5:[=DR<5YE6JYL
M[Z=-10NJZK)<2%0Q\OH1ZUEHI8\=Z$4MQ6A9VA=AQ61:06EF78<5TEC9!0#M
MHLK$+@XK7C0(,4QA'&%' J2BBD@$I:** "BBB@!*3MS2FDX//K0!QGB2ZDEU
MB.TC0RQLN2!50W$\.L6=PUN\,$0PQ/2NQ738([P7*H-X[U)?6<5]:O#,NY6Z
MBG<5CD/$RRW^I:8UK-Y;/T8?C45A;W,FM-#JEQO$3?NR_<^U=;_8]KFW;RQF
M ?)[4Z[TFVNIXYI$!>,[@:+A8=J?&GR@?W36=X9&-"/U:MJ:))XBCC*D8J*S
MLHK.V\B-<+SQ0,YW3_\ D*/]&JGH>FS7C7;QS[ )2"*ZJ+38(IC*B@,:?8Z?
M#8"00J%\QMQ^M%P,_6HC%X?G5FSM3D^M8EW;-)IFE7*J2L(W''XUU]U;)=VS
MP2C*.,$4V.RB2R^R!?W07;BBX%.QUBTFM5=IT1L<J3TIUU=P75A+Y,JR?(>0
M?:J;>%[ .2D( ;@U=M=&L[*$Q01;5(P:!'+:=?BP\+R2!<DRE<#W-4_*N!H\
MT"V3_O7W[L5V T&R%M]F\H>7NWX]ZTU15C6,#Y0,"BX'&W-\+KPA=1G@Q+M/
MM6UH5_9C2+6,SH&"8QFI1H-E]FN(/+&R<Y<>M5X/"]E ZE(@ O2@#<R&3*G@
M]ZY.$G_A)-20'I%U_.NJCC$<>P?='05572[=;N6X"#?*NUC0,Y2RTZ/4;9HW
M4$H2X)]15?1KR23Q5'%."KJI50?05VEII\%H2(DQFHO[$LAJBZ@(A]H48#4
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M]/#? <&(^(****Z7L<X4444#"DI:2@!:*** "DI:* $HI:* $HI:* $I:**
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M*** $)QUHZ4$9I: $QB@\<FBC'.: $Z\TN,CF@@GBC&!B@!, \>E X.*=10
MW%&<\TN.W:B@ SWI.,9I:,4 (,8S2&1!U8#ZFE)^4UQ\[WEYXAFMD.$5<CGZ
MTQ'7Y!'!!'L:<,'O7(VFH7MGJS6,^-@0M[UH:#?S7GFF3&%<@4 ;F IQZTN0
M.]'0Y[5Q$WB&\;Q"MO&!Y*28<X[4 =L64?>8#ZFCS$/\:_G6+J\,\]OYUN>
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M %TKQ[M7IX;X3@K_ !!10**Z7L8"4M%% !1110 4444 %%%% !1110 4444
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M.Q@P)JS<:?!=6ZPSHKJN/O"E<+'&3V\I\.75W.N7:3=&3_=.:[/2R3IEL?\
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M8+2T+L.*Z2RL0H&118V(4 XK86,*.!0,1(PB\5)1118 HHHH **** "BBB@
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M"@$BMA(PB\4#"- J@4^BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_/%:/^$LF_YXK0JTP]C$P?\ A4]A_P ]9?S_ /KT?\*GL/\ GK+^?_UZWO\
MA+)O^>*T?\)7-_SQ6CVTP]E$P?\ A5%A_P ]9?S_ /KT?\*HL/\ GK+^?_UZ
MWO\ A*YO^>*T?\)7-_SQ6CVTP]E$P?\ A5%A_P ]9?S_ /KT?\*HL/\ GK+^
M?_UZWO\ A*YO^>*T?\)7-_SQ6CVTP]E$P?\ A4]A_P ]9?S_ /KT?\*HL/\
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M*HL/^>LO^?QK>_X2N;_GBM'_  E<W_/%:/;3#V43!_X5/8?\]9?S_P#KT?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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4% !@48%%% !@4N*** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>gegguy50oztz000004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gegguy50oztz000004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" *W!J # 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MI#2TAH .U(>G-'4U'+/'"H,CJN3CDXH6HGL2"EIJ.KKE6##U!IU = I:2@4#
M%HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@!****8(**!2T@$HHHH!A1110 M)1118 HHI: "BBB@ HHHH
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MH ***3- "T4F:6@ HHHH **** "BBB@ HHHHN 44447 **** "BBB@ HHHH
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MBN4=C)(6)Y)J@/4- D+Z7"&.2%Y-:M8_AWC3(N/X:V*PEN6M@HHHJ1A1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MT4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4F:* "BBBD
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M_(*N/K0QPZF6>IHH/4T4T1U"BBBCJ+J%>C> _P#CPE_WJ\YKT;P'_P >$O\
MO5G5V.[ _P 0["BBBN4]T**** "EI.** "BBB@!:*2B@!:*2B@!:3BBB@ HH
MHH **6B@!**** "BBB@!:**2@!:*** "BBB@ HHHH **** "D-+2&@ HH[4G
M2@!<T5&\R1KN<@"LRX\1Z?;Y#RG/TIV;"YKT9KE9_&-N/]2P/U%9LOC.Y_A5
M,52@Q-G>;AZBDWK_ 'A^=>;OXNO7/"K4+>)]0/9?SI^S8N8].WK_ 'A^=&]?
M[P_.O+_^$EOO;\Z/^$EOO;\Z/9L.8]0WK_>'YT;U_O#\Z\O_ .$EOO;\Z/\
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M?SI?,3^\OYUXI_PF6I>WYT#QEJ7M^='U:0?6(GM?F)_>7\Z3S$_O+^=>+_\
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M_"_B*[OM9AAEZ,?6O21TK*4;&].HIH:_W#7D?B?_ )#EP/>O7'^X:\C\3_\
M(=N/K6E(X\<KHHV'^M;Z4R[_ -;3['_7-]*CN_\ 6UN>0U9$-:EE_P @JX^M
M95:ME_R"KCZT,(=3+/4T4'J:*:(ZA1111U%U"O1O ?\ R#Y?]ZO.:]&\!_\
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M:^B?E7;44>VGW#V43B?^%?VOHGY4?\*_M?\ 8_*NVHH]M/N'LHG$?\*^MO\
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MG&^NP,95#DUZ5;P);PJBC"BL9R-(H?#"D*!4  %2T@&*6L&S0**** "BBB@
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MJP;/H<UX#/XBOYFR\C#Z,:]!^'NM7-\9()CE8UX)J)T'!7*C43/0*,4G6EK
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M?\>$O^]6=78[\#_$.P[T445RGNA111B@ HI:2@ HHHH$+128HQ0,6BDQ1B@
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M4W-VD0R234$G^L;'J:U_"J"77HE/I7H/2)CNSU[3(%M]/A50 =@S5VHX1B)
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M:D9HQ7%?\)I)_P \EH_X323_ )Y+1R,.9':D5FZMI-OJEJT<BC)_B YKG/\
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MKS#VB/2J*\U_X68W_/%/SH_X68W_ #Q3\Z/J\P]HCTJBO-?^%F-_SQ3\Z/\
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M@\@T=^ ?RKJ/[7L H'D1'\*/[7L?^?>+\JAU'V'9'+\^A_*C!]#74?VQ9?\
M/M%^5']L67_/M%^5'.V%CE^G7-%;VH:E:SVC(D$:L>X%8'0\<U:8M Z=:O:;
M:RS3>8BY2/YF/M56!Q%.CL P!Z&NGG\06[Z=Y$=O'$<8+*.32J-[(%8P=4F2
M:]>1#E#T-=O\-EE%V"1\F#S7GP*^8.<C-=IH?BZ/1K81QPHQ'>L:T6X61I%I
M'L(HKS;_ (66W_/%/SH_X68W_/%/SK@]A/L='M$>DT5YK_PLQO\ GBGYT?\
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M^>2_G4>S97UR!WV:,UP7_"=O_P \E_.C_A.W_P">2_G1R,/K<#O<BC(K@?\
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M/%4/[!U'_GB*Z-O&89LFW0TG_"8K_P ^T=:*Z//E&DVW<YW^P-1S_J?UI?\
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M[G)J$WLP...2<TM+AD)1L9%-''6M8JY(<=J*4TE.P!1112L 44446 ****+
M%%%%%@"D-+118!>])D#ZT#@9I#P-U)@3K97) 98V*GT%,DAEB^]&RY]17;27
M7V#1(Y(57.S)R*A@FBUG2IVD4>9&G88J;LHX_P F1D#!&*CN!2)&TK8C!/M7
M7Z=!Y>DS!@IQ&<<50\+VJFYDFE7*A<BCF"Q@-!(O#H5/N*(TDEX1"3["NKUZ
M!;JR^UHN/FV]*328(K#2GOI%RRM@4N8+'-M87"IN\E\_[M0+'(S[54[O3%=0
MFN7LY8!%*YXPE5]+B<ZRKNN-SY.13OH%C :"5'VNI+'C&*22&2/Y"I7V(KO-
M3TI/[2@F@49+Y<50U:S6YUK9@ !AFES7"QR\5C-*GRQ.??%,D@DB.UXV7W(K
MK-5U;^QY1:VJJ"N"<BEWQ:[IAD9?W@..!BCF86.3@MIIGVQQL0>X%+-;21':
MZ,ON17:64?E:7,M@8Q.#@;\5E:Y<LULJ7*?OMO55XHYF%CGOLTNW<5.WL<4^
M.SGF7<L;$>H%=8T4/]@VY9>J<\59@65-(MSIYCX^_NQG%',%CAIHGB/[Q&'U
M%,K=U^X\X;70B0'DXP*PJM""BBBJ)N%%%%*PPHHHHL 44446 ****+ %%%%%
M@"BBBBP!11118 HHHHL 4444[V ***/I2L*P?3KWK0TW5)K"4%7PO<>U9_\
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M=:U4>4XI3;E=BT<\YZ4$<\5I:=HUUJ<BB)"5S\Q'I0YI((TW-Z%*V@>XD"1
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MFMNC HYF*R(3 /)\L<+C%9$GA:QE<N\0+'O6[]:!G%',PL8!\*V)/^J&*/\
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M$4T__GB*Z"BCG8<J.?\ ^$4T_P#YXBC_ (133_\ GB*WZ*.9ARHP/^$4T_\
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MZUV%%+VL^X<D3C_^%?Z1_P ^ZT?\*_TC_GW6NPHH]M/N'LXG'_\ "O\ 2/\
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M\C,L5K(Q!QD5=A\1+)8/,R%74XVGK7,Z5?&SED;RG<%B/E&:L16<\UM-/L8
MMG!'-%D%S9@\2O<3*J6[[1]YJ;<>)G$I2&!WVGYMM2Z#:G[',NPJQ/<5DH\N
MDWEWOB=_-/R[5I:!J:T7B421MF)@R#+"I7\01#38[I4.7;&WO67H]E)=2W<T
MB$+(O (JBEA<MJ LRI\J-@PXXHL@NS<N/$JQ6V[RV\PG[O>ETSQ&+FX6WE0J
MS<@FLK7-.>"]6X5"R!0, 4_28X;N_C<V\BL!C)%%D&IT.LW)AT]V5"W':N4T
MR^F,-XI1B'_2NROX_P#B7,@&>.E<WI44BVVHJ8V!/W<CZ4)H-2I9:O)IY<I
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MY%=)HUY8GQ/.4MMDJPEBWX&JEO:S1^,=1=HFVE>#MX[TNE6<[>*;PF-@K0,
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MM\O.ZK&J:=--JOFH"1CM44>DSMK$<K(0@3!-.Z!TYWT,N7Q!+=3R@L4\ML
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MB@!.312T4 )CL:,4M% !1^%+10 E%+10 E%+10 4444 %%%% !1110 4444
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MWEJ[10!3VWG]Y:-MY_>6KE% %/;>?WEI-MY_>6KM% %+;>?WEHVWG]Y:NT4
M4MMY_>6C;>?WEJ[10!2VWG]Y:-MY_>6KM% %+;>?WEI=MY_>6KE% %/;>?WE
MHVWG]Y:N44 4MMY_>6C;>?WEJ[10!2VWG9EH"W@/++5VC% #$WX^8BGT44 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %)2TE "TE%)0 N:,T44A!
M1FBDIC#-+FBB@23%HI**6PPI:2EIW 2BBB@!:**2D M)113 ,T9I#0/>D]&%
MA<T9HI#38(6DS12T!<,\49I*44"ZAFBDZ4M PS2TE&: 89YHS2#FC@_A0 N:
M*** "EHI* "BEHH **2B@ S1FBB@09I:2B@8M%%% !1244 +1244 +1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !24M% "4M%)0 M%
M)10 9HS1118$+1110 4444 %%%% !1110 4E+10 E+110 4444 %%)2T@$HH
MHI@%+244 +1244 +1112 3-&:**8"T444 )2T4E !2TE% "T4E'>@!:*2BD
MM%)13 6BDHH 6DS110 M)110 M)2TE "T4E% "T444 )2T44 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 E%+24 +VIN*=2&EN%["=*:\B(N6('U-*6P,F
MN%\6Z^\4YM86ZBHJ5%3C<THTG4E9'7'4[53CSD_[Z%/6^@<\2I_WT*\<$LC,
M3YCY)S]XU;M[F5#E9&X]ZX)8WJ>A]09[ LBL.&!^AIV:\YL/$-W"P!8;175Z
M=KL-V-I;#]ZZ*>,A(Y:F%G W**:K!AP:=75=-'+9IA2TF:*86"BBC.*5P%I*
M.]%, HH/%)G(XI7 K7EY':)OD!(%06&J0W[-Y8/RU4\1G_0G^E9'A-OWDW-<
MDJ[]IRG3&E>GS'9$@=>E,61'; 8$_6JNHRO':.4ZXKG-$N[Q[UA(#MQZ5K*K
M9V,X4W)'85%/.MO&7<@ 5(IXKE_%%VRGR%) (S16J\D.8*-/GERD\WBNVC<C
M:YQZ5H:7J\6IAC&"-O7-<UHFBQW\;--G@^M=-IFE0Z;Y@BS\W7-<^'=>4KRV
M-ZZI15H[FEFBDQ17><@M&**.U%A;D4TRP(7;[HK/AUVTFN1 CC<3C&ZDU]B-
M(F(->2>&Y'/C! 78CS>F:B4];'31HJ46^Q[B**1?NBEJ[',%%%)UH!"T4#WH
MS0 4449H8(*6DI"<"A .I*;DYI0>: >@ZBFYI:+ +244#WH ,TM)WH% M1:*
M**!A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44E%+< HJEJE[]A
MLWF] 37FO_"SY1<^62,;]O3WJXTW+8ERL>KT54T^Z-W9QS'^)0:M@YI6L-:H
M***1B%7)J=;C%HKDM8\>:9I%VUM,S>8IYP*UM$U^TUN 2VS9![&K<6E<A2U-
M>EI*.U26%+249H&+24M)1<0444=J  45%/)Y4+..U>::C\2);34)K<$?NVQT
MJHQ;)E*QZA2U@^&M:;6+!)VZL,]*W:35F-.Z%HI*3-(8ZBDHS20!111FF 44
M49S2U **S=7UFVT>T:XN#A5ZXZUS^G?$/2M0O%MHV<.QP,BK4)-7)<K,[*EI
MB.'0,ISFG5/J4+1129]*+@+12<XHW9% !1G-4M4NS9:=-<#JBYK \*^)9-:N
M9HW(^09'%!2@VKG64M)VYH-!(44"C)H **3-+SBF%@I::">G>E[4@%I*3)Z4
MM !111F@ HH)H- K!124M PHH/3B@4 !I:** "BDI: "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH *2EI* "BCM378*N32V"UV4=4O4L[-W<XRI KR"]N3>
MW;R.>YQ73^-=9\V0V<;?=.>*XU?G^4?7->7C*O-HCV\#0Y(\S+ SC([593D<
M ^]5QVQVKO?#FG07-H69%)'M7!3HRGHCKKUXTU<Y- H& 3DU-&[PN&!8$>E=
M/!HD<=Y/).-L8;*\5I0KI3_(I1F^E:T\(T]SCJ8J+6Q5T/71+B&8X(KJ <H"
MO-<QJ&C",_:;?@@Y(%:>BW_VJV&_AQQBO2H3E'W9GGUHIKFB:V3WI#CKFHYI
MEAC+-VKE-1\0R/*8H1D].#6\ZL8&5.E*9U^]?6C=TQS7!^;J;#> V/K5FR\0
M30S"*<8 ."2:Q6,C>QL\+*UT=IFDR,YJ&WN4GA$D9RIZ&EDF6)"[G&!TKJ52
M+C<Y>5WL2E@.M)O'8BN,U'Q!--.88!^(-0QS:DI$A#$?6N1XN*E9'4L+*UV;
MWB+)L7(]*RO"?+S5%=ZK]KLG2;Y&48QZU+X2_P!;-CD5SNI&=0WY)1I:G7E%
M*X89'O4<<$*ME%4'V%0ZC*8K1V'4"N<T75);B\*,21CUKKE5A%I,Y(TY2C='
M7DX%<?XJ;-TN,9VULZW)/':!X02<UQU]+/+(&F!!Q6&-JKEY3HP5%\W,=-X8
M/^C.2>]=%D8ZUYW93W<<9$()7OS6I>WUU%;Q,,YQSS44,0H1U"OAG*9V((H/
M2L'0-2-XK*Y^91S6[VS7H0J*4>9''.#B[!N ')I01TS7/^(-1:UCQ'US4GA^
MYENX/,DSUQ64:_-/E*]BU'F)_$'_ "")J\B\-?\ (Y1_]=:]>\0?\@>:O(?#
M7_(XQ_\ 76JFO>3.S"_PY'N0^[3=Z@[<\TV5BMNQ'4"O*=0\4WD/BO[("=OF
M =:UYCEI474;L>MCI29P?:H;9R]NK-U(K+\3WKV6DM+&?F!HYC+D;E8V-X)X
M(S3N:\P\(^([K4?$"02$[23W]Z[_ %B=K?399$^\!1S&E2BXOE9?+@=Z0R+W
M(KQ^+QQ=6M[.).=K< FJ]SXJU;4YBUNC #G"FH=5&ZP<CVD.K="*4]*\5L?&
M6HZ=>JER#U 8,>E>LZ-JD6JV*W$3 @^E5&HF95L-*FKFA@=:"P'?BHY95@B:
M1S@"O+_$GCJ0W+6]I@@$@D&B51(FC1E5/4]Z]=P_.C<.H->()KNMPK]H(<Q]
M>6J_)X_N7LU3 5@.<&I50W>"FCV$-QFC/S=L5QGA'4Y]2T\O(QY3@YK2G\^W
MM4=79FW<@FK3N<\J3B['1<=<THQVK%LKB6YO58D[=N,5M+TZ51D+1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 )1112B!B^)O^01+_NG^5?.
MP^:_VG_GK_6OHGQ)_P @F7_=;^5?.C8^WL2<8ES^M=^&2Y6<M65CZ1T'/]E6
M^?\ GFO\JTP:\]L?'^F6FG0Q"="RH 1^%:%I\0M'F.);E$)K"5.3;9I"I[IV
M9J"Z5GMI$7[Q7 J*QU&UU"+?;2!UQU%6F.%R:PLU(UO='@'B[1[]-;E,J$@G
M@YKLOAKI5[:D3R@B'!'6NCU;Q#X<MKQH+Z2+SEZAA6KHNJ:=J$ .GLAC_P!D
M5T3D^75&26IK\TG7K165J?B#3]*XNIPAQWK!*YJW8U<^E&17$3?$;2D?$<Z,
M*N6'CO1[MPANE#GM5\C(YT=91SFHH+B.X0/&=RGH:>1SG-9M&B=Q>:3@&FRR
M+$A=S@"N<O?&^CV;F-KI=X[548MHERLS>O2?LK_2OG#Q'QK]X1W>O6+GXBZ;
M)&Z+,AKR'5KA+K5+JX4Y61LBNNA#34Y:T]3VGX=?\B_;X_NUVO:N)^'/_( @
MS_=KM#A%))X%<]7XCHIOW1<9H%<]J7C'2=-<I+<J''8UDI\1],,F&G0+ZU*@
MQ\YVXQVI:QM,\1Z=JW%K.'/M6P,>M2XV&I7#FCM44]Q%:Q-)*^U0,DURUY\0
M-'AE:-+I"P[4XPE+8<I)(ZW@4IKAHOB/I9?$DZ**Z/2O$6GZP +:<.WH*<H2
M1,)7.9^(FG7EU8M) "5"\C->8Z#I%]+K$05""&Y(KWC5]1L;"V:2^91"!SNK
M"T_Q+X9FO%CMGA\US\N!6L)-1V,Y?$=)ID3P:=%&_+JN#FK8]3UJE>:E;6-O
MY\T@6,#.:Q8O'FA2RK&MXI9C@"L;-FM['4$TG ID,R3QB2,Y4]#233I!&7E.
MU1U-*P[DOTI/:N7D\>Z%'(R&]7<IP16[8:C!J$/FP.&4]Q18+E3Q-QH%W_N5
MPOPRYU"[/^S7=>)O^1?N_P#KG7#?#+F^N_\ =J3KI_PF>G_RH.,4R:40PM(>
MBC)K$TWQ-::I?M:0R*749P*#F2N;W6@4#VI3TIB:#@TA]JYY?%=FVJ"Q$BF3
M=MQ6_N[B@;BQQ(I.>@KG[KQ39VVJ-9/(HD!QBH=7\9:=I1\MIU\W^Z:12I29
MTQ_6EKSW_A9%N&RVP+ZUTNC^)[#5\+!,K.>PH13I22N;N?6C-':HY9%AC,CG
M"KR33,=;DF>*0^HKD=4\>:992-''.K..HK+7XD0\$[ I/6D;JA)H]"H) YKF
M;7QKIEU;;TN%+=Q4<GB.+4-(EFM7#%6V\4$JC);G2&[A\P1[_F-3*1V->8R-
M<FZ3]^X5^2V>E=YH\KO:JK\[1PQ[T#E"R-6BD%+3,A*6BB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** $-%*:;0%P)K \1ZU'IUD_S#<P('M6EJ5_%86KR
MNP&!G%>.^(-;?5;Y\,?*SP*YZU2R.W!X=U)792FN7O+AI7))/<T^/VJM'\O
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M<9^E=3HQ^,Y_:/X33\(^'9M=U59)$/DY^9R.,U[M8645C;1PQ* %&"1WK/\
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MJRX_G3Z!2C'VII>#/""7<*W]^OF^8,X<5W+>%]',13[!#T]*GT*)8-*AC48
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MI*!5G,A:***!A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M'I4NCQ-?ZL;O'R$5SMK;-=2JBC/->B:18K9VBKC!KU<+S5=&>9BU&EK'<O;
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M$[K'^]4*YZ"J:N33J2A*Z/)'^'VKJ^V,$*#V8UL67P[80%[@,9L=SFO0(YI
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MC3U>IKCI11BE[51Q"4M%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MI JT^YD:7H%CI<8\J%-X_B YK8'2DQD>E**9DY2D[L6BDI:!"4M%)0 M%%%
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M,/7S%_.E^U0_\]%_.O.!?7#G"O@"C[;/_?I?VE$7]GR/1OM,':1?SI?M</\
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MH **** "BBB@ HHHH 2BEI* N%'2B@]* 1%-<10#,LBH/4FH#JEG_P _,?\
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M]I:+*Y.:1=UB ?;?-4?*YP*DOMMKI*Q_=;-6X(?MVFV[=65LFLS79=UUY?\
M" *F4+0<NY4)7DH]BSHT,:V37+@$@]ZJR:O)YK H  >!5W2=L^EO #AB<UCS
M6<_G,/+/!XIM+V:L-?&[FW;A+:QEN2H+,,BH]+U1IKG;(H )XJ8+YVCO&O+J
MN"*SM'M)OM0W(0%/6KC=)&4K.]R[/=-#KK*HX+8I-=O72X* <8J"\.->(Q_$
M.:37(7:]9@#MQ3G-\C'2BN=&5Y[ 8[&HSU^M(..O2BO)N[GJI*QO>&O^/D?6
MNX%</X:_X^1]:[@5]#@/X9X.._B"TAI:0UW(X@I:2EI@%%%% !1110 4444
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MX:_X^1]:[@5P_AK_ (^1]:[@=J^AP'\,\''?Q!:0TM(:[D<04M)2TP"BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 )1110 =
MZQ/$?_(-?ZUM=N*SM6M7N[-HE')-85XMQLC2D[23//#U-(>2*Z#_ (1F?/W?
MUH_X1BX_N_K7ARPLV]$>W'%PMJSGSR<#H.M&0.1D5T'_  C%Q_=_6C_A&)_[
MOZU*PM5;(;Q5)[LQ%N'491CGZTC3RL=SL?SK<_X1BX_N_K1_PC%Q_=_6M(T:
MZ1+K4+W,#H<]Z08SEJZ#_A&+C^[^M'_",7']W]:SEA*LG=HM8JDMF<_CJ?7I
M1QWKH/\ A&;C^[^M'_",7']W]:/JE6^PY8NDUN<_@ \4<[MU=!_PC%Q_=_6C
M_A&;C^[^M'U.IV$L732M<Y\YSFCKUZUT'_",7']W]:/^$8N/[OZTOJE6UK!]
M:I7O<Y\[N_2CWKH/^$8N/[OZT?\ ",7']W]:/JE6VP_K=*^Y@9/4=#2>]=!_
MPC%Q_=_6C_A&+C^[^M'U2K;8'BZ7<Y\@9R:!STKH/^$8N/[OZT?\(Q<?W?UJ
MOJE2VPOK5/N<_D]*#@BN@_X1BX_N_K1_PC%Q_=_6I>#J=AK%TK;G/T5T'_",
M7']W]:#X9N/[OZT+"54M@^MTK[G/UV'A+_CS;_>K/_X1B<]5_6M[0]/>PMV1
MAR3FNS!8><9\S1R8S$0G"T67-2_X\W^E>=7'-Q(/>O2;J(S6[)ZURDOAN5YF
M8 \GUK7'TI3>AC@JL8+WCG!Z>E+NQU)_"M__ (1FXSPOZT?\(Q/_ '?UKSXX
M6JNAZ#Q5)[LQ%GF3E7./K2R7$LAY8_G6U_PC-Q_=_6C_ (1BX_N_K5^PKD^W
MH'/Y9^_(]:!C/S=:Z#_A&+C^[^M'_",3_P!W]:F6%JRU:*6*I+9G/D$_TH[8
MKH/^$8N/[OZT?\(Q<?W?UI+"5>P/%4GU.?P,<4HQFM__ (1BX_N_K1_PC%Q_
M=_6CZI5[!];I=SGQUSWHXSD]>U=!_P (Q<?W?UH_X1BX_N_K0L)470?UNE;<
MY_C&#U-!R,#M70?\(Q<?W?UH_P"$9N/[OZT+"55T$\52?4Y_/I00",CI70?\
M(Q<?W?UH_P"$8N/[OZTE@ZO8?UNE;<Y\]..E!P1D5T'_  C%Q_=_6C_A&+C^
M[^M4L)4[!];I=SGV[ ]Z!\N<=*Z#_A&+C^[^M'_",7']W]:7U2IV%];I=SGQ
MQ1SWKH/^$8N/[OZTO_",3_W?UH^J5.P?6Z5]SGN.U%=#_P (Q/\ W?UI/^$9
MGS]W]:/JE3L#Q=/N-\-?\?(^M=P.U<WI&C2V<NYAWKH\5[.#A*$;,\C%34YW
M0ZD-%%=FQRA2TE+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%)0 M(>E%(>10"//
M?BK_ ,@*/_KH/Z5XWWKWWQEH$VNZ8MO&,D/GK7!?\*ROQ_RS_6H:N>KA:\81
MLV>?T5Z!_P *RO\ _GG^M'_"LK[^Y^M*QUK%4^YY_1SV_&O0/^%97W]S]:/^
M%97_ /SS/YTN4'B:3=[GGPQ2Y./EKT#_ (5E?_\ /,_G1_PK*_\ ^>?ZT6&L
M53ZL\_HKT#_A65]_SS/YT?\ "LK[_GF?SHL"Q=-=3S_ZT#('%>@?\*ROO^>9
M_.C_ (5E??W#^=%@^MTULS@%P"I;IGFM^UU6SM;<^7O\P@@UT'_"LK[_ )YG
M\Z/^%97W]S]:.5F<L13ENSA?M#B1MK':233/-<MRQ_.N]_X5E??W#^='_"LK
M[^X?SHY6/ZQ2L<(D\L1)5C^=-\U\EBQRWO7>_P#"L[[^X?SH_P"%97W]P_G1
MRL7UBEW."$SJ"-QY]Z!-(JC+''L:[W_A65]_</YT?\*ROO\ GG^M%F4\32[G
M!/*TI_>'(I1/(L?EJQVFN\_X5E?_ //,_G1_PK*^_P">9_.BPGB*3ZG"_:7.
M 3P*0W$A8$MTZ5W?_"LK[_GF?SH_X5E??\\S^=%AO$TNYP+R&1B6/--]*] _
MX5E??\\_UI!\,[X_\L_UI\H?6:=MSL?AG_R+<?\ O&M?QA_R 9:;X1T:71=(
M2VE&"#FKVOV,FH::\$8RQJCR)33J\Q\XW7_'Q+_O&HNU>A2_#6^DF9_+ZG/6
MF_\ "L[[:1L/YU+B>M'%0Y=SS^BO0/\ A6=]M \L_G1_PK*^_P">9_.E9E/%
M4VMSS^BO0/\ A65]_P \S^='_"LK[_GF?SHY6-8NFNIY_17H'_"LK[^X?SH_
MX5E??\\S^='*Q+%4[WN>?^E'"L&KT#_A65]_SS/YT?\ "LK[_GF?SHY6/ZW3
M[G)/JKBQ6",]*S_,9E^8G&<]:[W_ (5E??\ /,_G1_PK*^_YYG\Z=C-8BE>]
MSAC>3&/RRW%(+J7&-U=U_P *ROO^>9_.C_A65]_SS/YTK,?UBE?<X:2\DE9=
MQ^9.F*)+N60*"W*]*[G_ (5E??\ //\ 6C_A65]_SS/YT<K#ZQ2N<)]HF/);
MYOK2&XD/5CGZUWG_  K*^_N'\Z/^%97W_//]:.5@L12O>YPS74AA\L'*^]1Q
M3/"V5/'>N]_X5E??W#^='_"L[[_GF?SHY6/ZS2[G#?;)0CJ#D-US0;R8QA-V
M !VKN?\ A65]_</YT?\ "LK[_GF?SHLQ?6*7<X1[B26,(Q^5>E1#U-=__P *
MROO[GZTO_"LK[^X?SI\K*6*I]SSX<<]J]/\ A=_[,:H_\*ROO^>9_.NO\'>%
M[C0Q^\7'S9ZTU$Y<3B(RC9'<#I12#I1SFK/)8ZDHI: $I:2EH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHI* "BBBILP$I,"G&DJB;M,0*,T[BBBE9="KW#BCBBBG8 XHXH
MHHL <4<4446 .*.***+ '%'%%%%@#BCBBBBP!Q1Q1118 XHXHHHL <4<4446
M .*.***+ '%)^%+12V 3\*.AHHH:$F%&!Z4M)0E<;8N*.*** #BCBBBG8 XH
MXHHHL <4<4446 .*.***+ '%'%%%%@#BCBBBBP!Q1Q1118 XHXHHHL <4<44
M46 .*,"BEI6 3 II ZT^D-&@"8XXHYHI:=Q:A24M%+<H*6DI:9-PHHHH&%%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %)2TE !24M% K"#UI:0BCG-%AI,7BBBEH 2BBBBP!11
M2TK )CVHQ[449IV"X8]J,>U%%%@N&/:C'M1118 Q[48]J*,T &/:C'M110 8
M]J,>U&:* #%&/:BBBP7# HP***+ ! I.*6B@3N)P*.M%'2F/0,4N*3-+VI6!
M.X8]J,>U%%%@#'M1CVHHS18+ACVHQ[444!<,>U&/:C-+FBP"8]J,>U+1F@!,
M>U&/:C(SBEHL F/:C'M2YHH 3'M1CVI:* $Q[48%+10 F*,"CBEHL F!1BC@
M4<9Q0 8I,"EHH"XG /6EHQ10 M%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !24M)2
M8!11130!1110 4M)12V 6BDHHN M%)11< )K/OM1%I,D>S);O5\YSP:P-<_X
M_83Z"F(VXY-\2N> 16?JFI_8I;90,B5\9K(DNKW4)8H+*;REC.) >]9^K6VH
M6NHV7VJX$D1D^51VI@=T6 7).*56!'!S7&:AJ]S+KDUA#-Y:Q@'FG:;JMXNI
MR6TKET$9((Z9Q0!V!<#O45W=+:VS3M]U:Y#3GUC4UFDCNPJJ[  ^QJ W6H7N
M@ZA'/-EHWV@F@#KWO_\ 1A-'&7R,X%4M0UIK2"#,1WS\ >E95F][8Z/YCRY.
MS*XK/U1+^Y?3)FG&9'X]NM ':V,LC6B&0'<>N:M9P>37-2W=]I5Q&+J;?&[;
M1CM4ZW\MQKK6R-F,*&]J0S?)Q131G;S2GI1<+"BEI**5P%I***8!1110 444
M4( I:2B@!:*2BE<!:*2BBX%>]NA:6[RD9VC--L+P7MFDX7 85!K>/[,F)[+7
M.MJ,UGH-@ENQ1ICMS3$=+J%Z+6$/][)QBG6-V;JW\PC;SWKDM8M-6M[6%Y;H
M."XX%(^K7"QK96\GER<$L:8'<A@W0]*0L!SNX'6N+@U#4+34(R]QYL&WYD7N
M:E>XU/4+U4MY_+C8\J: .N:15C+CD"J@U%9$E*+N9!G:.]<[#)J5N+FWN;C>
M6XC/I46F1WEL+Z9YPS*F1[4 ;LNKM#IJ7$L15WX"'K4^E74MU;B612F3T-<G
MJ#7VH:%8S&8;VEZG\*T[E]0TS386:;>2X!QZ<4 =5G%(#DUSU_J4SSQ6MM)M
ME9 Q-;T&XPIOY8#DT@):*2BE<8M%)11<!:0T4M,!**6B@!**** "EIN*=0 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 )12TE !1110%PHI:2@!&SC%9&J:K/8E?+M7E
M&.2*V/:H+O\ X]FH$<Y8^)[B]N3$+&0!3@FNG1BR XQGM7+Z9(T0U%TX8=#^
M5:&E7L]Q;R&1\L%S3L!M$^])O!.,\UQUYJUZEPZ+-VXJ RZS_9HNOM8WEL9]
MJ+ =QN4.!NY]*7BN,;^V&T_[5]K&\$#-6[K69VM4MH25N77_ %G;-%@N=.'4
MG -&>OM7*SQZM96R7KW8:-!N<#O4.K:K?2V^FM92F/[0V&I!<[ $-WH_&J6G
MVUU;Q_Z3*)&QU%96J7=Y=7YL;&3RI5Y+'N*+!<Z)7![Y]Z"P')Z5Q.M2ZOI,
M*R?:ODR,@"G7>MW4]U:P13[%>,%L^M.P7.T4@\@YHW 'DUQ^GZG>P:E';32&
M59#U7H*CA?5]3U2^BANMBPM\H(HL%SM<@\BDW+G'>N6M-2NX1=V]Q+OE@3.[
MWK,@U+4[FU%TMV!ST[T6%<[2]O%LX1(_0G%1R7SB5$2(LK+G<*Y#4I[[4=!2
M8R;?WH&#]:TTNKRSGMX'EW Q@\?046"YTX<!06.,BESGH:Y:.>_UBYW6TWEQ
M1':ZGO6SIEK?6YD^U3B12?E [4BKFE11@44 +VIK<#-+0: &DX7)KF1XFGFN
MIHHK&1A$V"1WKI6'RG)KB=(UDV5]J"FVDD_><;10&B.BTG6O[0EEB>(Q-'Z]
MZU&(.,-BN2M1,/MU]L9-PW*".11$FL76FF]2["@KD ]J=A7.KFF6*/<3TJB^
MJ'['YT,)D.[;M%<Q:3ZGJ&F>6]QF5<DL::ES?:9X=\U9OWGG8)'UHL%SMXG+
M1!G&"1G!J0$'H:XO4-;NOMMM:Q3;#)&&)_*EL]3OX-7M[>6;S4D/.*+!<[+<
M!G)Q3)9ECA:4\A1FN0@DU?5=3O(H;KRXXGP :;'<:A(-0LI)\^2G6@+G66=X
MEW;K,O0U8#JQP#FN&TL:G:Z'',DVX-D;0*M:+<W\MUF:Z"K_ ,\SUI!<ZFZF
M-O"TBH7('05B^'/$,NL-<"6T>#RI-HW=ZUM1D:.P=U.&"]?PKS31-<O1HNL7
M'FGS(IR%/IUIV"YZJS $#N>E!8 @9Y->-MK?B>>TFODOBL4 R01UIHU[Q--8
MI?"^/EJ-Q&.M.PN8]HSBF[@>,\UY/J?B[5G\.Z;<6UR4FGDVL?7I5&^U_P 2
MZ7*DDUZ764A  .A/_P"NBP<Q[-N!/!I2PZ5Y)#KGB#2M5C6_O#+"ZAL >M:L
M?B34'\:6-EYQ^S2Q[F7\J+!S'HV0*,CDYKSFZ\1:BOBNVM%N"(6;!6L@ZYXC
MU#5]2MK2\*)"^!Q]*.4.9'KH(89ZTC,H/) ->9^&?%&I(^H6VH3M*]M'D'WK
M$?Q-KNI3O<6U]LB7D(>O%%@YD>T4M<KX)UJXU;2@]UN,H8@EJZND.]PI*6BD
M,2EHI* %HI*6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "DI:* $HI:* $I:** "DI:2@ HHJ
M*:=(<;V R>YH EXHJ/[1%C.]1GWIGVJ+SO)WC?C.,T 3GK63JEA+=3QR1D?*
M*U><^U& 31=@<Q=:;>V3Q3V3*H/,H/>JEQ9:KJE[;RR.ODH^X CFNMFEBCQY
MA ],T^,HRADQ@^E.XCD-5\/2?VK)?KSO&.*L:1I=T+EY7QY10J >N<5U! /8
M'ZTUW2%,MA11<+&/H6G36-K.DI'S.Q&/<FJ4>BW:V-[&Q7,KY7%=)#-'.A:,
M@C/:GCVHN!BW&G3OI:0*1N"8JO/I%Q(FG#(_<-EJZ2FGKP*+A8Q_$=HES8DY
M = 2F3WJGX1M)OL0NKOFX)()]JV-0LEO5C5B0%;/!J>+R;=1$K*,=LT7 FI:
M3K2<@9- QU(3BBESZT@#BEIM.H 2BEHH8"444=J2 *,BH#=0[_++@-Z9IWG1
M E=ZY7KS3L!+Q1D5#'<1R\(X)]C4WO0 9%%-S4;742R+&7&YN@S0!#J5NUS9
M21IC++@5@W>A7,FDVB(5\RW.XUU&!2]J=P.-O(M7U.&.%64,K G([4MYX<N&
MB$RE?.&,FNP"@=@#]*..E',*QQ^FZ5=/J"/P(%&&!ZDUKV>G307N]L;<\5M!
M0.@ ^@HQFCF'8P[O39Y;L2*1MSFD33)EBNQD9E7"UN]!4/VJ'>4WKN'49HNQ
M6.>71KH:-9V^Y?,C?+?I6U=VJR:<RR8RJ$CZ@5:5HV8X92?0&F7,1FB*#OUH
MNPL<AX0MI[VXDU"ZY>.1D7Z _P#UJ[:J>G6,5A T<8X9LFK?UI#%HS2<&D((
M(V_C0 ZBDI: "EII('4@"E% "TE+118!**6B@!*6BB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MV8\3WRZS,%_=_*'YYYJO9R2&_F%I(7LMC8(Z9I<J"YZ6_C_P^F<W9X..G?\
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M@O3+JZ\S[-&N>3Q6E)H=H=,:P$:B-NH]:U>U07$\5K TTSJJKU8]J5V%C/\
M[ M#ISV9C7RW&"*4:%9"P%F8$:,+M'M5^WNH;J/=#(KCU!J?H*=V%CEK7P/I
MEM=>;Y$; '*C'2M.XT"SGG$IB7(((K2EF2%#([!5 R2:J-JML]F;F&19$ )R
MIHU"Q7NM!M;NY69T4L !TJMJ?A/3]397DA3>HP&(JYI&KQZO;F6-"H#$5I$<
M]>/2B["QSMGX/TVSNHYXX(PR=P*9<^"M-N)Y)7@C+.<YQ73<#I2XHNPL<_IO
MA/3].+LD*98=0*LVN@6EM>37"1KNE7:Q]16OCFC%%V%CF+OP7IUQ<^:L,:<Y
MZ5NZ?80Z=;B&! J^U63]*7O1<!:***0Q",BJ&I:7!J<:+.@;8<C-7SG/6C/-
M %6VLH[>T^SJH"8QBL&X\$Z;-<^<L,:\YQBNHZ>]%%Q6,B3P_92:>;,Q)L/;
M%4K+PA865RMQY2,Z'Y3CI71D=^]+3N%CR2U\._;_ !/?BXMOD,ORL1TZ5WFE
M^%K#2V+) A9NI K72VACD9U3#,<DU/FB["QSVJ>$=.U*<S-!&)">6QUJ>U\,
MZ?:VODQP(/<"MOBD[4786,FUT&UM;*2T1%$;L6(%5QX4TT6LL MX\2')XK>H
MZ&E=A8YZP\(V%E.)?*0LIRIQTI-0\(Z?>S&4PH'8Y9L=:Z,T@/6G<+%#3-)@
MTJV6*%%! ZCO5F>W6ZC <#@YYJ;-!YZ4AV*EQ80W-MY$BAE]ZI1Z$BR#S'#J
M.@/:MCH.*6@!J(J(%48"C %*1G!I?;%)R#0 ZBBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MQR:XF_6#?LE247(.%V XQ77:6)Q:)YV.@V_2@"]BC%+12&%%%% "8I<8HHH
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M%'M2&'3FE H P.:6D 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M6O\ ='Y444 &P$Y(!I#&KC#QJWU%%%  L2(,+&J@]<#%)]GB#9$29]=HHHH
M>44]5!_"EQCI110 M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
E10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>gegguy50oztz000002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gegguy50oztz000002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" -N!J # 2(  A$! Q$!_\0
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M-,I<T .S2Y-,S3A0 ZBBBD,**** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M4 %%%% !1110 4444 %%%% !24M% $<O05%FI)N@J&F@'9HS3**8AU%)FC-
M"T9I,T4@%S1FDI,T /S1FF9HS0 _-&:9FC-,0_-&:9FC-%AC\T9IE%(!V:,T
ME%,!<T9I,TF: 'YI,TVC- #J*3-&:0#LTF:3-)F@!^:,TW-)FF _-&:910 _
M-&:910 _-)3:,T#'44W-&:0AV:,TF:,T +FC-)10 N:,TE&:8"YXJ:+I5?-3
MP]*0$M%%%(84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M<T\BC(K,_M9?\BC^UE_R*+!<T\BC(K,_M9?\BC^UE_R*+!<T\BC(K,_M9?\
M(H_M9?\ (HL%S3R*,BLS^UE_R*/[67_(HL%S3R*,BLS^UE_R*/[67_(HL%S3
MR*,BLS^UE_R*/[67_(HL%S3R*,BLS^UE]?TH_M9?7]*5@N:>11Q69_:R_P"1
M1_:J^M 7-05=M#D5SW]K+CK6SI5R)TR/2DQIF/X@_P"/@GWK(1VBD#J>E;&O
M@?:&^M88)W8/2FD2SJ=+U83@1N>:VE.?QKSY':)PR&NITG55G01R'YAP*&AI
MFSTYI1DT@.1GM2BH*%HHHH **** "D-+24 4M6_Y!5U_US->8S?\BU8_]?(_
MF*].U;_D%77_ %S->8S?\BU8_P#7R/YBMZ2,IWN>GZ=_QY1_[H_E5KZU5TX9
MLH_]T?RJWFLI_$7%:%#66D72IC%]_'%<*L-E);7$CB476,Y)(&:[?4M9L].*
MQW)Y8<#&:PB^D:NSQQ,ZNW&,8HBC.H^Q9\,ZO%)9K:NV'C'))ZU;UG6X[* *
MC NQVC!S7*6%A;KJ=W:SNZ)#]T@XS1%I4U[JLD,)9[<<@L>:;(YI6+;W.HV]
MJEYYT98O@@'M75V.I0W5LK[U!  .3CFL*?PJJ6QV/(2!G!8UE:79QO%(+V62
M.16( 5B*D+R3L>@(X?HP/T-/KF/"4\LL=PKDE4DPI/I73T&T&VBCJO\ R#+C
M_<KBT_X\;7_>KM=6_P"09<?[E<4G_'C:_P"]6;.>ON=MIW_'HM7*IZ=_QYK5
MRJ1TP7NBT4E+3*"BBB@ HHHH 2@TM(2!UH !2UAS:XL,S)GH<=*C_P"$A7U_
M2G85SH**Y_\ X2%?7]*/^$A7U_2BP7.@HK _X2%?4?E1_P )"OJ/RHL%S?HK
M _X2%?4?E1_PD*^H_*BP7-^BL#_A(5]1^5'_  D*^H_*BP7-^BL#_A(5]1^5
M'_"0KZC\J+!<WZ*P/^$A7U'Y4?\ "0KZC\J+!<WZ*P/^$A7U'Y4?\)"OJ/RH
ML%S?HK _X2%?4?E1_P )"OJ/RHL%S?HK _X2%?4?E1_PD*^H_*BP7-^BL#_A
M(5]1^5'_  D*^H_*BP7-^BL#_A(5]1^5'_"0KZC\J+!<WZ*P/^$A7U'Y4?\
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M 4444P"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M%PL8?_"/I_>'Y4?\(^G]X?E6Y11<+&%_PCR?WQ^5'_"/)_?'Y5NT47"QA_\
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M2N',^QM7UIIFHL#<21L5X'SBHK72]*LWWQ.F?=Q6:/",>/\ 62Y_WS3AX3C
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 F.*,4M% $4\2R1,I]*XB\@-O<LI'4DUW9YXKF?$4&)1(
M!P!30F8/>G1L4D#>AIN>E!JR#N--D\VRC8GG%7*Q- F+Q;#_  BMRH9:$I:2
MEI#"BD[TM !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %,?IC%/
MIK' S0!#A=PSP:AEW,D@#X)'%3.N"&/Y4P0DMO+<=A3$5[&*9,[V)^M6I$)Q
M@\YIV=H)/-0BX^;IUIB&SF#<!(RAO0U(1&L.8P,^U9VI6+W#B9#BIX-Z($;K
MB@8[:"<9P34F3'C/--VA6#,<U-M5P*& A<.*< N.M1R(%(V\4;&)X:D CMAL
M4L3*IW$_C2-&2<DU'M)7CD4 6'D5T(4X-)&V1R.E0QH=X&*>#B3:>E,"4#.>
M<>E,:(9!VY-2$9(QT%.S0(8<J/N_C36.3@U+DM5=N7Q0 D6?-Q_#ZU+/N2%B
MH+'M3%!0<U8+!4R>E(9%$6,:DKM..:E(#KM(ZU$+E"VVI"#C.>O2@"E-=I:N
ML P#FK7!8-ZBJMS9*[>:PRW7-36_*C- %I :DI@ZXIV>:0Q:*** "BBB@ HH
MHH 2BEI* ,7Q"<6ZURH]:ZCQ'_J$^M<MVJT1(7J<UJZ6N5WCL:RNU:^E?ZH_
M6F"-*BBBD4%%%%( HHHI@)R3CH#5:74[.%O+DG13[U%K5V]EIDDZY++T JEI
MVCV]W"+F[02-(-PSVJTB6)>:V)'$%@//SPS+_#4,MAJ"0&=;F1FQG92:!;P6
MVK7Z1QA!NP/TKI/N\&CJ#V.7T:-+RX8WL8:XQS&W45LW&EVLD#$0*& XK,::
M&W\23.75'*X))^M7[_6;2TLWD\Y'.T\ U5FV+11.&OO&L_AZ=K62 S')()/0
M5T'ASQK;ZT1%*JQ2$X )ZUY)K^I'4-1>7!."0*DT 74.I17$4;D*>H%=KH1<
M+LY%5DI:'T'QCCI15#3;V*>SA!D7S"O(SR#5_./EQ7G223L=JU044#K@\4C9
MVMMZXI)7!NPN#1@UPNO7VKV.Z=)G$8.,4W0=1UB_N$D:9S$.HK54VT1SG>8-
M&#7%:1KEW/K4MO)*659,8I^KZW=6^N6L$<A5'DP1ZTE2;&YH[+%&*X[Q3K\V
MG20>5(5!?##VK=TW5([S2C=;Q]TG\A1[-\MPYUS6-3%)WKA=+\43WOB4P;SY
M(!XK2\1^)#9,MK;J6F=<@K3]D[BYU8ZG%)@UYP;_ ,0VZ?:7DE:/KMQ71:=X
MA.H:1<. 4FA3G/7-/V+>HO:(Z?%)7FT.LZQ=RS>5.^V,9(%;WA;Q#+J-R]G<
M!O,1<DFDZ32N-31U=%!X&:*R-+W"BBB@ HHHH ****0!1113 !6A9?=K/%:%
MET/TI,"Y1114C"BBB@ HHHH **** "BBDS0 M(:0D]/6C/:@!*4]*.E+1H%P
M%%)03@9ZT7$+7&MX9NX]0N9[>\>/SFR<5V0Z9I*:8I1YCDET+5!UU*4X_P ^
ME.&BZGG/]H2UU=%#)Y#DSHNI_P#00D_S^%-;P[>7$JB>\=E]ZZZCBD"B1P1^
M3#''UVC&:DQ2]12=*"]A<4'Z4@SUI<T##M0*2C/.* %%+2"EH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "L?7D!L'8]16Q69K@SI<E-"9QM'>BDJR#HO#C?O9![5T=<QX:_P!?
M+]*Z>H92"EI*6D4)WI:3O2T %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 5&YVL#4AJK<3K"P+=* %W[FR>@I>2>O':HSA@'7[O>G*."3T[4Q"G
MY@5J 0$D8J9)$#$Y%2!QC*D4 *JD#YCQ5>7!F&*@O[B:(X7I["G1,6 8]:8$
MA0-P:1&PV/2G<9I650NZ@"1E# 4FW#$5$CY.*DS^\- "2#"YS381A<&DDW.V
MT&I^(UR: !-IY[BJ;G]X3Z&K*C<"14$R%6 ]: )X_P#5Y]:<OI3(Q\F/2ESM
MI +NV9J!23)FEE?+XJ10!VH0"2/\E.DRUOQZ4V<8'%31Y* 4P,A8)1<(?>M;
M.T8:E*\_2FO&6()I (YX]<T@VQ\BAB$/S XJ)F /.<4P+*/EJE[U5BG4OBK6
M<U(Q:*** "BBB@ HHHH *2EHH PO$?\ J$^M<MVKJ?$?^H3ZURW:K1$A>U:^
ME?ZH_6LCM6OI7^J/UI@C2HHHI%!1112 ***,X%- 8GB>39HLVTYD[*.M5;+Q
M!Y=C%FUF^1>?EZU)<_Z5K\"-]W'(-;PCB10I5,#V%:(EG)7-X6G6YLLQ,QRZ
MMU-6+G7KA88E\N02.<!B.!53Q ]I8ZO9RQNN"^7&X>]:U_J5A=6@V%2[C"8(
MX-:J/6QFY)Z$=MH]O,QN=1=)9F'+ UF:MING74AL+2$^<1G>#D5=TW1[M[;%
MRW!Z8-,^RSZ)<BXX,!./4U/.KE<CL<=-\-K^+,WFQE,YVCK79>'-(TT6918-
MLB<-GN:Z5)5E12A'S+GFN<D:>WU';:8PQRWUJW4D]$2J:3)[_3$LF6[LQY8C
MY?/>M>QN#=V<<V>6&:P;_6A,!ISJPEE^4G'%;FG6_P!EL(8#U48K&29HF6\%
MAR>E W8SF@C)YI1PN*S3U*M<YWQC@:"Y_P!H5'X-_P"09(<=ZT]:TYM1TUK<
M=2<TFAZ;)IEJ8N.3FMXRT,G XG29(X?%-QO^0F;J:=KDBS>)[+RV#8FYQ^-;
M6M>$S<W(N+3Y92<DD]Z;I'A%K6Z%Q>?-)G(P<U:J)$NFV8'BY/M>J_9L9)?%
M5&O;K1@NDH&YXX''/%=I=>''GUMKSC:6R.:T)_#]C=70N94)D&/TJO:*UA>S
M=[GG5M9/HVO)NZNN[CWK1OOW7BZRDG'R&/.3T[5TVK^'6OKY+B(#Y0!^52ZO
MX>BU.T0./WZJ%!%)54Q^S:+5W>V8TICYB8V]-PKB-!$CIK4BY$9Y'OTJX/!N
MHLWER2#R?3=VKIK70HK+2Y+:(?-(N#FE&HDF@Y6>;6=[?6<EQ]G?"N,'BNO\
M%Z=R=2E=7DE7'%6K'PHL27 E /F+@59T#1[G2I60D?9P/E&>:)23@T.,6;X^
M[SRU+1SNXHKEM8V04444 %%%% !1110 4444  K0LNA^E9XK0LNA^E)@7***
M*D84444 %%%% !1110 ASCBDQ@4ZD'O0!6O[DVMF\JJ6*C( ZUQ[^/!',(C:
MS[B<?=-=PP!Z@$5Q%XD?_"0Q HO^L]*:!EW4/&$>GV-M-+;REIFVA0.13K+Q
M?%-=^3+;RQYZ,XP*ROB!(T!T]HE'RS9QBJ]O//K^I+;L%18L/TP>/_U4[(FY
MV.MZW#HU@+J16=20,+UYJ32M5BU.T-Q$"%'4&N+\2ZO -6&FW*220B,'Y!GG
M%.\':M!&[Z>BNHD8L XQ1RCYC3;QK&;F6*.UG<1MM)4$UI:3XE@U3S5$,D31
M]0_&:S?"'E^?J7F>7_KCC.*AU?9'K5M]DQAG_>;:+!S&F?$\;74\$<,A:'K@
M5EQ^/8Y=0>S%I<>8O7Y34OAM0?$FI;@#]:@TU%_X6)J.47;L&!CZT"N;%MXF
MBEO?LC1.LF,Y-)JGB:*RN!:PQ222,,[DY%9&HX7Q9-M&#Y/&*E\*K&TKM=X^
MT;SMW>F:!ENU\5#[7';W,,B;_P"-A@"K6I^)[73=0L[5U8_:ONN#P*I>-D@&
M@7#KM\X#Y=O6N<UZR:_30HAD2-'@9_&BP7.XU#7(K*>TCP6%PV 5Z5-JVJPZ
M7:F:7D < =ZX"XOG75--TY_O6\FW)_&KGC;4HI9X+4K(QCDRX09XIV%<ZW1-
M;AUC2_MJ*R=?E;KQ2Z?K,=_.8U!&"1S7'^'-7@;6+BU@1X[<0$@.,<X-:?AM
MT&HME@#D]ZEH%=G9BEI%(/0YI:104444 %%%% !1110 4444 %%%% !1110
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M;@K2&7 P>M2.I5"TG&*J6FH02W31 @X%,=K%N",YWO4[ LN.U5Y+Z&*?RV8
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M& E'\5 '1+PN,YI:B615 5F&ZGY &:0QU%,#!SP>E/I#"BBB@ HHHH ****
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MY'2O.9FAT[4M.&DAQ',W[P'G'6O1(B3&"W6DQCZ***0PHHHH **** "BBB@
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M4,@$TN#7@=C.\%Y&Z'!W#/YU[7HMZUU%&HY7:.:Z*4CV,#6YERFG<VR2H2H
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M(94@L(;>'RD48(P3BB/3H$7:H^7TJV:3H.*!6(#9P^1Y14%,],5#_9EN;5H
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MK1;&?4W?#7^OE^E=17+^&O\ 7R_2NHJ&4A*6DI:10G>EI.]+0 4444 %%%%
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M[49!^M#$YXI2.@')-69L!GH/O=JZK0UG$1\W.,<9JCI.DF1A+(.G0&ND1!&
MJBI921C>)"/(C^M<O73^)!^XC^M<P::"0=JU]*_U1^M9':M?2O\ 5'ZTP1I4
M444B@HHHI %%%%, HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHI %%%%, %:%ET/TK/%:%E
MT/TI,"Y1114C"BBB@ HHHH **** #%%%% "8%&*6B@!,4O:BB@!,4$<8I:*
M$Q1C-+10 F*6BB@ HHHH 3%+BBB@!,4N*** "DQ2T4 )BEHHH 2EHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M=U>!I R9 '6KMLWGQAG&<#BG818@?S(PQ&#4W6FH %&*=2*&OG%5UM8TE\S
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M>M&: "BC(HYI@%%%% !1110 4444  K0LNA^E9XK0LNA^E)@7****D84444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M4M(H3O2TG>EH **** "BBB@ HHHH **** "BBB@ HHHH **** $H/2BD?@4
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M?2F!J(3M /6GU6M)Q.FX<U9J1A1110 4444 %)2TE(##\1_ZA/K7+UU'B/\
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M1A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M>*T++H?I28%RBBBI&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ K-US_ )!<E:59NN?\@N2A <8:!0:!6O0SZF[X
M:_U\OTKJ*Y?PU_KY?I745FRD)2TE+2*$[TM)WI: "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@!#67<Y,QQQQ6F>F:JRA7_AYH0,R"DBMM9R1G.:V+7&P
M#/-9TEO*[X' J6!)HIE!/%42:W:CM0/NB@]*DH#C;4'F+\RGJ!3+R1HH-Z<8
MKEGU.>2YW)N SS5)"-IK$W$GF*^PYZ5I11L(]C-NJA9W!EPP!(K2&<9SBA@1
M^0I/I3GC#)MQBAI ' VYS2+)OW C&.F:0Q/)'EE?;K4"V> #G!'>K8Y48--<
M$]&H$1,@9\8_&IQPF,U7RP?%2J&W9)H > 2OH:JW=V+9>5R:M$[5)+8K-N85
MNY5Q,I ZC-- 6[:X,\8;;MR*L<8]:S1+Y.(E. O!JVDN],#MWH <6(/]*<I!
M&<4Q06;.>?2I0 HQBD A;:<]JIW%_%;*QD89[ U=*Y^E9.IZ:MTP8@<4T!-!
M=PN0T:@E^N.U:2'Y:Y/3)/(N9D(.$/%=-;3>:NX=Z&@+-%)1VJ1D4S#TS6-=
M9+$H, 5-?7;1S;4/X55D:8D'8VT]>*LEA%*(I4)DZ]16_$X>,$'-<W:2VUS<
M&)H\.#CFNCAC6) JC&*3&B3M2TAXH[U(Q:*** "DI:2@##\1_P"H3ZURW:NI
M\1_ZA/K7+=JM$2%[5KZ5_JC]:R.U:^E?ZH_6F"-*BBBD4%%%% [A1110(*!1
M10 4=\FBB@!<_-FD[8HHI6%8/XLT');.>/2BBF,**** "BBB@ HHHI %%%%
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M0 4444 %%%%( HHHI@ K0LNA^E9XK0LNA^E)@7****D84444 %%%% !1110
M4444 %%%% !1110 444A.* %I*,TF: N+13=V!R0*-ZXSN'YT["NA]%-#*>A
M!_&@,"*0QU)0,]Z* "BDR0>:6@!:*2EH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BD)..*,G% "T4T-VI:+ +129S1GG%(!:*
M3.!S1GC-, -%&>*!TYH ***3ZT +1129]: '44W.#@]Z7- "T4T$Y]J7/'%
M"T4F:,T %%&:* "BBCJ.* %HI.E+0 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !129H^M(!:S=<_Y!
M<E:.:H:O&TNG2*O4U2$SBC15HZ?<9^[0=/G[+5$FGX:_U\OTKJ*YW0+:2"60
MN,9%=#FI92%HI"<4<TABT4@.:6@ HHHH **** "BBB@ HHHH **** "BBB@
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M2TE+0,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHI* %HHHH
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M1)C1#%;^7M)Y-22-E<%:F89-1,/FYYJ!E1U+<**:L#?W*O)MW'Y<4\$$X!H
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MIZ,P<7EG^[<<L!U)I!:[N;\L\40R[A11',DRAXV#*>XKF$T74[J,237AVM_
M1TI=(NY+'4Y;&<G8HPI/0T#YM=3JLT=\YI,\9'2@^F*1KT'T4@I: "BBB@ H
MHHH **** "D%*>E-S0 N><4M(!SFBD M%%%, HHHH ***0\4 &3NQBC.>E'O
MGBD&,\&@ SDU0URR-_HUS:J<&1< U?XP<4@]S0A'/:+HCV.A?8F<Y*;<FN4/
M@_4H-2DE@NI45O05Z//<K$R*?XC@5+ST-5>P6N<DWA_4+C05MS?RK,K;M_<_
MI6$GA#4-2O%%[<2;%/5AZ5Z7[4=:.8.4Y?Q)X>;4]#%BDA&$"Y K;TFT^PZ7
M;VY.XQH%)J[VJE<WZ6US% R\R=*5PL<YXE\-2ZYJ-F[2'R8GRR8X(YI=4\#6
M$L,9M8$BDC.05%=<IXS5+4-22P:+>,^8VT478<IPNH^#KZ]MXS]HD616SG'I
M6A8>&[ZXC\F_N9)8P. _2NW4[CD'@BE)I\P<IYI+X6U:Q9X(;J:2)SG Z"MG
M0/!B65M-]J?SVE.[##I722:I''JD=B1\[KD&KU','*><7'A/4].NY9+&[E$<
MQSL7HM:.A^$)HII;N]N6FDD'"N/NFNSDGBB($CA<],T]64C<#D'O2Y@Y3@T\
M$J^OWUW,VY9H]J@CH>:N:+X?N=-M);$RL\;!L$^]=@>3TXI-W..WK1S,.4YC
MPAH$FB:?<P2.6,DK,"1ZD_XU#H/AJ33M4FN&D+!Y"V"*ZX8QUI<BCF#E./N_
M#3S^(;>^WG;&^2*37O#+ZEK%A=(Q402;N!]:[ @T#&*.8.5'''PJ9?$UY?2R
M$QS# 4CBK-MX.M+749KI0IWQE=N.G6NGP#VI1TSTHYF%CD]#\-OI>JF82$H<
M_+BNM)P.>*3(J@VIQ_;TLROS..*+W"QH=J*3MBDSCWI#'T444 %%%)0 =:6D
M[4"@!:*** "DI:2@!:*2B@!:*2B@ HHHH **** "BBB@ I:** "BBB@ HHHH
M *2EHH J7EFEU$00-WK7(7UD]K(00<>M=R:JWEG'=1%2!N]::8K'"YHZ=.:M
MWMD]K(1M.VJG"\]<U=R ZU?TW3WNY!D$(.<^M+IVG/=2@D84?K76V]LEM&%1
M<8H;';42VMTMT"J *L4G>EK/J6P%+24M !1110 4444 %%%% "4M%% !1124
M +1110 4444 )@ YQUI:** "BBB@ I#2T4 1< G(YK-GOV^U&V1&&.IQQ6D[
M 'FHBL?FEL4T)A'"$3*C#&D8$?[U2[QC/:JUW>1V_+*Q^@IB+2;MN2:1R0#C
MJ>E4+6YFEE'S#8>U6I)BN0:5AD-];M<6NUF'3G-85KHRQW <E6 /05T+%9X2
MO<"JL%K]G&]LDGBF@+GF*B@ 5/&<C-58U):K<8PM)L$-DSC-1%CCBK#]*@9"
M?F7@CUI(& 8XY/)H0?,3TIH4*=SFE,HE#A#R!5 /,B#.6'YU4W1R2XK-F\U9
M"3FI;-&:7(- %]K=57Y<<U(J;4P.]0%WSR>15E,M'UH 0L5 YI\9+'.:BRA;
MYC]VIX]A^8=Z0$M+2=:.](8M%%% !2=12T4 (.E+110 4444 %)2TE &'XC_
M -0GUKENU=3XC_U"?6N6[5:(D+VK7TK_ %1^M9':M?2O]4?K3!&E1112*"BB
MBD 4444P"B@^@IKMY:;AT'6@"*>3&$'\7%*H$,6YCPHS3(E\UBYZ=JK:S-Y-
MH$SR_ JHB9SVKW,%QJ F4=&'?WKJ+&[BN8EV'MC&:\]FB>*4Q'KFN@\-EX;P
M1L3TS5M:$)G1$&*<$<+WJU]X@TV9!)$?6F6[[E(/5>!6;+)CUHI1SUI.AJ;C
M"E &>>E-[TO.,#[M4M094FU".&<1'@FG3WT5O'YCCY<9KG=?G6#6D)!VA>U0
M:KJT-W:B*-7!VXY%4HDMG6)<Q20^;]U<9YJ@^O6\<FS:3SU%9-]/*MC:P(<"
M1.:T+/1;9K-"P)9AR<T["N:EO=0W*;E(/MFJUWJT%F^W&3Z UAP[[#59H(3\
MG0 U#<*L6I/)<J[*1V%*P7.E@U."X3<.OI5=]>MT)!4\&J>E1V4T^^+<&QC!
M-5=>L889/W8(SR:$AW-VVU.*Y.%4\U>P.HK.TZQACMXG4'<5S6B".14L:"BB
MBD4%%%%(04444P"BBB@ HHHI %%%%, %:%E]W\*SQ6A9=#28&#XA($Q)]:J:
M=J3VK@$G;Z5;\0<SGZUB$&G;0FYWMO<)<('4CITJQ7%:=J+6S@$G%=;;7*W$
M893]:EH:98HI.AHI%"T444 %%%% !333J0T 5KR;[/9R2CC:I-<EH5M_:NJ/
MJDHRCC !]16[XBN!!IK[OXE(KD-#U:ZEL5L=,!692268<5K%:&%3<]#*@ILX
MQC%85UX4L)9#+%$%D/>LP1>+HAO>:$@<G'I6GI'B%;B86ER"+CIDC J2DK[C
M(O#FF6TRRW 02#H2:HW$<>J:O;JA!CMVQ6[JFE+J+*Q)X'8UR_V&\\/WWGD@
MP%LG'/%-$ROS':7"+'92*HP M<+>B3$<B*6"MD@"NS2Z2]TMITZ.N>:RM$17
MN'4@'BD.6K)=-\002HJ/&T6.,OQ6G>/+)9%[20;^N15>^T.UO(2KJ1W&WCFL
MC3[BXTG4!I]P<QMR#[4BMC1TG5EO6:*52LJG;\W>MK&!S7*:O$=/OH]2BXA0
M9;%=+:SBXM(I1_&N:00V*.KZLNFQJI5B\G"XK)T_3+J^N_MMTX,;<JI'(JYX
MBMM_DSXXB.ZKFFW\,]FCEU7/8D"@S;UU-(#"@#M3J8LJ.H92#]#3J1T+844M
M(*6@ HHHH **** "BBB@ / JG#>))<21$X*^M6STKC+RX:WU61U)^]0!V8I:
MS--U);J, GYL5I#I0 M%%% !124M !2=Z6D- #)3LB9O0$UQ=QJ6IW4,MW:7
M2Q11.4*MU_SQ7:L-R,IZ$8KF+GPW*6:&V(%JYW."><T",JZU_45MPL<I+D<D
M"I+_ %V^CLK?RYLNR_-CM6K-X=<6NR#'F <9J'_A&'6V;9CSF'.3QFF!5EU*
M9H=-:23<Y;Y@*DOK[4[C4+E+6Z6)(EW;35VW\-*JV[R\RH<M@\5A^(&^RZI<
MFVCD\R4;6.#C%/06HX:YJ<FBQR)<?OS)M+U?L]0U*UU%;6[G\PM'O&/I47A[
M0S+HL:2#&)-W-;\FCH]^ET1\RIM%/0-3 T+6=0N]6>*XFP@<@*>XK0ULC^W+
M#--L_#\Z:L+R<K\I.W:>U:UWIR7-Y!.PYCZ4M U.:NM1U2>6\%I=+$MMR0:R
MM2OKN\TS3GEF#2M)][WKHKWP[.T\IM2!'<']]D]11+X4C^P06Z?\L3E>::L&
MI4_M'4=&0S7=RLT17 1.H-8LOC#4I7$\+.(MVW;BNG@\.R2.1>D-'C P:KOX
M4:.<) %%OG.#US1H&IFW%^9O%%C.%*OY/.?7BK>C:W?W6KM#/-A ^ I[BMF3
MP_#)?PW)7YHTVU3M?#<@U=;V?'[MODP>U+0-1OBZ&ZEDM?L\@0CU_&J-O?:E
M<0BT@N1'+"/F9NAKJ[ZP6\:,M_#TK)O/#[CY[,A7;[^31H&I-H>I32R-97+^
M9-&,LXZ&J.J7U_+JTEE9W BVINYK6TG2A9)O?_7D88U4U/0Y)[QKNU($S#:2
M3VI:#U(O#5_=7*.ES*)&#$9%4_$NLWUGJD,-O(4C9?F..*V-&T8:;&0.I.3S
MWJOKFA2ZE(H3;Y9'S9ZT]!:E&;5-0NOLT=M<"-F'S$]ZIVVLZF)KVWDN TD0
MX(]:UI_#KK';^00)(QC)-+8^&A"\TLW,DOWL&GH&IAG4=>ABAE>[!$S;5XZ5
MH0ZKJ-O<26=U/OE5-VX=*V)=$CE@MXR.(FW"JNIZ2//>\C'SLNTT:!J8;:IJ
M]O9&]>\5HO,V[1UZTS4-5^QZK:WK MB/) _"K&G^'KF[A,,Q'V3?N([YK;N/
M#5K<31%U)5%V]:- U.7MO%&I2:@&=V: G[N.U>@6LOG6R2 $;AGFN9MO#4T&
MH*YV>0#T[XKJD41H%'0=*EC'4M)2TAA24M)WH JSW:P2JK< U81UD 93D5A>
M(B5P1Z57TK52A6-SP:=@.HI*:CAU#*>#3OI2 **!ZTM "444AIBNQU)3"ZH,
ME@![FH_M,!;'G1_]]"D',NI.3BDR*YGQ)J=_I\)FMR"GL,US6C^/I&OA'>D[
M2<=*5T82KJ+L>EYI:RKO5HK6Q^VG+1X!PO)IVFZU:ZFFZ%L$=B>:+FD:D7H:
M=%)UI.G6F6]!])5.\U&WLE!F=5R<<G%%IJ,%X<1.K?0YJN5V%S*]B[12=J3/
M-24+13<XZU#]IBW[3-'GTW#-"5Q-V+&:6F YY!I3G'%#&M1<\XI,<THI:$!4
MO+)+J(J1\U<]'H;?:B"!L!YKK*3 ]*:8FB&WMTMXE1!@"IJ*#P,U+>HPHK+N
M=<L[6;RI95#?[PJW:W<5Y%YD3 K[&J<6E<E2399I:2EI%!1110 4444 %%--
M!Z<4 Q:6H/M$(;:9H]WIN%3 @C(.:8DPI:**0PHHHH **** "BBB@ HHHH *
M0TM(10!!.O0U&S;:L2=!3& (Z4T)E=,N<MPE2^4CCG!JIJLQM;+*=<U1L9[B
M1QY8W*>I)Z521)>CLXK,O,S'KG&:572Y8M&<XZUAZU>&-P$<DXY&:FT&7=!.
M68[CVIV&;/RQ'<QJU&ZSKD=*SPC'R\YP35]-J'RQQBI8#R IJ0=*C.#4E24#
M?=JF\AVLI_2KG:JZQ*K$DYS30$,L)EM>">E4K2"[ADX V'KDUK]CZ5C:E?&%
MO+4X;/2J0B[>(LD010-PIME;&-=\G!]JH)>3")1,@7GK6JDA^SY(YQ0 GE1;
M\[C^=0SL\1W#H.E4HH;@SEGR%SZU=N2 JQ@Y+"D!4CD9W9CWZUIVLH(V^E9:
M.HD$7\6<5L6\>Q>1S0!/D4M)14C%HHHH **** "BBB@ HHHH *2EI* ,/Q'_
M *A/K7+=JZGQ'_J$^M<MVJT1(7M6OI7^J/UK([5KZ5_JC]:8(TJ***104444
M@"@44"F HZU5F??((A]UNM322"*,L>E101\[ST;D&@"9$\M=HZ"L76 ;F6-5
M_P"639-;AZX[5EM;R+<W+NO[ME^4TX[B9R.J2!]3+*..*V[,A85NQZA:R9;<
MO=R8&<"MO3;=YM%V*,D/FM9;$+<Z!#N16'0BH)AY4JR+]T=:DMPR0!6'(J1U
M#1E3WK$T0*=R;AWI15:%V1RC=,\59[\4-"0@Y-*/?K1]*.^#0AG,:Q%YFM(6
M7*[?2C6K()9 QH.5["NAD:'S,2*N[UQ2AHI?EP&'H15ILEF%=:>TVF02J#O1
M.*BBUN>"V6 J-ZC XKHF>.+Y3C![5'Y5M(V1&F?I1<+&'IUI/=W3W<ZX+#(Q
M1>WDD5T\=S&NS'!"UT85$7@!<>E5GDM9'PRJS>XHN%CGM'BD?4_.B!\O'>K?
MB%'<KL&3BM\11HN415^@J)I(&.6P2/44)CL%F EG#_>VU/U^M1I+'C<I&!3O
M-7:6SQ4NX(=134<.,BD,BJ<$TAW'T4PR*O4TI=0NXGBBP#J*0,&&14;7$2'#
M-S19@2T4U'5QE3FG#DXH **.]% !1110 "M"RZ&L\5H670TF!@^(/]>?K6)D
MYK;\0']^?K6)G)JD0PXS6AIVI/:R!2?E-9W>ES@X[GI0P1WMO<)<1AE/.*GK
M T"&=%9GSM/2M\5#+0M%%%(84444 %(:6B@#E?&>6M(8O[[8-6/"^E0V&EQA
M5R_<D<T>*(6>"%P,[6R:NZ'*)=-1A6OV3+EUNS3XQ@BN6\3V*VH_M2$;98^
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M4LHE<# X#&O4OAH[OX=8NQ8[^YSZUY!XRO(+[Q$9K=]Z''->N_#+GPZW^_\
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MLLB?,.:!CH1MZ59'2HP%!&*EI, HHHI#"BBB@ HHHH **** "BBB@ I*6DH
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M/]!NA$GI5_1-*>U9KJY8/<2#YF]:V<9IPH+C&VP8!ZTM%+2+ 4444#"BBB@
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MU*70]6&\,%SMQBHV=CEFG&5NC*_^D>'M9\P JRL<<=LUZ,B67BS2P&V_: N
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M$!@MUE4 _P#/,TR2#6_$MXHFCDWGC)0@4U2BI<UQ>TER\I+X(M'O/%-M(%)
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M?2D"*I)  )ZTTQ6(K>WCMXQ&@X%3"C% &*0Q:*** $HR,4M)B@!.&%+1BEH
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M^E?ZH_6LCM6OI7^J/UI@C2HHHI%!1112 ****8!1110 4444 %%%% !1110
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MTJ2JUKEH5D_O#)JP.E2RA:***0!1110 4444 %%%% !1110 4E+24 8?B/\
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M/3(%7?#6E7VEVC0W<JR '";>PH;"PECX?%K<+*S D'-;]-!!/TIU1<H****
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M>1R,L<W ;)Y)XJ3XC7%K+'9QHZM+YG !Y%+JO@2]^W/=Z-*EO([98MWIFG^
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MP7/0=RYQD9^M-,L:GF1/^^A7,&\FB\2+:@YC$)/)]JP])276IKMY)G5HY2H
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M<<536_O7;*VQQ4^J.\FB3,Z;"!THL$IIJR+FF_\ (-M\_P!VK-5M-_Y!MO\
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MG/=2%$MIL[MP(S6YX@_U%O\ ]<U_E5C6O#9N+B.>+ (QFK&K:1-=10A& *H
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MBLX0HOUK.\3W]V-:M?LSL&:%6./H*O:IJ$_B;R[."WEA"N'+,..#4EYI[_\
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M<*H'T%*(U#;@!FGT4 0RP+(#P,D8S5;3-,ATV*1(1@2-N/UJ\::S+&NXGBF
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M4  K0LNA^E9XK0LNA^E)@7****D84444 %%%% !1110 4444 %%%% !1110
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MQ*_YTVBJL3<W_#CNTT@=B<#N:Z45S'AK_72_2NG%2QH6BBBD4)2T44 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !112'I0 'IFJE_(\%F\B@EATJT 1WJ.>/S
MHS'ZT <+:ZK>VMZ\ES*^-V5C;N*IMJ6JS:C)<132>6&SY0_E74IX;,EZ)[IQ
M*JGY1Z"D_P"$<DCO3+#*$C+9*TQ&#80W=]JWVEYVB)8$QFMWQ=J<VF:="T()
M=WVY'X5IQ:9%%-Y@4;CU-/U33(]2MQ&X!*G*Y[&@#A]/U'58KXI*\KJ4)YI8
M9M22QFU)KR0JDFWRO6NFL=!F@D+W$HD.,#Z59.BQ?8)+8@%7;=3 P+F>^O-0
ML(HKAXEE3+$4JW,MC%>YD+NG\5=)'I4:30R8'[L8%1MHT+BX#*#YO6BX'/QV
MMY/I+7S:@Q21,^76?:6E\+2*YBO'2,'.T5TL.AW$:&'SQ]GQA4]!5]-*1+-;
M=<!5H30'(&]OM6U*2&&Z>%43=QWQ4-O_ &I/:M-]ND&Q]N/7!KK;70X;:Y:5
M5 ++@FIH=)BAA:( 89LT[H5CD]5UJ]:6"SA9U=DY85!;ZOJ<6C7_ )ID+)]U
MSVKI[OP\DI\R,A9A]UO2GP:%BQFMYF#^;UHN@L<O:G4X4T^X>_DD6X/*^E7M
M+LYV\5WLOVDXZ[:Z'^QXA%;1X&(.E2V^GI;WTMTH&9*FZ&9&M7=Q<S?8H96M
MV4Y+CO63975Y::^;&2]:8>46S^%=/JFE"\ DA(24GEJJV?AU8+O[7*0\VW;N
M]J>@'.1/J4-K<:B]](R1R$>7Z]:N/=7>L& PW36V!@@=ZZ)M'B:QEML#:[;C
M52XT!LQFSD$6T8/O1H(P-,O;B:'5;>XF:3R> 3WZ4MKJ,^D6)>60E95Q&I[&
MN@L?#R6T=QNPSS?>/K6=KVC&<:= B$K$_.!1<#/N[W4GT6WN(Y) S-\P'8<4
M^*\<V(9IS*^?O5T5YH[26:P0,$ ZU':^'(8+3R\#.<YHN,YZRO[XZFDDT[I"
M!C:>E=)KFH-9Z,\T9YVY#"H#X>+W"EW!C'\-:EYIT5Y8&U=05QBE<#G(X[VU
MTPZD]^SJ5WB,U2E:_:W34!?N$<;A'6_#HDXB:">8/;]%3T%0GP[-O"></LX^
MZGH*>@'/V=QJ.K22A+N2+:N<5T?AVYG5/LEQ(99%Y+FK5CHD5C+(Z8&X8XJU
M;V$<$YF4#<1BC0#G-8U%K#Q "JDY3&*R-9MKP:5-=2:@SQDY\LUV5SH\-U>^
M?*H8[<"LV3PU+(&CEE#VY/W*- 9S5QJE_=VUK':2/"$3!V]ZL?VMJ4OD6C&2
M-_N[_P"]70W/AK*Q?9'6+:,&K2Z&I-N\A#/%U/K0(YT_;]/CG%Q=O,)%V@'^
M&LZ.WN(+2WD:X9E:3 'ITKN[S3([K&5&*@DT.%H(XL#"-N HN.QRRV%Q+XS^
M2Z93Y&?TJS=ZO<Z?$UD\C-=,V5SUQ731Z7''J7VP ;]NVL6^T@WGC&WNW3,:
MQX)Q]* 1T5AO-I$\C$LR@G-6NAX%-10BA1T'2G9I#%HHHI %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 444E "T4E+0 5F:Y_R"Y*TZS==_P"0
M7)30F<91116AFS=\-?Z^7Z5U%<OX:_U\OTKJ*S9<1**6BD4%%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 -;D8JK=R>
M5"3GFK+#!W=ZH7RDV[,.H--"91+S*K,[ H>HJ^J+):X P&%9V#,H50=WO5Z&
M0^6$_N<-5,19M%VIL_NU:Z5# >,CH>E3<YYJ2@I:2EI %%%% !VK(UF=H43;
MW-:]5+NV2Y&UQQ30F9MK.TJ[&<;B.M36]F89=Y(S3#I8A)>(G YY-1KJT&=C
MYR#BJ$:@/.#5A0,<57C 8*R]"*LKTJ64@I:2EI %%%% !1110 4444 %%%%
M!1110 4E+24 8?B/_4)]:Y;M74^(_P#4)]:Y;M5HB0O:M?2O]4?K61VK7TK_
M %1^M,$:5%%%(H****0!1113 **** "BBB@ HHHH !Q1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444  K0
MLNA^E9XK0LNA^E)@7****D84444 %%%% !1110 4444 %%%% !1110 4444
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M-?Z^7Z5U%<OX:_U\OTKJ*S92$I:2EI%!12=Z6@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** $.:J3Q,ZD"K9Z5&<EL'BF@,
MV5WB &Q1^%5XBVYCW-6;N2/=M!RU0VY#DIWJB32M'!7!^\*LU!;IL&W'-3]J
MEE!2TE+2 ***2@!:8V>,4^F/VIH#.U.XEAC^0 @G%8L5A]LN0K9'?BNBN-LA
MVX!J"-! ^0*8BU"K*BJ1]T8%6!TJ&,[CFIL4F,6BBBD 4444 %%%% !1110
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MG::\]FCC_LFY66,&[\WY,]<9->D8XQBJ3Z39R/O:%2WK33$SBM0LRT%M-(Y
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 "M"RZ5G"M&RZ4F!<HHHJ1A1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBD[T +128QWI: "BBB@ HHHH
M**** "BBD[T +1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MN*PEE8QVD0 'S8YJV!@THZ45)0E+24M "44M)0 M%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%)0 9HS1D4C9[?C0 O:HIYU@B+.>E17-U':1[F:N6U+4WNV(4_)[4TA-C-3
MOVO)3S\M402!M]:.]"^]60'TKH-"LMQ,KCIR*R+"U>YN H'RYYKM;: 00*@'
M04FRDB:CK1VH' J"A:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M\\G_ "H^SS?\\G_*G<+,CHJ3[/-_SR?\J/L\W_/)_P J+A8CHJ3[/-_SR?\
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M_P \G_*E<+$=%2?9YO\ GD_Y4?9YO^>3_E1<+$=%2?9YO^>3_E1]GF_YY/\
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MV>;_ )Y/^5%PL1T5)]GF_P">3_E1]GF_YY/^5*X69'14GV>;_GD_Y4?9YO\
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MI:0Q/:EI*6D,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MS , >M=$.G%+1<+&(VA*?M7S-^_Z^U5KSPU'<:?;PY):WY7WKI**+A8YK3]
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MZ/E2>U0)HROY9F8.4.10(Q=.CU#2[\-<WC3QL  A[5V8.4#=,BJDFGQ22AF
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M*+@4K?2[.WMOL\$2K'W44MEIMMIZNEO&$#G<<>M6]N.E+BBX *6BBD 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
@ !1110 4444 %%%% !1110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>16
<FILENAME>bdsx-20201231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-03-16T14:26:39.4386317+00:00 -->
<!-- Version            : 5.0.1.571 -->
<!-- Package ID         : dca80741ea2145de953066364db43c8f -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2020-01-31" xmlns:bdsx="http://biodesix.com/20201231" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2020-01-31" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://biodesix.com/20201231" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd" namespace="http://xbrl.sec.gov/country/2020-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd" namespace="http://xbrl.sec.gov/currency/2020-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd" namespace="http://xbrl.sec.gov/dei/2020-01-31" />
  <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
  <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd" namespace="http://xbrl.sec.gov/exch/2020-01-31" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/role/negated" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/role/net" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" namespace="http://xbrl.sec.gov/naics/2017-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd" namespace="http://xbrl.sec.gov/sic/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd" namespace="http://fasb.org/srt/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd" namespace="http://fasb.org/srt-roles/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd" namespace="http://fasb.org/srt-types/2020-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd" namespace="http://xbrl.sec.gov/stpr/2018-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd" namespace="http://fasb.org/us-gaap/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd" namespace="http://fasb.org/us-roles/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd" namespace="http://fasb.org/us-types/2020-01-31" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType id="TemplateLink" roleURI="http://biodesix.com/20201231/role/TemplateLink" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>00000 - Document - Template Link</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bdsx-20201231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:title="Calculation Links, all" xlink:type="simple" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bdsx-20201231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:title="Definition Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bdsx-20201231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bdsx-20201231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://biodesix.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20201231/taxonomy/role/StatementBalanceSheets" id="Role_StatementBalanceSheets">
        <link:definition>100010 - Statement - Balance Sheets</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20201231/taxonomy/role/StatementBalanceSheetsParenthetical" id="Role_StatementBalanceSheetsParenthetical">
        <link:definition>100020 - Statement - Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfOperations" id="Role_StatementStatementsOfOperations">
        <link:definition>100030 - Statement - Statements of Operations</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" id="Role_StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit">
        <link:definition>100040 - Statement - Statements of Convertible Preferred Stock and Stockholders&apos; Equity (Deficit)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" id="Role_StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical">
        <link:definition>100050 - Statement - Statements of Convertible Preferred Stock and Stockholders&apos; Equity (Deficit) (Parenthetical)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfCashFlows" id="Role_StatementStatementsOfCashFlows">
        <link:definition>100060 - Statement - Statements of Cash Flows</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusiness" id="Role_DisclosureOrganizationAndDescriptionOfBusiness">
        <link:definition>100070 - Disclosure - Organization and Description of Business</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPolicies">
        <link:definition>100080 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosureRecentAccountingPronouncements" id="Role_DisclosureRecentAccountingPronouncements">
        <link:definition>100090 - Disclosure - Recent Accounting Pronouncements</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosureBusinessCombinations" id="Role_DisclosureBusinessCombinations">
        <link:definition>100100 - Disclosure - Business Combinations</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosureFairValue" id="Role_DisclosureFairValue">
        <link:definition>100110 - Disclosure - Fair Value</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosurePropertyAndEquipment" id="Role_DisclosurePropertyAndEquipment">
        <link:definition>100120 - Disclosure - Property and Equipment</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssets" id="Role_DisclosureGoodwillAndIntangibleAssets">
        <link:definition>100130 - Disclosure - Goodwill and Intangible Assets</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosureAccruedLiabilities" id="Role_DisclosureAccruedLiabilities">
        <link:definition>100140 - Disclosure - Accrued Liabilities</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosureDebt" id="Role_DisclosureDebt">
        <link:definition>100150 - Disclosure - Debt</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStock" id="Role_DisclosureConvertiblePreferredStock">
        <link:definition>100160 - Disclosure - Convertible Preferred Stock</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosureWarrantsToPurchaseConvertiblePreferredStock" id="Role_DisclosureWarrantsToPurchaseConvertiblePreferredStock">
        <link:definition>100170 - Disclosure - Warrants to Purchase Convertible Preferred Stock</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosureEquity" id="Role_DisclosureEquity">
        <link:definition>100180 - Disclosure - Equity</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosureRevenue" id="Role_DisclosureRevenue">
        <link:definition>100190 - Disclosure - Revenue</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosureShareBasedCompensation" id="Role_DisclosureShareBasedCompensation">
        <link:definition>100200 - Disclosure - Share Based Compensation</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosureEarningsPerShare" id="Role_DisclosureEarningsPerShare">
        <link:definition>100210 - Disclosure - Earnings per Share</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosureIncomeTaxes" id="Role_DisclosureIncomeTaxes">
        <link:definition>100220 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingencies" id="Role_DisclosureCommitmentsAndContingencies">
        <link:definition>100230 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosureDefinedContribution401KPlan" id="Role_DisclosureDefinedContribution401KPlan">
        <link:definition>100240 - Disclosure - Defined Contribution 401(k) Plan</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>100250 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesTables">
        <link:definition>100260 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosureBusinessCombinationsTables" id="Role_DisclosureBusinessCombinationsTables">
        <link:definition>100270 - Disclosure - Business Combinations (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosureFairValueTables" id="Role_DisclosureFairValueTables">
        <link:definition>100280 - Disclosure - Fair Value (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentTables" id="Role_DisclosurePropertyAndEquipmentTables">
        <link:definition>100290 - Disclosure - Property and Equipment (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsTables" id="Role_DisclosureGoodwillAndIntangibleAssetsTables">
        <link:definition>100300 - Disclosure - Goodwill and Intangible Assets (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosureAccruedLiabilitiesTables" id="Role_DisclosureAccruedLiabilitiesTables">
        <link:definition>100310 - Disclosure - Accrued Liabilities (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosureDebtTables" id="Role_DisclosureDebtTables">
        <link:definition>100320 - Disclosure - Debt (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosureWarrantsToPurchaseConvertiblePreferredStockTables" id="Role_DisclosureWarrantsToPurchaseConvertiblePreferredStockTables">
        <link:definition>100330 - Disclosure - Warrants to Purchase Convertible Preferred Stock (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosureRevenueTables" id="Role_DisclosureRevenueTables">
        <link:definition>100340 - Disclosure - Revenue (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosureShareBasedCompensationTables" id="Role_DisclosureShareBasedCompensationTables">
        <link:definition>100350 - Disclosure - Share Based Compensation (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosureEarningsPerShareTables" id="Role_DisclosureEarningsPerShareTables">
        <link:definition>100360 - Disclosure - Earnings per Share (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosureIncomeTaxesTables" id="Role_DisclosureIncomeTaxesTables">
        <link:definition>100370 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables" id="Role_DisclosureCommitmentsAndContingenciesTables">
        <link:definition>100380 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails" id="Role_DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails">
        <link:definition>100390 - Disclosure - Organization and Description of Business - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
        <link:definition>100400 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfRevenueAndAccountsReceivableByThirdPartyPayorsAndOtherCustomersDetails" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfRevenueAndAccountsReceivableByThirdPartyPayorsAndOtherCustomersDetails">
        <link:definition>100410 - Disclosure - Summary of Significant Accounting Policies - Summary of Revenue and Accounts Receivable by Third-party Payors and Other Customers (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosureBusinessCombinationsAdditionalInformationDetails" id="Role_DisclosureBusinessCombinationsAdditionalInformationDetails">
        <link:definition>100420 - Disclosure - Business Combinations - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosureBusinessCombinationsSummaryOfAggregateConsiderationPaidByCompanyAndAllocationOfPurchasePriceToAssetsAcquiredAndLiabilitiesAssumedDetails" id="Role_DisclosureBusinessCombinationsSummaryOfAggregateConsiderationPaidByCompanyAndAllocationOfPurchasePriceToAssetsAcquiredAndLiabilitiesAssumedDetails">
        <link:definition>100430 - Disclosure - Business Combinations - Summary of Aggregate Consideration Paid by Company and Allocation of Purchase Price to Assets Acquired and Liabilities Assumed (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosureFairValueSummaryOfFairValueOfOutstandingBorrowingsDetails" id="Role_DisclosureFairValueSummaryOfFairValueOfOutstandingBorrowingsDetails">
        <link:definition>100440 - Disclosure - Fair Value - Summary of Fair Value of Outstanding Borrowings (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosureFairValueScheduleOfReportedFairValuesOfLiabilitiesDetails" id="Role_DisclosureFairValueScheduleOfReportedFairValuesOfLiabilitiesDetails">
        <link:definition>100450 - Disclosure - Fair Value - Schedule of Reported Fair Values of Liabilities (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosureFairValueScheduleOfChangesInFinancialLiabilitiesDetails" id="Role_DisclosureFairValueScheduleOfChangesInFinancialLiabilitiesDetails">
        <link:definition>100460 - Disclosure - Fair Value - Schedule of Changes in Financial Liabilities (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosureFairValueAdditionalInformationDetails" id="Role_DisclosureFairValueAdditionalInformationDetails">
        <link:definition>100470 - Disclosure - Fair Value - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" id="Role_DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails">
        <link:definition>100480 - Disclosure - Property and Equipment - Schedule of Property and Equipment (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfDepreciationExpenseRelatedToPropertyAndEquipmentDetails" id="Role_DisclosurePropertyAndEquipmentScheduleOfDepreciationExpenseRelatedToPropertyAndEquipmentDetails">
        <link:definition>100490 - Disclosure - Property and Equipment - Schedule of Depreciation Expense Related to Property and Equipment (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsScheduleOfChangesInGoodwillDetails" id="Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfChangesInGoodwillDetails">
        <link:definition>100500 - Disclosure - Goodwill and Intangible Assets - Schedule of Changes in Goodwill (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsScheduleOfIntangibleAssetsDetails" id="Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfIntangibleAssetsDetails">
        <link:definition>100510 - Disclosure - Goodwill and Intangible Assets - Schedule of Intangible Assets (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsScheduleOfAmortizationExpenseRelatedToDefiniteLivedIntangibleAssetsDetails" id="Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfAmortizationExpenseRelatedToDefiniteLivedIntangibleAssetsDetails">
        <link:definition>100520 - Disclosure - Goodwill and Intangible Assets - Schedule of Amortization Expense Related to Definite-Lived Intangible Assets (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsScheduleOfFutureEstimatedAmortizationExpenseOfIntangibleAssetsDetails" id="Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfFutureEstimatedAmortizationExpenseOfIntangibleAssetsDetails">
        <link:definition>100530 - Disclosure - Goodwill and Intangible Assets - Schedule of Future Estimated Amortization Expense of Intangible Assets (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails" id="Role_DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails">
        <link:definition>100540 - Disclosure - Goodwill and Intangible Assets - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails" id="Role_DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails">
        <link:definition>100550 - Disclosure - Accrued Liabilities - Schedule of Accrued Liabilities (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosureDebtSummaryOfLongTermNotesPayableDetails" id="Role_DisclosureDebtSummaryOfLongTermNotesPayableDetails">
        <link:definition>100560 - Disclosure - Debt - Summary of Long-term Notes Payable (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" id="Role_DisclosureDebtAdditionalInformationDetails">
        <link:definition>100570 - Disclosure - Debt - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosureDebtScheduledPrincipalRepaymentsMaturitiesOfLongTermObligationsDetails" id="Role_DisclosureDebtScheduledPrincipalRepaymentsMaturitiesOfLongTermObligationsDetails">
        <link:definition>100580 - Disclosure - Debt - Scheduled Principal Repayments (Maturities) of Long-term Obligations (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails" id="Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails">
        <link:definition>100590 - Disclosure - Convertible Preferred Stock - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosureWarrantsToPurchaseConvertiblePreferredStockSummaryOfActivityForConvertiblePreferredStockWarrantsDetails" id="Role_DisclosureWarrantsToPurchaseConvertiblePreferredStockSummaryOfActivityForConvertiblePreferredStockWarrantsDetails">
        <link:definition>100600 - Disclosure - Warrants to Purchase Convertible Preferred Stock - Summary of Activity for Convertible Preferred Stock Warrants (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosureWarrantsToPurchaseConvertiblePreferredStockAdditionalInformationDetails" id="Role_DisclosureWarrantsToPurchaseConvertiblePreferredStockAdditionalInformationDetails">
        <link:definition>100610 - Disclosure - Warrants to Purchase Convertible Preferred Stock - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosureEquityAdditionalInformationDetails" id="Role_DisclosureEquityAdditionalInformationDetails">
        <link:definition>100620 - Disclosure - Equity - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosureRevenueSummaryOfRevenueDetails" id="Role_DisclosureRevenueSummaryOfRevenueDetails">
        <link:definition>100630 - Disclosure - Revenue - Summary of Revenue (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosureRevenueAdditionalInformationDetails" id="Role_DisclosureRevenueAdditionalInformationDetails">
        <link:definition>100640 - Disclosure - Revenue - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails" id="Role_DisclosureShareBasedCompensationAdditionalInformationDetails">
        <link:definition>100650 - Disclosure - Share Based Compensation - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfPreTaxShareBasedCompensationExpenseDetails" id="Role_DisclosureShareBasedCompensationSummaryOfPreTaxShareBasedCompensationExpenseDetails">
        <link:definition>100660 - Disclosure - Share Based Compensation - Summary of Pre-tax Share-based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetails" id="Role_DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetails">
        <link:definition>100670 - Disclosure - Share Based Compensation - Summary of Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfWeightedAverageAssumptionsDetails" id="Role_DisclosureShareBasedCompensationSummaryOfWeightedAverageAssumptionsDetails">
        <link:definition>100680 - Disclosure - Share Based Compensation - Summary of Weighted Average Assumptions (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosureEarningsPerShareScheduleOfComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails" id="Role_DisclosureEarningsPerShareScheduleOfComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails">
        <link:definition>100690 - Disclosure - Earnings per Share - Schedule of Computation of Basic and Diluted Net Loss per Share Attributable to Common Stockholders (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosureEarningsPerShareScheduleOfCommonStockEquivalentsExcludedFromDilutedNetLossAttributableToCommonStockholdersDetails" id="Role_DisclosureEarningsPerShareScheduleOfCommonStockEquivalentsExcludedFromDilutedNetLossAttributableToCommonStockholdersDetails">
        <link:definition>100700 - Disclosure - Earnings per Share - Schedule of Common Stock Equivalents Excluded from Diluted Net Loss Attributable to Common Stockholders (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" id="Role_DisclosureIncomeTaxesAdditionalInformationDetails">
        <link:definition>100710 - Disclosure - Income Taxes - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" id="Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails">
        <link:definition>100720 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" id="Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails">
        <link:definition>100730 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfUnrecognizedTaxBenefitsDetails" id="Role_DisclosureIncomeTaxesReconciliationOfUnrecognizedTaxBenefitsDetails">
        <link:definition>100740 - Disclosure - Income Taxes - Reconciliation of Unrecognized Tax Benefits (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" id="Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
        <link:definition>100750 - Disclosure - Commitments and Contingencies - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumLeasePaymentsForOperatingLeaseObligationsDetails" id="Role_DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumLeasePaymentsForOperatingLeaseObligationsDetails">
        <link:definition>100760 - Disclosure - Commitments and Contingencies - Summary of Future Minimum Lease Payments for Operating Lease Obligations (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosureDefinedContribution401KPlanAdditionalInformationDetail" id="Role_DisclosureDefinedContribution401KPlanAdditionalInformationDetail">
        <link:definition>100770 - Disclosure - Defined Contribution 401(k) Plan - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="bdsx_IntangibleAssetsAccumulatedAmortizationExcludingGoodwill" name="IntangibleAssetsAccumulatedAmortizationExcludingGoodwill" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="bdsx_PutOptionLiabilityCurrent" name="PutOptionLiabilityCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="bdsx_DirectCostsAndExpenses" name="DirectCostsAndExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="bdsx_ChangeInFairValueOfContingentConsiderationExcludingAccretionExpense" name="ChangeInFairValueOfContingentConsiderationExcludingAccretionExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="bdsx_ChangeInFairValueOfPutOptionLiability" name="ChangeInFairValueOfPutOptionLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="bdsx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" name="TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="bdsx_StockIssuedDuringPeriodSharesConversionOfConvertibleSecuritiesCommonStock" name="StockIssuedDuringPeriodSharesConversionOfConvertibleSecuritiesCommonStock" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="bdsx_SaleOfStockTemporaryEquityPricePerShare" name="SaleOfStockTemporaryEquityPricePerShare" type="num:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="bdsx_TemporaryEquityIssuanceCosts" name="TemporaryEquityIssuanceCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="bdsx_AccruedInterestOnNotesPayableAndConvertibleNotesPayable" name="AccruedInterestOnNotesPayableAndConvertibleNotesPayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="bdsx_PaymentsForProceedsFromPatentCostsAndIntangibleAssetAcquisitionNet" name="PaymentsForProceedsFromPatentCostsAndIntangibleAssetAcquisitionNet" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="bdsx_PaymentsToAcquireOncimmune" name="PaymentsToAcquireOncimmune" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="bdsx_ConversionOfPreferredStockIntoCommonStock" name="ConversionOfPreferredStockIntoCommonStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="bdsx_ReclassificationOfPutOptionLiabilityToAdditionalPaidInCapital" name="ReclassificationOfPutOptionLiabilityToAdditionalPaidInCapital" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="bdsx_ValueOfPutOptionRecordedAtIssuanceOfConvertibleNotesPayable" name="ValueOfPutOptionRecordedAtIssuanceOfConvertibleNotesPayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="bdsx_ReclassificationOfWarrantLiabilityToAdditionalPaidInCapital" name="ReclassificationOfWarrantLiabilityToAdditionalPaidInCapital" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="bdsx_OrganizationAndDescriptionOfBusinessAbstract" name="OrganizationAndDescriptionOfBusinessAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bdsx_WarrantsForConvertiblePreferredStockTextBlock" name="WarrantsForConvertiblePreferredStockTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="bdsx_ReverseStockSplitPolicyTextBlock" name="ReverseStockSplitPolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="bdsx_ApprovalOfAmendedAndRestatedCertificateOfIncorporationPolicyTextBlock" name="ApprovalOfAmendedAndRestatedCertificateOfIncorporationPolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="bdsx_InitialPublicOfferingIPOPolicyTextBlock" name="InitialPublicOfferingIPOPolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="bdsx_DirectCostsAndExpensesPolicyTextBlock" name="DirectCostsAndExpensesPolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="bdsx_ContingentConsiderationPolicyTextBlock" name="ContingentConsiderationPolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="bdsx_WarrantLiabilityPolicyTextBlock" name="WarrantLiabilityPolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="bdsx_PutOptionLiabilityPolicyTextBlock" name="PutOptionLiabilityPolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="bdsx_ScheduleOfDepreciationAndAmortizationExpenseRelatedToPropertyAndEquipmentTableTextBlock" name="ScheduleOfDepreciationAndAmortizationExpenseRelatedToPropertyAndEquipmentTableTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="bdsx_NumberOfCancerTest" name="NumberOfCancerTest" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="bdsx_OrganizationAndDescriptionOfBusinessLineItems" name="OrganizationAndDescriptionOfBusinessLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bdsx_OrganizationAndDescriptionOfBusinessTable" name="OrganizationAndDescriptionOfBusinessTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bdsx_NumberOfCommercialBloodBasedTest" name="NumberOfCommercialBloodBasedTest" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="bdsx_NumberOfSARSCoV2Test" name="NumberOfSARSCoV2Test" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="bdsx_ConvertiblePreferredStockAndConvertibleNotesPayableConvertedToCommonStock" name="ConvertiblePreferredStockAndConvertibleNotesPayableConvertedToCommonStock" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="bdsx_IncreaseDecreaseInAccumulatedDeficit" name="IncreaseDecreaseInAccumulatedDeficit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" name="SummaryOfSignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bdsx_SummaryOfSignificantAccountingPoliciesTable" name="SummaryOfSignificantAccountingPoliciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bdsx_TestingServicesMember" name="TestingServicesMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bdsx_CovanceCentralLaboratoryServicesMember" name="CovanceCentralLaboratoryServicesMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bdsx_MedicareMember" name="MedicareMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bdsx_ProductLifeAndPatentLifeMember" name="ProductLifeAndPatentLifeMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bdsx_TheBigTenConferenceMember" name="TheBigTenConferenceMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bdsx_CenturaHealthcareMember" name="CenturaHealthcareMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bdsx_JanssenResearchAndDevelopmentLLCMember" name="JanssenResearchAndDevelopmentLLCMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bdsx_PfizerIncMember" name="PfizerIncMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bdsx_OncimmuneLimitedMember" name="OncimmuneLimitedMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bdsx_IntegratedDiagnosticsIncMember" name="IntegratedDiagnosticsIncMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bdsx_RepurchaseMember" name="RepurchaseMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bdsx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPurchaseOption" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPurchaseOption" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="bdsx_BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod" name="BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="bdsx_BusinessAcquisitionContingentConsiderationNumberOfInstallments" name="BusinessAcquisitionContingentConsiderationNumberOfInstallments" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="bdsx_BusinessCombinationContingentConsiderationArrangementsCommonSharesRedemptionAmount" name="BusinessCombinationContingentConsiderationArrangementsCommonSharesRedemptionAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="bdsx_BusinessCombinationContingentConsiderationShares" name="BusinessCombinationContingentConsiderationShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisLineItems" name="FairValueLiabilitiesMeasuredOnRecurringBasisLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisTable" name="FairValueLiabilitiesMeasuredOnRecurringBasisTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bdsx_ContingentConsiderationMember" name="ContingentConsiderationMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bdsx_PutOptionLiabilityMember" name="PutOptionLiabilityMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bdsx_WarrantLiabilityMember" name="WarrantLiabilityMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bdsx_ContingentValueRightsMember" name="ContingentValueRightsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bdsx_FairValueMeasurementWithUnobservableInputsReconciliationReclassifiedToAdditionalPaidInCapital" name="FairValueMeasurementWithUnobservableInputsReconciliationReclassifiedToAdditionalPaidInCapital" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="bdsx_PercentageOfProbabilitiesOfContingentConsiderationSuccessfulAchievementMilestoneDiscountRatesRange" name="PercentageOfProbabilitiesOfContingentConsiderationSuccessfulAchievementMilestoneDiscountRatesRange" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="bdsx_NotesPayable2018NotesMember" name="NotesPayable2018NotesMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bdsx_AVEOOncologyMember" name="AVEOOncologyMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bdsx_ContingentValueRightsShares" name="ContingentValueRightsShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="bdsx_ContingentValueRights" name="ContingentValueRights" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="bdsx_NetProceedsPercentageOfCashPaymentToCVRHolders" name="NetProceedsPercentageOfCashPaymentToCVRHolders" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="bdsx_ContingentValueRightsPercentage" name="ContingentValueRightsPercentage" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="bdsx_PercentageOfDevelopmentAndRegulatoryCostsExercisedUsingOptOutRight" name="PercentageOfDevelopmentAndRegulatoryCostsExercisedUsingOptOutRight" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="bdsx_DirectCostsAndExpensesMember" name="DirectCostsAndExpensesMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bdsx_PurchasedTechnologyMember" name="PurchasedTechnologyMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bdsx_PurchaseOptionMember" name="PurchaseOptionMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bdsx_IndefiniteLivedIntangibleAssetsExcludingGoodwillGross" name="IndefiniteLivedIntangibleAssetsExcludingGoodwillGross" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="bdsx_AccruedClinicalTrialExpenseCurrent" name="AccruedClinicalTrialExpenseCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="bdsx_PPPLoanMember" name="PPPLoanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bdsx_CARESActMember" name="CARESActMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bdsx_MarchTwoThousandAndTwentyConvertibleNotesMember" name="MarchTwoThousandAndTwentyConvertibleNotesMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bdsx_DecemberTwoThousandAndNineteenConvertibleNotesMember" name="DecemberTwoThousandAndNineteenConvertibleNotesMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bdsx_AugustTwoThousandAndNineteenConvertibleNotesMember" name="AugustTwoThousandAndNineteenConvertibleNotesMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bdsx_DebtInstrumentPercentageOfStatedInterestRatePaidInCash" name="DebtInstrumentPercentageOfStatedInterestRatePaidInCash" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="bdsx_DebtInstrumentPercentageOfStatedInterestRateAddedToPrincipalValueOfNotesPayable" name="DebtInstrumentPercentageOfStatedInterestRateAddedToPrincipalValueOfNotesPayable" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="bdsx_DebtInstrumentInterestAddedToPrincipalValue" name="DebtInstrumentInterestAddedToPrincipalValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="bdsx_DebtInstrumentPrepaymentPenaltyPercentage" name="DebtInstrumentPrepaymentPenaltyPercentage" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="bdsx_DebtInstrumentBackEndFacilityFeePercentage" name="DebtInstrumentBackEndFacilityFeePercentage" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="bdsx_DebtInstrumentAdditionalInterestExpenseFeePercentage" name="DebtInstrumentAdditionalInterestExpenseFeePercentage" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="bdsx_PayrollCostsExcludesCompensationOfEmployee" name="PayrollCostsExcludesCompensationOfEmployee" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="bdsx_PercentageForNonPayrollCosts" name="PercentageForNonPayrollCosts" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="bdsx_UpperLimitOfEmployeeSalaryToReduceForgiveness" name="UpperLimitOfEmployeeSalaryToReduceForgiveness" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="bdsx_PercentageOfUpperLimitOfEmployeeSalaryToReduceForgiveness" name="PercentageOfUpperLimitOfEmployeeSalaryToReduceForgiveness" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="bdsx_PercentageOfConversionPricePerShareOfCommonStock" name="PercentageOfConversionPricePerShareOfCommonStock" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="bdsx_DebtInstrumentMaturityDateExtended" name="DebtInstrumentMaturityDateExtended" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="bdsx_PercentageOfConversionPricePerShareOfConvertiblePreferredStock" name="PercentageOfConversionPricePerShareOfConvertiblePreferredStock" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="bdsx_IncreaseToPutOptionLiability" name="IncreaseToPutOptionLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="bdsx_SeriesA1PreferredStockMember" name="SeriesA1PreferredStockMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bdsx_SeriesA2PreferredStockMember" name="SeriesA2PreferredStockMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bdsx_SeriesA3PreferredStockMember" name="SeriesA3PreferredStockMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bdsx_SeriesB1ConvertiblePreferredStockMember" name="SeriesB1ConvertiblePreferredStockMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bdsx_NumberOfPreferredStockConvertedIntoCommonStock" name="NumberOfPreferredStockConvertedIntoCommonStock" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="bdsx_SeriesEConvertiblePreferredStockWarrantsMember" name="SeriesEConvertiblePreferredStockWarrantsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bdsx_SeriesGConvertiblePreferredStockWarrantsMember" name="SeriesGConvertiblePreferredStockWarrantsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bdsx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" type="num:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice" type="num:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="bdsx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" type="num:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice" type="num:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsReclassificationOfWarrantLiabilityToAdditionalPaidInCapitalWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsReclassificationOfWarrantLiabilityToAdditionalPaidInCapitalWeightedAverageExercisePrice" type="num:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="bdsx_DirectOfferingExpenses" name="DirectOfferingExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="bdsx_DiagnosticTestsMember" name="DiagnosticTestsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bdsx_AdvanceDeposits" name="AdvanceDeposits" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="bdsx_COVID19DiagnosticTestRevenueMember" name="COVID19DiagnosticTestRevenueMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bdsx_LungDiagnosticRevenueMember" name="LungDiagnosticRevenueMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bdsx_DeferredRevenueMember" name="DeferredRevenueMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bdsx_TwoThousandTwentyEquityIncentivePlanMember" name="TwoThousandTwentyEquityIncentivePlanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bdsx_TwoThousandSixPlanMember" name="TwoThousandSixPlanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bdsx_TwoThousandAndSixteenPlanMember" name="TwoThousandAndSixteenPlanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bdsx_TwoThousandSixPlanTwoThousandSixteenPlanAndTwoThousandTwentyEquityIncentivePlanMember" name="TwoThousandSixPlanTwoThousandSixteenPlanAndTwoThousandTwentyEquityIncentivePlanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bdsx_PerformanceConditionOptionsMember" name="PerformanceConditionOptionsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bdsx_BonusToOptionsProgramMember" name="BonusToOptionsProgramMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bdsx_OptionsAndRestrictedStockUnitsMember" name="OptionsAndRestrictedStockUnitsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bdsx_ServiceConditionRSUsMember" name="ServiceConditionRSUsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bdsx_DescriptionOfVotingPowerOrValueOfStockForEmployeeParticipationInOfferingPeriod" name="DescriptionOfVotingPowerOrValueOfStockForEmployeeParticipationInOfferingPeriod" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="bdsx_DescriptionOfOfferingPeriodUnderPlan" name="DescriptionOfOfferingPeriodUnderPlan" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="bdsx_NumberOfEqualAnnualInstallmentsForAwardVesting" name="NumberOfEqualAnnualInstallmentsForAwardVesting" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="bdsx_PercentageOfFullyDilutedEquityForBonusAwarded" name="PercentageOfFullyDilutedEquityForBonusAwarded" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="bdsx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1" name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="bdsx_OptionsToPurchaseCommonStockMember" name="OptionsToPurchaseCommonStockMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bdsx_EffectiveIncomeTaxRateReconciliationPermanentItems" name="EffectiveIncomeTaxRateReconciliationPermanentItems" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="bdsx_DeferredTaxAssetsResearchAndExperimentationTaxCarryforwardsSubjectToExpiration" name="DeferredTaxAssetsResearchAndExperimentationTaxCarryforwardsSubjectToExpiration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="bdsx_PercentageOfValuationAllowanceEqualToNetDeferredTaxAssets" name="PercentageOfValuationAllowanceEqualToNetDeferredTaxAssets" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="bdsx_BDX004Member" name="BDX004Member" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bdsx_FiclatuzumabMember" name="FiclatuzumabMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bdsx_NSCLCPOCTrialMember" name="NSCLCPOCTrialMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bdsx_POCClinicalTrialsMember" name="POCClinicalTrialsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bdsx_BioRadLicenseMember" name="BioRadLicenseMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bdsx_RevenueShareAgreementMember" name="RevenueShareAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="bdsx_PercentageOfDevelopmentAndRegulatoryCosts" name="PercentageOfDevelopmentAndRegulatoryCosts" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="bdsx_RemainingEstimatedObligation" name="RemainingEstimatedObligation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="bdsx_PercentageOfRoyaltyPaymentsOnNetSales" name="PercentageOfRoyaltyPaymentsOnNetSales" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="bdsx_PercentageOfLicenseIncomeGeneratedFromLicensing" name="PercentageOfLicenseIncomeGeneratedFromLicensing" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="bdsx_PercentageOfRoyaltyPaymentsOnNetRevenue" name="PercentageOfRoyaltyPaymentsOnNetRevenue" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="bdsx_LicenseAgreementExpiryDate" name="LicenseAgreementExpiryDate" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="bdsx_PercentageOfRevenueSharePaymentRelatedToAcquiredDiagnosticTestRecognizedRevenueForNonScreeningTests" name="PercentageOfRevenueSharePaymentRelatedToAcquiredDiagnosticTestRecognizedRevenueForNonScreeningTests" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="bdsx_MinimumAnnualVolumePercentageThereafter" name="MinimumAnnualVolumePercentageThereafter" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="bdsx_PeriodOfEscalationsOfSales" name="PeriodOfEscalationsOfSales" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="bdsx_RevenueShareExpenses" name="RevenueShareExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>17
<FILENAME>bdsx-20201231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-03-16T14:26:39.4386317+00:00 -->
<!-- Version            : 5.0.1.571 -->
<!-- Package ID         : dca80741ea2145de953066364db43c8f -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef xlink:type="simple" xlink:href="bdsx-20201231.xsd#TemplateLink" roleURI="http://biodesix.com/20201231/role/TemplateLink" />
  <link:roleRef roleURI="http://biodesix.com/20201231/taxonomy/role/StatementBalanceSheets" xlink:href="bdsx-20201231.xsd#Role_StatementBalanceSheets" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://biodesix.com/20201231/taxonomy/role/StatementBalanceSheets">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill" xlink:type="locator" xlink:label="us-gaap_Goodwill" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_PutOptionLiabilityCurrent" xlink:type="locator" xlink:label="bdsx_PutOptionLiabilityCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableToBankCurrent" xlink:type="locator" xlink:label="us-gaap_NotesPayableToBankCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:type="locator" xlink:label="us-gaap_LongTermNotesPayable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="10080.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="10090.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesNoncurrent" order="10100.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_WarrantsAndRightsOutstanding" order="10110.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LongTermNotesPayable" order="10120.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" order="10130.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="10140.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="10150.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="10160.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="10170.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_NotesPayableToBankCurrent" order="10180.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="bdsx_PutOptionLiabilityCurrent" order="10190.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="10200.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsNoncurrent" order="10210.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10220.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="10230.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent" order="10240.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_Goodwill" order="10250.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10260.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="10270.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent" order="10280.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfOperations" xlink:href="bdsx-20201231.xsd#Role_StatementStatementsOfOperations" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfOperations">
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_ChangeInFairValueOfContingentConsiderationExcludingAccretionExpense" xlink:type="locator" xlink:label="bdsx_ChangeInFairValueOfContingentConsiderationExcludingAccretionExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_DirectCostsAndExpenses" xlink:type="locator" xlink:label="bdsx_DirectCostsAndExpenses" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues" xlink:type="locator" xlink:label="us-gaap_Revenues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncome" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_ChangeInFairValueOfPutOptionLiability" xlink:type="locator" xlink:label="bdsx_ChangeInFairValueOfPutOptionLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense" xlink:type="locator" xlink:label="us-gaap_InterestExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeOther" xlink:type="locator" xlink:label="us-gaap_InterestIncomeOther" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_InterestIncomeOther" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_InterestExpense" order="10040.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="10050.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="bdsx_ChangeInFairValueOfPutOptionLiability" order="10060.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncome" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_Revenues" order="10080.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="10090.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="bdsx_DirectCostsAndExpenses" order="10100.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="10110.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="10120.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="bdsx_ChangeInFairValueOfContingentConsiderationExcludingAccretionExpense" order="10130.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfCashFlows" xlink:href="bdsx-20201231.xsd#Role_StatementStatementsOfCashFlows" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfCashFlows">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:type="locator" xlink:label="us-gaap_GainLossOnDispositionOfAssets1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:type="locator" xlink:label="us-gaap_ProvisionForDoubtfulAccounts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:type="locator" xlink:label="us-gaap_AmortizationOfFinancingCosts" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_AccruedInterestOnNotesPayableAndConvertibleNotesPayable" xlink:type="locator" xlink:label="bdsx_AccruedInterestOnNotesPayableAndConvertibleNotesPayable" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_ChangeInFairValueOfPutOptionLiability" xlink:type="locator" xlink:label="bdsx_ChangeInFairValueOfPutOptionLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="locator" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_PaymentsToAcquireOncimmune" xlink:type="locator" xlink:label="bdsx_PaymentsToAcquireOncimmune" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_PaymentsForProceedsFromPatentCostsAndIntangibleAssetAcquisitionNet" xlink:type="locator" xlink:label="bdsx_PaymentsForProceedsFromPatentCostsAndIntangibleAssetAcquisitionNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:type="locator" xlink:label="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:type="locator" xlink:label="us-gaap_ProceedsFromNotesPayable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:type="locator" xlink:label="us-gaap_ProceedsFromConvertibleDebt" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromConvertibleDebt" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromNotesPayable" order="10080.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="10090.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" order="10100.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="10110.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="bdsx_PaymentsForProceedsFromPatentCostsAndIntangibleAssetAcquisitionNet" order="10120.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="bdsx_PaymentsToAcquireOncimmune" order="10130.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProfitLoss" order="10140.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationAndAmortization" order="10150.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" order="10160.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="10170.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="10180.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" order="10190.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="bdsx_ChangeInFairValueOfPutOptionLiability" order="10200.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="bdsx_AccruedInterestOnNotesPayableAndConvertibleNotesPayable" order="10210.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AmortizationOfFinancingCosts" order="10220.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProvisionForDoubtfulAccounts" order="10230.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_GainLossOnDispositionOfAssets1" order="10240.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="10250.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets" order="10260.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet" order="10270.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="10280.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" order="10290.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosureBusinessCombinationsSummaryOfAggregateConsiderationPaidByCompanyAndAllocationOfPurchasePriceToAssetsAcquiredAndLiabilitiesAssumedDetails" xlink:href="bdsx-20201231.xsd#Role_DisclosureBusinessCombinationsSummaryOfAggregateConsiderationPaidByCompanyAndAllocationOfPurchasePriceToAssetsAcquiredAndLiabilitiesAssumedDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://biodesix.com/20201231/taxonomy/role/DisclosureBusinessCombinationsSummaryOfAggregateConsiderationPaidByCompanyAndAllocationOfPurchasePriceToAssetsAcquiredAndLiabilitiesAssumedDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill" xlink:type="locator" xlink:label="us-gaap_Goodwill" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPurchaseOption" xlink:type="locator" xlink:label="bdsx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPurchaseOption" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="bdsx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPurchaseOption" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="us-gaap_Goodwill" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" order="10060.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="us-gaap_PaymentsToAcquireBusinessesGross" order="10070.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" xlink:href="bdsx-20201231.xsd#Role_DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://biodesix.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="10020.00" priority="2" use="optional" weight="-1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsScheduleOfIntangibleAssetsDetails" xlink:href="bdsx-20201231.xsd#Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfIntangibleAssetsDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://biodesix.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsScheduleOfIntangibleAssetsDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_IntangibleAssetsAccumulatedAmortizationExcludingGoodwill" xlink:type="locator" xlink:label="bdsx_IntangibleAssetsAccumulatedAmortizationExcludingGoodwill" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsGrossExcludingGoodwill" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsGrossExcludingGoodwill" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="bdsx_IntangibleAssetsAccumulatedAmortizationExcludingGoodwill" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" order="10040.00" priority="2" use="optional" weight="-1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsScheduleOfFutureEstimatedAmortizationExpenseOfIntangibleAssetsDetails" xlink:href="bdsx-20201231.xsd#Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfFutureEstimatedAmortizationExpenseOfIntangibleAssetsDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://biodesix.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsScheduleOfFutureEstimatedAmortizationExpenseOfIntangibleAssetsDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" order="10060.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails" xlink:href="bdsx-20201231.xsd#Role_DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://biodesix.com/20201231/taxonomy/role/DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductWarrantyAccrualClassifiedCurrent" xlink:type="locator" xlink:label="us-gaap_ProductWarrantyAccrualClassifiedCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_AccruedClinicalTrialExpenseCurrent" xlink:type="locator" xlink:label="bdsx_AccruedClinicalTrialExpenseCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="bdsx_AccruedClinicalTrialExpenseCurrent" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_ProductWarrantyAccrualClassifiedCurrent" order="10040.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosureDebtSummaryOfLongTermNotesPayableDetails" xlink:href="bdsx-20201231.xsd#Role_DisclosureDebtSummaryOfLongTermNotesPayableDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://biodesix.com/20201231/taxonomy/role/DisclosureDebtSummaryOfLongTermNotesPayableDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:type="locator" xlink:label="us-gaap_LongTermNotesPayable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:type="locator" xlink:label="us-gaap_NotesPayableCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayable" xlink:type="locator" xlink:label="us-gaap_NotesPayable" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NotesPayable" xlink:to="us-gaap_NotesPayableCurrent" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NotesPayable" xlink:to="us-gaap_LongTermNotesPayable" order="10020.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosureDebtScheduledPrincipalRepaymentsMaturitiesOfLongTermObligationsDetails" xlink:href="bdsx-20201231.xsd#Role_DisclosureDebtScheduledPrincipalRepaymentsMaturitiesOfLongTermObligationsDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://biodesix.com/20201231/taxonomy/role/DisclosureDebtScheduledPrincipalRepaymentsMaturitiesOfLongTermObligationsDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt" xlink:type="locator" xlink:label="us-gaap_LongTermDebt" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" order="10060.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:href="bdsx-20201231.xsd#Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://biodesix.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_EffectiveIncomeTaxRateReconciliationPermanentItems" xlink:type="locator" xlink:label="bdsx_EffectiveIncomeTaxRateReconciliationPermanentItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="bdsx_EffectiveIncomeTaxRateReconciliationPermanentItems" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="10050.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="bdsx-20201231.xsd#Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://biodesix.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsNet" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="10020.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsGross" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="10050.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" order="10080.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="10090.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" order="10100.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumLeasePaymentsForOperatingLeaseObligationsDetails" xlink:href="bdsx-20201231.xsd#Role_DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumLeasePaymentsForOperatingLeaseObligationsDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://biodesix.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumLeasePaymentsForOperatingLeaseObligationsDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" order="10060.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>18
<FILENAME>bdsx-20201231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-03-16T14:26:39.4386317+00:00 -->
<!-- Version            : 5.0.1.571 -->
<!-- Package ID         : dca80741ea2145de953066364db43c8f -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
  <link:roleRef xlink:type="simple" xlink:href="bdsx-20201231.xsd#TemplateLink" roleURI="http://biodesix.com/20201231/role/TemplateLink" />
  <link:roleRef roleURI="http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:href="bdsx-20201231.xsd#Role_StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_StockIssuedDuringPeriodSharesConversionOfConvertibleSecuritiesCommonStock" xlink:type="locator" xlink:label="bdsx_StockIssuedDuringPeriodSharesConversionOfConvertibleSecuritiesCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="bdsx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_2" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="10260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="10280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="10420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="10440.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" order="10580.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bdsx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" order="10600.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="10740.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="10900.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="10920.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="11060.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="11080.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" order="11220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bdsx_StockIssuedDuringPeriodSharesConversionOfConvertibleSecuritiesCommonStock" order="11240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" order="11380.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="11540.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" xlink:href="bdsx-20201231.xsd#Role_StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalUnitsTotalCostToInvestors" xlink:type="locator" xlink:label="us-gaap_CapitalUnitsTotalCostToInvestors" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalUnitsDeductionsFromTotalCostToInvestors" xlink:type="locator" xlink:label="us-gaap_CapitalUnitsDeductionsFromTotalCostToInvestors" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_TemporaryEquityIssuanceCosts" xlink:type="locator" xlink:label="bdsx_TemporaryEquityIssuanceCosts" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_SaleOfStockTemporaryEquityPricePerShare" xlink:type="locator" xlink:label="bdsx_SaleOfStockTemporaryEquityPricePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesHPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesHPreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesHPreferredStockMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bdsx_SaleOfStockTemporaryEquityPricePerShare" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bdsx_TemporaryEquityIssuanceCosts" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CapitalUnitsDeductionsFromTotalCostToInvestors" order="10260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CapitalUnitsTotalCostToInvestors" order="10320.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails" xlink:href="bdsx-20201231.xsd#Role_DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://biodesix.com/20201231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_ConvertiblePreferredStockAndConvertibleNotesPayableConvertedToCommonStock" xlink:type="locator" xlink:label="bdsx_ConvertiblePreferredStockAndConvertibleNotesPayableConvertedToCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_NumberOfSARSCoV2Test" xlink:type="locator" xlink:label="bdsx_NumberOfSARSCoV2Test" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_NumberOfCommercialBloodBasedTest" xlink:type="locator" xlink:label="bdsx_NumberOfCommercialBloodBasedTest" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_NumberOfCancerTest" xlink:type="locator" xlink:label="bdsx_NumberOfCancerTest" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember" xlink:type="locator" xlink:label="us-gaap_IPOMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_OrganizationAndDescriptionOfBusinessTable" xlink:type="locator" xlink:label="bdsx_OrganizationAndDescriptionOfBusinessTable" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_OrganizationAndDescriptionOfBusinessLineItems" xlink:type="locator" xlink:label="bdsx_OrganizationAndDescriptionOfBusinessLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="bdsx_OrganizationAndDescriptionOfBusinessLineItems" xlink:to="bdsx_OrganizationAndDescriptionOfBusinessTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bdsx_OrganizationAndDescriptionOfBusinessTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bdsx_OrganizationAndDescriptionOfBusinessLineItems" xlink:to="bdsx_NumberOfCancerTest" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bdsx_OrganizationAndDescriptionOfBusinessLineItems" xlink:to="bdsx_NumberOfCommercialBloodBasedTest" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bdsx_OrganizationAndDescriptionOfBusinessLineItems" xlink:to="bdsx_NumberOfSARSCoV2Test" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bdsx_OrganizationAndDescriptionOfBusinessLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" order="10350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bdsx_OrganizationAndDescriptionOfBusinessLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" order="10370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bdsx_OrganizationAndDescriptionOfBusinessLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="10420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bdsx_OrganizationAndDescriptionOfBusinessLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="10440.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bdsx_OrganizationAndDescriptionOfBusinessLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="10460.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bdsx_OrganizationAndDescriptionOfBusinessLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="10480.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bdsx_OrganizationAndDescriptionOfBusinessLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="10530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bdsx_OrganizationAndDescriptionOfBusinessLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="10550.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bdsx_OrganizationAndDescriptionOfBusinessLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="10570.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bdsx_OrganizationAndDescriptionOfBusinessLineItems" xlink:to="bdsx_ConvertiblePreferredStockAndConvertibleNotesPayableConvertedToCommonStock" order="10590.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bdsx_OrganizationAndDescriptionOfBusinessLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="10610.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:href="bdsx-20201231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://biodesix.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillImpairmentLoss" xlink:type="locator" xlink:label="us-gaap_GoodwillImpairmentLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:type="locator" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:type="locator" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherInventorySupplies" xlink:type="locator" xlink:label="us-gaap_OtherInventorySupplies" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:type="locator" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCash" xlink:type="locator" xlink:label="us-gaap_RestrictedCash" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskPercentage1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsDescription" xlink:type="locator" xlink:label="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsDescription" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_IncreaseDecreaseInAccumulatedDeficit" xlink:type="locator" xlink:label="bdsx_IncreaseDecreaseInAccumulatedDeficit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillPeriodIncreaseDecrease" xlink:type="locator" xlink:label="us-gaap_GoodwillPeriodIncreaseDecrease" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_ProductLifeAndPatentLifeMember" xlink:type="locator" xlink:label="bdsx_ProductLifeAndPatentLifeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCurrentAssetsMember" xlink:type="locator" xlink:label="us-gaap_OtherCurrentAssetsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationAxis" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_MedicareMember" xlink:type="locator" xlink:label="bdsx_MedicareMember" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_CovanceCentralLaboratoryServicesMember" xlink:type="locator" xlink:label="bdsx_CovanceCentralLaboratoryServicesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:type="locator" xlink:label="srt_NameOfMajorCustomerDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:type="locator" xlink:label="srt_NameOfMajorCustomerDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis" xlink:type="locator" xlink:label="srt_MajorCustomersAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:type="locator" xlink:label="us-gaap_CustomerConcentrationRiskMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTypeDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:type="locator" xlink:label="us-gaap_SalesRevenueNetMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_TestingServicesMember" xlink:type="locator" xlink:label="bdsx_TestingServicesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember" xlink:type="locator" xlink:label="srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RestatementDomain" xlink:type="locator" xlink:label="srt_RestatementDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RestatementDomain" xlink:type="locator" xlink:label="srt_RestatementDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RestatementAxis" xlink:type="locator" xlink:label="srt_RestatementAxis" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_SummaryOfSignificantAccountingPoliciesTable" xlink:type="locator" xlink:label="bdsx_SummaryOfSignificantAccountingPoliciesTable" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:type="locator" xlink:label="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="bdsx_SummaryOfSignificantAccountingPoliciesTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_RestatementAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RestatementDomain" xlink:to="srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_ProductOrServiceAxis" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain_2" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="bdsx_TestingServicesMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_2" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_SalesRevenueNetMember" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" order="10280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain_2" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CustomerConcentrationRiskMember" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_MajorCustomersAxis" order="10360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain_2" order="10370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" order="10390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="bdsx_CovanceCentralLaboratoryServicesMember" order="10410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="bdsx_MedicareMember" order="10430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="10440.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain_2" order="10450.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="10470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_OtherCurrentAssetsMember" order="10490.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_RangeAxis" order="10560.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_2" order="10570.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10590.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10610.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10630.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="10720.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2" order="10730.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="10750.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="bdsx_ProductLifeAndPatentLifeMember" order="10770.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_GoodwillPeriodIncreaseDecrease" order="10800.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="bdsx_IncreaseDecreaseInAccumulatedDeficit" order="10820.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsDescription" order="10840.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" order="10890.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="10940.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" order="10990.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_RestrictedCash" order="11100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable" order="11170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_OtherInventorySupplies" order="11240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="11310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" order="11410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife" order="11520.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" order="11590.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_GoodwillImpairmentLoss" order="11660.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfRevenueAndAccountsReceivableByThirdPartyPayorsAndOtherCustomersDetails" xlink:href="bdsx-20201231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfRevenueAndAccountsReceivableByThirdPartyPayorsAndOtherCustomersDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://biodesix.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfRevenueAndAccountsReceivableByThirdPartyPayorsAndOtherCustomersDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskPercentage1" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_PfizerIncMember" xlink:type="locator" xlink:label="bdsx_PfizerIncMember" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_JanssenResearchAndDevelopmentLLCMember" xlink:type="locator" xlink:label="bdsx_JanssenResearchAndDevelopmentLLCMember" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_CovanceCentralLaboratoryServicesMember" xlink:type="locator" xlink:label="bdsx_CovanceCentralLaboratoryServicesMember" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_MedicareMember" xlink:type="locator" xlink:label="bdsx_MedicareMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:type="locator" xlink:label="us-gaap_AccountsReceivableMember" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_CenturaHealthcareMember" xlink:type="locator" xlink:label="bdsx_CenturaHealthcareMember" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_TheBigTenConferenceMember" xlink:type="locator" xlink:label="bdsx_TheBigTenConferenceMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:type="locator" xlink:label="srt_NameOfMajorCustomerDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis" xlink:type="locator" xlink:label="srt_MajorCustomersAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:type="locator" xlink:label="us-gaap_CustomerConcentrationRiskMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:type="locator" xlink:label="us-gaap_SalesRevenueNetMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_SalesRevenueNetMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CustomerConcentrationRiskMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="srt_MajorCustomersAxis" order="10240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="bdsx_TheBigTenConferenceMember" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="bdsx_CenturaHealthcareMember" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_AccountsReceivableMember" order="10370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="bdsx_MedicareMember" order="10750.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="bdsx_CovanceCentralLaboratoryServicesMember" order="10790.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="bdsx_JanssenResearchAndDevelopmentLLCMember" order="10810.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="bdsx_PfizerIncMember" order="10830.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" order="10860.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosureBusinessCombinationsAdditionalInformationDetails" xlink:href="bdsx-20201231.xsd#Role_DisclosureBusinessCombinationsAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://biodesix.com/20201231/taxonomy/role/DisclosureBusinessCombinationsAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_BusinessCombinationContingentConsiderationArrangementsCommonSharesRedemptionAmount" xlink:type="locator" xlink:label="bdsx_BusinessCombinationContingentConsiderationArrangementsCommonSharesRedemptionAmount" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_BusinessAcquisitionContingentConsiderationNumberOfInstallments" xlink:type="locator" xlink:label="bdsx_BusinessAcquisitionContingentConsiderationNumberOfInstallments" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_BusinessCombinationContingentConsiderationShares" xlink:type="locator" xlink:label="bdsx_BusinessCombinationContingentConsiderationShares" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod" xlink:type="locator" xlink:label="bdsx_BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:type="locator" xlink:label="us-gaap_CashAcquiredFromAcquisition" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill" xlink:type="locator" xlink:label="us-gaap_Goodwill" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherPaymentsToAcquireBusinesses" xlink:type="locator" xlink:label="us-gaap_OtherPaymentsToAcquireBusinesses" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_RepurchaseMember" xlink:type="locator" xlink:label="bdsx_RepurchaseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_IntegratedDiagnosticsIncMember" xlink:type="locator" xlink:label="bdsx_IntegratedDiagnosticsIncMember" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US" xlink:type="locator" xlink:label="country_US" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_OncimmuneLimitedMember" xlink:type="locator" xlink:label="bdsx_OncimmuneLimitedMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseMember" xlink:type="locator" xlink:label="us-gaap_LicenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="srt_ProductOrServiceAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_LicenseMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_2" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="bdsx_OncimmuneLimitedMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="srt_StatementGeographicalAxis" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_2" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_US" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="bdsx_IntegratedDiagnosticsIncMember" order="10390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10680.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10710.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10730.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_InvestmentTypeAxis" order="10840.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember_2" order="10850.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="10870.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="bdsx_RepurchaseMember" order="10890.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1" order="10940.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity" order="10960.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_OtherPaymentsToAcquireBusinesses" order="10980.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_PaymentsToAcquireBusinessesGross" order="11000.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_Goodwill" order="11050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure" order="11140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_CashAcquiredFromAcquisition" order="11230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="bdsx_BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod" order="11250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="bdsx_BusinessCombinationContingentConsiderationShares" order="11270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="bdsx_BusinessAcquisitionContingentConsiderationNumberOfInstallments" order="11290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="bdsx_BusinessCombinationContingentConsiderationArrangementsCommonSharesRedemptionAmount" order="11310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" order="11370.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosureBusinessCombinationsSummaryOfAggregateConsiderationPaidByCompanyAndAllocationOfPurchasePriceToAssetsAcquiredAndLiabilitiesAssumedDetails" xlink:href="bdsx-20201231.xsd#Role_DisclosureBusinessCombinationsSummaryOfAggregateConsiderationPaidByCompanyAndAllocationOfPurchasePriceToAssetsAcquiredAndLiabilitiesAssumedDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://biodesix.com/20201231/taxonomy/role/DisclosureBusinessCombinationsSummaryOfAggregateConsiderationPaidByCompanyAndAllocationOfPurchasePriceToAssetsAcquiredAndLiabilitiesAssumedDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill" xlink:type="locator" xlink:label="us-gaap_Goodwill" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPurchaseOption" xlink:type="locator" xlink:label="bdsx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPurchaseOption" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_OncimmuneLimitedMember" xlink:type="locator" xlink:label="bdsx_OncimmuneLimitedMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" order="10080.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="bdsx_OncimmuneLimitedMember" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_PaymentsToAcquireBusinessesGross" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="bdsx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPurchaseOption" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_Goodwill" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" order="10350.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosureFairValueSummaryOfFairValueOfOutstandingBorrowingsDetails" xlink:href="bdsx-20201231.xsd#Role_DisclosureFairValueSummaryOfFairValueOfOutstandingBorrowingsDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://biodesix.com/20201231/taxonomy/role/DisclosureFairValueSummaryOfFairValueOfOutstandingBorrowingsDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtFairValue" xlink:type="locator" xlink:label="us-gaap_LongTermDebtFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:type="locator" xlink:label="us-gaap_EstimateOfFairValueFairValueDisclosureMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:type="locator" xlink:label="us-gaap_CarryingReportedAmountFairValueDisclosureMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosureItemAmountsDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:type="locator" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementBasisAxis" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisTable" xlink:type="locator" xlink:label="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisTable" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisLineItems" xlink:type="locator" xlink:label="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisLineItems" xlink:to="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementBasisAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementBasisAxis" xlink:to="us-gaap_PortionAtFairValueFairValueDisclosureMember" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="us-gaap_PortionAtFairValueFairValueDisclosureMember" order="10060.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementBasisAxis" xlink:to="us-gaap_FairValueDisclosureItemAmountsDomain" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="us-gaap_CarryingReportedAmountFairValueDisclosureMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="us-gaap_EstimateOfFairValueFairValueDisclosureMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_2" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="10350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisLineItems" xlink:to="us-gaap_LongTermDebtFairValue" order="10440.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosureFairValueScheduleOfReportedFairValuesOfLiabilitiesDetails" xlink:href="bdsx-20201231.xsd#Role_DisclosureFairValueScheduleOfReportedFairValuesOfLiabilitiesDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://biodesix.com/20201231/taxonomy/role/DisclosureFairValueScheduleOfReportedFairValuesOfLiabilitiesDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_LiabilitiesFairValueDisclosure" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_ContingentValueRightsMember" xlink:type="locator" xlink:label="bdsx_ContingentValueRightsMember" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_WarrantLiabilityMember" xlink:type="locator" xlink:label="bdsx_WarrantLiabilityMember" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_PutOptionLiabilityMember" xlink:type="locator" xlink:label="bdsx_PutOptionLiabilityMember" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_ContingentConsiderationMember" xlink:type="locator" xlink:label="bdsx_ContingentConsiderationMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByLiabilityClassAxis" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisTable" xlink:type="locator" xlink:label="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisTable" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisLineItems" xlink:type="locator" xlink:label="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisLineItems" xlink:to="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="bdsx_ContingentConsiderationMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="bdsx_PutOptionLiabilityMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="bdsx_WarrantLiabilityMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="bdsx_ContingentValueRightsMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="10240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosure" order="10340.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosureFairValueScheduleOfChangesInFinancialLiabilitiesDetails" xlink:href="bdsx-20201231.xsd#Role_DisclosureFairValueScheduleOfChangesInFinancialLiabilitiesDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://biodesix.com/20201231/taxonomy/role/DisclosureFairValueScheduleOfChangesInFinancialLiabilitiesDetails">
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_FairValueMeasurementWithUnobservableInputsReconciliationReclassifiedToAdditionalPaidInCapital" xlink:type="locator" xlink:label="bdsx_FairValueMeasurementWithUnobservableInputsReconciliationReclassifiedToAdditionalPaidInCapital" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_ContingentValueRightsMember" xlink:type="locator" xlink:label="bdsx_ContingentValueRightsMember" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_WarrantLiabilityMember" xlink:type="locator" xlink:label="bdsx_WarrantLiabilityMember" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_PutOptionLiabilityMember" xlink:type="locator" xlink:label="bdsx_PutOptionLiabilityMember" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_ContingentConsiderationMember" xlink:type="locator" xlink:label="bdsx_ContingentConsiderationMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByLiabilityClassAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" order="10280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="bdsx_ContingentConsiderationMember" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="bdsx_PutOptionLiabilityMember" order="10350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="bdsx_WarrantLiabilityMember" order="10370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="bdsx_ContingentValueRightsMember" order="10390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" order="10420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" order="10500.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" order="10580.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="bdsx_FairValueMeasurementWithUnobservableInputsReconciliationReclassifiedToAdditionalPaidInCapital" order="10660.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosureFairValueAdditionalInformationDetails" xlink:href="bdsx-20201231.xsd#Role_DisclosureFairValueAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://biodesix.com/20201231/taxonomy/role/DisclosureFairValueAdditionalInformationDetails">
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_PercentageOfDevelopmentAndRegulatoryCostsExercisedUsingOptOutRight" xlink:type="locator" xlink:label="bdsx_PercentageOfDevelopmentAndRegulatoryCostsExercisedUsingOptOutRight" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_NetProceedsPercentageOfCashPaymentToCVRHolders" xlink:type="locator" xlink:label="bdsx_NetProceedsPercentageOfCashPaymentToCVRHolders" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_ContingentValueRightsPercentage" xlink:type="locator" xlink:label="bdsx_ContingentValueRightsPercentage" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_ContingentValueRights" xlink:type="locator" xlink:label="bdsx_ContingentValueRights" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_ContingentValueRightsShares" xlink:type="locator" xlink:label="bdsx_ContingentValueRightsShares" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_PutOptionLiabilityCurrent" xlink:type="locator" xlink:label="bdsx_PutOptionLiabilityCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_PercentageOfProbabilitiesOfContingentConsiderationSuccessfulAchievementMilestoneDiscountRatesRange" xlink:type="locator" xlink:label="bdsx_PercentageOfProbabilitiesOfContingentConsiderationSuccessfulAchievementMilestoneDiscountRatesRange" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesFPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesFPreferredStockMember" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_AVEOOncologyMember" xlink:type="locator" xlink:label="bdsx_AVEOOncologyMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember" xlink:type="locator" xlink:label="us-gaap_IPOMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesGPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesGPreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_NotesPayable2018NotesMember" xlink:type="locator" xlink:label="bdsx_NotesPayable2018NotesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="srt_RangeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain_2" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="bdsx_NotesPayable2018NotesMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesGPreferredStockMember" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="srt_CounterpartyNameAxis" order="10360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_2" order="10370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="10390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="bdsx_AVEOOncologyMember" order="10410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesFPreferredStockMember" order="10470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="bdsx_PercentageOfProbabilitiesOfContingentConsiderationSuccessfulAchievementMilestoneDiscountRatesRange" order="10580.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" order="10650.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="bdsx_PutOptionLiabilityCurrent" order="10720.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" order="10770.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="10790.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate" order="10810.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" order="10830.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="10850.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="10890.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="bdsx_ContingentValueRightsShares" order="10940.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="bdsx_ContingentValueRights" order="10960.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="bdsx_ContingentValueRightsPercentage" order="10980.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="bdsx_NetProceedsPercentageOfCashPaymentToCVRHolders" order="11000.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="bdsx_PercentageOfDevelopmentAndRegulatoryCostsExercisedUsingOptOutRight" order="11020.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" xlink:href="bdsx-20201231.xsd#Role_DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://biodesix.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:type="locator" xlink:label="us-gaap_ConstructionInProgressMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:type="locator" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquipmentMember" xlink:type="locator" xlink:label="us-gaap_EquipmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="10030.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10060.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_2" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="10240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="10520.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10560.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfDepreciationExpenseRelatedToPropertyAndEquipmentDetails" xlink:href="bdsx-20201231.xsd#Role_DisclosurePropertyAndEquipmentScheduleOfDepreciationExpenseRelatedToPropertyAndEquipmentDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://biodesix.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfDepreciationExpenseRelatedToPropertyAndEquipmentDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation" xlink:type="locator" xlink:label="us-gaap_Depreciation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_DirectCostsAndExpensesMember" xlink:type="locator" xlink:label="bdsx_DirectCostsAndExpensesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentMember" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByAssetClassAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_2" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="bdsx_DirectCostsAndExpensesMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_Depreciation" order="10240.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsScheduleOfIntangibleAssetsDetails" xlink:href="bdsx-20201231.xsd#Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfIntangibleAssetsDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://biodesix.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsScheduleOfIntangibleAssetsDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_IntangibleAssetsAccumulatedAmortizationExcludingGoodwill" xlink:type="locator" xlink:label="bdsx_IntangibleAssetsAccumulatedAmortizationExcludingGoodwill" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsGrossExcludingGoodwill" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="locator" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_IndefiniteLivedIntangibleAssetsExcludingGoodwillGross" xlink:type="locator" xlink:label="bdsx_IndefiniteLivedIntangibleAssetsExcludingGoodwillGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TrademarksMember" xlink:type="locator" xlink:label="us-gaap_TrademarksMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_PurchaseOptionMember" xlink:type="locator" xlink:label="bdsx_PurchaseOptionMember" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_PurchasedTechnologyMember" xlink:type="locator" xlink:label="bdsx_PurchasedTechnologyMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PatentsMember" xlink:type="locator" xlink:label="us-gaap_PatentsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" order="10050.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="10080.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_PatentsMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="bdsx_PurchasedTechnologyMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="bdsx_PurchaseOptionMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_2" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_TrademarksMember" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" order="10320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" order="10500.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="10680.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="bdsx_IndefiniteLivedIntangibleAssetsExcludingGoodwillGross" order="11430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" order="11610.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_IntangibleAssetsGrossExcludingGoodwill" order="12180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="bdsx_IntangibleAssetsAccumulatedAmortizationExcludingGoodwill" order="12360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="12540.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsScheduleOfAmortizationExpenseRelatedToDefiniteLivedIntangibleAssetsDetails" xlink:href="bdsx-20201231.xsd#Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfAmortizationExpenseRelatedToDefiniteLivedIntangibleAssetsDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://biodesix.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsScheduleOfAmortizationExpenseRelatedToDefiniteLivedIntangibleAssetsDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:type="locator" xlink:label="us-gaap_AmortizationOfIntangibleAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_DirectCostsAndExpensesMember" xlink:type="locator" xlink:label="bdsx_DirectCostsAndExpensesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="bdsx_DirectCostsAndExpensesMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="10140.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosureDebtSummaryOfLongTermNotesPayableDetails" xlink:href="bdsx-20201231.xsd#Role_DisclosureDebtSummaryOfLongTermNotesPayableDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://biodesix.com/20201231/taxonomy/role/DisclosureDebtSummaryOfLongTermNotesPayableDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:type="locator" xlink:label="us-gaap_LongTermNotesPayable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:type="locator" xlink:label="us-gaap_NotesPayableCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayable" xlink:type="locator" xlink:label="us-gaap_NotesPayable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:type="locator" xlink:label="us-gaap_ConvertibleNotesPayableCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentCarryingAmount" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_CARESActMember" xlink:type="locator" xlink:label="bdsx_CARESActMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_PPPLoanMember" xlink:type="locator" xlink:label="bdsx_PPPLoanMember" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_NotesPayable2018NotesMember" xlink:type="locator" xlink:label="bdsx_NotesPayable2018NotesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" order="10030.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="10060.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="bdsx_NotesPayable2018NotesMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="bdsx_PPPLoanMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_2" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="bdsx_CARESActMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentCarryingAmount" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ConvertibleNotesPayableCurrent" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" order="10340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_NotesPayable" order="10380.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_NotesPayableCurrent" order="10420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermNotesPayable" order="10460.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" xlink:href="bdsx-20201231.xsd#Role_DisclosureDebtAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://biodesix.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetails">
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_IncreaseToPutOptionLiability" xlink:type="locator" xlink:label="bdsx_IncreaseToPutOptionLiability" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_PercentageOfConversionPricePerShareOfConvertiblePreferredStock" xlink:type="locator" xlink:label="bdsx_PercentageOfConversionPricePerShareOfConvertiblePreferredStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_PutOptionLiabilityCurrent" xlink:type="locator" xlink:label="bdsx_PutOptionLiabilityCurrent" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_PercentageOfConversionPricePerShareOfCommonStock" xlink:type="locator" xlink:label="bdsx_PercentageOfConversionPricePerShareOfCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentRate" xlink:type="locator" xlink:label="us-gaap_DebtConversionConvertedInstrumentRate" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_DebtInstrumentMaturityDateExtended" xlink:type="locator" xlink:label="bdsx_DebtInstrumentMaturityDateExtended" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesIssued1" xlink:type="locator" xlink:label="us-gaap_NotesIssued1" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_PercentageOfUpperLimitOfEmployeeSalaryToReduceForgiveness" xlink:type="locator" xlink:label="bdsx_PercentageOfUpperLimitOfEmployeeSalaryToReduceForgiveness" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_UpperLimitOfEmployeeSalaryToReduceForgiveness" xlink:type="locator" xlink:label="bdsx_UpperLimitOfEmployeeSalaryToReduceForgiveness" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_PercentageForNonPayrollCosts" xlink:type="locator" xlink:label="bdsx_PercentageForNonPayrollCosts" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_PayrollCostsExcludesCompensationOfEmployee" xlink:type="locator" xlink:label="bdsx_PayrollCostsExcludesCompensationOfEmployee" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentDescription" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentDescription" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_DebtInstrumentAdditionalInterestExpenseFeePercentage" xlink:type="locator" xlink:label="bdsx_DebtInstrumentAdditionalInterestExpenseFeePercentage" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_DebtInstrumentBackEndFacilityFeePercentage" xlink:type="locator" xlink:label="bdsx_DebtInstrumentBackEndFacilityFeePercentage" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_DebtInstrumentPrepaymentPenaltyPercentage" xlink:type="locator" xlink:label="bdsx_DebtInstrumentPrepaymentPenaltyPercentage" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_DebtInstrumentInterestAddedToPrincipalValue" xlink:type="locator" xlink:label="bdsx_DebtInstrumentInterestAddedToPrincipalValue" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_DebtInstrumentPercentageOfStatedInterestRateAddedToPrincipalValueOfNotesPayable" xlink:type="locator" xlink:label="bdsx_DebtInstrumentPercentageOfStatedInterestRateAddedToPrincipalValueOfNotesPayable" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_DebtInstrumentPercentageOfStatedInterestRatePaidInCash" xlink:type="locator" xlink:label="bdsx_DebtInstrumentPercentageOfStatedInterestRatePaidInCash" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFeeAmount" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFeeAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentCarryingAmount" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_AugustTwoThousandAndNineteenConvertibleNotesMember" xlink:type="locator" xlink:label="bdsx_AugustTwoThousandAndNineteenConvertibleNotesMember" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_DecemberTwoThousandAndNineteenConvertibleNotesMember" xlink:type="locator" xlink:label="bdsx_DecemberTwoThousandAndNineteenConvertibleNotesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesHPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesHPreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodTwoMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodOneMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodAxis" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_MarchTwoThousandAndTwentyConvertibleNotesMember" xlink:type="locator" xlink:label="bdsx_MarchTwoThousandAndTwentyConvertibleNotesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestBearingDepositsMember" xlink:type="locator" xlink:label="us-gaap_InterestBearingDepositsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeAxis" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_CARESActMember" xlink:type="locator" xlink:label="bdsx_CARESActMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_PPPLoanMember" xlink:type="locator" xlink:label="bdsx_PPPLoanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesGPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesGPreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_NotesPayable2018NotesMember" xlink:type="locator" xlink:label="bdsx_NotesPayable2018NotesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="bdsx_NotesPayable2018NotesMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesGPreferredStockMember" order="10350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_RangeAxis" order="10520.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10550.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10570.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10590.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="bdsx_PPPLoanMember" order="10650.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" order="10660.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="10690.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="bdsx_CARESActMember" order="10710.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_InvestmentTypeAxis" order="10720.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="10750.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_InterestBearingDepositsMember" order="10770.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" order="11180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain_2" order="11190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" order="11210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="bdsx_MarchTwoThousandAndTwentyConvertibleNotesMember" order="11230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodAxis" order="11480.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodDomain_2" order="11490.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodDomain" order="11510.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodOneMember" order="11530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodTwoMember" order="11550.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesHPreferredStockMember" order="11610.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="11640.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="11670.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="11690.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="bdsx_DecemberTwoThousandAndNineteenConvertibleNotesMember" order="11750.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="bdsx_AugustTwoThousandAndNineteenConvertibleNotesMember" order="12270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentCarryingAmount" order="12740.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFeeAmount" order="12790.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" order="12830.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" order="12870.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="12910.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="bdsx_DebtInstrumentPercentageOfStatedInterestRatePaidInCash" order="12950.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="bdsx_DebtInstrumentPercentageOfStatedInterestRateAddedToPrincipalValueOfNotesPayable" order="12990.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="bdsx_DebtInstrumentInterestAddedToPrincipalValue" order="13030.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" order="13070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="bdsx_DebtInstrumentPrepaymentPenaltyPercentage" order="13140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="bdsx_DebtInstrumentBackEndFacilityFeePercentage" order="13160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="bdsx_DebtInstrumentAdditionalInterestExpenseFeePercentage" order="13180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" order="13230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentDescription" order="13350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="bdsx_PayrollCostsExcludesCompensationOfEmployee" order="13420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="bdsx_PercentageForNonPayrollCosts" order="13440.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="bdsx_UpperLimitOfEmployeeSalaryToReduceForgiveness" order="13460.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="bdsx_PercentageOfUpperLimitOfEmployeeSalaryToReduceForgiveness" order="13480.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_NotesIssued1" order="13530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="13550.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="bdsx_DebtInstrumentMaturityDateExtended" order="13570.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentRate" order="13650.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1" order="13670.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="bdsx_PercentageOfConversionPricePerShareOfCommonStock" order="13690.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="bdsx_PutOptionLiabilityCurrent" order="13710.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="13730.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="bdsx_PercentageOfConversionPricePerShareOfConvertiblePreferredStock" order="14190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="bdsx_IncreaseToPutOptionLiability" order="14320.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails" xlink:href="bdsx-20201231.xsd#Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://biodesix.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_NumberOfPreferredStockConvertedIntoCommonStock" xlink:type="locator" xlink:label="bdsx_NumberOfPreferredStockConvertedIntoCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesIssued" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_SeriesB1ConvertiblePreferredStockMember" xlink:type="locator" xlink:label="bdsx_SeriesB1ConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesGPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesGPreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesFPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesFPreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesEPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesEPreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesDPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesDPreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesCPreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesBPreferredStockMember" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_SeriesA3PreferredStockMember" xlink:type="locator" xlink:label="bdsx_SeriesA3PreferredStockMember" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_SeriesA2PreferredStockMember" xlink:type="locator" xlink:label="bdsx_SeriesA2PreferredStockMember" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_SeriesA1PreferredStockMember" xlink:type="locator" xlink:label="bdsx_SeriesA1PreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesHPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesHPreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesHPreferredStockMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="bdsx_SeriesA1PreferredStockMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="bdsx_SeriesA2PreferredStockMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="bdsx_SeriesA3PreferredStockMember" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesCPreferredStockMember" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesDPreferredStockMember" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesEPreferredStockMember" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesFPreferredStockMember" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesGPreferredStockMember" order="10350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="bdsx_SeriesB1ConvertiblePreferredStockMember" order="10390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" order="10420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare" order="10460.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" order="10500.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" order="10610.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="bdsx_NumberOfPreferredStockConvertedIntoCommonStock" order="11050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="11090.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosureWarrantsToPurchaseConvertiblePreferredStockSummaryOfActivityForConvertiblePreferredStockWarrantsDetails" xlink:href="bdsx-20201231.xsd#Role_DisclosureWarrantsToPurchaseConvertiblePreferredStockSummaryOfActivityForConvertiblePreferredStockWarrantsDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://biodesix.com/20201231/taxonomy/role/DisclosureWarrantsToPurchaseConvertiblePreferredStockSummaryOfActivityForConvertiblePreferredStockWarrantsDetails">
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsReclassificationOfWarrantLiabilityToAdditionalPaidInCapitalWeightedAverageExercisePrice" xlink:type="locator" xlink:label="bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsReclassificationOfWarrantLiabilityToAdditionalPaidInCapitalWeightedAverageExercisePrice" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="bdsx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="bdsx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsPeriodIncreaseDecrease" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsPeriodIncreaseDecrease" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_SeriesGConvertiblePreferredStockWarrantsMember" xlink:type="locator" xlink:label="bdsx_SeriesGConvertiblePreferredStockWarrantsMember" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_SeriesEConvertiblePreferredStockWarrantsMember" xlink:type="locator" xlink:label="bdsx_SeriesEConvertiblePreferredStockWarrantsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="bdsx_SeriesEConvertiblePreferredStockWarrantsMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="bdsx_SeriesGConvertiblePreferredStockWarrantsMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" order="10260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" order="10340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" order="10380.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsPeriodIncreaseDecrease" order="10420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="bdsx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" order="10530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice" order="10610.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="bdsx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" order="10690.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice" order="10770.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsReclassificationOfWarrantLiabilityToAdditionalPaidInCapitalWeightedAverageExercisePrice" order="10850.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosureEquityAdditionalInformationDetails" xlink:href="bdsx-20201231.xsd#Role_DisclosureEquityAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://biodesix.com/20201231/taxonomy/role/DisclosureEquityAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_DirectOfferingExpenses" xlink:type="locator" xlink:label="bdsx_DirectOfferingExpenses" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees" xlink:type="locator" xlink:label="us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DividendsCommonStock" xlink:type="locator" xlink:label="us-gaap_DividendsCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockVotingRights" xlink:type="locator" xlink:label="us-gaap_CommonStockVotingRights" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember" xlink:type="locator" xlink:label="us-gaap_IPOMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockVotingRights" order="10240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_DividendsCommonStock" order="10260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="10350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees" order="10370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="bdsx_DirectOfferingExpenses" order="10390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="10440.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="10460.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="10480.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="10500.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosureRevenueSummaryOfRevenueDetails" xlink:href="bdsx-20201231.xsd#Role_DisclosureRevenueSummaryOfRevenueDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://biodesix.com/20201231/taxonomy/role/DisclosureRevenueSummaryOfRevenueDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues" xlink:type="locator" xlink:label="us-gaap_Revenues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ServiceMember" xlink:type="locator" xlink:label="us-gaap_ServiceMember" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_DiagnosticTestsMember" xlink:type="locator" xlink:label="bdsx_DiagnosticTestsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_ProductOrServiceAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="bdsx_DiagnosticTestsMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ServiceMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_Revenues" order="10140.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosureRevenueAdditionalInformationDetails" xlink:href="bdsx-20201231.xsd#Role_DisclosureRevenueAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://biodesix.com/20201231/taxonomy/role/DisclosureRevenueAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_AdvanceDeposits" xlink:type="locator" xlink:label="bdsx_AdvanceDeposits" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues" xlink:type="locator" xlink:label="us-gaap_Revenues" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_DeferredRevenueMember" xlink:type="locator" xlink:label="bdsx_DeferredRevenueMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationAxis" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_LungDiagnosticRevenueMember" xlink:type="locator" xlink:label="bdsx_LungDiagnosticRevenueMember" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_COVID19DiagnosticTestRevenueMember" xlink:type="locator" xlink:label="bdsx_COVID19DiagnosticTestRevenueMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_ProductOrServiceAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="bdsx_COVID19DiagnosticTestRevenueMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="bdsx_LungDiagnosticRevenueMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="bdsx_DeferredRevenueMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_Revenues" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="bdsx_AdvanceDeposits" order="10320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" order="10380.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="10440.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails" xlink:href="bdsx-20201231.xsd#Role_DisclosureShareBasedCompensationAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://biodesix.com/20201231/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_PercentageOfFullyDilutedEquityForBonusAwarded" xlink:type="locator" xlink:label="bdsx_PercentageOfFullyDilutedEquityForBonusAwarded" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_NumberOfEqualAnnualInstallmentsForAwardVesting" xlink:type="locator" xlink:label="bdsx_NumberOfEqualAnnualInstallmentsForAwardVesting" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_DescriptionOfOfferingPeriodUnderPlan" xlink:type="locator" xlink:label="bdsx_DescriptionOfOfferingPeriodUnderPlan" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_DescriptionOfVotingPowerOrValueOfStockForEmployeeParticipationInOfferingPeriod" xlink:type="locator" xlink:label="bdsx_DescriptionOfVotingPowerOrValueOfStockForEmployeeParticipationInOfferingPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain" xlink:type="locator" xlink:label="us-gaap_VestingDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain" xlink:type="locator" xlink:label="us-gaap_VestingDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingAxis" xlink:type="locator" xlink:label="us-gaap_VestingAxis" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_ServiceConditionRSUsMember" xlink:type="locator" xlink:label="bdsx_ServiceConditionRSUsMember" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_OptionsAndRestrictedStockUnitsMember" xlink:type="locator" xlink:label="bdsx_OptionsAndRestrictedStockUnitsMember" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_BonusToOptionsProgramMember" xlink:type="locator" xlink:label="bdsx_BonusToOptionsProgramMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_PerformanceConditionOptionsMember" xlink:type="locator" xlink:label="bdsx_PerformanceConditionOptionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_TwoThousandSixPlanTwoThousandSixteenPlanAndTwoThousandTwentyEquityIncentivePlanMember" xlink:type="locator" xlink:label="bdsx_TwoThousandSixPlanTwoThousandSixteenPlanAndTwoThousandTwentyEquityIncentivePlanMember" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_TwoThousandAndSixteenPlanMember" xlink:type="locator" xlink:label="bdsx_TwoThousandAndSixteenPlanMember" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_TwoThousandSixPlanMember" xlink:type="locator" xlink:label="bdsx_TwoThousandSixPlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_TwoThousandTwentyEquityIncentivePlanMember" xlink:type="locator" xlink:label="bdsx_TwoThousandTwentyEquityIncentivePlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_EmployeeStockMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_2" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="bdsx_TwoThousandTwentyEquityIncentivePlanMember" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="10420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10450.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10490.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="bdsx_TwoThousandSixPlanMember" order="10550.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="bdsx_TwoThousandAndSixteenPlanMember" order="10570.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="bdsx_TwoThousandSixPlanTwoThousandSixteenPlanAndTwoThousandTwentyEquityIncentivePlanMember" order="10850.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="11060.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" order="11070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="11090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="bdsx_PerformanceConditionOptionsMember" order="11110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="11390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="bdsx_BonusToOptionsProgramMember" order="11530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="bdsx_OptionsAndRestrictedStockUnitsMember" order="11870.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="bdsx_ServiceConditionRSUsMember" order="11950.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_VestingAxis" order="12160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain_2" order="12170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" order="12190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" order="12210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" order="12230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="12260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" order="12280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" order="12330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate" order="12350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="bdsx_DescriptionOfVotingPowerOrValueOfStockForEmployeeParticipationInOfferingPeriod" order="12370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="bdsx_DescriptionOfOfferingPeriodUnderPlan" order="12390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" order="12480.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="12530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="12570.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="12740.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" order="12790.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="bdsx_NumberOfEqualAnnualInstallmentsForAwardVesting" order="12830.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="12870.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="12910.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" order="12990.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="13030.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="13070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="13110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="13180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="bdsx_PercentageOfFullyDilutedEquityForBonusAwarded" order="13250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="13290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="13310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="13360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" order="13410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="13430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" order="13520.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="13560.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" order="13580.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="13600.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfPreTaxShareBasedCompensationExpenseDetails" xlink:href="bdsx-20201231.xsd#Role_DisclosureShareBasedCompensationSummaryOfPreTaxShareBasedCompensationExpenseDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://biodesix.com/20201231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfPreTaxShareBasedCompensationExpenseDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="10140.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosureEarningsPerShareScheduleOfCommonStockEquivalentsExcludedFromDilutedNetLossAttributableToCommonStockholdersDetails" xlink:href="bdsx-20201231.xsd#Role_DisclosureEarningsPerShareScheduleOfCommonStockEquivalentsExcludedFromDilutedNetLossAttributableToCommonStockholdersDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://biodesix.com/20201231/taxonomy/role/DisclosureEarningsPerShareScheduleOfCommonStockEquivalentsExcludedFromDilutedNetLossAttributableToCommonStockholdersDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_ConvertibleDebtSecuritiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember" xlink:type="locator" xlink:label="us-gaap_WarrantMember" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_OptionsToPurchaseCommonStockMember" xlink:type="locator" xlink:label="bdsx_OptionsToPurchaseCommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="bdsx_OptionsToPurchaseCommonStockMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_ConvertibleDebtSecuritiesMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="10240.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:href="bdsx-20201231.xsd#Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://biodesix.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRoyalties" xlink:type="locator" xlink:label="us-gaap_PaymentsForRoyalties" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_RevenueShareExpenses" xlink:type="locator" xlink:label="bdsx_RevenueShareExpenses" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_PeriodOfEscalationsOfSales" xlink:type="locator" xlink:label="bdsx_PeriodOfEscalationsOfSales" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_MinimumAnnualVolumePercentageThereafter" xlink:type="locator" xlink:label="bdsx_MinimumAnnualVolumePercentageThereafter" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_PercentageOfRevenueSharePaymentRelatedToAcquiredDiagnosticTestRecognizedRevenueForNonScreeningTests" xlink:type="locator" xlink:label="bdsx_PercentageOfRevenueSharePaymentRelatedToAcquiredDiagnosticTestRecognizedRevenueForNonScreeningTests" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyExpense" xlink:type="locator" xlink:label="us-gaap_RoyaltyExpense" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_LicenseAgreementExpiryDate" xlink:type="locator" xlink:label="bdsx_LicenseAgreementExpiryDate" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_PercentageOfRoyaltyPaymentsOnNetRevenue" xlink:type="locator" xlink:label="bdsx_PercentageOfRoyaltyPaymentsOnNetRevenue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_PercentageOfLicenseIncomeGeneratedFromLicensing" xlink:type="locator" xlink:label="bdsx_PercentageOfLicenseIncomeGeneratedFromLicensing" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_PercentageOfRoyaltyPaymentsOnNetSales" xlink:type="locator" xlink:label="bdsx_PercentageOfRoyaltyPaymentsOnNetSales" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_RemainingEstimatedObligation" xlink:type="locator" xlink:label="bdsx_RemainingEstimatedObligation" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_PercentageOfDevelopmentAndRegulatoryCostsExercisedUsingOptOutRight" xlink:type="locator" xlink:label="bdsx_PercentageOfDevelopmentAndRegulatoryCostsExercisedUsingOptOutRight" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_PercentageOfDevelopmentAndRegulatoryCosts" xlink:type="locator" xlink:label="bdsx_PercentageOfDevelopmentAndRegulatoryCosts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesRentExpenseNet" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_OncimmuneLimitedMember" xlink:type="locator" xlink:label="bdsx_OncimmuneLimitedMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAxis" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_RevenueShareAgreementMember" xlink:type="locator" xlink:label="bdsx_RevenueShareAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_BioRadLicenseMember" xlink:type="locator" xlink:label="bdsx_BioRadLicenseMember" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_POCClinicalTrialsMember" xlink:type="locator" xlink:label="bdsx_POCClinicalTrialsMember" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_NSCLCPOCTrialMember" xlink:type="locator" xlink:label="bdsx_NSCLCPOCTrialMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_AVEOOncologyMember" xlink:type="locator" xlink:label="bdsx_AVEOOncologyMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_FiclatuzumabMember" xlink:type="locator" xlink:label="bdsx_FiclatuzumabMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesIndustryMember" xlink:type="locator" xlink:label="us-gaap_EquitySecuritiesIndustryMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesIndustryMember" xlink:type="locator" xlink:label="us-gaap_EquitySecuritiesIndustryMember_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesByIndustryAxis" xlink:type="locator" xlink:label="us-gaap_EquitySecuritiesByIndustryAxis" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_BDX004Member" xlink:type="locator" xlink:label="bdsx_BDX004Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesTable" xlink:type="locator" xlink:label="us-gaap_LossContingenciesTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:type="locator" xlink:label="us-gaap_LossContingenciesLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingenciesTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LossContingenciesTable" xlink:to="srt_ProductOrServiceAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="bdsx_BDX004Member" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_EquitySecuritiesByIndustryAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_EquitySecuritiesByIndustryAxis" xlink:to="us-gaap_EquitySecuritiesIndustryMember_2" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_EquitySecuritiesByIndustryAxis" xlink:to="us-gaap_EquitySecuritiesIndustryMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquitySecuritiesIndustryMember" xlink:to="bdsx_FiclatuzumabMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LossContingenciesTable" xlink:to="srt_CounterpartyNameAxis" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="bdsx_AVEOOncologyMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="10240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="bdsx_NSCLCPOCTrialMember" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="bdsx_POCClinicalTrialsMember" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="bdsx_BioRadLicenseMember" order="10650.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10700.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_2" order="10710.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10730.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bdsx_RevenueShareAgreementMember" order="10750.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="10840.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="10870.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="bdsx_OncimmuneLimitedMember" order="10890.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_OperatingLeasesRentExpenseNet" order="11000.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="bdsx_PercentageOfDevelopmentAndRegulatoryCosts" order="11070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="bdsx_PercentageOfDevelopmentAndRegulatoryCostsExercisedUsingOptOutRight" order="11140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="bdsx_RemainingEstimatedObligation" order="11160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="bdsx_PercentageOfRoyaltyPaymentsOnNetSales" order="11180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="bdsx_PercentageOfLicenseIncomeGeneratedFromLicensing" order="11200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="11250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="bdsx_PercentageOfRoyaltyPaymentsOnNetRevenue" order="11320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="bdsx_LicenseAgreementExpiryDate" order="11340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_RoyaltyExpense" order="11360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="bdsx_PercentageOfRevenueSharePaymentRelatedToAcquiredDiagnosticTestRecognizedRevenueForNonScreeningTests" order="11430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="bdsx_MinimumAnnualVolumePercentageThereafter" order="11450.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="bdsx_PeriodOfEscalationsOfSales" order="11470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="bdsx_RevenueShareExpenses" order="11490.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_PaymentsForRoyalties" order="11510.00" priority="2" use="optional" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>19
<FILENAME>bdsx-20201231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-03-16T14:26:39.4386317+00:00 -->
<!-- Version            : 5.0.1.571 -->
<!-- Package ID         : dca80741ea2145de953066364db43c8f -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/label/axisDefault" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd#axisDefault" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_IntangibleAssetsAccumulatedAmortizationExcludingGoodwill" xlink:type="locator" xlink:label="bdsx_IntangibleAssetsAccumulatedAmortizationExcludingGoodwill" />
    <link:label xml:lang="en-US" xlink:label="bdsx_IntangibleAssetsAccumulatedAmortizationExcludingGoodwill_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of accumulated amortization of intangible assets, excluding goodwill.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_IntangibleAssetsAccumulatedAmortizationExcludingGoodwill" xlink:to="bdsx_IntangibleAssetsAccumulatedAmortizationExcludingGoodwill_lbl" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport" xlink:type="locator" xlink:label="dei_DocumentAnnualReport" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentAnnualReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Annual Report</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentAnnualReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Annual Report</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Document Period End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" />
    <link:label xml:lang="en-US" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Fiscal Year End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:type="locator" xlink:label="dei_DocumentTransitionReport" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentTransitionReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Transition Report</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentTransitionReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Address Line1</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Address Line2</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address City Or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address State Or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of 12(b) Security</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_IcfrAuditorAttestationFlag" xlink:type="locator" xlink:label="dei_IcfrAuditorAttestationFlag" />
    <link:label xml:lang="en-US" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ICFR Auditor Attestation Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Icfr Auditor Attestation Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Well Known Seasoned Issuer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Well Known Seasoned Issuer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers" xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Voluntary Filers</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Voluntary Filers</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Current Reporting Status</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Interactive Data Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:type="locator" xlink:label="dei_EntityFilerCategory" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFilerCategory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Filer Category</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFilerCategory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness" xlink:type="locator" xlink:label="dei_EntitySmallBusiness" />
    <link:label xml:lang="en-US" xlink:label="dei_EntitySmallBusiness_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Small Business</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntitySmallBusiness_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityExTransitionPeriod" xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Ex Transition Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:type="locator" xlink:label="dei_EntityShellCompany" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityShellCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Shell Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityShellCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Common Stock, Shares Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock Shares Outstanding</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat" xlink:type="locator" xlink:label="dei_EntityPublicFloat" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityPublicFloat_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Public Float</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityPublicFloat_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Public Float</link:label>
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_PutOptionLiabilityCurrent" xlink:type="locator" xlink:label="bdsx_PutOptionLiabilityCurrent" />
    <link:label xml:lang="en-US" xlink:label="bdsx_PutOptionLiabilityCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Put option liability current.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_PutOptionLiabilityCurrent" xlink:to="bdsx_PutOptionLiabilityCurrent_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Financial Position [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents At Carrying Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts receivable, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Receivable Net Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsNoncurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non&#8209;current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsNoncurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Noncurrent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible assets, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Intangible Assets Net Excluding Goodwill</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other long-term assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill" xlink:type="locator" xlink:label="us-gaap_Goodwill" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Goodwill_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Goodwill</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Goodwill" xlink:to="us-gaap_Goodwill_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Goodwill_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total non&#8209;current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Assets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Assets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities, Convertible Preferred Stock and Stockholders&apos; Equity (Deficit)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities And Stockholders Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Liability Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableToBankCurrent" xlink:type="locator" xlink:label="us-gaap_NotesPayableToBankCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NotesPayableToBankCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current portion of notes payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableToBankCurrent" xlink:to="us-gaap_NotesPayableToBankCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NotesPayableToBankCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Notes Payable To Bank Current</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_PutOptionLiabilityCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Put option liability</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_PutOptionLiabilityCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Put Option Liability Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non&#8209;current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Noncurrent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsOutstanding" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant liability</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstanding" xlink:to="us-gaap_WarrantsAndRightsOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Warrants And Rights Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:type="locator" xlink:label="us-gaap_LongTermNotesPayable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongTermNotesPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long&#8209;term notes payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermNotesPayable" xlink:to="us-gaap_LongTermNotesPayable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongTermNotesPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Notes Payable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent consideration</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination Contingent Consideration Liability Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other long-term liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Liabilities Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total non&#8209;current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Liabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Liabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and contingencies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityAbstract" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preferred stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityAbstract" xlink:to="us-gaap_TemporaryEquityAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preferred stock, $0.001 par value, 0 (2020) and 174,237,067 (2019) authorized; 0 (2020) and 118,766,273 (2019) issued and outstanding; liquidation preference of $202,582 (2019)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Carrying Amount Attributable To Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders&apos; equity (deficit)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, $0.001 par value, 5,000,000 (2020) and 0 (2019) authorized; 0 (2020 and 2019) issued and outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, $0.001 par value, 200,000,000 (2020) and 190,000,000 (2019) authorized; 26,561,504 (2020) and 254,918 (2019) issued and outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid&#8209;in capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid In Capital</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings Accumulated Deficit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total stockholders&apos; equity (deficit)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities, convertible preferred stock and stockholders&apos; equity (deficit)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities And Stockholders Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preferred stock, par value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Par Or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesAuthorized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preferred stock, authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesAuthorized" xlink:to="us-gaap_TemporaryEquitySharesAuthorized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesIssued" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preferred stock, issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesIssued" xlink:to="us-gaap_TemporaryEquitySharesIssued_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Shares Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preferred stock, outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesOutstanding" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityLiquidationPreference" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityLiquidationPreference_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preferred stock, liquidation preference</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityLiquidationPreference" xlink:to="us-gaap_TemporaryEquityLiquidationPreference_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityLiquidationPreference_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Liquidation Preference</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, par value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Par Or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Shares Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, par value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Par Or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Outstanding</link:label>
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_DirectCostsAndExpenses" xlink:type="locator" xlink:label="bdsx_DirectCostsAndExpenses" />
    <link:label xml:lang="en-US" xlink:label="bdsx_DirectCostsAndExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Direct costs and expenses.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_DirectCostsAndExpenses" xlink:to="bdsx_DirectCostsAndExpenses_lbl" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_ChangeInFairValueOfContingentConsiderationExcludingAccretionExpense" xlink:type="locator" xlink:label="bdsx_ChangeInFairValueOfContingentConsiderationExcludingAccretionExpense" />
    <link:label xml:lang="en-US" xlink:label="bdsx_ChangeInFairValueOfContingentConsiderationExcludingAccretionExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Change in fair value of contingent consideration excluding accretion expense.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_ChangeInFairValueOfContingentConsiderationExcludingAccretionExpense" xlink:to="bdsx_ChangeInFairValueOfContingentConsiderationExcludingAccretionExpense_lbl" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_ChangeInFairValueOfPutOptionLiability" xlink:type="locator" xlink:label="bdsx_ChangeInFairValueOfPutOptionLiability" />
    <link:label xml:lang="en-US" xlink:label="bdsx_ChangeInFairValueOfPutOptionLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Change in fair value of put option liability.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_ChangeInFairValueOfPutOptionLiability" xlink:to="bdsx_ChangeInFairValueOfPutOptionLiability_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues" xlink:type="locator" xlink:label="us-gaap_Revenues" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Revenues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenues</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Revenues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_DirectCostsAndExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Direct costs and expenses</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_DirectCostsAndExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Direct Costs And Expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sales, marketing, general and administrative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Selling General And Administrative Expense</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_ChangeInFairValueOfContingentConsiderationExcludingAccretionExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in fair value of contingent consideration</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_ChangeInFairValueOfContingentConsiderationExcludingAccretionExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Change In Fair Value Of Contingent Consideration Excluding Accretion Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss from operations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:type="locator" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other income (expense):</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_OtherIncomeAndExpensesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Income And Expenses [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeOther" xlink:type="locator" xlink:label="us-gaap_InterestIncomeOther" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestIncomeOther_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeOther" xlink:to="us-gaap_InterestIncomeOther_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestIncomeOther_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Interest Income Other</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense" xlink:type="locator" xlink:label="us-gaap_InterestExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Interest expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Interest Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Change in fair value of warrant liability</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Adjustment Of Warrants</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_ChangeInFairValueOfPutOptionLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Change in fair value of put option liability</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_ChangeInFairValueOfPutOptionLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Change In Fair Value Of Put Option Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncome" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherNonoperatingIncome_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other income, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncome" xlink:to="us-gaap_OtherNonoperatingIncome_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherNonoperatingIncome_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Nonoperating Income</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total other expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Nonoperating Income Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Income Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share, basic and diluted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share Basic And Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average shares outstanding, basic and diluted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number Of Share Outstanding Basic And Diluted</link:label>
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="bdsx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" />
    <link:label xml:lang="en-US" xlink:label="bdsx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity stock issued during period shares new issues.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:to="bdsx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_StockIssuedDuringPeriodSharesConversionOfConvertibleSecuritiesCommonStock" xlink:type="locator" xlink:label="bdsx_StockIssuedDuringPeriodSharesConversionOfConvertibleSecuritiesCommonStock" />
    <link:label xml:lang="en-US" xlink:label="bdsx_StockIssuedDuringPeriodSharesConversionOfConvertibleSecuritiesCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of shares issued during the period as a result of the conversion of convertible securities classified as common stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_StockIssuedDuringPeriodSharesConversionOfConvertibleSecuritiesCommonStock" xlink:to="bdsx_StockIssuedDuringPeriodSharesConversionOfConvertibleSecuritiesCommonStock_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Stockholders Equity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Components</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Equity Components [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Component</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid-in Capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid In Capital [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Deficit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Class Of Stock [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Stock [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Preferred Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockMember" xlink:to="us-gaap_ConvertiblePreferredStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Temporary Equity Balance, Shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock issued upon exercise of stock options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Stock Options Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock issued upon exercise of stock options, shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Stock Options Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of Series H Preferred Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Stock Issued During Period Value New Issues</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of Series H Preferred Stock, shares</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Stock Issued During Period Shares New Issues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock&#8209;based compensation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock in initial public offering, net of discounts and commission of $5,040 and direct offering costs of $3,203</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value New Issues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock in initial public offering, net of discounts and commission and direct offering costs, shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares New Issues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of preferred stock into common stock upon initial public offering</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Conversion Of Convertible Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of preferred stock into common stock, shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Conversion Of Convertible Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of convertible debt into common stock upon initial public offering</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_StockIssuedDuringPeriodSharesConversionOfConvertibleSecuritiesCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of convertible debt into common stock, shares</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_StockIssuedDuringPeriodSharesConversionOfConvertibleSecuritiesCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Conversion Of Convertible Securities Common Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reclassification of preferred stock warrant liability and put option into additional paid-in capital upon initial public offering</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Additional Paid In Capital Warrant Issued</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss and comprehensive loss</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Temporary Equity Balance, Shares</link:label>
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_SaleOfStockTemporaryEquityPricePerShare" xlink:type="locator" xlink:label="bdsx_SaleOfStockTemporaryEquityPricePerShare" />
    <link:label xml:lang="en-US" xlink:label="bdsx_SaleOfStockTemporaryEquityPricePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Sale of stock, temporary equity, price per share.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_SaleOfStockTemporaryEquityPricePerShare" xlink:to="bdsx_SaleOfStockTemporaryEquityPricePerShare_lbl" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_TemporaryEquityIssuanceCosts" xlink:type="locator" xlink:label="bdsx_TemporaryEquityIssuanceCosts" />
    <link:label xml:lang="en-US" xlink:label="bdsx_TemporaryEquityIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity issuance costs.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_TemporaryEquityIssuanceCosts" xlink:to="bdsx_TemporaryEquityIssuanceCosts_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesHPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesHPreferredStockMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SeriesHPreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series H Convertible Preferred Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesHPreferredStockMember" xlink:to="us-gaap_SeriesHPreferredStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SeriesHPreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Series H Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_SaleOfStockTemporaryEquityPricePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of stock, temporary equity, price per share</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_SaleOfStockTemporaryEquityPricePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sale Of Stock Temporary Equity Price Per Share</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_TemporaryEquityIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_TemporaryEquityIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Issuance Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalUnitsDeductionsFromTotalCostToInvestors" xlink:type="locator" xlink:label="us-gaap_CapitalUnitsDeductionsFromTotalCostToInvestors" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CapitalUnitsDeductionsFromTotalCostToInvestors_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Discounts and commission</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalUnitsDeductionsFromTotalCostToInvestors" xlink:to="us-gaap_CapitalUnitsDeductionsFromTotalCostToInvestors_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CapitalUnitsDeductionsFromTotalCostToInvestors_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Capital Units Deductions From Total Cost To Investors</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalUnitsTotalCostToInvestors" xlink:type="locator" xlink:label="us-gaap_CapitalUnitsTotalCostToInvestors" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CapitalUnitsTotalCostToInvestors_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Direct offering costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalUnitsTotalCostToInvestors" xlink:to="us-gaap_CapitalUnitsTotalCostToInvestors_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CapitalUnitsTotalCostToInvestors_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Capital Units Total Cost To Investors</link:label>
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_AccruedInterestOnNotesPayableAndConvertibleNotesPayable" xlink:type="locator" xlink:label="bdsx_AccruedInterestOnNotesPayableAndConvertibleNotesPayable" />
    <link:label xml:lang="en-US" xlink:label="bdsx_AccruedInterestOnNotesPayableAndConvertibleNotesPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued interest on notes payable and convertible notes payable.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_AccruedInterestOnNotesPayableAndConvertibleNotesPayable" xlink:to="bdsx_AccruedInterestOnNotesPayableAndConvertibleNotesPayable_lbl" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_PaymentsForProceedsFromPatentCostsAndIntangibleAssetAcquisitionNet" xlink:type="locator" xlink:label="bdsx_PaymentsForProceedsFromPatentCostsAndIntangibleAssetAcquisitionNet" />
    <link:label xml:lang="en-US" xlink:label="bdsx_PaymentsForProceedsFromPatentCostsAndIntangibleAssetAcquisitionNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Payments for proceeds from patent costs and intangible asset acquisition, net.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_PaymentsForProceedsFromPatentCostsAndIntangibleAssetAcquisitionNet" xlink:to="bdsx_PaymentsForProceedsFromPatentCostsAndIntangibleAssetAcquisitionNet_lbl" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_PaymentsToAcquireOncimmune" xlink:type="locator" xlink:label="bdsx_PaymentsToAcquireOncimmune" />
    <link:label xml:lang="en-US" xlink:label="bdsx_PaymentsToAcquireOncimmune_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Payments to acquire Oncimmune.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_PaymentsToAcquireOncimmune" xlink:to="bdsx_PaymentsToAcquireOncimmune_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Cash Flows [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from operating activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProfitLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProfitLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Profit Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net loss to net cash, cash equivalents, and restricted cash used in operating activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation and amortization</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation And Amortization</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="locator" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization of convertible notes debt discount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amortization Of Debt Discount Premium</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock&#8209;based compensation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in fair value of warrant liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in contingent consideration</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_ChangeInFairValueOfPutOptionLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Change in fair value of put option</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_AccruedInterestOnNotesPayableAndConvertibleNotesPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued interest on notes payable and convertible notes payable</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_AccruedInterestOnNotesPayableAndConvertibleNotesPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Interest On Notes Payable And Convertible Notes Payable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:type="locator" xlink:label="us-gaap_AmortizationOfFinancingCosts" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AmortizationOfFinancingCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization of debt issuance costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCosts" xlink:to="us-gaap_AmortizationOfFinancingCosts_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AmortizationOfFinancingCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amortization Of Financing Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:type="locator" xlink:label="us-gaap_ProvisionForDoubtfulAccounts" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProvisionForDoubtfulAccounts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Provision for doubtful accounts</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProvisionForDoubtfulAccounts" xlink:to="us-gaap_ProvisionForDoubtfulAccounts_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProvisionForDoubtfulAccounts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Provision For Doubtful Accounts</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:type="locator" xlink:label="us-gaap_GainLossOnDispositionOfAssets1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GainLossOnDispositionOfAssets1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Loss on disposals of assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnDispositionOfAssets1" xlink:to="us-gaap_GainLossOnDispositionOfAssets1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GainLossOnDispositionOfAssets1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Gain Loss On Disposition Of Assets1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in operating assets and liabilities, net of assets acquired and liabilities assumed in acquisitions:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Operating Capital [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accounts receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accounts Receivable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Other Current Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other long-term assets and liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Other Noncurrent Assets And Liabilities Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable and other accrued liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accounts Payable And Accrued Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Contract With Customer Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash and cash equivalents and restricted cash used in operating activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Operating Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from investing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Investing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchase of property and equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments To Acquire Property Plant And Equipment</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_PaymentsForProceedsFromPatentCostsAndIntangibleAssetAcquisitionNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Patent costs and intangible asset acquisition, net</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_PaymentsForProceedsFromPatentCostsAndIntangibleAssetAcquisitionNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments For Proceeds From Patent Costs And Intangible Asset Acquisition Net</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_PaymentsToAcquireOncimmune_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Payments to acquire Oncimmune assets</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_PaymentsToAcquireOncimmune_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments To Acquire Oncimmune</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash and cash equivalents and restricted cash used in investing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Investing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from financing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Financing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from initial public offering</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Initial Public Offering</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from exercise of common stock options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Stock Options Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of series H preferred stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Convertible Preferred Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:type="locator" xlink:label="us-gaap_ProceedsFromConvertibleDebt" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromConvertibleDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuances of convertible notes payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromConvertibleDebt" xlink:to="us-gaap_ProceedsFromConvertibleDebt_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromConvertibleDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Convertible Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:type="locator" xlink:label="us-gaap_ProceedsFromNotesPayable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromNotesPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from paycheck protection program note payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromNotesPayable" xlink:to="us-gaap_ProceedsFromNotesPayable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromNotesPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Notes Payable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Equity financing costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments Of Stock Issuance Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:type="locator" xlink:label="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:to="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Payments For Other Financing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash and cash equivalents and restricted cash provided by financing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Financing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net increase (decrease) in cash and cash equivalents and restricted cash</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash, cash equivalents, and restricted cash &#8209; beginning of period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash, cash equivalents, and restricted cash &#8209; end of period</link:label>
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_ConversionOfPreferredStockIntoCommonStock" xlink:type="locator" xlink:label="bdsx_ConversionOfPreferredStockIntoCommonStock" />
    <link:label xml:lang="en-US" xlink:label="bdsx_ConversionOfPreferredStockIntoCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Conversion of preferred stock into common stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_ConversionOfPreferredStockIntoCommonStock" xlink:to="bdsx_ConversionOfPreferredStockIntoCommonStock_lbl" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_ReclassificationOfPutOptionLiabilityToAdditionalPaidInCapital" xlink:type="locator" xlink:label="bdsx_ReclassificationOfPutOptionLiabilityToAdditionalPaidInCapital" />
    <link:label xml:lang="en-US" xlink:label="bdsx_ReclassificationOfPutOptionLiabilityToAdditionalPaidInCapital_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Reclassification of put option liability to additional paid in capital.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_ReclassificationOfPutOptionLiabilityToAdditionalPaidInCapital" xlink:to="bdsx_ReclassificationOfPutOptionLiabilityToAdditionalPaidInCapital_lbl" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_ValueOfPutOptionRecordedAtIssuanceOfConvertibleNotesPayable" xlink:type="locator" xlink:label="bdsx_ValueOfPutOptionRecordedAtIssuanceOfConvertibleNotesPayable" />
    <link:label xml:lang="en-US" xlink:label="bdsx_ValueOfPutOptionRecordedAtIssuanceOfConvertibleNotesPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Value of put option recorded at issuance of convertible notes payable.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_ValueOfPutOptionRecordedAtIssuanceOfConvertibleNotesPayable" xlink:to="bdsx_ValueOfPutOptionRecordedAtIssuanceOfConvertibleNotesPayable_lbl" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_ReclassificationOfWarrantLiabilityToAdditionalPaidInCapital" xlink:type="locator" xlink:label="bdsx_ReclassificationOfWarrantLiabilityToAdditionalPaidInCapital" />
    <link:label xml:lang="en-US" xlink:label="bdsx_ReclassificationOfWarrantLiabilityToAdditionalPaidInCapital_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Reclassification of warrant liability to additional paid-in-capital.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_ReclassificationOfWarrantLiabilityToAdditionalPaidInCapital" xlink:to="bdsx_ReclassificationOfWarrantLiabilityToAdditionalPaidInCapital_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental cash flow information</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_ConversionOfPreferredStockIntoCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of preferred stock into common stock</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_ConversionOfPreferredStockIntoCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Conversion Of Preferred Stock Into Common Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:type="locator" xlink:label="us-gaap_ConversionOfStockAmountConverted1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConversionOfStockAmountConverted1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of convertible notes and accrued interest into common stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockAmountConverted1" xlink:to="us-gaap_ConversionOfStockAmountConverted1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConversionOfStockAmountConverted1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Conversion Of Stock Amount Converted1</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_ReclassificationOfPutOptionLiabilityToAdditionalPaidInCapital_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reclassification of put option liability to additional paid-in capital</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_ReclassificationOfPutOptionLiabilityToAdditionalPaidInCapital_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Reclassification Of Put Option Liability To Additional Paid In Capital</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_ValueOfPutOptionRecordedAtIssuanceOfConvertibleNotesPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Value of put option recorded at issuance of convertible debt payable</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_ValueOfPutOptionRecordedAtIssuanceOfConvertibleNotesPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Value Of Put Option Recorded At Issuance Of Convertible Notes Payable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet" xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestPaidNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid for interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestPaidNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Interest Paid Net</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_ReclassificationOfWarrantLiabilityToAdditionalPaidInCapital_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reclassification of warrant liability to additional paid-in capital</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_ReclassificationOfWarrantLiabilityToAdditionalPaidInCapital_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Reclassification Of Warrant Liability To Additional Paid In Capital</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" xlink:type="locator" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued business combination payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" xlink:to="us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Noncash Or Part Noncash Acquisition Value Of Liabilities Assumed1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesPaidNet" xlink:type="locator" xlink:label="us-gaap_IncomeTaxesPaidNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid for income taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Taxes Paid Net</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="locator" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Documents Incorporated by Reference</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Documents Incorporated By Reference [Text Block]</link:label>
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_OrganizationAndDescriptionOfBusinessAbstract" xlink:type="locator" xlink:label="bdsx_OrganizationAndDescriptionOfBusinessAbstract" />
    <link:label xml:lang="en-US" xlink:label="bdsx_OrganizationAndDescriptionOfBusinessAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Organization and description of business.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_OrganizationAndDescriptionOfBusinessAbstract" xlink:to="bdsx_OrganizationAndDescriptionOfBusinessAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="bdsx_OrganizationAndDescriptionOfBusinessAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Organization And Description Of Business [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Organization and Description of Business</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Organization Consolidation And Presentation Of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Significant Accounting Policies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements And Changes In Accounting Principles [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recent Accounting Pronouncements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements And Changes In Accounting Principles [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BusinessCombinationsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Business Combinations [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_BusinessCombinationsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business Combinations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="us-gaap_BusinessCombinationDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill And Intangible Assets Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Goodwill and Intangible Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill And Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payables And Accruals [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable And Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_DebtDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDisclosuresAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockDisclosuresAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Stock Disclosures [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDisclosuresAbstract" xlink:to="us-gaap_ClassOfStockDisclosuresAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockTextBlock" xlink:type="locator" xlink:label="us-gaap_PreferredStockTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Preferred Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockTextBlock" xlink:to="us-gaap_PreferredStockTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock [Text Block]</link:label>
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_WarrantsForConvertiblePreferredStockTextBlock" xlink:type="locator" xlink:label="bdsx_WarrantsForConvertiblePreferredStockTextBlock" />
    <link:label xml:lang="en-US" xlink:label="bdsx_WarrantsForConvertiblePreferredStockTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrants for convertible preferred stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_WarrantsForConvertiblePreferredStockTextBlock" xlink:to="bdsx_WarrantsForConvertiblePreferredStockTextBlock_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Warrants And Rights Note Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="us-gaap_WarrantsAndRightsNoteDisclosureAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="bdsx_WarrantsForConvertiblePreferredStockTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants to Purchase Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_WarrantsForConvertiblePreferredStockTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Warrants For Convertible Preferred Stock [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity Note [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue From Contract With Customer [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue From Contract With Customer [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Based Compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Compensation Related Costs Share Based Payments [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Earnings per Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Compensation And Retirement Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanTextBlock" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DefinedContributionPlanTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Defined Contribution 401(k) Plan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanTextBlock" xlink:to="us-gaap_DefinedContributionPlanTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DefinedContributionPlanTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan [Text Block]</link:label>
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_ReverseStockSplitPolicyTextBlock" xlink:type="locator" xlink:label="bdsx_ReverseStockSplitPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="bdsx_ReverseStockSplitPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of accounting policy for reverse stock split.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_ReverseStockSplitPolicyTextBlock" xlink:to="bdsx_ReverseStockSplitPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="bdsx_ReverseStockSplitPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reverse Stock Split</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_ReverseStockSplitPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Reverse Stock Split Policy [Text Block]</link:label>
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_ApprovalOfAmendedAndRestatedCertificateOfIncorporationPolicyTextBlock" xlink:type="locator" xlink:label="bdsx_ApprovalOfAmendedAndRestatedCertificateOfIncorporationPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="bdsx_ApprovalOfAmendedAndRestatedCertificateOfIncorporationPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of accounting policy for approval of amended and restated certificate of incorporation.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_ApprovalOfAmendedAndRestatedCertificateOfIncorporationPolicyTextBlock" xlink:to="bdsx_ApprovalOfAmendedAndRestatedCertificateOfIncorporationPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="bdsx_ApprovalOfAmendedAndRestatedCertificateOfIncorporationPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Approval of Amended and Restated Certificate of Incorporation</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_ApprovalOfAmendedAndRestatedCertificateOfIncorporationPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Approval Of Amended And Restated Certificate Of Incorporation Policy [Text Block]</link:label>
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_InitialPublicOfferingIPOPolicyTextBlock" xlink:type="locator" xlink:label="bdsx_InitialPublicOfferingIPOPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="bdsx_InitialPublicOfferingIPOPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of accounting policy for initial public offering.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_InitialPublicOfferingIPOPolicyTextBlock" xlink:to="bdsx_InitialPublicOfferingIPOPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="bdsx_InitialPublicOfferingIPOPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial Public Offering ("IPO")</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_InitialPublicOfferingIPOPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Initial Public Offering I P O Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of Presentation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Basis Of Accounting Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segment Reporting</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates" xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Use of Estimates</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Use Of Estimates</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue Recognition</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Recognition Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred Revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue From Contract With Customer Policy [Text Block]</link:label>
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_DirectCostsAndExpensesPolicyTextBlock" xlink:type="locator" xlink:label="bdsx_DirectCostsAndExpensesPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="bdsx_DirectCostsAndExpensesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Direct costs and expenses policy.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_DirectCostsAndExpensesPolicyTextBlock" xlink:to="bdsx_DirectCostsAndExpensesPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="bdsx_DirectCostsAndExpensesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Direct Costs and Expenses</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_DirectCostsAndExpensesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Direct Costs And Expenses Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense Policy</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sales, Marketing, General and Administrative Expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Selling General And Administrative Expenses Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentrations of Credit Risk and Other Uncertainties</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Credit Risk</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Cash</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents Restricted Cash And Cash Equivalents Policy</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:type="locator" xlink:label="us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts Receivable and Allowance for Doubtful Accounts</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:to="us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Receivables Trade And Other Accounts Receivable Allowance For Doubtful Accounts Policy</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventorySuppliesPolicy" xlink:type="locator" xlink:label="us-gaap_InventorySuppliesPolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InventorySuppliesPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Inventory</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventorySuppliesPolicy" xlink:to="us-gaap_InventorySuppliesPolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InventorySuppliesPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Inventory Supplies Policy</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:to="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill And Intangible Assets Intangible Assets Policy</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Goodwill</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:to="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill And Intangible Assets Goodwill Policy</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value of Financial Instruments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_ContingentConsiderationPolicyTextBlock" xlink:type="locator" xlink:label="bdsx_ContingentConsiderationPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="bdsx_ContingentConsiderationPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of accounting policy for contingent consideration.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_ContingentConsiderationPolicyTextBlock" xlink:to="bdsx_ContingentConsiderationPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="bdsx_ContingentConsiderationPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent Consideration</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_ContingentConsiderationPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contingent Consideration Policy [Text Block]</link:label>
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_WarrantLiabilityPolicyTextBlock" xlink:type="locator" xlink:label="bdsx_WarrantLiabilityPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="bdsx_WarrantLiabilityPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of accounting policy for warrant liability.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_WarrantLiabilityPolicyTextBlock" xlink:to="bdsx_WarrantLiabilityPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="bdsx_WarrantLiabilityPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant Liability</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_WarrantLiabilityPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Warrant Liability Policy [Text Block]</link:label>
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_PutOptionLiabilityPolicyTextBlock" xlink:type="locator" xlink:label="bdsx_PutOptionLiabilityPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="bdsx_PutOptionLiabilityPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of accounting policy for put-option liability</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_PutOptionLiabilityPolicyTextBlock" xlink:to="bdsx_PutOptionLiabilityPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="bdsx_PutOptionLiabilityPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Put Option Liability</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_PutOptionLiabilityPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Put Option Liability Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-Based Compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Option And Incentive Plans Policy</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss per Common Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recently Issued Accounting Standards Not Yet Adopted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:type="locator" xlink:label="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Revenue and Accounts Receivable by Third-party Payors and Other Customers</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:to="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedules Of Concentration Of Risk By Risk Factor [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationSegmentAllocationTableTextBlock" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationSegmentAllocationTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BusinessCombinationSegmentAllocationTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Aggregate Consideration Paid by Company and Allocation of Purchase Price to Assets Acquired and Liabilities Assumed</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationSegmentAllocationTableTextBlock" xlink:to="us-gaap_BusinessCombinationSegmentAllocationTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BusinessCombinationSegmentAllocationTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination Segment Allocation Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Fair Value of Outstanding Borrowings</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:to="us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Carrying Values And Estimated Fair Values Of Debt Instruments Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Reported Fair values of Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Liabilities Measured On Recurring Basis [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Changes in Financial Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Property and Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment [Text Block]</link:label>
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_ScheduleOfDepreciationAndAmortizationExpenseRelatedToPropertyAndEquipmentTableTextBlock" xlink:type="locator" xlink:label="bdsx_ScheduleOfDepreciationAndAmortizationExpenseRelatedToPropertyAndEquipmentTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="bdsx_ScheduleOfDepreciationAndAmortizationExpenseRelatedToPropertyAndEquipmentTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of depreciation and amortization expense related to property and equipment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_ScheduleOfDepreciationAndAmortizationExpenseRelatedToPropertyAndEquipmentTableTextBlock" xlink:to="bdsx_ScheduleOfDepreciationAndAmortizationExpenseRelatedToPropertyAndEquipmentTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="bdsx_ScheduleOfDepreciationAndAmortizationExpenseRelatedToPropertyAndEquipmentTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Depreciation Expense Related to Property and Equipment</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_ScheduleOfDepreciationAndAmortizationExpenseRelatedToPropertyAndEquipmentTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Depreciation And Amortization Expense Related To Property And Equipment Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfGoodwillTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfGoodwillTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Changes in Goodwill</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfGoodwillTextBlock" xlink:to="us-gaap_ScheduleOfGoodwillTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfGoodwillTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Goodwill [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Intangible Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:to="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Intangible Assets And Goodwill Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Amortization Expense Related to Definite-Lived Intangible Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets Amortization Expense Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Future Estimated Amortization Expense of Intangible Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Scheduleof Finite Lived Intangible Assets Future Amortization Expense Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Accrued Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Accrued Liabilities Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Long-term Notes Payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:to="us-gaap_ScheduleOfDebtInstrumentsTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Debt Instruments [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Scheduled Principal Repayments (Maturities) of Long-term Obligations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Maturities Of Long Term Debt Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Activity for Convertible Preferred Stock Warrants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Stockholders Equity Note Warrants Or Rights [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disaggregation Of Revenue Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Pre-tax Share-based Compensation Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Stock Option Activity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Compensation Stock Options Activity Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Weighted Average Assumptions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Computation of Basic and Diluted Net Loss per Share Attributable to Common Stockholders</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Earnings Per Share Basic And Diluted Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Common Stock Equivalents Excluded from Diluted Net Loss Attributable to Common Stockholders</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Effective Income Tax Rate Reconciliation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Effective Income Tax Rate Reconciliation Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Deferred Tax Assets and Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Deferred Tax Assets And Liabilities Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reconciliation of Unrecognized Tax Benefits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Unrecognized Tax Benefits Roll Forward Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Future Minimum Lease Payments for Operating Lease Obligations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Future Minimum Rental Payments For Operating Leases Table [Text Block]</link:label>
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_NumberOfCancerTest" xlink:type="locator" xlink:label="bdsx_NumberOfCancerTest" />
    <link:label xml:lang="en-US" xlink:label="bdsx_NumberOfCancerTest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of cancer test.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_NumberOfCancerTest" xlink:to="bdsx_NumberOfCancerTest_lbl" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_OrganizationAndDescriptionOfBusinessLineItems" xlink:type="locator" xlink:label="bdsx_OrganizationAndDescriptionOfBusinessLineItems" />
    <link:label xml:lang="en-US" xlink:label="bdsx_OrganizationAndDescriptionOfBusinessLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Organization and description of business.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_OrganizationAndDescriptionOfBusinessLineItems" xlink:to="bdsx_OrganizationAndDescriptionOfBusinessLineItems_lbl" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_OrganizationAndDescriptionOfBusinessTable" xlink:type="locator" xlink:label="bdsx_OrganizationAndDescriptionOfBusinessTable" />
    <link:label xml:lang="en-US" xlink:label="bdsx_OrganizationAndDescriptionOfBusinessTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Organization and description of business.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_OrganizationAndDescriptionOfBusinessTable" xlink:to="bdsx_OrganizationAndDescriptionOfBusinessTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="bdsx_OrganizationAndDescriptionOfBusinessTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Organization And Description Of Business [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_OrganizationAndDescriptionOfBusinessTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Organization And Description Of Business [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsidiary Sale Of Stock [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sale Of Stock Name Of Transaction [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember" xlink:type="locator" xlink:label="us-gaap_IPOMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IPOMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial Public Offering</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IPOMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">I P O [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_OrganizationAndDescriptionOfBusinessLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Organization And Description Of Business [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_OrganizationAndDescriptionOfBusinessLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Organization And Description Of Business [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_NumberOfCancerTest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of blood based lung cancer test</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_NumberOfCancerTest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Cancer Test</link:label>
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_NumberOfCommercialBloodBasedTest" xlink:type="locator" xlink:label="bdsx_NumberOfCommercialBloodBasedTest" />
    <link:label xml:lang="en-US" xlink:label="bdsx_NumberOfCommercialBloodBasedTest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of commercial blood based test.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_NumberOfCommercialBloodBasedTest" xlink:to="bdsx_NumberOfCommercialBloodBasedTest_lbl" />
    <link:label xml:lang="en-US" xlink:label="bdsx_NumberOfCommercialBloodBasedTest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of commercial blood-based test</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_NumberOfCommercialBloodBasedTest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Commercial Blood Based Test</link:label>
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_NumberOfSARSCoV2Test" xlink:type="locator" xlink:label="bdsx_NumberOfSARSCoV2Test" />
    <link:label xml:lang="en-US" xlink:label="bdsx_NumberOfSARSCoV2Test_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of SARS-CoV-2 test.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_NumberOfSARSCoV2Test" xlink:to="bdsx_NumberOfSARSCoV2Test_lbl" />
    <link:label xml:lang="en-US" xlink:label="bdsx_NumberOfSARSCoV2Test_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of SARS-CoV-2 test</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_NumberOfSARSCoV2Test_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of S A R S Co V2 Test</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reverse stock split, description</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityReverseStockSplit" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity Reverse Stock Split</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reverse stock split ratio</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity Note Stock Split Conversion Ratio1</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock, shares authorized</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock, par value</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Preferred stock, shares authorized</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Preferred stock, par value</link:label>
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_ConvertiblePreferredStockAndConvertibleNotesPayableConvertedToCommonStock" xlink:type="locator" xlink:label="bdsx_ConvertiblePreferredStockAndConvertibleNotesPayableConvertedToCommonStock" />
    <link:label xml:lang="en-US" xlink:label="bdsx_ConvertiblePreferredStockAndConvertibleNotesPayableConvertedToCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Convertible preferred stock and convertible notes payable converted to common stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_ConvertiblePreferredStockAndConvertibleNotesPayableConvertedToCommonStock" xlink:to="bdsx_ConvertiblePreferredStockAndConvertibleNotesPayableConvertedToCommonStock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Shares of common stock issued and sold</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock price per share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued Price Per Share</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_ConvertiblePreferredStockAndConvertibleNotesPayableConvertedToCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preferred stock and convertible notes payable converted into shares of common stock</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_ConvertiblePreferredStockAndConvertibleNotesPayableConvertedToCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock And Convertible Notes Payable Converted To Common Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants to purchase shares of common stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights</link:label>
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_IncreaseDecreaseInAccumulatedDeficit" xlink:type="locator" xlink:label="bdsx_IncreaseDecreaseInAccumulatedDeficit" />
    <link:label xml:lang="en-US" xlink:label="bdsx_IncreaseDecreaseInAccumulatedDeficit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase decrease in accumulated deficit.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_IncreaseDecreaseInAccumulatedDeficit" xlink:to="bdsx_IncreaseDecreaseInAccumulatedDeficit_lbl" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:type="locator" xlink:label="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" />
    <link:label xml:lang="en-US" xlink:label="bdsx_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary Of Significant Accounting Policies [Line Items].</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="bdsx_SummaryOfSignificantAccountingPoliciesLineItems_lbl" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_SummaryOfSignificantAccountingPoliciesTable" xlink:type="locator" xlink:label="bdsx_SummaryOfSignificantAccountingPoliciesTable" />
    <link:label xml:lang="en-US" xlink:label="bdsx_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary of significant accounting policies.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesTable" xlink:to="bdsx_SummaryOfSignificantAccountingPoliciesTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="bdsx_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Significant Accounting Policies [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RestatementAxis" xlink:type="locator" xlink:label="srt_RestatementAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_RestatementAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revision of Prior Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_RestatementAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restatement [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RestatementDomain" xlink:type="locator" xlink:label="srt_RestatementDomain" />
    <link:label xml:lang="en-US" xlink:label="srt_RestatementDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revision of Prior Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RestatementDomain" xlink:to="srt_RestatementDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_RestatementDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restatement [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember" xlink:type="locator" xlink:label="srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember" />
    <link:label xml:lang="en-US" xlink:label="srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revision of Prior Period, Error Correction, Adjustment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember" xlink:to="srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revision Of Prior Period Error Correction Adjustment [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_ProductOrServiceAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product and Service</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_ProductOrServiceAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Product Or Service [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:label xml:lang="en-US" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product and Service</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Products And Services [Domain]</link:label>
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_TestingServicesMember" xlink:type="locator" xlink:label="bdsx_TestingServicesMember" />
    <link:label xml:lang="en-US" xlink:label="bdsx_TestingServicesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Testing services.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_TestingServicesMember" xlink:to="bdsx_TestingServicesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bdsx_TestingServicesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Testing Services</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_TestingServicesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Testing Services [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration Risk Benchmark</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk By Benchmark [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration Risk Benchmark</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:type="locator" xlink:label="us-gaap_SalesRevenueNetMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SalesRevenueNetMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNetMember" xlink:to="us-gaap_SalesRevenueNetMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SalesRevenueNetMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sales Revenue Net [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration Risk Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk By Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTypeDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration Risk Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_ConcentrationRiskTypeDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:type="locator" xlink:label="us-gaap_CustomerConcentrationRiskMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Customer Concentration Risk</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerConcentrationRiskMember" xlink:to="us-gaap_CustomerConcentrationRiskMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis" xlink:type="locator" xlink:label="srt_MajorCustomersAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_MajorCustomersAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Customer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_MajorCustomersAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_MajorCustomersAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Major Customers [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:type="locator" xlink:label="srt_NameOfMajorCustomerDomain" />
    <link:label xml:lang="en-US" xlink:label="srt_NameOfMajorCustomerDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Customer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="srt_NameOfMajorCustomerDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_NameOfMajorCustomerDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Name Of Major Customer [Domain]</link:label>
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_CovanceCentralLaboratoryServicesMember" xlink:type="locator" xlink:label="bdsx_CovanceCentralLaboratoryServicesMember" />
    <link:label xml:lang="en-US" xlink:label="bdsx_CovanceCentralLaboratoryServicesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Covance Central Laboratory Services.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_CovanceCentralLaboratoryServicesMember" xlink:to="bdsx_CovanceCentralLaboratoryServicesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bdsx_CovanceCentralLaboratoryServicesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Covance Central Laboratory Services</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_CovanceCentralLaboratoryServicesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Covance Central Laboratory Services [Member]</link:label>
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_MedicareMember" xlink:type="locator" xlink:label="bdsx_MedicareMember" />
    <link:label xml:lang="en-US" xlink:label="bdsx_MedicareMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Medicare.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_MedicareMember" xlink:to="bdsx_MedicareMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bdsx_MedicareMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Medicare</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_MedicareMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Medicare [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance Sheet Location</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance Sheet Location</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_BalanceSheetLocationDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCurrentAssetsMember" xlink:type="locator" xlink:label="us-gaap_OtherCurrentAssetsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherCurrentAssetsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Current Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCurrentAssetsMember" xlink:to="us-gaap_OtherCurrentAssetsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherCurrentAssetsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Current Assets [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Range [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Range [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:label xml:lang="en-US" xlink:label="srt_MinimumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_MinimumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:label xml:lang="en-US" xlink:label="srt_MaximumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_MaximumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finite-Lived Intangible Assets by Major Class</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets By Major Class [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finite-Lived Intangible Assets, Major Class Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets Major Class Name [Domain]</link:label>
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_ProductLifeAndPatentLifeMember" xlink:type="locator" xlink:label="bdsx_ProductLifeAndPatentLifeMember" />
    <link:label xml:lang="en-US" xlink:label="bdsx_ProductLifeAndPatentLifeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Product life and patent life.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_ProductLifeAndPatentLifeMember" xlink:to="bdsx_ProductLifeAndPatentLifeMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bdsx_ProductLifeAndPatentLifeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product Life and Patent Life</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_ProductLifeAndPatentLifeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Product Life And Patent Life [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillPeriodIncreaseDecrease" xlink:type="locator" xlink:label="us-gaap_GoodwillPeriodIncreaseDecrease" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GoodwillPeriodIncreaseDecrease_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase in goodwill</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillPeriodIncreaseDecrease" xlink:to="us-gaap_GoodwillPeriodIncreaseDecrease_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GoodwillPeriodIncreaseDecrease_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill Period Increase Decrease</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_IncreaseDecreaseInAccumulatedDeficit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Reduction in accumulated deficit</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_IncreaseDecreaseInAccumulatedDeficit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accumulated Deficit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsDescription" xlink:type="locator" xlink:label="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsDescription" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Error corrections and prior period adjustments, description</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsDescription" xlink:to="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsDescription_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Error Corrections And Prior Period Adjustments Description</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of operating segments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Operating Segments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:type="locator" xlink:label="us-gaap_SegmentReportingAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SegmentReportingAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration Risk [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk [Table]</link:label>
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_TheBigTenConferenceMember" xlink:type="locator" xlink:label="bdsx_TheBigTenConferenceMember" />
    <link:label xml:lang="en-US" xlink:label="bdsx_TheBigTenConferenceMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">The Big Ten Conference.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_TheBigTenConferenceMember" xlink:to="bdsx_TheBigTenConferenceMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bdsx_TheBigTenConferenceMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">The Big Ten Conference</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_TheBigTenConferenceMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">The Big Ten Conference [Member]</link:label>
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_CenturaHealthcareMember" xlink:type="locator" xlink:label="bdsx_CenturaHealthcareMember" />
    <link:label xml:lang="en-US" xlink:label="bdsx_CenturaHealthcareMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Centura Healthcare.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_CenturaHealthcareMember" xlink:to="bdsx_CenturaHealthcareMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bdsx_CenturaHealthcareMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Centura Healthcare</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_CenturaHealthcareMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Centura Healthcare [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:type="locator" xlink:label="us-gaap_AccountsReceivableMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsReceivableMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts Receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableMember" xlink:to="us-gaap_AccountsReceivableMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsReceivableMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Receivable [Member]</link:label>
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_JanssenResearchAndDevelopmentLLCMember" xlink:type="locator" xlink:label="bdsx_JanssenResearchAndDevelopmentLLCMember" />
    <link:label xml:lang="en-US" xlink:label="bdsx_JanssenResearchAndDevelopmentLLCMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Janssen Research and Development, LLC.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_JanssenResearchAndDevelopmentLLCMember" xlink:to="bdsx_JanssenResearchAndDevelopmentLLCMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bdsx_JanssenResearchAndDevelopmentLLCMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Janssen Research and Development, LLC</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_JanssenResearchAndDevelopmentLLCMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Janssen Research And Development L L C [Member]</link:label>
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_PfizerIncMember" xlink:type="locator" xlink:label="bdsx_PfizerIncMember" />
    <link:label xml:lang="en-US" xlink:label="bdsx_PfizerIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Pfizer, Inc.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_PfizerIncMember" xlink:to="bdsx_PfizerIncMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bdsx_PfizerIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pfizer, Inc</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_PfizerIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pfizer Inc [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration Risk [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskPercentage1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration risk, percentage</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Percentage1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCash" xlink:type="locator" xlink:label="us-gaap_RestrictedCash" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedCash_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCash" xlink:to="us-gaap_RestrictedCash_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedCash_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:type="locator" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Allowance for doubtful accounts</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Allowance For Doubtful Accounts Receivable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherInventorySupplies" xlink:type="locator" xlink:label="us-gaap_OtherInventorySupplies" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherInventorySupplies_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Inventory</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherInventorySupplies" xlink:to="us-gaap_OtherInventorySupplies_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherInventorySupplies_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Inventory Supplies</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property, plant and equipment, useful Lives</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Useful Life</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:type="locator" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment of long-lived assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Impairment Of Long Lived Assets Held For Use</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finite-lived intangible asset, useful life</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Asset Useful Life</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:type="locator" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment of intangible assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Impairment Of Intangible Assets Excluding Goodwill</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillImpairmentLoss" xlink:type="locator" xlink:label="us-gaap_GoodwillImpairmentLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GoodwillImpairmentLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Goodwill impairments loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillImpairmentLoss" xlink:to="us-gaap_GoodwillImpairmentLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GoodwillImpairmentLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill Impairment Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Business Acquisitions By Acquisition [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Business Acquisitions By Acquisition [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseMember" xlink:type="locator" xlink:label="us-gaap_LicenseMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LicenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License Rights</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicenseMember" xlink:to="us-gaap_LicenseMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LicenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">License [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business Acquisition</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business Acquisition, Acquiree</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition Acquiree [Domain]</link:label>
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_OncimmuneLimitedMember" xlink:type="locator" xlink:label="bdsx_OncimmuneLimitedMember" />
    <link:label xml:lang="en-US" xlink:label="bdsx_OncimmuneLimitedMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Oncimmune Limited.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_OncimmuneLimitedMember" xlink:to="bdsx_OncimmuneLimitedMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bdsx_OncimmuneLimitedMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Oncimmune Limited</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_OncimmuneLimitedMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Oncimmune Limited [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Geographical [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:label xml:lang="en-US" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Segment Geographical [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US" xlink:type="locator" xlink:label="country_US" />
    <link:label xml:lang="en-US" xlink:label="country_US_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">United States</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_US" xlink:to="country_US_lbl" />
    <link:label xml:lang="en-US" xlink:label="country_US_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">UNITED STATES</link:label>
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_IntegratedDiagnosticsIncMember" xlink:type="locator" xlink:label="bdsx_IntegratedDiagnosticsIncMember" />
    <link:label xml:lang="en-US" xlink:label="bdsx_IntegratedDiagnosticsIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Integrated Diagnostics, Inc.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_IntegratedDiagnosticsIncMember" xlink:to="bdsx_IntegratedDiagnosticsIncMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bdsx_IntegratedDiagnosticsIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Integrated Diagnostics, Inc</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_IntegratedDiagnosticsIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Integrated Diagnostics Inc [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investment Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investment Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_InvestmentTypeCategorizationMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investment Type Categorization [Member]</link:label>
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_RepurchaseMember" xlink:type="locator" xlink:label="bdsx_RepurchaseMember" />
    <link:label xml:lang="en-US" xlink:label="bdsx_RepurchaseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Repurchase.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_RepurchaseMember" xlink:to="bdsx_RepurchaseMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bdsx_RepurchaseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Repurchase</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_RepurchaseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Repurchase [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BusinessAcquisitionLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business Acquisition [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BusinessAcquisitionLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total consideration amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination Consideration Transferred1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business acquisition description</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity" xlink:to="us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition Description Of Acquired Entity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherPaymentsToAcquireBusinesses" xlink:type="locator" xlink:label="us-gaap_OtherPaymentsToAcquireBusinesses" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherPaymentsToAcquireBusinesses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payments to acquire license rights</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherPaymentsToAcquireBusinesses" xlink:to="us-gaap_OtherPaymentsToAcquireBusinesses_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherPaymentsToAcquireBusinesses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Payments To Acquire Businesses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="us-gaap_PaymentsToAcquireBusinessesGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments To Acquire Businesses Gross</link:label>
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPurchaseOption" xlink:type="locator" xlink:label="bdsx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPurchaseOption" />
    <link:label xml:lang="en-US" xlink:label="bdsx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPurchaseOption_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Business combination recognized identifiable assets acquired and liabilities assumed purchase option.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPurchaseOption" xlink:to="bdsx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPurchaseOption_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total fair value of consideration transferred</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deposit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Marketable Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Inventory</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Inventory</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Property Plant And Equipment</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPurchaseOption_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchase option</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPurchaseOption_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Purchase Option</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accrued liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Accounts Payable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent consideration estimated fair value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure" xlink:to="us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contingent Consideration Classified As Equity Fair Value Disclosure</link:label>
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod" xlink:type="locator" xlink:label="bdsx_BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod" />
    <link:label xml:lang="en-US" xlink:label="bdsx_BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Business acquisition contingent consideration gross margin target period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod" xlink:to="bdsx_BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod_lbl" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_BusinessAcquisitionContingentConsiderationNumberOfInstallments" xlink:type="locator" xlink:label="bdsx_BusinessAcquisitionContingentConsiderationNumberOfInstallments" />
    <link:label xml:lang="en-US" xlink:label="bdsx_BusinessAcquisitionContingentConsiderationNumberOfInstallments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Business acquisition contingent consideration number of installments.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_BusinessAcquisitionContingentConsiderationNumberOfInstallments" xlink:to="bdsx_BusinessAcquisitionContingentConsiderationNumberOfInstallments_lbl" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_BusinessCombinationContingentConsiderationArrangementsCommonSharesRedemptionAmount" xlink:type="locator" xlink:label="bdsx_BusinessCombinationContingentConsiderationArrangementsCommonSharesRedemptionAmount" />
    <link:label xml:lang="en-US" xlink:label="bdsx_BusinessCombinationContingentConsiderationArrangementsCommonSharesRedemptionAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Business combination contingent consideration arrangements common shares redemption amount.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_BusinessCombinationContingentConsiderationArrangementsCommonSharesRedemptionAmount" xlink:to="bdsx_BusinessCombinationContingentConsiderationArrangementsCommonSharesRedemptionAmount_lbl" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_BusinessCombinationContingentConsiderationShares" xlink:type="locator" xlink:label="bdsx_BusinessCombinationContingentConsiderationShares" />
    <link:label xml:lang="en-US" xlink:label="bdsx_BusinessCombinationContingentConsiderationShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Business combination contingent consideration shares.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_BusinessCombinationContingentConsiderationShares" xlink:to="bdsx_BusinessCombinationContingentConsiderationShares_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:type="locator" xlink:label="us-gaap_CashAcquiredFromAcquisition" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAcquiredFromAcquisition_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business acquisition contingent consideration gross margin target</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAcquiredFromAcquisition" xlink:to="us-gaap_CashAcquiredFromAcquisition_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAcquiredFromAcquisition_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Acquired From Acquisition</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business acquisition contingent consideration gross margin target period</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition Contingent Consideration Gross Margin Target Period</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_BusinessCombinationContingentConsiderationShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent consideration shares</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_BusinessCombinationContingentConsiderationShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination Contingent Consideration Shares</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_BusinessAcquisitionContingentConsiderationNumberOfInstallments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent consideration number of installments</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_BusinessAcquisitionContingentConsiderationNumberOfInstallments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition Contingent Consideration Number Of Installments</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_BusinessCombinationContingentConsiderationArrangementsCommonSharesRedemptionAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent consideration arrangements, common shares, redemption amount</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_BusinessCombinationContingentConsiderationArrangementsCommonSharesRedemptionAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination Contingent Consideration Arrangements Common Shares Redemption Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent consideration cash payment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments To Acquire Businesses Net Of Cash Acquired</link:label>
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisLineItems" xlink:type="locator" xlink:label="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisLineItems" />
    <link:label xml:lang="en-US" xlink:label="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisLineItems" xlink:to="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisLineItems_lbl" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisTable" xlink:type="locator" xlink:label="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisTable" />
    <link:label xml:lang="en-US" xlink:label="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of information about liabilities measured at fair value on recurring basis.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisTable" xlink:to="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Liabilities Measured On Recurring Basis [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Liabilities Measured On Recurring Basis [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementBasisAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByMeasurementBasisAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Basis</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementBasisAxis" xlink:to="us-gaap_FairValueByMeasurementBasisAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByMeasurementBasisAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value By Measurement Basis [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:type="locator" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Disclosure Item Amounts [Default]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:to="us-gaap_PortionAtFairValueFairValueDisclosureMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Portion At Fair Value Fair Value Disclosure [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosureItemAmountsDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueDisclosureItemAmountsDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="us-gaap_FairValueDisclosureItemAmountsDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueDisclosureItemAmountsDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosure Item Amounts [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:type="locator" xlink:label="us-gaap_CarryingReportedAmountFairValueDisclosureMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CarryingReportedAmountFairValueDisclosureMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Carrying Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:to="us-gaap_CarryingReportedAmountFairValueDisclosureMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CarryingReportedAmountFairValueDisclosureMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Carrying Reported Amount Fair Value Disclosure [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:type="locator" xlink:label="us-gaap_EstimateOfFairValueFairValueDisclosureMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EstimateOfFairValueFairValueDisclosureMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:to="us-gaap_EstimateOfFairValueFairValueDisclosureMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EstimateOfFairValueFairValueDisclosureMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Estimate Of Fair Value Fair Value Disclosure [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Frequency</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value By Measurement Frequency [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Frequency</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement Frequency [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Recurring</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurements Recurring [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value By Fair Value Hierarchy Level [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurements Fair Value Hierarchy [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 2</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Level2 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Liabilities Measured On Recurring Basis [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Liabilities Measured On Recurring Basis [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtFairValue" xlink:type="locator" xlink:label="us-gaap_LongTermDebtFairValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongTermDebtFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Borrowings</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtFairValue" xlink:to="us-gaap_LongTermDebtFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongTermDebtFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Debt Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByLiabilityClassAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByLiabilityClassAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liability Class</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueByLiabilityClassAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByLiabilityClassAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value By Liability Class [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value by Liability Class</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation By Liability Class [Domain]</link:label>
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_ContingentConsiderationMember" xlink:type="locator" xlink:label="bdsx_ContingentConsiderationMember" />
    <link:label xml:lang="en-US" xlink:label="bdsx_ContingentConsiderationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Contingent consideration.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_ContingentConsiderationMember" xlink:to="bdsx_ContingentConsiderationMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bdsx_ContingentConsiderationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent Consideration</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_ContingentConsiderationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contingent Consideration [Member]</link:label>
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_PutOptionLiabilityMember" xlink:type="locator" xlink:label="bdsx_PutOptionLiabilityMember" />
    <link:label xml:lang="en-US" xlink:label="bdsx_PutOptionLiabilityMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Put option liability.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_PutOptionLiabilityMember" xlink:to="bdsx_PutOptionLiabilityMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bdsx_PutOptionLiabilityMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Put Option Liability</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_PutOptionLiabilityMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Put Option Liability [Member]</link:label>
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_WarrantLiabilityMember" xlink:type="locator" xlink:label="bdsx_WarrantLiabilityMember" />
    <link:label xml:lang="en-US" xlink:label="bdsx_WarrantLiabilityMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrant liability.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_WarrantLiabilityMember" xlink:to="bdsx_WarrantLiabilityMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bdsx_WarrantLiabilityMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant Liability</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_WarrantLiabilityMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Warrant Liability [Member]</link:label>
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_ContingentValueRightsMember" xlink:type="locator" xlink:label="bdsx_ContingentValueRightsMember" />
    <link:label xml:lang="en-US" xlink:label="bdsx_ContingentValueRightsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Contingent value rights.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_ContingentValueRightsMember" xlink:to="bdsx_ContingentValueRightsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bdsx_ContingentValueRightsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent Value Rights</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_ContingentValueRightsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contingent Value Rights [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 3</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Level3 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_LiabilitiesFairValueDisclosure" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueDisclosure" xlink:to="us-gaap_LiabilitiesFairValueDisclosure_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Fair Value Disclosure</link:label>
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_FairValueMeasurementWithUnobservableInputsReconciliationReclassifiedToAdditionalPaidInCapital" xlink:type="locator" xlink:label="bdsx_FairValueMeasurementWithUnobservableInputsReconciliationReclassifiedToAdditionalPaidInCapital" />
    <link:label xml:lang="en-US" xlink:label="bdsx_FairValueMeasurementWithUnobservableInputsReconciliationReclassifiedToAdditionalPaidInCapital_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value, measurement with unobservable inputs reconciliation reclassified to additional paid-in capital.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_FairValueMeasurementWithUnobservableInputsReconciliationReclassifiedToAdditionalPaidInCapital" xlink:to="bdsx_FairValueMeasurementWithUnobservableInputsReconciliationReclassifiedToAdditionalPaidInCapital_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balances</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Purchases</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in fair value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_FairValueMeasurementWithUnobservableInputsReconciliationReclassifiedToAdditionalPaidInCapital_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reclassified to additional paid-in capital</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_FairValueMeasurementWithUnobservableInputsReconciliationReclassifiedToAdditionalPaidInCapital_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement With Unobservable Inputs Reconciliation Reclassified To Additional Paid In Capital</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balances</link:label>
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_PercentageOfProbabilitiesOfContingentConsiderationSuccessfulAchievementMilestoneDiscountRatesRange" xlink:type="locator" xlink:label="bdsx_PercentageOfProbabilitiesOfContingentConsiderationSuccessfulAchievementMilestoneDiscountRatesRange" />
    <link:label xml:lang="en-US" xlink:label="bdsx_PercentageOfProbabilitiesOfContingentConsiderationSuccessfulAchievementMilestoneDiscountRatesRange_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of probabilities of contingent consideration successful achievement milestone discount rates range.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_PercentageOfProbabilitiesOfContingentConsiderationSuccessfulAchievementMilestoneDiscountRatesRange" xlink:to="bdsx_PercentageOfProbabilitiesOfContingentConsiderationSuccessfulAchievementMilestoneDiscountRatesRange_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="srt_MinimumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Minimum</link:label>
    <link:label xml:lang="en-US" xlink:label="srt_MaximumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Maximum</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongtermDebtTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term Debt, Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongtermDebtTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Longterm Debt Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongtermDebtTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term Debt, Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_LongtermDebtTypeDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongtermDebtTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Longterm Debt Type [Domain]</link:label>
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_NotesPayable2018NotesMember" xlink:type="locator" xlink:label="bdsx_NotesPayable2018NotesMember" />
    <link:label xml:lang="en-US" xlink:label="bdsx_NotesPayable2018NotesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Notes payable 2018 notes.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_NotesPayable2018NotesMember" xlink:to="bdsx_NotesPayable2018NotesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bdsx_NotesPayable2018NotesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2018 Notes</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_NotesPayable2018NotesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Notes Payable2018 Notes [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesGPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesGPreferredStockMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SeriesGPreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series G Preferred Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesGPreferredStockMember" xlink:to="us-gaap_SeriesGPreferredStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SeriesGPreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Series G Preferred Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:label xml:lang="en-US" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Repurchase Agreement Counterparty Name [Domain]</link:label>
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_AVEOOncologyMember" xlink:type="locator" xlink:label="bdsx_AVEOOncologyMember" />
    <link:label xml:lang="en-US" xlink:label="bdsx_AVEOOncologyMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Aveo oncology.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_AVEOOncologyMember" xlink:to="bdsx_AVEOOncologyMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bdsx_AVEOOncologyMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">AVEO Oncology</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_AVEOOncologyMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">A V E O Oncology [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesFPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesFPreferredStockMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SeriesFPreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series F Preferred Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesFPreferredStockMember" xlink:to="us-gaap_SeriesFPreferredStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SeriesFPreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Series F Preferred Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_PercentageOfProbabilitiesOfContingentConsiderationSuccessfulAchievementMilestoneDiscountRatesRange_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of probabilities of contingent consideration successful achievement of specified product gross margin targets discount rates range</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_PercentageOfProbabilitiesOfContingentConsiderationSuccessfulAchievementMilestoneDiscountRatesRange_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Probabilities Of Contingent Consideration Successful Achievement Milestone Discount Rates Range</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Warrant issued to purchase shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant, exercise price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants, expires period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Warrants And Rights Outstanding Maturity Date</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated air value of warrants issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:to="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Warrants Not Settleable In Cash Fair Value Disclosure</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Warrant issued to purchase shares</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Increase in value of the warrant liability</link:label>
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_ContingentValueRightsShares" xlink:type="locator" xlink:label="bdsx_ContingentValueRightsShares" />
    <link:label xml:lang="en-US" xlink:label="bdsx_ContingentValueRightsShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Contingent value rights shares.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_ContingentValueRightsShares" xlink:to="bdsx_ContingentValueRightsShares_lbl" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_ContingentValueRights" xlink:type="locator" xlink:label="bdsx_ContingentValueRights" />
    <link:label xml:lang="en-US" xlink:label="bdsx_ContingentValueRights_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Contingent value rights.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_ContingentValueRights" xlink:to="bdsx_ContingentValueRights_lbl" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_NetProceedsPercentageOfCashPaymentToCVRHolders" xlink:type="locator" xlink:label="bdsx_NetProceedsPercentageOfCashPaymentToCVRHolders" />
    <link:label xml:lang="en-US" xlink:label="bdsx_NetProceedsPercentageOfCashPaymentToCVRHolders_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Net proceeds percentage of cash payment to the cvr holders.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_NetProceedsPercentageOfCashPaymentToCVRHolders" xlink:to="bdsx_NetProceedsPercentageOfCashPaymentToCVRHolders_lbl" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_ContingentValueRightsPercentage" xlink:type="locator" xlink:label="bdsx_ContingentValueRightsPercentage" />
    <link:label xml:lang="en-US" xlink:label="bdsx_ContingentValueRightsPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Contingent value rights percentage.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_ContingentValueRightsPercentage" xlink:to="bdsx_ContingentValueRightsPercentage_lbl" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_PercentageOfDevelopmentAndRegulatoryCostsExercisedUsingOptOutRight" xlink:type="locator" xlink:label="bdsx_PercentageOfDevelopmentAndRegulatoryCostsExercisedUsingOptOutRight" />
    <link:label xml:lang="en-US" xlink:label="bdsx_PercentageOfDevelopmentAndRegulatoryCostsExercisedUsingOptOutRight_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of development and regulatory costs exercised using opt-out right.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_PercentageOfDevelopmentAndRegulatoryCostsExercisedUsingOptOutRight" xlink:to="bdsx_PercentageOfDevelopmentAndRegulatoryCostsExercisedUsingOptOutRight_lbl" />
    <link:label xml:lang="en-US" xlink:label="bdsx_ContingentValueRightsShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent value rights shares</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_ContingentValueRightsShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contingent Value Rights Shares</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_ContingentValueRights_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent value rights</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_ContingentValueRights_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contingent Value Rights</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_ContingentValueRightsPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent value rights percentage</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_ContingentValueRightsPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contingent Value Rights Percentage</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_NetProceedsPercentageOfCashPaymentToCVRHolders_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net proceeds percentage of cash payment to the CVR holders</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_NetProceedsPercentageOfCashPaymentToCVRHolders_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Proceeds Percentage Of Cash Payment To C V R Holders</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_PercentageOfDevelopmentAndRegulatoryCostsExercisedUsingOptOutRight_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of development and regulatory costs exercised using opt-out right</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_PercentageOfDevelopmentAndRegulatoryCostsExercisedUsingOptOutRight_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Development And Regulatory Costs Exercised Using Opt Out Right</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Property Plant And Equipment [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Property Plant And Equipment [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment By Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquipmentMember" xlink:type="locator" xlink:label="us-gaap_EquipmentMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lab Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquipmentMember" xlink:to="us-gaap_EquipmentMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equipment [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leasehold Improvements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Computer Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Computer Equipment [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Furniture and Fixtures</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Furniture And Fixtures [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:type="locator" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Software</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:to="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Software And Software Development Costs [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:type="locator" xlink:label="us-gaap_ConstructionInProgressMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Construction in Process</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionInProgressMember" xlink:to="us-gaap_ConstructionInProgressMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Construction In Progress [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property Plant And Equipment [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, gross</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less accumulated depreciation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Depreciation Depletion And Amortization Property Plant And Equipment</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total property and equipment, net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByAssetClassAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset Class</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueByAssetClassAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value By Asset Class [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset Class</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation By Asset Class [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentMember" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentMember" xlink:to="us-gaap_PropertyPlantAndEquipmentMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Domain]</link:label>
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_DirectCostsAndExpensesMember" xlink:type="locator" xlink:label="bdsx_DirectCostsAndExpensesMember" />
    <link:label xml:lang="en-US" xlink:label="bdsx_DirectCostsAndExpensesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Direct costs and expenses.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_DirectCostsAndExpensesMember" xlink:to="bdsx_DirectCostsAndExpensesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bdsx_DirectCostsAndExpensesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Direct Costs and Expenses</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_DirectCostsAndExpensesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Direct Costs And Expenses [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sales, Marketing, General and Administrative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Selling General And Administrative Expenses [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation" xlink:type="locator" xlink:label="us-gaap_Depreciation" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Depreciation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Depreciation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_Goodwill_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod" xlink:type="locator" xlink:label="us-gaap_GoodwillAcquiredDuringPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GoodwillAcquiredDuringPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Attributable to acquisition of Oncimmune, Ltd.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAcquiredDuringPeriod" xlink:to="us-gaap_GoodwillAcquiredDuringPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GoodwillAcquiredDuringPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill Acquired During Period</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_Goodwill_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNetAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets Net [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNetAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Finite Lived Intangible Assets [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Finite Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PatentsMember" xlink:type="locator" xlink:label="us-gaap_PatentsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PatentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Patents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PatentsMember" xlink:to="us-gaap_PatentsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PatentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Patents [Member]</link:label>
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_PurchasedTechnologyMember" xlink:type="locator" xlink:label="bdsx_PurchasedTechnologyMember" />
    <link:label xml:lang="en-US" xlink:label="bdsx_PurchasedTechnologyMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Purchased technology.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_PurchasedTechnologyMember" xlink:to="bdsx_PurchasedTechnologyMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bdsx_PurchasedTechnologyMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchased Technology</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_PurchasedTechnologyMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Purchased Technology [Member]</link:label>
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_PurchaseOptionMember" xlink:type="locator" xlink:label="bdsx_PurchaseOptionMember" />
    <link:label xml:lang="en-US" xlink:label="bdsx_PurchaseOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Purchase option.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_PurchaseOptionMember" xlink:to="bdsx_PurchaseOptionMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bdsx_PurchaseOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchase Option</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_PurchaseOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Purchase Option [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Indefinite-lived Intangible Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Indefinite Lived Intangible Assets By Major Class [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Indefinite-lived Intangible Assets, Major Class Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Indefinite Lived Intangible Assets Major Class Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TrademarksMember" xlink:type="locator" xlink:label="us-gaap_TrademarksMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TrademarksMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trademarks</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TrademarksMember" xlink:to="us-gaap_TrademarksMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TrademarksMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trademarks [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finite Lived Intangible Assets [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible assets subject to amortization, Cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Intangible assets subject to amortization, Accumulated Amortization</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets Accumulated Amortization</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Intangible assets subject to amortization, Net Carrying Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets Net</link:label>
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_IndefiniteLivedIntangibleAssetsExcludingGoodwillGross" xlink:type="locator" xlink:label="bdsx_IndefiniteLivedIntangibleAssetsExcludingGoodwillGross" />
    <link:label xml:lang="en-US" xlink:label="bdsx_IndefiniteLivedIntangibleAssetsExcludingGoodwillGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Indefinite lived intangible assets excluding goodwill gross.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_IndefiniteLivedIntangibleAssetsExcludingGoodwillGross" xlink:to="bdsx_IndefiniteLivedIntangibleAssetsExcludingGoodwillGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="bdsx_IndefiniteLivedIntangibleAssetsExcludingGoodwillGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible assets not subject to amortization, Cost</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_IndefiniteLivedIntangibleAssetsExcludingGoodwillGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Indefinite Lived Intangible Assets Excluding Goodwill Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="locator" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible assets not subject to amortization, Net Carrying Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Indefinite Lived Intangible Assets Excluding Goodwill</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsGrossExcludingGoodwill" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IntangibleAssetsGrossExcludingGoodwill_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible assets, Cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsGrossExcludingGoodwill_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IntangibleAssetsGrossExcludingGoodwill_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Intangible Assets Gross Excluding Goodwill</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_IntangibleAssetsAccumulatedAmortizationExcludingGoodwill_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Intangible assets, Accumulated Amortization</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_IntangibleAssetsAccumulatedAmortizationExcludingGoodwill_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Intangible Assets Accumulated Amortization Excluding Goodwill</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Intangible assets, Net Carrying Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:type="locator" xlink:label="us-gaap_AmortizationOfIntangibleAssets" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization expense related to definite-lived intangible assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amortization Of Intangible Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets Future Amortization Expense [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2021</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets Amortization Expense Next Twelve Months</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2022</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets Amortization Expense Year Two</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets Amortization Expense Year Three</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets Amortization Expense Year Four</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets Amortization Expense Year Five</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Thereafter</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets Amortization Expense After Year Five</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetImpairment" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GoodwillAndIntangibleAssetImpairment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairments of intangible assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:to="us-gaap_GoodwillAndIntangibleAssetImpairment_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GoodwillAndIntangibleAssetImpairment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill And Intangible Asset Impairment</link:label>
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_AccruedClinicalTrialExpenseCurrent" xlink:type="locator" xlink:label="bdsx_AccruedClinicalTrialExpenseCurrent" />
    <link:label xml:lang="en-US" xlink:label="bdsx_AccruedClinicalTrialExpenseCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued clinical trial expense current.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_AccruedClinicalTrialExpenseCurrent" xlink:to="bdsx_AccruedClinicalTrialExpenseCurrent_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Compensation related accruals</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Related Liabilities Current</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_AccruedClinicalTrialExpenseCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued clinical trial expense</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_AccruedClinicalTrialExpenseCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Clinical Trial Expense Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Accrued Liabilities Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductWarrantyAccrualClassifiedCurrent" xlink:type="locator" xlink:label="us-gaap_ProductWarrantyAccrualClassifiedCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProductWarrantyAccrualClassifiedCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant liability, current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductWarrantyAccrualClassifiedCurrent" xlink:to="us-gaap_ProductWarrantyAccrualClassifiedCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProductWarrantyAccrualClassifiedCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Product Warranty Accrual Classified Current</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total accrued liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentsAbstract" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instruments [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentsAbstract" xlink:to="us-gaap_DebtInstrumentsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument [Table]</link:label>
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_PPPLoanMember" xlink:type="locator" xlink:label="bdsx_PPPLoanMember" />
    <link:label xml:lang="en-US" xlink:label="bdsx_PPPLoanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">PPP loan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_PPPLoanMember" xlink:to="bdsx_PPPLoanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bdsx_PPPLoanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">PPP Loan</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_PPPLoanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">P P P Loan [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument, Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Name [Domain]</link:label>
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_CARESActMember" xlink:type="locator" xlink:label="bdsx_CARESActMember" />
    <link:label xml:lang="en-US" xlink:label="bdsx_CARESActMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">CARES act.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_CARESActMember" xlink:to="bdsx_CARESActMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bdsx_CARESActMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CARES Act</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_CARESActMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">C A R E S Act [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentCarryingAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Notes/Loan payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_DebtInstrumentCarryingAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Carrying Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:type="locator" xlink:label="us-gaap_ConvertibleNotesPayableCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConvertibleNotesPayableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible notes payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayableCurrent" xlink:to="us-gaap_ConvertibleNotesPayableCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConvertibleNotesPayableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Notes Payable Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Unamortized debt discount and debt issuance costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayable" xlink:type="locator" xlink:label="us-gaap_NotesPayable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NotesPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Notes payable, total</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayable" xlink:to="us-gaap_NotesPayable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NotesPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Notes Payable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:type="locator" xlink:label="us-gaap_NotesPayableCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NotesPayableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Less: current maturities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableCurrent" xlink:to="us-gaap_NotesPayableCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NotesPayableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Notes Payable Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestBearingDepositsMember" xlink:type="locator" xlink:label="us-gaap_InterestBearingDepositsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestBearingDepositsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest-bearing Deposits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestBearingDepositsMember" xlink:to="us-gaap_InterestBearingDepositsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestBearingDepositsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Interest Bearing Deposits [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShortTermDebtTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term Debt, Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShortTermDebtTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Short Term Debt Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShortTermDebtTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term Debt, Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="us-gaap_ShortTermDebtTypeDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShortTermDebtTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Short Term Debt Type [Domain]</link:label>
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_MarchTwoThousandAndTwentyConvertibleNotesMember" xlink:type="locator" xlink:label="bdsx_MarchTwoThousandAndTwentyConvertibleNotesMember" />
    <link:label xml:lang="en-US" xlink:label="bdsx_MarchTwoThousandAndTwentyConvertibleNotesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">March two thousand and twenty convertible notes.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_MarchTwoThousandAndTwentyConvertibleNotesMember" xlink:to="bdsx_MarchTwoThousandAndTwentyConvertibleNotesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bdsx_MarchTwoThousandAndTwentyConvertibleNotesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">March 2020 Notes</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_MarchTwoThousandAndTwentyConvertibleNotesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">March Two Thousand And Twenty Convertible Notes [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument, Redemption, Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Redemption Period [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument, Redemption, Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Redemption Period [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodOneMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodOneMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">First Tranche</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodOneMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodOneMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Redemption Period One [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodTwoMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodTwoMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Second Tranche</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodTwoMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodTwoMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Redemption Period Two [Member]</link:label>
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_DecemberTwoThousandAndNineteenConvertibleNotesMember" xlink:type="locator" xlink:label="bdsx_DecemberTwoThousandAndNineteenConvertibleNotesMember" />
    <link:label xml:lang="en-US" xlink:label="bdsx_DecemberTwoThousandAndNineteenConvertibleNotesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">December two thousand and nineteen convertible notes.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_DecemberTwoThousandAndNineteenConvertibleNotesMember" xlink:to="bdsx_DecemberTwoThousandAndNineteenConvertibleNotesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bdsx_DecemberTwoThousandAndNineteenConvertibleNotesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">December 2019 Notes</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_DecemberTwoThousandAndNineteenConvertibleNotesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">December Two Thousand And Nineteen Convertible Notes [Member]</link:label>
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_AugustTwoThousandAndNineteenConvertibleNotesMember" xlink:type="locator" xlink:label="bdsx_AugustTwoThousandAndNineteenConvertibleNotesMember" />
    <link:label xml:lang="en-US" xlink:label="bdsx_AugustTwoThousandAndNineteenConvertibleNotesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">August two thousand and nineteen convertible notes.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_AugustTwoThousandAndNineteenConvertibleNotesMember" xlink:to="bdsx_AugustTwoThousandAndNineteenConvertibleNotesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bdsx_AugustTwoThousandAndNineteenConvertibleNotesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">August 2019 Notes</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_AugustTwoThousandAndNineteenConvertibleNotesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">August Two Thousand And Nineteen Convertible Notes [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loan principle amount</link:label>
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_DebtInstrumentPercentageOfStatedInterestRatePaidInCash" xlink:type="locator" xlink:label="bdsx_DebtInstrumentPercentageOfStatedInterestRatePaidInCash" />
    <link:label xml:lang="en-US" xlink:label="bdsx_DebtInstrumentPercentageOfStatedInterestRatePaidInCash_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt instrument, percentage of stated interest rate, paid in cash.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_DebtInstrumentPercentageOfStatedInterestRatePaidInCash" xlink:to="bdsx_DebtInstrumentPercentageOfStatedInterestRatePaidInCash_lbl" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_DebtInstrumentPercentageOfStatedInterestRateAddedToPrincipalValueOfNotesPayable" xlink:type="locator" xlink:label="bdsx_DebtInstrumentPercentageOfStatedInterestRateAddedToPrincipalValueOfNotesPayable" />
    <link:label xml:lang="en-US" xlink:label="bdsx_DebtInstrumentPercentageOfStatedInterestRateAddedToPrincipalValueOfNotesPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt instrument, percentage of stated interest rate added to principal value of notes payable.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_DebtInstrumentPercentageOfStatedInterestRateAddedToPrincipalValueOfNotesPayable" xlink:to="bdsx_DebtInstrumentPercentageOfStatedInterestRateAddedToPrincipalValueOfNotesPayable_lbl" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_DebtInstrumentInterestAddedToPrincipalValue" xlink:type="locator" xlink:label="bdsx_DebtInstrumentInterestAddedToPrincipalValue" />
    <link:label xml:lang="en-US" xlink:label="bdsx_DebtInstrumentInterestAddedToPrincipalValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt instrument interest added to principal value.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_DebtInstrumentInterestAddedToPrincipalValue" xlink:to="bdsx_DebtInstrumentInterestAddedToPrincipalValue_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFeeAmount" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFeeAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentFeeAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Facility fee amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFeeAmount" xlink:to="us-gaap_DebtInstrumentFeeAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentFeeAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Fee Amount</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant issued to purchase shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Interest Rate Stated Percentage</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_DebtInstrumentPercentageOfStatedInterestRatePaidInCash_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of interest rate, paid in cash</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_DebtInstrumentPercentageOfStatedInterestRatePaidInCash_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Percentage Of Stated Interest Rate Paid In Cash</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_DebtInstrumentPercentageOfStatedInterestRateAddedToPrincipalValueOfNotesPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of interest rate added to principal value of notes payable</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_DebtInstrumentPercentageOfStatedInterestRateAddedToPrincipalValueOfNotesPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Percentage Of Stated Interest Rate Added To Principal Value Of Notes Payable</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_DebtInstrumentInterestAddedToPrincipalValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest added to principal value</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_DebtInstrumentInterestAddedToPrincipalValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Interest Added To Principal Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentFrequencyOfPeriodicPayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Frequency of periodic payment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" xlink:to="us-gaap_DebtInstrumentFrequencyOfPeriodicPayment_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentFrequencyOfPeriodicPayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Frequency Of Periodic Payment</link:label>
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_DebtInstrumentPrepaymentPenaltyPercentage" xlink:type="locator" xlink:label="bdsx_DebtInstrumentPrepaymentPenaltyPercentage" />
    <link:label xml:lang="en-US" xlink:label="bdsx_DebtInstrumentPrepaymentPenaltyPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt instrument prepayment penalty percentage.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_DebtInstrumentPrepaymentPenaltyPercentage" xlink:to="bdsx_DebtInstrumentPrepaymentPenaltyPercentage_lbl" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_DebtInstrumentBackEndFacilityFeePercentage" xlink:type="locator" xlink:label="bdsx_DebtInstrumentBackEndFacilityFeePercentage" />
    <link:label xml:lang="en-US" xlink:label="bdsx_DebtInstrumentBackEndFacilityFeePercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt instrument back-end facility fee percentage.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_DebtInstrumentBackEndFacilityFeePercentage" xlink:to="bdsx_DebtInstrumentBackEndFacilityFeePercentage_lbl" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_DebtInstrumentAdditionalInterestExpenseFeePercentage" xlink:type="locator" xlink:label="bdsx_DebtInstrumentAdditionalInterestExpenseFeePercentage" />
    <link:label xml:lang="en-US" xlink:label="bdsx_DebtInstrumentAdditionalInterestExpenseFeePercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt instrument additional interest expense fee percentage.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_DebtInstrumentAdditionalInterestExpenseFeePercentage" xlink:to="bdsx_DebtInstrumentAdditionalInterestExpenseFeePercentage_lbl" />
    <link:label xml:lang="en-US" xlink:label="bdsx_DebtInstrumentPrepaymentPenaltyPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt instrument, prepayment penalty</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_DebtInstrumentPrepaymentPenaltyPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Prepayment Penalty Percentage</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_DebtInstrumentBackEndFacilityFeePercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt instrument, back-end facility fee</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_DebtInstrumentBackEndFacilityFeePercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Back End Facility Fee Percentage</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_DebtInstrumentAdditionalInterestExpenseFeePercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt instrument, additional interest expense fee</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_DebtInstrumentAdditionalInterestExpenseFeePercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Additional Interest Expense Fee Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Early amortization of loan payment schedule</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" xlink:to="us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Convertible Remaining Discount Amortization Period1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentDescription" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentDescription" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loan description</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentDescription" xlink:to="us-gaap_DebtInstrumentDescription_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Description</link:label>
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_PayrollCostsExcludesCompensationOfEmployee" xlink:type="locator" xlink:label="bdsx_PayrollCostsExcludesCompensationOfEmployee" />
    <link:label xml:lang="en-US" xlink:label="bdsx_PayrollCostsExcludesCompensationOfEmployee_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Payroll costs excludes compensation of an employee.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_PayrollCostsExcludesCompensationOfEmployee" xlink:to="bdsx_PayrollCostsExcludesCompensationOfEmployee_lbl" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_PercentageForNonPayrollCosts" xlink:type="locator" xlink:label="bdsx_PercentageForNonPayrollCosts" />
    <link:label xml:lang="en-US" xlink:label="bdsx_PercentageForNonPayrollCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage for non-payroll costs.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_PercentageForNonPayrollCosts" xlink:to="bdsx_PercentageForNonPayrollCosts_lbl" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_UpperLimitOfEmployeeSalaryToReduceForgiveness" xlink:type="locator" xlink:label="bdsx_UpperLimitOfEmployeeSalaryToReduceForgiveness" />
    <link:label xml:lang="en-US" xlink:label="bdsx_UpperLimitOfEmployeeSalaryToReduceForgiveness_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Upper limit of employee salary to reduce forgiveness.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_UpperLimitOfEmployeeSalaryToReduceForgiveness" xlink:to="bdsx_UpperLimitOfEmployeeSalaryToReduceForgiveness_lbl" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_PercentageOfUpperLimitOfEmployeeSalaryToReduceForgiveness" xlink:type="locator" xlink:label="bdsx_PercentageOfUpperLimitOfEmployeeSalaryToReduceForgiveness" />
    <link:label xml:lang="en-US" xlink:label="bdsx_PercentageOfUpperLimitOfEmployeeSalaryToReduceForgiveness_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of upper limit of employee salary to reduce forgiveness.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_PercentageOfUpperLimitOfEmployeeSalaryToReduceForgiveness" xlink:to="bdsx_PercentageOfUpperLimitOfEmployeeSalaryToReduceForgiveness_lbl" />
    <link:label xml:lang="en-US" xlink:label="bdsx_PayrollCostsExcludesCompensationOfEmployee_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payroll costs excludes compensation of an employee</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_PayrollCostsExcludesCompensationOfEmployee_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payroll Costs Excludes Compensation Of Employee</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_PercentageForNonPayrollCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage for non-payroll costs</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_PercentageForNonPayrollCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Percentage For Non Payroll Costs</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_UpperLimitOfEmployeeSalaryToReduceForgiveness_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upper limit of employee salary to reduce forgiveness</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_UpperLimitOfEmployeeSalaryToReduceForgiveness_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Upper Limit Of Employee Salary To Reduce Forgiveness</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_PercentageOfUpperLimitOfEmployeeSalaryToReduceForgiveness_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of upper limit of employee salary to reduce forgiveness</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_PercentageOfUpperLimitOfEmployeeSalaryToReduceForgiveness_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Upper Limit Of Employee Salary To Reduce Forgiveness</link:label>
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_PercentageOfConversionPricePerShareOfCommonStock" xlink:type="locator" xlink:label="bdsx_PercentageOfConversionPricePerShareOfCommonStock" />
    <link:label xml:lang="en-US" xlink:label="bdsx_PercentageOfConversionPricePerShareOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of conversion price per share of common stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_PercentageOfConversionPricePerShareOfCommonStock" xlink:to="bdsx_PercentageOfConversionPricePerShareOfCommonStock_lbl" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_DebtInstrumentMaturityDateExtended" xlink:type="locator" xlink:label="bdsx_DebtInstrumentMaturityDateExtended" />
    <link:label xml:lang="en-US" xlink:label="bdsx_DebtInstrumentMaturityDateExtended_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt instrument maturity date extended.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_DebtInstrumentMaturityDateExtended" xlink:to="bdsx_DebtInstrumentMaturityDateExtended_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesIssued1" xlink:type="locator" xlink:label="us-gaap_NotesIssued1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NotesIssued1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible notes payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesIssued1" xlink:to="us-gaap_NotesIssued1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NotesIssued1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Notes Issued1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible notes, maturity date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Maturity Date</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_DebtInstrumentMaturityDateExtended_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Extended debt instrument date</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_DebtInstrumentMaturityDateExtended_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Maturity Date Extended</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentRate" xlink:type="locator" xlink:label="us-gaap_DebtConversionConvertedInstrumentRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtConversionConvertedInstrumentRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentRate" xlink:to="us-gaap_DebtConversionConvertedInstrumentRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtConversionConvertedInstrumentRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Conversion Converted Instrument Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Convertible Conversion Price1</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_PercentageOfConversionPricePerShareOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of conversion price per share of common stock</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_PercentageOfConversionPricePerShareOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Conversion Price Per Share Of Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_PutOptionLiabilityCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Estimated value of put option liability</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Debt instrument converted to common stock</link:label>
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_PercentageOfConversionPricePerShareOfConvertiblePreferredStock" xlink:type="locator" xlink:label="bdsx_PercentageOfConversionPricePerShareOfConvertiblePreferredStock" />
    <link:label xml:lang="en-US" xlink:label="bdsx_PercentageOfConversionPricePerShareOfConvertiblePreferredStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of conversion price per share of convertible preferred stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_PercentageOfConversionPricePerShareOfConvertiblePreferredStock" xlink:to="bdsx_PercentageOfConversionPricePerShareOfConvertiblePreferredStock_lbl" />
    <link:label xml:lang="en-US" xlink:label="bdsx_PercentageOfConversionPricePerShareOfConvertiblePreferredStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of conversion price per share of preferred stock</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_PercentageOfConversionPricePerShareOfConvertiblePreferredStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Conversion Price Per Share Of Convertible Preferred Stock</link:label>
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_IncreaseToPutOptionLiability" xlink:type="locator" xlink:label="bdsx_IncreaseToPutOptionLiability" />
    <link:label xml:lang="en-US" xlink:label="bdsx_IncreaseToPutOptionLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase to put option liability.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_IncreaseToPutOptionLiability" xlink:to="bdsx_IncreaseToPutOptionLiability_lbl" />
    <link:label xml:lang="en-US" xlink:label="bdsx_IncreaseToPutOptionLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase to put option liability</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_IncreaseToPutOptionLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase To Put Option Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MaturitiesOfLongTermDebtAbstract" xlink:type="locator" xlink:label="us-gaap_MaturitiesOfLongTermDebtAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MaturitiesOfLongTermDebtAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Maturities Of Long Term Debt [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MaturitiesOfLongTermDebtAbstract" xlink:to="us-gaap_MaturitiesOfLongTermDebtAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2021</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Debt Maturities Repayments Of Principal In Next Twelve Months</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2022</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Debt Maturities Repayments Of Principal In Year Two</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Debt Maturities Repayments Of Principal In Year Three</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Debt Maturities Repayments Of Principal In Year Four</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Debt Maturities Repayments Of Principal In Year Five</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Thereafter</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Debt Maturities Repayments Of Principal After Year Five</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt" xlink:type="locator" xlink:label="us-gaap_LongTermDebt" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongTermDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Long-term debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebt_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongTermDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Stock By Class [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Stock By Class [Table]</link:label>
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_SeriesA1PreferredStockMember" xlink:type="locator" xlink:label="bdsx_SeriesA1PreferredStockMember" />
    <link:label xml:lang="en-US" xlink:label="bdsx_SeriesA1PreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Series A-1 preferred stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_SeriesA1PreferredStockMember" xlink:to="bdsx_SeriesA1PreferredStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bdsx_SeriesA1PreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A-1 Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_SeriesA1PreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Series A1 Preferred Stock [Member]</link:label>
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_SeriesA2PreferredStockMember" xlink:type="locator" xlink:label="bdsx_SeriesA2PreferredStockMember" />
    <link:label xml:lang="en-US" xlink:label="bdsx_SeriesA2PreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Series A-2 preferred stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_SeriesA2PreferredStockMember" xlink:to="bdsx_SeriesA2PreferredStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bdsx_SeriesA2PreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A2 Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_SeriesA2PreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Series A2 Preferred Stock [Member]</link:label>
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_SeriesA3PreferredStockMember" xlink:type="locator" xlink:label="bdsx_SeriesA3PreferredStockMember" />
    <link:label xml:lang="en-US" xlink:label="bdsx_SeriesA3PreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Series A-3 preferred stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_SeriesA3PreferredStockMember" xlink:to="bdsx_SeriesA3PreferredStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bdsx_SeriesA3PreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A3 Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_SeriesA3PreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Series A3 Preferred Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesBPreferredStockMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series B Preferred Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesBPreferredStockMember" xlink:to="us-gaap_SeriesBPreferredStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Series B Preferred Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesCPreferredStockMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SeriesCPreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series C Preferred Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesCPreferredStockMember" xlink:to="us-gaap_SeriesCPreferredStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SeriesCPreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Series C Preferred Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesDPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesDPreferredStockMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SeriesDPreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series D Preferred Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesDPreferredStockMember" xlink:to="us-gaap_SeriesDPreferredStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SeriesDPreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Series D Preferred Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesEPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesEPreferredStockMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SeriesEPreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series E Preferred Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesEPreferredStockMember" xlink:to="us-gaap_SeriesEPreferredStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SeriesEPreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Series E Preferred Stock [Member]</link:label>
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_SeriesB1ConvertiblePreferredStockMember" xlink:type="locator" xlink:label="bdsx_SeriesB1ConvertiblePreferredStockMember" />
    <link:label xml:lang="en-US" xlink:label="bdsx_SeriesB1ConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Series B-1 Convertible Preferred Stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_SeriesB1ConvertiblePreferredStockMember" xlink:to="bdsx_SeriesB1ConvertiblePreferredStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bdsx_SeriesB1ConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series B1 Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_SeriesB1ConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Series B1 Convertible Preferred Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class Of Stock [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Stock [Line Items]</link:label>
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_NumberOfPreferredStockConvertedIntoCommonStock" xlink:type="locator" xlink:label="bdsx_NumberOfPreferredStockConvertedIntoCommonStock" />
    <link:label xml:lang="en-US" xlink:label="bdsx_NumberOfPreferredStockConvertedIntoCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of preferred stock converted into common stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_NumberOfPreferredStockConvertedIntoCommonStock" xlink:to="bdsx_NumberOfPreferredStockConvertedIntoCommonStock_lbl" />
    <link:label xml:lang="en-US" xlink:label="bdsx_NumberOfPreferredStockConvertedIntoCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of preferred stock converted into common stock</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_NumberOfPreferredStockConvertedIntoCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Preferred Stock Converted Into Common Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class Of Warrant Or Right [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Warrant or Right</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Warrant or Right</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right [Domain]</link:label>
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_SeriesEConvertiblePreferredStockWarrantsMember" xlink:type="locator" xlink:label="bdsx_SeriesEConvertiblePreferredStockWarrantsMember" />
    <link:label xml:lang="en-US" xlink:label="bdsx_SeriesEConvertiblePreferredStockWarrantsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Series E convertible preferred stock warrants.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_SeriesEConvertiblePreferredStockWarrantsMember" xlink:to="bdsx_SeriesEConvertiblePreferredStockWarrantsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bdsx_SeriesEConvertiblePreferredStockWarrantsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series E Convertible Preferred Stock Warrants</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_SeriesEConvertiblePreferredStockWarrantsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Series E Convertible Preferred Stock Warrants [Member]</link:label>
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_SeriesGConvertiblePreferredStockWarrantsMember" xlink:type="locator" xlink:label="bdsx_SeriesGConvertiblePreferredStockWarrantsMember" />
    <link:label xml:lang="en-US" xlink:label="bdsx_SeriesGConvertiblePreferredStockWarrantsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Series G convertible preferred stock warrants.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_SeriesGConvertiblePreferredStockWarrantsMember" xlink:to="bdsx_SeriesGConvertiblePreferredStockWarrantsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bdsx_SeriesGConvertiblePreferredStockWarrantsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series G Convertible Preferred Stock Warrants</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_SeriesGConvertiblePreferredStockWarrantsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Series G Convertible Preferred Stock Warrants [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class Of Warrant Or Right [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Outstanding &#8209; December 31, 2019, warrants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Granted, warrants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Forfeited/canceled, warrants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercised, warrants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsPeriodIncreaseDecrease" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsPeriodIncreaseDecrease" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsPeriodIncreaseDecrease_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Reclassification of warrant liability to additional paid-in capital, warrants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsPeriodIncreaseDecrease" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsPeriodIncreaseDecrease_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsPeriodIncreaseDecrease_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Period Increase Decrease</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Outstanding &#8209; December 31, 2020, warrants</link:label>
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="bdsx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="bdsx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award non options outstanding weighted average exercise price.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" xlink:to="bdsx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_lbl" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangements by share based payment award non options grants in period weighted average exercise price.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="bdsx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="bdsx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award non-options forfeitures and expirations in period weighted average exercise price.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="bdsx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangements by share based payment award non options exercises in period weighted average exercise price.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsReclassificationOfWarrantLiabilityToAdditionalPaidInCapitalWeightedAverageExercisePrice" xlink:type="locator" xlink:label="bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsReclassificationOfWarrantLiabilityToAdditionalPaidInCapitalWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsReclassificationOfWarrantLiabilityToAdditionalPaidInCapitalWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangements by share based payment award non options reclassification of warrant liability to additional paid in capital weighted average exercise price.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsReclassificationOfWarrantLiabilityToAdditionalPaidInCapitalWeightedAverageExercisePrice" xlink:to="bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsReclassificationOfWarrantLiabilityToAdditionalPaidInCapitalWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="bdsx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted average exercise price, Outstanding &#8209; December 31, 2019</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Non Options Outstanding Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price, Granted</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Non Options Grants In Period Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Weighted average exercise price, Forfeited/canceled</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Non Options Forfeitures And Expirations In Period Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price, Exercised</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Non Options Exercises In Period Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsReclassificationOfWarrantLiabilityToAdditionalPaidInCapitalWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price, Reclassification of warrant liability to additional paid-in capital</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsReclassificationOfWarrantLiabilityToAdditionalPaidInCapitalWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Non Options Reclassification Of Warrant Liability To Additional Paid In Capital Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted average exercise price,Outstanding &#8209; December, 31, 2020</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants expiry date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:to="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Righst Date From Which Warrants Or Rights Exercisable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockVotingRights" xlink:type="locator" xlink:label="us-gaap_CommonStockVotingRights" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockVotingRights_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, voting rights</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockVotingRights" xlink:to="us-gaap_CommonStockVotingRights_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockVotingRights_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Voting Rights</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DividendsCommonStock" xlink:type="locator" xlink:label="us-gaap_DividendsCommonStock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DividendsCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Dividends</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsCommonStock" xlink:to="us-gaap_DividendsCommonStock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DividendsCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Dividends Common Stock</link:label>
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_DirectOfferingExpenses" xlink:type="locator" xlink:label="bdsx_DirectOfferingExpenses" />
    <link:label xml:lang="en-US" xlink:label="bdsx_DirectOfferingExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Direct offering expenses.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_DirectOfferingExpenses" xlink:to="bdsx_DirectOfferingExpenses_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock price per share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sale Of Stock Price Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees" xlink:type="locator" xlink:label="us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Underwriting discounts and commissions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees" xlink:to="us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Expense Related To Distribution Or Servicing And Underwriting Fees</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_DirectOfferingExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Direct offering expenses</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_DirectOfferingExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Direct Offering Expenses</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Preferred stock, issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisaggregationOfRevenueTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disaggregation Of Revenue [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_DisaggregationOfRevenueTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisaggregationOfRevenueTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disaggregation Of Revenue [Table]</link:label>
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_DiagnosticTestsMember" xlink:type="locator" xlink:label="bdsx_DiagnosticTestsMember" />
    <link:label xml:lang="en-US" xlink:label="bdsx_DiagnosticTestsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Diagnostic tests.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_DiagnosticTestsMember" xlink:to="bdsx_DiagnosticTestsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bdsx_DiagnosticTestsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Diagnostic Tests</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_DiagnosticTestsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Diagnostic Tests [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ServiceMember" xlink:type="locator" xlink:label="us-gaap_ServiceMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ServiceMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Services</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ServiceMember" xlink:to="us-gaap_ServiceMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ServiceMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Service [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisaggregationOfRevenueLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disaggregation Of Revenue [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisaggregationOfRevenueLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disaggregation Of Revenue [Line Items]</link:label>
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_AdvanceDeposits" xlink:type="locator" xlink:label="bdsx_AdvanceDeposits" />
    <link:label xml:lang="en-US" xlink:label="bdsx_AdvanceDeposits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Advance deposits.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_AdvanceDeposits" xlink:to="bdsx_AdvanceDeposits_lbl" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_COVID19DiagnosticTestRevenueMember" xlink:type="locator" xlink:label="bdsx_COVID19DiagnosticTestRevenueMember" />
    <link:label xml:lang="en-US" xlink:label="bdsx_COVID19DiagnosticTestRevenueMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">COVID-19 diagnostic test revenue.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_COVID19DiagnosticTestRevenueMember" xlink:to="bdsx_COVID19DiagnosticTestRevenueMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bdsx_COVID19DiagnosticTestRevenueMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">COVID-19 Test Revenue</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_COVID19DiagnosticTestRevenueMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">C O V I D19 Diagnostic Test Revenue [Member]</link:label>
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_LungDiagnosticRevenueMember" xlink:type="locator" xlink:label="bdsx_LungDiagnosticRevenueMember" />
    <link:label xml:lang="en-US" xlink:label="bdsx_LungDiagnosticRevenueMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Lung diagnostic revenue.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_LungDiagnosticRevenueMember" xlink:to="bdsx_LungDiagnosticRevenueMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bdsx_LungDiagnosticRevenueMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lung Diagnostic Revenue</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_LungDiagnosticRevenueMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lung Diagnostic Revenue [Member]</link:label>
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_DeferredRevenueMember" xlink:type="locator" xlink:label="bdsx_DeferredRevenueMember" />
    <link:label xml:lang="en-US" xlink:label="bdsx_DeferredRevenueMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred revenue.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_DeferredRevenueMember" xlink:to="bdsx_DeferredRevenueMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bdsx_DeferredRevenueMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred Revenue</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_DeferredRevenueMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Revenue [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_AdvanceDeposits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Advance deposits</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_AdvanceDeposits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Advance Deposits</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue recognized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Liability Revenue Recognized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Stock Purchase Plan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockMember" xlink:to="us-gaap_EmployeeStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</link:label>
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_TwoThousandTwentyEquityIncentivePlanMember" xlink:type="locator" xlink:label="bdsx_TwoThousandTwentyEquityIncentivePlanMember" />
    <link:label xml:lang="en-US" xlink:label="bdsx_TwoThousandTwentyEquityIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">2020 equity incentive plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_TwoThousandTwentyEquityIncentivePlanMember" xlink:to="bdsx_TwoThousandTwentyEquityIncentivePlanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bdsx_TwoThousandTwentyEquityIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2020 Equity Incentive Plan</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_TwoThousandTwentyEquityIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Equity Incentive Plan [Member]</link:label>
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_TwoThousandSixPlanMember" xlink:type="locator" xlink:label="bdsx_TwoThousandSixPlanMember" />
    <link:label xml:lang="en-US" xlink:label="bdsx_TwoThousandSixPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">2006 Plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_TwoThousandSixPlanMember" xlink:to="bdsx_TwoThousandSixPlanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bdsx_TwoThousandSixPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2006 Plan</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_TwoThousandSixPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Six Plan [Member]</link:label>
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_TwoThousandAndSixteenPlanMember" xlink:type="locator" xlink:label="bdsx_TwoThousandAndSixteenPlanMember" />
    <link:label xml:lang="en-US" xlink:label="bdsx_TwoThousandAndSixteenPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">2016 Plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_TwoThousandAndSixteenPlanMember" xlink:to="bdsx_TwoThousandAndSixteenPlanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bdsx_TwoThousandAndSixteenPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2016 Plan</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_TwoThousandAndSixteenPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand And Sixteen Plan [Member]</link:label>
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_TwoThousandSixPlanTwoThousandSixteenPlanAndTwoThousandTwentyEquityIncentivePlanMember" xlink:type="locator" xlink:label="bdsx_TwoThousandSixPlanTwoThousandSixteenPlanAndTwoThousandTwentyEquityIncentivePlanMember" />
    <link:label xml:lang="en-US" xlink:label="bdsx_TwoThousandSixPlanTwoThousandSixteenPlanAndTwoThousandTwentyEquityIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand six plan two thousand sixteen plan and two thousand twenty equity incentive plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_TwoThousandSixPlanTwoThousandSixteenPlanAndTwoThousandTwentyEquityIncentivePlanMember" xlink:to="bdsx_TwoThousandSixPlanTwoThousandSixteenPlanAndTwoThousandTwentyEquityIncentivePlanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bdsx_TwoThousandSixPlanTwoThousandSixteenPlanAndTwoThousandTwentyEquityIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2006 Plan, 2016 Plan and 2020 Equity Incentive Plan</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_TwoThousandSixPlanTwoThousandSixteenPlanAndTwoThousandTwentyEquityIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Six Plan Two Thousand Sixteen Plan And Two Thousand Twenty Equity Incentive Plan [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Award Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]</link:label>
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_PerformanceConditionOptionsMember" xlink:type="locator" xlink:label="bdsx_PerformanceConditionOptionsMember" />
    <link:label xml:lang="en-US" xlink:label="bdsx_PerformanceConditionOptionsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Performance condition options.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_PerformanceConditionOptionsMember" xlink:to="bdsx_PerformanceConditionOptionsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bdsx_PerformanceConditionOptionsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Performance Condition Options</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_PerformanceConditionOptionsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Performance Condition Options [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Stock Units (RSUs)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock Units R S U [Member]</link:label>
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_BonusToOptionsProgramMember" xlink:type="locator" xlink:label="bdsx_BonusToOptionsProgramMember" />
    <link:label xml:lang="en-US" xlink:label="bdsx_BonusToOptionsProgramMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Bonus-to-options program.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_BonusToOptionsProgramMember" xlink:to="bdsx_BonusToOptionsProgramMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bdsx_BonusToOptionsProgramMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Bonus-To-Options Program</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_BonusToOptionsProgramMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Bonus To Options Program [Member]</link:label>
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_OptionsAndRestrictedStockUnitsMember" xlink:type="locator" xlink:label="bdsx_OptionsAndRestrictedStockUnitsMember" />
    <link:label xml:lang="en-US" xlink:label="bdsx_OptionsAndRestrictedStockUnitsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Options and restricted stock units.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_OptionsAndRestrictedStockUnitsMember" xlink:to="bdsx_OptionsAndRestrictedStockUnitsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bdsx_OptionsAndRestrictedStockUnitsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options and Restricted Stock Units</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_OptionsAndRestrictedStockUnitsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Options And Restricted Stock Units [Member]</link:label>
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_ServiceConditionRSUsMember" xlink:type="locator" xlink:label="bdsx_ServiceConditionRSUsMember" />
    <link:label xml:lang="en-US" xlink:label="bdsx_ServiceConditionRSUsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Service-condition RSUs.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_ServiceConditionRSUsMember" xlink:to="bdsx_ServiceConditionRSUsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bdsx_ServiceConditionRSUsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Service Condition R S Us</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_ServiceConditionRSUsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Service Condition R S Us [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingAxis" xlink:type="locator" xlink:label="us-gaap_VestingAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_VestingAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_VestingAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Vesting [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain" xlink:type="locator" xlink:label="us-gaap_VestingDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_VestingDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_VestingDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_VestingDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Vesting [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based Payment Arrangement, Tranche One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Award Tranche One [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based Payment Arrangement, Tranche Two</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Award Tranche Two [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares reserved for issuance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Capital Shares Reserved For Future Issuance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of number of shares of common stock issued and outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Percentage Of Outstanding Stock Maximum</link:label>
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_DescriptionOfVotingPowerOrValueOfStockForEmployeeParticipationInOfferingPeriod" xlink:type="locator" xlink:label="bdsx_DescriptionOfVotingPowerOrValueOfStockForEmployeeParticipationInOfferingPeriod" />
    <link:label xml:lang="en-US" xlink:label="bdsx_DescriptionOfVotingPowerOrValueOfStockForEmployeeParticipationInOfferingPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Description of voting power or value of stock for employee participation in offering period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_DescriptionOfVotingPowerOrValueOfStockForEmployeeParticipationInOfferingPeriod" xlink:to="bdsx_DescriptionOfVotingPowerOrValueOfStockForEmployeeParticipationInOfferingPeriod_lbl" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_DescriptionOfOfferingPeriodUnderPlan" xlink:type="locator" xlink:label="bdsx_DescriptionOfOfferingPeriodUnderPlan" />
    <link:label xml:lang="en-US" xlink:label="bdsx_DescriptionOfOfferingPeriodUnderPlan_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Description of offering period under plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_DescriptionOfOfferingPeriodUnderPlan" xlink:to="bdsx_DescriptionOfOfferingPeriodUnderPlan_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of earnings used for purchase of common stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Maximum Employee Subscription Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of fair market value of common stock for purchase under plan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Discount From Market Price Offering Date</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_DescriptionOfVotingPowerOrValueOfStockForEmployeeParticipationInOfferingPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Description of voting power or value of stock for employee participation in offering period</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_DescriptionOfVotingPowerOrValueOfStockForEmployeeParticipationInOfferingPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Description Of Voting Power Or Value Of Stock For Employee Participation In Offering Period</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_DescriptionOfOfferingPeriodUnderPlan_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Description of offering period under plan</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_DescriptionOfOfferingPeriodUnderPlan_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Description Of Offering Period Under Plan</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of common stock may be issued under incentive plan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional stock awards granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Option expiration period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period</link:label>
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_NumberOfEqualAnnualInstallmentsForAwardVesting" xlink:type="locator" xlink:label="bdsx_NumberOfEqualAnnualInstallmentsForAwardVesting" />
    <link:label xml:lang="en-US" xlink:label="bdsx_NumberOfEqualAnnualInstallmentsForAwardVesting_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of equal annual installments for award vesting.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_NumberOfEqualAnnualInstallmentsForAwardVesting" xlink:to="bdsx_NumberOfEqualAnnualInstallmentsForAwardVesting_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Rights</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_NumberOfEqualAnnualInstallmentsForAwardVesting_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of equal annual installments for award vesting</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_NumberOfEqualAnnualInstallmentsForAwardVesting_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Equal Annual Installments For Award Vesting</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of performance-condition options granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options vested</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options forfeited</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of outstanding stock options granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Remaining life of outstanding performance condition options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1</link:label>
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_PercentageOfFullyDilutedEquityForBonusAwarded" xlink:type="locator" xlink:label="bdsx_PercentageOfFullyDilutedEquityForBonusAwarded" />
    <link:label xml:lang="en-US" xlink:label="bdsx_PercentageOfFullyDilutedEquityForBonusAwarded_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of fully diluted equity for bonus awarded.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_PercentageOfFullyDilutedEquityForBonusAwarded" xlink:to="bdsx_PercentageOfFullyDilutedEquityForBonusAwarded_lbl" />
    <link:label xml:lang="en-US" xlink:label="bdsx_PercentageOfFullyDilutedEquityForBonusAwarded_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of fully diluted equity for bonus awarded</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_PercentageOfFullyDilutedEquityForBonusAwarded_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Fully Diluted Equity For Bonus Awarded</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price,vested</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Intrinsic value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock compensation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Allocated Share Based Compensation Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Sales, Marketing, General and Administrative</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total pre-tax share-based compensation expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized remaining stock based compensation balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Stock Options, Outstanding &#8209; December 31, 2019</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Options, Granted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Stock Options, Forfeited/canceled</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Stock Options, Exercised</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Stock Options, Outstanding &#8209; December 31, 2020</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Options, Exercisable &#8209; December 31, 2020</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted Average Exercise Price, Outstanding &#8209; December 31, 2019</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted Average Exercise Price, Granted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Forfeited/canceled</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Exercised</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted Average Exercise Price, Outstanding &#8209; December 31, 2020</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Exercisable &#8209; December 31, 2020</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="bdsx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1" />
    <link:label xml:lang="en-US" xlink:label="bdsx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award options granted weighted average remaining contractual term1.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1" xlink:to="bdsx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Contractual Life (Years), Outstanding - December 31, 2019</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Contractual Life (Years), Granted</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Granted Weighted Average Remaining Contractual Term1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Contractual Life (Years), Exercisable &#8209; December 31, 2020</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Aggregate Intrinsic Value, Outstanding - December 31, 2019</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Aggregate Intrinsic Value, Outstanding - December 31, 2020</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Outstanding - Exercisable &#8209; December 31, 2020</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions And Methodology [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk&#8209;free rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected term (in years)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected dividend yield</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting percentage</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Award Vesting Rights Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of RSUs granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">RSUs outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average grant date fair value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share Basic And Diluted Other Disclosures [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAbstract" xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLossAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Numerator</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAbstract" xlink:to="us-gaap_NetIncomeLossAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLossAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Income Loss [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net loss attributable to common stockholders</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Denominator</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities, Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Name [Domain]</link:label>
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_OptionsToPurchaseCommonStockMember" xlink:type="locator" xlink:label="bdsx_OptionsToPurchaseCommonStockMember" />
    <link:label xml:lang="en-US" xlink:label="bdsx_OptionsToPurchaseCommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Options to purchase common stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_OptionsToPurchaseCommonStockMember" xlink:to="bdsx_OptionsToPurchaseCommonStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bdsx_OptionsToPurchaseCommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options to Purchase Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_OptionsToPurchaseCommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Options To Purchase Common Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember" xlink:type="locator" xlink:label="us-gaap_WarrantMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WarrantMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WarrantMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Warrant [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Restricted Stock Units</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_ConvertibleDebtSecuritiesMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConvertibleDebtSecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtSecuritiesMember" xlink:to="us-gaap_ConvertibleDebtSecuritiesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConvertibleDebtSecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Debt Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Provision for income taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Expense Benefit</link:label>
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_EffectiveIncomeTaxRateReconciliationPermanentItems" xlink:type="locator" xlink:label="bdsx_EffectiveIncomeTaxRateReconciliationPermanentItems" />
    <link:label xml:lang="en-US" xlink:label="bdsx_EffectiveIncomeTaxRateReconciliationPermanentItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Effective income tax rate reconciliation permanent items.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_EffectiveIncomeTaxRateReconciliationPermanentItems" xlink:to="bdsx_EffectiveIncomeTaxRateReconciliationPermanentItems_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal statutory income tax rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State income taxes, net of federal benefit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation State And Local Income Taxes</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and developments credits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Tax Credits Research</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_EffectiveIncomeTaxRateReconciliationPermanentItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Permanent items</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_EffectiveIncomeTaxRateReconciliationPermanentItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Permanent Items</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in valuation allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Effective income tax rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Continuing Operations</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:type="locator" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Components Of Deferred Tax Assets [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred Tax Assets:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Net [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Operating Loss Carryforwards</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development tax credits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Tax Credit Carryforwards Research</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Property Plant And Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accruals and reserves</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Tax Deferred Expense Reserves And Accruals</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Valuation allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Valuation Allowance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total deferred tax assets after valuation allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesAbstract" xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred Tax Liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Intangible assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:to="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Total deferred tax liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Income Tax Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net deferred tax assets and liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Liabilities Net</link:label>
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_DeferredTaxAssetsResearchAndExperimentationTaxCarryforwardsSubjectToExpiration" xlink:type="locator" xlink:label="bdsx_DeferredTaxAssetsResearchAndExperimentationTaxCarryforwardsSubjectToExpiration" />
    <link:label xml:lang="en-US" xlink:label="bdsx_DeferredTaxAssetsResearchAndExperimentationTaxCarryforwardsSubjectToExpiration_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets research and experimentation tax carryforwards subject to expiration.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_DeferredTaxAssetsResearchAndExperimentationTaxCarryforwardsSubjectToExpiration" xlink:to="bdsx_DeferredTaxAssetsResearchAndExperimentationTaxCarryforwardsSubjectToExpiration_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Operating Loss Carryforwards Subject To Expiration</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_DeferredTaxAssetsResearchAndExperimentationTaxCarryforwardsSubjectToExpiration_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and experimentation tax carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_DeferredTaxAssetsResearchAndExperimentationTaxCarryforwardsSubjectToExpiration_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Research And Experimentation Tax Carryforwards Subject To Expiration</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardDescription" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardDescription" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TaxCreditCarryforwardDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Description of tax credit carryforward expiration</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardDescription" xlink:to="us-gaap_TaxCreditCarryforwardDescription_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TaxCreditCarryforwardDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward Description</link:label>
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_PercentageOfValuationAllowanceEqualToNetDeferredTaxAssets" xlink:type="locator" xlink:label="bdsx_PercentageOfValuationAllowanceEqualToNetDeferredTaxAssets" />
    <link:label xml:lang="en-US" xlink:label="bdsx_PercentageOfValuationAllowanceEqualToNetDeferredTaxAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of valuation allowance equal to net deferred tax assets.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_PercentageOfValuationAllowanceEqualToNetDeferredTaxAssets" xlink:to="bdsx_PercentageOfValuationAllowanceEqualToNetDeferredTaxAssets_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetExplanationOfChange" xlink:type="locator" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetExplanationOfChange" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetExplanationOfChange_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Valuation allowance, deferred tax asset, explanation of change</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetExplanationOfChange" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetExplanationOfChange_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetExplanationOfChange_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Allowance Deferred Tax Asset Explanation Of Change</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_PercentageOfValuationAllowanceEqualToNetDeferredTaxAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of valuation allowance equal to net deferred tax assets</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_PercentageOfValuationAllowanceEqualToNetDeferredTaxAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Valuation Allowance Equal To Net Deferred Tax Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="locator" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase in valuation allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Allowance Deferred Tax Asset Change In Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued interest related to uncertain tax positions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" xlink:to="us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits Interest On Income Taxes Accrued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:type="locator" xlink:label="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Reconciliation Of Unrecognized Tax Benefits Excluding Amounts Pertaining To Examined Tax Returns Roll Forward</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefits" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance at January 1</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additions for tax positions related to the current year</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additions for tax positions related to prior years</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reductions for tax positions related to prior years</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reductions related to settlements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:to="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reductions related to a lapse of statute</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:to="us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance at December 31</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExaminationDescription" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExaminationDescription" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxExaminationDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income tax examination details</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExaminationDescription" xlink:to="us-gaap_IncomeTaxExaminationDescription_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxExaminationDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Examination Description</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesTable" xlink:type="locator" xlink:label="us-gaap_LossContingenciesTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LossContingenciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss Contingencies [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LossContingenciesTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LossContingenciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Loss Contingencies [Table]</link:label>
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_BDX004Member" xlink:type="locator" xlink:label="bdsx_BDX004Member" />
    <link:label xml:lang="en-US" xlink:label="bdsx_BDX004Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Bdx004.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_BDX004Member" xlink:to="bdsx_BDX004Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="bdsx_BDX004Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">BDX004</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_BDX004Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">B D X004 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesByIndustryAxis" xlink:type="locator" xlink:label="us-gaap_EquitySecuritiesByIndustryAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquitySecuritiesByIndustryAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Industry Sector</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquitySecuritiesByIndustryAxis" xlink:to="us-gaap_EquitySecuritiesByIndustryAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquitySecuritiesByIndustryAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity Securities By Industry [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesIndustryMember" xlink:type="locator" xlink:label="us-gaap_EquitySecuritiesIndustryMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquitySecuritiesIndustryMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Industry Sector</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquitySecuritiesIndustryMember" xlink:to="us-gaap_EquitySecuritiesIndustryMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquitySecuritiesIndustryMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity Securities Industry [Member]</link:label>
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_FiclatuzumabMember" xlink:type="locator" xlink:label="bdsx_FiclatuzumabMember" />
    <link:label xml:lang="en-US" xlink:label="bdsx_FiclatuzumabMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Ficlatuzumab.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_FiclatuzumabMember" xlink:to="bdsx_FiclatuzumabMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bdsx_FiclatuzumabMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ficlatuzumab</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_FiclatuzumabMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Ficlatuzumab [Member]</link:label>
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_NSCLCPOCTrialMember" xlink:type="locator" xlink:label="bdsx_NSCLCPOCTrialMember" />
    <link:label xml:lang="en-US" xlink:label="bdsx_NSCLCPOCTrialMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Nsclc poc trial.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_NSCLCPOCTrialMember" xlink:to="bdsx_NSCLCPOCTrialMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bdsx_NSCLCPOCTrialMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">NSCLC POC Trial</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_NSCLCPOCTrialMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">N S C L C P O C Trial [Member]</link:label>
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_POCClinicalTrialsMember" xlink:type="locator" xlink:label="bdsx_POCClinicalTrialsMember" />
    <link:label xml:lang="en-US" xlink:label="bdsx_POCClinicalTrialsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Poc clinical trials.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_POCClinicalTrialsMember" xlink:to="bdsx_POCClinicalTrialsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bdsx_POCClinicalTrialsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">POC Clinical Trials</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_POCClinicalTrialsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">P O C Clinical Trials [Member]</link:label>
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_BioRadLicenseMember" xlink:type="locator" xlink:label="bdsx_BioRadLicenseMember" />
    <link:label xml:lang="en-US" xlink:label="bdsx_BioRadLicenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Bio-rad license.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_BioRadLicenseMember" xlink:to="bdsx_BioRadLicenseMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bdsx_BioRadLicenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Bio-Rad License</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_BioRadLicenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Bio Rad License [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Type Of Arrangement [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Arrangements And Nonarrangement Transactions [Member]</link:label>
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_RevenueShareAgreementMember" xlink:type="locator" xlink:label="bdsx_RevenueShareAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="bdsx_RevenueShareAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Revenue share agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_RevenueShareAgreementMember" xlink:to="bdsx_RevenueShareAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="bdsx_RevenueShareAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue Share Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_RevenueShareAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Share Agreement [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:type="locator" xlink:label="us-gaap_LossContingenciesLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LossContingenciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss Contingencies [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingenciesLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LossContingenciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesRentExpenseNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesRentExpenseNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Rent expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesRentExpenseNet" xlink:to="us-gaap_OperatingLeasesRentExpenseNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesRentExpenseNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases Rent Expense Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeasesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Leases [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2021</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases Future Minimum Payments Due Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2022</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases Future Minimum Payments Due In Two Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases Future Minimum Payments Due In Three Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases Future Minimum Payments Due In Four Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases Future Minimum Payments Due In Five Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Thereafter</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases Future Minimum Payments Due Thereafter</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases Future Minimum Payments Due</link:label>
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_PercentageOfDevelopmentAndRegulatoryCosts" xlink:type="locator" xlink:label="bdsx_PercentageOfDevelopmentAndRegulatoryCosts" />
    <link:label xml:lang="en-US" xlink:label="bdsx_PercentageOfDevelopmentAndRegulatoryCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of development and regulatory costs.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_PercentageOfDevelopmentAndRegulatoryCosts" xlink:to="bdsx_PercentageOfDevelopmentAndRegulatoryCosts_lbl" />
    <link:label xml:lang="en-US" xlink:label="bdsx_PercentageOfDevelopmentAndRegulatoryCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Responsible percentage of development and regulatory costs</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_PercentageOfDevelopmentAndRegulatoryCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Development And Regulatory Costs</link:label>
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_RemainingEstimatedObligation" xlink:type="locator" xlink:label="bdsx_RemainingEstimatedObligation" />
    <link:label xml:lang="en-US" xlink:label="bdsx_RemainingEstimatedObligation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Remaining estimated obligation.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_RemainingEstimatedObligation" xlink:to="bdsx_RemainingEstimatedObligation_lbl" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_PercentageOfRoyaltyPaymentsOnNetSales" xlink:type="locator" xlink:label="bdsx_PercentageOfRoyaltyPaymentsOnNetSales" />
    <link:label xml:lang="en-US" xlink:label="bdsx_PercentageOfRoyaltyPaymentsOnNetSales_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of royalty payments on net sales.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_PercentageOfRoyaltyPaymentsOnNetSales" xlink:to="bdsx_PercentageOfRoyaltyPaymentsOnNetSales_lbl" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_PercentageOfLicenseIncomeGeneratedFromLicensing" xlink:type="locator" xlink:label="bdsx_PercentageOfLicenseIncomeGeneratedFromLicensing" />
    <link:label xml:lang="en-US" xlink:label="bdsx_PercentageOfLicenseIncomeGeneratedFromLicensing_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of license income generated from licensing.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_PercentageOfLicenseIncomeGeneratedFromLicensing" xlink:to="bdsx_PercentageOfLicenseIncomeGeneratedFromLicensing_lbl" />
    <link:label xml:lang="en-US" xlink:label="bdsx_RemainingEstimatedObligation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Remaining estimated obligation</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_RemainingEstimatedObligation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Remaining Estimated Obligation</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_PercentageOfRoyaltyPaymentsOnNetSales_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of royalty payments on net sales</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_PercentageOfRoyaltyPaymentsOnNetSales_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Royalty Payments On Net Sales</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_PercentageOfLicenseIncomeGeneratedFromLicensing_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Percentage of license income generated from licensing</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_PercentageOfLicenseIncomeGeneratedFromLicensing_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of License Income Generated From Licensing</link:label>
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_PercentageOfRoyaltyPaymentsOnNetRevenue" xlink:type="locator" xlink:label="bdsx_PercentageOfRoyaltyPaymentsOnNetRevenue" />
    <link:label xml:lang="en-US" xlink:label="bdsx_PercentageOfRoyaltyPaymentsOnNetRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of royalty payments on net revenue.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_PercentageOfRoyaltyPaymentsOnNetRevenue" xlink:to="bdsx_PercentageOfRoyaltyPaymentsOnNetRevenue_lbl" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_LicenseAgreementExpiryDate" xlink:type="locator" xlink:label="bdsx_LicenseAgreementExpiryDate" />
    <link:label xml:lang="en-US" xlink:label="bdsx_LicenseAgreementExpiryDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">License agreement expiry date.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_LicenseAgreementExpiryDate" xlink:to="bdsx_LicenseAgreementExpiryDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="bdsx_PercentageOfRoyaltyPaymentsOnNetRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of royalty payments on net revenue</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_PercentageOfRoyaltyPaymentsOnNetRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Royalty Payments On Net Revenue</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_LicenseAgreementExpiryDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License expiry date</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_LicenseAgreementExpiryDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">License Agreement Expiry Date</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyExpense" xlink:type="locator" xlink:label="us-gaap_RoyaltyExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RoyaltyExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Royalty expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyExpense" xlink:to="us-gaap_RoyaltyExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RoyaltyExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Royalty Expense</link:label>
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_PercentageOfRevenueSharePaymentRelatedToAcquiredDiagnosticTestRecognizedRevenueForNonScreeningTests" xlink:type="locator" xlink:label="bdsx_PercentageOfRevenueSharePaymentRelatedToAcquiredDiagnosticTestRecognizedRevenueForNonScreeningTests" />
    <link:label xml:lang="en-US" xlink:label="bdsx_PercentageOfRevenueSharePaymentRelatedToAcquiredDiagnosticTestRecognizedRevenueForNonScreeningTests_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of revenue share payment related to acquired diagnostic test recognized revenue for non-screening tests.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_PercentageOfRevenueSharePaymentRelatedToAcquiredDiagnosticTestRecognizedRevenueForNonScreeningTests" xlink:to="bdsx_PercentageOfRevenueSharePaymentRelatedToAcquiredDiagnosticTestRecognizedRevenueForNonScreeningTests_lbl" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_MinimumAnnualVolumePercentageThereafter" xlink:type="locator" xlink:label="bdsx_MinimumAnnualVolumePercentageThereafter" />
    <link:label xml:lang="en-US" xlink:label="bdsx_MinimumAnnualVolumePercentageThereafter_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Minimum annual volume percentage thereafter.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_MinimumAnnualVolumePercentageThereafter" xlink:to="bdsx_MinimumAnnualVolumePercentageThereafter_lbl" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_PeriodOfEscalationsOfSales" xlink:type="locator" xlink:label="bdsx_PeriodOfEscalationsOfSales" />
    <link:label xml:lang="en-US" xlink:label="bdsx_PeriodOfEscalationsOfSales_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Period of escalations of sales.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_PeriodOfEscalationsOfSales" xlink:to="bdsx_PeriodOfEscalationsOfSales_lbl" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_RevenueShareExpenses" xlink:type="locator" xlink:label="bdsx_RevenueShareExpenses" />
    <link:label xml:lang="en-US" xlink:label="bdsx_RevenueShareExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Revenue share expenses.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_RevenueShareExpenses" xlink:to="bdsx_RevenueShareExpenses_lbl" />
    <link:label xml:lang="en-US" xlink:label="bdsx_PercentageOfRevenueSharePaymentRelatedToAcquiredDiagnosticTestRecognizedRevenueForNonScreeningTests_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Percentage of revenue share payment related to acquired diagnostic test recognized revenue for non-screening tests</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_PercentageOfRevenueSharePaymentRelatedToAcquiredDiagnosticTestRecognizedRevenueForNonScreeningTests_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Revenue Share Payment Related To Acquired Diagnostic Test Recognized Revenue For Non Screening Tests</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_MinimumAnnualVolumePercentageThereafter_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum annual volume percentage thereafter</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_MinimumAnnualVolumePercentageThereafter_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Minimum Annual Volume Percentage Thereafter</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_PeriodOfEscalationsOfSales_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Period of escalations of sales</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_PeriodOfEscalationsOfSales_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Period Of Escalations Of Sales</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_RevenueShareExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue share expenses</link:label>
    <link:label xml:lang="en-US" xlink:label="bdsx_RevenueShareExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Share Expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRoyalties" xlink:type="locator" xlink:label="us-gaap_PaymentsForRoyalties" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsForRoyalties_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveVerboseLabel">Royalty expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRoyalties" xlink:to="us-gaap_PaymentsForRoyalties_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsForRoyalties_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments For Royalties</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Defined contribution plan, employer discretionary contributions amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan Employer Discretionary Contribution Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanPlanNameExtensibleList" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanPlanNameExtensibleList" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DefinedContributionPlanPlanNameExtensibleList_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Defined Contribution Plan, Plan Name [Extensible List]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanPlanNameExtensibleList" xlink:to="us-gaap_DefinedContributionPlanPlanNameExtensibleList_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DefinedContributionPlanPlanNameExtensibleList_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan Plan Name Extensible List</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>20
<FILENAME>bdsx-20201231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-03-16T14:26:39.4396313+00:00 -->
<!-- Version            : 5.0.1.571 -->
<!-- Package ID         : dca80741ea2145de953066364db43c8f -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://biodesix.com/20201231/role/TemplateLink" xlink:href="bdsx-20201231.xsd#TemplateLink" xlink:type="simple" />
  <link:roleRef roleURI="http://biodesix.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="bdsx-20201231.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://biodesix.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="locator" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat" xlink:type="locator" xlink:label="dei_EntityPublicFloat" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:type="locator" xlink:label="dei_EntityShellCompany" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityExTransitionPeriod" xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness" xlink:type="locator" xlink:label="dei_EntitySmallBusiness" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:type="locator" xlink:label="dei_EntityFilerCategory" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers" xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_IcfrAuditorAttestationFlag" xlink:type="locator" xlink:label="dei_IcfrAuditorAttestationFlag" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:type="locator" xlink:label="dei_DocumentTransitionReport" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport" xlink:type="locator" xlink:label="dei_DocumentAnnualReport" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentAnnualReport" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="10670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="10730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="10790.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="10850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="10910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="10970.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="11030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="11090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="11150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="11210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_IcfrAuditorAttestationFlag" order="11270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="11330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="11390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="11450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityVoluntaryFilers" order="11510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="11570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent" order="11630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory" order="11690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness" order="11750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="11810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="11870.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany" order="11930.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="11990.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityPublicFloat" order="12050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock" order="12110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://biodesix.com/20201231/taxonomy/role/StatementBalanceSheets" xlink:href="bdsx-20201231.xsd#Role_StatementBalanceSheets" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://biodesix.com/20201231/taxonomy/role/StatementBalanceSheets">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityAbstract" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:type="locator" xlink:label="us-gaap_LongTermNotesPayable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_PutOptionLiabilityCurrent" xlink:type="locator" xlink:label="bdsx_PutOptionLiabilityCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableToBankCurrent" xlink:type="locator" xlink:label="us-gaap_NotesPayableToBankCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill" xlink:type="locator" xlink:label="us-gaap_Goodwill" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrentAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OtherAssetsCurrent" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="10730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="10770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_Goodwill" order="10810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrent" order="10850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="10890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="10930.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="11010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="11090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="11130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="11170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_NotesPayableToBankCurrent" order="11210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="bdsx_PutOptionLiabilityCurrent" order="11250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="11290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract" order="11330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_WarrantsAndRightsOutstanding" order="11410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LongTermNotesPayable" order="11450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" order="11490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="11530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrent" order="11570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="11610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="11650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_TemporaryEquityAbstract" order="11690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityAbstract" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="11770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="11810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="11890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="11930.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="11970.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="12010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="12050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="12090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://biodesix.com/20201231/taxonomy/role/StatementBalanceSheetsParenthetical" xlink:href="bdsx-20201231.xsd#Role_StatementBalanceSheetsParenthetical" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://biodesix.com/20201231/taxonomy/role/StatementBalanceSheetsParenthetical">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityLiquidationPreference" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesIssued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_TemporaryEquitySharesIssued" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_TemporaryEquityLiquidationPreference" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfOperations" xlink:href="bdsx-20201231.xsd#Role_StatementStatementsOfOperations" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfOperations">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncome" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_ChangeInFairValueOfPutOptionLiability" xlink:type="locator" xlink:label="bdsx_ChangeInFairValueOfPutOptionLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense" xlink:type="locator" xlink:label="us-gaap_InterestExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeOther" xlink:type="locator" xlink:label="us-gaap_InterestIncomeOther" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:type="locator" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_ChangeInFairValueOfContingentConsiderationExcludingAccretionExpense" xlink:type="locator" xlink:label="bdsx_ChangeInFairValueOfContingentConsiderationExcludingAccretionExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_DirectCostsAndExpenses" xlink:type="locator" xlink:label="bdsx_DirectCostsAndExpenses" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues" xlink:type="locator" xlink:label="us-gaap_Revenues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_Revenues" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="bdsx_DirectCostsAndExpenses" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="bdsx_ChangeInFairValueOfContingentConsiderationExcludingAccretionExpense" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherIncomeAndExpensesAbstract" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_InterestIncomeOther" order="10580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_InterestExpense" order="10620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="10660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="bdsx_ChangeInFairValueOfPutOptionLiability" order="10700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_OtherNonoperatingIncome" order="10740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="10780.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="10820.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="10860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="10900.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:href="bdsx-20201231.xsd#Role_StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_StockIssuedDuringPeriodSharesConversionOfConvertibleSecuritiesCommonStock" xlink:type="locator" xlink:label="bdsx_StockIssuedDuringPeriodSharesConversionOfConvertibleSecuritiesCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="bdsx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bdsx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" order="10590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="10730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="10890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="10910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="11050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="11070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" order="11210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bdsx_StockIssuedDuringPeriodSharesConversionOfConvertibleSecuritiesCommonStock" order="11230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" order="11370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="11530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_li0l2" order="11690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_li0l2" order="11710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" xlink:href="bdsx-20201231.xsd#Role_StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalUnitsTotalCostToInvestors" xlink:type="locator" xlink:label="us-gaap_CapitalUnitsTotalCostToInvestors" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalUnitsDeductionsFromTotalCostToInvestors" xlink:type="locator" xlink:label="us-gaap_CapitalUnitsDeductionsFromTotalCostToInvestors" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_TemporaryEquityIssuanceCosts" xlink:type="locator" xlink:label="bdsx_TemporaryEquityIssuanceCosts" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_SaleOfStockTemporaryEquityPricePerShare" xlink:type="locator" xlink:label="bdsx_SaleOfStockTemporaryEquityPricePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesHPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesHPreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesHPreferredStockMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bdsx_SaleOfStockTemporaryEquityPricePerShare" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bdsx_TemporaryEquityIssuanceCosts" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CapitalUnitsDeductionsFromTotalCostToInvestors" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CapitalUnitsTotalCostToInvestors" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfCashFlows" xlink:href="bdsx-20201231.xsd#Role_StatementStatementsOfCashFlows" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfCashFlows">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesPaidNet" xlink:type="locator" xlink:label="us-gaap_IncomeTaxesPaidNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" xlink:type="locator" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_ReclassificationOfWarrantLiabilityToAdditionalPaidInCapital" xlink:type="locator" xlink:label="bdsx_ReclassificationOfWarrantLiabilityToAdditionalPaidInCapital" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet" xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_ValueOfPutOptionRecordedAtIssuanceOfConvertibleNotesPayable" xlink:type="locator" xlink:label="bdsx_ValueOfPutOptionRecordedAtIssuanceOfConvertibleNotesPayable" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_ReclassificationOfPutOptionLiabilityToAdditionalPaidInCapital" xlink:type="locator" xlink:label="bdsx_ReclassificationOfPutOptionLiabilityToAdditionalPaidInCapital" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:type="locator" xlink:label="us-gaap_ConversionOfStockAmountConverted1" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_ConversionOfPreferredStockIntoCommonStock" xlink:type="locator" xlink:label="bdsx_ConversionOfPreferredStockIntoCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:type="locator" xlink:label="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:type="locator" xlink:label="us-gaap_ProceedsFromNotesPayable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:type="locator" xlink:label="us-gaap_ProceedsFromConvertibleDebt" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_PaymentsToAcquireOncimmune" xlink:type="locator" xlink:label="bdsx_PaymentsToAcquireOncimmune" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_PaymentsForProceedsFromPatentCostsAndIntangibleAssetAcquisitionNet" xlink:type="locator" xlink:label="bdsx_PaymentsForProceedsFromPatentCostsAndIntangibleAssetAcquisitionNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:type="locator" xlink:label="us-gaap_GainLossOnDispositionOfAssets1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:type="locator" xlink:label="us-gaap_ProvisionForDoubtfulAccounts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:type="locator" xlink:label="us-gaap_AmortizationOfFinancingCosts" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_AccruedInterestOnNotesPayableAndConvertibleNotesPayable" xlink:type="locator" xlink:label="bdsx_AccruedInterestOnNotesPayableAndConvertibleNotesPayable" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_ChangeInFairValueOfPutOptionLiability" xlink:type="locator" xlink:label="bdsx_ChangeInFairValueOfPutOptionLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="locator" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationAndAmortization" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" order="10540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="10580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="10620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" order="10660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="bdsx_ChangeInFairValueOfPutOptionLiability" order="10700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="bdsx_AccruedInterestOnNotesPayableAndConvertibleNotesPayable" order="10740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfFinancingCosts" order="10780.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProvisionForDoubtfulAccounts" order="10820.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnDispositionOfAssets1" order="10860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="10900.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="10980.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets" order="11020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet" order="11060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="11100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" order="11140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="11180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="11220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="11300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="bdsx_PaymentsForProceedsFromPatentCostsAndIntangibleAssetAcquisitionNet" order="11340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="bdsx_PaymentsToAcquireOncimmune" order="11380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="11420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="11460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="11540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="11580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" order="11620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromConvertibleDebt" order="11660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromNotesPayable" order="11700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="11740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" order="11780.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="11820.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="11860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="11900.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_li0l2" order="11940.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="11980.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="bdsx_ConversionOfPreferredStockIntoCommonStock" order="12060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_ConversionOfStockAmountConverted1" order="12100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="bdsx_ReclassificationOfPutOptionLiabilityToAdditionalPaidInCapital" order="12140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="bdsx_ValueOfPutOptionRecordedAtIssuanceOfConvertibleNotesPayable" order="12180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaidNet" order="12220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="bdsx_ReclassificationOfWarrantLiabilityToAdditionalPaidInCapital" order="12260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" order="12300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_IncomeTaxesPaidNet" order="12340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusiness" xlink:href="bdsx-20201231.xsd#Role_DisclosureOrganizationAndDescriptionOfBusiness" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://biodesix.com/20201231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusiness">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_OrganizationAndDescriptionOfBusinessAbstract" xlink:type="locator" xlink:label="bdsx_OrganizationAndDescriptionOfBusinessAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_OrganizationAndDescriptionOfBusinessAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies" xlink:href="bdsx-20201231.xsd#Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://biodesix.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosureRecentAccountingPronouncements" xlink:href="bdsx-20201231.xsd#Role_DisclosureRecentAccountingPronouncements" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://biodesix.com/20201231/taxonomy/role/DisclosureRecentAccountingPronouncements">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosureBusinessCombinations" xlink:href="bdsx-20201231.xsd#Role_DisclosureBusinessCombinations" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://biodesix.com/20201231/taxonomy/role/DisclosureBusinessCombinations">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_BusinessCombinationDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosureFairValue" xlink:href="bdsx-20201231.xsd#Role_DisclosureFairValue" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://biodesix.com/20201231/taxonomy/role/DisclosureFairValue">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosurePropertyAndEquipment" xlink:href="bdsx-20201231.xsd#Role_DisclosurePropertyAndEquipment" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://biodesix.com/20201231/taxonomy/role/DisclosurePropertyAndEquipment">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssets" xlink:href="bdsx-20201231.xsd#Role_DisclosureGoodwillAndIntangibleAssets" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://biodesix.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssets">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosureAccruedLiabilities" xlink:href="bdsx-20201231.xsd#Role_DisclosureAccruedLiabilities" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://biodesix.com/20201231/taxonomy/role/DisclosureAccruedLiabilities">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosureDebt" xlink:href="bdsx-20201231.xsd#Role_DisclosureDebt" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://biodesix.com/20201231/taxonomy/role/DisclosureDebt">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_DebtDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStock" xlink:href="bdsx-20201231.xsd#Role_DisclosureConvertiblePreferredStock" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://biodesix.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStock">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockTextBlock" xlink:type="locator" xlink:label="us-gaap_PreferredStockTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDisclosuresAbstract" xlink:to="us-gaap_PreferredStockTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosureWarrantsToPurchaseConvertiblePreferredStock" xlink:href="bdsx-20201231.xsd#Role_DisclosureWarrantsToPurchaseConvertiblePreferredStock" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://biodesix.com/20201231/taxonomy/role/DisclosureWarrantsToPurchaseConvertiblePreferredStock">
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_WarrantsForConvertiblePreferredStockTextBlock" xlink:type="locator" xlink:label="bdsx_WarrantsForConvertiblePreferredStockTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="bdsx_WarrantsForConvertiblePreferredStockTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosureEquity" xlink:href="bdsx-20201231.xsd#Role_DisclosureEquity" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://biodesix.com/20201231/taxonomy/role/DisclosureEquity">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosureRevenue" xlink:href="bdsx-20201231.xsd#Role_DisclosureRevenue" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://biodesix.com/20201231/taxonomy/role/DisclosureRevenue">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosureShareBasedCompensation" xlink:href="bdsx-20201231.xsd#Role_DisclosureShareBasedCompensation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://biodesix.com/20201231/taxonomy/role/DisclosureShareBasedCompensation">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosureEarningsPerShare" xlink:href="bdsx-20201231.xsd#Role_DisclosureEarningsPerShare" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://biodesix.com/20201231/taxonomy/role/DisclosureEarningsPerShare">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosureIncomeTaxes" xlink:href="bdsx-20201231.xsd#Role_DisclosureIncomeTaxes" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://biodesix.com/20201231/taxonomy/role/DisclosureIncomeTaxes">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingencies" xlink:href="bdsx-20201231.xsd#Role_DisclosureCommitmentsAndContingencies" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://biodesix.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingencies">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosureDefinedContribution401KPlan" xlink:href="bdsx-20201231.xsd#Role_DisclosureDefinedContribution401KPlan" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://biodesix.com/20201231/taxonomy/role/DisclosureDefinedContribution401KPlan">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanTextBlock" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="bdsx-20201231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://biodesix.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_PutOptionLiabilityPolicyTextBlock" xlink:type="locator" xlink:label="bdsx_PutOptionLiabilityPolicyTextBlock" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_WarrantLiabilityPolicyTextBlock" xlink:type="locator" xlink:label="bdsx_WarrantLiabilityPolicyTextBlock" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_ContingentConsiderationPolicyTextBlock" xlink:type="locator" xlink:label="bdsx_ContingentConsiderationPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventorySuppliesPolicy" xlink:type="locator" xlink:label="us-gaap_InventorySuppliesPolicy" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:type="locator" xlink:label="us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_DirectCostsAndExpensesPolicyTextBlock" xlink:type="locator" xlink:label="bdsx_DirectCostsAndExpensesPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates" xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_InitialPublicOfferingIPOPolicyTextBlock" xlink:type="locator" xlink:label="bdsx_InitialPublicOfferingIPOPolicyTextBlock" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_ApprovalOfAmendedAndRestatedCertificateOfIncorporationPolicyTextBlock" xlink:type="locator" xlink:label="bdsx_ApprovalOfAmendedAndRestatedCertificateOfIncorporationPolicyTextBlock" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_ReverseStockSplitPolicyTextBlock" xlink:type="locator" xlink:label="bdsx_ReverseStockSplitPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="bdsx_ReverseStockSplitPolicyTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="bdsx_ApprovalOfAmendedAndRestatedCertificateOfIncorporationPolicyTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="bdsx_InitialPublicOfferingIPOPolicyTextBlock" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="bdsx_DirectCostsAndExpensesPolicyTextBlock" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InventorySuppliesPolicy" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="bdsx_ContingentConsiderationPolicyTextBlock" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="bdsx_WarrantLiabilityPolicyTextBlock" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="bdsx_PutOptionLiabilityPolicyTextBlock" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:href="bdsx-20201231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://biodesix.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:type="locator" xlink:label="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosureBusinessCombinationsTables" xlink:href="bdsx-20201231.xsd#Role_DisclosureBusinessCombinationsTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://biodesix.com/20201231/taxonomy/role/DisclosureBusinessCombinationsTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationSegmentAllocationTableTextBlock" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationSegmentAllocationTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_BusinessCombinationSegmentAllocationTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosureFairValueTables" xlink:href="bdsx-20201231.xsd#Role_DisclosureFairValueTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://biodesix.com/20201231/taxonomy/role/DisclosureFairValueTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentTables" xlink:href="bdsx-20201231.xsd#Role_DisclosurePropertyAndEquipmentTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://biodesix.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentTables">
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_ScheduleOfDepreciationAndAmortizationExpenseRelatedToPropertyAndEquipmentTableTextBlock" xlink:type="locator" xlink:label="bdsx_ScheduleOfDepreciationAndAmortizationExpenseRelatedToPropertyAndEquipmentTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="bdsx_ScheduleOfDepreciationAndAmortizationExpenseRelatedToPropertyAndEquipmentTableTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsTables" xlink:href="bdsx-20201231.xsd#Role_DisclosureGoodwillAndIntangibleAssetsTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://biodesix.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfGoodwillTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ScheduleOfGoodwillTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosureAccruedLiabilitiesTables" xlink:href="bdsx-20201231.xsd#Role_DisclosureAccruedLiabilitiesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://biodesix.com/20201231/taxonomy/role/DisclosureAccruedLiabilitiesTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosureDebtTables" xlink:href="bdsx-20201231.xsd#Role_DisclosureDebtTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://biodesix.com/20201231/taxonomy/role/DisclosureDebtTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDebtInstrumentsTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosureWarrantsToPurchaseConvertiblePreferredStockTables" xlink:href="bdsx-20201231.xsd#Role_DisclosureWarrantsToPurchaseConvertiblePreferredStockTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://biodesix.com/20201231/taxonomy/role/DisclosureWarrantsToPurchaseConvertiblePreferredStockTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosureRevenueTables" xlink:href="bdsx-20201231.xsd#Role_DisclosureRevenueTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://biodesix.com/20201231/taxonomy/role/DisclosureRevenueTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosureShareBasedCompensationTables" xlink:href="bdsx-20201231.xsd#Role_DisclosureShareBasedCompensationTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://biodesix.com/20201231/taxonomy/role/DisclosureShareBasedCompensationTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosureEarningsPerShareTables" xlink:href="bdsx-20201231.xsd#Role_DisclosureEarningsPerShareTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://biodesix.com/20201231/taxonomy/role/DisclosureEarningsPerShareTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosureIncomeTaxesTables" xlink:href="bdsx-20201231.xsd#Role_DisclosureIncomeTaxesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://biodesix.com/20201231/taxonomy/role/DisclosureIncomeTaxesTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables" xlink:href="bdsx-20201231.xsd#Role_DisclosureCommitmentsAndContingenciesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://biodesix.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails" xlink:href="bdsx-20201231.xsd#Role_DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://biodesix.com/20201231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_ConvertiblePreferredStockAndConvertibleNotesPayableConvertedToCommonStock" xlink:type="locator" xlink:label="bdsx_ConvertiblePreferredStockAndConvertibleNotesPayableConvertedToCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_NumberOfSARSCoV2Test" xlink:type="locator" xlink:label="bdsx_NumberOfSARSCoV2Test" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_NumberOfCommercialBloodBasedTest" xlink:type="locator" xlink:label="bdsx_NumberOfCommercialBloodBasedTest" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_NumberOfCancerTest" xlink:type="locator" xlink:label="bdsx_NumberOfCancerTest" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_OrganizationAndDescriptionOfBusinessLineItems" xlink:type="locator" xlink:label="bdsx_OrganizationAndDescriptionOfBusinessLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember" xlink:type="locator" xlink:label="us-gaap_IPOMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_OrganizationAndDescriptionOfBusinessTable" xlink:type="locator" xlink:label="bdsx_OrganizationAndDescriptionOfBusinessTable" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_OrganizationAndDescriptionOfBusinessAbstract" xlink:type="locator" xlink:label="bdsx_OrganizationAndDescriptionOfBusinessAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_OrganizationAndDescriptionOfBusinessAbstract" xlink:to="bdsx_OrganizationAndDescriptionOfBusinessTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_OrganizationAndDescriptionOfBusinessTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_OrganizationAndDescriptionOfBusinessTable" xlink:to="bdsx_OrganizationAndDescriptionOfBusinessLineItems" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_OrganizationAndDescriptionOfBusinessLineItems" xlink:to="bdsx_NumberOfCancerTest" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_OrganizationAndDescriptionOfBusinessLineItems" xlink:to="bdsx_NumberOfCommercialBloodBasedTest" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_OrganizationAndDescriptionOfBusinessLineItems" xlink:to="bdsx_NumberOfSARSCoV2Test" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_OrganizationAndDescriptionOfBusinessLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_OrganizationAndDescriptionOfBusinessLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_OrganizationAndDescriptionOfBusinessLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_OrganizationAndDescriptionOfBusinessLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_OrganizationAndDescriptionOfBusinessLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_OrganizationAndDescriptionOfBusinessLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_OrganizationAndDescriptionOfBusinessLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_OrganizationAndDescriptionOfBusinessLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="10540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_OrganizationAndDescriptionOfBusinessLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_OrganizationAndDescriptionOfBusinessLineItems" xlink:to="bdsx_ConvertiblePreferredStockAndConvertibleNotesPayableConvertedToCommonStock" order="10580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_OrganizationAndDescriptionOfBusinessLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="10600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:href="bdsx-20201231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://biodesix.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillImpairmentLoss" xlink:type="locator" xlink:label="us-gaap_GoodwillImpairmentLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:type="locator" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:type="locator" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherInventorySupplies" xlink:type="locator" xlink:label="us-gaap_OtherInventorySupplies" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:type="locator" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCash" xlink:type="locator" xlink:label="us-gaap_RestrictedCash" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskPercentage1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsDescription" xlink:type="locator" xlink:label="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsDescription" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_IncreaseDecreaseInAccumulatedDeficit" xlink:type="locator" xlink:label="bdsx_IncreaseDecreaseInAccumulatedDeficit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillPeriodIncreaseDecrease" xlink:type="locator" xlink:label="us-gaap_GoodwillPeriodIncreaseDecrease" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:type="locator" xlink:label="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_ProductLifeAndPatentLifeMember" xlink:type="locator" xlink:label="bdsx_ProductLifeAndPatentLifeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCurrentAssetsMember" xlink:type="locator" xlink:label="us-gaap_OtherCurrentAssetsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationAxis" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_MedicareMember" xlink:type="locator" xlink:label="bdsx_MedicareMember" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_CovanceCentralLaboratoryServicesMember" xlink:type="locator" xlink:label="bdsx_CovanceCentralLaboratoryServicesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:type="locator" xlink:label="srt_NameOfMajorCustomerDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis" xlink:type="locator" xlink:label="srt_MajorCustomersAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:type="locator" xlink:label="us-gaap_CustomerConcentrationRiskMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:type="locator" xlink:label="us-gaap_SalesRevenueNetMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_TestingServicesMember" xlink:type="locator" xlink:label="bdsx_TestingServicesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember" xlink:type="locator" xlink:label="srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RestatementDomain" xlink:type="locator" xlink:label="srt_RestatementDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RestatementAxis" xlink:type="locator" xlink:label="srt_RestatementAxis" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_SummaryOfSignificantAccountingPoliciesTable" xlink:type="locator" xlink:label="bdsx_SummaryOfSignificantAccountingPoliciesTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="bdsx_SummaryOfSignificantAccountingPoliciesTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_RestatementAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RestatementDomain" xlink:to="srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_ProductOrServiceAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="bdsx_TestingServicesMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_SalesRevenueNetMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CustomerConcentrationRiskMember" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_MajorCustomersAxis" order="10030.08" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="bdsx_CovanceCentralLaboratoryServicesMember" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="bdsx_MedicareMember" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="10030.10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_OtherCurrentAssetsMember" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_RangeAxis" order="10030.12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="10030.14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="10740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="bdsx_ProductLifeAndPatentLifeMember" order="10760.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesTable" xlink:to="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" order="10780.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_GoodwillPeriodIncreaseDecrease" order="10790.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="bdsx_IncreaseDecreaseInAccumulatedDeficit" order="10810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsDescription" order="10830.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" order="10880.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="10930.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" order="10980.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_RestrictedCash" order="11090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable" order="11160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_OtherInventorySupplies" order="11230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="11300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" order="11400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife" order="11510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" order="11580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_GoodwillImpairmentLoss" order="11650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfRevenueAndAccountsReceivableByThirdPartyPayorsAndOtherCustomersDetails" xlink:href="bdsx-20201231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfRevenueAndAccountsReceivableByThirdPartyPayorsAndOtherCustomersDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://biodesix.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfRevenueAndAccountsReceivableByThirdPartyPayorsAndOtherCustomersDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskPercentage1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskLineItems" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_PfizerIncMember" xlink:type="locator" xlink:label="bdsx_PfizerIncMember" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_JanssenResearchAndDevelopmentLLCMember" xlink:type="locator" xlink:label="bdsx_JanssenResearchAndDevelopmentLLCMember" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_CovanceCentralLaboratoryServicesMember" xlink:type="locator" xlink:label="bdsx_CovanceCentralLaboratoryServicesMember" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_MedicareMember" xlink:type="locator" xlink:label="bdsx_MedicareMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:type="locator" xlink:label="us-gaap_AccountsReceivableMember" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_CenturaHealthcareMember" xlink:type="locator" xlink:label="bdsx_CenturaHealthcareMember" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_TheBigTenConferenceMember" xlink:type="locator" xlink:label="bdsx_TheBigTenConferenceMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:type="locator" xlink:label="srt_NameOfMajorCustomerDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis" xlink:type="locator" xlink:label="srt_MajorCustomersAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:type="locator" xlink:label="us-gaap_CustomerConcentrationRiskMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:type="locator" xlink:label="us-gaap_SalesRevenueNetMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:type="locator" xlink:label="us-gaap_SegmentReportingAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_ConcentrationRiskTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_SalesRevenueNetMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CustomerConcentrationRiskMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="srt_MajorCustomersAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="bdsx_TheBigTenConferenceMember" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="bdsx_CenturaHealthcareMember" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_AccountsReceivableMember" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="bdsx_MedicareMember" order="10740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="bdsx_CovanceCentralLaboratoryServicesMember" order="10780.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="bdsx_JanssenResearchAndDevelopmentLLCMember" order="10800.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="bdsx_PfizerIncMember" order="10820.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskLineItems" order="10840.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" order="10850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosureBusinessCombinationsAdditionalInformationDetails" xlink:href="bdsx-20201231.xsd#Role_DisclosureBusinessCombinationsAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://biodesix.com/20201231/taxonomy/role/DisclosureBusinessCombinationsAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_BusinessCombinationContingentConsiderationArrangementsCommonSharesRedemptionAmount" xlink:type="locator" xlink:label="bdsx_BusinessCombinationContingentConsiderationArrangementsCommonSharesRedemptionAmount" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_BusinessAcquisitionContingentConsiderationNumberOfInstallments" xlink:type="locator" xlink:label="bdsx_BusinessAcquisitionContingentConsiderationNumberOfInstallments" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_BusinessCombinationContingentConsiderationShares" xlink:type="locator" xlink:label="bdsx_BusinessCombinationContingentConsiderationShares" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod" xlink:type="locator" xlink:label="bdsx_BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:type="locator" xlink:label="us-gaap_CashAcquiredFromAcquisition" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill" xlink:type="locator" xlink:label="us-gaap_Goodwill" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherPaymentsToAcquireBusinesses" xlink:type="locator" xlink:label="us-gaap_OtherPaymentsToAcquireBusinesses" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionLineItems" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_RepurchaseMember" xlink:type="locator" xlink:label="bdsx_RepurchaseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_IntegratedDiagnosticsIncMember" xlink:type="locator" xlink:label="bdsx_IntegratedDiagnosticsIncMember" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US" xlink:type="locator" xlink:label="country_US" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_OncimmuneLimitedMember" xlink:type="locator" xlink:label="bdsx_OncimmuneLimitedMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseMember" xlink:type="locator" xlink:label="us-gaap_LicenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="srt_ProductOrServiceAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_LicenseMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="bdsx_OncimmuneLimitedMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="srt_StatementGeographicalAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_US" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="bdsx_IntegratedDiagnosticsIncMember" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_InvestmentTypeAxis" order="10030.08" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="10860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="bdsx_RepurchaseMember" order="10880.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionLineItems" order="10920.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1" order="10930.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity" order="10950.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_OtherPaymentsToAcquireBusinesses" order="10970.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_PaymentsToAcquireBusinessesGross" order="10990.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_Goodwill" order="11040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure" order="11130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_CashAcquiredFromAcquisition" order="11220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="bdsx_BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod" order="11240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="bdsx_BusinessCombinationContingentConsiderationShares" order="11260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="bdsx_BusinessAcquisitionContingentConsiderationNumberOfInstallments" order="11280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="bdsx_BusinessCombinationContingentConsiderationArrangementsCommonSharesRedemptionAmount" order="11300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" order="11360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosureBusinessCombinationsSummaryOfAggregateConsiderationPaidByCompanyAndAllocationOfPurchasePriceToAssetsAcquiredAndLiabilitiesAssumedDetails" xlink:href="bdsx-20201231.xsd#Role_DisclosureBusinessCombinationsSummaryOfAggregateConsiderationPaidByCompanyAndAllocationOfPurchasePriceToAssetsAcquiredAndLiabilitiesAssumedDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://biodesix.com/20201231/taxonomy/role/DisclosureBusinessCombinationsSummaryOfAggregateConsiderationPaidByCompanyAndAllocationOfPurchasePriceToAssetsAcquiredAndLiabilitiesAssumedDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill" xlink:type="locator" xlink:label="us-gaap_Goodwill" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPurchaseOption" xlink:type="locator" xlink:label="bdsx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPurchaseOption" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionLineItems" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_OncimmuneLimitedMember" xlink:type="locator" xlink:label="bdsx_OncimmuneLimitedMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="bdsx_OncimmuneLimitedMember" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionLineItems" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_PaymentsToAcquireBusinessesGross" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="bdsx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPurchaseOption" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_Goodwill" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosureFairValueSummaryOfFairValueOfOutstandingBorrowingsDetails" xlink:href="bdsx-20201231.xsd#Role_DisclosureFairValueSummaryOfFairValueOfOutstandingBorrowingsDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://biodesix.com/20201231/taxonomy/role/DisclosureFairValueSummaryOfFairValueOfOutstandingBorrowingsDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtFairValue" xlink:type="locator" xlink:label="us-gaap_LongTermDebtFairValue" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisLineItems" xlink:type="locator" xlink:label="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:type="locator" xlink:label="us-gaap_EstimateOfFairValueFairValueDisclosureMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:type="locator" xlink:label="us-gaap_CarryingReportedAmountFairValueDisclosureMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:type="locator" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosureItemAmountsDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementBasisAxis" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisTable" xlink:type="locator" xlink:label="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementBasisAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="us-gaap_PortionAtFairValueFairValueDisclosureMember" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementBasisAxis" xlink:to="us-gaap_FairValueDisclosureItemAmountsDomain" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="us-gaap_CarryingReportedAmountFairValueDisclosureMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="us-gaap_EstimateOfFairValueFairValueDisclosureMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisTable" xlink:to="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisLineItems" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisLineItems" xlink:to="us-gaap_LongTermDebtFairValue" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosureFairValueScheduleOfReportedFairValuesOfLiabilitiesDetails" xlink:href="bdsx-20201231.xsd#Role_DisclosureFairValueScheduleOfReportedFairValuesOfLiabilitiesDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://biodesix.com/20201231/taxonomy/role/DisclosureFairValueScheduleOfReportedFairValuesOfLiabilitiesDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_LiabilitiesFairValueDisclosure" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisLineItems" xlink:type="locator" xlink:label="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_ContingentValueRightsMember" xlink:type="locator" xlink:label="bdsx_ContingentValueRightsMember" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_WarrantLiabilityMember" xlink:type="locator" xlink:label="bdsx_WarrantLiabilityMember" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_PutOptionLiabilityMember" xlink:type="locator" xlink:label="bdsx_PutOptionLiabilityMember" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_ContingentConsiderationMember" xlink:type="locator" xlink:label="bdsx_ContingentConsiderationMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByLiabilityClassAxis" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisTable" xlink:type="locator" xlink:label="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="bdsx_ContingentConsiderationMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="bdsx_PutOptionLiabilityMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="bdsx_WarrantLiabilityMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="bdsx_ContingentValueRightsMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisTable" xlink:to="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisLineItems" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosure" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosureFairValueScheduleOfChangesInFinancialLiabilitiesDetails" xlink:href="bdsx-20201231.xsd#Role_DisclosureFairValueScheduleOfChangesInFinancialLiabilitiesDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://biodesix.com/20201231/taxonomy/role/DisclosureFairValueScheduleOfChangesInFinancialLiabilitiesDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_li0l2" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_FairValueMeasurementWithUnobservableInputsReconciliationReclassifiedToAdditionalPaidInCapital" xlink:type="locator" xlink:label="bdsx_FairValueMeasurementWithUnobservableInputsReconciliationReclassifiedToAdditionalPaidInCapital" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_ContingentValueRightsMember" xlink:type="locator" xlink:label="bdsx_ContingentValueRightsMember" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_WarrantLiabilityMember" xlink:type="locator" xlink:label="bdsx_WarrantLiabilityMember" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_PutOptionLiabilityMember" xlink:type="locator" xlink:label="bdsx_PutOptionLiabilityMember" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_ContingentConsiderationMember" xlink:type="locator" xlink:label="bdsx_ContingentConsiderationMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByLiabilityClassAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="bdsx_ContingentConsiderationMember" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="bdsx_PutOptionLiabilityMember" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="bdsx_WarrantLiabilityMember" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="bdsx_ContingentValueRightsMember" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="bdsx_FairValueMeasurementWithUnobservableInputsReconciliationReclassifiedToAdditionalPaidInCapital" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_li0l2" order="10730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosureFairValueAdditionalInformationDetails" xlink:href="bdsx-20201231.xsd#Role_DisclosureFairValueAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://biodesix.com/20201231/taxonomy/role/DisclosureFairValueAdditionalInformationDetails">
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_PercentageOfDevelopmentAndRegulatoryCostsExercisedUsingOptOutRight" xlink:type="locator" xlink:label="bdsx_PercentageOfDevelopmentAndRegulatoryCostsExercisedUsingOptOutRight" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_NetProceedsPercentageOfCashPaymentToCVRHolders" xlink:type="locator" xlink:label="bdsx_NetProceedsPercentageOfCashPaymentToCVRHolders" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_ContingentValueRightsPercentage" xlink:type="locator" xlink:label="bdsx_ContingentValueRightsPercentage" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_ContingentValueRights" xlink:type="locator" xlink:label="bdsx_ContingentValueRights" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_ContingentValueRightsShares" xlink:type="locator" xlink:label="bdsx_ContingentValueRightsShares" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_PutOptionLiabilityCurrent" xlink:type="locator" xlink:label="bdsx_PutOptionLiabilityCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_PercentageOfProbabilitiesOfContingentConsiderationSuccessfulAchievementMilestoneDiscountRatesRange" xlink:type="locator" xlink:label="bdsx_PercentageOfProbabilitiesOfContingentConsiderationSuccessfulAchievementMilestoneDiscountRatesRange" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesFPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesFPreferredStockMember" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_AVEOOncologyMember" xlink:type="locator" xlink:label="bdsx_AVEOOncologyMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember" xlink:type="locator" xlink:label="us-gaap_IPOMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesGPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesGPreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_NotesPayable2018NotesMember" xlink:type="locator" xlink:label="bdsx_NotesPayable2018NotesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="srt_RangeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="bdsx_NotesPayable2018NotesMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesGPreferredStockMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="srt_CounterpartyNameAxis" order="10030.08" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="bdsx_AVEOOncologyMember" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesFPreferredStockMember" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="bdsx_PercentageOfProbabilitiesOfContingentConsiderationSuccessfulAchievementMilestoneDiscountRatesRange" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" order="10640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="bdsx_PutOptionLiabilityCurrent" order="10710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" order="10760.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="10780.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate" order="10800.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" order="10820.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="10840.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="10880.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="bdsx_ContingentValueRightsShares" order="10930.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="bdsx_ContingentValueRights" order="10950.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="bdsx_ContingentValueRightsPercentage" order="10970.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="bdsx_NetProceedsPercentageOfCashPaymentToCVRHolders" order="10990.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="bdsx_PercentageOfDevelopmentAndRegulatoryCostsExercisedUsingOptOutRight" order="11010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" xlink:href="bdsx-20201231.xsd#Role_DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://biodesix.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:type="locator" xlink:label="us-gaap_ConstructionInProgressMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:type="locator" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquipmentMember" xlink:type="locator" xlink:label="us-gaap_EquipmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfDepreciationExpenseRelatedToPropertyAndEquipmentDetails" xlink:href="bdsx-20201231.xsd#Role_DisclosurePropertyAndEquipmentScheduleOfDepreciationExpenseRelatedToPropertyAndEquipmentDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://biodesix.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfDepreciationExpenseRelatedToPropertyAndEquipmentDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation" xlink:type="locator" xlink:label="us-gaap_Depreciation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_DirectCostsAndExpensesMember" xlink:type="locator" xlink:label="bdsx_DirectCostsAndExpensesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentMember" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByAssetClassAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="bdsx_DirectCostsAndExpensesMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_Depreciation" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsScheduleOfChangesInGoodwillDetails" xlink:href="bdsx-20201231.xsd#Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfChangesInGoodwillDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://biodesix.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsScheduleOfChangesInGoodwillDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill" xlink:type="locator" xlink:label="us-gaap_Goodwill_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod" xlink:type="locator" xlink:label="us-gaap_GoodwillAcquiredDuringPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill" xlink:type="locator" xlink:label="us-gaap_Goodwill" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_Goodwill" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAcquiredDuringPeriod" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_Goodwill_li0l2" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsScheduleOfIntangibleAssetsDetails" xlink:href="bdsx-20201231.xsd#Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfIntangibleAssetsDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://biodesix.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsScheduleOfIntangibleAssetsDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_IntangibleAssetsAccumulatedAmortizationExcludingGoodwill" xlink:type="locator" xlink:label="bdsx_IntangibleAssetsAccumulatedAmortizationExcludingGoodwill" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsGrossExcludingGoodwill" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="locator" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_IndefiniteLivedIntangibleAssetsExcludingGoodwillGross" xlink:type="locator" xlink:label="bdsx_IndefiniteLivedIntangibleAssetsExcludingGoodwillGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TrademarksMember" xlink:type="locator" xlink:label="us-gaap_TrademarksMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_PurchaseOptionMember" xlink:type="locator" xlink:label="bdsx_PurchaseOptionMember" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_PurchasedTechnologyMember" xlink:type="locator" xlink:label="bdsx_PurchasedTechnologyMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PatentsMember" xlink:type="locator" xlink:label="us-gaap_PatentsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_PatentsMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="bdsx_PurchasedTechnologyMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="bdsx_PurchaseOptionMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" order="10070.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_TrademarksMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="10670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="bdsx_IndefiniteLivedIntangibleAssetsExcludingGoodwillGross" order="11420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" order="11600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_IntangibleAssetsGrossExcludingGoodwill" order="12170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="bdsx_IntangibleAssetsAccumulatedAmortizationExcludingGoodwill" order="12350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="12530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsScheduleOfAmortizationExpenseRelatedToDefiniteLivedIntangibleAssetsDetails" xlink:href="bdsx-20201231.xsd#Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfAmortizationExpenseRelatedToDefiniteLivedIntangibleAssetsDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://biodesix.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsScheduleOfAmortizationExpenseRelatedToDefiniteLivedIntangibleAssetsDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:type="locator" xlink:label="us-gaap_AmortizationOfIntangibleAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_DirectCostsAndExpensesMember" xlink:type="locator" xlink:label="bdsx_DirectCostsAndExpensesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="bdsx_DirectCostsAndExpensesMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsScheduleOfFutureEstimatedAmortizationExpenseOfIntangibleAssetsDetails" xlink:href="bdsx-20201231.xsd#Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfFutureEstimatedAmortizationExpenseOfIntangibleAssetsDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://biodesix.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsScheduleOfFutureEstimatedAmortizationExpenseOfIntangibleAssetsDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails" xlink:href="bdsx-20201231.xsd#Role_DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://biodesix.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetImpairment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetImpairment" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails" xlink:href="bdsx-20201231.xsd#Role_DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://biodesix.com/20201231/taxonomy/role/DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductWarrantyAccrualClassifiedCurrent" xlink:type="locator" xlink:label="us-gaap_ProductWarrantyAccrualClassifiedCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_AccruedClinicalTrialExpenseCurrent" xlink:type="locator" xlink:label="bdsx_AccruedClinicalTrialExpenseCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="bdsx_AccruedClinicalTrialExpenseCurrent" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_ProductWarrantyAccrualClassifiedCurrent" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosureDebtSummaryOfLongTermNotesPayableDetails" xlink:href="bdsx-20201231.xsd#Role_DisclosureDebtSummaryOfLongTermNotesPayableDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://biodesix.com/20201231/taxonomy/role/DisclosureDebtSummaryOfLongTermNotesPayableDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:type="locator" xlink:label="us-gaap_LongTermNotesPayable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:type="locator" xlink:label="us-gaap_NotesPayableCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayable" xlink:type="locator" xlink:label="us-gaap_NotesPayable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:type="locator" xlink:label="us-gaap_ConvertibleNotesPayableCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentCarryingAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_CARESActMember" xlink:type="locator" xlink:label="bdsx_CARESActMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_PPPLoanMember" xlink:type="locator" xlink:label="bdsx_PPPLoanMember" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_NotesPayable2018NotesMember" xlink:type="locator" xlink:label="bdsx_NotesPayable2018NotesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentsAbstract" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentsAbstract" xlink:to="us-gaap_DebtInstrumentTable" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="bdsx_NotesPayable2018NotesMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="bdsx_PPPLoanMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" order="10050.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="bdsx_CARESActMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentLineItems" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentCarryingAmount" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ConvertibleNotesPayableCurrent" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_NotesPayable" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_NotesPayableCurrent" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermNotesPayable" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" xlink:href="bdsx-20201231.xsd#Role_DisclosureDebtAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://biodesix.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetails">
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_IncreaseToPutOptionLiability" xlink:type="locator" xlink:label="bdsx_IncreaseToPutOptionLiability" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_PercentageOfConversionPricePerShareOfConvertiblePreferredStock" xlink:type="locator" xlink:label="bdsx_PercentageOfConversionPricePerShareOfConvertiblePreferredStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_PutOptionLiabilityCurrent" xlink:type="locator" xlink:label="bdsx_PutOptionLiabilityCurrent" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_PercentageOfConversionPricePerShareOfCommonStock" xlink:type="locator" xlink:label="bdsx_PercentageOfConversionPricePerShareOfCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentRate" xlink:type="locator" xlink:label="us-gaap_DebtConversionConvertedInstrumentRate" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_DebtInstrumentMaturityDateExtended" xlink:type="locator" xlink:label="bdsx_DebtInstrumentMaturityDateExtended" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesIssued1" xlink:type="locator" xlink:label="us-gaap_NotesIssued1" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_PercentageOfUpperLimitOfEmployeeSalaryToReduceForgiveness" xlink:type="locator" xlink:label="bdsx_PercentageOfUpperLimitOfEmployeeSalaryToReduceForgiveness" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_UpperLimitOfEmployeeSalaryToReduceForgiveness" xlink:type="locator" xlink:label="bdsx_UpperLimitOfEmployeeSalaryToReduceForgiveness" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_PercentageForNonPayrollCosts" xlink:type="locator" xlink:label="bdsx_PercentageForNonPayrollCosts" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_PayrollCostsExcludesCompensationOfEmployee" xlink:type="locator" xlink:label="bdsx_PayrollCostsExcludesCompensationOfEmployee" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentDescription" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentDescription" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_DebtInstrumentAdditionalInterestExpenseFeePercentage" xlink:type="locator" xlink:label="bdsx_DebtInstrumentAdditionalInterestExpenseFeePercentage" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_DebtInstrumentBackEndFacilityFeePercentage" xlink:type="locator" xlink:label="bdsx_DebtInstrumentBackEndFacilityFeePercentage" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_DebtInstrumentPrepaymentPenaltyPercentage" xlink:type="locator" xlink:label="bdsx_DebtInstrumentPrepaymentPenaltyPercentage" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_DebtInstrumentInterestAddedToPrincipalValue" xlink:type="locator" xlink:label="bdsx_DebtInstrumentInterestAddedToPrincipalValue" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_DebtInstrumentPercentageOfStatedInterestRateAddedToPrincipalValueOfNotesPayable" xlink:type="locator" xlink:label="bdsx_DebtInstrumentPercentageOfStatedInterestRateAddedToPrincipalValueOfNotesPayable" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_DebtInstrumentPercentageOfStatedInterestRatePaidInCash" xlink:type="locator" xlink:label="bdsx_DebtInstrumentPercentageOfStatedInterestRatePaidInCash" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFeeAmount" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFeeAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentCarryingAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_AugustTwoThousandAndNineteenConvertibleNotesMember" xlink:type="locator" xlink:label="bdsx_AugustTwoThousandAndNineteenConvertibleNotesMember" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_DecemberTwoThousandAndNineteenConvertibleNotesMember" xlink:type="locator" xlink:label="bdsx_DecemberTwoThousandAndNineteenConvertibleNotesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesHPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesHPreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodTwoMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodOneMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodAxis" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_MarchTwoThousandAndTwentyConvertibleNotesMember" xlink:type="locator" xlink:label="bdsx_MarchTwoThousandAndTwentyConvertibleNotesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestBearingDepositsMember" xlink:type="locator" xlink:label="us-gaap_InterestBearingDepositsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeAxis" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_CARESActMember" xlink:type="locator" xlink:label="bdsx_CARESActMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_PPPLoanMember" xlink:type="locator" xlink:label="bdsx_PPPLoanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesGPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesGPreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_NotesPayable2018NotesMember" xlink:type="locator" xlink:label="bdsx_NotesPayable2018NotesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="bdsx_NotesPayable2018NotesMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesGPreferredStockMember" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_RangeAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="bdsx_PPPLoanMember" order="10640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="10680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="bdsx_CARESActMember" order="10700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_InvestmentTypeAxis" order="10030.08" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="10740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_InterestBearingDepositsMember" order="10760.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" order="10030.10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" order="11200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="bdsx_MarchTwoThousandAndTwentyConvertibleNotesMember" order="11220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodAxis" order="10030.12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodDomain" order="11500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodOneMember" order="11520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodTwoMember" order="11540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesHPreferredStockMember" order="11600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10030.14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="11660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="11680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="bdsx_DecemberTwoThousandAndNineteenConvertibleNotesMember" order="11740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="bdsx_AugustTwoThousandAndNineteenConvertibleNotesMember" order="12260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentLineItems" order="12720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentCarryingAmount" order="12730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFeeAmount" order="12780.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" order="12820.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" order="12860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="12900.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="bdsx_DebtInstrumentPercentageOfStatedInterestRatePaidInCash" order="12940.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="bdsx_DebtInstrumentPercentageOfStatedInterestRateAddedToPrincipalValueOfNotesPayable" order="12980.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="bdsx_DebtInstrumentInterestAddedToPrincipalValue" order="13020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" order="13060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="bdsx_DebtInstrumentPrepaymentPenaltyPercentage" order="13130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="bdsx_DebtInstrumentBackEndFacilityFeePercentage" order="13150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="bdsx_DebtInstrumentAdditionalInterestExpenseFeePercentage" order="13170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" order="13220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentDescription" order="13340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="bdsx_PayrollCostsExcludesCompensationOfEmployee" order="13410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="bdsx_PercentageForNonPayrollCosts" order="13430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="bdsx_UpperLimitOfEmployeeSalaryToReduceForgiveness" order="13450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="bdsx_PercentageOfUpperLimitOfEmployeeSalaryToReduceForgiveness" order="13470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_NotesIssued1" order="13520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="13540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="bdsx_DebtInstrumentMaturityDateExtended" order="13560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentRate" order="13640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1" order="13660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="bdsx_PercentageOfConversionPricePerShareOfCommonStock" order="13680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="bdsx_PutOptionLiabilityCurrent" order="13700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="13720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="bdsx_PercentageOfConversionPricePerShareOfConvertiblePreferredStock" order="14180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="bdsx_IncreaseToPutOptionLiability" order="14310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosureDebtScheduledPrincipalRepaymentsMaturitiesOfLongTermObligationsDetails" xlink:href="bdsx-20201231.xsd#Role_DisclosureDebtScheduledPrincipalRepaymentsMaturitiesOfLongTermObligationsDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://biodesix.com/20201231/taxonomy/role/DisclosureDebtScheduledPrincipalRepaymentsMaturitiesOfLongTermObligationsDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt" xlink:type="locator" xlink:label="us-gaap_LongTermDebt" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MaturitiesOfLongTermDebtAbstract" xlink:type="locator" xlink:label="us-gaap_MaturitiesOfLongTermDebtAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MaturitiesOfLongTermDebtAbstract" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MaturitiesOfLongTermDebtAbstract" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MaturitiesOfLongTermDebtAbstract" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MaturitiesOfLongTermDebtAbstract" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MaturitiesOfLongTermDebtAbstract" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MaturitiesOfLongTermDebtAbstract" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MaturitiesOfLongTermDebtAbstract" xlink:to="us-gaap_LongTermDebt" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails" xlink:href="bdsx-20201231.xsd#Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://biodesix.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_NumberOfPreferredStockConvertedIntoCommonStock" xlink:type="locator" xlink:label="bdsx_NumberOfPreferredStockConvertedIntoCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesIssued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_SeriesB1ConvertiblePreferredStockMember" xlink:type="locator" xlink:label="bdsx_SeriesB1ConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesGPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesGPreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesFPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesFPreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesEPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesEPreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesDPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesDPreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesCPreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesBPreferredStockMember" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_SeriesA3PreferredStockMember" xlink:type="locator" xlink:label="bdsx_SeriesA3PreferredStockMember" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_SeriesA2PreferredStockMember" xlink:type="locator" xlink:label="bdsx_SeriesA2PreferredStockMember" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_SeriesA1PreferredStockMember" xlink:type="locator" xlink:label="bdsx_SeriesA1PreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesHPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesHPreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesHPreferredStockMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="bdsx_SeriesA1PreferredStockMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="bdsx_SeriesA2PreferredStockMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="bdsx_SeriesA3PreferredStockMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesCPreferredStockMember" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesDPreferredStockMember" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesEPreferredStockMember" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesFPreferredStockMember" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesGPreferredStockMember" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="bdsx_SeriesB1ConvertiblePreferredStockMember" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" order="10600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="bdsx_NumberOfPreferredStockConvertedIntoCommonStock" order="11040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="11080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosureWarrantsToPurchaseConvertiblePreferredStockSummaryOfActivityForConvertiblePreferredStockWarrantsDetails" xlink:href="bdsx-20201231.xsd#Role_DisclosureWarrantsToPurchaseConvertiblePreferredStockSummaryOfActivityForConvertiblePreferredStockWarrantsDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://biodesix.com/20201231/taxonomy/role/DisclosureWarrantsToPurchaseConvertiblePreferredStockSummaryOfActivityForConvertiblePreferredStockWarrantsDetails">
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="bdsx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_li0l2" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsReclassificationOfWarrantLiabilityToAdditionalPaidInCapitalWeightedAverageExercisePrice" xlink:type="locator" xlink:label="bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsReclassificationOfWarrantLiabilityToAdditionalPaidInCapitalWeightedAverageExercisePrice" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="bdsx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="bdsx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsPeriodIncreaseDecrease" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsPeriodIncreaseDecrease" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_SeriesGConvertiblePreferredStockWarrantsMember" xlink:type="locator" xlink:label="bdsx_SeriesGConvertiblePreferredStockWarrantsMember" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_SeriesEConvertiblePreferredStockWarrantsMember" xlink:type="locator" xlink:label="bdsx_SeriesEConvertiblePreferredStockWarrantsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="bdsx_SeriesEConvertiblePreferredStockWarrantsMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="bdsx_SeriesGConvertiblePreferredStockWarrantsMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsPeriodIncreaseDecrease" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_li0l2" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="bdsx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice" order="10600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="bdsx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" order="10680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice" order="10760.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsReclassificationOfWarrantLiabilityToAdditionalPaidInCapitalWeightedAverageExercisePrice" order="10840.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="bdsx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_li0l2" order="10920.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosureWarrantsToPurchaseConvertiblePreferredStockAdditionalInformationDetails" xlink:href="bdsx-20201231.xsd#Role_DisclosureWarrantsToPurchaseConvertiblePreferredStockAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://biodesix.com/20201231/taxonomy/role/DisclosureWarrantsToPurchaseConvertiblePreferredStockAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosureEquityAdditionalInformationDetails" xlink:href="bdsx-20201231.xsd#Role_DisclosureEquityAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://biodesix.com/20201231/taxonomy/role/DisclosureEquityAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_DirectOfferingExpenses" xlink:type="locator" xlink:label="bdsx_DirectOfferingExpenses" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees" xlink:type="locator" xlink:label="us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DividendsCommonStock" xlink:type="locator" xlink:label="us-gaap_DividendsCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockVotingRights" xlink:type="locator" xlink:label="us-gaap_CommonStockVotingRights" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember" xlink:type="locator" xlink:label="us-gaap_IPOMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockVotingRights" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_DividendsCommonStock" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="bdsx_DirectOfferingExpenses" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosureRevenueSummaryOfRevenueDetails" xlink:href="bdsx-20201231.xsd#Role_DisclosureRevenueSummaryOfRevenueDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://biodesix.com/20201231/taxonomy/role/DisclosureRevenueSummaryOfRevenueDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues" xlink:type="locator" xlink:label="us-gaap_Revenues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ServiceMember" xlink:type="locator" xlink:label="us-gaap_ServiceMember" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_DiagnosticTestsMember" xlink:type="locator" xlink:label="bdsx_DiagnosticTestsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_DisaggregationOfRevenueTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_ProductOrServiceAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="bdsx_DiagnosticTestsMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ServiceMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_DisaggregationOfRevenueLineItems" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_Revenues" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosureRevenueAdditionalInformationDetails" xlink:href="bdsx-20201231.xsd#Role_DisclosureRevenueAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://biodesix.com/20201231/taxonomy/role/DisclosureRevenueAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_AdvanceDeposits" xlink:type="locator" xlink:label="bdsx_AdvanceDeposits" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues" xlink:type="locator" xlink:label="us-gaap_Revenues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueLineItems" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_DeferredRevenueMember" xlink:type="locator" xlink:label="bdsx_DeferredRevenueMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationAxis" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_LungDiagnosticRevenueMember" xlink:type="locator" xlink:label="bdsx_LungDiagnosticRevenueMember" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_COVID19DiagnosticTestRevenueMember" xlink:type="locator" xlink:label="bdsx_COVID19DiagnosticTestRevenueMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_DisaggregationOfRevenueTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_ProductOrServiceAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="bdsx_COVID19DiagnosticTestRevenueMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="bdsx_LungDiagnosticRevenueMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="bdsx_DeferredRevenueMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_DisaggregationOfRevenueLineItems" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_Revenues" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="bdsx_AdvanceDeposits" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails" xlink:href="bdsx-20201231.xsd#Role_DisclosureShareBasedCompensationAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://biodesix.com/20201231/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_PercentageOfFullyDilutedEquityForBonusAwarded" xlink:type="locator" xlink:label="bdsx_PercentageOfFullyDilutedEquityForBonusAwarded" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_NumberOfEqualAnnualInstallmentsForAwardVesting" xlink:type="locator" xlink:label="bdsx_NumberOfEqualAnnualInstallmentsForAwardVesting" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_DescriptionOfOfferingPeriodUnderPlan" xlink:type="locator" xlink:label="bdsx_DescriptionOfOfferingPeriodUnderPlan" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_DescriptionOfVotingPowerOrValueOfStockForEmployeeParticipationInOfferingPeriod" xlink:type="locator" xlink:label="bdsx_DescriptionOfVotingPowerOrValueOfStockForEmployeeParticipationInOfferingPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain" xlink:type="locator" xlink:label="us-gaap_VestingDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingAxis" xlink:type="locator" xlink:label="us-gaap_VestingAxis" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_ServiceConditionRSUsMember" xlink:type="locator" xlink:label="bdsx_ServiceConditionRSUsMember" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_OptionsAndRestrictedStockUnitsMember" xlink:type="locator" xlink:label="bdsx_OptionsAndRestrictedStockUnitsMember" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_BonusToOptionsProgramMember" xlink:type="locator" xlink:label="bdsx_BonusToOptionsProgramMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_PerformanceConditionOptionsMember" xlink:type="locator" xlink:label="bdsx_PerformanceConditionOptionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_TwoThousandSixPlanTwoThousandSixteenPlanAndTwoThousandTwentyEquityIncentivePlanMember" xlink:type="locator" xlink:label="bdsx_TwoThousandSixPlanTwoThousandSixteenPlanAndTwoThousandTwentyEquityIncentivePlanMember" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_TwoThousandAndSixteenPlanMember" xlink:type="locator" xlink:label="bdsx_TwoThousandAndSixteenPlanMember" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_TwoThousandSixPlanMember" xlink:type="locator" xlink:label="bdsx_TwoThousandSixPlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_TwoThousandTwentyEquityIncentivePlanMember" xlink:type="locator" xlink:label="bdsx_TwoThousandTwentyEquityIncentivePlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_EmployeeStockMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="bdsx_TwoThousandTwentyEquityIncentivePlanMember" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="bdsx_TwoThousandSixPlanMember" order="10540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="bdsx_TwoThousandAndSixteenPlanMember" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="bdsx_TwoThousandSixPlanTwoThousandSixteenPlanAndTwoThousandTwentyEquityIncentivePlanMember" order="10840.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10030.08" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="11080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="bdsx_PerformanceConditionOptionsMember" order="11100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="11380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="bdsx_BonusToOptionsProgramMember" order="11520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="bdsx_OptionsAndRestrictedStockUnitsMember" order="11860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="bdsx_ServiceConditionRSUsMember" order="11940.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_VestingAxis" order="10030.10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" order="12180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" order="12200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" order="12220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="12240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="12250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" order="12270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" order="12320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate" order="12340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="bdsx_DescriptionOfVotingPowerOrValueOfStockForEmployeeParticipationInOfferingPeriod" order="12360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="bdsx_DescriptionOfOfferingPeriodUnderPlan" order="12380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" order="12470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="12520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="12560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="12730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" order="12780.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="bdsx_NumberOfEqualAnnualInstallmentsForAwardVesting" order="12820.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="12860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="12900.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" order="12980.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="13020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="13060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="13100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="13170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="bdsx_PercentageOfFullyDilutedEquityForBonusAwarded" order="13240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="13280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="13300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="13350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" order="13400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="13420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" order="13510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="13550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" order="13570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="13590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfPreTaxShareBasedCompensationExpenseDetails" xlink:href="bdsx-20201231.xsd#Role_DisclosureShareBasedCompensationSummaryOfPreTaxShareBasedCompensationExpenseDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://biodesix.com/20201231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfPreTaxShareBasedCompensationExpenseDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetails" xlink:href="bdsx-20201231.xsd#Role_DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://biodesix.com/20201231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="bdsx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_li0l2" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_li0l2" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="bdsx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_li0l2" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfWeightedAverageAssumptionsDetails" xlink:href="bdsx-20201231.xsd#Role_DisclosureShareBasedCompensationSummaryOfWeightedAverageAssumptionsDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://biodesix.com/20201231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfWeightedAverageAssumptionsDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosureEarningsPerShareScheduleOfComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails" xlink:href="bdsx-20201231.xsd#Role_DisclosureEarningsPerShareScheduleOfComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://biodesix.com/20201231/taxonomy/role/DisclosureEarningsPerShareScheduleOfComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAbstract" xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:to="us-gaap_NetIncomeLossAbstract" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAbstract" xlink:to="us-gaap_NetIncomeLoss" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:to="us-gaap_EarningsPerShareAbstract" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosureEarningsPerShareScheduleOfCommonStockEquivalentsExcludedFromDilutedNetLossAttributableToCommonStockholdersDetails" xlink:href="bdsx-20201231.xsd#Role_DisclosureEarningsPerShareScheduleOfCommonStockEquivalentsExcludedFromDilutedNetLossAttributableToCommonStockholdersDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://biodesix.com/20201231/taxonomy/role/DisclosureEarningsPerShareScheduleOfCommonStockEquivalentsExcludedFromDilutedNetLossAttributableToCommonStockholdersDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_ConvertibleDebtSecuritiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember" xlink:type="locator" xlink:label="us-gaap_WarrantMember" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_OptionsToPurchaseCommonStockMember" xlink:type="locator" xlink:label="bdsx_OptionsToPurchaseCommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="bdsx_OptionsToPurchaseCommonStockMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_ConvertibleDebtSecuritiesMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" xlink:href="bdsx-20201231.xsd#Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://biodesix.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExaminationDescription" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExaminationDescription" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="locator" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_PercentageOfValuationAllowanceEqualToNetDeferredTaxAssets" xlink:type="locator" xlink:label="bdsx_PercentageOfValuationAllowanceEqualToNetDeferredTaxAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetExplanationOfChange" xlink:type="locator" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetExplanationOfChange" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardDescription" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardDescription" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_DeferredTaxAssetsResearchAndExperimentationTaxCarryforwardsSubjectToExpiration" xlink:type="locator" xlink:label="bdsx_DeferredTaxAssetsResearchAndExperimentationTaxCarryforwardsSubjectToExpiration" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="bdsx_DeferredTaxAssetsResearchAndExperimentationTaxCarryforwardsSubjectToExpiration" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_TaxCreditCarryforwardDescription" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetExplanationOfChange" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="bdsx_PercentageOfValuationAllowanceEqualToNetDeferredTaxAssets" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxExaminationDescription" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:href="bdsx-20201231.xsd#Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://biodesix.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_EffectiveIncomeTaxRateReconciliationPermanentItems" xlink:type="locator" xlink:label="bdsx_EffectiveIncomeTaxRateReconciliationPermanentItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="bdsx_EffectiveIncomeTaxRateReconciliationPermanentItems" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="bdsx-20201231.xsd#Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://biodesix.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesAbstract" xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:type="locator" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" order="10590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="10630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="10670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfUnrecognizedTaxBenefitsDetails" xlink:href="bdsx-20201231.xsd#Role_DisclosureIncomeTaxesReconciliationOfUnrecognizedTaxBenefitsDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://biodesix.com/20201231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfUnrecognizedTaxBenefitsDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefits_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefits" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:type="locator" xlink:label="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="us-gaap_UnrecognizedTaxBenefits_li0l2" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:href="bdsx-20201231.xsd#Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://biodesix.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRoyalties" xlink:type="locator" xlink:label="us-gaap_PaymentsForRoyalties" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_RevenueShareExpenses" xlink:type="locator" xlink:label="bdsx_RevenueShareExpenses" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_PeriodOfEscalationsOfSales" xlink:type="locator" xlink:label="bdsx_PeriodOfEscalationsOfSales" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_MinimumAnnualVolumePercentageThereafter" xlink:type="locator" xlink:label="bdsx_MinimumAnnualVolumePercentageThereafter" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_PercentageOfRevenueSharePaymentRelatedToAcquiredDiagnosticTestRecognizedRevenueForNonScreeningTests" xlink:type="locator" xlink:label="bdsx_PercentageOfRevenueSharePaymentRelatedToAcquiredDiagnosticTestRecognizedRevenueForNonScreeningTests" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyExpense" xlink:type="locator" xlink:label="us-gaap_RoyaltyExpense" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_LicenseAgreementExpiryDate" xlink:type="locator" xlink:label="bdsx_LicenseAgreementExpiryDate" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_PercentageOfRoyaltyPaymentsOnNetRevenue" xlink:type="locator" xlink:label="bdsx_PercentageOfRoyaltyPaymentsOnNetRevenue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_PercentageOfLicenseIncomeGeneratedFromLicensing" xlink:type="locator" xlink:label="bdsx_PercentageOfLicenseIncomeGeneratedFromLicensing" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_PercentageOfRoyaltyPaymentsOnNetSales" xlink:type="locator" xlink:label="bdsx_PercentageOfRoyaltyPaymentsOnNetSales" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_RemainingEstimatedObligation" xlink:type="locator" xlink:label="bdsx_RemainingEstimatedObligation" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_PercentageOfDevelopmentAndRegulatoryCostsExercisedUsingOptOutRight" xlink:type="locator" xlink:label="bdsx_PercentageOfDevelopmentAndRegulatoryCostsExercisedUsingOptOutRight" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_PercentageOfDevelopmentAndRegulatoryCosts" xlink:type="locator" xlink:label="bdsx_PercentageOfDevelopmentAndRegulatoryCosts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesRentExpenseNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:type="locator" xlink:label="us-gaap_LossContingenciesLineItems" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_OncimmuneLimitedMember" xlink:type="locator" xlink:label="bdsx_OncimmuneLimitedMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAxis" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_RevenueShareAgreementMember" xlink:type="locator" xlink:label="bdsx_RevenueShareAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_BioRadLicenseMember" xlink:type="locator" xlink:label="bdsx_BioRadLicenseMember" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_POCClinicalTrialsMember" xlink:type="locator" xlink:label="bdsx_POCClinicalTrialsMember" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_NSCLCPOCTrialMember" xlink:type="locator" xlink:label="bdsx_NSCLCPOCTrialMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_AVEOOncologyMember" xlink:type="locator" xlink:label="bdsx_AVEOOncologyMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_FiclatuzumabMember" xlink:type="locator" xlink:label="bdsx_FiclatuzumabMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesIndustryMember" xlink:type="locator" xlink:label="us-gaap_EquitySecuritiesIndustryMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesByIndustryAxis" xlink:type="locator" xlink:label="us-gaap_EquitySecuritiesByIndustryAxis" />
    <link:loc xlink:href="bdsx-20201231.xsd#bdsx_BDX004Member" xlink:type="locator" xlink:label="bdsx_BDX004Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesTable" xlink:type="locator" xlink:label="us-gaap_LossContingenciesTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LossContingenciesTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="srt_ProductOrServiceAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="bdsx_BDX004Member" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_EquitySecuritiesByIndustryAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquitySecuritiesByIndustryAxis" xlink:to="us-gaap_EquitySecuritiesIndustryMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquitySecuritiesIndustryMember" xlink:to="bdsx_FiclatuzumabMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="srt_CounterpartyNameAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="bdsx_AVEOOncologyMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="bdsx_NSCLCPOCTrialMember" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="bdsx_POCClinicalTrialsMember" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="bdsx_BioRadLicenseMember" order="10640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10030.08" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bdsx_RevenueShareAgreementMember" order="10740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="10030.10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="10860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="bdsx_OncimmuneLimitedMember" order="10880.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LossContingenciesLineItems" order="10980.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_OperatingLeasesRentExpenseNet" order="10990.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="bdsx_PercentageOfDevelopmentAndRegulatoryCosts" order="11060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="bdsx_PercentageOfDevelopmentAndRegulatoryCostsExercisedUsingOptOutRight" order="11130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="bdsx_RemainingEstimatedObligation" order="11150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="bdsx_PercentageOfRoyaltyPaymentsOnNetSales" order="11170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="bdsx_PercentageOfLicenseIncomeGeneratedFromLicensing" order="11190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="11240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="bdsx_PercentageOfRoyaltyPaymentsOnNetRevenue" order="11310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="bdsx_LicenseAgreementExpiryDate" order="11330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_RoyaltyExpense" order="11350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="bdsx_PercentageOfRevenueSharePaymentRelatedToAcquiredDiagnosticTestRecognizedRevenueForNonScreeningTests" order="11420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="bdsx_MinimumAnnualVolumePercentageThereafter" order="11440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="bdsx_PeriodOfEscalationsOfSales" order="11460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="bdsx_RevenueShareExpenses" order="11480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_PaymentsForRoyalties" order="11500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveVerboseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumLeasePaymentsForOperatingLeaseObligationsDetails" xlink:href="bdsx-20201231.xsd#Role_DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumLeasePaymentsForOperatingLeaseObligationsDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://biodesix.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumLeasePaymentsForOperatingLeaseObligationsDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://biodesix.com/20201231/taxonomy/role/DisclosureDefinedContribution401KPlanAdditionalInformationDetail" xlink:href="bdsx-20201231.xsd#Role_DisclosureDefinedContribution401KPlanAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://biodesix.com/20201231/taxonomy/role/DisclosureDefinedContribution401KPlanAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanPlanNameExtensibleList" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanPlanNameExtensibleList" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanPlanNameExtensibleList" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>bdsx-10k_20201231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:bdsx="http://biodesix.com/20201231"
  xmlns:country="http://xbrl.sec.gov/country/2020-01-31"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2020-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="bdsx-20201231.xsd" xlink:type="simple"/>
    <context id="C_0001439725_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001439725_20210312">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
        </entity>
        <period>
            <instant>2021-03-12</instant>
        </period>
    </context>
    <context id="C_0001439725_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001439725_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001439725_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001439725_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="C_0001439725_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="C_0001439725_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="C_0001439725_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="C_0001439725_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="C_0001439725_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001439725_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001439725_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001439725_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001439725_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001439725_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001439725_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001439725_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001439725_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001439725_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001439725_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001439725_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001439725_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001439725_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001439725_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001439725_us-gaapStatementClassOfStockAxis_us-gaapSeriesHPreferredStockMember_20190201_20190228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesHPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-01</startDate>
            <endDate>2019-02-28</endDate>
        </period>
    </context>
    <context id="C_0001439725_us-gaapStatementClassOfStockAxis_us-gaapSeriesHPreferredStockMember_20190301_20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesHPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="C_0001439725_us-gaapStatementClassOfStockAxis_us-gaapSeriesHPreferredStockMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesHPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001439725_20201019_20201019">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
        </entity>
        <period>
            <startDate>2020-10-19</startDate>
            <endDate>2020-10-19</endDate>
        </period>
    </context>
    <context id="C_0001439725_20201031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
        </entity>
        <period>
            <instant>2020-10-31</instant>
        </period>
    </context>
    <context id="C_0001439725_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20201027_20201027">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-27</startDate>
            <endDate>2020-10-27</endDate>
        </period>
    </context>
    <context id="C_0001439725_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20201027">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-27</instant>
        </period>
    </context>
    <context id="C_0001439725_srtRestatementAxis_srtRevisionOfPriorPeriodErrorCorrectionAdjustmentMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001439725_srtRestatementAxis_srtRevisionOfPriorPeriodErrorCorrectionAdjustmentMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001439725_srtProductOrServiceAxis_bdsxTestingServicesMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bdsx:TestingServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001439725_srtMajorCustomersAxis_bdsxTheBigTenConferenceMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bdsx:TheBigTenConferenceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001439725_srtMajorCustomersAxis_bdsxCenturaHealthcareMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bdsx:CenturaHealthcareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001439725_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001439725_srtMajorCustomersAxis_bdsxCovanceCentralLaboratoryServicesMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bdsx:CovanceCentralLaboratoryServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001439725_srtMajorCustomersAxis_bdsxMedicareMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bdsx:MedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001439725_srtMajorCustomersAxis_bdsxMedicareMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bdsx:MedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001439725_srtMajorCustomersAxis_bdsxTheBigTenConferenceMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bdsx:TheBigTenConferenceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001439725_srtMajorCustomersAxis_bdsxCenturaHealthcareMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bdsx:CenturaHealthcareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001439725_srtMajorCustomersAxis_bdsxMedicareMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bdsx:MedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001439725_srtMajorCustomersAxis_bdsxMedicareMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bdsx:MedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001439725_srtMajorCustomersAxis_bdsxCovanceCentralLaboratoryServicesMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bdsx:CovanceCentralLaboratoryServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001439725_srtMajorCustomersAxis_bdsxCovanceCentralLaboratoryServicesMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bdsx:CovanceCentralLaboratoryServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001439725_srtMajorCustomersAxis_bdsxJanssenResearchAndDevelopmentLLCMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bdsx:JanssenResearchAndDevelopmentLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001439725_srtMajorCustomersAxis_bdsxJanssenResearchAndDevelopmentLLCMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bdsx:JanssenResearchAndDevelopmentLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001439725_srtMajorCustomersAxis_bdsxPfizerIncMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bdsx:PfizerIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001439725_srtMajorCustomersAxis_bdsxPfizerIncMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bdsx:PfizerIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001439725_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001439725_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001439725_us-gaapBalanceSheetLocationAxis_us-gaapOtherCurrentAssetsMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001439725_us-gaapBalanceSheetLocationAxis_us-gaapOtherCurrentAssetsMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001439725_srtRangeAxis_srtMinimumMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001439725_srtRangeAxis_srtMaximumMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001439725_srtRangeAxis_srtMinimumMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_bdsxProductLifeAndPatentLifeMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bdsx:ProductLifeAndPatentLifeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001439725_srtRangeAxis_srtMaximumMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_bdsxProductLifeAndPatentLifeMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bdsx:ProductLifeAndPatentLifeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001439725_us-gaapBusinessAcquisitionAxis_bdsxOncimmuneLimitedMember_20191031_20191031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bdsx:OncimmuneLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-31</startDate>
            <endDate>2019-10-31</endDate>
        </period>
    </context>
    <context id="C_0001439725_us-gaapBusinessAcquisitionAxis_bdsxOncimmuneLimitedMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bdsx:OncimmuneLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001439725_srtProductOrServiceAxis_us-gaapLicenseMember_srtStatementGeographicalAxis_countryUS_us-gaapBusinessAcquisitionAxis_bdsxOncimmuneLimitedMember_20191031_20191031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bdsx:OncimmuneLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-31</startDate>
            <endDate>2019-10-31</endDate>
        </period>
    </context>
    <context id="C_0001439725_us-gaapBusinessAcquisitionAxis_bdsxOncimmuneLimitedMember_20191031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bdsx:OncimmuneLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-10-31</instant>
        </period>
    </context>
    <context id="C_0001439725_us-gaapBusinessAcquisitionAxis_bdsxIntegratedDiagnosticsIncMember_20180630_20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bdsx:IntegratedDiagnosticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-30</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="C_0001439725_us-gaapBusinessAcquisitionAxis_bdsxIntegratedDiagnosticsIncMember_20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bdsx:IntegratedDiagnosticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="C_0001439725_us-gaapBusinessAcquisitionAxis_bdsxIntegratedDiagnosticsIncMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bdsx:IntegratedDiagnosticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001439725_us-gaapBusinessAcquisitionAxis_bdsxIntegratedDiagnosticsIncMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20180630_20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bdsx:IntegratedDiagnosticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-30</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="C_0001439725_us-gaapBusinessAcquisitionAxis_bdsxIntegratedDiagnosticsIncMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bdsx:IntegratedDiagnosticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="C_0001439725_us-gaapBusinessAcquisitionAxis_bdsxIntegratedDiagnosticsIncMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bdsx:IntegratedDiagnosticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001439725_us-gaapBusinessAcquisitionAxis_bdsxIntegratedDiagnosticsIncMember_us-gaapInvestmentTypeAxis_bdsxRepurchaseMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bdsx:IntegratedDiagnosticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">bdsx:RepurchaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="C_0001439725_us-gaapBusinessAcquisitionAxis_bdsxIntegratedDiagnosticsIncMember_us-gaapInvestmentTypeAxis_bdsxRepurchaseMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20180630_20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bdsx:IntegratedDiagnosticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">bdsx:RepurchaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-30</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="C_0001439725_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementBasisAxis_us-gaapCarryingReportedAmountFairValueDisclosureMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001439725_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementBasisAxis_us-gaapEstimateOfFairValueFairValueDisclosureMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001439725_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementBasisAxis_us-gaapCarryingReportedAmountFairValueDisclosureMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001439725_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementBasisAxis_us-gaapEstimateOfFairValueFairValueDisclosureMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001439725_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByLiabilityClassAxis_bdsxContingentConsiderationMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:ContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001439725_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByLiabilityClassAxis_bdsxContingentConsiderationMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:ContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001439725_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByLiabilityClassAxis_bdsxPutOptionLiabilityMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:PutOptionLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001439725_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByLiabilityClassAxis_bdsxWarrantLiabilityMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:WarrantLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001439725_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByLiabilityClassAxis_bdsxContingentValueRightsMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:ContingentValueRightsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001439725_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByLiabilityClassAxis_bdsxPutOptionLiabilityMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:PutOptionLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001439725_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByLiabilityClassAxis_bdsxContingentConsiderationMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:ContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001439725_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByLiabilityClassAxis_bdsxWarrantLiabilityMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:WarrantLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001439725_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByLiabilityClassAxis_bdsxContingentValueRightsMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:ContingentValueRightsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001439725_us-gaapLongtermDebtTypeAxis_bdsxNotesPayable2018NotesMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesGPreferredStockMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:NotesPayable2018NotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesGPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001439725_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001439725_us-gaapStatementClassOfStockAxis_us-gaapSeriesFPreferredStockMember_20160131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesFPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-01-31</instant>
        </period>
    </context>
    <context id="C_0001439725_us-gaapStatementClassOfStockAxis_us-gaapSeriesFPreferredStockMember_20160101_20160131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesFPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-01-31</endDate>
        </period>
    </context>
    <context id="C_0001439725_srtCounterpartyNameAxis_bdsxAVEOOncologyMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesFPreferredStockMember_20200901_20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bdsx:AVEOOncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesFPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="C_0001439725_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapEquipmentMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001439725_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapEquipmentMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001439725_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001439725_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001439725_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapComputerEquipmentMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001439725_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapComputerEquipmentMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001439725_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001439725_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001439725_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapSoftwareAndSoftwareDevelopmentCostsMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001439725_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapSoftwareAndSoftwareDevelopmentCostsMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001439725_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapConstructionInProgressMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001439725_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapConstructionInProgressMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001439725_us-gaapFairValueByAssetClassAxis_us-gaapPropertyPlantAndEquipmentMember_us-gaapIncomeStatementLocationAxis_bdsxDirectCostsAndExpensesMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">bdsx:DirectCostsAndExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001439725_us-gaapFairValueByAssetClassAxis_us-gaapPropertyPlantAndEquipmentMember_us-gaapIncomeStatementLocationAxis_bdsxDirectCostsAndExpensesMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">bdsx:DirectCostsAndExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001439725_us-gaapFairValueByAssetClassAxis_us-gaapPropertyPlantAndEquipmentMember_us-gaapIncomeStatementLocationAxis_us-gaapSellingGeneralAndAdministrativeExpensesMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001439725_us-gaapFairValueByAssetClassAxis_us-gaapPropertyPlantAndEquipmentMember_us-gaapIncomeStatementLocationAxis_us-gaapSellingGeneralAndAdministrativeExpensesMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001439725_us-gaapFairValueByAssetClassAxis_us-gaapPropertyPlantAndEquipmentMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001439725_us-gaapFairValueByAssetClassAxis_us-gaapPropertyPlantAndEquipmentMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001439725_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapPatentsMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001439725_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_bdsxPurchasedTechnologyMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bdsx:PurchasedTechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001439725_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapPatentsMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001439725_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_bdsxPurchasedTechnologyMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bdsx:PurchasedTechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001439725_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_bdsxPurchaseOptionMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bdsx:PurchaseOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001439725_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapTrademarksMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001439725_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapTrademarksMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001439725_us-gaapIncomeStatementLocationAxis_bdsxDirectCostsAndExpensesMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">bdsx:DirectCostsAndExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001439725_us-gaapIncomeStatementLocationAxis_bdsxDirectCostsAndExpensesMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">bdsx:DirectCostsAndExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001439725_us-gaapIncomeStatementLocationAxis_us-gaapSellingGeneralAndAdministrativeExpensesMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001439725_us-gaapIncomeStatementLocationAxis_us-gaapSellingGeneralAndAdministrativeExpensesMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001439725_us-gaapLongtermDebtTypeAxis_bdsxNotesPayable2018NotesMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:NotesPayable2018NotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001439725_us-gaapLongtermDebtTypeAxis_bdsxNotesPayable2018NotesMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:NotesPayable2018NotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001439725_us-gaapDebtInstrumentAxis_bdsxCARESActMember_us-gaapLongtermDebtTypeAxis_bdsxPPPLoanMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bdsx:CARESActMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:PPPLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001439725_us-gaapLongtermDebtTypeAxis_bdsxNotesPayable2018NotesMember_20180228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:NotesPayable2018NotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-02-28</instant>
        </period>
    </context>
    <context id="C_0001439725_us-gaapLongtermDebtTypeAxis_bdsxNotesPayable2018NotesMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesGPreferredStockMember_20180228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:NotesPayable2018NotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesGPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-02-28</instant>
        </period>
    </context>
    <context id="C_0001439725_us-gaapLongtermDebtTypeAxis_bdsxNotesPayable2018NotesMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:NotesPayable2018NotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001439725_us-gaapLongtermDebtTypeAxis_bdsxNotesPayable2018NotesMember_20180201_20180228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:NotesPayable2018NotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-02-01</startDate>
            <endDate>2018-02-28</endDate>
        </period>
    </context>
    <context id="C_0001439725_srtRangeAxis_srtMinimumMember_us-gaapLongtermDebtTypeAxis_bdsxNotesPayable2018NotesMember_20180201_20180228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:NotesPayable2018NotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-02-01</startDate>
            <endDate>2018-02-28</endDate>
        </period>
    </context>
    <context id="C_0001439725_srtRangeAxis_srtMaximumMember_us-gaapLongtermDebtTypeAxis_bdsxNotesPayable2018NotesMember_20180201_20180228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:NotesPayable2018NotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-02-01</startDate>
            <endDate>2018-02-28</endDate>
        </period>
    </context>
    <context id="C_0001439725_us-gaapDebtInstrumentAxis_bdsxCARESActMember_us-gaapLongtermDebtTypeAxis_bdsxPPPLoanMember_20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bdsx:CARESActMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:PPPLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="C_0001439725_us-gaapLongtermDebtTypeAxis_bdsxPPPLoanMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:PPPLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001439725_us-gaapInvestmentTypeAxis_us-gaapInterestBearingDepositsMember_us-gaapLongtermDebtTypeAxis_bdsxPPPLoanMember_20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:InterestBearingDepositsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:PPPLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="C_0001439725_srtRangeAxis_srtMinimumMember_us-gaapDebtInstrumentAxis_bdsxCARESActMember_us-gaapLongtermDebtTypeAxis_bdsxPPPLoanMember_20200401_20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bdsx:CARESActMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:PPPLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="C_0001439725_us-gaapDebtInstrumentAxis_bdsxCARESActMember_us-gaapLongtermDebtTypeAxis_bdsxPPPLoanMember_20200401_20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bdsx:CARESActMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:PPPLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="C_0001439725_us-gaapShortTermDebtTypeAxis_bdsxMarchTwoThousandAndTwentyConvertibleNotesMember_20200301_20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">bdsx:MarchTwoThousandAndTwentyConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="C_0001439725_us-gaapShortTermDebtTypeAxis_bdsxMarchTwoThousandAndTwentyConvertibleNotesMember_20200801_20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">bdsx:MarchTwoThousandAndTwentyConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="C_0001439725_us-gaapDebtInstrumentRedemptionPeriodAxis_us-gaapDebtInstrumentRedemptionPeriodOneMember_us-gaapShortTermDebtTypeAxis_bdsxMarchTwoThousandAndTwentyConvertibleNotesMember_20200301_20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">bdsx:MarchTwoThousandAndTwentyConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="C_0001439725_us-gaapDebtInstrumentRedemptionPeriodAxis_us-gaapDebtInstrumentRedemptionPeriodTwoMember_us-gaapShortTermDebtTypeAxis_bdsxMarchTwoThousandAndTwentyConvertibleNotesMember_20200601_20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">bdsx:MarchTwoThousandAndTwentyConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_0001439725_us-gaapShortTermDebtTypeAxis_bdsxMarchTwoThousandAndTwentyConvertibleNotesMember_20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">bdsx:MarchTwoThousandAndTwentyConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="C_0001439725_us-gaapShortTermDebtTypeAxis_bdsxMarchTwoThousandAndTwentyConvertibleNotesMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesHPreferredStockMember_20200301_20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">bdsx:MarchTwoThousandAndTwentyConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesHPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="C_0001439725_us-gaapShortTermDebtTypeAxis_bdsxMarchTwoThousandAndTwentyConvertibleNotesMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesHPreferredStockMember_20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">bdsx:MarchTwoThousandAndTwentyConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesHPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="C_0001439725_us-gaapShortTermDebtTypeAxis_bdsxMarchTwoThousandAndTwentyConvertibleNotesMember_20201001_20201031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">bdsx:MarchTwoThousandAndTwentyConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-31</endDate>
        </period>
    </context>
    <context id="C_0001439725_us-gaapShortTermDebtTypeAxis_bdsxMarchTwoThousandAndTwentyConvertibleNotesMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">bdsx:MarchTwoThousandAndTwentyConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-31</instant>
        </period>
    </context>
    <context id="C_0001439725_us-gaapShortTermDebtTypeAxis_bdsxDecemberTwoThousandAndNineteenConvertibleNotesMember_20191201_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">bdsx:DecemberTwoThousandAndNineteenConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001439725_us-gaapShortTermDebtTypeAxis_bdsxDecemberTwoThousandAndNineteenConvertibleNotesMember_20200801_20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">bdsx:DecemberTwoThousandAndNineteenConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="C_0001439725_us-gaapDebtInstrumentRedemptionPeriodAxis_us-gaapDebtInstrumentRedemptionPeriodOneMember_us-gaapShortTermDebtTypeAxis_bdsxDecemberTwoThousandAndNineteenConvertibleNotesMember_20191201_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">bdsx:DecemberTwoThousandAndNineteenConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001439725_us-gaapDebtInstrumentRedemptionPeriodAxis_us-gaapDebtInstrumentRedemptionPeriodTwoMember_us-gaapShortTermDebtTypeAxis_bdsxDecemberTwoThousandAndNineteenConvertibleNotesMember_20200201_20200229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">bdsx:DecemberTwoThousandAndNineteenConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-01</startDate>
            <endDate>2020-02-29</endDate>
        </period>
    </context>
    <context id="C_0001439725_us-gaapShortTermDebtTypeAxis_bdsxDecemberTwoThousandAndNineteenConvertibleNotesMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">bdsx:DecemberTwoThousandAndNineteenConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001439725_us-gaapShortTermDebtTypeAxis_bdsxDecemberTwoThousandAndNineteenConvertibleNotesMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesHPreferredStockMember_20191201_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">bdsx:DecemberTwoThousandAndNineteenConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesHPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001439725_us-gaapShortTermDebtTypeAxis_bdsxDecemberTwoThousandAndNineteenConvertibleNotesMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesHPreferredStockMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">bdsx:DecemberTwoThousandAndNineteenConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesHPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001439725_us-gaapShortTermDebtTypeAxis_bdsxDecemberTwoThousandAndNineteenConvertibleNotesMember_20201001_20201031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">bdsx:DecemberTwoThousandAndNineteenConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-31</endDate>
        </period>
    </context>
    <context id="C_0001439725_us-gaapShortTermDebtTypeAxis_bdsxDecemberTwoThousandAndNineteenConvertibleNotesMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">bdsx:DecemberTwoThousandAndNineteenConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-31</instant>
        </period>
    </context>
    <context id="C_0001439725_us-gaapShortTermDebtTypeAxis_bdsxAugustTwoThousandAndNineteenConvertibleNotesMember_20190801_20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">bdsx:AugustTwoThousandAndNineteenConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="C_0001439725_us-gaapShortTermDebtTypeAxis_bdsxAugustTwoThousandAndNineteenConvertibleNotesMember_20200801_20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">bdsx:AugustTwoThousandAndNineteenConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="C_0001439725_us-gaapShortTermDebtTypeAxis_bdsxAugustTwoThousandAndNineteenConvertibleNotesMember_20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">bdsx:AugustTwoThousandAndNineteenConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="C_0001439725_us-gaapShortTermDebtTypeAxis_bdsxAugustTwoThousandAndNineteenConvertibleNotesMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesHPreferredStockMember_20190801_20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">bdsx:AugustTwoThousandAndNineteenConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesHPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="C_0001439725_us-gaapShortTermDebtTypeAxis_bdsxAugustTwoThousandAndNineteenConvertibleNotesMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesHPreferredStockMember_20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">bdsx:AugustTwoThousandAndNineteenConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesHPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="C_0001439725_us-gaapShortTermDebtTypeAxis_bdsxAugustTwoThousandAndNineteenConvertibleNotesMember_20191201_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">bdsx:AugustTwoThousandAndNineteenConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001439725_us-gaapShortTermDebtTypeAxis_bdsxAugustTwoThousandAndNineteenConvertibleNotesMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">bdsx:AugustTwoThousandAndNineteenConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001439725_us-gaapShortTermDebtTypeAxis_bdsxAugustTwoThousandAndNineteenConvertibleNotesMember_20201001_20201031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">bdsx:AugustTwoThousandAndNineteenConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-31</endDate>
        </period>
    </context>
    <context id="C_0001439725_us-gaapShortTermDebtTypeAxis_bdsxAugustTwoThousandAndNineteenConvertibleNotesMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">bdsx:AugustTwoThousandAndNineteenConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-31</instant>
        </period>
    </context>
    <context id="C_0001439725_us-gaapStatementClassOfStockAxis_us-gaapSeriesHPreferredStockMember_20190228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesHPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-02-28</instant>
        </period>
    </context>
    <context id="C_0001439725_us-gaapStatementClassOfStockAxis_us-gaapSeriesHPreferredStockMember_20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesHPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="C_0001439725_us-gaapStatementClassOfStockAxis_bdsxSeriesA1PreferredStockMember_20201027_20201027">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bdsx:SeriesA1PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-27</startDate>
            <endDate>2020-10-27</endDate>
        </period>
    </context>
    <context id="C_0001439725_us-gaapStatementClassOfStockAxis_bdsxSeriesA2PreferredStockMember_20201027_20201027">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bdsx:SeriesA2PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-27</startDate>
            <endDate>2020-10-27</endDate>
        </period>
    </context>
    <context id="C_0001439725_us-gaapStatementClassOfStockAxis_bdsxSeriesA3PreferredStockMember_20201027_20201027">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bdsx:SeriesA3PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-27</startDate>
            <endDate>2020-10-27</endDate>
        </period>
    </context>
    <context id="C_0001439725_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20201027_20201027">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-27</startDate>
            <endDate>2020-10-27</endDate>
        </period>
    </context>
    <context id="C_0001439725_us-gaapStatementClassOfStockAxis_us-gaapSeriesCPreferredStockMember_20201027_20201027">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-27</startDate>
            <endDate>2020-10-27</endDate>
        </period>
    </context>
    <context id="C_0001439725_us-gaapStatementClassOfStockAxis_us-gaapSeriesDPreferredStockMember_20201027_20201027">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-27</startDate>
            <endDate>2020-10-27</endDate>
        </period>
    </context>
    <context id="C_0001439725_us-gaapStatementClassOfStockAxis_us-gaapSeriesEPreferredStockMember_20201027_20201027">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesEPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-27</startDate>
            <endDate>2020-10-27</endDate>
        </period>
    </context>
    <context id="C_0001439725_us-gaapStatementClassOfStockAxis_us-gaapSeriesFPreferredStockMember_20201027_20201027">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesFPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-27</startDate>
            <endDate>2020-10-27</endDate>
        </period>
    </context>
    <context id="C_0001439725_us-gaapStatementClassOfStockAxis_us-gaapSeriesGPreferredStockMember_20201027_20201027">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesGPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-27</startDate>
            <endDate>2020-10-27</endDate>
        </period>
    </context>
    <context id="C_0001439725_us-gaapStatementClassOfStockAxis_us-gaapSeriesHPreferredStockMember_20201027_20201027">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesHPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-27</startDate>
            <endDate>2020-10-27</endDate>
        </period>
    </context>
    <context id="C_0001439725_us-gaapStatementClassOfStockAxis_bdsxSeriesB1ConvertiblePreferredStockMember_20201027_20201027">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bdsx:SeriesB1ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-27</startDate>
            <endDate>2020-10-27</endDate>
        </period>
    </context>
    <context id="C_0001439725_20201027_20201027">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
        </entity>
        <period>
            <startDate>2020-10-27</startDate>
            <endDate>2020-10-27</endDate>
        </period>
    </context>
    <context id="C_0001439725_us-gaapClassOfWarrantOrRightAxis_bdsxSeriesEConvertiblePreferredStockWarrantsMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">bdsx:SeriesEConvertiblePreferredStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001439725_us-gaapClassOfWarrantOrRightAxis_bdsxSeriesGConvertiblePreferredStockWarrantsMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">bdsx:SeriesGConvertiblePreferredStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001439725_us-gaapClassOfWarrantOrRightAxis_bdsxSeriesEConvertiblePreferredStockWarrantsMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">bdsx:SeriesEConvertiblePreferredStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001439725_us-gaapClassOfWarrantOrRightAxis_bdsxSeriesGConvertiblePreferredStockWarrantsMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">bdsx:SeriesGConvertiblePreferredStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001439725_srtProductOrServiceAxis_bdsxDiagnosticTestsMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bdsx:DiagnosticTestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001439725_srtProductOrServiceAxis_bdsxDiagnosticTestsMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bdsx:DiagnosticTestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001439725_srtProductOrServiceAxis_us-gaapServiceMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001439725_srtProductOrServiceAxis_us-gaapServiceMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001439725_srtProductOrServiceAxis_bdsxCOVID19DiagnosticTestRevenueMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bdsx:COVID19DiagnosticTestRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001439725_srtProductOrServiceAxis_bdsxLungDiagnosticRevenueMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bdsx:LungDiagnosticRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001439725_us-gaapBalanceSheetLocationAxis_bdsxDeferredRevenueMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">bdsx:DeferredRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001439725_us-gaapBalanceSheetLocationAxis_bdsxDeferredRevenueMember_20200101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">bdsx:DeferredRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-01</instant>
        </period>
    </context>
    <context id="C_0001439725_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20201031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-31</instant>
        </period>
    </context>
    <context id="C_0001439725_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001439725_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001439725_us-gaapPlanNameAxis_bdsxTwoThousandTwentyEquityIncentivePlanMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bdsx:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001439725_us-gaapPlanNameAxis_bdsxTwoThousandTwentyEquityIncentivePlanMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bdsx:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001439725_srtRangeAxis_srtMaximumMember_us-gaapPlanNameAxis_bdsxTwoThousandTwentyEquityIncentivePlanMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bdsx:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001439725_srtRangeAxis_srtMaximumMember_us-gaapPlanNameAxis_bdsxTwoThousandSixPlanMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bdsx:TwoThousandSixPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001439725_us-gaapPlanNameAxis_bdsxTwoThousandAndSixteenPlanMember_20160229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bdsx:TwoThousandAndSixteenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-02-29</instant>
        </period>
    </context>
    <context id="C_0001439725_srtRangeAxis_srtMaximumMember_us-gaapPlanNameAxis_bdsxTwoThousandAndSixteenPlanMember_20160229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bdsx:TwoThousandAndSixteenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-02-29</instant>
        </period>
    </context>
    <context id="C_0001439725_us-gaapPlanNameAxis_bdsxTwoThousandSixPlanTwoThousandSixteenPlanAndTwoThousandTwentyEquityIncentivePlanMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bdsx:TwoThousandSixPlanTwoThousandSixteenPlanAndTwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001439725_srtRangeAxis_srtMaximumMember_us-gaapPlanNameAxis_bdsxTwoThousandTwentyEquityIncentivePlanMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bdsx:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001439725_us-gaapAwardTypeAxis_bdsxPerformanceConditionOptionsMember_us-gaapPlanNameAxis_bdsxTwoThousandTwentyEquityIncentivePlanMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bdsx:PerformanceConditionOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bdsx:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001439725_us-gaapAwardTypeAxis_bdsxPerformanceConditionOptionsMember_us-gaapPlanNameAxis_bdsxTwoThousandTwentyEquityIncentivePlanMember_20190101_20190101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bdsx:PerformanceConditionOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bdsx:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-01-01</endDate>
        </period>
    </context>
    <context id="C_0001439725_us-gaapAwardTypeAxis_bdsxPerformanceConditionOptionsMember_us-gaapPlanNameAxis_bdsxTwoThousandTwentyEquityIncentivePlanMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bdsx:PerformanceConditionOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bdsx:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001439725_us-gaapAwardTypeAxis_bdsxPerformanceConditionOptionsMember_us-gaapPlanNameAxis_bdsxTwoThousandTwentyEquityIncentivePlanMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bdsx:PerformanceConditionOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bdsx:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001439725_srtRangeAxis_srtMinimumMember_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_bdsxTwoThousandTwentyEquityIncentivePlanMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bdsx:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001439725_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_bdsxBonusToOptionsProgramMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bdsx:BonusToOptionsProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001439725_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_bdsxBonusToOptionsProgramMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bdsx:BonusToOptionsProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001439725_us-gaapAwardTypeAxis_bdsxBonusToOptionsProgramMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bdsx:BonusToOptionsProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001439725_us-gaapAwardTypeAxis_bdsxBonusToOptionsProgramMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bdsx:BonusToOptionsProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001439725_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001439725_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001439725_us-gaapAwardTypeAxis_bdsxOptionsAndRestrictedStockUnitsMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bdsx:OptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001439725_us-gaapAwardTypeAxis_bdsxOptionsAndRestrictedStockUnitsMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bdsx:OptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001439725_us-gaapAwardTypeAxis_bdsxServiceConditionRSUsMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bdsx:ServiceConditionRSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001439725_srtRangeAxis_srtMinimumMember_us-gaapAwardTypeAxis_bdsxServiceConditionRSUsMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bdsx:ServiceConditionRSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001439725_us-gaapAwardTypeAxis_bdsxServiceConditionRSUsMember_us-gaapVestingAxis_us-gaapShareBasedCompensationAwardTrancheOneMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bdsx:ServiceConditionRSUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001439725_us-gaapAwardTypeAxis_bdsxServiceConditionRSUsMember_us-gaapVestingAxis_us-gaapShareBasedCompensationAwardTrancheTwoMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bdsx:ServiceConditionRSUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001439725_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001439725_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_bdsxOptionsToPurchaseCommonStockMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bdsx:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001439725_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_bdsxOptionsToPurchaseCommonStockMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bdsx:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001439725_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapWarrantMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001439725_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapWarrantMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001439725_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapRestrictedStockUnitsRSUMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001439725_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapRestrictedStockUnitsRSUMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001439725_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapConvertibleDebtSecuritiesMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001439725_srtCounterpartyNameAxis_bdsxAVEOOncologyMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_bdsxNSCLCPOCTrialMember_20201031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bdsx:AVEOOncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bdsx:NSCLCPOCTrialMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-31</instant>
        </period>
    </context>
    <context id="C_0001439725_srtCounterpartyNameAxis_bdsxAVEOOncologyMember_srtProductOrServiceAxis_bdsxBDX004Member_us-gaapEquitySecuritiesByIndustryAxis_bdsxFiclatuzumabMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_bdsxPOCClinicalTrialsMember_20201031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bdsx:AVEOOncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bdsx:BDX004Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:EquitySecuritiesByIndustryAxis">bdsx:FiclatuzumabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bdsx:POCClinicalTrialsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-31</instant>
        </period>
    </context>
    <context id="C_0001439725_srtCounterpartyNameAxis_bdsxAVEOOncologyMember_us-gaapEquitySecuritiesByIndustryAxis_bdsxFiclatuzumabMember_20200901_20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bdsx:AVEOOncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:EquitySecuritiesByIndustryAxis">bdsx:FiclatuzumabMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="C_0001439725_srtCounterpartyNameAxis_bdsxAVEOOncologyMember_20201202_20201202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bdsx:AVEOOncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-02</startDate>
            <endDate>2020-12-02</endDate>
        </period>
    </context>
    <context id="C_0001439725_srtCounterpartyNameAxis_bdsxAVEOOncologyMember_us-gaapEquitySecuritiesByIndustryAxis_bdsxFiclatuzumabMember_20201202_20201202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bdsx:AVEOOncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:EquitySecuritiesByIndustryAxis">bdsx:FiclatuzumabMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-02</startDate>
            <endDate>2020-12-02</endDate>
        </period>
    </context>
    <context id="C_0001439725_srtCounterpartyNameAxis_bdsxAVEOOncologyMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bdsx:AVEOOncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001439725_srtCounterpartyNameAxis_bdsxAVEOOncologyMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bdsx:AVEOOncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001439725_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_bdsxBioRadLicenseMember_20190801_20190831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bdsx:BioRadLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-01</startDate>
            <endDate>2019-08-31</endDate>
        </period>
    </context>
    <context id="C_0001439725_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_bdsxBioRadLicenseMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bdsx:BioRadLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001439725_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_bdsxBioRadLicenseMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bdsx:BioRadLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001439725_us-gaapBusinessAcquisitionAxis_bdsxOncimmuneLimitedMember_us-gaapTypeOfArrangementAxis_bdsxRevenueShareAgreementMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bdsx:OncimmuneLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bdsx:RevenueShareAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <unit id="U_xbrlishares">
        <measure>shares</measure>
    </unit>
    <unit id="U_iso4217USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="U_iso4217USD_xbrlishares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U_bdsxTest">
        <measure>bdsx:Test</measure>
    </unit>
    <unit id="U_xbrlipure">
        <measure>pure</measure>
    </unit>
    <unit id="U_bdsxsegment">
        <measure>bdsx:segment</measure>
    </unit>
    <unit id="U_bdsxInstallment">
        <measure>bdsx:Installment</measure>
    </unit>
    <dei:AmendmentFlag contextRef="C_0001439725_20200101_20201231" id="F_000001">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="C_0001439725_20200101_20201231" id="F_000005">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="C_0001439725_20200101_20201231" id="F_000006">0001439725</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate contextRef="C_0001439725_20200101_20201231" id="F_000007">--12-31</dei:CurrentFiscalYearEndDate>
    <bdsx:IncreaseDecreaseInAccumulatedDeficit
      contextRef="C_0001439725_srtRestatementAxis_srtRevisionOfPriorPeriodErrorCorrectionAdjustmentMember_20190101_20191231"
      decimals="-5"
      id="F_000358"
      unitRef="U_iso4217USD">-3400000</bdsx:IncreaseDecreaseInAccumulatedDeficit>
    <us-gaap:NumberOfOperatingSegments
      contextRef="C_0001439725_20200101_20201231"
      decimals="INF"
      id="F_000360_2"
      unitRef="U_bdsxsegment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="C_0001439725_srtRangeAxis_srtMinimumMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_bdsxProductLifeAndPatentLifeMember_20200101_20201231"
      id="F_000390">P9Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="C_0001439725_20190101_20191231"
      decimals="INF"
      id="F_000393"
      unitRef="U_iso4217USD">0</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:GoodwillAndIntangibleAssetImpairment
      contextRef="C_0001439725_20190101_20191231"
      decimals="INF"
      id="F_000527"
      unitRef="U_iso4217USD">0</us-gaap:GoodwillAndIntangibleAssetImpairment>
    <us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1
      contextRef="C_0001439725_srtRangeAxis_srtMinimumMember_us-gaapLongtermDebtTypeAxis_bdsxNotesPayable2018NotesMember_20180201_20180228"
      id="F_000562">P24M</us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1>
    <us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1
      contextRef="C_0001439725_srtRangeAxis_srtMaximumMember_us-gaapLongtermDebtTypeAxis_bdsxNotesPayable2018NotesMember_20180201_20180228"
      id="F_000563">P36M</us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_0001439725_20201231"
      decimals="INF"
      id="F_000659"
      unitRef="U_xbrlishares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="C_0001439725_20190101_20191231"
      decimals="INF"
      id="F_000821"
      unitRef="U_iso4217USD">0</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanPlanNameExtensibleList contextRef="C_0001439725_20200101_20201231" id="F_000822">bdsx:FourZeroOneKPlanMember</us-gaap:DefinedContributionPlanPlanNameExtensibleList>
    <us-gaap:DefinedContributionPlanPlanNameExtensibleList contextRef="C_0001439725_20190101_20191231" id="F_000823">bdsx:FourZeroOneKPlanMember</us-gaap:DefinedContributionPlanPlanNameExtensibleList>
    <us-gaap:NumberOfOperatingSegments
      contextRef="C_0001439725_20200101_20201231"
      decimals="INF"
      id="F_000360"
      unitRef="U_bdsxsegment">1</us-gaap:NumberOfOperatingSegments>
    <bdsx:BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod
      contextRef="C_0001439725_us-gaapBusinessAcquisitionAxis_bdsxIntegratedDiagnosticsIncMember_20180630_20180630"
      id="F_000416">P7Y</bdsx:BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="C_0001439725_us-gaapShortTermDebtTypeAxis_bdsxMarchTwoThousandAndTwentyConvertibleNotesMember_20200301_20200331"
      id="F_000572">2020-08-31</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="C_0001439725_us-gaapShortTermDebtTypeAxis_bdsxDecemberTwoThousandAndNineteenConvertibleNotesMember_20191201_20191231"
      id="F_000585">2020-08-31</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="C_0001439725_us-gaapShortTermDebtTypeAxis_bdsxAugustTwoThousandAndNineteenConvertibleNotesMember_20190801_20190930"
      id="F_000598">2020-08-31</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable contextRef="C_0001439725_20200101_20201231" id="F_000645">2028-02-29</us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="C_0001439725_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_bdsxBonusToOptionsProgramMember_20200101_20201231"
      id="F_000697">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_0001439725_20201231"
      id="F_000077"
      unitRef="U_iso4217USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_0001439725_20191231"
      id="F_000078"
      unitRef="U_iso4217USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="C_0001439725_20201231"
      id="F_000080"
      unitRef="U_iso4217USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="C_0001439725_20191231"
      id="F_000081"
      unitRef="U_iso4217USD"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="C_0001439725_20190101_20191231" id="F_000723">P7Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <bdsx:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1 contextRef="C_0001439725_20200101_20201231" id="F_000724">P0Y</bdsx:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="C_0001439725_20200101_20201231" id="F_000725">P7Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="C_0001439725_20200101_20201231" id="F_000726">P6Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="C_0001439725_20200101_20201231" id="F_000730">P5Y8M23D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <dei:DocumentType contextRef="C_0001439725_20200101_20201231" id="F_000000">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="C_0001439725_20200101_20201231" id="F_000002">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="C_0001439725_20200101_20201231" id="F_000003">2020-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalYearFocus contextRef="C_0001439725_20200101_20201231" id="F_000004">2020</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="C_0001439725_20200101_20201231" id="F_000008">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="C_0001439725_20200101_20201231" id="F_000009">001-39659</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="C_0001439725_20200101_20201231" id="F_000010">Biodesix, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="C_0001439725_20200101_20201231" id="F_000011">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="C_0001439725_20200101_20201231" id="F_000012">20-3986492</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="C_0001439725_20200101_20201231" id="F_000013">2970 Wilderness Place</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="C_0001439725_20200101_20201231" id="F_000014">Suite 100</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="C_0001439725_20200101_20201231" id="F_000015">Boulder</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="C_0001439725_20200101_20201231" id="F_000016">CO</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="C_0001439725_20200101_20201231" id="F_000017">80301</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="C_0001439725_20200101_20201231" id="F_000018">303</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="C_0001439725_20200101_20201231" id="F_000019">417-0500</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="C_0001439725_20200101_20201231" id="F_000020">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="C_0001439725_20200101_20201231" id="F_000022">BDSX</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="C_0001439725_20200101_20201231" id="F_000023">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="C_0001439725_20200101_20201231" id="F_000024">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="C_0001439725_20200101_20201231" id="F_000025">Yes</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="C_0001439725_20200101_20201231" id="F_000026">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="C_0001439725_20200101_20201231" id="F_000027">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="C_0001439725_20200101_20201231" id="F_000028">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="C_0001439725_20200101_20201231" id="F_000029">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="C_0001439725_20200101_20201231" id="F_000030">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="C_0001439725_20200101_20201231" id="F_000031">false</dei:EntityExTransitionPeriod>
    <dei:IcfrAuditorAttestationFlag contextRef="C_0001439725_20200101_20201231" id="F_000021">false</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany contextRef="C_0001439725_20200101_20201231" id="F_000032">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="C_0001439725_20201231"
      decimals="0"
      id="F_000034"
      unitRef="U_iso4217USD">344635079</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_0001439725_20210312"
      decimals="INF"
      id="F_000033"
      unitRef="U_xbrlishares">26577782</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock contextRef="C_0001439725_20200101_20201231" id="F_000273">
&lt;p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;DOCUMENTS INCORPORATED BY REFERENCE&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Portions of the Company&#x2019;s definitive Proxy Statement for its 2021 Annual Meeting of Shareholders are to be incorporated by reference into Part&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;III, as specifically set forth in Part III.)&lt;/p&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_0001439725_20201231"
      decimals="-3"
      id="F_000035"
      unitRef="U_iso4217USD">62126000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_0001439725_20191231"
      decimals="-3"
      id="F_000036"
      unitRef="U_iso4217USD">5286000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="C_0001439725_20201231"
      decimals="-3"
      id="F_000037"
      unitRef="U_iso4217USD">15304000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="C_0001439725_20191231"
      decimals="-3"
      id="F_000038"
      unitRef="U_iso4217USD">5292000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="C_0001439725_20201231"
      decimals="-3"
      id="F_000039"
      unitRef="U_iso4217USD">8710000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="C_0001439725_20191231"
      decimals="-3"
      id="F_000040"
      unitRef="U_iso4217USD">2122000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_0001439725_20201231"
      decimals="-3"
      id="F_000041"
      unitRef="U_iso4217USD">86140000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_0001439725_20191231"
      decimals="-3"
      id="F_000042"
      unitRef="U_iso4217USD">12700000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_0001439725_20201231"
      decimals="-3"
      id="F_000043"
      unitRef="U_iso4217USD">3178000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_0001439725_20191231"
      decimals="-3"
      id="F_000044"
      unitRef="U_iso4217USD">2120000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="C_0001439725_20201231"
      decimals="-3"
      id="F_000045"
      unitRef="U_iso4217USD">13260000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="C_0001439725_20191231"
      decimals="-3"
      id="F_000046"
      unitRef="U_iso4217USD">15092000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_0001439725_20201231"
      decimals="-3"
      id="F_000047"
      unitRef="U_iso4217USD">3461000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_0001439725_20191231"
      decimals="-3"
      id="F_000048"
      unitRef="U_iso4217USD">90000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Goodwill
      contextRef="C_0001439725_20201231"
      decimals="-3"
      id="F_000049"
      unitRef="U_iso4217USD">15031000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="C_0001439725_20191231"
      decimals="-3"
      id="F_000050"
      unitRef="U_iso4217USD">15031000</us-gaap:Goodwill>
    <us-gaap:AssetsNoncurrent
      contextRef="C_0001439725_20201231"
      decimals="-3"
      id="F_000051"
      unitRef="U_iso4217USD">34930000</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="C_0001439725_20191231"
      decimals="-3"
      id="F_000052"
      unitRef="U_iso4217USD">32333000</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets
      contextRef="C_0001439725_20201231"
      decimals="-3"
      id="F_000053"
      unitRef="U_iso4217USD">121070000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_0001439725_20191231"
      decimals="-3"
      id="F_000054"
      unitRef="U_iso4217USD">45033000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_0001439725_20201231"
      decimals="-3"
      id="F_000055"
      unitRef="U_iso4217USD">8964000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_0001439725_20191231"
      decimals="-3"
      id="F_000056"
      unitRef="U_iso4217USD">1717000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_0001439725_20201231"
      decimals="-3"
      id="F_000057"
      unitRef="U_iso4217USD">7789000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_0001439725_20191231"
      decimals="-3"
      id="F_000058"
      unitRef="U_iso4217USD">4180000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="C_0001439725_20201231"
      decimals="-3"
      id="F_000059"
      unitRef="U_iso4217USD">3532000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="C_0001439725_20191231"
      decimals="-3"
      id="F_000060"
      unitRef="U_iso4217USD">1283000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:NotesPayableToBankCurrent
      contextRef="C_0001439725_20201231"
      decimals="-3"
      id="F_000061"
      unitRef="U_iso4217USD">11840000</us-gaap:NotesPayableToBankCurrent>
    <us-gaap:NotesPayableToBankCurrent
      contextRef="C_0001439725_20191231"
      decimals="-3"
      id="F_000062"
      unitRef="U_iso4217USD">12159000</us-gaap:NotesPayableToBankCurrent>
    <bdsx:PutOptionLiabilityCurrent
      contextRef="C_0001439725_20191231"
      decimals="-3"
      id="F_000063"
      unitRef="U_iso4217USD">3261000</bdsx:PutOptionLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_0001439725_20201231"
      decimals="-3"
      id="F_000064"
      unitRef="U_iso4217USD">32125000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_0001439725_20191231"
      decimals="-3"
      id="F_000065"
      unitRef="U_iso4217USD">22600000</us-gaap:LiabilitiesCurrent>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="C_0001439725_20191231"
      decimals="-3"
      id="F_000066"
      unitRef="U_iso4217USD">329000</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:LongTermNotesPayable
      contextRef="C_0001439725_20201231"
      decimals="-3"
      id="F_000067"
      unitRef="U_iso4217USD">15926000</us-gaap:LongTermNotesPayable>
    <us-gaap:LongTermNotesPayable
      contextRef="C_0001439725_20191231"
      decimals="-3"
      id="F_000068"
      unitRef="U_iso4217USD">23812000</us-gaap:LongTermNotesPayable>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="C_0001439725_20201231"
      decimals="-3"
      id="F_000069"
      unitRef="U_iso4217USD">29932000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="C_0001439725_20191231"
      decimals="-3"
      id="F_000070"
      unitRef="U_iso4217USD">29114000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="C_0001439725_20201231"
      decimals="-3"
      id="F_000071"
      unitRef="U_iso4217USD">1921000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="C_0001439725_20191231"
      decimals="-3"
      id="F_000072"
      unitRef="U_iso4217USD">358000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="C_0001439725_20201231"
      decimals="-3"
      id="F_000073"
      unitRef="U_iso4217USD">47779000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="C_0001439725_20191231"
      decimals="-3"
      id="F_000074"
      unitRef="U_iso4217USD">53613000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="C_0001439725_20201231"
      decimals="-3"
      id="F_000075"
      unitRef="U_iso4217USD">79904000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="C_0001439725_20191231"
      decimals="-3"
      id="F_000076"
      unitRef="U_iso4217USD">76213000</us-gaap:Liabilities>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="C_0001439725_20201231"
      decimals="INF"
      id="F_000092"
      unitRef="U_iso4217USD_xbrlishares">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="C_0001439725_20191231"
      decimals="INF"
      id="F_000093"
      unitRef="U_iso4217USD_xbrlishares">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="C_0001439725_20201231"
      decimals="INF"
      id="F_000094"
      unitRef="U_xbrlishares">0</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="C_0001439725_20191231"
      decimals="INF"
      id="F_000095"
      unitRef="U_xbrlishares">174237067</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="C_0001439725_20201231"
      decimals="INF"
      id="F_000096"
      unitRef="U_xbrlishares">0</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_0001439725_20201231"
      decimals="INF"
      id="F_000098"
      unitRef="U_xbrlishares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="C_0001439725_20191231"
      decimals="INF"
      id="F_000097"
      unitRef="U_xbrlishares">118766273</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_0001439725_20191231"
      decimals="INF"
      id="F_000099"
      unitRef="U_xbrlishares">118766273</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityLiquidationPreference
      contextRef="C_0001439725_20191231"
      decimals="-3"
      id="F_000100"
      unitRef="U_iso4217USD">202582000</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="C_0001439725_20191231"
      decimals="-3"
      id="F_000079"
      unitRef="U_iso4217USD">193959000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_0001439725_20201231"
      decimals="INF"
      id="F_000101"
      unitRef="U_iso4217USD_xbrlishares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_0001439725_20191231"
      decimals="INF"
      id="F_000102"
      unitRef="U_iso4217USD_xbrlishares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_0001439725_20201231"
      decimals="INF"
      id="F_000103"
      unitRef="U_xbrlishares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_0001439725_20191231"
      decimals="INF"
      id="F_000104"
      unitRef="U_xbrlishares">0</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_0001439725_20201231"
      decimals="INF"
      id="F_000105"
      unitRef="U_xbrlishares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_0001439725_20191231"
      decimals="INF"
      id="F_000106"
      unitRef="U_xbrlishares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_0001439725_20201231"
      decimals="INF"
      id="F_000107"
      unitRef="U_xbrlishares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_0001439725_20191231"
      decimals="INF"
      id="F_000108"
      unitRef="U_xbrlishares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_0001439725_20201231"
      decimals="INF"
      id="F_000109"
      unitRef="U_iso4217USD_xbrlishares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_0001439725_20191231"
      decimals="INF"
      id="F_000110"
      unitRef="U_iso4217USD_xbrlishares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_0001439725_20201231"
      decimals="INF"
      id="F_000111"
      unitRef="U_xbrlishares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_0001439725_20191231"
      decimals="INF"
      id="F_000112"
      unitRef="U_xbrlishares">190000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_0001439725_20201231"
      decimals="INF"
      id="F_000113"
      unitRef="U_xbrlishares">26561504</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_0001439725_20201231"
      decimals="INF"
      id="F_000115"
      unitRef="U_xbrlishares">26561504</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_0001439725_20191231"
      decimals="INF"
      id="F_000114"
      unitRef="U_xbrlishares">254918</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_0001439725_20191231"
      decimals="INF"
      id="F_000116"
      unitRef="U_xbrlishares">254918</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="C_0001439725_20201231"
      decimals="-3"
      id="F_000082"
      unitRef="U_iso4217USD">27000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_0001439725_20191231"
      decimals="-3"
      id="F_000083"
      unitRef="U_iso4217USD">1000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="C_0001439725_20201231"
      decimals="-3"
      id="F_000084"
      unitRef="U_iso4217USD">299953000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="C_0001439725_20191231"
      decimals="-3"
      id="F_000085"
      unitRef="U_iso4217USD">2324000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_0001439725_20201231"
      decimals="-3"
      id="F_000086"
      unitRef="U_iso4217USD">-258814000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_0001439725_20191231"
      decimals="-3"
      id="F_000087"
      unitRef="U_iso4217USD">-227464000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="C_0001439725_20201231"
      decimals="-3"
      id="F_000088"
      unitRef="U_iso4217USD">41166000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001439725_20191231"
      decimals="-3"
      id="F_000089"
      unitRef="U_iso4217USD">-225139000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_0001439725_20201231"
      decimals="-3"
      id="F_000090"
      unitRef="U_iso4217USD">121070000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_0001439725_20191231"
      decimals="-3"
      id="F_000091"
      unitRef="U_iso4217USD">45033000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues
      contextRef="C_0001439725_20200101_20201231"
      decimals="-3"
      id="F_000117"
      unitRef="U_iso4217USD">45557000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_0001439725_20190101_20191231"
      decimals="-3"
      id="F_000118"
      unitRef="U_iso4217USD">24552000</us-gaap:Revenues>
    <bdsx:DirectCostsAndExpenses
      contextRef="C_0001439725_20200101_20201231"
      decimals="-3"
      id="F_000119"
      unitRef="U_iso4217USD">21998000</bdsx:DirectCostsAndExpenses>
    <bdsx:DirectCostsAndExpenses
      contextRef="C_0001439725_20190101_20191231"
      decimals="-3"
      id="F_000120"
      unitRef="U_iso4217USD">6074000</bdsx:DirectCostsAndExpenses>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_0001439725_20200101_20201231"
      decimals="-3"
      id="F_000121"
      unitRef="U_iso4217USD">10818000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_0001439725_20190101_20191231"
      decimals="-3"
      id="F_000122"
      unitRef="U_iso4217USD">10468000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="C_0001439725_20200101_20201231"
      decimals="-3"
      id="F_000123"
      unitRef="U_iso4217USD">34857000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="C_0001439725_20190101_20191231"
      decimals="-3"
      id="F_000124"
      unitRef="U_iso4217USD">30637000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <bdsx:ChangeInFairValueOfContingentConsiderationExcludingAccretionExpense
      contextRef="C_0001439725_20200101_20201231"
      decimals="-3"
      id="F_000125"
      unitRef="U_iso4217USD">818000</bdsx:ChangeInFairValueOfContingentConsiderationExcludingAccretionExpense>
    <bdsx:ChangeInFairValueOfContingentConsiderationExcludingAccretionExpense
      contextRef="C_0001439725_20190101_20191231"
      decimals="-3"
      id="F_000126"
      unitRef="U_iso4217USD">4114000</bdsx:ChangeInFairValueOfContingentConsiderationExcludingAccretionExpense>
    <us-gaap:OperatingExpenses
      contextRef="C_0001439725_20200101_20201231"
      decimals="-3"
      id="F_000127"
      unitRef="U_iso4217USD">68491000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_0001439725_20190101_20191231"
      decimals="-3"
      id="F_000128"
      unitRef="U_iso4217USD">51293000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_0001439725_20200101_20201231"
      decimals="-3"
      id="F_000129"
      unitRef="U_iso4217USD">-22934000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_0001439725_20190101_20191231"
      decimals="-3"
      id="F_000130"
      unitRef="U_iso4217USD">-26741000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeOther
      contextRef="C_0001439725_20200101_20201231"
      decimals="-3"
      id="F_000131"
      unitRef="U_iso4217USD">18000</us-gaap:InterestIncomeOther>
    <us-gaap:InterestIncomeOther
      contextRef="C_0001439725_20190101_20191231"
      decimals="-3"
      id="F_000132"
      unitRef="U_iso4217USD">55000</us-gaap:InterestIncomeOther>
    <us-gaap:InterestExpense
      contextRef="C_0001439725_20200101_20201231"
      decimals="-3"
      id="F_000133"
      unitRef="U_iso4217USD">7604000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="C_0001439725_20190101_20191231"
      decimals="-3"
      id="F_000134"
      unitRef="U_iso4217USD">3008000</us-gaap:InterestExpense>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="C_0001439725_20200101_20201231"
      decimals="-3"
      id="F_000135"
      unitRef="U_iso4217USD">1252000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="C_0001439725_20190101_20191231"
      decimals="-3"
      id="F_000136"
      unitRef="U_iso4217USD">104000</us-gaap:FairValueAdjustmentOfWarrants>
    <bdsx:ChangeInFairValueOfPutOptionLiability
      contextRef="C_0001439725_20190101_20191231"
      decimals="-3"
      id="F_000137"
      unitRef="U_iso4217USD">2000000</bdsx:ChangeInFairValueOfPutOptionLiability>
    <us-gaap:OtherNonoperatingIncome
      contextRef="C_0001439725_20200101_20201231"
      decimals="-3"
      id="F_000138"
      unitRef="U_iso4217USD">422000</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome
      contextRef="C_0001439725_20190101_20191231"
      decimals="-3"
      id="F_000139"
      unitRef="U_iso4217USD">1072000</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_0001439725_20200101_20201231"
      decimals="-3"
      id="F_000140"
      unitRef="U_iso4217USD">-8416000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_0001439725_20190101_20191231"
      decimals="-3"
      id="F_000141"
      unitRef="U_iso4217USD">-3985000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001439725_20200101_20201231"
      decimals="-3"
      id="F_000142"
      unitRef="U_iso4217USD">-31350000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001439725_20190101_20191231"
      decimals="-3"
      id="F_000143"
      unitRef="U_iso4217USD">-30726000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="C_0001439725_20200101_20201231"
      decimals="2"
      id="F_000144"
      unitRef="U_iso4217USD_xbrlishares">-6.48</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="C_0001439725_20190101_20191231"
      decimals="2"
      id="F_000145"
      unitRef="U_iso4217USD_xbrlishares">-126.97</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="C_0001439725_20200101_20201231"
      decimals="-3"
      id="F_000146"
      unitRef="U_xbrlishares">4838000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="C_0001439725_20190101_20191231"
      decimals="-3"
      id="F_000147"
      unitRef="U_xbrlishares">242000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_0001439725_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20181231"
      decimals="INF"
      id="F_000148"
      unitRef="U_xbrlishares">110071</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_0001439725_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20181231"
      decimals="-3"
      id="F_000149"
      unitRef="U_iso4217USD">183962000</us-gaap:StockholdersEquity>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_0001439725_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181231"
      decimals="INF"
      id="F_000150"
      unitRef="U_xbrlishares">215</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_0001439725_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181231"
      decimals="-3"
      id="F_000151"
      unitRef="U_iso4217USD">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001439725_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20181231"
      decimals="-3"
      id="F_000152"
      unitRef="U_iso4217USD">2107000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001439725_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20181231"
      decimals="-3"
      id="F_000153"
      unitRef="U_iso4217USD">-196738000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001439725_20181231"
      decimals="-3"
      id="F_000154"
      unitRef="U_iso4217USD">-194630000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_0001439725_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231"
      decimals="INF"
      id="F_000155"
      unitRef="U_xbrlishares">40</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_0001439725_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231"
      decimals="-3"
      id="F_000156"
      unitRef="U_iso4217USD">47000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_0001439725_20190101_20191231"
      decimals="-3"
      id="F_000157"
      unitRef="U_iso4217USD">47000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <bdsx:SaleOfStockTemporaryEquityPricePerShare
      contextRef="C_0001439725_us-gaapStatementClassOfStockAxis_us-gaapSeriesHPreferredStockMember_20190201_20190228"
      decimals="INF"
      id="F_000199"
      unitRef="U_iso4217USD_xbrlishares">1.15</bdsx:SaleOfStockTemporaryEquityPricePerShare>
    <bdsx:SaleOfStockTemporaryEquityPricePerShare
      contextRef="C_0001439725_us-gaapStatementClassOfStockAxis_us-gaapSeriesHPreferredStockMember_20190301_20190331"
      decimals="INF"
      id="F_000200"
      unitRef="U_iso4217USD_xbrlishares">1.15</bdsx:SaleOfStockTemporaryEquityPricePerShare>
    <bdsx:TemporaryEquityIssuanceCosts
      contextRef="C_0001439725_us-gaapStatementClassOfStockAxis_us-gaapSeriesHPreferredStockMember_20190101_20191231"
      decimals="-3"
      id="F_000201"
      unitRef="U_iso4217USD">3000</bdsx:TemporaryEquityIssuanceCosts>
    <bdsx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001439725_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20190101_20191231"
      decimals="INF"
      id="F_000158"
      unitRef="U_xbrlishares">8695</bdsx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues
      contextRef="C_0001439725_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20190101_20191231"
      decimals="-3"
      id="F_000159"
      unitRef="U_iso4217USD">9997000</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0001439725_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231"
      decimals="-3"
      id="F_000160"
      unitRef="U_iso4217USD">170000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0001439725_20190101_20191231"
      decimals="-3"
      id="F_000161"
      unitRef="U_iso4217USD">170000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001439725_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20190101_20191231"
      decimals="-3"
      id="F_000162"
      unitRef="U_iso4217USD">-30726000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001439725_20190101_20191231"
      decimals="-3"
      id="F_000163"
      unitRef="U_iso4217USD">-30726000</us-gaap:NetIncomeLoss>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_0001439725_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20191231"
      decimals="INF"
      id="F_000164"
      unitRef="U_xbrlishares">118766</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_0001439725_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20191231"
      decimals="-3"
      id="F_000165"
      unitRef="U_iso4217USD">193959000</us-gaap:StockholdersEquity>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_0001439725_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231"
      decimals="INF"
      id="F_000166"
      unitRef="U_xbrlishares">255</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_0001439725_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231"
      decimals="-3"
      id="F_000167"
      unitRef="U_iso4217USD">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001439725_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20191231"
      decimals="-3"
      id="F_000168"
      unitRef="U_iso4217USD">2324000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001439725_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20191231"
      decimals="-3"
      id="F_000169"
      unitRef="U_iso4217USD">-227464000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001439725_20191231"
      decimals="-3"
      id="F_000170"
      unitRef="U_iso4217USD">-225139000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_0001439725_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231"
      decimals="INF"
      id="F_000171"
      unitRef="U_xbrlishares">368</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_0001439725_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231"
      decimals="-3"
      id="F_000172"
      unitRef="U_iso4217USD">1340000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_0001439725_20200101_20201231"
      decimals="-3"
      id="F_000173"
      unitRef="U_iso4217USD">1340000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0001439725_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231"
      decimals="-3"
      id="F_000174"
      unitRef="U_iso4217USD">3709000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0001439725_20200101_20201231"
      decimals="-3"
      id="F_000175"
      unitRef="U_iso4217USD">3709000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:CapitalUnitsDeductionsFromTotalCostToInvestors
      contextRef="C_0001439725_20201231"
      decimals="-3"
      id="F_000202"
      unitRef="U_iso4217USD">5040000</us-gaap:CapitalUnitsDeductionsFromTotalCostToInvestors>
    <us-gaap:CapitalUnitsTotalCostToInvestors
      contextRef="C_0001439725_20201231"
      decimals="-3"
      id="F_000203"
      unitRef="U_iso4217USD">3203000</us-gaap:CapitalUnitsTotalCostToInvestors>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001439725_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231"
      decimals="INF"
      id="F_000176"
      unitRef="U_xbrlishares">4000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0001439725_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231"
      decimals="-3"
      id="F_000177"
      unitRef="U_iso4217USD">4000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0001439725_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231"
      decimals="-3"
      id="F_000178"
      unitRef="U_iso4217USD">63753000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0001439725_20200101_20201231"
      decimals="-3"
      id="F_000179"
      unitRef="U_iso4217USD">63757000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="C_0001439725_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20200101_20201231"
      decimals="INF"
      id="F_000180"
      unitRef="U_xbrlishares">-118766</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="C_0001439725_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20200101_20201231"
      decimals="-3"
      id="F_000181"
      unitRef="U_iso4217USD">-193959000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="C_0001439725_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231"
      decimals="INF"
      id="F_000182"
      unitRef="U_xbrlishares">20091</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="C_0001439725_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231"
      decimals="-3"
      id="F_000183"
      unitRef="U_iso4217USD">20000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="C_0001439725_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231"
      decimals="-3"
      id="F_000184"
      unitRef="U_iso4217USD">193939000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="C_0001439725_20200101_20201231"
      decimals="-3"
      id="F_000185"
      unitRef="U_iso4217USD">193959000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <bdsx:StockIssuedDuringPeriodSharesConversionOfConvertibleSecuritiesCommonStock
      contextRef="C_0001439725_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231"
      decimals="INF"
      id="F_000186"
      unitRef="U_xbrlishares">1848</bdsx:StockIssuedDuringPeriodSharesConversionOfConvertibleSecuritiesCommonStock>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
      contextRef="C_0001439725_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231"
      decimals="-3"
      id="F_000187"
      unitRef="U_iso4217USD">2000</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
      contextRef="C_0001439725_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231"
      decimals="-3"
      id="F_000188"
      unitRef="U_iso4217USD">26614000</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
      contextRef="C_0001439725_20200101_20201231"
      decimals="-3"
      id="F_000189"
      unitRef="U_iso4217USD">26616000</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="C_0001439725_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231"
      decimals="-3"
      id="F_000190"
      unitRef="U_iso4217USD">8274000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="C_0001439725_20200101_20201231"
      decimals="-3"
      id="F_000191"
      unitRef="U_iso4217USD">8274000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001439725_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20201231"
      decimals="-3"
      id="F_000192"
      unitRef="U_iso4217USD">-31350000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001439725_20200101_20201231"
      decimals="-3"
      id="F_000193"
      unitRef="U_iso4217USD">-31350000</us-gaap:NetIncomeLoss>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_0001439725_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231"
      decimals="INF"
      id="F_000194"
      unitRef="U_xbrlishares">26562</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_0001439725_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231"
      decimals="-3"
      id="F_000195"
      unitRef="U_iso4217USD">27000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001439725_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20201231"
      decimals="-3"
      id="F_000196"
      unitRef="U_iso4217USD">299953000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001439725_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20201231"
      decimals="-3"
      id="F_000197"
      unitRef="U_iso4217USD">-258814000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001439725_20201231"
      decimals="-3"
      id="F_000198"
      unitRef="U_iso4217USD">41166000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="C_0001439725_20200101_20201231"
      decimals="-3"
      id="F_000204"
      unitRef="U_iso4217USD">-31350000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_0001439725_20190101_20191231"
      decimals="-3"
      id="F_000205"
      unitRef="U_iso4217USD">-30726000</us-gaap:ProfitLoss>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_0001439725_20200101_20201231"
      decimals="-3"
      id="F_000206"
      unitRef="U_iso4217USD">2903000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_0001439725_20190101_20191231"
      decimals="-3"
      id="F_000207"
      unitRef="U_iso4217USD">2793000</us-gaap:DepreciationAndAmortization>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="C_0001439725_20200101_20201231"
      decimals="-3"
      id="F_000208"
      unitRef="U_iso4217USD">4389000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="C_0001439725_20190101_20191231"
      decimals="-3"
      id="F_000209"
      unitRef="U_iso4217USD">262000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:ShareBasedCompensation
      contextRef="C_0001439725_20200101_20201231"
      decimals="-3"
      id="F_000210"
      unitRef="U_iso4217USD">3709000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_0001439725_20190101_20191231"
      decimals="-3"
      id="F_000211"
      unitRef="U_iso4217USD">170000</us-gaap:ShareBasedCompensation>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="C_0001439725_20200101_20201231"
      decimals="-3"
      id="F_000212"
      unitRef="U_iso4217USD">1252000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="C_0001439725_20190101_20191231"
      decimals="-3"
      id="F_000213"
      unitRef="U_iso4217USD">104000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="C_0001439725_20200101_20201231"
      decimals="-3"
      id="F_000214"
      unitRef="U_iso4217USD">818000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="C_0001439725_20190101_20191231"
      decimals="-3"
      id="F_000215"
      unitRef="U_iso4217USD">4114000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <bdsx:ChangeInFairValueOfPutOptionLiability
      contextRef="C_0001439725_20190101_20191231"
      decimals="-3"
      id="F_000216"
      unitRef="U_iso4217USD">2000000</bdsx:ChangeInFairValueOfPutOptionLiability>
    <bdsx:AccruedInterestOnNotesPayableAndConvertibleNotesPayable
      contextRef="C_0001439725_20200101_20201231"
      decimals="-3"
      id="F_000217"
      unitRef="U_iso4217USD">1226000</bdsx:AccruedInterestOnNotesPayableAndConvertibleNotesPayable>
    <bdsx:AccruedInterestOnNotesPayableAndConvertibleNotesPayable
      contextRef="C_0001439725_20190101_20191231"
      decimals="-3"
      id="F_000218"
      unitRef="U_iso4217USD">799000</bdsx:AccruedInterestOnNotesPayableAndConvertibleNotesPayable>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="C_0001439725_20200101_20201231"
      decimals="-3"
      id="F_000219"
      unitRef="U_iso4217USD">144000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="C_0001439725_20190101_20191231"
      decimals="-3"
      id="F_000220"
      unitRef="U_iso4217USD">144000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="C_0001439725_20200101_20201231"
      decimals="-3"
      id="F_000221"
      unitRef="U_iso4217USD">296000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="C_0001439725_20190101_20191231"
      decimals="-3"
      id="F_000222"
      unitRef="U_iso4217USD">246000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="C_0001439725_20200101_20201231"
      decimals="-3"
      id="F_000223"
      unitRef="U_iso4217USD">-48000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="C_0001439725_20190101_20191231"
      decimals="-3"
      id="F_000224"
      unitRef="U_iso4217USD">-13000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="C_0001439725_20200101_20201231"
      decimals="-3"
      id="F_000225"
      unitRef="U_iso4217USD">10308000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="C_0001439725_20190101_20191231"
      decimals="-3"
      id="F_000226"
      unitRef="U_iso4217USD">3646000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets
      contextRef="C_0001439725_20200101_20201231"
      decimals="-3"
      id="F_000227"
      unitRef="U_iso4217USD">6588000</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets
      contextRef="C_0001439725_20190101_20191231"
      decimals="-3"
      id="F_000228"
      unitRef="U_iso4217USD">-1000</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet
      contextRef="C_0001439725_20200101_20201231"
      decimals="-3"
      id="F_000229"
      unitRef="U_iso4217USD">1808000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet
      contextRef="C_0001439725_20190101_20191231"
      decimals="-3"
      id="F_000230"
      unitRef="U_iso4217USD">-16000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="C_0001439725_20200101_20201231"
      decimals="-3"
      id="F_000231"
      unitRef="U_iso4217USD">11654000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="C_0001439725_20190101_20191231"
      decimals="-3"
      id="F_000232"
      unitRef="U_iso4217USD">1193000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="C_0001439725_20200101_20201231"
      decimals="-3"
      id="F_000233"
      unitRef="U_iso4217USD">2249000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="C_0001439725_20190101_20191231"
      decimals="-3"
      id="F_000234"
      unitRef="U_iso4217USD">791000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_0001439725_20200101_20201231"
      decimals="-3"
      id="F_000235"
      unitRef="U_iso4217USD">-21366000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_0001439725_20190101_20191231"
      decimals="-3"
      id="F_000236"
      unitRef="U_iso4217USD">-21726000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_0001439725_20200101_20201231"
      decimals="-3"
      id="F_000237"
      unitRef="U_iso4217USD">1945000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_0001439725_20190101_20191231"
      decimals="-3"
      id="F_000238"
      unitRef="U_iso4217USD">1310000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <bdsx:PaymentsForProceedsFromPatentCostsAndIntangibleAssetAcquisitionNet
      contextRef="C_0001439725_20200101_20201231"
      decimals="-3"
      id="F_000239"
      unitRef="U_iso4217USD">232000</bdsx:PaymentsForProceedsFromPatentCostsAndIntangibleAssetAcquisitionNet>
    <bdsx:PaymentsForProceedsFromPatentCostsAndIntangibleAssetAcquisitionNet
      contextRef="C_0001439725_20190101_20191231"
      decimals="-3"
      id="F_000240"
      unitRef="U_iso4217USD">106000</bdsx:PaymentsForProceedsFromPatentCostsAndIntangibleAssetAcquisitionNet>
    <bdsx:PaymentsToAcquireOncimmune
      contextRef="C_0001439725_20200101_20201231"
      decimals="-3"
      id="F_000241"
      unitRef="U_iso4217USD">750000</bdsx:PaymentsToAcquireOncimmune>
    <bdsx:PaymentsToAcquireOncimmune
      contextRef="C_0001439725_20190101_20191231"
      decimals="-3"
      id="F_000242"
      unitRef="U_iso4217USD">456000</bdsx:PaymentsToAcquireOncimmune>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_0001439725_20200101_20201231"
      decimals="-3"
      id="F_000243"
      unitRef="U_iso4217USD">-2927000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_0001439725_20190101_20191231"
      decimals="-3"
      id="F_000244"
      unitRef="U_iso4217USD">-1872000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="C_0001439725_20200101_20201231"
      decimals="-3"
      id="F_000245"
      unitRef="U_iso4217USD">72000000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_0001439725_20200101_20201231"
      decimals="-3"
      id="F_000246"
      unitRef="U_iso4217USD">1340000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_0001439725_20190101_20191231"
      decimals="-3"
      id="F_000247"
      unitRef="U_iso4217USD">47000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="C_0001439725_20190101_20191231"
      decimals="-3"
      id="F_000248"
      unitRef="U_iso4217USD">10000000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="C_0001439725_20200101_20201231"
      decimals="-3"
      id="F_000249"
      unitRef="U_iso4217USD">12955000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="C_0001439725_20190101_20191231"
      decimals="-3"
      id="F_000250"
      unitRef="U_iso4217USD">13044000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="C_0001439725_20200101_20201231"
      decimals="-3"
      id="F_000251"
      unitRef="U_iso4217USD">3085000</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_0001439725_20200101_20201231"
      decimals="-3"
      id="F_000252"
      unitRef="U_iso4217USD">8243000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_0001439725_20190101_20191231"
      decimals="-3"
      id="F_000253"
      unitRef="U_iso4217USD">3000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="C_0001439725_20200101_20201231"
      decimals="-3"
      id="F_000254"
      unitRef="U_iso4217USD">-6000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="C_0001439725_20190101_20191231"
      decimals="-3"
      id="F_000255"
      unitRef="U_iso4217USD">-116000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_0001439725_20200101_20201231"
      decimals="-3"
      id="F_000256"
      unitRef="U_iso4217USD">81131000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_0001439725_20190101_20191231"
      decimals="-3"
      id="F_000257"
      unitRef="U_iso4217USD">22972000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_0001439725_20200101_20201231"
      decimals="-3"
      id="F_000258"
      unitRef="U_iso4217USD">56838000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_0001439725_20190101_20191231"
      decimals="-3"
      id="F_000259"
      unitRef="U_iso4217USD">-626000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_0001439725_20191231"
      decimals="-3"
      id="F_000260"
      unitRef="U_iso4217USD">5468000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_0001439725_20181231"
      decimals="-3"
      id="F_000261"
      unitRef="U_iso4217USD">6094000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_0001439725_20201231"
      decimals="-3"
      id="F_000262"
      unitRef="U_iso4217USD">62306000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_0001439725_20191231"
      decimals="-3"
      id="F_000263"
      unitRef="U_iso4217USD">5468000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <bdsx:ConversionOfPreferredStockIntoCommonStock
      contextRef="C_0001439725_20200101_20201231"
      decimals="-3"
      id="F_000264"
      unitRef="U_iso4217USD">193959000</bdsx:ConversionOfPreferredStockIntoCommonStock>
    <us-gaap:ConversionOfStockAmountConverted1
      contextRef="C_0001439725_20200101_20201231"
      decimals="-3"
      id="F_000265"
      unitRef="U_iso4217USD">26616000</us-gaap:ConversionOfStockAmountConverted1>
    <bdsx:ReclassificationOfPutOptionLiabilityToAdditionalPaidInCapital
      contextRef="C_0001439725_20200101_20201231"
      decimals="-3"
      id="F_000266"
      unitRef="U_iso4217USD">6650000</bdsx:ReclassificationOfPutOptionLiabilityToAdditionalPaidInCapital>
    <bdsx:ValueOfPutOptionRecordedAtIssuanceOfConvertibleNotesPayable
      contextRef="C_0001439725_20200101_20201231"
      decimals="-3"
      id="F_000267"
      unitRef="U_iso4217USD">3389000</bdsx:ValueOfPutOptionRecordedAtIssuanceOfConvertibleNotesPayable>
    <bdsx:ValueOfPutOptionRecordedAtIssuanceOfConvertibleNotesPayable
      contextRef="C_0001439725_20190101_20191231"
      decimals="-3"
      id="F_000268"
      unitRef="U_iso4217USD">1261000</bdsx:ValueOfPutOptionRecordedAtIssuanceOfConvertibleNotesPayable>
    <us-gaap:InterestPaidNet
      contextRef="C_0001439725_20200101_20201231"
      decimals="-3"
      id="F_000269"
      unitRef="U_iso4217USD">1844000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="C_0001439725_20190101_20191231"
      decimals="-3"
      id="F_000270"
      unitRef="U_iso4217USD">1800000</us-gaap:InterestPaidNet>
    <bdsx:ReclassificationOfWarrantLiabilityToAdditionalPaidInCapital
      contextRef="C_0001439725_20200101_20201231"
      decimals="-3"
      id="F_000271"
      unitRef="U_iso4217USD">1624000</bdsx:ReclassificationOfWarrantLiabilityToAdditionalPaidInCapital>
    <us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1
      contextRef="C_0001439725_20190101_20191231"
      decimals="-3"
      id="F_000272"
      unitRef="U_iso4217USD">750000</us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="C_0001439725_20200101_20201231" id="F_000274">
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Note 1 &#x2013; Organization and Description of Business &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Biodesix, Inc. (the &#x201c;Company&#x201d;, &#x201c;Biodesix&#x201d;, &#x201c;we&#x201d; and &#x201c;our&#x201d;), formerly Elston Technologies, Inc., was incorporated in Delaware in 2005. The Company&#x2019;s headquarters are in Colorado, with laboratories in Colorado and Kansas. The Company conducts all of its operations within a single legal entity. Biodesix is a data-driven diagnostic solutions company leveraging state of the art technologies with its proprietary artificial intelligence platform to discover, develop, and commercialize solutions for clinical unmet needs, with a primary focus in lung disease. In addition to diagnostic tests, the Company provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics.&lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company performs its blood-based diagnostic tests for lung cancer in its laboratory facilities, which are located in Boulder, Colorado and De Soto, Kansas. In May 2020, the Federal Drug Administration (FDA) authorized performance of Bio-Rad SARS-CoV-2 Droplet Digital&#x2122; &lt;span style="letter-spacing:-0.15pt;"&gt;polymerase chain reaction &lt;/span&gt;(ddPCR) test to detect Coronavirus Disease 2019 (COVID-19) infection. In April 2020, the FDA authorized our Platelia SARS-CoV-2 Total Ab test to detect COVID-19 antibodies. Medical products that are granted an Emergency Use Authorization (EUA) are only permitted to commercialize their products under the terms and conditions provided in the authorization. The FDA may revoke an EUA where it is determined that the underlying health emergency no longer exists or warrants such authorization, if the conditions for the issuance of the EUA are no longer met, or if other circumstances make revocation appropriate to protect the public health or safety.&lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Blood-Based Lung Tests&lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company offers four blood-based lung cancer tests across the lung cancer continuum of care:&lt;/p&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:3.85%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:3.85%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/&gt;&lt;span style="font-size:10pt;font-family:'Times New Roman'"&gt;&#x2022;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"/&gt;&lt;span style="font-style:italic;color:#000000;"&gt;Nodify XL2&#xae; &lt;/span&gt;&lt;span style="color:#000000;"&gt;and &lt;/span&gt;&lt;span style="font-style:italic;color:#000000;"&gt;Nodify CDT&#x2122; &lt;/span&gt;&lt;span style="color:#000000;"&gt;tests, marketed as part of our Nodify Lung&lt;/span&gt;&lt;span style="font-style:italic;color:#000000;"&gt;&#x2122; &lt;/span&gt;&lt;span style="color:#000000;"&gt;Nodule Risk Assessment testing strategy, assess the risk of lung cancer to help identify the most appropriate treatment &lt;/span&gt;&lt;span style="letter-spacing:-0.15pt;color:#000000;"&gt;pathway. &lt;/span&gt;&lt;span style="letter-spacing:-0.4pt;color:#000000;"&gt;We &lt;/span&gt;&lt;span style="color:#000000;"&gt;believe we are the only company to offer two commercial blood-based tests to help physicians reclassify risk of malignancy in patients with suspicious lung&lt;/span&gt;&lt;span style="letter-spacing:-1.2pt;color:#000000;"&gt; &lt;/span&gt;&lt;span style="color:#000000;"&gt;nodules&lt;/span&gt;.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:3.85%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:3.85%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/&gt;&lt;span style="font-size:10pt;font-family:'Times New Roman'"&gt;&#x2022;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"/&gt;&lt;span style="font-style:italic;color:#000000;"&gt;GeneStrat&#xae; &lt;/span&gt;&lt;span style="color:#000000;"&gt;and &lt;/span&gt;&lt;span style="font-style:italic;letter-spacing:-0.15pt;color:#000000;"&gt;VeriStrat&#xae; &lt;/span&gt;&lt;span style="color:#000000;"&gt;tests, marketed as part of our Biodesix Lung Reflex&lt;/span&gt;&lt;span style="font-style:italic;color:#000000;"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;"&gt;testing strategy, are used following diagnosis of lung cancer to measure the presence of mutations in the tumor and the&lt;/span&gt;&lt;span style="letter-spacing:-0.75pt;color:#000000;"&gt; &lt;/span&gt;&lt;span style="color:#000000;"&gt;state of the patient&#x2019;s immune system to establish the patient&#x2019;s prognosis and help guide treatment decisions. The GeneStrat tumor profiling test and the VeriStrat immune profiling test have a three-day average turnaround time, providing physicians with timely results to facilitate treatment decisions.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;COVID-19 Tests&lt;span style="font-weight:normal;"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Using the Bio-Rad &lt;span style="letter-spacing:-0.15pt;"&gt;SARS-CoV-2 &lt;/span&gt;ddPCR test and the Platelia &lt;span style="letter-spacing:-0.15pt;"&gt;SARS-CoV-2 Total &lt;/span&gt;Ab tests, we operate and have commercialized the Biodesix &lt;span style="letter-spacing:-0.15pt;"&gt;WorkSafe &lt;/span&gt;testing&lt;span style="letter-spacing:-1.6pt;"&gt; &lt;/span&gt;program. The Company offers two SARS-CoV-2 tests:&lt;/p&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:3.85%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:3.85%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/&gt;&lt;span style="font-size:10pt;font-family:'Times New Roman'"&gt;&#x2022;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"/&gt;&lt;span style="font-style:italic;color:#000000;"&gt;Bio-Rad SARS-CoV-2 ddPCR &lt;/span&gt;&lt;span style="color:#000000;"&gt;test, which is authorized by the FDA to be performed by Clinical Laboratory Institute Amendments (CLIA) authorized laboratories that perform high complexity tests. The ddPCR test is designed to detect the presence of infection by the SARS-CoV-2 virus.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:3.85%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:3.85%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/&gt;&lt;span style="font-size:10pt;font-family:'Times New Roman'"&gt;&#x2022;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"/&gt;&lt;span style="font-style:italic;color:#000000;"&gt;Platelia SARS-CoV-2 Total Ab &lt;/span&gt;&lt;span style="color:#000000;"&gt;test, which is an antibody test, authorized by the FDA, intended for detecting a B-cell immune response to &lt;/span&gt;&lt;span style="letter-spacing:-0.15pt;color:#000000;"&gt;SARS-CoV-2, &lt;/span&gt;&lt;span style="color:#000000;"&gt;indicating recent or prior infection.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;These tests are utilized by healthcare providers, including hospitals and nursing homes, and are also offered to businesses and educational systems to assist in their back-to-work or back-to-school strategies, a crucial element of restarting economic activity.&lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In developing the Company's products, the Company has built or gained access to unique biorepositories, proprietary technology, and bioinformatics that it believes are important to the development of new targeted therapies, determining clinical trial eligibility and guiding treatment selection.&lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;All of the Company&#x2019;s testing services are made available through its clinical laboratories.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Reverse Stock Split&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;O&lt;span style="color:#000000;"&gt;n October 19, 2020, the Company obtained approval of an amended and restated certificate of incorporation effecting a 0.1684664-for-1 reverse stock split of its issued and outstanding common stock as converted. All common shares, stock options, and per share information presented in these financial statements and notes thereto have been adjusted, where applicable, to reflect the reverse stock split on a retroactive basis for all periods&lt;/span&gt; presented. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Approval of Amended and Restated Certificate of Incorporation&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In October 2020, the Company&#x2019;s Board of Directors and stockholders approved an amended and restated certificate of incorporation, which authorized 200,000,000 shares of common stock, par value $0.001 per share, and 5,000,000 shares of preferred stock, par value $0.001 per share. The amended and restated certificate of incorporation became effective on October 30, 2020.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Initial Public Offering&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On October 27, 2020, the Company completed its initial public offering, in which it issued and sold 4,000,000 shares of its common stock at a public offering price of $18.00 per share. The Company received net proceeds of $63.8 million after deducting underwriting discounts and commissions and offering expenses payable by the Company. In addition, in connection with the initial public offering, all shares of the Company&#x2019;s then-outstanding convertible preferred stock and convertible notes payable were automatically converted into 21,939,025 shares of common stock, and all then outstanding warrants to purchase the Company&#x2019;s Series G convertible preferred stock were automatically converted into warrants to purchase 103,326 shares of the Company&#x2019;s common stock.&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <bdsx:NumberOfCancerTest
      contextRef="C_0001439725_20200101_20201231"
      decimals="INF"
      id="F_000343"
      unitRef="U_bdsxTest">4</bdsx:NumberOfCancerTest>
    <bdsx:NumberOfCommercialBloodBasedTest
      contextRef="C_0001439725_20200101_20201231"
      decimals="INF"
      id="F_000344"
      unitRef="U_bdsxTest">2</bdsx:NumberOfCommercialBloodBasedTest>
    <bdsx:NumberOfSARSCoV2Test
      contextRef="C_0001439725_20200101_20201231"
      decimals="INF"
      id="F_000345"
      unitRef="U_bdsxTest">2</bdsx:NumberOfSARSCoV2Test>
    <bdsx:ReverseStockSplitPolicyTextBlock contextRef="C_0001439725_20200101_20201231" id="F_000292">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Reverse Stock Split&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;O&lt;span style="color:#000000;"&gt;n October 19, 2020, the Company obtained approval of an amended and restated certificate of incorporation effecting a 0.1684664-for-1 reverse stock split of its issued and outstanding common stock as converted. All common shares, stock options, and per share information presented in these financial statements and notes thereto have been adjusted, where applicable, to reflect the reverse stock split on a retroactive basis for all periods&lt;/span&gt; presented. &lt;/p&gt;</bdsx:ReverseStockSplitPolicyTextBlock>
    <us-gaap:StockholdersEquityReverseStockSplit contextRef="C_0001439725_20200101_20201231" id="F_000346">0.1684664-for-1</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="C_0001439725_20201019_20201019"
      decimals="7"
      id="F_000347"
      unitRef="U_xbrlipure">0.1684664</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <bdsx:ApprovalOfAmendedAndRestatedCertificateOfIncorporationPolicyTextBlock contextRef="C_0001439725_20200101_20201231" id="F_000293">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Approval of Amended and Restated Certificate of Incorporation&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In October 2020, the Company&#x2019;s Board of Directors and stockholders approved an amended and restated certificate of incorporation, which authorized 200,000,000 shares of common stock, par value $0.001 per share, and 5,000,000 shares of preferred stock, par value $0.001 per share. The amended and restated certificate of incorporation became effective on October 30, 2020.&lt;/p&gt;</bdsx:ApprovalOfAmendedAndRestatedCertificateOfIncorporationPolicyTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_0001439725_20201031"
      decimals="INF"
      id="F_000348"
      unitRef="U_xbrlishares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_0001439725_20201031"
      decimals="INF"
      id="F_000349"
      unitRef="U_iso4217USD_xbrlishares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_0001439725_20201031"
      decimals="INF"
      id="F_000350"
      unitRef="U_xbrlishares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_0001439725_20201031"
      decimals="INF"
      id="F_000351"
      unitRef="U_iso4217USD_xbrlishares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <bdsx:InitialPublicOfferingIPOPolicyTextBlock contextRef="C_0001439725_20200101_20201231" id="F_000294">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Initial Public Offering&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On October 27, 2020, the Company completed its initial public offering, in which it issued and sold 4,000,000 shares of its common stock at a public offering price of $18.00 per share. The Company received net proceeds of $63.8 million after deducting underwriting discounts and commissions and offering expenses payable by the Company. In addition, in connection with the initial public offering, all shares of the Company&#x2019;s then-outstanding convertible preferred stock and convertible notes payable were automatically converted into 21,939,025 shares of common stock, and all then outstanding warrants to purchase the Company&#x2019;s Series G convertible preferred stock were automatically converted into warrants to purchase 103,326 shares of the Company&#x2019;s common stock.&lt;/p&gt;</bdsx:InitialPublicOfferingIPOPolicyTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001439725_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20201027_20201027"
      decimals="INF"
      id="F_000352"
      unitRef="U_xbrlishares">4000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_0001439725_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20201027"
      decimals="INF"
      id="F_000353"
      unitRef="U_iso4217USD_xbrlishares">18.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="C_0001439725_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20201027_20201027"
      decimals="-5"
      id="F_000354"
      unitRef="U_iso4217USD">63800000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <bdsx:ConvertiblePreferredStockAndConvertibleNotesPayableConvertedToCommonStock
      contextRef="C_0001439725_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20201027_20201027"
      decimals="INF"
      id="F_000355"
      unitRef="U_xbrlishares">21939025</bdsx:ConvertiblePreferredStockAndConvertibleNotesPayableConvertedToCommonStock>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_0001439725_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20201027"
      decimals="INF"
      id="F_000356"
      unitRef="U_xbrlishares">103326</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="C_0001439725_20200101_20201231" id="F_000275">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Note 2 &#x2013; Summary of Significant Accounting Policies&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Basis of Presentation&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#212529;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s financial statements have been prepared in accordance with accounting principles generally accepted in the United States (U.S. GAAP). &lt;span style="color:#000000;"&gt;The 2019 balance sheet has been updated to reflect an increase in goodwill and a reduction in accumulated deficit of $3.4 million related to the correction of an immaterial error recorded as part of the acquisition of Integrated Diagnostics, Inc. in 2018.&lt;/span&gt;&#160;&#160;The Company determined that the reduction in the preexisting valuation allowance resulting from the acquisition should have been reflected as an income benefit within the tax provision rather than as a reduction in goodwill.&#160;&#160;The correction of the immaterial error had no impact on our 2020 or 2019 results of operations.&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Certain prior period amounts have been reclassified to conform to the current period presentation.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Segment Reporting&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The chief operating decision maker for the Company is the Chief Executive Officer, who reviews financial information for purposes of allocating resources and assessing financial performance.&#160;&#160;The Company has a &lt;span style="-sec-ix-hidden:F_000360"&gt;single&lt;/span&gt; operating segment focused on providing diagnostic testing services to customers. Substantially all of the Company&#x2019;s revenue and all long-lived assets were derived or located in the United States for the years ended December 31, 2020 and 2019.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Use of Estimates&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Significant items subject to such estimates include: revenue recognition; the useful lives of property and equipment; the recoverability of long-lived assets; the estimation of the fair value of intangible assets; the valuation of contingent consideration related to a business combination; stock options; income tax uncertainties, including a valuation allowance for deferred tax assets; and contingencies. The Company bases these estimates on historical and anticipated results, trends, and various other assumptions that the Company believes are reasonable under the circumstances, including assumptions as to future events. These estimates form the basis for making judgments about the carrying values of assets and liabilities and recognized revenue and expenses that are not readily apparent from other sources. Actual results could differ from those estimates and assumptions.&lt;/p&gt;

&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Revenue Recognition&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company generates revenues from (i) diagnostic tests and (ii) assay development and testing services (services revenue).&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Diagnostic test revenues consist of blood-based lung tests and COVID-19 tests, which are recognized in the amount expected to be received in exchange for diagnostic tests when the diagnostic tests are delivered. The Company determines the transaction price related to its blood-based lung diagnostic test contracts using a portfolio approach by considering the nature of the payer and historical price concessions granted to groups of customers. The transaction price associated with COVID-19 testing arrangements are determined on the basis of the individual contract with each customer.&lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Services revenue consists of various types of tests or other scientific services for a purpose as defined by any individual customer, which are often larger biopharmaceutical companies, as defined by a written agreement between the Company and the customer. These services are generally completed upon the delivery of testing results, or achievement of contractual milestone(s) as defined in the customer agreements. Revenue for these services is recognized upon delivery of the completed test results, or upon completion of the contractual milestone(s). &lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company recognizes revenues related to blood-based lung diagnostic billings based on estimates of the amounts ultimately expected to be collected from customers on a portfolio approach as discussed above. In determining the amount to accrue for a delivered test, the Company considers factors such as payment history, payer coverage, whether there is a reimbursement contract between the payer and the Company, payment as a percentage of agreed upon rate (if applicable), amount paid per test and any current developments or changes that could impact reimbursement. Variable consideration, if any, is estimated based on an analysis of historical experience and adjusted as better estimates become available. These estimates require significant judgment by management.&lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company also provides services to patients with whom the Company does not have contracts as defined in Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC 606). The Company recognizes revenue for these patients when contracts as defined in ASC 606 are established at the amount of consideration to which it expects to be entitled, or when the Company receives substantially all of the consideration subsequent to satisfaction and delivery of the performance obligations.&lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;See Note 13 &#x2014; &lt;span style="font-style:italic;"&gt;Revenue&lt;/span&gt; for additional information.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Deferred Revenue&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred revenue consists of payments received for research, development, and testing services fees received prior to the completion of performance of these tests and services. As of December 31, 2020, deferred revenue also includes $2.8 million in a Medicare advance payment on testing services which can either be paid back or earned back starting 1 year from receipt.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Direct Costs and Expenses&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The components of our cost of diagnostic tests and testing services consist of cost of materials, direct labor, including bonus, benefit and stock-based compensation, depreciation of laboratory equipment, rent costs, amortization of leasehold improvements and information technology costs associated with acquiring and processing test samples, including sample accessioning, test performance, quality control analyses, charges to collect and transport samples; curation of test results for physicians; and in some cases, license or royalty fees due to third parties.&lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Royalties for licensed technology are calculated as a percentage of revenues generated using the associated technology and recorded as expense at the time the related revenue is recognized. One-time royalty payments related to signing of license agreements or other milestones, such as issuance of new patents, are amortized to expense over the expected useful life of the patents. Costs associated with performing tests are expensed as the test is processed regardless of whether and when revenue is recognized with respect to that test.&lt;/p&gt;

&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Research and Development &lt;span style="color:#212529;"&gt;Expenses&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development expenses include external and internal costs incurred to develop our technology, collect clinical samples, and conduct clinical studies to develop and support our products. External costs consist primarily of payments to clinical trial sites, sample acquisition costs and laboratory supplies purchased in connection with the Company&#x2019;s discovery and preclinical activities, process development and clinical development activities.&#160; Internal costs consist primarily of salaries and benefits, reagents and supplies used in research and development laboratory work, infrastructure expenses, including allocated facility occupancy and information technology costs&lt;span style="Background-color:#FFFFFF;"&gt;.&lt;/span&gt; &lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;color:#212529;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company estimates and accrues its expenses resulting from its obligations under contracts with vendors and consultants in connection with conducting research and development activities. The financial terms of these contracts vary from contract to contract and may result in payments that do not match the periods over which materials or services are provided under such contracts.&lt;span style="color:#000000;"&gt;&#160;&#160;The Company&#x2019;s estimates depend on the timeliness and accuracy of the data provided by consultants and vendors regarding the status of each activity.&#160;&#160;The Company periodically evaluates the estimates to determine if adjustments are necessary or appropriate based on information received. Research and development costs are expensed as incurred. &lt;/span&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Sales, Marketing, General and Administrative Expenses&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Selling expenses consist primarily of costs associated with our sales organization, including our direct sales force and sales management, client services, marketing, and reimbursement, as well as business development personnel who are focused on our biopharmaceutical customers. These expenses consist primarily of salaries, commissions, bonuses, employee benefits, travel, and stock-based compensation, as well as marketing and educational activities and allocated overhead expenses. &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Sales, marketing, general and administrative expenses also include costs for our marketing and sales organizations, and other functions including finance, legal, human resources, and information technology. &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;These expenses consist principally of salaries, bonuses, employee benefits, travel, and stock-based compensation, as well as professional services fees such as consulting, audit, tax and legal fees, and general corporate costs and allocated overhead expenses.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Concentrations of Credit Risk and Other Uncertainties&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Substantially all of the Company&#x2019;s cash and cash equivalents are deposited with one major financial institution in the United States. The Company continually monitors its positions with, and the credit quality of, the financial institution with which it holds cash. Periodically throughout the year, the Company has maintained balances in various operating accounts in excess of federally insured limits. The Company has not experienced any losses on its deposits of cash and cash equivalents.&lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Several of the components of the Company's sample collection kit and test reagents, and certain test systems and related test kits are obtained from single-source suppliers. If these single-source suppliers fail to satisfy the Company's requirements on a timely basis, it could suffer delays in being able to deliver its diagnostic solutions, a possible loss of revenue, or incur higher costs, any of which could adversely affect its operating results.&lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s customers in excess of 10% of total revenue, and their related revenue as a percentage of total revenue were as follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:79.2%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.86%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:79.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.86%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:79.2%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Big Ten Conference&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;30&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:79.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Centura Healthcare&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:79.2%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Percent of total revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;47&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;One customer, Covance, exceeded 10% of total revenue during 2019, representing 21% of total revenue. In addition to the above table, we collect reimbursement on behalf of customers covered by Medicare, which accounted for 17% and 36% of the Company&#x2019;s total revenue for the years ended December 31, 2020 and 2019, respectively.&#160;&#160;The Company is subject to credit risk from its accounts receivable related to services provided to its customers. The Company does not perform evaluations of customers' financial condition and does not require collateral. The Company&#x2019;s third-party payors and other customers in excess of 10% of accounts receivable, and their related accounts receivable as a percentage of total accounts receivable were as follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.12%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Big Ten Conference&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;35&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Centura Healthcare&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;24&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Medicare&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;18&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Covance Central Laboratory Services&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;43&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Janssen Research and Development, LLC&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Pfizer, Inc&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.26%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Percent of total accounts receivable&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;76&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;83&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Cash and Cash Equivalents &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash equivalents consist of short-term, highly-liquid instruments with an original maturity of three months or less from the date of purchase. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Restricted Cash&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Restricted cash consists of deposits related to the Company&#x2019;s corporate credit card and a letter of credit related to an operating lease agreement. As of December 31, 2020 and 2019, the Company had $0.2 million restricted cash, respectively, which was included in &#x2018;Other current assets&#x2019; in the accompanying balance sheets.&#160;&#160; &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Accounts Receivable and Allowance for Doubtful Accounts&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accounts receivable are stated at the amount management expects to collect from customers based on their outstanding invoices. Management reviews accounts receivable &lt;span style="color:#000000;"&gt;quarterly&lt;/span&gt; to determine if any receivable will potentially be uncollectible and to estimate the amount of allowance for doubtful accounts necessary to reduce accounts receivable to its estimated net realizable value based on &lt;span style="color:#000000;"&gt;historical experience, customer creditworthiness, facts, and circumstances specific to outstanding balances, and payment terms. The Company&#x2019;s allowance for doubtful accounts was $0.2 million as of December 31, 2020 and 2019.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Inventory&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Inventory consists primarily of material supplies, which are consumed in the performance of testing services and charged to cost of sales. Inventory is stated at cost and reported within &#x2018;Other current assets&#x2019; in the balance sheet and were $3.2 million and $0.8 million as of December 31, 2020 and 2019, respectively.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Property and Equipment&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment are stated at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally between three and five years. Leasehold improvements are amortized using the straight-line method over the shorter of the estimated useful life of the asset or the term of the lease. Maintenance and repairs are charged to expense as incurred, and improvements and betterments are capitalized. When assets are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the balance sheet and any resulting gain or loss is reflected in the statements of operations and comprehensive loss in the period realized.&lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Long-lived assets to be held and used are evaluated for impairment when events or circumstances indicate the carrying value of a long-lived asset or asset group is less &lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;than &lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;the undiscounted cash flows from the use and eventual disposition over its remaining useful life. The Company assesses recoverability by comparing the sum or projected undiscounted cash flows from the use and eventual disposition of the asset or asset group to it carrying value, and records an impairment loss if the carrying value is greater &lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;than &lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;the undiscounted future cash flows.&lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; There were &lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; impairments for the years ended December 31, 2020 or 2019.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Intangible Assets&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intangible assets primarily consist of intangible assets acquired as part of business combinations, external costs associated with patent applications that are expected to be successful, and trademark costs. Finite-lived intangibles are stated at cost, net of accumulated amortization. The Company amortizes finite-lived intangible assets using the straight-line method over their estimated useful lives of 9 to 10 years, based on management's estimate of the period over which their economic benefits will be realized, product life and patent life. Trademarks are considered indefinite lived and are not amortized.  &lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intangible assets are reviewed for impairment whenever events or changes in circumstances indicate a reduction to fair value below their carrying amounts. There were no impairments for the years ended December 31, 2020 or 2019.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Goodwill&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Goodwill represents the excess of purchase price over amounts allocated to acquired assets and liabilities assumed in business combinations. The carrying value of goodwill is evaluated for impairment at least annually or more frequently when events or circumstances occur indicate a potential for impairment. The annual impairment test is performed on the last day of our fourth quarter. Prior to performing a quantitative evaluation, an assessment of qualitative factors may be performed to determine whether it is more likely than not that the fair value of the reporting unit exceeds its carrying value. In the event the Company determines that it is more likely than not the carrying value of our single reporting unit is higher than its estimated fair value, quantitative testing is performed comparing recorded values to estimated fair values. If impairment is present, the impairment loss is measured as the excess of the recorded goodwill over its implied fair value. &lt;span style="color:#000000;"&gt;There were no impairments for the years ended December 31, 2020 or 2019.&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Fair Value of Financial Instruments&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. GAAP for fair value establishes a hierarchy that prioritizes fair value measurements based on the types of inputs used for the various valuation techniques (market approach, income approach, and cost approach). We utilize a combination of market and income approaches to value our financial instruments. Our financial assets and liabilities are measured using inputs from the three levels of the fair value hierarchy. Fair value measurements are categorized within the fair value hierarchy based upon the lowest level of the most significant inputs used to determine fair value. The three levels of the hierarchy and the related inputs are as follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:86.08%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Inputs&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%; border-top:solid 0.75pt #000000;" valign="top"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:86.08%; border-top:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unadjusted quoted prices in active markets for identical assets and liabilities.&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%;" valign="top"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:86.08%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unadjusted quoted prices in active markets for similar assets and liabilities;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%;" valign="top"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:86.08%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active; or&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%;" valign="top"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:86.08%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Inputs other than quoted prices that are observable for the asset or liability.&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%;" valign="top"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:86.08%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unobservable inputs for the asset or liability.&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The carrying amounts of certain financial instruments including cash and cash equivalents, accounts receivable, prepaid expenses and other current assets, accounts payable and accrued liabilities approximate fair value due to their relatively short maturities.&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;See Note 5 &lt;span style="color:#000000;"&gt;&#x2014; &lt;/span&gt;&lt;span style="font-style:italic;color:#000000;"&gt;Fair Value &lt;/span&gt;&lt;span style="color:#000000;"&gt;for further discussion related to estimated fair value measurements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Contingent Consideration&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In connection with the purchase transaction with Integrated Diagnostics, Inc. (Indi), the Company recorded contingent consideration for amounts potentially payable to Indi&#x2019;s shareholder pursuant to the terms of the asset purchase agreement. The fair value of contingent consideration is assessed at each balance sheet date and changes, if any, to the fair value are recognized as operating expenses within the statements of operations. The estimated fair value of the contingent consideration is based upon significant assumptions including the probability of successful achievement of product gross margin targets included in the acquisition agreement, the estimated timing of achievement of the product gross margin targets, and discount rates. The estimated fair value could materially differ from actual values or fair values determined using different assumptions.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Warrant Liability&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prior to the completion of the Company&#x2019;s initial public offering in October 2020, certain warrants issued to purchase convertible preferred stock were classified as liabilities with changes in the estimated fair value of these liabilities recognized in our results of operations. Upon completion of the Company&#x2019;s initial public offering in October 2020, the warrants were automatically converted to warrants to purchase common stock. Accordingly, the warrants were remeasured to an estimate of fair value and recognized in our results of operations and then reclassified to additional paid-in capital.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Put Option Liability&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;During 2020 and 2019, the Company issued convertible debt&lt;span style="color:#000000;"&gt;&#160;&lt;/span&gt;with terms that provided for a conversion rate to the convertible debtholders that was more favorable than the price that other investors would pay for common stock in certain situations, including the completion of an initial public offering. As a result, the convertible debt is a financial instrument that was bifurcated into two instruments, a debt obligation and a put option liability, which represented the estimated fair value of the favorable conversion rate.&#160;&#160;The estimated fair value of the put option liability was separated from the convertible debt at inception and reported as a liability and debt discount, and amortized to interest expense. As a result of our initial public offering, the convertible debt was automatically converted to common stock and the put option liability was remeasured to an estimate of fair value and recognized in our results of operations and then reclassified to additional paid-in capital.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Share&#x2011;Based Compensation&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Stock Options&lt;span style="font-style:normal;"&gt; &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company grants service condition and performance condition stock options. Stock options are granted with exercise prices equal to the fair market value of our common stock on the date of grant. The grant date fair value of each employee stock option is estimated on the date of grant using the Black-Scholes option-pricing model, which requires the use of assumptions, including the expected term of the option, expected volatility of our stock price, expected dividend yield, and the risk-free interest rate, among others. These assumptions involve inherent uncertainties including market conditions and employee behavior that are generally outside of the Company&#x2019;s control. Service condition stock options are expensed based on the grant date fair value of the awards using the straight-line method over the requisite service period, adjusted for forfeitures as they occur. Performance-condition stock options vest based on achievement of multiple weighted performance goals, certification of performance achievement by the Compensation Committee of the Board of Directors, and continued service. For performance-condition stock options, compensation expense is updated for our expected performance level against performance goals at the end of each reporting period, which involves judgment as to achievement of certain performance metrics.&lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prior to our initial public offering in October 2020, the fair value of our common stock was determined by the Board of Directors in accordance with the methodologies outlined in the American Institute of Certified Public Accountants Practice Aid, Valuation of Privately-Held-Company Equity Securities Issued as Compensation Practice Aid (Practice Aid). In doing so, the Board of Directors determined the best estimate of fair value of our common stock, exercising reasonable judgment and considering numerous objective and subjective factors&lt;span style="color:#000000;"&gt;, by first determining the enterprise value of our business, and then allocating the value among the various classes of our equity securities to derive a per share value of our common stock. &lt;/span&gt;Subsequent&#160;to the Company&#x2019;s initial public offering, the fair value of the Company&#x2019;s common stock is determined based on its traded market price.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Restricted Stock Units (RSUs)&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company grants service-condition RSUs. As a result of our initial public offering, the grant date fair values of these RSUs are based on the closing market price of our common stock on the grant date. The service-condition RSUs vest based on continued service with compensation expense, net of forfeitures, recognized on a straight-line basis over the requisite service period. &lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;See Note 14 &#x2014; &lt;span style="font-style:italic;"&gt;Share-Based Compensation&lt;/span&gt; for additional information related to share-based compensation.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Net Loss per Common Share &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Basic net loss per common share is calculated by dividing net loss by the weighted-average number of common shares outstanding during the period, without consideration of common stock equivalents. Diluted net loss per common share is computed by dividing net loss by the weighted-average number of common share equivalents outstanding for the period, if dilutive, using the treasury stock method. Potentially dilutive securities consisting of options to purchase common stock, warrants to purchase common stock, restricted stock units and shares subject to purchase under our employee stock purchase plan were excluded from the calculation of diluted net loss per common share because their effect would be anti-dilutive for all periods presented. &lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Until the Company&#x2019;s initial public offering in October 2020, basic and diluted net loss attributable to common stockholders per share was calculated using the two-class method. The net loss was attributable entirely to common stockholders because the participating securities did not have a contractual obligation to share in the Company&#x2019;s losses.&#160;&#160;As the Company has reported a net loss for all periods presented, diluted net loss per common share is the same as basic net loss per common share for all periods presented.&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="C_0001439725_20200101_20201231" id="F_000295">
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Basis of Presentation&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#212529;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s financial statements have been prepared in accordance with accounting principles generally accepted in the United States (U.S. GAAP). &lt;span style="color:#000000;"&gt;The 2019 balance sheet has been updated to reflect an increase in goodwill and a reduction in accumulated deficit of $3.4 million related to the correction of an immaterial error recorded as part of the acquisition of Integrated Diagnostics, Inc. in 2018.&lt;/span&gt;&#160;&#160;The Company determined that the reduction in the preexisting valuation allowance resulting from the acquisition should have been reflected as an income benefit within the tax provision rather than as a reduction in goodwill.&#160;&#160;The correction of the immaterial error had no impact on our 2020 or 2019 results of operations.&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Certain prior period amounts have been reclassified to conform to the current period presentation.&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsDescription
      contextRef="C_0001439725_srtRestatementAxis_srtRevisionOfPriorPeriodErrorCorrectionAdjustmentMember_20200101_20201231"
      id="F_000359">The 2019 balance sheet has been updated to reflect an increase in goodwill and a reduction in accumulated deficit of $3.4 million related to the correction of an immaterial error recorded as part of the acquisition of Integrated Diagnostics, Inc. in 2018.</us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsDescription>
    <us-gaap:GoodwillPeriodIncreaseDecrease
      contextRef="C_0001439725_srtRestatementAxis_srtRevisionOfPriorPeriodErrorCorrectionAdjustmentMember_20190101_20191231"
      decimals="-5"
      id="F_000357"
      unitRef="U_iso4217USD">3400000</us-gaap:GoodwillPeriodIncreaseDecrease>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="C_0001439725_20200101_20201231" id="F_000296">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Segment Reporting&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The chief operating decision maker for the Company is the Chief Executive Officer, who reviews financial information for purposes of allocating resources and assessing financial performance.&#160;&#160;The Company has a &lt;span style="-sec-ix-hidden:F_000360"&gt;single&lt;/span&gt; operating segment focused on providing diagnostic testing services to customers. Substantially all of the Company&#x2019;s revenue and all long-lived assets were derived or located in the United States for the years ended December 31, 2020 and 2019.&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="C_0001439725_20200101_20201231" id="F_000297">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Use of Estimates&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Significant items subject to such estimates include: revenue recognition; the useful lives of property and equipment; the recoverability of long-lived assets; the estimation of the fair value of intangible assets; the valuation of contingent consideration related to a business combination; stock options; income tax uncertainties, including a valuation allowance for deferred tax assets; and contingencies. The Company bases these estimates on historical and anticipated results, trends, and various other assumptions that the Company believes are reasonable under the circumstances, including assumptions as to future events. These estimates form the basis for making judgments about the carrying values of assets and liabilities and recognized revenue and expenses that are not readily apparent from other sources. Actual results could differ from those estimates and assumptions.&lt;/p&gt;
</us-gaap:UseOfEstimates>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="C_0001439725_20200101_20201231" id="F_000298">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Revenue Recognition&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company generates revenues from (i) diagnostic tests and (ii) assay development and testing services (services revenue).&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Diagnostic test revenues consist of blood-based lung tests and COVID-19 tests, which are recognized in the amount expected to be received in exchange for diagnostic tests when the diagnostic tests are delivered. The Company determines the transaction price related to its blood-based lung diagnostic test contracts using a portfolio approach by considering the nature of the payer and historical price concessions granted to groups of customers. The transaction price associated with COVID-19 testing arrangements are determined on the basis of the individual contract with each customer.&lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Services revenue consists of various types of tests or other scientific services for a purpose as defined by any individual customer, which are often larger biopharmaceutical companies, as defined by a written agreement between the Company and the customer. These services are generally completed upon the delivery of testing results, or achievement of contractual milestone(s) as defined in the customer agreements. Revenue for these services is recognized upon delivery of the completed test results, or upon completion of the contractual milestone(s). &lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company recognizes revenues related to blood-based lung diagnostic billings based on estimates of the amounts ultimately expected to be collected from customers on a portfolio approach as discussed above. In determining the amount to accrue for a delivered test, the Company considers factors such as payment history, payer coverage, whether there is a reimbursement contract between the payer and the Company, payment as a percentage of agreed upon rate (if applicable), amount paid per test and any current developments or changes that could impact reimbursement. Variable consideration, if any, is estimated based on an analysis of historical experience and adjusted as better estimates become available. These estimates require significant judgment by management.&lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company also provides services to patients with whom the Company does not have contracts as defined in Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC 606). The Company recognizes revenue for these patients when contracts as defined in ASC 606 are established at the amount of consideration to which it expects to be entitled, or when the Company receives substantially all of the consideration subsequent to satisfaction and delivery of the performance obligations.&lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;See Note 13 &#x2014; &lt;span style="font-style:italic;"&gt;Revenue&lt;/span&gt; for additional information.&lt;/p&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock contextRef="C_0001439725_20200101_20201231" id="F_000299">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Deferred Revenue&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred revenue consists of payments received for research, development, and testing services fees received prior to the completion of performance of these tests and services. As of December 31, 2020, deferred revenue also includes $2.8 million in a Medicare advance payment on testing services which can either be paid back or earned back starting 1 year from receipt.&lt;/p&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="C_0001439725_srtProductOrServiceAxis_bdsxTestingServicesMember_20201231"
      decimals="-5"
      id="F_000361"
      unitRef="U_iso4217USD">2800000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <bdsx:DirectCostsAndExpensesPolicyTextBlock contextRef="C_0001439725_20200101_20201231" id="F_000300">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Direct Costs and Expenses&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The components of our cost of diagnostic tests and testing services consist of cost of materials, direct labor, including bonus, benefit and stock-based compensation, depreciation of laboratory equipment, rent costs, amortization of leasehold improvements and information technology costs associated with acquiring and processing test samples, including sample accessioning, test performance, quality control analyses, charges to collect and transport samples; curation of test results for physicians; and in some cases, license or royalty fees due to third parties.&lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Royalties for licensed technology are calculated as a percentage of revenues generated using the associated technology and recorded as expense at the time the related revenue is recognized. One-time royalty payments related to signing of license agreements or other milestones, such as issuance of new patents, are amortized to expense over the expected useful life of the patents. Costs associated with performing tests are expensed as the test is processed regardless of whether and when revenue is recognized with respect to that test.&lt;/p&gt;
</bdsx:DirectCostsAndExpensesPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="C_0001439725_20200101_20201231" id="F_000301">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Research and Development &lt;span style="color:#212529;"&gt;Expenses&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development expenses include external and internal costs incurred to develop our technology, collect clinical samples, and conduct clinical studies to develop and support our products. External costs consist primarily of payments to clinical trial sites, sample acquisition costs and laboratory supplies purchased in connection with the Company&#x2019;s discovery and preclinical activities, process development and clinical development activities.&#160; Internal costs consist primarily of salaries and benefits, reagents and supplies used in research and development laboratory work, infrastructure expenses, including allocated facility occupancy and information technology costs&lt;span style="Background-color:#FFFFFF;"&gt;.&lt;/span&gt; &lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;color:#212529;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company estimates and accrues its expenses resulting from its obligations under contracts with vendors and consultants in connection with conducting research and development activities. The financial terms of these contracts vary from contract to contract and may result in payments that do not match the periods over which materials or services are provided under such contracts.&lt;span style="color:#000000;"&gt;&#160;&#160;The Company&#x2019;s estimates depend on the timeliness and accuracy of the data provided by consultants and vendors regarding the status of each activity.&#160;&#160;The Company periodically evaluates the estimates to determine if adjustments are necessary or appropriate based on information received. Research and development costs are expensed as incurred. &lt;/span&gt;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock contextRef="C_0001439725_20200101_20201231" id="F_000302">
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Sales, Marketing, General and Administrative Expenses&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Selling expenses consist primarily of costs associated with our sales organization, including our direct sales force and sales management, client services, marketing, and reimbursement, as well as business development personnel who are focused on our biopharmaceutical customers. These expenses consist primarily of salaries, commissions, bonuses, employee benefits, travel, and stock-based compensation, as well as marketing and educational activities and allocated overhead expenses. &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Sales, marketing, general and administrative expenses also include costs for our marketing and sales organizations, and other functions including finance, legal, human resources, and information technology. &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;These expenses consist principally of salaries, bonuses, employee benefits, travel, and stock-based compensation, as well as professional services fees such as consulting, audit, tax and legal fees, and general corporate costs and allocated overhead expenses.&lt;/p&gt;</us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="C_0001439725_20200101_20201231" id="F_000303">
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Concentrations of Credit Risk and Other Uncertainties&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Substantially all of the Company&#x2019;s cash and cash equivalents are deposited with one major financial institution in the United States. The Company continually monitors its positions with, and the credit quality of, the financial institution with which it holds cash. Periodically throughout the year, the Company has maintained balances in various operating accounts in excess of federally insured limits. The Company has not experienced any losses on its deposits of cash and cash equivalents.&lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Several of the components of the Company's sample collection kit and test reagents, and certain test systems and related test kits are obtained from single-source suppliers. If these single-source suppliers fail to satisfy the Company's requirements on a timely basis, it could suffer delays in being able to deliver its diagnostic solutions, a possible loss of revenue, or incur higher costs, any of which could adversely affect its operating results.&lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s customers in excess of 10% of total revenue, and their related revenue as a percentage of total revenue were as follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:79.2%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.86%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:79.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.86%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:79.2%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Big Ten Conference&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;30&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:79.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Centura Healthcare&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:79.2%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Percent of total revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;47&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;One customer, Covance, exceeded 10% of total revenue during 2019, representing 21% of total revenue. In addition to the above table, we collect reimbursement on behalf of customers covered by Medicare, which accounted for 17% and 36% of the Company&#x2019;s total revenue for the years ended December 31, 2020 and 2019, respectively.&#160;&#160;The Company is subject to credit risk from its accounts receivable related to services provided to its customers. The Company does not perform evaluations of customers' financial condition and does not require collateral. The Company&#x2019;s third-party payors and other customers in excess of 10% of accounts receivable, and their related accounts receivable as a percentage of total accounts receivable were as follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.12%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Big Ten Conference&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;35&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Centura Healthcare&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;24&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Medicare&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;18&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Covance Central Laboratory Services&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;43&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Janssen Research and Development, LLC&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Pfizer, Inc&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.26%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Percent of total accounts receivable&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;76&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;83&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock contextRef="C_0001439725_20200101_20201231" id="F_000318">
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s customers in excess of 10% of total revenue, and their related revenue as a percentage of total revenue were as follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:79.2%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.86%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:79.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.86%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:79.2%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Big Ten Conference&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;30&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:79.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Centura Healthcare&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:79.2%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Percent of total revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;47&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;The Company&#x2019;s third-party payors and other customers in excess of 10% of accounts receivable, and their related accounts receivable as a percentage of total accounts receivable were as follows:
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.12%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Big Ten Conference&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;35&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Centura Healthcare&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;24&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Medicare&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;18&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Covance Central Laboratory Services&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;43&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Janssen Research and Development, LLC&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Pfizer, Inc&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.26%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Percent of total accounts receivable&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;76&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;83&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_0001439725_srtMajorCustomersAxis_bdsxTheBigTenConferenceMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20200101_20201231"
      decimals="2"
      id="F_000362"
      unitRef="U_xbrlipure">0.30</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_0001439725_srtMajorCustomersAxis_bdsxCenturaHealthcareMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20200101_20201231"
      decimals="2"
      id="F_000363"
      unitRef="U_xbrlipure">0.17</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_0001439725_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20200101_20201231"
      decimals="2"
      id="F_000364"
      unitRef="U_xbrlipure">0.47</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_0001439725_srtMajorCustomersAxis_bdsxCovanceCentralLaboratoryServicesMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20190101_20191231"
      decimals="2"
      id="F_000365"
      unitRef="U_xbrlipure">0.21</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_0001439725_srtMajorCustomersAxis_bdsxMedicareMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20200101_20201231"
      decimals="2"
      id="F_000366"
      unitRef="U_xbrlipure">0.17</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_0001439725_srtMajorCustomersAxis_bdsxMedicareMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20190101_20191231"
      decimals="2"
      id="F_000367"
      unitRef="U_xbrlipure">0.36</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_0001439725_srtMajorCustomersAxis_bdsxTheBigTenConferenceMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20200101_20201231"
      decimals="2"
      id="F_000368"
      unitRef="U_xbrlipure">0.35</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_0001439725_srtMajorCustomersAxis_bdsxCenturaHealthcareMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20200101_20201231"
      decimals="2"
      id="F_000369"
      unitRef="U_xbrlipure">0.24</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_0001439725_srtMajorCustomersAxis_bdsxMedicareMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20200101_20201231"
      decimals="2"
      id="F_000370"
      unitRef="U_xbrlipure">0.06</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_0001439725_srtMajorCustomersAxis_bdsxMedicareMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20190101_20191231"
      decimals="2"
      id="F_000371"
      unitRef="U_xbrlipure">0.18</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_0001439725_srtMajorCustomersAxis_bdsxCovanceCentralLaboratoryServicesMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20200101_20201231"
      decimals="2"
      id="F_000372"
      unitRef="U_xbrlipure">0.02</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_0001439725_srtMajorCustomersAxis_bdsxCovanceCentralLaboratoryServicesMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20190101_20191231"
      decimals="2"
      id="F_000373"
      unitRef="U_xbrlipure">0.43</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_0001439725_srtMajorCustomersAxis_bdsxJanssenResearchAndDevelopmentLLCMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20200101_20201231"
      decimals="2"
      id="F_000374"
      unitRef="U_xbrlipure">0.05</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_0001439725_srtMajorCustomersAxis_bdsxJanssenResearchAndDevelopmentLLCMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20190101_20191231"
      decimals="2"
      id="F_000375"
      unitRef="U_xbrlipure">0.12</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_0001439725_srtMajorCustomersAxis_bdsxPfizerIncMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20200101_20201231"
      decimals="2"
      id="F_000376"
      unitRef="U_xbrlipure">0.04</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_0001439725_srtMajorCustomersAxis_bdsxPfizerIncMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20190101_20191231"
      decimals="2"
      id="F_000377"
      unitRef="U_xbrlipure">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_0001439725_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20200101_20201231"
      decimals="2"
      id="F_000378"
      unitRef="U_xbrlipure">0.76</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_0001439725_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20190101_20191231"
      decimals="2"
      id="F_000379"
      unitRef="U_xbrlipure">0.83</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="C_0001439725_20200101_20201231" id="F_000304">
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Cash and Cash Equivalents &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash equivalents consist of short-term, highly-liquid instruments with an original maturity of three months or less from the date of purchase. &lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy contextRef="C_0001439725_20200101_20201231" id="F_000305">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Restricted Cash&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Restricted cash consists of deposits related to the Company&#x2019;s corporate credit card and a letter of credit related to an operating lease agreement. As of December 31, 2020 and 2019, the Company had $0.2 million restricted cash, respectively, which was included in &#x2018;Other current assets&#x2019; in the accompanying balance sheets.&#160;&#160; &lt;/p&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:RestrictedCash
      contextRef="C_0001439725_us-gaapBalanceSheetLocationAxis_us-gaapOtherCurrentAssetsMember_20201231"
      decimals="-5"
      id="F_000380"
      unitRef="U_iso4217USD">200000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="C_0001439725_us-gaapBalanceSheetLocationAxis_us-gaapOtherCurrentAssetsMember_20191231"
      decimals="-5"
      id="F_000381"
      unitRef="U_iso4217USD">200000</us-gaap:RestrictedCash>
    <us-gaap:ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy contextRef="C_0001439725_20200101_20201231" id="F_000306">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Accounts Receivable and Allowance for Doubtful Accounts&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accounts receivable are stated at the amount management expects to collect from customers based on their outstanding invoices. Management reviews accounts receivable &lt;span style="color:#000000;"&gt;quarterly&lt;/span&gt; to determine if any receivable will potentially be uncollectible and to estimate the amount of allowance for doubtful accounts necessary to reduce accounts receivable to its estimated net realizable value based on &lt;span style="color:#000000;"&gt;historical experience, customer creditworthiness, facts, and circumstances specific to outstanding balances, and payment terms. The Company&#x2019;s allowance for doubtful accounts was $0.2 million as of December 31, 2020 and 2019.&lt;/span&gt;&lt;/p&gt;</us-gaap:ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="C_0001439725_20191231"
      decimals="-5"
      id="F_000383"
      unitRef="U_iso4217USD">200000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="C_0001439725_20201231"
      decimals="-5"
      id="F_000382"
      unitRef="U_iso4217USD">200000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:InventorySuppliesPolicy contextRef="C_0001439725_20200101_20201231" id="F_000307">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Inventory&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Inventory consists primarily of material supplies, which are consumed in the performance of testing services and charged to cost of sales. Inventory is stated at cost and reported within &#x2018;Other current assets&#x2019; in the balance sheet and were $3.2 million and $0.8 million as of December 31, 2020 and 2019, respectively.&lt;/p&gt;</us-gaap:InventorySuppliesPolicy>
    <us-gaap:OtherInventorySupplies
      contextRef="C_0001439725_us-gaapBalanceSheetLocationAxis_us-gaapOtherCurrentAssetsMember_20201231"
      decimals="-5"
      id="F_000384"
      unitRef="U_iso4217USD">3200000</us-gaap:OtherInventorySupplies>
    <us-gaap:OtherInventorySupplies
      contextRef="C_0001439725_us-gaapBalanceSheetLocationAxis_us-gaapOtherCurrentAssetsMember_20191231"
      decimals="-5"
      id="F_000385"
      unitRef="U_iso4217USD">800000</us-gaap:OtherInventorySupplies>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="C_0001439725_20200101_20201231" id="F_000308">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Property and Equipment&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment are stated at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally between three and five years. Leasehold improvements are amortized using the straight-line method over the shorter of the estimated useful life of the asset or the term of the lease. Maintenance and repairs are charged to expense as incurred, and improvements and betterments are capitalized. When assets are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the balance sheet and any resulting gain or loss is reflected in the statements of operations and comprehensive loss in the period realized.&lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Long-lived assets to be held and used are evaluated for impairment when events or circumstances indicate the carrying value of a long-lived asset or asset group is less &lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;than &lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;the undiscounted cash flows from the use and eventual disposition over its remaining useful life. The Company assesses recoverability by comparing the sum or projected undiscounted cash flows from the use and eventual disposition of the asset or asset group to it carrying value, and records an impairment loss if the carrying value is greater &lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;than &lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;the undiscounted future cash flows.&lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; There were &lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; impairments for the years ended December 31, 2020 or 2019.&lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_0001439725_srtRangeAxis_srtMinimumMember_20200101_20201231"
      id="F_000386">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_0001439725_srtRangeAxis_srtMaximumMember_20200101_20201231"
      id="F_000387">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="C_0001439725_20200101_20201231"
      decimals="INF"
      id="F_000388"
      unitRef="U_iso4217USD">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="C_0001439725_20190101_20191231"
      decimals="INF"
      id="F_000389"
      unitRef="U_iso4217USD">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy contextRef="C_0001439725_20200101_20201231" id="F_000309">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Intangible Assets&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intangible assets primarily consist of intangible assets acquired as part of business combinations, external costs associated with patent applications that are expected to be successful, and trademark costs. Finite-lived intangibles are stated at cost, net of accumulated amortization. The Company amortizes finite-lived intangible assets using the straight-line method over their estimated useful lives of 9 to 10 years, based on management's estimate of the period over which their economic benefits will be realized, product life and patent life. Trademarks are considered indefinite lived and are not amortized.  &lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intangible assets are reviewed for impairment whenever events or changes in circumstances indicate a reduction to fair value below their carrying amounts. There were no impairments for the years ended December 31, 2020 or 2019.&lt;/p&gt;</us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="C_0001439725_srtRangeAxis_srtMaximumMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_bdsxProductLifeAndPatentLifeMember_20200101_20201231"
      id="F_000391">P10Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="C_0001439725_20200101_20201231"
      decimals="INF"
      id="F_000392"
      unitRef="U_iso4217USD">0</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy contextRef="C_0001439725_20200101_20201231" id="F_000310">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Goodwill&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Goodwill represents the excess of purchase price over amounts allocated to acquired assets and liabilities assumed in business combinations. The carrying value of goodwill is evaluated for impairment at least annually or more frequently when events or circumstances occur indicate a potential for impairment. The annual impairment test is performed on the last day of our fourth quarter. Prior to performing a quantitative evaluation, an assessment of qualitative factors may be performed to determine whether it is more likely than not that the fair value of the reporting unit exceeds its carrying value. In the event the Company determines that it is more likely than not the carrying value of our single reporting unit is higher than its estimated fair value, quantitative testing is performed comparing recorded values to estimated fair values. If impairment is present, the impairment loss is measured as the excess of the recorded goodwill over its implied fair value. &lt;span style="color:#000000;"&gt;There were no impairments for the years ended December 31, 2020 or 2019.&lt;/span&gt;&lt;/p&gt;</us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="C_0001439725_20200101_20201231"
      decimals="INF"
      id="F_000394"
      unitRef="U_iso4217USD">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="C_0001439725_20190101_20191231"
      decimals="INF"
      id="F_000395"
      unitRef="U_iso4217USD">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="C_0001439725_20200101_20201231" id="F_000311">
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Fair Value of Financial Instruments&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. GAAP for fair value establishes a hierarchy that prioritizes fair value measurements based on the types of inputs used for the various valuation techniques (market approach, income approach, and cost approach). We utilize a combination of market and income approaches to value our financial instruments. Our financial assets and liabilities are measured using inputs from the three levels of the fair value hierarchy. Fair value measurements are categorized within the fair value hierarchy based upon the lowest level of the most significant inputs used to determine fair value. The three levels of the hierarchy and the related inputs are as follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:86.08%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Inputs&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%; border-top:solid 0.75pt #000000;" valign="top"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:86.08%; border-top:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unadjusted quoted prices in active markets for identical assets and liabilities.&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%;" valign="top"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:86.08%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unadjusted quoted prices in active markets for similar assets and liabilities;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%;" valign="top"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:86.08%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active; or&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%;" valign="top"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:86.08%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Inputs other than quoted prices that are observable for the asset or liability.&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%;" valign="top"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:86.08%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unobservable inputs for the asset or liability.&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The carrying amounts of certain financial instruments including cash and cash equivalents, accounts receivable, prepaid expenses and other current assets, accounts payable and accrued liabilities approximate fair value due to their relatively short maturities.&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;See Note 5 &lt;span style="color:#000000;"&gt;&#x2014; &lt;/span&gt;&lt;span style="font-style:italic;color:#000000;"&gt;Fair Value &lt;/span&gt;&lt;span style="color:#000000;"&gt;for further discussion related to estimated fair value measurements.&lt;/span&gt;&lt;/p&gt;
</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <bdsx:ContingentConsiderationPolicyTextBlock contextRef="C_0001439725_20200101_20201231" id="F_000312">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Contingent Consideration&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In connection with the purchase transaction with Integrated Diagnostics, Inc. (Indi), the Company recorded contingent consideration for amounts potentially payable to Indi&#x2019;s shareholder pursuant to the terms of the asset purchase agreement. The fair value of contingent consideration is assessed at each balance sheet date and changes, if any, to the fair value are recognized as operating expenses within the statements of operations. The estimated fair value of the contingent consideration is based upon significant assumptions including the probability of successful achievement of product gross margin targets included in the acquisition agreement, the estimated timing of achievement of the product gross margin targets, and discount rates. The estimated fair value could materially differ from actual values or fair values determined using different assumptions.&lt;/p&gt;</bdsx:ContingentConsiderationPolicyTextBlock>
    <bdsx:WarrantLiabilityPolicyTextBlock contextRef="C_0001439725_20200101_20201231" id="F_000313">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Warrant Liability&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prior to the completion of the Company&#x2019;s initial public offering in October 2020, certain warrants issued to purchase convertible preferred stock were classified as liabilities with changes in the estimated fair value of these liabilities recognized in our results of operations. Upon completion of the Company&#x2019;s initial public offering in October 2020, the warrants were automatically converted to warrants to purchase common stock. Accordingly, the warrants were remeasured to an estimate of fair value and recognized in our results of operations and then reclassified to additional paid-in capital.&lt;/p&gt;</bdsx:WarrantLiabilityPolicyTextBlock>
    <bdsx:PutOptionLiabilityPolicyTextBlock contextRef="C_0001439725_20200101_20201231" id="F_000314">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Put Option Liability&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;During 2020 and 2019, the Company issued convertible debt&lt;span style="color:#000000;"&gt;&#160;&lt;/span&gt;with terms that provided for a conversion rate to the convertible debtholders that was more favorable than the price that other investors would pay for common stock in certain situations, including the completion of an initial public offering. As a result, the convertible debt is a financial instrument that was bifurcated into two instruments, a debt obligation and a put option liability, which represented the estimated fair value of the favorable conversion rate.&#160;&#160;The estimated fair value of the put option liability was separated from the convertible debt at inception and reported as a liability and debt discount, and amortized to interest expense. As a result of our initial public offering, the convertible debt was automatically converted to common stock and the put option liability was remeasured to an estimate of fair value and recognized in our results of operations and then reclassified to additional paid-in capital.&lt;/p&gt;</bdsx:PutOptionLiabilityPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="C_0001439725_20200101_20201231" id="F_000315">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Share&#x2011;Based Compensation&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Stock Options&lt;span style="font-style:normal;"&gt; &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company grants service condition and performance condition stock options. Stock options are granted with exercise prices equal to the fair market value of our common stock on the date of grant. The grant date fair value of each employee stock option is estimated on the date of grant using the Black-Scholes option-pricing model, which requires the use of assumptions, including the expected term of the option, expected volatility of our stock price, expected dividend yield, and the risk-free interest rate, among others. These assumptions involve inherent uncertainties including market conditions and employee behavior that are generally outside of the Company&#x2019;s control. Service condition stock options are expensed based on the grant date fair value of the awards using the straight-line method over the requisite service period, adjusted for forfeitures as they occur. Performance-condition stock options vest based on achievement of multiple weighted performance goals, certification of performance achievement by the Compensation Committee of the Board of Directors, and continued service. For performance-condition stock options, compensation expense is updated for our expected performance level against performance goals at the end of each reporting period, which involves judgment as to achievement of certain performance metrics.&lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prior to our initial public offering in October 2020, the fair value of our common stock was determined by the Board of Directors in accordance with the methodologies outlined in the American Institute of Certified Public Accountants Practice Aid, Valuation of Privately-Held-Company Equity Securities Issued as Compensation Practice Aid (Practice Aid). In doing so, the Board of Directors determined the best estimate of fair value of our common stock, exercising reasonable judgment and considering numerous objective and subjective factors&lt;span style="color:#000000;"&gt;, by first determining the enterprise value of our business, and then allocating the value among the various classes of our equity securities to derive a per share value of our common stock. &lt;/span&gt;Subsequent&#160;to the Company&#x2019;s initial public offering, the fair value of the Company&#x2019;s common stock is determined based on its traded market price.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Restricted Stock Units (RSUs)&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company grants service-condition RSUs. As a result of our initial public offering, the grant date fair values of these RSUs are based on the closing market price of our common stock on the grant date. The service-condition RSUs vest based on continued service with compensation expense, net of forfeitures, recognized on a straight-line basis over the requisite service period. &lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;See Note 14 &#x2014; &lt;span style="font-style:italic;"&gt;Share-Based Compensation&lt;/span&gt; for additional information related to share-based compensation.&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="C_0001439725_20200101_20201231" id="F_000316">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Net Loss per Common Share &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Basic net loss per common share is calculated by dividing net loss by the weighted-average number of common shares outstanding during the period, without consideration of common stock equivalents. Diluted net loss per common share is computed by dividing net loss by the weighted-average number of common share equivalents outstanding for the period, if dilutive, using the treasury stock method. Potentially dilutive securities consisting of options to purchase common stock, warrants to purchase common stock, restricted stock units and shares subject to purchase under our employee stock purchase plan were excluded from the calculation of diluted net loss per common share because their effect would be anti-dilutive for all periods presented. &lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Until the Company&#x2019;s initial public offering in October 2020, basic and diluted net loss attributable to common stockholders per share was calculated using the two-class method. The net loss was attributable entirely to common stockholders because the participating securities did not have a contractual obligation to share in the Company&#x2019;s losses.&#160;&#160;As the Company has reported a net loss for all periods presented, diluted net loss per common share is the same as basic net loss per common share for all periods presented.&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock contextRef="C_0001439725_20200101_20201231" id="F_000276">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Note 3 &#x2013; Recent Accounting Pronouncements&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Recently Issued Accounting Standards Not Yet Adopted&lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In February 2016, the FASB issued Accounting Standards Update (ASU) No. 2016-2, &lt;span style="font-style:italic;"&gt;Leases (Topic 842), &lt;/span&gt;which requires lessees to recognize a right-of-use asset and corresponding lease liability, including leases currently accounted for as operating leases. The ASU is effective for the Company for interim and annual periods beginning January 1, 2022. The Company expects to recognize right-of-use assets and lease obligations in its balance sheet upon adoption using the modified retrospective method as permitted by ASU No. 2018-11, &lt;span style="font-style:italic;"&gt;Leases (Topic 842): Targeted Improvements.&lt;/span&gt; The Company does not currently expect adoption of this standard will have a significant effect on its statements of operations or cash flows.&lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In June 2016, the FASB issued ASU No. 2016-13, &lt;span style="font-style:italic;"&gt;Financial Instruments-Credit Losses: Measurement of Credit Losses&lt;/span&gt; on Financial Instruments. This ASU requires measurement and recognition of expected credit losses for financial assets. This guidance will become effective for the Company beginning January 1, 2022 with early adoption permitted. The Company has not yet begun evaluating the potential effect of this standard on its financial statements. &lt;/p&gt;</us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="C_0001439725_20200101_20201231" id="F_000317">
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Recently Issued Accounting Standards Not Yet Adopted&lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In February 2016, the FASB issued Accounting Standards Update (ASU) No. 2016-2, &lt;span style="font-style:italic;"&gt;Leases (Topic 842), &lt;/span&gt;which requires lessees to recognize a right-of-use asset and corresponding lease liability, including leases currently accounted for as operating leases. The ASU is effective for the Company for interim and annual periods beginning January 1, 2022. The Company expects to recognize right-of-use assets and lease obligations in its balance sheet upon adoption using the modified retrospective method as permitted by ASU No. 2018-11, &lt;span style="font-style:italic;"&gt;Leases (Topic 842): Targeted Improvements.&lt;/span&gt; The Company does not currently expect adoption of this standard will have a significant effect on its statements of operations or cash flows.&lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In June 2016, the FASB issued ASU No. 2016-13, &lt;span style="font-style:italic;"&gt;Financial Instruments-Credit Losses: Measurement of Credit Losses&lt;/span&gt; on Financial Instruments. This ASU requires measurement and recognition of expected credit losses for financial assets. This guidance will become effective for the Company beginning January 1, 2022 with early adoption permitted. The Company has not yet begun evaluating the potential effect of this standard on its financial statements. &lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:BusinessCombinationDisclosureTextBlock contextRef="C_0001439725_20200101_20201231" id="F_000277">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Note 4 &#x2013; Business Combinations &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Oncimmune Limited&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On October 31, 2019, the Company purchased select assets and liabilities from Oncimmune Limited (Oncimmune) for total consideration of $1.2 million payable in quarterly installments commencing 30 days following the closing of the transaction. Concurrent with the Oncimmune purchase, the Company acquired an exclusive option to license rights within the United States to an additional indication for their product for $9.0 million.&#160;&#160;In September 2020, we notified Oncimmune that we would not exercise this option for the expansion of the field of use. As of December 31, 2020, the Company had paid the full $1.2 million consideration. &lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The acquisition was accounted for as business combination and resulted in the recognition of goodwill of $0.8 million representing expected synergies, including expected increases in future revenues as a result of expansion of the acquired technology into additional markets, and lower expected operating expenses. The Company finalized its purchase price allocation of the transaction as of December 31, 2019.&lt;/p&gt;

&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes the aggregate consideration paid by the Company and the allocation of the purchase price to assets acquired and liabilities assumed (in thousands): &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,206&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total fair value of consideration transferred&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,206&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deposit&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Inventory&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;241&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Purchase option&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;121&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Goodwill&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;827&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(3&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,206&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Integrated Diagnostics, Inc.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On June 30, 2018, the Company purchased select assets and liabilities from Integrated Diagnostics, Inc. (Indi) &lt;span style="Background-color:#FFFFFF;"&gt;for total consideration of $27.6 million, consisting of $8.0 million in the Company&#x2019;s Series G Preferred Stock and contingent consideration with an initial estimated fair value of $19.6 million.&#160;&#160;The acquisition was &lt;/span&gt;accounted for as a business combination and resulted in goodwill of $14.2 million representing expected synergies, including increases in future revenues as a result of expansion of the acquired technology into additional markets, and lower operating expenses.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The contingent consideration arrangement requires additional consideration to be paid by the Company to Indi upon attainment of a three-consecutive month gross margin target of $2.0 million within the &lt;span style="-sec-ix-hidden:F_000416"&gt;seven-year&lt;/span&gt; period after the acquisition date.&#160;If the gross margin target is met, the Company is required to issue 2,520,108 shares of common stock. For the six months following the achievement of the gross margin target, Indi has the option to require the Company to redeem these common shares for $37.0 million in cash over eight equal quarterly installments.&#160;&#160;If Indi elects to not exercise its option, the Company has 12 months to repurchase the common stock in two equal and consecutive quarterly cash installments totaling $37.0 million. &lt;/p&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="C_0001439725_us-gaapBusinessAcquisitionAxis_bdsxOncimmuneLimitedMember_20191031_20191031"
      decimals="-5"
      id="F_000396"
      unitRef="U_iso4217USD">1200000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:BusinessAcquisitionDescriptionOfAcquiredEntity
      contextRef="C_0001439725_us-gaapBusinessAcquisitionAxis_bdsxOncimmuneLimitedMember_20200101_20201231"
      id="F_000397">quarterly installments commencing 30 days following the closing of the transaction.</us-gaap:BusinessAcquisitionDescriptionOfAcquiredEntity>
    <us-gaap:OtherPaymentsToAcquireBusinesses
      contextRef="C_0001439725_srtProductOrServiceAxis_us-gaapLicenseMember_srtStatementGeographicalAxis_countryUS_us-gaapBusinessAcquisitionAxis_bdsxOncimmuneLimitedMember_20191031_20191031"
      decimals="-5"
      id="F_000398"
      unitRef="U_iso4217USD">9000000.0</us-gaap:OtherPaymentsToAcquireBusinesses>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="C_0001439725_us-gaapBusinessAcquisitionAxis_bdsxOncimmuneLimitedMember_20200101_20201231"
      decimals="-5"
      id="F_000399"
      unitRef="U_iso4217USD">1200000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:Goodwill
      contextRef="C_0001439725_us-gaapBusinessAcquisitionAxis_bdsxOncimmuneLimitedMember_20191031"
      decimals="-5"
      id="F_000400"
      unitRef="U_iso4217USD">800000</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationSegmentAllocationTableTextBlock contextRef="C_0001439725_20200101_20201231" id="F_000319">
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes the aggregate consideration paid by the Company and the allocation of the purchase price to assets acquired and liabilities assumed (in thousands): &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,206&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total fair value of consideration transferred&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,206&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deposit&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Inventory&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;241&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Purchase option&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;121&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Goodwill&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;827&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(3&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,206&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:BusinessCombinationSegmentAllocationTableTextBlock>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="C_0001439725_us-gaapBusinessAcquisitionAxis_bdsxOncimmuneLimitedMember_20191031_20191031"
      decimals="-3"
      id="F_000401"
      unitRef="U_iso4217USD">1206000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="C_0001439725_us-gaapBusinessAcquisitionAxis_bdsxOncimmuneLimitedMember_20191031_20191031"
      decimals="-3"
      id="F_000402"
      unitRef="U_iso4217USD">1206000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities
      contextRef="C_0001439725_us-gaapBusinessAcquisitionAxis_bdsxOncimmuneLimitedMember_20191031"
      decimals="-3"
      id="F_000403"
      unitRef="U_iso4217USD">6000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory
      contextRef="C_0001439725_us-gaapBusinessAcquisitionAxis_bdsxOncimmuneLimitedMember_20191031"
      decimals="-3"
      id="F_000404"
      unitRef="U_iso4217USD">14000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment
      contextRef="C_0001439725_us-gaapBusinessAcquisitionAxis_bdsxOncimmuneLimitedMember_20191031"
      decimals="-3"
      id="F_000405"
      unitRef="U_iso4217USD">241000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment>
    <bdsx:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPurchaseOption
      contextRef="C_0001439725_us-gaapBusinessAcquisitionAxis_bdsxOncimmuneLimitedMember_20191031"
      decimals="-3"
      id="F_000406"
      unitRef="U_iso4217USD">121000</bdsx:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPurchaseOption>
    <us-gaap:Goodwill
      contextRef="C_0001439725_us-gaapBusinessAcquisitionAxis_bdsxOncimmuneLimitedMember_20191031"
      decimals="-3"
      id="F_000407"
      unitRef="U_iso4217USD">827000</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable
      contextRef="C_0001439725_us-gaapBusinessAcquisitionAxis_bdsxOncimmuneLimitedMember_20191031"
      decimals="-3"
      id="F_000408"
      unitRef="U_iso4217USD">3000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
      contextRef="C_0001439725_us-gaapBusinessAcquisitionAxis_bdsxOncimmuneLimitedMember_20191031"
      decimals="-3"
      id="F_000409"
      unitRef="U_iso4217USD">1206000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="C_0001439725_us-gaapBusinessAcquisitionAxis_bdsxIntegratedDiagnosticsIncMember_20180630_20180630"
      decimals="-5"
      id="F_000410"
      unitRef="U_iso4217USD">27600000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="C_0001439725_us-gaapBusinessAcquisitionAxis_bdsxIntegratedDiagnosticsIncMember_20180630_20180630"
      decimals="-5"
      id="F_000411"
      unitRef="U_iso4217USD">8000000.0</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure
      contextRef="C_0001439725_us-gaapBusinessAcquisitionAxis_bdsxIntegratedDiagnosticsIncMember_20180630"
      decimals="-5"
      id="F_000412"
      unitRef="U_iso4217USD">19600000</us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure>
    <us-gaap:Goodwill
      contextRef="C_0001439725_us-gaapBusinessAcquisitionAxis_bdsxIntegratedDiagnosticsIncMember_20180630"
      decimals="-5"
      id="F_000413"
      unitRef="U_iso4217USD">14200000</us-gaap:Goodwill>
    <us-gaap:BusinessAcquisitionDescriptionOfAcquiredEntity
      contextRef="C_0001439725_us-gaapBusinessAcquisitionAxis_bdsxIntegratedDiagnosticsIncMember_20200101_20201231"
      id="F_000414">requires additional consideration to be paid by the Company to Indi upon attainment of a three-consecutive month</us-gaap:BusinessAcquisitionDescriptionOfAcquiredEntity>
    <us-gaap:CashAcquiredFromAcquisition
      contextRef="C_0001439725_us-gaapBusinessAcquisitionAxis_bdsxIntegratedDiagnosticsIncMember_20180630_20180630"
      decimals="-5"
      id="F_000415"
      unitRef="U_iso4217USD">2000000.0</us-gaap:CashAcquiredFromAcquisition>
    <bdsx:BusinessCombinationContingentConsiderationShares
      contextRef="C_0001439725_us-gaapBusinessAcquisitionAxis_bdsxIntegratedDiagnosticsIncMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20180630_20180630"
      decimals="INF"
      id="F_000417"
      unitRef="U_xbrlishares">2520108</bdsx:BusinessCombinationContingentConsiderationShares>
    <bdsx:BusinessCombinationContingentConsiderationArrangementsCommonSharesRedemptionAmount
      contextRef="C_0001439725_us-gaapBusinessAcquisitionAxis_bdsxIntegratedDiagnosticsIncMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20180630_20180630"
      decimals="-5"
      id="F_000419"
      unitRef="U_iso4217USD">37000000.0</bdsx:BusinessCombinationContingentConsiderationArrangementsCommonSharesRedemptionAmount>
    <bdsx:BusinessAcquisitionContingentConsiderationNumberOfInstallments
      contextRef="C_0001439725_us-gaapBusinessAcquisitionAxis_bdsxIntegratedDiagnosticsIncMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20180630"
      decimals="INF"
      id="F_000418"
      unitRef="U_bdsxInstallment">8</bdsx:BusinessAcquisitionContingentConsiderationNumberOfInstallments>
    <us-gaap:BusinessAcquisitionDescriptionOfAcquiredEntity
      contextRef="C_0001439725_us-gaapBusinessAcquisitionAxis_bdsxIntegratedDiagnosticsIncMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231"
      id="F_000420">If Indi elects to not exercise its option, the Company has 12 months to repurchase the common stock in two equal and consecutive quarterly cash installments totaling $37.0 million.</us-gaap:BusinessAcquisitionDescriptionOfAcquiredEntity>
    <bdsx:BusinessAcquisitionContingentConsiderationNumberOfInstallments
      contextRef="C_0001439725_us-gaapBusinessAcquisitionAxis_bdsxIntegratedDiagnosticsIncMember_us-gaapInvestmentTypeAxis_bdsxRepurchaseMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20180630"
      decimals="INF"
      id="F_000421"
      unitRef="U_bdsxInstallment">2</bdsx:BusinessAcquisitionContingentConsiderationNumberOfInstallments>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="C_0001439725_us-gaapBusinessAcquisitionAxis_bdsxIntegratedDiagnosticsIncMember_us-gaapInvestmentTypeAxis_bdsxRepurchaseMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20180630_20180630"
      decimals="-5"
      id="F_000422"
      unitRef="U_iso4217USD">37000000.0</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="C_0001439725_20200101_20201231" id="F_000278">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Note 5 - Fair Value&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Recurring Fair Value Measurements&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Our borrowing instruments are recorded at their carrying values in the balance sheets, which may differ from their respective fair values. The fair values of outstanding borrowings, which are classified as Level 2, approximate their carrying values at December&#160;31, 2020 and 2019, based on interest rates currently available for similar borrowings and were:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.85%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.56%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Carrying&#160;Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair&#160;Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Carrying&#160;Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair&#160;Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.56%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Borrowings&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;27,766&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;27,766&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;35,971&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;35,971&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.85%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The financial liabilities that are measured and recorded at estimated fair value on a recurring basis consist of our contingent consideration associated with our acquisition of Indi, and prior to the completion of our initial public offering in October 2020, the warrant liability and put option liability granted to certain holders of our convertible preferred stock and debt instruments, which were accounted for as liabilities and remeasured through our statements of operations. The table below presents the reported fair values of these liabilities, all of which are classified as Level 3 in the fair value hierarchy, as of the dates indicated (in thousands):&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%; border-bottom:solid 0.75pt #000000;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt; Description&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%; border-top:solid 0.75pt #000000;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contingent consideration&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;29,932&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;29,114&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Put option liability&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,261&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Warrant liability&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;372&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contingent value rights&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;60&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.85%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table presents the changes in these financial liabilities for the year ended December 31, 2020 (in thousands):&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 3 Rollforward&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contingent&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Consideration&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Put&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Option&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Liability&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Warrant&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Liability&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contingent&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value&#160;Rights&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Beginning balances&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;29,114&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,261&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;372&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;60&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Additions&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,389&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Changes in fair value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;818&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,252&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(60&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Reclassified to additional paid-in capital&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(6,650&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,624&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Ending balances&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;29,932&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Contingent Consideration&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In connection with the acquisition of Indi, the Company recorded contingent consideration for amounts contingently payable to Indi's selling shareholders pursuant to the Asset Purchase Agreement (See Note 4 &#x2013; &lt;span style="font-style:italic;"&gt;Business Combinations&lt;/span&gt;). The significant unobservable inputs used in the measurement of fair value include the probability of successful achievement of the specified product gross margin targets, the period in which the targets are expected to be achieved, and discount rates which ranged from 12.2% to 13.5%. Significant increases or decreases in any of these inputs would result in a significantly higher or lower fair value measurement. &lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contingent consideration is recorded in the balance sheets as long-term liabilities. The net change to contingent consideration during the years ended December 31, 2020 and 2019 was an increase of $0.8 million and $4.1 million, respectively, and are recorded as operating expenses in the statements of operations.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Put Option Liability&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The put option liability was valued based on the calculated returns as a result of the various discounts included in the Company&#x2019;s convertible notes payable and the related probability assessments of the various settlement scenarios. During 2020, the Company recognized an addition to the put option liability of $3.4 million in connection with a favorable conversion rate granted to holders of issued convertible debt. The put option liability was settled upon the closing of the Company&#x2019;s initial public offering in October 2020 and reclassified to additional paid-in capital. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Warrant Liability &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;In connection with entering into the 2018 Notes, the Company issued to the lender a warrant to purchase 613,333 shares of Series G convertible preferred stock, at an exercise price of $0.75 per share, subject to adjustment upon specified dilutive issuances. The warrant was immediately exercisable upon issuance and expires on February 23, 2028. The estimated fair value of the warrant on the issuance date of $0.3&#160;million was recorded as a debt discount and as a preferred stock warrant liability. Through the effective date of the Company&#x2019;s initial public offering, the Series G warrants were remeasured to an estimate of fair value using a Black Scholes pricing model. As a result of the Company&#x2019;s initial public offering, the preferred stock warrants were automatically converted to warrants to purchase 103,326 shares of common stock with a weighted average exercise price of $4.46 and were also transferred to additional paid-in capital.&#160;&#160;During 2020, the Company recorded an increase in the value of the warrant liability of $1.3 million.&lt;/span&gt; &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Contingent Value Rights&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In addition to the shares of Series F Preferred Stock that were issued in January 2016, investors who purchased more than their pro&#x2011;rata amount in the financing described above received a calculated number of contingent value rights (CVRs). In connection with the Series F financing, the Company issued 3,999 CVRs originally valued at $0.5 million. One CVR represents 0.00375% of the Company&#x2019;s interest in the drug ficlatuzumab. The initial estimated value of the CVRs were recorded as a liability and as a reduction to the Series F proceeds. Upon receipt by the Company or a milestone, royalty, or any other type of payment from the Company&#x2019;s ownership rights in the drug, the Company was required to make a cash payment to the CVR holders equal to 15% of net proceeds, as defined. In September 2020, the Company exercised its opt-out right with AVEO Oncology (AVEO) for the payment of 50% of development and regulatory costs for ficlatuzumab. As a result, the CVRs were settled effective December 2, 2020. See Note 17 &#x2013; &lt;span style="font-style:italic;"&gt;Commitments and Contingencies&lt;/span&gt; for a discussion of the Co-Development Agreement with AVEO. &lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Non-Financial Assets and Liabilities&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Our non-financial assets, which primarily consist of property and equipment, goodwill, and other intangible assets, are not required to be carried at fair value on a recurring basis and are reported at carrying value. There were no changes to the valuation methods during the periods presented.&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock contextRef="C_0001439725_20200101_20201231" id="F_000320">The fair values of outstanding borrowings, which are classified as Level 2, approximate their carrying values at December&#160;31, 2020 and 2019, based on interest rates currently available for similar borrowings and were:
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.85%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.56%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Carrying&#160;Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair&#160;Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Carrying&#160;Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair&#160;Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.56%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Borrowings&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;27,766&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;27,766&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;35,971&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;35,971&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.85%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock>
    <us-gaap:LongTermDebtFairValue
      contextRef="C_0001439725_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementBasisAxis_us-gaapCarryingReportedAmountFairValueDisclosureMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231"
      decimals="-3"
      id="F_000423"
      unitRef="U_iso4217USD">27766000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="C_0001439725_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementBasisAxis_us-gaapEstimateOfFairValueFairValueDisclosureMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231"
      decimals="-3"
      id="F_000424"
      unitRef="U_iso4217USD">27766000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="C_0001439725_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementBasisAxis_us-gaapCarryingReportedAmountFairValueDisclosureMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231"
      decimals="-3"
      id="F_000425"
      unitRef="U_iso4217USD">35971000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="C_0001439725_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementBasisAxis_us-gaapEstimateOfFairValueFairValueDisclosureMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231"
      decimals="-3"
      id="F_000426"
      unitRef="U_iso4217USD">35971000</us-gaap:LongTermDebtFairValue>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock contextRef="C_0001439725_20200101_20201231" id="F_000321">The table below presents the reported fair values of these liabilities, all of which are classified as Level 3 in the fair value hierarchy, as of the dates indicated (in thousands):
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%; border-bottom:solid 0.75pt #000000;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt; Description&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%; border-top:solid 0.75pt #000000;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contingent consideration&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;29,932&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;29,114&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Put option liability&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,261&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Warrant liability&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;372&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contingent value rights&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;60&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.85%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="C_0001439725_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByLiabilityClassAxis_bdsxContingentConsiderationMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231"
      decimals="-3"
      id="F_000427"
      unitRef="U_iso4217USD">29932000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="C_0001439725_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByLiabilityClassAxis_bdsxContingentConsiderationMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231"
      decimals="-3"
      id="F_000428"
      unitRef="U_iso4217USD">29114000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="C_0001439725_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByLiabilityClassAxis_bdsxPutOptionLiabilityMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231"
      decimals="-3"
      id="F_000429"
      unitRef="U_iso4217USD">3261000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="C_0001439725_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByLiabilityClassAxis_bdsxWarrantLiabilityMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231"
      decimals="-3"
      id="F_000430"
      unitRef="U_iso4217USD">372000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="C_0001439725_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByLiabilityClassAxis_bdsxContingentValueRightsMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231"
      decimals="-3"
      id="F_000431"
      unitRef="U_iso4217USD">60000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="C_0001439725_20200101_20201231" id="F_000322">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table presents the changes in these financial liabilities for the year ended December 31, 2020 (in thousands):&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 3 Rollforward&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contingent&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Consideration&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Put&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Option&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Liability&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Warrant&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Liability&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contingent&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value&#160;Rights&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Beginning balances&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;29,114&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,261&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;372&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;60&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Additions&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,389&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Changes in fair value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;818&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,252&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(60&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Reclassified to additional paid-in capital&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(6,650&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,624&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Ending balances&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;29,932&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="C_0001439725_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByLiabilityClassAxis_bdsxContingentConsiderationMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231"
      decimals="-3"
      id="F_000432"
      unitRef="U_iso4217USD">29114000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="C_0001439725_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByLiabilityClassAxis_bdsxPutOptionLiabilityMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231"
      decimals="-3"
      id="F_000433"
      unitRef="U_iso4217USD">3261000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="C_0001439725_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByLiabilityClassAxis_bdsxWarrantLiabilityMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231"
      decimals="-3"
      id="F_000434"
      unitRef="U_iso4217USD">372000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="C_0001439725_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByLiabilityClassAxis_bdsxContingentValueRightsMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231"
      decimals="-3"
      id="F_000435"
      unitRef="U_iso4217USD">60000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases
      contextRef="C_0001439725_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByLiabilityClassAxis_bdsxPutOptionLiabilityMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20200101_20201231"
      decimals="-3"
      id="F_000436"
      unitRef="U_iso4217USD">3389000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="C_0001439725_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByLiabilityClassAxis_bdsxContingentConsiderationMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20200101_20201231"
      decimals="-3"
      id="F_000437"
      unitRef="U_iso4217USD">818000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="C_0001439725_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByLiabilityClassAxis_bdsxWarrantLiabilityMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20200101_20201231"
      decimals="-3"
      id="F_000438"
      unitRef="U_iso4217USD">1252000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="C_0001439725_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByLiabilityClassAxis_bdsxContingentValueRightsMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20200101_20201231"
      decimals="-3"
      id="F_000439"
      unitRef="U_iso4217USD">-60000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <bdsx:FairValueMeasurementWithUnobservableInputsReconciliationReclassifiedToAdditionalPaidInCapital
      contextRef="C_0001439725_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByLiabilityClassAxis_bdsxPutOptionLiabilityMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20200101_20201231"
      decimals="-3"
      id="F_000440"
      unitRef="U_iso4217USD">-6650000</bdsx:FairValueMeasurementWithUnobservableInputsReconciliationReclassifiedToAdditionalPaidInCapital>
    <bdsx:FairValueMeasurementWithUnobservableInputsReconciliationReclassifiedToAdditionalPaidInCapital
      contextRef="C_0001439725_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByLiabilityClassAxis_bdsxWarrantLiabilityMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20200101_20201231"
      decimals="-3"
      id="F_000441"
      unitRef="U_iso4217USD">-1624000</bdsx:FairValueMeasurementWithUnobservableInputsReconciliationReclassifiedToAdditionalPaidInCapital>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="C_0001439725_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByLiabilityClassAxis_bdsxContingentConsiderationMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231"
      decimals="-3"
      id="F_000442"
      unitRef="U_iso4217USD">29932000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <bdsx:PercentageOfProbabilitiesOfContingentConsiderationSuccessfulAchievementMilestoneDiscountRatesRange
      contextRef="C_0001439725_srtRangeAxis_srtMinimumMember_20200101_20201231"
      decimals="INF"
      id="F_000443"
      unitRef="U_xbrlipure">0.122</bdsx:PercentageOfProbabilitiesOfContingentConsiderationSuccessfulAchievementMilestoneDiscountRatesRange>
    <bdsx:PercentageOfProbabilitiesOfContingentConsiderationSuccessfulAchievementMilestoneDiscountRatesRange
      contextRef="C_0001439725_srtRangeAxis_srtMaximumMember_20200101_20201231"
      decimals="INF"
      id="F_000444"
      unitRef="U_xbrlipure">0.135</bdsx:PercentageOfProbabilitiesOfContingentConsiderationSuccessfulAchievementMilestoneDiscountRatesRange>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="C_0001439725_20200101_20201231"
      decimals="-5"
      id="F_000445"
      unitRef="U_iso4217USD">800000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="C_0001439725_20190101_20191231"
      decimals="-5"
      id="F_000446"
      unitRef="U_iso4217USD">4100000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <bdsx:PutOptionLiabilityCurrent
      contextRef="C_0001439725_20201231"
      decimals="-5"
      id="F_000447"
      unitRef="U_iso4217USD">3400000</bdsx:PutOptionLiabilityCurrent>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="C_0001439725_us-gaapLongtermDebtTypeAxis_bdsxNotesPayable2018NotesMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesGPreferredStockMember_20201231"
      decimals="INF"
      id="F_000448"
      unitRef="U_xbrlishares">613333</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_0001439725_us-gaapLongtermDebtTypeAxis_bdsxNotesPayable2018NotesMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesGPreferredStockMember_20201231"
      decimals="INF"
      id="F_000449"
      unitRef="U_iso4217USD_xbrlishares">0.75</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate contextRef="C_0001439725_20201231" id="F_000450">2028-02-23</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:WarrantsNotSettleableInCashFairValueDisclosure
      contextRef="C_0001439725_20201231"
      decimals="-5"
      id="F_000451"
      unitRef="U_iso4217USD">300000</us-gaap:WarrantsNotSettleableInCashFairValueDisclosure>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_0001439725_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20201231"
      decimals="INF"
      id="F_000452"
      unitRef="U_xbrlishares">103326</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_0001439725_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20201231"
      decimals="2"
      id="F_000453"
      unitRef="U_iso4217USD_xbrlishares">4.46</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="C_0001439725_20200101_20201231"
      decimals="-5"
      id="F_000454"
      unitRef="U_iso4217USD">1300000</us-gaap:FairValueAdjustmentOfWarrants>
    <bdsx:ContingentValueRightsShares
      contextRef="C_0001439725_us-gaapStatementClassOfStockAxis_us-gaapSeriesFPreferredStockMember_20160131"
      decimals="INF"
      id="F_000455"
      unitRef="U_xbrlishares">3999</bdsx:ContingentValueRightsShares>
    <bdsx:ContingentValueRights
      contextRef="C_0001439725_us-gaapStatementClassOfStockAxis_us-gaapSeriesFPreferredStockMember_20160131"
      decimals="-5"
      id="F_000456"
      unitRef="U_iso4217USD">500000</bdsx:ContingentValueRights>
    <bdsx:ContingentValueRightsPercentage
      contextRef="C_0001439725_us-gaapStatementClassOfStockAxis_us-gaapSeriesFPreferredStockMember_20160101_20160131"
      decimals="INF"
      id="F_000457"
      unitRef="U_xbrlipure">0.0000375</bdsx:ContingentValueRightsPercentage>
    <bdsx:NetProceedsPercentageOfCashPaymentToCVRHolders
      contextRef="C_0001439725_us-gaapStatementClassOfStockAxis_us-gaapSeriesFPreferredStockMember_20160101_20160131"
      decimals="2"
      id="F_000458"
      unitRef="U_xbrlipure">0.15</bdsx:NetProceedsPercentageOfCashPaymentToCVRHolders>
    <bdsx:PercentageOfDevelopmentAndRegulatoryCostsExercisedUsingOptOutRight
      contextRef="C_0001439725_srtCounterpartyNameAxis_bdsxAVEOOncologyMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesFPreferredStockMember_20200901_20200930"
      decimals="2"
      id="F_000459"
      unitRef="U_xbrlipure">0.50</bdsx:PercentageOfDevelopmentAndRegulatoryCostsExercisedUsingOptOutRight>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="C_0001439725_20200101_20201231" id="F_000279">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Note 6 &#x2013; Property and Equipment &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment consist of the following (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Lab equipment&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,730&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,221&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,845&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,894&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Computer equipment&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;871&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;869&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Furniture and fixtures&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;424&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;427&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Software&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;651&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;503&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Construction in process&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;381&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;592&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,902&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,506&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less accumulated depreciation&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(6,724&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(6,386&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total property and equipment, net&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,178&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,120&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Depreciation expense related to property and equipment, reported in &#x2018;Direct costs and expenses&#x2019; and &#x2018;Sales, marketing, general and administrative&#x2019; was: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.85%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Direct costs and expenses&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;361&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;183&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Sales, marketing, general and administrative&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;478&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;636&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;839&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;819&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Disposals of Property and Equipment&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gains on disposal of property and equipment were not significant for the years ended December&#160;31, 2020 and 2019, and are included in &#x2018;Sales, marketing, general and administrative&#x2019; in the statements of operations.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="C_0001439725_20200101_20201231" id="F_000323">
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment consist of the following (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Lab equipment&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,730&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,221&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,845&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,894&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Computer equipment&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;871&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;869&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Furniture and fixtures&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;424&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;427&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Software&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;651&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;503&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Construction in process&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;381&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;592&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,902&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,506&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less accumulated depreciation&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(6,724&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(6,386&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total property and equipment, net&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,178&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,120&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001439725_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapEquipmentMember_20201231"
      decimals="-3"
      id="F_000460"
      unitRef="U_iso4217USD">5730000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001439725_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapEquipmentMember_20191231"
      decimals="-3"
      id="F_000461"
      unitRef="U_iso4217USD">4221000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001439725_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20201231"
      decimals="-3"
      id="F_000462"
      unitRef="U_iso4217USD">1845000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001439725_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20191231"
      decimals="-3"
      id="F_000463"
      unitRef="U_iso4217USD">1894000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001439725_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapComputerEquipmentMember_20201231"
      decimals="-3"
      id="F_000464"
      unitRef="U_iso4217USD">871000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001439725_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapComputerEquipmentMember_20191231"
      decimals="-3"
      id="F_000465"
      unitRef="U_iso4217USD">869000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001439725_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20201231"
      decimals="-3"
      id="F_000466"
      unitRef="U_iso4217USD">424000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001439725_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20191231"
      decimals="-3"
      id="F_000467"
      unitRef="U_iso4217USD">427000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001439725_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapSoftwareAndSoftwareDevelopmentCostsMember_20201231"
      decimals="-3"
      id="F_000468"
      unitRef="U_iso4217USD">651000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001439725_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapSoftwareAndSoftwareDevelopmentCostsMember_20191231"
      decimals="-3"
      id="F_000469"
      unitRef="U_iso4217USD">503000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001439725_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapConstructionInProgressMember_20201231"
      decimals="-3"
      id="F_000470"
      unitRef="U_iso4217USD">381000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001439725_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapConstructionInProgressMember_20191231"
      decimals="-3"
      id="F_000471"
      unitRef="U_iso4217USD">592000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001439725_20201231"
      decimals="-3"
      id="F_000472"
      unitRef="U_iso4217USD">9902000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001439725_20191231"
      decimals="-3"
      id="F_000473"
      unitRef="U_iso4217USD">8506000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_0001439725_20201231"
      decimals="-3"
      id="F_000474"
      unitRef="U_iso4217USD">6724000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_0001439725_20191231"
      decimals="-3"
      id="F_000475"
      unitRef="U_iso4217USD">6386000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_0001439725_20201231"
      decimals="-3"
      id="F_000476"
      unitRef="U_iso4217USD">3178000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_0001439725_20191231"
      decimals="-3"
      id="F_000477"
      unitRef="U_iso4217USD">2120000</us-gaap:PropertyPlantAndEquipmentNet>
    <bdsx:ScheduleOfDepreciationAndAmortizationExpenseRelatedToPropertyAndEquipmentTableTextBlock contextRef="C_0001439725_20200101_20201231" id="F_000324">
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Depreciation expense related to property and equipment, reported in &#x2018;Direct costs and expenses&#x2019; and &#x2018;Sales, marketing, general and administrative&#x2019; was: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.85%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Direct costs and expenses&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;361&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;183&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Sales, marketing, general and administrative&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;478&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;636&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;839&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;819&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</bdsx:ScheduleOfDepreciationAndAmortizationExpenseRelatedToPropertyAndEquipmentTableTextBlock>
    <us-gaap:Depreciation
      contextRef="C_0001439725_us-gaapFairValueByAssetClassAxis_us-gaapPropertyPlantAndEquipmentMember_us-gaapIncomeStatementLocationAxis_bdsxDirectCostsAndExpensesMember_20200101_20201231"
      decimals="-3"
      id="F_000478"
      unitRef="U_iso4217USD">361000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_0001439725_us-gaapFairValueByAssetClassAxis_us-gaapPropertyPlantAndEquipmentMember_us-gaapIncomeStatementLocationAxis_bdsxDirectCostsAndExpensesMember_20190101_20191231"
      decimals="-3"
      id="F_000479"
      unitRef="U_iso4217USD">183000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_0001439725_us-gaapFairValueByAssetClassAxis_us-gaapPropertyPlantAndEquipmentMember_us-gaapIncomeStatementLocationAxis_us-gaapSellingGeneralAndAdministrativeExpensesMember_20200101_20201231"
      decimals="-3"
      id="F_000480"
      unitRef="U_iso4217USD">478000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_0001439725_us-gaapFairValueByAssetClassAxis_us-gaapPropertyPlantAndEquipmentMember_us-gaapIncomeStatementLocationAxis_us-gaapSellingGeneralAndAdministrativeExpensesMember_20190101_20191231"
      decimals="-3"
      id="F_000481"
      unitRef="U_iso4217USD">636000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_0001439725_us-gaapFairValueByAssetClassAxis_us-gaapPropertyPlantAndEquipmentMember_20200101_20201231"
      decimals="-3"
      id="F_000482"
      unitRef="U_iso4217USD">839000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_0001439725_us-gaapFairValueByAssetClassAxis_us-gaapPropertyPlantAndEquipmentMember_20190101_20191231"
      decimals="-3"
      id="F_000483"
      unitRef="U_iso4217USD">819000</us-gaap:Depreciation>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock contextRef="C_0001439725_20200101_20201231" id="F_000280">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Note 7 &#x2013; Goodwill and Intangible Assets&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Goodwill&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Changes in goodwill for the years ended December 31, 2020 and 2019 were (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85.12%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.8%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85.12%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at January 1, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14,204&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:85.12%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160;Attributable to acquisition of Oncimmune, Ltd.&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;827&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:85.12%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at December 31 2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,031&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85.12%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:85.12%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,031&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Intangible Assets, Net&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intangible assets consist of the following (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.85%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.92%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.64%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.92%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cost&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accumulated&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortization&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net Carrying Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cost&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accumulated&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortization&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net Carrying Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.92%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intangible assets subject to amortization&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.2%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.44%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.2%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.2%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.24%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.2%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.92%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Patents&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.2%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,474&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.44%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(494&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.2%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;980&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.2%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,245&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.24%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(411&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.2%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;834&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.92%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Purchased technology&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.2%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16,900&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.44%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4,694&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.2%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,206&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.2%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16,900&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.24%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,817&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.2%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14,083&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.92%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Purchase option&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.2%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.44%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.2%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.2%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;121&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.24%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(17&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.2%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;104&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.92%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intangible assets not subject to amortization&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.2%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.44%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.2%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.2%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.24%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.2%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.92%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Trademarks&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;74&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.44%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;74&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;71&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;71&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.92%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.2%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;18,448&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.44%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(5,188&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.2%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,260&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.2%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;18,337&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.24%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(3,245&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.2%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,092&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortization expense related to definite-lived intangible assets was (in thousands): &lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:73.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.16%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:73.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:73.04%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Direct costs and expenses&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.98%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:73.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Sales, marketing, general and administrative&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,051&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,959&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:73.04%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.98%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,064&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,974&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Future estimated amortization expense of intangible assets is (in thousands):&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%; border-top:solid 0.75pt #000000;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,946&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,940&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2023&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,936&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2024&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,928&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2025&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,924&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,512&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,186&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;There have been no impairments of intangible assets for the twelve-month periods ended December 31, 2020 and December 31, 2019.&lt;/p&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfGoodwillTextBlock contextRef="C_0001439725_20200101_20201231" id="F_000325">
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Changes in goodwill for the years ended December 31, 2020 and 2019 were (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85.12%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.8%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85.12%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at January 1, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14,204&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:85.12%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160;Attributable to acquisition of Oncimmune, Ltd.&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;827&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:85.12%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at December 31 2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,031&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85.12%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:85.12%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,031&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:Goodwill
      contextRef="C_0001439725_20181231"
      decimals="-3"
      id="F_000484"
      unitRef="U_iso4217USD">14204000</us-gaap:Goodwill>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="C_0001439725_20190101_20191231"
      decimals="-3"
      id="F_000485"
      unitRef="U_iso4217USD">827000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:Goodwill
      contextRef="C_0001439725_20191231"
      decimals="-3"
      id="F_000486"
      unitRef="U_iso4217USD">15031000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="C_0001439725_20201231"
      decimals="-3"
      id="F_000487"
      unitRef="U_iso4217USD">15031000</us-gaap:Goodwill>
    <us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock contextRef="C_0001439725_20200101_20201231" id="F_000326">
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intangible assets consist of the following (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.85%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.92%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.64%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.92%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cost&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accumulated&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortization&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net Carrying Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cost&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accumulated&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortization&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net Carrying Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.92%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intangible assets subject to amortization&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.2%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.44%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.2%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.2%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.24%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.2%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.92%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Patents&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.2%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,474&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.44%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(494&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.2%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;980&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.2%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,245&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.24%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(411&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.2%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;834&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.92%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Purchased technology&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.2%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16,900&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.44%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4,694&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.2%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,206&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.2%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16,900&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.24%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,817&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.2%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14,083&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.92%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Purchase option&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.2%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.44%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.2%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.2%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;121&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.24%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(17&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.2%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;104&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.92%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intangible assets not subject to amortization&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.2%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.44%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.2%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.2%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.24%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.2%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.92%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Trademarks&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;74&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.44%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;74&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;71&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;71&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.92%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.2%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;18,448&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.44%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(5,188&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.2%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,260&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.2%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;18,337&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.24%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(3,245&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.2%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,092&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="C_0001439725_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapPatentsMember_20201231"
      decimals="-3"
      id="F_000488"
      unitRef="U_iso4217USD">1474000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="C_0001439725_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapPatentsMember_20201231"
      decimals="-3"
      id="F_000490"
      unitRef="U_iso4217USD">494000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="C_0001439725_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapPatentsMember_20201231"
      decimals="-3"
      id="F_000492"
      unitRef="U_iso4217USD">980000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="C_0001439725_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapPatentsMember_20191231"
      decimals="-3"
      id="F_000494"
      unitRef="U_iso4217USD">1245000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="C_0001439725_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapPatentsMember_20191231"
      decimals="-3"
      id="F_000497"
      unitRef="U_iso4217USD">411000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="C_0001439725_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapPatentsMember_20191231"
      decimals="-3"
      id="F_000500"
      unitRef="U_iso4217USD">834000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="C_0001439725_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_bdsxPurchasedTechnologyMember_20201231"
      decimals="-3"
      id="F_000489"
      unitRef="U_iso4217USD">16900000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="C_0001439725_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_bdsxPurchasedTechnologyMember_20201231"
      decimals="-3"
      id="F_000491"
      unitRef="U_iso4217USD">4694000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="C_0001439725_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_bdsxPurchasedTechnologyMember_20201231"
      decimals="-3"
      id="F_000493"
      unitRef="U_iso4217USD">12206000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="C_0001439725_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_bdsxPurchasedTechnologyMember_20191231"
      decimals="-3"
      id="F_000495"
      unitRef="U_iso4217USD">16900000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="C_0001439725_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_bdsxPurchasedTechnologyMember_20191231"
      decimals="-3"
      id="F_000498"
      unitRef="U_iso4217USD">2817000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="C_0001439725_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_bdsxPurchasedTechnologyMember_20191231"
      decimals="-3"
      id="F_000501"
      unitRef="U_iso4217USD">14083000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="C_0001439725_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_bdsxPurchaseOptionMember_20191231"
      decimals="-3"
      id="F_000496"
      unitRef="U_iso4217USD">121000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="C_0001439725_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_bdsxPurchaseOptionMember_20191231"
      decimals="-3"
      id="F_000499"
      unitRef="U_iso4217USD">17000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="C_0001439725_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_bdsxPurchaseOptionMember_20191231"
      decimals="-3"
      id="F_000502"
      unitRef="U_iso4217USD">104000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <bdsx:IndefiniteLivedIntangibleAssetsExcludingGoodwillGross
      contextRef="C_0001439725_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapTrademarksMember_20201231"
      decimals="-3"
      id="F_000503"
      unitRef="U_iso4217USD">74000</bdsx:IndefiniteLivedIntangibleAssetsExcludingGoodwillGross>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="C_0001439725_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapTrademarksMember_20201231"
      decimals="-3"
      id="F_000504"
      unitRef="U_iso4217USD">74000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <bdsx:IndefiniteLivedIntangibleAssetsExcludingGoodwillGross
      contextRef="C_0001439725_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapTrademarksMember_20191231"
      decimals="-3"
      id="F_000505"
      unitRef="U_iso4217USD">71000</bdsx:IndefiniteLivedIntangibleAssetsExcludingGoodwillGross>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="C_0001439725_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapTrademarksMember_20191231"
      decimals="-3"
      id="F_000506"
      unitRef="U_iso4217USD">71000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="C_0001439725_20201231"
      decimals="-3"
      id="F_000507"
      unitRef="U_iso4217USD">18448000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <bdsx:IntangibleAssetsAccumulatedAmortizationExcludingGoodwill
      contextRef="C_0001439725_20201231"
      decimals="-3"
      id="F_000508"
      unitRef="U_iso4217USD">5188000</bdsx:IntangibleAssetsAccumulatedAmortizationExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="C_0001439725_20201231"
      decimals="-3"
      id="F_000509"
      unitRef="U_iso4217USD">13260000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="C_0001439725_20191231"
      decimals="-3"
      id="F_000510"
      unitRef="U_iso4217USD">18337000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <bdsx:IntangibleAssetsAccumulatedAmortizationExcludingGoodwill
      contextRef="C_0001439725_20191231"
      decimals="-3"
      id="F_000511"
      unitRef="U_iso4217USD">3245000</bdsx:IntangibleAssetsAccumulatedAmortizationExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="C_0001439725_20191231"
      decimals="-3"
      id="F_000512"
      unitRef="U_iso4217USD">15092000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock contextRef="C_0001439725_20200101_20201231" id="F_000327">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortization expense related to definite-lived intangible assets was (in thousands): &lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:73.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.16%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:73.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:73.04%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Direct costs and expenses&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.98%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:73.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Sales, marketing, general and administrative&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,051&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,959&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:73.04%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.98%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,064&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,974&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="C_0001439725_us-gaapIncomeStatementLocationAxis_bdsxDirectCostsAndExpensesMember_20200101_20201231"
      decimals="-3"
      id="F_000513"
      unitRef="U_iso4217USD">13000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="C_0001439725_us-gaapIncomeStatementLocationAxis_bdsxDirectCostsAndExpensesMember_20190101_20191231"
      decimals="-3"
      id="F_000514"
      unitRef="U_iso4217USD">15000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="C_0001439725_us-gaapIncomeStatementLocationAxis_us-gaapSellingGeneralAndAdministrativeExpensesMember_20200101_20201231"
      decimals="-3"
      id="F_000515"
      unitRef="U_iso4217USD">2051000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="C_0001439725_us-gaapIncomeStatementLocationAxis_us-gaapSellingGeneralAndAdministrativeExpensesMember_20190101_20191231"
      decimals="-3"
      id="F_000516"
      unitRef="U_iso4217USD">1959000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="C_0001439725_20200101_20201231"
      decimals="-3"
      id="F_000517"
      unitRef="U_iso4217USD">2064000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="C_0001439725_20190101_20191231"
      decimals="-3"
      id="F_000518"
      unitRef="U_iso4217USD">1974000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock contextRef="C_0001439725_20200101_20201231" id="F_000328">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Future estimated amortization expense of intangible assets is (in thousands):&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%; border-top:solid 0.75pt #000000;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,946&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,940&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2023&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,936&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2024&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,928&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2025&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,924&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,512&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,186&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="C_0001439725_20201231"
      decimals="-3"
      id="F_000519"
      unitRef="U_iso4217USD">1946000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="C_0001439725_20201231"
      decimals="-3"
      id="F_000520"
      unitRef="U_iso4217USD">1940000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="C_0001439725_20201231"
      decimals="-3"
      id="F_000521"
      unitRef="U_iso4217USD">1936000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="C_0001439725_20201231"
      decimals="-3"
      id="F_000522"
      unitRef="U_iso4217USD">1928000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
      contextRef="C_0001439725_20201231"
      decimals="-3"
      id="F_000523"
      unitRef="U_iso4217USD">1924000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
      contextRef="C_0001439725_20201231"
      decimals="-3"
      id="F_000524"
      unitRef="U_iso4217USD">3512000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="C_0001439725_20201231"
      decimals="-3"
      id="F_000525"
      unitRef="U_iso4217USD">13186000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:GoodwillAndIntangibleAssetImpairment
      contextRef="C_0001439725_20200101_20201231"
      decimals="INF"
      id="F_000526"
      unitRef="U_iso4217USD">0</us-gaap:GoodwillAndIntangibleAssetImpairment>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="C_0001439725_20200101_20201231" id="F_000281">
&lt;p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Note 8 &#x2013; Accrued Liabilities &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amounts reported in &#x2018;Accrued liabilities&#x2019; in the balance sheets were (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Compensation related accruals&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,975&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,165&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued clinical trial expense&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;715&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;620&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other expenses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,099&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,352&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Warrant liability, current&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;43&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total accrued liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,789&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,180&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="C_0001439725_20200101_20201231" id="F_000329">
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amounts reported in &#x2018;Accrued liabilities&#x2019; in the balance sheets were (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Compensation related accruals&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,975&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,165&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued clinical trial expense&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;715&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;620&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other expenses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,099&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,352&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Warrant liability, current&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;43&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total accrued liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,789&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,180&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_0001439725_20201231"
      decimals="-3"
      id="F_000528"
      unitRef="U_iso4217USD">3975000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_0001439725_20191231"
      decimals="-3"
      id="F_000529"
      unitRef="U_iso4217USD">1165000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <bdsx:AccruedClinicalTrialExpenseCurrent
      contextRef="C_0001439725_20201231"
      decimals="-3"
      id="F_000530"
      unitRef="U_iso4217USD">715000</bdsx:AccruedClinicalTrialExpenseCurrent>
    <bdsx:AccruedClinicalTrialExpenseCurrent
      contextRef="C_0001439725_20191231"
      decimals="-3"
      id="F_000531"
      unitRef="U_iso4217USD">620000</bdsx:AccruedClinicalTrialExpenseCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_0001439725_20201231"
      decimals="-3"
      id="F_000532"
      unitRef="U_iso4217USD">3099000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_0001439725_20191231"
      decimals="-3"
      id="F_000533"
      unitRef="U_iso4217USD">2352000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:ProductWarrantyAccrualClassifiedCurrent
      contextRef="C_0001439725_20191231"
      decimals="-3"
      id="F_000534"
      unitRef="U_iso4217USD">43000</us-gaap:ProductWarrantyAccrualClassifiedCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_0001439725_20201231"
      decimals="-3"
      id="F_000535"
      unitRef="U_iso4217USD">7789000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_0001439725_20191231"
      decimals="-3"
      id="F_000536"
      unitRef="U_iso4217USD">4180000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DebtDisclosureTextBlock contextRef="C_0001439725_20200101_20201231" id="F_000282">
&lt;p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Note 9 &#x2013; Debt&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Notes Payable&lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Long-term notes payable were as follows (in thousands): &lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018 Notes&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;24,972&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;24,270&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Payroll protection plan&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,107&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Convertible notes payable&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,159&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unamortized debt discount and debt issuance costs&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(313&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,458&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;27,766&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;35,971&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less: current maturities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,840&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,159&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Long-term notes payable&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,926&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;23,812&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In February 2018, the Company issued long-term debt of $23.0 million to Innovatus Life Sciences Lending Fund (Innovatus or Lender) (the 2018 Notes).&#160;&#160;Innovatus is also a holder of the Company&#x2019;s common stock.&lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;At the time of issuance, the Company paid a facility fee of $0.2 million and issued a warrant to Innovatus, with an initial estimated fair value of $0.3 million, for the purchase of 613,333 shares of Series G preferred stock. The facility fee and the estimated warrant fair value were recorded as debt discount and is amortized to interest expense over the term of the 2018 Notes.&#160;&#160;The 2018 Notes bear annual interest at 10%, of which 7.5% is payable in cash, with the remaining 2.5% added to principal through December 31, 2020.&#160;&#160;Total interest added to principal was $1.7 million and $1.1 million as of December 31, 2020 and 2019, respectively. Commencing March 2021 and continuing through the maturity date February 2023, the outstanding principal is repayable in 24 equal monthly installments.&#160;&#160;&lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The loan may be prepaid by the Company at any time, subject to a prepayment penalty of up to 3% of the principal amount, depending on the date of prepayment. Upon payment of the 2018 Notes at maturity or prepayment on any earlier date, unless waived, a 2% back-end facility fee will apply to the amounts paid or prepaid. The 2% fee is recognized as additional interest expense over the loan term. The 2018 Notes are senior to all of the Company&#x2019;s other indebtedness including any contingent consideration payable to Indi.&lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The 2018 Notes contain customary affirmative covenants, and contain negative covenants limiting the ability of the Company to, among other things, incur future debt, transfer assets except for the ordinary course of business, make acquisitions, make certain restricted payments, or to sell assets, subject to certain exceptions.&#160; In addition, the 2018 Notes require the Company to comply with a minimum daily liquidity covenant and a rolling monthly revenue requirement. Failure to comply with the covenants and loan requirements may result in early amortization of the loan in a 24- or 36-month payment schedule. As of December 31, 2020, the Company was in compliance with all terms and covenants.&lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company granted the Lender a security interest in all of the Company&#x2019;s assets through a pledge and security agreement, patent security agreement and trademark security agreement, each between the Company and the Lender. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Paycheck Protection Program Note Payable&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In April 2020, the Company entered into a loan pursuant to the Paycheck Protection Program under the CARES Act, as administered by the U.S. Small Business Administration (the SBA). The loan, in the principal amount of $3.1 million (the PPP Loan), was disbursed by JPMorgan Chase Bank (JPM) pursuant to a Paycheck Protection Program Promissory Note and Agreement (the Note and Agreement).&lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The PPP Loan matures on the two-year anniversary of the funding date, April 2022, and bears interest at a fixed rate of 1.00% per annum. Monthly principal and interest payments, less the amount of any potential forgiveness (as discussed below), will commence in September 2021. The Company did not provide any collateral or guarantees in connection with the PPP Loan, nor did the Company pay any facility charge to obtain the PPP Loan. The Note and Agreement provides for customary events of default, including those relating to failure to make payment, bankruptcy, breaches of representations and material adverse effects. The Company may prepay the principal of the PPP Loan at any time without incurring any prepayment charges.&lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;All or a portion of the PPP Loan may be forgiven by the SBA and JPM upon application by the Company.&#160; Under the CARES Act, loan forgiveness is available for the sum of documented payroll costs, covered rent payments, and covered utilities during the eight-week period beginning on the approval date of the PPP Loan. For purposes of the CARES Act, payroll costs exclude compensation of an individual employee earning more than $100,000, prorated annually. Not more than 40% of the forgiven amount may be for non-payroll costs. Forgiveness is reduced if full-time headcount declines, or if salaries and wages for employees with salaries of $100,000 or less annually are reduced by more than 25%.&#160;The Company currently intends to repay the PPP loan in accordance with the underlying terms and conditions.&#160;&#160;To the extent we elect to seek forgiveness, the Company cannot assure that the PPP Loan will be forgiven, in whole or in part. If the loan is forgiven in part or in whole, and legal release is received, the Company will&#160;reduce the liability by the amount forgiven and record a gain on extinguishment in the statements of operations.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Convertible Notes Payable&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;March 2020 Notes&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In March 2020, the Company issued $10.0 million of convertible notes primarily to existing stockholders that were originally scheduled to mature in &lt;span style="-sec-ix-hidden:F_000572"&gt;August 2020&lt;/span&gt; (the March 2020 Notes). In August 2020, the Company and its lenders agreed to extend the maturity date to June 30, 2021. The March 2020 Notes were issued in two tranches of $&lt;span&gt;5.0 million&lt;/span&gt;, with the first in March 2020 and the second in June 2020.&#160;&#160;Interest on the March 2020 Notes was 3% per annum, payable in full upon maturity through conversion to Series H Preferred Stock at 80% of the original issuance price of $1.15 per share.&#160;&#160;Under the terms of the March 2020 Notes, on or before the maturity date and if the March 2020 Notes are unpaid, the outstanding principal and unpaid accrued interest under the March 2020 Notes shall be automatically converted into common stock in an initial public offering at a conversion price of 80% of the per share price of common stock sold in the initial public offering. The discount on the automatic conversion was separated from the March 2020 Notes and reported as a debt discount and put option liability of $2.5 million and was amortized over the term of the March 2020 Notes.&#160;&#160;Following the closing of the initial public offering in October 2020, the March 2020 Notes were automatically converted into 703,503 shares of common stock at a conversion price of $14.40, or 80% of the initial public offering price per common share.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;December 2019 Notes&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In December 2019, the Company issued $6.0 million of convertible notes primarily to existing preferred shareholders that were originally scheduled to mature in &lt;span style="-sec-ix-hidden:F_000585"&gt;August 2020&lt;/span&gt; (the December 2019 Notes). In August 2020, the Company and its lenders agreed to extend the maturity date to June 30, 2021. The December 2019 Notes were issued in two tranches of &lt;span&gt;$3.0 million&lt;/span&gt;, the first in December 2019 and the second in February 2020.&#160;&#160;Interest on the December 2019 Notes was 3% per annum and payable in full upon maturity through the conversion to Series H Preferred Stock at 80% of the original issuance price of $1.15 per share. Under the terms of the December 2019 Notes, on or before the maturity date and if the December 2019 Notes are unpaid, the outstanding principal and unpaid accrued interest under the December 2019 Notes shall be automatically converted into common stock in an initial public offering at a conversion price of 80% of the per share price of common stock sold in the initial public offering. The discount on the automatic conversion was separated from the December 2019 Notes and reported as a debt discount and put option liability of $1.5 million and was amortized over the term of the December 2019 Notes. Following the closing of the initial public offering in October 2020, the December 2019 Notes were automatically converted into 426,386 shares of common stock at a conversion price of $14.40, or 80% of the initial public offering price per common share.&lt;/p&gt;

&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;August 2019 Notes&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In August and September 2019 (the August 2019 Notes), the Company issued $10.0 million of convertible notes primarily to existing preferred shareholders that were originally scheduled to mature in &lt;span style="-sec-ix-hidden:F_000598"&gt;August 2020&lt;/span&gt;. In August 2020, the Company and its lenders agreed to extend the maturity date to June 30, 2021. Interest on the August 2019 Notes was 3% per annum and payable in full upon maturity through the conversion to Series H Preferred Stock at 95% of the original issuance price of $1.15 per share. Under the terms of the August 2019 Notes, on or before the maturity date and if the August 2019 Notes are unpaid, the outstanding principal and unpaid accrued interest under the August 2019 Notes shall be automatically converted into common stock in an initial public offering at a conversion price of 95% of the per share price of common stock sold in the initial public offering.&lt;span style="color:#000000;"&gt;&#160;&lt;/span&gt;In connection with the issuance of the December 2019 Notes, the conversion price on the August 2019 Notes was amended to 80%&lt;span style="color:#000000;"&gt;.&lt;/span&gt; The initial discount on the automatic conversion created an initial put option liability of $0.5 million that was separated from the August 2019 Notes. The amendment to the conversion price of the August 2019 Notes in December 2019 resulted in an increase to the put option liability of $2.0 million to a total estimated value of $2.5 million as of December 31, 2019.&#160;&#160;The increase in the value of the put option liability was reflected as a change in put option in the 2019 statement of operations. Following the closing of the initial public offering in October 2020, the August 2019 Notes were automatically converted into 718,391 shares of common stock at a conversion price of $14.40, or 80% of the initial public offering price per common share.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Scheduled principal repayments (maturities) of long-term obligations as of December 31, 2020 were as follows (in thousands): &lt;/p&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:79.7%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ending December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.34%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:79.7%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.34%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,840&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:79.7%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.34%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,919&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:79.7%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2023&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.34%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,320&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:79.7%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2024&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.34%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:79.7%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2025&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.34%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:79.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.34%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:79.7%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.34%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;28,079&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ScheduleOfDebtInstrumentsTextBlock contextRef="C_0001439725_20200101_20201231" id="F_000330">
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Long-term notes payable were as follows (in thousands): &lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018 Notes&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;24,972&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;24,270&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Payroll protection plan&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,107&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Convertible notes payable&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,159&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unamortized debt discount and debt issuance costs&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(313&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,458&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;27,766&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;35,971&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less: current maturities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,840&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,159&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Long-term notes payable&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,926&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;23,812&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="C_0001439725_us-gaapLongtermDebtTypeAxis_bdsxNotesPayable2018NotesMember_20201231"
      decimals="-3"
      id="F_000537"
      unitRef="U_iso4217USD">24972000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="C_0001439725_us-gaapLongtermDebtTypeAxis_bdsxNotesPayable2018NotesMember_20191231"
      decimals="-3"
      id="F_000538"
      unitRef="U_iso4217USD">24270000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="C_0001439725_us-gaapDebtInstrumentAxis_bdsxCARESActMember_us-gaapLongtermDebtTypeAxis_bdsxPPPLoanMember_20201231"
      decimals="-3"
      id="F_000539"
      unitRef="U_iso4217USD">3107000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:ConvertibleNotesPayableCurrent
      contextRef="C_0001439725_20191231"
      decimals="-3"
      id="F_000540"
      unitRef="U_iso4217USD">13159000</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="C_0001439725_20201231"
      decimals="-3"
      id="F_000541"
      unitRef="U_iso4217USD">313000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="C_0001439725_20191231"
      decimals="-3"
      id="F_000542"
      unitRef="U_iso4217USD">1458000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:NotesPayable
      contextRef="C_0001439725_20201231"
      decimals="-3"
      id="F_000543"
      unitRef="U_iso4217USD">27766000</us-gaap:NotesPayable>
    <us-gaap:NotesPayable
      contextRef="C_0001439725_20191231"
      decimals="-3"
      id="F_000544"
      unitRef="U_iso4217USD">35971000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableCurrent
      contextRef="C_0001439725_20201231"
      decimals="-3"
      id="F_000545"
      unitRef="U_iso4217USD">11840000</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent
      contextRef="C_0001439725_20191231"
      decimals="-3"
      id="F_000546"
      unitRef="U_iso4217USD">12159000</us-gaap:NotesPayableCurrent>
    <us-gaap:LongTermNotesPayable
      contextRef="C_0001439725_20201231"
      decimals="-3"
      id="F_000547"
      unitRef="U_iso4217USD">15926000</us-gaap:LongTermNotesPayable>
    <us-gaap:LongTermNotesPayable
      contextRef="C_0001439725_20191231"
      decimals="-3"
      id="F_000548"
      unitRef="U_iso4217USD">23812000</us-gaap:LongTermNotesPayable>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="C_0001439725_us-gaapLongtermDebtTypeAxis_bdsxNotesPayable2018NotesMember_20180228"
      decimals="-5"
      id="F_000549"
      unitRef="U_iso4217USD">23000000.0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentFeeAmount
      contextRef="C_0001439725_us-gaapLongtermDebtTypeAxis_bdsxNotesPayable2018NotesMember_20180228"
      decimals="-5"
      id="F_000550"
      unitRef="U_iso4217USD">200000</us-gaap:DebtInstrumentFeeAmount>
    <us-gaap:WarrantsNotSettleableInCashFairValueDisclosure
      contextRef="C_0001439725_us-gaapLongtermDebtTypeAxis_bdsxNotesPayable2018NotesMember_20180228"
      decimals="-5"
      id="F_000552"
      unitRef="U_iso4217USD">300000</us-gaap:WarrantsNotSettleableInCashFairValueDisclosure>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="C_0001439725_us-gaapLongtermDebtTypeAxis_bdsxNotesPayable2018NotesMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesGPreferredStockMember_20180228"
      decimals="INF"
      id="F_000551"
      unitRef="U_xbrlishares">613333</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="C_0001439725_us-gaapLongtermDebtTypeAxis_bdsxNotesPayable2018NotesMember_20180228"
      decimals="INF"
      id="F_000553"
      unitRef="U_xbrlipure">0.10</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <bdsx:DebtInstrumentPercentageOfStatedInterestRatePaidInCash
      contextRef="C_0001439725_us-gaapLongtermDebtTypeAxis_bdsxNotesPayable2018NotesMember_20180228"
      decimals="INF"
      id="F_000554"
      unitRef="U_xbrlipure">0.075</bdsx:DebtInstrumentPercentageOfStatedInterestRatePaidInCash>
    <bdsx:DebtInstrumentPercentageOfStatedInterestRateAddedToPrincipalValueOfNotesPayable
      contextRef="C_0001439725_us-gaapLongtermDebtTypeAxis_bdsxNotesPayable2018NotesMember_20180228"
      decimals="INF"
      id="F_000555"
      unitRef="U_xbrlipure">0.025</bdsx:DebtInstrumentPercentageOfStatedInterestRateAddedToPrincipalValueOfNotesPayable>
    <bdsx:DebtInstrumentInterestAddedToPrincipalValue
      contextRef="C_0001439725_us-gaapLongtermDebtTypeAxis_bdsxNotesPayable2018NotesMember_20201231"
      decimals="-5"
      id="F_000556"
      unitRef="U_iso4217USD">1700000</bdsx:DebtInstrumentInterestAddedToPrincipalValue>
    <bdsx:DebtInstrumentInterestAddedToPrincipalValue
      contextRef="C_0001439725_us-gaapLongtermDebtTypeAxis_bdsxNotesPayable2018NotesMember_20191231"
      decimals="-5"
      id="F_000557"
      unitRef="U_iso4217USD">1100000</bdsx:DebtInstrumentInterestAddedToPrincipalValue>
    <us-gaap:DebtInstrumentFrequencyOfPeriodicPayment
      contextRef="C_0001439725_us-gaapLongtermDebtTypeAxis_bdsxNotesPayable2018NotesMember_20200101_20201231"
      id="F_000558">Commencing March 2021 and continuing through the maturity date February 2023, the outstanding principal is repayable in 24 equal monthly installments.</us-gaap:DebtInstrumentFrequencyOfPeriodicPayment>
    <bdsx:DebtInstrumentPrepaymentPenaltyPercentage
      contextRef="C_0001439725_us-gaapLongtermDebtTypeAxis_bdsxNotesPayable2018NotesMember_20180201_20180228"
      decimals="INF"
      id="F_000559"
      unitRef="U_xbrlipure">0.03</bdsx:DebtInstrumentPrepaymentPenaltyPercentage>
    <bdsx:DebtInstrumentBackEndFacilityFeePercentage
      contextRef="C_0001439725_us-gaapLongtermDebtTypeAxis_bdsxNotesPayable2018NotesMember_20180201_20180228"
      decimals="2"
      id="F_000560"
      unitRef="U_xbrlipure">0.02</bdsx:DebtInstrumentBackEndFacilityFeePercentage>
    <bdsx:DebtInstrumentAdditionalInterestExpenseFeePercentage
      contextRef="C_0001439725_us-gaapLongtermDebtTypeAxis_bdsxNotesPayable2018NotesMember_20180201_20180228"
      decimals="2"
      id="F_000561"
      unitRef="U_xbrlipure">0.02</bdsx:DebtInstrumentAdditionalInterestExpenseFeePercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="C_0001439725_us-gaapDebtInstrumentAxis_bdsxCARESActMember_us-gaapLongtermDebtTypeAxis_bdsxPPPLoanMember_20200430"
      decimals="-5"
      id="F_000564"
      unitRef="U_iso4217USD">3100000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentDescription
      contextRef="C_0001439725_us-gaapLongtermDebtTypeAxis_bdsxPPPLoanMember_20200101_20201231"
      id="F_000565">The PPP Loan matures on the two-year anniversary of the funding date, April 2022, and bears interest at a fixed rate of 1.00% per annum. Monthly principal and interest payments, less the amount of any potential forgiveness (as discussed below), will commence in September 2021. The Company did not provide any collateral or guarantees in connection with the PPP Loan, nor did the Company pay any facility charge to obtain the PPP Loan.</us-gaap:DebtInstrumentDescription>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="C_0001439725_us-gaapInvestmentTypeAxis_us-gaapInterestBearingDepositsMember_us-gaapLongtermDebtTypeAxis_bdsxPPPLoanMember_20200430"
      decimals="INF"
      id="F_000566"
      unitRef="U_xbrlipure">0.0100</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <bdsx:PayrollCostsExcludesCompensationOfEmployee
      contextRef="C_0001439725_srtRangeAxis_srtMinimumMember_us-gaapDebtInstrumentAxis_bdsxCARESActMember_us-gaapLongtermDebtTypeAxis_bdsxPPPLoanMember_20200401_20200430"
      decimals="INF"
      id="F_000567"
      unitRef="U_iso4217USD">100000</bdsx:PayrollCostsExcludesCompensationOfEmployee>
    <bdsx:PercentageForNonPayrollCosts
      contextRef="C_0001439725_us-gaapDebtInstrumentAxis_bdsxCARESActMember_us-gaapLongtermDebtTypeAxis_bdsxPPPLoanMember_20200401_20200430"
      decimals="INF"
      id="F_000568"
      unitRef="U_xbrlipure">0.40</bdsx:PercentageForNonPayrollCosts>
    <bdsx:UpperLimitOfEmployeeSalaryToReduceForgiveness
      contextRef="C_0001439725_us-gaapDebtInstrumentAxis_bdsxCARESActMember_us-gaapLongtermDebtTypeAxis_bdsxPPPLoanMember_20200401_20200430"
      decimals="INF"
      id="F_000569"
      unitRef="U_iso4217USD">100000</bdsx:UpperLimitOfEmployeeSalaryToReduceForgiveness>
    <bdsx:PercentageOfUpperLimitOfEmployeeSalaryToReduceForgiveness
      contextRef="C_0001439725_us-gaapDebtInstrumentAxis_bdsxCARESActMember_us-gaapLongtermDebtTypeAxis_bdsxPPPLoanMember_20200401_20200430"
      decimals="INF"
      id="F_000570"
      unitRef="U_xbrlipure">0.25</bdsx:PercentageOfUpperLimitOfEmployeeSalaryToReduceForgiveness>
    <us-gaap:NotesIssued1
      contextRef="C_0001439725_us-gaapShortTermDebtTypeAxis_bdsxMarchTwoThousandAndTwentyConvertibleNotesMember_20200301_20200331"
      decimals="-5"
      id="F_000571"
      unitRef="U_iso4217USD">10000000.0</us-gaap:NotesIssued1>
    <bdsx:DebtInstrumentMaturityDateExtended
      contextRef="C_0001439725_us-gaapShortTermDebtTypeAxis_bdsxMarchTwoThousandAndTwentyConvertibleNotesMember_20200801_20200831"
      id="F_000573">2021-06-30</bdsx:DebtInstrumentMaturityDateExtended>
    <us-gaap:NotesIssued1
      contextRef="C_0001439725_us-gaapDebtInstrumentRedemptionPeriodAxis_us-gaapDebtInstrumentRedemptionPeriodOneMember_us-gaapShortTermDebtTypeAxis_bdsxMarchTwoThousandAndTwentyConvertibleNotesMember_20200301_20200331"
      decimals="-5"
      id="F_000574"
      unitRef="U_iso4217USD">5000000.0</us-gaap:NotesIssued1>
    <us-gaap:NotesIssued1
      contextRef="C_0001439725_us-gaapDebtInstrumentRedemptionPeriodAxis_us-gaapDebtInstrumentRedemptionPeriodTwoMember_us-gaapShortTermDebtTypeAxis_bdsxMarchTwoThousandAndTwentyConvertibleNotesMember_20200601_20200630"
      decimals="-5"
      id="F_000575"
      unitRef="U_iso4217USD">5000000.0</us-gaap:NotesIssued1>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="C_0001439725_us-gaapShortTermDebtTypeAxis_bdsxMarchTwoThousandAndTwentyConvertibleNotesMember_20200331"
      decimals="INF"
      id="F_000576"
      unitRef="U_xbrlipure">0.03</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtConversionConvertedInstrumentRate
      contextRef="C_0001439725_us-gaapShortTermDebtTypeAxis_bdsxMarchTwoThousandAndTwentyConvertibleNotesMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesHPreferredStockMember_20200301_20200331"
      decimals="INF"
      id="F_000577"
      unitRef="U_xbrlipure">0.80</us-gaap:DebtConversionConvertedInstrumentRate>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="C_0001439725_us-gaapShortTermDebtTypeAxis_bdsxMarchTwoThousandAndTwentyConvertibleNotesMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesHPreferredStockMember_20200331"
      decimals="INF"
      id="F_000578"
      unitRef="U_iso4217USD_xbrlishares">1.15</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <bdsx:PercentageOfConversionPricePerShareOfCommonStock
      contextRef="C_0001439725_us-gaapShortTermDebtTypeAxis_bdsxMarchTwoThousandAndTwentyConvertibleNotesMember_20200301_20200331"
      decimals="INF"
      id="F_000579"
      unitRef="U_xbrlipure">0.80</bdsx:PercentageOfConversionPricePerShareOfCommonStock>
    <bdsx:PutOptionLiabilityCurrent
      contextRef="C_0001439725_us-gaapShortTermDebtTypeAxis_bdsxMarchTwoThousandAndTwentyConvertibleNotesMember_20200331"
      decimals="-5"
      id="F_000580"
      unitRef="U_iso4217USD">2500000</bdsx:PutOptionLiabilityCurrent>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="C_0001439725_us-gaapShortTermDebtTypeAxis_bdsxMarchTwoThousandAndTwentyConvertibleNotesMember_20201001_20201031"
      decimals="INF"
      id="F_000581"
      unitRef="U_xbrlishares">703503</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="C_0001439725_us-gaapShortTermDebtTypeAxis_bdsxMarchTwoThousandAndTwentyConvertibleNotesMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201031"
      decimals="INF"
      id="F_000582"
      unitRef="U_iso4217USD_xbrlishares">14.40</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <bdsx:PercentageOfConversionPricePerShareOfCommonStock
      contextRef="C_0001439725_us-gaapShortTermDebtTypeAxis_bdsxMarchTwoThousandAndTwentyConvertibleNotesMember_20201001_20201031"
      decimals="INF"
      id="F_000583"
      unitRef="U_xbrlipure">0.80</bdsx:PercentageOfConversionPricePerShareOfCommonStock>
    <us-gaap:NotesIssued1
      contextRef="C_0001439725_us-gaapShortTermDebtTypeAxis_bdsxDecemberTwoThousandAndNineteenConvertibleNotesMember_20191201_20191231"
      decimals="-5"
      id="F_000584"
      unitRef="U_iso4217USD">6000000.0</us-gaap:NotesIssued1>
    <bdsx:DebtInstrumentMaturityDateExtended
      contextRef="C_0001439725_us-gaapShortTermDebtTypeAxis_bdsxDecemberTwoThousandAndNineteenConvertibleNotesMember_20200801_20200831"
      id="F_000586">2021-06-30</bdsx:DebtInstrumentMaturityDateExtended>
    <us-gaap:NotesIssued1
      contextRef="C_0001439725_us-gaapDebtInstrumentRedemptionPeriodAxis_us-gaapDebtInstrumentRedemptionPeriodOneMember_us-gaapShortTermDebtTypeAxis_bdsxDecemberTwoThousandAndNineteenConvertibleNotesMember_20191201_20191231"
      decimals="-5"
      id="F_000587"
      unitRef="U_iso4217USD">3000000.0</us-gaap:NotesIssued1>
    <us-gaap:NotesIssued1
      contextRef="C_0001439725_us-gaapDebtInstrumentRedemptionPeriodAxis_us-gaapDebtInstrumentRedemptionPeriodTwoMember_us-gaapShortTermDebtTypeAxis_bdsxDecemberTwoThousandAndNineteenConvertibleNotesMember_20200201_20200229"
      decimals="-5"
      id="F_000588"
      unitRef="U_iso4217USD">3000000.0</us-gaap:NotesIssued1>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="C_0001439725_us-gaapShortTermDebtTypeAxis_bdsxDecemberTwoThousandAndNineteenConvertibleNotesMember_20191231"
      decimals="INF"
      id="F_000589"
      unitRef="U_xbrlipure">0.03</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtConversionConvertedInstrumentRate
      contextRef="C_0001439725_us-gaapShortTermDebtTypeAxis_bdsxDecemberTwoThousandAndNineteenConvertibleNotesMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesHPreferredStockMember_20191201_20191231"
      decimals="INF"
      id="F_000590"
      unitRef="U_xbrlipure">0.80</us-gaap:DebtConversionConvertedInstrumentRate>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="C_0001439725_us-gaapShortTermDebtTypeAxis_bdsxDecemberTwoThousandAndNineteenConvertibleNotesMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesHPreferredStockMember_20191231"
      decimals="INF"
      id="F_000591"
      unitRef="U_iso4217USD_xbrlishares">1.15</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <bdsx:PercentageOfConversionPricePerShareOfCommonStock
      contextRef="C_0001439725_us-gaapShortTermDebtTypeAxis_bdsxDecemberTwoThousandAndNineteenConvertibleNotesMember_20191201_20191231"
      decimals="INF"
      id="F_000592"
      unitRef="U_xbrlipure">0.80</bdsx:PercentageOfConversionPricePerShareOfCommonStock>
    <bdsx:PutOptionLiabilityCurrent
      contextRef="C_0001439725_us-gaapShortTermDebtTypeAxis_bdsxDecemberTwoThousandAndNineteenConvertibleNotesMember_20191231"
      decimals="-5"
      id="F_000593"
      unitRef="U_iso4217USD">1500000</bdsx:PutOptionLiabilityCurrent>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="C_0001439725_us-gaapShortTermDebtTypeAxis_bdsxDecemberTwoThousandAndNineteenConvertibleNotesMember_20201001_20201031"
      decimals="INF"
      id="F_000594"
      unitRef="U_xbrlishares">426386</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="C_0001439725_us-gaapShortTermDebtTypeAxis_bdsxDecemberTwoThousandAndNineteenConvertibleNotesMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201031"
      decimals="INF"
      id="F_000595"
      unitRef="U_iso4217USD_xbrlishares">14.40</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <bdsx:PercentageOfConversionPricePerShareOfCommonStock
      contextRef="C_0001439725_us-gaapShortTermDebtTypeAxis_bdsxDecemberTwoThousandAndNineteenConvertibleNotesMember_20201001_20201031"
      decimals="INF"
      id="F_000596"
      unitRef="U_xbrlipure">0.80</bdsx:PercentageOfConversionPricePerShareOfCommonStock>
    <us-gaap:NotesIssued1
      contextRef="C_0001439725_us-gaapShortTermDebtTypeAxis_bdsxAugustTwoThousandAndNineteenConvertibleNotesMember_20190801_20190930"
      decimals="-5"
      id="F_000597"
      unitRef="U_iso4217USD">10000000.0</us-gaap:NotesIssued1>
    <bdsx:DebtInstrumentMaturityDateExtended
      contextRef="C_0001439725_us-gaapShortTermDebtTypeAxis_bdsxAugustTwoThousandAndNineteenConvertibleNotesMember_20200801_20200831"
      id="F_000599">2021-06-30</bdsx:DebtInstrumentMaturityDateExtended>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="C_0001439725_us-gaapShortTermDebtTypeAxis_bdsxAugustTwoThousandAndNineteenConvertibleNotesMember_20190930"
      decimals="INF"
      id="F_000600"
      unitRef="U_xbrlipure">0.03</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <bdsx:PercentageOfConversionPricePerShareOfConvertiblePreferredStock
      contextRef="C_0001439725_us-gaapShortTermDebtTypeAxis_bdsxAugustTwoThousandAndNineteenConvertibleNotesMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesHPreferredStockMember_20190801_20190930"
      decimals="INF"
      id="F_000601"
      unitRef="U_xbrlipure">0.95</bdsx:PercentageOfConversionPricePerShareOfConvertiblePreferredStock>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="C_0001439725_us-gaapShortTermDebtTypeAxis_bdsxAugustTwoThousandAndNineteenConvertibleNotesMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesHPreferredStockMember_20190930"
      decimals="INF"
      id="F_000602"
      unitRef="U_iso4217USD_xbrlishares">1.15</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <bdsx:PercentageOfConversionPricePerShareOfCommonStock
      contextRef="C_0001439725_us-gaapShortTermDebtTypeAxis_bdsxAugustTwoThousandAndNineteenConvertibleNotesMember_20190801_20190930"
      decimals="INF"
      id="F_000604"
      unitRef="U_xbrlipure">0.95</bdsx:PercentageOfConversionPricePerShareOfCommonStock>
    <bdsx:PercentageOfConversionPricePerShareOfConvertiblePreferredStock
      contextRef="C_0001439725_us-gaapShortTermDebtTypeAxis_bdsxAugustTwoThousandAndNineteenConvertibleNotesMember_20191201_20191231"
      decimals="INF"
      id="F_000603"
      unitRef="U_xbrlipure">0.80</bdsx:PercentageOfConversionPricePerShareOfConvertiblePreferredStock>
    <bdsx:PutOptionLiabilityCurrent
      contextRef="C_0001439725_us-gaapShortTermDebtTypeAxis_bdsxAugustTwoThousandAndNineteenConvertibleNotesMember_20190930"
      decimals="-5"
      id="F_000605"
      unitRef="U_iso4217USD">500000</bdsx:PutOptionLiabilityCurrent>
    <bdsx:IncreaseToPutOptionLiability
      contextRef="C_0001439725_us-gaapShortTermDebtTypeAxis_bdsxAugustTwoThousandAndNineteenConvertibleNotesMember_20191231"
      decimals="-5"
      id="F_000606"
      unitRef="U_iso4217USD">2000000.0</bdsx:IncreaseToPutOptionLiability>
    <bdsx:PutOptionLiabilityCurrent
      contextRef="C_0001439725_us-gaapShortTermDebtTypeAxis_bdsxAugustTwoThousandAndNineteenConvertibleNotesMember_20191231"
      decimals="-5"
      id="F_000607"
      unitRef="U_iso4217USD">2500000</bdsx:PutOptionLiabilityCurrent>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="C_0001439725_us-gaapShortTermDebtTypeAxis_bdsxAugustTwoThousandAndNineteenConvertibleNotesMember_20201001_20201031"
      decimals="INF"
      id="F_000608"
      unitRef="U_xbrlishares">718391</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="C_0001439725_us-gaapShortTermDebtTypeAxis_bdsxAugustTwoThousandAndNineteenConvertibleNotesMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201031"
      decimals="INF"
      id="F_000609"
      unitRef="U_iso4217USD_xbrlishares">14.40</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <bdsx:PercentageOfConversionPricePerShareOfCommonStock
      contextRef="C_0001439725_us-gaapShortTermDebtTypeAxis_bdsxAugustTwoThousandAndNineteenConvertibleNotesMember_20201001_20201031"
      decimals="INF"
      id="F_000610"
      unitRef="U_xbrlipure">0.80</bdsx:PercentageOfConversionPricePerShareOfCommonStock>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock contextRef="C_0001439725_20200101_20201231" id="F_000331">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Scheduled principal repayments (maturities) of long-term obligations as of December 31, 2020 were as follows (in thousands): &lt;/p&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:79.7%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ending December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.34%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:79.7%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.34%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,840&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:79.7%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.34%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,919&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:79.7%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2023&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.34%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,320&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:79.7%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2024&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.34%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:79.7%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2025&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.34%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:79.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.34%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:79.7%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.34%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;28,079&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
      contextRef="C_0001439725_20201231"
      decimals="-3"
      id="F_000611"
      unitRef="U_iso4217USD">11840000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="C_0001439725_20201231"
      decimals="-3"
      id="F_000612"
      unitRef="U_iso4217USD">13919000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
      contextRef="C_0001439725_20201231"
      decimals="-3"
      id="F_000613"
      unitRef="U_iso4217USD">2320000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebt
      contextRef="C_0001439725_20201231"
      decimals="-3"
      id="F_000614"
      unitRef="U_iso4217USD">28079000</us-gaap:LongTermDebt>
    <us-gaap:PreferredStockTextBlock contextRef="C_0001439725_20200101_20201231" id="F_000283">
&lt;p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Note 10 &#x2013; Convertible Preferred Stock&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company had issued convertible preferred stock from time to time to fund its operations and to make acquisitions. In February and March 2019, the Company issued 8,695,621 shares of Series H Preferred Stock at $1.15 per share for total cash proceeds of $10.0 million.&lt;span style="color:#000000;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;The Company&#x2019;s convertible preferred stock was reported as temporary equity in the Company&#x2019;s balance sheet because the preferred shareholders held a majority of the Company&#x2019;s Board of Directors seats and as a result could have caused certain events to occur outside of the Company&#x2019;s control, with the result the Company could have been obligated to redeem the convertible preferred stock.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Immediately prior to the Company&#x2019;s initial public offering and as of December 31, 2019, the Company had issued 118,766,273 convertible preferred shares. On October 27, 2020, upon closing of the Company&#x2019;s initial public offering, each outstanding share of Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock, Series G Preferred Stock and Series H Preferred Stock automatically converted into 0.1684664 share of common stock; and each share of Series B-1 Preferred Stock automatically converted into 0.196 shares of common stock. In the aggregate, all Series of preferred stock were converted into 20,090,745 shares of common stock. As a result, as of December 31, 2020 there are no longer any series of convertible preferred stock outstanding.&lt;/p&gt;
</us-gaap:PreferredStockTextBlock>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="C_0001439725_us-gaapStatementClassOfStockAxis_us-gaapSeriesHPreferredStockMember_20190228"
      decimals="INF"
      id="F_000615"
      unitRef="U_xbrlishares">8695621</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="C_0001439725_us-gaapStatementClassOfStockAxis_us-gaapSeriesHPreferredStockMember_20190331"
      decimals="INF"
      id="F_000616"
      unitRef="U_xbrlishares">8695621</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="C_0001439725_us-gaapStatementClassOfStockAxis_us-gaapSeriesHPreferredStockMember_20190331"
      decimals="2"
      id="F_000618"
      unitRef="U_iso4217USD_xbrlishares">1.15</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="C_0001439725_us-gaapStatementClassOfStockAxis_us-gaapSeriesHPreferredStockMember_20190228"
      decimals="2"
      id="F_000617"
      unitRef="U_iso4217USD_xbrlishares">1.15</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="C_0001439725_us-gaapStatementClassOfStockAxis_us-gaapSeriesHPreferredStockMember_20190301_20190331"
      decimals="-5"
      id="F_000620"
      unitRef="U_iso4217USD">10000000.0</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="C_0001439725_us-gaapStatementClassOfStockAxis_us-gaapSeriesHPreferredStockMember_20190201_20190228"
      decimals="-5"
      id="F_000619"
      unitRef="U_iso4217USD">10000000.0</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="C_0001439725_20191231"
      decimals="INF"
      id="F_000621"
      unitRef="U_xbrlishares">118766273</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="C_0001439725_us-gaapStatementClassOfStockAxis_bdsxSeriesA1PreferredStockMember_20201027_20201027"
      decimals="7"
      id="F_000622"
      unitRef="U_xbrlipure">0.1684664</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="C_0001439725_us-gaapStatementClassOfStockAxis_bdsxSeriesA2PreferredStockMember_20201027_20201027"
      decimals="7"
      id="F_000623"
      unitRef="U_xbrlipure">0.1684664</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="C_0001439725_us-gaapStatementClassOfStockAxis_us-gaapSeriesEPreferredStockMember_20201027_20201027"
      decimals="7"
      id="F_000628"
      unitRef="U_xbrlipure">0.1684664</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="C_0001439725_us-gaapStatementClassOfStockAxis_bdsxSeriesA3PreferredStockMember_20201027_20201027"
      decimals="7"
      id="F_000624"
      unitRef="U_xbrlipure">0.1684664</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="C_0001439725_us-gaapStatementClassOfStockAxis_us-gaapSeriesFPreferredStockMember_20201027_20201027"
      decimals="7"
      id="F_000629"
      unitRef="U_xbrlipure">0.1684664</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="C_0001439725_us-gaapStatementClassOfStockAxis_us-gaapSeriesGPreferredStockMember_20201027_20201027"
      decimals="7"
      id="F_000630"
      unitRef="U_xbrlipure">0.1684664</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="C_0001439725_us-gaapStatementClassOfStockAxis_us-gaapSeriesHPreferredStockMember_20201027_20201027"
      decimals="7"
      id="F_000631"
      unitRef="U_xbrlipure">0.1684664</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="C_0001439725_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20201027_20201027"
      decimals="7"
      id="F_000625"
      unitRef="U_xbrlipure">0.1684664</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="C_0001439725_us-gaapStatementClassOfStockAxis_us-gaapSeriesCPreferredStockMember_20201027_20201027"
      decimals="7"
      id="F_000626"
      unitRef="U_xbrlipure">0.1684664</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="C_0001439725_us-gaapStatementClassOfStockAxis_us-gaapSeriesDPreferredStockMember_20201027_20201027"
      decimals="7"
      id="F_000627"
      unitRef="U_xbrlipure">0.1684664</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="C_0001439725_us-gaapStatementClassOfStockAxis_bdsxSeriesB1ConvertiblePreferredStockMember_20201027_20201027"
      decimals="3"
      id="F_000632"
      unitRef="U_xbrlipure">0.196</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <bdsx:NumberOfPreferredStockConvertedIntoCommonStock
      contextRef="C_0001439725_20201027_20201027"
      decimals="INF"
      id="F_000633"
      unitRef="U_xbrlishares">20090745</bdsx:NumberOfPreferredStockConvertedIntoCommonStock>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_0001439725_20201231"
      decimals="INF"
      id="F_000634"
      unitRef="U_xbrlishares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <bdsx:WarrantsForConvertiblePreferredStockTextBlock contextRef="C_0001439725_20200101_20201231" id="F_000284">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Note 11 &#x2013; Warrants to Purchase Convertible Preferred Stock&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company issued warrants to purchase shares of convertible preferred stock in conjunction with the sale of certain of the convertible preferred shares and issuance of debt. The estimated grant date fair value as well as the estimated fair value at each reporting date of the warrants was determined using the Black&#x2011;Scholes option pricing model with weighted average assumptions substantially consistent with those disclosed for stock options (see Note 14 &#x2013; &lt;span style="font-style:italic;"&gt;Shared Based Compensation&lt;/span&gt;), other than term, which is the contractual term of the warrant and the use of the exercise price and estimated fair value of the underlying series of convertible preferred stock. At December 31, 2019 and through the closing of the Company&#x2019;s initial public offering, the preferred warrants were classified as liabilities with estimated fair value remeasured at each reporting date reported within in the accompanying statements of operations.&lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table presents the activity for convertible preferred stock warrants (in thousands, except weighted average exercise price):&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Series E&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Series G&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Warrants&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercise&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;price&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Warrants&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercise&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;price&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding &#x2011; December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;925&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.00&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;613&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.75&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Granted&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Forfeited/canceled&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(925&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(5.00&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Reclassification of warrant liability to additional paid-in capital&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(613&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.75&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding &#x2011; December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Upon closing of the Company&#x2019;s initial public offering, the then outstanding Series G convertible preferred stock was automatically converted to common stock and the outstanding warrants to purchase Series G convertible preferred stock were automatically converted to warrants to purchase 103,326 shares of common stock at $4.46 per share and expire in &lt;span style="-sec-ix-hidden:F_000645"&gt;February 2028&lt;/span&gt;. The warrants were remeasured to an estimate of fair value as of the initial public offering with the change in fair value of $1.3 million recognized in our statements of operations. The carrying value of the warrants was reclassified to additional paid-in capital as a result of the initial public offering.&lt;/p&gt;</bdsx:WarrantsForConvertiblePreferredStockTextBlock>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="C_0001439725_20200101_20201231" id="F_000332">
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table presents the activity for convertible preferred stock warrants (in thousands, except weighted average exercise price):&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Series E&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Series G&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Warrants&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercise&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;price&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Warrants&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercise&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;price&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding &#x2011; December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;925&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.00&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;613&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.75&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Granted&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Forfeited/canceled&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(925&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(5.00&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Reclassification of warrant liability to additional paid-in capital&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(613&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.75&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding &#x2011; December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="C_0001439725_us-gaapClassOfWarrantOrRightAxis_bdsxSeriesEConvertiblePreferredStockWarrantsMember_20191231"
      decimals="-3"
      id="F_000635"
      unitRef="U_xbrlishares">925000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <bdsx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_0001439725_us-gaapClassOfWarrantOrRightAxis_bdsxSeriesEConvertiblePreferredStockWarrantsMember_20191231"
      decimals="2"
      id="F_000639"
      unitRef="U_iso4217USD_xbrlishares">5.00</bdsx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="C_0001439725_us-gaapClassOfWarrantOrRightAxis_bdsxSeriesGConvertiblePreferredStockWarrantsMember_20191231"
      decimals="-3"
      id="F_000636"
      unitRef="U_xbrlishares">613000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <bdsx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_0001439725_us-gaapClassOfWarrantOrRightAxis_bdsxSeriesGConvertiblePreferredStockWarrantsMember_20191231"
      decimals="2"
      id="F_000640"
      unitRef="U_iso4217USD_xbrlishares">0.75</bdsx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures
      contextRef="C_0001439725_us-gaapClassOfWarrantOrRightAxis_bdsxSeriesEConvertiblePreferredStockWarrantsMember_20200101_20201231"
      decimals="-3"
      id="F_000637"
      unitRef="U_xbrlishares">925000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures>
    <bdsx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="C_0001439725_us-gaapClassOfWarrantOrRightAxis_bdsxSeriesEConvertiblePreferredStockWarrantsMember_20200101_20201231"
      decimals="2"
      id="F_000641"
      unitRef="U_iso4217USD_xbrlishares">5.00</bdsx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsPeriodIncreaseDecrease
      contextRef="C_0001439725_us-gaapClassOfWarrantOrRightAxis_bdsxSeriesGConvertiblePreferredStockWarrantsMember_20200101_20201231"
      decimals="-3"
      id="F_000638"
      unitRef="U_xbrlishares">613000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsPeriodIncreaseDecrease>
    <bdsx:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsReclassificationOfWarrantLiabilityToAdditionalPaidInCapitalWeightedAverageExercisePrice
      contextRef="C_0001439725_us-gaapClassOfWarrantOrRightAxis_bdsxSeriesGConvertiblePreferredStockWarrantsMember_20200101_20201231"
      decimals="2"
      id="F_000642"
      unitRef="U_iso4217USD_xbrlishares">-0.75</bdsx:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsReclassificationOfWarrantLiabilityToAdditionalPaidInCapitalWeightedAverageExercisePrice>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_0001439725_20201231"
      decimals="INF"
      id="F_000643"
      unitRef="U_xbrlishares">103326</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_0001439725_20201231"
      decimals="2"
      id="F_000644"
      unitRef="U_iso4217USD_xbrlishares">4.46</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="C_0001439725_20200101_20201231"
      decimals="-5"
      id="F_000646"
      unitRef="U_iso4217USD">1300000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="C_0001439725_20200101_20201231" id="F_000285">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Note 12 &#x2013; Equity&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Common Stock&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s Restated Certificate of Incorporation authorizes the Company to issue up to 200,000,000 shares of common stock with a par value of $0.001 per share. The holder of each share of common stock is entitled to one vote per share. The common shareholders are entitled to dividends whenever funds and assets are legally available and when and if declared by the Board of Directors. The Company is currently subject to restrictions on the payment of dividends (see Note 9 - &lt;span style="font-style:italic;"&gt;Debt&lt;/span&gt;) and no dividends have been declared as of December 31, 2020.&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On October 27, 2020, the Company issued and sold 4,000,000 shares of common stock in a registered initial public offering at a price to the public of $18.00 per share. The net proceeds to the Company were &lt;span style="Background-color:#FFFFFF;"&gt;approximately &lt;/span&gt;$63.8 million, after deducting underwriting discounts and commissions of $5.0 million and direct offering expenses of approximately $3.2 million. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Preferred Stock&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s Restated Certificate of Incorporation authorizes the Company to issue up to 5,000,000 shares of preferred stock with a par value of $0.001 per share. As of December 31, 2020, no shares of preferred stock were issued or outstanding.&lt;/p&gt;
</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_0001439725_20201231"
      decimals="INF"
      id="F_000647"
      unitRef="U_xbrlishares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_0001439725_20201231"
      decimals="INF"
      id="F_000648"
      unitRef="U_iso4217USD_xbrlishares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockVotingRights contextRef="C_0001439725_20200101_20201231" id="F_000649">The holder of each share of common stock is entitled to one vote per share.</us-gaap:CommonStockVotingRights>
    <us-gaap:DividendsCommonStock
      contextRef="C_0001439725_20200101_20201231"
      decimals="INF"
      id="F_000650"
      unitRef="U_iso4217USD">0</us-gaap:DividendsCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001439725_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20201027_20201027"
      decimals="INF"
      id="F_000651"
      unitRef="U_xbrlishares">4000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="C_0001439725_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20201027"
      decimals="INF"
      id="F_000652"
      unitRef="U_iso4217USD_xbrlishares">18.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="C_0001439725_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20201027_20201027"
      decimals="-5"
      id="F_000653"
      unitRef="U_iso4217USD">63800000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ExpenseRelatedToDistributionOrServicingAndUnderwritingFees
      contextRef="C_0001439725_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20201027_20201027"
      decimals="-5"
      id="F_000654"
      unitRef="U_iso4217USD">5000000.0</us-gaap:ExpenseRelatedToDistributionOrServicingAndUnderwritingFees>
    <bdsx:DirectOfferingExpenses
      contextRef="C_0001439725_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20201027_20201027"
      decimals="-5"
      id="F_000655"
      unitRef="U_iso4217USD">3200000</bdsx:DirectOfferingExpenses>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_0001439725_20201231"
      decimals="INF"
      id="F_000656"
      unitRef="U_xbrlishares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_0001439725_20201231"
      decimals="INF"
      id="F_000657"
      unitRef="U_iso4217USD_xbrlishares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_0001439725_20201231"
      decimals="INF"
      id="F_000658"
      unitRef="U_xbrlishares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:RevenueFromContractWithCustomerTextBlock contextRef="C_0001439725_20200101_20201231" id="F_000286">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Note 13 - Revenue&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s revenue is generated from (i) diagnostic tests and (ii) assay development and testing services. Diagnostic test revenues consist of blood-based lung tests and COVID-19 tests, which are recognized in the amount expected to be received in exchange for diagnostic tests when the diagnostic tests are delivered. The Company conducts diagnostic tests and delivers the completed test results to the prescribing physician or patient, as applicable. The fees for diagnostic tests are billed either to a third party such as Medicare, medical facilities, commercial insurance payers, or to the patient. The Company determines the transaction price related to its diagnostic test contracts by considering the nature of the payer and historical price concessions granted to groups of customers. For diagnostic test revenue, the Company estimates the transaction price, which is the amount of consideration it expects to be entitled to receive in exchange for providing services based on its historical collection experience, using a portfolio approach. The Company recognizes revenues for diagnostic tests upon delivery of the tests to the physicians requesting the tests or patient, as applicable.&lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Services revenue consists of on-market tests, pipeline tests, custom diagnostic testing, and other scientific services for a purpose as defined by any individual customer, which is often with large biopharmaceutical companies. The performance obligations and related revenue for these sales is defined by a written agreement between the Company and the customer. These services are generally completed upon the delivery of testing results, or other contractually defined milestone(s), to the customer. Revenue for these services is recognized upon delivery of the completed test results, or upon completion of the contractual milestone(s). &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Revenues consisted of the following (in thousands): &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.12%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.26%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Diagnostic tests&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;40,919&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17,315&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Services&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,638&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,237&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.26%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;45,557&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;24,552&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s fiscal 2020 diagnostic test revenue consists of $28.3 million in COVID-19 test revenue, which began in late fiscal 2020, and $12.6 million in lung diagnostic revenue.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Contract Liabilities&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contract liabilities consist of cash payments from customers received in advance of delivery (advance deposits). As products are shipped and control transfers, the Company recognizes the deferred revenue in &#x2018;Revenues&#x2019; in the statements of operations. At January 1 and December&#160;31, 2020, $1.3 million and $3.5 million, respectively, of advance deposits were reported in &#x2018;Deferred revenue&#x2019; in the accompanying balance sheets. Of the $1.3 million in deferred revenue recorded at January 1, 2020, $0.7 million was recognized in revenues during the year ended December&#160;31, 2020. The deferred revenue of $3.5 million at December&#160;31, 2020 is expected to be recognized in revenues during 2021 as test results are delivered.&lt;/p&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock contextRef="C_0001439725_20200101_20201231" id="F_000333">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Revenues consisted of the following (in thousands): &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.12%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.26%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Diagnostic tests&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;40,919&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17,315&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Services&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,638&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,237&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.26%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;45,557&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;24,552&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:Revenues
      contextRef="C_0001439725_srtProductOrServiceAxis_bdsxDiagnosticTestsMember_20200101_20201231"
      decimals="-3"
      id="F_000660"
      unitRef="U_iso4217USD">40919000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_0001439725_srtProductOrServiceAxis_bdsxDiagnosticTestsMember_20190101_20191231"
      decimals="-3"
      id="F_000661"
      unitRef="U_iso4217USD">17315000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_0001439725_srtProductOrServiceAxis_us-gaapServiceMember_20200101_20201231"
      decimals="-3"
      id="F_000662"
      unitRef="U_iso4217USD">4638000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_0001439725_srtProductOrServiceAxis_us-gaapServiceMember_20190101_20191231"
      decimals="-3"
      id="F_000663"
      unitRef="U_iso4217USD">7237000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_0001439725_20200101_20201231"
      decimals="-3"
      id="F_000664"
      unitRef="U_iso4217USD">45557000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_0001439725_20190101_20191231"
      decimals="-3"
      id="F_000665"
      unitRef="U_iso4217USD">24552000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_0001439725_srtProductOrServiceAxis_bdsxCOVID19DiagnosticTestRevenueMember_20200101_20201231"
      decimals="-5"
      id="F_000666"
      unitRef="U_iso4217USD">28300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_0001439725_srtProductOrServiceAxis_bdsxLungDiagnosticRevenueMember_20200101_20201231"
      decimals="-5"
      id="F_000667"
      unitRef="U_iso4217USD">12600000</us-gaap:Revenues>
    <bdsx:AdvanceDeposits
      contextRef="C_0001439725_us-gaapBalanceSheetLocationAxis_bdsxDeferredRevenueMember_20200101"
      decimals="-5"
      id="F_000669"
      unitRef="U_iso4217USD">1300000</bdsx:AdvanceDeposits>
    <bdsx:AdvanceDeposits
      contextRef="C_0001439725_us-gaapBalanceSheetLocationAxis_bdsxDeferredRevenueMember_20201231"
      decimals="-5"
      id="F_000668"
      unitRef="U_iso4217USD">3500000</bdsx:AdvanceDeposits>
    <bdsx:AdvanceDeposits
      contextRef="C_0001439725_us-gaapBalanceSheetLocationAxis_bdsxDeferredRevenueMember_20200101"
      decimals="-5"
      id="F_000670"
      unitRef="U_iso4217USD">1300000</bdsx:AdvanceDeposits>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="C_0001439725_20200101_20201231"
      decimals="-5"
      id="F_000671"
      unitRef="U_iso4217USD">700000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="C_0001439725_20201231"
      decimals="-5"
      id="F_000672"
      unitRef="U_iso4217USD">3500000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="C_0001439725_20200101_20201231" id="F_000287">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Note 14 &#x2013; Share Based Compensation&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;2016 Equity Incentive Plan and Predecessor 2006 Equity Incentive Plan&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In February 2016, the Company adopted the 2016 Equity Incentive Plan (2016 Plan) as a successor to and continuation of the prior 2006 Equity Incentive Plan (2006 Plan). The 2016 Plan provides for the grant of incentive stock options, non-statutory stock options, stock appreciation rights, restricted stock awards, restricted stock units, and other stock awards to directors, employees, and consultants. Awards granted under the 2016 Plan or the 2006 Plan that expired or otherwise terminated, or were forfeited, cancelled, or repurchased by the Company, became available for future issuance under the 2016 Plan. In addition, shares subject to an award were withheld to satisfy a participant&#x2019;s tax withholding obligations, or were reacquired by the Company as consideration for the exercise or purchase price of a stock award also became available for future issuance under the 2016 Incentive Plan.&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;2020 Equity Incentive Plan&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Effective upon the closing of our initial public offering, the Company&#x2019;s Board of Directors approved the 2020 Equity Incentive Plan (2020 Plan), which replaced the 2016 Plan. &lt;span style="Background-color:#FFFFFF;"&gt;&#160;The 2020 Plan provides for the grant of incentive stock options, non-statutory stock options, stock appreciation rights, restricted stock awards, restricted stock units, performance awards and other stock awards. Officers, directors, employees, consultants, agents, and independent contractors who provide services to the Company may receive awards. The terms of all awards are governed by an agreement between the Company and the recipients, as administered and approved by the Compensation Committee of the Board of Directors.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Employee Stock Purchase Plan&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Effective with our initial public offering in October 2020, the Company&#x2019;s Board of Directors and its stockholders approved the Company&#x2019;s Employee Stock Purchase Plan (ESPP). A total of 338,106 shares of our common stock have been reserved for issuance under the ESPP. The maximum number of shares of our common stock available under the ESPP will automatically increase on the first trading day of each calendar year, commencing January 2021, by an amount equal to the lesser of (i) 1% of the shares of our common stock issued and outstanding on December 31 of the immediately preceding calendar year, and (ii) an amount determined by our Board of Directors.&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.77%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Subject to any plan limitations, the ESPP allows eligible employees to contribute, normally through payroll deductions, up to 15% of their earnings for the purchase of the Company&#x2019;s common stock at a discounted price per share. The price at which common stock is purchased under the ESPP is equal to 85% of the fair market value of the Company&#x2019;s common stock on the first or last day of the offering period, whichever is lower. No employee may participate in an offering period if the employee owns 5% or more of the total combined voting power or value of the Company&#x2019;s stock. The initial offering period will commence from January 1, 2021 through August 31, 2021.  On a going forward basis, the ESPP provides for successive six-month offering periods beginning on September 1st and March 1st of each year.&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Shares Reserved Subject to All Plans&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The number of shares reserved for issuance under the 2020 Plan is 1,893,395, plus an annual increase added on the first day of each calendar year, beginning with the calendar year ending December&#160;31, 2022, and continuing until, and including, the calendar year ending December&#160;31, 2030. The annual increase will be equal to the lesser of (i)&#160;4% of the number of shares of our common stock issued and outstanding as of December&#160;31st of the immediately preceding calendar year and (ii)&#160;such lesser amount determined by the Board of Directors. Up to 1,893,395 shares of our common stock that may be issued under the 2020 Plan may be issued in satisfaction of incentive stock option awards.&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Under the 2006 Plan, the Company is authorized to grant &lt;span style="Background-color:#FFFFFF;"&gt;incentive stock options, non-statutory stock options, stock appreciation rights, restricted stock awards and restricted stock units&lt;/span&gt; up to 831,389 total award shares.&lt;span style="Background-color:#FFFFFF;"&gt; No additional awards may be granted under the 2006 Plan. Unallocated shares under the 2006 Plan were added to the shares available for issuance under the 2016 Plan.&lt;/span&gt;&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;Under the 2016 Plan, which is a successor to and continuation of the 2006 Plan, the Company is authorized to grant incentive stock options, non-statutory stock options, stock appreciation rights, restricted stock awards, restricted stock units and stock appreciation rights up to 1,431,964 total shares, plus any shares subject to stock awards made under the 2006 Plan&lt;/span&gt;.&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;Our Compensation Committee may grant other stock awards that are based on or related to shares of our common stock, such as awards of shares of common stock granted as bonus and not subject to any vesting conditions, deferred stock units, stock purchase rights, and shares of our common stock issued in lieu of our obligations to pay cash under any compensatory plan or arrangement. To date, t&lt;/span&gt;&lt;span style="color:#000000;"&gt;he Company has granted service-condition RSUs.&lt;/span&gt;&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;To the extent an equity award granted under the 2020 Plan (other than any substitute award) or granted under any other equity plan maintained by us under which awards are outstanding as of the effective date of the 2020 Plan (the Prior Plans) expires or otherwise terminates without having been exercised or paid in full, or is settled in cash, the shares subject to such award will become available for future grant under the 2020 Plan. In addition, to the extent shares subject to an award are withheld to satisfy a participant&#x2019;s tax withholding obligation upon the exercise or settlement of such award (other than any substitute award) or to pay the exercise price of a stock option granted under the 2020 Plan or a Prior Plan, such shares will become available for future grant under the 2020 Plan. The total number of shares available for grant under all Plans was 4,647,380 at December 31, 2020.&lt;/p&gt;

&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Description of Awards Granted&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has granted incentive stock options, non-statutory stock options, performance-based stock options, and restricted stock units. &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Incentive stock options, which may only be issued to employees, are granted at an exercise price per share equal to the fair market value per share of the underlying common stock on the grant date, and vest over time as determined by the Compensation Committee, provided that the term of the options may not exceed ten years from the date of grant. Accelerated vesting may occur in the event of an optionee's death, disability, or other events.&lt;span style="Background-color:#FFFFFF;"&gt; &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;Non-statutory stock options may be issued to non-employees and directors, with exercise prices, vesting conditions, option term and other conditions as determined by the Compensation Committee.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Performance-based stock options are typically granted on an annual basis and consist of a performance-based and service-based component. The performance targets and vesting conditions for performance-condition options are based on achievement of recognized revenue targets. Performance-based options vest in three equal annual installments beginning one year after the grant date, pending certification of performance achievement by the Compensation Committee and continued service. The fair value of performance-condition awards is based on the closing market price of the Company&#x2019;s common stock on the grant date. Compensation expense, net of forfeitures, is updated for the Company&#x2019;s expected performance level against performance goals at the end of each reporting period. On January 1, 2019, the Company granted 168,466 performance-condition options, with an exercise price of $0.77 per share and a term of ten years. During the year ended December 31, 2020, the performance conditions were met and 56,155 options vested. During the year ended December 31, 2019, the performance conditions were not met and 56,155 options were forfeited. As of December 31, 2020, there were 56,156 performance condition options outstanding with a remaining life of approximately eight years. &lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Restricted stock units and the related terms and conditions are awarded at the discretion of the Compensation Committee. RSU&lt;span style="Background-color:#FFFFFF;color:#000000;"&gt; holders &lt;/span&gt;have a contractual right to receive a share of common stock when vested. RSUs generally vest over three years. RSU agreements may provide for accelerated vesting in the event of a stock unit holder's death, disability, or retirement or other events.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Bonus-To-Options Program&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company also has a Bonus-to-Options Program (the &#x201c;Bonus Option Program&#x201d;), which is separate from predecessor Plans and was initially adopted by the Board of Directors in 2008, and subsequently amended and restated in 2010, 2011 and 2015. For fiscal year 2021, the Bonus Option Program is subject to the shares reserved under the 2020 Plan. The Bonus Option Program, which is limited to participation of the Chief Executive Officer, direct reports to the Chief Executive Officer and Vice Presidents of the Company, allows participants who so elect to convert all or a portion of their annual cash bonus into fully vested, non-qualified stock options to purchase shares of common stock (Bonus Options).&lt;span style="font-size:12pt;"&gt; &lt;/span&gt;The exercise price for the options under the Bonus Option Program equals the then current price for the shares of the common stock as of the grant date, as disclosed below under &#x201c;&lt;span style="font-style:italic;"&gt;Fair Value of Common Stock&lt;/span&gt;&#x201d;. Bonus Options issued must be exercised within a &lt;span style="-sec-ix-hidden:F_000697"&gt;ten-year&lt;/span&gt; term. A maximum of 1% of the fully diluted equity, as of December 31 of the year for which the bonus was awarded, may be issued in any one year to the participants. As of December 31, 2020, there were 173,229 options outstanding under the Bonus Option Program. &lt;span style="color:#000000;"&gt;These options are fully vested and have a weighted average exercise price of $11.11 per share and have an intrinsic value of approximately $1.6 million as of December 31, 2020&lt;/span&gt;.&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; &lt;span style="color:#000000;"&gt;During the twelve-month period ended December 31, 2020, the Company accrued $3.4 million as stock compensation expense associated with the estimate of options to be delivered to eligible participants under the Bonus Option Program and which were granted in February 2021 by the Compensation Committee of the Board of Directors.&#160;&#160;In determining the amount of stock compensation to recognize under the Bonus Option Program, the Company estimates the bonus attainment for the year and determines the expected number of options to be delivered to eligible participants.&#160;&#160;A Black-Scholes option pricing model is used to determine the estimated fair value of the expected number of options to be delivered to eligible participants.&#160;&#160;The key elements in determining the estimated fair value include assumptions for volatility, the risk free interest rate, expected dividends and strike price, utilizing the measurement date closing stock price until the grants are authorized.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Share-Based Compensation Expense&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Pre-tax share-based compensation expense reported in the Company&#x2019;s statements of operations was (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.78%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.52%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.78%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.5%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.78%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;589&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;33&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.78%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Sales, marketing, general and administrative&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,120&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;137&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.78%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,709&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.5%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;170&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The unrecognized remaining share-based compensation expense for options and RSUs was approximately $0.6 million as of December 31, 2020, and is expected to be amortized to expense over the next 3.7 years.&lt;/p&gt;
&lt;p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Stock Options&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock option activity during the year ended December 31, 2020, excluding the Bonus Option Program described above, was (in thousands, except weighted average exercise price and weighted average contractual life):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:27.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.28%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number of&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.28%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercise&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Price&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.28%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contractual&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Life (Years)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.28%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Aggregate&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intrinsic&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding - December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.28%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,916&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.28%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.72&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.28%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000723"&gt;7.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.28%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Granted&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.28%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;828&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.28%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.81&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.28%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000724"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.28%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Forfeited/canceled&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.28%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(55&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.28%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.60&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.28%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.28%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:27.7%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.28%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(368&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:14.28%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3.65&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:14.28%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:14.28%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:27.7%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding &#x2011; December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.28%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,321&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.28%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.82&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.28%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000725"&gt;7.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.28%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;42,580&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:27.7%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercisable &#x2011; December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.28%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,190&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.28%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.35&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.28%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000726"&gt;6.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.28%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21,194&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Fair Value of Common Stock&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prior to the Company&#x2019;s initial public offering, the fair value of the Company&#x2019;s common stock underlying the stock options was determined by the Board of Directors with assistance from management and, in part, on input from an independent third-party valuation firm. The Board of Directors determined the fair value of common stock by considering a number of objective and subjective factors, including valuations of comparable companies, sales of convertible preferred stock, operating and financial performance, the lack of liquidity of the Company&#x2019;s common stock and the general and industry-specific economic outlook. Subsequent&#160;to the Company&#x2019;s initial public offering, the fair value of the Company&#x2019;s common stock is determined based on its closing market price.&lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The fair value of each option grant prior was estimated on the grant date using the Black&#x2011;Scholes option pricing model with the following weighted average assumptions for the year ended December 31, 2020:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Risk&#x2011;free rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.34&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected term (in years)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000730"&gt;5.73&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;77&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company estimated volatility based on the historical volatility of its peer group and average expected life based on the review of historical exercise behavior of option grants with similar vesting periods. &lt;span style="color:#000000;"&gt;&#160;&lt;/span&gt; &lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Restricted Stock Units and Restricted Stock Unit Activity&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Service-condition RSUs were granted to Board members and vest over three years, 40% over the first two years and the remaining 60% over the third year from the grant date. During the year ended December&#160;31, 2020, the Company granted 52,736 service-condition RSUs. As of December 31, 2020, there were 79,104 RSUs outstanding, with a weighted average grant date fair value of $6.83 per share.&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_0001439725_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20201031"
      decimals="INF"
      id="F_000673"
      unitRef="U_xbrlishares">338106</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
      contextRef="C_0001439725_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20200101_20201231"
      decimals="INF"
      id="F_000674"
      unitRef="U_xbrlipure">0.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate
      contextRef="C_0001439725_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20201231"
      decimals="INF"
      id="F_000675"
      unitRef="U_xbrlipure">0.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate
      contextRef="C_0001439725_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20200101_20201231"
      decimals="INF"
      id="F_000676"
      unitRef="U_xbrlipure">0.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate>
    <bdsx:DescriptionOfVotingPowerOrValueOfStockForEmployeeParticipationInOfferingPeriod
      contextRef="C_0001439725_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20200101_20201231"
      id="F_000677">No employee may participate in an offering period if the employee owns 5% or more of the total combined voting power or value of the Company&#x2019;s stock.</bdsx:DescriptionOfVotingPowerOrValueOfStockForEmployeeParticipationInOfferingPeriod>
    <bdsx:DescriptionOfOfferingPeriodUnderPlan
      contextRef="C_0001439725_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20200101_20201231"
      id="F_000678">The initial offering period will commence from January 1, 2021 through August 31, 2021.  On a going forward basis, the ESPP provides for successive six-month offering periods beginning on September 1st and March 1st of each year.</bdsx:DescriptionOfOfferingPeriodUnderPlan>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_0001439725_us-gaapPlanNameAxis_bdsxTwoThousandTwentyEquityIncentivePlanMember_20201231"
      decimals="INF"
      id="F_000679"
      unitRef="U_xbrlishares">1893395</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
      contextRef="C_0001439725_us-gaapPlanNameAxis_bdsxTwoThousandTwentyEquityIncentivePlanMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231"
      decimals="INF"
      id="F_000680"
      unitRef="U_xbrlipure">0.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="C_0001439725_srtRangeAxis_srtMaximumMember_us-gaapPlanNameAxis_bdsxTwoThousandTwentyEquityIncentivePlanMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231"
      decimals="INF"
      id="F_000681"
      unitRef="U_xbrlishares">1893395</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="C_0001439725_srtRangeAxis_srtMaximumMember_us-gaapPlanNameAxis_bdsxTwoThousandSixPlanMember_20201231"
      decimals="INF"
      id="F_000682"
      unitRef="U_xbrlishares">831389</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_0001439725_us-gaapPlanNameAxis_bdsxTwoThousandAndSixteenPlanMember_20160229"
      decimals="INF"
      id="F_000683"
      unitRef="U_xbrlishares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="C_0001439725_srtRangeAxis_srtMaximumMember_us-gaapPlanNameAxis_bdsxTwoThousandAndSixteenPlanMember_20160229"
      decimals="INF"
      id="F_000684"
      unitRef="U_xbrlishares">1431964</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_0001439725_us-gaapPlanNameAxis_bdsxTwoThousandSixPlanTwoThousandSixteenPlanAndTwoThousandTwentyEquityIncentivePlanMember_20201231"
      decimals="INF"
      id="F_000685"
      unitRef="U_xbrlishares">4647380</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="C_0001439725_srtRangeAxis_srtMaximumMember_us-gaapPlanNameAxis_bdsxTwoThousandTwentyEquityIncentivePlanMember_20200101_20201231"
      id="F_000686">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights
      contextRef="C_0001439725_us-gaapAwardTypeAxis_bdsxPerformanceConditionOptionsMember_us-gaapPlanNameAxis_bdsxTwoThousandTwentyEquityIncentivePlanMember_20200101_20201231"
      id="F_000687">Performance-based options vest in three equal annual installments beginning one year after the grant date</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights>
    <bdsx:NumberOfEqualAnnualInstallmentsForAwardVesting
      contextRef="C_0001439725_us-gaapAwardTypeAxis_bdsxPerformanceConditionOptionsMember_us-gaapPlanNameAxis_bdsxTwoThousandTwentyEquityIncentivePlanMember_20200101_20201231"
      decimals="INF"
      id="F_000688"
      unitRef="U_bdsxInstallment">3</bdsx:NumberOfEqualAnnualInstallmentsForAwardVesting>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_0001439725_us-gaapAwardTypeAxis_bdsxPerformanceConditionOptionsMember_us-gaapPlanNameAxis_bdsxTwoThousandTwentyEquityIncentivePlanMember_20190101_20190101"
      decimals="INF"
      id="F_000689"
      unitRef="U_xbrlishares">168466</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_0001439725_us-gaapAwardTypeAxis_bdsxPerformanceConditionOptionsMember_us-gaapPlanNameAxis_bdsxTwoThousandTwentyEquityIncentivePlanMember_20190101_20190101"
      decimals="2"
      id="F_000690"
      unitRef="U_iso4217USD_xbrlishares">0.77</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="C_0001439725_us-gaapAwardTypeAxis_bdsxPerformanceConditionOptionsMember_us-gaapPlanNameAxis_bdsxTwoThousandTwentyEquityIncentivePlanMember_20190101_20190101"
      id="F_000691">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="C_0001439725_us-gaapAwardTypeAxis_bdsxPerformanceConditionOptionsMember_us-gaapPlanNameAxis_bdsxTwoThousandTwentyEquityIncentivePlanMember_20200101_20201231"
      decimals="INF"
      id="F_000692"
      unitRef="U_xbrlishares">56155</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_0001439725_us-gaapAwardTypeAxis_bdsxPerformanceConditionOptionsMember_us-gaapPlanNameAxis_bdsxTwoThousandTwentyEquityIncentivePlanMember_20190101_20191231"
      decimals="INF"
      id="F_000693"
      unitRef="U_xbrlishares">56155</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_0001439725_us-gaapAwardTypeAxis_bdsxPerformanceConditionOptionsMember_us-gaapPlanNameAxis_bdsxTwoThousandTwentyEquityIncentivePlanMember_20201231"
      decimals="INF"
      id="F_000694"
      unitRef="U_xbrlishares">56156</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_0001439725_us-gaapAwardTypeAxis_bdsxPerformanceConditionOptionsMember_us-gaapPlanNameAxis_bdsxTwoThousandTwentyEquityIncentivePlanMember_20200101_20201231"
      id="F_000695">P8Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_0001439725_srtRangeAxis_srtMinimumMember_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_bdsxTwoThousandTwentyEquityIncentivePlanMember_20200101_20201231"
      id="F_000696">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <bdsx:PercentageOfFullyDilutedEquityForBonusAwarded
      contextRef="C_0001439725_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_bdsxBonusToOptionsProgramMember_20200101_20201231"
      decimals="INF"
      id="F_000698"
      unitRef="U_xbrlipure">0.01</bdsx:PercentageOfFullyDilutedEquityForBonusAwarded>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_0001439725_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_bdsxBonusToOptionsProgramMember_20201231"
      decimals="INF"
      id="F_000699"
      unitRef="U_xbrlishares">173229</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="C_0001439725_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_bdsxBonusToOptionsProgramMember_20201231"
      decimals="2"
      id="F_000700"
      unitRef="U_iso4217USD_xbrlishares">11.11</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_0001439725_us-gaapAwardTypeAxis_bdsxBonusToOptionsProgramMember_20201231"
      decimals="-5"
      id="F_000701"
      unitRef="U_iso4217USD">1600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001439725_us-gaapAwardTypeAxis_bdsxBonusToOptionsProgramMember_20200101_20201231"
      decimals="-5"
      id="F_000702"
      unitRef="U_iso4217USD">3400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="C_0001439725_20200101_20201231" id="F_000334">
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Pre-tax share-based compensation expense reported in the Company&#x2019;s statements of operations was (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.78%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.52%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.78%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.5%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.78%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;589&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;33&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.78%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Sales, marketing, general and administrative&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,120&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;137&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.78%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,709&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.5%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;170&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001439725_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20200101_20201231"
      decimals="-3"
      id="F_000703"
      unitRef="U_iso4217USD">589000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001439725_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20190101_20191231"
      decimals="-3"
      id="F_000704"
      unitRef="U_iso4217USD">33000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001439725_us-gaapIncomeStatementLocationAxis_us-gaapSellingGeneralAndAdministrativeExpensesMember_20200101_20201231"
      decimals="-3"
      id="F_000705"
      unitRef="U_iso4217USD">3120000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001439725_us-gaapIncomeStatementLocationAxis_us-gaapSellingGeneralAndAdministrativeExpensesMember_20190101_20191231"
      decimals="-3"
      id="F_000706"
      unitRef="U_iso4217USD">137000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001439725_20200101_20201231"
      decimals="-3"
      id="F_000707"
      unitRef="U_iso4217USD">3709000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001439725_20190101_20191231"
      decimals="-3"
      id="F_000708"
      unitRef="U_iso4217USD">170000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="C_0001439725_us-gaapAwardTypeAxis_bdsxOptionsAndRestrictedStockUnitsMember_20201231"
      decimals="-5"
      id="F_000709"
      unitRef="U_iso4217USD">600000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_0001439725_us-gaapAwardTypeAxis_bdsxOptionsAndRestrictedStockUnitsMember_20200101_20201231"
      id="F_000710">P3Y8M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="C_0001439725_20200101_20201231" id="F_000335">
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock option activity during the year ended December 31, 2020, excluding the Bonus Option Program described above, was (in thousands, except weighted average exercise price and weighted average contractual life):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:27.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.28%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number of&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.28%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercise&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Price&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.28%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contractual&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Life (Years)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.28%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Aggregate&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intrinsic&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding - December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.28%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,916&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.28%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.72&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.28%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000723"&gt;7.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.28%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Granted&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.28%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;828&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.28%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.81&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.28%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000724"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.28%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Forfeited/canceled&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.28%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(55&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.28%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.60&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.28%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.28%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:27.7%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.28%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(368&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:14.28%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3.65&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:14.28%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:14.28%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:27.7%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding &#x2011; December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.28%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,321&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.28%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.82&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.28%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000725"&gt;7.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.28%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;42,580&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:27.7%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercisable &#x2011; December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.28%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,190&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.28%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.35&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.28%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000726"&gt;6.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.28%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21,194&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_0001439725_20191231"
      decimals="-3"
      id="F_000711"
      unitRef="U_xbrlishares">1916000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_0001439725_20191231"
      decimals="2"
      id="F_000717"
      unitRef="U_iso4217USD_xbrlishares">1.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_0001439725_20200101_20201231"
      decimals="-3"
      id="F_000712"
      unitRef="U_xbrlishares">828000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_0001439725_20200101_20201231"
      decimals="2"
      id="F_000718"
      unitRef="U_iso4217USD_xbrlishares">2.81</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="C_0001439725_20200101_20201231"
      decimals="-3"
      id="F_000713"
      unitRef="U_xbrlishares">55000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="C_0001439725_20200101_20201231"
      decimals="2"
      id="F_000719"
      unitRef="U_iso4217USD_xbrlishares">0.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_0001439725_20200101_20201231"
      decimals="-3"
      id="F_000714"
      unitRef="U_xbrlishares">368000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_0001439725_20200101_20201231"
      decimals="2"
      id="F_000720"
      unitRef="U_iso4217USD_xbrlishares">3.65</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_0001439725_20201231"
      decimals="-3"
      id="F_000715"
      unitRef="U_xbrlishares">2321000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_0001439725_20201231"
      decimals="2"
      id="F_000721"
      unitRef="U_iso4217USD_xbrlishares">1.82</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_0001439725_20201231"
      decimals="-3"
      id="F_000727"
      unitRef="U_iso4217USD">42580000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_0001439725_20201231"
      decimals="-3"
      id="F_000716"
      unitRef="U_xbrlishares">1190000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="C_0001439725_20201231"
      decimals="2"
      id="F_000722"
      unitRef="U_iso4217USD_xbrlishares">2.35</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="C_0001439725_20201231"
      decimals="-3"
      id="F_000728"
      unitRef="U_iso4217USD">21194000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="C_0001439725_20200101_20201231" id="F_000336">
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The fair value of each option grant prior was estimated on the grant date using the Black&#x2011;Scholes option pricing model with the following weighted average assumptions for the year ended December 31, 2020:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Risk&#x2011;free rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.34&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected term (in years)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000730"&gt;5.73&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;77&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_0001439725_20200101_20201231"
      decimals="4"
      id="F_000729"
      unitRef="U_xbrlipure">0.0034</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_0001439725_20200101_20201231"
      decimals="2"
      id="F_000731"
      unitRef="U_xbrlipure">0.77</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights
      contextRef="C_0001439725_us-gaapAwardTypeAxis_bdsxServiceConditionRSUsMember_20200101_20201231"
      id="F_000732">vest over three years, 40% over the first two years and the remaining 60% over the third year from the grant date.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_0001439725_srtRangeAxis_srtMinimumMember_us-gaapAwardTypeAxis_bdsxServiceConditionRSUsMember_20200101_20201231"
      id="F_000733">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="C_0001439725_us-gaapAwardTypeAxis_bdsxServiceConditionRSUsMember_us-gaapVestingAxis_us-gaapShareBasedCompensationAwardTrancheOneMember_20200101_20201231"
      decimals="2"
      id="F_000734"
      unitRef="U_xbrlipure">0.40</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="C_0001439725_us-gaapAwardTypeAxis_bdsxServiceConditionRSUsMember_us-gaapVestingAxis_us-gaapShareBasedCompensationAwardTrancheTwoMember_20200101_20201231"
      decimals="2"
      id="F_000735"
      unitRef="U_xbrlipure">0.60</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="C_0001439725_us-gaapAwardTypeAxis_bdsxServiceConditionRSUsMember_20200101_20201231"
      decimals="INF"
      id="F_000736"
      unitRef="U_xbrlishares">52736</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="C_0001439725_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20201231"
      decimals="INF"
      id="F_000737"
      unitRef="U_xbrlishares">79104</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_0001439725_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20201231"
      decimals="2"
      id="F_000738"
      unitRef="U_iso4217USD_xbrlishares">6.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EarningsPerShareTextBlock contextRef="C_0001439725_20200101_20201231" id="F_000288">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Note 15 &#x2013; Earnings per Share&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Excluded from determination of diluted net loss attributable to common stockholders for the periods presented because inclusion would be anti-dilutive are the instruments below, the terms of which are described in further detail in Note 14 &#x2013; &lt;span style="font-style:italic;"&gt;Share Based Compensation.&#160;&#160;&lt;/span&gt;The potentially dilutive securities as of December 31, 2020 and 2019 primarily represent the shares subject to future issuance under stock options awards, warrants and RSUs and would be subject to the treasury stock method when dilutive. The number of common shares that convertible debt was assumed to convert to was based on the Company&#x2019;s estimated common stock price as of December 31, 2019, as determined by the Company&#x2019;s Board of Directors with assistance from a valuation firm. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.38%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.08%; border-bottom:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December 31&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.38%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.38%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Numerator&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.76%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.76%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.38%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss attributable to common stockholders&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(31,350&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(30,726&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.38%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.76%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.76%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.38%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Denominator&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.76%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.76%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.38%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-average shares outstanding used&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; in computing net loss per share, basic and diluted&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,838&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;242&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.38%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss per share, basic and diluted&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(6.48&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(126.97&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following outstanding common stock equivalents were excluded from diluted net loss attributable to common stockholders for the periods presented because inclusion would be anti-dilutive (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.38%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.08%; border-bottom:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December 31&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.38%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-top:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.38%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options to purchase common stock&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,495&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,104&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.38%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Convertible preferred stock&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;119,257&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.38%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Warrants&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;103&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,538&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.38%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Restricted stock units&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;79&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;26&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.38%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Convertible debt &lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21,131&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.38%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,677&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;144,056&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.85%;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="C_0001439725_20200101_20201231" id="F_000337">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.38%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.08%; border-bottom:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December 31&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.38%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.38%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Numerator&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.76%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.76%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.38%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss attributable to common stockholders&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(31,350&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(30,726&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.38%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.76%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.76%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.38%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Denominator&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.76%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.76%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.38%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-average shares outstanding used&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; in computing net loss per share, basic and diluted&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,838&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;242&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.38%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss per share, basic and diluted&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(6.48&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(126.97&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001439725_20200101_20201231"
      decimals="-3"
      id="F_000739"
      unitRef="U_iso4217USD">-31350000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001439725_20190101_20191231"
      decimals="-3"
      id="F_000740"
      unitRef="U_iso4217USD">-30726000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="C_0001439725_20200101_20201231"
      decimals="-3"
      id="F_000741"
      unitRef="U_xbrlishares">4838000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="C_0001439725_20190101_20191231"
      decimals="-3"
      id="F_000742"
      unitRef="U_xbrlishares">242000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="C_0001439725_20200101_20201231"
      decimals="2"
      id="F_000743"
      unitRef="U_iso4217USD_xbrlishares">-6.48</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="C_0001439725_20190101_20191231"
      decimals="2"
      id="F_000744"
      unitRef="U_iso4217USD_xbrlishares">-126.97</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="C_0001439725_20200101_20201231" id="F_000338">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following outstanding common stock equivalents were excluded from diluted net loss attributable to common stockholders for the periods presented because inclusion would be anti-dilutive (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.38%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.08%; border-bottom:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December 31&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.38%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-top:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.38%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options to purchase common stock&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,495&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,104&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.38%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Convertible preferred stock&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;119,257&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.38%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Warrants&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;103&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,538&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.38%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Restricted stock units&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;79&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;26&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.38%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Convertible debt &lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21,131&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.38%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,677&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;144,056&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.85%;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001439725_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_bdsxOptionsToPurchaseCommonStockMember_20200101_20201231"
      decimals="-3"
      id="F_000745"
      unitRef="U_xbrlishares">2495000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001439725_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_bdsxOptionsToPurchaseCommonStockMember_20190101_20191231"
      decimals="-3"
      id="F_000746"
      unitRef="U_xbrlishares">2104000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001439725_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20190101_20191231"
      decimals="-3"
      id="F_000747"
      unitRef="U_xbrlishares">119257000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001439725_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapWarrantMember_20200101_20201231"
      decimals="-3"
      id="F_000748"
      unitRef="U_xbrlishares">103000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001439725_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapWarrantMember_20190101_20191231"
      decimals="-3"
      id="F_000749"
      unitRef="U_xbrlishares">1538000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001439725_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapRestrictedStockUnitsRSUMember_20200101_20201231"
      decimals="-3"
      id="F_000750"
      unitRef="U_xbrlishares">79000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001439725_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapRestrictedStockUnitsRSUMember_20190101_20191231"
      decimals="-3"
      id="F_000751"
      unitRef="U_xbrlishares">26000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001439725_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapConvertibleDebtSecuritiesMember_20190101_20191231"
      decimals="-3"
      id="F_000752"
      unitRef="U_xbrlishares">21131000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001439725_20200101_20201231"
      decimals="-3"
      id="F_000753"
      unitRef="U_xbrlishares">2677000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001439725_20190101_20191231"
      decimals="-3"
      id="F_000754"
      unitRef="U_xbrlishares">144056000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="C_0001439725_20200101_20201231" id="F_000289">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Note 16 - Income Taxes&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Since inception, the Company has incurred net taxable losses, and accordingly, no current provision for income taxes has been recorded.&lt;span style="font-size:12pt;"&gt; &lt;/span&gt;The effective income tax rate of the provision for income taxes differs from the federal statutory rate as follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Years Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Federal statutory income tax rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;State income taxes, net of federal benefit&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and developments credits&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Permanent items&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(6&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Change in valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(16&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(23&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Effective income tax rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The tax effects of temporary differences that give rise to significant portions of the deferred income tax assets and liabilities are as follows (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Years Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred Tax Assets:&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net operating loss carryforwards&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;53,128&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;50,360&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development tax credits&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,860&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,040&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;279&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;370&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock-based compensation&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;865&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accruals and reserves&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,406&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;286&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;58,538&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;54,056&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(56,083&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(51,135&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total deferred tax assets after valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,455&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,921&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred Tax Liabilities:&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intangible assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,455&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,921&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total deferred tax liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,455&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,921&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net deferred tax assets and liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;At December 31, 2020, the Company had $233.6 million and $3.6 million of net operating loss and research and experimentation tax carryforwards, respectively, which are set to expire beginning in 2026. The Internal Revenue Code contains provisions that may limit the net operating loss carryovers available to be used in any year if certain events occur, including significant changes in ownership interest. &lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In assessing the realizability of its deferred tax assets, the Company considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. The Company considers the scheduled reversal of deferred tax liabilities, projected future taxable income, and tax planning strategies in making this assessment. As the Company does not have any historical taxable income, projections of future taxable income over the periods in which the deferred tax assets are deductible, and after consideration of the history of operating losses, the Company does not believe it is more likely than not that it will realize the benefits of net deferred tax assets and, accordingly, has established a valuation allowance equal to 100% of net deferred tax assets. The valuation allowance increased by $4.9 million during 2020 and $7.0 million during 2019.&lt;/p&gt;

&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;During 2020, the Company determined that it now has uncertain&lt;span style="color:#000000;"&gt; tax positions related to its U.S. research and development credits. As of December 31, 2020 and 2019, there was no accrued interest related to uncertain tax positions. The Company does not believe it is reasonably possible that its unrecognized tax benefits will significantly change in the next twelve months&lt;/span&gt;. A reconciliation of beginning and ending balances for unrecognized tax benefits is as follows (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at January 1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Additions for tax positions related to the current year&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;106&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Additions for tax positions related to prior years&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;609&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Reductions for tax positions related to prior years&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Reductions related to settlements&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Reductions related to a lapse of statute&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at December 31&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;715&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company monitors proposed and issued tax law, regulations, and cases to determine the potential impact of uncertain income tax positions. At December 31, 2020, the Company had not identified any potential subsequent events that would have a material impact on unrecognized income tax benefits within the next twelve months.&lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;All years will remain open for examining by federal and state authorities for three and four years, respectively, from the date of utilization of any net operating loss carryforwards. &lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_0001439725_20200101_20201231"
      decimals="INF"
      id="F_000755"
      unitRef="U_iso4217USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="C_0001439725_20200101_20201231" id="F_000339">The effective income tax rate of the provision for income taxes differs from the federal statutory rate as follows:
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Years Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Federal statutory income tax rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;State income taxes, net of federal benefit&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and developments credits&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Permanent items&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(6&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Change in valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(16&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(23&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Effective income tax rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_0001439725_20200101_20201231"
      decimals="INF"
      id="F_000756"
      unitRef="U_xbrlipure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_0001439725_20190101_20191231"
      decimals="INF"
      id="F_000757"
      unitRef="U_xbrlipure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="C_0001439725_20200101_20201231"
      decimals="2"
      id="F_000758"
      unitRef="U_xbrlipure">0.02</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="C_0001439725_20190101_20191231"
      decimals="2"
      id="F_000759"
      unitRef="U_xbrlipure">0.04</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="C_0001439725_20200101_20201231"
      decimals="2"
      id="F_000760"
      unitRef="U_xbrlipure">-0.01</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="C_0001439725_20190101_20191231"
      decimals="2"
      id="F_000761"
      unitRef="U_xbrlipure">0.02</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <bdsx:EffectiveIncomeTaxRateReconciliationPermanentItems
      contextRef="C_0001439725_20200101_20201231"
      decimals="2"
      id="F_000762"
      unitRef="U_xbrlipure">0.06</bdsx:EffectiveIncomeTaxRateReconciliationPermanentItems>
    <bdsx:EffectiveIncomeTaxRateReconciliationPermanentItems
      contextRef="C_0001439725_20190101_20191231"
      decimals="2"
      id="F_000763"
      unitRef="U_xbrlipure">0.04</bdsx:EffectiveIncomeTaxRateReconciliationPermanentItems>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_0001439725_20200101_20201231"
      decimals="2"
      id="F_000764"
      unitRef="U_xbrlipure">-0.16</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_0001439725_20190101_20191231"
      decimals="2"
      id="F_000765"
      unitRef="U_xbrlipure">-0.23</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="C_0001439725_20200101_20201231" id="F_000340">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The tax effects of temporary differences that give rise to significant portions of the deferred income tax assets and liabilities are as follows (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Years Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred Tax Assets:&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net operating loss carryforwards&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;53,128&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;50,360&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development tax credits&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,860&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,040&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;279&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;370&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock-based compensation&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;865&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accruals and reserves&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,406&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;286&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;58,538&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;54,056&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(56,083&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(51,135&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total deferred tax assets after valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,455&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,921&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred Tax Liabilities:&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intangible assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,455&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,921&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total deferred tax liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,455&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,921&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net deferred tax assets and liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_0001439725_20201231"
      decimals="-3"
      id="F_000766"
      unitRef="U_iso4217USD">53128000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_0001439725_20191231"
      decimals="-3"
      id="F_000767"
      unitRef="U_iso4217USD">50360000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_0001439725_20201231"
      decimals="-3"
      id="F_000768"
      unitRef="U_iso4217USD">2860000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_0001439725_20191231"
      decimals="-3"
      id="F_000769"
      unitRef="U_iso4217USD">3040000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment
      contextRef="C_0001439725_20201231"
      decimals="-3"
      id="F_000770"
      unitRef="U_iso4217USD">279000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment
      contextRef="C_0001439725_20191231"
      decimals="-3"
      id="F_000771"
      unitRef="U_iso4217USD">370000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_0001439725_20201231"
      decimals="-3"
      id="F_000772"
      unitRef="U_iso4217USD">865000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
      contextRef="C_0001439725_20201231"
      decimals="-3"
      id="F_000773"
      unitRef="U_iso4217USD">1406000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
      contextRef="C_0001439725_20191231"
      decimals="-3"
      id="F_000774"
      unitRef="U_iso4217USD">286000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_0001439725_20201231"
      decimals="-3"
      id="F_000775"
      unitRef="U_iso4217USD">58538000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_0001439725_20191231"
      decimals="-3"
      id="F_000776"
      unitRef="U_iso4217USD">54056000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_0001439725_20201231"
      decimals="-3"
      id="F_000777"
      unitRef="U_iso4217USD">56083000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_0001439725_20191231"
      decimals="-3"
      id="F_000778"
      unitRef="U_iso4217USD">51135000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_0001439725_20201231"
      decimals="-3"
      id="F_000779"
      unitRef="U_iso4217USD">2455000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_0001439725_20191231"
      decimals="-3"
      id="F_000780"
      unitRef="U_iso4217USD">2921000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
      contextRef="C_0001439725_20201231"
      decimals="-3"
      id="F_000781"
      unitRef="U_iso4217USD">2455000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
      contextRef="C_0001439725_20191231"
      decimals="-3"
      id="F_000782"
      unitRef="U_iso4217USD">2921000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="C_0001439725_20201231"
      decimals="-3"
      id="F_000783"
      unitRef="U_iso4217USD">2455000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="C_0001439725_20191231"
      decimals="-3"
      id="F_000784"
      unitRef="U_iso4217USD">2921000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration
      contextRef="C_0001439725_20201231"
      decimals="-5"
      id="F_000785"
      unitRef="U_iso4217USD">233600000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration>
    <bdsx:DeferredTaxAssetsResearchAndExperimentationTaxCarryforwardsSubjectToExpiration
      contextRef="C_0001439725_20201231"
      decimals="-5"
      id="F_000786"
      unitRef="U_iso4217USD">3600000</bdsx:DeferredTaxAssetsResearchAndExperimentationTaxCarryforwardsSubjectToExpiration>
    <us-gaap:TaxCreditCarryforwardDescription contextRef="C_0001439725_20200101_20201231" id="F_000787">expire beginning in 2026</us-gaap:TaxCreditCarryforwardDescription>
    <us-gaap:ValuationAllowanceDeferredTaxAssetExplanationOfChange contextRef="C_0001439725_20200101_20201231" id="F_000788">Company does not believe it is more likely than not that it will realize the benefits of net deferred tax assets and, accordingly, has established a valuation allowance equal to 100% of net deferred tax assets.</us-gaap:ValuationAllowanceDeferredTaxAssetExplanationOfChange>
    <bdsx:PercentageOfValuationAllowanceEqualToNetDeferredTaxAssets
      contextRef="C_0001439725_20200101_20201231"
      decimals="INF"
      id="F_000789"
      unitRef="U_xbrlipure">1</bdsx:PercentageOfValuationAllowanceEqualToNetDeferredTaxAssets>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="C_0001439725_20200101_20201231"
      decimals="-5"
      id="F_000790"
      unitRef="U_iso4217USD">4900000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="C_0001439725_20190101_20191231"
      decimals="-5"
      id="F_000791"
      unitRef="U_iso4217USD">7000000.0</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued
      contextRef="C_0001439725_20191231"
      decimals="INF"
      id="F_000793"
      unitRef="U_iso4217USD">0</us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued>
    <us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued
      contextRef="C_0001439725_20201231"
      decimals="INF"
      id="F_000792"
      unitRef="U_iso4217USD">0</us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock contextRef="C_0001439725_20200101_20201231" id="F_000341">A reconciliation of beginning and ending balances for unrecognized tax benefits is as follows (in thousands):
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at January 1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Additions for tax positions related to the current year&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;106&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Additions for tax positions related to prior years&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;609&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Reductions for tax positions related to prior years&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Reductions related to settlements&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Reductions related to a lapse of statute&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at December 31&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;715&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="C_0001439725_20200101_20201231"
      decimals="-3"
      id="F_000794"
      unitRef="U_iso4217USD">106000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="C_0001439725_20200101_20201231"
      decimals="-3"
      id="F_000795"
      unitRef="U_iso4217USD">609000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_0001439725_20201231"
      decimals="-3"
      id="F_000796"
      unitRef="U_iso4217USD">715000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:IncomeTaxExaminationDescription contextRef="C_0001439725_20200101_20201231" id="F_000797">All years will remain open for examining by federal and state authorities for three and four years, respectively, from the date of utilization of any net operating loss carryforwards.</us-gaap:IncomeTaxExaminationDescription>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="C_0001439725_20200101_20201231" id="F_000290">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Note 17 &#x2013; Commitments and Contingencies &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Leases&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company leases facilities under non&#x2011;cancelable operating leases. Rent expense &lt;span style="Background-color:#FFFFFF;"&gt;was $1.7 million&lt;/span&gt; and $2.1 million for the years ended December 31, 2020 and 2019, respectively.&lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Future minimum lease payments for operating lease obligations are as follows as of December 31, 2020 (in thousands): &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%; border-bottom:solid 0.75pt #000000;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ending December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%; border-top:solid 0.75pt #000000;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;703&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;724&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2023&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;112&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2024&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2025&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,539&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Co&#x2011;Development Agreement&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In April 2014 and amended in October 2016, the Company entered into a worldwide agreement with AVEO to develop and commercialize AVEO's hepatocyte growth factor inhibitory antibody ficlatuzumab with the Company's proprietary companion diagnostic test, BDX004, a version of the Company&#x2019;s serum protein test that is commercially available to help physicians guide treatment decisions for patients with advanced non&#x2011;small cell lung cancer (NSCLC). Under the terms of the agreement, AVEO will conduct a proof&#x2011;of&#x2011;concept (POC) clinical study of ficlatuzumab for NSCLC in which BDX004 will be used to select clinical trial subjects (the NSCLC POC Trial). The Company and AVEO will share equally in the costs of the NSCLC POC Trial, and each will be responsible for 50% of development and regulatory costs associated with all future clinical trials agreed upon by the Company and AVEO. The Company and AVEO continue to conduct POC clinical trials of ficlatuzumab in combination with BDX004 with each responsible for 50% of development and regulatory costs. &lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In September 2020, the Company exercised its opt-out right with AVEO for the payment of 50% of development and regulatory costs for ficlatuzumab effective December 2, 2020. The Company had $0.3 million in remaining obligations related to the AVEO agreement as of the opt-out date. Following the effective date, the Company is entitled to a 10% royalty of net sales of ficlatuzumab and 25% of license income generated from the licensing of ficlatuzumab from AVEO.&lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expenses related to this agreement for the &lt;span style="color:#000000;"&gt;years ended December 31, 2020 and 2019 &lt;/span&gt;were approximately $0.9&lt;span style="Background-color:#FFFF00;"&gt; &lt;/span&gt;million and $0.9 million, respectively. &lt;/p&gt;
&lt;p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;License Agreement&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In August 2019, we entered into a non-exclusive license agreement with Bio-Rad Laboratories, Inc. (Bio-Rad) (the Bio-Rad License). Under the terms of the Bio-Rad License, the Company received a non-exclusive license, without the right to grant sublicenses, to utilize certain of Bio-Rad&#x2019;s intellectual property, machinery, materials, reagents, supplies and know-how necessary for the performance of Droplet Digital PCR&#x2122; (ddPCR) in cancer detection testing for third parties in the United States. The Company also agreed to purchase all of the necessary supplies and reagents for such testing exclusively from Bio-Rad, pursuant to a separately executed supply agreement (the Supply Agreement) with Bio-Rad. As further consideration for the non-exclusive license, the Company agreed to pay a royalty of 2.5% on the net revenue received for the performance of such ddPCR testing collected from third parties.&#160;&#160;The Bio-Rad License expires in August 2024. Either party may terminate for the other&#x2019;s uncured material breach or bankruptcy events. Bio-Rad may terminate the Bio-Rad License if the Company does not purchase licensed products under the Supply Agreement for a consecutive twelve-month period or for any material breach by us of the Supply Agreement.&#160;&#160;The Company incurred royalty expense of $0.1 million and $0.1 million for the years ended December 31, 2020 and 2019, respectively, under the Bio-Rad License.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Revenue Share Agreement&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As part of the acquisition of Oncimmune, the Company entered into several agreements to govern the relationship between the parties. The Company agreed to a revenue share payment related to an acquired diagnostic test of 8% of recognized revenue for non-screen tests up to an annual minimum volume and 5% thereafter, with an escalating minimum through the first four years of sales. Revenue share expenses of $0.3 million were recognized for the year ended December 31, 2020.&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:OperatingLeasesRentExpenseNet
      contextRef="C_0001439725_20200101_20201231"
      decimals="-5"
      id="F_000798"
      unitRef="U_iso4217USD">1700000</us-gaap:OperatingLeasesRentExpenseNet>
    <us-gaap:OperatingLeasesRentExpenseNet
      contextRef="C_0001439725_20190101_20191231"
      decimals="-5"
      id="F_000799"
      unitRef="U_iso4217USD">2100000</us-gaap:OperatingLeasesRentExpenseNet>
    <us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock contextRef="C_0001439725_20200101_20201231" id="F_000342">
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Future minimum lease payments for operating lease obligations are as follows as of December 31, 2020 (in thousands): &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%; border-bottom:solid 0.75pt #000000;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ending December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%; border-top:solid 0.75pt #000000;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;703&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;724&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2023&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;112&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2024&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2025&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,539&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent
      contextRef="C_0001439725_20201231"
      decimals="-3"
      id="F_000800"
      unitRef="U_iso4217USD">703000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears
      contextRef="C_0001439725_20201231"
      decimals="-3"
      id="F_000801"
      unitRef="U_iso4217USD">724000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears
      contextRef="C_0001439725_20201231"
      decimals="-3"
      id="F_000802"
      unitRef="U_iso4217USD">112000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDue
      contextRef="C_0001439725_20201231"
      decimals="-3"
      id="F_000803"
      unitRef="U_iso4217USD">1539000</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
    <bdsx:PercentageOfDevelopmentAndRegulatoryCosts
      contextRef="C_0001439725_srtCounterpartyNameAxis_bdsxAVEOOncologyMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_bdsxNSCLCPOCTrialMember_20201031"
      decimals="2"
      id="F_000804"
      unitRef="U_xbrlipure">0.50</bdsx:PercentageOfDevelopmentAndRegulatoryCosts>
    <bdsx:PercentageOfDevelopmentAndRegulatoryCosts
      contextRef="C_0001439725_srtCounterpartyNameAxis_bdsxAVEOOncologyMember_srtProductOrServiceAxis_bdsxBDX004Member_us-gaapEquitySecuritiesByIndustryAxis_bdsxFiclatuzumabMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_bdsxPOCClinicalTrialsMember_20201031"
      decimals="2"
      id="F_000805"
      unitRef="U_xbrlipure">0.50</bdsx:PercentageOfDevelopmentAndRegulatoryCosts>
    <bdsx:PercentageOfDevelopmentAndRegulatoryCostsExercisedUsingOptOutRight
      contextRef="C_0001439725_srtCounterpartyNameAxis_bdsxAVEOOncologyMember_us-gaapEquitySecuritiesByIndustryAxis_bdsxFiclatuzumabMember_20200901_20200930"
      decimals="2"
      id="F_000806"
      unitRef="U_xbrlipure">0.50</bdsx:PercentageOfDevelopmentAndRegulatoryCostsExercisedUsingOptOutRight>
    <bdsx:RemainingEstimatedObligation
      contextRef="C_0001439725_srtCounterpartyNameAxis_bdsxAVEOOncologyMember_20201202_20201202"
      decimals="-5"
      id="F_000807"
      unitRef="U_iso4217USD">300000</bdsx:RemainingEstimatedObligation>
    <bdsx:PercentageOfRoyaltyPaymentsOnNetSales
      contextRef="C_0001439725_srtCounterpartyNameAxis_bdsxAVEOOncologyMember_us-gaapEquitySecuritiesByIndustryAxis_bdsxFiclatuzumabMember_20201202_20201202"
      decimals="2"
      id="F_000808"
      unitRef="U_xbrlipure">0.10</bdsx:PercentageOfRoyaltyPaymentsOnNetSales>
    <bdsx:PercentageOfLicenseIncomeGeneratedFromLicensing
      contextRef="C_0001439725_srtCounterpartyNameAxis_bdsxAVEOOncologyMember_us-gaapEquitySecuritiesByIndustryAxis_bdsxFiclatuzumabMember_20201202_20201202"
      decimals="2"
      id="F_000809"
      unitRef="U_xbrlipure">0.25</bdsx:PercentageOfLicenseIncomeGeneratedFromLicensing>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_0001439725_srtCounterpartyNameAxis_bdsxAVEOOncologyMember_20200101_20201231"
      decimals="-5"
      id="F_000810"
      unitRef="U_iso4217USD">900000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_0001439725_srtCounterpartyNameAxis_bdsxAVEOOncologyMember_20190101_20191231"
      decimals="-5"
      id="F_000811"
      unitRef="U_iso4217USD">900000</us-gaap:ResearchAndDevelopmentExpense>
    <bdsx:PercentageOfRoyaltyPaymentsOnNetRevenue
      contextRef="C_0001439725_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_bdsxBioRadLicenseMember_20190801_20190831"
      decimals="3"
      id="F_000812"
      unitRef="U_xbrlipure">0.025</bdsx:PercentageOfRoyaltyPaymentsOnNetRevenue>
    <bdsx:LicenseAgreementExpiryDate
      contextRef="C_0001439725_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_bdsxBioRadLicenseMember_20190801_20190831"
      id="F_000813">2024-08</bdsx:LicenseAgreementExpiryDate>
    <us-gaap:RoyaltyExpense
      contextRef="C_0001439725_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_bdsxBioRadLicenseMember_20200101_20201231"
      decimals="-5"
      id="F_000814"
      unitRef="U_iso4217USD">100000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="C_0001439725_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_bdsxBioRadLicenseMember_20190101_20191231"
      decimals="-5"
      id="F_000815"
      unitRef="U_iso4217USD">100000</us-gaap:RoyaltyExpense>
    <bdsx:PercentageOfRevenueSharePaymentRelatedToAcquiredDiagnosticTestRecognizedRevenueForNonScreeningTests
      contextRef="C_0001439725_us-gaapBusinessAcquisitionAxis_bdsxOncimmuneLimitedMember_us-gaapTypeOfArrangementAxis_bdsxRevenueShareAgreementMember_20200101_20201231"
      decimals="2"
      id="F_000816"
      unitRef="U_xbrlipure">0.08</bdsx:PercentageOfRevenueSharePaymentRelatedToAcquiredDiagnosticTestRecognizedRevenueForNonScreeningTests>
    <bdsx:MinimumAnnualVolumePercentageThereafter
      contextRef="C_0001439725_us-gaapBusinessAcquisitionAxis_bdsxOncimmuneLimitedMember_us-gaapTypeOfArrangementAxis_bdsxRevenueShareAgreementMember_20200101_20201231"
      decimals="INF"
      id="F_000817"
      unitRef="U_xbrlipure">0.05</bdsx:MinimumAnnualVolumePercentageThereafter>
    <bdsx:PeriodOfEscalationsOfSales
      contextRef="C_0001439725_us-gaapBusinessAcquisitionAxis_bdsxOncimmuneLimitedMember_us-gaapTypeOfArrangementAxis_bdsxRevenueShareAgreementMember_20200101_20201231"
      id="F_000818">through the first four years of sales</bdsx:PeriodOfEscalationsOfSales>
    <bdsx:RevenueShareExpenses
      contextRef="C_0001439725_us-gaapBusinessAcquisitionAxis_bdsxOncimmuneLimitedMember_us-gaapTypeOfArrangementAxis_bdsxRevenueShareAgreementMember_20200101_20201231"
      decimals="-5"
      id="F_000819"
      unitRef="U_iso4217USD">300000</bdsx:RevenueShareExpenses>
    <us-gaap:DefinedContributionPlanTextBlock contextRef="C_0001439725_20200101_20201231" id="F_000291">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Note 18 &#x2013; Defined Contribution 401(k) Plan&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company sponsors a 401(k) defined contribution plan covering all eligible employees. The Company did not make any discretionary or employer matching contributions under the plan during the years ended December 31, 2020 or 2019.&lt;/p&gt;</us-gaap:DefinedContributionPlanTextBlock>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="C_0001439725_20200101_20201231"
      decimals="INF"
      id="F_000820"
      unitRef="U_iso4217USD">0</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140148459927368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Mar. 12, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001439725<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39659<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Biodesix, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">20-3986492<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2970 Wilderness Place<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Boulder<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CO<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">80301<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">303<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">417-0500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">BDSX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well Known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,577,782<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="nump">$ 344,635,079<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text">
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DOCUMENTS INCORPORATED BY REFERENCE</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Portions of the Company&#8217;s definitive Proxy Statement for its 2021 Annual Meeting of Shareholders are to be incorporated by reference into Part</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">III, as specifically set forth in Part III.)</p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140148459533576">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 62,126<span></span>
</td>
<td class="nump">$ 5,286<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">15,304<span></span>
</td>
<td class="nump">5,292<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">8,710<span></span>
</td>
<td class="nump">2,122<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">86,140<span></span>
</td>
<td class="nump">12,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>Non&#8209;current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">3,178<span></span>
</td>
<td class="nump">2,120<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">13,260<span></span>
</td>
<td class="nump">15,092<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other long-term assets</a></td>
<td class="nump">3,461<span></span>
</td>
<td class="nump">90<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">15,031<span></span>
</td>
<td class="nump">15,031<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total non&#8209;current assets</a></td>
<td class="nump">34,930<span></span>
</td>
<td class="nump">32,333<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">121,070<span></span>
</td>
<td class="nump">45,033<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">8,964<span></span>
</td>
<td class="nump">1,717<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">7,789<span></span>
</td>
<td class="nump">4,180<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">3,532<span></span>
</td>
<td class="nump">1,283<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableToBankCurrent', window );">Current portion of notes payable</a></td>
<td class="nump">11,840<span></span>
</td>
<td class="nump">12,159<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_PutOptionLiabilityCurrent', window );">Put option liability</a></td>
<td class="nump">3,400<span></span>
</td>
<td class="nump">3,261<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">32,125<span></span>
</td>
<td class="nump">22,600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Non&#8209;current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">329<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Long&#8209;term notes payable</a></td>
<td class="nump">15,926<span></span>
</td>
<td class="nump">23,812<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration</a></td>
<td class="nump">29,932<span></span>
</td>
<td class="nump">29,114<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">1,921<span></span>
</td>
<td class="nump">358<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total non&#8209;current liabilities</a></td>
<td class="nump">47,779<span></span>
</td>
<td class="nump">53,613<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">79,904<span></span>
</td>
<td class="nump">76,213<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityAbstract', window );"><strong>Convertible preferred stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible preferred stock, $0.001 par value, 0 (2020) and 174,237,067 (2019) authorized; 0 (2020) and 118,766,273 (2019) issued and outstanding; liquidation preference of $202,582 (2019)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">193,959<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity (deficit)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value, 5,000,000 (2020) and 0 (2019) authorized; 0 (2020 and 2019) issued and outstanding</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value, 200,000,000 (2020) and 190,000,000 (2019) authorized; 26,561,504 (2020) and 254,918 (2019) issued and outstanding</a></td>
<td class="nump">27<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid&#8209;in capital</a></td>
<td class="nump">299,953<span></span>
</td>
<td class="nump">2,324<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(258,814)<span></span>
</td>
<td class="num">(227,464)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity (deficit)</a></td>
<td class="nump">41,166<span></span>
</td>
<td class="num">(225,139)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities, convertible preferred stock and stockholders' equity (deficit)</a></td>
<td class="nump">$ 121,070<span></span>
</td>
<td class="nump">$ 45,033<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_PutOptionLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Put option liability current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_PutOptionLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableToBankCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Current portion of the total carrying amount as of the balance sheet date due within one year or the operating cycle, if longer, on all notes payable to banks paid on an installment with long term maturities. This can include the amount of any loans from the applicant firm. This does not, however, include any mortgage balances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a)(1),20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableToBankCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140148490816760">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement Of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Convertible preferred stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible preferred stock, authorized</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">174,237,067<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible preferred stock, issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">118,766,273<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">118,766,273<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Convertible preferred stock, liquidation preference</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 202,582<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, authorized</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">190,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued</a></td>
<td class="nump">26,561,504<span></span>
</td>
<td class="nump">254,918<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding</a></td>
<td class="nump">26,561,504<span></span>
</td>
<td class="nump">254,918<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLiquidationPreference">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLiquidationPreference</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65877616&amp;loc=d3e177068-122764<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (27)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140148459593080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Operations - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 45,557<span></span>
</td>
<td class="nump">$ 24,552<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_DirectCostsAndExpenses', window );">Direct costs and expenses</a></td>
<td class="nump">21,998<span></span>
</td>
<td class="nump">6,074<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">10,818<span></span>
</td>
<td class="nump">10,468<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Sales, marketing, general and administrative</a></td>
<td class="nump">34,857<span></span>
</td>
<td class="nump">30,637<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_ChangeInFairValueOfContingentConsiderationExcludingAccretionExpense', window );">Change in fair value of contingent consideration</a></td>
<td class="nump">818<span></span>
</td>
<td class="nump">4,114<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">68,491<span></span>
</td>
<td class="nump">51,293<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(22,934)<span></span>
</td>
<td class="num">(26,741)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeOther', window );">Interest income</a></td>
<td class="nump">18<span></span>
</td>
<td class="nump">55<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(7,604)<span></span>
</td>
<td class="num">(3,008)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liability</a></td>
<td class="num">(1,252)<span></span>
</td>
<td class="num">(104)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_ChangeInFairValueOfPutOptionLiability', window );">Change in fair value of put option liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncome', window );">Other income, net</a></td>
<td class="nump">422<span></span>
</td>
<td class="nump">1,072<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Total other expense</a></td>
<td class="num">(8,416)<span></span>
</td>
<td class="num">(3,985)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (31,350)<span></span>
</td>
<td class="num">$ (30,726)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share, basic and diluted</a></td>
<td class="num">$ (6.48)<span></span>
</td>
<td class="num">$ (126.97)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted-average shares outstanding, basic and diluted</a></td>
<td class="nump">4,838<span></span>
</td>
<td class="nump">242<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_ChangeInFairValueOfContingentConsiderationExcludingAccretionExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in fair value of contingent consideration excluding accretion expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_ChangeInFairValueOfContingentConsiderationExcludingAccretionExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_ChangeInFairValueOfPutOptionLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in fair value of put option liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_ChangeInFairValueOfPutOptionLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_DirectCostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Direct costs and expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_DirectCostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income earned from interest bearing assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140148460471304">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Convertible Preferred Stock</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2018</a></td>
<td class="num">$ (194,630)<span></span>
</td>
<td class="nump">$ 183,962<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 2,107<span></span>
</td>
<td class="num">$ (196,738)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary Equity Balance, Shares at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110,071<span></span>
</td>
<td class="nump">215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Common stock issued upon exercise of stock options</a></td>
<td class="nump">47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Common stock issued upon exercise of stock options, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">Issuance of Series H Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,997<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Series H Preferred Stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,695<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock&#8209;based compensation expense</a></td>
<td class="nump">170<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">170<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss and comprehensive loss</a></td>
<td class="num">(30,726)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(30,726)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2019</a></td>
<td class="num">$ (225,139)<span></span>
</td>
<td class="nump">$ 193,959<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">2,324<span></span>
</td>
<td class="num">(227,464)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary Equity Balance, Shares at Dec. 31, 2019</a></td>
<td class="nump">118,766,273<span></span>
</td>
<td class="nump">118,766<span></span>
</td>
<td class="nump">255<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Common stock issued upon exercise of stock options</a></td>
<td class="nump">$ 1,340<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,340<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Common stock issued upon exercise of stock options, shares</a></td>
<td class="nump">368,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">368<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock&#8209;based compensation expense</a></td>
<td class="nump">$ 3,709<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,709<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock in initial public offering, net of discounts and commission of $5,040 and direct offering costs of $3,203</a></td>
<td class="nump">63,757<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">63,753<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock in initial public offering, net of discounts and commission and direct offering costs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of preferred stock into common stock upon initial public offering</a></td>
<td class="nump">193,959<span></span>
</td>
<td class="num">$ (193,959)<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
<td class="nump">193,939<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of preferred stock into common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(118,766)<span></span>
</td>
<td class="nump">20,091<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt', window );">Conversion of convertible debt into common stock upon initial public offering</a></td>
<td class="nump">26,616<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">26,614<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_StockIssuedDuringPeriodSharesConversionOfConvertibleSecuritiesCommonStock', window );">Conversion of convertible debt into common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,848<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Reclassification of preferred stock warrant liability and put option into additional paid-in capital upon initial public offering</a></td>
<td class="nump">8,274<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,274<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss and comprehensive loss</a></td>
<td class="num">(31,350)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(31,350)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2020</a></td>
<td class="nump">$ 41,166<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27<span></span>
</td>
<td class="nump">$ 299,953<span></span>
</td>
<td class="num">$ (258,814)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary Equity Balance, Shares at Dec. 31, 2020</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,562<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_StockIssuedDuringPeriodSharesConversionOfConvertibleSecuritiesCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities classified as common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_StockIssuedDuringPeriodSharesConversionOfConvertibleSecuritiesCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary equity stock issued during period shares new issues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustment to additional paid in capital resulting from the recognition of convertible debt instruments as two separate components - a debt component and an equity component. This bifurcation may result in a basis difference associated with the liability component that represents a temporary difference for purposes of applying accounting for income taxes. The initial recognition of deferred taxes for the tax effect of that temporary difference is as an adjustment to additional paid in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=51819886&amp;loc=SL6014347-161799<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326096&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109126253&amp;loc=d3e4724-112606<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of new stock classified as temporary equity issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140148464193848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Feb. 28, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalUnitsDeductionsFromTotalCostToInvestors', window );">Discounts and commission</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,040<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalUnitsTotalCostToInvestors', window );">Direct offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,203<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesHPreferredStockMember', window );">Series H Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_SaleOfStockTemporaryEquityPricePerShare', window );">Sale of stock, temporary equity, price per share</a></td>
<td class="nump">$ 1.15<span></span>
</td>
<td class="nump">$ 1.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_TemporaryEquityIssuanceCosts', window );">Issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_SaleOfStockTemporaryEquityPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale of stock, temporary equity, price per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_SaleOfStockTemporaryEquityPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_TemporaryEquityIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary equity issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_TemporaryEquityIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalUnitsDeductionsFromTotalCostToInvestors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deductions from cost to investors of capital shares or other capital units for fees, loads and other charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04.16(b)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401414&amp;loc=d3e603758-122996<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalUnitsDeductionsFromTotalCostToInvestors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalUnitsTotalCostToInvestors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cost to investors of each class of capital shares or other capital units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04.16(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401414&amp;loc=d3e603758-122996<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalUnitsTotalCostToInvestors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesHPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesHPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140148461297864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (31,350)<span></span>
</td>
<td class="num">$ (30,726)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash, cash equivalents, and restricted cash used in operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">2,903<span></span>
</td>
<td class="nump">2,793<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of convertible notes debt discount</a></td>
<td class="nump">4,389<span></span>
</td>
<td class="nump">262<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock&#8209;based compensation expense</a></td>
<td class="nump">3,709<span></span>
</td>
<td class="nump">170<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liability</a></td>
<td class="nump">1,252<span></span>
</td>
<td class="nump">104<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in contingent consideration</a></td>
<td class="nump">818<span></span>
</td>
<td class="nump">4,114<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_ChangeInFairValueOfPutOptionLiability', window );">Change in fair value of put option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_AccruedInterestOnNotesPayableAndConvertibleNotesPayable', window );">Accrued interest on notes payable and convertible notes payable</a></td>
<td class="nump">1,226<span></span>
</td>
<td class="nump">799<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt issuance costs</a></td>
<td class="nump">144<span></span>
</td>
<td class="nump">144<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Provision for doubtful accounts</a></td>
<td class="nump">296<span></span>
</td>
<td class="nump">246<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Loss on disposals of assets</a></td>
<td class="nump">48<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities, net of assets acquired and liabilities assumed in acquisitions:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(10,308)<span></span>
</td>
<td class="num">(3,646)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets', window );">Other current assets</a></td>
<td class="num">(6,588)<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet', window );">Other long-term assets and liabilities</a></td>
<td class="num">(1,808)<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and other accrued liabilities</a></td>
<td class="nump">11,654<span></span>
</td>
<td class="nump">1,193<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">2,249<span></span>
</td>
<td class="nump">791<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash and cash equivalents and restricted cash used in operating activities</a></td>
<td class="num">(21,366)<span></span>
</td>
<td class="num">(21,726)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(1,945)<span></span>
</td>
<td class="num">(1,310)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_PaymentsForProceedsFromPatentCostsAndIntangibleAssetAcquisitionNet', window );">Patent costs and intangible asset acquisition, net</a></td>
<td class="num">(232)<span></span>
</td>
<td class="num">(106)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_PaymentsToAcquireOncimmune', window );">Payments to acquire Oncimmune assets</a></td>
<td class="num">(750)<span></span>
</td>
<td class="num">(456)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash and cash equivalents and restricted cash used in investing activities</a></td>
<td class="num">(2,927)<span></span>
</td>
<td class="num">(1,872)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from initial public offering</a></td>
<td class="nump">72,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of common stock options</a></td>
<td class="nump">1,340<span></span>
</td>
<td class="nump">47<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Proceeds from issuance of series H preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from issuances of convertible notes payable</a></td>
<td class="nump">12,955<span></span>
</td>
<td class="nump">13,044<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Proceeds from paycheck protection program note payable</a></td>
<td class="nump">3,085<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Equity financing costs</a></td>
<td class="num">(8,243)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities', window );">Other</a></td>
<td class="num">(6)<span></span>
</td>
<td class="num">(116)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash and cash equivalents and restricted cash provided by financing activities</a></td>
<td class="nump">81,131<span></span>
</td>
<td class="nump">22,972<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash and cash equivalents and restricted cash</a></td>
<td class="nump">56,838<span></span>
</td>
<td class="num">(626)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash &#8209; beginning of period</a></td>
<td class="nump">5,468<span></span>
</td>
<td class="nump">6,094<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash &#8209; end of period</a></td>
<td class="nump">62,306<span></span>
</td>
<td class="nump">5,468<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental cash flow information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_ConversionOfPreferredStockIntoCommonStock', window );">Conversion of preferred stock into common stock</a></td>
<td class="nump">193,959<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountConverted1', window );">Conversion of convertible notes and accrued interest into common stock</a></td>
<td class="nump">26,616<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_ReclassificationOfPutOptionLiabilityToAdditionalPaidInCapital', window );">Reclassification of put option liability to additional paid-in capital</a></td>
<td class="nump">6,650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_ValueOfPutOptionRecordedAtIssuanceOfConvertibleNotesPayable', window );">Value of put option recorded at issuance of convertible debt payable</a></td>
<td class="nump">3,389<span></span>
</td>
<td class="nump">1,261<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">1,844<span></span>
</td>
<td class="nump">1,800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_ReclassificationOfWarrantLiabilityToAdditionalPaidInCapital', window );">Reclassification of warrant liability to additional paid-in capital</a></td>
<td class="nump">$ 1,624<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1', window );">Accrued business combination payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 750<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_AccruedInterestOnNotesPayableAndConvertibleNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued interest on notes payable and convertible notes payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_AccruedInterestOnNotesPayableAndConvertibleNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_ChangeInFairValueOfPutOptionLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in fair value of put option liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_ChangeInFairValueOfPutOptionLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_ConversionOfPreferredStockIntoCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Conversion of preferred stock into common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_ConversionOfPreferredStockIntoCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_PaymentsForProceedsFromPatentCostsAndIntangibleAssetAcquisitionNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments for proceeds from patent costs and intangible asset acquisition, net.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_PaymentsForProceedsFromPatentCostsAndIntangibleAssetAcquisitionNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_PaymentsToAcquireOncimmune">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments to acquire Oncimmune.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_PaymentsToAcquireOncimmune</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_ReclassificationOfPutOptionLiabilityToAdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reclassification of put option liability to additional paid in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_ReclassificationOfPutOptionLiabilityToAdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_ReclassificationOfWarrantLiabilityToAdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reclassification of warrant liability to additional paid-in-capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_ReclassificationOfWarrantLiabilityToAdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_ValueOfPutOptionRecordedAtIssuanceOfConvertibleNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of put option recorded at issuance of convertible notes payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_ValueOfPutOptionRecordedAtIssuanceOfConvertibleNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockAmountConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockAmountConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent operating assets after deduction of noncurrent operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of [all] liabilities that an Entity assumes in acquiring a business or in consideration for an asset received in a noncash (or part noncash) acquisition. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsForOtherFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121599337&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140148457944488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Description of Business<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_OrganizationAndDescriptionOfBusinessAbstract', window );"><strong>Organization And Description Of Business [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization and Description of Business</a></td>
<td class="text">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note 1 &#8211; Organization and Description of Business </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Biodesix, Inc. (the &#8220;Company&#8221;, &#8220;Biodesix&#8221;, &#8220;we&#8221; and &#8220;our&#8221;), formerly Elston Technologies, Inc., was incorporated in Delaware in 2005. The Company&#8217;s headquarters are in Colorado, with laboratories in Colorado and Kansas. The Company conducts all of its operations within a single legal entity. Biodesix is a data-driven diagnostic solutions company leveraging state of the art technologies with its proprietary artificial intelligence platform to discover, develop, and commercialize solutions for clinical unmet needs, with a primary focus in lung disease. In addition to diagnostic tests, the Company provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company performs its blood-based diagnostic tests for lung cancer in its laboratory facilities, which are located in Boulder, Colorado and De Soto, Kansas. In May 2020, the Federal Drug Administration (FDA) authorized performance of Bio-Rad SARS-CoV-2 Droplet Digital&#8482; <span style="letter-spacing:-0.15pt;">polymerase chain reaction </span>(ddPCR) test to detect Coronavirus Disease 2019 (COVID-19) infection. In April 2020, the FDA authorized our Platelia SARS-CoV-2 Total Ab test to detect COVID-19 antibodies. Medical products that are granted an Emergency Use Authorization (EUA) are only permitted to commercialize their products under the terms and conditions provided in the authorization. The FDA may revoke an EUA where it is determined that the underlying health emergency no longer exists or warrants such authorization, if the conditions for the issuance of the EUA are no longer met, or if other circumstances make revocation appropriate to protect the public health or safety.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Blood-Based Lung Tests</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company offers four blood-based lung cancer tests across the lung cancer continuum of care:</p>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:3.85%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="width:3.85%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/><span style="font-style:italic;color:#000000;">Nodify XL2&#174; </span><span style="color:#000000;">and </span><span style="font-style:italic;color:#000000;">Nodify CDT&#8482; </span><span style="color:#000000;">tests, marketed as part of our Nodify Lung</span><span style="font-style:italic;color:#000000;">&#8482; </span><span style="color:#000000;">Nodule Risk Assessment testing strategy, assess the risk of lung cancer to help identify the most appropriate treatment </span><span style="letter-spacing:-0.15pt;color:#000000;">pathway. </span><span style="letter-spacing:-0.4pt;color:#000000;">We </span><span style="color:#000000;">believe we are the only company to offer two commercial blood-based tests to help physicians reclassify risk of malignancy in patients with suspicious lung</span><span style="letter-spacing:-1.2pt;color:#000000;"> </span><span style="color:#000000;">nodules</span>.</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:3.85%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="width:3.85%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/><span style="font-style:italic;color:#000000;">GeneStrat&#174; </span><span style="color:#000000;">and </span><span style="font-style:italic;letter-spacing:-0.15pt;color:#000000;">VeriStrat&#174; </span><span style="color:#000000;">tests, marketed as part of our Biodesix Lung Reflex</span><span style="font-style:italic;color:#000000;">&#174; </span><span style="color:#000000;">testing strategy, are used following diagnosis of lung cancer to measure the presence of mutations in the tumor and the</span><span style="letter-spacing:-0.75pt;color:#000000;"> </span><span style="color:#000000;">state of the patient&#8217;s immune system to establish the patient&#8217;s prognosis and help guide treatment decisions. The GeneStrat tumor profiling test and the VeriStrat immune profiling test have a three-day average turnaround time, providing physicians with timely results to facilitate treatment decisions.</span></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">COVID-19 Tests<span style="font-weight:normal;">&#160;&#160;</span></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Using the Bio-Rad <span style="letter-spacing:-0.15pt;">SARS-CoV-2 </span>ddPCR test and the Platelia <span style="letter-spacing:-0.15pt;">SARS-CoV-2 Total </span>Ab tests, we operate and have commercialized the Biodesix <span style="letter-spacing:-0.15pt;">WorkSafe </span>testing<span style="letter-spacing:-1.6pt;"> </span>program. The Company offers two SARS-CoV-2 tests:</p>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:3.85%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="width:3.85%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/><span style="font-style:italic;color:#000000;">Bio-Rad SARS-CoV-2 ddPCR </span><span style="color:#000000;">test, which is authorized by the FDA to be performed by Clinical Laboratory Institute Amendments (CLIA) authorized laboratories that perform high complexity tests. The ddPCR test is designed to detect the presence of infection by the SARS-CoV-2 virus.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:3.85%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="width:3.85%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/><span style="font-style:italic;color:#000000;">Platelia SARS-CoV-2 Total Ab </span><span style="color:#000000;">test, which is an antibody test, authorized by the FDA, intended for detecting a B-cell immune response to </span><span style="letter-spacing:-0.15pt;color:#000000;">SARS-CoV-2, </span><span style="color:#000000;">indicating recent or prior infection.</span></p></td></tr></table></div>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These tests are utilized by healthcare providers, including hospitals and nursing homes, and are also offered to businesses and educational systems to assist in their back-to-work or back-to-school strategies, a crucial element of restarting economic activity.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In developing the Company's products, the Company has built or gained access to unique biorepositories, proprietary technology, and bioinformatics that it believes are important to the development of new targeted therapies, determining clinical trial eligibility and guiding treatment selection.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All of the Company&#8217;s testing services are made available through its clinical laboratories.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Reverse Stock Split</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">O<span style="color:#000000;">n October 19, 2020, the Company obtained approval of an amended and restated certificate of incorporation effecting a 0.1684664-for-1 reverse stock split of its issued and outstanding common stock as converted. All common shares, stock options, and per share information presented in these financial statements and notes thereto have been adjusted, where applicable, to reflect the reverse stock split on a retroactive basis for all periods</span> presented. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Approval of Amended and Restated Certificate of Incorporation</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In October 2020, the Company&#8217;s Board of Directors and stockholders approved an amended and restated certificate of incorporation, which authorized 200,000,000 shares of common stock, par value $0.001 per share, and 5,000,000 shares of preferred stock, par value $0.001 per share. The amended and restated certificate of incorporation became effective on October 30, 2020.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Initial Public Offering</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On October 27, 2020, the Company completed its initial public offering, in which it issued and sold 4,000,000 shares of its common stock at a public offering price of $18.00 per share. The Company received net proceeds of $63.8 million after deducting underwriting discounts and commissions and offering expenses payable by the Company. In addition, in connection with the initial public offering, all shares of the Company&#8217;s then-outstanding convertible preferred stock and convertible notes payable were automatically converted into 21,939,025 shares of common stock, and all then outstanding warrants to purchase the Company&#8217;s Series G convertible preferred stock were automatically converted into warrants to purchase 103,326 shares of the Company&#8217;s common stock.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_OrganizationAndDescriptionOfBusinessAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Organization and description of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_OrganizationAndDescriptionOfBusinessAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140148465547816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note 2 &#8211; Summary of Significant Accounting Policies</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Basis of Presentation</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#212529;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s financial statements have been prepared in accordance with accounting principles generally accepted in the United States (U.S. GAAP). <span style="color:#000000;">The 2019 balance sheet has been updated to reflect an increase in goodwill and a reduction in accumulated deficit of $3.4 million related to the correction of an immaterial error recorded as part of the acquisition of Integrated Diagnostics, Inc. in 2018.</span>&#160;&#160;The Company determined that the reduction in the preexisting valuation allowance resulting from the acquisition should have been reflected as an income benefit within the tax provision rather than as a reduction in goodwill.&#160;&#160;The correction of the immaterial error had no impact on our 2020 or 2019 results of operations.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain prior period amounts have been reclassified to conform to the current period presentation.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Segment Reporting</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The chief operating decision maker for the Company is the Chief Executive Officer, who reviews financial information for purposes of allocating resources and assessing financial performance.&#160;&#160;The Company has a <span style="-sec-ix-hidden:F_000360">single</span> operating segment focused on providing diagnostic testing services to customers. Substantially all of the Company&#8217;s revenue and all long-lived assets were derived or located in the United States for the years ended December 31, 2020 and 2019.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Significant items subject to such estimates include: revenue recognition; the useful lives of property and equipment; the recoverability of long-lived assets; the estimation of the fair value of intangible assets; the valuation of contingent consideration related to a business combination; stock options; income tax uncertainties, including a valuation allowance for deferred tax assets; and contingencies. The Company bases these estimates on historical and anticipated results, trends, and various other assumptions that the Company believes are reasonable under the circumstances, including assumptions as to future events. These estimates form the basis for making judgments about the carrying values of assets and liabilities and recognized revenue and expenses that are not readily apparent from other sources. Actual results could differ from those estimates and assumptions.</p>

<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Revenue Recognition</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company generates revenues from (i) diagnostic tests and (ii) assay development and testing services (services revenue).</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Diagnostic test revenues consist of blood-based lung tests and COVID-19 tests, which are recognized in the amount expected to be received in exchange for diagnostic tests when the diagnostic tests are delivered. The Company determines the transaction price related to its blood-based lung diagnostic test contracts using a portfolio approach by considering the nature of the payer and historical price concessions granted to groups of customers. The transaction price associated with COVID-19 testing arrangements are determined on the basis of the individual contract with each customer.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Services revenue consists of various types of tests or other scientific services for a purpose as defined by any individual customer, which are often larger biopharmaceutical companies, as defined by a written agreement between the Company and the customer. These services are generally completed upon the delivery of testing results, or achievement of contractual milestone(s) as defined in the customer agreements. Revenue for these services is recognized upon delivery of the completed test results, or upon completion of the contractual milestone(s). </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes revenues related to blood-based lung diagnostic billings based on estimates of the amounts ultimately expected to be collected from customers on a portfolio approach as discussed above. In determining the amount to accrue for a delivered test, the Company considers factors such as payment history, payer coverage, whether there is a reimbursement contract between the payer and the Company, payment as a percentage of agreed upon rate (if applicable), amount paid per test and any current developments or changes that could impact reimbursement. Variable consideration, if any, is estimated based on an analysis of historical experience and adjusted as better estimates become available. These estimates require significant judgment by management.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company also provides services to patients with whom the Company does not have contracts as defined in Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC 606). The Company recognizes revenue for these patients when contracts as defined in ASC 606 are established at the amount of consideration to which it expects to be entitled, or when the Company receives substantially all of the consideration subsequent to satisfaction and delivery of the performance obligations.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">See Note 13 &#8212; <span style="font-style:italic;">Revenue</span> for additional information.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Deferred Revenue</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue consists of payments received for research, development, and testing services fees received prior to the completion of performance of these tests and services. As of December 31, 2020, deferred revenue also includes $2.8 million in a Medicare advance payment on testing services which can either be paid back or earned back starting 1 year from receipt.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Direct Costs and Expenses</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The components of our cost of diagnostic tests and testing services consist of cost of materials, direct labor, including bonus, benefit and stock-based compensation, depreciation of laboratory equipment, rent costs, amortization of leasehold improvements and information technology costs associated with acquiring and processing test samples, including sample accessioning, test performance, quality control analyses, charges to collect and transport samples; curation of test results for physicians; and in some cases, license or royalty fees due to third parties.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Royalties for licensed technology are calculated as a percentage of revenues generated using the associated technology and recorded as expense at the time the related revenue is recognized. One-time royalty payments related to signing of license agreements or other milestones, such as issuance of new patents, are amortized to expense over the expected useful life of the patents. Costs associated with performing tests are expensed as the test is processed regardless of whether and when revenue is recognized with respect to that test.</p>

<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Research and Development <span style="color:#212529;">Expenses</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses include external and internal costs incurred to develop our technology, collect clinical samples, and conduct clinical studies to develop and support our products. External costs consist primarily of payments to clinical trial sites, sample acquisition costs and laboratory supplies purchased in connection with the Company&#8217;s discovery and preclinical activities, process development and clinical development activities.&#160; Internal costs consist primarily of salaries and benefits, reagents and supplies used in research and development laboratory work, infrastructure expenses, including allocated facility occupancy and information technology costs<span style="Background-color:#FFFFFF;">.</span> </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;color:#212529;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company estimates and accrues its expenses resulting from its obligations under contracts with vendors and consultants in connection with conducting research and development activities. The financial terms of these contracts vary from contract to contract and may result in payments that do not match the periods over which materials or services are provided under such contracts.<span style="color:#000000;">&#160;&#160;The Company&#8217;s estimates depend on the timeliness and accuracy of the data provided by consultants and vendors regarding the status of each activity.&#160;&#160;The Company periodically evaluates the estimates to determine if adjustments are necessary or appropriate based on information received. Research and development costs are expensed as incurred. </span></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Sales, Marketing, General and Administrative Expenses</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Selling expenses consist primarily of costs associated with our sales organization, including our direct sales force and sales management, client services, marketing, and reimbursement, as well as business development personnel who are focused on our biopharmaceutical customers. These expenses consist primarily of salaries, commissions, bonuses, employee benefits, travel, and stock-based compensation, as well as marketing and educational activities and allocated overhead expenses. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales, marketing, general and administrative expenses also include costs for our marketing and sales organizations, and other functions including finance, legal, human resources, and information technology. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These expenses consist principally of salaries, bonuses, employee benefits, travel, and stock-based compensation, as well as professional services fees such as consulting, audit, tax and legal fees, and general corporate costs and allocated overhead expenses.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Concentrations of Credit Risk and Other Uncertainties</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Substantially all of the Company&#8217;s cash and cash equivalents are deposited with one major financial institution in the United States. The Company continually monitors its positions with, and the credit quality of, the financial institution with which it holds cash. Periodically throughout the year, the Company has maintained balances in various operating accounts in excess of federally insured limits. The Company has not experienced any losses on its deposits of cash and cash equivalents.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Several of the components of the Company's sample collection kit and test reagents, and certain test systems and related test kits are obtained from single-source suppliers. If these single-source suppliers fail to satisfy the Company's requirements on a timely basis, it could suffer delays in being able to deliver its diagnostic solutions, a possible loss of revenue, or incur higher costs, any of which could adversely affect its operating results.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s customers in excess of 10% of total revenue, and their related revenue as a percentage of total revenue were as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:79.2%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.86%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:79.2%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.86%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:79.2%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Big Ten Conference</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:79.2%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Centura Healthcare</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:79.2%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Percent of total revenue</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">One customer, Covance, exceeded 10% of total revenue during 2019, representing 21% of total revenue. In addition to the above table, we collect reimbursement on behalf of customers covered by Medicare, which accounted for 17% and 36% of the Company&#8217;s total revenue for the years ended December 31, 2020 and 2019, respectively.&#160;&#160;The Company is subject to credit risk from its accounts receivable related to services provided to its customers. The Company does not perform evaluations of customers' financial condition and does not require collateral. The Company&#8217;s third-party payors and other customers in excess of 10% of accounts receivable, and their related accounts receivable as a percentage of total accounts receivable were as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.26%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.12%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">As of December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.26%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Big Ten Conference</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Centura Healthcare</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Medicare</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Covance Central Laboratory Services</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Janssen Research and Development, LLC</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.26%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pfizer, Inc</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.26%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Percent of total accounts receivable</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">76</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">83</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Cash and Cash Equivalents </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents consist of short-term, highly-liquid instruments with an original maturity of three months or less from the date of purchase. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Restricted Cash</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash consists of deposits related to the Company&#8217;s corporate credit card and a letter of credit related to an operating lease agreement. As of December 31, 2020 and 2019, the Company had $0.2 million restricted cash, respectively, which was included in &#8216;Other current assets&#8217; in the accompanying balance sheets.&#160;&#160; </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Accounts Receivable and Allowance for Doubtful Accounts</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts receivable are stated at the amount management expects to collect from customers based on their outstanding invoices. Management reviews accounts receivable <span style="color:#000000;">quarterly</span> to determine if any receivable will potentially be uncollectible and to estimate the amount of allowance for doubtful accounts necessary to reduce accounts receivable to its estimated net realizable value based on <span style="color:#000000;">historical experience, customer creditworthiness, facts, and circumstances specific to outstanding balances, and payment terms. The Company&#8217;s allowance for doubtful accounts was $0.2 million as of December 31, 2020 and 2019.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Inventory</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inventory consists primarily of material supplies, which are consumed in the performance of testing services and charged to cost of sales. Inventory is stated at cost and reported within &#8216;Other current assets&#8217; in the balance sheet and were $3.2 million and $0.8 million as of December 31, 2020 and 2019, respectively.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Property and Equipment</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment are stated at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally between three and five years. Leasehold improvements are amortized using the straight-line method over the shorter of the estimated useful life of the asset or the term of the lease. Maintenance and repairs are charged to expense as incurred, and improvements and betterments are capitalized. When assets are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the balance sheet and any resulting gain or loss is reflected in the statements of operations and comprehensive loss in the period realized.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Long-lived assets to be held and used are evaluated for impairment when events or circumstances indicate the carrying value of a long-lived asset or asset group is less </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">than </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the undiscounted cash flows from the use and eventual disposition over its remaining useful life. The Company assesses recoverability by comparing the sum or projected undiscounted cash flows from the use and eventual disposition of the asset or asset group to it carrying value, and records an impairment loss if the carrying value is greater </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">than </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the undiscounted future cash flows.</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> There were </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">no</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> impairments for the years ended December 31, 2020 or 2019.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Intangible Assets</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible assets primarily consist of intangible assets acquired as part of business combinations, external costs associated with patent applications that are expected to be successful, and trademark costs. Finite-lived intangibles are stated at cost, net of accumulated amortization. The Company amortizes finite-lived intangible assets using the straight-line method over their estimated useful lives of 9 to 10 years, based on management's estimate of the period over which their economic benefits will be realized, product life and patent life. Trademarks are considered indefinite lived and are not amortized.  </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible assets are reviewed for impairment whenever events or changes in circumstances indicate a reduction to fair value below their carrying amounts. There were no impairments for the years ended December 31, 2020 or 2019.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Goodwill</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Goodwill represents the excess of purchase price over amounts allocated to acquired assets and liabilities assumed in business combinations. The carrying value of goodwill is evaluated for impairment at least annually or more frequently when events or circumstances occur indicate a potential for impairment. The annual impairment test is performed on the last day of our fourth quarter. Prior to performing a quantitative evaluation, an assessment of qualitative factors may be performed to determine whether it is more likely than not that the fair value of the reporting unit exceeds its carrying value. In the event the Company determines that it is more likely than not the carrying value of our single reporting unit is higher than its estimated fair value, quantitative testing is performed comparing recorded values to estimated fair values. If impairment is present, the impairment loss is measured as the excess of the recorded goodwill over its implied fair value. <span style="color:#000000;">There were no impairments for the years ended December 31, 2020 or 2019.</span></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Fair Value of Financial Instruments</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. GAAP for fair value establishes a hierarchy that prioritizes fair value measurements based on the types of inputs used for the various valuation techniques (market approach, income approach, and cost approach). We utilize a combination of market and income approaches to value our financial instruments. Our financial assets and liabilities are measured using inputs from the three levels of the fair value hierarchy. Fair value measurements are categorized within the fair value hierarchy based upon the lowest level of the most significant inputs used to determine fair value. The three levels of the hierarchy and the related inputs are as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.08%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:86.08%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inputs</p></td>
</tr>
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%; border-top:solid 0.75pt #000000;" valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:86.08%; border-top:solid 0.75pt #000000;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unadjusted quoted prices in active markets for identical assets and liabilities.</p></td>
</tr>
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%;" valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:86.08%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unadjusted quoted prices in active markets for similar assets and liabilities;</p></td>
</tr>
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%;" valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:86.08%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active; or</p></td>
</tr>
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%;" valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:86.08%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inputs other than quoted prices that are observable for the asset or liability.</p></td>
</tr>
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%;" valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:86.08%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unobservable inputs for the asset or liability.</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The carrying amounts of certain financial instruments including cash and cash equivalents, accounts receivable, prepaid expenses and other current assets, accounts payable and accrued liabilities approximate fair value due to their relatively short maturities.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">See Note 5 <span style="color:#000000;">&#8212; </span><span style="font-style:italic;color:#000000;">Fair Value </span><span style="color:#000000;">for further discussion related to estimated fair value measurements.</span></p>

<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Contingent Consideration</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the purchase transaction with Integrated Diagnostics, Inc. (Indi), the Company recorded contingent consideration for amounts potentially payable to Indi&#8217;s shareholder pursuant to the terms of the asset purchase agreement. The fair value of contingent consideration is assessed at each balance sheet date and changes, if any, to the fair value are recognized as operating expenses within the statements of operations. The estimated fair value of the contingent consideration is based upon significant assumptions including the probability of successful achievement of product gross margin targets included in the acquisition agreement, the estimated timing of achievement of the product gross margin targets, and discount rates. The estimated fair value could materially differ from actual values or fair values determined using different assumptions.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Warrant Liability</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to the completion of the Company&#8217;s initial public offering in October 2020, certain warrants issued to purchase convertible preferred stock were classified as liabilities with changes in the estimated fair value of these liabilities recognized in our results of operations. Upon completion of the Company&#8217;s initial public offering in October 2020, the warrants were automatically converted to warrants to purchase common stock. Accordingly, the warrants were remeasured to an estimate of fair value and recognized in our results of operations and then reclassified to additional paid-in capital.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Put Option Liability</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During 2020 and 2019, the Company issued convertible debt<span style="color:#000000;">&#160;</span>with terms that provided for a conversion rate to the convertible debtholders that was more favorable than the price that other investors would pay for common stock in certain situations, including the completion of an initial public offering. As a result, the convertible debt is a financial instrument that was bifurcated into two instruments, a debt obligation and a put option liability, which represented the estimated fair value of the favorable conversion rate.&#160;&#160;The estimated fair value of the put option liability was separated from the convertible debt at inception and reported as a liability and debt discount, and amortized to interest expense. As a result of our initial public offering, the convertible debt was automatically converted to common stock and the put option liability was remeasured to an estimate of fair value and recognized in our results of operations and then reclassified to additional paid-in capital.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Share&#8209;Based Compensation</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Stock Options<span style="font-style:normal;"> </span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company grants service condition and performance condition stock options. Stock options are granted with exercise prices equal to the fair market value of our common stock on the date of grant. The grant date fair value of each employee stock option is estimated on the date of grant using the Black-Scholes option-pricing model, which requires the use of assumptions, including the expected term of the option, expected volatility of our stock price, expected dividend yield, and the risk-free interest rate, among others. These assumptions involve inherent uncertainties including market conditions and employee behavior that are generally outside of the Company&#8217;s control. Service condition stock options are expensed based on the grant date fair value of the awards using the straight-line method over the requisite service period, adjusted for forfeitures as they occur. Performance-condition stock options vest based on achievement of multiple weighted performance goals, certification of performance achievement by the Compensation Committee of the Board of Directors, and continued service. For performance-condition stock options, compensation expense is updated for our expected performance level against performance goals at the end of each reporting period, which involves judgment as to achievement of certain performance metrics.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to our initial public offering in October 2020, the fair value of our common stock was determined by the Board of Directors in accordance with the methodologies outlined in the American Institute of Certified Public Accountants Practice Aid, Valuation of Privately-Held-Company Equity Securities Issued as Compensation Practice Aid (Practice Aid). In doing so, the Board of Directors determined the best estimate of fair value of our common stock, exercising reasonable judgment and considering numerous objective and subjective factors<span style="color:#000000;">, by first determining the enterprise value of our business, and then allocating the value among the various classes of our equity securities to derive a per share value of our common stock. </span>Subsequent&#160;to the Company&#8217;s initial public offering, the fair value of the Company&#8217;s common stock is determined based on its traded market price.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><span style="font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Restricted Stock Units (RSUs)</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company grants service-condition RSUs. As a result of our initial public offering, the grant date fair values of these RSUs are based on the closing market price of our common stock on the grant date. The service-condition RSUs vest based on continued service with compensation expense, net of forfeitures, recognized on a straight-line basis over the requisite service period. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">See Note 14 &#8212; <span style="font-style:italic;">Share-Based Compensation</span> for additional information related to share-based compensation.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Net Loss per Common Share </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic net loss per common share is calculated by dividing net loss by the weighted-average number of common shares outstanding during the period, without consideration of common stock equivalents. Diluted net loss per common share is computed by dividing net loss by the weighted-average number of common share equivalents outstanding for the period, if dilutive, using the treasury stock method. Potentially dilutive securities consisting of options to purchase common stock, warrants to purchase common stock, restricted stock units and shares subject to purchase under our employee stock purchase plan were excluded from the calculation of diluted net loss per common share because their effect would be anti-dilutive for all periods presented. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Until the Company&#8217;s initial public offering in October 2020, basic and diluted net loss attributable to common stockholders per share was calculated using the two-class method. The net loss was attributable entirely to common stockholders because the participating securities did not have a contractual obligation to share in the Company&#8217;s losses.&#160;&#160;As the Company has reported a net loss for all periods presented, diluted net loss per common share is the same as basic net loss per common share for all periods presented.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140148458191048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Recent Accounting Pronouncements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract', window );"><strong>New Accounting Pronouncements And Changes In Accounting Principles [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note 3 &#8211; Recent Accounting Pronouncements</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Recently Issued Accounting Standards Not Yet Adopted</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2016, the FASB issued Accounting Standards Update (ASU) No. 2016-2, <span style="font-style:italic;">Leases (Topic 842), </span>which requires lessees to recognize a right-of-use asset and corresponding lease liability, including leases currently accounted for as operating leases. The ASU is effective for the Company for interim and annual periods beginning January 1, 2022. The Company expects to recognize right-of-use assets and lease obligations in its balance sheet upon adoption using the modified retrospective method as permitted by ASU No. 2018-11, <span style="font-style:italic;">Leases (Topic 842): Targeted Improvements.</span> The Company does not currently expect adoption of this standard will have a significant effect on its statements of operations or cash flows.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2016, the FASB issued ASU No. 2016-13, <span style="font-style:italic;">Financial Instruments-Credit Losses: Measurement of Credit Losses</span> on Financial Instruments. This ASU requires measurement and recognition of expected credit losses for financial assets. This guidance will become effective for the Company beginning January 1, 2022 with early adoption permitted. The Company has not yet begun evaluating the potential effect of this standard on its financial statements. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=113356391&amp;loc=SL49131195-203048<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -URI http://asc.fasb.org/topic&amp;trid=2122394<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=113356391&amp;loc=SL49131195-203048<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section S99<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=112272810&amp;loc=SL108384541-122693<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (i)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=113356391&amp;loc=SL49131195-203048<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (j)<br> -URI http://asc.fasb.org/extlink&amp;oid=113356391&amp;loc=SL49131195-203048<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 11.M.Q2)<br> -URI http://asc.fasb.org/extlink&amp;oid=112272810&amp;loc=d3e31137-122693<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(1)<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(2)<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140148456465672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combinations<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Business Combinations</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note 4 &#8211; Business Combinations </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Oncimmune Limited</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On October 31, 2019, the Company purchased select assets and liabilities from Oncimmune Limited (Oncimmune) for total consideration of $1.2 million payable in quarterly installments commencing 30 days following the closing of the transaction. Concurrent with the Oncimmune purchase, the Company acquired an exclusive option to license rights within the United States to an additional indication for their product for $9.0 million.&#160;&#160;In September 2020, we notified Oncimmune that we would not exercise this option for the expansion of the field of use. As of December 31, 2020, the Company had paid the full $1.2 million consideration. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The acquisition was accounted for as business combination and resulted in the recognition of goodwill of $0.8 million representing expected synergies, including expected increases in future revenues as a result of expansion of the acquired technology into additional markets, and lower expected operating expenses. The Company finalized its purchase price allocation of the transaction as of December 31, 2019.</p>

<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the aggregate consideration paid by the Company and the allocation of the purchase price to assets acquired and liabilities assumed (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,206</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total fair value of consideration transferred</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,206</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deposit</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inventory</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">241</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchase option</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">121</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Goodwill</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">827</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued liabilities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,206</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Integrated Diagnostics, Inc.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On June 30, 2018, the Company purchased select assets and liabilities from Integrated Diagnostics, Inc. (Indi) <span style="Background-color:#FFFFFF;">for total consideration of $27.6 million, consisting of $8.0 million in the Company&#8217;s Series G Preferred Stock and contingent consideration with an initial estimated fair value of $19.6 million.&#160;&#160;The acquisition was </span>accounted for as a business combination and resulted in goodwill of $14.2 million representing expected synergies, including increases in future revenues as a result of expansion of the acquired technology into additional markets, and lower operating expenses.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The contingent consideration arrangement requires additional consideration to be paid by the Company to Indi upon attainment of a three-consecutive month gross margin target of $2.0 million within the <span style="-sec-ix-hidden:F_000416">seven-year</span> period after the acquisition date.&#160;If the gross margin target is met, the Company is required to issue 2,520,108 shares of common stock. For the six months following the achievement of the gross margin target, Indi has the option to require the Company to redeem these common shares for $37.0 million in cash over eight equal quarterly installments.&#160;&#160;If Indi elects to not exercise its option, the Company has 12 months to repurchase the common stock in two equal and consecutive quarterly cash installments totaling $37.0 million. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI http://asc.fasb.org/topic&amp;trid=2303972<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140148457918360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note 5 - Fair Value</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Recurring Fair Value Measurements</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our borrowing instruments are recorded at their carrying values in the balance sheets, which may differ from their respective fair values. The fair values of outstanding borrowings, which are classified as Level 2, approximate their carrying values at December&#160;31, 2020 and 2019, based on interest rates currently available for similar borrowings and were:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.85%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">As of December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.56%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Carrying&#160;Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fair&#160;Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Carrying&#160;Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fair&#160;Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.56%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Borrowings</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,766</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,766</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,971</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,971</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.85%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The financial liabilities that are measured and recorded at estimated fair value on a recurring basis consist of our contingent consideration associated with our acquisition of Indi, and prior to the completion of our initial public offering in October 2020, the warrant liability and put option liability granted to certain holders of our convertible preferred stock and debt instruments, which were accounted for as liabilities and remeasured through our statements of operations. The table below presents the reported fair values of these liabilities, all of which are classified as Level 3 in the fair value hierarchy, as of the dates indicated (in thousands):</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">As of December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%; border-bottom:solid 0.75pt #000000;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> Description</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%; border-top:solid 0.75pt #000000;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contingent consideration</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,932</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,114</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Put option liability</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,261</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrant liability</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">372</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contingent value rights</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.85%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table presents the changes in these financial liabilities for the year ended December 31, 2020 (in thousands):</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Level 3 Rollforward</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Contingent</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Consideration</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Put</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Option</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Liability</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Warrant</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Liability</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Contingent</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Value&#160;Rights</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Beginning balances</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,114</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,261</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">372</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additions</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,389</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Changes in fair value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">818</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,252</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(60</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reclassified to additional paid-in capital</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,650</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,624</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ending balances</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,932</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Contingent Consideration</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the acquisition of Indi, the Company recorded contingent consideration for amounts contingently payable to Indi's selling shareholders pursuant to the Asset Purchase Agreement (See Note 4 &#8211; <span style="font-style:italic;">Business Combinations</span>). The significant unobservable inputs used in the measurement of fair value include the probability of successful achievement of the specified product gross margin targets, the period in which the targets are expected to be achieved, and discount rates which ranged from 12.2% to 13.5%. Significant increases or decreases in any of these inputs would result in a significantly higher or lower fair value measurement. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contingent consideration is recorded in the balance sheets as long-term liabilities. The net change to contingent consideration during the years ended December 31, 2020 and 2019 was an increase of $0.8 million and $4.1 million, respectively, and are recorded as operating expenses in the statements of operations.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Put Option Liability</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The put option liability was valued based on the calculated returns as a result of the various discounts included in the Company&#8217;s convertible notes payable and the related probability assessments of the various settlement scenarios. During 2020, the Company recognized an addition to the put option liability of $3.4 million in connection with a favorable conversion rate granted to holders of issued convertible debt. The put option liability was settled upon the closing of the Company&#8217;s initial public offering in October 2020 and reclassified to additional paid-in capital. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Warrant Liability </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">In connection with entering into the 2018 Notes, the Company issued to the lender a warrant to purchase 613,333 shares of Series G convertible preferred stock, at an exercise price of $0.75 per share, subject to adjustment upon specified dilutive issuances. The warrant was immediately exercisable upon issuance and expires on February 23, 2028. The estimated fair value of the warrant on the issuance date of $0.3&#160;million was recorded as a debt discount and as a preferred stock warrant liability. Through the effective date of the Company&#8217;s initial public offering, the Series G warrants were remeasured to an estimate of fair value using a Black Scholes pricing model. As a result of the Company&#8217;s initial public offering, the preferred stock warrants were automatically converted to warrants to purchase 103,326 shares of common stock with a weighted average exercise price of $4.46 and were also transferred to additional paid-in capital.&#160;&#160;During 2020, the Company recorded an increase in the value of the warrant liability of $1.3 million.</span> </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><span style="font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Contingent Value Rights</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to the shares of Series F Preferred Stock that were issued in January 2016, investors who purchased more than their pro&#8209;rata amount in the financing described above received a calculated number of contingent value rights (CVRs). In connection with the Series F financing, the Company issued 3,999 CVRs originally valued at $0.5 million. One CVR represents 0.00375% of the Company&#8217;s interest in the drug ficlatuzumab. The initial estimated value of the CVRs were recorded as a liability and as a reduction to the Series F proceeds. Upon receipt by the Company or a milestone, royalty, or any other type of payment from the Company&#8217;s ownership rights in the drug, the Company was required to make a cash payment to the CVR holders equal to 15% of net proceeds, as defined. In September 2020, the Company exercised its opt-out right with AVEO Oncology (AVEO) for the payment of 50% of development and regulatory costs for ficlatuzumab. As a result, the CVRs were settled effective December 2, 2020. See Note 17 &#8211; <span style="font-style:italic;">Commitments and Contingencies</span> for a discussion of the Co-Development Agreement with AVEO. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Non-Financial Assets and Liabilities</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our non-financial assets, which primarily consist of property and equipment, goodwill, and other intangible assets, are not required to be carried at fair value on a recurring basis and are reported at carrying value. There were no changes to the valuation methods during the periods presented.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140148461695800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property Plant And Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note 6 &#8211; Property and Equipment </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment consist of the following (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">As of December 31,</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lab equipment</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,730</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,221</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,845</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,894</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer equipment</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">871</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">869</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture and fixtures</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">424</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">427</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Software</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">651</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">503</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Construction in process</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">381</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">592</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,902</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,506</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less accumulated depreciation</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,724</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,386</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total property and equipment, net</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,178</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,120</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation expense related to property and equipment, reported in &#8216;Direct costs and expenses&#8217; and &#8216;Sales, marketing, general and administrative&#8217; was: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.85%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year ended December 31,</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Direct costs and expenses</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">361</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">183</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales, marketing, general and administrative</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">478</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">636</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; Total</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">839</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">819</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Disposals of Property and Equipment</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gains on disposal of property and equipment were not significant for the years ended December&#160;31, 2020 and 2019, and are included in &#8216;Sales, marketing, general and administrative&#8217; in the statements of operations.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140148458146552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill And Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Goodwill and Intangible Assets</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note 7 &#8211; Goodwill and Intangible Assets</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Goodwill</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Changes in goodwill for the years ended December 31, 2020 and 2019 were (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85.12%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.8%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85.12%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at January 1, 2019</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,204</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:85.12%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;Attributable to acquisition of Oncimmune, Ltd.</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">827</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:85.12%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31 2019</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,031</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85.12%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:85.12%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2020</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,031</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Intangible Assets, Net</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible assets consist of the following (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.85%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.92%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.64%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2020</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2019</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.92%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Accumulated</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Amortization</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Net Carrying Value</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Accumulated</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Amortization</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Net Carrying Value</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.92%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible assets subject to amortization</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.2%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.44%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.2%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.2%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.24%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.2%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.92%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Patents</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.2%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,474</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.44%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(494</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.2%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">980</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.2%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,245</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.24%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(411</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.2%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">834</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.92%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchased technology</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.2%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,900</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.44%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,694</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.2%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,206</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.2%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,900</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.24%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,817</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.2%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,083</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.92%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchase option</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.2%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.44%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.2%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.2%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">121</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.24%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(17</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.2%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.92%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible assets not subject to amortization</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.2%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.44%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.2%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.2%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.24%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.2%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.92%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Trademarks</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.44%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.92%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; Total</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.2%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,448</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.44%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,188</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.2%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,260</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.2%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,337</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.24%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,245</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.2%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,092</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amortization expense related to definite-lived intangible assets was (in thousands): </p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:73.04%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.16%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year ended December 31,</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:73.04%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:73.04%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Direct costs and expenses</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.98%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:73.04%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales, marketing, general and administrative</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,051</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,959</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:73.04%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; Total</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.98%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,064</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,974</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Future estimated amortization expense of intangible assets is (in thousands):</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">As of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%; border-top:solid 0.75pt #000000;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,946</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,940</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,936</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,928</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2025</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,924</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thereafter</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,512</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,186</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There have been no impairments of intangible assets for the twelve-month periods ended December 31, 2020 and December 31, 2019.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140148457037784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables And Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued Liabilities</a></td>
<td class="text">
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note 8 &#8211; Accrued Liabilities </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amounts reported in &#8216;Accrued liabilities&#8217; in the balance sheets were (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Compensation related accruals</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,975</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,165</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued clinical trial expense</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">715</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">620</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other expenses</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,099</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,352</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrant liability, current</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total accrued liabilities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,789</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,180</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140148457929688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt</a></td>
<td class="text">
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note 9 &#8211; Debt</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Notes Payable</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Long-term notes payable were as follows (in thousands): </p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">As of December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2018 Notes</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,972</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,270</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Payroll protection plan</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,107</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Convertible notes payable</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,159</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unamortized debt discount and debt issuance costs</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(313</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,458</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,766</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,971</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: current maturities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,840</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,159</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Long-term notes payable</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,926</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,812</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2018, the Company issued long-term debt of $23.0 million to Innovatus Life Sciences Lending Fund (Innovatus or Lender) (the 2018 Notes).&#160;&#160;Innovatus is also a holder of the Company&#8217;s common stock.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At the time of issuance, the Company paid a facility fee of $0.2 million and issued a warrant to Innovatus, with an initial estimated fair value of $0.3 million, for the purchase of 613,333 shares of Series G preferred stock. The facility fee and the estimated warrant fair value were recorded as debt discount and is amortized to interest expense over the term of the 2018 Notes.&#160;&#160;The 2018 Notes bear annual interest at 10%, of which 7.5% is payable in cash, with the remaining 2.5% added to principal through December 31, 2020.&#160;&#160;Total interest added to principal was $1.7 million and $1.1 million as of December 31, 2020 and 2019, respectively. Commencing March 2021 and continuing through the maturity date February 2023, the outstanding principal is repayable in 24 equal monthly installments.&#160;&#160;</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The loan may be prepaid by the Company at any time, subject to a prepayment penalty of up to 3% of the principal amount, depending on the date of prepayment. Upon payment of the 2018 Notes at maturity or prepayment on any earlier date, unless waived, a 2% back-end facility fee will apply to the amounts paid or prepaid. The 2% fee is recognized as additional interest expense over the loan term. The 2018 Notes are senior to all of the Company&#8217;s other indebtedness including any contingent consideration payable to Indi.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The 2018 Notes contain customary affirmative covenants, and contain negative covenants limiting the ability of the Company to, among other things, incur future debt, transfer assets except for the ordinary course of business, make acquisitions, make certain restricted payments, or to sell assets, subject to certain exceptions.&#160; In addition, the 2018 Notes require the Company to comply with a minimum daily liquidity covenant and a rolling monthly revenue requirement. Failure to comply with the covenants and loan requirements may result in early amortization of the loan in a 24- or 36-month payment schedule. As of December 31, 2020, the Company was in compliance with all terms and covenants.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company granted the Lender a security interest in all of the Company&#8217;s assets through a pledge and security agreement, patent security agreement and trademark security agreement, each between the Company and the Lender. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Paycheck Protection Program Note Payable</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In April 2020, the Company entered into a loan pursuant to the Paycheck Protection Program under the CARES Act, as administered by the U.S. Small Business Administration (the SBA). The loan, in the principal amount of $3.1 million (the PPP Loan), was disbursed by JPMorgan Chase Bank (JPM) pursuant to a Paycheck Protection Program Promissory Note and Agreement (the Note and Agreement).</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The PPP Loan matures on the two-year anniversary of the funding date, April 2022, and bears interest at a fixed rate of 1.00% per annum. Monthly principal and interest payments, less the amount of any potential forgiveness (as discussed below), will commence in September 2021. The Company did not provide any collateral or guarantees in connection with the PPP Loan, nor did the Company pay any facility charge to obtain the PPP Loan. The Note and Agreement provides for customary events of default, including those relating to failure to make payment, bankruptcy, breaches of representations and material adverse effects. The Company may prepay the principal of the PPP Loan at any time without incurring any prepayment charges.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All or a portion of the PPP Loan may be forgiven by the SBA and JPM upon application by the Company.&#160; Under the CARES Act, loan forgiveness is available for the sum of documented payroll costs, covered rent payments, and covered utilities during the eight-week period beginning on the approval date of the PPP Loan. For purposes of the CARES Act, payroll costs exclude compensation of an individual employee earning more than $100,000, prorated annually. Not more than 40% of the forgiven amount may be for non-payroll costs. Forgiveness is reduced if full-time headcount declines, or if salaries and wages for employees with salaries of $100,000 or less annually are reduced by more than 25%.&#160;The Company currently intends to repay the PPP loan in accordance with the underlying terms and conditions.&#160;&#160;To the extent we elect to seek forgiveness, the Company cannot assure that the PPP Loan will be forgiven, in whole or in part. If the loan is forgiven in part or in whole, and legal release is received, the Company will&#160;reduce the liability by the amount forgiven and record a gain on extinguishment in the statements of operations.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Convertible Notes Payable</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">March 2020 Notes</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2020, the Company issued $10.0 million of convertible notes primarily to existing stockholders that were originally scheduled to mature in <span style="-sec-ix-hidden:F_000572">August 2020</span> (the March 2020 Notes). In August 2020, the Company and its lenders agreed to extend the maturity date to June 30, 2021. The March 2020 Notes were issued in two tranches of $<span>5.0 million</span>, with the first in March 2020 and the second in June 2020.&#160;&#160;Interest on the March 2020 Notes was 3% per annum, payable in full upon maturity through conversion to Series H Preferred Stock at 80% of the original issuance price of $1.15 per share.&#160;&#160;Under the terms of the March 2020 Notes, on or before the maturity date and if the March 2020 Notes are unpaid, the outstanding principal and unpaid accrued interest under the March 2020 Notes shall be automatically converted into common stock in an initial public offering at a conversion price of 80% of the per share price of common stock sold in the initial public offering. The discount on the automatic conversion was separated from the March 2020 Notes and reported as a debt discount and put option liability of $2.5 million and was amortized over the term of the March 2020 Notes.&#160;&#160;Following the closing of the initial public offering in October 2020, the March 2020 Notes were automatically converted into 703,503 shares of common stock at a conversion price of $14.40, or 80% of the initial public offering price per common share.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">December 2019 Notes</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2019, the Company issued $6.0 million of convertible notes primarily to existing preferred shareholders that were originally scheduled to mature in <span style="-sec-ix-hidden:F_000585">August 2020</span> (the December 2019 Notes). In August 2020, the Company and its lenders agreed to extend the maturity date to June 30, 2021. The December 2019 Notes were issued in two tranches of <span>$3.0 million</span>, the first in December 2019 and the second in February 2020.&#160;&#160;Interest on the December 2019 Notes was 3% per annum and payable in full upon maturity through the conversion to Series H Preferred Stock at 80% of the original issuance price of $1.15 per share. Under the terms of the December 2019 Notes, on or before the maturity date and if the December 2019 Notes are unpaid, the outstanding principal and unpaid accrued interest under the December 2019 Notes shall be automatically converted into common stock in an initial public offering at a conversion price of 80% of the per share price of common stock sold in the initial public offering. The discount on the automatic conversion was separated from the December 2019 Notes and reported as a debt discount and put option liability of $1.5 million and was amortized over the term of the December 2019 Notes. Following the closing of the initial public offering in October 2020, the December 2019 Notes were automatically converted into 426,386 shares of common stock at a conversion price of $14.40, or 80% of the initial public offering price per common share.</p>

<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">August 2019 Notes</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August and September 2019 (the August 2019 Notes), the Company issued $10.0 million of convertible notes primarily to existing preferred shareholders that were originally scheduled to mature in <span style="-sec-ix-hidden:F_000598">August 2020</span>. In August 2020, the Company and its lenders agreed to extend the maturity date to June 30, 2021. Interest on the August 2019 Notes was 3% per annum and payable in full upon maturity through the conversion to Series H Preferred Stock at 95% of the original issuance price of $1.15 per share. Under the terms of the August 2019 Notes, on or before the maturity date and if the August 2019 Notes are unpaid, the outstanding principal and unpaid accrued interest under the August 2019 Notes shall be automatically converted into common stock in an initial public offering at a conversion price of 95% of the per share price of common stock sold in the initial public offering.<span style="color:#000000;">&#160;</span>In connection with the issuance of the December 2019 Notes, the conversion price on the August 2019 Notes was amended to 80%<span style="color:#000000;">.</span> The initial discount on the automatic conversion created an initial put option liability of $0.5 million that was separated from the August 2019 Notes. The amendment to the conversion price of the August 2019 Notes in December 2019 resulted in an increase to the put option liability of $2.0 million to a total estimated value of $2.5 million as of December 31, 2019.&#160;&#160;The increase in the value of the put option liability was reflected as a change in put option in the 2019 statement of operations. Following the closing of the initial public offering in October 2020, the August 2019 Notes were automatically converted into 718,391 shares of common stock at a conversion price of $14.40, or 80% of the initial public offering price per common share.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Scheduled principal repayments (maturities) of long-term obligations as of December 31, 2020 were as follows (in thousands): </p>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:79.7%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year Ending December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.34%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">As of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:79.7%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.34%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,840</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:79.7%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.34%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,919</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:79.7%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.34%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,320</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:79.7%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.34%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:79.7%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2025</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.34%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:79.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thereafter</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.34%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:79.7%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.34%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,079</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140148475957000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Preferred Stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockDisclosuresAbstract', window );"><strong>Class Of Stock Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockTextBlock', window );">Convertible Preferred Stock</a></td>
<td class="text">
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note 10 &#8211; Convertible Preferred Stock</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company had issued convertible preferred stock from time to time to fund its operations and to make acquisitions. In February and March 2019, the Company issued 8,695,621 shares of Series H Preferred Stock at $1.15 per share for total cash proceeds of $10.0 million.<span style="color:#000000;">&#160;</span></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The Company&#8217;s convertible preferred stock was reported as temporary equity in the Company&#8217;s balance sheet because the preferred shareholders held a majority of the Company&#8217;s Board of Directors seats and as a result could have caused certain events to occur outside of the Company&#8217;s control, with the result the Company could have been obligated to redeem the convertible preferred stock.</span></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Immediately prior to the Company&#8217;s initial public offering and as of December 31, 2019, the Company had issued 118,766,273 convertible preferred shares. On October 27, 2020, upon closing of the Company&#8217;s initial public offering, each outstanding share of Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock, Series G Preferred Stock and Series H Preferred Stock automatically converted into 0.1684664 share of common stock; and each share of Series B-1 Preferred Stock automatically converted into 0.196 shares of common stock. In the aggregate, all Series of preferred stock were converted into 20,090,745 shares of common stock. As a result, as of December 31, 2020 there are no longer any series of convertible preferred stock outstanding.</p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for terms, amounts, nature of changes, rights and privileges, dividends, and other matters related to preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140148461648584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants to Purchase Convertible Preferred Stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract', window );"><strong>Warrants And Rights Note Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_WarrantsForConvertiblePreferredStockTextBlock', window );">Warrants to Purchase Convertible Preferred Stock</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note 11 &#8211; Warrants to Purchase Convertible Preferred Stock</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company issued warrants to purchase shares of convertible preferred stock in conjunction with the sale of certain of the convertible preferred shares and issuance of debt. The estimated grant date fair value as well as the estimated fair value at each reporting date of the warrants was determined using the Black&#8209;Scholes option pricing model with weighted average assumptions substantially consistent with those disclosed for stock options (see Note 14 &#8211; <span style="font-style:italic;">Shared Based Compensation</span>), other than term, which is the contractual term of the warrant and the use of the exercise price and estimated fair value of the underlying series of convertible preferred stock. At December 31, 2019 and through the closing of the Company&#8217;s initial public offering, the preferred warrants were classified as liabilities with estimated fair value remeasured at each reporting date reported within in the accompanying statements of operations.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table presents the activity for convertible preferred stock warrants (in thousands, except weighted average exercise price):</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Series E</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Series G</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Warrants</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Exercise</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">price</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Warrants</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Exercise</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">price</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding &#8209; December 31, 2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">925</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.00</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">613</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.75</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited/canceled</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(925</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5.00</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reclassification of warrant liability to additional paid-in capital</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(613</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.75</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding &#8209; December 31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon closing of the Company&#8217;s initial public offering, the then outstanding Series G convertible preferred stock was automatically converted to common stock and the outstanding warrants to purchase Series G convertible preferred stock were automatically converted to warrants to purchase 103,326 shares of common stock at $4.46 per share and expire in <span style="-sec-ix-hidden:F_000645">February 2028</span>. The warrants were remeasured to an estimate of fair value as of the initial public offering with the change in fair value of $1.3 million recognized in our statements of operations. The carrying value of the warrants was reclassified to additional paid-in capital as a result of the initial public offering.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_WarrantsForConvertiblePreferredStockTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants for convertible preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_WarrantsForConvertiblePreferredStockTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsNoteDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140148465648072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Equity</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note 12 &#8211; Equity</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Common Stock</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s Restated Certificate of Incorporation authorizes the Company to issue up to 200,000,000 shares of common stock with a par value of $0.001 per share. The holder of each share of common stock is entitled to one vote per share. The common shareholders are entitled to dividends whenever funds and assets are legally available and when and if declared by the Board of Directors. The Company is currently subject to restrictions on the payment of dividends (see Note 9 - <span style="font-style:italic;">Debt</span>) and no dividends have been declared as of December 31, 2020.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On October 27, 2020, the Company issued and sold 4,000,000 shares of common stock in a registered initial public offering at a price to the public of $18.00 per share. The net proceeds to the Company were <span style="Background-color:#FFFFFF;">approximately </span>$63.8 million, after deducting underwriting discounts and commissions of $5.0 million and direct offering expenses of approximately $3.2 million. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Preferred Stock</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s Restated Certificate of Incorporation authorizes the Company to issue up to 5,000,000 shares of preferred stock with a par value of $0.001 per share. As of December 31, 2020, no shares of preferred stock were issued or outstanding.</p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140148457968584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue From Contract With Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenue</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note 13 - Revenue</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s revenue is generated from (i) diagnostic tests and (ii) assay development and testing services. Diagnostic test revenues consist of blood-based lung tests and COVID-19 tests, which are recognized in the amount expected to be received in exchange for diagnostic tests when the diagnostic tests are delivered. The Company conducts diagnostic tests and delivers the completed test results to the prescribing physician or patient, as applicable. The fees for diagnostic tests are billed either to a third party such as Medicare, medical facilities, commercial insurance payers, or to the patient. The Company determines the transaction price related to its diagnostic test contracts by considering the nature of the payer and historical price concessions granted to groups of customers. For diagnostic test revenue, the Company estimates the transaction price, which is the amount of consideration it expects to be entitled to receive in exchange for providing services based on its historical collection experience, using a portfolio approach. The Company recognizes revenues for diagnostic tests upon delivery of the tests to the physicians requesting the tests or patient, as applicable.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Services revenue consists of on-market tests, pipeline tests, custom diagnostic testing, and other scientific services for a purpose as defined by any individual customer, which is often with large biopharmaceutical companies. The performance obligations and related revenue for these sales is defined by a written agreement between the Company and the customer. These services are generally completed upon the delivery of testing results, or other contractually defined milestone(s), to the customer. Revenue for these services is recognized upon delivery of the completed test results, or upon completion of the contractual milestone(s). </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenues consisted of the following (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.26%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.12%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.26%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Diagnostic tests</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40,919</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,315</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.26%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Services</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,638</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,237</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.26%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total revenue</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45,557</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,552</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s fiscal 2020 diagnostic test revenue consists of $28.3 million in COVID-19 test revenue, which began in late fiscal 2020, and $12.6 million in lung diagnostic revenue.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Contract Liabilities</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contract liabilities consist of cash payments from customers received in advance of delivery (advance deposits). As products are shipped and control transfers, the Company recognizes the deferred revenue in &#8216;Revenues&#8217; in the statements of operations. At January 1 and December&#160;31, 2020, $1.3 million and $3.5 million, respectively, of advance deposits were reported in &#8216;Deferred revenue&#8217; in the accompanying balance sheets. Of the $1.3 million in deferred revenue recorded at January 1, 2020, $0.7 million was recognized in revenues during the year ended December&#160;31, 2020. The deferred revenue of $3.5 million at December&#160;31, 2020 is expected to be recognized in revenues during 2021 as test results are delivered.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130556-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130550-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130558-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140148457902552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share Based Compensation</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note 14 &#8211; Share Based Compensation</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">2016 Equity Incentive Plan and Predecessor 2006 Equity Incentive Plan</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2016, the Company adopted the 2016 Equity Incentive Plan (2016 Plan) as a successor to and continuation of the prior 2006 Equity Incentive Plan (2006 Plan). The 2016 Plan provides for the grant of incentive stock options, non-statutory stock options, stock appreciation rights, restricted stock awards, restricted stock units, and other stock awards to directors, employees, and consultants. Awards granted under the 2016 Plan or the 2006 Plan that expired or otherwise terminated, or were forfeited, cancelled, or repurchased by the Company, became available for future issuance under the 2016 Plan. In addition, shares subject to an award were withheld to satisfy a participant&#8217;s tax withholding obligations, or were reacquired by the Company as consideration for the exercise or purchase price of a stock award also became available for future issuance under the 2016 Incentive Plan.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><span style="font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">2020 Equity Incentive Plan</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effective upon the closing of our initial public offering, the Company&#8217;s Board of Directors approved the 2020 Equity Incentive Plan (2020 Plan), which replaced the 2016 Plan. <span style="Background-color:#FFFFFF;">&#160;The 2020 Plan provides for the grant of incentive stock options, non-statutory stock options, stock appreciation rights, restricted stock awards, restricted stock units, performance awards and other stock awards. Officers, directors, employees, consultants, agents, and independent contractors who provide services to the Company may receive awards. The terms of all awards are governed by an agreement between the Company and the recipients, as administered and approved by the Compensation Committee of the Board of Directors.</span></p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Employee Stock Purchase Plan</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effective with our initial public offering in October 2020, the Company&#8217;s Board of Directors and its stockholders approved the Company&#8217;s Employee Stock Purchase Plan (ESPP). A total of 338,106 shares of our common stock have been reserved for issuance under the ESPP. The maximum number of shares of our common stock available under the ESPP will automatically increase on the first trading day of each calendar year, commencing January 2021, by an amount equal to the lesser of (i) 1% of the shares of our common stock issued and outstanding on December 31 of the immediately preceding calendar year, and (ii) an amount determined by our Board of Directors.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.77%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Subject to any plan limitations, the ESPP allows eligible employees to contribute, normally through payroll deductions, up to 15% of their earnings for the purchase of the Company&#8217;s common stock at a discounted price per share. The price at which common stock is purchased under the ESPP is equal to 85% of the fair market value of the Company&#8217;s common stock on the first or last day of the offering period, whichever is lower. No employee may participate in an offering period if the employee owns 5% or more of the total combined voting power or value of the Company&#8217;s stock. The initial offering period will commence from January 1, 2021 through August 31, 2021.  On a going forward basis, the ESPP provides for successive six-month offering periods beginning on September 1st and March 1st of each year.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Shares Reserved Subject to All Plans</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The number of shares reserved for issuance under the 2020 Plan is 1,893,395, plus an annual increase added on the first day of each calendar year, beginning with the calendar year ending December&#160;31, 2022, and continuing until, and including, the calendar year ending December&#160;31, 2030. The annual increase will be equal to the lesser of (i)&#160;4% of the number of shares of our common stock issued and outstanding as of December&#160;31st of the immediately preceding calendar year and (ii)&#160;such lesser amount determined by the Board of Directors. Up to 1,893,395 shares of our common stock that may be issued under the 2020 Plan may be issued in satisfaction of incentive stock option awards.</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the 2006 Plan, the Company is authorized to grant <span style="Background-color:#FFFFFF;">incentive stock options, non-statutory stock options, stock appreciation rights, restricted stock awards and restricted stock units</span> up to 831,389 total award shares.<span style="Background-color:#FFFFFF;"> No additional awards may be granted under the 2006 Plan. Unallocated shares under the 2006 Plan were added to the shares available for issuance under the 2016 Plan.</span></p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Under the 2016 Plan, which is a successor to and continuation of the 2006 Plan, the Company is authorized to grant incentive stock options, non-statutory stock options, stock appreciation rights, restricted stock awards, restricted stock units and stock appreciation rights up to 1,431,964 total shares, plus any shares subject to stock awards made under the 2006 Plan</span>.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Our Compensation Committee may grant other stock awards that are based on or related to shares of our common stock, such as awards of shares of common stock granted as bonus and not subject to any vesting conditions, deferred stock units, stock purchase rights, and shares of our common stock issued in lieu of our obligations to pay cash under any compensatory plan or arrangement. To date, t</span><span style="color:#000000;">he Company has granted service-condition RSUs.</span></p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To the extent an equity award granted under the 2020 Plan (other than any substitute award) or granted under any other equity plan maintained by us under which awards are outstanding as of the effective date of the 2020 Plan (the Prior Plans) expires or otherwise terminates without having been exercised or paid in full, or is settled in cash, the shares subject to such award will become available for future grant under the 2020 Plan. In addition, to the extent shares subject to an award are withheld to satisfy a participant&#8217;s tax withholding obligation upon the exercise or settlement of such award (other than any substitute award) or to pay the exercise price of a stock option granted under the 2020 Plan or a Prior Plan, such shares will become available for future grant under the 2020 Plan. The total number of shares available for grant under all Plans was 4,647,380 at December 31, 2020.</p>

<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Description of Awards Granted</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has granted incentive stock options, non-statutory stock options, performance-based stock options, and restricted stock units. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Incentive stock options, which may only be issued to employees, are granted at an exercise price per share equal to the fair market value per share of the underlying common stock on the grant date, and vest over time as determined by the Compensation Committee, provided that the term of the options may not exceed ten years from the date of grant. Accelerated vesting may occur in the event of an optionee's death, disability, or other events.<span style="Background-color:#FFFFFF;"> </span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Non-statutory stock options may be issued to non-employees and directors, with exercise prices, vesting conditions, option term and other conditions as determined by the Compensation Committee.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Performance-based stock options are typically granted on an annual basis and consist of a performance-based and service-based component. The performance targets and vesting conditions for performance-condition options are based on achievement of recognized revenue targets. Performance-based options vest in three equal annual installments beginning one year after the grant date, pending certification of performance achievement by the Compensation Committee and continued service. The fair value of performance-condition awards is based on the closing market price of the Company&#8217;s common stock on the grant date. Compensation expense, net of forfeitures, is updated for the Company&#8217;s expected performance level against performance goals at the end of each reporting period. On January 1, 2019, the Company granted 168,466 performance-condition options, with an exercise price of $0.77 per share and a term of ten years. During the year ended December 31, 2020, the performance conditions were met and 56,155 options vested. During the year ended December 31, 2019, the performance conditions were not met and 56,155 options were forfeited. As of December 31, 2020, there were 56,156 performance condition options outstanding with a remaining life of approximately eight years. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted stock units and the related terms and conditions are awarded at the discretion of the Compensation Committee. RSU<span style="Background-color:#FFFFFF;color:#000000;"> holders </span>have a contractual right to receive a share of common stock when vested. RSUs generally vest over three years. RSU agreements may provide for accelerated vesting in the event of a stock unit holder's death, disability, or retirement or other events.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Bonus-To-Options Program</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company also has a Bonus-to-Options Program (the &#8220;Bonus Option Program&#8221;), which is separate from predecessor Plans and was initially adopted by the Board of Directors in 2008, and subsequently amended and restated in 2010, 2011 and 2015. For fiscal year 2021, the Bonus Option Program is subject to the shares reserved under the 2020 Plan. The Bonus Option Program, which is limited to participation of the Chief Executive Officer, direct reports to the Chief Executive Officer and Vice Presidents of the Company, allows participants who so elect to convert all or a portion of their annual cash bonus into fully vested, non-qualified stock options to purchase shares of common stock (Bonus Options).<span style="font-size:12pt;"> </span>The exercise price for the options under the Bonus Option Program equals the then current price for the shares of the common stock as of the grant date, as disclosed below under &#8220;<span style="font-style:italic;">Fair Value of Common Stock</span>&#8221;. Bonus Options issued must be exercised within a <span style="-sec-ix-hidden:F_000697">ten-year</span> term. A maximum of 1% of the fully diluted equity, as of December 31 of the year for which the bonus was awarded, may be issued in any one year to the participants. As of December 31, 2020, there were 173,229 options outstanding under the Bonus Option Program. <span style="color:#000000;">These options are fully vested and have a weighted average exercise price of $11.11 per share and have an intrinsic value of approximately $1.6 million as of December 31, 2020</span>.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> <span style="color:#000000;">During the twelve-month period ended December 31, 2020, the Company accrued $3.4 million as stock compensation expense associated with the estimate of options to be delivered to eligible participants under the Bonus Option Program and which were granted in February 2021 by the Compensation Committee of the Board of Directors.&#160;&#160;In determining the amount of stock compensation to recognize under the Bonus Option Program, the Company estimates the bonus attainment for the year and determines the expected number of options to be delivered to eligible participants.&#160;&#160;A Black-Scholes option pricing model is used to determine the estimated fair value of the expected number of options to be delivered to eligible participants.&#160;&#160;The key elements in determining the estimated fair value include assumptions for volatility, the risk free interest rate, expected dividends and strike price, utilizing the measurement date closing stock price until the grants are authorized.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><span style="font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Share-Based Compensation Expense</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pre-tax share-based compensation expense reported in the Company&#8217;s statements of operations was (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.78%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.52%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.78%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.5%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.78%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">589</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.78%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales, marketing, general and administrative</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,120</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.5%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">137</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.78%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,709</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.5%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">170</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The unrecognized remaining share-based compensation expense for options and RSUs was approximately $0.6 million as of December 31, 2020, and is expected to be amortized to expense over the next 3.7 years.</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Stock Options</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock option activity during the year ended December 31, 2020, excluding the Bonus Option Program described above, was (in thousands, except weighted average exercise price and weighted average contractual life):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:27.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.28%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Options</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.28%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Exercise</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Price</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.28%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Contractual</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Life (Years)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.28%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding - December 31, 2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.28%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,916</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.28%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.72</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.28%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000723">7.6</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.28%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.28%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">828</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.28%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.81</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.28%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000724">&#8212;</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.28%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited/canceled</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.28%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(55</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.28%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.60</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.28%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.28%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:27.7%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.28%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(368</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:14.28%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.65</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:14.28%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:14.28%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:27.7%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding &#8209; December 31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.28%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,321</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.28%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.82</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.28%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000725">7.4</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.28%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42,580</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:27.7%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercisable &#8209; December 31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.28%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,190</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.28%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.35</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.28%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000726">6.3</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.28%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,194</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Fair Value of Common Stock</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to the Company&#8217;s initial public offering, the fair value of the Company&#8217;s common stock underlying the stock options was determined by the Board of Directors with assistance from management and, in part, on input from an independent third-party valuation firm. The Board of Directors determined the fair value of common stock by considering a number of objective and subjective factors, including valuations of comparable companies, sales of convertible preferred stock, operating and financial performance, the lack of liquidity of the Company&#8217;s common stock and the general and industry-specific economic outlook. Subsequent&#160;to the Company&#8217;s initial public offering, the fair value of the Company&#8217;s common stock is determined based on its closing market price.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair value of each option grant prior was estimated on the grant date using the Black&#8209;Scholes option pricing model with the following weighted average assumptions for the year ended December 31, 2020:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk&#8209;free rate</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.34</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term (in years)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000730">5.73</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">77</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company estimated volatility based on the historical volatility of its peer group and average expected life based on the review of historical exercise behavior of option grants with similar vesting periods. <span style="color:#000000;">&#160;</span> </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><span style="font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Restricted Stock Units and Restricted Stock Unit Activity</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Service-condition RSUs were granted to Board members and vest over three years, 40% over the first two years and the remaining 60% over the third year from the grant date. During the year ended December&#160;31, 2020, the Company granted 52,736 service-condition RSUs. As of December 31, 2020, there were 79,104 RSUs outstanding, with a weighted average grant date fair value of $6.83 per share.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140148464613416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings per Share</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note 15 &#8211; Earnings per Share</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Excluded from determination of diluted net loss attributable to common stockholders for the periods presented because inclusion would be anti-dilutive are the instruments below, the terms of which are described in further detail in Note 14 &#8211; <span style="font-style:italic;">Share Based Compensation.&#160;&#160;</span>The potentially dilutive securities as of December 31, 2020 and 2019 primarily represent the shares subject to future issuance under stock options awards, warrants and RSUs and would be subject to the treasury stock method when dilutive. The number of common shares that convertible debt was assumed to convert to was based on the Company&#8217;s estimated common stock price as of December 31, 2019, as determined by the Company&#8217;s Board of Directors with assistance from a valuation firm. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.38%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.08%; border-bottom:solid 0.75pt #000000;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.38%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.38%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Numerator</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.76%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.76%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.38%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss attributable to common stockholders</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(31,350</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(30,726</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.38%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.76%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.76%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.38%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Denominator</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.76%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.76%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.38%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average shares outstanding used</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; in computing net loss per share, basic and diluted</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,838</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">242</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.38%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share, basic and diluted</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6.48</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(126.97</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following outstanding common stock equivalents were excluded from diluted net loss attributable to common stockholders for the periods presented because inclusion would be anti-dilutive (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.38%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.08%; border-bottom:solid 0.75pt #000000;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.38%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-top:solid 0.75pt #000000;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.38%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options to purchase common stock</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,495</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,104</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.38%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Convertible preferred stock</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">119,257</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.38%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrants</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">103</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,538</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.38%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted stock units</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">79</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.38%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Convertible debt </p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,131</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.38%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,677</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">144,056</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.85%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140148458155272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note 16 - Income Taxes</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since inception, the Company has incurred net taxable losses, and accordingly, no current provision for income taxes has been recorded.<span style="font-size:12pt;"> </span>The effective income tax rate of the provision for income taxes differs from the federal statutory rate as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December 31,</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal statutory income tax rate</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State income taxes, net of federal benefit</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and developments credits</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Permanent items</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in valuation allowance</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(16</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(23</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effective income tax rate</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The tax effects of temporary differences that give rise to significant portions of the deferred income tax assets and liabilities are as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December 31,</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred Tax Assets:</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net operating loss carryforwards</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53,128</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50,360</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development tax credits</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,860</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,040</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">279</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">370</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">865</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accruals and reserves</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,406</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">286</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">58,538</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54,056</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Valuation allowance</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(56,083</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(51,135</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax assets after valuation allowance</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,455</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,921</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred Tax Liabilities:</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible assets</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,455</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,921</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax liabilities</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,455</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,921</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net deferred tax assets and liabilities</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At December 31, 2020, the Company had $233.6 million and $3.6 million of net operating loss and research and experimentation tax carryforwards, respectively, which are set to expire beginning in 2026. The Internal Revenue Code contains provisions that may limit the net operating loss carryovers available to be used in any year if certain events occur, including significant changes in ownership interest. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In assessing the realizability of its deferred tax assets, the Company considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. The Company considers the scheduled reversal of deferred tax liabilities, projected future taxable income, and tax planning strategies in making this assessment. As the Company does not have any historical taxable income, projections of future taxable income over the periods in which the deferred tax assets are deductible, and after consideration of the history of operating losses, the Company does not believe it is more likely than not that it will realize the benefits of net deferred tax assets and, accordingly, has established a valuation allowance equal to 100% of net deferred tax assets. The valuation allowance increased by $4.9 million during 2020 and $7.0 million during 2019.</p>

<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During 2020, the Company determined that it now has uncertain<span style="color:#000000;"> tax positions related to its U.S. research and development credits. As of December 31, 2020 and 2019, there was no accrued interest related to uncertain tax positions. The Company does not believe it is reasonably possible that its unrecognized tax benefits will significantly change in the next twelve months</span>. A reconciliation of beginning and ending balances for unrecognized tax benefits is as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at January 1</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additions for tax positions related to the current year</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">106</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additions for tax positions related to prior years</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">609</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reductions for tax positions related to prior years</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reductions related to settlements</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reductions related to a lapse of statute</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">715</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company monitors proposed and issued tax law, regulations, and cases to determine the potential impact of uncertain income tax positions. At December 31, 2020, the Company had not identified any potential subsequent events that would have a material impact on unrecognized income tax benefits within the next twelve months.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All years will remain open for examining by federal and state authorities for three and four years, respectively, from the date of utilization of any net operating loss carryforwards. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140148459321496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments And Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note 17 &#8211; Commitments and Contingencies </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Leases</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company leases facilities under non&#8209;cancelable operating leases. Rent expense <span style="Background-color:#FFFFFF;">was $1.7 million</span> and $2.1 million for the years ended December 31, 2020 and 2019, respectively.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Future minimum lease payments for operating lease obligations are as follows as of December 31, 2020 (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%; border-bottom:solid 0.75pt #000000;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year Ending December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%; border-top:solid 0.75pt #000000;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">703</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">724</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">112</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2025</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thereafter</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,539</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Co&#8209;Development Agreement</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In April 2014 and amended in October 2016, the Company entered into a worldwide agreement with AVEO to develop and commercialize AVEO's hepatocyte growth factor inhibitory antibody ficlatuzumab with the Company's proprietary companion diagnostic test, BDX004, a version of the Company&#8217;s serum protein test that is commercially available to help physicians guide treatment decisions for patients with advanced non&#8209;small cell lung cancer (NSCLC). Under the terms of the agreement, AVEO will conduct a proof&#8209;of&#8209;concept (POC) clinical study of ficlatuzumab for NSCLC in which BDX004 will be used to select clinical trial subjects (the NSCLC POC Trial). The Company and AVEO will share equally in the costs of the NSCLC POC Trial, and each will be responsible for 50% of development and regulatory costs associated with all future clinical trials agreed upon by the Company and AVEO. The Company and AVEO continue to conduct POC clinical trials of ficlatuzumab in combination with BDX004 with each responsible for 50% of development and regulatory costs. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In September 2020, the Company exercised its opt-out right with AVEO for the payment of 50% of development and regulatory costs for ficlatuzumab effective December 2, 2020. The Company had $0.3 million in remaining obligations related to the AVEO agreement as of the opt-out date. Following the effective date, the Company is entitled to a 10% royalty of net sales of ficlatuzumab and 25% of license income generated from the licensing of ficlatuzumab from AVEO.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expenses related to this agreement for the <span style="color:#000000;">years ended December 31, 2020 and 2019 </span>were approximately $0.9<span style="Background-color:#FFFF00;"> </span>million and $0.9 million, respectively. </p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">License Agreement</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2019, we entered into a non-exclusive license agreement with Bio-Rad Laboratories, Inc. (Bio-Rad) (the Bio-Rad License). Under the terms of the Bio-Rad License, the Company received a non-exclusive license, without the right to grant sublicenses, to utilize certain of Bio-Rad&#8217;s intellectual property, machinery, materials, reagents, supplies and know-how necessary for the performance of Droplet Digital PCR&#8482; (ddPCR) in cancer detection testing for third parties in the United States. The Company also agreed to purchase all of the necessary supplies and reagents for such testing exclusively from Bio-Rad, pursuant to a separately executed supply agreement (the Supply Agreement) with Bio-Rad. As further consideration for the non-exclusive license, the Company agreed to pay a royalty of 2.5% on the net revenue received for the performance of such ddPCR testing collected from third parties.&#160;&#160;The Bio-Rad License expires in August 2024. Either party may terminate for the other&#8217;s uncured material breach or bankruptcy events. Bio-Rad may terminate the Bio-Rad License if the Company does not purchase licensed products under the Supply Agreement for a consecutive twelve-month period or for any material breach by us of the Supply Agreement.&#160;&#160;The Company incurred royalty expense of $0.1 million and $0.1 million for the years ended December 31, 2020 and 2019, respectively, under the Bio-Rad License.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Revenue Share Agreement</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As part of the acquisition of Oncimmune, the Company entered into several agreements to govern the relationship between the parties. The Company agreed to a revenue share payment related to an acquired diagnostic test of 8% of recognized revenue for non-screen tests up to an annual minimum volume and 5% thereafter, with an escalating minimum through the first four years of sales. Revenue share expenses of $0.3 million were recognized for the year ended December 31, 2020.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140148458142088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Defined Contribution 401(k) Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Compensation And Retirement Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanTextBlock', window );">Defined Contribution 401(k) Plan</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note 18 &#8211; Defined Contribution 401(k) Plan</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company sponsors a 401(k) defined contribution plan covering all eligible employees. The Company did not make any discretionary or employer matching contributions under the plan during the years ended December 31, 2020 or 2019.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -URI http://asc.fasb.org/subtopic&amp;trid=2235116<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140148465428248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_ReverseStockSplitPolicyTextBlock', window );">Reverse Stock Split</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Reverse Stock Split</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">O<span style="color:#000000;">n October 19, 2020, the Company obtained approval of an amended and restated certificate of incorporation effecting a 0.1684664-for-1 reverse stock split of its issued and outstanding common stock as converted. All common shares, stock options, and per share information presented in these financial statements and notes thereto have been adjusted, where applicable, to reflect the reverse stock split on a retroactive basis for all periods</span> presented. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_ApprovalOfAmendedAndRestatedCertificateOfIncorporationPolicyTextBlock', window );">Approval of Amended and Restated Certificate of Incorporation</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Approval of Amended and Restated Certificate of Incorporation</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In October 2020, the Company&#8217;s Board of Directors and stockholders approved an amended and restated certificate of incorporation, which authorized 200,000,000 shares of common stock, par value $0.001 per share, and 5,000,000 shares of preferred stock, par value $0.001 per share. The amended and restated certificate of incorporation became effective on October 30, 2020.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_InitialPublicOfferingIPOPolicyTextBlock', window );">Initial Public Offering ("IPO")</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Initial Public Offering</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On October 27, 2020, the Company completed its initial public offering, in which it issued and sold 4,000,000 shares of its common stock at a public offering price of $18.00 per share. The Company received net proceeds of $63.8 million after deducting underwriting discounts and commissions and offering expenses payable by the Company. In addition, in connection with the initial public offering, all shares of the Company&#8217;s then-outstanding convertible preferred stock and convertible notes payable were automatically converted into 21,939,025 shares of common stock, and all then outstanding warrants to purchase the Company&#8217;s Series G convertible preferred stock were automatically converted into warrants to purchase 103,326 shares of the Company&#8217;s common stock.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Basis of Presentation</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#212529;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s financial statements have been prepared in accordance with accounting principles generally accepted in the United States (U.S. GAAP). <span style="color:#000000;">The 2019 balance sheet has been updated to reflect an increase in goodwill and a reduction in accumulated deficit of $3.4 million related to the correction of an immaterial error recorded as part of the acquisition of Integrated Diagnostics, Inc. in 2018.</span>&#160;&#160;The Company determined that the reduction in the preexisting valuation allowance resulting from the acquisition should have been reflected as an income benefit within the tax provision rather than as a reduction in goodwill.&#160;&#160;The correction of the immaterial error had no impact on our 2020 or 2019 results of operations.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain prior period amounts have been reclassified to conform to the current period presentation.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Reporting</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Segment Reporting</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The chief operating decision maker for the Company is the Chief Executive Officer, who reviews financial information for purposes of allocating resources and assessing financial performance.&#160;&#160;The Company has a <span style="-sec-ix-hidden:F_000360">single</span> operating segment focused on providing diagnostic testing services to customers. Substantially all of the Company&#8217;s revenue and all long-lived assets were derived or located in the United States for the years ended December 31, 2020 and 2019.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Significant items subject to such estimates include: revenue recognition; the useful lives of property and equipment; the recoverability of long-lived assets; the estimation of the fair value of intangible assets; the valuation of contingent consideration related to a business combination; stock options; income tax uncertainties, including a valuation allowance for deferred tax assets; and contingencies. The Company bases these estimates on historical and anticipated results, trends, and various other assumptions that the Company believes are reasonable under the circumstances, including assumptions as to future events. These estimates form the basis for making judgments about the carrying values of assets and liabilities and recognized revenue and expenses that are not readily apparent from other sources. Actual results could differ from those estimates and assumptions.</p>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Revenue Recognition</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company generates revenues from (i) diagnostic tests and (ii) assay development and testing services (services revenue).</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Diagnostic test revenues consist of blood-based lung tests and COVID-19 tests, which are recognized in the amount expected to be received in exchange for diagnostic tests when the diagnostic tests are delivered. The Company determines the transaction price related to its blood-based lung diagnostic test contracts using a portfolio approach by considering the nature of the payer and historical price concessions granted to groups of customers. The transaction price associated with COVID-19 testing arrangements are determined on the basis of the individual contract with each customer.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Services revenue consists of various types of tests or other scientific services for a purpose as defined by any individual customer, which are often larger biopharmaceutical companies, as defined by a written agreement between the Company and the customer. These services are generally completed upon the delivery of testing results, or achievement of contractual milestone(s) as defined in the customer agreements. Revenue for these services is recognized upon delivery of the completed test results, or upon completion of the contractual milestone(s). </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes revenues related to blood-based lung diagnostic billings based on estimates of the amounts ultimately expected to be collected from customers on a portfolio approach as discussed above. In determining the amount to accrue for a delivered test, the Company considers factors such as payment history, payer coverage, whether there is a reimbursement contract between the payer and the Company, payment as a percentage of agreed upon rate (if applicable), amount paid per test and any current developments or changes that could impact reimbursement. Variable consideration, if any, is estimated based on an analysis of historical experience and adjusted as better estimates become available. These estimates require significant judgment by management.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company also provides services to patients with whom the Company does not have contracts as defined in Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC 606). The Company recognizes revenue for these patients when contracts as defined in ASC 606 are established at the amount of consideration to which it expects to be entitled, or when the Company receives substantially all of the consideration subsequent to satisfaction and delivery of the performance obligations.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">See Note 13 &#8212; <span style="font-style:italic;">Revenue</span> for additional information.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Deferred Revenue</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Deferred Revenue</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue consists of payments received for research, development, and testing services fees received prior to the completion of performance of these tests and services. As of December 31, 2020, deferred revenue also includes $2.8 million in a Medicare advance payment on testing services which can either be paid back or earned back starting 1 year from receipt.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_DirectCostsAndExpensesPolicyTextBlock', window );">Direct Costs and Expenses</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Direct Costs and Expenses</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The components of our cost of diagnostic tests and testing services consist of cost of materials, direct labor, including bonus, benefit and stock-based compensation, depreciation of laboratory equipment, rent costs, amortization of leasehold improvements and information technology costs associated with acquiring and processing test samples, including sample accessioning, test performance, quality control analyses, charges to collect and transport samples; curation of test results for physicians; and in some cases, license or royalty fees due to third parties.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Royalties for licensed technology are calculated as a percentage of revenues generated using the associated technology and recorded as expense at the time the related revenue is recognized. One-time royalty payments related to signing of license agreements or other milestones, such as issuance of new patents, are amortized to expense over the expected useful life of the patents. Costs associated with performing tests are expensed as the test is processed regardless of whether and when revenue is recognized with respect to that test.</p>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Research and Development <span style="color:#212529;">Expenses</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses include external and internal costs incurred to develop our technology, collect clinical samples, and conduct clinical studies to develop and support our products. External costs consist primarily of payments to clinical trial sites, sample acquisition costs and laboratory supplies purchased in connection with the Company&#8217;s discovery and preclinical activities, process development and clinical development activities.&#160; Internal costs consist primarily of salaries and benefits, reagents and supplies used in research and development laboratory work, infrastructure expenses, including allocated facility occupancy and information technology costs<span style="Background-color:#FFFFFF;">.</span> </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;color:#212529;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company estimates and accrues its expenses resulting from its obligations under contracts with vendors and consultants in connection with conducting research and development activities. The financial terms of these contracts vary from contract to contract and may result in payments that do not match the periods over which materials or services are provided under such contracts.<span style="color:#000000;">&#160;&#160;The Company&#8217;s estimates depend on the timeliness and accuracy of the data provided by consultants and vendors regarding the status of each activity.&#160;&#160;The Company periodically evaluates the estimates to determine if adjustments are necessary or appropriate based on information received. Research and development costs are expensed as incurred. </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock', window );">Sales, Marketing, General and Administrative Expenses</a></td>
<td class="text">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Sales, Marketing, General and Administrative Expenses</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Selling expenses consist primarily of costs associated with our sales organization, including our direct sales force and sales management, client services, marketing, and reimbursement, as well as business development personnel who are focused on our biopharmaceutical customers. These expenses consist primarily of salaries, commissions, bonuses, employee benefits, travel, and stock-based compensation, as well as marketing and educational activities and allocated overhead expenses. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales, marketing, general and administrative expenses also include costs for our marketing and sales organizations, and other functions including finance, legal, human resources, and information technology. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These expenses consist principally of salaries, bonuses, employee benefits, travel, and stock-based compensation, as well as professional services fees such as consulting, audit, tax and legal fees, and general corporate costs and allocated overhead expenses.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of Credit Risk and Other Uncertainties</a></td>
<td class="text">
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Concentrations of Credit Risk and Other Uncertainties</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Substantially all of the Company&#8217;s cash and cash equivalents are deposited with one major financial institution in the United States. The Company continually monitors its positions with, and the credit quality of, the financial institution with which it holds cash. Periodically throughout the year, the Company has maintained balances in various operating accounts in excess of federally insured limits. The Company has not experienced any losses on its deposits of cash and cash equivalents.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Several of the components of the Company's sample collection kit and test reagents, and certain test systems and related test kits are obtained from single-source suppliers. If these single-source suppliers fail to satisfy the Company's requirements on a timely basis, it could suffer delays in being able to deliver its diagnostic solutions, a possible loss of revenue, or incur higher costs, any of which could adversely affect its operating results.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s customers in excess of 10% of total revenue, and their related revenue as a percentage of total revenue were as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:79.2%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.86%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:79.2%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.86%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:79.2%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Big Ten Conference</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:79.2%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Centura Healthcare</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:79.2%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Percent of total revenue</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">One customer, Covance, exceeded 10% of total revenue during 2019, representing 21% of total revenue. In addition to the above table, we collect reimbursement on behalf of customers covered by Medicare, which accounted for 17% and 36% of the Company&#8217;s total revenue for the years ended December 31, 2020 and 2019, respectively.&#160;&#160;The Company is subject to credit risk from its accounts receivable related to services provided to its customers. The Company does not perform evaluations of customers' financial condition and does not require collateral. The Company&#8217;s third-party payors and other customers in excess of 10% of accounts receivable, and their related accounts receivable as a percentage of total accounts receivable were as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.26%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.12%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">As of December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.26%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Big Ten Conference</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Centura Healthcare</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Medicare</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Covance Central Laboratory Services</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Janssen Research and Development, LLC</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.26%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pfizer, Inc</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.26%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Percent of total accounts receivable</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">76</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">83</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text">
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Cash and Cash Equivalents </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents consist of short-term, highly-liquid instruments with an original maturity of three months or less from the date of purchase. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Restricted Cash</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Restricted Cash</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash consists of deposits related to the Company&#8217;s corporate credit card and a letter of credit related to an operating lease agreement. As of December 31, 2020 and 2019, the Company had $0.2 million restricted cash, respectively, which was included in &#8216;Other current assets&#8217; in the accompanying balance sheets.&#160;&#160; </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy', window );">Accounts Receivable and Allowance for Doubtful Accounts</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Accounts Receivable and Allowance for Doubtful Accounts</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts receivable are stated at the amount management expects to collect from customers based on their outstanding invoices. Management reviews accounts receivable <span style="color:#000000;">quarterly</span> to determine if any receivable will potentially be uncollectible and to estimate the amount of allowance for doubtful accounts necessary to reduce accounts receivable to its estimated net realizable value based on <span style="color:#000000;">historical experience, customer creditworthiness, facts, and circumstances specific to outstanding balances, and payment terms. The Company&#8217;s allowance for doubtful accounts was $0.2 million as of December 31, 2020 and 2019.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventorySuppliesPolicy', window );">Inventory</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Inventory</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inventory consists primarily of material supplies, which are consumed in the performance of testing services and charged to cost of sales. Inventory is stated at cost and reported within &#8216;Other current assets&#8217; in the balance sheet and were $3.2 million and $0.8 million as of December 31, 2020 and 2019, respectively.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Property and Equipment</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment are stated at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally between three and five years. Leasehold improvements are amortized using the straight-line method over the shorter of the estimated useful life of the asset or the term of the lease. Maintenance and repairs are charged to expense as incurred, and improvements and betterments are capitalized. When assets are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the balance sheet and any resulting gain or loss is reflected in the statements of operations and comprehensive loss in the period realized.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Long-lived assets to be held and used are evaluated for impairment when events or circumstances indicate the carrying value of a long-lived asset or asset group is less </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">than </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the undiscounted cash flows from the use and eventual disposition over its remaining useful life. The Company assesses recoverability by comparing the sum or projected undiscounted cash flows from the use and eventual disposition of the asset or asset group to it carrying value, and records an impairment loss if the carrying value is greater </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">than </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the undiscounted future cash flows.</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> There were </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">no</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> impairments for the years ended December 31, 2020 or 2019.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy', window );">Intangible Assets</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Intangible Assets</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible assets primarily consist of intangible assets acquired as part of business combinations, external costs associated with patent applications that are expected to be successful, and trademark costs. Finite-lived intangibles are stated at cost, net of accumulated amortization. The Company amortizes finite-lived intangible assets using the straight-line method over their estimated useful lives of 9 to 10 years, based on management's estimate of the period over which their economic benefits will be realized, product life and patent life. Trademarks are considered indefinite lived and are not amortized.  </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible assets are reviewed for impairment whenever events or changes in circumstances indicate a reduction to fair value below their carrying amounts. There were no impairments for the years ended December 31, 2020 or 2019.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy', window );">Goodwill</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Goodwill</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Goodwill represents the excess of purchase price over amounts allocated to acquired assets and liabilities assumed in business combinations. The carrying value of goodwill is evaluated for impairment at least annually or more frequently when events or circumstances occur indicate a potential for impairment. The annual impairment test is performed on the last day of our fourth quarter. Prior to performing a quantitative evaluation, an assessment of qualitative factors may be performed to determine whether it is more likely than not that the fair value of the reporting unit exceeds its carrying value. In the event the Company determines that it is more likely than not the carrying value of our single reporting unit is higher than its estimated fair value, quantitative testing is performed comparing recorded values to estimated fair values. If impairment is present, the impairment loss is measured as the excess of the recorded goodwill over its implied fair value. <span style="color:#000000;">There were no impairments for the years ended December 31, 2020 or 2019.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value of Financial Instruments</a></td>
<td class="text">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Fair Value of Financial Instruments</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. GAAP for fair value establishes a hierarchy that prioritizes fair value measurements based on the types of inputs used for the various valuation techniques (market approach, income approach, and cost approach). We utilize a combination of market and income approaches to value our financial instruments. Our financial assets and liabilities are measured using inputs from the three levels of the fair value hierarchy. Fair value measurements are categorized within the fair value hierarchy based upon the lowest level of the most significant inputs used to determine fair value. The three levels of the hierarchy and the related inputs are as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.08%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:86.08%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inputs</p></td>
</tr>
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%; border-top:solid 0.75pt #000000;" valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:86.08%; border-top:solid 0.75pt #000000;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unadjusted quoted prices in active markets for identical assets and liabilities.</p></td>
</tr>
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%;" valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:86.08%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unadjusted quoted prices in active markets for similar assets and liabilities;</p></td>
</tr>
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%;" valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:86.08%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active; or</p></td>
</tr>
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%;" valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:86.08%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inputs other than quoted prices that are observable for the asset or liability.</p></td>
</tr>
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%;" valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:86.08%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unobservable inputs for the asset or liability.</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The carrying amounts of certain financial instruments including cash and cash equivalents, accounts receivable, prepaid expenses and other current assets, accounts payable and accrued liabilities approximate fair value due to their relatively short maturities.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">See Note 5 <span style="color:#000000;">&#8212; </span><span style="font-style:italic;color:#000000;">Fair Value </span><span style="color:#000000;">for further discussion related to estimated fair value measurements.</span></p>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_ContingentConsiderationPolicyTextBlock', window );">Contingent Consideration</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Contingent Consideration</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the purchase transaction with Integrated Diagnostics, Inc. (Indi), the Company recorded contingent consideration for amounts potentially payable to Indi&#8217;s shareholder pursuant to the terms of the asset purchase agreement. The fair value of contingent consideration is assessed at each balance sheet date and changes, if any, to the fair value are recognized as operating expenses within the statements of operations. The estimated fair value of the contingent consideration is based upon significant assumptions including the probability of successful achievement of product gross margin targets included in the acquisition agreement, the estimated timing of achievement of the product gross margin targets, and discount rates. The estimated fair value could materially differ from actual values or fair values determined using different assumptions.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_WarrantLiabilityPolicyTextBlock', window );">Warrant Liability</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Warrant Liability</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to the completion of the Company&#8217;s initial public offering in October 2020, certain warrants issued to purchase convertible preferred stock were classified as liabilities with changes in the estimated fair value of these liabilities recognized in our results of operations. Upon completion of the Company&#8217;s initial public offering in October 2020, the warrants were automatically converted to warrants to purchase common stock. Accordingly, the warrants were remeasured to an estimate of fair value and recognized in our results of operations and then reclassified to additional paid-in capital.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_PutOptionLiabilityPolicyTextBlock', window );">Put Option Liability</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Put Option Liability</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During 2020 and 2019, the Company issued convertible debt<span style="color:#000000;">&#160;</span>with terms that provided for a conversion rate to the convertible debtholders that was more favorable than the price that other investors would pay for common stock in certain situations, including the completion of an initial public offering. As a result, the convertible debt is a financial instrument that was bifurcated into two instruments, a debt obligation and a put option liability, which represented the estimated fair value of the favorable conversion rate.&#160;&#160;The estimated fair value of the put option liability was separated from the convertible debt at inception and reported as a liability and debt discount, and amortized to interest expense. As a result of our initial public offering, the convertible debt was automatically converted to common stock and the put option liability was remeasured to an estimate of fair value and recognized in our results of operations and then reclassified to additional paid-in capital.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-Based Compensation</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Share&#8209;Based Compensation</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Stock Options<span style="font-style:normal;"> </span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company grants service condition and performance condition stock options. Stock options are granted with exercise prices equal to the fair market value of our common stock on the date of grant. The grant date fair value of each employee stock option is estimated on the date of grant using the Black-Scholes option-pricing model, which requires the use of assumptions, including the expected term of the option, expected volatility of our stock price, expected dividend yield, and the risk-free interest rate, among others. These assumptions involve inherent uncertainties including market conditions and employee behavior that are generally outside of the Company&#8217;s control. Service condition stock options are expensed based on the grant date fair value of the awards using the straight-line method over the requisite service period, adjusted for forfeitures as they occur. Performance-condition stock options vest based on achievement of multiple weighted performance goals, certification of performance achievement by the Compensation Committee of the Board of Directors, and continued service. For performance-condition stock options, compensation expense is updated for our expected performance level against performance goals at the end of each reporting period, which involves judgment as to achievement of certain performance metrics.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to our initial public offering in October 2020, the fair value of our common stock was determined by the Board of Directors in accordance with the methodologies outlined in the American Institute of Certified Public Accountants Practice Aid, Valuation of Privately-Held-Company Equity Securities Issued as Compensation Practice Aid (Practice Aid). In doing so, the Board of Directors determined the best estimate of fair value of our common stock, exercising reasonable judgment and considering numerous objective and subjective factors<span style="color:#000000;">, by first determining the enterprise value of our business, and then allocating the value among the various classes of our equity securities to derive a per share value of our common stock. </span>Subsequent&#160;to the Company&#8217;s initial public offering, the fair value of the Company&#8217;s common stock is determined based on its traded market price.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><span style="font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Restricted Stock Units (RSUs)</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company grants service-condition RSUs. As a result of our initial public offering, the grant date fair values of these RSUs are based on the closing market price of our common stock on the grant date. The service-condition RSUs vest based on continued service with compensation expense, net of forfeitures, recognized on a straight-line basis over the requisite service period. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">See Note 14 &#8212; <span style="font-style:italic;">Share-Based Compensation</span> for additional information related to share-based compensation.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss per Common Share</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Net Loss per Common Share </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic net loss per common share is calculated by dividing net loss by the weighted-average number of common shares outstanding during the period, without consideration of common stock equivalents. Diluted net loss per common share is computed by dividing net loss by the weighted-average number of common share equivalents outstanding for the period, if dilutive, using the treasury stock method. Potentially dilutive securities consisting of options to purchase common stock, warrants to purchase common stock, restricted stock units and shares subject to purchase under our employee stock purchase plan were excluded from the calculation of diluted net loss per common share because their effect would be anti-dilutive for all periods presented. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Until the Company&#8217;s initial public offering in October 2020, basic and diluted net loss attributable to common stockholders per share was calculated using the two-class method. The net loss was attributable entirely to common stockholders because the participating securities did not have a contractual obligation to share in the Company&#8217;s losses.&#160;&#160;As the Company has reported a net loss for all periods presented, diluted net loss per common share is the same as basic net loss per common share for all periods presented.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Issued Accounting Standards Not Yet Adopted</a></td>
<td class="text">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Recently Issued Accounting Standards Not Yet Adopted</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2016, the FASB issued Accounting Standards Update (ASU) No. 2016-2, <span style="font-style:italic;">Leases (Topic 842), </span>which requires lessees to recognize a right-of-use asset and corresponding lease liability, including leases currently accounted for as operating leases. The ASU is effective for the Company for interim and annual periods beginning January 1, 2022. The Company expects to recognize right-of-use assets and lease obligations in its balance sheet upon adoption using the modified retrospective method as permitted by ASU No. 2018-11, <span style="font-style:italic;">Leases (Topic 842): Targeted Improvements.</span> The Company does not currently expect adoption of this standard will have a significant effect on its statements of operations or cash flows.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2016, the FASB issued ASU No. 2016-13, <span style="font-style:italic;">Financial Instruments-Credit Losses: Measurement of Credit Losses</span> on Financial Instruments. This ASU requires measurement and recognition of expected credit losses for financial assets. This guidance will become effective for the Company beginning January 1, 2022 with early adoption permitted. The Company has not yet begun evaluating the potential effect of this standard on its financial statements. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_ApprovalOfAmendedAndRestatedCertificateOfIncorporationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for approval of amended and restated certificate of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_ApprovalOfAmendedAndRestatedCertificateOfIncorporationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_ContingentConsiderationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for contingent consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_ContingentConsiderationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_DirectCostsAndExpensesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Direct costs and expenses policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_DirectCostsAndExpensesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_InitialPublicOfferingIPOPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for initial public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_InitialPublicOfferingIPOPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_PutOptionLiabilityPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for put-option liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_PutOptionLiabilityPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_ReverseStockSplitPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reverse stock split.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_ReverseStockSplitPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_WarrantLiabilityPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_WarrantLiabilityPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108315417&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventorySuppliesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the basis and manner that goods are added and removed from inventory for supplies to be consumed directly or indirectly in production. If inventory is carried at cost, this disclosure includes the nature of the cost elements included in inventory and how cost is determined (such as FIFO, LIFO, average).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventorySuppliesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the allowance for doubtful accounts for trade and other accounts receivable balances, and when impairments, charge-offs or recoveries are recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=d3e5144-111524<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140148458071832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock', window );">Summary of Revenue and Accounts Receivable by Third-party Payors and Other Customers</a></td>
<td class="text">
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s customers in excess of 10% of total revenue, and their related revenue as a percentage of total revenue were as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:79.2%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.86%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:79.2%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.86%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:79.2%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Big Ten Conference</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:79.2%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Centura Healthcare</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:79.2%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Percent of total revenue</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>The Company&#8217;s third-party payors and other customers in excess of 10% of accounts receivable, and their related accounts receivable as a percentage of total accounts receivable were as follows:
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.26%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.12%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">As of December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.26%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Big Ten Conference</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Centura Healthcare</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Medicare</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Covance Central Laboratory Services</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Janssen Research and Development, LLC</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.26%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pfizer, Inc</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.26%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Percent of total accounts receivable</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">76</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">83</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13537-108611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13531-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6327-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6442-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140148488577464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combinations (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationSegmentAllocationTableTextBlock', window );">Summary of Aggregate Consideration Paid by Company and Allocation of Purchase Price to Assets Acquired and Liabilities Assumed</a></td>
<td class="text">
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the aggregate consideration paid by the Company and the allocation of the purchase price to assets acquired and liabilities assumed (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,206</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total fair value of consideration transferred</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,206</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deposit</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inventory</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">241</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchase option</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">121</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Goodwill</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">827</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued liabilities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,206</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationSegmentAllocationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationSegmentAllocationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140148465495176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock', window );">Summary of Fair Value of Outstanding Borrowings</a></td>
<td class="text">The fair values of outstanding borrowings, which are classified as Level 2, approximate their carrying values at December&#160;31, 2020 and 2019, based on interest rates currently available for similar borrowings and were:
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.85%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">As of December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.56%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Carrying&#160;Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fair&#160;Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Carrying&#160;Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fair&#160;Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.56%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Borrowings</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,766</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,766</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,971</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,971</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.85%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock', window );">Schedule of Reported Fair values of Liabilities</a></td>
<td class="text">The table below presents the reported fair values of these liabilities, all of which are classified as Level 3 in the fair value hierarchy, as of the dates indicated (in thousands):
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">As of December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%; border-bottom:solid 0.75pt #000000;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> Description</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%; border-top:solid 0.75pt #000000;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contingent consideration</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,932</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,114</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Put option liability</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,261</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrant liability</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">372</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contingent value rights</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.85%;font-family:Times New Roman;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Schedule of Changes in Financial Liabilities</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table presents the changes in these financial liabilities for the year ended December 31, 2020 (in thousands):</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Level 3 Rollforward</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Contingent</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Consideration</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Put</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Option</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Liability</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Warrant</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Liability</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Contingent</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Value&#160;Rights</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Beginning balances</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,114</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,261</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">372</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additions</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,389</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Changes in fair value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">818</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,252</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(60</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reclassified to additional paid-in capital</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,650</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,624</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ending balances</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,932</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).  Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to carrying amount and estimated fair value of short-term and long-term debt instruments or arrangements, including but not limited to, identification of terms, features, and collateral requirements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140148457915480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property Plant And Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment</a></td>
<td class="text">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment consist of the following (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">As of December 31,</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lab equipment</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,730</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,221</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,845</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,894</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer equipment</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">871</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">869</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture and fixtures</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">424</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">427</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Software</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">651</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">503</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Construction in process</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">381</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">592</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,902</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,506</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less accumulated depreciation</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,724</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,386</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total property and equipment, net</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,178</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,120</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_ScheduleOfDepreciationAndAmortizationExpenseRelatedToPropertyAndEquipmentTableTextBlock', window );">Schedule of Depreciation Expense Related to Property and Equipment</a></td>
<td class="text">
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation expense related to property and equipment, reported in &#8216;Direct costs and expenses&#8217; and &#8216;Sales, marketing, general and administrative&#8217; was: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.85%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year ended December 31,</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Direct costs and expenses</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">361</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">183</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales, marketing, general and administrative</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">478</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">636</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; Total</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">839</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">819</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_ScheduleOfDepreciationAndAmortizationExpenseRelatedToPropertyAndEquipmentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of depreciation and amortization expense related to property and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_ScheduleOfDepreciationAndAmortizationExpenseRelatedToPropertyAndEquipmentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140148458012904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill And Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Schedule of Changes in Goodwill</a></td>
<td class="text">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Changes in goodwill for the years ended December 31, 2020 and 2019 were (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85.12%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.8%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85.12%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at January 1, 2019</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,204</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:85.12%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;Attributable to acquisition of Oncimmune, Ltd.</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">827</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:85.12%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31 2019</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,031</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85.12%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:85.12%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2020</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,031</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock', window );">Schedule of Intangible Assets</a></td>
<td class="text">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible assets consist of the following (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.85%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.92%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.64%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2020</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2019</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.92%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Accumulated</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Amortization</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Net Carrying Value</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Accumulated</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Amortization</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Net Carrying Value</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.92%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible assets subject to amortization</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.2%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.44%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.2%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.2%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.24%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.2%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.92%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Patents</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.2%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,474</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.44%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(494</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.2%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">980</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.2%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,245</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.24%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(411</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.2%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">834</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.92%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchased technology</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.2%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,900</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.44%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,694</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.2%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,206</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.2%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,900</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.24%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,817</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.2%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,083</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.92%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchase option</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.2%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.44%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.2%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.2%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">121</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.24%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(17</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.2%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.92%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible assets not subject to amortization</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.2%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.44%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.2%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.2%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.24%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.2%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.92%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Trademarks</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.44%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.92%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; Total</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.2%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,448</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.44%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,188</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.2%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,260</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.2%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,337</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.24%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,245</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.2%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,092</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock', window );">Schedule of Amortization Expense Related to Definite-Lived Intangible Assets</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amortization expense related to definite-lived intangible assets was (in thousands): </p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:73.04%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.16%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year ended December 31,</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:73.04%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:73.04%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Direct costs and expenses</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.98%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:73.04%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales, marketing, general and administrative</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,051</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,959</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:73.04%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; Total</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.98%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,064</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,974</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of Future Estimated Amortization Expense of Intangible Assets</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Future estimated amortization expense of intangible assets is (in thousands):</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">As of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%; border-top:solid 0.75pt #000000;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,946</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,940</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,936</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,928</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2025</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,924</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thereafter</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,512</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,186</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140148461778888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables And Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Liabilities</a></td>
<td class="text">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amounts reported in &#8216;Accrued liabilities&#8217; in the balance sheets were (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Compensation related accruals</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,975</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,165</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued clinical trial expense</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">715</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">620</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other expenses</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,099</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,352</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrant liability, current</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total accrued liabilities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,789</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,180</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140148465639672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Summary of Long-term Notes Payable</a></td>
<td class="text">
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Long-term notes payable were as follows (in thousands): </p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">As of December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2018 Notes</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,972</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,270</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Payroll protection plan</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,107</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Convertible notes payable</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,159</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unamortized debt discount and debt issuance costs</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(313</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,458</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,766</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,971</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: current maturities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,840</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,159</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Long-term notes payable</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,926</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,812</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Scheduled Principal Repayments (Maturities) of Long-term Obligations</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Scheduled principal repayments (maturities) of long-term obligations as of December 31, 2020 were as follows (in thousands): </p>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:79.7%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year Ending December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.34%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">As of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:79.7%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.34%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,840</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:79.7%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.34%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,919</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:79.7%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.34%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,320</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:79.7%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.34%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:79.7%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2025</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.34%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:79.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thereafter</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.34%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:79.7%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.34%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,079</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28541-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21506-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(e),(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21521-112644<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21538-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=75038535&amp;loc=d3e64711-112823<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140148490879896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants to Purchase Convertible Preferred Stock (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract', window );"><strong>Warrants And Rights Note Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Summary of Activity for Convertible Preferred Stock Warrants</a></td>
<td class="text">
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table presents the activity for convertible preferred stock warrants (in thousands, except weighted average exercise price):</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Series E</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Series G</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Warrants</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Exercise</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">price</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Warrants</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Exercise</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">price</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding &#8209; December 31, 2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">925</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.00</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">613</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.75</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited/canceled</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(925</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5.00</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reclassification of warrant liability to additional paid-in capital</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(613</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.75</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding &#8209; December 31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsNoteDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140148458174392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue From Contract With Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Summary of Revenue</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenues consisted of the following (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.26%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.12%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.26%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Diagnostic tests</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40,919</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,315</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.26%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Services</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,638</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,237</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.26%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total revenue</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45,557</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,552</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140148458062904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Summary of Pre-tax Share-based Compensation Expense</a></td>
<td class="text">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pre-tax share-based compensation expense reported in the Company&#8217;s statements of operations was (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.78%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.52%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.78%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.5%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.78%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">589</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.78%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales, marketing, general and administrative</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,120</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.5%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">137</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.78%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,709</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.5%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">170</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity</a></td>
<td class="text">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock option activity during the year ended December 31, 2020, excluding the Bonus Option Program described above, was (in thousands, except weighted average exercise price and weighted average contractual life):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:27.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.28%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Options</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.28%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Exercise</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Price</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.28%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Contractual</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Life (Years)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.28%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding - December 31, 2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.28%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,916</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.28%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.72</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.28%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000723">7.6</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.28%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.28%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">828</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.28%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.81</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.28%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000724">&#8212;</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.28%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited/canceled</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.28%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(55</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.28%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.60</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.28%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.28%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:27.7%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.28%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(368</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:14.28%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.65</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:14.28%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:14.28%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:27.7%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding &#8209; December 31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.28%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,321</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.28%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.82</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.28%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000725">7.4</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.28%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42,580</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:27.7%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercisable &#8209; December 31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.28%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,190</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.28%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.35</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.28%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000726">6.3</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.28%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,194</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Summary of Weighted Average Assumptions</a></td>
<td class="text">
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair value of each option grant prior was estimated on the grant date using the Black&#8209;Scholes option pricing model with the following weighted average assumptions for the year ended December 31, 2020:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk&#8209;free rate</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.34</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term (in years)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000730">5.73</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">77</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140148458045224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Computation of Basic and Diluted Net Loss per Share Attributable to Common Stockholders</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.38%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.08%; border-bottom:solid 0.75pt #000000;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.38%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.38%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Numerator</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.76%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.76%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.38%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss attributable to common stockholders</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(31,350</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(30,726</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.38%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.76%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.76%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.38%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Denominator</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.76%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.76%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.38%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average shares outstanding used</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; in computing net loss per share, basic and diluted</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,838</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">242</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.38%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share, basic and diluted</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6.48</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(126.97</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Common Stock Equivalents Excluded from Diluted Net Loss Attributable to Common Stockholders</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following outstanding common stock equivalents were excluded from diluted net loss attributable to common stockholders for the periods presented because inclusion would be anti-dilutive (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.38%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.08%; border-bottom:solid 0.75pt #000000;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.38%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-top:solid 0.75pt #000000;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.38%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options to purchase common stock</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,495</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,104</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.38%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Convertible preferred stock</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">119,257</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.38%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrants</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">103</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,538</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.38%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted stock units</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">79</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.38%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Convertible debt </p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,131</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.38%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,677</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">144,056</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.85%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140148466358456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Effective Income Tax Rate Reconciliation</a></td>
<td class="text">The effective income tax rate of the provision for income taxes differs from the federal statutory rate as follows:
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December 31,</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal statutory income tax rate</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State income taxes, net of federal benefit</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and developments credits</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Permanent items</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in valuation allowance</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(16</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(23</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effective income tax rate</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets and Liabilities</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The tax effects of temporary differences that give rise to significant portions of the deferred income tax assets and liabilities are as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December 31,</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred Tax Assets:</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net operating loss carryforwards</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53,128</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50,360</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development tax credits</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,860</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,040</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">279</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">370</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">865</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accruals and reserves</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,406</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">286</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">58,538</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54,056</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Valuation allowance</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(56,083</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(51,135</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax assets after valuation allowance</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,455</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,921</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred Tax Liabilities:</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible assets</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,455</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,921</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax liabilities</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,455</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,921</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net deferred tax assets and liabilities</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Reconciliation of Unrecognized Tax Benefits</a></td>
<td class="text">A reconciliation of beginning and ending balances for unrecognized tax benefits is as follows (in thousands):
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at January 1</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additions for tax positions related to the current year</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">106</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additions for tax positions related to prior years</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">609</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reductions for tax positions related to prior years</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reductions related to settlements</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reductions related to a lapse of statute</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">715</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 55<br> -Paragraph 217<br> -URI http://asc.fasb.org/extlink&amp;oid=121610041&amp;loc=d3e36027-109320<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140148464209352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments And Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock', window );">Summary of Future Minimum Lease Payments for Operating Lease Obligations</a></td>
<td class="text">
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Future minimum lease payments for operating lease obligations are as follows as of December 31, 2020 (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%; border-bottom:solid 0.75pt #000000;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year Ending December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%; border-top:solid 0.75pt #000000;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">703</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">724</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">112</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2025</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thereafter</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,539</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121573735&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140148461698408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Description of Business - Additional Information (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Oct. 27, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th"><div>Oct. 19, 2020</div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>Test </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 31, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_OrganizationAndDescriptionOfBusinessLineItems', window );"><strong>Organization And Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_NumberOfCancerTest', window );">Number of blood based lung cancer test | Test</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_NumberOfCommercialBloodBasedTest', window );">Number of commercial blood-based test | Test</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_NumberOfSARSCoV2Test', window );">Number of SARS-CoV-2 test | Test</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Reverse stock split, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">0.1684664-for-1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Reverse stock split ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1684664<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">190,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from initial public offering | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 72,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">103,326<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">Initial Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_OrganizationAndDescriptionOfBusinessLineItems', window );"><strong>Organization And Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares of common stock issued and sold</a></td>
<td class="nump">4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Common stock price per share | $ / shares</a></td>
<td class="nump">$ 18.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from initial public offering | $</a></td>
<td class="nump">$ 63,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_ConvertiblePreferredStockAndConvertibleNotesPayableConvertedToCommonStock', window );">Convertible preferred stock and convertible notes payable converted into shares of common stock</a></td>
<td class="nump">21,939,025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares of common stock</a></td>
<td class="nump">103,326<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">103,326<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_ConvertiblePreferredStockAndConvertibleNotesPayableConvertedToCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Convertible preferred stock and convertible notes payable converted to common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_ConvertiblePreferredStockAndConvertibleNotesPayableConvertedToCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_NumberOfCancerTest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of cancer test.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_NumberOfCancerTest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_NumberOfCommercialBloodBasedTest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of commercial blood based test.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_NumberOfCommercialBloodBasedTest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_NumberOfSARSCoV2Test">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of SARS-CoV-2 test.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_NumberOfSARSCoV2Test</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_OrganizationAndDescriptionOfBusinessLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Organization and description of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_OrganizationAndDescriptionOfBusinessLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140148458323288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">$ 3,532,000<span></span>
</td>
<td class="nump">$ 1,283,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Allowance for doubtful accounts</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment of long-lived assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Impairment of intangible assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairments loss</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful Lives</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Product Life and Patent Life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-lived intangible asset, useful life</a></td>
<td class="text">9 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful Lives</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Product Life and Patent Life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-lived intangible asset, useful life</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember', window );">Other Current Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherInventorySupplies', window );">Inventory</a></td>
<td class="nump">$ 3,200,000<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Revenue | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">47.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Revenue | Customer Concentration Risk | Covance Central Laboratory Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Revenue | Customer Concentration Risk | Medicare</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">17.00%<span></span>
</td>
<td class="nump">36.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bdsx_TestingServicesMember', window );">Testing Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">$ 2,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RestatementAxis=srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember', window );">Revision of Prior Period, Error Correction, Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillPeriodIncreaseDecrease', window );">Increase in goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,400,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_IncreaseDecreaseInAccumulatedDeficit', window );">Reduction in accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,400,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsDescription', window );">Error corrections and prior period adjustments, description</a></td>
<td class="text">The 2019 balance sheet has been updated to reflect an increase in goodwill and a reduction in accumulated deficit of $3.4 million related to the correction of an immaterial error recorded as part of the acquisition of Integrated Diagnostics, Inc. in 2018.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_IncreaseDecreaseInAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in accumulated deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_IncreaseDecreaseInAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_SummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary Of Significant Accounting Policies [Line Items].</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_SummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121599337&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=d3e5074-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121599337&amp;loc=SL82919249-210447<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121599878&amp;loc=SL82895884-210446<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of a prior period adjustment to previously issued financial statements, including an adjustment that is a correction of an error. At a minimum, the description may include the nature and reasons for the adjustment and the periods affected by the adjustment, as well as (1) the effect of the correction on each financial statement line item and any per-share amounts affected for each prior period presented (2) the cumulative effect of the change on retained earnings or other appropriate components of equity or net assets in the statement of financial position, as of the beginning of the earliest period presented, and (3) the effect of the prior period adjustment (both gross and net of applicable income tax) on the net income of each prior period presented in the entity's annual report for the year in which the adjustments are made.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2921-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherInventorySupplies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of other supplies used within the manufacturing or production process expected to be consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherInventorySupplies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bdsx_ProductLifeAndPatentLifeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bdsx_ProductLifeAndPatentLifeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=bdsx_CovanceCentralLaboratoryServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=bdsx_CovanceCentralLaboratoryServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=bdsx_MedicareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=bdsx_MedicareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bdsx_TestingServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bdsx_TestingServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140148461485896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Summary of Revenue and Accounts Receivable by Third-party Payors and Other Customers (Details) - Customer Concentration Risk<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">47.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Revenue | The Big Ten Conference</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Revenue | Centura Healthcare</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">17.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Revenue | Medicare</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">17.00%<span></span>
</td>
<td class="nump">36.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Revenue | Covance Central Laboratory Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Accounts Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">76.00%<span></span>
</td>
<td class="nump">83.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Accounts Receivable | The Big Ten Conference</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Accounts Receivable | Centura Healthcare</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">24.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Accounts Receivable | Medicare</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="nump">18.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Accounts Receivable | Covance Central Laboratory Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">43.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Accounts Receivable | Janssen Research and Development, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Accounts Receivable | Pfizer, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=bdsx_TheBigTenConferenceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=bdsx_TheBigTenConferenceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=bdsx_CenturaHealthcareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=bdsx_CenturaHealthcareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=bdsx_MedicareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=bdsx_MedicareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=bdsx_CovanceCentralLaboratoryServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=bdsx_CovanceCentralLaboratoryServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=bdsx_JanssenResearchAndDevelopmentLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=bdsx_JanssenResearchAndDevelopmentLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=bdsx_PfizerIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=bdsx_PfizerIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140148464238760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combinations - Additional Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Oct. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2018 </div>
<div>USD ($) </div>
<div>Installment </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,031<span></span>
</td>
<td class="nump">$ 15,031<span></span>
</td>
<td class="nump">$ 14,204<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=bdsx_OncimmuneLimitedMember', window );">Oncimmune Limited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Total consideration amount</a></td>
<td class="nump">$ 1,206<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity', window );">Business acquisition description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">quarterly installments commencing 30 days following the closing of the transaction.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash</a></td>
<td class="nump">1,206<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">827<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=bdsx_IntegratedDiagnosticsIncMember', window );">Integrated Diagnostics, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Total consideration amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity', window );">Business acquisition description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">requires additional consideration to be paid by the Company to Indi upon attainment of a three-consecutive month<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure', window );">Contingent consideration estimated fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAcquiredFromAcquisition', window );">Business acquisition contingent consideration gross margin target</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod', window );">Business acquisition contingent consideration gross margin target period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=bdsx_IntegratedDiagnosticsIncMember', window );">Integrated Diagnostics, Inc | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity', window );">Business acquisition description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">If Indi elects to not exercise its option, the Company has 12 months to repurchase the common stock in two equal and consecutive quarterly cash installments totaling $37.0 million.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_BusinessCombinationContingentConsiderationShares', window );">Contingent consideration shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,520,108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_BusinessAcquisitionContingentConsiderationNumberOfInstallments', window );">Contingent consideration number of installments | Installment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_BusinessCombinationContingentConsiderationArrangementsCommonSharesRedemptionAmount', window );">Contingent consideration arrangements, common shares, redemption amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=bdsx_IntegratedDiagnosticsIncMember', window );">Integrated Diagnostics, Inc | Common Stock | Repurchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_BusinessAcquisitionContingentConsiderationNumberOfInstallments', window );">Contingent consideration number of installments | Installment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Contingent consideration cash payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">License Rights | Oncimmune Limited | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherPaymentsToAcquireBusinesses', window );">Payments to acquire license rights</a></td>
<td class="nump">$ 9,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business acquisition contingent consideration gross margin target period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_BusinessAcquisitionContingentConsiderationNumberOfInstallments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business acquisition contingent consideration number of installments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_BusinessAcquisitionContingentConsiderationNumberOfInstallments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_BusinessCombinationContingentConsiderationArrangementsCommonSharesRedemptionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business combination contingent consideration arrangements common shares redemption amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_BusinessCombinationContingentConsiderationArrangementsCommonSharesRedemptionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_BusinessCombinationContingentConsiderationShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business combination contingent consideration shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_BusinessCombinationContingentConsiderationShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>With respect to a business combination completed during the period, this element provides a description of the business, other than the name, which may include the industry, size, products and other important information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAcquiredFromAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAcquiredFromAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of contingent consideration in a business combination that is classified in shareholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPaymentsToAcquireBusinesses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with other payments to acquire businesses including deposit on pending acquisitions and preacquisition costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPaymentsToAcquireBusinesses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=bdsx_OncimmuneLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=bdsx_OncimmuneLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=bdsx_IntegratedDiagnosticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=bdsx_IntegratedDiagnosticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=bdsx_RepurchaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=bdsx_RepurchaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140148465843128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combinations - Summary of Aggregate Consideration Paid by Company and Allocation of Purchase Price to Assets Acquired and Liabilities Assumed (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,031<span></span>
</td>
<td class="nump">$ 15,031<span></span>
</td>
<td class="nump">$ 14,204<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=bdsx_OncimmuneLimitedMember', window );">Oncimmune Limited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash</a></td>
<td class="nump">$ 1,206<span></span>
</td>
<td class="nump">$ 1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Total fair value of consideration transferred</a></td>
<td class="nump">1,206<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities', window );">Deposit</a></td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory', window );">Inventory</a></td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="nump">241<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPurchaseOption', window );">Purchase option</a></td>
<td class="nump">121<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">827<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable', window );">Accrued liabilities</a></td>
<td class="num">(3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Total</a></td>
<td class="nump">$ 1,206<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPurchaseOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business combination recognized identifiable assets acquired and liabilities assumed purchase option.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPurchaseOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments in debt and equity securities, including, but not limited to, held-to-maturity, trading and available-for-sale expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of inventory recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=121600890&amp;loc=d3e2207-128464<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=121600890&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of property, plant, and equipment recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=121600890&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=bdsx_OncimmuneLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=bdsx_OncimmuneLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140148461427384">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value - Summary of Fair Value of Outstanding Borrowings (Details) - Fair Value, Recurring - Level 2 - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Carrying Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisLineItems', window );"><strong>Fair Value Liabilities Measured On Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Borrowings</a></td>
<td class="nump">$ 27,766<span></span>
</td>
<td class="nump">$ 35,971<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisLineItems', window );"><strong>Fair Value Liabilities Measured On Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Borrowings</a></td>
<td class="nump">$ 27,766<span></span>
</td>
<td class="nump">$ 35,971<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140148466404552">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value - Schedule of Reported Fair Values of Liabilities (Details) - Fair Value, Recurring - Level 3 - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=bdsx_ContingentConsiderationMember', window );">Contingent Consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisLineItems', window );"><strong>Fair Value Liabilities Measured On Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">$ 29,932<span></span>
</td>
<td class="nump">$ 29,114<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=bdsx_PutOptionLiabilityMember', window );">Put Option Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisLineItems', window );"><strong>Fair Value Liabilities Measured On Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,261<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=bdsx_WarrantLiabilityMember', window );">Warrant Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisLineItems', window );"><strong>Fair Value Liabilities Measured On Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">372<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=bdsx_ContingentValueRightsMember', window );">Contingent Value Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisLineItems', window );"><strong>Fair Value Liabilities Measured On Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=bdsx_ContingentConsiderationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=bdsx_ContingentConsiderationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=bdsx_PutOptionLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=bdsx_PutOptionLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=bdsx_WarrantLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=bdsx_WarrantLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=bdsx_ContingentValueRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=bdsx_ContingentValueRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140148460851640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value - Schedule of Changes in Financial Liabilities (Details) - Fair Value, Recurring - Level 3<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Contingent Consideration</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning balances</a></td>
<td class="nump">$ 29,114<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Changes in fair value</a></td>
<td class="nump">818<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending balances</a></td>
<td class="nump">29,932<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Put Option Liability</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning balances</a></td>
<td class="nump">3,261<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases', window );">Additions</a></td>
<td class="nump">3,389<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_FairValueMeasurementWithUnobservableInputsReconciliationReclassifiedToAdditionalPaidInCapital', window );">Reclassified to additional paid-in capital</a></td>
<td class="num">(6,650)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Warrant Liability</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning balances</a></td>
<td class="nump">372<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Changes in fair value</a></td>
<td class="nump">1,252<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_FairValueMeasurementWithUnobservableInputsReconciliationReclassifiedToAdditionalPaidInCapital', window );">Reclassified to additional paid-in capital</a></td>
<td class="num">(1,624)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Contingent Value Rights</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning balances</a></td>
<td class="nump">60<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Changes in fair value</a></td>
<td class="num">$ (60)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_FairValueMeasurementWithUnobservableInputsReconciliationReclassifiedToAdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, measurement with unobservable inputs reconciliation reclassified to additional paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_FairValueMeasurementWithUnobservableInputsReconciliationReclassifiedToAdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of purchases of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=bdsx_ContingentConsiderationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=bdsx_ContingentConsiderationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=bdsx_PutOptionLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=bdsx_PutOptionLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=bdsx_WarrantLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=bdsx_WarrantLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=bdsx_ContingentValueRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=bdsx_ContingentValueRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140148464247736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jan. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Oct. 27, 2020</div></th>
<th class="th"><div>Feb. 28, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 818<span></span>
</td>
<td class="nump">$ 4,114<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_PutOptionLiabilityCurrent', window );">Put option liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,400<span></span>
</td>
<td class="nump">3,261<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant, exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Warrants, expires period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Feb. 23,  2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure', window );">Estimated air value of warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrant issued to purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">103,326<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Increase in value of the warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,252<span></span>
</td>
<td class="nump">$ 104<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">Initial Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant, exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrant issued to purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">103,326<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">103,326<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesFPreferredStockMember', window );">Series F Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_ContingentValueRightsShares', window );">Contingent value rights shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_ContingentValueRights', window );">Contingent value rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_ContingentValueRightsPercentage', window );">Contingent value rights percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_NetProceedsPercentageOfCashPaymentToCVRHolders', window );">Net proceeds percentage of cash payment to the CVR holders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesFPreferredStockMember', window );">Series F Preferred Stock | AVEO Oncology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_PercentageOfDevelopmentAndRegulatoryCostsExercisedUsingOptOutRight', window );">Percentage of development and regulatory costs exercised using opt-out right</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=bdsx_NotesPayable2018NotesMember', window );">2018 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure', window );">Estimated air value of warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=bdsx_NotesPayable2018NotesMember', window );">2018 Notes | Series G Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Warrant issued to purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">613,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">613,333<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant, exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_PercentageOfProbabilitiesOfContingentConsiderationSuccessfulAchievementMilestoneDiscountRatesRange', window );">Percentage of probabilities of contingent consideration successful achievement of specified product gross margin targets discount rates range</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_PercentageOfProbabilitiesOfContingentConsiderationSuccessfulAchievementMilestoneDiscountRatesRange', window );">Percentage of probabilities of contingent consideration successful achievement of specified product gross margin targets discount rates range</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_ContingentValueRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingent value rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_ContingentValueRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_ContingentValueRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingent value rights percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_ContingentValueRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_ContingentValueRightsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingent value rights shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_ContingentValueRightsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_NetProceedsPercentageOfCashPaymentToCVRHolders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net proceeds percentage of cash payment to the cvr holders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_NetProceedsPercentageOfCashPaymentToCVRHolders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_PercentageOfDevelopmentAndRegulatoryCostsExercisedUsingOptOutRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of development and regulatory costs exercised using opt-out right.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_PercentageOfDevelopmentAndRegulatoryCostsExercisedUsingOptOutRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_PercentageOfProbabilitiesOfContingentConsiderationSuccessfulAchievementMilestoneDiscountRatesRange">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of probabilities of contingent consideration successful achievement milestone discount rates range.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_PercentageOfProbabilitiesOfContingentConsiderationSuccessfulAchievementMilestoneDiscountRatesRange</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_PutOptionLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Put option liability current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_PutOptionLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of warrants not settleable in cash classified as equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsNotSettleableInCashFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesFPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesFPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=bdsx_AVEOOncologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=bdsx_AVEOOncologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=bdsx_NotesPayable2018NotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=bdsx_NotesPayable2018NotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesGPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesGPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140148465555480">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment - Schedule of Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 9,902<span></span>
</td>
<td class="nump">$ 8,506<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation</a></td>
<td class="num">(6,724)<span></span>
</td>
<td class="num">(6,386)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total property and equipment, net</a></td>
<td class="nump">3,178<span></span>
</td>
<td class="nump">2,120<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Lab Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">5,730<span></span>
</td>
<td class="nump">4,221<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">1,845<span></span>
</td>
<td class="nump">1,894<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">871<span></span>
</td>
<td class="nump">869<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">424<span></span>
</td>
<td class="nump">427<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember', window );">Software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">651<span></span>
</td>
<td class="nump">503<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in Process</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 381<span></span>
</td>
<td class="nump">$ 592<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140148460908680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment - Schedule of Depreciation Expense Related to Property and Equipment (Details) - Property and Equipment - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 839<span></span>
</td>
<td class="nump">$ 819<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_PropertyPlantAndEquipmentMember', window );">Direct Costs and Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">361<span></span>
</td>
<td class="nump">183<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_PropertyPlantAndEquipmentMember', window );">Sales, Marketing, General and Administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 478<span></span>
</td>
<td class="nump">$ 636<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_PropertyPlantAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_PropertyPlantAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=bdsx_DirectCostsAndExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=bdsx_DirectCostsAndExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140148464446200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Schedule of Changes in Goodwill (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill And Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Beginning balance</a></td>
<td class="nump">$ 14,204<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Attributable to acquisition of Oncimmune, Ltd.</a></td>
<td class="nump">827<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Ending balance</a></td>
<td class="nump">$ 15,031<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAcquiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAcquiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140148473225480">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Schedule of Intangible Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets subject to amortization, Net Carrying Value</a></td>
<td class="nump">$ 13,186<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Intangible assets, Cost</a></td>
<td class="nump">18,448<span></span>
</td>
<td class="nump">$ 18,337<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_IntangibleAssetsAccumulatedAmortizationExcludingGoodwill', window );">Intangible assets, Accumulated Amortization</a></td>
<td class="num">(5,188)<span></span>
</td>
<td class="num">(3,245)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, Net Carrying Value</a></td>
<td class="nump">13,260<span></span>
</td>
<td class="nump">15,092<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember', window );">Trademarks</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_IndefiniteLivedIntangibleAssetsExcludingGoodwillGross', window );">Intangible assets not subject to amortization, Cost</a></td>
<td class="nump">74<span></span>
</td>
<td class="nump">71<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Intangible assets not subject to amortization, Net Carrying Value</a></td>
<td class="nump">74<span></span>
</td>
<td class="nump">71<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember', window );">Patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangible assets subject to amortization, Cost</a></td>
<td class="nump">1,474<span></span>
</td>
<td class="nump">1,245<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Intangible assets subject to amortization, Accumulated Amortization</a></td>
<td class="num">(494)<span></span>
</td>
<td class="num">(411)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets subject to amortization, Net Carrying Value</a></td>
<td class="nump">980<span></span>
</td>
<td class="nump">834<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bdsx_PurchasedTechnologyMember', window );">Purchased Technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangible assets subject to amortization, Cost</a></td>
<td class="nump">16,900<span></span>
</td>
<td class="nump">16,900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Intangible assets subject to amortization, Accumulated Amortization</a></td>
<td class="num">(4,694)<span></span>
</td>
<td class="num">(2,817)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets subject to amortization, Net Carrying Value</a></td>
<td class="nump">$ 12,206<span></span>
</td>
<td class="nump">14,083<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bdsx_PurchaseOptionMember', window );">Purchase Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangible assets subject to amortization, Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">121<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Intangible assets subject to amortization, Accumulated Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(17)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets subject to amortization, Net Carrying Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 104<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_IndefiniteLivedIntangibleAssetsExcludingGoodwillGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indefinite lived intangible assets excluding goodwill gross.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_IndefiniteLivedIntangibleAssetsExcludingGoodwillGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_IntangibleAssetsAccumulatedAmortizationExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated amortization of intangible assets, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_IntangibleAssetsAccumulatedAmortizationExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated amortization of intangible assets, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsGrossExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bdsx_PurchasedTechnologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bdsx_PurchasedTechnologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bdsx_PurchaseOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bdsx_PurchaseOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140148460635560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Schedule of Amortization Expense Related to Definite-Lived Intangible Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense related to definite-lived intangible assets</a></td>
<td class="nump">$ 2,064<span></span>
</td>
<td class="nump">$ 1,974<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=bdsx_DirectCostsAndExpensesMember', window );">Direct Costs and Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense related to definite-lived intangible assets</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Sales, Marketing, General and Administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense related to definite-lived intangible assets</a></td>
<td class="nump">$ 2,051<span></span>
</td>
<td class="nump">$ 1,959<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=bdsx_DirectCostsAndExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=bdsx_DirectCostsAndExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140148458054424">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Schedule of Future Estimated Amortization Expense of Intangible Assets (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract', window );"><strong>Finite Lived Intangible Assets Future Amortization Expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2021</a></td>
<td class="nump">$ 1,946<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2022</a></td>
<td class="nump">1,940<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2023</a></td>
<td class="nump">1,936<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2024</a></td>
<td class="nump">1,928<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2025</a></td>
<td class="nump">1,924<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive', window );">Thereafter</a></td>
<td class="nump">3,512<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets subject to amortization, Net Carrying Value</a></td>
<td class="nump">$ 13,186<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140148456734408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill And Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetImpairment', window );">Impairments of intangible assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total loss recognized during the period from the impairment of goodwill plus the loss recognized in the period resulting from the impairment of the carrying amount of intangible assets, other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140148462569080">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Liabilities - Schedule of Accrued Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables And Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Compensation related accruals</a></td>
<td class="nump">$ 3,975<span></span>
</td>
<td class="nump">$ 1,165<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_AccruedClinicalTrialExpenseCurrent', window );">Accrued clinical trial expense</a></td>
<td class="nump">715<span></span>
</td>
<td class="nump">620<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other expenses</a></td>
<td class="nump">3,099<span></span>
</td>
<td class="nump">2,352<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductWarrantyAccrualClassifiedCurrent', window );">Warrant liability, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued liabilities</a></td>
<td class="nump">$ 7,789<span></span>
</td>
<td class="nump">$ 4,180<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_AccruedClinicalTrialExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued clinical trial expense current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_AccruedClinicalTrialExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductWarrantyAccrualClassifiedCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for estimated claims under standard and extended warranty protection rights granted to customers. For classified balance sheets, represents the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=68068213&amp;loc=d3e12524-110249<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 25<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68070138&amp;loc=d3e11281-110244<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductWarrantyAccrualClassifiedCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140148461701880">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt - Summary of Long-term Notes Payable (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Apr. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Feb. 28, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayableCurrent', window );">Convertible notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,159<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Unamortized debt discount and debt issuance costs</a></td>
<td class="num">$ (313)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,458)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes payable, total</a></td>
<td class="nump">27,766<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,971<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Less: current maturities</a></td>
<td class="nump">11,840<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,159<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Long&#8209;term notes payable</a></td>
<td class="nump">15,926<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,812<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=bdsx_NotesPayable2018NotesMember', window );">2018 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Notes/Loan payable</a></td>
<td class="nump">24,972<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,270<span></span>
</td>
<td class="nump">$ 23,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=bdsx_PPPLoanMember', window );">PPP Loan | CARES Act</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Notes/Loan payable</a></td>
<td class="nump">$ 3,107<span></span>
</td>
<td class="nump">$ 3,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleNotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=bdsx_NotesPayable2018NotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=bdsx_NotesPayable2018NotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=bdsx_PPPLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=bdsx_PPPLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bdsx_CARESActMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bdsx_CARESActMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140148380157656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="8">1 Months Ended</th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2020</div></th>
<th class="th"><div>Aug. 31, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Apr. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Feb. 29, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Feb. 28, 2018</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure', window );">Estimated air value of warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_PutOptionLiabilityCurrent', window );">Estimated value of put option liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,261,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,400,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Debt instrument converted to common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,091<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=bdsx_MarchTwoThousandAndTwentyConvertibleNotesMember', window );">March 2020 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesIssued1', window );">Convertible notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Convertible notes, maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Aug. 31,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_DebtInstrumentMaturityDateExtended', window );">Extended debt instrument date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jun. 30,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_PercentageOfConversionPricePerShareOfCommonStock', window );">Percentage of conversion price per share of common stock</a></td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_PutOptionLiabilityCurrent', window );">Estimated value of put option liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Debt instrument converted to common stock</a></td>
<td class="nump">703,503<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=bdsx_MarchTwoThousandAndTwentyConvertibleNotesMember', window );">March 2020 Notes | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price</a></td>
<td class="nump">$ 14.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=bdsx_MarchTwoThousandAndTwentyConvertibleNotesMember', window );">March 2020 Notes | First Tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesIssued1', window );">Convertible notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=bdsx_MarchTwoThousandAndTwentyConvertibleNotesMember', window );">March 2020 Notes | Second Tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesIssued1', window );">Convertible notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=bdsx_DecemberTwoThousandAndNineteenConvertibleNotesMember', window );">December 2019 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesIssued1', window );">Convertible notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Convertible notes, maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Aug. 31,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_DebtInstrumentMaturityDateExtended', window );">Extended debt instrument date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jun. 30,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_PercentageOfConversionPricePerShareOfCommonStock', window );">Percentage of conversion price per share of common stock</a></td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_PutOptionLiabilityCurrent', window );">Estimated value of put option liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Debt instrument converted to common stock</a></td>
<td class="nump">426,386<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=bdsx_DecemberTwoThousandAndNineteenConvertibleNotesMember', window );">December 2019 Notes | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price</a></td>
<td class="nump">$ 14.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=bdsx_DecemberTwoThousandAndNineteenConvertibleNotesMember', window );">December 2019 Notes | First Tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesIssued1', window );">Convertible notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=bdsx_DecemberTwoThousandAndNineteenConvertibleNotesMember', window );">December 2019 Notes | Second Tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesIssued1', window );">Convertible notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=bdsx_AugustTwoThousandAndNineteenConvertibleNotesMember', window );">August 2019 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesIssued1', window );">Convertible notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Convertible notes, maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Aug. 31,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_DebtInstrumentMaturityDateExtended', window );">Extended debt instrument date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jun. 30,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_PercentageOfConversionPricePerShareOfCommonStock', window );">Percentage of conversion price per share of common stock</a></td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_PutOptionLiabilityCurrent', window );">Estimated value of put option liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Debt instrument converted to common stock</a></td>
<td class="nump">718,391<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_PercentageOfConversionPricePerShareOfConvertiblePreferredStock', window );">Percentage of conversion price per share of preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_IncreaseToPutOptionLiability', window );">Increase to put option liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=bdsx_AugustTwoThousandAndNineteenConvertibleNotesMember', window );">August 2019 Notes | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price</a></td>
<td class="nump">$ 14.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesHPreferredStockMember', window );">Series H Convertible Preferred Stock | March 2020 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentRate', window );">Conversion rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesHPreferredStockMember', window );">Series H Convertible Preferred Stock | December 2019 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentRate', window );">Conversion rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesHPreferredStockMember', window );">Series H Convertible Preferred Stock | August 2019 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_PercentageOfConversionPricePerShareOfConvertiblePreferredStock', window );">Percentage of conversion price per share of preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=bdsx_NotesPayable2018NotesMember', window );">2018 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Loan principle amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,270,000<span></span>
</td>
<td class="nump">$ 23,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,972,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFeeAmount', window );">Facility fee amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure', window );">Estimated air value of warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_DebtInstrumentPercentageOfStatedInterestRatePaidInCash', window );">Percentage of interest rate, paid in cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_DebtInstrumentPercentageOfStatedInterestRateAddedToPrincipalValueOfNotesPayable', window );">Percentage of interest rate added to principal value of notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_DebtInstrumentInterestAddedToPrincipalValue', window );">Interest added to principal value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,700,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFrequencyOfPeriodicPayment', window );">Frequency of periodic payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Commencing March 2021 and continuing through the maturity date February 2023, the outstanding principal is repayable in 24 equal monthly installments.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_DebtInstrumentPrepaymentPenaltyPercentage', window );">Debt instrument, prepayment penalty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_DebtInstrumentBackEndFacilityFeePercentage', window );">Debt instrument, back-end facility fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_DebtInstrumentAdditionalInterestExpenseFeePercentage', window );">Debt instrument, additional interest expense fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=bdsx_NotesPayable2018NotesMember', window );">2018 Notes | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1', window );">Early amortization of loan payment schedule</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=bdsx_NotesPayable2018NotesMember', window );">2018 Notes | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1', window );">Early amortization of loan payment schedule</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=bdsx_NotesPayable2018NotesMember', window );">2018 Notes | Series G Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Warrant issued to purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">613,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">613,333<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=bdsx_PPPLoanMember', window );">PPP Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentDescription', window );">Loan description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The PPP Loan matures on the two-year anniversary of the funding date, April 2022, and bears interest at a fixed rate of 1.00% per annum. Monthly principal and interest payments, less the amount of any potential forgiveness (as discussed below), will commence in September 2021. The Company did not provide any collateral or guarantees in connection with the PPP Loan, nor did the Company pay any facility charge to obtain the PPP Loan.<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=bdsx_PPPLoanMember', window );">PPP Loan | Interest-bearing Deposits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=bdsx_PPPLoanMember', window );">PPP Loan | CARES Act</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Loan principle amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,107,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_PercentageForNonPayrollCosts', window );">Percentage for non-payroll costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_UpperLimitOfEmployeeSalaryToReduceForgiveness', window );">Upper limit of employee salary to reduce forgiveness</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_PercentageOfUpperLimitOfEmployeeSalaryToReduceForgiveness', window );">Percentage of upper limit of employee salary to reduce forgiveness</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=bdsx_PPPLoanMember', window );">PPP Loan | Minimum | CARES Act</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_PayrollCostsExcludesCompensationOfEmployee', window );">Payroll costs excludes compensation of an employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_DebtInstrumentAdditionalInterestExpenseFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt instrument additional interest expense fee percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_DebtInstrumentAdditionalInterestExpenseFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_DebtInstrumentBackEndFacilityFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt instrument back-end facility fee percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_DebtInstrumentBackEndFacilityFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_DebtInstrumentInterestAddedToPrincipalValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt instrument interest added to principal value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_DebtInstrumentInterestAddedToPrincipalValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_DebtInstrumentMaturityDateExtended">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt instrument maturity date extended.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_DebtInstrumentMaturityDateExtended</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_DebtInstrumentPercentageOfStatedInterestRateAddedToPrincipalValueOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt instrument, percentage of stated interest rate added to principal value of notes payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_DebtInstrumentPercentageOfStatedInterestRateAddedToPrincipalValueOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_DebtInstrumentPercentageOfStatedInterestRatePaidInCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt instrument, percentage of stated interest rate, paid in cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_DebtInstrumentPercentageOfStatedInterestRatePaidInCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_DebtInstrumentPrepaymentPenaltyPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt instrument prepayment penalty percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_DebtInstrumentPrepaymentPenaltyPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_IncreaseToPutOptionLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase to put option liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_IncreaseToPutOptionLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_PayrollCostsExcludesCompensationOfEmployee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payroll costs excludes compensation of an employee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_PayrollCostsExcludesCompensationOfEmployee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_PercentageForNonPayrollCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage for non-payroll costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_PercentageForNonPayrollCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_PercentageOfConversionPricePerShareOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of conversion price per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_PercentageOfConversionPricePerShareOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_PercentageOfConversionPricePerShareOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of conversion price per share of convertible preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_PercentageOfConversionPricePerShareOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_PercentageOfUpperLimitOfEmployeeSalaryToReduceForgiveness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of upper limit of employee salary to reduce forgiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_PercentageOfUpperLimitOfEmployeeSalaryToReduceForgiveness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_PutOptionLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Put option liability current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_PutOptionLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_UpperLimitOfEmployeeSalaryToReduceForgiveness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upper limit of employee salary to reduce forgiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_UpperLimitOfEmployeeSalaryToReduceForgiveness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Dividend or interest rate associated with the financial instrument issued in exchange for the original debt being converted in a noncash or part noncash transaction. Noncash are transactions that affect recognized assets or liabilities but that do not result in cash receipts or cash payments. Part noncash refers to that portion of the transaction not resulting in cash receipts or cash payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031898-161870<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Remaining amortization period for discount on the liability component of convertible debt which may be settled in cash upon conversion, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031898-161870<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Identification of the lender and information about a contractual promise to repay a short-term or long-term obligation, which includes borrowings under lines of credit, notes payable, commercial paper, bonds payable, debentures, and other contractual obligations for payment. This may include rationale for entering into the arrangement, significant terms of the arrangement, which may include amount, repayment terms, priority, collateral required, debt covenants, borrowing capacity, call features, participation rights, conversion provisions, sinking-fund requirements, voting rights, basis for conversion if convertible and remarketing provisions. The description may be provided for individual debt instruments, rational groupings of debt instruments, or by debt in total.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=75038535&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the fee that accompanies borrowing money under the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFrequencyOfPeriodicPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the frequency of periodic payments (monthly, quarterly, annual).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=75038535&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFrequencyOfPeriodicPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of notes issued in noncash investing and financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of warrants not settleable in cash classified as equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsNotSettleableInCashFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=bdsx_MarchTwoThousandAndTwentyConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=bdsx_MarchTwoThousandAndTwentyConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=bdsx_DecemberTwoThousandAndNineteenConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=bdsx_DecemberTwoThousandAndNineteenConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=bdsx_AugustTwoThousandAndNineteenConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=bdsx_AugustTwoThousandAndNineteenConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesHPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesHPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=bdsx_NotesPayable2018NotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=bdsx_NotesPayable2018NotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesGPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesGPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=bdsx_PPPLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=bdsx_PPPLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_InterestBearingDepositsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_InterestBearingDepositsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bdsx_CARESActMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bdsx_CARESActMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140148458005112">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt - Scheduled Principal Repayments (Maturities) of Long-term Obligations (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MaturitiesOfLongTermDebtAbstract', window );"><strong>Maturities Of Long Term Debt [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2021</a></td>
<td class="nump">$ 11,840<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2022</a></td>
<td class="nump">13,919<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2023</a></td>
<td class="nump">2,320<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 28,079<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MaturitiesOfLongTermDebtAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MaturitiesOfLongTermDebtAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140148461823640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Preferred Stock - Additional Information (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Oct. 27, 2020 </div>
<div>shares</div>
</th>
<th class="th"><div>Oct. 19, 2020</div></th>
<th class="th">
<div>Mar. 31, 2019 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 28, 2019 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible preferred stock, issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">118,766,273<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Convertible preferred stock, par value | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Proceeds from issuance of series H preferred stock | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Reverse stock split ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1684664<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_NumberOfPreferredStockConvertedIntoCommonStock', window );">Number of preferred stock converted into common stock</a></td>
<td class="nump">20,090,745<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">118,766,273<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesHPreferredStockMember', window );">Series H Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible preferred stock, issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,695,621<span></span>
</td>
<td class="nump">8,695,621<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Convertible preferred stock, par value | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.15<span></span>
</td>
<td class="nump">$ 1.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Proceeds from issuance of series H preferred stock | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Reverse stock split ratio</a></td>
<td class="nump">0.1684664<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=bdsx_SeriesA1PreferredStockMember', window );">Series A-1 Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Reverse stock split ratio</a></td>
<td class="nump">0.1684664<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=bdsx_SeriesA2PreferredStockMember', window );">Series A2 Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Reverse stock split ratio</a></td>
<td class="nump">0.1684664<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=bdsx_SeriesA3PreferredStockMember', window );">Series A3 Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Reverse stock split ratio</a></td>
<td class="nump">0.1684664<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Reverse stock split ratio</a></td>
<td class="nump">0.1684664<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Reverse stock split ratio</a></td>
<td class="nump">0.1684664<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember', window );">Series D Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Reverse stock split ratio</a></td>
<td class="nump">0.1684664<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesEPreferredStockMember', window );">Series E Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Reverse stock split ratio</a></td>
<td class="nump">0.1684664<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesFPreferredStockMember', window );">Series F Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Reverse stock split ratio</a></td>
<td class="nump">0.1684664<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesGPreferredStockMember', window );">Series G Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Reverse stock split ratio</a></td>
<td class="nump">0.1684664<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=bdsx_SeriesB1ConvertiblePreferredStockMember', window );">Series B1 Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Reverse stock split ratio</a></td>
<td class="nump">0.196<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_NumberOfPreferredStockConvertedIntoCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of preferred stock converted into common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_NumberOfPreferredStockConvertedIntoCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65877616&amp;loc=d3e177068-122764<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (27)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesHPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesHPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=bdsx_SeriesA1PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=bdsx_SeriesA1PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=bdsx_SeriesA2PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=bdsx_SeriesA2PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=bdsx_SeriesA3PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=bdsx_SeriesA3PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesEPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesEPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesFPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesFPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesGPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesGPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=bdsx_SeriesB1ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=bdsx_SeriesB1ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140148489868808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants to Purchase Convertible Preferred Stock - Summary of Activity for Convertible Preferred Stock Warrants (Details)<br> shares in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=bdsx_SeriesEConvertiblePreferredStockWarrantsMember', window );">Series E Convertible Preferred Stock Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class Of Warrant Or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Outstanding &#8209; December 31, 2019, warrants | shares</a></td>
<td class="nump">925<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures', window );">Forfeited/canceled, warrants | shares</a></td>
<td class="num">(925)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, Outstanding &#8209; December 31, 2019 | $ / shares</a></td>
<td class="nump">$ 5.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Forfeited/canceled | $ / shares</a></td>
<td class="num">$ (5.00)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=bdsx_SeriesGConvertiblePreferredStockWarrantsMember', window );">Series G Convertible Preferred Stock Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class Of Warrant Or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Outstanding &#8209; December 31, 2019, warrants | shares</a></td>
<td class="nump">613<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsPeriodIncreaseDecrease', window );">Reclassification of warrant liability to additional paid-in capital, warrants | shares</a></td>
<td class="num">(613)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, Outstanding &#8209; December 31, 2019 | $ / shares</a></td>
<td class="nump">$ 0.75<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsReclassificationOfWarrantLiabilityToAdditionalPaidInCapitalWeightedAverageExercisePrice', window );">Weighted average exercise price, Reclassification of warrant liability to additional paid-in capital | $ / shares</a></td>
<td class="num">$ (0.75)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non-options forfeitures and expirations in period weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non options outstanding weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsReclassificationOfWarrantLiabilityToAdditionalPaidInCapitalWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangements by share based payment award non options reclassification of warrant liability to additional paid in capital weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsReclassificationOfWarrantLiabilityToAdditionalPaidInCapitalWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares under non-option equity instrument agreements that were cancelled as a result of occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of equity instruments other than options outstanding, including both vested and non-vested instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) in the number of shares under non-option equity instrument agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=bdsx_SeriesEConvertiblePreferredStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=bdsx_SeriesEConvertiblePreferredStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=bdsx_SeriesGConvertiblePreferredStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=bdsx_SeriesGConvertiblePreferredStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140148456576056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants to Purchase Convertible Preferred Stock - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract', window );"><strong>Warrants And Rights Note Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares of common stock</a></td>
<td class="nump">103,326<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant, exercise price</a></td>
<td class="nump">$ 4.46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable', window );">Warrants expiry date</a></td>
<td class="text">Feb. 29,  2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liability</a></td>
<td class="nump">$ 1,252<span></span>
</td>
<td class="nump">$ 104<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date the warrants or rights are exercisable, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsNoteDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140148489843240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 27, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Oct. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">190,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockVotingRights', window );">Common stock, voting rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The holder of each share of common stock is entitled to one vote per share.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsCommonStock', window );">Dividends</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from initial public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 72,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">Initial Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares of common stock issued and sold</a></td>
<td class="nump">4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Common stock price per share</a></td>
<td class="nump">$ 18.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from initial public offering</a></td>
<td class="nump">$ 63,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees', window );">Underwriting discounts and commissions</a></td>
<td class="nump">5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_DirectOfferingExpenses', window );">Direct offering expenses</a></td>
<td class="nump">$ 3,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_DirectOfferingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Direct offering expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_DirectOfferingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockVotingRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockVotingRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid common stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 405<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6957935&amp;loc=d3e64057-112817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expense related to distribution, servicing and underwriting fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140148458757384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue - Summary of Revenue (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 45,557<span></span>
</td>
<td class="nump">$ 24,552<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bdsx_DiagnosticTestsMember', window );">Diagnostic Tests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">40,919<span></span>
</td>
<td class="nump">17,315<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 4,638<span></span>
</td>
<td class="nump">$ 7,237<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bdsx_DiagnosticTestsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bdsx_DiagnosticTestsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140148460318072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jan. 01, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 45,557<span></span>
</td>
<td class="nump">$ 24,552<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized</a></td>
<td class="nump">700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">3,532<span></span>
</td>
<td class="nump">$ 1,283<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=bdsx_DeferredRevenueMember', window );">Deferred Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_AdvanceDeposits', window );">Advance deposits</a></td>
<td class="nump">3,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bdsx_COVID19DiagnosticTestRevenueMember', window );">COVID-19 Test Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">28,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bdsx_LungDiagnosticRevenueMember', window );">Lung Diagnostic Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 12,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_AdvanceDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Advance deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_AdvanceDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=bdsx_DeferredRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=bdsx_DeferredRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bdsx_COVID19DiagnosticTestRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bdsx_COVID19DiagnosticTestRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bdsx_LungDiagnosticRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bdsx_LungDiagnosticRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140148460371096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Based Compensation - Additional Information (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jan. 01, 2019 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>Installment </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 31, 2020 </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 29, 2016 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of performance-condition options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">828,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.81<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of outstanding stock options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,321,000<span></span>
</td>
<td class="nump">1,916,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Remaining life of outstanding performance condition options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years 4 months 24 days<span></span>
</td>
<td class="text">7 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Intrinsic value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 42,580<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock compensation expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,709<span></span>
</td>
<td class="nump">$ 170<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">RSUs outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79,104<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=bdsx_BonusToOptionsProgramMember', window );">Bonus-To-Options Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Intrinsic value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock compensation expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=bdsx_OptionsAndRestrictedStockUnitsMember', window );">Options and Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized remaining stock based compensation balance | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Amortization period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=bdsx_ServiceConditionRSUsMember', window );">Service Condition R S Us</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights', window );">Vesting term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">vest over three years, 40% over the first two years and the remaining 60% over the third year from the grant date.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of RSUs granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,736<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=bdsx_ServiceConditionRSUsMember', window );">Service Condition R S Us | Share-based Payment Arrangement, Tranche One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=bdsx_ServiceConditionRSUsMember', window );">Service Condition R S Us | Share-based Payment Arrangement, Tranche Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Bonus-To-Options Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Option expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of outstanding stock options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">173,229<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_PercentageOfFullyDilutedEquityForBonusAwarded', window );">Percentage of fully diluted equity for bonus awarded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price,vested | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Service Condition R S Us</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bdsx_TwoThousandTwentyEquityIncentivePlanMember', window );">2020 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of shares reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,893,395<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bdsx_TwoThousandTwentyEquityIncentivePlanMember', window );">2020 Equity Incentive Plan | Performance Condition Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Option expiration period</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights', window );">Vesting term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Performance-based options vest in three equal annual installments beginning one year after the grant date<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_NumberOfEqualAnnualInstallmentsForAwardVesting', window );">Number of equal annual installments for award vesting | Installment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of performance-condition options granted</a></td>
<td class="nump">168,466<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Exercise price | $ / shares</a></td>
<td class="nump">$ 0.77<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Options vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,155<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Options forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,155<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of outstanding stock options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,156<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Remaining life of outstanding performance condition options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bdsx_TwoThousandTwentyEquityIncentivePlanMember', window );">2020 Equity Incentive Plan | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Option expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bdsx_TwoThousandTwentyEquityIncentivePlanMember', window );">2020 Equity Incentive Plan | Minimum | Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bdsx_TwoThousandTwentyEquityIncentivePlanMember', window );">2020 Equity Incentive Plan | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Percentage of number of shares of common stock issued and outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bdsx_TwoThousandTwentyEquityIncentivePlanMember', window );">2020 Equity Incentive Plan | Common Stock | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Number of common stock may be issued under incentive plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,893,395<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bdsx_TwoThousandSixPlanMember', window );">2006 Plan | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">831,389<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bdsx_TwoThousandAndSixteenPlanMember', window );">2016 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Additional stock awards granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bdsx_TwoThousandAndSixteenPlanMember', window );">2016 Plan | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,431,964<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bdsx_TwoThousandSixPlanTwoThousandSixteenPlanAndTwoThousandTwentyEquityIncentivePlanMember', window );">2006 Plan, 2016 Plan and 2020 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Additional stock awards granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,647,380<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember', window );">Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of shares reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">338,106<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Percentage of number of shares of common stock issued and outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate', window );">Percentage of earnings used for purchase of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate', window );">Percentage of fair market value of common stock for purchase under plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_DescriptionOfVotingPowerOrValueOfStockForEmployeeParticipationInOfferingPeriod', window );">Description of voting power or value of stock for employee participation in offering period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">No employee may participate in an offering period if the employee owns 5% or more of the total combined voting power or value of the Company&#8217;s stock.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_DescriptionOfOfferingPeriodUnderPlan', window );">Description of offering period under plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The initial offering period will commence from January 1, 2021 through August 31, 2021.  On a going forward basis, the ESPP provides for successive six-month offering periods beginning on September 1st and March 1st of each year.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_DescriptionOfOfferingPeriodUnderPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of offering period under plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_DescriptionOfOfferingPeriodUnderPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_DescriptionOfVotingPowerOrValueOfStockForEmployeeParticipationInOfferingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of voting power or value of stock for employee participation in offering period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_DescriptionOfVotingPowerOrValueOfStockForEmployeeParticipationInOfferingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_NumberOfEqualAnnualInstallmentsForAwardVesting">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of equal annual installments for award vesting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_NumberOfEqualAnnualInstallmentsForAwardVesting</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_PercentageOfFullyDilutedEquityForBonusAwarded">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of fully diluted equity for bonus awarded.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_PercentageOfFullyDilutedEquityForBonusAwarded</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of service or performance condition required to be met for earning right to award under share-based payment arrangement. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Discount rate from fair value on offering date that participants pay for shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of equity instruments other than options outstanding, including both vested and non-vested instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=bdsx_BonusToOptionsProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=bdsx_BonusToOptionsProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=bdsx_OptionsAndRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=bdsx_OptionsAndRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=bdsx_ServiceConditionRSUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=bdsx_ServiceConditionRSUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=bdsx_TwoThousandTwentyEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=bdsx_TwoThousandTwentyEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=bdsx_PerformanceConditionOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=bdsx_PerformanceConditionOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=bdsx_TwoThousandSixPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=bdsx_TwoThousandSixPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=bdsx_TwoThousandAndSixteenPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=bdsx_TwoThousandAndSixteenPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=bdsx_TwoThousandSixPlanTwoThousandSixteenPlanAndTwoThousandTwentyEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=bdsx_TwoThousandSixPlanTwoThousandSixteenPlanAndTwoThousandTwentyEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140148456758072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Based Compensation - Summary of Pre-tax Share-based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total pre-tax share-based compensation expense</a></td>
<td class="nump">$ 3,709<span></span>
</td>
<td class="nump">$ 170<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total pre-tax share-based compensation expense</a></td>
<td class="nump">589<span></span>
</td>
<td class="nump">33<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Sales, Marketing, General and Administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total pre-tax share-based compensation expense</a></td>
<td class="nump">$ 3,120<span></span>
</td>
<td class="nump">$ 137<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140148459840344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Based Compensation - Summary of Stock Option Activity (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Stock Options, Outstanding &#8209; December 31, 2019</a></td>
<td class="nump">1,916<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock Options, Granted</a></td>
<td class="nump">828<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Stock Options, Forfeited/canceled</a></td>
<td class="num">(55)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Stock Options, Exercised</a></td>
<td class="num">(368)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Stock Options, Outstanding &#8209; December 31, 2020</a></td>
<td class="nump">2,321<span></span>
</td>
<td class="nump">1,916<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Stock Options, Exercisable &#8209; December 31, 2020</a></td>
<td class="nump">1,190<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding &#8209; December 31, 2019</a></td>
<td class="nump">$ 1.72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Granted</a></td>
<td class="nump">2.81<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Forfeited/canceled</a></td>
<td class="nump">0.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercised</a></td>
<td class="nump">3.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding &#8209; December 31, 2020</a></td>
<td class="nump">1.82<span></span>
</td>
<td class="nump">$ 1.72<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercisable &#8209; December 31, 2020</a></td>
<td class="nump">$ 2.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Contractual Life (Years), Outstanding - December 31, 2019</a></td>
<td class="text">7 years 4 months 24 days<span></span>
</td>
<td class="text">7 years 7 months 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1', window );">Weighted Average Contractual Life (Years), Granted</a></td>
<td class="text">0 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Contractual Life (Years), Exercisable &#8209; December 31, 2020</a></td>
<td class="text">6 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding - December 31, 2020</a></td>
<td class="nump">$ 42,580<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Outstanding - Exercisable &#8209; December 31, 2020</a></td>
<td class="nump">$ 21,194<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award options granted weighted average remaining contractual term1.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140148458010520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Based Compensation - Summary of Weighted Average Assumptions (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions And Methodology [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk&#8209;free rate</a></td>
<td class="nump">0.34%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">5 years 8 months 23 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">77.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140148457912600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per Share - Schedule of Computation of Basic and Diluted Net Loss per Share Attributable to Common Stockholders (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAbstract', window );"><strong>Numerator</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to common stockholders</a></td>
<td class="num">$ (31,350)<span></span>
</td>
<td class="num">$ (30,726)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Denominator</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted-average shares outstanding, basic and diluted</a></td>
<td class="nump">4,838<span></span>
</td>
<td class="nump">242<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share, basic and diluted</a></td>
<td class="num">$ (6.48)<span></span>
</td>
<td class="num">$ (126.97)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140148461442712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per Share - Schedule of Common Stock Equivalents Excluded from Diluted Net Loss Attributable to Common Stockholders (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="nump">2,677<span></span>
</td>
<td class="nump">144,056<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">119,257<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=bdsx_OptionsToPurchaseCommonStockMember', window );">Options to Purchase Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="nump">2,495<span></span>
</td>
<td class="nump">2,104<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="nump">103<span></span>
</td>
<td class="nump">1,538<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="nump">79<span></span>
</td>
<td class="nump">26<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember', window );">Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,131<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=bdsx_OptionsToPurchaseCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=bdsx_OptionsToPurchaseCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140148465664696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration', window );">Net operating loss carryforwards</a></td>
<td class="nump">233,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_DeferredTaxAssetsResearchAndExperimentationTaxCarryforwardsSubjectToExpiration', window );">Research and experimentation tax carryforwards</a></td>
<td class="nump">$ 3,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardDescription', window );">Description of tax credit carryforward expiration</a></td>
<td class="text">expire beginning in 2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetExplanationOfChange', window );">Valuation allowance, deferred tax asset, explanation of change</a></td>
<td class="text">Company does not believe it is more likely than not that it will realize the benefits of net deferred tax assets and, accordingly, has established a valuation allowance equal to 100% of net deferred tax assets.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_PercentageOfValuationAllowanceEqualToNetDeferredTaxAssets', window );">Percentage of valuation allowance equal to net deferred tax assets</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Increase in valuation allowance</a></td>
<td class="nump">$ 4,900,000<span></span>
</td>
<td class="nump">$ 7,000,000.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued', window );">Accrued interest related to uncertain tax positions</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationDescription', window );">Income tax examination details</a></td>
<td class="text">All years will remain open for examining by federal and state authorities for three and four years, respectively, from the date of utilization of any net operating loss carryforwards.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_DeferredTaxAssetsResearchAndExperimentationTaxCarryforwardsSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets research and experimentation tax carryforwards subject to expiration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_DeferredTaxAssetsResearchAndExperimentationTaxCarryforwardsSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_PercentageOfValuationAllowanceEqualToNetDeferredTaxAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of valuation allowance equal to net deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_PercentageOfValuationAllowanceEqualToNetDeferredTaxAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A brief description of status of the tax examination, significant findings to date, and the entity's position with respect to the findings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A description of the origin, nature, and characteristics of the tax credit carryforward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense accrued for an underpayment of income taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetExplanationOfChange">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A description of and reason for the change during the period in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetExplanationOfChange</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140148456662856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal statutory income tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State income taxes, net of federal benefit</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch', window );">Research and developments credits</a></td>
<td class="num">(1.00%)<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_EffectiveIncomeTaxRateReconciliationPermanentItems', window );">Permanent items</a></td>
<td class="num">(6.00%)<span></span>
</td>
<td class="num">(4.00%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(16.00%)<span></span>
</td>
<td class="num">(23.00%)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_EffectiveIncomeTaxRateReconciliationPermanentItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation permanent items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_EffectiveIncomeTaxRateReconciliationPermanentItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140148461507592">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred Tax Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 53,128<span></span>
</td>
<td class="nump">$ 50,360<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development tax credits</a></td>
<td class="nump">2,860<span></span>
</td>
<td class="nump">3,040<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="nump">279<span></span>
</td>
<td class="nump">370<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">865<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals', window );">Accruals and reserves</a></td>
<td class="nump">1,406<span></span>
</td>
<td class="nump">286<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total</a></td>
<td class="nump">58,538<span></span>
</td>
<td class="nump">54,056<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(56,083)<span></span>
</td>
<td class="num">(51,135)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Total deferred tax assets after valuation allowance</a></td>
<td class="nump">2,455<span></span>
</td>
<td class="nump">2,921<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesAbstract', window );"><strong>Deferred Tax Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets', window );">Intangible assets</a></td>
<td class="num">(2,455)<span></span>
</td>
<td class="num">(2,921)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="num">$ (2,455)<span></span>
</td>
<td class="num">$ (2,921)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140148459321496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation of Unrecognized Tax Benefits (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Reconciliation Of Unrecognized Tax Benefits Excluding Amounts Pertaining To Examined Tax Returns Roll Forward</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Additions for tax positions related to the current year</a></td>
<td class="nump">$ 106<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Additions for tax positions related to prior years</a></td>
<td class="nump">609<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance at December 31</a></td>
<td class="nump">$ 715<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140148461811768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 02, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Aug. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Oct. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesRentExpenseNet', window );">Rent expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,700<span></span>
</td>
<td class="nump">$ 2,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,818<span></span>
</td>
<td class="nump">10,468<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bdsx_RevenueShareAgreementMember', window );">Revenue Share Agreement | Oncimmune Limited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_PercentageOfRevenueSharePaymentRelatedToAcquiredDiagnosticTestRecognizedRevenueForNonScreeningTests', window );">Percentage of revenue share payment related to acquired diagnostic test recognized revenue for non-screening tests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_MinimumAnnualVolumePercentageThereafter', window );">Minimum annual volume percentage thereafter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_PeriodOfEscalationsOfSales', window );">Period of escalations of sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">through the first four years of sales<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_RevenueShareExpenses', window );">Revenue share expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bdsx_BioRadLicenseMember', window );">Bio-Rad License</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_PercentageOfRoyaltyPaymentsOnNetRevenue', window );">Percentage of royalty payments on net revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_LicenseAgreementExpiryDate', window );">License expiry date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2024-08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalty expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bdsx_AVEOOncologyMember', window );">AVEO Oncology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_RemainingEstimatedObligation', window );">Remaining estimated obligation</a></td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bdsx_AVEOOncologyMember', window );">AVEO Oncology | NSCLC POC Trial</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_PercentageOfDevelopmentAndRegulatoryCosts', window );">Responsible percentage of development and regulatory costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesByIndustryAxis=bdsx_FiclatuzumabMember', window );">Ficlatuzumab | AVEO Oncology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_PercentageOfDevelopmentAndRegulatoryCostsExercisedUsingOptOutRight', window );">Percentage of development and regulatory costs exercised using opt-out right</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_PercentageOfRoyaltyPaymentsOnNetSales', window );">Percentage of royalty payments on net sales</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_PercentageOfLicenseIncomeGeneratedFromLicensing', window );">Percentage of license income generated from licensing</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bdsx_BDX004Member', window );">BDX004 | Ficlatuzumab | AVEO Oncology | POC Clinical Trials</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_PercentageOfDevelopmentAndRegulatoryCosts', window );">Responsible percentage of development and regulatory costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_LicenseAgreementExpiryDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License agreement expiry date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_LicenseAgreementExpiryDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_MinimumAnnualVolumePercentageThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum annual volume percentage thereafter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_MinimumAnnualVolumePercentageThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_PercentageOfDevelopmentAndRegulatoryCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of development and regulatory costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_PercentageOfDevelopmentAndRegulatoryCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_PercentageOfDevelopmentAndRegulatoryCostsExercisedUsingOptOutRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of development and regulatory costs exercised using opt-out right.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_PercentageOfDevelopmentAndRegulatoryCostsExercisedUsingOptOutRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_PercentageOfLicenseIncomeGeneratedFromLicensing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of license income generated from licensing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_PercentageOfLicenseIncomeGeneratedFromLicensing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_PercentageOfRevenueSharePaymentRelatedToAcquiredDiagnosticTestRecognizedRevenueForNonScreeningTests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of revenue share payment related to acquired diagnostic test recognized revenue for non-screening tests.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_PercentageOfRevenueSharePaymentRelatedToAcquiredDiagnosticTestRecognizedRevenueForNonScreeningTests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_PercentageOfRoyaltyPaymentsOnNetRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of royalty payments on net revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_PercentageOfRoyaltyPaymentsOnNetRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_PercentageOfRoyaltyPaymentsOnNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of royalty payments on net sales.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_PercentageOfRoyaltyPaymentsOnNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_PeriodOfEscalationsOfSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of escalations of sales.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_PeriodOfEscalationsOfSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_RemainingEstimatedObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Remaining estimated obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_RemainingEstimatedObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_RevenueShareExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue share expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_RevenueShareExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesRentExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121573735&amp;loc=d3e41499-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesRentExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=bdsx_RevenueShareAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=bdsx_RevenueShareAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=bdsx_OncimmuneLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=bdsx_OncimmuneLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bdsx_BioRadLicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bdsx_BioRadLicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=bdsx_AVEOOncologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=bdsx_AVEOOncologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bdsx_NSCLCPOCTrialMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bdsx_NSCLCPOCTrialMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesByIndustryAxis=bdsx_FiclatuzumabMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesByIndustryAxis=bdsx_FiclatuzumabMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bdsx_BDX004Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bdsx_BDX004Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bdsx_POCClinicalTrialsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bdsx_POCClinicalTrialsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140148457998440">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Summary of Future Minimum Lease Payments for Operating Lease Obligations (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent', window );">2021</a></td>
<td class="nump">$ 703<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears', window );">2022</a></td>
<td class="nump">724<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears', window );">2023</a></td>
<td class="nump">112<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Total</a></td>
<td class="nump">$ 1,539<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121573735&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121580752&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121573735&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121580752&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121580752&amp;loc=d3e38371-112697<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121573735&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121573735&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121580752&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140148458099480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Defined Contribution 401(k) Plan - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Compensation And Retirement Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Defined contribution plan, employer discretionary contributions amount</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanPlanNameExtensibleList', window );">Defined Contribution Plan, Plan Name [Extensible List]</a></td>
<td class="text">bdsx:FourZeroOneKPlanMember<span></span>
</td>
<td class="text">bdsx:FourZeroOneKPlanMember<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanPlanNameExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates name of defined contribution plan designed to provide retirement benefits. Includes, but is not limited to, legal name of plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanPlanNameExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>srt-types:extensibleListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>100
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M"?@:3*WK#D2@3#]PI#=:[))O!"NAM0B3RRUG,&DS 'Y?"Z%/-^8%V6>FNW\
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MTMZA2-O+>=ET_\&VQP83D+>-Y%4_6#&H6+W[)=_[0!P,@*%C .H'H','X'X
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MI!5$N0<N%XIO[39RQ97>E-K#5/]O &$,]/4UY^II87:F]3^1V7]02P,$%
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MP@7N 76(19@L@@&H%Z2 1Z%^YE*BK>#E&2Y$U0D36_M/">P?]G&ZY.)YB >
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MO/Y279](5E9?5K=,2I97AWN"4\(U0-W?,2:?3O3'VO;_!<O_ %!+ P04
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MF@OT?2V$WF^,0#/OQW\!4$L#!!0    ( "IX<%(627$]+@@  (4B   8
M>&PO=V]R:W-H965T<R]S:&5E=#<N>&ULI5IM;^,V$OXK@J\XM,!Z+9*R;.\E
M 7:=%BUP;8/-M?>9EFB;MWIQ22K9W*^_(:6(MOB29.]+(LE#\IGAS#PSE*X>
M6_%%'AE3R=>Z:N3U[*C4Z<-B(8LCJZE\WYY8 [_L6U%3!;?BL) GP6AI!M75
M J=IOJ@I;V8W5^;9G;BY:CM5\8;=B41V=4W%TR=6M8_7,S1[?O"9'XY*/UC<
M7)WH@=TS]<?I3L#=8IREY#5K)&^;1+#]]>PC^K#-5GJ D?B3LT=Y=IUH579M
M^T7?_%)>SU*-B%6L4'H*"O\>V)95E9X)</PU3#H;U]0#SZ^?9__)* _*[*AD
MV[;Z-R_5\7JVGB4EV].N4I_;QY_9H-!2SU>TE31_D\=!-ITE12=56P^# 4'-
MF_X__3H8XFP R@,#\#  3P=D@0%D&$",HCTRH]8M5?3F2K2/B=#2,)N^,+8Q
MHT$;WNAMO%<"?N4P3MW<*ZH8;(N22;M/ME0>DY]@:V4R3_ZXOTV^_^Z'Y+N$
M-\F_CFTG:5/*JX6"9?7@13$L\:E? @>60#CYM6W4428_-B4K+R=8 -X1-'X&
M_0E'9[QEQ?N$H'<)3G'J ;1]]7"TB< AHPV)F8\$YC-6VQNK[45;)Q!C@BK>
M''HGY8HS&5DF&Y?)S#)98)G?(*BK5GIWH!^9FY$Z<A]NY@21)1CGX=PN/K%T
MA?-1[ +8<@2VC.K_L?P/.&KO1*J%X"[:IN 52YH!L7ZJKPLPU#OS-V%_=?R!
M5GK,NP3\"D9))7BA6-D+=!*NP/'>:,Q\Q)Q'C7G+(.L5G/:Y!-:G=2L4_Z]Y
MX+-P/]WRS'1XDY*)?3U"JPWQ6W<U(EU%D7X\ Z9C%(S[P.#)3ANX54Q"UMJI
MI.2R:+M&^;"O'%@966\FV%TAG&,_]/4(?1V%?J_:XLO?_[;&Z>8?.M?"UK8U
M$)#LE6%?]37S(5X[8,@JG2)VA= J]2/>C(@W4<3;(VT.3/O=GG*1@(=V3!O]
MD0I!&_!F3G>\XNK)!WKCXL%+/ 'M$4HS/VB4VB2>OA(V>(<.%H@K?2EY::+'
M[]+#I.=8UF@]P>L1RA *(3ZC'?1-ACYU"D(^@'@[3'KAI&D:V'.$+1@<#[&B
M$)U)-XKI/)2 <_:A=:)/5 >:SA!NX V_>FV+/<YPEF@'?5RIU6834,?2$2)O
MRA@F/W I.]H4#-20RL_BQ(6<95/$<:%+Q);94)S:[D3[P$UE"(5I4K;=3NV[
M"C*^26E^M)DG(3OV]0AE ;9#EN[0,HKVGYK2 "NDW%,K:65*)RHE"R!=NA'D
M1)DK@P*\@2S%H3Q>EY@8DQ,6-3B-0S\G,V#4=X:?1S7 \L#/ D)B(J=_[^J>
MF8V,Y-K+Y(<()2/+=.@%JAOV6Y<0#,J#4&RY5#5'*4D=HWKD2![<?\MJ*$YK
MOZLC$U"<"Z'3;&3C78*:Y\NU ]/#8P&(EL90G,=ZB%7;'.:0TNK KGM!NP0U
M1VO7MAX>"Q@66QK#<1H;]_\\[;9&%3JDZ!?08Y>M$,J7TRSF%0L5:MB2&HZ3
MVBW;,Z&C1K 'UG1>Y\4>"L/9M+3Q2*TV :_ EN=PG.=^&VKPGLXF9?C_684/
MVKF$-L>(Y-/$[)<+=B+8<A]^6R_&@;/EZ]L';"D+OT!9G2B.4-.:HD5H^Z@G
M8T)MTI-NAKSV<0EICC;9<FH>GQA!@4('6^;"<>:Z@V;?5(9RV&^H>( C3$EC
M4L1Y4C><X%7"):LY)M-"UR>%TM &6U+#\<;MCCZ-G>; 4LGOT&[6==>P2#+&
M;F\V7SD-LD\J6X9 6V+#<6+[]L![V7\']3Q<AS=X-=7/1YWK5:#/PY82\?I-
M8;?G#12;KP\[2VPX3FQ0*1:,E6-TP\RT@JYA5_$"0A'R+RSJ-9!+6*MP[T L
M9Y$X9UT"8E^9*'B?%:#7K:%*E+H)'GH:[]81#QF1;.J9'JEL%0!O"8O$"6MB
MS><6 <!+,"24>S]#;GLF-:.(KRLC+EFA-&Q:2U<D3E=^=-)_"!+IQ8BO%]LL
MITG7)T;24'-#SDX'X^W8I1J LS@R\ @@#36<9</E0=#::!)5Q&V^H.I=!@!:
M*B-Q*OL1<A&0EXW98(M(/+RTQMGT&,PG%BBNB.4N$N<N4])Z07F(9EIO^&10
MJ& EEHQ(G(S>GM=/NM,MX6[W](HD.2CHDM(:03DPU=%S^H@WH=Q.+'F1E\F+
M-X5@NMKYOF3]U0_FM.DMNGM5<_EHF:_)M-OPB,WS4+%(+&N1>".W?<-Y]'",
MF>S8@3>-WC1=^$&6;$NO8FY3M\QR1R]7*D\WH8QC29*\<(KY#7HQW6I%-7()
M-,<D=2+-%;M0_/+5AZ79+(T6&/?=Z529%U5 ]\5SM0$^V+_)=,X++Y>QA)B]
M<"QI>$4.!V<3[M/5<GM!Z]Y7,1XVW)#-,G"LEUDZS.)T>(G-94#S%F-ZDODZ
MR"[SX3P/I<?,,E\69[[/K*B@(N=[7HR'D?: UQZFFUJ^+$W7H:LYRLNYR2XG
M#MOM1>PR89XO Q5'=O:&+<Z$?[K'T.9UEM 9FZJ+"NE\ \P):X2X,Y<0B?L&
MQB.%<![H^C-+G%F<.$UMKFUJ#E>?/<,+TW,*N7:.@+U2H6HOLUR:Q;G4YRS.
M:Y=O\)3<>>>)<AQ(L9DEQ>S%HTH3:+M.PB]2ZAC; 9_W]=S0H_J*Y6'><SPK
MQW$79R_T:R8.YCL'O4;7J/XU^?AT_);BH_F"8/+\$_JP[;^(L-/T'VC\2@40
MF4PJMH<IT_<KV$_1?_/0WZCV9#X;V+5*M;6Y/#):,J$%X/=]"UEGN-$+C%^>
MW/P/4$L#!!0    ( "IX<%*2'"; +0H  +H8   8    >&PO=V]R:W-H965T
M<R]S:&5E=#@N>&ULM5G;<MM&$GW/5TPQJ:Q3Q;LNEBU95:04)ZJU(Y7DV%NU
MM0]#8$C,"L# ,P-1]-?OZ9X!"$JTG3SL@VWBTCW=I[M/=\-G:V/O7::4%X]%
M7KHWO<S[ZO5HY)),%=(-3:5*/%D:6TB/2[L:N<HJF;)0D8^FX_'QJ)"Z[)V?
M\;T;>WYF:I_K4MU8X>JBD'8S5[E9O^E->LV-6[W*/-T8G9]5<J7NE/^SNK&X
M&K5:4EVHTFE3"JN6;WJSR>OY(;W/+WS4:NTZOP5YLC#FGBZNTC>],1FD<I5X
MTB#QSX.Z4'E.BF#&YZBSUQY)@MW?C?:W[#M\64BG+DS^2:<^>],[Z8E4+66=
M^UNS_EU%?XY(7V)RQW^+=7CW:-H32>V\*:(P+"AT&?Z5CQ&'CL#)^"L"TR@P
M9;O#06SEI?3R_,R:M;#T-K31#W:5I6&<+BDH=][BJ8:</[^V*UGJ+S) 5*;B
M4KG$ZHJOS5+,:P<)Y\Y&'J>1S"B)FN=!\_0KFB=3\=Z4/G/BUS)5Z:Z"$<QL
M;9TVMLZGW]1XJ9*A.)CTQ70\'7]#WT'K^P'K._@KOL^>^'Z]]5W\>[9PWB*!
M_O.-4P_;4P_YU,/_ ^+?UOR'\4I,Q,\_GDPGDU/Q5P\2<VU2Y?1C7UR50/B%
MSQ0KF8Y/+TQ1R7+#5Y/3?G.[D7AZ?ZWB'3XOWC2UC7=_Z0NB$67SC?@U1VZ7
MXH-*LM+D9J65"^?WQ5HZH<O$V,I8Z56*"]B>R[6TBGZ#<(Z&X@.L[)@W>7GJ
M1 9:^EQ+ZY5U(KZ->H6:U$"O]IG(Y8*T&HL#NX_9XG_*TH'RNKI%8LJT3CST
MY3G!IO$3G&@95\=*H48*@+G*E<C52N9"E5[[S;"%5FC(BQ05.D@M:*@4J9:K
MTCBO$^%,7@=E23PS5P\X8 6-PGE 0.=25."9\!W$@DMD465-!9<\B)7>TDN=
M:-BA2P_"TRM5)DI4N?2$O_ &Q[O$X) ^*.P!U%SU&0 8@/"0J/ZB.H9!3"3(
M-YU :5T6Z!:E4JF+H$J<KXG4\2)(BW#-:QB/4Q0H<XC "IFFFE./3V^=]\IY
MJ/$=Q.'+@P9L8J%-E4EP;Z)@!QT= &H]=\H^Z 17/I.><B:O4]75;A4,L$G6
MWUKO+0%#QP+>X#4=W@"R:1%!Z_'/49%-^4133#>43U('64)X.X[0(C<F'5 '
M29_YS_@R8HE$I"P!2#)ML@)8F>@< %*9K#.=9)S?N4F:"IF;.D\IH#L9?:G$
MG?%(_B:U$8GW<L,4&E!_JR %1"YMO1*S%#U&$]FQFR_>7LY^$;+V&>KE"\Z)
M'I&13"':#&YE*NYFMW>#"_-Q,(4:4^5(CTN]TE[F*,W#D^FIJ$R^ 8;P7B09
M9@5$1H:^/&=<YHS+.X+@ R/2Q=$LEU302S#)#HQ=Q *.,K'&.?:K^Q UC&C7
M=<&! W"O?V!*.C[]X0^3ZN5&_.O=].<?)R\/ W/%FQ>7'QK[8YHBQ^\5 0Z*
MJJ@:H8^LB@)L?R.">S4(X5:[>S%S#DQ+&=5DGF"0U0KY)ODA&VWI9>C<\<R
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MPG$AY%U4G^R\Q0YCJ)+<R\3WW0-:R%NB@A[03=]W] LM8?8D7SMRYEG-!"E
M!S&KM]W. :#OA[]T<K+A+_))X[*L*ST;R$5-9OH<HDA,'H$G8?GK-[^^>G%.
M+@!_!5/B"#=$< +WU9,0L&+^EZIW"W[.LM[34_9CN29]5G4YW.[MVLI$QXR@
M]2H+^"#URA6HLF3_-U!M'DH>9-,;<1'(;)<V10%'4QWM]6 Q5E:XH7TQ]J+O
MP-4E^7 MA*=K#3%@L0]8X_&7( 6*H#"V-7NH(7$P460AB :6L*'0(?)!&B5N
MU;7C5NP)AQ^V4Z@XWA*)0TNF P/9'&:'Q#1W'=BLZL7,4RY5P):HCTJM:RJW
M<Q5DWV]?9K;8K*<'WDHN7UZ(>"*/0,-^*ZHK9T<GK5I&Z$<H1@8I2BSDP'C/
M X@"1Q!4+F!7]AEA2D4J@^UR()&I3;>B^1>NW:X-^2&E)?^GY+U 1AB_#Z8N
M;CLW8*Q9=5:\AH4=;JT*H!<N;X\C!P3? OT@(KK66*^V.)9QJVQ6J=U[?JA'
M)?B-S</5VPD%:LO ?6R8?& :T#;V?O\@I5^US=,4MY# CWJ(*:FN3U66"<R(
M8_?:TZ]0$>GDY_7WQ%J?HC?7T;!N@GJ)6MZED@L$ LVJ+^1G6CFQDLL$=DA=
M:_F!#N( @BA8K^4S8VW0+TPWJ=[@-OEX8X\UR3SMR+%]U00M\BJO@ ?_HBP[
M9;N)2,5LG&42Y5&#1)_8UG:].&(<K>Q9"@0O]C.%$'&D5A9B;UF/\#^+XT0\
MY3:+L>M%?H+JIJ(<@2@A8Q968P^=_+@2(<F*X8OE224$IHI,T!*LH2 6;L*#
MF=_WUK@*8T5:Q$O9AW GL58, H+\:I7%LCHBIASR7<R+7PE'V!_)O#GR0A#Q
M$>FT<R\#510+@_],O5=42U 7PM 1])3B'ICJ-SI_B1")472BB4@M+#N 9F=<
M#1J.'1H-."BJB<ZU=V4 +3$.R77 U'T+GYG0C&8)6DFR0TZ=8R8QXE*LMLDD
MIFKI,7@P''!&ZY0CPH\AG$@2#Q33-Y7IJKYXWM(_Q?T?G]T\?S#]Q'5;\798
MN^\_N[DNOK[X^I-ZG !-W ;,^"DZ=6(&3F(J\=CU:QS&D&J4(&'BRA.;!/6=
M]R]ZU6V8E*&V%:-4\" 2BBT'+!3YP)T=G.1 ZCI!L&0=/$8'K%%D3U_V2S6]
M'/@= &82^18M;65EU V\L;;@/-'E(TD473T-V/S"APE'7TQ95574/OI12TYS
M]-9TY7J6JMELVBM<6IN,EEQ&R*>D@)[M9JG'&EU!/R&YR4S9"YIRLR#U\8G!
M68R @C\.J=?8LB^^N)H_":D=9("*GVU%,D>R8*H=K^MQ"6=^N!&1 -*XPCI&
MPH45#%H8!'&DQZ9C X^/=-H2#5\6>_I>D)^YL!W@%2./1&+B-_?2!PV_*%O(
MCFG@3<$!?2.>\J2+?D1HXEK[@3Y-1=:TDK4)7]HNC:T6;3/2SPMR)Y9.\)3#
M4[6,((I(5#"L[)9F<2$(YMD,#$>,Q6=%)V:!/7=2+6+('W$$<G3K5F"8<"E)
M0:29H<&6ZZ:MV]5>)CIR/CFSQEXPAM),I2:(V"KT!A*6Q9#R%><AV0NF[V;R
M<"* L^)W\BF0/& D:6M%=TQ%EJ1;"7:J99=C@)\,8^X7?0I;%),+B4LC^:XU
M&0O:2:-1.@ED#_ O#:]"Y@X2 ;GJVKVIB136I(K$FM7'$:(BQ<@Q_3M^Q*E+
MJV.KE'N0<C)'I68\)PQO\(U\D%AI",+(&-F>3JIAL$]Y:NSKX92,EM6$3*VI
M ]'+S!F<%V\:>\[/^ITFJ!/<-+9X1 UD1WD37<_HY@<WD'CH?1M'(;*'E<;>
MPE9@T(R9HH(IB_@-P.N1#)%WY4+^:9D$68.XO=>3DJGBY&) VUF_ '.+602Q
M(':HX#*/5F01:^2*:!WO=8'3;%XF62@+DG1M-;TF21>:&SZY8#5/\2*)X0/F
M9$^D47Y(92B$TA<$(XWFA%RC'T0QZ9E1TD^MGX2Q*XK++.A+24XU.T=!/S5/
MA?Q\\NM *BN:YF=D6!JWK&>8G?B&,70(+S]FY'@0)(.S(8^NWF?6#+KK5QDX
M?]^[@47&HT/,UY<!I1.4 PTU:*/@D0"A%_>"%FVT0, GDO@"H;8"S[YE*RZ
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MYA-R!@N,?CQ@3?PKZ$D6>(?^:9]O3/MK./C:Q)Z3PPKA8>&+F<35&6V$5M!
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M))T];#7L1VYK(,F9^::$RB+#*W//T:CE!JNB':GN)PS&K&CLH*%3 )&TC>-
M+A65^8[/U!J>,Y\)VJZ[PZ+\%?N]O)!SG45G+;IX?XGUJ*1=ROD%Q,G09>@@
MVPVZ/3657/"=,6X>%T2:^3JS6 IQK/A45#\]F_O@MZ"IB[?/W6?$CT+AI*G"
MI8!@R.83<B8(#:=R&MR0"DP!3OL;49Z<QKKT_AMN3L2;+@M<TE5F!'74OM8_
M4;O^YF_CA3]",D=+<B%H]^&7=ISSD?E&VYA+Y\[7H&;3%S7ZX$%.:I_(\+$)
M"#<'T>YYRL:8@9T"F$I->.-^28OZ5"=M?/35G88(1>\N/:)M"[&"0YRO)73*
M.BD)H7]$7./88%^#KLKL?0O9DOY'8**A"-Q);<1+VE0,?D9#HU:/0D)GQOVM
M;'A\J[BDZ^5!WTN,:O3")K1DE57?RN*88&93[3Y8SM;3]%"(<%<HOX8U9/?+
MQH:[,)$QE,)"?GJ<_V-IVC&#3EW6,,/=E$Q)!9=)Y3[A 3TTCR:(>0KN/@CH
M%7<SRSGL(YCL *,5#ZU5>A\);N7$I))J3X2"^XE8K\0=/+*\M&F2V[&+?4A1
M]0:]0,<+!S4('@K-5;ML^3\1(7[$I+]Z;L>FXE=)<B=>OL3DB:#$?E[DZ]:.
M7","D;T<-?>=.K5/<8RR069.0_YXC<0U% 9I&XS?CB\1Q:MX7--TO^.4[DM%
M-;3SS_R]OOB%N,-]?.8!>?KDYPP.YH:H3R!*HF29D0NIV5PB%2J@XV'53GDV
M+]YD/YW"RLY&N1 KK9L/'J+$:C4R@T%8$G8&INM13C!9(IS!KN@X?.>:A@%3
M$^FAA LM9*@LQ[)$@2=@ TZF#?'ID640=""TD]N)2\?KL.+[Z+3F(,'[&L//
M7O&/9Y=G[YO0XO_[V [2\ZRE17D9A1ZG: ?Y"8VT+$R?ROSLZE^=LG<;5YON
MQ(1/3T^7TW,\$[>61GEQ35@VN^LH)#VEQY4KFJ!G9,Q7#./:!;(XG"WS2A8B
M#;_F?G[VB(A/'O7B>7I$;MZ3^\R^Y#FI,$EWP\EJ[&RZI,!7REUR#30M4*0Y
MI&3\UNQ#QE/ZUPX4$\K^47S91$E"*W H8'"J2+(=/N?-#6?A/L!7X3I  K6,
MH_ .4$25>T<']Y>GK$ZFUMS$X*]!7V=W&EY-MT4&#R^]7\B_WOERA/NOR%=Z
MD&>R@[4Z>16;+T;IV0</J]X'QM,6,6](B?9KDDDDGRR_EP#=PX//Y:?M>BIQ
M82]),OZ7(R_F)'6N]T$]QU[<SI:G8K@JH=E->/GQ-I(2E:QT<#G6I#7H()0)
MZI[*V<@6)D\^N7UW:D,);*?(G%[@CCK&\M"UB^3"?@QD#^\H^DALU<&5(0!:
M82/(NPUY:4**#K&/-QS.[" )2/]J8_G!4DK7R>7$D/O<!-]6NXMMTB;@,]XD
M?NG5;KW%Z&^>IYY-G]Z?%;LL(VW.4?(A^.;M4+SV^!?=?-\ODE^@/*P%(%+E
M=VJ,Y$F5]-12;AC3GM^0CP^O3:[:>/B\E16EQU[ (F@#"05YC0,'M02+>C='
MWGG SF+RWA(2TQ3QI*TVAK3#W:+8VVQT?C<<;I&_>'$@X>^GKY7^G[F"P8$C
M4@D>AQ9M;Z7>T&6.")_"@SG/-AOH#)@D93'N>$4![GAR@*^Z:U(<3#,>*23D
M;RNXBR?>Z3E^K8QOJ0 ?R,"=(]$@F6H*)L>A>,-"F(C>"]^V<;($J3*3RDEE
M%T-Q _@%]R_^^O0Y \EUTL)7W+ $O5$827-0*V&.%H0.N@W2ZE'\)7L%QUSG
M;OT[)G"_6N_(RX7TC[8KG<]+]/ '3)V!L+KJ6<B8'JJ/+WRAF:<7T. _Y8=<
MPMDBA(;'E.+\-NK4U$FZ[7EMR@_G-R49-D ,3W".C>"!35NA=U+R8N&U-CXK
M+&_"\$ S.\#NF(1,RB4R_RS^N&OAH7B YU":=\*L3)[C*_=H']\[6U>Q3Q#=
M+.=+..Q\\X2[V&BG?+4,\ W_);3[YH:&EMYAV%HP,WNY2K(7/;L@'*(-2:?I
MVNP83KW7&HM9J, 2U2=[,.4667B%P2D!S)O"LX#TI'2PG;OE6[2?6P_C\T77
M9U 5R8W.XO5D=@K;;FG=P"\:DCR!7-/HN-O2*]/YJ;WL<$3QAG1N6S>H*6VY
M809TVEP_5RW?5<0QQ6O!!W=$TPD7L7DPP,0U.KF'P08FR2UD%%VYC[WMXKTC
M=*S:<,>4HE=YX=:GMCC+>HM#S8^4TK^;S'=9!^E.=R!1K$%9+;]^*/OW[0M\
ME4)1X/ U2UYC5<;[>!E<WH]S^(('_TJQ9"T2#M+ /DD)MIR3_!=L7BZ01Y!W
M:S(71@_K^#BFWB?' 3Z++SK&H:_ZCLG@XSW;6'14-)PE0I\P$W$MHD./O94=
M:*L(&XBWN,4"L7_FB(._IJ]S(B;L^"T.YS\1^IQ[RX*"^X#6J5*#JN*5&"_3
MYU*73EW<3S\]D)<XM-RRT,Y.\2!A%-=DH40G[/H$KV?>1$G^,+Q<*8J%7F?R
M[XYI*.+MN-V9NP>12Y#K7^&CS^[.<'!+UR&O?/ F"@M )ASO;4Z93[G/HEN1
MO-I-,FGLH#""IYDU]CULN !MA?U]9#_G=3HFEU\"P2';:;YD?5QBY-'#WA?W
MW]V\[Q_<X44DNH]'N<W*^$M7NM()99F=!N[DPA=F9=S/X!YO>$MLDM9!3OL3
M<15Q)J:I/\#D(^3S]]F.02U4 Q.C,$N]2N[0SLV.ON3G4U8G?5_!XY"@8"?P
M?,+]^P?1\1K!&([]6EC!#_,++DNFL_:_>U;Q[^AJB5>@%WMQ-5@+_!C%)F^4
MSHV\_@1JLM"NO&3&/NN\2MZ&%\"9V(E+"'E\G,S"1YCU^+]P-;?=W+T-WYSS
M)VPBZ[5,]^/3:GXS#B\@J/GECK/$U1@Z#D+VNAD!:[(F29[%#TL56*OG&GE[
MG^%4+#3[=+@T2SL8A9:159SQ3(XKZ9$.<\@%1T:9W,6.1<B:K M'7/:CYA="
M1MP+E)YK]<G36]C2P*76VK-<%;CEU, "V#NX\\ NSEO5=;BYJ54=%(S?TX/U
MOQ>M+EA=)(5Q0+49B)&+<?#9L93/DA?K$]2%?4\4*Q&-V_:<D3Q(!: IK()Q
MV4H0F([K<--+)KR3=Q_P.PFE!S (5D6&-[RPQF3OB(J7?KGC7;2IF>2BW,]A
MM$]#5ESGB:_'C%LY>5*SSQ )?8%J;S9<65A\ L9.2\74JXL?)F^))E._XG=A
M\\L%FT%>&!V^+?SKMI_)6Z;CX_*N[I\Y^X76IR4-O9A_\]4]BLKX_=?R86BW
M_,[I13L,[8;_Q%TWV^$!^GW9$BCH!RP07D+^P_\"4$L#!!0    ( "IX<%(R
MM]_UFP(  /,%   9    >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;*U4;6_:
M,!#^*Z=,FEJ)DA=HBQ@@!3:T3FV%2MDT3?M@DH-83>S,=DK[[W=VTI1*A7W9
ME\1G/_?<<S[?C792/>@,T<!3D0L]]C)CRJ'OZR3#@NFN+%'0R4:J@ADRU=;7
MI4*6.J<B]Z,@N/ +QH4W&;F]A9J,9&5R+G"A0%=%P=3S%'.Y&WNA][)QQ[>9
ML1O^9%2R+2[1K,J%(LMO65)>H-!<"E"X&7MQ.)SV+=X!OG/<Z;TUV$S64CY8
MXRH=>X$5A#DFQC(P^CWB#//<$I&,/PVGUX:TCOOK%_:YRYUR63.-,YG_X*G)
MQM[ @Q0WK,K-G=Q]Q2:?<\N7R%R[+^QJ["6!DTH;633.I*#@HOZSI^8>]AP&
MP0&'J'&(G.XZD%/YF1DV&2FY V71Q&87+E7G3>*XL$59&D6GG/S,Y X3% ;B
M))&5,%QL8:&DH'6"=/5&CWQ#42S63QK&:<T8'6 ,([B1PF0:OH@4T[<$/LEK
M-48O&J?14<;/F'2A%W8@"J+@"%^OS;GG^'H'^&[IK1Q,&&*1PBQC8HL:KL1;
M(!<)+W,Z^!6OM5'TI'X?T=-O]?2=GOY_K,%QQEMI$'KP\<,@"L-/\*\ #2!_
MABNM*TSWD4O#1,I4JH%(X2>-B3B5I2$07<X<UZJB7J;*A!<=,!G"/%Y.@1^A
M694I(W4G\7)U2IQ=YWL6=> :J;LTG-S+DB<PZ$>G[^T-X9ZI+3H!1:GD8YU"
MU\KY5@D\)&6Y>@T6]CHPYX)1-5E.CE3*RK&<S12FW,"UU!1V"#<4OE(N L@-
MO#E]K_#^7B,62#+MN-'@;J'NR7:WG6AQW<BO\'H<WE"67&C(<4.N0??RW -5
MCYC:,+)T;;V6AH:$6V8TE5%9 )UO)#V"QK !VCD_^0M02P,$%     @ *GAP
M4JSK+$A,!0  /PP  !D   !X;"]W;W)K<VAE971S+W-H965T,3$N>&ULI5?;
M;MPV$'W75Q!;HT@ 9R_:C>TDM@%?TM1%TQAQTCX4?>!2LQ)AB51(RIOMU_<,
M=?&NXQ@H\N(5;S-GSIP9TL=KZVY]013$UZHT_F14A%"_GDR\*JB2?FQK,EA9
M65?)@*'+)[YV)+-XJ"HGZ71Z,*FD-J/3XSAW[4Z/;1-*;>C:"=]4E72;<RKM
M^F0T&_43'W5>!)Z8G![7,J<;"I_K:X?19+"2Z8J,U]8(1ZN3T=GL]?F"]\<-
M?VI:^ZUOP9$LK;WEP55V,IHR("I)!;8@\7-'%U26; @POG0V1X-+/KC]W5O_
M)<:.6);2TX4M_])9*$Y&1R.1T4HV9?AHU[]2%\]+MJ=LZ>-?L6[WSN<CH1H?
M;-4=!H)*F_97?NUXV#IP-/W.@;0[D$;<K:.(\E(&>7KL[%HXW@UK_!%#C:<!
M3AM.RDUP6-4X%T[/&X\9[\6%K9;:2*;*'T\"3/.&B>K,G+=FTN^8F:7BO36A
M\.*MR2C;-3 !I@%8V@,[3Y^T>$EJ+.:S?9%.T^D3]N9#H/-H;_Y_ A5_GRU]
M<)#&/T^X6 PN%M'%XD>Y?-K,'S:06(B??SI*9[,WXG'@'XS25=48$K_K2@?*
M,",^J&"7Y#K:9J_V12B(S]72;$3=.%5 P)EHBT)([REX(4TF2BV7NM1!DQ<K
M9ZM'[#\;IIX+- ,1;)"E4 "C,W(1EK KL3<;IQ!J6?*XEANY+$EH([XTT@5R
MY08#CY,E*AO.E:WPH;3)Q7PJ,KF!?UNB5? ,HU>E]?P-TSQ$LHR7L:+'B,RH
MQCD80M6$(FZX!]['N\N"5%\:[1"/-(*^JA+LWI&P=<0?+)A0:#DD')>SCW:!
MGBU\-I&'FR #6,)66)!9IODDF- FTZJE(=)3D':B=C9K0#7/[+T:3WMFQN+*
MB!NJ U6<,-;XOEB3,#;HE8[9[,,(A0R\M+9-F?$&P":GM.<E[7OHG4\L(DS?
M)8,G8 [G,&@\C<69YT\45^NX+[!=C@J9(74Z:\\W9;F;U9V<C\4G;(JL^DB%
M6$MH2BG;&*:+<6%BV:M8W:LX*L^11P/%QHYE1\KF1O=RRJW-UO ;I34='PT@
M'.$2\D@]BP-!0]"L[(TAET/%^["'Y&8[JYC"Q>61/3A;-:%Q[.^.3(,I1MVA
M86??\#@()Y JC"UMSE)F&=QK /?:+4IJOZTINP;#@W/<H\Q8AP<2\RUU/>DK
ML%+J?QDF=->+%PJ"( 7JQ:JAQAX4 D/_-JFS5ZW]K7**M=A>OW#DV[#RW%$.
M23\HY9C_Y6:W=DPKB6_1/(#+K'3-Y;[<=KL,UIN*VTK,NVT\-OCGKY,+Z8MD
M+YGMI].#Y%/L,2N)2KJ394/L;A=FI&%%: +9<.J2:O2,@/%!<F60WF#=)IDM
MDFO'20AM( 1@-3>A)%W,DNL^@+:<DEDZ2]YUVDN.TL/D3"G7T$X,R;-Y\GSP
M>@6YYT"%/9=:YL;ZH!6D<&5PD:$Y_\;%/)_&U!S]0&=^TL^S*W2AI_MS>C@^
MZ*MHOUWWH>NP>T?W+:HOR YDO(X.WWAT+<=8WHEKO)\B\6B)5MU&M##'MK@C
M[WJ._5FR480"7 2?50QB-[M[D.W!?9=\K+?PW'?]2 =!Y,1Y13%'[?GM"GV@
M'BN6]*C4L<)4BJ9FHR'@>1MM J+$1D?T@DV1:OA5*2I^_(C<670X5%?.W.&'
M0DOY%JM;%XKGUO-B0](]]OB8;#WJ*C2U^'3E_HF^VK[OAMGA=7S6/@KOM[=/
MZ_<1D1<EK7!T.CY\.6KOMWX0;!V?B$L;\.",GP5>^.1X ]97%F^2;L .AO\9
M3O\#4$L#!!0    ( "IX<%(W8#VVY0D   ,:   9    >&PO=V]R:W-H965T
M<R]S:&5E=#$R+GAM;)U9VW+;.!)]UU>@O-Y=ITK1A9)E.W%<93O)[FPE$U<\
MDWG8V@>(A"1,2((#@%8T7[^G&R!%V9(S,R\V20"-OIP^Z(8NU\9^=2NEO/A6
MY*5[<[3ROGHU'+ITI0KI!J92)486QA;2X]4NAZZR2F:\J,B'R6@T&Q92ET=7
ME_SMSEY=FMKGNE1W5KBZ**3=W*C<K-\<C8^:#Y_U<N7IP_#JLI)+=:_\S]6=
MQ=NPE9+I0I5.FU)8M7AS=#U^=3.E^3SABU9KUWD69,G<F*_T\D/VYFA$"JE<
MI9XD2/Q[4+<JSTD0U/@MRCQJMZ2%W>=&^GNV';;,I5.W)O]%9W[UYNC\2&1J
M(>O<?S;K?ZMHSRG)2TWN^*]8A[F3Z9%(:^=-$1=#@T*7X;_\%OW067 ^.K @
MB0L2UCMLQ%J^E5Y>75JS%I9F0QH]L*F\&LKIDH)R[RU&-=;YJ_=26_%%YK6Z
M''K(HZ_#-*Z]"6N3 VO'B?AH2K]RXEV9J6Q7P!"*M-HDC38WR;,2WZIT(";C
MODA&R>@9>9/6N@G+FWS7.O%6NS0WKK;*B?]>SYVW ,3_GMECVNXQY3VF?\F#
MSZ_]T7@E3L5+T5'TLTIK:W6Y['[\J"2ICFSP3GRJ@41CH2?-TB5LJ<.(M J9
MDAJ+< CIA5\IB$BEM1N:^D"R'%;0 ,"<RS)5@L'C^F*]TND*V-J(3"\6RHJ%
M-444 :]5BA-(+$BK(&D@?EKM?!!F(9#YSLLRHPU;+5OQI&&:2^?T0I..3GQ0
M#RH725_(JK+FFT:FJ0.*PR(@1!5S*->@1& K/(PO^IR=F4"JZ](K:.R%A2PG
MR)]P3[X1\D'J7,YS*&W 3+K 6\>7CH6ML?95[YJ-Z6[7H^UZM%7OME&,H]/;
M!NJ9D9MVE]YQ+SGKG\UFW8?):?_B;+Q]8,_J$A'2,A>YEG.=:Z]ACE_!#^3'
M(H B8ZV[88?I[,:L$QORBZ19$5QPEH9K#.@5CN*X67KU&(2SPDBFX$$F3^<,
M%"&1:^U7/%FFO]7::1['^A\0\CZK4ED-[WK#*$M-4>6JF43K=(DUL*FJY[E.
M\158"T 6GU)OR-ODZ3XO7\.?$NHT#MB$'6JH7+'0[<"2)D)!;)PJZW$@B97)
M88+KF/> $4T P!&&?<E[X-CT*XO-U-QW\ZD!+2$"YJ:FY@T(.P!N-R8A FU
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M]C 3%\,H>"8?!NIG83;DP ;6R!I?C$<!-\.0&@Y.=WXPK+3#,>.W6YSK8(@
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M5)1=O5"X6DI3T!&YHR#TG7M@M>>LZ+$1$QD?U6+LH^J12<$.3U5BBYYRIY?
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M9D&')E5L'\.;AAC5GM!"AE6LT6ZL6&$'X\GPM.LL'/$=&+6[X>8Z];N227T
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M793!!H59A4"SU=,HN,UMO4!1Z:NJ$7(4UH4<0-+@(DQ24/GHV$E;V=AQ=<[
M^OEL127?KD(E,&NA\]S%WX-"5< !.,+4%%4_2_@$?_.001$WL-5+B6K,@5T4
M2+=8(B%IR9;8 [=OX6/#+;#=H_[US:0_N;E -L_JDN,[S\D5 \:!@!(SCKWJ
M",(UR^5\Q)0K'B&4!:,(B=C^XWY<[M (Q)G./ E(LCH-O.PE B=#ZRB[JV$'
MF:EC&#L- ?BBQ'$ ;26/CK2R6_Q"R&T0%UZV] IV0N\AVO#50J#?X&-+X!J(
MPGRF_'*Z_*4] C!@JPR9^.*TFY(&[O4UDNG*KW;5#(=$HEV:0O]#<1ECR>X_
MB^FRT;O)+@&BK\1D((W.(%WUYM#3^:\Y9;:$>RIN"SK&V9++AIIS2C>X71L=
M+Q>_[E_TU89^<7?A7W-O#E4AO(R#XCP/Z$^!"C>74Y=^K&D#Y&T[2NN67ZQD
MJCIW[1,BZ0"A)]]PM5I'2X,"CDH.VUHSN6TAV,X;S7XP5OL6$*C2L*):X-2*
M:N^6&#LS>6U-E9NJW4'8BB<8E@'(Y-;!J4I32&/%;L%GOP3>Y+>,M^"; *F)
M^:G:#XEZ#J0(2!P0L%PZ,Y->B3<L.=#:-6]D@54MN"P#P!ND(N*$E8@\%;J%
MM;O2\"RL37Q^^%KRD[9A45%]!]'*ENVV-]$5T!X$3^UV8@=SZSKU#.:#F[L:
M\S5IV19 P^Q3;I:U15.=5]*C>.UAP89K5)7N)Q76/-1]9($F=H.:]/6>&X7,
M%5Z['E=YH,=5<K[&7%1IT51<:_F&#G?&UE+S+L[K+.,V$2"A5%65V<VEW>O'
MR!5'4^W7Y!,P-O= W\<&38?I=]IA56L+CS3'Y)_4&VN:2'&?RUJ VP04BLU"
M7^0HSO-;0O<:9BZ-'O-*BHQHNQU*.*/\?TS^)7#V/3+4%A7+D(&A;N"QT_[E
M]*H_N1Y29;3+^T#3?E!E4NBUST&NB?OO;K5?#D3V'TL\4<OJS&+OSH##%& 0
M]?1V'K(Q2XAO\BSF2)5I]:N+ABM(BSKM/0_E9)N>[M>!S4 7^&SW;&MA?+\8
MM)MCL9)62) OJ-LE*DU.479PRNZ\UO<U4&J36.7Z::&ZM#9A8U"N4<^)HK$
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M0*.\:S.(!>@=J &CQ1Z&K9LA!NB\Q$AEXR.LIYH?PCA<0] PAM!4UXJF(LK
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M1\,;EC6]EFA\ .WO-%U<;WB!X?U=_ 902P,$%     @ *GAP4N:CQLQA(@
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MAJTAV!J"#2=HF\0T32?K@&2 A<H<Y\BJ[18FY0&J@<\E3 % S)*+HG"/-PJ
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M*%IDFAU/4\DT*?(^GS.P8R!_&B"AY/' 6>%DL4!J@8=[T\*)FHQ.X9OY,SC
M_OE9&(%RM4$"+<&P EK-M,YIE6_.SV;/0)$7!=DDJQ;&PX%W+%0[./SZKC;T
M(3<-J22F?P0-MH&RC^6HA4A_ @NM@3WLU![E4[+<A^B:(=>I/#=,^H 5D+*E
MV$1WIMW0RZ-81&GE<33$K_!=>1)+=9+B!F'I,8#LQ#]G\6LAOR-)VX'- [2=
MP=)[KQ( 1)"[BWGZ_.QY>KIX,LJGN 1"C7!%VN9.U;5"=,(\NZ[.-F#,#>[H
M!O8.,_\\N9/[81U<;WYZEIXMSN_!:;BC*>9]ZICWZ22OO2+M XM=LVH<E?Y?
M,4U(]VX#@_K6:U= )DA"5M *#*\ZA[<UDZ/RAA@P&TP"S-XD:UWJFK ,S_7.
M*_?D Y N?+K!=<!(_3"[F24_7UQ</V2.7)S.GX/V+6@!=G3@(!B,;I>3@ T4
M.B@46!/\FP:9(EE757X'S,I4!6\1IU:E -YMNX)F #\ 3$:R=[XYFSUV#%[K
MPJZ L,).:V$]ML ,6-\@ A!10%Q@'<!CP ;**F2+NK44HK(_.M,8._0*S)MU
M35._-FI=5@T0(1A%H&]G"!OL^MF,E#$8?HA'F)J-#E Q+%3\:<":A0+1LC(,
M*= Q&E,.Z Z !I] QN^"LY^BS6>.-I]-$M6-7B-Y@ D!.@V/?8@NOW *.OEL
M8_0*[$6-FA+EJ<X,.9-;]1&D+MIBH5HQ#7^D46\^Z:PC=0IZ"21^C48#4LDM
MNH4!>8=V)\X(C+ZK&N9L(-<JX[4!9Q6( ,VR&Y"M =_PO9\(P*29@$QC58+4
MJA)\N] 3Z'[NT/U\$E<?&E)?;X!@D/2:(6Q_V0P$+7.TLO0YR/^L>W"7IMTS
MLSMN!0P!@:-(!!2H-8U  L2S2K1;2K#7;=D+@!-#+4VVC]CB2 ':4SD> V!;
ME&AAU-* ?6YD*E2Q1=5T3I&0W,&EQP;Q,KF88OCWJ&LQ!@_Z"R58@/B.4]YY
M1\K<CR'Y1QPWBSQS$';;)FFZY>^TYPK^!!O'8PBD5]'E^H5;!B7*NB3)\9+F
M[QJ]Z@K8UJTU4I%'X$0((#B%'>[AI<"2@9U=,P(H2E!4Y?JD(-N&<<0O"@!R
M_(079:RM2T8KJ.$U:=)P&#YWHP+TPY^-R;405"!%5;+L@!> ?5!)+@'WO+'(
M.7Q)-C)8Q:WZ!#95QF(0#S 5_+ 'ZU='5KTC%8%,G%M5C^,MN&*Z,(08'HC9
M%$-#C7B;_C1@ZHT!V&HT$9AZ80;0:;0?(+NN: &H%@1L+C[MK8)#[V H.J6'
MQ!Z*K*4NC,931 \8=595DAU%9B3+;E.#DD(3*.MM/IA7D8FRZEK@@P2IIN6]
M13MAC; )/5G@39SJ]RY?"]4OP=[B=<'VV>-#(H#[V%!(]$]"R0!S,)?79"[B
M/G.#=L .30B@E55=;05;(F1GR476=H!P03"<6U<@MZ-9R^^#Z]=,")8IQ38_
M];&UTWNC-;B9]YX%!T-G7SQ+1'EL&N$F!'D-;_&!>0A;ML9! B\(^A\8> *;
M57N@]%M=5,3P++,0(W!LC:YO#:JK!^XOF1S,JM?QI'Y9XMJ&;)9E 9;3"3(%
M''>'DLTM?_GNMZO7)V"5T5?.&Z]U2 =BW+'8)$K(1 (LM?>NX"W]"0QK8$EF
MW/YV[] )((E]@ A8+]<HR&J,-X4(S<&Y!!U5,C\#<ZJR49F$EM#]"^01>HT'
M>^TM1F(#PXA-TC4L>5#"KRHP$3F4H0 !R[V3>E83@'!#EA2!"EX2"@3 8"!2
M&" 8F&EQ#M?H=#!PZ[KJ=JS9*)*L:Q%:AUL"<JA B>% 4LS1(1',Z,RLK7HC
MY F6<I1R7C((M :<KEN3(Q?:[?/,&C=KX9FALQ71ER4BFLC*PG:_$V>)S@Y.
M6O@=Y'!)L1%/L11CLW88RC:TS1'*)6JX?0280!'28 4N>9D4JE[#_$M3[<!1
MVZI,=^3E4?!!E:1)>E,GZ+?C6+6N-=LO2]W>:2% 2US6,O 88$GKX$<@O+?C
M@QW=3M L5+NW^!#[DC4);AX-WUN&0+0J8A\W#&X)#*A*_:!Y&,(OW&9A\EL
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ME70(2,(XICX(N0P$?**Q4KN+V@O+?IH71__$."IU)AT=Q'Z/$-)79IW\JDN
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M<*%_G7__\1>*DF-)[0J&GLZ>/CE.:OY)1?[05COZ&<-EU;;5EO[$*Q!TC2_
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MA;(XB?EEB:,O:'< OR^5LKN-,] -T[,O4$L#!!0    ( "IX<%+$_,.=I@(
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M?#[HA<PTW=\L4&]\QRTU4O_Z:4D/)AAG0.<KK7&_< ':)WCZ%U!+ P04
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MDA(JVG)[H[8?H:]G[/@*Q8W_DFT7.\E"4K3&*M&#,0/!9/>G#_TY[ '.XA<
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M*<?3X>#4"7'$'/J9^0.XJ6E-'<_KLTE(=N!JG0^_\DEW/AP]AWY^OB7?NRK
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M:X%DF654_'X/*3\L+&P]WOC$=GME;MC+>4%WL 'UI5@+/;.;+ G+()>,YTC
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M/RAK@/<+*<UF8P,T?R>&?P!02P,$%     @ *GAP4M3O@U!V @  IP4  !D
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M:*@6BN_*L_J:*WWR+R\3HM^K12&@GV\X5T^+XOC??.Y9_@=02P,$%     @
M*GAP4O/!K>;L @  WP@  !D   !X;"]W;W)K<VAE971S+W-H965T-3,N>&UL
MO5;;;AHQ$/V5T2H/B91D+]Q"!$A<DC12(D6A:1^J/AAV "M>F]I#2/OUM;W+
M<BF@/O'"VMZ9,W/FF)EM+95^-S-$@L],2-,.9D3SVS TXQEFS%RK.4K[9J)T
MQLAN]30T<XTL]4Z9"),HJH<9XS+HM/S9B^ZTU(($E_BBP2RRC.G?/11JV0[B
M8'7PRJ<S<@=AIS5G4QPBO<U?M-V%)4K*,Y2&*PD:)^V@&]_VX\@Y>(MO')=F
M8PV.RDBI=[=Y3-M!Y#)"@6-R$,P^/K"/0C@DF\>O C0H8SK'S?4*_=Z3MV1&
MS&!?B>\\I5D[N D@Q0E;"'I5RR]8$*HYO+$2QO_"LK"- A@O#*FL<+899%SF
M3_99%&+#(:X?<$@*AV37H7K H5(X5#S1/#-/:\"(=5I:+4$[:XOF%KXVWMNR
MX=+)."1MWW+K1YT'I=(E%P*83.%1$I-3/A((76.0#%S!T%Z<=&%/U 2ZF=+$
M_S OP-VGO4H&X14%(TR!% QPPB4GO'JRTNR#.Q\@,2[,A05^&P[@_.P"SH!+
M^#I3"V-3,*V0+"N76S@N&/1R!LD!!G$"STK2S,"=3#'=!@AM.<J:)*N:])*C
MB ,<7T,EOH0D2J(]"?7_VSUN'DFG4DI4\7B5 WCWOJ9PJ*8_GJP]/!)FYN>1
M:-4R6M5'JQZ(MJ4Q%AKKM<;I2F/A\^'K?)C/9Y^ ><2ZC^CZRD<GB>K55OBQ
M6=1_C>)F8VVT1:96DJD=)3/@VK8+Z"MC"^5N>'%IS9%"U4OL^@ED:931&B>7
M)8]8VZQX94>4/2:U_9+<E$1NCA(9,H'F$IZ9?D?B<GH)#RA1L[P#=5/;X[@A
MS5QW/U*W9AFN>0*5XFC=3J.3ZU2$W/[_U.(=J?98Q<U:<T>M<&-49*BG?H(:
M&*N%I+Q#EJ?EE.[ZV;1SWG/3VX^@-4P^^JVT4RX-")Q8R.BZ8:^/SJ=IOB$U
M]P-II,B.-[^<V2\0U,[ OI\H1:N-"U!^TW3^ E!+ P04    "  J>'!2U>5<
M;YX"    !P  &0   'AL+W=O<FMS:&5E=',O<VAE970U-"YX;6R%E6U/VS 0
MQ[^*%?$")$:>^HC:2H7"AK1-B )[,>V%VUP;#\?N;*>!??J=G1"5X=(WB>W<
MW>]_%_L\JJ1ZTCF (<\%%WH<Y,9LSL-0+W,HJ#Z3&Q#X925500U.U3K4&P4T
M<TX%#Y,HZH4%92*8C-S:K9J,9&DX$W"KB"Z+@JJ7"^"R&@=Q\+IPQ]:YL0OA
M9+2A:YB#>=C<*IR%;92,%2 TDX(H6(V#:7Q^,;3VSN"10:5WQL1FLI#RR4YN
MLG$064' 86EL!(JO+5P"YS80ROC3Q Q:I'7<';]&OW:Y8RX+JN%2\A\L,_DX
M& 0D@Q4MN;F3U1=H\NG:>$O)M7N2JK&- K(LM9%%XXP*"B;J-WUNZK#CD,1[
M')+&(7&Z:Y!3.:.&3D9*5D19:XQF!RY5YXWBF+ _96X4?F7H9R:?I<PJQCFA
M(B,WPE"Q9@L.9*HU&$T^D3EN@ZS$%;DBUZ4I%9 K;1C6 S(R+:0R["]U!;YZ
MQIVBG>'[0,<S,)1Q?4*."!/D/I>E1J0>A0:SL%K"9:/XHE:<[%$\@^492>-3
MDD1)]#"?D>.CD[=10JQ!6XBD+43BPJ9[PEXSP0R0K[A'?(5H4O<F_'.ZT$;A
M_OKU@8ZTU9$Z'9T].C"KV%>4VJOGO.Q)VT[B8:<W"K<>5J=E=0ZQ$A^K]NJ^
M945^5K=E=0^Q4A^KZV&E>_+JM:S>(5;'Q^IY6,G S^JWK/XA5M?'ZOM8'3]K
MT+(&'[+N<\#&NS*@?,3!.V+:C1,_<=@2AQ\2=PX"K0^"+A>_L:,2(PG=.0RG
MY#O>()=4J1<FUN21\A)\(H?OMW$:#_[_W^%.0[-WPS>JUDQHPF&%?M%9'[-4
M=;^M)T9N7(];2(,=TPUSO*) 60/\OI+2O$YLVVPOO<D_4$L#!!0    ( "IX
M<%*Y/;P90@(  #L%   9    >&PO=V]R:W-H965T<R]S:&5E=#4U+GAM;(U4
MR6[;,!#]%4+H(0%::W.<-I %R'87'P(8,=(>BAYH:201H4B5I*SD[\M%5MS
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MW15K5VX$X-R22NH&GA>Y)2;,21,[-A=IPBM%"8.Y0+(J2RS>[H'R[=CQG?W
M UD7R@RX:;+!:UB >MK,A>ZY;92<E, DX0P)6(V=B7\WC0W> GX3V,J#-C*5
M+#E_,9WO^=CQC""@D"D3 >O?*TR!4A-(R_C7Q'3:E(9XV-Y'_VIKU[4LL80I
MI\\D5\78N750#BM<4?7 M]^@J6=HXF6<2OM%VP;K.2BKI.)E0]8*2L+J/]XU
M/AP0_,$)0M 0@L\2PH80VD)K9;:L&58X303?(F'0.III6&\L6U=#F%G%A1)Z
MEFB>2B=9)BK(T0^"EX0214"B+VBA-TM>44!\A?H0ES-0F%!YI;%/BQFZO+A"
M%X@P]%CP2F*6R\156IW)X6:-DOM:27!"R0RR&Q3ZURCP J^'/OTTW1]]I+O:
MD]:8H#4FL/'"$_'F^ TOJ:YUPO+: TPE^C-92B7TWOM[)D78I@AMBL&)%%->
MZL,HL:I/!,5*VXR;5'T&UN$B&\X<S]<T',7#Q'T]M*D+\OWH'?1!Z:!5.CBK
M=+\',CU!,DR1$D1_86?T0Y_4.M[P0$7L'ROM8B*S\GU"AZW0X5FAOU0!8J^K
MU\-A)VGHC49'RKJ@(!P&_=*B5EIT5MHS%@(SA6ASCMZN]?D6 ICJV^Q11\$@
M[,\?M_GCL_D?N=)+AIN5I.^GN<^EN+.)XOCVV*4N:.#?'B^@>W WF7?A)Q9K
MPB2BL-(T[R;6-8KZKJT[BF_L=;7D2E]^MEGHYPF$ >CY%>=JWS$W8/O@I?\!
M4$L#!!0    ( "IX<%(O<Z9 40,  ,4*   9    >&PO=V]R:W-H965T<R]S
M:&5E=#4W+GAM;+5676_3,!3]*U9 ""2VQ$[2I*.MM+5#3!JH6AD\(![<]+:U
M2.QB.RL@?CRV$[*N34-?>&EBYY[C<S]\>P=;(;^I-8!&/XJ<JZ&WUGISX?LJ
M6T-!U;G8 #=?ED(65)NE7/EJ(X$N'*C(?1($/;^@C'NC@=N;RM% E#IG'*82
MJ;(HJ/QY!;G8#CWL_=VX8ZNUMAO^:+"A*YB!OM],I5GY#<N"%< 5$QQ)6 Z]
M2WQQC4,+<!:?&&S5SCNRKLR%^&87-XNA%UA%D$.F+04UCP<80YY;)J/C>TWJ
M-6=:X.[[7_:WSGGCS)PJ&(O\,UOH]=!+/;2 )2US?2>V[Z!V*+9\F<B5^T7;
MRC9)/)252HNB!AL%!>/5D_ZH [$#P-$1 *D!Y%1 6 /"4P%1#8A.!<0UP+GN
M5[Z[P$VHIJ.!%%LDK;5ALR\N^@YMXL6X+929EN8K,S@]FL!<HS,TJ^H$B26Z
M%7QUID$6Z(/0H-"4_J3S'-#+"6C*<O7*F-_/)NCE\U?H.6(<?5R+4E&^4 -?
M&T66U\_JTZ^JT\G1T[-S%.+7B 0D:(&/N^&7&VG@P5'XY.33<;\%?MT-?POS
M<T12!T^?PGV3A285I$D%<7QA5RINN-*R-#=1HR^WQ@#=:"C4UP[ZL*$/'7UT
MA'XL^ -(S6PNN<OLILIL6^ JJIZCLKWF881#')L@/;0HB!H%4:>">TX+813\
M@H6YR\;9!5.9*(VKIGJJ':9427D&*!-*MQ94=*#L+,1A(ZR27QG%NT8XBM-V
M^7$C/^Z4_V$W:*^1%IKF;0KC@\-)DO1Z>Q(/K<*XG^!VB;U&8J]3XBTH=6':
MAI2V@$P;+273#%H#V3L0@'$:!7LR6ZS(T4)(&IE)MTS38EX\2TG0?^,:S;_*
M\2HY5!'WR7Y(#ZU(F&+2KC5MM*:=6NWEKCIAQQWL-V3]_W'%<?#8S8-_UZA_
M*RCO"F=-\B1243\A>_&LS7I/S$BR5R+7;69A$ 3M<<<[_TRXTY?I=(J<)[_1
M^/+N>H8N,]T5I,<^B_]+H\6/G19WM]H3LW#89$,<)$^C.VZWV@^NOS,!V 'O
M/94KQA7*86E@P7EB<BVKF:E::+%Q0\%<:#-BN->UF3-!6@/S?2F,#_7"SAG-
MY#KZ U!+ P04    "  J>'!2I@_#0$(+  "10   &0   'AL+W=O<FMS:&5E
M=',O<VAE970U."YX;6RU7.MOVS@2_[SW5Q#!'= "::SWHT@#Y-DXW>X&S?;V
MP^$^R!(="]7#2U%Y'/:/OR$EF[(M#>6V#H+&LC3#X9#SF]]09$^?2_:M6E#*
MR4N>%=6'HP7GR_>3214O:!Y5)^62%G!G7K(\XG#)'B?5DM$HD4)Y-K$,PYOD
M45H<G9W*[^[9V6E9\RPMZ#TC59WG$7N]H%GY_.'(/%I]\25]7'#QQ>3L=!D]
MT@?*OR[O&5Q-UEJ2-*=%E98%873^X>C<?/_)-'PA(1_Y=TJ?J\YG(OHR*\MO
MXF*:?#@RA$DTHS$7.B+X\T0O:98)56#(7ZW6HW6C0K#[>:7]1O8>>C.+*GI9
M9G^F"5]\. J.2$+G49WQ+^7S+6U[Y I]<9E5\E_RW#SK&T<DKBM>YJTP6)"G
M1?,W>FD]T1$ /?T"5BM@;0MX P)V*V!O"S@# DXKX(P5<%L!=ZQ)7BO@C6W!
M;P7\L2T$K4 PUJUA*Q".;<$T5B-G;(D$@V.]'NQFTC6S1$ZQJXA'9Z>L?"9,
M/ _ZQ <Y3Z4\S*RT$#'UP!G<34&.GUW1&2?OR'F2I&**1QF9%DVDB@G_YHKR
M*,VJM_#(UX<K\N:?;T\G')H5PI.X;>*B:<(::,(DG\N"+RIR720TZ9&_P^4M
MG?PG3?N8@@GX:^TT:^6T"PO5^'O,3XAM'A/+L(P>@RYQ\?/Z$16_PL7OZ@+$
MC4'Q:TWK2X:*W^#BGR.&&O\1%[^ALQ-BA8/BM[CX%8U7K9MAC_AT3.N!% _Z
M9B(N_D"7*]?UMOYIM/';?=^8AO8Z=FVIS\9B=UI4G-60Y3CYSZ_P )ERFE?_
M1=0[:_6.5.\,J+^N> HX0!,2I8P\15E-23DGSQ%C4<$KDE95W1^/C5Y/ZA5)
M_>G,-L3/Z>2IQQYW;8\[TIZU+<N:DW(IH2I+HUF:I?RU;U*YNP99GMFUJ#&\
MYSD'L=Q;6^ZAEE^6>0XF/O R_H8,C+]6YQ]BW(.U^@"U5JI/E?JX+)XH$W[G
M)5S(KE2[76D\V*AV.QX$=A>:_?X+UQ:%J$6 .?%"1@WYK>2T0CII&BKQ&8?P
MHMG)K"9J];3@E-&*$P:3M@]H-?+VB6'\"[/$4I98FODG1S"=9904PH%D&;U&
M<-5KE;43!*9A(%%@*KPR[?WL. 8NPVL&44N2(2?A*E>Y]!^__*)!55/AGJD!
MOA=.!5, :KX9"0,V7FKTK1)V8Z.)V:BPT,3!\)ZR&$R"LD?@8!.BLLY9LC2F
M9$FA;EI$K+V+QNR%IJG V)V([=CL+[C9706@)HZ@WX_]-ZWF[GRV7&PZ*Q@V
M_8,!Y46KNXN4OF&[ACU@E4)O$X?O;; D?Y.1^<=4>&R&A\!.2X&S98Q "C6A
M^SS8J@BZ0.6<./W^LQ1L6SCL]OCO)F4 XW\ [8D7%.N?0F3+.H@#%=1:>T(M
M!OFMKFZ(N!CB6PI*+1SZ>ISY0"%.DC'>5&!HN0?QIH(?2T?@QGOSRMH%'-R;
M"G L'>#$-)\!M(OZ0TN%+ 495G 0_RF\L' "IZ-"MQIY'16R%;#88X!EW$C>
MMKJZ(^EA(VDKD+%QD/D.)G2K43F>"=D*IFR<..[-A#3ZQC,ANU,$XTCW,YF0
MIJE!)G3['8*;W56(:H^MRO>N@NW=NMS$F)"M -C&F=X/,:%6=Y<).99G!]Z
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M .[/2TCJ[85H8/V_$)S]'U!+ P04    "  J>'!2#__-3$8"  !/!0  &0
M 'AL+W=O<FMS:&5E=',O<VAE970U.2YX;6R%5%U/VS 4_2M6Q -(@R1.6SZ4
M1@*J:9.&J"AL#],>W.2VL7#BS+ZA\.]W[830C7:\)+[V/?><8_LZW6CS:$L
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M&JD!_;"D%P^,2Z#UE=;X&K@N'-[0[ ]02P,$%     @ *GAP4O\JT#S6!
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MP!>8$0ZR$CR4F> G\J0\_KF@*X[+E(\\(>-4HWDS'=-Y'1,Z$-./F>@#%)\
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MP;:(!O\VR<*=>AW^MS2K3.V>[4'8/1S\,-H21JV$-QC;<-"4QL3=O.:BJ'"
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M=!HAHF/68:!=C=N7V@!K;.^U]_9==.O$Z5179/5MW[ZKUM+<=[GNP.TX>L(
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MFLL2%*9++QI?KN?6WAD\<*SUT1EL)CLIGZSP/5EZ@26$ F-C$1A]GO$*A;!
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M;]HP$/XK5M0/K=22-PBT J0"G39IK:JRKI]-<A"KCIW93NG^_<Y.R%(&K%_
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M4#8 OZ^E-#O#;M ^K=,_4$L#!!0    ( "IX<%)TD4N2>P,  /4,   9
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M4'8!/E]):?8#NT']I3/Y#U!+ P04    "  J>'!2*<BFDR0$  #6"P  &0
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MFM+6[=YI!:MJ/^MK96ES^&-)JQJU,Z#[7"F[$UR ?OE/?P-02P,$%     @
M*GAP4M.6 7XD!0   !4  !D   !X;"]W;W)K<VAE971S+W-H965T-S8N>&UL
MM5AM;]I($/XK*]236ND"]O*:BB ED+21T@L*;>^DTWU8[,%>U?;2W36$ZG[\
MS=H&0V+61#J^@(WWF7EF9^:9Q<.UD#]4"*#)<QPEZJH1:KW\V&HI+X28J:98
M0H)/%D+&3..M#%IJ*8'Y&2B.6M1Q>JV8\:0Q&F:_3>5H*%(=\02FDJ@TCIG<
MW$ DUE<-M[']X8D'H38_M$;#)0M@!OK;<BKQKK6SXO,8$L5%0B0LKAK7[L=/
M;<< LA7?.:S5WC4QH<R%^&%N[OVKAF,8002>-B88?JU@#%%D+"&/GX71QLZG
M >Y?;ZW?9<%C,'.F8"RB/[FOPZO&H$%\6+ TTD]B_1F*@+K&GB<BE7V2=;'6
M:1 O55K$!1@9Q#S)O]ESL1%[ +=S!$ + #T5T"X [5,!G0+0>0%H#XX N@6@
M>ZJ'7@'HG0KH%X!^EJQ\=[/43)AFHZ$4:R+-:K1F+K+\9FC,"$],*<ZTQ*<<
M<7HT%G',-=:65H0E/AF+1/,D@,3CH,@%N?9];FJ&1>0^R2O?5-#["6C&(_4!
MEWR;3<C[=Q_(.\(3\C44J4)#:MC22,\X:7D%E9N<"CU"90)>DSCT=T(=ZE3
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MJ-P!N[^1TAP"UWW=VYF_ E!+ P04    "  J>'!2Y^B "IL"  !R!@  &0
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MCVG.D4*NU"P>-8?20$3;8T.P6BP^0"X99K>]9!:G<Z17B%S7G:4]VR]/06^
MKSI,<4)I2$LS#O#-TG\R]_,,-47E2B.56QIXT^7^=N!)T:$B6!::1<G3HAVE
M?QW']I#3Z:]C(K1Z6^CY<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @
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MNY5LV93EI3MWJ[YK7NS^-63W;RWGOP!02P,$%     @ *GAP4GH$ UU< @
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M?WJ^_@U02P$"% ,4    "  J>'!2!T%-8H$   "Q    $
M@ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( "IX<%+TOAN0[@
M "L"   1              "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4
M Q0    ( "IX<%*97)PC$ 8  )PG   3              "  <P!  !X;"]T
M:&5M92]T:&5M93$N>&UL4$L! A0#%     @ *GAP4K-2>-J!!@  <AH  !@
M             ("!#0@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4
M Q0    ( "IX<%)35AZ5308  #,;   8              " @<0.  !X;"]W
M;W)K<VAE971S+W-H965T,BYX;6Q02P$"% ,4    "  J>'!2+HH:]44#  "5
M#   &               @(%'%0  >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL
M4$L! A0#%     @ *GAP4IT!&?F#!   SP\  !@              ("!PA@
M 'AL+W=O<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0    ( "IX<%+>?WEF
MG 4  #L8   8              " @7L=  !X;"]W;W)K<VAE971S+W-H965T
M-2YX;6Q02P$"% ,4    "  J>'!2,))N^-X"  #[!P  &
M@(%-(P  >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @ *GAP
M4A9)<3TN"   A2(  !@              ("!828  'AL+W=O<FMS:&5E=',O
M<VAE970W+GAM;%!+ 0(4 Q0    ( "IX<%*2'"; +0H  +H8   8
M      " @<4N  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4
M"  J>'!2/AA&.DH>  "07   &               @($H.0  >&PO=V]R:W-H
M965T<R]S:&5E=#DN>&UL4$L! A0#%     @ *GAP4C*WW_6; @  \P4  !D
M             ("!J%<  'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"
M% ,4    "  J>'!2K.LL2$P%   _#   &0              @(%Z6@  >&PO
M=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    ( "IX<%(W8#VVY0D
M  ,:   9              " @?U?  !X;"]W;W)K<VAE971S+W-H965T,3(N
M>&UL4$L! A0#%     @ *GAP4DWYS[B; P  -0@  !D              ("!
M&6H  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4    "  J>'!2
M[/NF8DP$   1"@  &0              @('K;0  >&PO=V]R:W-H965T<R]S
M:&5E=#$T+GAM;%!+ 0(4 Q0    ( "IX<%(+V?L$H0(  )P%   9
M      " @6YR  !X;"]W;W)K<VAE971S+W-H965T,34N>&UL4$L! A0#%
M  @ *GAP4AX69G$U"P  T!L  !D              ("!1G4  'AL+W=O<FMS
M:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4    "  J>'!2OTU:330$  #'"@
M&0              @(&R@   >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+
M 0(4 Q0    ( "IX<%*,C0M,3 0  )0*   9              " @1V%  !X
M;"]W;W)K<VAE971S+W-H965T,3@N>&UL4$L! A0#%     @ *GAP4H)LAB]^
M P  )@@  !D              ("!H(D  'AL+W=O<FMS:&5E=',O<VAE970Q
M.2YX;6Q02P$"% ,4    "  J>'!2GJ4#''H&  #H#P  &0
M@(%5C0  >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    ( "IX
M<%(8-R;PS!$  /TW   9              " @0:4  !X;"]W;W)K<VAE971S
M+W-H965T,C$N>&UL4$L! A0#%     @ *GAP4E?:[TVI P  00@  !D
M         ("!":8  'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"% ,4
M    "  J>'!2H&I8/<@'  !D$P  &0              @('IJ0  >&PO=V]R
M:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    ( "IX<%(LG$Z'/P@  /P3
M   9              " @>BQ  !X;"]W;W)K<VAE971S+W-H965T,C0N>&UL
M4$L! A0#%     @ *GAP4FINHU%Y @  BP4  !D              ("!7KH
M 'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q02P$"% ,4    "  J>'!2YJ/&
MS&$B  #D<@  &0              @($.O0  >&PO=V]R:W-H965T<R]S:&5E
M=#(V+GAM;%!+ 0(4 Q0    ( "IX<%(!"1YF+ ,  ,\&   9
M  " @:;?  !X;"]W;W)K<VAE971S+W-H965T,C<N>&UL4$L! A0#%     @
M*GAP4L92.576 @  *08  !D              ("!">,  'AL+W=O<FMS:&5E
M=',O<VAE970R."YX;6Q02P$"% ,4    "  J>'!2&2:JC20$  !A"@  &0
M            @($6Y@  >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4
M Q0    ( "IX<%+5&)T!9@,  -4'   9              " @7'J  !X;"]W
M;W)K<VAE971S+W-H965T,S N>&UL4$L! A0#%     @ *GAP4L5CKTEG!
M6 L  !D              ("!#NX  'AL+W=O<FMS:&5E=',O<VAE970S,2YX
M;6Q02P$"% ,4    "  J>'!2Q/S#G:8"  ".!0  &0              @(&L
M\@  >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0    ( "IX<%+3
M])_J1 ,  &T'   9              " @8GU  !X;"]W;W)K<VAE971S+W-H
M965T,S,N>&UL4$L! A0#%     @ *GAP4@E-J8<% P   @<  !D
M     ("!!/D  'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( "IX<%(HGCBBBP(  ((%   9              "
M@5H, 0!X;"]W;W)K<VAE971S+W-H965T,SDN>&UL4$L! A0#%     @ *GAP
M4G"EASB"!   2Q$  !D              ("!' \! 'AL+W=O<FMS:&5E=',O
M<VAE970T,"YX;6Q02P$"% ,4    "  J>'!2%IO$//8%  ".&@  &0
M        @('5$P$ >&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0
M   ( "IX<%)P]"5!3 0  )86   9              " @0(: 0!X;"]W;W)K
M<VAE971S+W-H965T-#(N>&UL4$L! A0#%     @ *GAP4LUD*S!H!0  $!8
M !D              ("!A1X! 'AL+W=O<FMS:&5E=',O<VAE970T,RYX;6Q0
M2P$"% ,4    "  J>'!2 S.%?V$#  #X"@  &0              @($D) $
M>&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+ 0(4 Q0    ( "IX<%(KFOXQ
M9 (  ((&   9              " @;PG 0!X;"]W;W)K<VAE971S+W-H965T
M-#4N>&UL4$L! A0#%     @ *GAP4JZHCQG# @  *0D  !D
M ("!5RH! 'AL+W=O<FMS:&5E=',O<VAE970T-BYX;6Q02P$"% ,4    "  J
M>'!2;#-5]90#  ! #0  &0              @(%1+0$ >&PO=V]R:W-H965T
M<R]S:&5E=#0W+GAM;%!+ 0(4 Q0    ( "IX<%)_*-JGT 4  #L:   9
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M970U,BYX;6Q02P$"% ,4    "  J>'!2\\&MYNP"  #?"   &0
M    @(&A1 $ >&PO=V]R:W-H965T<R]S:&5E=#4S+GAM;%!+ 0(4 Q0    (
M "IX<%+5Y5QOG@(    '   9              " @<1' 0!X;"]W;W)K<VAE
M971S+W-H965T-30N>&UL4$L! A0#%     @ *GAP4KD]O!E" @  .P4  !D
M             ("!F4H! 'AL+W=O<FMS:&5E=',O<VAE970U-2YX;6Q02P$"
M% ,4    "  J>'!2NZ&#:*("  #\!@  &0              @($230$ >&PO
M=V]R:W-H965T<R]S:&5E=#4V+GAM;%!+ 0(4 Q0    ( "IX<%(O<Z9 40,
M ,4*   9              " @>M/ 0!X;"]W;W)K<VAE971S+W-H965T-3<N
M>&UL4$L! A0#%     @ *GAP4J8/PT!""P  D4   !D              ("!
M<U,! 'AL+W=O<FMS:&5E=',O<VAE970U."YX;6Q02P$"% ,4    "  J>'!2
M#__-3$8"  !/!0  &0              @('L7@$ >&PO=V]R:W-H965T<R]S
M:&5E=#4Y+GAM;%!+ 0(4 Q0    ( "IX<%+_*M \U@0  %L:   9
M      " @6EA 0!X;"]W;W)K<VAE971S+W-H965T-C N>&UL4$L! A0#%
M  @ *GAP4D*8!5I- P  ) L  !D              ("!=F8! 'AL+W=O<FMS
M:&5E=',O<VAE970V,2YX;6Q02P$"% ,4    "  J>'!2X8%E;>0"   E!P
M&0              @('Z:0$ >&PO=V]R:W-H965T<R]S:&5E=#8R+GAM;%!+
M 0(4 Q0    ( "IX<%).^$5"V ,  (D.   9              " @15M 0!X
M;"]W;W)K<VAE971S+W-H965T-C,N>&UL4$L! A0#%     @ *GAP4CT'Z)":
M @  L@<  !D              ("!)'$! 'AL+W=O<FMS:&5E=',O<VAE970V
M-"YX;6Q02P$"% ,4    "  J>'!2S!F5TAH#  !I"@  &0
M@('U<P$ >&PO=V]R:W-H965T<R]S:&5E=#8U+GAM;%!+ 0(4 Q0    ( "IX
M<%)-EJ"E!PH  %HV   9              " @49W 0!X;"]W;W)K<VAE971S
M+W-H965T-C8N>&UL4$L! A0#%     @ *GAP4J!14$7V @  &PD  !D
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M=#<Q+GAM;%!+ 0(4 Q0    ( "IX<%(IR*:3) 0  -8+   9
M  " @9J2 0!X;"]W;W)K<VAE971S+W-H965T-S(N>&UL4$L! A0#%     @
M*GAP4M&88T+: @  G0@  !D              ("!]98! 'AL+W=O<FMS:&5E
M=',O<VAE970W,RYX;6Q02P$"% ,4    "  J>'!2[1<8WEL#  "V"@  &0
M            @($&F@$ >&PO=V]R:W-H965T<R]S:&5E=#<T+GAM;%!+ 0(4
M Q0    ( "IX<%*>DT9RE (   @&   9              " @9B= 0!X;"]W
M;W)K<VAE971S+W-H965T-S4N>&UL4$L! A0#%     @ *GAP4M.6 7XD!0
M !4  !D              ("!8Z ! 'AL+W=O<FMS:&5E=',O<VAE970W-BYX
M;6Q02P$"% ,4    "  J>'!20='__$0"  !'!0  &0              @(&^
MI0$ >&PO=V]R:W-H965T<R]S:&5E=#<W+GAM;%!+ 0(4 Q0    ( "IX<%+G
MZ( *FP(  '(&   9              " @3FH 0!X;"]W;W)K<VAE971S+W-H
M965T-S@N>&UL4$L! A0#%     @ *GAP4LL%ZVM4 @  3 P   T
M     ( !"ZL! 'AL+W-T>6QE<RYX;6Q02P$"% ,4    "  J>'!2EXJ[',
M   3 @  "P              @ &*K0$ 7W)E;',O+G)E;'-02P$"% ,4
M"  J>'!2-;U#O\$%  !:,P  #P              @ %SK@$ >&PO=V]R:V)O
M;VLN>&UL4$L! A0#%     @ *GAP4GH$ UU< @  (2X  !H
M ( !8;0! 'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @
M*GAP4BXH"M@5 @  _"P  !,              ( !];8! %M#;VYT96YT7U1Y
><&5S72YX;6Q02P4&     %8 5@"1%P  .[D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>232</ContextCount>
  <ElementCount>486</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>98</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="bdsx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="bdsx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010 - Statement - Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20201231/taxonomy/role/StatementBalanceSheets</Role>
      <ShortName>Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="bdsx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100020 - Statement - Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20201231/taxonomy/role/StatementBalanceSheetsParenthetical</Role>
      <ShortName>Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="bdsx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100030 - Statement - Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfOperations</Role>
      <ShortName>Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="bdsx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100040 - Statement - Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit</Role>
      <ShortName>Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="bdsx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100050 - Statement - Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical</Role>
      <ShortName>Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="bdsx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>100060 - Statement - Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfCashFlows</Role>
      <ShortName>Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="bdsx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>100070 - Disclosure - Organization and Description of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20201231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusiness</Role>
      <ShortName>Organization and Description of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="bdsx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>100080 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="bdsx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>100090 - Disclosure - Recent Accounting Pronouncements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20201231/taxonomy/role/DisclosureRecentAccountingPronouncements</Role>
      <ShortName>Recent Accounting Pronouncements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="bdsx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>100100 - Disclosure - Business Combinations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20201231/taxonomy/role/DisclosureBusinessCombinations</Role>
      <ShortName>Business Combinations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="bdsx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>100110 - Disclosure - Fair Value</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20201231/taxonomy/role/DisclosureFairValue</Role>
      <ShortName>Fair Value</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="bdsx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>100120 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20201231/taxonomy/role/DisclosurePropertyAndEquipment</Role>
      <ShortName>Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="bdsx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>100130 - Disclosure - Goodwill and Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssets</Role>
      <ShortName>Goodwill and Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="bdsx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>100140 - Disclosure - Accrued Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20201231/taxonomy/role/DisclosureAccruedLiabilities</Role>
      <ShortName>Accrued Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="bdsx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>100150 - Disclosure - Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20201231/taxonomy/role/DisclosureDebt</Role>
      <ShortName>Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="bdsx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>100160 - Disclosure - Convertible Preferred Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStock</Role>
      <ShortName>Convertible Preferred Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="bdsx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>100170 - Disclosure - Warrants to Purchase Convertible Preferred Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20201231/taxonomy/role/DisclosureWarrantsToPurchaseConvertiblePreferredStock</Role>
      <ShortName>Warrants to Purchase Convertible Preferred Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="bdsx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>100180 - Disclosure - Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20201231/taxonomy/role/DisclosureEquity</Role>
      <ShortName>Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="bdsx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>100190 - Disclosure - Revenue</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20201231/taxonomy/role/DisclosureRevenue</Role>
      <ShortName>Revenue</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="bdsx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>100200 - Disclosure - Share Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20201231/taxonomy/role/DisclosureShareBasedCompensation</Role>
      <ShortName>Share Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="bdsx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>100210 - Disclosure - Earnings per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20201231/taxonomy/role/DisclosureEarningsPerShare</Role>
      <ShortName>Earnings per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="bdsx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>100220 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20201231/taxonomy/role/DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="bdsx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>100230 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="bdsx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>100240 - Disclosure - Defined Contribution 401(k) Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20201231/taxonomy/role/DisclosureDefinedContribution401KPlan</Role>
      <ShortName>Defined Contribution 401(k) Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="bdsx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>100250 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://biodesix.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="bdsx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>100260 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://biodesix.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="bdsx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>100270 - Disclosure - Business Combinations (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20201231/taxonomy/role/DisclosureBusinessCombinationsTables</Role>
      <ShortName>Business Combinations (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://biodesix.com/20201231/taxonomy/role/DisclosureBusinessCombinations</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="bdsx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>100280 - Disclosure - Fair Value (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20201231/taxonomy/role/DisclosureFairValueTables</Role>
      <ShortName>Fair Value (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://biodesix.com/20201231/taxonomy/role/DisclosureFairValue</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="bdsx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>100290 - Disclosure - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://biodesix.com/20201231/taxonomy/role/DisclosurePropertyAndEquipment</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="bdsx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>100300 - Disclosure - Goodwill and Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsTables</Role>
      <ShortName>Goodwill and Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://biodesix.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssets</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="bdsx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>100310 - Disclosure - Accrued Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20201231/taxonomy/role/DisclosureAccruedLiabilitiesTables</Role>
      <ShortName>Accrued Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://biodesix.com/20201231/taxonomy/role/DisclosureAccruedLiabilities</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="bdsx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>100320 - Disclosure - Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20201231/taxonomy/role/DisclosureDebtTables</Role>
      <ShortName>Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://biodesix.com/20201231/taxonomy/role/DisclosureDebt</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="bdsx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>100330 - Disclosure - Warrants to Purchase Convertible Preferred Stock (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20201231/taxonomy/role/DisclosureWarrantsToPurchaseConvertiblePreferredStockTables</Role>
      <ShortName>Warrants to Purchase Convertible Preferred Stock (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://biodesix.com/20201231/taxonomy/role/DisclosureWarrantsToPurchaseConvertiblePreferredStock</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="bdsx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>100340 - Disclosure - Revenue (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20201231/taxonomy/role/DisclosureRevenueTables</Role>
      <ShortName>Revenue (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://biodesix.com/20201231/taxonomy/role/DisclosureRevenue</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="bdsx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>100350 - Disclosure - Share Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20201231/taxonomy/role/DisclosureShareBasedCompensationTables</Role>
      <ShortName>Share Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://biodesix.com/20201231/taxonomy/role/DisclosureShareBasedCompensation</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="bdsx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>100360 - Disclosure - Earnings per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20201231/taxonomy/role/DisclosureEarningsPerShareTables</Role>
      <ShortName>Earnings per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://biodesix.com/20201231/taxonomy/role/DisclosureEarningsPerShare</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="bdsx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>100370 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20201231/taxonomy/role/DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://biodesix.com/20201231/taxonomy/role/DisclosureIncomeTaxes</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="bdsx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>100380 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://biodesix.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingencies</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="bdsx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>100390 - Disclosure - Organization and Description of Business - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20201231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails</Role>
      <ShortName>Organization and Description of Business - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="bdsx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>100400 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="bdsx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>100410 - Disclosure - Summary of Significant Accounting Policies - Summary of Revenue and Accounts Receivable by Third-party Payors and Other Customers (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfRevenueAndAccountsReceivableByThirdPartyPayorsAndOtherCustomersDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Summary of Revenue and Accounts Receivable by Third-party Payors and Other Customers (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="bdsx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>100420 - Disclosure - Business Combinations - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20201231/taxonomy/role/DisclosureBusinessCombinationsAdditionalInformationDetails</Role>
      <ShortName>Business Combinations - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="bdsx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>100430 - Disclosure - Business Combinations - Summary of Aggregate Consideration Paid by Company and Allocation of Purchase Price to Assets Acquired and Liabilities Assumed (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20201231/taxonomy/role/DisclosureBusinessCombinationsSummaryOfAggregateConsiderationPaidByCompanyAndAllocationOfPurchasePriceToAssetsAcquiredAndLiabilitiesAssumedDetails</Role>
      <ShortName>Business Combinations - Summary of Aggregate Consideration Paid by Company and Allocation of Purchase Price to Assets Acquired and Liabilities Assumed (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="bdsx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>100440 - Disclosure - Fair Value - Summary of Fair Value of Outstanding Borrowings (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20201231/taxonomy/role/DisclosureFairValueSummaryOfFairValueOfOutstandingBorrowingsDetails</Role>
      <ShortName>Fair Value - Summary of Fair Value of Outstanding Borrowings (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="bdsx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>100450 - Disclosure - Fair Value - Schedule of Reported Fair Values of Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20201231/taxonomy/role/DisclosureFairValueScheduleOfReportedFairValuesOfLiabilitiesDetails</Role>
      <ShortName>Fair Value - Schedule of Reported Fair Values of Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="bdsx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>100460 - Disclosure - Fair Value - Schedule of Changes in Financial Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20201231/taxonomy/role/DisclosureFairValueScheduleOfChangesInFinancialLiabilitiesDetails</Role>
      <ShortName>Fair Value - Schedule of Changes in Financial Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="bdsx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>100470 - Disclosure - Fair Value - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20201231/taxonomy/role/DisclosureFairValueAdditionalInformationDetails</Role>
      <ShortName>Fair Value - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="bdsx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>100480 - Disclosure - Property and Equipment - Schedule of Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails</Role>
      <ShortName>Property and Equipment - Schedule of Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="bdsx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>100490 - Disclosure - Property and Equipment - Schedule of Depreciation Expense Related to Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfDepreciationExpenseRelatedToPropertyAndEquipmentDetails</Role>
      <ShortName>Property and Equipment - Schedule of Depreciation Expense Related to Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="bdsx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>100500 - Disclosure - Goodwill and Intangible Assets - Schedule of Changes in Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsScheduleOfChangesInGoodwillDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Schedule of Changes in Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="bdsx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>100510 - Disclosure - Goodwill and Intangible Assets - Schedule of Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsScheduleOfIntangibleAssetsDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Schedule of Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="bdsx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>100520 - Disclosure - Goodwill and Intangible Assets - Schedule of Amortization Expense Related to Definite-Lived Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsScheduleOfAmortizationExpenseRelatedToDefiniteLivedIntangibleAssetsDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Schedule of Amortization Expense Related to Definite-Lived Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="bdsx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>100530 - Disclosure - Goodwill and Intangible Assets - Schedule of Future Estimated Amortization Expense of Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsScheduleOfFutureEstimatedAmortizationExpenseOfIntangibleAssetsDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Schedule of Future Estimated Amortization Expense of Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="bdsx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>100540 - Disclosure - Goodwill and Intangible Assets - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="bdsx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>100550 - Disclosure - Accrued Liabilities - Schedule of Accrued Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20201231/taxonomy/role/DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails</Role>
      <ShortName>Accrued Liabilities - Schedule of Accrued Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="bdsx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>100560 - Disclosure - Debt - Summary of Long-term Notes Payable (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://biodesix.com/20201231/taxonomy/role/DisclosureDebtSummaryOfLongTermNotesPayableDetails</Role>
      <ShortName>Debt - Summary of Long-term Notes Payable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="bdsx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>100570 - Disclosure - Debt - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetails</Role>
      <ShortName>Debt - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="bdsx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>100580 - Disclosure - Debt - Scheduled Principal Repayments (Maturities) of Long-term Obligations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20201231/taxonomy/role/DisclosureDebtScheduledPrincipalRepaymentsMaturitiesOfLongTermObligationsDetails</Role>
      <ShortName>Debt - Scheduled Principal Repayments (Maturities) of Long-term Obligations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="bdsx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>100590 - Disclosure - Convertible Preferred Stock - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails</Role>
      <ShortName>Convertible Preferred Stock - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="bdsx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>100600 - Disclosure - Warrants to Purchase Convertible Preferred Stock - Summary of Activity for Convertible Preferred Stock Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20201231/taxonomy/role/DisclosureWarrantsToPurchaseConvertiblePreferredStockSummaryOfActivityForConvertiblePreferredStockWarrantsDetails</Role>
      <ShortName>Warrants to Purchase Convertible Preferred Stock - Summary of Activity for Convertible Preferred Stock Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="bdsx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>100610 - Disclosure - Warrants to Purchase Convertible Preferred Stock - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20201231/taxonomy/role/DisclosureWarrantsToPurchaseConvertiblePreferredStockAdditionalInformationDetails</Role>
      <ShortName>Warrants to Purchase Convertible Preferred Stock - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="bdsx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>100620 - Disclosure - Equity - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20201231/taxonomy/role/DisclosureEquityAdditionalInformationDetails</Role>
      <ShortName>Equity - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="bdsx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>100630 - Disclosure - Revenue - Summary of Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20201231/taxonomy/role/DisclosureRevenueSummaryOfRevenueDetails</Role>
      <ShortName>Revenue - Summary of Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="bdsx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>100640 - Disclosure - Revenue - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20201231/taxonomy/role/DisclosureRevenueAdditionalInformationDetails</Role>
      <ShortName>Revenue - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="bdsx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>100650 - Disclosure - Share Based Compensation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20201231/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails</Role>
      <ShortName>Share Based Compensation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="bdsx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>100660 - Disclosure - Share Based Compensation - Summary of Pre-tax Share-based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20201231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfPreTaxShareBasedCompensationExpenseDetails</Role>
      <ShortName>Share Based Compensation - Summary of Pre-tax Share-based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="bdsx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>100670 - Disclosure - Share Based Compensation - Summary of Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20201231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetails</Role>
      <ShortName>Share Based Compensation - Summary of Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="bdsx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>100680 - Disclosure - Share Based Compensation - Summary of Weighted Average Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20201231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfWeightedAverageAssumptionsDetails</Role>
      <ShortName>Share Based Compensation - Summary of Weighted Average Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="bdsx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>100690 - Disclosure - Earnings per Share - Schedule of Computation of Basic and Diluted Net Loss per Share Attributable to Common Stockholders (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20201231/taxonomy/role/DisclosureEarningsPerShareScheduleOfComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails</Role>
      <ShortName>Earnings per Share - Schedule of Computation of Basic and Diluted Net Loss per Share Attributable to Common Stockholders (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="bdsx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>100700 - Disclosure - Earnings per Share - Schedule of Common Stock Equivalents Excluded from Diluted Net Loss Attributable to Common Stockholders (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20201231/taxonomy/role/DisclosureEarningsPerShareScheduleOfCommonStockEquivalentsExcludedFromDilutedNetLossAttributableToCommonStockholdersDetails</Role>
      <ShortName>Earnings per Share - Schedule of Common Stock Equivalents Excluded from Diluted Net Loss Attributable to Common Stockholders (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="bdsx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>100710 - Disclosure - Income Taxes - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails</Role>
      <ShortName>Income Taxes - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="bdsx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>100720 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails</Role>
      <ShortName>Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="bdsx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>100730 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails</Role>
      <ShortName>Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="bdsx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>100740 - Disclosure - Income Taxes - Reconciliation of Unrecognized Tax Benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20201231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfUnrecognizedTaxBenefitsDetails</Role>
      <ShortName>Income Taxes - Reconciliation of Unrecognized Tax Benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="bdsx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>100750 - Disclosure - Commitments and Contingencies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="bdsx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>100760 - Disclosure - Commitments and Contingencies - Summary of Future Minimum Lease Payments for Operating Lease Obligations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumLeasePaymentsForOperatingLeaseObligationsDetails</Role>
      <ShortName>Commitments and Contingencies - Summary of Future Minimum Lease Payments for Operating Lease Obligations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="bdsx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>100770 - Disclosure - Defined Contribution 401(k) Plan - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20201231/taxonomy/role/DisclosureDefinedContribution401KPlanAdditionalInformationDetail</Role>
      <ShortName>Defined Contribution 401(k) Plan - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="bdsx-10k_20201231.htm">bdsx-10k_20201231.htm</File>
    <File>bdsx-20201231.xsd</File>
    <File>bdsx-20201231_cal.xml</File>
    <File>bdsx-20201231_def.xml</File>
    <File>bdsx-20201231_lab.xml</File>
    <File>bdsx-20201231_pre.xml</File>
    <File>bdsx-ex1051_388.htm</File>
    <File>bdsx-ex231_271.htm</File>
    <File>bdsx-ex311_269.htm</File>
    <File>bdsx-ex312_268.htm</File>
    <File>bdsx-ex321_267.htm</File>
    <File>bdsx-ex322_266.htm</File>
    <File>bdsx-ex45_270.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>gegguy50oztz000001.jpg</File>
    <File>gegguy50oztz000002.jpg</File>
    <File>gegguy50oztz000003.jpg</File>
    <File>gegguy50oztz000004.jpg</File>
    <File>gegguy50oztz000005.jpg</File>
    <File>gegguy50oztz000006.jpg</File>
    <File>gegguy50oztz000007.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/country/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>106
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "bdsx-10k_20201231.htm": {
   "axisCustom": 0,
   "axisStandard": 34,
   "contextCount": 232,
   "dts": {
    "calculationLink": {
     "local": [
      "bdsx-20201231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "bdsx-20201231_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "bdsx-10k_20201231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "bdsx-20201231_lab.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml",
      "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "bdsx-20201231_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml",
      "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "bdsx-20201231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd",
      "https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 698,
   "entityCount": 1,
   "hidden": {
    "http://biodesix.com/20201231": 3,
    "http://fasb.org/us-gaap/2020-01-31": 24,
    "http://xbrl.sec.gov/dei/2020-01-31": 4,
    "total": 31
   },
   "keyCustom": 82,
   "keyStandard": 404,
   "memberCustom": 50,
   "memberStandard": 47,
   "nsprefix": "bdsx",
   "nsuri": "http://biodesix.com/20201231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "baseRef": "bdsx-10k_20201231.htm",
      "contextRef": "C_0001439725_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "role": "http://biodesix.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "baseRef": "bdsx-10k_20201231.htm",
      "contextRef": "C_0001439725_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "bdsx-10k_20201231.htm",
      "contextRef": "C_0001439725_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100090 - Disclosure - Recent Accounting Pronouncements",
     "role": "http://biodesix.com/20201231/taxonomy/role/DisclosureRecentAccountingPronouncements",
     "shortName": "Recent Accounting Pronouncements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "bdsx-10k_20201231.htm",
      "contextRef": "C_0001439725_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "bdsx-10k_20201231.htm",
      "contextRef": "C_0001439725_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100100 - Disclosure - Business Combinations",
     "role": "http://biodesix.com/20201231/taxonomy/role/DisclosureBusinessCombinations",
     "shortName": "Business Combinations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "bdsx-10k_20201231.htm",
      "contextRef": "C_0001439725_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "bdsx-10k_20201231.htm",
      "contextRef": "C_0001439725_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100110 - Disclosure - Fair Value",
     "role": "http://biodesix.com/20201231/taxonomy/role/DisclosureFairValue",
     "shortName": "Fair Value",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "bdsx-10k_20201231.htm",
      "contextRef": "C_0001439725_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "bdsx-10k_20201231.htm",
      "contextRef": "C_0001439725_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100120 - Disclosure - Property and Equipment",
     "role": "http://biodesix.com/20201231/taxonomy/role/DisclosurePropertyAndEquipment",
     "shortName": "Property and Equipment",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "bdsx-10k_20201231.htm",
      "contextRef": "C_0001439725_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "bdsx-10k_20201231.htm",
      "contextRef": "C_0001439725_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100130 - Disclosure - Goodwill and Intangible Assets",
     "role": "http://biodesix.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssets",
     "shortName": "Goodwill and Intangible Assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "bdsx-10k_20201231.htm",
      "contextRef": "C_0001439725_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "bdsx-10k_20201231.htm",
      "contextRef": "C_0001439725_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100140 - Disclosure - Accrued Liabilities",
     "role": "http://biodesix.com/20201231/taxonomy/role/DisclosureAccruedLiabilities",
     "shortName": "Accrued Liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "bdsx-10k_20201231.htm",
      "contextRef": "C_0001439725_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "bdsx-10k_20201231.htm",
      "contextRef": "C_0001439725_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100150 - Disclosure - Debt",
     "role": "http://biodesix.com/20201231/taxonomy/role/DisclosureDebt",
     "shortName": "Debt",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "bdsx-10k_20201231.htm",
      "contextRef": "C_0001439725_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "bdsx-10k_20201231.htm",
      "contextRef": "C_0001439725_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100160 - Disclosure - Convertible Preferred Stock",
     "role": "http://biodesix.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStock",
     "shortName": "Convertible Preferred Stock",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "bdsx-10k_20201231.htm",
      "contextRef": "C_0001439725_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "bdsx-10k_20201231.htm",
      "contextRef": "C_0001439725_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bdsx:WarrantsForConvertiblePreferredStockTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100170 - Disclosure - Warrants to Purchase Convertible Preferred Stock",
     "role": "http://biodesix.com/20201231/taxonomy/role/DisclosureWarrantsToPurchaseConvertiblePreferredStock",
     "shortName": "Warrants to Purchase Convertible Preferred Stock",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "bdsx-10k_20201231.htm",
      "contextRef": "C_0001439725_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bdsx:WarrantsForConvertiblePreferredStockTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "bdsx-10k_20201231.htm",
      "contextRef": "C_0001439725_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100180 - Disclosure - Equity",
     "role": "http://biodesix.com/20201231/taxonomy/role/DisclosureEquity",
     "shortName": "Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "bdsx-10k_20201231.htm",
      "contextRef": "C_0001439725_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-10k_20201231.htm",
      "contextRef": "C_0001439725_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100010 - Statement - Balance Sheets",
     "role": "http://biodesix.com/20201231/taxonomy/role/StatementBalanceSheets",
     "shortName": "Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-10k_20201231.htm",
      "contextRef": "C_0001439725_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "bdsx-10k_20201231.htm",
      "contextRef": "C_0001439725_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100190 - Disclosure - Revenue",
     "role": "http://biodesix.com/20201231/taxonomy/role/DisclosureRevenue",
     "shortName": "Revenue",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "bdsx-10k_20201231.htm",
      "contextRef": "C_0001439725_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "bdsx-10k_20201231.htm",
      "contextRef": "C_0001439725_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100200 - Disclosure - Share Based Compensation",
     "role": "http://biodesix.com/20201231/taxonomy/role/DisclosureShareBasedCompensation",
     "shortName": "Share Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "bdsx-10k_20201231.htm",
      "contextRef": "C_0001439725_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "bdsx-10k_20201231.htm",
      "contextRef": "C_0001439725_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100210 - Disclosure - Earnings per Share",
     "role": "http://biodesix.com/20201231/taxonomy/role/DisclosureEarningsPerShare",
     "shortName": "Earnings per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "bdsx-10k_20201231.htm",
      "contextRef": "C_0001439725_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "bdsx-10k_20201231.htm",
      "contextRef": "C_0001439725_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100220 - Disclosure - Income Taxes",
     "role": "http://biodesix.com/20201231/taxonomy/role/DisclosureIncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "bdsx-10k_20201231.htm",
      "contextRef": "C_0001439725_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "bdsx-10k_20201231.htm",
      "contextRef": "C_0001439725_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100230 - Disclosure - Commitments and Contingencies",
     "role": "http://biodesix.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "bdsx-10k_20201231.htm",
      "contextRef": "C_0001439725_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "bdsx-10k_20201231.htm",
      "contextRef": "C_0001439725_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100240 - Disclosure - Defined Contribution 401(k) Plan",
     "role": "http://biodesix.com/20201231/taxonomy/role/DisclosureDefinedContribution401KPlan",
     "shortName": "Defined Contribution 401(k) Plan",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "bdsx-10k_20201231.htm",
      "contextRef": "C_0001439725_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bdsx-10k_20201231.htm",
      "contextRef": "C_0001439725_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bdsx:ReverseStockSplitPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100250 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://biodesix.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bdsx-10k_20201231.htm",
      "contextRef": "C_0001439725_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bdsx:ReverseStockSplitPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:ConcentrationRiskCreditRisk",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bdsx-10k_20201231.htm",
      "contextRef": "C_0001439725_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100260 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "role": "http://biodesix.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:ConcentrationRiskCreditRisk",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bdsx-10k_20201231.htm",
      "contextRef": "C_0001439725_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bdsx-10k_20201231.htm",
      "contextRef": "C_0001439725_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationSegmentAllocationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100270 - Disclosure - Business Combinations (Tables)",
     "role": "http://biodesix.com/20201231/taxonomy/role/DisclosureBusinessCombinationsTables",
     "shortName": "Business Combinations (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bdsx-10k_20201231.htm",
      "contextRef": "C_0001439725_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationSegmentAllocationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bdsx-10k_20201231.htm",
      "contextRef": "C_0001439725_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100280 - Disclosure - Fair Value (Tables)",
     "role": "http://biodesix.com/20201231/taxonomy/role/DisclosureFairValueTables",
     "shortName": "Fair Value (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bdsx-10k_20201231.htm",
      "contextRef": "C_0001439725_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-10k_20201231.htm",
      "contextRef": "C_0001439725_20201231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:TemporaryEquityParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "U_iso4217USD_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100020 - Statement - Balance Sheets (Parenthetical)",
     "role": "http://biodesix.com/20201231/taxonomy/role/StatementBalanceSheetsParenthetical",
     "shortName": "Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-10k_20201231.htm",
      "contextRef": "C_0001439725_20201231",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:TemporaryEquitySharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bdsx-10k_20201231.htm",
      "contextRef": "C_0001439725_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100290 - Disclosure - Property and Equipment (Tables)",
     "role": "http://biodesix.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentTables",
     "shortName": "Property and Equipment (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bdsx-10k_20201231.htm",
      "contextRef": "C_0001439725_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bdsx-10k_20201231.htm",
      "contextRef": "C_0001439725_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100300 - Disclosure - Goodwill and Intangible Assets (Tables)",
     "role": "http://biodesix.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsTables",
     "shortName": "Goodwill and Intangible Assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bdsx-10k_20201231.htm",
      "contextRef": "C_0001439725_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bdsx-10k_20201231.htm",
      "contextRef": "C_0001439725_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100310 - Disclosure - Accrued Liabilities (Tables)",
     "role": "http://biodesix.com/20201231/taxonomy/role/DisclosureAccruedLiabilitiesTables",
     "shortName": "Accrued Liabilities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bdsx-10k_20201231.htm",
      "contextRef": "C_0001439725_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bdsx-10k_20201231.htm",
      "contextRef": "C_0001439725_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100320 - Disclosure - Debt (Tables)",
     "role": "http://biodesix.com/20201231/taxonomy/role/DisclosureDebtTables",
     "shortName": "Debt (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bdsx-10k_20201231.htm",
      "contextRef": "C_0001439725_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "bdsx:WarrantsForConvertiblePreferredStockTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bdsx-10k_20201231.htm",
      "contextRef": "C_0001439725_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100330 - Disclosure - Warrants to Purchase Convertible Preferred Stock (Tables)",
     "role": "http://biodesix.com/20201231/taxonomy/role/DisclosureWarrantsToPurchaseConvertiblePreferredStockTables",
     "shortName": "Warrants to Purchase Convertible Preferred Stock (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "bdsx:WarrantsForConvertiblePreferredStockTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bdsx-10k_20201231.htm",
      "contextRef": "C_0001439725_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bdsx-10k_20201231.htm",
      "contextRef": "C_0001439725_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100340 - Disclosure - Revenue (Tables)",
     "role": "http://biodesix.com/20201231/taxonomy/role/DisclosureRevenueTables",
     "shortName": "Revenue (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bdsx-10k_20201231.htm",
      "contextRef": "C_0001439725_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bdsx-10k_20201231.htm",
      "contextRef": "C_0001439725_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100350 - Disclosure - Share Based Compensation (Tables)",
     "role": "http://biodesix.com/20201231/taxonomy/role/DisclosureShareBasedCompensationTables",
     "shortName": "Share Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bdsx-10k_20201231.htm",
      "contextRef": "C_0001439725_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bdsx-10k_20201231.htm",
      "contextRef": "C_0001439725_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100360 - Disclosure - Earnings per Share (Tables)",
     "role": "http://biodesix.com/20201231/taxonomy/role/DisclosureEarningsPerShareTables",
     "shortName": "Earnings per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bdsx-10k_20201231.htm",
      "contextRef": "C_0001439725_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bdsx-10k_20201231.htm",
      "contextRef": "C_0001439725_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100370 - Disclosure - Income Taxes (Tables)",
     "role": "http://biodesix.com/20201231/taxonomy/role/DisclosureIncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bdsx-10k_20201231.htm",
      "contextRef": "C_0001439725_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bdsx-10k_20201231.htm",
      "contextRef": "C_0001439725_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100380 - Disclosure - Commitments and Contingencies (Tables)",
     "role": "http://biodesix.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables",
     "shortName": "Commitments and Contingencies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bdsx-10k_20201231.htm",
      "contextRef": "C_0001439725_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-10k_20201231.htm",
      "contextRef": "C_0001439725_20200101_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100030 - Statement - Statements of Operations",
     "role": "http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfOperations",
     "shortName": "Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-10k_20201231.htm",
      "contextRef": "C_0001439725_20200101_20201231",
      "decimals": "-3",
      "lang": null,
      "name": "bdsx:DirectCostsAndExpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bdsx-10k_20201231.htm",
      "contextRef": "C_0001439725_20200101_20201231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "bdsx:NumberOfCancerTest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_bdsxTest",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100390 - Disclosure - Organization and Description of Business - Additional Information (Details)",
     "role": "http://biodesix.com/20201231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails",
     "shortName": "Organization and Description of Business - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bdsx-10k_20201231.htm",
      "contextRef": "C_0001439725_20200101_20201231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "bdsx:NumberOfCancerTest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_bdsxTest",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-10k_20201231.htm",
      "contextRef": "C_0001439725_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ContractWithCustomerLiabilityCurrent",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100400 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)",
     "role": "http://biodesix.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
     "shortName": "Summary of Significant Accounting Policies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:AllowanceForDoubtfulAccountsReceivable",
       "span",
       "p",
       "us-gaap:ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bdsx-10k_20201231.htm",
      "contextRef": "C_0001439725_20201231",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
       "us-gaap:ConcentrationRiskCreditRisk",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bdsx-10k_20201231.htm",
      "contextRef": "C_0001439725_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20200101_20201231",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100410 - Disclosure - Summary of Significant Accounting Policies - Summary of Revenue and Accounts Receivable by Third-party Payors and Other Customers (Details)",
     "role": "http://biodesix.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfRevenueAndAccountsReceivableByThirdPartyPayorsAndOtherCustomersDetails",
     "shortName": "Summary of Significant Accounting Policies - Summary of Revenue and Accounts Receivable by Third-party Payors and Other Customers (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
       "us-gaap:ConcentrationRiskCreditRisk",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bdsx-10k_20201231.htm",
      "contextRef": "C_0001439725_srtMajorCustomersAxis_bdsxTheBigTenConferenceMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20200101_20201231",
      "decimals": "2",
      "lang": null,
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-10k_20201231.htm",
      "contextRef": "C_0001439725_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100420 - Disclosure - Business Combinations - Additional Information (Details)",
     "role": "http://biodesix.com/20201231/taxonomy/role/DisclosureBusinessCombinationsAdditionalInformationDetails",
     "shortName": "Business Combinations - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bdsx-10k_20201231.htm",
      "contextRef": "C_0001439725_us-gaapBusinessAcquisitionAxis_bdsxOncimmuneLimitedMember_20200101_20201231",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:BusinessAcquisitionDescriptionOfAcquiredEntity",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-10k_20201231.htm",
      "contextRef": "C_0001439725_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100430 - Disclosure - Business Combinations - Summary of Aggregate Consideration Paid by Company and Allocation of Purchase Price to Assets Acquired and Liabilities Assumed (Details)",
     "role": "http://biodesix.com/20201231/taxonomy/role/DisclosureBusinessCombinationsSummaryOfAggregateConsiderationPaidByCompanyAndAllocationOfPurchasePriceToAssetsAcquiredAndLiabilitiesAssumedDetails",
     "shortName": "Business Combinations - Summary of Aggregate Consideration Paid by Company and Allocation of Purchase Price to Assets Acquired and Liabilities Assumed (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:BusinessCombinationSegmentAllocationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bdsx-10k_20201231.htm",
      "contextRef": "C_0001439725_us-gaapBusinessAcquisitionAxis_bdsxOncimmuneLimitedMember_20191031",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bdsx-10k_20201231.htm",
      "contextRef": "C_0001439725_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementBasisAxis_us-gaapCarryingReportedAmountFairValueDisclosureMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LongTermDebtFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100440 - Disclosure - Fair Value - Summary of Fair Value of Outstanding Borrowings (Details)",
     "role": "http://biodesix.com/20201231/taxonomy/role/DisclosureFairValueSummaryOfFairValueOfOutstandingBorrowingsDetails",
     "shortName": "Fair Value - Summary of Fair Value of Outstanding Borrowings (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bdsx-10k_20201231.htm",
      "contextRef": "C_0001439725_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementBasisAxis_us-gaapCarryingReportedAmountFairValueDisclosureMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LongTermDebtFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bdsx-10k_20201231.htm",
      "contextRef": "C_0001439725_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByLiabilityClassAxis_bdsxContingentConsiderationMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LiabilitiesFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100450 - Disclosure - Fair Value - Schedule of Reported Fair Values of Liabilities (Details)",
     "role": "http://biodesix.com/20201231/taxonomy/role/DisclosureFairValueScheduleOfReportedFairValuesOfLiabilitiesDetails",
     "shortName": "Fair Value - Schedule of Reported Fair Values of Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bdsx-10k_20201231.htm",
      "contextRef": "C_0001439725_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByLiabilityClassAxis_bdsxContingentConsiderationMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LiabilitiesFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bdsx-10k_20201231.htm",
      "contextRef": "C_0001439725_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByLiabilityClassAxis_bdsxContingentConsiderationMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100460 - Disclosure - Fair Value - Schedule of Changes in Financial Liabilities (Details)",
     "role": "http://biodesix.com/20201231/taxonomy/role/DisclosureFairValueScheduleOfChangesInFinancialLiabilitiesDetails",
     "shortName": "Fair Value - Schedule of Changes in Financial Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bdsx-10k_20201231.htm",
      "contextRef": "C_0001439725_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByLiabilityClassAxis_bdsxContingentConsiderationMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-10k_20201231.htm",
      "contextRef": "C_0001439725_20200101_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100470 - Disclosure - Fair Value - Additional Information (Details)",
     "role": "http://biodesix.com/20201231/taxonomy/role/DisclosureFairValueAdditionalInformationDetails",
     "shortName": "Fair Value - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bdsx-10k_20201231.htm",
      "contextRef": "C_0001439725_20201231",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:WarrantsAndRightsOutstandingMaturityDate",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bdsx-10k_20201231.htm",
      "contextRef": "C_0001439725_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100480 - Disclosure - Property and Equipment - Schedule of Property and Equipment (Details)",
     "role": "http://biodesix.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails",
     "shortName": "Property and Equipment - Schedule of Property and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bdsx-10k_20201231.htm",
      "contextRef": "C_0001439725_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-10k_20201231.htm",
      "contextRef": "C_0001439725_20181231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100040 - Statement - Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit)",
     "role": "http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit",
     "shortName": "Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-10k_20201231.htm",
      "contextRef": "C_0001439725_20181231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "bdsx:ScheduleOfDepreciationAndAmortizationExpenseRelatedToPropertyAndEquipmentTableTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bdsx-10k_20201231.htm",
      "contextRef": "C_0001439725_us-gaapFairValueByAssetClassAxis_us-gaapPropertyPlantAndEquipmentMember_20200101_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100490 - Disclosure - Property and Equipment - Schedule of Depreciation Expense Related to Property and Equipment (Details)",
     "role": "http://biodesix.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfDepreciationExpenseRelatedToPropertyAndEquipmentDetails",
     "shortName": "Property and Equipment - Schedule of Depreciation Expense Related to Property and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "bdsx:ScheduleOfDepreciationAndAmortizationExpenseRelatedToPropertyAndEquipmentTableTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bdsx-10k_20201231.htm",
      "contextRef": "C_0001439725_us-gaapFairValueByAssetClassAxis_us-gaapPropertyPlantAndEquipmentMember_20200101_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bdsx-10k_20201231.htm",
      "contextRef": "C_0001439725_20181231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100500 - Disclosure - Goodwill and Intangible Assets - Schedule of Changes in Goodwill (Details)",
     "role": "http://biodesix.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsScheduleOfChangesInGoodwillDetails",
     "shortName": "Goodwill and Intangible Assets - Schedule of Changes in Goodwill (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bdsx-10k_20201231.htm",
      "contextRef": "C_0001439725_20190101_20191231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:GoodwillAcquiredDuringPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bdsx-10k_20201231.htm",
      "contextRef": "C_0001439725_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsNet",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100510 - Disclosure - Goodwill and Intangible Assets - Schedule of Intangible Assets (Details)",
     "role": "http://biodesix.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsScheduleOfIntangibleAssetsDetails",
     "shortName": "Goodwill and Intangible Assets - Schedule of Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bdsx-10k_20201231.htm",
      "contextRef": "C_0001439725_20201231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:IntangibleAssetsGrossExcludingGoodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bdsx-10k_20201231.htm",
      "contextRef": "C_0001439725_20200101_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100520 - Disclosure - Goodwill and Intangible Assets - Schedule of Amortization Expense Related to Definite-Lived Intangible Assets (Details)",
     "role": "http://biodesix.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsScheduleOfAmortizationExpenseRelatedToDefiniteLivedIntangibleAssetsDetails",
     "shortName": "Goodwill and Intangible Assets - Schedule of Amortization Expense Related to Definite-Lived Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bdsx-10k_20201231.htm",
      "contextRef": "C_0001439725_20200101_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bdsx-10k_20201231.htm",
      "contextRef": "C_0001439725_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100530 - Disclosure - Goodwill and Intangible Assets - Schedule of Future Estimated Amortization Expense of Intangible Assets (Details)",
     "role": "http://biodesix.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsScheduleOfFutureEstimatedAmortizationExpenseOfIntangibleAssetsDetails",
     "shortName": "Goodwill and Intangible Assets - Schedule of Future Estimated Amortization Expense of Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bdsx-10k_20201231.htm",
      "contextRef": "C_0001439725_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bdsx-10k_20201231.htm",
      "contextRef": "C_0001439725_20200101_20201231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:GoodwillAndIntangibleAssetImpairment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100540 - Disclosure - Goodwill and Intangible Assets - Additional Information (Details)",
     "role": "http://biodesix.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails",
     "shortName": "Goodwill and Intangible Assets - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bdsx-10k_20201231.htm",
      "contextRef": "C_0001439725_20200101_20201231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:GoodwillAndIntangibleAssetImpairment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bdsx-10k_20201231.htm",
      "contextRef": "C_0001439725_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100550 - Disclosure - Accrued Liabilities - Schedule of Accrued Liabilities (Details)",
     "role": "http://biodesix.com/20201231/taxonomy/role/DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails",
     "shortName": "Accrued Liabilities - Schedule of Accrued Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bdsx-10k_20201231.htm",
      "contextRef": "C_0001439725_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bdsx-10k_20201231.htm",
      "contextRef": "C_0001439725_20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ConvertibleNotesPayableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100560 - Disclosure - Debt - Summary of Long-term Notes Payable (Details)",
     "role": "http://biodesix.com/20201231/taxonomy/role/DisclosureDebtSummaryOfLongTermNotesPayableDetails",
     "shortName": "Debt - Summary of Long-term Notes Payable (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bdsx-10k_20201231.htm",
      "contextRef": "C_0001439725_20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ConvertibleNotesPayableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bdsx-10k_20201231.htm",
      "contextRef": "C_0001439725_20201231",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:WarrantsNotSettleableInCashFairValueDisclosure",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100570 - Disclosure - Debt - Additional Information (Details)",
     "role": "http://biodesix.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetails",
     "shortName": "Debt - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bdsx-10k_20201231.htm",
      "contextRef": "C_0001439725_us-gaapShortTermDebtTypeAxis_bdsxMarchTwoThousandAndTwentyConvertibleNotesMember_20200331",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bdsx-10k_20201231.htm",
      "contextRef": "C_0001439725_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100580 - Disclosure - Debt - Scheduled Principal Repayments (Maturities) of Long-term Obligations (Details)",
     "role": "http://biodesix.com/20201231/taxonomy/role/DisclosureDebtScheduledPrincipalRepaymentsMaturitiesOfLongTermObligationsDetails",
     "shortName": "Debt - Scheduled Principal Repayments (Maturities) of Long-term Obligations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bdsx-10k_20201231.htm",
      "contextRef": "C_0001439725_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-10k_20201231.htm",
      "contextRef": "C_0001439725_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CapitalUnitsDeductionsFromTotalCostToInvestors",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100050 - Statement - Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)",
     "role": "http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical",
     "shortName": "Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-10k_20201231.htm",
      "contextRef": "C_0001439725_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CapitalUnitsDeductionsFromTotalCostToInvestors",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-10k_20201231.htm",
      "contextRef": "C_0001439725_20191231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:TemporaryEquitySharesIssued",
      "reportCount": 1,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100590 - Disclosure - Convertible Preferred Stock - Additional Information (Details)",
     "role": "http://biodesix.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails",
     "shortName": "Convertible Preferred Stock - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:PreferredStockTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bdsx-10k_20201231.htm",
      "contextRef": "C_0001439725_20201027_20201027",
      "decimals": "INF",
      "lang": null,
      "name": "bdsx:NumberOfPreferredStockConvertedIntoCommonStock",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "bdsx:WarrantsForConvertiblePreferredStockTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bdsx-10k_20201231.htm",
      "contextRef": "C_0001439725_us-gaapClassOfWarrantOrRightAxis_bdsxSeriesEConvertiblePreferredStockWarrantsMember_20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100600 - Disclosure - Warrants to Purchase Convertible Preferred Stock - Summary of Activity for Convertible Preferred Stock Warrants (Details)",
     "role": "http://biodesix.com/20201231/taxonomy/role/DisclosureWarrantsToPurchaseConvertiblePreferredStockSummaryOfActivityForConvertiblePreferredStockWarrantsDetails",
     "shortName": "Warrants to Purchase Convertible Preferred Stock - Summary of Activity for Convertible Preferred Stock Warrants (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "bdsx:WarrantsForConvertiblePreferredStockTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bdsx-10k_20201231.htm",
      "contextRef": "C_0001439725_us-gaapClassOfWarrantOrRightAxis_bdsxSeriesEConvertiblePreferredStockWarrantsMember_20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "bdsx:WarrantsForConvertiblePreferredStockTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bdsx-10k_20201231.htm",
      "contextRef": "C_0001439725_20201231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "reportCount": 1,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100610 - Disclosure - Warrants to Purchase Convertible Preferred Stock - Additional Information (Details)",
     "role": "http://biodesix.com/20201231/taxonomy/role/DisclosureWarrantsToPurchaseConvertiblePreferredStockAdditionalInformationDetails",
     "shortName": "Warrants to Purchase Convertible Preferred Stock - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-10k_20201231.htm",
      "contextRef": "C_0001439725_20201231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100620 - Disclosure - Equity - Additional Information (Details)",
     "role": "http://biodesix.com/20201231/taxonomy/role/DisclosureEquityAdditionalInformationDetails",
     "shortName": "Equity - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bdsx-10k_20201231.htm",
      "contextRef": "C_0001439725_20200101_20201231",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:CommonStockVotingRights",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-10k_20201231.htm",
      "contextRef": "C_0001439725_20200101_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100630 - Disclosure - Revenue - Summary of Revenue (Details)",
     "role": "http://biodesix.com/20201231/taxonomy/role/DisclosureRevenueSummaryOfRevenueDetails",
     "shortName": "Revenue - Summary of Revenue (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bdsx-10k_20201231.htm",
      "contextRef": "C_0001439725_srtProductOrServiceAxis_bdsxDiagnosticTestsMember_20200101_20201231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-10k_20201231.htm",
      "contextRef": "C_0001439725_20200101_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100640 - Disclosure - Revenue - Additional Information (Details)",
     "role": "http://biodesix.com/20201231/taxonomy/role/DisclosureRevenueAdditionalInformationDetails",
     "shortName": "Revenue - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bdsx-10k_20201231.htm",
      "contextRef": "C_0001439725_20200101_20201231",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:ContractWithCustomerLiabilityRevenueRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bdsx-10k_20201231.htm",
      "contextRef": "C_0001439725_20200101_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100650 - Disclosure - Share Based Compensation - Additional Information (Details)",
     "role": "http://biodesix.com/20201231/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails",
     "shortName": "Share Based Compensation - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bdsx-10k_20201231.htm",
      "contextRef": "C_0001439725_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20201231",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bdsx-10k_20201231.htm",
      "contextRef": "C_0001439725_20200101_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100660 - Disclosure - Share Based Compensation - Summary of Pre-tax Share-based Compensation Expense (Details)",
     "role": "http://biodesix.com/20201231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfPreTaxShareBasedCompensationExpenseDetails",
     "shortName": "Share Based Compensation - Summary of Pre-tax Share-based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bdsx-10k_20201231.htm",
      "contextRef": "C_0001439725_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20200101_20201231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bdsx-10k_20201231.htm",
      "contextRef": "C_0001439725_20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100670 - Disclosure - Share Based Compensation - Summary of Stock Option Activity (Details)",
     "role": "http://biodesix.com/20201231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetails",
     "shortName": "Share Based Compensation - Summary of Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bdsx-10k_20201231.htm",
      "contextRef": "C_0001439725_20200101_20201231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bdsx-10k_20201231.htm",
      "contextRef": "C_0001439725_20200101_20201231",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100680 - Disclosure - Share Based Compensation - Summary of Weighted Average Assumptions (Details)",
     "role": "http://biodesix.com/20201231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfWeightedAverageAssumptionsDetails",
     "shortName": "Share Based Compensation - Summary of Weighted Average Assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bdsx-10k_20201231.htm",
      "contextRef": "C_0001439725_20200101_20201231",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-10k_20201231.htm",
      "contextRef": "C_0001439725_20200101_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100060 - Statement - Statements of Cash Flows",
     "role": "http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfCashFlows",
     "shortName": "Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-10k_20201231.htm",
      "contextRef": "C_0001439725_20200101_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-10k_20201231.htm",
      "contextRef": "C_0001439725_20200101_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100690 - Disclosure - Earnings per Share - Schedule of Computation of Basic and Diluted Net Loss per Share Attributable to Common Stockholders (Details)",
     "role": "http://biodesix.com/20201231/taxonomy/role/DisclosureEarningsPerShareScheduleOfComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails",
     "shortName": "Earnings per Share - Schedule of Computation of Basic and Diluted Net Loss per Share Attributable to Common Stockholders (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bdsx-10k_20201231.htm",
      "contextRef": "C_0001439725_20200101_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100700 - Disclosure - Earnings per Share - Schedule of Common Stock Equivalents Excluded from Diluted Net Loss Attributable to Common Stockholders (Details)",
     "role": "http://biodesix.com/20201231/taxonomy/role/DisclosureEarningsPerShareScheduleOfCommonStockEquivalentsExcludedFromDilutedNetLossAttributableToCommonStockholdersDetails",
     "shortName": "Earnings per Share - Schedule of Common Stock Equivalents Excluded from Diluted Net Loss Attributable to Common Stockholders (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bdsx-10k_20201231.htm",
      "contextRef": "C_0001439725_20200101_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bdsx-10k_20201231.htm",
      "contextRef": "C_0001439725_20200101_20201231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100710 - Disclosure - Income Taxes - Additional Information (Details)",
     "role": "http://biodesix.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails",
     "shortName": "Income Taxes - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bdsx-10k_20201231.htm",
      "contextRef": "C_0001439725_20200101_20201231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bdsx-10k_20201231.htm",
      "contextRef": "C_0001439725_20200101_20201231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100720 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)",
     "role": "http://biodesix.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails",
     "shortName": "Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bdsx-10k_20201231.htm",
      "contextRef": "C_0001439725_20200101_20201231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     }
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bdsx-10k_20201231.htm",
      "contextRef": "C_0001439725_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100730 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)",
     "role": "http://biodesix.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails",
     "shortName": "Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bdsx-10k_20201231.htm",
      "contextRef": "C_0001439725_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R75": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bdsx-10k_20201231.htm",
      "contextRef": "C_0001439725_20200101_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100740 - Disclosure - Income Taxes - Reconciliation of Unrecognized Tax Benefits (Details)",
     "role": "http://biodesix.com/20201231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfUnrecognizedTaxBenefitsDetails",
     "shortName": "Income Taxes - Reconciliation of Unrecognized Tax Benefits (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bdsx-10k_20201231.htm",
      "contextRef": "C_0001439725_20200101_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R76": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bdsx-10k_20201231.htm",
      "contextRef": "C_0001439725_20200101_20201231",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasesRentExpenseNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100750 - Disclosure - Commitments and Contingencies - Additional Information (Details)",
     "role": "http://biodesix.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
     "shortName": "Commitments and Contingencies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bdsx-10k_20201231.htm",
      "contextRef": "C_0001439725_20200101_20201231",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasesRentExpenseNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R77": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bdsx-10k_20201231.htm",
      "contextRef": "C_0001439725_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100760 - Disclosure - Commitments and Contingencies - Summary of Future Minimum Lease Payments for Operating Lease Obligations (Details)",
     "role": "http://biodesix.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumLeasePaymentsForOperatingLeaseObligationsDetails",
     "shortName": "Commitments and Contingencies - Summary of Future Minimum Lease Payments for Operating Lease Obligations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bdsx-10k_20201231.htm",
      "contextRef": "C_0001439725_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R78": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:DefinedContributionPlanTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bdsx-10k_20201231.htm",
      "contextRef": "C_0001439725_20200101_20201231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100770 - Disclosure - Defined Contribution 401(k) Plan - Additional Information (Detail)",
     "role": "http://biodesix.com/20201231/taxonomy/role/DisclosureDefinedContribution401KPlanAdditionalInformationDetail",
     "shortName": "Defined Contribution 401(k) Plan - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:DefinedContributionPlanTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bdsx-10k_20201231.htm",
      "contextRef": "C_0001439725_20200101_20201231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "bdsx-10k_20201231.htm",
      "contextRef": "C_0001439725_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100070 - Disclosure - Organization and Description of Business",
     "role": "http://biodesix.com/20201231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusiness",
     "shortName": "Organization and Description of Business",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "bdsx-10k_20201231.htm",
      "contextRef": "C_0001439725_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "bdsx-10k_20201231.htm",
      "contextRef": "C_0001439725_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100080 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://biodesix.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "bdsx-10k_20201231.htm",
      "contextRef": "C_0001439725_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 98,
   "tag": {
    "bdsx_AVEOOncologyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aveo oncology.",
        "label": "A V E O Oncology [Member]",
        "terseLabel": "AVEO Oncology"
       }
      }
     },
     "localname": "AVEOOncologyMember",
     "nsuri": "http://biodesix.com/20201231",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://biodesix.com/20201231/taxonomy/role/DisclosureFairValueAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_AccruedClinicalTrialExpenseCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://biodesix.com/20201231/taxonomy/role/DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails": {
       "order": 10020.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued clinical trial expense current.",
        "label": "Accrued Clinical Trial Expense Current",
        "terseLabel": "Accrued clinical trial expense"
       }
      }
     },
     "localname": "AccruedClinicalTrialExpenseCurrent",
     "nsuri": "http://biodesix.com/20201231",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bdsx_AccruedInterestOnNotesPayableAndConvertibleNotesPayable": {
     "auth_ref": [],
     "calculation": {
      "http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfCashFlows": {
       "order": 10210.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued interest on notes payable and convertible notes payable.",
        "label": "Accrued Interest On Notes Payable And Convertible Notes Payable",
        "terseLabel": "Accrued interest on notes payable and convertible notes payable"
       }
      }
     },
     "localname": "AccruedInterestOnNotesPayableAndConvertibleNotesPayable",
     "nsuri": "http://biodesix.com/20201231",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bdsx_AdvanceDeposits": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Advance deposits.",
        "label": "Advance Deposits",
        "terseLabel": "Advance deposits"
       }
      }
     },
     "localname": "AdvanceDeposits",
     "nsuri": "http://biodesix.com/20201231",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureRevenueAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bdsx_ApprovalOfAmendedAndRestatedCertificateOfIncorporationPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for approval of amended and restated certificate of incorporation.",
        "label": "Approval Of Amended And Restated Certificate Of Incorporation Policy [Text Block]",
        "terseLabel": "Approval of Amended and Restated Certificate of Incorporation"
       }
      }
     },
     "localname": "ApprovalOfAmendedAndRestatedCertificateOfIncorporationPolicyTextBlock",
     "nsuri": "http://biodesix.com/20201231",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bdsx_AugustTwoThousandAndNineteenConvertibleNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "August two thousand and nineteen convertible notes.",
        "label": "August Two Thousand And Nineteen Convertible Notes [Member]",
        "terseLabel": "August 2019 Notes"
       }
      }
     },
     "localname": "AugustTwoThousandAndNineteenConvertibleNotesMember",
     "nsuri": "http://biodesix.com/20201231",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_BDX004Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bdx004.",
        "label": "B D X004 [Member]",
        "terseLabel": "BDX004"
       }
      }
     },
     "localname": "BDX004Member",
     "nsuri": "http://biodesix.com/20201231",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_BioRadLicenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bio-rad license.",
        "label": "Bio Rad License [Member]",
        "terseLabel": "Bio-Rad License"
       }
      }
     },
     "localname": "BioRadLicenseMember",
     "nsuri": "http://biodesix.com/20201231",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_BonusToOptionsProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bonus-to-options program.",
        "label": "Bonus To Options Program [Member]",
        "terseLabel": "Bonus-To-Options Program"
       }
      }
     },
     "localname": "BonusToOptionsProgramMember",
     "nsuri": "http://biodesix.com/20201231",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business acquisition contingent consideration gross margin target period.",
        "label": "Business Acquisition Contingent Consideration Gross Margin Target Period",
        "terseLabel": "Business acquisition contingent consideration gross margin target period"
       }
      }
     },
     "localname": "BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod",
     "nsuri": "http://biodesix.com/20201231",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureBusinessCombinationsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "bdsx_BusinessAcquisitionContingentConsiderationNumberOfInstallments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business acquisition contingent consideration number of installments.",
        "label": "Business Acquisition Contingent Consideration Number Of Installments",
        "terseLabel": "Contingent consideration number of installments"
       }
      }
     },
     "localname": "BusinessAcquisitionContingentConsiderationNumberOfInstallments",
     "nsuri": "http://biodesix.com/20201231",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureBusinessCombinationsAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "bdsx_BusinessCombinationContingentConsiderationArrangementsCommonSharesRedemptionAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business combination contingent consideration arrangements common shares redemption amount.",
        "label": "Business Combination Contingent Consideration Arrangements Common Shares Redemption Amount",
        "terseLabel": "Contingent consideration arrangements, common shares, redemption amount"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsCommonSharesRedemptionAmount",
     "nsuri": "http://biodesix.com/20201231",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureBusinessCombinationsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bdsx_BusinessCombinationContingentConsiderationShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business combination contingent consideration shares.",
        "label": "Business Combination Contingent Consideration Shares",
        "terseLabel": "Contingent consideration shares"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationShares",
     "nsuri": "http://biodesix.com/20201231",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureBusinessCombinationsAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "bdsx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPurchaseOption": {
     "auth_ref": [],
     "calculation": {
      "http://biodesix.com/20201231/taxonomy/role/DisclosureBusinessCombinationsSummaryOfAggregateConsiderationPaidByCompanyAndAllocationOfPurchasePriceToAssetsAcquiredAndLiabilitiesAssumedDetails": {
       "order": 10040.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business combination recognized identifiable assets acquired and liabilities assumed purchase option.",
        "label": "Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Purchase Option",
        "terseLabel": "Purchase option"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPurchaseOption",
     "nsuri": "http://biodesix.com/20201231",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureBusinessCombinationsSummaryOfAggregateConsiderationPaidByCompanyAndAllocationOfPurchasePriceToAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bdsx_CARESActMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CARES act.",
        "label": "C A R E S Act [Member]",
        "terseLabel": "CARES Act"
       }
      }
     },
     "localname": "CARESActMember",
     "nsuri": "http://biodesix.com/20201231",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetails",
      "http://biodesix.com/20201231/taxonomy/role/DisclosureDebtSummaryOfLongTermNotesPayableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_COVID19DiagnosticTestRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "COVID-19 diagnostic test revenue.",
        "label": "C O V I D19 Diagnostic Test Revenue [Member]",
        "terseLabel": "COVID-19 Test Revenue"
       }
      }
     },
     "localname": "COVID19DiagnosticTestRevenueMember",
     "nsuri": "http://biodesix.com/20201231",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureRevenueAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_CenturaHealthcareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Centura Healthcare.",
        "label": "Centura Healthcare [Member]",
        "terseLabel": "Centura Healthcare"
       }
      }
     },
     "localname": "CenturaHealthcareMember",
     "nsuri": "http://biodesix.com/20201231",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfRevenueAndAccountsReceivableByThirdPartyPayorsAndOtherCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_ChangeInFairValueOfContingentConsiderationExcludingAccretionExpense": {
     "auth_ref": [],
     "calculation": {
      "http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfOperations": {
       "order": 10130.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in fair value of contingent consideration excluding accretion expense.",
        "label": "Change In Fair Value Of Contingent Consideration Excluding Accretion Expense",
        "terseLabel": "Change in fair value of contingent consideration"
       }
      }
     },
     "localname": "ChangeInFairValueOfContingentConsiderationExcludingAccretionExpense",
     "nsuri": "http://biodesix.com/20201231",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bdsx_ChangeInFairValueOfPutOptionLiability": {
     "auth_ref": [],
     "calculation": {
      "http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfCashFlows": {
       "order": 10200.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfOperations": {
       "order": 10060.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in fair value of put option liability.",
        "label": "Change In Fair Value Of Put Option Liability",
        "negatedLabel": "Change in fair value of put option liability",
        "verboseLabel": "Change in fair value of put option"
       }
      }
     },
     "localname": "ChangeInFairValueOfPutOptionLiability",
     "nsuri": "http://biodesix.com/20201231",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfCashFlows",
      "http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bdsx_ContingentConsiderationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent consideration.",
        "label": "Contingent Consideration [Member]",
        "terseLabel": "Contingent Consideration"
       }
      }
     },
     "localname": "ContingentConsiderationMember",
     "nsuri": "http://biodesix.com/20201231",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureFairValueScheduleOfChangesInFinancialLiabilitiesDetails",
      "http://biodesix.com/20201231/taxonomy/role/DisclosureFairValueScheduleOfReportedFairValuesOfLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_ContingentConsiderationPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for contingent consideration.",
        "label": "Contingent Consideration Policy [Text Block]",
        "terseLabel": "Contingent Consideration"
       }
      }
     },
     "localname": "ContingentConsiderationPolicyTextBlock",
     "nsuri": "http://biodesix.com/20201231",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bdsx_ContingentValueRights": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent value rights.",
        "label": "Contingent Value Rights",
        "terseLabel": "Contingent value rights"
       }
      }
     },
     "localname": "ContingentValueRights",
     "nsuri": "http://biodesix.com/20201231",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureFairValueAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bdsx_ContingentValueRightsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent value rights.",
        "label": "Contingent Value Rights [Member]",
        "terseLabel": "Contingent Value Rights"
       }
      }
     },
     "localname": "ContingentValueRightsMember",
     "nsuri": "http://biodesix.com/20201231",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureFairValueScheduleOfChangesInFinancialLiabilitiesDetails",
      "http://biodesix.com/20201231/taxonomy/role/DisclosureFairValueScheduleOfReportedFairValuesOfLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_ContingentValueRightsPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent value rights percentage.",
        "label": "Contingent Value Rights Percentage",
        "terseLabel": "Contingent value rights percentage"
       }
      }
     },
     "localname": "ContingentValueRightsPercentage",
     "nsuri": "http://biodesix.com/20201231",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureFairValueAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bdsx_ContingentValueRightsShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent value rights shares.",
        "label": "Contingent Value Rights Shares",
        "terseLabel": "Contingent value rights shares"
       }
      }
     },
     "localname": "ContingentValueRightsShares",
     "nsuri": "http://biodesix.com/20201231",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureFairValueAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "bdsx_ConversionOfPreferredStockIntoCommonStock": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Conversion of preferred stock into common stock.",
        "label": "Conversion Of Preferred Stock Into Common Stock",
        "terseLabel": "Conversion of preferred stock into common stock"
       }
      }
     },
     "localname": "ConversionOfPreferredStockIntoCommonStock",
     "nsuri": "http://biodesix.com/20201231",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bdsx_ConvertiblePreferredStockAndConvertibleNotesPayableConvertedToCommonStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible preferred stock and convertible notes payable converted to common stock.",
        "label": "Convertible Preferred Stock And Convertible Notes Payable Converted To Common Stock",
        "terseLabel": "Convertible preferred stock and convertible notes payable converted into shares of common stock"
       }
      }
     },
     "localname": "ConvertiblePreferredStockAndConvertibleNotesPayableConvertedToCommonStock",
     "nsuri": "http://biodesix.com/20201231",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "bdsx_CovanceCentralLaboratoryServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Covance Central Laboratory Services.",
        "label": "Covance Central Laboratory Services [Member]",
        "terseLabel": "Covance Central Laboratory Services"
       }
      }
     },
     "localname": "CovanceCentralLaboratoryServicesMember",
     "nsuri": "http://biodesix.com/20201231",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://biodesix.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfRevenueAndAccountsReceivableByThirdPartyPayorsAndOtherCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_DebtInstrumentAdditionalInterestExpenseFeePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument additional interest expense fee percentage.",
        "label": "Debt Instrument Additional Interest Expense Fee Percentage",
        "terseLabel": "Debt instrument, additional interest expense fee"
       }
      }
     },
     "localname": "DebtInstrumentAdditionalInterestExpenseFeePercentage",
     "nsuri": "http://biodesix.com/20201231",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bdsx_DebtInstrumentBackEndFacilityFeePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument back-end facility fee percentage.",
        "label": "Debt Instrument Back End Facility Fee Percentage",
        "terseLabel": "Debt instrument, back-end facility fee"
       }
      }
     },
     "localname": "DebtInstrumentBackEndFacilityFeePercentage",
     "nsuri": "http://biodesix.com/20201231",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bdsx_DebtInstrumentInterestAddedToPrincipalValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument interest added to principal value.",
        "label": "Debt Instrument Interest Added To Principal Value",
        "terseLabel": "Interest added to principal value"
       }
      }
     },
     "localname": "DebtInstrumentInterestAddedToPrincipalValue",
     "nsuri": "http://biodesix.com/20201231",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bdsx_DebtInstrumentMaturityDateExtended": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument maturity date extended.",
        "label": "Debt Instrument Maturity Date Extended",
        "terseLabel": "Extended debt instrument date"
       }
      }
     },
     "localname": "DebtInstrumentMaturityDateExtended",
     "nsuri": "http://biodesix.com/20201231",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "bdsx_DebtInstrumentPercentageOfStatedInterestRateAddedToPrincipalValueOfNotesPayable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument, percentage of stated interest rate added to principal value of notes payable.",
        "label": "Debt Instrument Percentage Of Stated Interest Rate Added To Principal Value Of Notes Payable",
        "terseLabel": "Percentage of interest rate added to principal value of notes payable"
       }
      }
     },
     "localname": "DebtInstrumentPercentageOfStatedInterestRateAddedToPrincipalValueOfNotesPayable",
     "nsuri": "http://biodesix.com/20201231",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bdsx_DebtInstrumentPercentageOfStatedInterestRatePaidInCash": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument, percentage of stated interest rate, paid in cash.",
        "label": "Debt Instrument Percentage Of Stated Interest Rate Paid In Cash",
        "terseLabel": "Percentage of interest rate, paid in cash"
       }
      }
     },
     "localname": "DebtInstrumentPercentageOfStatedInterestRatePaidInCash",
     "nsuri": "http://biodesix.com/20201231",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bdsx_DebtInstrumentPrepaymentPenaltyPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument prepayment penalty percentage.",
        "label": "Debt Instrument Prepayment Penalty Percentage",
        "terseLabel": "Debt instrument, prepayment penalty"
       }
      }
     },
     "localname": "DebtInstrumentPrepaymentPenaltyPercentage",
     "nsuri": "http://biodesix.com/20201231",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bdsx_DecemberTwoThousandAndNineteenConvertibleNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "December two thousand and nineteen convertible notes.",
        "label": "December Two Thousand And Nineteen Convertible Notes [Member]",
        "terseLabel": "December 2019 Notes"
       }
      }
     },
     "localname": "DecemberTwoThousandAndNineteenConvertibleNotesMember",
     "nsuri": "http://biodesix.com/20201231",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_DeferredRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred revenue.",
        "label": "Deferred Revenue [Member]",
        "terseLabel": "Deferred Revenue"
       }
      }
     },
     "localname": "DeferredRevenueMember",
     "nsuri": "http://biodesix.com/20201231",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureRevenueAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_DeferredTaxAssetsResearchAndExperimentationTaxCarryforwardsSubjectToExpiration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets research and experimentation tax carryforwards subject to expiration.",
        "label": "Deferred Tax Assets Research And Experimentation Tax Carryforwards Subject To Expiration",
        "terseLabel": "Research and experimentation tax carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsResearchAndExperimentationTaxCarryforwardsSubjectToExpiration",
     "nsuri": "http://biodesix.com/20201231",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bdsx_DescriptionOfOfferingPeriodUnderPlan": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of offering period under plan.",
        "label": "Description Of Offering Period Under Plan",
        "terseLabel": "Description of offering period under plan"
       }
      }
     },
     "localname": "DescriptionOfOfferingPeriodUnderPlan",
     "nsuri": "http://biodesix.com/20201231",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bdsx_DescriptionOfVotingPowerOrValueOfStockForEmployeeParticipationInOfferingPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of voting power or value of stock for employee participation in offering period.",
        "label": "Description Of Voting Power Or Value Of Stock For Employee Participation In Offering Period",
        "terseLabel": "Description of voting power or value of stock for employee participation in offering period"
       }
      }
     },
     "localname": "DescriptionOfVotingPowerOrValueOfStockForEmployeeParticipationInOfferingPeriod",
     "nsuri": "http://biodesix.com/20201231",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bdsx_DiagnosticTestsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Diagnostic tests.",
        "label": "Diagnostic Tests [Member]",
        "terseLabel": "Diagnostic Tests"
       }
      }
     },
     "localname": "DiagnosticTestsMember",
     "nsuri": "http://biodesix.com/20201231",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureRevenueSummaryOfRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_DirectCostsAndExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfOperations": {
       "order": 10100.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Direct costs and expenses.",
        "label": "Direct Costs And Expenses",
        "terseLabel": "Direct costs and expenses"
       }
      }
     },
     "localname": "DirectCostsAndExpenses",
     "nsuri": "http://biodesix.com/20201231",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bdsx_DirectCostsAndExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Direct costs and expenses.",
        "label": "Direct Costs And Expenses [Member]",
        "terseLabel": "Direct Costs and Expenses"
       }
      }
     },
     "localname": "DirectCostsAndExpensesMember",
     "nsuri": "http://biodesix.com/20201231",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsScheduleOfAmortizationExpenseRelatedToDefiniteLivedIntangibleAssetsDetails",
      "http://biodesix.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfDepreciationExpenseRelatedToPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_DirectCostsAndExpensesPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Direct costs and expenses policy.",
        "label": "Direct Costs And Expenses Policy [Text Block]",
        "terseLabel": "Direct Costs and Expenses"
       }
      }
     },
     "localname": "DirectCostsAndExpensesPolicyTextBlock",
     "nsuri": "http://biodesix.com/20201231",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bdsx_DirectOfferingExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Direct offering expenses.",
        "label": "Direct Offering Expenses",
        "terseLabel": "Direct offering expenses"
       }
      }
     },
     "localname": "DirectOfferingExpenses",
     "nsuri": "http://biodesix.com/20201231",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bdsx_EffectiveIncomeTaxRateReconciliationPermanentItems": {
     "auth_ref": [],
     "calculation": {
      "http://biodesix.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 10040.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective income tax rate reconciliation permanent items.",
        "label": "Effective Income Tax Rate Reconciliation Permanent Items",
        "negatedLabel": "Permanent items"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationPermanentItems",
     "nsuri": "http://biodesix.com/20201231",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value Liabilities Measured On Recurring Basis [Line Items]",
        "terseLabel": "Fair Value Liabilities Measured On Recurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisLineItems",
     "nsuri": "http://biodesix.com/20201231",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureFairValueScheduleOfReportedFairValuesOfLiabilitiesDetails",
      "http://biodesix.com/20201231/taxonomy/role/DisclosureFairValueSummaryOfFairValueOfOutstandingBorrowingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about liabilities measured at fair value on recurring basis.",
        "label": "Fair Value Liabilities Measured On Recurring Basis [Table]",
        "terseLabel": "Fair Value Liabilities Measured On Recurring Basis [Table]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisTable",
     "nsuri": "http://biodesix.com/20201231",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureFairValueScheduleOfReportedFairValuesOfLiabilitiesDetails",
      "http://biodesix.com/20201231/taxonomy/role/DisclosureFairValueSummaryOfFairValueOfOutstandingBorrowingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bdsx_FairValueMeasurementWithUnobservableInputsReconciliationReclassifiedToAdditionalPaidInCapital": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, measurement with unobservable inputs reconciliation reclassified to additional paid-in capital.",
        "label": "Fair Value Measurement With Unobservable Inputs Reconciliation Reclassified To Additional Paid In Capital",
        "terseLabel": "Reclassified to additional paid-in capital"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationReclassifiedToAdditionalPaidInCapital",
     "nsuri": "http://biodesix.com/20201231",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureFairValueScheduleOfChangesInFinancialLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bdsx_FiclatuzumabMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ficlatuzumab.",
        "label": "Ficlatuzumab [Member]",
        "terseLabel": "Ficlatuzumab"
       }
      }
     },
     "localname": "FiclatuzumabMember",
     "nsuri": "http://biodesix.com/20201231",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_IncreaseDecreaseInAccumulatedDeficit": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase decrease in accumulated deficit.",
        "label": "Increase Decrease In Accumulated Deficit",
        "negatedLabel": "Reduction in accumulated deficit"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccumulatedDeficit",
     "nsuri": "http://biodesix.com/20201231",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bdsx_IncreaseToPutOptionLiability": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase to put option liability.",
        "label": "Increase To Put Option Liability",
        "terseLabel": "Increase to put option liability"
       }
      }
     },
     "localname": "IncreaseToPutOptionLiability",
     "nsuri": "http://biodesix.com/20201231",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bdsx_IndefiniteLivedIntangibleAssetsExcludingGoodwillGross": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indefinite lived intangible assets excluding goodwill gross.",
        "label": "Indefinite Lived Intangible Assets Excluding Goodwill Gross",
        "terseLabel": "Intangible assets not subject to amortization, Cost"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwillGross",
     "nsuri": "http://biodesix.com/20201231",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsScheduleOfIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bdsx_InitialPublicOfferingIPOPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for initial public offering.",
        "label": "Initial Public Offering I P O Policy [Text Block]",
        "terseLabel": "Initial Public Offering (\"IPO\")"
       }
      }
     },
     "localname": "InitialPublicOfferingIPOPolicyTextBlock",
     "nsuri": "http://biodesix.com/20201231",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bdsx_IntangibleAssetsAccumulatedAmortizationExcludingGoodwill": {
     "auth_ref": [],
     "calculation": {
      "http://biodesix.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsScheduleOfIntangibleAssetsDetails": {
       "order": 10020.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated amortization of intangible assets, excluding goodwill.",
        "label": "Intangible Assets Accumulated Amortization Excluding Goodwill",
        "negatedLabel": "Intangible assets, Accumulated Amortization"
       }
      }
     },
     "localname": "IntangibleAssetsAccumulatedAmortizationExcludingGoodwill",
     "nsuri": "http://biodesix.com/20201231",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsScheduleOfIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bdsx_IntegratedDiagnosticsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Integrated Diagnostics, Inc.",
        "label": "Integrated Diagnostics Inc [Member]",
        "terseLabel": "Integrated Diagnostics, Inc"
       }
      }
     },
     "localname": "IntegratedDiagnosticsIncMember",
     "nsuri": "http://biodesix.com/20201231",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureBusinessCombinationsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_JanssenResearchAndDevelopmentLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Janssen Research and Development, LLC.",
        "label": "Janssen Research And Development L L C [Member]",
        "terseLabel": "Janssen Research and Development, LLC"
       }
      }
     },
     "localname": "JanssenResearchAndDevelopmentLLCMember",
     "nsuri": "http://biodesix.com/20201231",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfRevenueAndAccountsReceivableByThirdPartyPayorsAndOtherCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_LicenseAgreementExpiryDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License agreement expiry date.",
        "label": "License Agreement Expiry Date",
        "terseLabel": "License expiry date"
       }
      }
     },
     "localname": "LicenseAgreementExpiryDate",
     "nsuri": "http://biodesix.com/20201231",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "gYearMonthItemType"
    },
    "bdsx_LungDiagnosticRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lung diagnostic revenue.",
        "label": "Lung Diagnostic Revenue [Member]",
        "terseLabel": "Lung Diagnostic Revenue"
       }
      }
     },
     "localname": "LungDiagnosticRevenueMember",
     "nsuri": "http://biodesix.com/20201231",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureRevenueAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_MarchTwoThousandAndTwentyConvertibleNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "March two thousand and twenty convertible notes.",
        "label": "March Two Thousand And Twenty Convertible Notes [Member]",
        "terseLabel": "March 2020 Notes"
       }
      }
     },
     "localname": "MarchTwoThousandAndTwentyConvertibleNotesMember",
     "nsuri": "http://biodesix.com/20201231",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_MedicareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medicare.",
        "label": "Medicare [Member]",
        "terseLabel": "Medicare"
       }
      }
     },
     "localname": "MedicareMember",
     "nsuri": "http://biodesix.com/20201231",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://biodesix.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfRevenueAndAccountsReceivableByThirdPartyPayorsAndOtherCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_MinimumAnnualVolumePercentageThereafter": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum annual volume percentage thereafter.",
        "label": "Minimum Annual Volume Percentage Thereafter",
        "terseLabel": "Minimum annual volume percentage thereafter"
       }
      }
     },
     "localname": "MinimumAnnualVolumePercentageThereafter",
     "nsuri": "http://biodesix.com/20201231",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bdsx_NSCLCPOCTrialMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nsclc poc trial.",
        "label": "N S C L C P O C Trial [Member]",
        "terseLabel": "NSCLC POC Trial"
       }
      }
     },
     "localname": "NSCLCPOCTrialMember",
     "nsuri": "http://biodesix.com/20201231",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_NetProceedsPercentageOfCashPaymentToCVRHolders": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net proceeds percentage of cash payment to the cvr holders.",
        "label": "Net Proceeds Percentage Of Cash Payment To C V R Holders",
        "terseLabel": "Net proceeds percentage of cash payment to the CVR holders"
       }
      }
     },
     "localname": "NetProceedsPercentageOfCashPaymentToCVRHolders",
     "nsuri": "http://biodesix.com/20201231",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureFairValueAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bdsx_NotesPayable2018NotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Notes payable 2018 notes.",
        "label": "Notes Payable2018 Notes [Member]",
        "terseLabel": "2018 Notes"
       }
      }
     },
     "localname": "NotesPayable2018NotesMember",
     "nsuri": "http://biodesix.com/20201231",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetails",
      "http://biodesix.com/20201231/taxonomy/role/DisclosureDebtSummaryOfLongTermNotesPayableDetails",
      "http://biodesix.com/20201231/taxonomy/role/DisclosureFairValueAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_NumberOfCancerTest": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of cancer test.",
        "label": "Number Of Cancer Test",
        "terseLabel": "Number of blood based lung cancer test"
       }
      }
     },
     "localname": "NumberOfCancerTest",
     "nsuri": "http://biodesix.com/20201231",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "bdsx_NumberOfCommercialBloodBasedTest": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of commercial blood based test.",
        "label": "Number Of Commercial Blood Based Test",
        "terseLabel": "Number of commercial blood-based test"
       }
      }
     },
     "localname": "NumberOfCommercialBloodBasedTest",
     "nsuri": "http://biodesix.com/20201231",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "bdsx_NumberOfEqualAnnualInstallmentsForAwardVesting": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of equal annual installments for award vesting.",
        "label": "Number Of Equal Annual Installments For Award Vesting",
        "terseLabel": "Number of equal annual installments for award vesting"
       }
      }
     },
     "localname": "NumberOfEqualAnnualInstallmentsForAwardVesting",
     "nsuri": "http://biodesix.com/20201231",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "bdsx_NumberOfPreferredStockConvertedIntoCommonStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of preferred stock converted into common stock.",
        "label": "Number Of Preferred Stock Converted Into Common Stock",
        "terseLabel": "Number of preferred stock converted into common stock"
       }
      }
     },
     "localname": "NumberOfPreferredStockConvertedIntoCommonStock",
     "nsuri": "http://biodesix.com/20201231",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "bdsx_NumberOfSARSCoV2Test": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of SARS-CoV-2 test.",
        "label": "Number Of S A R S Co V2 Test",
        "terseLabel": "Number of SARS-CoV-2 test"
       }
      }
     },
     "localname": "NumberOfSARSCoV2Test",
     "nsuri": "http://biodesix.com/20201231",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "bdsx_OncimmuneLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Oncimmune Limited.",
        "label": "Oncimmune Limited [Member]",
        "terseLabel": "Oncimmune Limited"
       }
      }
     },
     "localname": "OncimmuneLimitedMember",
     "nsuri": "http://biodesix.com/20201231",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureBusinessCombinationsAdditionalInformationDetails",
      "http://biodesix.com/20201231/taxonomy/role/DisclosureBusinessCombinationsSummaryOfAggregateConsiderationPaidByCompanyAndAllocationOfPurchasePriceToAssetsAcquiredAndLiabilitiesAssumedDetails",
      "http://biodesix.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_OptionsAndRestrictedStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Options and restricted stock units.",
        "label": "Options And Restricted Stock Units [Member]",
        "terseLabel": "Options and Restricted Stock Units"
       }
      }
     },
     "localname": "OptionsAndRestrictedStockUnitsMember",
     "nsuri": "http://biodesix.com/20201231",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_OptionsToPurchaseCommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Options to purchase common stock.",
        "label": "Options To Purchase Common Stock [Member]",
        "terseLabel": "Options to Purchase Common Stock"
       }
      }
     },
     "localname": "OptionsToPurchaseCommonStockMember",
     "nsuri": "http://biodesix.com/20201231",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureEarningsPerShareScheduleOfCommonStockEquivalentsExcludedFromDilutedNetLossAttributableToCommonStockholdersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_OrganizationAndDescriptionOfBusinessAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization and description of business.",
        "label": "Organization And Description Of Business [Abstract]"
       }
      }
     },
     "localname": "OrganizationAndDescriptionOfBusinessAbstract",
     "nsuri": "http://biodesix.com/20201231",
     "xbrltype": "stringItemType"
    },
    "bdsx_OrganizationAndDescriptionOfBusinessLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization and description of business.",
        "label": "Organization And Description Of Business [Line Items]",
        "terseLabel": "Organization And Description Of Business [Line Items]"
       }
      }
     },
     "localname": "OrganizationAndDescriptionOfBusinessLineItems",
     "nsuri": "http://biodesix.com/20201231",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bdsx_OrganizationAndDescriptionOfBusinessTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization and description of business.",
        "label": "Organization And Description Of Business [Table]",
        "terseLabel": "Organization And Description Of Business [Table]"
       }
      }
     },
     "localname": "OrganizationAndDescriptionOfBusinessTable",
     "nsuri": "http://biodesix.com/20201231",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bdsx_POCClinicalTrialsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Poc clinical trials.",
        "label": "P O C Clinical Trials [Member]",
        "terseLabel": "POC Clinical Trials"
       }
      }
     },
     "localname": "POCClinicalTrialsMember",
     "nsuri": "http://biodesix.com/20201231",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_PPPLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PPP loan.",
        "label": "P P P Loan [Member]",
        "terseLabel": "PPP Loan"
       }
      }
     },
     "localname": "PPPLoanMember",
     "nsuri": "http://biodesix.com/20201231",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetails",
      "http://biodesix.com/20201231/taxonomy/role/DisclosureDebtSummaryOfLongTermNotesPayableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_PaymentsForProceedsFromPatentCostsAndIntangibleAssetAcquisitionNet": {
     "auth_ref": [],
     "calculation": {
      "http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfCashFlows": {
       "order": 10120.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments for proceeds from patent costs and intangible asset acquisition, net.",
        "label": "Payments For Proceeds From Patent Costs And Intangible Asset Acquisition Net",
        "negatedLabel": "Patent costs and intangible asset acquisition, net"
       }
      }
     },
     "localname": "PaymentsForProceedsFromPatentCostsAndIntangibleAssetAcquisitionNet",
     "nsuri": "http://biodesix.com/20201231",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bdsx_PaymentsToAcquireOncimmune": {
     "auth_ref": [],
     "calculation": {
      "http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfCashFlows": {
       "order": 10130.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments to acquire Oncimmune.",
        "label": "Payments To Acquire Oncimmune",
        "negatedLabel": "Payments to acquire Oncimmune assets"
       }
      }
     },
     "localname": "PaymentsToAcquireOncimmune",
     "nsuri": "http://biodesix.com/20201231",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bdsx_PayrollCostsExcludesCompensationOfEmployee": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payroll costs excludes compensation of an employee.",
        "label": "Payroll Costs Excludes Compensation Of Employee",
        "terseLabel": "Payroll costs excludes compensation of an employee"
       }
      }
     },
     "localname": "PayrollCostsExcludesCompensationOfEmployee",
     "nsuri": "http://biodesix.com/20201231",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bdsx_PercentageForNonPayrollCosts": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage for non-payroll costs.",
        "label": "Percentage For Non Payroll Costs",
        "terseLabel": "Percentage for non-payroll costs"
       }
      }
     },
     "localname": "PercentageForNonPayrollCosts",
     "nsuri": "http://biodesix.com/20201231",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bdsx_PercentageOfConversionPricePerShareOfCommonStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of conversion price per share of common stock.",
        "label": "Percentage Of Conversion Price Per Share Of Common Stock",
        "terseLabel": "Percentage of conversion price per share of common stock"
       }
      }
     },
     "localname": "PercentageOfConversionPricePerShareOfCommonStock",
     "nsuri": "http://biodesix.com/20201231",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bdsx_PercentageOfConversionPricePerShareOfConvertiblePreferredStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of conversion price per share of convertible preferred stock.",
        "label": "Percentage Of Conversion Price Per Share Of Convertible Preferred Stock",
        "terseLabel": "Percentage of conversion price per share of preferred stock"
       }
      }
     },
     "localname": "PercentageOfConversionPricePerShareOfConvertiblePreferredStock",
     "nsuri": "http://biodesix.com/20201231",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bdsx_PercentageOfDevelopmentAndRegulatoryCosts": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of development and regulatory costs.",
        "label": "Percentage Of Development And Regulatory Costs",
        "terseLabel": "Responsible percentage of development and regulatory costs"
       }
      }
     },
     "localname": "PercentageOfDevelopmentAndRegulatoryCosts",
     "nsuri": "http://biodesix.com/20201231",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bdsx_PercentageOfDevelopmentAndRegulatoryCostsExercisedUsingOptOutRight": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of development and regulatory costs exercised using opt-out right.",
        "label": "Percentage Of Development And Regulatory Costs Exercised Using Opt Out Right",
        "terseLabel": "Percentage of development and regulatory costs exercised using opt-out right"
       }
      }
     },
     "localname": "PercentageOfDevelopmentAndRegulatoryCostsExercisedUsingOptOutRight",
     "nsuri": "http://biodesix.com/20201231",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://biodesix.com/20201231/taxonomy/role/DisclosureFairValueAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bdsx_PercentageOfFullyDilutedEquityForBonusAwarded": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of fully diluted equity for bonus awarded.",
        "label": "Percentage Of Fully Diluted Equity For Bonus Awarded",
        "terseLabel": "Percentage of fully diluted equity for bonus awarded"
       }
      }
     },
     "localname": "PercentageOfFullyDilutedEquityForBonusAwarded",
     "nsuri": "http://biodesix.com/20201231",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bdsx_PercentageOfLicenseIncomeGeneratedFromLicensing": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of license income generated from licensing.",
        "label": "Percentage Of License Income Generated From Licensing",
        "verboseLabel": "Percentage of license income generated from licensing"
       }
      }
     },
     "localname": "PercentageOfLicenseIncomeGeneratedFromLicensing",
     "nsuri": "http://biodesix.com/20201231",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bdsx_PercentageOfProbabilitiesOfContingentConsiderationSuccessfulAchievementMilestoneDiscountRatesRange": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of probabilities of contingent consideration successful achievement milestone discount rates range.",
        "label": "Percentage Of Probabilities Of Contingent Consideration Successful Achievement Milestone Discount Rates Range",
        "terseLabel": "Percentage of probabilities of contingent consideration successful achievement of specified product gross margin targets discount rates range"
       }
      }
     },
     "localname": "PercentageOfProbabilitiesOfContingentConsiderationSuccessfulAchievementMilestoneDiscountRatesRange",
     "nsuri": "http://biodesix.com/20201231",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureFairValueAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bdsx_PercentageOfRevenueSharePaymentRelatedToAcquiredDiagnosticTestRecognizedRevenueForNonScreeningTests": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of revenue share payment related to acquired diagnostic test recognized revenue for non-screening tests.",
        "label": "Percentage Of Revenue Share Payment Related To Acquired Diagnostic Test Recognized Revenue For Non Screening Tests",
        "verboseLabel": "Percentage of revenue share payment related to acquired diagnostic test recognized revenue for non-screening tests"
       }
      }
     },
     "localname": "PercentageOfRevenueSharePaymentRelatedToAcquiredDiagnosticTestRecognizedRevenueForNonScreeningTests",
     "nsuri": "http://biodesix.com/20201231",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bdsx_PercentageOfRoyaltyPaymentsOnNetRevenue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of royalty payments on net revenue.",
        "label": "Percentage Of Royalty Payments On Net Revenue",
        "terseLabel": "Percentage of royalty payments on net revenue"
       }
      }
     },
     "localname": "PercentageOfRoyaltyPaymentsOnNetRevenue",
     "nsuri": "http://biodesix.com/20201231",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bdsx_PercentageOfRoyaltyPaymentsOnNetSales": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of royalty payments on net sales.",
        "label": "Percentage Of Royalty Payments On Net Sales",
        "terseLabel": "Percentage of royalty payments on net sales"
       }
      }
     },
     "localname": "PercentageOfRoyaltyPaymentsOnNetSales",
     "nsuri": "http://biodesix.com/20201231",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bdsx_PercentageOfUpperLimitOfEmployeeSalaryToReduceForgiveness": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of upper limit of employee salary to reduce forgiveness.",
        "label": "Percentage Of Upper Limit Of Employee Salary To Reduce Forgiveness",
        "terseLabel": "Percentage of upper limit of employee salary to reduce forgiveness"
       }
      }
     },
     "localname": "PercentageOfUpperLimitOfEmployeeSalaryToReduceForgiveness",
     "nsuri": "http://biodesix.com/20201231",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bdsx_PercentageOfValuationAllowanceEqualToNetDeferredTaxAssets": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of valuation allowance equal to net deferred tax assets.",
        "label": "Percentage Of Valuation Allowance Equal To Net Deferred Tax Assets",
        "terseLabel": "Percentage of valuation allowance equal to net deferred tax assets"
       }
      }
     },
     "localname": "PercentageOfValuationAllowanceEqualToNetDeferredTaxAssets",
     "nsuri": "http://biodesix.com/20201231",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bdsx_PerformanceConditionOptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Performance condition options.",
        "label": "Performance Condition Options [Member]",
        "terseLabel": "Performance Condition Options"
       }
      }
     },
     "localname": "PerformanceConditionOptionsMember",
     "nsuri": "http://biodesix.com/20201231",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_PeriodOfEscalationsOfSales": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of escalations of sales.",
        "label": "Period Of Escalations Of Sales",
        "terseLabel": "Period of escalations of sales"
       }
      }
     },
     "localname": "PeriodOfEscalationsOfSales",
     "nsuri": "http://biodesix.com/20201231",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bdsx_PfizerIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pfizer, Inc.",
        "label": "Pfizer Inc [Member]",
        "terseLabel": "Pfizer, Inc"
       }
      }
     },
     "localname": "PfizerIncMember",
     "nsuri": "http://biodesix.com/20201231",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfRevenueAndAccountsReceivableByThirdPartyPayorsAndOtherCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_ProductLifeAndPatentLifeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product life and patent life.",
        "label": "Product Life And Patent Life [Member]",
        "terseLabel": "Product Life and Patent Life"
       }
      }
     },
     "localname": "ProductLifeAndPatentLifeMember",
     "nsuri": "http://biodesix.com/20201231",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_PurchaseOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase option.",
        "label": "Purchase Option [Member]",
        "terseLabel": "Purchase Option"
       }
      }
     },
     "localname": "PurchaseOptionMember",
     "nsuri": "http://biodesix.com/20201231",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsScheduleOfIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_PurchasedTechnologyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchased technology.",
        "label": "Purchased Technology [Member]",
        "terseLabel": "Purchased Technology"
       }
      }
     },
     "localname": "PurchasedTechnologyMember",
     "nsuri": "http://biodesix.com/20201231",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsScheduleOfIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_PutOptionLiabilityCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://biodesix.com/20201231/taxonomy/role/StatementBalanceSheets": {
       "order": 10190.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Put option liability current.",
        "label": "Put Option Liability Current",
        "terseLabel": "Put option liability",
        "verboseLabel": "Estimated value of put option liability"
       }
      }
     },
     "localname": "PutOptionLiabilityCurrent",
     "nsuri": "http://biodesix.com/20201231",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetails",
      "http://biodesix.com/20201231/taxonomy/role/DisclosureFairValueAdditionalInformationDetails",
      "http://biodesix.com/20201231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bdsx_PutOptionLiabilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Put option liability.",
        "label": "Put Option Liability [Member]",
        "terseLabel": "Put Option Liability"
       }
      }
     },
     "localname": "PutOptionLiabilityMember",
     "nsuri": "http://biodesix.com/20201231",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureFairValueScheduleOfChangesInFinancialLiabilitiesDetails",
      "http://biodesix.com/20201231/taxonomy/role/DisclosureFairValueScheduleOfReportedFairValuesOfLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_PutOptionLiabilityPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for put-option liability",
        "label": "Put Option Liability Policy [Text Block]",
        "terseLabel": "Put Option Liability"
       }
      }
     },
     "localname": "PutOptionLiabilityPolicyTextBlock",
     "nsuri": "http://biodesix.com/20201231",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bdsx_ReclassificationOfPutOptionLiabilityToAdditionalPaidInCapital": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reclassification of put option liability to additional paid in capital.",
        "label": "Reclassification Of Put Option Liability To Additional Paid In Capital",
        "terseLabel": "Reclassification of put option liability to additional paid-in capital"
       }
      }
     },
     "localname": "ReclassificationOfPutOptionLiabilityToAdditionalPaidInCapital",
     "nsuri": "http://biodesix.com/20201231",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bdsx_ReclassificationOfWarrantLiabilityToAdditionalPaidInCapital": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reclassification of warrant liability to additional paid-in-capital.",
        "label": "Reclassification Of Warrant Liability To Additional Paid In Capital",
        "terseLabel": "Reclassification of warrant liability to additional paid-in capital"
       }
      }
     },
     "localname": "ReclassificationOfWarrantLiabilityToAdditionalPaidInCapital",
     "nsuri": "http://biodesix.com/20201231",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bdsx_RemainingEstimatedObligation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining estimated obligation.",
        "label": "Remaining Estimated Obligation",
        "terseLabel": "Remaining estimated obligation"
       }
      }
     },
     "localname": "RemainingEstimatedObligation",
     "nsuri": "http://biodesix.com/20201231",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bdsx_RepurchaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Repurchase.",
        "label": "Repurchase [Member]",
        "terseLabel": "Repurchase"
       }
      }
     },
     "localname": "RepurchaseMember",
     "nsuri": "http://biodesix.com/20201231",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureBusinessCombinationsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_RevenueShareAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue share agreement.",
        "label": "Revenue Share Agreement [Member]",
        "terseLabel": "Revenue Share Agreement"
       }
      }
     },
     "localname": "RevenueShareAgreementMember",
     "nsuri": "http://biodesix.com/20201231",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_RevenueShareExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue share expenses.",
        "label": "Revenue Share Expenses",
        "terseLabel": "Revenue share expenses"
       }
      }
     },
     "localname": "RevenueShareExpenses",
     "nsuri": "http://biodesix.com/20201231",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bdsx_ReverseStockSplitPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for reverse stock split.",
        "label": "Reverse Stock Split Policy [Text Block]",
        "terseLabel": "Reverse Stock Split"
       }
      }
     },
     "localname": "ReverseStockSplitPolicyTextBlock",
     "nsuri": "http://biodesix.com/20201231",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bdsx_SaleOfStockTemporaryEquityPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of stock, temporary equity, price per share.",
        "label": "Sale Of Stock Temporary Equity Price Per Share",
        "terseLabel": "Sale of stock, temporary equity, price per share"
       }
      }
     },
     "localname": "SaleOfStockTemporaryEquityPricePerShare",
     "nsuri": "http://biodesix.com/20201231",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "bdsx_ScheduleOfDepreciationAndAmortizationExpenseRelatedToPropertyAndEquipmentTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of depreciation and amortization expense related to property and equipment.",
        "label": "Schedule Of Depreciation And Amortization Expense Related To Property And Equipment Table [Text Block]",
        "terseLabel": "Schedule of Depreciation Expense Related to Property and Equipment"
       }
      }
     },
     "localname": "ScheduleOfDepreciationAndAmortizationExpenseRelatedToPropertyAndEquipmentTableTextBlock",
     "nsuri": "http://biodesix.com/20201231",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bdsx_SeriesA1PreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series A-1 preferred stock.",
        "label": "Series A1 Preferred Stock [Member]",
        "terseLabel": "Series A-1 Preferred Stock"
       }
      }
     },
     "localname": "SeriesA1PreferredStockMember",
     "nsuri": "http://biodesix.com/20201231",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_SeriesA2PreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series A-2 preferred stock.",
        "label": "Series A2 Preferred Stock [Member]",
        "terseLabel": "Series A2 Preferred Stock"
       }
      }
     },
     "localname": "SeriesA2PreferredStockMember",
     "nsuri": "http://biodesix.com/20201231",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_SeriesA3PreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series A-3 preferred stock.",
        "label": "Series A3 Preferred Stock [Member]",
        "terseLabel": "Series A3 Preferred Stock"
       }
      }
     },
     "localname": "SeriesA3PreferredStockMember",
     "nsuri": "http://biodesix.com/20201231",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_SeriesB1ConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series B-1 Convertible Preferred Stock.",
        "label": "Series B1 Convertible Preferred Stock [Member]",
        "terseLabel": "Series B1 Convertible Preferred Stock"
       }
      }
     },
     "localname": "SeriesB1ConvertiblePreferredStockMember",
     "nsuri": "http://biodesix.com/20201231",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_SeriesEConvertiblePreferredStockWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series E convertible preferred stock warrants.",
        "label": "Series E Convertible Preferred Stock Warrants [Member]",
        "terseLabel": "Series E Convertible Preferred Stock Warrants"
       }
      }
     },
     "localname": "SeriesEConvertiblePreferredStockWarrantsMember",
     "nsuri": "http://biodesix.com/20201231",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureWarrantsToPurchaseConvertiblePreferredStockSummaryOfActivityForConvertiblePreferredStockWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_SeriesGConvertiblePreferredStockWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series G convertible preferred stock warrants.",
        "label": "Series G Convertible Preferred Stock Warrants [Member]",
        "terseLabel": "Series G Convertible Preferred Stock Warrants"
       }
      }
     },
     "localname": "SeriesGConvertiblePreferredStockWarrantsMember",
     "nsuri": "http://biodesix.com/20201231",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureWarrantsToPurchaseConvertiblePreferredStockSummaryOfActivityForConvertiblePreferredStockWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_ServiceConditionRSUsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Service-condition RSUs.",
        "label": "Service Condition R S Us [Member]",
        "terseLabel": "Service Condition R S Us"
       }
      }
     },
     "localname": "ServiceConditionRSUsMember",
     "nsuri": "http://biodesix.com/20201231",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award non-options forfeitures and expirations in period weighted average exercise price.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Non Options Forfeitures And Expirations In Period Weighted Average Exercise Price",
        "negatedLabel": "Weighted average exercise price, Forfeited/canceled"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://biodesix.com/20201231",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureWarrantsToPurchaseConvertiblePreferredStockSummaryOfActivityForConvertiblePreferredStockWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "bdsx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award non options outstanding weighted average exercise price.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Non Options Outstanding Weighted Average Exercise Price",
        "periodEndLabel": "Weighted average exercise price,Outstanding \u2011 December, 31, 2020",
        "periodStartLabel": "Weighted average exercise price, Outstanding \u2011 December 31, 2019"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://biodesix.com/20201231",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureWarrantsToPurchaseConvertiblePreferredStockSummaryOfActivityForConvertiblePreferredStockWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangements by share based payment award non options exercises in period weighted average exercise price.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Non Options Exercises In Period Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://biodesix.com/20201231",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureWarrantsToPurchaseConvertiblePreferredStockSummaryOfActivityForConvertiblePreferredStockWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangements by share based payment award non options grants in period weighted average exercise price.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Non Options Grants In Period Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://biodesix.com/20201231",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureWarrantsToPurchaseConvertiblePreferredStockSummaryOfActivityForConvertiblePreferredStockWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsReclassificationOfWarrantLiabilityToAdditionalPaidInCapitalWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangements by share based payment award non options reclassification of warrant liability to additional paid in capital weighted average exercise price.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Non Options Reclassification Of Warrant Liability To Additional Paid In Capital Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, Reclassification of warrant liability to additional paid-in capital"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsReclassificationOfWarrantLiabilityToAdditionalPaidInCapitalWeightedAverageExercisePrice",
     "nsuri": "http://biodesix.com/20201231",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureWarrantsToPurchaseConvertiblePreferredStockSummaryOfActivityForConvertiblePreferredStockWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "bdsx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award options granted weighted average remaining contractual term1.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Granted Weighted Average Remaining Contractual Term1",
        "terseLabel": "Weighted Average Contractual Life (Years), Granted"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://biodesix.com/20201231",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "bdsx_StockIssuedDuringPeriodSharesConversionOfConvertibleSecuritiesCommonStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities classified as common stock.",
        "label": "Stock Issued During Period Shares Conversion Of Convertible Securities Common Stock",
        "terseLabel": "Conversion of convertible debt into common stock, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecuritiesCommonStock",
     "nsuri": "http://biodesix.com/20201231",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "bdsx_SummaryOfSignificantAccountingPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary Of Significant Accounting Policies [Line Items].",
        "label": "Summary Of Significant Accounting Policies [Line Items]",
        "terseLabel": "Summary Of Significant Accounting Policies [Line Items]"
       }
      }
     },
     "localname": "SummaryOfSignificantAccountingPoliciesLineItems",
     "nsuri": "http://biodesix.com/20201231",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bdsx_SummaryOfSignificantAccountingPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of significant accounting policies.",
        "label": "Summary Of Significant Accounting Policies [Table]",
        "terseLabel": "Summary Of Significant Accounting Policies [Table]"
       }
      }
     },
     "localname": "SummaryOfSignificantAccountingPoliciesTable",
     "nsuri": "http://biodesix.com/20201231",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bdsx_TemporaryEquityIssuanceCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary equity issuance costs.",
        "label": "Temporary Equity Issuance Costs",
        "terseLabel": "Issuance costs"
       }
      }
     },
     "localname": "TemporaryEquityIssuanceCosts",
     "nsuri": "http://biodesix.com/20201231",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bdsx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary equity stock issued during period shares new issues.",
        "label": "Temporary Equity Stock Issued During Period Shares New Issues",
        "terseLabel": "Issuance of Series H Preferred Stock, shares"
       }
      }
     },
     "localname": "TemporaryEquityStockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://biodesix.com/20201231",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "bdsx_TestingServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Testing services.",
        "label": "Testing Services [Member]",
        "terseLabel": "Testing Services"
       }
      }
     },
     "localname": "TestingServicesMember",
     "nsuri": "http://biodesix.com/20201231",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_TheBigTenConferenceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Big Ten Conference.",
        "label": "The Big Ten Conference [Member]",
        "terseLabel": "The Big Ten Conference"
       }
      }
     },
     "localname": "TheBigTenConferenceMember",
     "nsuri": "http://biodesix.com/20201231",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfRevenueAndAccountsReceivableByThirdPartyPayorsAndOtherCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_TwoThousandAndSixteenPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2016 Plan.",
        "label": "Two Thousand And Sixteen Plan [Member]",
        "terseLabel": "2016 Plan"
       }
      }
     },
     "localname": "TwoThousandAndSixteenPlanMember",
     "nsuri": "http://biodesix.com/20201231",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_TwoThousandSixPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2006 Plan.",
        "label": "Two Thousand Six Plan [Member]",
        "terseLabel": "2006 Plan"
       }
      }
     },
     "localname": "TwoThousandSixPlanMember",
     "nsuri": "http://biodesix.com/20201231",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_TwoThousandSixPlanTwoThousandSixteenPlanAndTwoThousandTwentyEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand six plan two thousand sixteen plan and two thousand twenty equity incentive plan.",
        "label": "Two Thousand Six Plan Two Thousand Sixteen Plan And Two Thousand Twenty Equity Incentive Plan [Member]",
        "terseLabel": "2006 Plan, 2016 Plan and 2020 Equity Incentive Plan"
       }
      }
     },
     "localname": "TwoThousandSixPlanTwoThousandSixteenPlanAndTwoThousandTwentyEquityIncentivePlanMember",
     "nsuri": "http://biodesix.com/20201231",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_TwoThousandTwentyEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2020 equity incentive plan.",
        "label": "Two Thousand Twenty Equity Incentive Plan [Member]",
        "terseLabel": "2020 Equity Incentive Plan"
       }
      }
     },
     "localname": "TwoThousandTwentyEquityIncentivePlanMember",
     "nsuri": "http://biodesix.com/20201231",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_UpperLimitOfEmployeeSalaryToReduceForgiveness": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upper limit of employee salary to reduce forgiveness.",
        "label": "Upper Limit Of Employee Salary To Reduce Forgiveness",
        "terseLabel": "Upper limit of employee salary to reduce forgiveness"
       }
      }
     },
     "localname": "UpperLimitOfEmployeeSalaryToReduceForgiveness",
     "nsuri": "http://biodesix.com/20201231",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bdsx_ValueOfPutOptionRecordedAtIssuanceOfConvertibleNotesPayable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of put option recorded at issuance of convertible notes payable.",
        "label": "Value Of Put Option Recorded At Issuance Of Convertible Notes Payable",
        "terseLabel": "Value of put option recorded at issuance of convertible debt payable"
       }
      }
     },
     "localname": "ValueOfPutOptionRecordedAtIssuanceOfConvertibleNotesPayable",
     "nsuri": "http://biodesix.com/20201231",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bdsx_WarrantLiabilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrant liability.",
        "label": "Warrant Liability [Member]",
        "terseLabel": "Warrant Liability"
       }
      }
     },
     "localname": "WarrantLiabilityMember",
     "nsuri": "http://biodesix.com/20201231",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureFairValueScheduleOfChangesInFinancialLiabilitiesDetails",
      "http://biodesix.com/20201231/taxonomy/role/DisclosureFairValueScheduleOfReportedFairValuesOfLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_WarrantLiabilityPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for warrant liability.",
        "label": "Warrant Liability Policy [Text Block]",
        "terseLabel": "Warrant Liability"
       }
      }
     },
     "localname": "WarrantLiabilityPolicyTextBlock",
     "nsuri": "http://biodesix.com/20201231",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bdsx_WarrantsForConvertiblePreferredStockTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants for convertible preferred stock.",
        "label": "Warrants For Convertible Preferred Stock [Text Block]",
        "terseLabel": "Warrants to Purchase Convertible Preferred Stock"
       }
      }
     },
     "localname": "WarrantsForConvertiblePreferredStockTextBlock",
     "nsuri": "http://biodesix.com/20201231",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureWarrantsToPurchaseConvertiblePreferredStock"
     ],
     "xbrltype": "textBlockItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "United States"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureBusinessCombinationsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r575",
      "r576",
      "r577"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "verboseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r578"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "verboseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r573"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated By Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address Address Line1",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address Address Line2",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address City Or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address State Or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r579"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r579"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r581"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r579"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r580"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r579"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r579"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r579"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r579"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well Known Seasoned Issuer",
        "terseLabel": "Entity Well Known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r575",
      "r576",
      "r577"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Icfr Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r572"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Security12b Title",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r574"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r66",
      "r109"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://biodesix.com/20201231/taxonomy/role/DisclosureFairValueAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r190",
      "r299",
      "r305",
      "r528"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Major Customers [Axis]",
        "terseLabel": "Customer"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://biodesix.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfRevenueAndAccountsReceivableByThirdPartyPayorsAndOtherCustomersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r327",
      "r329",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r525",
      "r529"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum",
        "verboseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetails",
      "http://biodesix.com/20201231/taxonomy/role/DisclosureFairValueAdditionalInformationDetails",
      "http://biodesix.com/20201231/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails",
      "http://biodesix.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r327",
      "r329",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r525",
      "r529"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum",
        "verboseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetails",
      "http://biodesix.com/20201231/taxonomy/role/DisclosureFairValueAdditionalInformationDetails",
      "http://biodesix.com/20201231/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails",
      "http://biodesix.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r190",
      "r299",
      "r305",
      "r528"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name Of Major Customer [Domain]",
        "terseLabel": "Customer"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://biodesix.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfRevenueAndAccountsReceivableByThirdPartyPayorsAndOtherCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r187",
      "r299",
      "r303",
      "r487",
      "r524",
      "r526"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product Or Service [Axis]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureBusinessCombinationsAdditionalInformationDetails",
      "http://biodesix.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://biodesix.com/20201231/taxonomy/role/DisclosureRevenueAdditionalInformationDetails",
      "http://biodesix.com/20201231/taxonomy/role/DisclosureRevenueSummaryOfRevenueDetails",
      "http://biodesix.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r187",
      "r299",
      "r303",
      "r487",
      "r524",
      "r526"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Products And Services [Domain]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureBusinessCombinationsAdditionalInformationDetails",
      "http://biodesix.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://biodesix.com/20201231/taxonomy/role/DisclosureRevenueAdditionalInformationDetails",
      "http://biodesix.com/20201231/taxonomy/role/DisclosureRevenueSummaryOfRevenueDetails",
      "http://biodesix.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r315",
      "r327",
      "r329",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r525",
      "r529"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Axis]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetails",
      "http://biodesix.com/20201231/taxonomy/role/DisclosureFairValueAdditionalInformationDetails",
      "http://biodesix.com/20201231/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails",
      "http://biodesix.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r315",
      "r327",
      "r329",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r525",
      "r529"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Member]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetails",
      "http://biodesix.com/20201231/taxonomy/role/DisclosureFairValueAdditionalInformationDetails",
      "http://biodesix.com/20201231/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails",
      "http://biodesix.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Repurchase Agreement Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://biodesix.com/20201231/taxonomy/role/DisclosureFairValueAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RestatementAxis": {
     "auth_ref": [
      "r114",
      "r115",
      "r116",
      "r117",
      "r120",
      "r121",
      "r124",
      "r125",
      "r126",
      "r128",
      "r129",
      "r130",
      "r131",
      "r132",
      "r146",
      "r200",
      "r201",
      "r367",
      "r399",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement [Axis]",
        "terseLabel": "Revision of Prior Period"
       }
      }
     },
     "localname": "RestatementAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RestatementDomain": {
     "auth_ref": [
      "r114",
      "r115",
      "r116",
      "r117",
      "r120",
      "r121",
      "r124",
      "r125",
      "r126",
      "r128",
      "r129",
      "r130",
      "r131",
      "r132",
      "r146",
      "r200",
      "r201",
      "r367",
      "r399",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement [Domain]",
        "terseLabel": "Revision of Prior Period"
       }
      }
     },
     "localname": "RestatementDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember": {
     "auth_ref": [
      "r124",
      "r125",
      "r128",
      "r129",
      "r131",
      "r132"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision Of Prior Period Error Correction Adjustment [Member]",
        "terseLabel": "Revision of Prior Period, Error Correction, Adjustment"
       }
      }
     },
     "localname": "RevisionOfPriorPeriodErrorCorrectionAdjustmentMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r188",
      "r189",
      "r299",
      "r304",
      "r527",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Geographical [Domain]",
        "terseLabel": "Geographical"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureBusinessCombinationsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r188",
      "r189",
      "r299",
      "r304",
      "r527",
      "r558",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Geographical [Axis]",
        "terseLabel": "Geographical"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureBusinessCombinationsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r46"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "Accounts Payable And Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "Accrued Liabilities"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureAccruedLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://biodesix.com/20201231/taxonomy/role/StatementBalanceSheets": {
       "order": 10150.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
        "label": "Accounts Receivable [Member]",
        "terseLabel": "Accounts Receivable"
       }
      }
     },
     "localname": "AccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfRevenueAndAccountsReceivableByThirdPartyPayorsAndOtherCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r3",
      "r32",
      "r191",
      "r192"
     ],
     "calculation": {
      "http://biodesix.com/20201231/taxonomy/role/StatementBalanceSheets": {
       "order": 10270.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable Net Current",
        "terseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://biodesix.com/20201231/taxonomy/role/DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://biodesix.com/20201231/taxonomy/role/StatementBalanceSheets": {
       "order": 10160.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities Current",
        "terseLabel": "Accrued liabilities",
        "totalLabel": "Total accrued liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails",
      "http://biodesix.com/20201231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r42",
      "r234"
     ],
     "calculation": {
      "http://biodesix.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails": {
       "order": 10020.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation Depletion And Amortization Property Plant And Equipment",
        "negatedLabel": "Less accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r33",
      "r367"
     ],
     "calculation": {
      "http://biodesix.com/20201231/taxonomy/role/StatementBalanceSheets": {
       "order": 10070.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.",
        "label": "Additional Paid In Capital",
        "terseLabel": "Additional paid\u2011in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r114",
      "r115",
      "r117",
      "r363",
      "r364",
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid In Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt": {
     "auth_ref": [
      "r257"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustment to additional paid in capital resulting from the recognition of convertible debt instruments as two separate components - a debt component and an equity component. This bifurcation may result in a basis difference associated with the liability component that represents a temporary difference for purposes of applying accounting for income taxes. The initial recognition of deferred taxes for the tax effect of that temporary difference is as an adjustment to additional paid in capital.",
        "label": "Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt",
        "terseLabel": "Conversion of convertible debt into common stock upon initial public offering"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r330",
      "r332",
      "r370",
      "r371"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value",
        "terseLabel": "Stock\u2011based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": {
     "auth_ref": [
      "r256",
      "r269",
      "r276"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.",
        "label": "Adjustments To Additional Paid In Capital Warrant Issued",
        "terseLabel": "Reclassification of preferred stock warrant liability and put option into additional paid-in capital upon initial public offering"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash, cash equivalents, and restricted cash used in operating activities"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r332",
      "r359",
      "r369"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Allocated Share Based Compensation Expense",
        "terseLabel": "Total pre-tax share-based compensation expense",
        "verboseLabel": "Stock compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails",
      "http://biodesix.com/20201231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfPreTaxShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivable": {
     "auth_ref": [
      "r193",
      "r202",
      "r203",
      "r205"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable.",
        "label": "Allowance For Doubtful Accounts Receivable",
        "terseLabel": "Allowance for doubtful accounts"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "auth_ref": [
      "r77",
      "r93",
      "r469"
     ],
     "calculation": {
      "http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfCashFlows": {
       "order": 10160.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.",
        "label": "Amortization Of Debt Discount Premium",
        "terseLabel": "Amortization of convertible notes debt discount"
       }
      }
     },
     "localname": "AmortizationOfDebtDiscountPremium",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "auth_ref": [
      "r74",
      "r93",
      "r471"
     ],
     "calculation": {
      "http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfCashFlows": {
       "order": 10220.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt issuance costs.",
        "label": "Amortization Of Financing Costs",
        "terseLabel": "Amortization of debt issuance costs"
       }
      }
     },
     "localname": "AmortizationOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r93",
      "r217",
      "r225"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization Of Intangible Assets",
        "terseLabel": "Amortization expense related to definite-lived intangible assets"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsScheduleOfAmortizationExpenseRelatedToDefiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r143"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount",
        "terseLabel": "Total"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureEarningsPerShareScheduleOfCommonStockEquivalentsExcludedFromDilutedNetLossAttributableToCommonStockholdersDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r143"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureEarningsPerShareScheduleOfCommonStockEquivalentsExcludedFromDilutedNetLossAttributableToCommonStockholdersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureEarningsPerShareScheduleOfCommonStockEquivalentsExcludedFromDilutedNetLossAttributableToCommonStockholdersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r143"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureEarningsPerShareScheduleOfCommonStockEquivalentsExcludedFromDilutedNetLossAttributableToCommonStockholdersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Arrangements And Nonarrangement Transactions [Member]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r107",
      "r170",
      "r179",
      "r185",
      "r196",
      "r429",
      "r433",
      "r460",
      "r496",
      "r515"
     ],
     "calculation": {
      "http://biodesix.com/20201231/taxonomy/role/StatementBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r4",
      "r5",
      "r65",
      "r107",
      "r196",
      "r429",
      "r433",
      "r460"
     ],
     "calculation": {
      "http://biodesix.com/20201231/taxonomy/role/StatementBalanceSheets": {
       "order": 10200.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets Current [Abstract]",
        "terseLabel": "Current assets"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsNoncurrent": {
     "auth_ref": [
      "r14",
      "r15",
      "r16",
      "r17",
      "r18",
      "r19",
      "r20",
      "r21",
      "r107",
      "r196",
      "r429",
      "r433",
      "r460"
     ],
     "calculation": {
      "http://biodesix.com/20201231/taxonomy/role/StatementBalanceSheets": {
       "order": 10210.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.",
        "label": "Assets Noncurrent",
        "totalLabel": "Total non\u2011current assets"
       }
      }
     },
     "localname": "AssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets Noncurrent [Abstract]",
        "terseLabel": "Non\u2011current assets"
       }
      }
     },
     "localname": "AssetsNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r333",
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureRevenueAdditionalInformationDetails",
      "http://biodesix.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r438",
      "r439"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureRevenueAdditionalInformationDetails",
      "http://biodesix.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis Of Accounting Policy Policy [Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r326",
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureBusinessCombinationsAdditionalInformationDetails",
      "http://biodesix.com/20201231/taxonomy/role/DisclosureBusinessCombinationsSummaryOfAggregateConsiderationPaidByCompanyAndAllocationOfPurchasePriceToAssetsAcquiredAndLiabilitiesAssumedDetails",
      "http://biodesix.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r326",
      "r328",
      "r412",
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureBusinessCombinationsAdditionalInformationDetails",
      "http://biodesix.com/20201231/taxonomy/role/DisclosureBusinessCombinationsSummaryOfAggregateConsiderationPaidByCompanyAndAllocationOfPurchasePriceToAssetsAcquiredAndLiabilitiesAssumedDetails",
      "http://biodesix.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity": {
     "auth_ref": [
      "r411"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "With respect to a business combination completed during the period, this element provides a description of the business, other than the name, which may include the industry, size, products and other important information.",
        "label": "Business Acquisition Description Of Acquired Entity",
        "terseLabel": "Business acquisition description"
       }
      }
     },
     "localname": "BusinessAcquisitionDescriptionOfAcquiredEntity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureBusinessCombinationsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureBusinessCombinationsAdditionalInformationDetails",
      "http://biodesix.com/20201231/taxonomy/role/DisclosureBusinessCombinationsSummaryOfAggregateConsiderationPaidByCompanyAndAllocationOfPurchasePriceToAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "auth_ref": [
      "r419",
      "r420",
      "r422"
     ],
     "calculation": {
      "http://biodesix.com/20201231/taxonomy/role/DisclosureBusinessCombinationsSummaryOfAggregateConsiderationPaidByCompanyAndAllocationOfPurchasePriceToAssetsAcquiredAndLiabilitiesAssumedDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.",
        "label": "Business Combination Consideration Transferred1",
        "terseLabel": "Total consideration amount",
        "totalLabel": "Total fair value of consideration transferred"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferred1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureBusinessCombinationsAdditionalInformationDetails",
      "http://biodesix.com/20201231/taxonomy/role/DisclosureBusinessCombinationsSummaryOfAggregateConsiderationPaidByCompanyAndAllocationOfPurchasePriceToAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": {
     "auth_ref": [
      "r92",
      "r425"
     ],
     "calculation": {
      "http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfCashFlows": {
       "order": 10190.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.",
        "label": "Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1",
        "terseLabel": "Change in contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureFairValueAdditionalInformationDetails",
      "http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": {
     "auth_ref": [
      "r418",
      "r421"
     ],
     "calculation": {
      "http://biodesix.com/20201231/taxonomy/role/StatementBalanceSheets": {
       "order": 10130.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.",
        "label": "Business Combination Contingent Consideration Liability Noncurrent",
        "terseLabel": "Contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "auth_ref": [
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).",
        "label": "Business Combination Disclosure [Text Block]",
        "terseLabel": "Business Combinations"
       }
      }
     },
     "localname": "BusinessCombinationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureBusinessCombinations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities": {
     "auth_ref": [
      "r415"
     ],
     "calculation": {
      "http://biodesix.com/20201231/taxonomy/role/DisclosureBusinessCombinationsSummaryOfAggregateConsiderationPaidByCompanyAndAllocationOfPurchasePriceToAssetsAcquiredAndLiabilitiesAssumedDetails": {
       "order": 10010.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investments in debt and equity securities, including, but not limited to, held-to-maturity, trading and available-for-sale expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Marketable Securities",
        "terseLabel": "Deposit"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureBusinessCombinationsSummaryOfAggregateConsiderationPaidByCompanyAndAllocationOfPurchasePriceToAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable": {
     "auth_ref": [
      "r415"
     ],
     "calculation": {
      "http://biodesix.com/20201231/taxonomy/role/DisclosureBusinessCombinationsSummaryOfAggregateConsiderationPaidByCompanyAndAllocationOfPurchasePriceToAssetsAcquiredAndLiabilitiesAssumedDetails": {
       "order": 10060.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.",
        "label": "Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Accounts Payable",
        "negatedLabel": "Accrued liabilities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureBusinessCombinationsSummaryOfAggregateConsiderationPaidByCompanyAndAllocationOfPurchasePriceToAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory": {
     "auth_ref": [
      "r414",
      "r415"
     ],
     "calculation": {
      "http://biodesix.com/20201231/taxonomy/role/DisclosureBusinessCombinationsSummaryOfAggregateConsiderationPaidByCompanyAndAllocationOfPurchasePriceToAssetsAcquiredAndLiabilitiesAssumedDetails": {
       "order": 10020.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of inventory recognized as of the acquisition date.",
        "label": "Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Inventory",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureBusinessCombinationsSummaryOfAggregateConsiderationPaidByCompanyAndAllocationOfPurchasePriceToAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": {
     "auth_ref": [
      "r414",
      "r415"
     ],
     "calculation": {
      "http://biodesix.com/20201231/taxonomy/role/DisclosureBusinessCombinationsSummaryOfAggregateConsiderationPaidByCompanyAndAllocationOfPurchasePriceToAssetsAcquiredAndLiabilitiesAssumedDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.",
        "label": "Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Net",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureBusinessCombinationsSummaryOfAggregateConsiderationPaidByCompanyAndAllocationOfPurchasePriceToAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": {
     "auth_ref": [
      "r414",
      "r415"
     ],
     "calculation": {
      "http://biodesix.com/20201231/taxonomy/role/DisclosureBusinessCombinationsSummaryOfAggregateConsiderationPaidByCompanyAndAllocationOfPurchasePriceToAssetsAcquiredAndLiabilitiesAssumedDetails": {
       "order": 10030.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date.",
        "label": "Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Property Plant And Equipment",
        "terseLabel": "Property and equipment"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureBusinessCombinationsSummaryOfAggregateConsiderationPaidByCompanyAndAllocationOfPurchasePriceToAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationSegmentAllocationTableTextBlock": {
     "auth_ref": [
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill in a business combination.",
        "label": "Business Combination Segment Allocation Table [Text Block]",
        "terseLabel": "Summary of Aggregate Consideration Paid by Company and Allocation of Purchase Price to Assets Acquired and Liabilities Assumed"
       }
      }
     },
     "localname": "BusinessCombinationSegmentAllocationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureBusinessCombinationsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combinations [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CapitalUnitsDeductionsFromTotalCostToInvestors": {
     "auth_ref": [
      "r542"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deductions from cost to investors of capital shares or other capital units for fees, loads and other charges.",
        "label": "Capital Units Deductions From Total Cost To Investors",
        "terseLabel": "Discounts and commission"
       }
      }
     },
     "localname": "CapitalUnitsDeductionsFromTotalCostToInvestors",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalUnitsTotalCostToInvestors": {
     "auth_ref": [
      "r541"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost to investors of each class of capital shares or other capital units.",
        "label": "Capital Units Total Cost To Investors",
        "terseLabel": "Direct offering costs"
       }
      }
     },
     "localname": "CapitalUnitsTotalCostToInvestors",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CarryingReportedAmountFairValueDisclosureMember": {
     "auth_ref": [
      "r455",
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured as reported on the statement of financial position (balance sheet).",
        "label": "Carrying Reported Amount Fair Value Disclosure [Member]",
        "terseLabel": "Carrying Value"
       }
      }
     },
     "localname": "CarryingReportedAmountFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureFairValueSummaryOfFairValueOfOutstandingBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashAcquiredFromAcquisition": {
     "auth_ref": [
      "r79"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business).",
        "label": "Cash Acquired From Acquisition",
        "terseLabel": "Business acquisition contingent consideration gross margin target"
       }
      }
     },
     "localname": "CashAcquiredFromAcquisition",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureBusinessCombinationsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r2",
      "r39",
      "r95"
     ],
     "calculation": {
      "http://biodesix.com/20201231/taxonomy/role/StatementBalanceSheets": {
       "order": 10260.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash And Cash Equivalents At Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r13",
      "r96",
      "r102"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash And Cash Equivalents Policy [Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r13",
      "r96",
      "r102",
      "r494"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.",
        "label": "Cash And Cash Equivalents Restricted Cash And Cash Equivalents Policy",
        "terseLabel": "Restricted Cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r88",
      "r95",
      "r101"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents, and restricted cash \u2011 end of period",
        "periodStartLabel": "Cash, cash equivalents, and restricted cash \u2011 beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r88",
      "r461"
     ],
     "calculation": {
      "http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect",
        "totalLabel": "Net increase (decrease) in cash and cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class Of Stock Disclosures [Abstract]"
       }
      }
     },
     "localname": "ClassOfStockDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r105",
      "r107",
      "r136",
      "r137",
      "r138",
      "r140",
      "r142",
      "r149",
      "r150",
      "r151",
      "r196",
      "r460"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class Of Stock [Domain]",
        "terseLabel": "Class of Stock"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://biodesix.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetails",
      "http://biodesix.com/20201231/taxonomy/role/DisclosureEarningsPerShareScheduleOfCommonStockEquivalentsExcludedFromDilutedNetLossAttributableToCommonStockholdersDetails",
      "http://biodesix.com/20201231/taxonomy/role/DisclosureFairValueAdditionalInformationDetails",
      "http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class Of Stock [Line Items]",
        "terseLabel": "Class Of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://biodesix.com/20201231/taxonomy/role/DisclosureEquityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable": {
     "auth_ref": [
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date the warrants or rights are exercisable, in CCYY-MM-DD format.",
        "label": "Class Of Warrant Or Righst Date From Which Warrants Or Rights Exercisable",
        "terseLabel": "Warrants expiry date"
       }
      }
     },
     "localname": "ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureWarrantsToPurchaseConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "auth_ref": [
      "r279",
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Class Of Warrant Or Right [Axis]",
        "terseLabel": "Class of Warrant or Right"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureWarrantsToPurchaseConvertiblePreferredStockSummaryOfActivityForConvertiblePreferredStockWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.",
        "label": "Class Of Warrant Or Right [Domain]",
        "terseLabel": "Class of Warrant or Right"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureWarrantsToPurchaseConvertiblePreferredStockSummaryOfActivityForConvertiblePreferredStockWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1",
        "terseLabel": "Warrant, exercise price"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureFairValueAdditionalInformationDetails",
      "http://biodesix.com/20201231/taxonomy/role/DisclosureWarrantsToPurchaseConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class Of Warrant Or Right [Line Items]",
        "terseLabel": "Class Of Warrant Or Right [Line Items]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureWarrantsToPurchaseConvertiblePreferredStockSummaryOfActivityForConvertiblePreferredStockWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.",
        "label": "Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right",
        "terseLabel": "Warrant issued to purchase shares",
        "verboseLabel": "Warrant issued to purchase shares"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetails",
      "http://biodesix.com/20201231/taxonomy/role/DisclosureFairValueAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights",
        "terseLabel": "Warrants to purchase shares of common stock",
        "verboseLabel": "Warrant issued to purchase shares"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureFairValueAdditionalInformationDetails",
      "http://biodesix.com/20201231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails",
      "http://biodesix.com/20201231/taxonomy/role/DisclosureWarrantsToPurchaseConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "auth_ref": [
      "r279",
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Class Of Warrant Or Right [Table]",
        "terseLabel": "Class Of Warrant Or Right [Table]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureWarrantsToPurchaseConvertiblePreferredStockSummaryOfActivityForConvertiblePreferredStockWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r57",
      "r242",
      "r502",
      "r521"
     ],
     "calculation": {
      "http://biodesix.com/20201231/taxonomy/role/StatementBalanceSheets": {
       "order": 10020.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments And Contingencies",
        "terseLabel": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments And Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r239",
      "r240",
      "r241",
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments And Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r59"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock Capital Shares Reserved For Future Issuance",
        "terseLabel": "Number of shares reserved for issuance"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r114",
      "r115"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureBusinessCombinationsAdditionalInformationDetails",
      "http://biodesix.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetails",
      "http://biodesix.com/20201231/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails",
      "http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r31"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock Par Or Stated Value Per Share",
        "terseLabel": "Common stock, par value",
        "verboseLabel": "Common stock, par value"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureEquityAdditionalInformationDetails",
      "http://biodesix.com/20201231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails",
      "http://biodesix.com/20201231/taxonomy/role/StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r31"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock Shares Authorized",
        "terseLabel": "Common stock, authorized",
        "verboseLabel": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureEquityAdditionalInformationDetails",
      "http://biodesix.com/20201231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails",
      "http://biodesix.com/20201231/taxonomy/role/StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r31"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock Shares Issued",
        "terseLabel": "Common stock, issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r31",
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock Shares Outstanding",
        "terseLabel": "Common stock, outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://biodesix.com/20201231/taxonomy/role/StatementBalanceSheets": {
       "order": 10060.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock Value",
        "terseLabel": "Common stock, $0.001 par value, 200,000,000 (2020) and 190,000,000 (2019) authorized; 26,561,504 (2020) and 254,918 (2019) issued and outstanding"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommonStockVotingRights": {
     "auth_ref": [
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.",
        "label": "Common Stock Voting Rights",
        "terseLabel": "Common stock, voting rights"
       }
      }
     },
     "localname": "CommonStockVotingRights",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureEquityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation And Retirement Disclosure [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components Of Deferred Tax Assets [Abstract]"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxAssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment [Member]",
        "terseLabel": "Computer Equipment"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r159",
      "r160",
      "r190",
      "r457",
      "r458"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://biodesix.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfRevenueAndAccountsReceivableByThirdPartyPayorsAndOtherCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r159",
      "r160",
      "r190",
      "r457",
      "r458",
      "r540"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk By Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://biodesix.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfRevenueAndAccountsReceivableByThirdPartyPayorsAndOtherCustomersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r159",
      "r160",
      "r190",
      "r457",
      "r458",
      "r540"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk By Type [Axis]",
        "terseLabel": "Concentration Risk Type"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://biodesix.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfRevenueAndAccountsReceivableByThirdPartyPayorsAndOtherCustomersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r154",
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk Credit Risk",
        "terseLabel": "Concentrations of Credit Risk and Other Uncertainties"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Concentration Risk [Line Items]",
        "terseLabel": "Concentration Risk [Line Items]"
       }
      }
     },
     "localname": "ConcentrationRiskLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfRevenueAndAccountsReceivableByThirdPartyPayorsAndOtherCustomersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r159",
      "r160",
      "r190",
      "r457",
      "r458"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk Percentage1",
        "terseLabel": "Concentration risk, percentage"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://biodesix.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfRevenueAndAccountsReceivableByThirdPartyPayorsAndOtherCustomersDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTable": {
     "auth_ref": [
      "r157",
      "r159",
      "r160",
      "r161",
      "r457",
      "r459"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Concentration Risk [Table]",
        "terseLabel": "Concentration Risk [Table]"
       }
      }
     },
     "localname": "ConcentrationRiskTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfRevenueAndAccountsReceivableByThirdPartyPayorsAndOtherCustomersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r159",
      "r160",
      "r190",
      "r457",
      "r458"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://biodesix.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfRevenueAndAccountsReceivableByThirdPartyPayorsAndOtherCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConstructionInProgressMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction In Progress [Member]",
        "terseLabel": "Construction in Process"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure": {
     "auth_ref": [
      "r441"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of contingent consideration in a business combination that is classified in shareholders' equity.",
        "label": "Contingent Consideration Classified As Equity Fair Value Disclosure",
        "terseLabel": "Contingent consideration estimated fair value"
       }
      }
     },
     "localname": "ContingentConsiderationClassifiedAsEquityFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureBusinessCombinationsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r281",
      "r282",
      "r300"
     ],
     "calculation": {
      "http://biodesix.com/20201231/taxonomy/role/StatementBalanceSheets": {
       "order": 10170.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract With Customer Liability Current",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureRevenueAdditionalInformationDetails",
      "http://biodesix.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://biodesix.com/20201231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "auth_ref": [
      "r301"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract With Customer Liability Revenue Recognized",
        "terseLabel": "Revenue recognized"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureRevenueAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConversionOfStockAmountConverted1": {
     "auth_ref": [
      "r98",
      "r99",
      "r100"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Conversion Of Stock Amount Converted1",
        "terseLabel": "Conversion of convertible notes and accrued interest into common stock"
       }
      }
     },
     "localname": "ConversionOfStockAmountConverted1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebtSecuritiesMember": {
     "auth_ref": [
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities that can be exchanged for equity of the debt issuer at the option of the issuer or the holder.",
        "label": "Convertible Debt Securities [Member]",
        "terseLabel": "Convertible Debt"
       }
      }
     },
     "localname": "ConvertibleDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureEarningsPerShareScheduleOfCommonStockEquivalentsExcludedFromDilutedNetLossAttributableToCommonStockholdersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConvertibleNotesPayableCurrent": {
     "auth_ref": [
      "r50"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.",
        "label": "Convertible Notes Payable Current",
        "terseLabel": "Convertible notes payable"
       }
      }
     },
     "localname": "ConvertibleNotesPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureDebtSummaryOfLongTermNotesPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option.",
        "label": "Convertible Preferred Stock [Member]",
        "terseLabel": "Convertible Preferred Stock"
       }
      }
     },
     "localname": "ConvertiblePreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureEarningsPerShareScheduleOfCommonStockEquivalentsExcludedFromDilutedNetLossAttributableToCommonStockholdersDetails",
      "http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r158",
      "r190"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer Concentration Risk"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://biodesix.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfRevenueAndAccountsReceivableByThirdPartyPayorsAndOtherCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtConversionConvertedInstrumentRate": {
     "auth_ref": [
      "r98",
      "r100"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Dividend or interest rate associated with the financial instrument issued in exchange for the original debt being converted in a noncash or part noncash transaction. Noncash are transactions that affect recognized assets or liabilities but that do not result in cash receipts or cash payments. Part noncash refers to that portion of the transaction not resulting in cash receipts or cash payments.",
        "label": "Debt Conversion Converted Instrument Rate",
        "terseLabel": "Conversion rate"
       }
      }
     },
     "localname": "DebtConversionConvertedInstrumentRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Debt"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureDebt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r22",
      "r23",
      "r24",
      "r497",
      "r499",
      "r514"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetails",
      "http://biodesix.com/20201231/taxonomy/role/DisclosureDebtSummaryOfLongTermNotesPayableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r24",
      "r258",
      "r499",
      "r514"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Debt Instrument Carrying Amount",
        "terseLabel": "Loan principle amount",
        "verboseLabel": "Notes/Loan payable"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetails",
      "http://biodesix.com/20201231/taxonomy/role/DisclosureDebtSummaryOfLongTermNotesPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The price per share of the conversion feature embedded in the debt instrument.",
        "label": "Debt Instrument Convertible Conversion Price1",
        "terseLabel": "Conversion price"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1": {
     "auth_ref": [
      "r261"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining amortization period for discount on the liability component of convertible debt which may be settled in cash upon conversion, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument Convertible Remaining Discount Amortization Period1",
        "terseLabel": "Early amortization of loan payment schedule"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DebtInstrumentDescription": {
     "auth_ref": [
      "r22",
      "r24",
      "r270",
      "r497",
      "r499",
      "r508",
      "r514"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the lender and information about a contractual promise to repay a short-term or long-term obligation, which includes borrowings under lines of credit, notes payable, commercial paper, bonds payable, debentures, and other contractual obligations for payment. This may include rationale for entering into the arrangement, significant terms of the arrangement, which may include amount, repayment terms, priority, collateral required, debt covenants, borrowing capacity, call features, participation rights, conversion provisions, sinking-fund requirements, voting rights, basis for conversion if convertible and remarketing provisions. The description may be provided for individual debt instruments, rational groupings of debt instruments, or by debt in total.",
        "label": "Debt Instrument Description",
        "terseLabel": "Loan description"
       }
      }
     },
     "localname": "DebtInstrumentDescription",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentFeeAmount": {
     "auth_ref": [
      "r54"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the fee that accompanies borrowing money under the debt instrument.",
        "label": "Debt Instrument Fee Amount",
        "terseLabel": "Facility fee amount"
       }
      }
     },
     "localname": "DebtInstrumentFeeAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFrequencyOfPeriodicPayment": {
     "auth_ref": [
      "r55",
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the frequency of periodic payments (monthly, quarterly, annual).",
        "label": "Debt Instrument Frequency Of Periodic Payment",
        "terseLabel": "Frequency of periodic payment"
       }
      }
     },
     "localname": "DebtInstrumentFrequencyOfPeriodicPayment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r52"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument Interest Rate Stated Percentage",
        "terseLabel": "Interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetails",
      "http://biodesix.com/20201231/taxonomy/role/DisclosureDebtSummaryOfLongTermNotesPayableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentMaturityDate": {
     "auth_ref": [
      "r53",
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format.",
        "label": "Debt Instrument Maturity Date",
        "terseLabel": "Convertible notes, maturity date"
       }
      }
     },
     "localname": "DebtInstrumentMaturityDate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r55"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument Name [Domain]",
        "terseLabel": "Debt Instrument, Name"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetails",
      "http://biodesix.com/20201231/taxonomy/role/DisclosureDebtSummaryOfLongTermNotesPayableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodAxis": {
     "auth_ref": [
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about timing of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument Redemption Period [Axis]",
        "terseLabel": "Debt Instrument, Redemption, Period"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodDomain": {
     "auth_ref": [
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period as defined under terms of the debt agreement for debt redemption features.",
        "label": "Debt Instrument Redemption Period [Domain]",
        "terseLabel": "Debt Instrument, Redemption, Period"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodOneMember": {
     "auth_ref": [
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period one representing most current period of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument Redemption Period One [Member]",
        "terseLabel": "First Tranche"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodOneMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodTwoMember": {
     "auth_ref": [
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period two representing second most current period of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument Redemption Period Two [Member]",
        "terseLabel": "Second Tranche"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodTwoMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r55",
      "r110",
      "r270",
      "r273",
      "r274",
      "r275",
      "r469",
      "r470",
      "r472",
      "r511"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Debt Instrument [Table]",
        "terseLabel": "Debt Instrument [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetails",
      "http://biodesix.com/20201231/taxonomy/role/DisclosureDebtSummaryOfLongTermNotesPayableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": {
     "auth_ref": [
      "r259",
      "r471"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs.",
        "label": "Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net",
        "negatedLabel": "Unamortized debt discount and debt issuance costs"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureDebtSummaryOfLongTermNotesPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instruments [Abstract]"
       }
      }
     },
     "localname": "DebtInstrumentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r26",
      "r27",
      "r388",
      "r498",
      "r513"
     ],
     "calculation": {
      "http://biodesix.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 10020.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Income Tax Liabilities",
        "negatedTotalLabel": "Total deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r389"
     ],
     "calculation": {
      "http://biodesix.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 10040.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets Gross",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r391"
     ],
     "calculation": {
      "http://biodesix.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets Liabilities Net",
        "totalLabel": "Net deferred tax assets and liabilities"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r391"
     ],
     "calculation": {
      "http://biodesix.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 10010.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets Net",
        "totalLabel": "Total deferred tax assets after valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets Net [Abstract]",
        "terseLabel": "Deferred Tax Assets:"
       }
      }
     },
     "localname": "DeferredTaxAssetsNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r395",
      "r396"
     ],
     "calculation": {
      "http://biodesix.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 10060.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates.",
        "label": "Deferred Tax Assets Operating Loss Carryforwards Subject To Expiration",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment": {
     "auth_ref": [],
     "calculation": {
      "http://biodesix.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 10080.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.",
        "label": "Deferred Tax Assets Property Plant And Equipment",
        "terseLabel": "Property and equipment"
       }
      }
     },
     "localname": "DeferredTaxAssetsPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "auth_ref": [
      "r393",
      "r395",
      "r396"
     ],
     "calculation": {
      "http://biodesix.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 10070.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.",
        "label": "Deferred Tax Assets Tax Credit Carryforwards Research",
        "terseLabel": "Research and development tax credits"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r395",
      "r396"
     ],
     "calculation": {
      "http://biodesix.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 10090.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals": {
     "auth_ref": [
      "r395",
      "r396"
     ],
     "calculation": {
      "http://biodesix.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 10100.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals.",
        "label": "Deferred Tax Assets Tax Deferred Expense Reserves And Accruals",
        "terseLabel": "Accruals and reserves"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r390"
     ],
     "calculation": {
      "http://biodesix.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 10050.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets Valuation Allowance",
        "negatedLabel": "Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities [Abstract]",
        "terseLabel": "Deferred Tax Liabilities:"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets": {
     "auth_ref": [
      "r395",
      "r396"
     ],
     "calculation": {
      "http://biodesix.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 10030.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.",
        "label": "Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets",
        "negatedLabel": "Intangible assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan.",
        "label": "Defined Contribution Plan Employer Discretionary Contribution Amount",
        "terseLabel": "Defined contribution plan, employer discretionary contributions amount"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureDefinedContribution401KPlanAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanPlanNameExtensibleList": {
     "auth_ref": [
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates name of defined contribution plan designed to provide retirement benefits. Includes, but is not limited to, legal name of plan.",
        "label": "Defined Contribution Plan Plan Name Extensible List",
        "terseLabel": "Defined Contribution Plan, Plan Name [Extensible List]"
       }
      }
     },
     "localname": "DefinedContributionPlanPlanNameExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureDefinedContribution401KPlanAdditionalInformationDetail"
     ],
     "xbrltype": "extensibleListItemType"
    },
    "us-gaap_DefinedContributionPlanTextBlock": {
     "auth_ref": [
      "r324",
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for defined contribution plan.",
        "label": "Defined Contribution Plan [Text Block]",
        "terseLabel": "Defined Contribution 401(k) Plan"
       }
      }
     },
     "localname": "DefinedContributionPlanTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureDefinedContribution401KPlan"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r93",
      "r232"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation expense"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfDepreciationExpenseRelatedToPropertyAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationAndAmortization": {
     "auth_ref": [
      "r93",
      "r232"
     ],
     "calculation": {
      "http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfCashFlows": {
       "order": 10150.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.",
        "label": "Depreciation And Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation Of Revenue [Line Items]",
        "terseLabel": "Disaggregation Of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureRevenueAdditionalInformationDetails",
      "http://biodesix.com/20201231/taxonomy/role/DisclosureRevenueSummaryOfRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r299",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation Of Revenue [Table]",
        "terseLabel": "Disaggregation Of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureRevenueAdditionalInformationDetails",
      "http://biodesix.com/20201231/taxonomy/role/DisclosureRevenueSummaryOfRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation Of Revenue Table [Text Block]",
        "terseLabel": "Summary of Revenue"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureRevenueTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Disclosure Of Compensation Related Costs Share Based Payments [Text Block]",
        "terseLabel": "Share Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureShareBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DividendsCommonStock": {
     "auth_ref": [
      "r276",
      "r507"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).",
        "label": "Dividends Common Stock",
        "terseLabel": "Dividends"
       }
      }
     },
     "localname": "DividendsCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Denominator"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureEarningsPerShareScheduleOfComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r141"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share Basic And Diluted",
        "terseLabel": "Net loss per share, basic and diluted"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureEarningsPerShareScheduleOfComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails",
      "http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share Basic And Diluted Other Disclosures [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r102",
      "r143",
      "r144"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share Policy [Text Block]",
        "terseLabel": "Net Loss per Common Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r143",
      "r144",
      "r145",
      "r147"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Earnings per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureEarningsPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r377"
     ],
     "calculation": {
      "http://biodesix.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Continuing Operations",
        "totalLabel": "Effective income tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r377",
      "r405"
     ],
     "calculation": {
      "http://biodesix.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 10010.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate",
        "terseLabel": "Federal statutory income tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r377",
      "r405"
     ],
     "calculation": {
      "http://biodesix.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 10050.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance",
        "terseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r377",
      "r405"
     ],
     "calculation": {
      "http://biodesix.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 10020.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation State And Local Income Taxes",
        "terseLabel": "State income taxes, net of federal benefit"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": {
     "auth_ref": [
      "r377",
      "r405"
     ],
     "calculation": {
      "http://biodesix.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 10030.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.",
        "label": "Effective Income Tax Rate Reconciliation Tax Credits Research",
        "terseLabel": "Research and developments credits"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://biodesix.com/20201231/taxonomy/role/DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails": {
       "order": 10010.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee Related Liabilities Current",
        "terseLabel": "Compensation related accruals"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]",
        "terseLabel": "Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfPreTaxShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r360"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized",
        "terseLabel": "Unrecognized remaining stock based compensation balance"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1",
        "terseLabel": "Amortization period"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock [Member]",
        "terseLabel": "Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services.",
        "label": "Equipment [Member]",
        "terseLabel": "Lab Equipment"
       }
      }
     },
     "localname": "EquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r114",
      "r115",
      "r117",
      "r121",
      "r129",
      "r132",
      "r148",
      "r197",
      "r269",
      "r276",
      "r363",
      "r364",
      "r365",
      "r398",
      "r399",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r530",
      "r531",
      "r532"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureBusinessCombinationsAdditionalInformationDetails",
      "http://biodesix.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetails",
      "http://biodesix.com/20201231/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails",
      "http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquitySecuritiesByIndustryAxis": {
     "auth_ref": [
      "r206"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by industry sector, examples include but are not limited to, commercial, industrial, agricultural, financial services, technology, healthcare and real estate.",
        "label": "Equity Securities By Industry [Axis]",
        "terseLabel": "Industry Sector"
       }
      }
     },
     "localname": "EquitySecuritiesByIndustryAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquitySecuritiesIndustryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Industry sector consisting of government, private and corporate entities engaged in business activities, including but not limited to, commercial, industrial, agricultural, financial services, technology, healthcare and real estate.",
        "label": "Equity Securities Industry [Member]",
        "terseLabel": "Industry Sector"
       }
      }
     },
     "localname": "EquitySecuritiesIndustryMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsDescription": {
     "auth_ref": [
      "r130",
      "r131"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of a prior period adjustment to previously issued financial statements, including an adjustment that is a correction of an error. At a minimum, the description may include the nature and reasons for the adjustment and the periods affected by the adjustment, as well as (1) the effect of the correction on each financial statement line item and any per-share amounts affected for each prior period presented (2) the cumulative effect of the change on retained earnings or other appropriate components of equity or net assets in the statement of financial position, as of the beginning of the earliest period presented, and (3) the effect of the prior period adjustment (both gross and net of applicable income tax) on the net income of each prior period presented in the entity's annual report for the year in which the adjustments are made.",
        "label": "Error Corrections And Prior Period Adjustments Description",
        "terseLabel": "Error corrections and prior period adjustments, description"
       }
      }
     },
     "localname": "ErrorCorrectionsAndPriorPeriodAdjustmentsDescription",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EstimateOfFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured as an estimate of fair value.",
        "label": "Estimate Of Fair Value Fair Value Disclosure [Member]",
        "terseLabel": "Fair Value"
       }
      }
     },
     "localname": "EstimateOfFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureFairValueSummaryOfFairValueOfOutstandingBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees": {
     "auth_ref": [
      "r504"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expense related to distribution, servicing and underwriting fees.",
        "label": "Expense Related To Distribution Or Servicing And Underwriting Fees",
        "terseLabel": "Underwriting discounts and commissions"
       }
      }
     },
     "localname": "ExpenseRelatedToDistributionOrServicingAndUnderwritingFees",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "auth_ref": [
      "r93",
      "r264"
     ],
     "calculation": {
      "http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfCashFlows": {
       "order": 10180.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfOperations": {
       "order": 10050.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.",
        "label": "Fair Value Adjustment Of Warrants",
        "negatedLabel": "Change in fair value of warrant liability",
        "terseLabel": "Change in fair value of warrant liability",
        "verboseLabel": "Increase in value of the warrant liability"
       }
      }
     },
     "localname": "FairValueAdjustmentOfWarrants",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureFairValueAdditionalInformationDetails",
      "http://biodesix.com/20201231/taxonomy/role/DisclosureWarrantsToPurchaseConvertiblePreferredStockAdditionalInformationDetails",
      "http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfCashFlows",
      "http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]",
        "verboseLabel": "Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureFairValueAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r441",
      "r442",
      "r443",
      "r450"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureFairValueAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "auth_ref": [
      "r446"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of asset.",
        "label": "Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation By Asset Class [Domain]",
        "terseLabel": "Asset Class"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfDepreciationExpenseRelatedToPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "auth_ref": [
      "r441",
      "r450"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of asset.",
        "label": "Fair Value By Asset Class [Axis]",
        "terseLabel": "Asset Class"
       }
      }
     },
     "localname": "FairValueByAssetClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfDepreciationExpenseRelatedToPropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r442",
      "r477",
      "r478",
      "r479"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value By Fair Value Hierarchy Level [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureFairValueScheduleOfChangesInFinancialLiabilitiesDetails",
      "http://biodesix.com/20201231/taxonomy/role/DisclosureFairValueScheduleOfReportedFairValuesOfLiabilitiesDetails",
      "http://biodesix.com/20201231/taxonomy/role/DisclosureFairValueSummaryOfFairValueOfOutstandingBorrowingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByLiabilityClassAxis": {
     "auth_ref": [
      "r449",
      "r450"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of liability.",
        "label": "Fair Value By Liability Class [Axis]",
        "terseLabel": "Liability Class"
       }
      }
     },
     "localname": "FairValueByLiabilityClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureFairValueScheduleOfChangesInFinancialLiabilitiesDetails",
      "http://biodesix.com/20201231/taxonomy/role/DisclosureFairValueScheduleOfReportedFairValuesOfLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementBasisAxis": {
     "auth_ref": [
      "r441",
      "r451"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement basis.",
        "label": "Fair Value By Measurement Basis [Axis]",
        "terseLabel": "Measurement Basis"
       }
      }
     },
     "localname": "FairValueByMeasurementBasisAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureFairValueSummaryOfFairValueOfOutstandingBorrowingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r441",
      "r442",
      "r444",
      "r445",
      "r452"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Fair Value By Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureFairValueScheduleOfChangesInFinancialLiabilitiesDetails",
      "http://biodesix.com/20201231/taxonomy/role/DisclosureFairValueScheduleOfReportedFairValuesOfLiabilitiesDetails",
      "http://biodesix.com/20201231/taxonomy/role/DisclosureFairValueSummaryOfFairValueOfOutstandingBorrowingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosureItemAmountsDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value.",
        "label": "Fair Value Disclosure Item Amounts [Domain]",
        "terseLabel": "Fair Value Measurement"
       }
      }
     },
     "localname": "FairValueDisclosureItemAmountsDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureFairValueSummaryOfFairValueOfOutstandingBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r449"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureFairValue"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r316",
      "r317",
      "r322",
      "r323",
      "r442",
      "r478"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value Inputs Level2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureFairValueSummaryOfFairValueOfOutstandingBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r442",
      "r479"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value Inputs Level3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureFairValueScheduleOfChangesInFinancialLiabilitiesDetails",
      "http://biodesix.com/20201231/taxonomy/role/DisclosureFairValueScheduleOfReportedFairValuesOfLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r441",
      "r442"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).  Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.",
        "label": "Fair Value Liabilities Measured On Recurring Basis [Text Block]",
        "terseLabel": "Schedule of Reported Fair values of Liabilities"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureFairValueTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": {
     "auth_ref": [
      "r446"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents classes of liabilities measured and disclosed at fair value.",
        "label": "Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation By Liability Class [Domain]",
        "terseLabel": "Fair Value by Liability Class"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureFairValueScheduleOfChangesInFinancialLiabilitiesDetails",
      "http://biodesix.com/20201231/taxonomy/role/DisclosureFairValueScheduleOfReportedFairValuesOfLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]",
        "terseLabel": "Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureFairValueScheduleOfChangesInFinancialLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "auth_ref": [
      "r446",
      "r450"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3.",
        "label": "Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Table]",
        "terseLabel": "Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Table]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureFairValueScheduleOfChangesInFinancialLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r446",
      "r450"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.",
        "label": "Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Text Block]",
        "terseLabel": "Schedule of Changes in Financial Liabilities"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureFairValueTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Fair Value Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureFairValueScheduleOfChangesInFinancialLiabilitiesDetails",
      "http://biodesix.com/20201231/taxonomy/role/DisclosureFairValueScheduleOfReportedFairValuesOfLiabilitiesDetails",
      "http://biodesix.com/20201231/taxonomy/role/DisclosureFairValueSummaryOfFairValueOfOutstandingBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement Policy Policy [Text Block]",
        "terseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "auth_ref": [
      "r447"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).",
        "label": "Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings",
        "terseLabel": "Changes in fair value"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureFairValueScheduleOfChangesInFinancialLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases": {
     "auth_ref": [
      "r448"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of purchases of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Purchases",
        "terseLabel": "Additions"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureFairValueScheduleOfChangesInFinancialLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "auth_ref": [
      "r446"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value",
        "periodEndLabel": "Ending balances",
        "periodStartLabel": "Beginning balances"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureFairValueScheduleOfChangesInFinancialLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r477",
      "r478",
      "r479"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Measurements Fair Value Hierarchy [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureFairValueScheduleOfChangesInFinancialLiabilitiesDetails",
      "http://biodesix.com/20201231/taxonomy/role/DisclosureFairValueScheduleOfReportedFairValuesOfLiabilitiesDetails",
      "http://biodesix.com/20201231/taxonomy/role/DisclosureFairValueSummaryOfFairValueOfOutstandingBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r449",
      "r452"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value Measurements Recurring [Member]",
        "terseLabel": "Fair Value, Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureFairValueScheduleOfChangesInFinancialLiabilitiesDetails",
      "http://biodesix.com/20201231/taxonomy/role/DisclosureFairValueScheduleOfReportedFairValuesOfLiabilitiesDetails",
      "http://biodesix.com/20201231/taxonomy/role/DisclosureFairValueSummaryOfFairValueOfOutstandingBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite Lived Intangible Asset Useful Life",
        "terseLabel": "Finite-lived intangible asset, useful life"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r224"
     ],
     "calculation": {
      "http://biodesix.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsScheduleOfIntangibleAssetsDetails": {
       "order": 10040.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite Lived Intangible Assets Accumulated Amortization",
        "negatedLabel": "Intangible assets subject to amortization, Accumulated Amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsScheduleOfIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": {
     "auth_ref": [],
     "calculation": {
      "http://biodesix.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsScheduleOfFutureEstimatedAmortizationExpenseOfIntangibleAssetsDetails": {
       "order": 10060.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite Lived Intangible Assets Amortization Expense After Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsScheduleOfFutureEstimatedAmortizationExpenseOfIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r226"
     ],
     "calculation": {
      "http://biodesix.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsScheduleOfFutureEstimatedAmortizationExpenseOfIntangibleAssetsDetails": {
       "order": 10010.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite Lived Intangible Assets Amortization Expense Next Twelve Months",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsScheduleOfFutureEstimatedAmortizationExpenseOfIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life.",
        "label": "Finite Lived Intangible Assets Amortization Expense Table [Text Block]",
        "terseLabel": "Schedule of Amortization Expense Related to Definite-Lived Intangible Assets"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "auth_ref": [
      "r226"
     ],
     "calculation": {
      "http://biodesix.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsScheduleOfFutureEstimatedAmortizationExpenseOfIntangibleAssetsDetails": {
       "order": 10050.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite Lived Intangible Assets Amortization Expense Year Five",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsScheduleOfFutureEstimatedAmortizationExpenseOfIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r226"
     ],
     "calculation": {
      "http://biodesix.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsScheduleOfFutureEstimatedAmortizationExpenseOfIntangibleAssetsDetails": {
       "order": 10040.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite Lived Intangible Assets Amortization Expense Year Four",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsScheduleOfFutureEstimatedAmortizationExpenseOfIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r226"
     ],
     "calculation": {
      "http://biodesix.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsScheduleOfFutureEstimatedAmortizationExpenseOfIntangibleAssetsDetails": {
       "order": 10030.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite Lived Intangible Assets Amortization Expense Year Three",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsScheduleOfFutureEstimatedAmortizationExpenseOfIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r226"
     ],
     "calculation": {
      "http://biodesix.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsScheduleOfFutureEstimatedAmortizationExpenseOfIntangibleAssetsDetails": {
       "order": 10020.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite Lived Intangible Assets Amortization Expense Year Two",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsScheduleOfFutureEstimatedAmortizationExpenseOfIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r218",
      "r220",
      "r224",
      "r228",
      "r488",
      "r492"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite Lived Intangible Assets By Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://biodesix.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsScheduleOfIntangibleAssetsDetails",
      "http://biodesix.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite Lived Intangible Assets Future Amortization Expense [Abstract]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r224",
      "r492"
     ],
     "calculation": {
      "http://biodesix.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsScheduleOfIntangibleAssetsDetails": {
       "order": 10030.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite Lived Intangible Assets Gross",
        "terseLabel": "Intangible assets subject to amortization, Cost"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsScheduleOfIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsScheduleOfAmortizationExpenseRelatedToDefiniteLivedIntangibleAssetsDetails",
      "http://biodesix.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsScheduleOfIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r218",
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite Lived Intangible Assets Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://biodesix.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsScheduleOfIntangibleAssetsDetails",
      "http://biodesix.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r224",
      "r488"
     ],
     "calculation": {
      "http://biodesix.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsScheduleOfFutureEstimatedAmortizationExpenseOfIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://biodesix.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsScheduleOfIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite Lived Intangible Assets Net",
        "totalLabel": "Intangible assets subject to amortization, Net Carrying Value"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsScheduleOfFutureEstimatedAmortizationExpenseOfIntangibleAssetsDetails",
      "http://biodesix.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsScheduleOfIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite Lived Intangible Assets Net [Abstract]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture And Fixtures [Member]",
        "terseLabel": "Furniture and Fixtures"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnDispositionOfAssets1": {
     "auth_ref": [
      "r93"
     ],
     "calculation": {
      "http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfCashFlows": {
       "order": 10240.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.",
        "label": "Gain Loss On Disposition Of Assets1",
        "negatedLabel": "Loss on disposals of assets"
       }
      }
     },
     "localname": "GainLossOnDispositionOfAssets1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r208",
      "r210",
      "r495"
     ],
     "calculation": {
      "http://biodesix.com/20201231/taxonomy/role/DisclosureBusinessCombinationsSummaryOfAggregateConsiderationPaidByCompanyAndAllocationOfPurchasePriceToAssetsAcquiredAndLiabilitiesAssumedDetails": {
       "order": 10050.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      },
      "http://biodesix.com/20201231/taxonomy/role/StatementBalanceSheets": {
       "order": 10250.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureBusinessCombinationsAdditionalInformationDetails",
      "http://biodesix.com/20201231/taxonomy/role/DisclosureBusinessCombinationsSummaryOfAggregateConsiderationPaidByCompanyAndAllocationOfPurchasePriceToAssetsAcquiredAndLiabilitiesAssumedDetails",
      "http://biodesix.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsScheduleOfChangesInGoodwillDetails",
      "http://biodesix.com/20201231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAcquiredDuringPeriod": {
     "auth_ref": [
      "r211"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.",
        "label": "Goodwill Acquired During Period",
        "terseLabel": "Attributable to acquisition of Oncimmune, Ltd."
       }
      }
     },
     "localname": "GoodwillAcquiredDuringPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsScheduleOfChangesInGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetImpairment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total loss recognized during the period from the impairment of goodwill plus the loss recognized in the period resulting from the impairment of the carrying amount of intangible assets, other than goodwill.",
        "label": "Goodwill And Intangible Asset Impairment",
        "terseLabel": "Impairments of intangible assets"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetImpairment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill And Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r230"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for goodwill and intangible assets.",
        "label": "Goodwill And Intangible Assets Disclosure [Text Block]",
        "terseLabel": "Goodwill and Intangible Assets"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": {
     "auth_ref": [
      "r102",
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.",
        "label": "Goodwill And Intangible Assets Goodwill Policy",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy": {
     "auth_ref": [
      "r102",
      "r221"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined.",
        "label": "Goodwill And Intangible Assets Intangible Assets Policy",
        "terseLabel": "Intangible Assets"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsIntangibleAssetsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "auth_ref": [
      "r93",
      "r209",
      "r212",
      "r214"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill Impairment Loss",
        "terseLabel": "Goodwill impairments loss"
       }
      }
     },
     "localname": "GoodwillImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillPeriodIncreaseDecrease": {
     "auth_ref": [
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill Period Increase Decrease",
        "terseLabel": "Increase in goodwill"
       }
      }
     },
     "localname": "GoodwillPeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IPOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First sale of stock by a private company to the public.",
        "label": "I P O [Member]",
        "terseLabel": "Initial Public Offering"
       }
      }
     },
     "localname": "IPOMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureEquityAdditionalInformationDetails",
      "http://biodesix.com/20201231/taxonomy/role/DisclosureFairValueAdditionalInformationDetails",
      "http://biodesix.com/20201231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r93",
      "r229"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.",
        "label": "Impairment Of Intangible Assets Excluding Goodwill",
        "terseLabel": "Impairment of intangible assets"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": {
     "auth_ref": [
      "r93",
      "r231",
      "r236"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).",
        "label": "Impairment Of Long Lived Assets Held For Use",
        "terseLabel": "Impairment of long-lived assets"
       }
      }
     },
     "localname": "ImpairmentOfLongLivedAssetsHeldForUse",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r237"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsScheduleOfAmortizationExpenseRelatedToDefiniteLivedIntangibleAssetsDetails",
      "http://biodesix.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfDepreciationExpenseRelatedToPropertyAndEquipmentDetails",
      "http://biodesix.com/20201231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfPreTaxShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsScheduleOfAmortizationExpenseRelatedToDefiniteLivedIntangibleAssetsDetails",
      "http://biodesix.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfDepreciationExpenseRelatedToPropertyAndEquipmentDetails",
      "http://biodesix.com/20201231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfPreTaxShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r378",
      "r387",
      "r392",
      "r403",
      "r406",
      "r408",
      "r409",
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureIncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExaminationDescription": {
     "auth_ref": [
      "r380"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A brief description of status of the tax examination, significant findings to date, and the entity's position with respect to the findings.",
        "label": "Income Tax Examination Description",
        "terseLabel": "Income tax examination details"
       }
      }
     },
     "localname": "IncomeTaxExaminationDescription",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r108",
      "r131",
      "r132",
      "r169",
      "r376",
      "r404",
      "r407",
      "r523"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense Benefit",
        "terseLabel": "Provision for income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "auth_ref": [
      "r97"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.",
        "label": "Income Taxes Paid Net",
        "terseLabel": "Cash paid for income taxes"
       }
      }
     },
     "localname": "IncomeTaxesPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfCashFlows": {
       "order": 10280.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase Decrease In Accounts Payable And Accrued Liabilities",
        "terseLabel": "Accounts payable and other accrued liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfCashFlows": {
       "order": 10250.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase Decrease In Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfCashFlows": {
       "order": 10290.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase Decrease In Contract With Customer Liability",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase Decrease In Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities, net of assets acquired and liabilities assumed in acquisitions:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherCurrentAssets": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfCashFlows": {
       "order": 10260.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in current assets classified as other.",
        "label": "Increase Decrease In Other Current Assets",
        "negatedLabel": "Other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherCurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet": {
     "auth_ref": [],
     "calculation": {
      "http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfCashFlows": {
       "order": 10270.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent operating assets after deduction of noncurrent operating liabilities classified as other.",
        "label": "Increase Decrease In Other Noncurrent Assets And Liabilities Net",
        "negatedLabel": "Other long-term assets and liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r219",
      "r227"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite Lived Intangible Assets By Major Class [Axis]",
        "terseLabel": "Indefinite-lived Intangible Assets"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsScheduleOfIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r227"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite Lived Intangible Assets Excluding Goodwill",
        "terseLabel": "Intangible assets not subject to amortization, Net Carrying Value"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsScheduleOfIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r219",
      "r227"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.",
        "label": "Indefinite Lived Intangible Assets Major Class Name [Domain]",
        "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsScheduleOfIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IntangibleAssetsGrossExcludingGoodwill": {
     "auth_ref": [],
     "calculation": {
      "http://biodesix.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsScheduleOfIntangibleAssetsDetails": {
       "order": 10010.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill.",
        "label": "Intangible Assets Gross Excluding Goodwill",
        "terseLabel": "Intangible assets, Cost"
       }
      }
     },
     "localname": "IntangibleAssetsGrossExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsScheduleOfIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r216",
      "r222"
     ],
     "calculation": {
      "http://biodesix.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsScheduleOfIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://biodesix.com/20201231/taxonomy/role/StatementBalanceSheets": {
       "order": 10230.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets Net Excluding Goodwill",
        "terseLabel": "Intangible assets, net",
        "totalLabel": "Intangible assets, Net Carrying Value"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsScheduleOfIntangibleAssetsDetails",
      "http://biodesix.com/20201231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestBearingDepositsMember": {
     "auth_ref": [
      "r493",
      "r500"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash on deposit with financial institutions that earns interest, either at a fixed or market rate.",
        "label": "Interest Bearing Deposits [Member]",
        "terseLabel": "Interest-bearing Deposits"
       }
      }
     },
     "localname": "InterestBearingDepositsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r69",
      "r168",
      "r468",
      "r471",
      "r505"
     ],
     "calculation": {
      "http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfOperations": {
       "order": 10040.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeOther": {
     "auth_ref": [],
     "calculation": {
      "http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfOperations": {
       "order": 10030.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest income earned from interest bearing assets classified as other.",
        "label": "Interest Income Other",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InterestIncomeOther",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r86",
      "r89",
      "r97"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid Net",
        "terseLabel": "Cash paid for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventorySuppliesPolicy": {
     "auth_ref": [
      "r63",
      "r102",
      "r207"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the basis and manner that goods are added and removed from inventory for supplies to be consumed directly or indirectly in production. If inventory is carried at cost, this disclosure includes the nature of the cost elements included in inventory and how cost is determined (such as FIFO, LIFO, average).",
        "label": "Inventory Supplies Policy",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventorySuppliesPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]",
        "terseLabel": "Investment Type"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureBusinessCombinationsAdditionalInformationDetails",
      "http://biodesix.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investment Type Categorization [Member]",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureBusinessCombinationsAdditionalInformationDetails",
      "http://biodesix.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold Improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r49",
      "r107",
      "r180",
      "r196",
      "r430",
      "r433",
      "r434",
      "r460"
     ],
     "calculation": {
      "http://biodesix.com/20201231/taxonomy/role/StatementBalanceSheets": {
       "order": 10010.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r37",
      "r107",
      "r196",
      "r460",
      "r501",
      "r519"
     ],
     "calculation": {
      "http://biodesix.com/20201231/taxonomy/role/StatementBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities And Stockholders Equity",
        "totalLabel": "Total liabilities, convertible preferred stock and stockholders' equity (deficit)"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities And Stockholders Equity [Abstract]",
        "terseLabel": "Liabilities, Convertible Preferred Stock and Stockholders' Equity (Deficit)"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r51",
      "r107",
      "r196",
      "r430",
      "r433",
      "r434",
      "r460"
     ],
     "calculation": {
      "http://biodesix.com/20201231/taxonomy/role/StatementBalanceSheets": {
       "order": 10090.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities Current [Abstract]",
        "terseLabel": "Current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "auth_ref": [
      "r441"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial and nonfinancial obligations.",
        "label": "Liabilities Fair Value Disclosure",
        "terseLabel": "Total liabilities"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureFairValueScheduleOfReportedFairValuesOfLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "auth_ref": [
      "r10",
      "r11",
      "r12",
      "r24",
      "r25",
      "r107",
      "r196",
      "r430",
      "r433",
      "r434",
      "r460"
     ],
     "calculation": {
      "http://biodesix.com/20201231/taxonomy/role/StatementBalanceSheets": {
       "order": 10100.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.",
        "label": "Liabilities Noncurrent",
        "totalLabel": "Total non\u2011current liabilities"
       }
      }
     },
     "localname": "LiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities Noncurrent [Abstract]",
        "terseLabel": "Non\u2011current liabilities"
       }
      }
     },
     "localname": "LiabilitiesNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicenseMember": {
     "auth_ref": [
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.",
        "label": "License [Member]",
        "terseLabel": "License Rights"
       }
      }
     },
     "localname": "LicenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureBusinessCombinationsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r24",
      "r260",
      "r499",
      "r516"
     ],
     "calculation": {
      "http://biodesix.com/20201231/taxonomy/role/DisclosureDebtScheduledPrincipalRepaymentsMaturitiesOfLongTermObligationsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long Term Debt",
        "totalLabel": "Long-term debt"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureDebtScheduledPrincipalRepaymentsMaturitiesOfLongTermObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtFairValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.",
        "label": "Long Term Debt Fair Value",
        "terseLabel": "Borrowings"
       }
      }
     },
     "localname": "LongTermDebtFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureFairValueSummaryOfFairValueOfOutstandingBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive": {
     "auth_ref": [
      "r112",
      "r254"
     ],
     "calculation": {
      "http://biodesix.com/20201231/taxonomy/role/DisclosureDebtScheduledPrincipalRepaymentsMaturitiesOfLongTermObligationsDetails": {
       "order": 10060.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long Term Debt Maturities Repayments Of Principal After Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureDebtScheduledPrincipalRepaymentsMaturitiesOfLongTermObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "auth_ref": [
      "r112",
      "r254"
     ],
     "calculation": {
      "http://biodesix.com/20201231/taxonomy/role/DisclosureDebtScheduledPrincipalRepaymentsMaturitiesOfLongTermObligationsDetails": {
       "order": 10010.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long Term Debt Maturities Repayments Of Principal In Next Twelve Months",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureDebtScheduledPrincipalRepaymentsMaturitiesOfLongTermObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": {
     "auth_ref": [
      "r112",
      "r254"
     ],
     "calculation": {
      "http://biodesix.com/20201231/taxonomy/role/DisclosureDebtScheduledPrincipalRepaymentsMaturitiesOfLongTermObligationsDetails": {
       "order": 10050.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long Term Debt Maturities Repayments Of Principal In Year Five",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureDebtScheduledPrincipalRepaymentsMaturitiesOfLongTermObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": {
     "auth_ref": [
      "r112",
      "r254"
     ],
     "calculation": {
      "http://biodesix.com/20201231/taxonomy/role/DisclosureDebtScheduledPrincipalRepaymentsMaturitiesOfLongTermObligationsDetails": {
       "order": 10040.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long Term Debt Maturities Repayments Of Principal In Year Four",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureDebtScheduledPrincipalRepaymentsMaturitiesOfLongTermObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "auth_ref": [
      "r112",
      "r254"
     ],
     "calculation": {
      "http://biodesix.com/20201231/taxonomy/role/DisclosureDebtScheduledPrincipalRepaymentsMaturitiesOfLongTermObligationsDetails": {
       "order": 10030.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long Term Debt Maturities Repayments Of Principal In Year Three",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureDebtScheduledPrincipalRepaymentsMaturitiesOfLongTermObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "auth_ref": [
      "r112",
      "r254"
     ],
     "calculation": {
      "http://biodesix.com/20201231/taxonomy/role/DisclosureDebtScheduledPrincipalRepaymentsMaturitiesOfLongTermObligationsDetails": {
       "order": 10020.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long Term Debt Maturities Repayments Of Principal In Year Two",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureDebtScheduledPrincipalRepaymentsMaturitiesOfLongTermObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermNotesPayable": {
     "auth_ref": [
      "r55"
     ],
     "calculation": {
      "http://biodesix.com/20201231/taxonomy/role/DisclosureDebtSummaryOfLongTermNotesPayableDetails": {
       "order": 10020.0,
       "parentTag": "us-gaap_NotesPayable",
       "weight": 1.0
      },
      "http://biodesix.com/20201231/taxonomy/role/StatementBalanceSheets": {
       "order": 10120.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.",
        "label": "Long Term Notes Payable",
        "terseLabel": "Long\u2011term notes payable"
       }
      }
     },
     "localname": "LongTermNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureDebtSummaryOfLongTermNotesPayableDetails",
      "http://biodesix.com/20201231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r55"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Longterm Debt Type [Axis]",
        "terseLabel": "Long-term Debt, Type"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetails",
      "http://biodesix.com/20201231/taxonomy/role/DisclosureDebtSummaryOfLongTermNotesPayableDetails",
      "http://biodesix.com/20201231/taxonomy/role/DisclosureFairValueAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r55",
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Longterm Debt Type [Domain]",
        "terseLabel": "Long-term Debt, Type"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetails",
      "http://biodesix.com/20201231/taxonomy/role/DisclosureDebtSummaryOfLongTermNotesPayableDetails",
      "http://biodesix.com/20201231/taxonomy/role/DisclosureFairValueAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]",
        "terseLabel": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r251",
      "r252"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]",
        "terseLabel": "Loss Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MaturitiesOfLongTermDebtAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maturities Of Long Term Debt [Abstract]"
       }
      }
     },
     "localname": "MaturitiesOfLongTermDebtAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfCashFlows": {
       "order": 10030.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided By Used In Financing Activities",
        "totalLabel": "Net cash and cash equivalents and restricted cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided By Used In Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfCashFlows": {
       "order": 10020.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided By Used In Investing Activities",
        "totalLabel": "Net cash and cash equivalents and restricted cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided By Used In Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r88",
      "r91",
      "r94"
     ],
     "calculation": {
      "http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfCashFlows": {
       "order": 10010.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided By Used In Operating Activities",
        "totalLabel": "Net cash and cash equivalents and restricted cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided By Used In Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r0",
      "r67",
      "r68",
      "r71",
      "r94",
      "r107",
      "r120",
      "r124",
      "r125",
      "r126",
      "r127",
      "r131",
      "r132",
      "r139",
      "r170",
      "r178",
      "r181",
      "r184",
      "r186",
      "r196",
      "r460",
      "r503",
      "r522"
     ],
     "calculation": {
      "http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income Loss",
        "terseLabel": "Net loss and comprehensive loss",
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss attributable to common stockholders"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureEarningsPerShareScheduleOfComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails",
      "http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income Loss [Abstract]",
        "terseLabel": "Numerator"
       }
      }
     },
     "localname": "NetIncomeLossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureEarningsPerShareScheduleOfComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Accounting Pronouncements And Changes In Accounting Principles [Abstract]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": {
     "auth_ref": [
      "r118",
      "r119",
      "r122",
      "r123",
      "r133",
      "r134",
      "r135",
      "r198",
      "r199",
      "r310",
      "r311",
      "r312",
      "r313",
      "r366",
      "r400",
      "r401",
      "r402",
      "r489",
      "r490",
      "r491",
      "r534",
      "r535",
      "r536",
      "r537",
      "r539"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.",
        "label": "New Accounting Pronouncements And Changes In Accounting Principles [Text Block]",
        "terseLabel": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureRecentAccountingPronouncements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements Policy Policy [Text Block]",
        "terseLabel": "Recently Issued Accounting Standards Not Yet Adopted"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1": {
     "auth_ref": [
      "r98",
      "r99",
      "r100"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of [all] liabilities that an Entity assumes in acquiring a business or in consideration for an asset received in a noncash (or part noncash) acquisition. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Noncash Or Part Noncash Acquisition Value Of Liabilities Assumed1",
        "terseLabel": "Accrued business combination payments"
       }
      }
     },
     "localname": "NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesIssued1": {
     "auth_ref": [
      "r98",
      "r99",
      "r100"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value of notes issued in noncash investing and financing activities.",
        "label": "Notes Issued1",
        "terseLabel": "Convertible notes payable"
       }
      }
     },
     "localname": "NotesIssued1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesPayable": {
     "auth_ref": [
      "r24",
      "r499",
      "r516"
     ],
     "calculation": {
      "http://biodesix.com/20201231/taxonomy/role/DisclosureDebtSummaryOfLongTermNotesPayableDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.",
        "label": "Notes Payable",
        "totalLabel": "Notes payable, total"
       }
      }
     },
     "localname": "NotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureDebtSummaryOfLongTermNotesPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesPayableCurrent": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://biodesix.com/20201231/taxonomy/role/DisclosureDebtSummaryOfLongTermNotesPayableDetails": {
       "order": 10010.0,
       "parentTag": "us-gaap_NotesPayable",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.",
        "label": "Notes Payable Current",
        "terseLabel": "Less: current maturities"
       }
      }
     },
     "localname": "NotesPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureDebtSummaryOfLongTermNotesPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesPayableToBankCurrent": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://biodesix.com/20201231/taxonomy/role/StatementBalanceSheets": {
       "order": 10180.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Current portion of the total carrying amount as of the balance sheet date due within one year or the operating cycle, if longer, on all notes payable to banks paid on an installment with long term maturities. This can include the amount of any loans from the applicant firm. This does not, however, include any mortgage balances.",
        "label": "Notes Payable To Bank Current",
        "terseLabel": "Current portion of notes payable"
       }
      }
     },
     "localname": "NotesPayableToBankCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r165"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number Of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfOperations": {
       "order": 10090.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r170",
      "r178",
      "r181",
      "r184",
      "r186"
     ],
     "calculation": {
      "http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfOperations": {
       "order": 10010.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income Loss",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDue": {
     "auth_ref": [
      "r473",
      "r475"
     ],
     "calculation": {
      "http://biodesix.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumLeasePaymentsForOperatingLeaseObligationsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.",
        "label": "Operating Leases Future Minimum Payments Due",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumLeasePaymentsForOperatingLeaseObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent": {
     "auth_ref": [
      "r473",
      "r475"
     ],
     "calculation": {
      "http://biodesix.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumLeasePaymentsForOperatingLeaseObligationsDetails": {
       "order": 10010.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases Future Minimum Payments Due Current",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumLeasePaymentsForOperatingLeaseObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears": {
     "auth_ref": [
      "r473",
      "r475"
     ],
     "calculation": {
      "http://biodesix.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumLeasePaymentsForOperatingLeaseObligationsDetails": {
       "order": 10050.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases Future Minimum Payments Due In Five Years",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInFiveYears",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumLeasePaymentsForOperatingLeaseObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears": {
     "auth_ref": [
      "r473",
      "r475"
     ],
     "calculation": {
      "http://biodesix.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumLeasePaymentsForOperatingLeaseObligationsDetails": {
       "order": 10040.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases Future Minimum Payments Due In Four Years",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInFourYears",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumLeasePaymentsForOperatingLeaseObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears": {
     "auth_ref": [
      "r473",
      "r475"
     ],
     "calculation": {
      "http://biodesix.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumLeasePaymentsForOperatingLeaseObligationsDetails": {
       "order": 10030.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases Future Minimum Payments Due In Three Years",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInThreeYears",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumLeasePaymentsForOperatingLeaseObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears": {
     "auth_ref": [
      "r473",
      "r475"
     ],
     "calculation": {
      "http://biodesix.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumLeasePaymentsForOperatingLeaseObligationsDetails": {
       "order": 10020.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases Future Minimum Payments Due In Two Years",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInTwoYears",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumLeasePaymentsForOperatingLeaseObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter": {
     "auth_ref": [
      "r473",
      "r475"
     ],
     "calculation": {
      "http://biodesix.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumLeasePaymentsForOperatingLeaseObligationsDetails": {
       "order": 10060.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases Future Minimum Payments Due Thereafter",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueThereafter",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumLeasePaymentsForOperatingLeaseObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesRentExpenseNet": {
     "auth_ref": [
      "r474"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.",
        "label": "Operating Leases Rent Expense Net",
        "terseLabel": "Rent expense"
       }
      }
     },
     "localname": "OperatingLeasesRentExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r1",
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization Consolidation And Presentation Of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Organization and Description of Business"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusiness"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r8",
      "r50"
     ],
     "calculation": {
      "http://biodesix.com/20201231/taxonomy/role/DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails": {
       "order": 10030.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities Current",
        "terseLabel": "Other expenses"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://biodesix.com/20201231/taxonomy/role/StatementBalanceSheets": {
       "order": 10280.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets Current",
        "terseLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://biodesix.com/20201231/taxonomy/role/StatementBalanceSheets": {
       "order": 10240.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets Noncurrent",
        "terseLabel": "Other long-term assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCurrentAssetsMember": {
     "auth_ref": [
      "r438",
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other current assets.",
        "label": "Other Current Assets [Member]",
        "terseLabel": "Other Current Assets"
       }
      }
     },
     "localname": "OtherCurrentAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherIncomeAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Income And Expenses [Abstract]",
        "terseLabel": "Other income (expense):"
       }
      }
     },
     "localname": "OtherIncomeAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherInventorySupplies": {
     "auth_ref": [
      "r62"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of other supplies used within the manufacturing or production process expected to be consumed within one year or operating cycle, if longer.",
        "label": "Other Inventory Supplies",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "OtherInventorySupplies",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://biodesix.com/20201231/taxonomy/role/StatementBalanceSheets": {
       "order": 10140.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities Noncurrent",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncome": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfOperations": {
       "order": 10070.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income",
        "terseLabel": "Other income, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncome",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfOperations": {
       "order": 10020.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income Expense",
        "totalLabel": "Total other expense"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherPaymentsToAcquireBusinesses": {
     "auth_ref": [
      "r80"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with other payments to acquire businesses including deposit on pending acquisitions and preacquisition costs.",
        "label": "Other Payments To Acquire Businesses",
        "terseLabel": "Payments to acquire license rights"
       }
      }
     },
     "localname": "OtherPaymentsToAcquireBusinesses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureBusinessCombinationsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PatentsMember": {
     "auth_ref": [
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law.",
        "label": "Patents [Member]",
        "verboseLabel": "Patents"
       }
      }
     },
     "localname": "PatentsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsScheduleOfIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables And Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsForRoyalties": {
     "auth_ref": [
      "r90"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid for royalties during the current period.",
        "label": "Payments For Royalties",
        "positiveVerboseLabel": "Royalty expense"
       }
      }
     },
     "localname": "PaymentsForRoyalties",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r85"
     ],
     "calculation": {
      "http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfCashFlows": {
       "order": 10090.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments Of Stock Issuance Costs",
        "negatedLabel": "Equity financing costs"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "auth_ref": [
      "r80",
      "r423"
     ],
     "calculation": {
      "http://biodesix.com/20201231/taxonomy/role/DisclosureBusinessCombinationsSummaryOfAggregateConsiderationPaidByCompanyAndAllocationOfPurchasePriceToAssetsAcquiredAndLiabilitiesAssumedDetails": {
       "order": 10070.0,
       "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.",
        "label": "Payments To Acquire Businesses Gross",
        "terseLabel": "Cash"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureBusinessCombinationsAdditionalInformationDetails",
      "http://biodesix.com/20201231/taxonomy/role/DisclosureBusinessCombinationsSummaryOfAggregateConsiderationPaidByCompanyAndAllocationOfPurchasePriceToAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "auth_ref": [
      "r80"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.",
        "label": "Payments To Acquire Businesses Net Of Cash Acquired",
        "terseLabel": "Contingent consideration cash payment"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureBusinessCombinationsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfCashFlows": {
       "order": 10110.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments To Acquire Property Plant And Equipment",
        "negatedLabel": "Purchase of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r333",
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PortionAtFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured at fair value for financial reporting purposes.",
        "label": "Portion At Fair Value Fair Value Disclosure [Member]",
        "terseLabel": "Fair Value Disclosure Item Amounts [Default]"
       }
      }
     },
     "localname": "PortionAtFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureFairValueSummaryOfFairValueOfOutstandingBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r30"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock Par Or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value",
        "verboseLabel": "Preferred stock, par value"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureEquityAdditionalInformationDetails",
      "http://biodesix.com/20201231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails",
      "http://biodesix.com/20201231/taxonomy/role/StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r30"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock Shares Authorized",
        "terseLabel": "Preferred stock, authorized",
        "verboseLabel": "Preferred stock, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureEquityAdditionalInformationDetails",
      "http://biodesix.com/20201231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails",
      "http://biodesix.com/20201231/taxonomy/role/StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r30"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock Shares Issued",
        "terseLabel": "Preferred stock, issued",
        "verboseLabel": "Preferred stock, issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureEquityAdditionalInformationDetails",
      "http://biodesix.com/20201231/taxonomy/role/StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r30"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock Shares Outstanding",
        "terseLabel": "Preferred stock, outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureEquityAdditionalInformationDetails",
      "http://biodesix.com/20201231/taxonomy/role/StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockTextBlock": {
     "auth_ref": [
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for terms, amounts, nature of changes, rights and privileges, dividends, and other matters related to preferred stock.",
        "label": "Preferred Stock [Text Block]",
        "terseLabel": "Convertible Preferred Stock"
       }
      }
     },
     "localname": "PreferredStockTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStock"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://biodesix.com/20201231/taxonomy/role/StatementBalanceSheets": {
       "order": 10050.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock Value",
        "terseLabel": "Preferred stock, $0.001 par value, 5,000,000 (2020) and 0 (2019) authorized; 0 (2020 and 2019) issued and outstanding"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromConvertibleDebt": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfCashFlows": {
       "order": 10070.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.",
        "label": "Proceeds From Convertible Debt",
        "terseLabel": "Proceeds from issuances of convertible notes payable"
       }
      }
     },
     "localname": "ProceedsFromConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfCashFlows": {
       "order": 10040.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.",
        "label": "Proceeds From Issuance Initial Public Offering",
        "terseLabel": "Proceeds from initial public offering"
       }
      }
     },
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureEquityAdditionalInformationDetails",
      "http://biodesix.com/20201231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails",
      "http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfCashFlows": {
       "order": 10060.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.",
        "label": "Proceeds From Issuance Of Convertible Preferred Stock",
        "terseLabel": "Proceeds from issuance of series H preferred stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfConvertiblePreferredStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromNotesPayable": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfCashFlows": {
       "order": 10080.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a borrowing supported by a written promise to pay an obligation.",
        "label": "Proceeds From Notes Payable",
        "terseLabel": "Proceeds from paycheck protection program note payable"
       }
      }
     },
     "localname": "ProceedsFromNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": {
     "auth_ref": [
      "r84",
      "r85",
      "r111"
     ],
     "calculation": {
      "http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfCashFlows": {
       "order": 10100.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities classified as other.",
        "label": "Proceeds From Payments For Other Financing Activities",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "ProceedsFromPaymentsForOtherFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r82",
      "r362"
     ],
     "calculation": {
      "http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfCashFlows": {
       "order": 10050.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds From Stock Options Exercised",
        "terseLabel": "Proceeds from exercise of common stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductWarrantyAccrualClassifiedCurrent": {
     "auth_ref": [
      "r50",
      "r250",
      "r253"
     ],
     "calculation": {
      "http://biodesix.com/20201231/taxonomy/role/DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails": {
       "order": 10040.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for estimated claims under standard and extended warranty protection rights granted to customers. For classified balance sheets, represents the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Product Warranty Accrual Classified Current",
        "terseLabel": "Warrant liability, current"
       }
      }
     },
     "localname": "ProductWarrantyAccrualClassifiedCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r0",
      "r67",
      "r68",
      "r87",
      "r107",
      "r120",
      "r131",
      "r132",
      "r170",
      "r178",
      "r181",
      "r184",
      "r186",
      "r196",
      "r428",
      "r431",
      "r432",
      "r435",
      "r436",
      "r460",
      "r506"
     ],
     "calculation": {
      "http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfCashFlows": {
       "order": 10140.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Profit Loss",
        "terseLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property Plant And Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r42",
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Property Plant And Equipment By Type [Axis]",
        "terseLabel": "Long-Lived Tangible Asset"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r238",
      "r559",
      "r560",
      "r561"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property Plant And Equipment Disclosure [Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosurePropertyAndEquipment"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r41",
      "r233"
     ],
     "calculation": {
      "http://biodesix.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails": {
       "order": 10010.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property Plant And Equipment Gross",
        "terseLabel": "Property and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property Plant And Equipment [Line Items]",
        "terseLabel": "Property Plant And Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfDepreciationExpenseRelatedToPropertyAndEquipmentDetails",
      "http://biodesix.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property Plant And Equipment [Member]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfDepreciationExpenseRelatedToPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r17",
      "r18",
      "r235",
      "r520"
     ],
     "calculation": {
      "http://biodesix.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://biodesix.com/20201231/taxonomy/role/StatementBalanceSheets": {
       "order": 10220.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property Plant And Equipment Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Total property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails",
      "http://biodesix.com/20201231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r40",
      "r102",
      "r235",
      "r559",
      "r560"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property Plant And Equipment Policy [Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r17",
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property Plant And Equipment [Text Block]",
        "terseLabel": "Schedule of Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r17",
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Property Plant And Equipment Type [Domain]",
        "terseLabel": "Long-Lived Tangible Asset"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property Plant And Equipment Useful Life",
        "terseLabel": "Property, plant and equipment, useful Lives"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ProvisionForDoubtfulAccounts": {
     "auth_ref": [
      "r72",
      "r204"
     ],
     "calculation": {
      "http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfCashFlows": {
       "order": 10230.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.",
        "label": "Provision For Doubtful Accounts",
        "terseLabel": "Provision for doubtful accounts"
       }
      }
     },
     "localname": "ProvisionForDoubtfulAccounts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy": {
     "auth_ref": [
      "r38",
      "r102",
      "r194"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the allowance for doubtful accounts for trade and other accounts receivable balances, and when impairments, charge-offs or recoveries are recognized.",
        "label": "Receivables Trade And Other Accounts Receivable Allowance For Doubtful Accounts Policy",
        "terseLabel": "Accounts Receivable and Allowance for Doubtful Accounts"
       }
      }
     },
     "localname": "ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Reconciliation Of Unrecognized Tax Benefits Excluding Amounts Pertaining To Examined Tax Returns Roll Forward"
       }
      }
     },
     "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r374",
      "r571"
     ],
     "calculation": {
      "http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfOperations": {
       "order": 10110.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research And Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research And Development Expense [Member]",
        "terseLabel": "Research and Development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfPreTaxShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r102",
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research And Development Expense Policy",
        "terseLabel": "Research and Development Expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCash": {
     "auth_ref": [
      "r101",
      "r494",
      "r517"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCash",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units R S U [Member]",
        "terseLabel": "Restricted Stock Units (RSUs)",
        "verboseLabel": "Restricted Stock Units"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureEarningsPerShareScheduleOfCommonStockEquivalentsExcludedFromDilutedNetLossAttributableToCommonStockholdersDetails",
      "http://biodesix.com/20201231/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r34",
      "r276",
      "r367",
      "r518",
      "r534",
      "r539"
     ],
     "calculation": {
      "http://biodesix.com/20201231/taxonomy/role/StatementBalanceSheets": {
       "order": 10080.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings Accumulated Deficit",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r114",
      "r115",
      "r117",
      "r121",
      "r129",
      "r132",
      "r197",
      "r363",
      "r364",
      "r365",
      "r398",
      "r399",
      "r530",
      "r532"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue From Contract With Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r103",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue From Contract With Customer Policy [Text Block]",
        "terseLabel": "Deferred Revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r302",
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue From Contract With Customer [Text Block]",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureRevenue"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r103",
      "r104"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue Recognition Policy [Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r70",
      "r107",
      "r166",
      "r167",
      "r177",
      "r182",
      "r183",
      "r187",
      "r188",
      "r190",
      "r196",
      "r460",
      "r506"
     ],
     "calculation": {
      "http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfOperations": {
       "order": 10080.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "terseLabel": "Revenues"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureRevenueAdditionalInformationDetails",
      "http://biodesix.com/20201231/taxonomy/role/DisclosureRevenueSummaryOfRevenueDetails",
      "http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RoyaltyExpense": {
     "auth_ref": [
      "r75"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.",
        "label": "Royalty Expense",
        "terseLabel": "Royalty expense"
       }
      }
     },
     "localname": "RoyaltyExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale Of Stock Name Of Transaction [Domain]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureEquityAdditionalInformationDetails",
      "http://biodesix.com/20201231/taxonomy/role/DisclosureFairValueAdditionalInformationDetails",
      "http://biodesix.com/20201231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails",
      "http://biodesix.com/20201231/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale Of Stock Price Per Share",
        "terseLabel": "Common stock price per share"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureEquityAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SalesRevenueNetMember": {
     "auth_ref": [
      "r159",
      "r190"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.",
        "label": "Sales Revenue Net [Member]",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "SalesRevenueNetMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://biodesix.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfRevenueAndAccountsReceivableByThirdPartyPayorsAndOtherCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule Of Accrued Liabilities Table [Text Block]",
        "terseLabel": "Schedule of Accrued Liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureAccruedLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r143"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]",
        "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureEarningsPerShareScheduleOfCommonStockEquivalentsExcludedFromDilutedNetLossAttributableToCommonStockholdersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r143"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block]",
        "terseLabel": "Schedule of Common Stock Equivalents Excluded from Diluted Net Loss Attributable to Common Stockholders"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureEarningsPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r412",
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule Of Business Acquisitions By Acquisition [Table]",
        "terseLabel": "Schedule Of Business Acquisitions By Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureBusinessCombinationsAdditionalInformationDetails",
      "http://biodesix.com/20201231/taxonomy/role/DisclosureBusinessCombinationsSummaryOfAggregateConsiderationPaidByCompanyAndAllocationOfPurchasePriceToAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information pertaining to carrying amount and estimated fair value of short-term and long-term debt instruments or arrangements, including but not limited to, identification of terms, features, and collateral requirements.",
        "label": "Schedule Of Carrying Values And Estimated Fair Values Of Debt Instruments Table [Text Block]",
        "terseLabel": "Summary of Fair Value of Outstanding Borrowings"
       }
      }
     },
     "localname": "ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureFairValueTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDebtInstrumentsTextBlock": {
     "auth_ref": [
      "r55",
      "r110",
      "r270",
      "r273",
      "r274",
      "r275",
      "r469",
      "r470",
      "r472",
      "r511"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.",
        "label": "Schedule Of Debt Instruments [Text Block]",
        "terseLabel": "Summary of Long-term Notes Payable"
       }
      }
     },
     "localname": "ScheduleOfDebtInstrumentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureDebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule Of Deferred Tax Assets And Liabilities Table [Text Block]",
        "terseLabel": "Schedule of Deferred Tax Assets and Liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r142"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule Of Earnings Per Share Basic And Diluted Table [Text Block]",
        "terseLabel": "Schedule of Computation of Basic and Diluted Net Loss per Share Attributable to Common Stockholders"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureEarningsPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule Of Effective Income Tax Rate Reconciliation Table [Text Block]",
        "terseLabel": "Schedule of Effective Income Tax Rate Reconciliation"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r332",
      "r358",
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]",
        "terseLabel": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfPreTaxShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r332",
      "r358",
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block]",
        "terseLabel": "Summary of Pre-tax Share-based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r218",
      "r223",
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule Of Finite Lived Intangible Assets [Table]",
        "terseLabel": "Schedule Of Finite Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsScheduleOfAmortizationExpenseRelatedToDefiniteLivedIntangibleAssetsDetails",
      "http://biodesix.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsScheduleOfIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock": {
     "auth_ref": [
      "r476"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.",
        "label": "Schedule Of Future Minimum Rental Payments For Operating Leases Table [Text Block]",
        "terseLabel": "Summary of Future Minimum Lease Payments for Operating Lease Obligations"
       }
      }
     },
     "localname": "ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "auth_ref": [
      "r213",
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.",
        "label": "Schedule Of Goodwill [Text Block]",
        "terseLabel": "Schedule of Changes in Goodwill"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock": {
     "auth_ref": [
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.",
        "label": "Schedule Of Intangible Assets And Goodwill Table [Text Block]",
        "terseLabel": "Schedule of Intangible Assets"
       }
      }
     },
     "localname": "ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "auth_ref": [
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.",
        "label": "Schedule Of Maturities Of Long Term Debt Table [Text Block]",
        "terseLabel": "Scheduled Principal Repayments (Maturities) of Long-term Obligations"
       }
      }
     },
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureDebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r42",
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Schedule Of Property Plant And Equipment [Table]",
        "terseLabel": "Schedule Of Property Plant And Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfDepreciationExpenseRelatedToPropertyAndEquipmentDetails",
      "http://biodesix.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r333",
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]",
        "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r339",
      "r350",
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Schedule Of Share Based Compensation Stock Options Activity Table [Text Block]",
        "terseLabel": "Summary of Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table [Text Block]",
        "terseLabel": "Summary of Weighted Average Assumptions"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r58",
      "r105",
      "r149",
      "r150",
      "r265",
      "r267",
      "r268",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule Of Stock By Class [Table]",
        "terseLabel": "Schedule Of Stock By Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://biodesix.com/20201231/taxonomy/role/DisclosureEquityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "auth_ref": [
      "r279",
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Schedule Of Stockholders Equity Note Warrants Or Rights [Text Block]",
        "terseLabel": "Summary of Activity for Convertible Preferred Stock Warrants"
       }
      }
     },
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureWarrantsToPurchaseConvertiblePreferredStockTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "auth_ref": [
      "r386",
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits.",
        "label": "Schedule Of Unrecognized Tax Benefits Roll Forward Table [Text Block]",
        "terseLabel": "Reconciliation of Unrecognized Tax Benefits"
       }
      }
     },
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "auth_ref": [
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.",
        "label": "Scheduleof Finite Lived Intangible Assets Future Amortization Expense Table [Text Block]",
        "terseLabel": "Schedule of Future Estimated Amortization Expense of Intangible Assets"
       }
      }
     },
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": {
     "auth_ref": [
      "r157",
      "r159",
      "r160",
      "r161",
      "r457",
      "r459"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Schedules Of Concentration Of Risk By Risk Factor [Text Block]",
        "terseLabel": "Summary of Revenue and Accounts Receivable by Third-party Payors and Other Customers"
       }
      }
     },
     "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "localname": "SegmentReportingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r102",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r188"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting Policy Policy [Text Block]",
        "terseLabel": "Segment Reporting"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfOperations": {
       "order": 10120.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling General And Administrative Expense",
        "terseLabel": "Sales, marketing, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling General And Administrative Expenses [Member]",
        "terseLabel": "Sales, Marketing, General and Administrative",
        "verboseLabel": "Sales, Marketing, General and Administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsScheduleOfAmortizationExpenseRelatedToDefiniteLivedIntangibleAssetsDetails",
      "http://biodesix.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfDepreciationExpenseRelatedToPropertyAndEquipmentDetails",
      "http://biodesix.com/20201231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfPreTaxShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock": {
     "auth_ref": [
      "r102",
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.",
        "label": "Selling General And Administrative Expenses Policy [Text Block]",
        "terseLabel": "Sales, Marketing, General and Administrative Expenses"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SeriesBPreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Outstanding nonredeemable series B preferred stock or outstanding series B preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Series B Preferred Stock [Member]",
        "terseLabel": "Series B Preferred Stock"
       }
      }
     },
     "localname": "SeriesBPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeriesCPreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Outstanding nonredeemable series C preferred stock or outstanding series C preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Series C Preferred Stock [Member]",
        "terseLabel": "Series C Preferred Stock"
       }
      }
     },
     "localname": "SeriesCPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeriesDPreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Outstanding nonredeemable series D preferred stock or outstanding series D preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Series D Preferred Stock [Member]",
        "terseLabel": "Series D Preferred Stock"
       }
      }
     },
     "localname": "SeriesDPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeriesEPreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Outstanding nonredeemable series E preferred stock or outstanding series E preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Series E Preferred Stock [Member]",
        "terseLabel": "Series E Preferred Stock"
       }
      }
     },
     "localname": "SeriesEPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeriesFPreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Outstanding nonredeemable series F preferred stock or outstanding series F preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Series F Preferred Stock [Member]",
        "terseLabel": "Series F Preferred Stock"
       }
      }
     },
     "localname": "SeriesFPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://biodesix.com/20201231/taxonomy/role/DisclosureFairValueAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeriesGPreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Outstanding nonredeemable series G preferred stock or outstanding series G preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Series G Preferred Stock [Member]",
        "terseLabel": "Series G Preferred Stock"
       }
      }
     },
     "localname": "SeriesGPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://biodesix.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetails",
      "http://biodesix.com/20201231/taxonomy/role/DisclosureFairValueAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeriesHPreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Outstanding nonredeemable series H preferred stock or outstanding series H preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Series H Preferred Stock [Member]",
        "terseLabel": "Series H Convertible Preferred Stock"
       }
      }
     },
     "localname": "SeriesHPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://biodesix.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetails",
      "http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ServiceMember": {
     "auth_ref": [
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, and financial service.",
        "label": "Service [Member]",
        "terseLabel": "Services"
       }
      }
     },
     "localname": "ServiceMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureRevenueSummaryOfRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfCashFlows": {
       "order": 10170.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share Based Compensation",
        "terseLabel": "Stock\u2011based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1",
        "terseLabel": "Vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights": {
     "auth_ref": [
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of service or performance condition required to be met for earning right to award under share-based payment arrangement. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Rights",
        "terseLabel": "Vesting term"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate": {
     "auth_ref": [
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discount rate from fair value on offering date that participants pay for shares.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Discount From Market Price Offering Date",
        "terseLabel": "Percentage of fair market value of common stock for purchase under plan"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period",
        "verboseLabel": "Number of RSUs granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant date fair value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions And Methodology [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate",
        "terseLabel": "Risk\u2011free rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]",
        "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate": {
     "auth_ref": [
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Maximum Employee Subscription Rate",
        "terseLabel": "Percentage of earnings used for purchase of common stock"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": {
     "auth_ref": [
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of non-option equity instruments exercised by participants.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised",
        "terseLabel": "Exercised, warrants"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureWarrantsToPurchaseConvertiblePreferredStockSummaryOfActivityForConvertiblePreferredStockWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures": {
     "auth_ref": [
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares under non-option equity instrument agreements that were cancelled as a result of occurrence of a terminating event.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures",
        "negatedLabel": "Forfeited/canceled, warrants"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureWarrantsToPurchaseConvertiblePreferredStockSummaryOfActivityForConvertiblePreferredStockWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": {
     "auth_ref": [
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net number of non-option equity instruments granted to participants.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted",
        "terseLabel": "Granted, warrants"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureWarrantsToPurchaseConvertiblePreferredStockSummaryOfActivityForConvertiblePreferredStockWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": {
     "auth_ref": [
      "r340",
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number",
        "periodEndLabel": "Outstanding \u2011 December 31, 2020, warrants",
        "periodStartLabel": "Outstanding \u2011 December 31, 2019, warrants",
        "terseLabel": "RSUs outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails",
      "http://biodesix.com/20201231/taxonomy/role/DisclosureWarrantsToPurchaseConvertiblePreferredStockSummaryOfActivityForConvertiblePreferredStockWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsPeriodIncreaseDecrease": {
     "auth_ref": [
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (decrease) in the number of shares under non-option equity instrument agreements.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Period Increase Decrease",
        "negatedLabel": "Reclassification of warrant liability to additional paid-in capital, warrants"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsPeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureWarrantsToPurchaseConvertiblePreferredStockSummaryOfActivityForConvertiblePreferredStockWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized",
        "terseLabel": "Number of shares authorized"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant",
        "terseLabel": "Additional stock awards granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number",
        "terseLabel": "Stock Options, Exercisable \u2011 December 31, 2020"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Exercisable \u2011 December 31, 2020"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "auth_ref": [
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period",
        "negatedLabel": "Stock Options, Forfeited/canceled"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price of options that were either forfeited or expired.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Forfeited/canceled"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period",
        "terseLabel": "Options forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross",
        "terseLabel": "Stock Options, Granted",
        "verboseLabel": "Number of performance-condition options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails",
      "http://biodesix.com/20201231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r361"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value",
        "periodEndLabel": "Aggregate Intrinsic Value, Outstanding - December 31, 2020",
        "periodStartLabel": "Aggregate Intrinsic Value, Outstanding - December 31, 2019",
        "verboseLabel": "Intrinsic value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails",
      "http://biodesix.com/20201231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r341",
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number",
        "periodEndLabel": "Stock Options, Outstanding \u2011 December 31, 2020",
        "periodStartLabel": "Stock Options, Outstanding \u2011 December 31, 2019",
        "terseLabel": "Number of outstanding stock options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails",
      "http://biodesix.com/20201231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r340"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price",
        "periodEndLabel": "Weighted Average Exercise Price, Outstanding \u2011 December 31, 2020",
        "periodStartLabel": "Weighted Average Exercise Price, Outstanding \u2011 December 31, 2019"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price,vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Percentage Of Outstanding Stock Maximum",
        "terseLabel": "Percentage of number of shares of common stock issued and outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": {
     "auth_ref": [
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued under share-based payment arrangement.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period",
        "terseLabel": "Number of common stock may be issued under incentive plan"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r331",
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price",
        "terseLabel": "Exercise price",
        "verboseLabel": "Weighted Average Exercise Price, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails",
      "http://biodesix.com/20201231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share Based Compensation Award Tranche One [Member]",
        "terseLabel": "Share-based Payment Arrangement, Tranche One"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share Based Compensation Award Tranche Two [Member]",
        "terseLabel": "Share-based Payment Arrangement, Tranche Two"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheTwoMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r102",
      "r333",
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share Based Compensation Option And Incentive Plans Policy",
        "terseLabel": "Share-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "auth_ref": [
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of vesting of award under share-based payment arrangement.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Award Vesting Rights Percentage",
        "terseLabel": "Vesting percentage"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period",
        "terseLabel": "Option expiration period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r354",
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1",
        "terseLabel": "Expected term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r361"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1",
        "terseLabel": "Aggregate Intrinsic Value, Outstanding - Exercisable \u2011 December 31, 2020"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1",
        "terseLabel": "Weighted Average Contractual Life (Years), Exercisable \u2011 December 31, 2020"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2",
        "terseLabel": "Weighted Average Contractual Life (Years), Outstanding - December 31, 2019",
        "verboseLabel": "Remaining life of outstanding performance condition options"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails",
      "http://biodesix.com/20201231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options vested.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares",
        "terseLabel": "Options vested"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "Shares Issued Price Per Share",
        "terseLabel": "Common stock price per share"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShortTermDebtTypeAxis": {
     "auth_ref": [
      "r47"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of short-term debt arrangement.",
        "label": "Short Term Debt Type [Axis]",
        "terseLabel": "Short-term Debt, Type"
       }
      }
     },
     "localname": "ShortTermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShortTermDebtTypeDomain": {
     "auth_ref": [
      "r45"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing.",
        "label": "Short Term Debt Type [Domain]",
        "terseLabel": "Short-term Debt, Type"
       }
      }
     },
     "localname": "ShortTermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r113"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SoftwareAndSoftwareDevelopmentCostsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchased software applications and internally developed software for sale, licensing or long-term internal use.",
        "label": "Software And Software Development Costs [Member]",
        "terseLabel": "Software"
       }
      }
     },
     "localname": "SoftwareAndSoftwareDevelopmentCostsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r29",
      "r30",
      "r31",
      "r105",
      "r107",
      "r136",
      "r137",
      "r138",
      "r140",
      "r142",
      "r149",
      "r150",
      "r151",
      "r196",
      "r269",
      "r460"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Statement Class Of Stock [Axis]",
        "terseLabel": "Class of Stock"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://biodesix.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetails",
      "http://biodesix.com/20201231/taxonomy/role/DisclosureEarningsPerShareScheduleOfCommonStockEquivalentsExcludedFromDilutedNetLossAttributableToCommonStockholdersDetails",
      "http://biodesix.com/20201231/taxonomy/role/DisclosureFairValueAdditionalInformationDetails",
      "http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r61",
      "r114",
      "r115",
      "r117",
      "r121",
      "r129",
      "r132",
      "r148",
      "r197",
      "r269",
      "r276",
      "r363",
      "r364",
      "r365",
      "r398",
      "r399",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r530",
      "r531",
      "r532"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Statement Equity Components [Axis]",
        "terseLabel": "Equity Components"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureBusinessCombinationsAdditionalInformationDetails",
      "http://biodesix.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetails",
      "http://biodesix.com/20201231/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails",
      "http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Of Stockholders Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r114",
      "r115",
      "r117",
      "r148",
      "r487"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r60",
      "r269",
      "r270",
      "r276"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.",
        "label": "Stock Issued During Period Shares Conversion Of Convertible Securities",
        "terseLabel": "Conversion of preferred stock into common stock, shares",
        "verboseLabel": "Debt instrument converted to common stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetails",
      "http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r30",
      "r31",
      "r269",
      "r276"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period Shares New Issues",
        "terseLabel": "Issuance of common stock in initial public offering, net of discounts and commission and direct offering costs, shares",
        "verboseLabel": "Shares of common stock issued and sold"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureEquityAdditionalInformationDetails",
      "http://biodesix.com/20201231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails",
      "http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r30",
      "r31",
      "r269",
      "r276",
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Stock Issued During Period Shares Stock Options Exercised",
        "negatedLabel": "Stock Options, Exercised",
        "terseLabel": "Common stock issued upon exercise of stock options, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetails",
      "http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r61",
      "r269",
      "r276"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.",
        "label": "Stock Issued During Period Value Conversion Of Convertible Securities",
        "terseLabel": "Conversion of preferred stock into common stock upon initial public offering"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r30",
      "r31",
      "r269",
      "r276"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period Value New Issues",
        "terseLabel": "Issuance of common stock in initial public offering, net of discounts and commission of $5,040 and direct offering costs of $3,203"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r61",
      "r269",
      "r276"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period Value Stock Options Exercised",
        "terseLabel": "Common stock issued upon exercise of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r31",
      "r35",
      "r36",
      "r107",
      "r195",
      "r196",
      "r460"
     ],
     "calculation": {
      "http://biodesix.com/20201231/taxonomy/role/StatementBalanceSheets": {
       "order": 10040.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders Equity",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "totalLabel": "Total stockholders' equity (deficit)"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/StatementBalanceSheets",
      "http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders Equity [Abstract]",
        "terseLabel": "Stockholders' equity (deficit)"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders Equity Note [Abstract]"
       }
      }
     },
     "localname": "StockholdersEquityNoteAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r106",
      "r276",
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders Equity Note Disclosure [Text Block]",
        "terseLabel": "Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": {
     "auth_ref": [
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.",
        "label": "Stockholders Equity Note Stock Split Conversion Ratio1",
        "terseLabel": "Reverse stock split ratio"
       }
      }
     },
     "localname": "StockholdersEquityNoteStockSplitConversionRatio1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://biodesix.com/20201231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_StockholdersEquityReverseStockSplit": {
     "auth_ref": [
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.",
        "label": "Stockholders Equity Reverse Stock Split",
        "terseLabel": "Reverse stock split, description"
       }
      }
     },
     "localname": "StockholdersEquityReverseStockSplit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Subsidiary Sale Of Stock [Axis]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureEquityAdditionalInformationDetails",
      "http://biodesix.com/20201231/taxonomy/role/DisclosureFairValueAdditionalInformationDetails",
      "http://biodesix.com/20201231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails",
      "http://biodesix.com/20201231/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental cash flow information"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardDescription": {
     "auth_ref": [
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A description of the origin, nature, and characteristics of the tax credit carryforward.",
        "label": "Tax Credit Carryforward Description",
        "terseLabel": "Description of tax credit carryforward expiration"
       }
      }
     },
     "localname": "TaxCreditCarryforwardDescription",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity [Abstract]",
        "terseLabel": "Convertible preferred stock"
       }
      }
     },
     "localname": "TemporaryEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": {
     "auth_ref": [],
     "calculation": {
      "http://biodesix.com/20201231/taxonomy/role/StatementBalanceSheets": {
       "order": 10030.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity Carrying Amount Attributable To Parent",
        "terseLabel": "Convertible preferred stock, $0.001 par value, 0 (2020) and 174,237,067 (2019) authorized; 0 (2020) and 118,766,273 (2019) issued and outstanding; liquidation preference of $202,582 (2019)"
       }
      }
     },
     "localname": "TemporaryEquityCarryingAmountAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityLiquidationPreference": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity Liquidation Preference",
        "terseLabel": "Convertible preferred stock, liquidation preference"
       }
      }
     },
     "localname": "TemporaryEquityLiquidationPreference",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityParOrStatedValuePerShare": {
     "auth_ref": [
      "r9",
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.",
        "label": "Temporary Equity Par Or Stated Value Per Share",
        "terseLabel": "Convertible preferred stock, par value"
       }
      }
     },
     "localname": "TemporaryEquityParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://biodesix.com/20201231/taxonomy/role/StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_TemporaryEquitySharesAuthorized": {
     "auth_ref": [
      "r28"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity Shares Authorized",
        "terseLabel": "Convertible preferred stock, authorized"
       }
      }
     },
     "localname": "TemporaryEquitySharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TemporaryEquitySharesIssued": {
     "auth_ref": [
      "r28"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity Shares Issued",
        "terseLabel": "Convertible preferred stock, issued"
       }
      }
     },
     "localname": "TemporaryEquitySharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://biodesix.com/20201231/taxonomy/role/StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TemporaryEquitySharesOutstanding": {
     "auth_ref": [
      "r28"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity Shares Outstanding",
        "periodEndLabel": "Temporary Equity Balance, Shares",
        "periodStartLabel": "Temporary Equity Balance, Shares",
        "terseLabel": "Convertible preferred stock, outstanding"
       }
      }
     },
     "localname": "TemporaryEquitySharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://biodesix.com/20201231/taxonomy/role/StatementBalanceSheetsParenthetical",
      "http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of new stock classified as temporary equity issued during the period.",
        "label": "Temporary Equity Stock Issued During Period Value New Issues",
        "terseLabel": "Issuance of Series H Preferred Stock"
       }
      }
     },
     "localname": "TemporaryEquityStockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TrademarksMember": {
     "auth_ref": [
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style.",
        "label": "Trademarks [Member]",
        "terseLabel": "Trademarks"
       }
      }
     },
     "localname": "TrademarksMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsScheduleOfIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Type Of Arrangement [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r375",
      "r381"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "Balance at December 31",
        "periodStartLabel": "Balance at January 1"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r382"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions",
        "terseLabel": "Reductions for tax positions related to prior years"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities": {
     "auth_ref": [
      "r384"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from settlements with taxing authorities.",
        "label": "Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities",
        "terseLabel": "Reductions related to settlements"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "auth_ref": [
      "r383"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.",
        "label": "Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions",
        "terseLabel": "Additions for tax positions related to the current year"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r382"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions",
        "terseLabel": "Additions for tax positions related to prior years"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued": {
     "auth_ref": [
      "r379"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest expense accrued for an underpayment of income taxes.",
        "label": "Unrecognized Tax Benefits Interest On Income Taxes Accrued",
        "terseLabel": "Accrued interest related to uncertain tax positions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations": {
     "auth_ref": [
      "r385"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.",
        "label": "Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations",
        "terseLabel": "Reductions related to a lapse of statute"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r152",
      "r153",
      "r155",
      "r156",
      "r162",
      "r163",
      "r164"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use Of Estimates",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r391"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance Deferred Tax Asset Change In Amount",
        "terseLabel": "Increase in valuation allowance"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetExplanationOfChange": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A description of and reason for the change during the period in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance Deferred Tax Asset Explanation Of Change",
        "terseLabel": "Valuation allowance, deferred tax asset, explanation of change"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetExplanationOfChange",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingAxis": {
     "auth_ref": [
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Axis]",
        "terseLabel": "Vesting"
       }
      }
     },
     "localname": "VestingAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingDomain": {
     "auth_ref": [
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Domain]",
        "terseLabel": "Vesting"
       }
      }
     },
     "localname": "VestingDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "terseLabel": "Warrants"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureEarningsPerShareScheduleOfCommonStockEquivalentsExcludedFromDilutedNetLossAttributableToCommonStockholdersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantsAndRightsNoteDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants And Rights Note Disclosure [Abstract]"
       }
      }
     },
     "localname": "WarrantsAndRightsNoteDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_WarrantsAndRightsOutstanding": {
     "auth_ref": [],
     "calculation": {
      "http://biodesix.com/20201231/taxonomy/role/StatementBalanceSheets": {
       "order": 10110.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.",
        "label": "Warrants And Rights Outstanding",
        "terseLabel": "Warrant liability"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingMaturityDate": {
     "auth_ref": [
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in CCYY-MM-DD format.",
        "label": "Warrants And Rights Outstanding Maturity Date",
        "terseLabel": "Warrants, expires period"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingMaturityDate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureFairValueAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_WarrantsNotSettleableInCashFairValueDisclosure": {
     "auth_ref": [
      "r441"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of warrants not settleable in cash classified as equity.",
        "label": "Warrants Not Settleable In Cash Fair Value Disclosure",
        "terseLabel": "Estimated air value of warrants issued"
       }
      }
     },
     "localname": "WarrantsNotSettleableInCashFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetails",
      "http://biodesix.com/20201231/taxonomy/role/DisclosureFairValueAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted Average Number Of Share Outstanding Basic And Diluted",
        "terseLabel": "Weighted-average shares outstanding, basic and diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://biodesix.com/20201231/taxonomy/role/DisclosureEarningsPerShareScheduleOfComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails",
      "http://biodesix.com/20201231/taxonomy/role/StatementStatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 7
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(24))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4332-108586"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(25))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(e),(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04.(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "27",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e22044-107793"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(26))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=112272810&loc=d3e31137-122693"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=112272810&loc=SL108384541-122693"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "250",
   "URI": "http://asc.fasb.org/topic&trid=2122394"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1278-109256"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2626-109256"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(10))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70229-108054"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(11))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(12))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8672-108599"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4428-111522"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4531-111522"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5074-111524"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5144-111524"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(16))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599878&loc=SL82895884-210446"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121647567&loc=SL82921835-210448"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "http://asc.fasb.org/topic&trid=2144416"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2420-110228"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14394-108349"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14453-108349"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14472-108349"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(23))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=68070138&loc=d3e11281-110244"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=121555522&loc=d3e12021-110248"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=121555522&loc=d3e12053-110248"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=68068213&loc=d3e12524-110249"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=d3e1835-112601"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=109126253&loc=d3e4724-112606"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=51819886&loc=SL6014347-161799"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031898-161870"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031898-161870"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21553-112644"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21484-112644"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21488-112644"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 4.C)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.C)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130531-203044"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130532-203044"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130551-203045"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130558-203045"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130561-203045"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130564-203045"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130550-203045"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(i)(2)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "http://asc.fasb.org/subtopic&trid=2235116"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)-(4)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(a)",
   "Topic": "720",
   "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=SL37586934-109318"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32705-109319"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32857-109319"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "217",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121610041&loc=d3e36027-109320"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "740"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "740"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "740"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330215-122817"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "37",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121600890&loc=d3e2207-128464"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121647850&loc=d3e4845-128472"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5263-128473"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "38",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5504-128473"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "b",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e7008-128479"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "http://asc.fasb.org/topic&trid=2303972"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a)(1),20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "182",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121582272&loc=SL5629052-113961"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=116690757&loc=d3e13220-108610"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13433-108611"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13467-108611"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13476-108611"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13531-108611"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13537-108611"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13537-108611"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28541-108399"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28555-108399"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(Note 3)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=121580752&loc=d3e38371-112697"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=121573735&loc=d3e41499-112717"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=121573735&loc=d3e41502-112717"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=121573735&loc=d3e41502-112717"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(1)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(2)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(3)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=117340910&loc=d3e59706-112781"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.14)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Subparagraph": "(a)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Subparagraph": "(c)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Subparagraph": "e",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=108315417&loc=d3e61044-112788"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15)(b)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=99380617&loc=SL75241803-196195"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04.16(b)(1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04.16(b)(3))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=SL120429264-123010"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=SL120429264-123010"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r572": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r573": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r574": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r575": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r576": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r577": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r578": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r579": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r580": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r581": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(5))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(5))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(7)(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(8))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.3)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e7018-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3367-108585"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3000-108585"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(27)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4273-108586"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4297-108586"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4304-108586"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4313-108586"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>107
<FILENAME>0001564590-21-013512-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001564590-21-013512-xbrl.zip
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MP<:ZAF@NT31<=1KN#%PON)]%EU^Q(^K]HWL_<$.?.5;+L>X?80W&9RZ(5"_
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ML -6VPF8T\>5;OD^#_POXZ_LWZY'C0CC)UUWSJ[.;F_.[CW![+0+N&+5WO%
M>-9R*?_#](*]W+%%@257HYFQZ*_AAMY O?F"1+RHO\V7\W_5ZP=9:I<Y=@F(
M?!FW'2L$Z3F.;[L4ILV"\#_AD'578Q78L#,;[C&931OG5YQ=%O342:_URS'*
MXMU2KY[>KY<)'JD,.,PA,PT0*_,]V=:GRK:NG^[7J\2Q6\=$:[+!3XO:X'#'
M?KU<NIST_=2;\1]5(M1JT EH\/5F45]-<D<YZ&1E-*PLD6DT?#M47FF7>#7H
MI)R>Z\)T4F$G7 7HI+2>LB7M^2_"O6/6%5B^$VFH)U'MR9-JT=#R-N>,I7@=
M^CHI7 3RI&+T56%95G'Z*JV<>VG\JJH,K#A]E5T^?@E]X7!8-Q.,)E]D.C^#
M;B&&P]"!51_"VEM9 Q-#ZF]Z+8P<ZE-E@_@^U3B9#@!;?8_3K]N$=3.GKJAN
MP>1?SH$\9]>BN-J9^_9VL/7G#^+IH\=]-_1,[N-7],V ,XOF^_,'2SS@OR/#
M#\8V4-.0>7WA['7=('"''^NCX)/Z)G!']!&?O2<<)*6/]9\^]>!M>STV%/;X
MXSULCV]<\T?CSATR1_[FB__PCPV\<^?S?_VC<53_]/.'4>:57=>#T= +SMT0
ML,QHUIJ'<,.(699P^O1+(QE)L;'1^_?AQV='^LA%?Q!\=+#PK*UNQA%&W]#3
M Z!T'VO3PK<.EU<],$\P>*6A+MSY;/SLCY@SL:8V[P4?]X]H)8R?/^ 5K[LB
M\S:$;F*VZ#L?L3HG]Y9[CUK/KFM;:5(XRK,7RR[\M^OV_<6YT;EOW5]TC"V:
M6.?B[-M=^[X-LVI=GQL7_SK[K77]ZX5Q=O/U:[O3:=]<;VRV^;A]I=G^R?P!
MT'G@.KO&>>VL9C3KAP>G.6:H.$?-L./:PC(:*<91/^3BG33;'AS5&H<_15]Y
MM"+JN]* 3D%FQFDV9ZY# 9H_62?-7][<?35^!GD%%UV'0Y!U)FEOEZB]P7\[
MAL-0 [*X )PT0Y36J)#L&$H&WO'>A*XW0^EJU/=^)ZF8O.5S!KYG[%,"X)HD
MBY-D:E+[*Q+@6NG/>/>5>3_D'&X<_C["']"9HJG(G<;]^(3J^\\!0VDMM_R7
M':!0D]LV$(H).QU_5CM/G[,2WW1MFXU\_C'ZXY/Q**Q@ ) *ZR#?0'I;8!D/
M]&Z@.'<4/T9>?* NS:_4I>D*/V=W +\HL <=WG>Y\:UM=,9#N'2U/9C/_LU9
M[-]RG)#9=WSD>D$A&#"HWT#PRXZ H8$=!9-T[2ZS;3?HND](R:?'!T>?IH "
M*.+G#X'U[)Z<'KWNIKPH8[2NK[^UKHR[B]N;NWOC]MM=YUOK^MZXOS% 3;D'
M743R3&/?N+DS&H?OK/?&S:5Q_]N%D5)C8A6F=78//ZM;3O</C/2B?I#T_H$8
MZ_.TO;(N\;8!)>?2]8Q@P(V>\$UF&V/./ /,/&XMD'G[LXC^EJS "VDA+DWU
M'RVLRPCW#BPVQL%P9^?S.3>EZ;W?V%TPK(-9P[JD>?T%3[J$;_QB4AG_FF:V
M:>;;$EH /JFX<)DOS:LH7$YFZI;X4%G>94T"YF - F8^\9=7P-S?M:X[;90D
M:Q,R8%S0Q:E7W5[<M6_.C<N[FZ_RPM?Z7YSD:[W[C0A?++ @?/0E&Y<"4!7X
M#<2<6H*YL'":AH4+\@3CW?+F8@(./N_MGQX=GDYRO/9RE,W+T6RN$^OF4ENC
M/DUM=[PO?'QN@!$PQ2CN"RB)W!=/NT;;,6M+*U/E]QZ^NWAB9D!K9[@](UDS
M@_F&/^(FGH%9AG ,$?C&V8!Y,+WWFN^6=^54X$@F,WXER)95J.4</[(P<#^M
MH%S+59O0XP[KDWK<$IRXK&:W >:<#W>-:;C#C@$>J-J44TN- R@(T!N? 92M
MIG[[^+21YS[@.Z6I:[-'L'IS:N!Z\S*;UYS>O'OVU%81![+1PS)J4K,.6M+)
MT<%I<]&^*$6U AQ&&W&\3GWB'?&)X7J&&PRX9_P[](1O"1-W ,3A"\CY\LY=
MI/&"EL#K,T?\ASZ_KPPG;X!(VK6[6J=F7 Q'MCO&D)@MIHHL"AG7;NU]-<'C
M51%^?QKA6Y;E8>R5_.=*.+Q1$-U/C^O&G\(&#0J#N(Q;FYE3 GB!X[EQD&=0
MS6*#ZH0"\!/TMC682)7<^<.YBWP&?]YX]^ZC4] 4=4/<\R([?31W$"3O;KQ;
MT.4 _PL:Q6<W6M];AB:.YV['K0NJM?U_Q:BPCO[YI+Z/,9):S\LEPM5ZHXMC
MY 'EBQ&S#?[$3:HP!%^#Q..^UGI22P94:2!9SI+_V^CE3EQ?__6/DV;C^)-O
M!-SFHP'<8SADCNT:0#IVB"X. ZQ?!@QK\8_&N_FLGSD;0PG0@MN*,_M^?7^2
MU=\_XW]O9/SOV#_0OL6I+&-8'C2.]^J'TT)>NP%7B^C*SQ#YCQ%?</Q)+KSA
M$7-PCUO&*/3\$!W$@6O %6@FJ*/"YKON>T18#-1HF?"DE_6 EL,O&=T_D.M\
M,(H"#IX1%_NG/WTRLMS@$S?4:\>'H\#XAXS3?&61LMZ3:A'8=,K F3DP3$R\
M*B)P&XL7D,8PPE"<X%46<6(5T]2:=X;-NJ81CR&GOK:/9:USE.$X[XJIF]M/
M_1HA/U^K8U@"2/YD#C!5T' =XW$@X)M$"N<Q]*;CGM(KC(N18WE?:C'EVM4.
M-ZS"S%6/FYF  :7IC!O-+@FI@GX1:D!B4(7E70.8$+<@Y,8_ZS6XU!AA NI@
MQ=.RQN:,S=16K2K$<A+91N92#K++G/TI82?E04&OX'GG7V^#GI8 K3=$3_NS
M8.Q"28["<4]3)_\H@Z)#_WLPZZY;G?/6?QN_VFZ7V0:F_/ @AQ-RKK]HFXWA
M_H0Q/"]/CA0,D/WH9YJ3*5>=96H[%IX=@D4^-LP!-W\8,-@?AI +D0HO$[[!
MC$>PS?=^..XC+ QG/CS7@A_\$%UMS#<LWA..C#Z["VTN5_:@?ABM:VI/8(EK
M"EO2ZSPQ\G $PMAD8-GO?/Z+^]G$\JG]F1-&GXH_I]N-O&^<S\4SCN;^A*7Y
M'5>FHQ:F3>M23$I<N]/,N<*4CSZ]*?ITW !X_>]0(*<#@_<P^-FC= 9_ >?O
M8S"%#+)/^+]F%*/.^;0RXX3Q#]<.G8!Y%&#M%<P>(CY8!Y'DY@NDTI=@Q*VC
MRL<!I["D+&E^--XUE/=_ "")5&D9S+9CTDS3;)>K"^#)SY%I"DXC#0))%W^F
M-! +?G7Z=.G(XR:G<Y!&4SZ/LN%\XQT\%*9K^"'8J_[ Q7!A0Y9>@1M9,,EF
MC\R?YC&Z6<WF/4@"QS+>-5-3[H(^ A=U_PT3PIOH>K@3QZ,>ACE(/HV$ALO\
MP#BMRR=8;.R_'#O..&L_"SWTP\C$)]3O Q84S>G37%DQKC20,($FAR((@)2Y
M#;3IN51[WQX;_(%[8Z.-M@@SZ<CYG 5,IM-,L&ORC+2(F=)_X,VAS1)^[NS=
M&^_PS^-/S?UF+=:20(X!*X\H:G\3#"R''[,D]]^_'*_-"*1(+2FNJ&(]S6M;
MR&O>A/%@PVRXP4P3>,UCR#!(;V@Y.#._A9<Y>S-^\&$$\(<2.,@2ICN$U1SO
MHH2$AX$PP77K&WW/?0P&T<\U$)B<1D9V"B6[4H0)Q@\TZY_FC8]^;GR*+GOV
M@OGCBRY$ :DNGC/6Z$IE20'3=_>:D=Q/"_O:RYW9-LMZ9MNHUTYF'-M.^\L;
MI[7]=96B>!4NNT*2E#N2(COY!=%>[A3J>FUM13I>9646^B6GIW]X6#M96^F8
M_,G\+[H 2I#D7(%&K;Z-%%"0#IKUVL')5BU#2^/""KC0K#6:VPX+\7GSI%BM
MG99#JDXJ'JF= RT!%>5?=IH[B]#]J':P7G1?>8C-1NUPO9RV^A!KQ^OEA7DC
MS!\0L74*WGS;^61V.0[O#)"^[WKC%<\)Z8$D*DSU0#PRO)YE<2U=MN>-RQ:M
M<VJ=<SMUSH[T<,AUB-T<\J-R8&B0>*,*Z'R)-J/ %!%2U.9@TS5-JZP7OQX_
M+36H]8O"I8:U=OFTU*C6+R^VA[#6#I_:9IE"^(O91Q:E(:0<^0QO05F?*XCW
M9]3>B_;T5]K2,[FCI2HROA%;HH18O=2P2LEB&U%U%V#U<T'-+W-D^@)/W?A9
M?F_!J3GFT"\*P?2R$3441\,MBL4,7"/TY8D[#$:6?P_B.M-1D H&K^"[[#&^
M_%' J^&UA@/3=?$0_4'XY(ERF&,*9N,!/=;)PXO]@#D6\RS?P&)WPIH=X&TT
M]M^Q]S,/SV=%NBR.WYB/JC-*_%T\)66U92'[S935?E.Q):F82A5R@0EX&&+!
M@H!C*42D 2 '+(@*PV6RF5]<-(+Y/AB?^%5$(KS7XQ2AY*@2)'BGP, E!^@/
M-]!S;<-]@+$D9)E$>X2PA%Y,? ?U@U2:?8=Y70:/W;MYLOF8HC7?-0Z-;[4.
M=H(Z;AYA3OY[G'@R2Y6XT+6!WE+$WQ/>4$9XC>#=#"\"?J%H?(M&S$)+!&I<
MM8SGZ@7(O9DA][;9\UKX.M=K)8M^:;.^)O@7#URD8"I_P&T[PFCCW;SDB[EQ
M0X6C_)Y/OYB3:U4$0V=4VNS@1->FD,XEIDV% FY!B@;FF;%^'\ *27A(.68J
MH]:=3-.(4=>4.;C^5 YN-@77>(?WJUBY=-ZN"I![;P!Y4+ \!0OV,*@<1N%3
MF"L;@5KP)( (N#TV_JG([I+"3^$YH2,D(7W[+GSW ,;UK7.^DR;'&6D^MX3#
ME[;+G@M:E41H<1,&8/L4%I?N2..$0\L-U,\[G_</#G:/]@]WZ\=QT?QHH)^-
M+D,5*!RA'(/ER#2NP5?M&J;M^B@41D#"M.S_!,ND<610L"\* )E1@'=?,]]B
M?T<I@1U2V%1F8,VXGXZ1CC0ZI<U-O1S?@<\UF6VJ"&<#V^WLJB3X1_6[C3']
M@<R@I0LBZO"FJ6/H^BBY,!D4=HZT0R[/(^-V0KM&EYL,1P3O^S^APXW]NAK0
MN_AU7>5:AO>-%[P.T,%UXJ?_'<JBZ;NS0J<9+O&#I"@BO3BXM-H,+ MFX1H1
MW_G9XO+Q2J59T'##@#1P*J]%=P 9P8XWFK01#5JP!5Q'/7WEZS)L-Z,:IWPO
MO99Z+OLWR;L7\V$#-/-FF@_;UY<+.;%YM'MX?+Q[?-*<8D2YR?/$5_-X9@<K
M/RGTS:TO8Q@D*'2.R>]AQ%]LF% QJ<:!1D<HDKR0Y\RBK@ )GM^<??MZ<7W?
M,=K79S=WMS=W+>QU^^4OX^[B\N+NXOKLHKKV]2T:!BK6'"'E+(GQ)J:*PM$?
MN'$+ FML4-5/LDC0.$9=GMA)-@ TOG).!@ \C7AAX&*]41\KW*F4%)&B.(1]
M+Z(YM&)<XQ;PK;IHU6ZW=U/-+F2^CL]IK8(!JK\X/P,NBTHA9Q6\]*RSU6MF
M]Z,N4O%N%4?1$DN_J-'U\F.=\=1!?$8Z O-YK^MQ]@.T+<"8C\Q^9&/ [P^K
MOWVU5NNO\,HEZE;,&L1K5,^\IY0.@) SE#T@I5YO.<O1L&0H+ L+"47(P,P?
M?<\-'0N?YGH?_W%)_\6P$'NDHR_N:!-EG9/XRWM<+/E5-(+:TI7!7L!9KN:B
MJK"4-$IFHJS,NK;B9+\"&W$&:]+UQ)9M0/35EV0%Y9X<U4I<5&XEYEE:>02!
M6S3P8(,;)O%L_=V?9ZS]!J3D;>ONWFCG..'<X(J?K".:9+7E?6.X5+RJ&=6[
M?@E,*O$^;1LP'=5.#LN]!^V #]4Q3^T-8-2LU=Q4F@XS!AYZY_[1OK_X^KWQ
M_<NW3OOZHM.!GZ;.B2QNJBY='^DHV!8.'A1%8<[Q>0_+60!RTS#WAE!L7P-8
M20"LI1%LHPC6^G[7[OS^_;)U=G]S5P#%[H3_P[AD9N!Z&LE*Q$H'AQK*2@)E
M7S24;0C*KAM?OG^[OKOHW%S]<7'^O7/?NKS\?G;SE4X2"X#:-\?C8- ]< N/
MWGH].N:63G&-<&7A,&I:J2&N#!#7U BW266M^?WV[N;VXNZ^?5$$U6X]=\0]
M+ ^K8:P\7*1AK#0PMJ]A;),PMO_]ZN+7UA6"V=G%Q7G[^M<B:';%^\S&^"B3
M4QU<#6HEXBD-:J4!M0,-:IL$M8/O7]O7%]\[K<N+^[^^G[<[9U<WG6]WA12U
MK_"/T6$]'HR-<^%C+'_H::VM3/RUY0"7>_5IA8\VS'*Y\\PUK&UEW,7Z<29+
MVV\ANF'!.I0C[$IN0?LM!%]IMG]-MB\>L[ZMF% E,^=0FSF;-',.OW]MW?U^
M<?_]\N;N^]W%K^W._5WK^KY#IVTWU]\O_OM;$8-'YHAC<MO\'-.+OT,1C'?A
M"IORV"CY4^:Z&5^QM >FO#F6(?LL&K>A9PZ8+S-7Y;VI!FG:EBH/$S?J#8VB
MY4#1(XVBFT31H^^=BZN+L_N+\^^7[>O6]5F[=?7]O'7?*H"=G:@>PV5<>@@;
MJ6F *P]_:8 K#< =:X#;), =@YIXW?KU@@*PR!O^K=-I@WX(WU[]U6EWOE\6
M4A.GBK6A>SST?:$JO+4<9H]]03I?@H=GKF/)$H-XS1WW0SN@2VY&7+Y&ZX,E
MXM9&O:GALB1PJ</P-XN7K>___0WLZ/9]Z[[]QP5^N(K^5F>)!?#RO['PJ<#:
MBP^<H ^^L*//J8-%H]5UPZCFEX$1_1H.R\.-C88.Y2\)')YH--PD&IZDK.(.
MH*!2(SO?;F^OZ.]6D4RE1!^,RVE)AV$G'(UL^LR\L3:>2\9]&OY* W^G&OXV
M"7^GW\]^:UW_>M'YWKY&[:_UZ]V%@L _V_>_?6^=G16 OS,J]8QURPGT0/UC
M?8\K&*0J^RU92YSA%V KMY+2XGA#RKT8:XX:)\O#IAHGRX.3VFK>+%"VOI_=
M7-_?W5QU9#+!><& 6ZQYZ+FV5 <II<#2 ;?EXBX-;^6!-YW0OEEX^_+]Y@YT
MP,N;NZ^M^_;-=0%DNZ&&(6U'UC>'7S6FE8>EMAS3<J^^3B+84B#3T<0ZB:"4
M200ZBT#SO<XBT*;-I&D#D]7(L,FR@_7OY^V["ZPYV/E^\:^+LV\4ZG#9/KNX
MPUR"N]N; L;.N? X%2+<-2Z>N!E2G,--KR?,*#?@+&J#8_R*[3K1HZV=V"7B
MQ$;C2$-A2:!0UY#>+!0V4@!X=O/U]N*Z4]3;DZ >MA3CCJ]=/B7C+PUPY0$X
M7;5PLP#7_-X!?+MKW__U_>;/:U#P?FO??@=%[[[5OO[^Y>+ZHD@N@$KE'!LW
MCPYH=P,QHN9EW N8<(POW.&@]F&T@OR=M+\D?T E LQ-)-6061Z.U9!9'LC4
M%1(W"YG[,3[>75R1-HB@V9&?+LZ_WQ<)@(W D7 /DYX -/T,$M[C(&5O8["A
M99B8-*F--CP(-$J+:XNY5,RIT;$\Z*A++6X6'0^^W]ZUK\_:MZTK#(:]^79]
MW[[^]?OEQ44'5,V[/]I%XF-O/>&88@0:8RKP]9)SE2/ O0=AZI"P,G'>ED-?
M[M77X1-;BG?Z&%6'3Y0Q?.(/S?::[77TA#: )@T@781QLP;0X?>+?_W6_M*^
M[\S*E/[>.?NMT.'A0'1%X.\:,S*EC8XYX%9H:PNH3*S7:!QK["L)]AUIZ-LD
M]!UAY5D,(/O]>^?;UZ^MN[^*E(* IQJ-^M[O1B<<PK3'&M3*PU.S0>U#P+HV
MAV\M\5",K#,S_6E9_?+MO3)%9"8\E7OI5S::HUE4M_PH7IJ*A)K.P(OF,V)]
MOM?U./NQQWHPG8_,?F1C?\?X\-HK7:;-+38(>E%S_>])NS\VY?#HW%Z@/FU<
MW]Q?&'<7O[;NL$6= 6+G3_AS[^KFYG?\G!0F6M/<-TA;Q[6CTU?EVON!\(V6
MXX1@>]SQD>L%6(DD$=<FW,:$XV.I^$?F67NVZ_[ @QH_5=*)BMF%\MS&#3T#
M)A?Z@3<V@@$+X-,#=G8V_+#K8ZT3-',\X?^0UX>.*4_)L4A\S6C9=OK1+F73
MPF.<S+<] X8=N)XPX5D]9L)W:J#<PGHKP>)9[<(UIAU:$_/P>!]FB%_B)'IA
M$'K<Z,6FF1D5-=V%*^.*IFY<T737Z(8^C,#W#:RG'_#^F&8XLEETN.]V_\U-
M#!>E6X=)=!06XE<O3#^0^<8CAQ5A_NQQ)@OM<<?"&W#$<W>J9K1A'=TA-TRL
MT[]KC-T0_G0,@<0H>N-%N]R%MW!O*!Q06V!F?F@.<%Q8&+99_X3[BH=Y =^E
M;QJ?HE^ZW!;\8>IKW"_AA#.^#VUK\DON!V(XX]G\:03K.?DMT!*LQN2W0S:>
M_ IW9NH[-^!$H_;TY1ZWQ/3K_,&L(3\*VXZ^<I&$N>' OE&L,.P]?/8Y+:B/
M/TLZ]P5  /,,F!90&-;8]6LE$%W50K0_N3%@L,A=('%+K?,"LH;U[G-[C/B
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M0>6S/#QG"+F2&5H>5)>JM3S0\D#+@W++@R$>A*)$2)\)>^DR#KL(Z!1D!'(
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M'*:Y)O:'JZ&X&9FQ2# TZN7'TQL*#_,4)?5(MN+2.JZ!R7?H5TI8FQ*VX:E
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M^E[M]+L4>]WC-^_C6",85&94:\']Y*L4OBNRGIBYZAP+XE=)(G1'!SZ*)*H
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M6!:R0AD>'@3C.1X@7,!H-5##[J*UHPKL6XF/:4(!D0=G'G>LC'E![B,:M/#
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M8'WI$@$3\J-YK.5'A;E RP\M/[3\V!KY<1,?%5P\C;CCHW/WXBD*V#G#*HV
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M C%S!B_Y!B[0W?K2;WD^S@.9/;%"EJV<L_2T\V8H+?^&B/#7_1YT_ZW['5U
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M+6*7(Y [F<DE*!@Y @*3&^ 5AWF"%)>OW +S.GRNGLADM1.X,K3&Z>S;*%?
M]4:N:N.0\@,*![.<HUW*%,E#W84-4_N5)!%T61==8F/E)HEB%J(J>0;E^)+*
M!K ..]<P%L]]:AZ)-Q5&U1T;A\?UGR9/W5.%M^E5C=K13T11Z /,NCH;]=JQ
M_"WU0Z$BAX5&7W89D=KF8C?F*#KUHH(]'0^S7LGD%Y69S]<JF]QB6=*RV%VJ
M_F6.O,04]16<^HI[%%?A++K@_,=Z5UP5 RU,<6(AC<\J>X05%C/8R7MH8R]3
M7C0.8$K9K*K6@RH(&A$2 9NRWG?A+0,Z>"@T=#LQ@PJ)OF<K#F8OQPRU8F(L
MKT(_5;7J>;!>O:)87K">'%Q.K&XL"=43H\33KF*[1,71"]V"QRT%]9,1=G^B
M8Y."Q>_3YR)D19>EH<*7Y8S/\YG$.L<1DO4 ['S^N)+E,O.1\ZL=3%Y)!X/Y
M4FA>XG5LDR\#XLB90O<2;TOC[\9>6K"JPHIO2Y \WRM7?V,B!38VR4(E-U9?
MT EM;6.O1JUEU;?)@\_U_6]*7J)29-HA'ES'>/EFC\/+'=#V^L?A.HAS^X[#
MRTWS:SX.C]72O*K%:/U5FI9]1>2?7/-K0)[:J2YDSUA"R_>?S:W0+OL&#$,4
M9FCG+)^P]'OR)NNO,!&IRZU]2_(6:%AZ)HAH%AZDKO<UN371Y5]@459B_MH<
M2V\*+!?S.<94Z-2<2DHXK=5IK4YK=2^JU9W9S/<WH KYZ);RB_@7EA:]>,K+
MS$'N(DS+%_Y9M[:RA*]K):UH"S15\H!R:]WU5SOP )OO80;TVJF,YRZ2M?1T
M>DRLFRUS%RM<>J%\OF[BRE_I:_D"KP/77O<TNG$/@#6_:"1,[##PM@J7'>O"
M9=JPT8:--FRT85.VPF53)08HY6C]TI;*A:_;[,FK6B^OFRC=>MWKM78K)+<:
MM_QFR*:[:YY'[K8&2T]C[2H[]<5:N];.UGUN8;*<;O+EEZJ[[F6*RU;,C 5[
M41QQG;X(,(YB[19(E)&UYAG-;KOW>@=P93ZXVH 1+0W<O/%:I=UTU\E;?G_Y
MI<)$EQSO*'=]=%7))=];EI](7GF[@:5:X158#6#=+WDW</UUMUKPN#]R'7_M
M"Y:7S9=_@^/F7*OE7\%,$S72O,K[\B\"H_&]KGQ938M<>Z&T%^I->Z'6<;R^
MD4!#F>%>FM/;Y5_!GT:RS%YI[)P5W$SLQ_JGL>[C='?]QO.(>\)=^V[D5=Y7
MV&_ FIQQ!\N_I+UV#T!>?7>5K9C37;V*#I/UQS4,.5_[++CC@:I<H$/BTF_J
MNQN05+V\)N[RK]A0"L%F)'O^E(L5?/VV^[AF3U,J)7Z]OH=";N55?#6>PT@?
M7?N;4$]>H4S?\RGVTIHN2X[]V7+U<=)5^PK=^.[L_.G]QV+W/&=N[GS^<Y#;
MZ_DBZ;HR%38WX;] [G52&F-SLTQ79MS42W.?);S NTQ/%(S#7O&%N>.D7V!R
M(T]5I=_<*X?<$O"\7,W<7^B5A2(85EY1=RCRNME?8G*YPQI>@A<*X(N2KR\'
M+U2\$(L24R.+7B@[U*G6&JIY@:H%/8S:8J0J?,A"?++3'-4:]GC4&$&VV<-N
MY%C3R73W%'139SDJ# 5OV]B4"X)XXR47N8#BM.(["^C0J[\LI]_G97;/DT=M
M5OY BA?8P=RE05YBCL"(&YN9SZDWR 8W<,!LFV.U[IP2ZB5>JBNE5.0 1!_Z
MZ4,_?>CWHH=^]]C[6'9B*Z#)+AFT6=P^WHAK;?DWL;['.7JBBYC$RSG6V;I#
M! OD5:X_"WGI-RB;9.T367M8/II8ZYX%X&?NE)+U1_Z7]F"YD =]A85*&E$4
M<<\L=U;.67X3:0/\OO+1:9&"E_\_>V_>W,:1I ]_E0I->$**(#DD=5L[&T%1
MME<[DJ40Y?&^[W^%1@$HJ]$%]T$(_O2_S*SJ$R"[LL&B  TV=F2)[.ZZL_)X
M\LEAH>;@U]:D\#5;MT)7(N7$ G047SJFP8$GN._G*HTT"F3)**UT,+MV3 4]
MF%T'L^M@=MVIV?6&QR8\[&YLL.>'O86#9Q<%APZJ9)K/PJM=MMCTU]"S%3PO
M#DM0^N9[#6=D20V5!0F]*!Q*_\$3YIMT.SP5/7B>>'#]5R<R074QM+2:PT?V
MGATVM$@<S+._A6\PM$0)OBA4=^;;K_M6N$1OS62P86AK[8;/[_-EY]C"F [=
M +J>#F;S?IH0![/Y8#8?S.:[35&T)<QW+H X/%JEYZ,BS13#2!^>NV9B'84G
M]PH?J?3F(-@BI$2LEX''D144\0FM]'J'*K?0WA$F-@VN^@;W:RSDZCY.8G R
MM$3YI"]MYP&Z=S"';\[/01'>,:7@H @?%.&#(GRGBO G-2UBF1M6H<]AE^Y4
M)?>@-585XO<=D;(TZ9? 3=S#I:LF.F'E3@9638=OJV-^&'2XA64C5KYAQ,%^
MS>([L!E4<JU3DWP/T6DGNV3L'1(=;FG-9 (7X/3.T]]W)=D=<P'KS'5Q"?:Q
M^BJ.Q8<B%1\)N*9RF:[$19KKB<9HH7B;Y*"U:[RGE'AX\?:1^ A7([;D\GC\
MJE8\[<S"DY,7W[0V!XX85 ,P5U2LU41HET29&)%IK.@C<A7-$H/LL6"&Q+&
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M2/BAQL%B9NMSP_*==&/'I':O]EVO8XG!K "3.>UW V\E:TD3S#P<;?=Y 0Q
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MWL0!DG*Z#7DRBG9R>?QR6SMM%3EJD;S$'#Y)L@??6B?J5E4Y8;7#C.0^YFZ
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M\ \$&6^5,7ZG0./]H(?\G5T?(M:*B\KPT>@Z0 &YT/VU+NX(#NF%G.NH*8.
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MM^[3O>76W7&CHK6YOF$_$(+HA1MH>U%WI?LVK+/' T#)O,?=I]+5Z.38XS&
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MVQ-+2B>%VNCIO=/YZ#[T^_="!.H?I-P*DZ5S?[BD]_88'"6Y-WC9\);45S1
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M 9\+703"3"8JO8?Y"LUR?B^T]L&-X7N"200'2:QS H8_+$0B&#S>'#QF'OK
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M@=:$-Z3_'EA0M_"^FP4C9V ;\RM266@WAG<AZ?L@]1S.L3K 4[(5_6*)YS@
ML/=3>3DH[ >%_3]:8=\1 /9/R4PFD2)R+KCP%JE6N4Q7XN*M*)F:+>,BU>9Q
M'%ZE U2@YC<QL38'9/;>[LJ#)#Y(XH,DOE-)'$%[.BGN(;'=T[P?CD"TE)&!
MA^'+AS-\&)_^_K?'+UZ]"3R.2"[D"/DNO<N-[# ,>&*RW#?K>)O]E9CK^Z
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M\TS4!2'3.&^,TV+*[%ETNXJ_*8!9Q+P-W(O/N"-GN)[35<4^8-S^H1M"QKR
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M']H3Y64H^NZW3<9D=4F=B-^5L$F6:/)N=%A799%S(\JP Q'<?4SU'$LGD[=
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MA M[>B)^0S/2W8!H@,8FF6H4^W@5C#9?G'#GH*0C2I7C"1QQ\>;7B^;=@UX
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M0!6_B0[&U 9\&7@;FMA/%:HUXUA@C?P==(Y:'Q=JN5.^-W-1N6C1ZVY,H3W
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M\ C,$[%OS:OM;FJ ?TSA1R;$HF L\0+*D4]DAC5?^$_$P(6_E^?# #O0MA8
MN#[1$47Q;4E-L(EQHIJGZ*0HT38$/"6H7;S!(>815<PWN1N+HW[7[IR*5S$B
M_>)<\52L=?^)7'H)%98A(:%98*5)TO>>F)G8A'AO(9NZ0)RF\V<OWT-3\0KT
MAC@IP _I;>_+[<+/N"K)A)5.I_22L_NJ3Z=13&B**&[APH4IKZ1WB]SV!E.P
M(EM,M=XG"5\?:)L9$5N0I[@&ZOI??SG[[OE+VMPB.&M^1G=Z =]'9P338CS[
MR> Y6<2ABFO;6>?LK+R^+#V!K7C^_?G+.F!LY0R2N+FADG/:UPJ=!C[]3ZQX
M.7]V]KT>&SQ;%L+\]N$2'WD+AP1K&S&SB&";6*I)^;K7:DURXTGQHZ?TI6+E
MBUX%_>GO$R*@%&XE(4W6O^/::M6D?\DZ"E-P99K;XP>GPT]PX(3(2=?,=H5E
M040:/"OOD!2W6Z(L\T/2[T+2ZG!*Q3-&N,*7G2=X!1#\-IU"^9ELW\#L']V=
M,"<\<GL_:M8T',L[&C6A.OOLP=V!S14^"9SI.>ZJO&#Z+)V1^+D.K$:#7^/H
MY&>;S<>:VNL^:W]IUX/7C$]::%(*63-ZXA :[M7+BWT+]Y19F(6J3@\?$M-;
MT>U#XO@R]R5E/K 56'_^&D0//,.SZZ[5$EF)6!V]NWIOKK7[Y]_ 8"[5259O
M1OQP\4ZZDQ5[G.:FCZ)3FIZQSW$3E8MW!N1Z$\9,EWRGZ_! 7%OG1+ANE_S$
MH6I>3!.J9OS1C]K)^L*>%:,?6W43U$=T'?J4D@]Z*OHHLYHQ2KGR>SPEA=U2
M-2D0WI:>+9ASM2L %-X\4Z'Z/U*V*SJX^9Q8-]58EI,**Q DQH+)6FNLO5@U
M+N$G[<J#I[2(/[^^ :.I?*8!$?"T+-UOUWV<%(4?4U[2HF9E;Z'*K/"TX>J0
MYPJMG"46*B/]LVFM,7GT>9,%%@\8I^8UY+'X[F5ZE[]C[?DK,+@2^JM)MYD5
ME2Z'%T-^P?6U!25TW*SC2D02#49T'MG0BDD\0^0C7#A=H(. 1D392JXT?<"K
M@-0$JD1N6NS!^$%J[K[]/JDI+VCI3J,@SWTU5_L<:9;E95R3>F-.O2AL0NOE
M*W]0^S"M2Z\H%XNW45JX9:I>%CI)4]YPXW/7[FWK?FE(X.(85,30 WY9<&.G
M,L-?9*N"P@06?LK+BH?&6-_EJ3L5-Y$HP%**U4Z10 #.%J;:2AEI^0\RAD#X
MB><:"P8KE8L(\FX7"7^$12DG5&ABUG]DBT%9'.,:TMB6"#_#=QAK")4WY7-?
M.8H?B=CC<CZV(1Y/8^=X4$:7?*!57$9+]MH9C3-W@Q5@5J:1]*J*,Y,U0IQ9
M\-LIGWUD;W<8?]NS.98):/MVTE/0*NFDIP#J]*3';TR!GTR4SVC:5@>?]-3N
ML1\<YS7*:5',:\K[TC#;)CV7/Z;]]2-8QY3'GT?>=NISB!=3ED;&S3+M'=A&
M,ICT#.:.>/\C';X-,$]Y#M;/..E).)ETHY5%:N)R2)>=3=FH)JCR"DPYPHH+
MS\=83RB#I:FNL=X$C/X682!R;=^9'TGQC9%-=H2NJ3)&VXX&[PN)X:I/^;SI
M&@D_SJ,LH>!$ G_5R'M$/5(&/A*UQA C.N,-C7N90D G%9^$U5JHD.HE%KB"
MJHPU_?KAZO653C3&8<1Y:@HTX(WI_E=./%;KKS#6@_DW:68"1#-<(4WT:W^
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MO,TW=U7#T?@[46B</HXJ((_SAW)'$2#CPZW6H?WWW[*@<XTN3K]_,88UVB>
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M#<A(_'!G)C\[6F8K>T%5Y)VMB0UA&[1(W4JZ7>#<D1(!DM;(3!"\F'@+8Z%
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M)3^:H4<S]&B&3LL,O=PD:NC\^:_##!T^RX,%93768*9%?GJ<V*\:'/#\_-G
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M'FD,O,NZ=J)932L>)ZRD6ZBD.+_H_*I<A-K'@^X9/#G&<Q)'VH5DO$ZE:ZC
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M.E6;YE%UIVT=>E[<A%B;']OFU/%L=31%6:M0!U_CY2;]Z48!T#JM"-[&=2B
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M"9/1F)LI7!0%!4 =P6*-$)YI/@=U"Y$8XCG^NX(00; *=GDJPX3>/WE+VOQ
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M$R4!A*U5.CW4?_G<)9XI;^&G"[[/R?EE3>S3TK[O.;8H"AKR4SA.Q\PYUCF
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M[C)M0BAQAO"NL:DC%MF6C6@B,@..I)HTP&QAF:RZ"&V!/VHW"=:A1QD?B[!
MO/1D]1MH<\(8-@YJA<B(QXO2!=H=J2XE57CIR/F4NGH:P&5Y7NJ_0FCDAOV1
M)4;PLVSI6MK,&XC,E1UII2F)$L=^R*0L"XWAY\+KS>C>V4 V%/UK,8 B?)S
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M1G$M(BFY#XSD&LZ.8(.+=0)'"26#4/Z5.R]2.K?T.Z&.$.,J/=6N5A5RRO2
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M=SN:>,?=IG*W,PFPV]T.97W7":_'5*>/YM3S>6N![[J-%7/K. A%/V:[F*Z
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MEFO)F<PZF*Z;3_$%1Y*S15JBTW('QH,7?9L@'Z.?T@_F!1\R),@$3!H*$:
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M"\7 PMUGLK*RNG1MAT33+5_V$3O?N+(ZN+C[:^X?7-R#BWMP<;^0B_L1N"%
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M?/9$:&1[K%U?%):\/E]!HMB$!0)<7)KB_/HWG[Q4%4"PFVR)<E/+^>!1=Y-
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M!BG /?A6<\&,Z/V_L]4#X6)\T;<C65!J/U%N5OHNZ(HMN0^@R252]+4F4!W
MK?*E5?GC,PKB?N)N-FZT;<U35\=KM-PR3N9N#:@ B#J],'M2O1;_/).\?MR<
M1S*PU"1^W  6%L(G1C)X:?:L=RTGK''1M!$*0<42Y\^'QC5<9$-\PE2E_6Z;
M!;UEIR/0:GR'P\I"G#AM4VE'+#:FCZ+]<.K&8'$FF@$:/B=\/DH%:=@S L:P
MT5@F?^QU\>.J>O TQ9-3W$CH-$T@3#?]OD8-.G-*@!.,LPBK*]J@#G8Y];Q
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MNWK?U,W#/  %V3GE+>P=,7V0J\>L%8;=/>5-[%U]\#"7C\S9)P(\_KR1]O&
M[]P#S(@+UGI]7M)JR65*?5BP23+;3&50CDSIBXL3,0UJJLAU;9O.WFJ+#AW[
M<B4M,L!YW54?."Q-'%0#<A-OA&FL+8<SA;VM5@N@>,RT?.^-3*1:H"6M2;@
M+V5T26M="_T8BIPU^E)M>O=587&-5P](6G R6G<=/Y.+T/3CC5-PRY0GU1/'
M+&1@UL1: 'LEC0GC_F+9MK UNOB+C0<=]P?4[Y:X3/[AI!@<'^)3S?\'>#+6
M7U=-VQV'P!T%7,G(X\.O:X!^::DVE^*EM&K4V-F2M*_?FC^US;&:MVCQJQUW
MP4&ED(&.MW1$PB(,)C#0WS1IT>77<EF=S3$P[)5MO!O@V,T8#]S&CH4]5CR
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M0 5V!H._1'B3=W>3BK)196+#GACD)@P:Z$']]*>,]/6ZW[1USC9.2!1#O#
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MU=%Y=^[V;(U^G^Z.*7*#Q][*T?<Q)0E8')NS,&_^V*_8DZON3ZD#V.K>N]"
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M-!HZJ#0##[[XY;]??GMQ];7$3RK4^\T4K;^IF(.T)(_6CDU6$D,KB2$XOXU
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M;SQ/_*;X[=(X4WI3?IZB04VZCF!=<%W@7Z^^#NO[U"ISOC[1RIP3L&H>"MX
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MKY[[0I6ULV$G69S"'EX%"7 . LICG.IK$@( 80_MGJ]%G:)P$E!37#"G+>1
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M&A65 8*(HR5<IM^3HK=+[7N;T:AA.\OI4^39LYP^R^FSG/ZP86YMDK-ZDAB
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MXN-=NAJ.<4(JGJ-ZP-;+W3PZQJ?CQR@>:+9U;BP:Q0.6\XN=&O)I> R*BH(
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M>K8YR10^)ZX3X%],ZWSJ@$; /RWIF0(T1C:,GY.ILP60!SSQH3B_"P1!!)N
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M,\YD3YUV26F?2CGHD7Z0\+E'%K@U/@:SA6_DP7R"WI^@XV>SNFO@4)=!""G
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M^(5"G=#8*R55!&-+[YZMD,<O53JV)R$9\M%WO!K?L'\BL8[C%\F\E\K!IW+
MCQXA'7VI? G-R*_"#.-CAU;V58?'KY>M;CAY?:@5)B._ATU1C!\_]<T/2@XJ
MM9;*U^X*VKAHQA'!I5&=V=R49IGOJ<*_.OJBD&C!Y+"?KO,R.>R3PSXY[(_M
ML(\=@/\'J_=%GM9C^^)7KHIQY(%LC<+(PW"(9&S_R09@1C>I]]W]HP5-:C3&
M]],\3O/)^X1L)XY]+%$F,_(0UX>4BWR "',YT-AR/#H^%=V;W=A.^M[I]J<:
M6-*$X\BCB!\T>A&*SY:.+;SSO^RV1S?&Z"4=8U^+PD0R]FN,?AB?5NG+!T3E
MM,'IJ03,'N4<6E2IL;7,JLKW7KFG>SG:+KZQ;3MI>H,5N?]8QZ_:V(8DVO6*
MW(Q^0L>/_6N8<NP7L:'1*1YYNK&9*1XYQ2.G>.1H?4&"S/%=6C0FN93FXZ!R
M2 M'34DOO&# 88'HDU_1=YJV,/.BNI4.ZJ'!M^$V^M/Y5Y<G;;K>SR%=>.HN
M)E-N#1KJ!0).IYD\V/<4M*T_T$LZTT;_I@]ATJ=3?+\H.B95Y7ZE>PII9PX"
M+T!XP.*YCJ</R([N77 \U'[EB\,VM6DP':U'!@P?ER(SRI[^T60SB[UHWS;D
M8M-&]J54C@FGJNWL7[*T@1P;W>Q=P8B(0L"CX(JI?D>081V;HA8S*]@-\*/+
MI)K3D1?L D"ADL .3\F.$)? 6=1$_/.FRC-^945^UL(W$*/3-O*TAH83/->=
M2S'9'J>KAR?;8[(])MOC46T/9W?8MF.EYJ8+%A@_4KIRO/?Y_=6;BXO]PE "
MX./F4>26NN+CW[]Q<;9B:<MME+:@<F_U.I8_D3V3-(L578^"_VI!8B)B""T
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MY+"6 (>I'$VEO!3S&QN<\#;<!BQ3B+^'.#X_V[ZWW#160/G]',.G7IF_;&G
MM:@J+,^<7HMD0 +_ZFGPC##RY4^_7;T^>_EU<'V?9212!1WY++3D6&NE!4E5
M!J/:,D'KXB.K(:?%ZV"VPIE7(!N:X=",]+9?1IE8.H=^1FZ^5[^]CE6?RZ;A
M4_>+6DR?8"W#M?X4M!DM'"_8/_+J[.<T<W=HH.5>UQ7Y+VWR.K]&K"IY<_DS
M?>WSO[_Z1A9+#W'C;-.>>.Y8O?C.LY* !RJ'N+ $NTRS7+#?X1)ZNS*F#<YR
M, *4"LFW/<OT>C/.0>KQYWL9?PA^0O-?F RTWA$1,#RD-8[KW8:UE4W&L^;F
MF@#8>DOK5< )C!1'F-^&A5JV:NS67>G?E?QI*+K*D<UB-9 ZA+6(^F55B9[/
MV7J<@>X@?R*U-SM9'^%K2"I'(B"L=>6#DEGE;VR*(,P4#ZU68,]' R_(X: -
MH=L#MHP^+$QB.,Y>CK'752M.5@(C>^-JU0.?E@9:+G'@2<-"-D7O">6F[/>P
M- FI^9I&8Q]!.O2076BJ1<X-'*YHGA];9BXEX=6U7T*IRRB9E1[+WVW8&?]7
MQPKS38W=S%SP"R_.&8R\$2M?7E:HJ<7V$C6L=[W;?9[TW#!U,2VA&)\ZS?A%
MC<L%!2<@*I&Q'C;\0EP4* \1DRYX9W@P0;PMBL/YH!=N4^E#1.L!HA=KJ9'I
M!2LY,T6+1+<)60\%LCQI'?.;!K[*?TP<IT^S"'HJ_)\*_Z?"_T<M_.?[BU5\
M%!?C.!,9M34'$?8K)CV>?D%]DJG5^W3%=%+-DVJ>5/.(JIG5<F!J!^D:L8?I
M0=9'AO4^OPN^O8\"?WG^XGC^RL#!F;3XZ4KTI,4G+3YI\4?7XA^  [%?'QM=
M$GN.<73[9[KO6QS=7D@7W,A#''8A?L! 5;DO7O+10^S/('A\=^3HC%F9:25N
M.?9^[$N9=73G:D?><KX86WX7^=B2NS\/PM%#<,;F>(@BSO6,3C-:5F-KU/$/
M\-YT)L>?*X3R1Q[C)J]12##VFXS]&IN4[IYK4QZ";?0!.[\GMM&GTAKR]Z??
M&C(YNT_,\)^<W<G9_1_M[!ZR7?LYNX_K$!]/7;*W/WP\F<SH++_[NY#')]X.
M](>?,!OV^&SW62?'9.Q-&9T\YB]8*K,HTK]FM0X@V#IVB$5>+[HU8&/&Y_8V
M[_/15=<?78/VH[U!HCYD<\:6M*AH>FR-/#KONBOA'OE-R)]^(FOU 61NR4W>
MUF-SQOG^E[%/_OA7Y('!U@^@(,W^-O[+R,:,;X:-+<BVTG_L(X\:@9''>/N7
MB-<77W[^;/[\V<OGI[[SX]^.8"(:>8A7+T<>X-?SM^>7YR,/@E#05WL&98\>
MY+,O7\SG\[//1'K'WIBN!%S#^"(<]ZTE7+)4 S.M=:VH:%_;;R*?'8^V6X&C
M<G04TH\,_,*=$P';@C2:;#;H9LC+L+<C;NU("]\"(KT<TD&NN*'<T]==7Z/6
M3#N<;.F9]OTS#)]%'G MC\ZB0*^(;\3ZE-O-&E.3Y%US/RLOD%T+X"S,JXRI
MS7J]/'YE9JX]LN'^R,,:T12D+ =BF0+B1#_#1V\N?[:=@<VBSN>V,Y+!,,VF
M]1ULFX-Z@[::@:9^FM./!D\9D"D#\C\Z S+UTTR5V$]33"?5/*GF235/_313
M/\TI2_2DQ2<M/FGQOU"+HVIF.#S55LSEXJ(T(?;,U?6/?[NZ_B?]_Q>>7OX#
MDKUAP&?/8G.)^SA6%2UZ%J[4PPN'/R1W-UTU)WGLIJMFNFJFJ^8CM6Y.E:I3
MI>K32?M/E:I3I>I4J?K$)&VJ5)TJ54?59%.EZE2I.NH 4Z7J5*DZ5:I.E:J/
M?^"G2M6#*E6?-I_D=VE>=$+]$G*?QV2$/19"AZI.TP)Y(0-XA\Q[2NNT"Q%<
MJQ.1O(W"Z &3GT6YO[.$=4)IW3$;22%,-C3 /"_ :QTP43BVR1E33M>Y821[
MY9ADJHZJ1S5#<Y@;D..%G(8]WFCZSA]=EC,AC>.0OJ]R=B]BRH_+ (W"V1YC
M4,ZD4\KBB6+B(:+*88K)M3+/"^]%3/?F"")]YE[8(6.R!B<Q80TK28DKYV6X
M>2L93(A&0_B:646D]^6UCI<CH QA@A2E<H <_".O,M/D[Y/?J_K=6Q1/VX50
MIF]/CZ(\T7N6_W:-?:N($<2M#-C$\ALFBK"48%QSAG" 97[!"63>1^:8NJD\
M=0(M"Y,WW1JF,F/F0&-:I>KV4_24;V!?8@I+ T8OI;U*%\(+QSQOJ7"=Y .4
M:O0-8]Y)I3KMV1]=:7]H\C])?S!ADY'#9%G8Z4S2_PJ3]INN!GM8:[D0+KIK
ME"6__'J6O'KQZD7B&5A(/K[__JV?=H\_S7*E@?4 IN=U%:R?733Z4TMKDDO6
MD>G4A+SH7AJU\^2'/@FBIRZT)#-NU[3@! Q([/_$ L<90:&G46[TKA1.&9-9
M@G0]"2$-V7GRBR-?A,BY0L0AH8CN1R$,4W8QYGV@Q0'M)NA,^?]V.(1KDX+$
M/&1E>"/T(C_3ZPF[)X[VMX[BZ4UMF*.0_\2D2&]^_O8-_NOY$($.5\Q_&BPZ
MI)VW+8G/#\MZ/+;._ET8GJ0OP2OGRQ^ND MWY+&DHD5V546#P]92:&[W*#@6
M)U5\)$Z6IJ:AU:Y9WEGSK+IU&K0O;+H:I(/,&S-(HNYR^]:KGEEN,-;PM7"&
ML>#0,Y02[)Q?QY[X!F>I[5A60/X;3Y^IR:"8\V7N+Q>[#"&7+[.+EIFL18]4
M&.O,/&6640Y'# )6E:4I0&ZS@*'!W2*!70#]]R^:&4P0[;]8DHD@S&BZEI'A
MPV0]F7"VT-JRW<4-'OKEQM0WS*O'>PQ*7V8!JPU-%E84&U:T+<6=KI&^^<+9
MR"P8H"$V/##S%<HBT3.N\[FPT<QS95%6RTZ72QF&F*E7+[^8"X;O^-U4O;,^
MZT[_O?C*3@-&/]KT[?<@RRT%I;'<S]%^QR8)+>"-D:4/.'70I&,MRGTBJO_V
MO^Y(P;K2#V[,TNGQRO$+A(:A_)'6BTYL1H?"CRW<:K2\IBS94I0)Y@V_<K=0
M^^?RQ[<XK/1_F&*:5&I[MU%:]-3N"VO?Y[,]7Z$*7D#LIF ;5N108-U[2\WG
MEJ0,S+ZMKCS/ZLQQ D9_C=B;'T6]?D1%^M8:\8X-=L +"O60\J)Z>W7HM-_D
M56 0WSEZL:8C$2D;7F(XKE;0F1AQ[=9W&3'6.K.WOV^.5Y/L7S)'F@:$A#QU
M%K*>>Q.<7\@%Z+P;=_I"ABZVX'88<">^VQ>DMZS;)BO@R"'EZKR?D:JRA.L0
M%><&WS82AW!?U/N&K6;VC-DP!I-N%XD8$[@.G,>9._WA./PD>4[OL"X\XW3J
M&@,=LZIR(?:8597QU0PK [API=FE>C7D,F/-)8/#*P@DVCIM_8<W]I&BEJ,'
MSYDH6VAW<S$.\:#;DMX"_-%8/WLOSZ#=\4WF-Z8?W/%5V<!$I6'HW#I;8$MD
M3QPS\^NGCYEYJAW$V\5F'V<>5][T "FWB'9@[K!J&(J^A(JG'YTCG7.>O.7H
MEM =LKX@Q<[6B#[3?E.>[N(DZPHS:&MZ,)-,KFB9<+3)CBOT#-(T^8%"H@X?
M3/25LCSJF,(53]]5FGC[=GJW9FJCZF\S?GO<GQJ72V_Q9:@0WU+?6 ='X@+D
M+9]5RS.[1K&/H SO_C5S&#/L %=0JNBT]AZ/B['PPV;*6 @%2/=&(S8TAHXF
MX^F9>3DXGA('/6MA'-WQ9R547'8M-BP(-Y_PN?I=-I%]DGDDREYVE>.>K[H_
MNCIOLESM,K9;Y(+A\.-&[/Q6F(_9 .]:<LO^=#>/B_T*0@(M<>^)644;C;O7
M2T)LW8E=A4E;N0(W._T@>GHH/17=LNSCKC&H8SC7>\[9=A8-(+V3#_EI0?AZ
MC<"<'\%SAY)<(Y1C+]9?RQS']BT+'3F!;*SBW+.].OQ:'/BB=X@70XX7!\DY
MK#MCS_(,H:-N;2$I[)9)W#TT%O'7KD2!_B+?<$XF,P7=/C0GTA+7AD?=8<ST
M%(W:*?&"R+JJ5PT>X#!4[?WD14U'<GL<CG:Q"BS9W8>I8@VD0CQ&-9/P+S^!
MP$H*=?%V$B1:WY[7&SOENLX+FCF-1=_,\N42/-FMB]D*X2GF.+P6&G/LJR@;
MCU8-M/7ZGP"5]([L5)!8V@YKW>TZ!G*LF0,:3C[<]VL^6-L!\9BR.7#>0F^M
M[AF^V+4MJUJ*5J)[EKM9(B\L):&H.3:<;(I4/M+X.B*Y+6YB.OA5S5 ?B_PF
M+_"):>'X.2=MYATWEZ)22Z%OGP\XF2YV'@C<C^1L<#0(3Y%_Y!F"/8YB&7Z3
M/8V1JQGI"O5(A,@:J9N'\L82U+ 1#?+>#ON!??W#?J5^X1XY;?\;*7\Y:!AV
M. ^<6=L<-*O0DSULI-#M/>R7U8/+$&\1#L1CCQ!_7[7A0=/"M33NK((5/FAF
MSL0_;#BK'P_[E=</AZV>5;R'+N%PA&1(H=X7(WFD$ GG,DF#Y"'4DRI2W!X2
MS+ A";(5OD5,(N=<+&?\+.G[O.9L2A=9!_-T\0YF;!5D(=C?D:G2M4/?#[6G
M6&A&5/FF IN[6#%<!L'9E(X]FJPZ6#J:ZM0MA)^0PL?*(4=]B>(=LO)YJ5X;
M<GO;:I;\%SV';J3(*<2E1M\NC%@ %VL2#%KMY W:-X$8!BO\V>7%F^=G5J+H
M<GZF(SV'I%W^],-%]$<=\/F.5)M-Q=D4 +)G+B<N7O7OFME3>56?<MNHP,W+
M.1)-3-V=)[_ AR"Q2L61;$P4?AL,)]R3/6EOJP19$1+N'^F,0?7,9!KZU:H6
M>XK]ENT\R%8$\4Z]:A(.SN/2_SU/ONMJN$F(,LSXZ[UJ%-DFO,"U)GAI&X,<
M_6N7.I:L^;,?7O_2/!?KOI8B"^^6!V^.K+I7PT!YTV"&K_ @4Z!DHU&]#TTM
MYG7&Q2.Y'L>ND=C% FE,9^S9'*$FV 6%C=V <]0N:'H/,^+2DF5BB\Z#!:"W
MN?KM-;V-"\:XY"&GT*V(H2H*,W%I]!GW$B+/F4GH@CTI!;=CNQ=U*464(+*H
M&=R/S0)$8_J_2U8K+,1Q13B!,V_DW5R?]Q+&MZP]:5$L@IT1*@9@8O+?M"X@
M5>LP*"7@['+-T7@>I2$EEFW5!&TJV)1ROM+:51+YHA#OP6-^Y\G%8E'I]Z06
M)2I@\(4G'*T)2T]V/3*1DDC$B*34I-FCU.07CH@A@U,EUQT*/%I#IV!5W1H^
M; [X+RZO<).:2VBBL<60O#A88-D[0QI, RRU@1*UZ[*=&G<K&01E[)N%PVW2
MAD-SG-*G,?P7.-AQFTO=$>U79W/.]B*4R]*XLI9E7C>V  H3PW+W5Y?4@[<'
MTHR7"_]5WG$P(S[#6O[BO3NM1J+3RQDQ[\)!%4:530TR<LB]LL]G"YOD>$L4
M1_PM=M(/2XP][<K/($X#P;A%>9@5NF!U3:.Z6*M$1!5&-UN12_#*1EK\-G!,
MB,TRGS57>X:C:%!-UD92C8\C[FNO- ZLVFTK2OIAY9<?UW+YGFZ(JI:TO]<Z
M7+#V'M51.-IA9"++&[IF1-H1!*%5WNB%MJZ @+&/I<Z'5HT_++6%O7.!^.WJ
MH&5'QZ59'?[\7M"&:]VXJB'0.+THVIIC# 7VF^-[S\SY]?DL(7D@54*3$#4*
MY>8*<.2K)(.<@?<%.<T=73CK4*M)\5&_U))!.[8J"!50E=;US/Z =K&NBN8Y
MQP;E^A(;*=+:LHMREW&D48K[,LDPEZV6/H77IK4ZCMI O3YAL&5UNFSI,J'+
MGVN>JT47X [#U* E1O0,:E%2X)L5DJ]T))(Z;]Z=22HV*,->UNG:W%;U.SV-
M$J3D:CP2Z#O1HG0TV>#C>FXX5C@B>,/]2E?D5M97^CY82=(1 R_#'A8$BE[W
MELP945B&#1W^SY_FZ3KMU6FI][8ITH7H+ZYBY3JU@@]6U^!RH#MNPW7HRP*&
M+&)_2#_I@Y?&9.R]16IRE6:^*)0>@>)4+W/.="+']%U9W18F0RFJ>\+6V+05
M_YF6'0)[KUZ\_(I>W-@3:N&?!;B7IQX&$>V$1"KX-ZH^< V?DV(#7/#*%.SB
M.BLG95AA^ ,KMC(1T+LKL?QY,_SF7%8;O+0JY17=\NX+:Y8!\K-Y]]2T"UX6
MM8&LQ'F]G-2<L[FSXO@A?NB,PX>LPGWZ/_[M?X5VHPK< >;C_N(\"Z-<\LA4
MBGD9C%FL1&\D:@*@;R0FSU*4),I)95NU9B]E^U#,PHK&-<2G8)=OSK%C#^TL
MQ2ALU#CIQQ)S!_IS5/95M:PJ]+(4.7W(.OAC3;MJ-140H?QV(@/(IUKFJKE6
M39H$/MN"K14DGIMJ-IB.O:S*ZQIV.-NDL%8C,YA?2\I<#S&##U;*UCQV+D1_
MMW>X!'[='TWZ))OYU]AD^QU %YH=-N!.NT3GJQ<G6J+SM/V4G5!0?^DL$&>T
M\3ADE:5>O1>N&FHH_&@S'FYA_VC3<9THONR2%8L40]L('(?\T0>RU87%Y0@&
M=AE'X+0ZL+':B-4%_U?8*3@W.TJWQ<'UWL<>%3<GX%+^LGJP/@R7G]PMK.,C
M(=9HB<0GS4U5W+!'1>-CE3B.A\3B>XT92SL T!?9?F";LC8:>HU2&(%'$392
MNK; U 6-Q>P?>H>XAPPV@P]"^F:F[UY?7L3.=%CUPH9FW\D,4_V#@5B:B+[;
MDB/580X&\CI4@L#ZX-1S*_VF/2RN6FCW54L/!)!6B%8VY"PO5C-[LKEEM%NF
M"S(%^)]@KD'#+RVC*>036DNZ03E"5]79.V,V_/D.-]X[[U["(UX4\>J;M-#P
M?08',9]WUMCKAQ_4LXF*KOJ]._8W[O"XAZ(FBMQ'")%4'2'_@@93#+U%SY/7
M/L(/,-&@QC(49P1AZ]:ZD-KA.!R.%U!5-M)<"U0GW5IB)MJF3RXWDOZHNX$*
M;;6,;4L>^H"V3I#,X]J4L*KI71\,805>J@\?6S&B?>.0EMRJOD.0-].%(?L)
MC56.%(ZH**P%KI@SWQL6YC-^*OL=J+,D\%$>]C<_, M!JSAG7_Z!+,'.8=!V
MBCWF3*' ZM(<%YI@? Q/T<>_MUU%']5@YV*&* QD!VF]V;X.#SNCSFD3+X7[
MDZ7TB2_LM=&UYH9&ZP5* [D:8X/1*BY-VJ'+-0VDR<?94)(E=>VJ ^[I+M]T
M)IE![$%-)^ ZETX%2'7:5*4+ P16R!*2JG5^W,QC</HSR9]$_<0H?C7K?/$H
M5\I3[&JUA>%26>U!'&@KI,I7 DT[[MM98JO4)$09]T ?%5B5O4+;G+C._EX+
M0G+BKENO6,O, XETUU,3WD\2Z\:K'!==T#89EZ+N7=-'Q\+LD7):!NM@=4A<
M\S^\72Y2$$Z/C<F<-0G="NM-*Z4 ' V+[I'(8L5RQ?4*]$X[[I+]0B/\5G>^
M37([A'10K=/#,8_X^_2^^\W316\@R0<-03)YV! IZ=[#W@)W[D$_(-DX;$Y
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MR>M@")<PC\+IE0I_MG*>+'.@SC1Q4@5](X=3K7Z @^:A!?=QTTX9_<'B7S3
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M4_6\;F'7].#.#4 /SF1KPKWS#%G]78SVKKEK6K.VNV>OJ#WVT-U;.FRC.#+
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M&Z+RZ!&DVGOD05P)V:G+KZN#'WD<6V8W]GKM:= =/<#> *C':Y0#XPE'#W0
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MG:P,G?/5 +.$"*BI%0PTI84-P+F73I#G]C:4&\["8T+9T@]?OB#54;_# F1
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MZ:Q2T.*T'36&Y_*V@<6RW6NTZ:2LF4F?@V#>VL MRIMU$S9;!5S70Q:4ZIO
MY>*8(#T45XB&.C6@9-,K4B1Y+_CO 0 7UIJ@([H$"X$#P^?5I=/,@+?H ]IB
M:[I'D$2M^.XHZ]STS6#;T&$M4M=VM3NPM&6B.M@/7W]@@TMS9^)R?TFP5EN=
M#7H]X0IJ.6_(+!B^UB=L@0_3)@'PRR:]X\(MYRGL))#:P?D<Z)A+VW,T\^L)
MHLNRN.O!?G>-;7356U1BGESS&;=V"E45OU<$FV$IT-U W$/);Y#E,,G=B(&6
ME4']G7OJ&3MGD]K+<)7/\U8L6M_+UO=.'8W\M]]>_(W4F9;&0MKO^HZ\?D5A
M(K8<UN=)5R+Y3]N1F?A!&4K/? C6A;ZWG6_E.G1;&Z!-/*-C!(7KBYRAE'9H
M8ZUB<B_NE)N'"0CU(++&;5ZX'OD9=UH)(?6.Y]RJM_#MKV>_OG79H[<KL'Z?
M)ZX2AD;XSXYD'EV^TC#,)1LTY?_L&H8[L*O; X&Y_$_ P&1F4:2U-NO'@[@J
M^9NTR&W#.?V(;J*5,(\C@$9_LM!RMMHGM&3IZ5S-^>SMY27M()\)<23\F[:5
M?_^>D=ZU0><Q *390BH3/$U.H<5&]IC,P6K:K5=&12E+D!+RW3!N\BVC44%/
M^NI3;O$D<QLB6N0;I1(1J;0=-ERNZG@D0<&@:#EUD(/J=62Y((@SQH.;E/43
MPU;(]RTCQ_:JS.-<&/<]*U!*@I=T&3BZP&]0F-72[I C/-2NS*.BOX'A%'PZ
ME([MN82JT7XD0)"<)LU+:6JR[?20':\YP\PAYNB<,*Z-"X-?HDB*2HUH;M'6
M@(KOS.8]3S4TY2^OF:]MK(KJFNL;G4EKV3#B:%!T($^^>/6G,,@6H&YRWWZ9
M9FKO:RV0JL<W5L"O@G38F[CM^EM?=OI:6^,4D^#-U9MO7U\\YR13(%@\',U.
MI%8N= W%(C*@T-Q,D6$=_:!4J&PX]8?2ZE:XWMG==F%("\JB*</M1PR#U5T%
M004'E"_5<C$BB.^4Y:K:&&=]%U@'ZTG@NI51L%/YD(9^P8W2L&'F1JKH7*2E
MJR44A ]$>0'.@NO>>248R&+9'XIENY1*WBX NHD&%;Y/[3N0<3@[R?O"+8EV
M=W8MKN[/IY87_'K*"W[J><'?+70R<"+(&D 4%AP#2P,O4MMQ)7;CXI)IVZ:+
M=PY:H30MN>'O0J]GL.[!%BDSZY!P[.#G@]^58A1E3EBF"X4I<KG#F4M61-UK
MK@BBC[FI'2QA^XQZS3==45J2G[B$Y?Z7<,6Z$4C0++G):X%PL8UN:\!\<YH5
MP7!<SA7*C@2.3592BT> 98FNA+Q9*425_!$;6:UO4\!CT-BX.!@@1E[)?<V-
MZ(OXZN3JEV#*'-;26PYYF\3R]<4&@ET2BPV%&%NWALE4UU6M%2$SU_\IJZVH
MIJ(BK66!/] ,\ !V3)P):9%8(L2<4DM[;&;WB1R1LR<VGPA%5M;;60,V*,X1
MSA:)R*WP> B1;:$7PO ,F_UAG<U6\]LP'ECMGN8::.20BBX9O'F=R(*[4(A1
M. 1+IKG4%9#PN!,_V$L<H&)$7?ZE5@Z%VL%V V@O\4*;3GYWSW4L31(-P;1#
M,QU=JEV]\-!&HA,;(U6>I"O%MUK[CEPD[N] ZKFM/X*)H?@1JX3HLJI<!<AU
M$">#R@CF3U<*YP%K,+N>MT@,N4JL?@U?%5/V!-F6?8HJGC[Q00"JWH-8#GB?
M'H"7O]-4$P<0D0!3BB@KL&@AAS<1M0EZ718#2?31TF*$V A>\.1Q_Y7,F\.K
M&D@$U:67Y,?>G66==EE7:*^[[DXA01;=G&T8X:B2*/G1;[!X@ C(VFEZ1"HN
M3&>'0ESEF6O(P13_%K3KM$D@,%WI6JLR/R->#SVBS7_HMI-C83=>O(;"+&'R
MTI^$-51" O__O[WXMV1!RD,;QMR_-XB2Z+_U.?*+,U[J36/^P_['-T#8;%<D
M!W1<982:_S?CJ-9U2=Y+M7&/D2^+@)'[U1IN5H.,W-;IYM]V>3T\_WN]@2_W
M%4.:>%7_Q_]#:UGM+Y*]QKH#@>Q#7^/_^UN;/;@^GYW__8NGL#Y#QWS'*W_(
M4@ZY,7MID\PL*DDPR8#_( OVND8=\5GX&A_EE;CDY<MO@IMPQ]9_JC(?[>F.
MG1G<1?KI@*6L/WO!_Q_2RZ\OAKZVHP6V_^MDGR'",O,]QSIV*'?ECSP.>[8C
MCP'C</RM4<=B]/4:>[4</,[(XU3+L?>DK3LS]CF1=JQV]''($!M[!(Y]MV.+
M5^#PC;[_U<D?QOTOE:.W76SXEHM4OOAZRSZ@_ZGQ/S#3Z?^2)3\9]$_0N)D,
M^LF@GPSZ1S7HMREP KPRCLY(2>*\V]$X'^G3^]7WET=?<E4]:>R3E-Y)8T\:
M>]+8CZJQ/5BO+5V7*M;.:.V845!0Z^N$6+#+H" YSN7MI\*_/EJ%<U_-?EK\
M5,M"KLJ N6,FC$HS+<"6''F(4577Z+..NG*#JY?>J6NX$#/N)*39@%OF9B>&
M:BL,1%P.(;B%?(O/DG?YXMU<B@T:4RQ)^NBXZ:RT<0*30\>$!Z*_!S!'&R"D
MN4^8-+FJ6NF_DEK:R(&WFB^X8X][T3I&_>LO"V#\*\4:82*JA:MMGCG",Z1Q
MD+ZY"7M-W>P'5W8X/>1P)@0M C7AT@EI@OJP_0C59YR=0NDN-RSIG[F+S289
ME6(C.FY<D>;+4 %5)]_:@D,=[MP-\Y%I&:#B-T90 ;C):8MU59@%?!H[0@&W
MRR0(*B:5PCM4CF@V+62Y#2I6P%74SBQ9KE+(SI0N3)'&R,5/,C.G26FJS\-U
M:]DF (E^ NTL+\-5R=D^^J+M@GWVT]4_GV_S#_BFY-31R3I)T +^"'!&%@D5
MH]N,\*=>+_N[B9D*T^2RDA:%?]@EN=1-YBI86IK%-I*#!74%8:M 1TLE2,L%
MX,R%1Z/DG/7U #QH^)9ZP@"+IPIZ<-TSUM&)C++*H3*"5 4XR.@%HZM36EWI
MT=RM6/$C]76LOA/*1YNJM>!"\Y"\+_?MQQ#0KGQ7HN>1\[VT3]REBL0WGQ"(
ME112">%%JY![EGHH8KH@/0("RH"@65]GX3Z -A7$R-:0DD-W&QZ3.L8/A_#?
MKT)PJ#R]KBDMGKW3LC:K#FIII<W;CH4A((562#+;J$\_0^'1LBM<-8ME:J*K
MXD9>'G4]M0.#MEW*"IVX"+NWE+&Y5R2?#I$UQWB_W-F5N]H;5/IX&H'D?OZ
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MV%! ]V3<>^/@I/@I&:V(8 2$4^)3S*VMK-^5= A&QBQ9K$ .55YSY_% PRN
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M;3*HMWA8RW@-=[?<X/4EC8O!,Y&/H[4O7Q>P)W+#?&F $=&552CB'IJ@$K
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ME;6UP*ESY2E#PV0X8?D+\N(YY3XE"?%NSDB;ZVDR2H:F*&#J'9AWR"Y4N<I
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M@B%G/X;)5LJPT;%4$ O7KAR)NND9<"))2B8O82Z5/EOS-*)]3:!7&5)>-D,
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M%\$'VLTRXV!="=.>().E/8]HAVC?PQ8;?A%<M]SMH(U4ID("(5_4?UJ]HE]
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MC>J9P0.6"!^0X@M_=W0=&3 )!+4V29Y\O9B-O%:@ZB!-PW_<'J\(=S0#!BF
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M^LX7C].^1\"V 3T/@5[+7)&EW/]^B2+2>X&8COP\@B*+Q4-4N?5/R:2)]U[
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MO[O8*A.+K!*T9T5WS(#M"LH]<,"G;\\?\&DT%,],:;XW0_& L=$>#K\;!>Y
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M.+-L/J' WSJC%$^ZLG8C383*F;^VS-TU)O$G19]Q9JU5"F:6L ]K,!M@OW$
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M*C;N$6[_(OA^BY^>QJ3$AW:Z(,[T@LF='6+PC+^XS)*8_B"BEF\D< J7B\H
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MOLZ/PEO5(;;)"L9K2S>O0+BJ/R<N.X7)I-EM2#1?I]H:$T6V^+'I@[B?9'^
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M.=^"U-D9D<!#"C*Y<:5)+[3I=2YQD%RQ-G>Q.6"_O0JCJ3_;0MWDYH,==6_
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MN(N*L;AZ_\?UF\/>A8 MA'(2!7C,(HOX19WV4MW5V$]&$F_BG1]EX@\_+@G
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MM H<Z7U0I'BS?*OXW>K<L,UI"6P.&>[*4Y+=ZI> 6\"N8,N@W"E&,W>+>.@
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MO/CN#).C)\XP<1T@VJ6$/'7:G0/50Y21[X+63NLC1SWOI'=F'?@<I=E&:4Y
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M]]>R9OUTMI12H)#_YX76)O0ZG+;\M80V[31>DK*"[X3OY&/&/A;KB\E+J]0
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M[T3K_>U#_.3+!1='/2TE^E-%5OXV&A^.=E73]?R'^'T31/'"EC"NU1[S.WA
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M37PW?YXQ4^PUIU!>+59\\?:Z?@O[P"_J6]* K^Y+JLV$64)ME("9"Y];!RX
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M. =,3<^@(J2.)\8!].$&8\.%+QPD67?VK$:4-S\@<@,/=_F)CFW8DR$"#*_
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MV$6%:MSM&/TTG858]7]XGO7#=IS"FN,U5;T#1X2<6"$"KP .4(>ZPP &S,*
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M@A$OACO)^HTT%AW* >8\!-S2,^=6[XY$S*GU8^;<I2U[BS.G#N:LG) A^"<
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M#OE+L:WE+<8.4_23^L13%RQ4'"\("/H.-42#ODE[-DWW$GBUM'E_I0=CPFV
M7* \:-<CPU;!UD@9;GFCS8$OW/SN;\N]J:G-=C7.+<+F5&9?G@2-(P4 A0*)
M@\2+(_&M*2W)23S?[?V&VM4/I' .-H=D#4!]3Q(L4R+*G/E*,.7.BJJ,C< V
M%<.U%,MV%B&SZ*D:SA80L'"P7I7PF. -9?2&OOT<^XXMC6*PX1EM3?@9&;[+
MX0BNF'\C/OY)6-"!:YU&]C-KPD-_<)4^=DY:U9CI PM!(DF!PP.D%AUZ >8\
M!-QV9,ZMV3.[,.<+689UYM1T'L1UP9V5DS7D!LI=_]_E5S'KV+ACOO&=1?F!
M0/$681 :KE@5) O*AXFNRU,K:T45!G1A?K%5TG.>RM;DH*4U'$3&\&(Q&S/_
M<B*]ELL'BYA3Z)^XE5)+[36KD1B -2   X)_R'Y=91],F(D)NWM@PL3#]?16
M-?H&EJ3PD> LY>8E$=O'@8=WH3%V&'_5LN_2/?S&L_XMC<*LW\[.EY1?VWGA
M6]=LA<G_D/GKWZKI\Z>,1_9GRQNXVRE3#-/T9G/#O>>2K%QX(;\^5V,>T"LV
M?Y[OON$H<\,/Q4R^<,H"IDQLUW!-F[_.%3UD8H)F<))X73*LOUS&U  4(5MY
MK__9<2M^GJF_?* YMZC'8Y\9?QP;$_X\[PWGAW'/+?*[LC4HIZ5>=Q/WY1A^
M.K\\'=V<_UM5SB^&R855*G$CL1*7\&22IV]N![>CKZ.+VYMOP\N+WT;7M^>?
MOHR^75V/SD;7UZ/3;S>WE\-_?;LY^GBSTEBAST//Y0P>VB+-?.6S"?-]9BDW
MH6?^(1-Z\J<I?QKF!_]'&?VYL,-[Y<TIF]BF';X](/%X8[O<N'F+@#]UL/5@
M^U.UF"8E:\9; ;\<-;CCQ!Q'N!+<1*]^CYT/^?O&C;XW%J'W(=Y(X"Z"8\P#
M]G[YPP<E=E$:C3@.W/\4W.@.FMV3=JOL,_1U#)"6F8!&AU:/';G>O=)]5PX%
MOSG^X!R+SA&%:*)]TDUX1O[90#:I1<XGU9,<R:RPO4!=%*-!*F?D:8!'Q_S5
M1E]@YBH)V]";S3P7=JT::,&NT5CRE5W3]VC7XIJ@DUZ=EG_ ET&DX TGAVQ
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M P$4P!;ICUQTM[K[/Q-8_68X"U9D7/7:B8P78JSD#7[49JN!2(R8T!(U)RB
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M5C)URF'MJZV2%DB2F/01M0L@21HP0!D(H "2S$"2O3))<A\'8#I-M=M.7'<
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M\ $.T5K!!P 4T"KX / !"JN5[^[-"7CAH-ONI?9ZNZ?VM&H,78#!.H 3</
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M0E<** Q,TU_($5,A$[.G%*[F4?.SN7%OB%9HHBWY=FNT^%UZ6@2O!<:KOC#
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M6QW,GR_U>QA/&H\O7?-@B@_C-;73QK 5<A)'U1J "R']]84!7)B%"[<ZGQ?
MA7D4PFNJUD>/-G("1R6(WXC8E;'G6\Q?KG#@.;:E1!]4Y&/-#9&5.O#(_I1-
MF"_:K_GLCKF+TDZGKSLG>T"F<@I#Q6Z]A,URX6INVVA %3DZN< %9VC#&=KJ
MR[[M# WYM<07_FZ'T^$BX*O$_*4?=%]X1D!7]5:_$EX0K DI:P(2IH,%U.8
MH ()%T7"6SWB\R3AQ./9NOUJ%/W#8!#-2!185D <@0L6*J813&4I@?R!_;FP
M^:HS-SX;X+,@]&TS9/'[BR!JD;[689YKW!U*#F@H$(UE?[!U8E%AZ*CBM.D9
M9<?JH-VB],</FEMM^;B='7+K*4?56LSZ=/\K-Z/G[N72B Y6-G1_ ^1T36UV
MJE%L"6N"LPFPW]",JN($GBV&9[<: >;$L[D>:. \V]7!L]43R,/N'$A\\:F:
M<G@ZJ-6J+PPHW*2+#52$! P@"$A_?6$ 0=#%IO8J@AANSP/)Q8;QQ/%^!,K$
M]V:*[=ZQ 'O&U-2"QK+7WCK1@ $$3A<;J @)&$ 0D/[ZP@""H(M-[57DX"(\
MK7G2I0W"U<(WIT; %&^BS'U1%AS>R\IA44D\G_$;IJ<G8'"8I_K"  ;/5&RT
M->SKRK@7YBVX]08FMW4^NXK-WY7#+S9PK='2 NZABWB_U:Y$B5&M+  J=6%S
M:RGX5&$ ]66BOJV97SE17S[=QII: ]1'3<H.NWBV F&Y$8IQVZ87Q =Y;3<T
MW.^V[!LN>OPKAM#<P!;JHBHN0Y@.DJREI:(* WR53+[*:O37V I^KAR5,\_G
M+HK)F!6<^=XLLHY#81RYLW*^,HUR^LG@P3#N. %L[1!04X>/0DVZ$)[#UM92
M\*G" ,K+0GFMQCXI+W%;+JU1C4.OM=)\ F'YOOM_5R%6CS16";TH*O>9<NER
MK9HMW#A:+ZU.&MU(JT"<:"Y8&:C0C;0P/TA[T@]:[5&L3&H^(7VW78UM!U@&
M*F$_N+0*!AH:4QFHP*6%<:F>!Y<FSA6TVM7(%< RT,LG%+C-3WSQLW?OQDEL
M O!1957T :P&3N@J6HSKLS5:[)FNHN=+(UI*]VZUKW<KY3/!F*#F .8;FE$U
MG$"SQ=#LUO"PG&@VU^;=FMKK5J-R#\8$>0DBBT_5DL/108E5?6% <25=;* B
M)&  04#ZZPL#"((N-K57$<1PY?;NGMBNX9K8,2:F%C26O?;6B08,('"ZV$!%
M2,  @H#TUQ<&$ 1=;&JO(@<7X57@X''<'V YGHE'=8:CS!=CQS85;S)A/E\:
M>JH"$H>%JB\,(/&CC^FKC=I;+4S7>J.<!\'"<$UV'EG *VD +V/[5WCS[JZN
M\N^L1)$1#  !&.I(?_SNN-3Q==>/*$#0E#:X1@;WO_[2TS6=H#+4WB8A;"HY
M;&(_F6_:T0 DTYO-N#L2A)[YA^+-!8]CEZQ\':&Q[+4W531@0/R4)7[JO!0_
MW0A[=QF9NU%L#JT]##UJMA VD9,MJGH/UH/TUQ<&L%X6UMN>^;<3ZR7OAU2-
MH_TUUVR$WF7O6,9Y>Q%Z!\RW^9U\5N8^FS#?9U84AM/3&S@B,%?UA0&."++I
M='"@J2-@"$A_?6$ 0V0)5;=G]#Y1X'(Y&7KN'?-#,?GG:NDHRT"V^$&]#92Y
M4!0UQ+4$0'@ZK@VB/>65QO+/A_S%N7%O\-_H:0[\%ABL^L( OR6+W])_R6]9
M\U9.V7BG6;S)?!1=[;?;\%&HB155E0?A0?KK"P,(+P/AM1MY$5XN07E3;;1:
M(#QJ8H6@G  (FT$YC[K-*3/_4.8^C\(C;><_?O>-F8S+$9:3T14:RUY[DT4#
M!G@I6;P4[24OY4*D(:\B<U=X3,X]E!Y"<G(B157=ZTAV.!U;-BBHYZ&! Z*F
MTD$8_;FPP_NUAK&F%X0X!5N^+M!8]MJ;)!HP("K*,K2LK6^%1?%D],N)K*):
M%EH-A<TK/#3JJ7JKB="(FEQAQB>L;"T%GRH,(+M,9+<U"#LSV24^^ HV(R<X
M!$9I;@3/RT&G\>)NS#J53S0W?+Z*AQUD7X93YI>E&NL^Q1[0(*X?5$GO96QJ
M.168*E2;(\9W@@L^S*8/LS5E?'T?<^G/G'F^-*AGRYQEPE'CK\3PJU'C#_Y-
MIQ+^#0P'E8@>5%L%^PV-J0Q4H-K"J/;%%ON[4NUK&81MJM4TD&TE1:^&"0?B
MB%RP4#'%0%C#M:(?V)\+FT,A-%J^Z+,@]&TS9/'[<]^[LRW^V_B>U.A8^%-5
M(.D';,2B/FD1834K@N6FPU4LG@?MD:5WR+9Z=G,[+N9Z7\7&^=/]KP&SSMV<
MTQ[)2A<T56MJE7+08(NJ88O \72P@%[5 4MP?&D<O]6A/">.S^-PN:ZK_-O
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MCA_P4.2*DMB\&6?:&7*-U(=!)+*>^"4R^?2K1[J+=#M1GKWTYO15BF=8.OY
M=E#?L+'I$E7#*6,1KTY VL=SVQ3]MV1^G1HI6P&U' .J/OB^_00(DWMY^!3!
M2SQ;)F[%L]BE)]@,^PM&>V+QW*G+K^*U?.<W8D$?&?_?8]%SW1RQ##+O-/)G
M-@DP#Y@KB<S[?\DWBM,U!RPR0'>JML E892#I;69VY'4UBP=C,:SXM3O&A_]
M,>TW*%IV4E-,"*[R+IL.0-2K76J M:H)6H;GHCZ96IZA6F)&3O0<PZN2)&3\
MIAW^=0*A5&[IX10[^RD60(@>WS"7/QPX-08UGX!(B7Z:=('2_,$+I4(BK$FM
MT&"A'GTSNU(IN8WEO6890!'+,@>F)IY383T-,!.3:W@Y%=4*RWE(H>1M0KRX
MFK3^7%?G= 9I(#QUP2:%O#Z/GY@9YHS'C2J[1)\*1W;N\V0/49+O&,CK1?+[
M<\73[9B2S!\/LP?4SZ\,RYR."#%*GI,49#$2NIRW&)*.3AV6:!;F+\3E7.IT
M&"2-$Z79<G@_G6OZUB\_("*CK/CM!)P2MA!]FJ*#>W38DPI'U!-L?"+$C',_
MY/$06K.D<#4$];=$.25OWT/&+7F0TD4T9VW4BL"EJZ%X'['N_*A/'1LH_Y;[
MPG[SU7O>.%B>5:=4" 6CJ:4N=O7TE&O/2SU8,Q5&J*7@W,"J!F'#P&@3JP0=
MCJ&**Y7PG!WBIR3"QV:4=9<2<$@&[$2#0;G- OH=]GQ-^[?F\9CDVH*906CP
M,P]PZ>1MC4Z+)Y[I96AB=S06.0CQ>PB!]"] "+3MZV+P?>+(T8#'D:QIFL-A
MQZ[WAM:DWAWT>_61V6=UN]T<]\8#J\\F@\.;E6.$+MC-%<0D(>C+12U[!L0O
M;'%X&)+T<EX9M/"$)SX.RV$I0DE"#% 6@#@!-6/US =>%XW-(; U*Y-4DR8D
MGO&B&M%"E\[Q!-A"&\Y2OXNVB.L:?M5-)^'2SW;2\5\DYBA8PE<7?8F_QE9Z
M0Q16ZA2M1S4+2<;8I@,9Y3L4M!$&:&12#0Y5H(?Q^$_:L\][Y:84$CV[WR:O
M03C\X!%V_.__ZHW>\<Z\(9O$8)&<1WE<C&92%"DC)ZCH.?T\/@1;1XA29FSB
ML6S,T@^+Q2@(<6(Z\O29#F/!?#Y0EG+YJRD>SK(#_AEB>3__FQ(2F$F]/N;;
MQL"+=*.9^BO^JW08*X15%@=LO(EV>FO 7(G*^?T0D5+%[ZM+%[ETOEJ+NCVK
MS@L[EX6BL"OE%#Q^"F& 'U!U*DDV/ &"=-J;0,@U+!7W;%$^AKJ''<MX$^.<
M(J@^/5/9CF&?[U%B/^T%G>F!G"& \ER3=_R((^S0@A(EKF)F=L+QZU0M&@.]
MQ4?]&=L/0B/&?LQ7:)E!L)#!#]NDHD)\_T,D6:$X21-MSX]PG[:#3GF..1%T
M]1A!<6H)%-(PKJPH!H++$,2B<,IVJ(&>B+C\<(W1*<[E7FCA_NB,"_=W25BO
MRWCW)YV.W6=V?6B.1O5NISFJFP/+J@_ZK<G('M@#9C=?K5O)SI!G^\.!4:Z2
M["O7E*^IZ:]\E"=(8B@T.?\X3QI[GM)%6R5L9,@MV6OG37ZX!)JSUP[\!6R:
MN<A<<B+8LAS]O$[^)1[^YLP3-1^S%$EI1B@CI(1AKMUZ2KND#Y3L,Y2,WU!\
ME1RE0+"/O)4E$,N8I748\"GVPYH"&A( 8YE73W@HS*>I+'.1(D<$8 &68:_,
M0O*PGH@B<LF\#D;!3\NC2,24F2R!T%9@7C8TXI C)$2H$S I/B^D-8$ XT6"
MTB22!3"&L"%IHK9@O'V; GOX@N"+>+F/$(<<A@&+PYO)<X[,T_#[V\HM@2S[
MED.[HL BPR1:,QXJ/TAX3L1+<K6^IZ 7F=3T;.?1L6.:D<.WSY_,<+-R/>=^
M-?-^2;6E"A 9)-J,%G-QRLW$H Z!J"R'FBSCQ"7Y'+HP(%-!B![Q9,/CUW4I
MU:205=!0U2 ?T(1GN'C),E@WK:BV_&@#2W7PN^9#P'CT.&;1$Q/J(U5#QF4)
M_P26S5PF2P_(TL*]>"Z$1.C<0M)#I+@X5L?-8^[M,;G7*V4'-PP,9CBCB[T.
MWZCK%[9"KBG= DB[=%LB^:,NU0E5@T,+S"R.<O5R_<+0I>NDSXN_*Y%:T7H;
MZT:RG8.D+]7!<;(I_E*QB>OLX1A/I;R'T.!_QKM::4 W46P^V$J7_P'D:,G^
M8ZL7_C-YZ<2X\5LX*VPK"HL3PN?PG1!)/?()8.K%8\7;8%AL68&0&C-U$Z(5
M0K8TE9OL$+LZTE4)/GN'*L%(B+FQ7M2$_>9Y@ =&]XS$ 1)- >(G2,YL' <A
M%__$;JJ:F'H!91FUY&V4YIVS  ,E;%2)P2&J@Q!PZN;WVIDHUYO>U.2^YZ;#
M;U@E?05IA^) 1<$Y9,.XVQ4!) \"Q8%59A<-XP^4)0R=,TD(&DA$2X>=2QFP
M4[&@#A2FNQ N17%Y* R!0QV*:(WBXI9!I\K81D(1J3&C?$5RLS4?>XN\F1$J
M.2(9=:-E3--IY^ZK5 VFI@W)6#LU49_M\OXT%2>H"3;RX6.8*A#M("6PR9KC
M=!*I4MESCX5Y9F#+"T:O/UW=?WBS^A/7.#O!$>.D7E_=7QO]9O]-KAIWR0HI
M5C[=!B+ HG6*!Y/72EK0HBA%JCW@;DC)GV&QGRPTYZ8I%):)QBRZ>(L0QW%-
ME[RGP*V4?EQ]!))]#WX,Q%.D<D/X93@1J(VRKTO>*C--#K;RL/E8^!SD]IXQ
M@\]![? ZLN7Y=_D0. E7Y2$6&7)1.9P]>MOQG"=7D"->A%7;UT+*_@6:<RU\
MTAGE#8YQC/-19H 3_ES.,4ZRMU6Q@/#/81J[3JC41DX#S8WXS*41)HPIW^9%
M$DE-CPI#EX9*1FH#(+P.(Q[8,*YH9;DCT%J:IT\RQN@NQ,E(N$>%53]WZ6V5
MKGP6J>O%-8<<Z^NL[GCGF]M Q&!4;"5;_ +E9&BF%BZOK:)JK[O>0!-U^01*
MK .W'XF\$G6A3UCF%_<0@"<,YA#.P^:/B+"PM1&Z!^ \15_X8]*\J$7'TQS7
M$K/GT4X6JM-L9BX)\"N\UP"^L53P%Y'U?SFKM"+G"TL0W5Z:=G_0:O?JDV8/
M6[[T6G6SU6[6^V9_U+,Z@,UZO0LQ:T1E@\A,2B8)?4GV[9NP-/ 1<1*+96F6
MSQ-^*].D.:50,H3RB[+V#1M!<3)2HQGU0&WL>S'\65;D)9?118R)BP)JB[#"
M9G-XBI.<@BI#?Y.#V9H1\ "+$I  \T#YTD'*+A9YXD5W#&CPEGMZ)JW6[*0M
MLOB#<CDTJCJD9!ZUKL#[7;QTA^*KT$2CG3DXY+\2G;K@%71MB3ZLV/2:\5=L
MTBDRH5K?%7$2/@IBLN!!%-SP&)FS ?F+8;%\*3]UA<@N/656\AN\&BD98Y >
MT8(1##&<LDQZ&V@7"CG:LL!?F"XLB9R4'3/NF1Q ^5A!RAL&/1^$ED85OM)V
M'9&O$W2P58E +P&>Q1+UR2O"\B1S(@\?;)$=IL@C%27UH>(\5U;GBD-<&:[@
MI E1;>"*,W#NOC.9KH9QZ[$Z?59R30$G21*'XF%8#>J#X'.:5TMSF$F."_NU
MB,R'.D\8>[[A@;Q'BA8PJ6S\)7(#F!/AI0\RT9,46$S4(2(\IW>]4MN$BCCI
M64/ Y N(6D0BT?I8*"/1Z $B3A<+(. ],B>#E*;P;24)^0NQIZ6H(>'5 _#L
M+>\I7=+I=JMY_L?;6YU.KSO>[C3[O:[5G-1[9A^@3FLXJH_MGEEO#>W6<-)J
M]8:VO>YX>W?,M/7Q=J>9 ]]?1=@!B/!C&G<(S,*Q89D#U4,=<'.BD.XK9%EY
M=4=<=7KU/@5ZFP;4G!W>RQ!$/>5.:H=$1 B_ "7W1!$6=@2F'S@H@L_$02";
MS--#"#>J#48E5DE:#2;82!2&8:"G_#4"N,11CGPB0<)X3A@'GR[;HC8 B6>6
M(P$HQ,_ #*QU4H-SQ$W9!J2A$Y%KD\@LO4=B)6!?09BX!A?7)B\ VT77U)>+
MG>F*/&7S.%ADR4)$&UO9HI6ZN"X7'20?SOPA^:(H"Z<[.YN($9JN&<CJ,0&Y
M0P3,YD,"@Y-MQF*'09&L*+3!UKZ(=B>!&8*AL'A)G)"E3/V<*^NXQ:0L6)=E
MQ7,:1+H)A6]HS_V)_@^D6W:P?)%SN3)>@%PNP*,3K9 *%A(%7KHJA7]3$L>B
MUC%-GI/P AZR94LP%"!X@)E6)V?D7&BN..)=+2"*D%)V/RT'QK.Y,,U@I<MX
MQ!O$_.1/GI#Q>T#\W_B&F2DGKO')M5*_$:?9/AU@ &FLJ<R;8W,^CD)YVB8)
M2A'I9@ZWQ:&)+8A#F#=96F/M-<^"NQF)"4@9!C$L\Y*Z"IH@QVMT!2<A<+.2
MM+]M1F:Z+%%&(KE"5:^"8QSJRA #JZUCHB]59"3-LHMND' JB=8'C)?XB@J9
M=.%BD@C5A= !7WHAE1>9,C1?= ,\R$R43L[]5-V6V4X\QB\0'V&%EZ"^=#KI
M;.F=4FCYSC^,3JU_Y84- )NN;#PVIJ[DL,"73ZL510A(36>RV#-$.'VB#/M+
M@*W_C09P4GI#T)08FZ7J12;1A"2E)GBE#UZ=3T)@$R(!07D>3$]DK%3/B9\0
M233^05B/.";G/Z>GV37$#+R!.K=N<BPJ[Y5#F0;E&)\*AIYPH@.UEA=7!E1-
M!/L0HOUWZ;H;:J1R3PP7MJ(<*5.5%K(-5)'(I*9V$*KQ["#^E@%&\Q>,*:@%
MF (KK&U(&2I;2VB0&UZ0.BIY(4V %'0;4V:F-?5K:WW.3V*YRBK"\:"HK)E5
MV82!ZHF1$&=,E:$<9$F<%V@!^WE^:1)[EAQB*Z6<0P16,UQP:,#<:0QD2.])
MUM9@Q,MB3;'28*\*<M09M7E13<%1N3Q-C6%2YI12)@(%$.$6!7B'M5-X\P=C
M)F0=?9J_4LJ4;#/)E/AJG:IM&OIPQ!S3:BR1ZWAWC;6Z7L13[U^=\/LU !4G
MPG^]]#E<A^>4NG:WU1T,.W7&+*O>'7?L^JC=M.OMD6T-1O9@V.Q;A5F;<B=M
M,L0D,,NI:2 Y27ANR8S\KEY6.^_J^ZVO3UMFR/$R_0//O@"T*^7;-/HEP18>
M#H'X$TRT>D&=3R)4>F]D;E1GR[%D,A)7-?,]AXHA,:*D]Q![\$VUM(:8<TJ>
M9OF3VM)]4/7]HAI-%%WAX1S?8,.X4^,2,;A"7I7#L_3\9)P9R@&?-" :TU#T
MFEP.3"Z\B_X_H;AG(,X()LP6Y<VPP!A36ZXS<Z(E<N"+,,Q,JQ5Y.:7KTV@D
M)&D42B[P&OTB?IU_ =<CV7:EJ#H]0U:8\_=0YME$0A 9_]U)K]4D22B1&!0-
M0_AQJI@MQ9&K.,;"/WQWA,0GXR4H=<";'-0Y9I )+42B-S+A4/ )O(SKIO5X
MBZ4=B'I2<4R&52-B #S=CJBA]/)BV3"F&Y,VK'5!$C9F)',T?\67Q7U<2M*S
M]=!W8PF24+-"N@:,0J6<*5+U(<7 - R4!<E)-\W)EJ4IM S3IF$&:$KX-7"2
MQD0%Q)%P8ZV3:^4NT-U;4\#.@.QN)QD3?3M!P_QA@?_]1 73ARI":0W%?4&;
M=9HM-JAW!N-!O6O;H_JP:_7J8]8UN_V^/>D/1F<]<FA5)BFMB,]8KE;S)U(Y
M&@R8R(JPQTZ0.S=><6J=^:YHBHG0'N]Y)[/*CXV^^(#9YPR3Y<MZ2\,;GS%8
MEF\T'5%;E'X6*ZCC+$RB@_P%=>Q\VVP,>LHOOR&QLK_ZD%*4+VHP:K3%JK:G
MOO@Q6466'?B+$\KUV@FUIR-TJS$Z!*%+$U.N)#NL#M.H_WC5?E4&%@P:P_XR
M#PK+*)XM_J=OHOI_6!+Z"S8L*I\ZK)H*?2 [='I&Y)7C9^$#CNX)5+,O')ZD
M,&!$QS;XYT3M'W7SJ)K5.C(ON&?0O#@?#[*.5^FQ;56\C'H19!G(7_*^,:@L
MHU_=1CJU[ZU"%%8:TXZYA@_.@_&-><:U[^',=\]BY5.>*L9H)2![:K.0J"<S
M6)I/&_C4SZ"?_7FEH(( %_,2H* TS-MU=G,_5S66.^F]2U*IZ^8TAT'T&Y[$
MR6NQ87JS=<K ^H+Q36VON-TJ7IE[XX?%!_C4%$LNU'D^5-,AKF!_8='&AWQ;
MS)GZ?;FTW$<+9T$HMV[;R:7;>OO5^TY^_%KY%$8;MJQN_%0*&*93(-GQ"5X4
M!Z;QO\QTHRE>4]?ID#+PI:P@H#P!IF;53GCM6>S2D$V%;)N+\YX+V8153HWR
MV0.VUN"L )LV;N>"V6P_QN*-=N,%L4&KTQB4FRW"P.1J:TH(W@[!H)(K35D1
MP18!Z3KF5=( EI676V;C7H2?&OZI\*_[0O#O?,%<][S G#9VST%[/U-U+/Q6
M%,L>_9+4AID_%]XGJ77^?9*V:G.T=@S0J#FVFZQ?-UF[7>^R?K,^-%MF'>S4
MH#V:F%US_1B@'>^TK7G03O<#"BX8X/=;.]J0%U2E0E79:1$GO\!PZS%EEL6U
M_\@O]^*U!88=+5;=6I#S_G!2)_:F$6-^\5<[HX#>X9- ?$_7]%#W<](29ZE%
M;>E@Q)H!Y%D8T6[E8$2>9S1R03;AEJV+:1B#08ZI9CPE-[^6)B'X>#MJ:KJ3
MS"P;/DN!]SR1K7F382C\ZI[HL[RS3.1F/[^X3,@%EY7WS\D'_D1WBG8F>FZ&
M;N6(OK7"=?H%"K?B,EC6<.XV!;DFNUPZC\PM[@WD9":JBHN] 5[!3OI*)7=I
M>5,?NJ>EMAN5#0221D9BN-;2Y*K<' K1]E-V))+7P).O_5VY4(S]J)QT?()\
MA!P!0A>](KRJVC#6(P?N^->@@O;J>WG4$K>.+7&IZ:ILH\5;7:R_M+>"?JNN
M[JTB<^$UOE4?SE_IRS6:7(L5%0KHFX 'S]/V^XWVAJ/!@R9J*YO.DVGR4Q*_
M-,F&]3<^^F6X\=%I-5H;RE&J=^,C/P"DS,F_4Y_DEH1I);H'40X?5&XSJ#U2
M:5A1LCN(W<9@N/O11L5=5MDOZSV+C97V8B>VE86,JQ0'2F8B.XU!6YO(G4UD
M:Z1-Y/GSL41 OY"M OM?+I \FQO/%\V%LI;NZ7N!Y\&GSG:AEBZ?W.F\-M?U
ML[P7GL60^?!K<M!UTCO/O<NHNJR4;?NI?"S23E\KAN93$9_:VR4/JNWTJ32E
M74+N:2TKX_7-ZB8"RM->0^.!<E'].!V0-1NVBO&K[<UW#N%'Y]( HUP!?+M[
M%@%\I>R2CL^U(ZBBW)>5#3S\KK8_+G%T72D=T<'S:>DO[]V53Q&TB];FI[)L
MT"'S[B'SH%GR6\KEBI3S]Y3+IP85LT8Z4-;FOXIR7U8VZ$!Y#R_<TEYXAW8A
MK:%VPV43>9V3./&!/F_*98BN7$;:ELN0?;G*IR,:*&G+5%DVZ'3%'D#I\%/)
M#M/=L%QIC+;&3V73!)W&T&ZABG)?5C;H-,8>WOD( ZC.USMOG=[H=K1[+ILJ
MZ/3&:>G_3_A0R#SC*PN9&6!'; \;_3XRUY]C3^V:\?GS=?FT1$,H;9LJRP:=
MX-@#0KW4$*=B""5,J;2D5YZMV%&PHB6&4%LG.,ZC(T&EK)1.<&BW4$6Y+RL;
M=()C#^]\^.%*9^R=MZ_?T.</I5.%<B0X= OV#%/N)O#HH&;<>%:)>@M7EQ]E
M]>7EF2JA6;53[\9GL4M#,Q6:'7[&(;?&8(M+C,&V'Y5]%A!,F[6R9%$T#C@#
MYZ(5YFQ8E6WGJ'' B^& PX_=/0<<L'TNIJF!P#GJ1?GS-;8?X\S:=N,%<0&&
M3^7FBS N:Z<2EP_#'8)7)5>@L@*#W2<+99A726-85EYN.:CC1?BI4:"* E]J
MF$<9L=W6.9[!>;0KT?;N K) &D%HC=*\/'":2".(XR&(E^HE7D8$L75V:'@>
M5Y&TO7N)]-'/$8H;_-9V'G?;>&:?/^VRKZSE!5%#/7*\V!2REOL-E\8O,<BW
M8RGZVLP7SILAEL_A__SR5PRZY,+RPCL0#VOQ#1;\P?6M[VL4=P709J :<[24
M0<Q6R@82I#U?93E7D4@=RJMPTXE IZS]9667KC% '+I*1?]0R&0@0PHVV-^X
MP5ZCW?VI/,).FV/*YH#GH1-2DBZ<^@$\AP6SFC&%-[J+NNO 1VW#\4+@\XR^
M\.1$2"?#!\?H>*9KS,PH#IQH07F^:<"8,8-W3T/XA.&R,#0F@3^#OS##-B.&
MGP('8TW-D#6,1-9305XCU_F2TY5R_97!:ATK8O8ZN3^ N+?.2=Y3*I'$7Y*0
M*UNS4-Z%C(<H>S:;^Z%#.6C7Q$]$/LGFM3^;F]Z"^KH/WJ%>!'.\4,T,*V"V
M$\&3 IOL@PE2'8&6X-/$WY1GH6;,&0(-[P$^"%)NF ^@%*@\#>.*UO 1  W"
M#Z/3JADH8_1<A" U=2W&U+2-OZU!:T[H=V&UO]]_5.':,-?'-JL0FP':!]/%
MF^7W4\:BS[Y%[D9%5;>PR. Z#C"HO0I#%H5*0F891=5["8SJK\6>!;O)]0,\
MXF[RF#"[FV9C5?GVTB\,4 $7]QIDQ;*&OY@S^- C<Q<U T"7-36>S!#,K>7&
M-D.[:Y! ]M_1(@V+K](P:9E"5O%3*#5XND)R@Y(WYIL&FPZ[#AL<6?#_[FAT
M<\5D*1P/OP6FS<# TNKR</W*=?TG7,8G/_@(.#.:Q*[\E#;":*DD-8R4:&0+
M$LH9\ A#TLZ0'[\D8WV5/Q0TS  D-R*3:D9<N&?X(< :'L28:$L-]@-U)T2;
M"WMQX=\<:%BR2 %T((0'^*0=#ICK.()G>A@Y@<H\^M@CHV'\ECXQ8(\.>PI7
M'5,:_P/!D"?)G:7=J_=_Q68 #L%=_,_/^+'WN":;(9!R/&8X$P.-N?*P)S (
MQMR/X*6.Z;H+8\S $(I=.%(&X"%@,,#N@ ]22 #^P\Q(ARVE(UFW!Z\*0S-8
MX#/ 0\466[DI^"MZ0OD6&[Z(5 #I_P_]'?!2S%(RKJ7!%!PL0$(PC<29P,&1
MWK6$&\)3/@'"G )1PK!F3, ^PO_@5BTGL.(9<@<6;J!1="9@A6!]*M.$31/?
MF9L+XAJ2&?CX;84/WT0GM+5[^-=<:Y=U=BY5[+6V;I.GV7V5N?9P+[#*3=Y]
M-W]H;@!##:%.N_FK7-'3C?<(<H*-<>+YW'68=CUD=Q.R7)(S23:58OYY *(:
MP%I0V-#,P7=<(Q2R(&$7>AS\"LB3+0$56#%\(1D0C&W13H(9"D5_)6ZYID >
MCOPM7X31H U@D-*E.*'BS.A3^,T  I$ ?XD!]4Y +X/MZ%E/#):_AR7+)8KH
M[3F%.6G$T%EA4U(3XNT5(>42"2?8]^;8(M_:>VO3F8TM&KM9T%S!P%V (6VT
MN(/-1@#W,9="EW!?+H-HB-0FLZ^B="'_MBTO^G>O-1X/AH-VW1X.K7IWU!O7
M1TU[4A^V!AUK-!Z;$VMX&399$IKXF%#YD@QT9H=,[G )\).-I-0A0+5X%O/D
MBLWF@%T=TK$&R'[Z$UI8C'UC_%@<HI%&.PG1MHD+K[L(PV<LFOJ 8Q]!7_"O
M*>J-0X:PT 5="7D2DPG#6S,>F,<"@=&C)\8 !1?IS3 7*1?JS>_TQL_.9!W<
M"H/HJ^D]\/,L+,%V/&<6SXIK7\A9@?8XP(V066_M. "\;8?,6U*OZW]WV^->
MO]?KU\TFZX!*C8?UL6DVZ[U!?S*Q!Q8;6*U7[RF;NVPWB'/%1,C!KQ<F@OEC
M;R*\GP"'_V?I&(76OBU!C 4S@[#@<$:A4</XC)F_*5@2PYG- Q ZGCQ'.8<X
M+HA P;8754K,\X1C@>1.6$9P,?6./V!L)/] N4B,=QT@M4< 0L 0TPGXRA0P
M@S&<A[E+RD:A [-YV)7=#OQB3,G0='M@U,EBP@8;QK^FS!.Z1'\,6.0$&$W"
M9M U/CGP#ML)YS[%F!.>_TPP4I'ZBV?-8"%V>KR0QT4\[@YCEX#; VR=#B5\
ML"P.1L(3#+A3P$<6B.\$B";2N  *.=(# Q,PV$\(4B2>D>!$Q[=%X R[7NEM
M<S)34&Z Q]0L>+>?!SN-3?]4QRX6Y*.F@=S2W'Q@]3'0Y'O=G,".WIKND[D
M2/7S2<Y35VD]6:SVH,=11G_4'-M-!A: M=OU+NLWZT.S9=;!L S:HXG9->WF
M*IB2/("U)KVQU;/KXXD),&78M>MF=VSBCYU1L]EC;=MZM68E+X1WFN<&"=:D
ME4ZXJL\^5F8X:&"$_0*K.&;&E+G\&"A&BX5VB&&:C$P49IG /H(])5#SA,:/
M/7)[$BPEN8 7CB53>Y89!)2VYQDW3/&!A<DN !_!_X'%)',T8 219)*DE%2,
MIK"HDJ\0<Z_@@B@1)D\,)Z[_I!Q<QR%WEL3,V'2%RW)(@<E-\Q/%&7@89*/B
MES.926(@_C_,PN+WS+'CXM'Y>$'^!58G 4$\0X:#K_V3NZAGKG$)'*B"1%G@
M)1&L"6Q@(73",TU%K+GKFZP27)#)!S#YB%5*SO2S$\M)',6$KB3G&Z5>/TH]
M+)<24Z5>Z.[)HUQZY";1C=L)NHW/:+1YMN=_P5M\\@,(=7;+C:1)H9LOG_)!
MC1?/DJ!F]PWDRCF?OX$U590;-^#YF\\,2BU"BG$,"0.@\E*D:# /C_'S>3KX
MT,H3CBT+_'(<_-7W;3Q5A/CZQ@.$\8"GB)R#RS_KTP]^4""I8G"R7%*23=F<
MP*[I(8A2[^?D/F9:?\44GT/8#V"$/C7&+ 4"30 H8\?C$7'-@-6P ,O_,%@/
M\0$^!N?B/ .^'5%>#Q/IEHBBP>OR3!\_NN>)AC%B'0O/JP$Q<=@1854)%H/S
M9S>,3X"J(B; <+KJ<$7:L$9GV B@E=2!R+B(S&$&CXE<#.CMZG=(RFR9JG&"
M-7G%$>ZW4*E'N4(GOFTRQDM*_ *I,_&2XG>$'Q:\Z8,+)$@;/@2^'5L1OAIL
MS1UQ&7_8*2&'ME%MMY"D%LEHUM**@[3<X^]IF8($LR+M0J3GAWB" 4 1?P:T
M'3./31PJ675=%#29H:DAKL9M\,P9KR8@>16(70I@F)P+.C8+2#!LQB7%$*&9
MQX- SX_2Q%[#6%<S?'X1>MZ>\/P;ELNL#GL9,D4)?:<HB)0P*XB"35ZG0@@&
MM&0"#Y/E)PS0KF!M$F[P6AA>]I' S%V!T"A7(J$"H65U^.4'%N7!RZ6O/12B
M4\X 5T"C9X&-'4X!6[DJTC480_Y)8PM4%TF-%X 4)U1ZN0L\(0A82/)&IP\_
MT%FK9?R(+K!$ G5>*":57EE)370**[CU */I.CSWX3 "#[+N8B7:X#X[GR1[
MD$MTPN(LG!G1T0<>" "PQI,\^#M8:F9, O97#!^!7ZU-U?D )0+55"6E>TOO
MXNOD[U&7@)4CN$914)(4)1HNKLLVJ33%AW=,X#\ GD0]8<.X P\7( 7%-\GT
MX9_A[0![\"!"[!O(A.!)))AFHNT*?-*5'\1R.Q^LQ,RD>L-T+9EB12 $%: X
MM& BD^M\9T BRIF@FR,8AZM7C+1PR;RFA3)@8'Q)5)@=4G(LRSTLC^'2]$@$
M4B!9LA8!&->N9)54("$1K;FY]<!S\%X+037,:65J']/=U+(4EG4_&0:FV3J>
M)&,V_VZHEFVJ#\6*H(DJ%/@XKE?\T"N788--@]S& HYG58\36[PX48,D$PG/
M<IW,ZQOKJS>?Y49S5432=*3N]#/LJ#P9D%&N_F>/%1\ZY?&"686M_'T^_("W
M_X&R\QL7P[3@Y[!E/ZT6/P;K6/:(C2<6'L-UZMUQ>X#_ZM='_19KF2USTI_T
M"F]M_QF##DX6>YZCKL<0AT$-2&[C#VG$("X#YX,NYB:]>W?>@.+WQGW#^/7J
MZHZD67$>8"[-L>N$4X0"8*%9@.,>%MS\S]$%.B)&3[\S2V4R6^AO1(LY#[<=
M;QY3Y"XP ?X15^7'H9$X3;#NUM1S_D++_1I#/D9)B\ WK6D-2Q_\&5-^P0L!
MPO0S;QK&OY@11PX&EK!Z!;;P>E/^1"R<R#Z+>PKAM-#U)PQ7+ELVC-O,GXKP
M4\!27\$S%6+SR>D0OYCIXOR,Q($HY$R(WC ^%1"9UW9$[ '8\9^T;+7H08(I
M\5Q"'?^)4547K$ N8(:4#$%=L=K?1)^HL"P#2U1']JU@.^FK*8E$'I+G?\1C
MJ?@&;2D6PH=O"[3IT*4(\$IQJ9SNF(OK^/]XA<4%S'7QTCTP,/E9W/6GGS,+
M?6O&D?].7.;'NR/F/&1OY3_>&:(C0+,I!CMMZHAX@&X$K<9PR\:NA78\6PYS
M$?T&/J/4;M<ZXIG-B=J-YH8&^[H[T>'58-C?R(;5:G!)++@A$[Q-HU;8W/%L
M4F&7E"H9I-:I-(/;I\L5^K5V9^;8-EZW.Y;=V5+4+XG^OWNFC8$@0,"_8A__
MAS*5= YATMT8 =!Y@.W@%N@&ZVJ<W2B-^:J2=6IKZW3!UNERR;NC\0D=6*09
M%)B>__ZOWNB=-C]ETQ)M@[0-*C-Y"VU0%N[DS0_>DE(2C(Z7V*JDB(LJ7LB.
MD7&"KVC[5#8-TO9)VZ<RDY=GA?A54'XFGS53B;'QQ]AU@_+E\B@GN<LB#=5"
MQV>GX&%'VQYM>\Z0O+][BE&1QZ4[V993-XG>^Y4G+P7(E//)DD%LI\J"""_I
MKSP,%VTQ\2N6[-5L+;4SKJWJ<X?EWMCEP)9=#7AX[:_HM*1\?VXNDG:,\,L@
M9DN'[GB0_X-7I"L'X';,1$M9^!4=0%,+'M[#0?9*ELG$2[EP<L^8\04<M]%;
M7V9&C:S:[U;>"-Q4JYNID-E\'^S5>ZHRP7I*X#)>I(S#D'=A37KUKJK3RQ0]
MK*VDNNR.#IWS[^BP54.&=1T=)N->?]#JL;K5[;!ZEPV[]6&[/:IW.R8;CEBS
M/^K;:SLZ[%S*MOT=P%9R>0&OY>!$#BQ2!9I>B]LJ]/W#M_C?099?IA!_A:SO
MTO\^H9.1(=0E6>,;#]GL,5X-2]?QZ+Z4+->GIYC*7V] )AX",H0?'?/!\\$N
M6N +;SRK8;R^\6SG3;8Q>5)Z;*7DM%1R$I*2CEWM="N]*EA??&[2JC6<0IB'
M_9+ 6,-"0RS EJW9J<-KMH5!LA>EM_JW7$EZX>J<4'9BH(N#S+2F2]V#:%2!
M:/"(5Y=JHHUO32Y*>1._#&7Y#QX5QF%OOJ0#?((XE'*YHC9#? LKG9+8_+H-
M*?5V:DD=W:V8\PN8*8 B>0C\L>P_@6TKDUN8 '>F#N,]GNB>A[@L]Q!@73I7
M!2/"5E%1ME<Y[T(.:$QTG4B84UOJ6P7_BZN@:YJ95XEU%;Z.5V#*M@@&RNPZ
MLL&G7#MI^@GB9SN3"4@8E46"!N ]#5&VGRE)#=/20UE0R;_)LA3=\4I5)V.R
M_P4 V,3;DX()VE8OV3%!(".AT"49Z>1J#]?KV=QE:J>6Y5;6>.<4XZ%Y/ :.
MP*= &'F=KW%K13Y> T!AJ"4AU!,G'MXC"6,.=Q.C"8+U"!^C"YT0&L&CL' X
MC$#J^!T0"^_\@@7AUDR->LA?*-<YH_46*V29;RM6$ENQQ8'HSI8SA+^C&7M!
MJN"7$XK0%K%Z%A:-YQ_\5CQ2A-,I^6"69K,9FE8D4H,:\0=H27%P0_[A&#Z(
M<FP^$D2]NZQZ#M%D9PN:R*)F#& 4]N#C;9O,+=(!@MPZ7K+E/?AV-$_=C'FZ
MBZ-;LG+:0!7J<!P9G$:7::,^QJ1-:R;4"..B&A2;C:,-20 >PU%DS=$I 3QQ
MW<-_=&QQ8\,4#^9Q.S5+D_8R^SX.',4CL*L_O]]I/OH!1YMXM,"Q!=Y4I8_Q
M](\##PKI7N03807 I_1J5=WIVKHPJX!L8MD"(PNGLM8*KQ>N-DXT!,@42EY;
MN1W"IRN38.D.Q\X$3).XWH!D>?+59!D )?XH'U[^()IFTO"B.0BMSX4VR6[*
M+NC)55]F;[+L"G67F)09-K,)T:Y:#>TO9'.3AR3)'98<F?!V*$#V>;*[I*>Z
MB01,'TB@$;\AD2/'D6DG5NR!AED:O*(B('N&3_)>:0%/"]B(^UCC9S(R)N^L
M%!+D/'U*[J;E/09Z'S!601L"A*:E<"M*G04P7>8\,FP7_/Q>12OO%XKL3J?9
MMH<C>U ?C[J#>K<]:M>']L2N]UC39&;+ML<#ZS(:$A#-$30U1^^(](9*^V=Y
MK#*YXWM2)"Y*85%N.>W:I>1V+\5AJZV-'C@>%=,J4!%L)S&4ZFB+]"_<$ODB
MMC7NU1\IRT'/E"V>V \66(YL_Q#B,0R8"S4](FX_9F[F9XR>N!LHYT+2XWDX
M3__D?\@Z#<K5,'"U_H*QS(JI"T3B:E8]6NGB],$UK>_U>PN0 P;_]( Z;@0_
M,/-MYJ8^D9I7A$F33?3N:0I@&0:DO:V4WMO\^;7TCX\^'@S)U MU+*"=$"F5
MS]D.HB%@V,)AKNC 33<;G?![?8)W(!.WA<ZRABX-$RN(;7ABA'IXJRD@>/4C
M?FW*LQFQ)Z"-*/22>Q&\2X2#.XN$\&,V-1\I@I4E&FFG?)S9!*LN"MK0) >^
M"_*5$\TP)W'"&=O9.[Z%TD$9*(C%[*T[=G'^AMC12:H*;RP%M)2U<W22Y <3
MYF /SE"T8UCPQB -XRY5IGK17A!EIGM8RGK-L$'Y' >#D2E@6?U\\$TWY($]
M)?4DQ%0_HSYPO$C(+DT\_C!SHH@E1/K@XSA+G"$"LDV-0>3E9N$O)34:QB?L
M0[MYBS5"P,D;90-Y4,IX;B>-65#4$^E6=\ O!IO8HQTHE=N_G .'NB"M0-K=
M0W*,:ZR0\=#X,[8?> ^8D+>AR5!=0GKU72 <H(%K#V?/KWU7DFI:@V!7ITRR
MRI4SWPA+E42I$+R\:/&2=\R8$)&3$PFNBD"F![0]8#9<>HY(*UT1F 0GCAT0
M0/.X(;_F:@ ?N^,[$"/,R-G=4?,,>,65 ]+P1W+)'[X'1'@$*707=6QI6I=>
M$J=1@!&^9Y8XES=N>$@+6\MHD/IHX[7ZTQMJ9F/[-!O*KQ710"$4#2N@4&,U
MA%]!ZYITM[SEC!D"-L<X(Q5QKKQT)H"?\1"+8ZL#?_PGGP-$'PGCY$?1$&AM
MK%Y#IDZ< -L4B?4GC@X=#_BKD&57+3LXU=+H0C2#DM\4<0IY*K4I X4@O'<#
MF0G.FC!E#;4$"&@KJ+7\T*B89@T)\>[C<<A;/?&@M&#D[]K@+N]G\GY-31ED
M-4,:?FS.0^TM;>E@R>-7<61$]_P+#)Y?'W#D4+0,4=I.13]'6Y4R,IR'/;][
MJ*NOO][_'KZI5*2HX#O<_.YIL)7@7)[?@[? IQ*VST!ZR_5#)>X0+06+8\;T
M+3Q@7+WZ)=R=0[?B/&L%<$T:"2O OZ8FUA#&+X46\!ZP^QLCB\9E=8=-BO]:
M72,I\%NOY"(E55^5C.(3E"G]GR8A'8^W4ULJX", 4.?L59F8^M,MBZERH]M^
M,0-$.B'$=K344IU]G3ZC^ 5T SOD$0R[YNI)=%HGVF?0HPP$$@0#-=^5NY/&
MAW:'@P9-UQ)]Q<<+GJ AO"V_(Z(@&<K731SS\L 0D(_Y##?UB6%FPK4=)P-@
MDI 6#!1\9*G>1WD*&46E!+H!,8<;RVG>Q=N0\Q)?8!/JZS/[D?7T<C/.!-X%
MBP,(7U,2-%% )QL+L1D>%C:,.Z5N3'Y-#0=$*WM1220S+46']K7-Y_HT-57"
M +Z6F&  14Z<72* RCPC]K!LC6*6;&(R[9#K@CFDT@#V0]1+I<=:0J $7^V-
MW!LSR\1$I&AW#LX7UL./+\<8Y45./2$7V5&<-D\<2%J.LA=R0B>]OQ$Y[O.J
M0L:D[;RB;(GH9@1R,(XC6:RHBHD\;4Y#4$R$*'9!D>PGOTYA;2+4B%62M] !
MH?HFE/> >MRN?J7">AK0X%C.W!13J1.]L!V;;N=.S4?>DM"+ E'LIIP&2_<I
MTRW+5,0%LC!SF'L59@[_IW0J*4]<TUT5REQM"^%V^#M"<T;-^L8;#'*Q?&\7
M4A=!@O8@!PE LD6N">A]%_B>C[ES.FV_\NQK7A-UXZF?<3P+\[KA07'#<"_<
M\#SXN*_2$D[L<)C8>F=\99B[,%*2&5FZRCA\-6C+C9I=PZ&7;EQ[&2>FG/Y@
M;D324V'$/?IP.D@!GAG_!PIX98.+9?:9NXT;S_C$QD%L MP SO9YS/KIZOZ#
M+&9:283?Z0S#>'UU__L;H$B#OEMOUS9'.C0).#1>?_/G(+[#;OM-3>8EEPX8
M<9PCXVG.),[$T)L"3']2CT-9_LZ3O0'.>/<YTJ+IOFI!3WJ2Y_(%B(MNP&QQ
MQ4T66:GEZORSW$O!5NE(E?"%Q!*J_:<F$IAZ=&9BVBXUOI>F>,Q #BA=_$_3
M(WKS/M7M[ @>?AJTM.O\GD5+'-IFZL7H:,&A%L!J]3Y5P9NV.!=.W?',M_G9
M0<"BP _G8F/B2- D_T+G9 2+D0""U<-ZJ[47K]\:WZAR'9YXHTQ.EA?+,I2P
M??@N.NZ459PXZ58HB0),"85@\M$VPM&K9?\"%8J4<^%@8ZQT4R<*GKMJ_S/V
M6)%:I]SLUUN=+;BYL@=W_3I@ML.C7Q:^-93FZ'0\I?Y5,AFXL/)9J C 3%Q9
M8@24ZX=J*9?D?G)V:O$7<93&3ZB7VD2+IS_$CCQVHRE(U(6Z6*D+M584?9@!
M6A ICXF^9'4:D2$*\@)T$1X8>\F8"AG=)A,TI* N"[:0W'13J0SST&4EMMNB
M)JT]R.&&#^+(ZCIMWOW1"3$C"9PX4)M[6(;(_0_99-BT[;HU[@WKW5Y_4A^R
M)HCH8&39;6MB6RWS@L!?-P%_DNJ&0O;P>?FCE=CJ:&CJ%@1U-D,+]-D!K5@+
ME<X@%W:;ALM\PL1R\;?,;F VW24WM;H]/64Z<L0Q7B>_>L.MD!_1.,&E/-??
M=A_OD0O=5BAXYO;G-R((78-IK5%S\3CYM*OTJELR'R_9D]AE,A>O-6I!R)+\
M0QT74N^I,[]:C79^%@CPWR5[*ZY/ NHI'B18:-^4!7\$^Q0X9,1O)U=B/M,O
M./1F7;GM<PBP;"'?BRE'X$ZPY >"> Y0,+QG'M7A=9HX'$EV[$\*[<5)D3B&
M5VZS-G(#!8'+LL%#4G622J(4X*Q8I].J/)ZM"]%/"H<'*!5L"E4V$4;-7.S$
M,T,Z0,1KB:)*.W.(8<OR+>%UG2"Y[8B_V4/4<\.(;['T[\Y<$#&_^8*UDF-L
MW4R;,(C$>,?;0-3F$5O%HS_S?0N&PH?OI4?^E?D/@3F?8I$[?8/BBV#Q^_UQ
M5&;4:!:J3":!!0CQGD$0.TMS@$_4R8Y'!:ED\&L63&15$<HDU:X$4X0T2/ $
MJ R$4+FH-L%R3?PA%A<)L!1H>5Y/;2F;9E.M/?]^#%AM#W'(#09>(PF_!NM'
M'+VDLN]G[3*^X.P3UM^6;D=3\G<Y%%\U_T[$ 7@ GU;'+<4%Z0RP/3QFMUDX
M[/&@WK!8+)J-8;%8)+>4Y 5[?EZS\%B A81J[B/Y*_PJX,$YMA>*\3@?!Y@R
M+^;UO&J%0TZ;$X] PX*P7G'!+UTIQEWTQ^15;SCL1JESS;<#R(9+&.2X_+8.
MMDO(CE64Q7/I<M3^#>8JTU(PZ_.BRL=Z9UP^MFOD5Y@!SYG[%4#WGE&!Z%4B
M1M\001[T1.),C+$"*PE4A_$,5DV3QDCK'QX"]H!9WVQ,0DY:*;(GS"CN9>25
M=4F;T6@LSUHOF(;ZFBR]'X?P@?#-VR+W5YEY56KGSK%I?7\(P'7:=9'+^$3_
M]V[O1HBBZV&ST=XPLJH:(Y.NS7"Z76//0[&BU1AU-2=V:_#\\KPH[G2[W42K
MIRG@OCH:"=S[$T2)%\RJOY6/2[VM1_!MY)0"&2GU<5%=C'</F7+S<D\4:J_+
MDG0R8XAQ!+'M1^+O2;C5@2B\UF[V5XPD+ILT:YNSA7O8IO/Y<?&3[<>('-N-
MZGCM;W28D6M'J(0147KF4$*@54&6E1]H%8[P6\>\2EK%TB.QP[)20[4,5&N?
MV7GPY<(V;<'.#=<5#PCA4*]*'"B'-A%<TV0_K1'3!JJL?,KC+(VASH9Y6LDT
M"B@7!SZRN0^8OGRJHF' B2Q4I0Q0:1,IU?;?N^= .EOD0+XFW6UN:#;TQ,&*
MCRNJ5Y$UXE>>_3DM5KGBM2K7O,::?_(WJH3#;Z9=]8Y71MA1$R3GD1RIE$'1
MB.;4'+CQ'F%1?K HGRYH3*--4'79H('-/L"F>TA@D]C*$P$8[)*J$4RY1%0C
MF%-SX"[ &S5BK@\V3IACX5WY%$/#&6V/JLL&#6?V@3.Y@5DO"6>DX<3A6A%\
MXA=I.T\$;]K=EL8W99-9C6].S8$[>6>0MQDHGT9H8*,-4779H('-/L"FGYDN
M_:*H1IA+/OGQ5)F:MH8RI9-2#65.S0'91Z9\JJ QC+9 U66#QC#[8)A<9\7C
MM\G*@(YA>Z!!1]G$JBR@0W>TR;#ERK("[ .NM%HJX;WK"C*FK"Y2-YLX&U;I
M+C?;\>_U[I GUV#X '7#ZA]X0]3PCC>Z/A&NZIP%JM+F:4F\WY0;=.F>*N7!
M69H7)31DNCO$V5_+TOUM3I"6VJ8-]-X8[0L[;G60[GQ3&MO&95R*^#IM.$;Z
M[&>Z4PB_Q7;4ZWK;;R3&BS7&7M7]?/O>^9Q"QYY2=0.:_!#0G.*/COG@^6'D
M6&'-N/&LH@& )Z#D=J\\>1OY6S%RL-.DN0O#9PS(6L<7X_6-9SMOLB,+/Q39
ML5?O7W*<5K>5&PYRO/9I*5$4F@!%4A\R;/8[S>0?Q1-%VH-&WF'(D2*UI5GR
M>Q#IR.V 7XXPPS7#DXIF@]^#S06Y_=6X"QCGLW%/ ^_Y8%J:S((SM[+21Q.X
M3"^9S\Y@T3,2^&R?U#VHG^OP=YTL(B.9USB+G88]7858_!PM/L&K_\ WIQ,?
MC\*9-2.11FLD-3/.:M5$(3%S-#=8R-QNM-#SY@BU<ET&7N: ]/DT[:Z;,[7#
M0*%3S!%:,3Y(.^H='36J2J%A,@-XQ@.?N5LT;*?;*KQH>HRQBALU(#=>,9DH
MK C74@=JWQBSE>-LX"\(.,0<[2@R'4\..#;A@P%C=7P4LV(^/QLV-LW-7GQ
M+V=PH3 B$Z=@[VE5<G=B<#J)I.XG $\*Q<KB5MOKW*HR,S(#Z>I TKKSHSYU
M;%";MV+[\+0034Q]P<Q SI3F4]8-FG25&A?A"'!6O? 4-]STK&*&@].FHRQD
MA=\)P;%1"FAVMK&&8S_&@>N$4S/ 'B\*RP:;JGT+'/2]>-0!F2B>D$ROY#@
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M;TF63R<TP-*FJ+ILT !+A^#EX4,Y=41[""W]U66#]A![A."=Y@6$X *\GS@
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MQS/%='3\VOLW#>,;O! +89V)8^$:8N5TS7#H4,N(0]B^X]'B9NF1$M(KG;$
M'Z .+_2I>>"/Q5$7?BJ,+0N6,(E=H/?488_)]_'#X9Q9O$$#?,V.K<@ ZP@+
MY@)E1/ _+ HY5^:@;#XM!DR2Q5DH/F  20WV QX6\5X/8R;?9M<,T[,-VPDM
M9),!C /1XT\(<%Z$;4P"?V:L.;7\,0Y<!SC%,H>6G4Q%]QT++-B7^<!N)W<)
M!1P6WDX*COCN$\)<I73YS7%9&($H?Q3K_8K+_8KK7'-\&081?80. N&'WQS/
MF<6S;8JA;[Y\2@[WZNU7[UOM1OYL[R<DZ<X$ZI:80.:/O0G4:?3R!&H8]XHB
M@3H$#$>G&F >X%'B!Y!<M"I<],-$Q9[\V+7!UH2Q&]%G5*4$4S(%.\@"?)3K
M/\$_%+U3-+)AK+'1K>:61KHTJ.JZR.(Z86J6A5T255I@61G9@A (!8@H8L',
M<)U$T+C!\\"^6C0H!H6ZT+#;,9Z7T^,7S 1+S3Q\XT=FD<P8G5;-0'$AXP)2
M,S*>X+U@CB7OD<U_V[T4HK=<"B%MN&+""_3E*B![1B?^?!3.C7=%OJE0Q9*B
MA-8:Y5E_F:*7:$?_U?MF(S_XP #Q<7'S2*D]*)*;<UP&BK1&@B*MT7J*=!NM
M0HK44.G19SF/S%UP/X6.+)%OD"A_3@L#443WY@DS0JXS LM'6T-1$Y^#K336
MV8&RX\^[.#+X+68CX<1Y8T^T.6#F@4&T*VF/%F0OR(K;8, 09?F<KR Z5NR:
M"&0"%L6!1Q;-E Y" "=\D1^'":X))09+K*( L006!^\(GCZR('(0W'D^@B")
M45'N\!L!XZ]5$9P)@#0,$S%37PU(-7(YF@O!M>-OP<9^Y(83;44>3(-;^P_*
MM9<TXY+ =R6)]C.A@RSNR%V+OXX#S!QNL'CKU;K3R-\'2PR=DP\W3/#:CWY
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MS49GRY.R0L!J 8%9\!*(5:7SV'?M9W)L7_;\'S,#@\&Z;.,CL^A2IM%IU4J
M_$Y]9%02!NDBT=)9+^TP3N<PVD=T&*W.7EF1BGL4#)Y*X#Z>Q:U*^Y?CW[;3
M&J8M9(7XAYE:;2'/AEVZP\FQTI)%N41]%_R,HQM]'_1BCG_UT>YN1[NY*2'J
MP<OF)FN?3"?XPW1C]F%Q%88LNG;-,%1;JQ6>%(ON:N)C-Y[ES]A]9$8,__C9
MM_A1&CX)C]JXW:6>Z_@08725UJ9+AV*%/4[[I>QQJHU+"6S]=G&>)K_6!NUJ
MM:O=W=7F9IF<I:MMC82KW=05M34LU<@3;5STD5U9J+]+E9$^V*LB!#IU7E-S
M1-]</R@:&N8&I90/#<DY<,QU03I^Y28:JWLS!GK_9$2WG%?&M.W1E34737*M
M!.?#$>V #^6 <P-7+L8!;YVBZ'=T)YHR"W6)LA25O9W-_VM0;QI].;XZCO>\
M[[?J(QM].?Y(."HW,>;(.&J'A,.P,RHCWM$&IE0^0;MA[8;/FF7:#9\]"W=W
MP[EY-D=WPUNG'88M[89?2#IU'YME35QJ#;)?,QCY2DXA!T)_QWJF.=CIDD4X
M]T-0',.?&'=JHY=$Z=;LKK]Q=[S5S0FMVZ^FX\'F/,,6.\6-KNYH8SRQ@,$W
M(R,$@^!,' L>A0VSC&C*C 4S@W"I-P)G?Z=5,S @H*>A2:KQVA)XF.-9;FQG
M6N3LT_8&OHU+"&7FEKB%6R"+&S:X?FS4@=T$\GDZ4'AC#Q?1>NE5O+34?*JW
MAF)'TR#U" ^L/@Z8^;UN3F!';TWWR5R$KXR?R]0XJYT_[O_5]^TGQ\5T_HT7
MF=Z# Z:37&\(^F^Y?A@'!VV)U1INS>_37_#[XD?,&'!U;;TS)/%(/5/R&9Q^
MSS*.*TW_2^+"7>RDV.;ZGFRY$0AI6S;Y@$/*T;;^IC38^GH*X@(O! /^(.5H
MG4,Q<KZ$.Z77Y '\.(1?AV_>/JL#VLXNN90=T Z.UH>]1NL0USTKFU]I-YK]
MREV?/4T?AE8C=S/\<!T4]H NIPF^=9."HS<I.)01+8W2?S!=T[.884;&/TTO
M-H.%01[\="T]*FEF+\V,E(;:I\OO-]&'Z<S\;IGYW#Q7&96M[Q0_W+M3?*M;
M:S=+-9"U4NIYDJH]X=1U!;U:M7<518$SCGE4'/F&:?T5.Z%#>NM/C%L/5&<6
M>ZQF?([LQE'*"C@2T&PZ.6+0Q<;EX@A!"WW/X>7A1RX]G)P\H#4,F/TQ#H E
M=RQP?'O#\)IM#_C;@S*A#ZWJY44H%:RH4](3RA'#,?(3:R!(!?E0&@ARCH5'
ME<Q\Z,+&$^"7W'S;[=(G^P_::_5JS<YYM4G4AN)BSUI:G<;@W&BMCU8NA;I+
MQD<;EC)E2?;GR$5##*TQ)6>'3C:<.MG ZQEUMJ&*5DG'".5*)NA<P<OE"@9[
MY0I6MPTX\UQ!"=6\"I<5GUO(?_Z75G+7<6KPIFC]%99<CB^]PK)\.>K*LY-;
M+<A ?;5E->U-HA;2)'3"",M=\'[+Q'==_PELQXO>7NDTACU]>R6+>[N#QNB4
M!5F7#G5EEY:6+J?:>,^EU3SB19=VI]'O;E=T49UYHL>.O<^A'*8DK#FBM8*X
MKWIG%2>R0MU&9\N"PLI:H5*,.-96:,<L^67!U'+;+@U:JW$YN]_89O2E=B:9
M-AI^&)7 ?SR+6Y5V, >&N<>?)%MF2I_$K T:W:ZV:SNR[\JRXEGLFA&SM^Z?
M=@G;GOE!Y/R'FM=ILWXV;#NJ61^=9$!XF2FMT>J9<.\+BXQK,P@6>/9%C8ZU
MD3L;YND4K8ZYM173,?>YL:M\,?=IRQ%*RI&3F+\A50YI^Z=C<QV;5\G8Z)3K
M19MUC6IU;%YQ(W>:F_:BD.%R(_=\;7<8C_]D5D2=#<N $*BLX7(94)H;?(6F
MJ5+7]T[+CMY6?K[:]_>TPFAVS"N=6-?"7DUV]+<KO-'N06N,9H=27**IJX6]
M NS0P4/9.:05IE3LT,&#%O;*L$-[A[)S2"M,J=BAO8,6]LJP8[!=W9AV#UIC
M-#NT>]#"7BUVZ."A[!S2"G.Q%63EG]5R9T:PJ%"7B%VH9:F4X3A9 W=RLM7V
MH;OW9A\N]WC^Y,!WV&?GD=G+39Y_#?PP7-/063QBS1,^+'XS__2#:]<,PZL?
M3BB_(@S@;]0'[YF]WVO=0;=,K=\KI?PZIKQ<ZE9-ED_FR'B=6K4]V>N=7=FH
MN8,K4ZZLJM<X3^C<4@_6'6G_=2JQ>Z,K[;3K.G]JZQCLC&*P47L'Q_6%1:5P
M4J-A4SNI2MI2'61I6=:>ZA)HO[NGZI8R6]@:/2-;V.[VM".KI*G5CDS+\@4X
M,EYZ6&U/MD>V,#>4N*39PM7.3<D6MDHUZ+A2.G_";*%V75J,S]YUZ1ALYQBL
MU]SEF.M8V<)-3FK8T4=:Y;&ENI#S8(6<<6!-S9#91L2LJ0?+>ECHJDZ-$32U
M-5 X>FGGZ+3)VK$=_DCLX;?$'+Y(C6>_-FKJ\\=JV@(=^VI9OA1JZTK/O7*W
MK;+E;@_HZ[JUOJX'K6*&5]>#:C&^#&KKZ&V/4IO.*=.\AXS=VK5VLZ\=6B4M
M@8[=M"Q?"K6U5]O#J_7*G9-\3B6ISDE6UQ9HOZ9E^5*HK>M)]\I)[M)(I10Y
MR6?XNG9MV!IH5U>]G*3V<EJ,+X/:.GK;H_1TEW.WH^<DGQ.[=6O-84<[M-)8
M EVA>N@*5<.?ZZG4E^K<M '14.+(#!BV6VTM[Y60=QT&:EF^%&KK DQMO"LE
M\+JN4,ORI5!; V]MNZLD[QIX:UF^%&IKV[U']5R_/-5SMY0^WKH!2*NMNU15
M4]&UT]*R?"G4UJ5Q>Y7&[=*(XNBE<;LZ,EWWINO>+HRPVH55A]HZ[MJC[NVD
M UJ>XZR:NG-$>=3\7(O:2D[H5($,DS0(_A0983S^DUF1$?F&J>!(7>]VB4Y-
MVY;R00A-;RW=YTAM'>QI6;X4:F]9W:8)KL7['*FM:]FT+%\*M36HUM)]N=36
MH%K+\J506UMJ+=V72VUMJ;4L7PJUMRS7T@37XGV.U-:F6LORI5!;@VHMW1=4
MC9,IO3'&?F"S0!(R]%W'-O@'#5K]W R 8I?==^I;8-H,EOP]/+#(J_4V1Z#\
MV<G]D:W,.A9(^E3<$AW=S[X(3W2)<*9$.!G7@^6Z;V]@4Y/B&M]??EANC SZ
MU??M)\=UM[RLN>&Q1=/:4]N[88!/6CD\*%7AL#8BIS B:I2I/:GVI)HC^=HJ
M[4HW<^G4'6JTXIS2>QPI M8DUTIP1AS1<=B!XK#N\E7-74,Q'85I$U(F$Z*C
ML/)8;:T$9>.(]J,'\J.]\\IG;NJ$,"A5^SEM1+0GK03)M1*<#4=XL:1VI3J?
M>88LT=[C$DFNE>!L.*+CL /%8;F6WV7.9^HH[*RE<_LBV9=UJJOK9&T_QIYN
M[4;5O"K_K_'-CTSW=,6RE25_"2P2TFZE.5K'HTJ:K+^5 O <EE\:$640T2"/
MB%9,/MD%!Q4=Q&XW.WY8ZW:'9<0UVHJ4RO"O22 <S]>JE!O[KOU,'I2:X%I'
M+L+39@MMM:L]WN267G.X= J\U:R6H[G>7JTUU)[WK&7RT#-=UE0A:Z>KU:/L
MZJ'#VS-GX.XN-S<L;<6 F>,%MYU:N]_4+O:<15 'M]K/:AW1?E;[6=7/MIH'
M2".O/O_>-HW<Z91JMJBV(J4T_-K3:D][QCIR,D^;K6_6KO:(:>16Z_!IY&>X
M7HAQNSWM><]9)H^51M9.5SO=,U0/'=Z>.0-W=[FYD>7/3B,_)[CMU9JCMG:Q
M+R."7,RDE*T3R&/4AO\<F4 9^*WM/+Z7+/X2SUC@6$4*^F<<1LYDL5E%,^3X
M:1<-S*PXLZA42SKM7"WAI^)[$%EL.F=>R+[AUK_!&C^XOO5]PR%,L]5L*:<Q
M#-1CCF0)8K:CU*A4Z5%84QI#I1+)8)Q*1L (W.,L=GG3I.XBB0TG-[O]R0R-
MUXYG1%,_#DW/#M^\-9"'0" 4,+042'2AGO]XU02J,]=%)01=3WX6ND\_9\CZ
MUHPC_YU0;B";:\Y#]E;^XYTA+$2S*28K'/CJPZ#3:&ZX=GMX3'GQV;)68S#4
MMS8+2 ZK@YT#S?NOCN>"V]V-#=HEO0IAG@4$9L%+X+R21%;_Q\S 8+ NV_C(
M++I49W1:M>.HR'$&0I2$TJ>ZZ79J<U]N2Z2-_^F,?_N(QG_4& UW#\$J[APP
M<M">X-*RF8W.013APOES$JO5:F72_]IL;6FV6B-MMBX P!8?K'-,>[G Z:,3
M,"L"HQ-&H6%ZMLQK'7J2V1JO@8CV<@E>_A-&?7IX#$X,MXL3]-'@;D>#G>5#
M#S5I?SM9/O?8IH&4Y<_8?61&; 8$^NQ;]"AJ%H45/]R 7J/]O/)L<7:B=L%?
M.AHI:A_5ZI3I"+%2-N <PB1-?>T0+]LAMIK;A:#:(^[F$7-#8T[L$5LCX1$W
M-51LE:INM5)&0!\AG9@!]Z $8<V %7]G$9"J9CPPCP6F2S&Z:<\<SPGA49'S
MR/1!4Q71RKH,;,5MU>G"^&<Q1>.6#&[I'1.WB(_<,]?%DF%N:P&]7&4L[:[1
M_5;UP^T:;/;82&<K<Z):=&U2#N57.]JMGMJ(:[=:.HYLGD6B_>I^?C4W=*&$
M?G5#CF"[>SFU46^D_6J9A+5<:87*#@$XP0R&%<F#RI*_!"CG'&\&5NPX9,OZ
M 'V]^.414N[BY-X(Z<4R!/UN69!,H=FNE%DX<89 ^T[M.\O/LM*7$FCG^?+.
M<_B"SO.%T@ #[3P+A*K$W3:>V31B!YW)KBC;XZ.XNT9.SN^M*;-CE_F3-7TV
M/L51'##=;6,+,>&D@LU%H-+88<-<U7[#GZSHL^'DVFR4N<O&V+2^/P1^[-EU
M0?Q/]'_O#A!4-AOM+6<95[4;Q\MS0\+XD:YL>L:=QR-J2:O?&.ZE)9=\U_$J
M!%LKS&@E-KS<I:0J^][^+OXQ5;(\)_0E8=/V9VFPM1)@C0K>; %-:I5/DPB'
M7"[13XOU]#VC%TX.'I-%O0SLTQ>07B@CF!OZMEL?TB^PMF]/S'UDO\&*IIN.
MVYZ3*.SV]TP4:D-2)H-?3B!TN1P M6N73T\TSCF1>:JX]2D'&SB6T5!E)ZC2
MSLW-VPVJ8(_;;T_^(1'*OO-JM0G0 .1B.0!:U2F?&F@ HJU/==F@ <@^ *3U
M @!D&C!V0 C2.8\D2<6-@(8@1X<@W?*I@88@VOI4EPT:@NP#07+#%7>'()_\
M.#@@ FD/-0(IFYQI!')J#OQ_]MY]N6TDR1=^@O,."._T^>P(DB; NSWC"%FV
M^FBCVU)8ZI[8OSJ*0%'$& 38N$CF/OV7656X$0#%.XM$;<3V6!((5N7MEYF5
ME0E:U9-/#90'HJQ/?=F@/)!M/)!"#_<M/!!X]I >R+8WRI0-N'@/9.V;-O6X
M[_$XI3XEDY#ZZOZ-#/R0%2KE*?!7K-JH3G8G=BG/)^?Y%'KU;^;Y7*&9/;3[
MTVGT=.,LW!]E4,[013I$:QN]TQK(S9D->O$=U4%2C88DM&>J ]'E7S)2K8GV
M[UT5)@JL\*Z^T?!@^:-.0Q^>1Q'-.5L<B7L;+7<9VKIE3WOK1D>7TB6(I9>T
M*7FFVIA25]O<*A3ZH?_J>=:+[6";\B6K<#N;$]O')N?;]OR\_7:3LQ+-@)IH
M*5Y C0+J9LV$ZQ5,A&8G"PC*.Q_!J[5P2K6079ALSF"14VT.0N99@4:!@Y:6
M[6NAX1K92*FEW^JC5ED[K!,+:F7;#?Q*W9B7 =SVJ]BWJ-XT^;1XV-'43UO,
M/='FV*?D1Y,E23\0YX4L@C?:^U,3^TA?6=5AS1@6:F&O3!. +PSNR0*-*8X1
M,$T_HM9O-AG;CAW:-/AB!Z;C!9%_L&9JN/WAVJ)V^D8AW[R0:D/M__[7T-#U
MCYH@F9:AF;:*#QVC<'\[[G1W-RG2_Z!][)#T_5=)+QE"7<V8T&H^G7L^]K&S
M7<Z,_L>8%TY*/_:7P4>-M:\#3",.<4VJ!5.*YOT%P:Z\M=T)3$5-NNGQ%?3[
MKTYZ.VA^I+89D3@[U5?'J:^VS^O+T#ZOTVYUUIR)6)_V><O=Y&2-]$]]5B()
MN[:>5"0E_!Q$L>0VB0J>Y.&%9-U=.ZWA%I-U:HY?LG<%W8F-M0:V4QO+XS4&
ME9D%RD:>/V,Q;:YLY/GS498RJ4J>BF#@<MW(:V^&!8U\U(=/'3[_ [.EQ GD
M4S&&9Y?+C3.NB%+53J=ED;&>'Z$JF3:K62@,G_HZFSO>@M+OW%9F#N2N(]]_
MO6!AAVKPT:!W&;5,M;(5LMIT!:5*/23@DX+2\^3;YE!:J&[9#4IWFE2J]Q64
MGI_,J73!J3D0UU&9CNW:H$]:"$\X\8Q0^31(.3FJ(49]V< =&>6G;.2G=)+1
M!&,K^/E!6+QK8? >T=Z)2^#;!_RI*S+0S\,14?HL 1L4FBGIKR\;%)IM@V;Z
M/M&L/.9.T:QOJ*DYTLF,BII/S8&[<$K].$A6I^JG5P YR%Y[.R0'&Y1?L8U?
M46A>SXQ<\9KJP4_%VZ.1\CEDDR=9=5TAG9+^^K)!(=TV2%=HDKX#TNUP:&TT
M.KWSZ 9:<UT_9:?/4_=.D(8M_R8^/!<F#3\6#<WD^BG3C:SZ\N?\KF9M=?/J
M\O"S*2/BR'*M2AHNR7/Y5-%8J8-BU5J5QCNQZZ)!9_.@K3#?X=[WK,@,A5^X
MN.)7'*\=$@3VQ*;6/HX_NYVSB,^4>3C#&*Z&\P'8J 9^&3G?NE$&OT:Q1U90
M/>]FZNH6UF:WL-3XAOT[3X7Q#4<_UATT!L/S.-95MN:\<$-AN#R\4'JE,%QA
M^&$PO#!LY>@'UMV&/CR/<O!SMC5J^-*R[N67EU]"]0R40CWC%SH.]SOCA'W2
M=D$)K\+T>_^R3#?\B[1U:S"BW6:/6+UF5^^-FL/)8-P<=XC5Z;>) 3NZG"$I
MHV1("E*Y8JX&[NSU&21E.\LLT [!P)B;[&[#O02:&)*S<K1+>JFT.-H%27#K
M!B B;-S4/B2MBIQZ^U5Z2C;3Y3</;'9(_1G\"HD]Y\3F\UD(CN%R'.\E6![5
MHJG!*6IPB@PQI2KM62KM48-39&W&>\4F'<HP/N6HE:224%_-03ES"Z?01AY>
M2%U(JGK\2S\'10&0#$9M*T4Y?(0C*:N4S3M_QIYRKHFR>:HURO'=-Y#XH<;R
MJ/(=#*G["[*>QZES_;,XUU=G]IN=V0_*SB#3HZ%KXOL+8 B?<[_B>$A\',].
M\.@$W_*XF-.KGW;P%[:!8_96'%NA 68__\[2?KN5[1G=!BS@+,[\:V5"9#7U
M"F$5PDK )X6PY\FWS1&V,,[K) B[2Q>8;L,8G$=57:U,B,HDG)H#H&V^YSC:
MW ==X_9@[A!7/LU03H\R2/5E@^I!MXW?4IB=MIO?DO]TXK5<7WW_^G!EAL)1
M><W)N;^__\TC[CX2!YV&WAXHKT8V0975B-010J4\WZV1T68W%@P)E:'V-DE%
M6L?EP+7G/E,_M/%.1>Y6AGRZH8#BY"Q00"&+,M0>*.1@0QUMD@1D5](O!1M4
M_F>+_$^W<'TXXX-ESYH.W-)![S3TWGGT9:JYLLO7P+*&=Y/^ )WU0$G_EUJ@
M;>-0L^S Q RM1ESQ&SL((N*:%!0V"&5L;%E#MLD*G:IS[]FP2C7V7H]_;S=W
MA?351V$9F_M%6-M[G\[L:';E6NQ187&OT>!^H]NTL,R<6^GRM/Q>RTID+7BM
M+,4[A:TRL$%6@ZVP]6Q8I;#U8-A:V@3O4-BZ2QZBT>T-%?">A1B^.WU:HKY'
MM;+:<'4&HB[^*#ZIVS_'/44I3'+.'IT<:I2%,6@,^GUIG!5U9B*Y[BMH5-"H
M^*2@\;C06)B7N38T[A#&=WJ-T4!7T"B;^*AR BG9\AL-@@^:R4M\-%"OR)=U
M'&8-N2,K8*J3C;-AE3K9.)1[4YAHN6G1Y X) %UO#+ORM.Q0IQ7RF@:%J/+P
M0B'J!;!*(>JA$+4P7_*8UQ ,J:XA*$0]]V1"#2<_5PS6D]#SJ2%S9(73\QZ5
MJYJ+JK'<IW:;"BV^T0X_@AD^1BF"WFN,#'E*$:K\IDJ#7RN[(6TF0N&Q-(9<
MX;'"8X7'N^!QH2'XQGB\2S/O3F.HRS,NXUSPF,M/+#ZK).T8:8SW;+@\_!9G
MS<>\_!;-J&^;9<3 K>O&O$SQLIOOM8SN+_)HUJVKW="Q'Q%_H6%#^X863JEV
M[<WFQ%VP+@;4TIPDI\!Z&W@3[1^;:^2>6]UNVZ)_V#:,84ZK>XGJ]E%U6\4C
M/0TXX^ N0T^[=5WOF811H/UF3ZCV8-K4-8%COU$7]4Z[ <75WJ9/>3[[$_7?
M:6^1M.E@M'<M+GO\O^DG[$"#A7D:T::> Q]$>F>8PMJ0#3X&0*'9#-84A)[Y
MHX4"7"64[7,3RJN0;3B$;\7-Q[TT\K(Y)X"D1)L0TW;L<*%-*-U.,GN%)CQY
MR;RA],1"V6X5P22126PY(O24:"^@14#+G* VM!<[G,)SF@VDL(FCT0!(2T+X
MQ(38/@)1M"WM"C<+_\U7$, .'V@8.A2W?.M>DV!Z U_V)WX77C)TO"#R5R'P
MH4E:O. ?D[2!*,]D;1[YYI0$C#@K:/-S[#MV, 7P#'+$*;0TN'9($-Q-!(WN
M?(;<@"FPYKO) S5%X=<U<1QJ?5Y\)>8T_^R!Z"4^^Q""4#!CS-?Y@*:%O2!^
M ,"/!K_>^W1"?9]:[($5-+_]=K/*9?K4USN-3J>$$YR82';^E=JOVCS^4F'Q
MM$=@4$[[41.0:ZEXQ^J0$?,7ZE/-IR9Z0J Q04D#'S3 27\?T"0;I]'"2S7Z
M<TY=E(9GRN6#8:(PSZEAS]GUQ]R?M#$E/GR)&X$:)N\EX:O2-6?*DI&MPIV7
MO-&Z%>_^#G1@;+7NJ8]S=<G3,96."8#0NJ;QYI->!-=?&DA!<#G-Z>942,J;
M<7%+)$@WC)*,),@2Y1[@@YNE$Y)CT.H5Z8'R)TYM0$0T$Y8H3#B*F4]G!.PX
M>!H;$ZNW-;&N+%"61^_>MUW3GA.'6?&[R9JQU*&I:)12D>":47WG\:J!?A!7
M/4VU+]1D;]<Z>D/#S&M>8[TPIYS%][R V=@"*_LKZ!]3NY32QQP)F4-)O54<
MWI!S/+:@PD Z*I1$^DM4*-YE2*G 4*H@48PZ^.H&:&PPQ\%%S]19M&*M%8%D
MEC"OS#"[\>G?$<0:B[L)**OM6;8).YJM+L?853S:>EM/Y>03^-[PA29:G]\)
MN$:X59UM%5=@NQ'^)=8RM%:BF'VA66!%LI&FT>'>O!>%04AXZ)0J&%A GV9L
MH-'58//P!PAXPJD#@2F0!9PDW'W06@[.L\J\C[CHA)$0>@^.!Z[[C"S =T G
MB,4]XT4N%B+HN"Q8P-30@FC\'Y W-%F$?X!)B0:^"W& %2"NT1S_NC& C%8!
M2/)%]_Q[CN1O,/E\'2.*/N8OL>.6BAUA85X#7C,7T3S&_/ (DUYX/*5F2_MC
MCI/(!&T+/B"R)!%^B"8R?&"F<Z&!(^C88#'PW0V@O4.# ) %S(35 ,9MRIQ^
M>P5S/A/SQU?7NA'>,D2TI^6.D<?O$MY@%K0)3,A[^"]@=#4RGX,% /E%BG.6
M!3P;$-/9MGATL#$-]14T!$RR\2W$B5'J*P\'SH":2#MF4TWOR65A#< 623:T
M(L)AQ@>7RRF:%7"(HP+JVA@J@Z4!QE3DJ3SXI:^A11V#6^FBF(/".1%3,-0$
MCAU/J!OPS\"VJ$_XG#^! "R;8=F7E>1:(B<2@:"['T%X.T.0)).)C9$S6 3X
MZS-851#T1H*V^+!+GY;^KCGVS XY#(-VC+GNY#D#]&R@XJ!]8[P)I_ !>#6P
M)?*U201FB[*XN,&/!2#N!H$)*+R>_C3I/$P2)!!%VRXN%J)GG^=)QE%@(Y,;
M8/]^P!+,OR,[8((6_\JD/EL]2AS@-0;JPC;"$UR< HJ*SKXR!VCQ1_DR\)W"
M=0<!202ZL6R+T7.R84MY&F "%2T)SXZ!0^?:LV@&]AB$ <@('[&0=C%I&>&)
MAK,HD;RQ)^)3^'-$X^_@V' #[T :+GT)?G_**7P?4Z_,1P,&]$"8R G1\4&0
M6,39"*X4@I?LD_ $ >>HB53K])ML30DF!>:46I%#6]I5N8^:SZ=B4(/RA^NU
M6>MB3AA@!.I_( 1/K/[R=#&FPQ-FC"C/)/',/= XX+FY16HID?35-D]H2^P*
M@Q_F4.N)IZB2=Y$GGS*N-X!G(6-9X4\\J>43"\)^_T?I9RD!1WQ,PQ=*W;Q7
MZ&9W :%'.<NJ3_%RAW8;^<'Y<[7JL[/,J34"*/4_;G::MMFJ]BTV-TVC+8@Z
M]>,MS<$+:(Y]2GXTR01V]($X+V01O-'>GX3X0'L1FW'SD7@[QM#XRS+=\"_2
MUJW!B':;/6+UFEV]-VH.)X-Q<]PA5J??)H:.OJ5X";6NPN47#-LC<S#H#YN#
M4;?3[/:,89,,QU:S.VH3JS^:3'ITM.'Y\7XV7V&?AFN+E9"5L>=864FQ(?:T
MS4U6M8%0@0<(AMO\H=VG X_AGV"69@S.M/NTHKMB@WWY UN ZRL(O)P2(&)V
M  PPF%J,8!G0@:>.9X!A[/:O(E+$;#9[(\X]U:Y,,)+,WT6(#_C+10#]1^NA
MI3W,T))_%GZ+=B6>$TXH.[5]^'SUCGO N!STE$I#Q^T.T?J%)AUR3H%M=SOM
MZBQ99U66C!$1WJCA*]\UF+-AV<$8G4;&C/^^_]WSGX#3U^R\[3-Q?VAOX9?O
M<JPG*QD/_SNS@\ #=Y0I"N+?50*D; G%W[_;BR=S^MJH8D*Q7[@<G1>,+S0P
M?9MYT3M$K25BDL\9/F8XSU,B>+#']2=\\9H+<2(&88P?8"@A7*I)Q%,P/#^2
M& N#1T!XCA;D3M"(-K%_@C#Y(E>S<?!?N/FVSQ.U6_<9/HOO2:B7_(6_]S/L
M"/;[A<X]")>"O6EIX0BNU2XYA-/FE)]+0J#_NPAM,M;-M5):I[$:2UFE61BD
M.JO,\-"9Q4(#$-XGX"LSJV^YRD-\RU2>.MX+&@+,Z)@\K<Q2O0\0U_$P!7/+
MW.;&R&#9%MYJ@H5YS[9%1?+ <8 9/GP;!$%/$6'N.Q6QC.L*&Y'$7[$H-E"#
MV!OS124+]M8DZV1.0?M9(.>-6>29?4<A\\Q66V)[Q((#%C>G$3Z&CB&+S2PZ
M(1#R-3*9D7#J!1A6PN[8CQZ>8L=1)8NC!2,:VABLI1_-0W,!__8Q'N!GYSZ=
M \=01%FHS!:%!^,^\H98J'!4HY,)T"C(4QJC4)ZR7,(YH9R)0F<RSXS&7A3R
M-((?9W<RF4].S/W$CJ<L3W*8K$%0AV%Y&I)GK!Q+UL?2'SL;X$0P%@"L:1%F
MCS&3:9O<S<AG]..LQA]EO@SSB+*JA04+SR <+%D6IV:"B)4F6)[)S!=/LF#V
M@H\D:K!8'ETAUG4H5>HXS,<_12%J =9?6)$?)Y48(8&>] <:#=M#909VN9E\
M.6P,)![$)4Z<Y[1&N\%$;>2#H>-RNK2_W#HQU0,:05EB@KI!D@1AZ0_+!KW"
M@R$ZFSO>@E+,F+@\/\,2/O#4%@Y9_HSRGJ^'-3__RE<37&=6<S?Y*KY]!0X$
M/B"'^\0M-_SP.T\WY<W\X3PW <FEX+"B0$=OMQOM$KQHH$GS68T-+V;!HTTP
M?!FR;XR_PSS1$W %:?GFN5DFG-(%7D7(#,J6-(9)#IP2NR!@,S478&/<9D[\
MF;)D%1W4,C(Q.IJ A^0X369YIY18O'X)5N1@&,,2J?!,0!S""JA0K5^ FAR#
M8G4).# F3VT7O^3/!?^8@UGX#=/0J6(\X!<L'KWO;/69+<G*RBUT BG./*)8
M(]@12<POL._;Z\:@7:$;=Y.+H';V^*JDEJ>5EM+%#HKHEN?PC*QK!>@5I0X+
M8DV2(3>QV"_-:./?68[ 63!(RR2W77Z L%3!QU,.0#4$RA?XER-.(P+$P P0
MY_,8)L@!6$02!!'G>YCW$ICKFW$36%;A9>HYE.DN'G_Y84N[S>;[@]1XB ?$
ML^QS'+P=^@2 "(XCQ4B:'_M1?JR<R_?#U_,-<A'EWV+'1T;"'Q$F*C59KB6J
M)\'_>4*'V,/3&'11(SN8,C=/>,E!7$W*S(HW%Z=ZJ]V_?>7FMCY:V, /S,QJ
M%0=-^TC-Q?O;SW9*?-\-=I@4^;3Y!O>0<Y3FS.?636N8VJ777C9'PD&AXIN1
M[9:]3W_=^CY,(:)X++.H;*F/+]XC1%@!*.&5:SV^ %47RP.#LS:W$]O<SLKR
MMO:J*R^@NF9&SD53$1_>Y-N\#(/"&EF(RNJR^9V5@-L[5FSM^39(!0/$^$C2
MXC$L.V<&:_'/ ,@>RU0SH&;3_MF<VA:(S0=!6$"&J^@)(F?&KG^^QT]\XCF]
M92%]U\+#X,S3>>:R7 8>E+-3L8"?I%E\(X@D)75K::U4,<LVZ*RH&?E=O.8+
MO.4K>SNUCBX%PU@*AB@%6<<&-\?.C"VRP#0<==]\^N_(I5JGS4Z(]>7\!D\2
M+!.<LUDH#1K_%X_5#<1IB'\P_FY^B7-0WKQZ;6W*\P*<(?!Z\9MY^60V![?Z
MR3N7+MV3.(6:;DZ^\N:81R<?D..@Y.O'Y.NO.I[HE1BY2JLG[$NF['YB^_S0
M/R/\\?DZ&"R/)4@UICR%@O(XPQMG1XKZ0X+-0X*#IJOW+>%YP5ZG.#/)1S>R
MER$PY.6YL\1"QS46'*4"<4U37!OZ?UIR5TECEY6VN6LS*#1W0:I<)]\G=HY7
M)A(= ((?D\J;7>#Z?Q47N%;8HF66#5?D-V+ 3X>@@[]@;G##L.I"W>"5$OD,
M<5+NW.-W']7WVA\SBCS RPC%")EI"Z-7SO"DV6,>Y K^+-N?!AHF""/'=.*)
M*KF\_\-<IO+/LAQ'Y&+-[:J"?GP#?PK#<9\["L(JIN?UA9?#EGB,3"(\,@EM
MD[F19JQPO$8@>Q&:!?SI3==Y-(;P"38.%&8'$GA.F+$4B6!N;!-&E1F9)=&#
M/ST@9_ /N$[&96E"@4WT.A&RE&PYT@?@^L?!?P4#N .9W+:,CPMB[F99@Z 8
MT#GA6>:)[\TJ!)!E)/ H1I0UE]SHG$?P7<PER60XMLIU#I<R<5%XQ][[6_S:
MUUND'@5BE[H:E-R0R]WC0F*G=UY+[[<N$SYG:6X\Q_%>XA,BO-S-3H,FJV0!
M1>7.##UQUBO"M/+@8J7^;WXS>UB(TYE6<M?X"SOJXKXKT]P@U>A8NQD/T@O;
MQ^:VWHY++-HEZKPB=SUH=QJ]]LH+USF5KK27NP'Y\)6!Q)("^=>_(]1P;P8.
M*.8ULV">,>XY1I5!>+=5<CS$3FPVA:%AYZQ@:+7<K@E#5>:$RR:"5"S"S"%:
ME6U>O\!8AFQL4L"/]THO,B&;V^&><K+#';-(U1H0KS:O!-]LEX:4NI5J@->-
M^4VN5^X=]_>4E\UTSD"-.$R&=MBKSM"6".YQD[3#55?O]YVDW5(L#I&I+2'\
M:\E:GJO=0LT*21+ID[6'UM_-:5C(;TB?L=U>V(U8V UCM*JJ?)NT;2YCFU>"
M8M(VVY5@=>*V5)VVR-T.7^F%=ZC<[0X"OT,"ET?@:^5P^07)0^5Q1Z6-W@Z:
MQ]V*XOO)'ZXP4U(D<T>%&/PH,>").;)%1E>K2..66*--,KEEQFR?R=RR]\N;
MSQT9)PND]^^&G%U2MU06CYK7'74.G]?=&_PNMZ?:/;E;P@"L/-Y74K<R#MES
M7G=4B/5/E]?=VC/>.KG;-?J-SK X!^3(R=W1*_<.909V^3*\H_ZY =/ITKSL
M9=EN!Y?5:T(__UX3Z[:*N(R$?9+>O-!TO=@?^AC9:[NP6Y;V+6S_W9Y2^J,=
M<XW5)H\O>6,'361NX1^C536(>ZNT/DI&?S0LR^@?-6\_6M5Q<M]Y^ZUXO^^L
M_7+*L:!#VR0<^^U71AP<*N&XK3J-5M\1.XMT8[^M;^.Y)43))Y&.S(5]);PJ
M#>,R2T=E+;P/G(+LMT]3AG)*?I2P8>L$9,$V;9)^+!JV?28?BV^7-O78;W=/
M%N'MV]W91*OWD7C,.3%YSS@-3)C;<EO>#2:Q**MRZDLP(9:["I^!FZZ8&K"Q
M-&Q5T24':NR<E%[)SU9<4_*8D8BULLXF1,B\545&DO:4.>ZW>X?/'._)CUH>
M@;0B;\Q#B?)L?4'F^0$ $WIV 5PTZ2LSCN4Z4SBEYQUP>84*XQJR,*#QF_?(
MO7QZ[59\T:-7Y.-)E&EU5??J474$_A/FQGUM/^FKWQY(*^:O46G5\4A99V1]
M5)C@E B@ *2$D)72B+H#MAA;1<3G5^84&P"QQ@WI)\0+F=0G'1.6&B;L\22F
M!*_V?P[3;Q<*F4YW#K-E6+]]B;T^;'1&);TPCWH*TV^_-F]3VMA&NC.8OE[=
M?D=*#UVJ0OMCG#J4)0_9A:@E(R12H7<3D3L$TW(WB2=#,]ICUN@1UO796<VX
M8J-3@%F3S/&<"8+2'=I=G[R]X4.2,$ZC[J2'8Z"]G26T>X>2D@X']D!,GN)6
MDQ5CL3C:8!LC1#1X&\,_+MK!NP]QCWK+?HZ)QT_L<)(T'T+-QC*+2=;_>H.=
MR:GCX*QJ$,WD9S$%F_T<S]7FLZ]9O]!Y0#_$__BHB?G8;9!!_@V^-"/D!Z/6
MH#"WNW2(_-X'=!>:+.UV\K2M-/X/M@?^RK- 67$Z\3#UULA8S9?L//5C#$\_
MC:TH3D\/L8\:ZJ/+!A.=7H7T0:O3W4:'*NL%+D"KV$289<"^Y TOFXZZ[)N?
MW)[45/[R\65JA[2)&(U;>/')_&+AJF@0WPMW0E:G DE\'(]"&M3B1^^G48IJ
MG&(NQ>42O=15D(#L:VC",>R7-'SZAWPLZN<\N.W9E %Z'Q>S#YR7AF\;9_3U
M0GXDFPE),R3?D]C_;I),Y+YUO\'2'E^H\TS9O)!5.=K20>.=55G4.$75>?-)
MUQO#DD2>?%)Z'#]'&GE;W].9V9;ET--Y.I?+ YR'))\B*$=&V9_ZLH$[*\H7
MV<P7*51B;N2+8)+X\<4[F O2:8STD7)!9!,SY8*<G@>@6!WY%$&Y(,K^U)<-
MR@79Q@7I[.Z"3/V5,P!W<D*,1L=0:1#IY$SY(*?G >A55SY%4#Z(LC_U98/R
M09 W0T,W)&1.[75$8?0),+HGGR(HC%;VI[YL4!BM,%H>/DA3.+GNU8MZE/@_
M3JE/67<Y=>5"!G[4Y,J%0IISKL:7B.C2A'XK8,7R(KS4:+3V:,;ZK6'OW'@C
M":H<@AUGIR=29$76J<Y?Q3Q5P2\'&]>LX-\+*R_:B=C\6+O0$C][K'VPP^IA
MHSU8NV+N2-"KKV_H3V0ON-S$8K-*PH[A(KUGK1;@MY;]?)+.'DO=<8OMW:MZ
M?QC#0C%'OC'>/EI\:&(IU+H*T^_E?<[-8<<P1\->DPQZM-DUQMWFF$QHDP[(
M<-!MCSOC@5DJ4$C!X;S,9I71-'O?=5.CM*VX8*L936]K+)S1/VJ9+C3+77,O
MJ=WY8Z;+]918<?/R;,?N3%=NUMF)-\R#9;*V=>)_)Y%HD9WV]^(SZ; Y]P^J
M$?/OR YLT?CK-C.>#I_Z74S'KIB.NGFG+KTPK..1SN:>#U_(^S#Q#EV\<]<:
MC8QV;E!K&,--NFUML>.^9#ON;-9?;-CHCWJ-OE'L,+:JY=BJQM:[-1K3"[W>
MENAY3_P[GW<5_Q/;YL4]LDY 6V--!ZIRKX7! Q+M=4ESC(K&SBLZ/:/8B9Z1
M)@FF8- \DU(KV*YCI%%H.G\OWG<#AO%6=-[=K7OM[@(2=S+N['.2:U\O=-^3
M<.]QI]YER5EC:$5E1\T-6C*O&LS>/C?W(+?MSU4!3,Z-8 [4X&.PTH?@;433
M*7AA;&\TR@Q.W#]T^9UCXK"^UL&4TE ;4Y-$ >_(7C$[9$H=^ +P0?[C^:*;
M;ME[/WO$MUAK-]NG9NCYV"&8A-R'85U.>>M>V%0$+YR29ZJQ[P97"?9(8+GT
MF?61 X?',\W(9WW>;8M6?2/J@>\YC;1IM_B&K/^3^;8QI6[<BHZWX(:]4CK+
MM"0N)77K$L7R=C:CE@V$<!;8S8^9]U(J5W:YYVPM:Y*;]T S/O'F/IE1:$6P
MG4]6V7=\A3^EZ\/&H-]O&(/B6)$J>6&K:6EWF0Z[@X;HLLM&C2RUZ%V3V@V-
M$G#OLX,/."ZG#MQ54U]VX1KIWXP5?^M4_NUSY5^N*__RI?(O7RO_<E/YEU^+
M;BF;*57EL^[2K7BYN:M1N'K*OD3812Y^&/.RWS[,'3LS,?H[!G#K],NMQ&KL
M\<KW>:57(#4V<34&R3^RLCUX/0 J;+>0&3G1=HWC;+>\$_61MIOSQ+X>9\/E
M(U"/S]_.<;9;<+1/QM^;HVRX4XBJ3K;A7X^SX6(;YU-MN"J6VK-(%U)R)]OP
MY^-LN)"1.]F&KX^SX4(:Z60;_K+5AMLMO3_L]OO=UQ,#LOPB]:2STQ?^[W_U
M1A^9L\D\[V5O^W/1V]ZO\]F1Q/G\K%=FHM81B0X3B=':H\?9P08;U_3TY%,,
MU!L:CF<39(>G"WD0[!N_\UR23GZXUK<(MX;7N+,;OHZ_Y1:^9+TQ#BN)\UH
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M;SEW[QGK[@1OCR>^^9"PWVD-*V/"AD8F()'P82LR$>F!!("D+Y@L@1\LB)F
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MD,KL15$KNZARQ=N\_?@&.AHWE=5^L\E8])4\[T:JR8Z<=$?9AJ8F":;Q#)R
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MQZVD+_6+'6"7<&ROCP:4-8=FCA=0;4)M]BL3/1>< <#^"AZ9&$^?S/P4LM
MA##!7&>FA2+M)Q'KL&^+&7!EBVT!7Y,1V8UX$$UF.B@J'VZ9KPT[BD^IPT )
MK4\P6?"10Q!>V["2,$GBA.0G?QI,)B)4IJ=XNE6?$A.DRR]L""4UWVD_EB4J
MQL6SAO."'&). +JR6;9J@,?>5I3)R_KE3]KIGO&DG4T\@56NA#'J=;K@@C3!
M S&:W?9PT!R/VKWF0!]U27]HD$%/KW0ES@MH7QG=>S+X!\>W M/9;,Q+@O:O
MDPF/P=-I!NA>,TLYT;S(KYK'FO,!$FM;G/W,)X(\)_Y!%6T1R.%O#,CC##(
MC4/,K&O!H6+=R:9<<1_C[Y7>*<C.OA .0;F?@&F,"4 -.@GE_D+&5P#GX8FZ
ML=.!8CBG3!:380_(II>I%],F'3&Q-%9V1A;),)EX(8]3[CWP(9Z.DRP<AV8
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MOD[,9G<XZC?' XLTR6!HD4F[WV^3WH8IJ/U$BSM_I0@+QIYC[1A,;1M-?/-
M__0>:Q&MZQ^UF+=,7AAW=]KHH-4?G8Z\ISQ.6/^_VM>?>.<03"-S/.(+<CS_
M /;0LIT(#:=+0\WQ O 80S *XXA?(H)0+WO%;@JBA %??!5*Y*'P4F) F=LQ
MIB:) LIO.@;X'2]>Y.#OP14-[2;[.G9%TJ?L%79J .$AQWOA[@RNDB'KR]0V
MI^QI"U0:5D;Q_J$VB7PTE[@?8COX&RYKW4367LDN0*B+\J<QNZQE;7<K2SX1
MU&/J< Y?X.)E16>A)=N B A<M= &$2#EG@!SP<$JC?#Z&8@5R QXXX)B_,8L
M@YGXPBC2?!*%X(5K=A!$[#(LNV*[=+.6H$D/  &)SS.%+$.! (G_2*B>>2NC
MJT])$/D+\;(9#:<>/#VE;K(G?DDVO=8:"P!?93@E8>Y"JD7'(;N>Q^[*\?2
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MN6TJ!.%133HU/PUF+OSQ?U!+ P04    "  J>'!2;H5$^E\;  "F/@$ $0
M &)D<W@M,C R,#$R,S$N>'-D[5W=<^,VDG^_JOL?>'ZXFM2M;,N>F61\F=V2
MO[*^LRV5K)GDGK8@$I*PH4@%)&TK?_TU0(("29 @*<J#V>(\)#+1:'3CUVPT
M&A_\^6^O:]=ZQC0@OO?Y:'A\>F1AS_8=XBT_'T7!  4V(4=_^^N__]O/_S$8
M6->W=X_6R [),[XF@>WZ043QNZ>''ZS?+J?WUI.]PFMD7?MVM,9>: VL51AN
M+DY.7EY>CIT%\0+?C4)H*CBV_?6)-1@(QE<4(U9@7:,06_S?A75V>C8<G)X/
MAA]GP_<79Q\OSC\=OS__Z>/Y\,?_.CV].#V5&'R-=;"D?Q?6A^/3X^'QAQ^'
M$N$$V;^C);;NKB5"QT8_G?[X?HC1V?#]!P=_^G!^^O'C^<?WSOS]N?W30I;4
MWVPI6:Y"ZYW] Q<1]/4\[+IX:]T2#WDV0:[U)#3]BW7GV<?6R'6M*:L66%,<
M8/J,G>.$ZVO@7 1QSP$:7G#A ;]H_?E(ZKS7.76/?;H\<4)Z$FXW^ 2(!D"%
M*;&/DGH.)FDE7B' ]O'2?SZ!@A.0]'1P.AR<#P5YC3:R_,$>V.,@K;5 P9S7
M$"6*5H)P0]52L1*H,/PI5X&&9<VD1:IVB%W2#+$5Y',G>$WIY\1W<$!>N54R
MVN'9CI(Q<\(L;R;,V>GIAY.X4!)=*;2B?>BQ)4(;95>R A5>B-B!6D=>Q/KR
MQVP51D34((/XYR?P1H9@L%C0VW[DA72K;B0I5$CF$N_WBE98\1P%:2NO!?J7
M<TX]_/3ITPDO306** 6'5"914JH0";_:*W4E5I*I@,*0DGD4XEN?KJ_Q D4N
MP!AY?T3()0N"'?")+F8.+4,@%8>(+G'XB-8XV" ;U[2KP%'U ?38\.2WA_O8
MEQZ!@[ L[B+(>N/3T(H]Q;UO<W]9T>OLKX$ >, >#89GH/ Q,#NRO(*P5=9Q
MLJ<8P@):B;$SG]9BB!>5M?^AK&7UFUVOS:#J91%_#'965RE#U0O75ASY34G_
M:BR0ZGUK*9$8D]B/IG+DQ[-V=B$/I8_Q2,?LXQ.SS^''6O:I'HWW%6=?69K)
M44 F=9#\5U-L"NZU76^XE)X@:E/?Q3 VVN'-Z\9%'@I]_AHUZAA&GN$UP#MF
MM_#W/C)RIAY>0MCJM!),9M"!(.$^0K1W=[L )/XYV,4BM:RF&,"T%$1$>^Q'
M4]/-1XJUP>!<"@'?"7;#@,>L>CE*H\7.9& 0!PTEB2L=1AX>QS>5IQC\MS43
M,??@OP:[64@]0\G/7%KVBASKQSV3/&G2+ZH)0Y?R-#8<4>=@$C4V'>7T5)((
M>9X?<C'X,_%TLR'>PD\>P4,6B%XPU6; S"(0OL_P&D:2$-_S*0LK^C*]JP[_
M8U^;K=AL%I4*)$1R\()XA(M_ROY9 SD%(YJR6%L_G^1KY)E% 7;&WE_Y[PW%
M 3#A/2/53DBJ:MK(M2.W1<6=9.7UDJ<"B1Q HI^F>&'QN>1%,O97SSA/-M3?
M8!H2,!-IPLH9K"A>?#YB*8.!@/$?H.$QX"9("@UDP>.@YSHE$5)P"$G(6%SM
MB#ABP5\LY*;-,#/^?!3 *^3B0\Z^3[Y-IP+Z33LU:S#J/KU.:;1=^HT4=]&\
MJ>)0!;OE.M^S8E/5!<?25-V\+U)K/9&H&BN?NO9ZCCQ$K[[GK[>Q?,+CBO^/
M/.?& ZFV=S"&T#67Z(@/&E,@_T<M\BI//U2X^O0G\APK9F=)_)HY_]8NO/VH
ML;_SWPO")Y"9Y_DND<OR7D\KC,-  JV$0 ?3D,&4UH7?274KKM_#T@:6":+P
M:(5# CVBQ2A+K0/LK!HPZUV&W0\]@#4!3'\$X\48Q@NNBO(%*Z'4 7>>!V['
MQ_(7UHY3#UD+R*Y\[YD-\G,7PSB[P)1BYRGT[=]A\.+_7_FN@VEP\T<$(P\+
MNFP2ZM!MQU1G".^K#4%JU$I;M7AS?.R4&_Y/M/&#_[;B]JUWB03]2_]F%J3U
M]!VWH+.M#P>WK7Z Z<+64+"Z=?T7[?BR(]0A_U&#/#"R.*<>,,UD*=T\-*9+
MY)$_N0KPBE[CP*9DP_X:+RZC@'@XD %L6%$'Z(]\ I7RA#]DMOQUE1@SC 7K
M'N&Z"#]%ZS6BV_'BB2P] @X.P6S7YFO;Q%M.?!=<'E9C7+.J#N6?"B@GC!F@
M$FMKQ]L2S'N<Z^(\Q3;.P$.!+()9$_>/2GPU572X?BK@&C/,X)AAV:-9%TWA
MYZ[\]9QXA8F:AE"#W/"T@)Q@8\E\>KCJPG6+"/V*W @K,=J5ZH 9%H!A=2U>
MN4>C+AJ3.!N^94E=".TWS/<H@5$2ZC Z*V DV,1Y7\&HQZLN7K_XOO-"7!=@
MN --O"6;O(V" )>,6U7T.O3."^@);AR]'3\K9MBC6!=%&/5IA)U[@N;$)6%9
M4*D@TV'VOH!9PL22N/1 U07J&L_5[I 7Z,#X4 "#5>M[OV[OEV;(E)"44^MP
M^EC J2(SUL-7%[Y?$:4P5PUF_B2B]@H%#0%M4E\'<3%](KA;H6\)_CWN7> >
MYXB5D"9%.K2*:9"X8H]!_13',_9*YEBB3(>"*FG!:_8PU,XHKA#%E^!9G"M_
MO<%>4-A<HR/5@'16S$]P1A;G9,FL>M1J.S!$/>(M@PFFO#/5KBQ/I$.JF+ 0
M+"R8$L>P]1C5Q>C. S(\0Z\E<R>Y7(=,,4T1U[9X]1Z3^O'Z>DU"GKX>>>#&
M>%X;>Z6+)E7T.LR*R0F)&\]/9/CU(-:?\H(@F*/!SQJ#1.]/A_\[<9%ZW*JB
MUX%8S%8DW"R9G07\WOW^@\58]CAVNYC9P:)FW<7-LV(ZI/[BIO5._.JWF'1L
M C,$L]U]#"!AH(._F&5I G_<2 _^7LNB%5!7D.N +>96E$ND/8;MUTHK@,O3
MZ- JYE9VZZ8]1)TLH%:@54&N ZZ8CE$OIO8@=KFJ6H&EOI8&TO-B\J9ZA;6'
MMH.EU@I$2XEU0!9S.XIEUQZ]5NNO%7A)Q3J$BCD>5KF'Y)"K>A7(->>B [B8
M$&JZPM<;0]MEI@J@LQ0Z$(L)H:1^CTU':T]5L_VJ"CKD%,F=DG6H'LJ]%Z0J
M0"PAU<%73,X4%Z=ZX/99I:K K$BE@ZN8<I%7K'J@NERZJ@!.7TL'9#$;4[F,
MU2-[D&-[(\?AHB)7NH/D&H>(N.V/]%4RU=E%,=E3][@?FWNF+<MWJK!#N[SQ
MWG@Z7D%I;#X=L-48T'O%OJ#ZJRV]";VU":54R7P'G$I"%+"3@N29N?W+[6Q%
MJ#-!--Q.T-:G;-09ARM,KZ(@A.&?!OM;7=>2Z RUF#IK9*@2L9@J,N<H1+9V
M,EOSK<6E'FR8V%8L-Z?FDENIZ+V9=[/<V-@O-F:B,ZYBUD^]--D[O,-:0NI4
M1LLEY3=(0U@;$">YY&B"B'.Y94D"Y+&EL9'K)I>MCA<B<S>AQ,8S/UX(&=E_
M1(1B!VBE!#N416OL-+6P;R*<SG*+Z<PRRY4\8*J E=' 8BHP]Y<H$7O(5 U6
M,\V/<DU8QC19<1+*\#KR8D:B3_^&[+&LGUI>^F2\&$<A^Y8%^Z[1I4^I_\*2
M,%4FW9Z;S@:+V5AIJT#&\*3G[/*R7:/6KM7>4O:Q%'N%G<C%+"QC=U)C)RT*
MQ@OIO:QG*4VYZ2REF/W-6DK27AREQ2U*%/Q*HLQ":6\I'5C*U0IY2QS<>;?B
M6U_M[:06+YV5%)/,I5:2M&<13_I266\BW9A(X[B\7DT=_,6D=0;^/@(_Y)ZT
MW:NL*JT"OSTWG4$4D]\E.]JROJ%LVUMO*-T:RC4&%<'Q,D%O7MGZ+9YB]GT&
M9^9W:T1M6](96.TMDUD#D\6Q$GFL1""^F:0WP,-OO%3$'H*ZRM#VXZ@QJ ^-
M-VR61C5IO=YJ#F,U^9*]C::,H<YFB@GN1C:CV 3<6\Q!+&:TAHEILL*:'X6N
M8TWP/7G&!19[F];>+>MLL)@';V2#LGRJ 5'(..!"]B;[9B9[&X5LSU<0DC7#
M0F%'!W"$^S2J,]2F=\[E##46S4IE4UMN[U4/;J*-4PQM>>D,JIC#UAI4GX@X
MW.$;:<PKE%691SM..N,HIJU5QW9R8Z'J8$]O&FU.]J0+5O>^MYQANG[T0QQ,
MT)9MUZBRAMJ5=090S$CS4T&9M2W&?Q!" Q9OP4J:Z$%O!WKCD4%;20=R,>^<
M@-P[^D[?YL1).A-*/)MLD#O%&[3E.YD?$,1EW%?NWM?QW"7+>!>#]EW?G[7.
M2(JY:.$)1-M6VKBU:]UZMVO_AZRWD(3H3:K#RU\;.Y!VG'0&4\PM5QTM[)U-
M=Y;1X.SH;FN7'9)G$FYO?5I*+/A6V=);M:VQOH_%1'3CTZ[9G6.)C!989F6M
MM)G>< ]IN(V=7%>\=897S&:W,+S>%W9[UW)C:ZE136<(Q91R\FW 'M[NX$V.
M-.3/9%1!JZFB@[68@!7'*I1G+7I,VV+:^)VM4T^';OG]"OU;VQW"ZHL4FI\2
M;,Y&AW^#6QIZ@SBT0:0N>L*N:7A5$R5K5LWMI UWG?DHKO L-Q]IM  1!M W
M,?5@7J06*W.];75M6SSD'O-3XF*.MX<M57#3V4XQ"UO/=N(Y0]SF;IK:&TK7
MAO(K)LL56\Z'>1M:8GZ\:Z/-SN[-5&<VBB_BUC(;T;*5-&U);??6L_\51-)F
M2L @"I,#D0 +L=F-&,2-H/<?<7CO!VFE41A?ZL[6SV8^N^D$;$7ZR'SEE/4M
M!=!993'YJ[@N*;?W<R<EOZZ#R1G?XQ%+:H&H%I-5XB"+R](KL<"6+'%ORQW;
MLK (ELUX1BY;Y+EYM=W(P<XM]==9NSJ801]$"HU5_UA,*M>QZM0B+4E82TAK
M+4#<HHWWEGT0RY9N$FL\W:Q;5V=%Q0QQYFZR?EYY$+AWWN-FL< L3-Z53E'(
M/F#O>S9Q21,[:,=49R#5GUO*.9BT88G(8FU;V<9[\^G(?*Z3Q1IXG&R_].IN
MTMN'G\YHBGGI"J,1;7)C2?9UYN^OZ.UE'WO)OGSCQ1>/PI.E1_[D2%]B#X2N
M7DIOSTUG*\4L=\Y6<JX#+$9ND5N-:+.WDTXOTVRQ>:<=+YV-%#/AU1=O]F'+
MF]C'[@X;?I+C 01>1^M[S.Y82K;<W?ITO.$W&WE+7E!S(^'A6]79G.H[X]4V
M)U^Q$Q]M262SN R6D(YOVTGE2PK[#8A[[FE=E'W8L,+S-/U&8A4KG3VI-C8O
M*C^?J'5C_\KV\?/):^!<H,V&@-[\6?+$\_Q8DO@A>X9=S,_T,S#G3O#ZC\*A
M)-N.UI%;/ #'TA[P#HI31D>6A];X\U'[^B%H\/GH=4Y=<K'V/8");N]"O&::
M'5E!- ]"$G*D?Z%^M!&D!$B.K/@W. 8P_1EG1#QV-U<(<@%WEG[Y?!12]J5P
M!(PHLL//1POD!EC4G2.P&QNH'#PG4.VDHI,F41@OU(A >WL501S.6^.]4$%@
MBIHVS!MT>EX3B!;#*S_@0TFR>!D()<M*.];0B>+;_0Z"9'Q3P9TG7267CDUA
MYG+!U&+9P2@L+2J+[NB$U7?>=T6[K^@=%?'WI/\,KS<^!0'C#8$\IWL7!!%V
MKB/*;AKF@O!L<O"(7WA1^O*TK"SW3\ +WZ9WJOJA4O9X@VS I[O29MDG;">G
M2:0TONB;#AD:V5^(Y8OB;SYEK8!?2BK62=+>J$L>Z^I%:R8T?_;M=<U)S$!E
M[Q<?-$I>A1S-]^01DC.S$ -AL+1P[,EG->/)F+!7N41T1.OJWU,?21/-"?5M
MC)V K?1-($+TTF B%T7RRWD#'@P_XEV0U0$G8WJN3C@F%)[YR6W%8Y@_K]>1
MA_-=HJ+XKE25O7SV5 < ZBO&C 85C.F(&F_+%-LN"@+^;8 X9UR,F@#L=*[+
M;L"^\Z[0AH0HG9/MR<28_JIC./G8DJ7 J0.3SU",*YFP0>6&]V)A3&>U,J[D
MC-,^IM6 A3%]5<>P:GT**6E']$ZS.IE8-61Q[X$[(_Z[2FEQYJWJ2.<,OX:7
MKN2*&U9*PE;?8Y%K*)Y_^]"5G1BA 8[/N&[ E/G76+8%=?5TIFHXVFRH_XQ<
M=C$;]AS^)8<I!)XL67?%8.-O-;_E"CP@B]%9HR7=T!$S4_OJCN5BP8-%<Q!X
MO !39N_G9%S2&[7)3=57G=PKT;8FL:FZEJ3I2I2M2VVJMOD!ND1-+9FI^A5C
MVQ(-:Q":JJ/Z2FGVT9Z*&S95-TSSSVP6>N9@[$WMS\=H/<<4PGH6#](9#%NB
M*U0E<J!&O! O,?WV*M2)->_AOTS2H$F *E4R,$*MH\%,GMTUJ-!"72>\6$$Y
MM:,Y[[3#*9X:IK]>0WL0;,"[Y#O\O)#2@$OIC#1G(?;3:/ITY7\]4ZF4+3-2
MC?++24K3N<ECYE)+\UR=,#1Q;00F!Y1MZKG&\?_O/&D# =OU89-P%V/7H?UV
M28;* ;S6-TH+_KIQ-0,]=CT=,CZ[416CO39S52#1$Z;/Q,;! V:>;+<0IBS,
M!$V.OT;$^^8@7L%4GZW1P4.*W'LT9_-YGV[5BM6E-E'3!^R O5&<U2C_U$3)
M(2!W(AMF< NV>!@OB[$_LIKHJ$S4;+;"EV0YPQX,;3 $8K"MW)M43F"B/NS%
M $9_Q\@-5T5C*RTV49?_05X08&^* XRHO>(A]C-V?3X?O+^_RJI6E]I$32<+
M\B?$F)Z=>Z'RCTV4/5T7OB=K:,G)JE!6:J(F;+?$DO*0CZ"EYX,,=E  14=E
MHF93O$FN&<SJ4GQNHO2*+U!/TZ-'=P[00B"'I'W"%1^3%M<MQNDZT0^';*'C
M6<,A-R.G"XF[K2TE*6H0-0@>$%T2;P;_Q6&\KR[?GWLPDKM-F-&WGVS55TQD
M%NX87J[+]](T[QXUEV[S$_4MJN%+6J+3B*T&+'EUL<.2IPRFV,'Q=3.C-9N/
M5;R<>W/^KO8+U.^ 6-WF'2?JF9C'2;=Y2Z[V 2-V?,<9,S<=438S9[?#%+,<
M+2L;F.MHHDDFX]&BHM%YCQ(3SJ<)*HE,C'**:XBYR4!IN8G:Y-=\L[J4E9JH
MR<Z4^%LT99>D%9)2%20FZI3ZA,01L-)?2;CZXOGS --GQO?.VT1A[IZ!W1X]
MM@2@V=!WX$:^JR$<HEJ;'=Y<QM__GJ>>N/1DUU-DVS!V+R)W9*\(?N8,'XB+
M@Q"494=8623#KG4)IBSH2=W$&[24F'1\/(2U]NVC!'F5ZNQT^!/_._N65I*8
M^):.OMZ,QY[MN_XRYS]5)29JH'2,V2"UDJ33>+2;>8Y2WDIES$D!U/%4CS %
M3X[ R*[D"@6KY$C(S+_Z.OU[?.-<^FXUK&6@!U%BMU.F$F*9S$#59$BDI#C?
M5KMDB]P^W?(MES>O;%]'@)TO,'-<0K@YCD*NH6IT:<O)P Y2[SK-^MQJ&A.]
MK\A$.C-LKSS%,%)!8+(^\31(K4JVS$0M[CRGZOODA>LL>(9TM_C0JK(I U#]
M@Z]7+FAI(W=&"7*3ERUW,T8=2E,4KS5'F$SN?92WZ^Q#$PWZ:C2]>1K986Y.
MG'MJHN0/;*%X]N+/5GX4((^MY\Q>@&*;W_Z6V['1M)J)NE]CFTN7U>.1P#N"
M^6:'B@YH5]?$7AA%RR@(V_1!FYHF]@#[9BM;7:(1>R['=T_\P)6X0H#-_T4&
M)ECM+*%=[2YCP&[F=4TT&3E.?$PA^;IM<LQ7=0*X<[:F]YQ02*F,NE<T54P9
MPVL$+SFTJ?CH\01[R VWQ=ED@PHF3ILRTE\B^_<;S[E%-L_IWV*LT[>ZAO$*
MRQ<1QA:<A)\U5*];U\!. %=$?==-IOG\FP6!_%69\>)FO7']+=[EI!O4^$[3
M^K<^??0]6=%BRD1%8R"^7S; E&_7V^'R!+U"MS-_BIW(9HHL8?K)]A8(+1M6
M,@;E.M<,28-VJ[[9@X&!YI')[Z97Y60N$,M\CT75"_7J&:A\UHD_H)#=%+>]
MAN#MYC7D=Q6HW;V:,K/'#4J^O7XU02HY.-80ZE(N!@(O3HBQCX6774Q936-*
M&%MG7'N"AG P&F:!R4Z JVE,G.HF$I_5T*J$QF"MSFMH54)CKE:7PU(OH5*P
M!KF)NHI-OEF)T[.V)=?4-:W5Z5IZ5V=7.6PWI:B)^Y]48->O92+FL0Z_M-*\
M?BTC-5=_HWNW=?MRNR-)-@^,7A!U8.X4#ZK!. K9X,<6NG*?2Q7+SCS62'OM
M#5O,A"[[WIS;37Y.JWZ@U_\7;E9W7GPZHY-.[[C53CN^*_>VO^'!;'"!"?N.
M2;+K@,22=8O%P>7X+M&I8:%"S3=_-1HV_*_:_WM<&OI62!U,1!,QC3=)B5L*
MU9_Y*)9^3]G W:%?=L=&88^8LM#$,&SD\(LTKO'&#\@N6UUX_#VE+:[&7^^N
MAY^R*+!+5;TH?P]"#4H34;N/O.5.:*5JE20FZB0^/:K4IJ301#VDO2#Q=J#D
M(Q0>RV"29\R^)I:[6Z1!#<,U?B*OE?KER@W79L0%9EMY*I52DQFN6X)$]HG0
M@6]EV\.,NV1N8C]"K,T_ ,@_*N/%05L2Y^7V;>H)3=3OTO>B8.8GDDZHOZ1H
MG=6LDL1$G1))DTO$(78.DVS9%X_D [AZM"9JF5R EAK;].E+,7E82F&B1IG[
M5+_Z\?U\+YB.Q5??.#"W/A7KZ!-$(>(AF_BN$$_,,R:9JTFZYII)J[_%50&U
M5JDE';,"?_$<3)F75?9'*:V)6HH%$!A"D#L"RV5[J7;7I "$?";^-;X*,;]L
M4K>6K+DQ=\'*"^RWD>MNKXD;@:N*1U/0@3MIKLAN1T+#2@8NPO,DQUR?QYSG
MLS%R/AGG4V53S-P=@,T_ 0RR@$G,,%T/,UF@MVPVLR_$F+N/$FW8[H;XK)6T
MO*@<12LI31QQ;L#]V2P,91\66>,9>F7;LK.W$\!;!%%=\CJD:9,V-0U\P<1L
M&^2/#Y1)MRFR=!TEC)ZW!"17B-(M1+G,U(.G:/Y/Z(*9OUL;R,_AN^)J2DJJ
MX=Y!%E_$GL-U_1?&@H]!,_\1AX4N4CGMA@P,M*_+Z]].3]_GYA.99R:ZA5MB
MNRB,_HS6:)Z5755BH@:/3U?W5Y/Q%3\CF;L50U5DH@X@8^:H9W["759LHBZ7
MQ)\BYQYF8U[^2DYED8DZ)!E9'OF,EA3'U\;DKA>M(#%1)]G;5EYOH'+/F@I=
MNN-N-H:D$>@-M+YFI]'&<Y<L,V-W-8TQ"W=-[V":^EM^OBKYR.V8?<*7?1U;
M"6P%L8%CK"QYXD;BH/07[&%^;S'[M'%<(LV+&U<S7'45:(D_JHMQ2FZ@J@E$
MJ5?E\3$_7I"N U90R._M\O\@%G^ .>CJVVN5040:/!)8T@^$B0N8\^NWXLKF
MI&Y\X.H)G -F+HROR2O!/U13!AK. WCS=;2.,U]??3=:2^<-9RM,,5J$TET'
M=<D-5#7.8HX7-P$$A?%NM?$B[^5+*4Q,><J&FM]<HRXS9H26)LL_GS#E GL%
ML<5?_Q]02P,$%     @ *GAP4BTL 3^?$0  @1D! !4   !B9'-X+3(P,C Q
M,C,Q7V-A;"YX;6SM7=MRXS82?=^J_0>N\Y+4KFS)GJLKDY1LV2E5><8JV[GL
M4PHB(0D[)*$ I&WEZQ<@19&2> % "B24^&'&ELA&GX-;H]%H?/_CJ^=:SY!0
MA/U/)X/3_HD%?1L[R)]_.@EI#U ;H9,??_CG/[[_5Z]GC6['7ZRA':!G.$+4
M=C$-"?SV\?-WUF]7#W?6'?*_3@&%U@C;H0?]P.I9BR!87IZ=O;R\G#HSY%/L
MA@$KC)[:V#NS>KU$]#6!@']AC4  K>CGTCKOGP]Z_8O>X-W3X,WE^;O+BX^G
M;RX^O+L8O/]WOW_9[V<$_!*CL#(_E];;T_[IX/3M^T'FP0FPOX(YM,:CS(..
M#3[TW[\90' ^>//6@1_?7O3?O;MX]\:9OKFP/\RRFN+EBJ#Y(K"^M;^+5&1X
M?1^Z+EQ9M\@'OHV :STF2/]CC7W[U!JZKO7 7Z/6 Z20/$/G="W59;Q=N@EY
MK$I\&OWYZ23#WNN4N*>8S,_.^_V+L^3ID_7CKWO/OUQ$3P\^?OQX%GV[>92B
MO >9V,'9;Y_O'NT%]$"/557 D/ "*+JDT8=WV([J2$ OJ_ )_E<O>:S'/^H-
MSGL7@]-7ZIPP-BPKYH-@%S[ F17I?AFLEO#3"47>TN4J19\M")Q].IDZ])6)
M.>\/SF,AWSQ!]A1K17<1:"[GYX?Q1N<IP@ZDZ#5J@,E[9_RIL^T7SW*4$1,6
M@%?L8V\52WT,F$C>&ZZ RQE]7$ 8T"H0#^S5W\M?W>8DJZX-7#MTH[KB6+:>
MAZ\!]!WH)%*XCDW@B8I/%'"QO85O+3YJ"3- IU%S8./+'(!E5,X9= .:?!(Q
MT>L/UJWBF_7'O]\'"TB&E++BKD-"F K;5+B\?6*2?.B"*72C8:SP[3,-6@]M
M&X=^0!^@#=$SF+KP"PP4]"^7HP/)-:"+H>_P_V[^")D.+BN:#H-K0,B*31F_
M #>$,I $!>K ]A/&S@MR71GUTW=T:)AIOU^P;]?J %D!.G0?^VPRF2/69M?E
MP^#FU79#;FBH,"\F3P>R"<%+2(+5A(V% 6O+O!TO^>C(5))!5"Y'RSA5HVFU
MTZJ4IX(V9H&H2'DEJ[3;MQSX)[]/PN!^&<__8(I<%*PD:*J2H(.O+SB = )6
M?)Y[PE? _ZI0SR5"M,R7V \(L(-?4;"X#FF /4A4ZD-.GB:;AH3020I'4*D7
M%@O1:9>MVT<-BVQ7@C9K($-=#9.@0(H.%%<A13ZD]!I[4[9RYL,-;^1L%F<J
ML-\H<B !6Z.0&M":!>G@X@[[\R=(O.R@)0,Q_WT=FO_*S'7 #7??B3T<]V'
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M-V^3!]YVS!4=$/MLFK^>X"F*O0C&8\GC&CDF"^3ZR@QG3W?.;S+.ZP5>/.(
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MT_[D+@\1T)9[.2JF0PQ=HK+1<#&7V'0V7(LK M(T,Y=_/VX4D&AMRB7>GST
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MPD9[6% N0R4-;8T=J_K_WN%?R5? OBUR%'5(=^D^N1-J*H3 /ISBY[7$8/F
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MVLX4>G$NT%;7/-&D%FWTG0K[DFK8JFJQK[A9XMATTKE<QU*[$.R7!UO:^B,
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MY\%LPJN6N[3>&OYM7;MV5Y6N&;C7 #UK</72G]G-^NO]O/2X<7B'O6Y$S6N
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M7Q:(",WG'V!"0BDB,FVB?9S$-(;F\2O4<!]9B@9-0Z0X..CW&B#:I6(?I+]
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M[^^&5.4I HT=G<BD6.;ZX0,:Z]TI2M;QL'M"T\U[,X2\6@Y+@C7M(986RW,
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M[D8DS!]P0OZ9;3['2OG;"4(6E-]'V+[)%U&S9N.9R8_BU.<!PVKS&I..?W2
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MOWFL<>7@H]2M S["S0<7/RN*-[UV=1E[F/;U2236A_VTMQ>OR_GA[G(UXRQ
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MP1*U8&1;G>JIJ((QX)S!=A)/YX[)^K/PJ]?9U6>8AG&F]LZW!#$[X/42=^V
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MT7!G2^=* XV5=>X]J+VNR!VP>!2UYF@>9SQ(<HA6;)#A>%-G.+X(M: !C=#
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M+G1>T*XC1?<WPX/<25(&C>K&2=MM4T=YU1WJ?#[2E04/*VIRGH,"L06HYIG
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M9%6M10YO^S,6K@IS\SMJ;7>;,$R/,!(.E&QL:::IVECG3G%QO)+AW/T[Q-4
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M*E*KI8IOT<C 3OK729JXK-DF^E9,DN;@TZKILJB\(*)6-P,M5WXKLK!3Q:C
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ME:8XO<!I"MG-JTWT]V.64\GD+T+IT]8%1YW7?*YR!I@HH);E#-32^.!(!E:
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MYKP9]=Y#G-*Z'G8]R@_O5<83Z^IT+=BA)FQL/UIT11?X@I(QH)P7<L*/.'^
M>8X@O^MW$60OALVA52F;@RK'R;Y;7F5YO"?01:"ZWTZWQ)]*V/EBW"\G5<2[
MQU55M+TN;-MN2WB#FCF_?)N]J':E=K>1:"\J/-Q8*J<@H[\?LYRF-^HUDXMA
MW21A"ND@XJ1VW/P%ELY;OU3DY,V9!Z8ZZ=/X41HV'SGA-.=\<Z:P(A\.[&60
M&GUZ1M3>^+U5%5LQLQ*[]O'?KQ&)@(P:@X$9?(3Y78I#"*-,S'#3R><N.%'-
M/>*+G^__C%%$5B/2]J%*5K>P7HF-F[L/,*?'$4P&NE42SCQ".H,?N!QT-J,Q
M/WQ-P0L7QP>CTX0?&^C?7K2J69K%+9&.S0A6TYUUEJN-T <+DT5N-,"U-:EE
M0Z*%7M+7D?"!:I-NT^'S$5&3.5W@+,_*1%;T4T8DV1YRLI&6/C>RQLI"'Q4]
MUC/T28EJP5BE1EJ)!D(J6Y4YCL"12D=?V'V#CSDW<1_,VJ(Q];4Y,4'.UT7Z
MP$N$/2MT1P\2VAP,ZHRC\2#A@\MQS :'U_*/(^!(=-M3NHQ/U//Y2@8UX1MW
M%L>SQ 9 Q$QQ]4]$*5?_ZQP[JH==\@;-4B.6MBSXT[:"%^!G< _^;&O0OBQO
MABO=S-8V7XZ&>@O1!('X256M'"93=8@< 285(&+1<ZQ%"D0>PA<8'1$O^"/.
MG9_NB.ZI)J_^<8S9()1;L<G3-"CGE^3AX,)%P;FH.62\ 6/.T*[8^]4B31EG
MK*OKM6"*;,/IQ#\'-7%^TFFK)45.'T$)\HXZ#]W&K[3%+Y$PIF>+K+S=#\]3
M01!KJ'(%:)73Y)A[G9\6;-PU'&^TNGA)D7. F_/^7BOTLO&.7]*J7 %:,EZF
MUQK,CI-54JA?U.U\51^.%BD'CA(\U0KWPSF&-(\GU.*9E@L#%Y9DRURIO:65
M+C3%<;,_I)C?'E)HB2=%QJ#=X#!9!\9>,@,B-S^L7@8FK* WCR%!8V@LY287
M>'\X$F,QB/N#) QN%_23=)'JYHQ\FPRF8,&2NO(4 C2D_<4:,!S3),Z/*20K
ML>OX,_U)8[(8HV)P57V0JH,'"$I>+&-<<O/#)R0PPO):\Q</U(9B(T"Q6#,?
MO,L_!6S,Y8]""IVES#5:^\@3-4A8RC)QD(4N^/GA/^H08FTMK@8NU$2*^5KU
M#_&0B)\*+;9*2[(\/8:TA.DFN4OQ,QFKAL.-TS%9+ S3=5*?4'&C=QG8 7#F
MR2PE!15649W/L* >1&X8(HS54OXRF,Z[U6F2)4/-0>KQUFY[H4:AP.@9VJUO
MK:D4X)1)&]_::B(U%W0R26,YU.;UMA]H5R0KGE90<@ 5H^S0P^@^"I;,SGBC
M*,^]J@F;C$<)2O0;(AE/^F$<(B<NM G#XYX6(,'H$AY2&/(W9\G/"-(?B(2;
M/4[S^)_L]X.J4G$V>SSU,;<E@Z%U?,^M(X'/5)(J;4X6,$$M((@$"?UP8>MF
M@UU!LWH3:?58%LQ"E I48K&@(@HV6KADY4+YX- _0EO%IC@/4.$>C_1G6G/<
M.\\E8S4';GOHGI]8R0/K*Z!:>C5"Q$*OT391!YW**7W &/@1H:91Z>L0VZ\H
M;Q$H,[9UCXSS$Q"@6*9>JM7BMJ>I+>L0VWGWOOGLO:@Q]2(K=S)8:_UK3:9?
MDS>[,JGA=M&68?I2S:<;BHHFTOU-HWF/:%%6P(0%36D[\6R9XK3!!8YZ)GR2
ME(-]K*M\>"/7X%DA@RQD,ED&.TGQ6>"1RM@MDQN_24*\AP\YV;NP5"5U$[J-
M4EPICY+11V>$K'W'X<Q Q0V4[/SP'1FDL(+J/$8%30"RS IZ8-CJR^ )0M:!
M<;4@7:?##*\Q)=3G-3;3;F/I5;W+.(4AK[Z@4^;G TPRY1?&QXEH=@L9(^JD
M@0QG6%RA9EFO@J</W6"D<,+2JO,6$S$H%8!<5("4#,VOL+L?".H9PT88PW*/
M]R%"\_D'F, T0#3''NWC),YR^CS+*U2/ )J$3=Z24V#DH/8O0# [ S\&Z2^0
M=A\Y X4DS$2;LO@Q>^I!CHTTOBIX"U\M.%=X;CIX+NZ]XI&4BG,VOZ</CDC'
M0< 7#]R*V=</%^K5.Q[3BT\Z1EWU6CF7_ 'CZ%.,D!TI^2L09*V;YH4]G,/G
M.$FH2SX%1)JQ!UZ<>%LYODWXCR.9QZ/+(\VMWC$Y5;QOG(Z^I8S1=7!HD>=I
M_'3,63(YQR"@7+.8.2O>T5>)X_W^F, S<)M'"Z^9E1#$*AKU&:W"STM&H.0$
M."MP)_'.RH*N?Y64%3I7_$F19;S^FDSX.63-%F[(YI!W6^"'+1]AOGFBBX%0
MJ2!+EJ+!V944![LG48PEX$TI:J;EL11MX/;7DK$GY<:*R&(]_8ZW#K;=.&Q$
M,H/68=-4;32:FN+BMGW8A %[VD!,&N_>%F)R&E\/ML@^K&X.N(-<KTU%ZXL&
MIZ,B(1>/T!0,_/"7?GWC475XI5O44*IZNF&H0WWQW%'T",.7!"/\?%+,]8]0
MT.TG/T3139OXDAO(*W8^)/BGD<%R^O(3A4992P5!S<M"5UJW T##LEOWSNV!
MVJJF8S:_;&@-(C&G[DA[%)-?^.2)O2BTG;"K(.\TWN=Z@+.QYW7VQ4:]$B]7
M7!7!W?"2]OST8_!WG&I=35 F;5*YH,3*19U)*< ;U+] ]V/]J LW-M3URJ!%
M;50'MUWG)\ $6/+>Q(2*:@5]#/8:?6>UR#L#O(_=$OY\UL"=RK(*#Q\U!GDO
M'T9AA<#+>WL;\J7N%3RF003W0?J+1N:E^UU]R-JT[#MBS<$/]QK4/)[2BF]:
M1FT%+];*<-CG;W6ZW\C1<W(F=>NN \Y4^O?6MQXX2K#*'4G=VNJ#,Q^$<H>*
M"_;"&5&%<C><:5I.('/4$4> *> P9<>GO].J5UHD(C1*.&-EL-Y[W6"7'#G5
M^@Z=G*<MT2MG9/Q"6PZQ]88EIQND[@3+ 6XN.MTHN*;8^$04RWMWG3(-.0<>
M!65%9J#DY.J8+U!P9:_0REV!E?TF/ J>2RNM+H(T/=&2.=8:P'N?%6&5KK)R
MZ(O6()3SNX\*/90&C@HGDD!7GT-TI#6499VF]!K5A+KFT9<6-R>GD4)JBZ<S
MXXX;PE(:\%R6V;+6CSZ<7)H9!3:'8WT&,+Z127!NLIGQ?.SR^=Q*"E#5EB^Q
M05#5E<73FQ[:SC+X'5Z+F[JO2PQM@Y _P1D 8VW@F_CZ[%[>D_LP]&TYBB:@
MRG"8P8]]RK$I HGUU+D.T% '+S'1IN1T\BL+J82#[0'+):)T$TX>#WP*Z:$!
MVP9_R+S)).XJ(HTE+M16#VZ:L O:WN[:>E&92:8H&73#'J7LX#:O:('%77N0
M0FZ>9 '8JNOI;(3]F&(DD<5J>O8;1=0#X':G4DDY=Q;W^LA>U6O$7F9PEB_3
M2O!QDCZ<Y#MG<I$+TYYAN'^OZ$*NO,W()9 E,9KC\N[8H5!7OH_P<_[X":)7
M^"-.\A=;A092G-P<?$USMC_=$2C>>V_S*NA+'FO*ZGK=2$L>=_:%1"H0X!(!
M+I(_\V:/_OX+!NGC)^PN"%0,YK*(@J$3E_^P1I=O0ZSMZ0W-KA). [^F<A"_
MQOY[,V&OU*5#F\6L)D!9.O'I;U;KTPV@S;RZUNY*037V;"J*][Y]3?3BUK4Y
MASF-@')TXMC?KM6Q&R@;^76MVW4B:NK55!+_G9I\UK%3,PZSF@#YK!.G_MUJ
MG5I$V<RI*]VN$U%CIQYMA.V!4V]VQ&C=>W:+S5S&T&#KX.+I"TQA0'FLT=/[
MH==V]QY=KQAF \=GTBSF_E6GW:2MN9O](8A3U0>UY>A9Z P\0M]![5!%.Z/]
MFST]X57"LJ^3\Z1.UX!;X8IU9^>DZXJ@9FIZNV 3AND11A?DDW$8H,<T#E#A
MVA?'-)5T'VE2FF7CTZ2=7!(HV(*PX MRRKBJH0@Y:Q_N RC B!5U.L<YZ=7^
M@/ )PGM>E7(;!T\QBO,89@I&J$!,/Q!,$K<?O2_PGJ+"I]VR;B>@Z 7(D] M
MCQ]65J7W6!41N^0&"G9 X <*AN85CW-%PD8!V6@87,^84',X)3_ &%8+VDFH
MG$3 ;4YV5X5D9N%OBI*^/XU3MF]WC%_U-I\?D4X2)ZRF-;\Q02(<I?<H13=7
M3XE'QS#_2Y"F09*?-GQ&9*W(XEU,XHFZ[TB3-'J[6H:%?6\J. )4 '<Z*Q>P
M?GB6*IQ84Z<K@:YPNH(G*)F"@BNHV5I97%1ES8[#NW!_X)'^S!>R9!"HYCC[
M2WM/^4V2Y2G;^F4ZE<J#)$S>ANLE:?F9N*<<"$R\JQJ>@@9+ZFN./6Q3 .47
M>7J_;LM\'+VQT[(?OQ[2&<-CT&ZL/(WC3/?];JO\T,W0FP1W=[<X4'Z,H/DM
MW9[X(A4WSP_<W0%$6/B0K>O7-![6A3]:;3PQ0%1*Z5MX6\"^H.7Z"=#_2XDO
M]Y"O& U4GPSH^[:MR.2F\7\K.ODX&0PU\A]2CW\*'YH)EFBVWQRC7D?]81JV
M=.^R-WX+AC./FM]/@C-H_O;:V+L%8L 5])K1#RR-+C;W5P^;,%=<&[6_ICF-
M-\DX61TQ%F0O[L5AYH"V\8@Z/-)LX^B.J94P,%\BN1"U<)T+L 'WX HP2?U8
M)MWJM+D?)&$K=-VZ:V;?F<EO?>M>/P70X$1R:ZM'O5,PAE944CC,X!%E6Y7-
M'A_5#C7&Z=B"HTG7Q;.S'W$.L[=L*W<(3C3EX:-C#. TZ!U]>O,9DP$_J;K^
M<%XSN\H%3HBMY+1"CEG)';</C1/ *4KZT(Q3=E$V5/&C+1]AYI?72$*&U13H
M-SRHBPSC!0IF"QVD-X/&3TG1$11&EW$64F^^2^$^/NXW2<0^FF7'@.!+VP^J
MMFTW9F4K-"JS=M$K3Q "1#2@1H4H($B*W\2%&""D<OCANK;L97!.U 1GK;8Q
M/K.*1E** PIY6'4X_T)I)TPFI;[S=H*(&#15(D+S>_H0BG3LURI\%"?0,\#^
MY(<S]NH=C^G%)QTC4;UW4^L3YX:KL6"TO$J<96EX"[/LCV7U%]@'^3&=*+Q9
MRJ)'EH,.UH"N%WX^+/9N$F(),,O/89"2_=HE/. LSC5>39T@9-2L>9BPD\;:
MC-V;)\X/E S]\ 8YO+"2^KS&!C5A ><M6)9*4#^\D%78(TSW=+WU2(:G>I0_
M0$ ?C%Z"]AV$L7E#?K-G2\TS0%GYX1SCF& I57FI?R2H'CR6JF>:7^:0OS-6
M]3/^01(6$7!UPK\F'Q@^X!]5EZ<HC'J"I>/]'XFZ7QX_X<<7?,R")"*[ZL=/
M9&EV:B<%%<__E>EJ'F,K\G%20<!D /DG#/)""I;$RID<(&PGHWVH,]"%'9NH
M?4T0BQ&0XTM]A^>LS2L:%AD2$D=#F(.2.TNE<?Z@FZ#WHBCB'D9P?Z#N=@?3
M&$=FM:3]U&SE4/NHSU!X5[,] YRQ'Y.T I"#6?%AE?H/VD!NNV98H.5#!6M;
M"Z;5K$/T7*$V6Y7K.IU-MOYU3*UK@$[>Y517T7,XW3:!ZBE):9*N\*M8V/>^
MZSC-R+8G#9+PQ9.=IRJ"TJ[64N-*T))V.,+7SP4E60_;=CJ!I"L8*Q8.TCZ0
MN$&T)J_K0BCM=2T]K@0N::^CFSUEKQM(&%W"D!%J[EX_Q@G,(4P,LT9ZQ#7S
M"CK,G.2/2D&Z*:2D$,;/))*1*6!C%%8'>W-'46!._.M[6VFEY8:&6J/JI)=*
M(6PDF(;Z>1Z?CUGN)"[ID-;M]ZG,RDW_3R;&VB*2@0E@0_VO#.Y&DT..M<U(
MM-2P4&-$=J.0]C+0Q5V41DT;NQ>4QDD8'VAC:[5K*(/K/'$(9"$9TN#P#+>[
MAYS6<9=%*O?D'W=!3/Y]$60O"BL]/?+:D[X..T>K/5K;+N02#Y4TM$-YQN2A
MC<IY#5!*_DD^0V0BOP,AD<J'0&MH'=@"+..-K2Q8]2:*8/2([[AC!8@]ZK[=
MJ59[N^$[@Q](R.&+@X" RDI?=#^4TH)7*B[]0N,&V-J<1\4(=;Q*&F0+[E;R
M[>6IZ4H3-*VXR2B/.5R@-O8A._?/K.7 [C=9"87/W];P&D+3"^@""5LIQHJD
M@V.7(&3-<L$.3B\JETL#=W$93/NVE.4I!@-I7<)E\H:YPA!8$]WMKFBNNTWO
MX^>7_..1[H'(/ '#XE[,18 0C,Y/5T'XTORLNS;-].)G$>4(N9<@@R!["=*%
MN^.*LR:?1^N953\DC%.U9:%C7-Q=*V%+,Q]#AA24@U%D6IGK@6T@UE0(4LZ
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MX!#E0<P>9GJ$&4Q?X.8&I3?'_)A"\E(3*590"3,:Q(V\8"S'S'P0^7HD4P=
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ML($^XP7B$K[ &!U(\L3CL_H3VU+D]"U$@KSYZ%,PI:_2"6S]"!DJ "(-3<X
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M,B%!*258#%N;PP!%'JF,DF.4[.X/Y"XT*8(<'WO:J9HVD#8NAB(&.82\:QK
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MW.&_X0^+C_ ?ZR"#__W_4$L#!!0    ( "IX<%(8)I$N@F<  ! )"  5
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M;,%L[O,.68TA 6[5BH\[9'/FNJ'ER)W^XK<=,#FCHRRCA0-<H@X^ZE)Z4D[
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M/%$CZ1/FW,U[<:B ;?OB*$U?[OU*K%.OZ-N5&#4=.^@B]+&+?)9=_$R7G7'
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MMIP"[STT2B.V!;S5+>H,?RY6#V7YT^.9^B=@$W&LK=/#L1RI8=]B5PJ5=.(
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M4)^-!$K^>,J87AF:9R-'\]C()36V-H?-S+:>*F&KO#1E()Y_F$"L![%X&^;
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ML-UY]K"A%3K$CZ98KK!Y8??J<H7/S3QZL*S7&E<8!\K,LP9,JJ[R88ZV$(2
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M8->B]KKE=!'+ AEED)$L0A/HZ0WW=QQLCJY??O'^Y1\>C>0REL1NM7OU;<W
M'PY^YYRW?>D <D3_EK7<7)#9<HGCX\P:%]VZE]8.!Y90HQ4=7/05'R XA;*5
M_4I-A#OBTS-C.^&2E>^[MCR7U:'1L=\DF#I!C-,Z<7U"FN-AR @.6P*>7!3
ML7&E]^'_3C1.<8K%F6)QIEB<*18'BH=,+,X4$SW%1$\QT5-,]!03?0*Z$]S
M2OW84URD]KC([A;3],C)SH]@NP"&$0#>90##6"(E.PU@F*(>59Y\0(C#***7
M-(4XC#"4J8L0!S-CF7H2!<T)%J,(<AI>@H7AW7:&FV!A:)#/H!,L#*V]-. $
MB_<CN94,+,'B_4A,0!W&B]*G;EYC:]*[TH$*#7<D!;$<?)G.5"_3#E%2RZ?
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M*E<A,YP?$#U62QG>R^GHG(D,UYJQ/MZT?&?+N&B A'O7!') D+)UX]<&Y5G
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M/?@"6>RM_0KMB(\#B5ZE#83TS.6%,A#%]%*&+ZDV7Q,O<2C+3*B9FOY9P9N
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M7O :2?7NPQ.=+!%<H+&T7A/9[#*=H Q&3%DG*,.K!B@L]FEZ'[9ZJ 0L*_X
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MV1466D#<8/5H;8>HZY(0>Z<5VO_B!/LW[05XU=*)II",W:814B,I/9UUCIF
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MU0,X[P<?2I7#3:+E%N0A].R-Y:.<NA3G2)A4?WKEWMHBN,QIIG4"FO)B7TX
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M+)[13\;")^.I%<.TW/O<957^$\&UUN-/ZIXJ.'AF2D%5X%6^./&B5F8+Q;8
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M"NAKGY7*F1G*-?&LE%0H'Q)<;^H7[U;SJJQB"NMN/UWU;"W6*A=&IP&DC&I
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M 3D1Q"<3?/OC"#3#EI;>>G#988Y5E/JKBG"G.]A:7"]VO^^I@LM<??!^KTP
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M7[9*D#-J\CY).75F47TA=6!:\*LR%W)-,)D"HM4O!H"#<)EN9[\#6KG;G?]
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M[NHQ2J)G;%Z1+\DF5_$ 3T,JQW=:SL4IAXGW62R9Y?RHXC2*/33Q"&^DI^>
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M<B"!O6='LO00'!H#,P*3CZ5*AO(J%.JFRV+&Z[>FT=7HQ2'=:IY50B?K(.7
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M    8F1S>"UE>#,Q,5\R-CDN:'1M[5QM;QLW$OY>H/^!59'" 22MUF]I),=
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MMLAID8W(S]WS?I]\^M+OAU=*/0Q+SW%J5#H]#D*PK;_Z+%A^TU@U _ZB.KW
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MM9[IN249/._E4P?D-$][9'!SU;\FGRX'7WH#TKWYI=];\>,.<'J)$Z30Z6E
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M8D]F6OY?3NWY[U988WV,/./-_VYY= ]?9UNX=KMQ:('OZ@RWO5BO<R<&K.,
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M'G3:M)/3NQ$)T$<J-P%PJ\E=$#UO3-K=H=\[[[5;?F_0Q_ >CCZU^C[X@SU
M.4#N"7RR1E;;@E&WG8'DUNI.!5HC:'4&EWZWLT?M>]1*K-XY1S X!_^B"Z/6
M\*S5[X[,P9\?NE^@U?:UI.HX]^?BW_-4L<GJ!U$[MH[>O7XD3@7BA?^/@J['
M(1"<TT#S RR8FH&:46AQ/B<1#&DBI (Q@3,F0IJR905Z/+#@0"N]>752K3J-
MMH@3PE=9RVV\!9SG'*<'US'_ #0@FW!%B03*0\:GT*$!C<=(!C6W@E!7'2 I
M3%A$PVL#1C282R0M=)[P$+K+8$;XE"*3Q#%+4VTL_FG-D"@*,RHI6KEI5FY[
M:17:#0%2$&Y8!9*Y3.>( R@!UYGTYI5[=-PH$@DM(J%(%-JTJ5WHZ #"Y3)#
MB1P33E-SL(SH"EI!!I<.H K*B:KH8?$*OG*Q0 ^GU,LC*F17D,71>R.B$V5@
MER+CB,)8R)#*]X9CH,%1E"8D0-#6[82$8=DN@S(?HL,](DE*O?)+ _$,U0RC
M"G,U6T'J2PA7Q<H8LT8Y2:Z:A^=BQA0U]=(ZIA:2),9N27 W26=I41BIG<TB
M$K12X4W>6W/+X+\OP&^FS\[A'E&%9<XL(/5VJTE96FH'C-,W?)PF#;U_^*P3
M_HQ0_D E>@SJMTKV[D4MI(&01->J?,'OBSV9*_%_.77@OMU@C;MCY EO_G^6
M1_?P=;:%=VXW#BWPW9SAIA=WZ]R* >/4Q]I=T-MD'D4KI,$XB33?K#E(TF]S
M)FF,M)WJHIX6+.G6#@C2G 2W?A"^71/!-6.MV:I@ _==[;"A>>QV=.!%ZHLN
M_'A'3M@SP[.,Z#TS[)EA*S-4]\SPG)B!<>UH-K\^'RG".)X$6'[B*&F#,(F\
MD4B::H:H:#&)(L!A%%&)D#_2!"DCK62C)HP3'NA^G##,WL=E1QO4FD<YP8B$
MYCZE):D49RMK)^+8%CT[QL:#WK7=O[G.K2*9D=Q#>*U(E_Q]A?%@EKM1C>N9
M\#HG;PA=JWJR15RS3NI;Q(>'ULGQAMS.#;B+:\N!!1KE%J0B8B$XUG$]P0.H
MSL"$2/2^\:ARL=',]EZW;VZM[G@R+RDZF%$>?"0RF(%[E+TS<+=P[1.$<DLN
M/!\GGDP\G*V\1R)W30F[O!#]*4"S4QN&@[->'RY:P\ON$-J#S[WN!HY;BM-3
M3)"]30\K)'JM7ST7AF*,#VL71.(#%SYC+1C=Y\$O:M-/&-WM&:,3.%^?-P:3
M"0NH_"[$G_'Q86WKP_YE^>-+-NWBEPI-N_A-Q+]02P,$%     @ *GAP4EVR
MGM[S&@  N;P  !$   !B9'-X+65X-#5?,C<P+FAT;>T]:W/;-K;?=^;^!ZQ[
MVTUG:/F1>+NUT\PXMIMF;IMD;*?=^^D.1$(2&HI@"5*R]M??\P!(D)(<.W8>
M5MB9)A$)XG%PWCCGX.G?3U^?7/[OFS/QR^5OOXHW;Y__^O)$;&WO[/SQ^&1G
MY_3RE%\\&>SNB<M"9E:7VF0RW=DY>[4EMB9EF1_N[,SG\\'\\< 4XYW+\YU)
M.4V?[*3&6#5(RF3KV7_][2D^H[^53/#O4I>I@G\,$WNUK:Z>'/S?_@^[ V@%
M[W;\RZ<[OOG?M[?%JQ?BQ&0S592J$+.#P>Y@?W"P*[:WL<'0) OX^V]/<V'+
M1:I^VBK55;DM4SW.#@L]GI1'4UF,=;8]-&5IIH>[>?VD-#G]I"]TEJBL/-S]
M]FADLG)[KO#;PZ%)DR-^8O5_U.$>MM]Z]ETVM/G1TYW\V4<=N#,N_1S)J4X7
MAY=ZJJQXI>;BW$QEYIKB1 XS4TQERIV7N'4C> !/,\6M9K+0$D84KN'6L[.K
MB1[J$G;[X*.OZ?; C*$K5=QNY,>#@[W/"-#3LXN3\Y=O+E^^?B5>_RPN?SD3
MYV<O7EY<GA^_NOSNFW_M[_UP="$NSD[>GK^\?'EVX=Z>G9^= BV>7[R%9N+R
M-;:@/O;V?3?!-V?_/OGE^-6+,W%\<HFO]WY\_"02QQ?B^+>S5Z=GIQV(7@N_
MO75;QQ#0)6Q%?!2;U!2'W^S2?[<&IMN(VT/S<J+$R*2IF>ML+&PUA8DO1*)L
M7.@AC%/"^UCF.$E8K(G?"3,2S[6!%OHJ$B^S>!")1]@*0;^_>W1BIKG,%A']
MW#ORC^>J^Z2R]1.9)?ZIJ0KW]'MZC#U/)>"HA@GDA9EI"[S2XBR@J9!3!3!-
MJ&FA; DM$Q$#.],C'<,/;*>SV!2Y*21R66JY]LOA(I5S&]&H*QL4:JQMZ;HB
MJK5"C@NEH'$I2B/F$QU/Q%S19S@1J3,&W 2(1!70O% BES!#@"Y-9D3#O5"9
M*F"-)\%<?Y5S__JB=*LY53!%Z&,@GJM85E;1ZV8+-< F2Q="^LV,!'"?Q,!H
MF2E%#&B 4Y)IZKO6&6()CUA.9 GP7H@A/)_"1$K)ZUJ8:B!^-@ WZ&*:IPIF
MPUB2XX<1-A!V8JH4@30":0(??= .1==O#3Z\_=9$,.L<(0ZC\1;A-C3CT@ \
M<97%L'M6*&;<UB_D.,LJV)]SA5 !&",TIF)O=_M_!JNY04W[R]QA)3?X4&J_
M$S<]MHQ4L9H.8=,>[T5B?W=_-ZIIG$A\%8779#J1">+$U#A$C\1_[PYV0;<!
M+!<SF5: []"UG0#(([=- .9$5 " 0ERHF+8,^+#'=157A28".;N*)S(;*W$<
ME_B:^3#LCD>!<&)A8S\[1I@4ATP$(;@2KZ1-Y%_B16J&L*$7*H49B-]D\4Z5
M;D[8"N"7$$]<3$&^^3&>GU[\>^ ZOY=M_QPBU/&:!XRVKS^,]U?EQ!0P899K
MVMI*(K5#P_W=@P@$+_[/F$ITT9)\R$- 5[<E8@6\?*2_A\]V5WUV0VKHDA5^
M=($?M43@(PT#K9I=3OP**<F-U SAQVSH[BE"TF]U6]G8>H;38)89N5Z1"[)\
MR@L]TZD:A\S320AD$..,X#XJS%24L.O(+NEOX*?(-H=&%B3D$ET G9G"#L33
M'9S,LP=+/^%6?:1%W(MJ>!NM&C89II2(<T*#NZ[J/K79.VW5137\$]D[8&6(
MV+6>(_,<E"5XNY:L (M+8"X9"0/XBF0#S)JU1*_5D3[:M&MZ0QH(^0$I'@ E
M-,<3'!BH0ND9$)/; 8L=X9>C"G\ Y8&N!A.=29W*80IL:[2&L$#3RP1J+(D&
MQ4RQ,I6 IE9,=:9(D4&6%PY%"BBJB["6+%P=O]*94X5-E94.:JO')F#68R&)
M;P19_&Z(VV\845QV$?<]* I=B9DI \DU8.;G.TD,&1<3.6-S1 YUJDNBJ[B:
M5BE*8^S @J'"VA4I72B3VY+A ^5ZYNT#-A$31>. J9)*:^$S5.^74;8MSLL)
MV K\!5,NL(;"7&FT/H% U%^H_>-^14))D(%6%3,B]5*.QZ3/4@_;"P52&.D
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M'XL$/[Z-]*9>R/V920_)U^ 4$:<TK[<NO+,5%?-59C2HX*A  /Y.#:AEH'4
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M&W'M2Y4).I'*H,50.Q\L*%ZN7UZ.!>5&D4T.H_*JU)HUL<I7V%)D:@PJ" Y
M>LRZTQ>0N+ \K0CJ3JX.5:9&FM44V#)@P5:1*Z!LW'387PX/V 8*7'R=<64F
MJFP$JEF6H/>K@%]@=((*25XN7DN!PIU0E<6ZMJ!2 ?9)=\S4WFF<2&XLC!I
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MG#2 P" 0 3'!Z0?T^T- 2'2&^"S)N?.D%P $[&40(0$1$>$9(F+B,V< J"\
M!YVA(+YR3>C664JH.0FK$Y6P?_B[<VRWBSY3:_6LL8M8.#\_3TI#2W>5GN,Z
M)Q<WCZB8N(2DE/2=NPJ*2LHJJMHZNGKZ!H8PRX>/K!Y;V]BZN+JY>WAZ>0>\
M"'P9]"H8&1$9%1T3^S8.G9J6GI&9E9V3^Z&X!/NQM*R\HJZ^H;&IN>5+:V]?
M_\#@T-?AD8G)J>F9V;GYA<7UC<VM[9W=O?T#O%X$("*"/Y]_JA<%H!?AF3-$
M9TCP>A$0>N 1*,X07Q,Z>^46E,3<B9)5V/\<U>WP=T6?S[.):*U16SCWD-*P
MBTYPK.-5.]7L?T^QY_^W-/M+L7_H-0*Z2$0 +!X1!0@"VCW@2O4C_3_7_[G^
M'[_21$%0!:K_X>MJ"B'R'A(&XDI%_I_K7W2IDJO"N&]<R>[*'?G6HJ4$0GE7
MCU75-KZ\E2_/Z(\L:UJ.6?9H-BXZ 27E[?<<EUL@9G)Q;M,^TZ9/FW+X(XSB
M9+'AI?1#PZQ>* /<-SQ:VWXODWLS9$E_$\-3@82K5,6&EY*^$$U\VI0VG#(K
MYSUN@"V/;5,Z<PQ7K,JK)^[,+7?VPNB85<A')TQ9I*[R4T'OW_^?<"]M;[2;
MB+_JS@6"#*IFU^ +Y01*+G>UE8170P/(+77(%E7&PK:@RLHPKE3_0"KH3>)_
MP75>@<K*CU0($/;W1GO)<$&!@Q]$!57X_\&EK ZBTG+/C46'T%"L1G]*_62,
M$5T7JRKUWD>RJ$@6HG"4,D+71\.PR6[9(QE?:H(N=C3:4/6)1 I'JA67F)2^
M<#C0K98?TCC4*C'XGJP:J=W7>T!7&# Q?;51J\_5J RCIWX"$H ;?; S&K O
MF<HNU@P=5\T\>)3X<W7EW/A6UN*!V$!3:B>8U%LWD:=.3@ZV,"[P/.:=19B_
M#4=A&:NC<V:UU+/Y WUPZA>:+.^AFP1<<KSOF8@?R;7YE4 5;IDK4-TG^.]=
M(Y<OH._IF=9Z\8<E]#6<Y]6R04?INPNU=!)1M'3<*$^<NII$?FFTY&' ^TU#
MQ"6!S/)>X];&5Y:#&,]>Z^3Z6,DWE.^GT"U[<#Z;]!:33]/;1_!'#'WE*(D:
MCRT]&<^7C2$]^7DU0DO0>>D7(Z]5>(EF OP-RL1R<FWB 06N_6N</LH]A3 "
MK?SY2Z-VI#8V>$<TC6TL0?MAJZU,['S^]L *W15V1FW$Q^43T%PNSM7Y@V^^
M#UK1O[<8&.HZPIIUQA[:=N&\,7-*O.0V%U:M>] =T@/)1]MFG?FP[_6N(@Q$
M6^\R25.??(G)3O^IRDW_&K T2RJ2"_3_C4L5!/LO9^;TZWXT;[;31+4(I3(N
M-ZQ^I[*JPI@.7*^M?4,B;R V/S)3IY#9FN%G9<K[1>/IT/<EH][0]MDF8J9B
M=)&]D!Y%9/3UE'D7U4MTECD%^U#T8^OW!6,QEU6P_4^Q\>9GL\ZF7%'B$&FF
M=KBG5]8W0FRG$D:F_[Z\ MO_0I]-4I*$.KX[98"UOU#L=I'0A:V\TLL9R4$/
MR:XOH& Y><;?C6UQ"A]6NI[J/&,9?PPGJQ0W;#+H*3.MEV60R<PIE64>6*C/
M\')X(3G0Z/UJGE>Z,I; .A79\OZ_:\?T)06Z6;]K26?*@U/#G=,MR@UE:3F3
MNLB&%3A7IX?,E;QM]2XPVT^B+G0\3E47,8D920^/-)!G*")+ET5YS+A]^H)1
M6;<(ZIG1F]=';U0+*E0.3GO:SW"]T@2AE]/[,E==U'U&R/L*KOD^R(\M,QE-
M;$9O'U^SMRA67C&@)HK@;4=,&(U?-];X7.T,?_Q)Q>-1OK'!J*HQRQ3[@<[@
M=)0#1=^L1ON6+5=J^26_OY:=6T0-OSN@CC1(57Q!%.%'@^0"RJ/_[J7*A;?I
M/S)^>@9^\'P*<6I*>9F1-;VB)*F(,=-<@]GUB2GE#:JIE-P0QH]">:\"!8/1
M..$AC4CK*R*;99-5N?:*.X87XL(,#@;G7HOI#:26)KX4EGXFUN%>V*K3"TN6
M"6V4TMDUS'OLYCRX867Y1L[6OZJB[=G>]G:>'F3]I]!./N[%L>T^Y6.^Q<YO
MD;X?EG ^$G-*WP1JYXJ.%NFY-UCET@\CXMNJP./@SFKPQ/1&FW63(G^'5[QO
MGVGDVA1.]JO/H)A%A,P:97QV8><)J,9&X0S4^'$?D"^I0"5:6MU /(T";J W
M?X^<WOR_.)5J:?66_2,L:FD36*>G^M%$_-V58X#JC-LZY4Q&>NH;8JK[W"FD
MSQ=G^.U'#!E I EK(@NFB,GC1QGQRT42K=*3N4*5US5:.OJWAP6W!:L/4YR0
M'=6!,9JB1$79??F-*R,Y,CK,ZAY9FKU)C=>\+G\(*Z>NK7M</G=UBC-#'7XU
MXN;TT]2*^HGOLE]PU>*/,Q4>+^H)W;J&'-0=1D%UTC7J1>$Q] &LI4]X5L)2
M/BP67%Q;?2-!0MV9%6_N-'MQS7MP)SEW^(MSV&6^[YW<*E1Q\CG9=@,O+M<'
MDS_55?=5:'DM(-O(&'*HV]:AT8&]LT%T8_YKH>V&%_UQ7+R4Z)NXG(F[W'E^
M2E(83;"K+V^GZ"6Q!OG4:D97ZFBEG'3B5"2O<-U?WOQW,V7@O_PU^K^^ 8D"
M9N?GH"H!10$WYIX8W*TKOKSM57*3UD<R3MQNG9,^^IE[&-S-#5_>SU@[KZ^[
MA<NB.JE]4KDU^J[>7GMI3VX=CR]HK&FD5Y2^*GS2_^ &+GJJ8]?)-&XM_NRJ
MG6OS5EZ!HNB/906>B 2LG"V2"R,^]P"J +A@%#TQL-X/O9$P>G/'5"1WX',D
M5\8#4I@J-[Z2 ''P4]TG],CX4X_#_K9](_YR@;_V[M_-@-<*;X(_R0 _\![O
M_P:$2!$%FE\P53=.53HWH:<:C:XVRI*358K0PZ$GZ5@?!R1DFDRPMTKUSF'S
M"<B[(IN?G$BT5EH4"]XG@1U#"JR2HK-R$"W20PO'<)X*FN9(N0X&P;V=V 7#
MN9R#P<#8(Q^UK?S-_F.;!G;"F(B8YV<@KD/I1Y(G()3BP5"\Q'>Q!<@ER%1/
M#3;:X<66\,_)M&[KU#=#Y[<)>__]5H@JT0*</0*?RS()>X!JN 2J NQ>EHS_
M@?CW/W!%BI:,'743]O9YDR+5WK[3,FRF,A#05.DP-_',;/K&4L;N,\C?'/H2
MX:*3\F56R4%Q8I&WDV.]8 +"(IG;-<70-R1FVO'Z[399?3^TW%?!R^R(HQ2W
MA:@S02Q:[]A)H;1'Y108@K(Q?/("M;OI)Z 7%2>@_KZ=>U(HG=&:U-"V1=[6
MV@F!VFW1WR1\4BA= !#K?(#<2-Y3^WFL#EZ+'3_L63;81^G]H4!,"/YB5G<"
M&D-9U+_=]FU;Y *@5<DX2K([8ZB]>X+'ZLR-04*+A[%XN93F3*$GH/,OWRW:
M0"9N],N=PI88\#!$%>^7VHD;IQ)8_I; \'2BXPE3]5]$UO)"_4+]/<MO79B+
MR\"35!X8[M+UP!/0")L>)[&?V"*-B]=.>%M_=,>]=ZWG1^V/0LFBPJIO8JY5
MO>GPY2V:1N^H6%+>;OG>Z+6:,\$;Z=D%DC$XT-6V$5*W=G$:E>7Z?$ED+&ZV
M'3&3IMMV?-U7@MG!.U53K"]-T>C2IE77P6#:TQ?3Y=?CU518!)3</W"%.;WA
M:9#63V;Q9+^P-VB@YU!1GL57K#@JI26CY7Y%/*.7O>3ZHN$=BKYP@_PFM3?U
M"1^Y-\8ZA.V\SE,C;O6Q5]7>*EDFD<JQ9\WO1-WM$6"K#9L_KN/]N,PC:4EQ
MM\A_5Y%;@..R4=6+-0*Q+L[V#HM\E;+'/TDER'^2=U8EG8":]-NR[Q51OI>@
M-M[[!MT6R_K@3L+VU4-P-Y A]K"NR@='::_6WXNHL\_Q1E/3-+;[7)K!K1W-
MC]:.@1,]?QY='XG-2<-1FJ@!7G!1"F5Q.@Y0UF]B&($5'=?:%DU>BU\TS40]
MJ'^[H]ZV")&6$-P-FC,5?^H <-3<4]\6U%9Z;][N(_ WOD-'G/3)>+ZAFL Z
MT;DPMP$+"U!B\)1BP"HV9>"77K+_6'-.:>"K"W-']3_@0GAXUJ(U,/V4]K8H
M#L,R*Y?L?0+R?.;J8(;7VO(7W]]H!U4!;W=\EXXG]GM.F:P[[&FX0;25CCAA
MR3E'\P X82?Q;V"S/0TL1'L?3SZ8M8B0EL>PS,GE_9W__;TE;;S:B;9)F:B\
M%JDNN[%3JPP!]M3$419HG\X]]FONA)V./\QY&VHG9 ;DU#F/.+VS<K*V;2XD
M[*P 0,5MW!J& E#GIPZ>;=(I6V6I+H<_; %C7P; FW\'FW;ODOU#ZK6?>YIN
MFGBE*K)RTA9[R6U]PK;Q]CYEX>EP.H[?@KMZ_(&C1KU!0=;41DESY2H3@?Q>
MS2_$3.!:U4H5B@;%G?">1G.N;W?NKKK4B+J @[*<^KDQ,CU/A6BJ,ZO[+GZ8
MPWK3AD&FC<I.0(Z#$O77$J_?]*:!#%;8J-1%6M?!T>ZR)R"UM?%O;G-%GJ_N
M.TIB#-:: ]^M[5F%.(_U-R#IGAI0LX'"DP<K EJR\PS;;N?T02GE%D)Y%"5D
MB)EGHU_I<';KHSR_->EK9HLEIH73KRF+)4H+I.<C$S6T!P3$\AC<.+),Y1:C
MF'GZYI);KV1#8/LXD]L;$\$BI7/0@L8&9Q+*&[P=[KZJ;=K@?%M?67:]^ZW.
M60E#%),_&9O3A4H_VK7+D2E,.%!\\9J02M([7E:^B6'M?Y+>+W8^,SK8OIDZ
MD9XV*2W:Y!(*1R/^T6J4Z>/<X<"XYYUFH<4&(^./G+MBDPWKR*+,[W)A&1?7
MA8@-*$UT;_0X=3=1FW1E;H8W\EO->R0[])J7X38& WS[PK S8H\ML7(" L!J
MI(\E XOA18X\>I1C YLRNJLQ B2[0/_<N3S]NXZ]$4+1KG&KA_CE3CMU-[<)
M\-I[-P>]HP7$Q(/%L<SD@8>"^6S?2_&[ .\S1TMUIX "O+->(-';=NA$Y;;(
M?T"Y_\UQSN-GR/,NG5,ZXF,RZN_9-B09A*Y^^_LLD+7W8@[::@ /(KUM6_D\
MEH-6N:&_.SPOCN9L 7[# 9Q\  X7EH3^+8(@'N$GX'T'I=5@W3>^MIP5IX!0
MO(<. :&W#@$0 IL"!V -/ 3#@E?C_RX!8BUY<6RK%OAW? 6*ES#5)^EO[OM@
M'5>P:(.8@ Q4JP/L:["4HW\S0CUB0AX/..51 TC?K^G\-P.0 5Y_ M+;S0#^
M?Z@'Q(M3#*>QFK2_IA]?2[8=RT3M:6Z;:2L-I(.-@E?E+0Y0O\4/0M3YYA[B
MI=_) Z1/%RQHV&7ZLVTOX;GJ_F*NNXO?>0"4[ ^4G%E^P'<!+Y_O_$%)P)*3
M7"U^2NAI,(!,R '#^'T-T&_;D RQ^CP#B$Z%TG^%J//)\^D%+.<#S V$BJ5P
MN<I_T"+^T.[J,9?XPFYMMR1]!P!<IQ[FB0("3,ZB.E&S]Z]@4-BP\_U4I&WJ
M20000&H 4^/#2.S 5U\GYJ%9P>Q?DP8#TWGD@F'X$ @$D_</C]V8AT[9UHY1
M3P(!;S$)J!6\<K9FDP>FP:;!*\ BUD6>DB(1 *5/MZQ;SO:7]+45DJ%4'ZOU
M!"(U4\,)!.WXHG3V2[L5L47>W5L[^8^9M3-#':P++3W3<#<_'/,V '')X 3T
M4[\4/] +##P\ <'P QI@RZ8.2C>*K.P34(LXOO83P(H)_JH('PTN6;8FS?XN
M_7!S2S!QH+43["VN?054@5J7MDH2YU/\R8'*#_&K\IO-6D5O88(@Z_/CL-;2
M.N^KB'7H/-4+__[>H6M3<K9SJL'WF):0%+/N\A$%"AJR[4L>F-U SK=XS:>:
M8>%,"\W-TF]6X6Y!CR^T6Z >;]+^43T$L)I+C@^00UUR#M#RF&L(F[L[H0O'
M$TIXXBGP6H(MD![W-,2 1#CP]0148N$# 2!4P XA7?\UKO8KY5D?5)*OT"7A
MDQW7J S]>O(I4(L3)<:^G?95&5+RP(?9=[[#BQ%QV6&S1>R=_?I98Y1T1D]X
MNM/6\$)<:MFA&?/"AKF)GT/!DY$E=X\'5-%>N_G?I=BL)[G;K&RL8D4;7)VB
M']@,B$O 7JNI9Z18]*BH_4L>-O_;ZV7(C_L@106]BIKGG7(;973Y!?"&-S;S
M+2'TMT:J=N\/K&+/!PO<9AXN8#O;XEPT8)LD#!8V<I93<(Z5QL[4TPA3) VH
M50N.[30ZT+N+.%/$?8ME[WU JG4K_7IA"RP8:7RH!6VD/_MN3\MC00W]Q+I;
MC*H7BA:Y:<M!914I>O:=DJA52#>]?P?'U3118W,51>L.$%7<3IIH7.;ILU$5
M-?7,?/X[[KUT[K/5\#K:9-N>-T733J;*WOI./^3NV(7:-8<-A#Y$"_!MR6=&
M/O<BC'+M( %1+AAG9L7O#3H?Q$9(\[L86V"/M#GC"J6HPR0+RWC9SA/S<U _
M3'.IFY1RXWBI>T;,36*,K+3,A94IJ[>L@U"3US"X>*S:5J1"S %JO,UPKY=;
MY/7K3SW[?L5.>T.:F0OW;7H"0Q5];??3?^@]44>S<U\M=&FBCQBV(:>SDPDA
M':ZJ1C;11.B!"- ;Y%?@@KF+9"_E#61)<QTKJ1)#[&(8CZ<&(ZG*TPL'X%?E
M[J:&]"3;9IC;<E)!DVWO==,'424 38\M=WIJQ%M;?HZK.VEK*6)7D!!2[I1^
M5568JC[9[0BDJGEV292K9/KGSRVYEZ&W%E044ZBBG$9['W=#G6RIXF9##NDU
M?,EH:5)G(X =\L%&V)<,*,Y55"+GK=D/Z/->0UV ^^,^1<UW&0!^@M;T ?T3
MS7>YZN?(2V%;$,(]A2?/QTT$]-^+?3:\_41P D5"W 2?]^49YG?]RJ8 L@.W
MECM1V^6'YC2@&0SX/U$HYFU1RUU+'R59)]U<775XU[DWA5.H1.VJ6QX)GX#>
M:)^ JN!F30U@LM&C>ADRRR,1%AOA*S?W0UT5GBW$04+I45TAD?.01#>Y);0N
MV63X=26B@R&E_G5#=4/TK=$P)QSJNO0*)A[[9LJH@G_("Y-A;"7./+ Y'E)0
MTS%Y55&H+-+$@!MF);9S0_WZ>2HMY+98^6?JG!%/84OQ9!^[K'!F)V/+ERHS
M9YY^#G4#D\\:8 =#N]I81FS'0V797!X]&W(OB@G<EZ1NZWRGU3XV%-C3N'U5
MM(C;J^>R<S-5IA21W4:GNKO\Q;7 @=4TIHZ&1^;:X>%&&NF63%\R-):W'4AO
M#^*82I7H[/3:P%')JG;0?"$^ZQM4%JG547<>BQ1](E7W#!U3>I>J%.BY$GUT
M;P4]!RDP&WJ"&\[7O'9FXA4X\?'<UZ$B->4D>W6#DI+1Y#L:'2:KCPH_*UR5
MCWIXH%5F !-2B5Q0 Y:NS$!(#;^$9P[P3P=%EJV[!E^_@L$<YM22;05X+Z@H
M^F9W807L[=3T:)"2;$P+<D4ZWU_&Q#(I7->0UJZ<#;^F<'4.28Z]00K3C"V?
M];,1NJ!PW<:ED?<5MXV( BUU8"JJ+LR7VUB/2JO/IM^8CXI48\OJ=?"[?BVK
MD"DL+64%S7/?LW!]Y;7C60S+QIM]WT[>;M>N(,?;R#[QJ5&KHD0WRM089EUR
M7MV(.X$A TN^Y/?+P96!Y3L8NX]KG?&$_M/<;%]U]TJ6#(*^7 GQT2.G<FT&
M'29Q@ .PL2>@&/X3T-/^VK47<,AF8^U/],XZHV4JJC41ZTMLM7YQX$'X1,&/
M ANO#2/<?J[+GHLV]FH$S=1(]5;N 7GKNXC.,?.@4,T)=0O8J-9GSO[][U,Q
MU^OONJCO5S;!Q]/7</&<1JY?=H V3/L>?S('@@>+O.'EL^II[*3&:VYA6U;!
MOUDX$URTA7%$U1^X6LZ4FK7HAF?!>%8N%\I')7&[,SKO#B3=FN"56MF>)K_*
M.%0B. I6S4;;I[MX!5]YN=UH7.@=.>LAX[CEB[9N6E<Z\L\XT'_U!8<%>FZ,
M_?HM\-?>D!W,E=A@,'BL8.V06=YZ'*LGNOU7-LT$2AB6;V99V_D5W^V\7/9"
M+PCN[<8NZ)!H;^?MF.$S:[8K^V%W">6EK2BBL5C6Q);+QWVFT6MS.#F&)5-;
MS;/5G!-=1]ZE@Q\*UI)>FAWI>)-Y[38@]G9@6Z2;)Z!7)Z#U96S'G2FY=H\U
MPUD6LN=A_0-?B)!.LJX8!9$Y]K=:?0A2L[K$EF+ JU:4)K2=A@/Y.;@ +RN^
MJ+6NHJ21T.-83(L44N9V\4>+LM^LFK["XUI=$<1LW"[T$PJ&WB*,1-+'AS6K
M9WKV[GS*%1*H[O"H4'J]C"5[]1!Z;5'$5 KIJJ5"]#.XM72P*)&]<X1N\<WW
MY#OLR"D>9S+YJOCZ&I&8@4&&&+ZL'+&%C](O:-?./W#\=$ _G2A!^:U^,LV0
MEBL3:;I-<K]$VZ>W^_3!T/_\$83_G8L#1$(4:5P:+*L8X_0VQ:[%<S)_+])(
M77XX3?%XBG13Q2IB4C'BMAHEK"^P)2JP#*T6=R^BB.^[K8"/5AA)QY>TA*';
MH2%&(%]K^9HHWRD_J4+4[;7VTGSVM^9R9/<R+"+*@QP>.[F[7+R+HZZT_''X
M^EW%O0R/&&EU[',+KB9?)WT_D&N^B5)WS]W)J37)"YN0)2U$'25M@;NHSJ$*
M>32CQ]$UH)/UV4[#70:6O/I@R%*!N??.C!+#">C<7<38,;YK9X7\?(8=AJHE
M!O%(CN_=FL+M+BD=L:SCR0I;(U#6]=&,#K^_ VP\3]D\4E,J,6\-$\%=ML9_
M!ZKQ<Z( .WAQ:I@[8_849.(LZG"\ +P6H'3\<[!2FFON;\A 978!O%L+6Y[/
M6F$_12;^A?R\^1?R3L0E'2?$VG,\+6KO%AL@D$D!575Z0#2CYA&+$UZ0/&^'
M%TV)KL5L6[*;)B:<<O.S=GPO-X34WZ[X=Z5D7;9E&!RVY(9\3Y<HFAZI2K+*
M8/,9$-$R$3_\HGFH2^TN^&(N9D*!2GN>M?'UOD>1Q*'N,DV0>#A8EWI*Z./P
M%&2%=(>)?W>A.WE'::/0.[LWSJ[7T<9&R"!-F]R@QVI 0[8N9P'= ":?))$I
ME]\>!=V<169<_TA=Z'@"6O-30OVRQQF\/<HZJ([Q<D..>/=J3\=)<8* N4>A
MFB,M4M!Z1%WMZU/=,:EX+3NH? Q)>"0=]O1[$#[;0"$>Z$L+6&HU.PV/70=4
MMC6_T2WPZ ._T#7W](L0^,6A7C8#YJQ,1<%99I2 3I-T YBK)'D-PXK'GOF%
M#=G3#_^%/8K'KOJ%3?('&U%7B9_"(^HA083U3C$MCRS.+&AG7=%D&B3('FDL
M4$Y=7=WS<O2EKIR"^S/)=6W%IJ:!@[4&^LWG!N5\*AUN4*WO<2ID\]X#K^$,
M\4/?'"@<ZC[*RDS$AYHZ-JHV)F$7#R!!=EMO_<*$:AD3M/,,E1Z$//$:B_UQ
MX74WLX5V/R5RP;Z&^5M3K=39R@>@PS2JQ9EH+[E0'8IF,('A"<@5"EB6.CFE
ML%FTI#H?,.SC(Q;Q9\\C<9<O0&Z99  :[I[ZCI_A 2E@EIUGSRM5N7;Z5AE?
M 6YF-OSO!R=1]4N:MU0 W0_ZNO7MU92PR8[32@SP'VI&\, H@FBIPFHJ=MN:
M *K%<QUJ\3%3JHWJJGHOZPQI<PL5//L\(QMH8_LRDG9)&YS0.TR6N%M 65,!
M[\0QG0/:"@Q1X.$<IG]P2VO&KBEC-<Q[PXQJW*B*4N&:'ET3F4(6.:7-F[<I
M@?T>/X;*J3]V.B8G"GQSN'NTX&//_V#']XFG<<7'VJS.4HEK?9Q7I3#F:P.C
ML>B[VLK.[=)#O.NR-RN$[2XD?J^)[MZ3P"E\0V3HZB6*+G-EIKOJ3B93KCPM
ML']$])QWY%#_[9%N"=A*+<1C2?NE>YQN]*27.A5Y!1?ULO%F3]K$4H!#H=$-
MR;;)&O^:B&X;4[>OVG3W$H8ZW>UG%B]#U O06S]I%S=44@QO,3C=("@R-D :
M]]U;R!)-LZ1?,NIC@%I]+"*G3ZKD[:[BQQC8ZJ5*$C:S;FM$3VE_+TRZ(DF+
MFMHM8&+>^[IXV98F_W8QN9 "3XD#$Z'PS.,J9$'V2/PW13_&)W09[RO4OM&M
M7IZ^D=/D8NK>;*&2]@)RB;\]I"$@,E+IB!=N-\=:.68#U[07+7"6BWKB2#*!
M+<W.!'8#MG2;>EX4NAU<F+IS0_8$A*,NJ-T-!*\5V!\K>)-1X8JTRWS.N<L>
MXJCSP4 G#@ > #O!-$ !;) S:EK'A)('MAB<!-ABY/76<@ )!QX@]T*&V0?P
MB5[RT_U0$@3L!V\F*A_OQ/JO=XKFDM<*6  N0)-(.DAQ9%;@3?T7E2\P-@+^
M2=Z)VM/K/GV8,2]:XN.U2SNPL".[=20></6BR'8F^&5W-GO9T5+W?J=+HU.-
MV+J6C5Z!PX5G^T&VV;HYG'"D:TX39[)GK,:'7LU(RJ!G>U*%#UR[;)_VM7F(
MJ(O06$E)Y:&MHEUR1_EN7/N6I.[-/2+Q.-YJYJ'679MD.U4UYNC2K#U]:/6#
MBWPINXW>2D%5Y^'F]%^<WTTOM10V\7J^NY_M1[!@'"UD$E9FCLF3K1F:\'E/
MSEYU8(5!O;0F.>@:K*9S4G Y]-J5,/"$M6]B]O3"3T"(;: B";0![YZ 8%O
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MW;O';CF^2PM7%MO,_LAU1W%:HA"N5V_8SW?.7.8&TP?XU6Y-'6G#YS#EW?:
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MV+E&;UW'08_'O3/]HS:C,*[4(KE_Q9]R(H(8?*2%V>6$)&913SLW=&NLEUK
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M]DS2L?4K%C91'VC+;,@Z6A24&N#'M8+6NY4-5:";#26ZGQI6!55X0PST;'[
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M)4&PF$BJ-+/NR'*1V*!K:>?#)(D@K/ L\..S/>4H/JB()@1]-Z/W<KEMS3H
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M*VU 5E=7-7C&&PGO>CZ#@<4*U]09<59IZ018>Z5HP28\Z7V&Y?[>KMD! :U
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M]&H55O6GL(]+,]OF*=YKUSV#2S_ KBL2I_[V>J(R9T))3SR[60XQ0,U*QIK
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MNB>;PRQ(S3Z\B&43+Z3,Z9M1F0@%''4*NLC;PH0V[N@N7@^3J-6NRI!$<^J
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MP-,W:*.'RW^..HYEU46V7$66U_(((7D)99T%#9&OR]:!#E@MU^JPY*_*V[2
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M@2NH2VN3_.+N5!T5+-MSE]/HQ GM9_-]Q$R7_NV:M:YXA*B?B\ =P&<E.9?
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M/[BY_A".)/P;K4**M'^(_#OU?P'!_6F:"O<EK9TT5]NI>JJHOQ*%KR:YA!+
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MT(]?XW<_G@V>EY,U^(G%?K\'?",&DKZ1$I(SD[EA:G>[.2E!P+]8J3TC)85
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M,Q"RTP0PGUE/H@JNOSVN-BFB.%;]IS_0_B^CJE6_.SE/@U2[_;>G.$G/,"C
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MZE-^:_S@G$! XLN.:AE_K.=B0Y$LNET&UFRI7<+FD_*O5LH+1"XIP^/!&Y7
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M<KC$RN3998G\;X"F$I>+3(Y\](X40^7+.+AN_(#FK2 :M%,UY#> RUV/4G5
MU+NR[[EH:+#KH"]I,2W3"@-@>&K!_(YD]0]D2M_6EFG5>D"US*N"*8R0M-O=
M'G^I0YPM9O<)=LX^DD!DG^+U4_K_*YY:L>3_)S_-^S=^^@*J6'P8\V9N^+2J
ML.7IGTQ5C>^FKK:N5H'<Y&3PWR]0XUWSV'PB)X<R0Y2S9BE)J9[ NU$% 3-E
MI-UI1<Q4?L;:&%P#/VPUZU7)FT!-7WT>+XOS7?T4$TS3\M8&:+",I/1=F)Y/
MI_;*%-43@=AB!^IC_JX4307^EZC8B.$,&5@G@312-+[=SC3D2X7*+J+&@*7
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M?.FSF(&_60[67M&N,.&B\)7]/RC6_-]@_Z')2!4WOA NH%[[7R0/"OYY47%
M"7<FU $M8;8J&;SZ#)!R( ?+;_B@E+4.5<1(3M$OPOB2JRDO.(_>E5$]IK;S
ME!!2<:>"BS!6&BXC[?6?MAF6(.VD"W ,-+C.4R/N.]ZS59=U?3;<E-<5Z]GC
MDN)OPD['O'%"$B1ONO_.@7#<&&HRV%_).5%J?5N+,+1H^".(I->#:KDH8>D"
M]X EK7;>,RWCLJ,TPG[3=&5&;B&$Z&2 ZSGUU]B+#]XM8#JU+M-0( [X\T#&
MVX6\U]0+],ATNJ&; G/P%C</>[(WV8AJKB&(344(7=))+\!"X&W *,S1V3X#
MQ6CA]'"J<4,3PT8V%,($]E'8KB YFDRGO!<&2%BE0ZDR,<0L8SUGVMOM3LQR
MM%<"2];,B'O; O)O0ITY<F=XMT$:FEO&8+ITQDU4L=9-M40=P'![$\*M6^ >
M[FR>#RFH]$$GO@G\\\+27M8:=[6H)5& 3!EGQLWT=)71/7^S7E T7:?R]FPU
M>=HKK=_UN[_/!KSFYW_QS1G[-H9_XF2O&=<XDK^3DJ=MOEX(_0ZMECTI%W#%
M,*?S#YZY0D/TS_W-X E1'="/V^!%[33GKYL%1?1QY,C&\TVFC2*Z@=+3X9:J
MG/@W_DR^%JPN&?0(X0H# G>OT0,Y*U^\(G("<GR!]Z.W@X$]^9W3'!R5"HN"
MC@E$6X@M<F3&?'S"S74[YW2,[JN0) K![\2/>G7JW[?0=G@<BVDQ^DB/P1Y'
M":9H<\:W+!V?6&_T"&?"PATDZ7DZ8)I%BWOF>"L),LB!^/7EDH76!OB1:O-0
MGDX*W:U9KH1[K1V\$<16A5)&(C"5\82E\ON!ZDCZP8O2D#$%/O'HM_E,OO,Q
M/.7R)WT$H%7I$;JE&JA2M RPXX%Y!FN#6*B*[Q1-1]GG>P\K4//Q954"3WA[
M?-G#<7"9!>[0^CPDW&>4G[/0]@@44*'XF!@!MOQ1;S-3>/(!T/0H*:0J]U#E
MX4L'DG8GJ QP\)'L;AE)B9C8!SMR/K]ZF?&T8ON=VA=/J2A$6 5&&/UM*D[F
M?P.XR BQ2+*L39;"OE.'(3F>W'\QP#%;0Q@3*,5^![H>]6,-(6-9CN8=>-ZM
M//A0O(\HD>R'^SW]*' >.,M2%G>3M>.LZM)@PGZJ8D34A9,IU:3A,<Z>\+(9
M:^AP8(%ZG%&*DZ>M7'.[J%]3M-[K$ '+QB@6FKQE_EW,:^YIX >AM,='\.$H
MY9#3."&BC51OB(R%69% .>4WF0G@P%?9XPYQRTY>AT +'Q46UY^!0NCHPWWB
MV,%YI?GR)D7FYN80I'V&.=Z)P4BU"W>CZ)5MP2SOF'%C+0:8J8O1%<^I YPM
MNLN29NXS\F[H_$S;=^D>+/E03'B8KLP:;2@@:N$F5Y\QG9X07X%S?$XZIX8_
MU5NH<G[GI;7FZ)[IM]/[J7J7@FOQ4'A7:K?4^;$(AK- WJFTI.8E?2^EQ;<7
M)H]-A9"._%84&/?.N\H#5=[J7U8_Z,S=IO@HQ=VJV.%^/\@^->'3X!:&&F06
M\ ^D8?]7V/^.XO'-WOL]-[05RHSC3;6S:/I""W#TTR]2.>-7JZV*![[(G8 (
M7[*_8SLQ@]J][]<I9C>2+HQ0U^I&J?-@)U'[H!0:?WV<!UR,!+GA=1EE^X\Z
MO;H**Y6&6335]-32\-=FRY:?#Z47IUA]BRUE/J(DS$YH"']<E)*EH%QZ<3A;
M:M79)^^["R:IF2/-MB,G$V$,&IO0I-XUX-C-*+%)S$N=FJSLT5ZS ^UJ$<1Q
MOA\Q3PHI.['0#&37&5&[A[(QG?>=9ABQ0%_:<];H3>'J2! 5:$JCG/M9&M@X
MKIVT^&P2F>-R@0H'(7 P2[737W0-GH?+#&.,O7_DP1U.) P.'&*:KA#A%W W
M;8P/]T<DM_HK$X='Y4$0I?W^G:I9EV@:CX""> B%#B^2@!N-:MCON#F&D5S
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M;U57?[096<AP/2_A*-BL<NUD;9GRY*H5J^][5V/8$428.@777UQKJF0:D3&
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MA.Y"2N]>*FIM40-R3:Q.FG\&DNX=,7?G;YL4QJR,6A[?4<0$K8>7T\D(\N&
M9>B7LK[N0H+J(B6_FT%DX_ >]&:;];8_O).,!1@FZVK_66_[&Z+^/U)["^>E
M-N(++ZHT??5U@)TUL'5Z4HL]OG8;I,(J-Z:QS@!X=7O8IBB_PL:.\174]#=
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MX<69]8C.?]3FXJV28'>678C"( J/"^HP=75=+2-=S#TCO1RA?WO<U=@@XW'
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M=Z7DPA*]N1XK])VYI7435X7L60Y#+I,?S66$O#\#/@YT'UF>;65A? 6LIP#
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M9V[BJ6CBU#Z4,2'U ^M$(?A+G$Z\ZG/CM]DT=_@P:\NZ5!S&7Q>)!LFXBJ'
MY--HS25)0IYS+P8Y#@U2)GHEKW?THGD($9-0I6FBNO4%;:\WV#^C5HV6<XXD
MNQ+1#241SK]P&" -Y2)?8B]JJP$-[#PU?Y]Q*F\)(41R,-]-W]:<(]^+&5!I
MMW6[)+G9KJ3E;>4A3=8>=?C.*U6V3*9-^_5NRQUM-S UOP+(8EX!MV.+J(44
MC1XX OD>6E."K(:IOB7?G N_&5=SL^%,6MQ;#RH66Q8.[%0]ER@)'K15F_IP
M=GR-']Q$+IR@L*D06#1E/@'N2#&1LV,,[(,WSKM@RO4,FY8I+E>JW$#MFZ\
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MVP@B[5+<6"-4[S+:"(^[[RC688U"4I;&!R8)G'<DVRI#I9E@%SRZX?-M<5;
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MOSI^ERGJ*^D[X20&_*"+B.P,JH+?]:K807VI!T4 _@!_ #L;0>X1\PJF7U!
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MLH6TH7^(TMI!IJ,I2_?[67Q(DCBJ@X$>TAT_5F69M[M-<APXTW#R>M6>Y <
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MQ2]%@B)O=D365.CU,?I$$_GV@SU\!)+7C"GE9KRC&=29CM!(^*$?\5^^&I^
ME0[9BQU(OX:YDA'&CXRDY[]FUM47C6/I@\ED+NT>[^*'>ME#Z;PYT9R5XSS%
MT=9ZB1(NB!*U9%E+APXTI.Z1;=MO/NJLNI,I1[Z!$/"(*!N,TJVP@QW3Y;#C
MO%3<\\$\GQLM9ZPX_B,BPVUVU,XF;AH+;SY3K[R51=4;NPC%1X#/2(S-:R8S
M[$?-1HAE[W"' OE!WOZRT,^'A8Z^8%='YB4_Q$.A@Q$)C08QZD<E3"E#RL8Q
M\QV=5$^5X/['N+W]SZCNS^=N$ZK)[QBLX ?1KY)_L92^MT6J:2C!#$[R4R2>
MB^&YM45J[[E; 9X+\J$'YWQI/<W'[_6=3Q]&;K)Q/G]?*_V)SGB))S:L"/]I
MO'KN:Z#9G*E,@;PCU78_&@VJ"X_Q+A2-V+II'J6+@BB[7]^V:.?R>)>H6,P\
M6 +N4N''X8US&%,ED];0\77F7)D%]=_KZ^X A9*P%P-= D[A$2U[28"9#@%\
M*%WS&*)AVI$,$K.TZT/ L@/HB(Z+K34>=$8MRC;7=L3.0J 0@/D'Y(,%;DUR
M9K^1&[0CF$%VP$-F%("SJL&T:PW@@9$_ :"#K+ ?\$AS"$S032RI<%&XG8F!
M( QW*D(?UWH_)? )#7BF<8^GO0JE?8!D1&^2K]]M+E=![EYX_7?0<5XU.[@^
MG26 9#J5&X6^12C NT?F(NG]3==IS@&WY=&#T2A\DJG4J/MY _=<L47>*%,4
M?&,99?GV2!)/UIZ 'B/S%<$I6<*2Y%BI! 1@^:S$18?"5VO_N52/R,^_95(6
MJ6[YA-A<W@0U&JC.UACV'6BOXI\DU"\&UF;( KBZ81Y1 E^U2.+6 ON48B
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M%]_0XH>L:?M#1J!8.I+X5ZV%7=X=HL<;4?'QSF3IO8U8U \>UWB25XP)KDC
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M;\N"IK_@0_9"Y-.N[T2]SRPF/U;66.K4:SO3'X QFWP+D\,Z3$',SZ]K''X
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ME;V1KEI2*1-Q8:/KG#YT0 X\V8(>V&<^E"Q EU*LBF',*:4LH, ,^E,'K7^
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M(WD]7CH!SP]G.&*62S>F@&DQG-/M.T:OOT0N4>*RV9I;Z0WP=0NHD_2G///
M%_DBB!D'=C(!SZPYW(]DV,I7@EOF##GF)YD$=<^8UH4PJEK8VI!S>?U_[5UW
M5)/-F@]2/P04+[TJX:,%@E)$.@@!!6D!0PV(U("A"]($I2A%.J%)D5 $ 4$"
MA":($+I I!.Z](X%$(1%U+MW5_8<=N_NV;OW[!^3<][W>>8WOZ?,DSEG)I,,
MJ]P-Y[_(C4A<PCD9E\EK;YB7J;O2IW18,[-ZWR3.&F]B[T2M*Z_$7YF I;X.
M$>/I1C%'KFF3UK(:LZ!ED+2ARFQY2P:M;N<WW#/6MJ R!P"I7ORG/.3=ZI'<
M6U"S*H&"KU2E]A(5I,&MZ&'TQPR(\@9!V(E.P9UAY&E_,'HJP$8*0HWNJB2V
MLD\K6X^%A%EK&\BMC%;U-\VF>MA[Q1I?!M*N -DW%$@CPV%S&I55EPM>GD9N
M=ND:EMY[Z#WJ7B^>%0WB^+2D16W6G LOB??9,7-A<\L;N-$++F-EM"%";OM$
M8(BL/^*<A@FMY%$&.*=K8DM=3-^WJMU0R_O>2$IIF-5<,).=A(C4&B/Y3+-=
M+6]PRO+ELSE$#[98 #ZOP1=5TJQB\RS"6>;O",L-W?F33U_VB?F2E[$&GSN\
MO5Y;FD4L[Z60 VG<AQ*<$A&.CSFOT.ZM6BDB'%*_#)([0\<]?*?"S.:6;J:'
MN".\U/X%#XF#B0N(IOUJC8;<A.B3N6]F[*2GP'X-BD+OTD5KXZ)SQCZSI?&&
M:>!7GJIBZYC(LS78] >D+%$1@[>J752-.FO6&X,;AC1/J[@X*S ^VPAT?1L?
MN$;\IVNGTIGP-.CN,G>(DQ,.C5GO8<(^)K&>F,4X8A Y^'Y2\UFR=[;$9".-
M$J+5?SSS$W9>4JE\W@)>F3B+*;E6R0>R<I-\_68&15H*];O=_F77TX/Z.5:L
MOK5'_$,$:["]=;A2CX;]PCXP^8M3)DZ1E8.S#)KP-H$FX994P(4=N]6HBO*>
M9KNYQ]N\[(B+4F!1-2F\!:>1#E2[++70KT5*K:?@F[DA9N?40ZV,G,!W?)_%
M]'+&[AP \OW:8I<_^G7Q[N6O0A[/Y\EU2>QM^K5%EAZN&672-S,G;TL):/U\
M0/]0S",(JD*N?_&LFXO=U_--<]SY< "(9SPM\IOB<ZQA= _TEP:G3<J^I_R,
MVC&(QRI"&CHB0G]R>[XK,_ZQ]0 @ &8 9F;]>OC)-?6DBO''*7H<0SS/Y%@+
M:7_CJ#EI_;LB*.AW/^8ZE;#3\P[-'M9DK1V=GQV*&"S=]-)_(*G^DCF5_DX\
M+"CI]]XF@BW'A.L8/M+'\,D^CL_Q5I\PKIK'9<K)$0V."^$Q[G$[\<N36_A[
M7"$-C?]U0.G0WSM#L<O_JNCYEQ\V_\VX',J_LO$X,L>D[:D3Y_SO9'3_SGEY
M0M^LGC0JQ\T#W>,R0O^DWOF[)O6)"\]_,"U/EO+'5M'C2L>Q<_H(T8SKWR8/
MF(%KCV_OKZ_YRE/K9E+N?X^#&*=='4VLLW!%[\UM'UFPRS+VL  $/UYURM=
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MEX#\:H3O\\V!G)[(;'G@9A8A"3>Y\YY(IHR8]1#D(3=G@[R G^(UN!<#9RI
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M"!8E <#&T)P]"\*0)8;&GPGA?FHO 52&'WX$VC_FP,H-PL<D:L'NOS$,F6$
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M\O%GV%#-<>7NL>&1D)L!+#9)#=YIMJ-J87<?*8DI.#KMZIW1?L/LPQ^ZAC!
MA3'7NE:/\E@SEZ5<-"4Y:!9?%>7TB0JI\NBAR4I9Y1C+RRC2(_T-(V-_A\4E
M"2#C?+GP;\%*^_(J<@<@G53&:,C$0OH$=9P*&GMW8+Q-P)DEZ)1P;O)LG+FH
MG)3IS%AU+CE2BL\".8AI?+5M@/D1O)LI3_J1"KL@MD;&8(14MA ]4%IM0"Z+
M2.=$_T6^Q3UJCPXQ!G_["P&W(D2+AWQ1N2.N\><K*Z5#G %%MS(5#0-=2VXU
M6!PXS()S<86+DTH8=,W;#$6KPR+RE@XY)5(1)=A]&5^2?-X)V&404QL[:09U
MYP<A H\4YA#EW3T=KM] VFVW'TOIJEHC'Z_'\F?F6SDZ>^(Q--+?5S<1&;)U
M3EU+W(/T.'M(Y,C29 J#LZX.Y]<PIT]>WCF6-I8[$U8&5M@%QN,B>G]##5-(
M5<*@J1[\R)\'R9JSL62@?@_QH"J7S++A)2*>^I2\,2G.=U/ 3>OQZM?C@\!S
M8=:UER#R5L4Z@?F1"0;S<W<"[]7TX+^*[<XC%8$/=)(TM>BL.F%OGPE[01F*
M5F1:(VW]^ H03C32=7&2TK1QCK].%8!W=&8U5JH,LV9JEE;$.":K#.]PD$L
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M2Y*AX#YOS.>1FM*A=G,8KU;= Y:]N*N/55A&0--JG\Z^_*U_QSXV_/8F_!'
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M>8NK>_.O96MAGS^^QU::Y/*1G,SQ#+H+\?=JBOZ8.&LL8!F/L]R3J[8'Y$R
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M+2K]&LEC7<>_.O#_&'OKH+B>=FL40G!+""1HT. . PPNP8,-KL%AF"##X)8
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M92&=P4E+'U'2YU1AO]JN4+'JLUZ'1R^57KQCSB+.G?TA>O?ZR!5LA@6B'!5
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M]LV]@ KUSS=.<>0!-V-T9=YT;,EB)#0*$H"+Y[*N*P.^J[AG,3.EYE+I[&)
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M>E3PEVT[%BB^:9Q^\541]?_[9V1,::S%M.;(0ZCF9QS;ZZ)%(4]Z"9I="'T
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M7N^5PI\8)_A_N.S^5\N?_G/HXN<LRL3ZZX7,' -_I5\V1'GD0??GN)2$^/!
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M4F(P^ 7?"F*HJ^M5@4^[R\:BR?%V$YZ*^&!IKN=#5\1QP=+BOD.X(6-P3*=
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MMTO8^VTZXV038GG#SMY2G9!OSIIE&RI)ZJ1R>%@"9PM1>BB"_\K 8D?2_)5
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M$/@>+TCWF\0QZ"5NH\!DSL+(? '1-FO;3*IN:=N9UDJ^199O'\,E"A(_9M2
MSXVCOOLA9I,JMTSKG'F[6[J8@N:9]1226O&##UCN]6MTS!"L4Q9FA\V7=@ZC
MA,_V&5Q2&7_XW4P-1:' UNY31GT^9W\I(+(A8/6ZUOK1MUP!$9;TVN P'U\$
M8K4NQBWR_(. JSC@IY7]KMW#T2':CX0IIB>>YVWF:D!JV?5Q2-!0BYB^!%<N
M>,G#]-J'LQXL99\%K<X^L*0(KK1T&$0M41;F=4=V]HD>UJ];Q4SVJV]$I]8E
MNY)4B;^P87@]*_<T/$0^D_VQJ-D#EM=TU$[>LXF$3FI!\I/RO@;G[/$^>_5M
M/=62I;'5"ZFKV=.*':-!O2_G5B1CM^SS)"F):Y +NQBDAL>=MK"0*2NB<2^4
M*U1<4]LF+U7L!JHL6L'CH17.B*Z3=9K^()>%)KD@[T4$8U1EJI#O'9'O[Y<T
MRX.T7RT(U7G43;_>*-\DZ8S7J+%EFA5_D\YC;%DZ!+>M"'45TC%UUZGSW U[
M%K@CB[S._=B23ADWDOTI2Y1)]FWE$$@:8?\"D];C$L<=B:+JLI Q.9\0[FCJ
MZ(MB5*AG:M\:L,!81>?HX?;C6ZD@"+XPOM'F"P[PLYA3U?I$,,.A$&P6.D)"
M&:N$-IQC4)&73J@57,XW7]2"8EF["N6K5L;5E.0#R.;'BIC7S8?D:KE<QG4S
ML/M65U2K2GS52RR0ABU>6@JD@DN=&E!J CA;VC?F%S/=S ]?.I'/^1BTGV-X
MXM(L,/!M4;(^4%Y6[)VZ6@#&>V<)/HLE! 1.1T 2<:6::J,+9!6*Q9!N#J31
M[/61G;U0EB]240@=,*X,V59>4CY[WLJ47K0BZQ13!1026# EINEHF<OQ==Q=
MV[[:0??KC>4;78K)TY[]+-* #9STP=:;(#665H)UP4=]H;\TC:9XY X1PU?>
MEXJRG%ZWT[VET U$K&=P7[9/:&]QN*JI006#70]J//O%%57C'+.='PU9%Z&(
M"+K)2:HH&LM9-RHD2YQJ,C)21S_/,'U*AK/>^?$.#?95N ($RQ*"Q$B(B-^M
M#ZC";^8)(.<4?^RXJ4NS801E#=#L1&(4\(^ "[!= L];, *6"DXU('6^8G":
MHG]Y2>??DY"K[P !"3N)O6?+V28\_=!0 ?-$_4$^!GL18<X^]4_./A<WUTXN
M%@5,D%,/K](X^!BI]=/R.K&L3LZK_G*8]3,7GX7%XJ^Y?_D"Z$<XU0-_)D2<
M3$*E/VTGQJG+VFB8XC2#KS2IG6=&QR8H+#^F&M\ML0[G"7B,%!17>-DF:1A[
M3I!SS<UWKC?O3C<3G9''9#6B;ZA?MO!2 W86H:AEX6WKE+LY%D"<4##/6+O7
M:%TCX\OUG]N#YR")O2[FU6$!S>=7]>!5%:L2&K,H#@[^\BEX4]?U$M0-2<!<
MTZ&5BM,8&!@G9(,*;%]4XS(+NI[YIZ81Q[FD(,^8QSR]0I;XK3DYR D!4GF'
MGJ)'G&.&<_G 04HXC4@<7[@+&#2B'K>A&#*:D8@CNB#08&E1#[K>P"UW7[+W
MZ1Y"XXFFP>-5#X])\MRP"1)'P;WN2_W3EVK/>%'8UZX:!*<E>3W,Y@WZ/D!<
M5FUAP;]AY)&F9&+@(W'M%;[#DF*8<%?G7(G#%?<7W]Y)E7[SF4Y]Y132@S5\
M57WG%5%FRN?;!]:[?3?R+VX,[_;-/>7N*^3)6/TZ=RT4)[(-RZF$/;MA7"PM
M3,YOG)-YH)_#FZ.GLJ)("OMYNQ.\.GW(0%]Y5JXFD68, '5YK3MKBM?3?9OE
M3#;.)F]+R5A*KH$\2;EQ,;VM4V=GHV97O,%36Z$6^6;L0-SV_.L7IXERKX<+
M/<*;MW[35R)(/=25J]HJKI"EJ8GR899*=;$ILV+GSF^BU)CC;5VDF&Y-DG:[
MRL^]<J0-JZN,BMV^-E<3*0HIN":(DXG<TV6<Y'"=;#FD]SU[2Y"W6T^A6T^:
MWN5!&TB)DZ@OEFRN+U*0@4*-DP7D-.;[ML>,'L$5W@8"NZ6 7S%,=V)W.SIU
MJ/3L*:EAC<6$$1[.4T% JPCA+KA8%.B/O@Y.WX?# H>?Q^/59#HOB#%0FLD>
M-$ N;[".0B4S]'DT(*RCUJV/E2>:G0>#PO._=M#C\"Z*\UR&%8_%S/9128VF
MN)SA;%1H5ZMX[LFJ>+OV6TBU5Y<A_\O'O#?>"$;PBNE3LR%J<1 S438==,YQ
M9%'JPSQ:Q*FE@'Z8=A&C6TII8 [3_QW=%*S1B?V/W:#\7>:_<IQR8:Q:^.>I
M1,"24?Q/?RFHE&]4K\2#BB<3MCI[.817X56_Q99%G?)/CB56-$Y_0*?O59SR
MEJ^]R^*8[YM/V4Z5;OJ+[RKXQR!B=0G,)A$VIJG@/_?_K^%D&_YL)!B$TC"-
M^=?>*4]":B+NW^X1 8SF:D1,6">6O**L)T:K)<:EGH4K7;:X]YQ,=)X^-#87
M9]762#ZOHW:,\(UVI?R<SEW)Z>V<=%X25TLR)V$\WW<T-W+MBY52I8B8JF/.
M<3A;DP2#U *#IG+YQBXH4W2R/I=(B<"#SFS90A6;7X-7@JC/K1K90D-L5OS
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M9_4->-][^GVU8K,C*#)@CQQ]5ZLZ^F@3-\A0\KXRO2+HR1HAWIPV]9Q6S*2
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M1S@D10*SW6=!"A 8C+T,M(;G0D%R!/ LM#B-PR&=-P!B*7!/@*O^"!<#Q%D
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M>I#N)&P [9R&C<':R_#@1,Y0MP-&FF4.ZC:@MGM -:'[';MHV,=J8]V#I22
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MX?-J@IL#^NA*0)[_ LJQ( LD_EI<>%EYW@+ JVMR&/?^62@FX^*TV,<OHRE
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MN![$" (1$!&<O$"_7P1G",\2G2,^?X'D(C"@\ KH# $AX9FSA$1$9\\"4"\
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MZO*H#O4K\^M&1W'LWZLB4HF_UZ<FY88NRF">=>MY*>I<)!90&#+J5]78Y)4
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MGD@GZXPGT%(-$-ADC.,_9+N& QCX<>LO?#?_H_&]_LAC4"T,$2]S,D?RP0N
MTI.ZF"VCV1 K]WZQ<6-=-84+DDOF="1S[70DK=D":(KZ?K++410E7_)$%QS#
M=_MS%D15/9["_&YC&&9KHZL>7E6,6&ZU.A<JJ'?KS7<T87"JT'<7F@W&#1'W
MG7LEGR0>&^E0-$\4ZYH_O9' N,B(VQ>V<Q  C*?"J<\G3A]:=TZ<(0WCE7S#
MMZ%YK_I'EO!RX"<JFC26^T,J8?/%AI]?K=CKMOG:$[H5E%$1%NB2MW(%<'\^
MNBR%23,?["H]!KW2EFHA']]1^E).1]+;Y13K?Z!\5\9;)-+.CJU^D4ZU=*BO
M4@CZZ> R:NIAC&>O8&0(JVH*O#(UPAXR"D-6?W1.V<G)]="DIKXT=OB=E/N&
M,>JI]8F>.F?X\1Z#]Y3[B>YF>;DWUTR2YB!W^G\(.#*4_\VGH, (DZ3EO4Z@
M?0*T'9F QE_\W6)^./)*><"4./)6>;Q3ZCLR5/Z-@.QO1#P!$S30X@=4_X<!
M)X _ Y>N_Z$@68^W>3-DG+='JOJ.^JZJ,YE=6_2GA]\]SIVX[2C>-UV/08=L
M97ZG;O\,_9M PPD!M46\3P0C:HTS#KR=$E:C%J1_QD$>U,5L\^(AG2>#UG[N
MJA8RXEWNM/GWP1 \N/VT/QQ'OJR(]VA @5]G./ NOXGGOA%8M7P]7M5W(./\
M^$;*A]3L!R!Y] ;Z-"I,FJY&X]EB7(VQ!AJ&+WX"2U6/CD%NB#NF HB*ZCC7
M]D-VVN!3^=ZF_I:O'3 @0.*[Z2_^61-^/.2W"O%M]WZ%S\?MX!-LCIB$4=.V
M"C,<Q64\>T"C"C0+ZZ2./P[K<?LX)[?W1UN'BPWM <[\>"DHZ$_AU\27I1\A
MO!!X(^SCG"=^KL8LF/R,XSADOQ-=/*N.)S!8\7<"B'&!GDJ\F(+XQE0OQ#&^
M%]!0==R-[H-O>_U(1AKK4WSX"7[7M4*I@N_JO_)F%4\YU,)1\ )3)WE:9!:S
MDDK-2TK(9#'T YKLWTBW8$&N2XGI]6_1*(9?X8YW$UFX8QECM>8V2;Z\YVL!
M=HB*^^;\Q5/!JTCCH 42@]ETPA!.:+2^8=SJ00A &0//;@OQ'-ZTR=+WRJ^C
M*,[?QCQKEU,NS,MO#KH2/EBI^B61_H(LS4QRR5OA-=]/^B%G_&XSJLQ%NL0J
M2+<*5OF,Q4H)3DBD7JYP$+3Y--_ J")W7X$[].LW1]<&5K[QYHS!"396X7<"
M"[6?/15S^$(?=9G;/5SO#[(V8:VJ<OC%?9,C.3_7JM.162M_.9IV.J[H14LZ
MPQL=;@3U?$'K-/?AZ-9XH./S8>PZQ4IC*'L<Q#5HR*_2R4N[?3!!29%+Y57H
M*^*./NG*B8M>M,,?;LRR<"-G) DPE:T%LL]_> W0]=-,'&FJ+NOJQP4-Q&1\
MR4'+_YQ^+#YG6KWKDZG,[7:O7&A]32U_]U56'7C#0-0BGCMX+("TIZ1FIER7
M@9TO+;U\%U%?M/^=.[_*TQ'U\UP%11UM]CPJXFF 2^G%US8C8W:"YW_VRF(N
M0:65+>WNZ[&E1>LLU'@+IZ>ZS085+E9R;9_U0Y/!6ZXX/&[1E;KXQZ _ 8/*
MXRC4U(L@@$<(]P"A?&X_)Z"R3*KZ[S:'X(<,;:0"L;I;"\@+^]A7?8K%>WB'
MFMN@.%C<ZW\'Q'.K3 ]O)\1I4Y7+M-V\_4L 4E4=Q_ ( 2R2-<9=-1%^_/H\
M;;*53$881@"_P2\/=?SR8 &615KZZ?*(3\<O#ZS/$'KH[]Y;CQ@7PC,).6VD
M@5GF_C$+L K6^'?O;4'PLYPVV4I295+%?Q=7%4<A]5N6;YI DO6"RRYW+E>=
M\ BLH75@#9FN?L"O(<;?C6Z(UT.&H;]SRH'G,/64TRA\NV5%W'=U.?Z$B/H)
M.ZYYIRM(\9#='=_TIC#JOU\V 0*&%SY@X!><:_KI$)FUOV@P>YB>:#S\=!Y\
MP @"8%V(6C.\5KW@<OLM4NDG0-63X&7"BQ_R.Z8$G9!Q(^Z#X6,"/M>^Q\=5
M_]_8?XB8R&[%Q'>?H./M"X3FXM-HH7C:J"ZLD^74 W$)S^1OXR%V[YT:[[3)
M;C8U4,0"Y*=/' "(&P&(VH=XZ@E >,0K32_$ZS%#Y]^5)O [ZG4!KO(0'^=/
M&6G]6_#Y0^1W@Q^0$=_^]P%_<!&UIJ<DY/9[U)^,XG46. ]PL]B(.(W?$"":
M!Z<#>I^"Y-[=MIT_2:;X()5'"UB^#G9:W53#I!. 4.Z_:"\5#7!)UH87&D@6
MU;NJ6S<'3J>)K\-G"R\KAJ83E?W6NQ@@C<MOO>/;KFT>:6RP.:",NA.!@8SK
MB",_NKO-",32D[RG/G!K?U J_+OI/Z8!<I(SP?Q>AZ1A1H(ZH-5/^B7Q37_$
M!2HY>H#%8MBOX+8(UW(-P%?O\)(MADKYN<<37CJRLFD]Y)_@+E]^<OWQ7%-?
M):M33NJ-&]T9:6^KAT6FO $7#9FNV<DS0I38-!^J'X-N#@7G6BE--G$G!_KM
M]_V]D$>7'X,,#>/E=>^*9#X&-DC9P;F/=7-/2_E;?EH\6\(:[BC.Y#N^E#!%
MF#/)IAW!,:A9^A^E/-,>8C1G8>G% \0[%TIR8CC7VSR)H?F"EC@=1Z-,4_FA
MB%*=;^7XRC3E1#MYS AJZQN?0$U];]=L<?9-LX9</%-1?."M$;R1NGZ=Z.Z=
M:Y[&J8D*-( ZDJ'AO1FS^\KF236!=UFW:X=L*$"IJG]5(_I>#AP8.SQR()Y.
M?RC@*@89[F3X@D"$3/:_&*&''Q&-+XTZO)T\J!F-WB]ZX%7_.^E/):Q&+C#\
MC+OM^OG0!;"D<N+^IIY\7S$93+6L(E72*H/SX/U>;W.%L[OTOB+2I#70C+E=
MY2M:I'9H=XYQ:TBQJS#W\'':MY==&YNIS:U1S&297;1"/L@DFVRX"2(K7,1)
M,/X-;=2'K B3[_;)85$IN< V)NL*%@:]^8\OFX%M;!=#Y.6&'MUFN"Z)U&)(
M[Z&N0Z>,E ^A=O) ;'[WJ'51D;7G#[E0HRKTQ YK:ME;TU]Z_"+#.ZQ83&M\
M8Z)*K];-YDK[K)'[]7L8@F54VLJ*PU1"KI#DF%,J$^E>KK8F^X07$<>YZ-64
M],1""A!LMW,7UI1+"]+4[((E7OAKIPEE ]%G)"-?7(^;.[1,]G_I+9P02!EA
M!&QMUX"_@)WIN21E566%5QDB-^?[D"KNK!+T'&_RU"KWY>/IL[MEF\_J^0\,
MWS LF6D316VU\DT_RV$.H8LR0DUG%/)>LR*['U&UV7\[,#@QQ\_LY9KGCYX
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MLD1?!=;WJF8KR96N@YLT)76^67P[97&(TBCV(I31EQ+#?1%*"7O^"5C1T%J
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M4].H0ZKFKE-QP8XD.0"<8\&BE+1:&Y*H#2+0[") PK\4R/Q?'O8EX+0\/2M
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M=;7[-R;.HJE;R"1GMS"D98S4)D=Y&I9?F@.SXS$MULVK:XZ:L4"LQUHP#TC
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M=RMB_(G8X9HZL&P- @$M:FV@%S;(_GLD(1-K:7911$_ZK,PNJBZ'<Z]SB6-
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MT>62)L^1#%8QT <B?!4<D:&B17Z2,/1'VFM@K!8)$*)_F;;(#JI2!#)VC"
MYD2+7\SOD^!G/P)!M NDK;0G5L<PD.2-,89)79+T=GBJ$#]O\:9MX/=)M^:B
M#](;^Q2\?O4!#$\U>&RNZ6?WF-&R4&5C-=L)Y_=>V]5/"T$$)/LK[<Q'^:L3
MTXS[YB+)='A.'ST^@#36@)S(.-QOC&#/01#247VYY[ T+X 0#=:S;Q1@K-%
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M>/&,-#1/>>-N&KH?JB:(KTBH%VR_E%P?+*K6=7KUSNC1_6/,GED"/XS@-U*
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M.[=SJ8#.MTN/,D2#O6J+KID) 5Y7L*"1!UF*(X1K$PF=",F/:F1N0LH*(_)
M )%F*%QA7Q<!D!(2'#'VT9V)!3A#M.37,,29B[& 9N ]X'W( :B<<!G2+7@O
MN+"UW,UR&!@(PE$E&_MMZ"%A*S9][Z/F3,)Y,U?#.;35Y$%&X3__QK2@?&5"
MW':[(MU42K@#6/?A*-&:G.^)V56?*,,TQ/KS;+B?_D(X-^Y 'N,P9[V& 69W
MQNWBPIN\B'8Q@C,I44CA.Z/>YR(T@Q91H9*:E_W4:- @X]N<]8!F-.C)$3I"
MXX6T;A)*;ABVI"Q$34R-LCXQOLTAU"M/FM8C+@#[.)&!<*04EB.-4+.&"BO0
M0N5R)20T@._N0F82K?T%0F' Q]QK%9>;/A LH=PO&VFODPF4QFM.:$WG/[&[
M10;THLX@Z-O0#"YOE[9X8"(5?/W>=D.FV9/"-]$^L()ML'K<^)Q##A2JYS=T
M8UR&^?:4TO1CD3464.?* (FZIQ_'.(_6E%2.3HZ2"54T2WG9MA<56[%]:C@N
M4TB@/NFE$$\LY7KP(J)*?*7-L$';5%NNHZ0NY[&O\+D V!"0W0D%D-9. NO0
M (:%J(F4<&_4PSQ7ZS5O[C.5GMPP<CO*8!IR9R_%$2237&ZY%*6KW:L&AP,@
M&AIBHYV89>^R#S"&?NDAH0W(-9!?#U_\RY)U#9TV9.HYJ- _#H@B*< 4%! <
M%,R10:$E,@?GY_B,Y6B^$10FRB9Y(2J4E\U>M8 !G$]*N+,D+EH:11;E 2VL
M^Y-=XG"XP VUBW<@*!V*+2'.Q=%,8QH%W(77>B-$Q4-7E!8S&GS4HH> 61H<
M8 P18X1:MP",X Z.5>@U]C(V2@F2 [4529V)._\6TUH;XY"$NAKZ"A_+D6L
M]<6Z6;-XB8EW1'R+L21#8J,H@_;UO@V$&!,3]ZAVQT9'H3Z/!N>:/7I\U-[Y
MR1K05/99M.>,S?O20U 4I-'=[W):0'$_:$OBIN,.K'Q6',JVP>'4036"&!D.
MV=7.*WS\05@2>7"; W9M1%H7-:10H'NO(3HB<%U$U]. JL26S]Z2AARXI0-K
M15GC O*3H%0:1+B(7I9<P@CMD9#13$H 5 ^WJ\8^PO0O?[W[_\7KZ?A8"2V0
MP,3X!R#Q]I?O*SXSLH7BD/$\CTK1VO$;3RG"608.*IVNC1E?#Y,5(+OE8U:N
MVTR3X,L_Z9S!IG;5V^VP]]'L( ]58*)PAZBI6#E4V>OFC8MZSD1(Q3=6EBNC
M!<DL%P/%NB++-DUSL;*T".!T_7<3ZDR&DH)=/BUN1<./I/?2DHHVI&PLYT (
MM< ^8E.A^MG8Z"Q+YF P19)&XG!B4+1S"Y+O:F"F<T"%>VMW_?W6(_8[D^(+
M62K7?(2;KIT^;TVR:GE;-C=]-\L<E9[VTD3XKJY2"F%Z[>/^'K!.<XG[.Y<X
MD9Z>JP0S"A.F,>431[LS;,&!I,O;BQGF2-/Q]$,(PI,(8%)+E2*(R!FT*&A,
M8CX8TO=;#.-?BN<.#.0HHU^%RXCKL/!&7B=O-5@I:QB1F_ T3)_B,!">IC(Q
MUYW\/JFHP:<71P-P:RUS QMJ35WT["7C*#OW8K,RAGSJTB3#R(?TSL4!O;C$
MMANDA=;S @BA?$],;,-8%"Y'XEG^Z=8ZYIG--,.0)3QE8.]1$B(_N2VP;(8F
M"U3;[R>5J)/&PA"@9M6Z:S8=H,'&92QJ!7Z#'E]P,9VY\3YJONG=Q8/3C M7
M=Z@N["6$;-R5OW4^?EGK"87\EQ)0.=,%F_1I&5&-=(XM0S)<7DY7F=<J^?9<
MVGO'C"Y))51%T@U'X'[$#<?&I,-H%2L2VG$$0SEKNDEWQ:"G.W<BC8;UV%WU
MH\*@>5EM.EWVB;L-.W>UO><M9Z<6'R>VA6R_2O5\IKW&?AN$TY/0N6NQ)RUF
M5BM)A@?+12>63BM]T=PDOJC"3\%TMRY=<R^KPU$%@JIAR-RWTE?I 31X@T&6
M)$./E72.+XA@6K>Y@DL:.05\A+7L V?N>6(EHMSN]4IMB70=,R0G2*0$!SX3
M# -];35+CRBI8'IT/:G!T;Y/JA,3=OXZ:&HGC<:FIK']YOJ1L8UN(.CAU;XV
M0A&$A75#KMA CHCL.;G%6.[6*Q)*.C567GNS@X([QY@Q)4T)+\;Y&R)#?0*U
MV"'Y]^U6T5?[@.<(#'%.,3O?K\CNB1+$X7//[;;"4/\#PX ;XKUN*Z!7&W%7
M$)"'8;A6T<\_ (O6?:1!&];S:<!8S^*2^ C50-Z-JS 9$4NW/?C*@-J.8MJV
M#4=E,_M,X S;BMPPM<O&Q& #DSI:7GCCAGBYX%.#&6#EFV'R(C2U;NSB5A]%
MQ-$%Q$9%9?+JNV$[G??<(KQ6P>*82ZW%MJ)-8]L3\Z\<2UA82@*(.)>Z5B18
M@8T!'DM$[>9MSY&ZLW8JTXU7]([R.Z=_ !:X+5FEPWN313Q#!%-N8)VO16]&
M7*VF"EZ4:9@%^E3WLM\P/TFQW>B[VV K+U#\H3@IE6=>,_& VRAR1_><5KDY
M.S4V0-UW/JDB6+9F1H--FG09L7GM^V;P4MPD6:&Z3Z'4VR\>IL-O<WU%&^:\
MQ"D@D>;/<7D%RGI4.1<:L\W8 KV+B"NTW1?]'],[V)M'4CO-OA9($:MIHY=W
M$12I?RO+!+^9K&7GWN"#*$C$@B:[-75?BSOX2B-%>O(6U;U*'D[1AY@KS.(^
M?TNF.+^SG%:&2G:99T(Q!=])%*JEJ@MX;;V?"^>+CR$-+I_<A<-]JYOT%DLV
M=FWG^4K5+3KIB2@Q@/.]1\$5RTZMQ5 S]8#;QYS\",5+\D8Y>05C;=<G]:.H
MWF=CG_C?)%:P)'S;)RA'F#N:O5(Y>MVK.BJ2<M29R27J<Q63P2.JAI>1));/
M=@6G'1I]J!B?YB/SFU]5C-@,3HQH55I5SC3Z40\F%+[B24E_Y7-8Y,QT<V77
M!%W;?XM;L-#MSB5Z4(:F?+[SB^\BF'*UH3 "K:><]MNZI;-:_EQ)-.0<)*PD
MTWY&NPJSKU=ZV519%@NPNWQ^4!"&W-ZG_K R9)6IYCFMF"%/VG<ZLXH*WO1.
M[0DR,^H7/+'<XPWSHGY-%?71-_8ZLXK=#572NWF=FH-[W3RSZB02 EBE]V\S
MKZ*QD>KH>8D>XB(  DHH]AEZHIU+U^89+N?V01KYYM%"<;:R+/=+,@[RBF>'
M8@4<39A<_]SQ<\)L&'%2U 6E9*L?@.J@SAU]S//@$1-_#GT9+KKKFRS75B/]
MS!W'J'OCJLZ-R%\3)&.'5, ):>DT/=^'YJOW,;QANL#DES_QU0S4V?"I<V\0
MT&> I4E;NN8OW)@]HU70<2N[YG!* O3N/(?N0##O3:IH:Q2BPW6R3;-1F*HK
M4KDH9!&I-;-0TLP5OR1K?@'D@5_]$H:,]<;GA<I:13]JY#YM7IZ\5 XSEW2G
MF[G^8"#1RY&,I=AQU.O]FXIMPBLIPE^^VPKOJ;FM%6V8KQX;(#=2<_U?RPR[
M<TJ[N_=BL0W)+M?Z=39RZ_;JWS184Y<A]INA8;1!D3N+6GQI?')L0-2 9.Q-
M-W]&6^& :JFYF7XZ0$Y.N^,/0&>8G,O3+1-F=5[E4O>RDKOJZ @@O::Y^'ZE
M:"9K:G^^[-,C[;B(_N&7B-&K/*T*?7=AM9_O>>KVV_.&MMXY+J7=)32E$JY]
M?)U,?*9FVV.'+%(BM?,T;GJV,?NPJMCB^=>+4J5=LP,TDD,TY]LCMW9 IV^>
MU<0L@$^Z7^.:CW?=.DILK'0O$-"]SSX,ZUSOS[<2%3;F92$VEUS*$@B3%?8\
MOY/V[.ZYB;LUQG54=6:3/1/[0SZ<G4H%<S0AX]Z?%WD+0VL6[#&(<'V?%%A@
M0$#Z7D^<K<O,9XXR=_-/<[N?'9D7;,W4E@D.*FYP\TV[S2Z22KQ D=&EQ&6G
MO=7PKGV14O+%TL]6F[#CWNZLMI,JL7.:,GC!ML+3B\D0 6(F '24KS$7*M8E
MO5$*2I_T));=6:&A@(Z,M=DQK&;X^ZPD3FPTIV;K>T\&X#9"NE\-W>*+Y;M?
MV2W36KBQV_"HY#5UV\,]<#*S;XAID_I%-[F[ZNFP=-B6@/!XDI7XDEQ8-7J<
M&+RF&+"69,G)69<89&N_>_D6WR=SU&!-76],DE<%QILY,2\X[^JYD*<MX'C;
MDX-.SV71R," "BI#8$5/0SJG+N&+S$F&O/9W1U5I[L1)X*CCU#=E8W[YG].I
M"F.TF5P5@3DZ7ID: ?ZJG]()2I[:"3=YN-0]0&:[3V\[U*5-LWF98QTVWL';
M)E1&E[6*K>1NRM2]+Q.T<;H1['B3T^5&]8FQSWTCF]H)])*Z QQPN57O*P.'
M6<%(FS,J>KH^739^/'15V3U[UR5+IK#JZ+5P0?P[.754SLN B1ED^5AHLD4?
M8"5&6(83\B%@9GLY'675S^YYD3ON$JYM]N5,_7>/D8?69=+TH0J3938"'A@C
MZ=-:LA7;T(4[VFCDYET]BJ3=M&,9T%Q(E%[?R.%&?6$;';1?8$-[ )DV![<5
MC]G7;VJZ+63/=5F@^JNP*_<#HWT'>[U>%EOLD\*-0!,K]Z1@C]9W*WV;."PJ
MZGH9*GX7\*T@K3&QB];VS0Q<(3.D,(<#Y]-VNXH/2TAR"CPRJ>$2OF@@.O95
MVI6C,HD<*16;T!*"&' 3AD$]7DTJV8.R-+;O/@@@BC.S+:D,K5*_8#>M7=T'
M,"O<3)<R7-Q;%8#M%9Q7WK3J.=H6?,"KM21V[1*ED'5IYYND*P\K#N(OWGW\
MR,7(%+A_XT(O+H_PCG!*H/Z;C-*IUR1M3+,&O''436L8UP\SSX_*H-$Q6E\Q
M'7--0QXEA3M@:1DEJ[#5>=AQOJR@8N2QLKM!;\^.1#++-G^<9.=.^3>=&7C1
MB$[78&GPBXV)\L^%.,-M:IG\Z&$!ELZ#O&(+A@%;_@DOU<;(\DO5<KS[5==P
M._-+>O@.Z/ZE:P>5BC:-:8=:EHZ.5ZK4/]I,V33(_0 4AN&JLUI813-MCI$S
M,[L53O7)VO(],]B\H!=VUJ'9'\BBISYQ-JVUR:J(G)JG[I0E834-H<^+NGTJ
M-S^]+;]$K^E]K5+4U8!#[\N3FM"E![K3%QOJTR$7'! 0UZ685FG!Z0*:J)UL
M; 1QW><PT[9]SY5$?0%SQQ3CH!#YM<E*+R@%@[-'_"LP'SW'-)3:-^RSC@2_
M.YP\)?+QLKDVVM8BY\*P\:QS&87CNXC2]*,Z\!*'QHS C'E4(_*@Q31S>_%I
MIY-]!1% :RD/PT\#$9W+,=K=PTPCJ (]BT@R,##PDMS-$9?G=)E= 6FO!9K4
MB5&FRXEST%<":X(B1>RH.4]AU06ZUCMW@NF>U-4C[^"6(\QO9GR.D.A0F!IT
MM&N[8QR4T)5LO3[RBOC2(Q-!KI>Z#"D)I&]+HAM3-QI1D:*6^/D)L[.DRMU*
MTGF8&T$)]KWR5?<L>9YD60+S!\K4 =<P?L]HHM&?OM5J15M<NBII<[XRF#^4
MFD<<"#'^Z]2\5$IJPO#SJ,4VW4MI%=.ZW\9PK;;8WLV)"I]*RYLL:++5%Z6:
M#%ZF$UC_YL9X8N<[$_'9I2U>$5Y:<U;A)!J5<!_Q6F9'CZ0I4]$REN<U8M:\
M+@)SFO)E(RL&^4F^J@ROV'/U/7G0[(0A9I%!T09%1\8%U$\; RI#3KY@@QRP
MB)D;SM[:-Q?+-Z%W)QHV_"A3+A(8D,)J16?T<(V[UTUL0%;D';SR93,J9=_R
MQ^[>)_;PL_:<2/+QI'S-FG,Y/(AA"L8H,#$HR0PGU=?5Z#0QKF.RG)C4IXR@
M:OTV(A+]X*%@VF-==Q&A'0WS7>7RDCON :66CO+VI/K:C/4M\6V)F/KBP:97
MXJ!$@X(Q-K_%8)(QC7/T"D6*&7DE!S\ %T(; @WY,]PN##G.OI5- E5KWQ)=
M\::L4+VN;7L"/V>0VS/5=P3:BOM6,'KK._V&L[92F26;.QU^^211W5)_KD,G
M38Y[@BO&TT;,ZUH><5^7\QW4TTY)!;:AO@&EL7'_ ASH_EJHOKBNV2GU%AV0
MW^XYYD9*-YWXGE6TH)^3?,E7L,N8)6A=FL]II=NW&GZ%VF4RKFC0=$YN#906
M65X42O.D[3IIGH_7^<6+66_C755C^S.6HP=<BXOKAQ3N9,GJ]A/0ZSR09Y]0
MKCH1"W-)GS'S.*0RS<NI+QY=5W!!<Z)OK7$?E<<;W#&=?(_4#<4Q++0KF+ZF
MA?)C8^@HE]=(Z_R#G,/H9VOS>%VM0T5,*V\)ZZM9O:/_EC4AQ!TLV?O*HMH.
M.U]WH1;DK'JQU*,?_>X)_Z-E,X^O9::+^[>P_FD.M\WN?GUE[NPGDN*RFK<8
M';GQ'BG+3\MGFJ78I1U\X2O&!EA#VAR[SF7XIB@99JOA%U%OADSS9"L_IB!"
M*SG[*I? 5.'&1_P_ /<;+&\\KKC)S>X%M-NL",W7%O.Y,N"MH9UG5;M>6Z9Y
M[68+ E-D-8ABF*F579)\T=N,OHH1GM*_ GF+G@O^5"<03/JDQ+8@Q#7#DTBD
M[[DD@Z^HZ_<7+7;B49Q3Q:L-*:=TDZ\< VYW*Y/?/6++G<>D9ZU2F0]4ZIY,
MO Q*OK3UV2L@9363Y#5H6W9R\-/,U<W(T?>KS>Y6+,YONF/4D:3G)(VWX$Q"
MZ/;Z9NE9"A:=4]:7XU^U[%M.0>?;'K ,3%YU^@$ "ZFV)N":2LZA9,NA%MEJ
MZO*F>18XWV2-.Z(O Q>?N@8]82::_%3A*7N"DZ^ZB7SGWO,#<*7])GR;_]VC
MO,QK/,6O^=V&GQ#QS3Q*%N3NWYC(?J!T4VKNGHB4[<,)0>X&D>&BQ9OU,_FR
M$@:7%<UE+0KS<YSQR^Y&O@KMDNFY@L55YTLI*1$:208%. 7J2UVO_+U'M*(I
M*[>'C.:#\G!;W<2TW$2E$P%I0/-)*:ZZOOM%)#$B<BZAC(?)%GR)YWVPL%H2
M8TQ\_)5N5<]G5BX1HP\_N+$H0<U6WC@$T#50(@^?8"@*)QG]+I3ZO7%K7WHH
M<?-4IKY,THL-WLVHONW&87K\,!F'8X%*MYCVV2Z66 ;5#3;=2!<P6B.2>5H.
MM=&'.WE_L')<"6<_+O:X;]YH%(--!7H5&->2F!5)KC\<6.+&'1<OQ&DV$6+*
MAP^K\;W6N7]W/O/_ZTM8&"Y7\.(J09\RM0S$/-I(E3* #"HEW0\<H=X;87_O
M.@F<0 C>>D)Z+W6V++KQ?E]OA*6";9U 7B!6;:^#%]3E*5(:9T^;FV<JY8W>
M*_+1!+N1\I1&>N>&DDA(*4+&'2/")5'0F"BEAQ'#^)GH@T<<W@.J(D'<V?7.
MKBQH(V:>.&^Z,!$;!$U W#>AP)GHIL6Z@VT]VU<B83XUAD:@<^Z9VRPGQDF]
M$QD1\W4RU'J6^O2T2Q[&X]3G$7(SJB)&B#8 V8@QKVBN?)&O(18@N;WHEZX6
M1NF;7]P93E:-F0.L(I5AXR"Z1$GB<)]M[1KI8\U[J3O2$_DMJ1V>?.C/FK!Q
MLB\PMH#1E'<,#%V*^=ZE5Z22,DVI!4W=]ZX1O!AR)R0?4JR!V<-0H'2WQ9O&
M5!>L(OD@]4*]N)PDI# %6=S^-0\0B4UN.."$TKV#;:^/@G/\:\1\7 )$R^FJ
M2$*:&I>.K$ @"8O*^-(VF*B=-7PBWBK&"-Q46"#9/5#,I6Z\JT]\F\^DE9J(
M1>F@@*Y(SDAZ$A&H,_@&>\&QK([,.Q?*:@4\!Y \0#L*+6BJI)&D_@# ZI F
M;Z(-!AEHE4G$-:7[$NY]BLW!Z")%6=^9!F,#ZY=>F0[?F6CB1M:[$1);+PN]
MQL7$6T3>H%<N^0+$O2!4![JQGH,Y.26'?P?F@]B)N=+LWP:E7<Q:LGNOJLHA
M:F7X#'DR?3-NC2<[7SS8)RD>S:7#P!!B/(J (E^R,D_70K1/C!^.A%$F=.9H
MST&*+1PBE6<;).ZE5M'+2N%%?O53RU]PB*6G09 MZ)^"K(X][ 8P2DAAN0V-
M;H=S;B])-%528^D%WVIP1:MB@=9BU^T?-NC@V9]!EV^".>2*]G4_:O0Z%,H(
M\JOW8@73[^^(2!\4K2+]MC4ZN_3/^?I"#,=-[FN5A9<E8%19<B$^%C -(@*P
MRGBP>YPG^ZE)^WIOB 0C'<0DMULA&9D:P[$.JH\Y^ZKX,=W#1-GWL2GO@"#)
M.N=BP7&$C[TB0HK9'^@F3JI-[%O) ?RFP7,-:.<#Y'(PIF^?!?;S6R2V<J6>
M2S'8XHB6U!RF,#*L%+[[^)ATJIF#1B0FJV+:[69W_5.$[%@.=*3OD"N+9M&L
M.G#Q"1^=]C':Y!"XNVG9"#V,KQB8?27 YU1/2>\4<*E<LN?I52'.3C2C$=D\
MC]X/0(LH%627;<I-U$LV50P@.-_"Y_VA(JEO2!8U#B7GCA,8BHV:!1;*#6R)
MR&9/%3G32*O)*Y>X-QT \LPI 40CQB!W;K94]A!$@)M\(=WU8:WW+LGC 5>#
M)5,B8WN+BVH%YAB(0QQK#H9\_*F^B#^XP;)AI1BC@+CUY$+>N8#T]=ET/K)O
MHR;G:$A<-D,>C7E0=]I7RZT^0;M5E,S4)WLRRRTB+65\UF'*!5+L;6[X=M7-
M6MFM1E8H(CI[&JHR7915PQJ7HE\S7G'(?+UANUFKK^BC!921$00H-B(K%":F
M(YFM\=E 5!2[I<\X\LXUC/028K!M,7L$2M2I*O58:C),@=!LN@S9%"5? \*N
M#7$OOX"&U@=%)>&ME3<7<-V1W"B\IOB$TK?K85=^1'83\$3_Y?B]VUBJB[7J
M[%$T>/*G'/5&^ZQ")Y2>0\NRU?6U#0R:^M>*/C2T9+4,>9PF'@R9Y8^T:6I2
M2SK$!Y&C52*SFD/!:^H.'T3\.:.(M=H9P"-&-3QKY&CEH")O>8'X%\? 0\;[
M CCJT[:"N;!I!B'F]P"55$RJDT#<?@>0VN)6^I-^?!((!8VFN OQSIG=G3F,
M;M^M2];34S1+3AP@/RU"$5TCZV+U7'G3S*A^92G\)6)EN^U2A8V=YN0K\D<T
M-/.BH[$T]Q%2S_)+#'2O!IL.?()J$--=_S_LO6547,^V+]H)!!*<!-<$UR1
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MIQF1XK)VF9:]-.N;ZN>#8$&H!S$+B:FV0=&#=;)U/Y3^J*EVH3GVM9\81U,
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MBJO^O>8+?:3",9W:FOU,H.8]H)+[%6G#T6 ";O'[$/$$/>WPHV8.$ZV/'7E
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M4L6B]=)O!)MRK,EUIUE ][S5:!-8]SI&8ZQBEUZ,%51RBS5Z7,@KY[WL<)=
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M^,GQ,:>6FNIXJ3?ZY*YJ_N8UWVB<#[R@?O2IKY7&4K$74(E3SADSXE,CRSU
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M1J-44CL3]TAT[,")6@-T\?1VWCZHCK%Y*7)F23E$4&"V/>B';0I.?-N&[NY
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M%:7,BU%>GXWV=J9+Y+0/,EU@*%N:HXS#ATQ1\A1P5US[)OUQ9">R32W6?>Z
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M&-G0SW"[$J)R@96\I$@W#?SN3TC=NIFXHY[C]<9 -*RR>9>22K:EUZWDS<%
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MP1[E,_">&\[MWPP4DOZ![&ZN=7(L37DW68O@*VV\1@&K37S^=R/%]X"DG_>
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M>$Z,D[GRDPSLI?Q4Q.RX'CI@CBMYF\2S7<W:#Q5DK2W\@$Y/DS3)VZLHVA&
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MT8+<UN+9ULVP_7X<_+5\J;ST07/C3MADP4ND"TF<M\:T68$X!GK\II\P(@*
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MF>OYC_I/,[N(5#/-^]H?%G+^?#9)= 07%;](@*N!)2IA(OR,,W?J-B#..^Y
MF*DMZXB,9>N8B&/6O;VE81_7O\P9HP'%,CTVJ7L+/!8/\T+?M0D>VKK<DO-@
MJV TN'_CT8%&;J5HM/_$'&(HWRH/^BO7P.UO]SXRYU09HX_;<KK]TW^5_Z1+
M5TN1PKY+HONF"/+OW/_!^S!?0(?W;&1R*HM42'AI^'L,M6)^&?&"ZOX',?;,
M*G[*=7W8<Y)Z1]W6HO20-G9EN[^1@F'VGG\P=U[[J9_RS&)Z;9B21ON:=$RJ
M1)4^\@N;.IJJOS#O <!_$&S>QLBW2C*..5);NQK"\T53XKP:=WI$O?;Y([1N
MCF^-5[6+, I<?C%KB.H<_>ZZ'K&6/"A7.)RKF7^0.L.? %-\_S%P5_6N>NG7
M4<XZ/W%YA<R"/];&M+VQ!Q#D5OT=5?^(?$8WW6CP=Q=?L@ 2HDAG!<&1<?<_
M!"=!&?Z,U20:*MWL<YX+ZW[3$QC"_#5C#O^?=62[X,#AQQX+XW5K>V]BZ8BT
MNC0Q4V#H#&J$'&H$.*ZD4R^;$I+\Y#^[!O)PR((?M5FCN"2R=7H.^2XC?,!P
M9:J?D@9R7;,?1ZJ?/6 IB#+5'V M@B$KY,&1YD>9VH@OVXHAJXU*N>1'68B$
M82V$H8+P4)06KA5?5NCM7S>(7<@-2FB_.4A+2?7#1=<11H+0D3U7-_=_* IX
M ,K\_X3X'V0VID9%>D@BFR! ^4(&DY\'<:3%49G, '^0T6%44#Z</Q%N!9MS
M8?\O7XUYV#@B!%_H-185XL?9^Q974I,R-<H#_8$(AJR$>",Y;U9[&89APK?%
M8%/&71A[>NRS-,(1&%O&76'>K#06@-Y4@ ML7/>8;.@'8(2EIOHC-L,'(,,P
MGB!+4QDG2R]946X+$5 %"[324S%+3$5Z<GL_XLIJOW21#3:E['W[XH^$+UB/
M"<P2<;3P#\!R@W$ R8<4)F8_X)]):WY_) $IX6 <$.DP #%I\$%4QH7//84I
M%V3;K 6>4GV 2:6G )Q"TC"^P _^AW?BP<PJ]_",A^6QQY,0$Z+S %)1IB[0
M843(6L&#^*YEWX:3NC"IU6EQ]C\M9.V_N/U^A:S+MASN*K[N(62T%9<T 2G_
MPD3F:EA,6ETW0N;W@JH6$K DX#+V%6J>!=QBTS*M1/^L?ZE@GX%DJX+8R0%1
M>F(%5C=,R9WISI?2>3D';(-;2\C8JO#/[C2GB?Z(\RXHMA5@C]BX+ZLQ2P<M
MD9ZW X4,)ZF,C)F0U"#G[ #XVI+9@3_VO+)$>":-YXW)/;C.&^X!PF]$<%P#
M%A3I!($@T7<](JXW<)NJ2I8N>FF7P?32/?DT_ H2U]'#Y"9M^E]YJP>00'JT
M@<;> @Z$5;FJOU?&6>EFSR*ML:OC72VFA;D5MMWIVJK'.B8#*"U-!=D[6S$&
M$VJ'$B/4:2DAZ:D/IUT\;%WZ8Y#@065"F?QP9H@RG'%ZJK^GYMD&4*TVW<BX
MEZWI0',R?=$*6P%WCK^$G*)XG&LJ8,P9Y9M:D7#,;B\C 7V*,YT.VGFQM9]=
MX&1UQ?&SZ7[GE3)_*>#<&%;4!@<]!T9PKCHMR,"2(IKB25$&D@TVN^!02"'^
MWH)=/CV*X)?2$1(&Z[7?%6M">Z;*E2.G+T8EG&XJ)XXR/+C60I68ED.HDT>4
M/D>D[NGC3'&/<[^,BZRLJJBJG%/[V0\1RA!Q,F/(<&IFRA I UATYY9RF:I+
MO%;^"D]8QA=I1S=:&25$%3XP3I'%>I:2HM)CB#>EF7D Y8X>8>EE>VM2$;:
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MJT .ZOF @2UZ4.X7,6<!2_&5A,R]3GR92[NJ-]P9,VKJ$7%.;$6GFPJ69?<
M]$V;]'#-:%51 <"&S#T@WQ^)<6?:DP=7KAGB1,JU_I,%JL3:4,O4M(4'<![+
M^THZ0M06Q:9I?<U2M&=PDU4()@P,H>Q86:M=VVX!^EWD3PU://L1CPAZMYU(
M,L+J)CXU=)#ZZ0+?C7(55=]YX[VW\Q S)4\(BE.2MZML-LG6VZGONS33(B%N
MVZ]OI/*WY.M:R\XZHD-\"C!4.$-W,<JZ+BB E:.ER>=J 2D_R7)ST[EGJ*B,
MTQEAUT/S'/6P!_8_<XG#^OK'IB[J\23.=-APCIHJ4]2ZSJ-SSQA>DS+K;O M
M<YVPVV:2J7_?D4/@11^SP)O$LO <%0D['AMAD2X:Y5_7LAY26-I@+*#Y;G@K
M;SBU5T_R>4[T6V!^MHLE;5"].-_"L[7J28@?C]-W-,GA9<HN'$:O3>DE3A3E
MYB%WT\ZOM?O82WDFN!H#54Y:A+*?D@FK6NV>($P005EGWTN68\A:%06GF RK
M3/6%A1YSOPZV,8UPIIN:F&MK!=.L6FN0,HMPO0WXQCR5R)M5B5V!:[L/24<6
M7HC).=[$0B?_Q<1O-6FZ2959 .__(\#]]119KR\GW !Z+.]6TG=S\NM7U35K
M"V'/SZ"!GSHME5AU!93ZGV;Z=U;(HA<'V/=BP9L"I4M_>88+M,N]\:,";XLB
M^ '-N1Z/*]4FPY"="@.D$2>S?]D_ZO:8B\UT&H17=EYU/I9NE&C%P7SI\+J[
MB8-B8F3N!* O*]4K/"Y+ZX]C757]<N )5V2-^J08KAYM)::70XIZ9_H4,>8Q
M7=^RAC B@ZD#0F"MO_+(8A"FP<N\YQV[$DZ+W=X_)2&NBP%Q._">$P@G:4$1
M8.1VHHQ-99DLDH-WLMY(V:P%1IE2B'MG;3.':A\%-@!7R(QQG#YZJ/M2B6I%
MQ*$5G.E23 9^._J&BDUC^Q^_W.80K++G+XX8^A>IK$<+5^.R)M2O'I.X5FRJ
M*=OGDO_J)F?*$KWR5(I,,^0PH!C ->@1-O9#O36N>8'O\YTNLZXR_$OUZG)H
MZ%>/>\!I;GF.LUV TBL6ZR"<8M/YL9#6-)9?N)^>D5@N"Z ^AC/0Y)W=.V19
M@1>P,?';?P3<OV<GBB ,5FP^J#2-=P.0921(^K*^C#$=&P/.-V-3KLFBI04S
M.H.&%KAECZ7\+*!>TNNU!Y>RBBHQHB_ H?==&)4"!TVPLP-F$!_O"SE7GKT?
MONN81?315$-1B&T+DU#H5COR1Y8K^K>,4TU:.\WPR]:LGY8_5X%L#C'?9%V*
MY2>5D0^.^0>L)+"J741U%!XU3M.+ "NL4[NP9()XS"LL0"G(.388X%V1K^[(
MRG"C?=ML#A]F;ZO[1)<C#EJ#33=*/%6K,Z*J [29/[Q;T5Z*P?]:QWMZ6IW&
M%3$#IWEJL=^\1SBVQW@-"; @.%9[>P5@!_%<=@7 )=)8(8H>-)H3EJJCZHD.
M[?T8B"U:]1HXA:)0R,0-R];%'A;+1[:"W@:QT(5@C442J%O(/3M+70"O"\6>
MOK@4PS-2I],52E6?S*K@*>05$=_G@$RDKQOW#_G_7"<?HH\7EK!1[D%_NCR4
M435,'K;W%'NJZ <_Q&(I9+T0)W69T[ZH8<AHWEA!H)T)-7VL/))LIUY/XY7"
M[:#?$(=.!]*V+%D/_1JKP0S'.USZ)[=4)M\77%#+\!T8):@"U=\2")O \9)1
M<-=EVS +H.A$O,\E$AE:*:ZL=K(/I5D%64+? ;X@JFWK\484"0/LU9'7E.B
M0QT3WNJ[4\_PE76=Y3_4(0?<4LV@:@D-[IM#5=298D4YB:..A:N3/E]_H&GH
MG;T:E\;"1U;JXX#W]VPSY2.(W7M7JZY+V10Z?W,H;P)4[)]>KL1^G7+IN:VA
M\_M2%'\ /KL1X$99@X G,IQ1.L*0$1%87*Y,]$-9@]S:)4LBU#?ZA<9;1 J
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MX-ONK[$*)!=V035-\BX3W2W;EE"HD(DYN.WE1E[/U'#L_UP:);I:U=QBU4Q
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MTYW0Q[$:8W#*\+'MX>\3]:883V_ $.9A$4Q76(/T.FLR$;B>A@E%TW(O,L<
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M&8'8ONU9D&@:W.T?]*%350)[$:$C,RWW31_"?K5 )@A#7>'?_#FA4X=3"X'
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ML@\XM+B3#,ZAAT5O_D"6]'SE#PX0-=KJ"(B5.'\.0G(#@:D\I">]?B(")9(
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MWB'USZ7\"SZ_/XP\H.@?Y;JJQ:!M>G,V]>-.D0*";JS!X/_B;=F/EI9\M[-
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ME<MO)83U)-3V 0DDF]T8(%[X^-1!G^BNQIXSRSBD4XE(,3%C']!R;&=B>?5
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M!*8MTMV"ET0SS=_12Q@P9=%[YRJM"]VF,PO:CM82(6!U2J#I0W/FB4@\;4!
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M?I5R8,-Q3)LD;N=S+4.!+6P\]W+_Z<*Z9'6Q!;.E?A#Q5CV5>$IQI5_ALD#
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MGV:ACH)-N;!IQ[RFT;-"Z,L>==1.--GX=0)[K^U:-=RH^T@??U)^!6XJBX3
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MG1V$]8Y$L3GUSBX<.."#>CMGM6.&98W)]=B<FF<IR-_QJ@>X5)M2D"KP'$$
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M=.^X7B_"@=R^0Z57(-<8VBMLD5,0D=E>*8<(^I-ZC>L"'*O0YE<9Y3< O!M
MWB7P,^Y%Q.#$A3@H\[K/44NGX@(42>8U!%]]Q<D1J.+LHZ!EPQ_X/G;4N!IX
M9%+\- 05)"A)!I62<G,'BGU)K#A>9):R/D&M+GR(6CV.D22U=+EEIU^'D9FK
MUM4&6A"P&2QO=:P>TKB P-I&*O@=K#=Q144YAO/G(1_R7?0<0YC&:)]HT!WC
M;[ ^%+SXFO"*4SC.H?,IWVKLZN@)UC?RFJXLJR*Z6J^$(\WC^S'$Z(USM/AV
M8'#)L,3#UM</C*2MN@X(+STH"ZV+"XU_?*#IO;($S&/[=)1Y0:W;,_U-PK63
MR,X*=;=TOS(2&YPB#BN<:[%FYWI>%IM X"L'DKC4%[-D:DX8M$2<N"W8C$BO
M$& 0L1$X1.*/]G?]3XBZ]I:WROI\Y4Y>V#M#O0$T!5OH^W1D_-1\3B_]?;Y)
M^7+G_(MVMOXK)"'M ;'D0G*1,+5YU[?.:<"\M&,ZMT4A5W+H=Q0*^2[?[-T%
MI)P5Z?[L,?[Q<SZ#^UGH49'';H_$2(]E;O=V,4D$WX9FNN!SI[SPH(1(6/6;
MI6R*BN6^K\FBQX,5A%:-YC< 2M4;0(,Z#;['X-L:<0\D;:\,R:7=LM'%VY5"
M>(E\ V Z&K\!W*Z;/9(=XS$;D9++1L[5:;=+9IC(%E'(\OC'#L)'O5_:VI76
MQ_<'VRL(AROK]6\ +#> KP7DB*;^FB&RV'BNA<6X>BT>!QFL-252Y,7YY2SB
M/MJ*F"/;4^5Q\>1:,'_1Z@O\(]H$ MZB*OD*C"S)@@8M^-J)%Z)3-?2#BI*2
M<H6S7%#:DBK905%VGY*^4H,IN ;9N&8 SY!FVEUTI4P'Z),[T[%"=+2K^$SH
MV0U M1J'R]S6RVIS/%'F<+(_D6@DF=.3\)+96A]SV37OFJF*V2$$K2<$6O"I
M3)X7V4JX K4PF_6JC'KAW6*Y$ZO<5YGO$_G>;VT03QC*U9%?^:.6[YIKI[H:
M/TGG;L&PD5;X^$:B2M!QO  I=Q.SY&.GQ.D[[@2HHD1,6_<;O9I(SJ)L0OZN
M:.^E)VVN+OY7R%[,(<E221ACDQDYMA73.KD$5+C]C,W-6K9B[Z+<P>];H"*'
M!(8Y1=^;;@"I=SR*4^M3=2P8^WUTGXNF''C\B<=;?#>W:MG9!(6HM (CM_PK
MK06%_=#9F((?$7.R2XC< _B4 :R953J"8^T6$;%5"E;RFSODU!MZ=N\+)3D+
MQ_E8]<-WM#_35!(2:'=\7:WE4&T0^&@$U\#MTC>(_Q@AN&RJ99,.P=#E5KW4
MYFZV5/'*.I;B^]+GH8!1B4_AB[[8!/I:Z6R242[C]0)*Z(?AX'O87-[5YA!;
MHO=U#G_FT+_-HT>M=](EW.1[5H2L6(>JQEXJE%S"K5-_;&1RYHR@,\/(=S7?
MZKN(52"3L%&?"H$U&V@4_=N1SC7U[8(4%]JL_+ V,U *:C:!U11)T(U7@_JH
M2G ";@"C/!=CJ3GSK.622$?A;6J#5&XVD[Q?^LPW]_64A45Y\1!0,AY:$;Z-
M#\/IZW,.DPJ3Q%5&K!$P<K=MI'.VG8:N);I2(PD>B9(+X<$<TF)^GD+_A_L4
M_[NYG&P;EX9_FF2>UV*-^[00PM_I2"E85G\"%OMW9,,?X4L3)]BIXR6&OY#$
M/4+2 :%B[Y9R--CUT.)8',#**K-H>UFZ%-!FHLDC_>)A8VG<(L?S0L@[^PC+
M4[A-V]L>:18%&([:W,?HY3%_A7-M124>5NFMZ2(IZ4+U#]DBT9!@KZT811K]
M*1>^9%('>S6$UQ,,^1VP3]DSW#U\? )4JJI:)M&A&F>06DKLC4-]/99ATSR*
M$VFY88;&&L.H/%?;L?5G!$"S>R"D;(8&00+B!E-W[5Y)S7#6]E1:='YT323+
MSL5$F'6]U+S<*9Y&@=O$:)9W1WC-(VZJB'O]@Z)Y4(3HLB UTZ#,%D2>5^4U
M:(XRRJ19*\]%,PAQ!9!G>2C&XFUQ)BE_*)W'O6HLERY'G-S1L+E?(UBJ:X>^
M('N:^=4&>Q9%;]05E[KVS0[928[SO9'>#ZL8_FK=@;WZ=G27VZA"EL;PQ_0J
M00@:CQ>)_!**W%/?>(:&2=GW P_?]HA41ZV(E^"=)+&\E$+#CR:MR&'WZW;+
M"-:Q,:4[[(-;,><8K)8'XQ*_,H[#$.^5=+MDBMQ])-9X9<"7_^F>*T]TZ"NP
MO59UT9 P8!-*:%C[8"K9FZF]C&M(E(1EV4.+W)[U.N,+"<\,?*EMS$HPEUP;
M8MD35[KW=D?^:USW-[()TZ,,C*-*9@'QDF<N<@7"MC7YD#=6W]=H$\8_0EY]
MJN%]?Z08^>%CKUD741:SN,,WG$()1Y*B1%^.#HA9[>.I&\ XYF*MDL-4=2"3
M8-/]#<E8#EJ\%\0%E])X&Q%D)4O3V0T@5N*I+EM%@&ZPL5&-NGI07@LF*I!6
M)0\/&S@*@,'25P!@HG3;/"Q^&, \DO(4!1$/C1HD4DCTK\MI][]$B*2_LWC&
MWTY<>LA?;Q3< '!\.GFND2V0('\"MO1W%.$/ N#A2EFDYK_M531LJ?1(H^2G
M&IB$?RN^1'%$#CK@G4K"0S\) N.C51CQ,TEKL.AMK,<MMK14Y;42)=Q.N2+J
M/K:Q77=#8(_R;FAW9(_A[=]/,>@/>72"AE8T:U%F0X.#&E7UA>,6A HHON6S
M9SK/0;!%\?9Y,S$Q:78[<T-RN4VU*DL#AMG9Z*<_1PL#+8HFO]";VC^;6Q C
M)N("CSQH"V(7DS$&S[Q;S4C[^. J2>BM^+[EPVFZE]W51G/9&6G?N-,T7[8Z
M\*L[3+=QH$SPYN9:(+*7M96]F(^))R]0*6&L'L 78G!O(T2DM<,--3*,Y6M#
MG:.IDSL GZ9%/I<:I,T:)\8+UVW#?E71[C%:KC:+*ONP\TD+3:HN8]@*(?X+
M6"S1"8F--14148;%N%@ <39X[%YPFE9HCWWT<19K J.P>ILR"*!U04;J;[VL
M7DSR^2F_4_8=HN<NZW^0*@A _R_.H?K_F_B_.^-G&L(AQ9M!@*X TU.%I6)M
M6HX:!ZE/IO*FQ>(9QX^*W4Y49@[*K^DL;PGY+@)(08-<[FC;OGU^[B73E;%;
M:/PO$)T/*'UOO+YXM5M.9K7]DO048 NT:"-*K62FNJTF\3 F(N;C'S[J_P6Z
M<SK_UO2Z\SG_5L'Y<_J<_UG"_UM296:KDE>@&P#%OL^$ZF7;/:EZPTVUNQRW
MTK],-^H?W=7_;9)POAU\Q V@%BK2,G^(=0-X33+X=X8X /K';Y3\]\@O)C*3
MW + 4/)*NJT>[1I^.^$6JR6O)'V&OE$>C_IP*%(_LY;T<;H#X8$(,&6OUW-1
MJ#_\"3CP?Y$"?!$M.I$B8<PBJI9BH."F/H#!T:.+YE .D7IF-@&!+%$%O\3O
MI,EGZXQ(\KW*>^B"K=?[!?.?9F\  V+2D[8^:RDI6.RWA1GO:I5YMSC> (10
M*(UJ;@!)?KY<];>ET^^J]5U@#5P>XWD%K%U[H .&_]H$SS:/R-&@ZA_> D:5
M4K)9["JET[A/X%?4Q-/ .:Y8 BT1L]@U2J<Q+-3NM0N!J^<7[;[\AO_WC_4O
M+1#^I@7CNAVJV_O<7B $?YRH<:B._K9(O4$T!?R(Y5HO& Z8Q"O_XR7+;^E^
M4WH5'G@0C6?1QLJ+8.J%!MVC_B'XT5?I18B^Y#M75*VN[HEB PC(W?9 #O8E
M@(^X&.\@VW>UM.8"E&':N@VXW QGF0E<3..5"1,007K;Y_'LO2OKSCNXJM\D
M+>RH&,GM7E.7NR=EW[H[_F:X5 F5) # T93J1PG"4X_ZHQGO?XGNHCGD^D8;
M)[[L0I7*G-E/!J\L$"\--]N$XW#.4Y7_:1_%;[>-_Y&/ O@K3B)L>/#W[ 9)
M=S<YTTS7IU.:8JQ@WNF*F6'F6ISR+2+W>@9>.>8?[8W]/8ESJLHCJ^4\3*LF
M^P:#PP A7!I$HH!CO ,IOO_+X&X_"8@%8'VQ:;B5>CX>;&YU]SGHVWCW"N0L
MBM1!W'G_/=-:#@ !/@4Z_F;EO8 ! K:NA>AO '><LG&9] : R.W]ESMC./^!
M"9N!2 )A_#?Q48BJ(%8 K5?+<4&\X=D];_R\N]>!:?(&T-KNR_VOBD+YE9A0
MHP*:B'-#Y=Y*[SF*HB7,'_4.K?%<'G%SXR'@_+_]6]+/;Y4B8W!XR"@"'IC0
M&C?4*B8_ '&AU,KNB0I2+7A$ A$X^H?K8W^%M9% Q"T04A;+3LC.!A-."W"(
MA:N@UK9./7XP?Q9?!VBW[2NO190HN@DV<F5Q?@TZ!B\T0HX0X*4):CV[S($/
MS%FW^IO?IL(COY?0J>./N^DED@V1?0E>JR>I*0JU"'M*&5ORX%^/NT:XUT>,
MF%X3VU49H;R;*Q)6_(2D\1WW&7WUB-WG 4QK]7Q/G_/<#.:D+-X,WHVY^FYE
M8D,>?_;=AYJZ^>93C?/PH?TRMT#PL]-8PBE_8C/:0@*,Q-5;$S,=CNJ#+H'G
ME'D7"853R,K FX*T,1=YD%ZL%!U>W)%#2N@E;,<Z>@=-TC(\V+KCM/7"9R.U
M)JO<2_RQP:]4C01C)@AM.;YT<H-;VJ]IZ&UVBO16:A$TC&V]'@"A<?L?QTFZ
M3$=W7[7;OI2VVLB3^]5K^V#8AQ^2G3O'^C9RMC2R:OB-;U4U]N7P&NPP8.P5
M* <C?TM1HKOJ=8T$V,"M PSE?3CW0B?:Q\VGWJI&MF;34$*TWP$:O@^#1E(W
MC+(CAW4+2W8PZ[\<*&3@&/V9DBZJ_&YZ8 NF;N3&-D72W5Y8 +[ 3N_H:.N6
MG:F9/O=L6,4 _CJA;<#.-%LO0IM#U]*5!Q\/1N6<U3!]V7KJ2"'C4H-[LM_>
MI7R!4BRAE@+KEQ5MYV(Y=!=?Y?',?+Q \(@4'V*BS/^0$7**8LC".<1N&5XD
MG.\_\R@J'0-(WHN,CW9DBB9O,2+^_E"WAS ((R C([S5OBP)]M3J;5*QC2='
MR$-Y' A@$)D$6-@<<XP?;%1,OW*DF[O\C%^%\-GZ8F@AU\FJ+]D3BPRB+9E>
M7.(!T:<6"%-X+U%4/ZA7PL>RQ>6 5*,$'BL5*QD3S-5TBN7+QK[<;NDT-;H^
MA-)/JL-0.9HG>2&S(Q6,%42N;=68KD391GH-;60J_"K\8")[><4-I;\?=E@(
MT$*($8EAU1Z_QU%1MV1+IW:T7:!RM6QX/W+<E_]C$<*>%NZIE@"4C\Y15W,O
M005E6@Y-#O*'2F#@W3\9(L<(2 <D#$E9((22=+\E,R4Y8B=XQ7,]V"![_"VG
M=RK2?LL@M8\:< CBVF8(T6WV?E@U6(B?B%!-N\8]"A.PEW*4<$5^NR<O*R]C
M]*N3RE&*WD]F0 K<F.C>^QGW #7982.]#].EO^TCCX'':;%<1A/7R*<"]\LD
ME&IAO/J1P93::IOEM:"C:^[Q=8CGQK3ZL](E#RHUV$AFVH+1$[=TO'(P4=2M
MML7*8)&1@M)'W;$F)631=@^;N=W@?J#>FSY;&!MGA.*+'^Q-][,6-\_PL_IY
MBZ4[^+@^(J7DU3V.PL<' $R0\#8%AN 1E>B,?8B^=R>!(N]I[-D\_#Z6$F8&
M*1@2I3 1\;^41HY]H#V /JTP92;DDVC@@SA[ST:!'CE/Q$-V$]K8;FE5\[$
M/&)#T=_.:$@:Y0BK"7&4!\DT__4E&!X2)8:,?X 6ZM03 NO\M+8,S+-?L<4(
M.?)XDDS0^>((N14_WU.<KJMRS0-;:#)/3K:9V)9(IHH':10X@L@WI3^1K<$X
M;YGPBZ!A%?<4;G(0_2],N?R_HI*"'XER <JC,2=4FYYNHYA7I@JVOC.>;7B7
M@F4=<FQK".DD<'UT>"CH(V>X[2ZRMBOWW,H/1T)>.Z*%#?[9'-[/.5>Q$.F$
MOM,.HJ+;DI=-_@<O*5!@>-@U!46("?D&H*.6%(WH4Y!R_^^TBXP^XI1[=B)+
M_7:G6/8>],,Z7_MHDV"MWA73^J93/1T"BB^?3"J+P/%EGM]?:N!B8/J1W#KM
M&Z//WPRT&8UF4;X!0')_J(%9?5A.4Z2VJ&?13#2/*7%!69/*-LXD+6S?FSU.
M5LO*&1E&S6JO^OL.(S)<\<5+\GE@KR3L[9^,6"_&$,T0/[X!%$(\?&!FMY*%
MPDRCME*A%MMW @/+7U?_ZX="*7F[Y!7 2>%72ED++B^(67B&CO&9WNF&E"\_
M)>$/^/?9/C,CS/"<+KKOE_ER\ZVQYS%OJ4/P>.IT7WGYMBDN,!M1OE7'.^LU
M)<E.TQ74BFUDPVMN\I8*(_Y\[_/8YX$G$2C0E]ORC^;A%3[Y<W-N+B<[-NGZ
M$39G;B?Y2;A^,N7,T<XMQ)24A1J?JISW/V<4/%%8#AW_2 1WR5TD)7_J/B%?
MY2;-HGL#&-,/HJ#6=L*O=1MF]HOW8USB%N>]50O?@$_D#J4I3L0O9)/V6DK*
MS?RE*:E4D'L6&Q]:ZZ:;X4PILTRMBS -C]8_/[#0G!C/*QKYW(133+FD)TC
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M>*YLY%,A7%,M$6 _\*R(MB5<S_(\:%_6D:[%!<%$_Q,7M1)9L2@2&M?G55C
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MG(?V3[_$8I@_>0_Z?[K[[JBHMF3O)JM$%9"," I(D"@YB63).:CDG'.4C-!
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MU&5%R$Y-Q&:0;85K?5VQV8C*2(? ^K+1+3&;" ;<6?FJZ\'ND\W!/,GNAO0
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MM>G]"4[\OVY!\5=1Q5TIXAJL$%ZUZ^\O[/J5V[:M9Y]QRT4[N,2*$GQX9?V
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M8$G1D$UW;76ADB4NS[5I7I'9[?GI<P;$BDJA$G/XKED3D%F5:J%AJ<3@-&@
MN=QCK+"&^8(7ONDQ_';+W?@N&<H_58,"*[7^9W8Q(MFPZ#&-%)I+=>T8VXZ9
M9>QE+Y=$@9_\G, ];KS ;%CW:8C8QR-R&"];9.!*Z?$-0'A<Z@: _+'7[W'F
M(%*( 3B&DTJX--?]Q,_JOU;;P1]AY7A>6"(<R339844#Z^Y[5N!D1\'#3(NQ
MJH1O.>]5XF/,U7W_ $Z*KC5J@=?&)[]N,FY8/;+H-9GL-*3--.\70;4*'IE2
M@D0>F\5X['2;2 7LL,'Z% IZ.<FH\67$PLM1X=H,F<L@&V!JUPW@+O5Z;=SI
M.^W*,B1;B NL<Y^;DY,/9]VRDKK<.[2Y]MJY?FHKO8 PW(ZQB72CR6D7Q#(X
M6_%X+[\4= /X>3#!R ]W.S<<Z8HRHTJ3QXL7@).2%WE\0NK6:S,D7,U9HZ _
MM./N/A' -&]N1"RK/DKI_5P>=_81ZT);?>$K?S*JL&=0(AM'7HM\8HW:RJKY
MI("\FR?@#YM7.JSQN(U)58K.D1FP5SE;EO\!!_[PUZM<N[$&M,D&XB]W.)5F
M.SGRQ<B&#2&T7 K([0VL>X7(#S8X!FT?&^U'N19DO '9/+2=FI1^?@,0*,@O
M[L*I2>"FE F%"@>)&AB72"VF/M TU%\1H)J0D'IAA#O[I*4&91/7312-#AK3
M5AEY,GI?2[5-@*QL$ESCJ*9E;JW$OMZ;(A5D8X1!&$OU4\MX9 DX_QUCI2S1
M/$\U:%V_C'%T;64/WB2K0THN(#R>J&?*B203>"Z-_RY732,WNVU3#I(M2E;'
M94J*L:5'KQ!AA_5%2.H]3\U5E!!&R3.3K'LS;4^^M@G +9'3X41, SA09>#S
MO#O=1O+V^H%4B&$I7;1_*/6CRR6@_UM%C=9@Q U@&=4*B\:9R\4O^VWB?@P^
M>?27<K^G&PJR+?^/#WSY^TL2$8"W]/E2THT-%MS,2/ H:KS+\+3X84$/I$1=
M\<[J]MK8M.+M*(-'9NO8@R_>MS1_CE@RTV9'F^WBEMCKGT@W:^IC+0W.Q.:E
MC>3I<P4)F=!_"^QF_KK)'+[!4V:SR_E.U\10^U2?-Z+<WV9JEJB\23\.;G7J
MHEQ5G2SV9-_KO8.,L3]4;DE%$4$P;84W- 1NTE<Y,;4WB@-V31PI?!O-A06$
M2MN5*Y.,Z<3:+F)43? M88^P[X#KFI*68C/I). <3Q%B-48M\0+9+^O>-P6G
MCS1-V-F9[:<FV]X "'F[]9K3W>"SL,08#MRHAN]EZ3B3Z8O('6D^_0]F]N*Y
M!*6*QD@AY1I.(9>1%DF;)4J66F1(\/J,-J/O7I:#3<]2-P:F]ZA@D]ZG<&A7
M<Q1E[Z(,8(\9;6IP"9<?C56NVT"SC^74 3*/:^I!\LW3_>N+HK@U\]Y6@,AS
M94R'MR8Z,2[$NHYH(H(J."Z_5NO^OO M=UB<A)<Y'9<Q3G3ODVB,^A@%9=.G
MEV*S? "81^,70=>@9D2'_ @[?0N?=D+18(^:_[>2.]OE1W=W#M=_Q(4M-"_!
MQ&KRJCZ#Y#($J,M"*QO3H!6/Q3\,WNFTFP%FN"NF3%./<\T_$[JRK 3-]>G#
M6K0LOY.1T]47,_ZDSL1P>AKFM']@D%WR@QWB<LQ,"Y\^8%I DUM,_NS)<+!B
MGF%C2B,._NI2'Z-1%S\Y0&5+<_1N_GU-_6RU1Z]33\5]3&4+'A5EYCJN!_J,
M H/R#84*S.-VY3O$3^K/Y$^(==@]_.W#Q4=(*;4_\;*UM!M\H^%.$F'I?Z^2
M]L*!QTLWV*!ULN&3Y+"=7I]\T.R^[B/,=$5\[E>WSH[C3Z,3C7N "24^Z"1+
M" 4XG:_FN2-'2>\35?:(&GN6'*;QLNC.&'RG?$6(I>19:+.LV/0%A-C1!FK3
M,DL,KNDPH8J:DY.YA#?H.G@^,JB_$L%[]WHX#>U,_'OQM'H=T5T/7^C0:H.L
M&Y/1\"?C>.D#+<&^".1:QTM,H4M4D,MAD:%0.&^?;J%EH(!JO(\&?6>MM%V:
MT0"7#$E@\90(*!A7WRRSAX]S"\2MR1M<2$B K9M)O<PJN!J)-JU0JM]A:V%^
M)F,T#JX:1SFDEIL&$4HO\Z[5);QC.)Z3?D?+ZB9B#2^:7IW8IM&X7WIX=^CV
M"5%WIA]ENO"\CM]T%"]!N?&S9R41W#N".UU35S[ZP#!FFI;Q(^&Q.THFXID?
MNGM#>,Y\)II\FWN$'UZ*HGT1.^19N05&^HKO4_L3TF6-N(S^1,,@SPI(O%\Q
MV3D3./9?0J5H-U:'[8A4@7.*RXA5L.]YVC_-%(A-Q E%Z:W.<=H;::#=^8:E
M+ 70K*D!#=RGDD>_T$C0[W(B!VD2%'TFX25&"V@EJSTXJ4Y^<P,HHP<V>$&F
M9\'L0P78) $;>JXJV"*M@7:8P+.9OAE@ W8.?DM_ CA@W^VQ9B\3>M9J%M;^
M\X&\,27Q)XD;M[[9;%^X@'G2I$ ?',#)=BF"]_ L[%6'F.MA6?Q&K,+S!M4D
M,BK-<Z9Z\ODI]Q\YB;3MD,9AMAT33231)VET& >S93W9.!(+5B^,[<QA %)\
M&]3.XO8<R"$M>*NLGOSGAE;)PU<F6EH"7TFT" F[\"<RJVK1+EK*;(C5Z\M-
MWIYZXR8D.K!,6&YIHUB7:T)5 0O.<S!KH.1#&-/&GQ.LN=L1*J3!?%U;A%+A
M>5TK:1SP#%S: X)\Y$UQ\V 57XP&.*@:&"#A[32X']PTMDX>'SD,! AML@2*
MTC7<?DVX?D"9HW6YCO$%7$]X*LONIW\ N7Z ^Y\VY>\:$%XR/!*%G@W?!@Q8
M@V4?7-/_H^!&X/Q2U 3&K03^+XF<O5B#\[HU<>HKDC;_=@F7S?DLVK\TO<+V
M.-1&^[VGO_( 'C.KR?^HVA!T#5P06_SMIF-.9>UO6;D$-P 8R=H-X"]]*?S>
M#=HZ<=(_Z/DGJO_5IC,(S%'L+X3<'QI,?G>MP;OJ.[LT&W6M<J(U/=Y#?RM<
M]?ECMH;'M>C?NNLAALL$+][QAF.& 3HA5 <<0%<7:)>G R%3191:4[P1#.@,
MP*-:(X%(H7]., /+6/ GF3($(BJ4+:@[L!VYGH\1XQGGRK:# *5\YXHM^]&]
M&*!HD)3EKXTU/D1@@9:O/Z<ZZVAH>V,^XO8*]RT<%)+10X(#N,R&V59JB3BH
M7)JH1K6NJ6M#Z^IVJ5S-J8#3X$"=(ALCDI)G'-A*2EBDM41(.&L<DU;L2J7@
M6"\3[C\K+;^S&F$>E;=N0^QI/O86].'L.QETDU.<?%D>IA-B0P'B<!0<87>U
M\4DE?9)K>U%$S:($]"")XAW*JZG)C)F3[Y%>$N"- 9_:]IE<;'=>#,CNL%0_
MOA_\JE@UE(S8P-S6FZW&O1 KVM&+D80Z.Q0?VI9:>X*SP@BS&99J6WZ"R!\5
MECPNL6O']3B3I;:IHKHG):4F7TR^I93_CW\TNDDZLV4NWJRD;+#*62J6([^A
M '$?-2FRYZ6&;'?3O3%P (?%WFQS'3Z=+8YP!7]9!$1?!M.Q-" N,Q"( &>U
MY?F1D]I^;J]R_*#^SL_#R,_Q'K16W_^\==9FE(,3&*[?2>D897\$7C"=7O_<
MFA[7DRNK80%*8@N+(,E(87];':ML/0Z.!'8)V9!!"Y,U5/"*6)T,;@"1MD5?
MDGOY\^8B&?O]L-P2$4 E6>S8'E9H?.\P710 7*XV_/\ ;*BF@HZX543T1E2O
ML]4@N,M!MH$DRPE;(I= :>F)W%)Q#2,OHL\JWK/T6W=.DSC9.PE(#V_#,:WU
M^TH?%6S:6"OA8/TOAL>0;9I1M(\_*&ZIG*GK47^+B[\P$_2_W))^P<@ CN8$
MF7@;CUNY_Q%U&2P3:^/R-TKN!\7L!0Z,UO &8'XK^XOKL4V[/7Q,: UHWU>D
MD8/.5_JH_H7"?_'/?WJ<B_>"8?A'^M^HQ^<:PU(HO1N T7%1 8A0'F"6:&K<
M2*F**)Z>1J'T*F4"F-"';F/S?VMH_O_O)3SZ@G0S'0C('Y]"O7F9/98'?,6$
M(;:=/>J7@/RTH!HH3BSZ'24S)5)ZC45&C"9SR\@Q/8;BW>/X0ZJ&@ZDM5]I_
M2J3DPW>4]MXM87Y+%%\PPMZW0= #F&Y%8JI\-"]O?X+^\;_!T K[I3'G6-GZ
M]@[TR(@-5; (JWS4?M<H]0?!S,%$+OF?W?$OQJ(-:,P'/>H>H#S6N$BSK6CI
MWS<#]N^^;J;^#U!+ P04    "  J>'!2";5Y #?T  "@5 $ %@   &=E9V=U
M>34P;WIT>C P,# P-BYJ<&?LNP=4%&NS-CH(@F1!0$"2 I($)$F."D/..4F.
M$L:1G 149"1'07+..><D2<DYRA"%(><DW(&]M^+^MIYSSW?/7?^_UC>LE]5T
M5]=;]5354]7M>#YZ/@.X*2DF(09 0$  Z,%_ .<3@,> &\C(*,C7;Z"@H*"B
MWD##P,/$0$?'(,*]A8U'2DQ.1DI,0D)!Q41#<>\!)0D)+2?=@X<L[.SLY#3<
M_%RL?$QL[*P72A!045$QT#$(,3$)6>^2W&7]?_TY;P#@W$!,04Y!1+@'N(:#
M@(B#<-X"( < $*XC7'X ?WX0KB$B74=&N8&*A@X7*+T)N(: B'@-"?'Z=20D
M^%4W^'4 $LYUW+LLPLBW%/11[H'P6#V#$V]0BA0VXBOV;5*Q&3SW0D4CN$U(
M1$Q]GX:6CIZ=XQ$G%S?/XR>B8D!Q"4DE9155-74-34,C8Q-3,W,+\ L[>P='
M)V?O5Z_?^+SUA82$AH5'1+Z/BDY*3DE-2\_(S"HJ+BDM*Z^HK&IJ;OG8VM;>
MT=D_,#@T/#(Z-@Z=G9M?6%SZNKRRM;VSN[=_<'AT?.$7 @ 1X:_//_J% _?K
M&A(2(A+*A5\(UQPN!'"0KM]E0<855D#1!]VZQ^IY T\D.+&P$96237$3W^!Y
M'QH!%3N4>NO"M4O/_GN.>?V///ONV ^_Q@$8B CPX"'B  0!N_Y*L]0!41D2
MY@]PV6A2E<X!KY/UX_1"R35W>HA LRZQDS'[.90#',L#38W)$)44%^Q31GY!
MP:T-FB7@Q=&9V_PIK*UP4J%+,$MD5B7-!>6OL\L>4//E<\ .7%*7OR>7Y'C@
M. 5E+>6'P%?X7NGIYX">FOA8QW. 0 D8.$1!-FY:X-$T,' .6)J6ZPX\U'3V
M.#WI.!H)W($!V=T4$=86?Z< !M? ;,,V*OA]ZRM&'NTEQVL*9 +V=_B]SPCB
MXN%W;+N_^+%9C4>\)O=>\DH0]O]]&NHW2W;/ 4<'H3OY9$O# 6YFQRF($^W[
MY'_AUW<.0)>3.P?$.PGR;*V;+48.Z:'5!.I? 9#\9PWFWQ1)'T](_UI#:-,
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ME8_T1<D_OIGU[FBS,"Q&H^4CP0J3)]"'MTV&A[]MJPIZ_T4'UL"\[L+<[/Y
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M9KJW4)#L%_-2%O!R-,47H8=V1@K)MULZ41@@<Z>/H9F[1.U673A<JOS++Z;
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MVMU _P2&]MF7;].#M['"7:!G_A;,,DOC]:Y^:J;Y'(5)H!E9_CM':N0SZ+Y
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MC17QW;76^XNW9M1[Y<B@*%.3;,/%^;*=](N0I&I2*TNH$<C1%ZW@Z.64=EL
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M^24F5TC@DC%RE!^/%;>?&$3R&=3:_ W<OR"2PK\)SR&^OO$+B1^,R?Q3'E[
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M(DD+Z"):PGNQ#'3M18AF@TD$->?2X@%*PDK" "4*H@"\?W-1XRD(76>D)LW
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MP'Q<GWC9)V='0N>/.@P[GXHSIRHR>KTU="$S>3S'KR($3$$TJA*AHWD.5&]
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M4>(_%^4.H<%%$B:_ E!=/R@2VC1Z-;M]LJ.2::9A.NO,K:X^)O#NY\T:=ZX
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M;GI92#^TU7T,?/ (S;N#C84LGDP<03A_V;(/?OB'!2^$VB9G4C[LN_,;Q,H
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M%:#6JH^E_YP ;E"1EX<6.G/LY(DJ$(1!([3W^Q>6 F+"^OWZZ$>O -]UUJ6
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M>#?AX#M,9\%72LI7[RBO/[ P3T4)G307-AZ&%^B!^=^K3__6^/ZYGF[N?T=
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MP8JO?T> &%G3)ZU,7LU4,XZP3/E>KI5@&)?=W]>TT/$?"M2+_]][[!^,Z/]
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MNG=-+G*X-J+Y4K(KT>%L;"5ML-.=NV#GJQ3/&Q'M5Q@;LMLKF]M?3:CF>*X
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M&UK2\Q"*448W@0/MC\?O)"/BC- .^I;%A\K?7 226!SRM7Y"29R#W-'=1,M
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M<W"3;S.E<58?O888%^,FA&2+)MH-@KJ\'LD];FQ:7"O=(#GD=;B\!;%9-IH
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M@^@CU ;  D_-[!:&B4%\0P0RULEIR19#I N^'I26,G.C:[@@;1D-Q(:P(?[
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M'(':B@]<7.*+-,\5BM.;J\:;YNI$W,Y3-<GG&5YJ<Z^I'^ZX%4[3<\?O=IU
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M0D);DY%C7IALY>8F&?E\1;]U3$5H&B_5.FX]]R:^WV@#4SPL.VV1K*<Q\Q8
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M]KF.7-A-7//"#Y^OR>W9O+*]!3P-)"V$Q)_I9QB]'G Z+<GO=G\>0IG&TG!
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M'N:V2P^]MV%NUH%"*VC((XV='8UGOF1FD%%^[M9+/$P)Z81; ,83C#Z]H%O
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M5_2)419!S=,2F38?H@Y6>I_*6F0AS:DS;Z*F\='\IX:'Q7K #I,#B^&"5CZ
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M.\YQ?)J\0GON29=(T;4(-*J1#AT4A*DI@8,ALA_=+S?2M1>3<'<3,>/KK9*
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M+< ##(*<6=^\W+\%?**C8W8,8YR]("<[IKW9R!N["VR^_"E(2I=H]D@9M><
MZ\JG1&@.IMG[*Y7=551,\"WN\\$Y]41ZT9.?OXLF*4OM5[?T$NXFFW(!<=]=
MU)E:P?>/2 SO'_;I^-_-Q,SO(G=IZ'27ALH-]\^Q&M#*]J!((LU7-.<-Z./O
M<;'RA8D^:"5JAG(NT"+--7X0=U/RF ODF'0IF7CH,&,<#'SL^E25&6VCNT"'
M34ZZG7!OL(0NTN*K<J1'+E;,,X*'4Q?*F*+ZF'QK#3-IC\U.1CU3B4Q)D!&A
MDUQ+*,7K*;I#):@KWQS8ITFDW73PYT+IBA[9H,!_L'/9U@U>]"0EFB-?U65I
MBO,+BXXT4GI7N.&ZP& K$X!@A;F@#5[:&&$.\B\9+3=J+LGKX&5L"HLS+W_Z
MH-OWB_UT :CB3:"322J#U:QX]@UPQ)_[:3C,336F4=,D,.M.A76#*:I \[5&
M&=N\.3+6QP6<+.42P&0+VM<[I(8)F5 ZJ^'!^Z_'8[[2WOD.-(7XEY7<][NY
MD7/O,L5?*QWKM]XK0HAVJA-GR#>B^^#H&XHBE"LQ=]ZC/&6U'-YZ"T]*)]25
M1M=;P%/'6X#+I)9V7+C0RJ//>X1*4ZW '=E4I@773Y71L-.9;2GMT"V/L21K
MA?M84-Y'[,O](T;#.V7>E_U>A8E( S8<BMB1.L1J?$'_<5\P#7=\.>$1+_"I
MD7.A&GO.$\6I91NV/9FJKE6Y!6TUT!()+HPC YZ)RP[1\<DTD-,+.U($GQ47
MF7L]1^G5\.L<3WGV=3Y/,VE6GP\2>;@%F1J>16I0/&(V_<DWL,W8J"DIW'KF
M!///@HAXQ*9U% .^NQLH IMY;B%P[8ZIF-50IT^'AN 9/'&0_FQFZ"MFR^7P
MCO<X=(SD:;%3/45D+7[$@9'96+:ZD8?39IKD Q/E+,M[C,JQ\X-MFD91+XN(
M"VUP$?% EXR8#^F!!G#+39P-2>X/#?8[,N+'&CVL*"*T>;:EB@CDDN[F+I2F
MH('E-S_$3+7<YS+\GRJ1/T7G!8EINF-FHDC.P/9BYY5'_\VQV[=-78G]Y1O!
M-W?!4"O!C!G%",_X<@4_#,+-F':1N-^TK.2;[ SJ!\G6;QY#4MTGJ9M/2HT#
MO[@>EBF*?%N"?F6_W\3R;(;N0B.2?C>5D'Q 0 7"^P>=IG=) O?G)N3]T24>
M1_QUFUQO1+KUIV&9.1E%I+D<R*,>3":O#FK.5;=;']R@U"<B$:7 >;A-QO7#
MM/OU+65J8MV5.F$ZK7E2YL^M&3OIM4<S9^HYE*5(<J-8S;U(ZBI#PGD,IX&.
MAJJ-0J_M3>B:';.0M1=3 J67+1SY4@3U6%%0(^ULM:R7^4[>E28NQNLGC_,J
M83I8;3]JOJ[<WZP- #5?+WB;CXY,;*TM[E21<-D%=1^2;>J:UN=,ZQ*E<32V
MCA<9R.-O,6,VLP52(%9,9ZJLNB/SLE7UNL".4?ACT1O"Y68G7A,'(*4QE++%
M&DA1/T^8KH]T8AWB'1;.3/&_=\#WW_/';TWLK<)W"5Y/6*::A'5V)0\#SRPX
M:I3? L)K]_DF[-Q>^)=X8MRMB.?PFK> .DW'N,6]<[CI>S)F2=Y^.*QY/JOV
M;K"9]ZQ03W:^E?P%?Q;9%^\8RD#&\!2.P7-4^9M+;]X!W"P8PG6!H/S!W=:W
MJ+M*\TG%=<1J$014C?J;,?O91'>]F*9Y9$G'@^R[ZLF#IGV>C+L]W[A4Y=#D
M=BA#JJU4%O)#!:QJL%IN:T;J [G.N@4\M#P?PVU+6'9>5D!,80?S:N)%Y_4I
MYW-T:9]5WZS-?7/5[I@#B>:YA)W*SS\&3U\+%^/2FIL-A%TPU]Q=]++86"N.
M7Y7 YN/DQIY^W&<,B9JA;$V+^8RZ6-*HEJ\M2BG+%C]EB"MU_#Y@9*EB?E[3
M <C[V#V0EXM##Y]QQ79&:QI63^GS21YF8<ZYLT2&%6SQ\0<ZQGM=^]-S9-R"
MW.V:1$4T:WH&+]_2K]QM<93J\JCFYKE2EBE 4JF2UA8VB=>+.[*Y0=+EJ8KU
MA*O,'GKY<Q*KQ0.%$OSC#QV3XHO7JQ^_T/ATVH03DH?&4D QS/$^/SRP<8[N
MJW)_..NY=ZNN2GO"QT[&/4UP_=Q<4V5L!_C'K"%NLJ0Q__AP[K?@*%&M/&D,
M(+AK4,3S8D01)(!P'_XA]KN9^^%W,P25AK32'$[SANCNVJ51: _:13SQ.?"%
M8Y#W FZ*^+F&HEN:F.A-CM <\"+LYP990-]NDEV-VGV ?.6S>[<O&HY\]!#I
M"+6]V9$Q(QC7W>8G/?W_B'G+N"C;K7UX:&F1;J6[NU'I!LFA06KH3BE!1!H!
M&2GI&I#N[NXNZ7+H!O$%U'O?^WGV?N+_?'@_##]^S'FM<ZUC'>M8ZV3FNFY%
MUJXF/%.N14&Q$:> 3L9X);4-*T&9^][HQ#A_K[1X]VKRT!27#>^_TF%UWRK1
M[\>D;U%W_ND2ZS8[152 %.Y\>DMZ-*$)=I0>Z2U*PN7/3K3JU13<?[*=D."I
M7CQC:(GAT645V!HVB3UD[M[X*I@B0R23J%,);ZGC26>I"(*Y[LX4M@%Q!J6=
M\,YXC""I=$Y_./$2JA7(?8"TKI9]<,=:1WGLE&^U4?!QD>).O"B!01=&9]ST
M:A&(Z%RY>IQZP>&9R1Q74C0N-6ZA8J#:.QD\Q<GC+U$8@**(P?UKUA>A*IUK
M0Y/U?94^C+(V9AY0RBHSFY!J'"<4;FBI, *K\]H859/Y"P<*4XQO$Z22;A/>
ME.:,)2Q _IL"OVOY#J'23<,MAGG/AG97D#65B,X)69QLNF0D;G^ABX#Y67A%
MC)!]P[A$2?E)GA#PM3774/DE*OP%^5/<0<M;ZKJR#WU/>!.FU?5>:->. \]'
M.5D;:+D8XM2"PG;H!@@+Y_A4[R</A,*_D%W.O4>6^Q[YX"]W<FU_/YNR$-UW
MW3;EHJIFT2/RX!J&72&$GP!*>!+UL?GM5E\LLM$&>LL/0YZNH"QR.=*@(J6N
MU",D@_-PE[@>]X-5*1+S6%DO@A6]/,Z.N7W>R9BXR'[W+JZXGO'+1,&&^^ZP
M]LO\?8X?/$&];^VM+??;W[NGRW3_1T"G!VWHOA"=0F7"V9?FEB+,1B^-MP(-
M'0VI,RJ?J+DI/=76$MB7MJ<J!<*>Z.MS(*N$AH_'7_E/<#%NR71KSC8I@@8F
M]RS&\VMFNV@*9W:J\.P%*"LG^2F*DW8C&!.3WP4Q952"ZNJ2Z-Z7$IQ!/LLU
M<'BP/A'\Z%9-T.$Q=;8P-),5(F@3NZ\N"$PH3S0+#S%TZB#I3BVD$Z1L'"[4
MF=(<A\1Y2OGK3IR]R\U.HP9I(M<[78RSNX<>,?:PQ$LNT>K$K'9H3B$'1Q]*
M#*]K<.@DBQ0;N7DM?XT_**N4@DU,FY%+MSCJ\T:S)A8$'A8YDN,:B.--)#:?
MY"=<_3B]P@&;T7D1L?CW8FG*?Z>,?GTPF;\[$B'AL>JSJH-E-2:5TV==Y-JD
MHCV?8BF3D0+1=[ZK$%Q\_M._$NF@]<\EM?H/9%&17@P0IJ4X>F001\+AQ)K(
MZ.XUDOP$=/4W[6M"(N+64C%\5W=L/;D]I[?U7IT)WV V"X0BX'Y9=!\*+P?.
M03P]O@3-:)WI;#0M$X[+;GX_,O\Q>T5I7$4M+BK[@L1WWJ"W]DNH@T9)8%KB
M<=<-I6?"S77/W7 ]ZMO*G><[5)]Z/N"#O=[UH^,F3^BNB50WQ:EV]'UM+(I,
M_@E8)AIOVEQ4NMZ(O)"L8+T\C[V]+$[_O8HU@?P<_RAC-^8[N:;4X-)!N)7!
M\3[MCV.I&TJ=WUM,C8CHWN\?R2*ZQ[JN]'OI3\!?:V7NVL3DW3%-Y,AWB?M$
MZ9?%OLCK#Y<JISVNF 49FW9_;9QQBP61N_59NSL,@+92'RQ*_6]=D)IZ/2UR
M%UG3OPS,N_HX_,.ELDD8YEUXY+H)AE>U(JX_ 6]!JC\!J1ZB^V#1ORYK?'^T
M>KMR^\I#YAXW'U>]P)VMR[E_>&CQ^[*4)P^!?4R]<R&V3^D!A=+OK'>!^=YM
MC&MW<;]SE@CQN']WU;T/7VXR]^Z"7T^[1;C)O?I>AWEG]IN[G<H0SY')C]G[
M_9U2RWHB%2I.I.+N8\\\RD"Z,RKW"X(A\H/P':HUX'W@(W?0;J0I\8QZ>5><
M\+3?K1(9;U3U=?!E$*EA:3EU]CZ\6["8E<1=_^X6[AZP]WS70H&W< 8O+N]C
MRF67NO]Y-5_\U4>/7,BWE?<W5^ZVL-*^FS7N\;BB[+T/2>87>W[\0N';A9W*
M;[R4_@YN[@-KR'YEHZCOWJS@/RA(_E?R#%YZ./P$W/EI\#]*V8-5VG\BPM\(
M]E\P@?J_-_O'6;G_PEGXL,C_EV+XL_]_J#'R7PY\:7=(_6;0F]#[]U+P_>O]
M^U)XT7"?N+_ 4J(7O7<#TO>5X='EZMW[+ZMNO'HBSZTZ$MY5X-8_-XRB$UTH
M3A/*O&=MR@,/E/ 9K5$Q8NDMHLMU%&K9VA VRNG@X' T*=W&%Q@9$20<8NV>
MDLI&7[TJQY+XSME\FHIIT),GNPO_%H\VZ#Q?]"Y&OI5%\9\ F'O6WN[\+H8"
MB/%:]+O2.A&W?ULY&0^5\\OOXCMP&_]M'GBDDJSO8/C_41'^QZ2]_!7/;W$D
MU_L?J<>O:WX7)/1O8LCUG\0Y]]<E_UIJ[%2''K(-VHHF,?6Y5_+,H3N/$Z:H
MKI F1NY5'QSLN[HH[UMW!X1GR$] @@?[+=0'@^(>6-7[#U]_N_$=Z[CI;D74
M[Q5P;>"0GFNA>R^PUFGOD>U5^JWD9"WD@I'H.PB.S)GD!T3WL4G!WF]@\/)1
M+/D]$+_JG?5W\:1B6#&Q,:_!_1(Q#*297UGSI<9\=8<L _L-ZJ7:U>IW5L/(
M%-%EXG&9EJK8R#-+XC8=/TJ\4:^;.[U[T-"$A_VEIJAJ,:<I-YV6(5)"P/_<
MS!ZDZQ?-&O\[;/^VUL?QW\GX0_ZN:'^5XZ]+KM;J[J&M^@>Q1OZYF3WH<\;#
M)6K_F\7_'<\9'F@;]S_A^:L'VC+\&[V)_>_,_DU'Q0XFLP)O(W_)\R^Z"&5V
M_2Z*.\69=P>I=-U1\&[?R>S - /QO)?[<'X$ONA>J1\_/8#V5(CA3GA8%*S)
M.G2?$;R'N=W*&8FP*!*<W_JJ859#+)>E&(I,[:61F$DIY!"JH)LHN=,5N&C!
M"W5<$Z=!OH7>Z<RCTY^ WZ$U$JCQ3]^1Z\'=P@4NCWW6L,\V*0B_%QW\ FWW
M[L"\?.>R_N7O+)O<9]F+2NG,6E.M^0X)LG'1S;</=1QI17[<>H=)P\&+>Y-9
M?Y:*?I\^%T*]Q8*^N'67^9VVLR\_ 4)4]Z@M_6EJK]SO8_P>Y6O65?/-X"]K
MD1=2%9B_7+BB" O[_E<R2L5_?";;]/=M%<[U'4)^T(8_OGAM_I*PWK"? -A[
M%\AG2O;<R6\H9]_]B6OAMS-3C9=_4O'+VX>E^#>4M7\MA?ZU-"0J\L'3!TJ8
M!E[S" _!WK';2_G7D,+U#U_.AQZ44>X7:&?2!C/V#U:O?EE-<_>\,3^_GVOV
M4^0?K-&(]-Y9[D&]YA >@B,C&^>0";@+/G#Y^O@G@.7H8>'#MA_%'R*;24_1
MNPL>$W/IA.>(_ *=_"!BZ93MEY<>]/>3A'?(+UA[D-=_!31U7;(F$WE^7XZ>
M/R+@GV!>H'MM1C]8ZQ$?N;?YK+!14/= ]$+*A03*UN-_>Y]3@[S[.87-=Z;8
MYTCM/D%K77\BBMYSQW;WO'2_%OKT$^#Z\>+-C7?CRP?T8W]9C?R=4'.6^S0)
M^OXE'<*^_RG[OU P]?_M;-5/P)_LN_S._O6OG7]Y\?U.7<M,Y@]8_WI?ZJ_L
M_N5IS@-23V\'(IV:F_X54<]_N?@G)-'?%BO^A<4'+GNP/U!%. ;_S-KKH5+^
MXO$#K#\!?Y'JUTH#FK]1U>\GX!^1__/ZIM^6[Y%\2!K2_09P_Z84_R#Q'^KK
MS_M2?Y'WWR!!^AL)%S*4459FET^9\;SJI(Z,$]X?[PVF<^N'PERI2X+E1^,1
MN=:]0OEPRC]MQ!=UN?:)%9EWNH[.;QL9JW8)!SE/KX!?807 ?"F(546Q+Q-"
MKA?-Y7IW_L3E%DK[#^B\'S\,MK_S_/K[F-!Y@L3I_T(/FOZ+K/R:@E0BO_U3
M/;K]HQX%_\:TW]C^Q^IU_9.%>S^@O^'^R_:?C)/_R3CT'PF9^RLA_ZR-?R3D
M;R2V^PGXI4S+H?=M^L^X(!R#^3MY<_](WI_+&L[_WBO_0<\_MNZK\R?@E]PL
M/6BB-&58DC7Y'_H@W>.:YGY$=2?39O[+4+'BJ_</TD0M^E!Q)A</12]4R:RS
MZ1^)846*QOHG&VE ,OG[HFXX_C4K1"7>=^![%XSC8H4>WZG77:E_$OU^-S+P
MOQ%=#_P)N!.HQM]*]B!\,T^U?P.VEY%TR7%W\%)9WCWJ.G]B0KY0[,668WJW
MDN*A.$K$CNX@0'._RT->P.^2A^4PC"7?NR^CA]3^<K@#\YJ'9_Z _$*J^*[Y
M*HK.9/U->_]LG_!'=1YH0_ZO://F/Q3S0PJ0_BT?ZS_]DT(]\ ;FGU7_;RS[
MO9KVEP3^H^2:_BM*_C;][G=#$_R[2+C^)U'Y9Y'X3RKD]A\0B?RM0<__DPY&
M[/Q/=;#VW^C@ W2/+NY\)-_YL[^O,NG3OZU->7Y_3GHS@'DM0+_G4>QW4O"!
M\3V11:(;KX,^& EGA*AX05D4Q4='0]!BY-7J_?UC\M/RWC.95(B9?)V<L@).
M8JAB)!IF685 R\V^Z,-G6PRHZ,8RFUK9REF7NFXX6BS6)DA@M]%82APS/[S
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MR7Z%\B9A!2C\'#GSB6\N8>QLLM_"-P>I"HWRQH KA)2%<\D%="U:L :,&&R
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M"Y[K5FKCKLOE+O 6JKD6&5U&2HS4U90Q7Q9TS_*PE1VB9'\6LH5^_Z%!P(^
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MLN^_(@8V@4$URVZ("[V%8@>@$28A0=RDHO5 6V-/STFJ1AB:R\W0\SXIFP[
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MQ/"O2H:2/I47=[-*8K/A_F^+#JH 65$PNZB'"K-.2$DYXPGS%MCKO''%,"$
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M& &F%J*UH\.VJ5FI*+8:]YLTI1Y)2QH]@>$8D<QX^:D,]6=7?[RN2J'!OI"
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M:]-EADJ%D;U7CX]$U/?BFL^OG69ET2'$FD99M:23@>3IGI,C"PE CG=)]53
MZ@+3S!"*"E5)5;:E[6%;^N*$F?[=@#=AM.FVY/-84*[W>6D(N4Z 0HS@G24J
M3E<WSCS.E+2)"@\S %VJL'5KQR_(&3?(\*ZO4B -:<,6G6IJ39L!C3%5" _S
M)M*Z0-+.Z 0CR*U]E7T:HNC*Q?&C5KU*V/L@BHWFF5*S_\.>H+T'!"GNTWE
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MY0.LM4PZ@KJ33U 5G7^@;%IIXTZI,R<Y[H>./--U3_RUQ\1AO12KL+B_*:L
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M[M]G:G,@]?<7WVEWF$1,ND]\%9Q89BY:O-SH(<<S,U?^<.J^K- @MV+=47V
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M8_(%1K^^VAP+MIWJ'/M\OV)]L?CVVPW Y[!BFN1='!0K.,0$>@,(\K&XN@'
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M)6@?NEY0F?AH8-L6$J#"4N Y4/RK0J,=KG#NU:O[,<RN,$I%J*)(3[1AD#8
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M&;2EI\!X2"3-1\&M;[+ZQ;,1$J5WS[H8)BR3K1(OUHIXC/ED **D\%0PFN>
M5 LSX$P!FP\*TH[5PI1!:A;>^Q_O'I/$PW4]56I>GM=V:*?(D'@$0%[$6M4(
MC)$[+&;=-$1Y.6#[D0F_A]$MR2<K+5?8A;-C@N.GK=\(;C%KM38V07\XUO6?
M93..&2_7S![;M$[M0'U>NAH^[M&+])P2UQ[W!$UG\TT5-"?SBUEJ2LS:1?\T
MIR%OY%_D]4K7*HQ83 O?<[5GV8)TA) :]=C'3_)\=$^K_&77S;=B'Z5J=#V
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MG1^L:\(]<)_#SIH2'%HX%#---?B@S%*D77>S1R;Y)5;@+BK&]:?J=P]TWD8
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M,S$N:'1M4$L! A0#%     @ *GAP4FZ%1/I?&P  ICX! !$
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M &)D<W@M,C R,#$R,S%?<')E+GAM;%!+ 0(4 Q0    ( "IX<%)H[4U3VBX
M +!; 0 3              "  ;^$!@!B9'-X+65X,3 U,5\S.#@N:'1M4$L!
M A0#%     @ *GAP4@IO)#X/ P  -@D  !(              ( !RK,& &)D
M<W@M97@R,S%?,C<Q+FAT;5!+ 0(4 Q0    ( "IX<%)-:GU(AP@  )=4   2
M              "  0FW!@!B9'-X+65X,S$Q7S(V.2YH=&U02P$"% ,4
M"  J>'!24B]J>J4(  !<50  $@              @ ' OP8 8F1S>"UE>#,Q
M,E\R-C@N:'1M4$L! A0#%     @ *GAP4N'L0G8U!0  ;R$  !(
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M96=G=7DU,&]Z='HP,# P,#(N:G!G4$L! A0#%     @ *GAP4I>8.O6Z\@
MU@\! !8              ( !7\<( &=E9V=U>34P;WIT>C P,# P,RYJ<&=0
M2P$"% ,4    "  J>'!2BZC7UWL; 0 D2P$ %@              @ %-N@D
M9V5G9W5Y-3!O>G1Z,# P,# T+FIP9U!+ 0(4 Q0    ( "IX<%)_-(&AAZT
M -?\   6              "  ?S5"@!G96=G=7DU,&]Z='HP,# P,#4N:G!G
M4$L! A0#%     @ *GAP4@FU>0 W]   H%0! !8              ( !MX,+
M &=E9V=U>34P;WIT>C P,# P-BYJ<&=02P$"% ,4    "  J>'!2=L/S8:@^
M 0 SA@$ %@              @ $B> P 9V5G9W5Y-3!O>G1Z,# P,# W+FIP
79U!+!08     %  4 "H%  #^M@T    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
